ID	Gene Name	Species	BBID	BIOCARTA	COG_ONTOLOGY	GOTERM_BP_DIRECT	GOTERM_CC_DIRECT	GOTERM_MF_DIRECT	INTERPRO	KEGG_PATHWAY	OMIM_DISEASE	PIR_SUPERFAMILY	SMART	UP_KW_BIOLOGICAL_PROCESS	UP_KW_CELLULAR_COMPONENT	UP_KW_DISEASE	UP_KW_DOMAIN	UP_KW_LIGAND	UP_KW_MOLECULAR_FUNCTION	UP_KW_PTM	UP_SEQ_FEATURE
DECR1	2,4-dienoyl-CoA reductase 1(DECR1)	Homo sapiens				GO:0006635~fatty acid beta-oxidation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005829~cytosol,GO:1902494~catalytic complex,	GO:0008670~2,4-dienoyl-CoA reductase (NADPH) activity,GO:0016491~oxidoreductase activity,GO:0042802~identical protein binding,GO:0070402~NADPH binding,	IPR002347:Glucose/ribitol dehydrogenase,					KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,	KW-0496~Mitochondrion,		KW-0809~Transit peptide,	KW-0521~NADP,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:NADP,BINDING:Substrate,MUTAGEN:K->A: Reduces enzyme activity by over 99%.,MUTAGEN:N->A: Reduces enzyme activity by 97%.,MUTAGEN:S->A: Reduces enzyme activity by over 99%.,MUTAGEN:Y->A: Reduces enzyme activity by 99%. Strongly reduced affinity for substrate and for NADP.,NP_BIND:NADP,TRANSIT:Mitochondrion,
ADO	2-aminoethanethiol dioxygenase(ADO)	Homo sapiens				GO:0000098~sulfur amino acid catabolic process,	GO:0005829~cytosol,	GO:0005515~protein binding,GO:0016702~oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen,GO:0046872~metal ion binding,GO:0047800~cysteamine dioxygenase activity,	IPR011051:RmlC-like cupin domain,IPR012864:Cysteamine dioxygenase,	hsa00430:Taurine and hypotaurine metabolism,hsa01100:Metabolic pathways,								KW-0408~Iron,KW-0479~Metal-binding,	KW-0223~Dioxygenase,KW-0560~Oxidoreductase,		REGION:Disordered,
HMGCR	3-hydroxy-3-methylglutaryl-CoA reductase(HMGCR)	Homo sapiens				GO:0006695~cholesterol biosynthetic process,GO:0006743~ubiquinone metabolic process,GO:0007399~nervous system development,GO:0007568~aging,GO:0007584~response to nutrient,GO:0008299~isoprenoid biosynthetic process,GO:0008542~visual learning,GO:0010664~negative regulation of striated muscle cell apoptotic process,GO:0010666~positive regulation of cardiac muscle cell apoptotic process,GO:0015936~coenzyme A metabolic process,GO:0016126~sterol biosynthetic process,GO:0019216~regulation of lipid metabolic process,GO:0019222~regulation of metabolic process,GO:0032874~positive regulation of stress-activated MAPK cascade,GO:0038183~bile acid signaling pathway,GO:0042177~negative regulation of protein catabolic process,GO:0042632~cholesterol homeostasis,GO:0043407~negative regulation of MAP kinase activity,GO:0045445~myoblast differentiation,GO:0045471~response to ethanol,GO:0048643~positive regulation of skeletal muscle tissue development,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0050709~negative regulation of protein secretion,GO:0061045~negative regulation of wound healing,GO:0061179~negative regulation of insulin secretion involved in cellular response to glucose stimulus,GO:0070328~triglyceride homeostasis,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0070723~response to cholesterol,GO:1900222~negative regulation of beta-amyloid clearance,	GO:0005778~peroxisomal membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016021~integral component of membrane,	GO:0004420~hydroxymethylglutaryl-CoA reductase (NADPH) activity,GO:0005515~protein binding,GO:0042282~hydroxymethylglutaryl-CoA reductase activity,GO:0042802~identical protein binding,GO:0050661~NADP binding,GO:0051721~protein phosphatase 2A binding,GO:0070402~NADPH binding,	IPR000731:Sterol-sensing domain,IPR002202:Hydroxymethylglutaryl-CoA reductase, class I/II,IPR004554:Hydroxymethylglutaryl-CoA reductase, eukaryotic/arcaheal type,IPR004816:Hydroxymethylglutaryl-CoA reductase, metazoan,IPR009023:Hydroxymethylglutaryl-CoA reductase, class I/II, NAD/NADP-binding,IPR009029:Hydroxymethylglutaryl-CoA reductase, class I/II, substrate-binding,IPR023074:Hydroxymethylglutaryl-CoA reductase, class I/II, catalytic domain,IPR023076:Hydroxymethylglutaryl-CoA reductase, class I/II, conserved site,IPR023282:Hydroxymethylglutaryl-CoA reductase, N-terminal,	hsa00900:Terpenoid backbone biosynthesis,hsa01100:Metabolic pathways,hsa04152:AMPK signaling pathway,hsa04976:Bile secretion,	Low density lipoprotein cholesterol level QTL 3~Low density lipoprotein cholesterol level QTL 3,Statins, attenuated cholesterol lowering by~Statins, attenuated cholesterol lowering by,			KW-0152~Cholesterol biosynthesis,KW-0153~Cholesterol metabolism,KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,KW-0752~Steroid biosynthesis,KW-0753~Steroid metabolism,KW-0756~Sterol biosynthesis,KW-1207~Sterol metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0576~Peroxisome,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0521~NADP,	KW-0560~Oxidoreductase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Charge relay system,ACT_SITE:Proton donor,CARBOHYD:N-linked (GlcNAc...) asparagine,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:SSD,MOTIF:INSIG-binding motif,MUTAGEN:G->D: Does not affect hydroxymethylglutaryl-CoA reductase activity.,MUTAGEN:K->R: Abolishes sterol-mediated ubiquitination and degradation; when associated with R-248.,MUTAGEN:K->R: Abolishes sterol-mediated ubiquitination and degradation; when associated with R-89.,MUTAGEN:YIY->AIA: Reduced sterol-mediated release from the ER. Not deglycosylated in response to sterols.,NP_BIND:NADP,REGION:Coenzyme A binding,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
HMGCS1	3-hydroxy-3-methylglutaryl-CoA synthase 1(HMGCS1)	Homo sapiens		h_s1pPathway:SREBP control of lipid synthesis,		GO:0001889~liver development,GO:0006084~acetyl-CoA metabolic process,GO:0006629~lipid metabolic process,GO:0006695~cholesterol biosynthetic process,GO:0007420~brain development,GO:0008584~male gonad development,GO:0009645~response to low light intensity stimulus,GO:0010142~farnesyl diphosphate biosynthetic process, mevalonate pathway,GO:0014074~response to purine-containing compound,GO:0019216~regulation of lipid metabolic process,GO:0019222~regulation of metabolic process,GO:0033197~response to vitamin E,GO:0042493~response to drug,GO:0046690~response to tellurium ion,GO:0071372~cellular response to follicle-stimulating hormone stimulus,GO:0071397~cellular response to cholesterol,GO:0071404~cellular response to low-density lipoprotein particle stimulus,	GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0004421~hydroxymethylglutaryl-CoA synthase activity,GO:0016746~transferase activity, transferring acyl groups,GO:0016853~isomerase activity,GO:0042803~protein homodimerization activity,GO:0043177~organic acid binding,	IPR000590:Hydroxymethylglutaryl-coenzyme A synthase, active site,IPR010122:Hydroxymethylglutaryl-CoA synthase, eukaryotic,IPR013528:Hydroxymethylglutaryl-coenzyme A synthase, N-terminal,IPR013746:Hydroxymethylglutaryl-coenzyme A synthase C-terminal,IPR016039:Thiolase-like,	hsa00280:Valine, leucine and isoleucine degradation,hsa00650:Butanoate metabolism,hsa00900:Terpenoid backbone biosynthesis,hsa01100:Metabolic pathways,hsa03320:PPAR signaling pathway,				KW-0152~Cholesterol biosynthesis,KW-0153~Cholesterol metabolism,KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,KW-0752~Steroid biosynthesis,KW-0753~Steroid metabolism,KW-0756~Sterol biosynthesis,KW-1207~Sterol metabolism,	KW-0963~Cytoplasm,				KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Acyl-thioester intermediate,ACT_SITE:Proton donor/acceptor,BINDING:Coenzyme A,DOMAIN:HMG_CoA_synt_C,DOMAIN:HMG_CoA_synt_N,MUTAGEN:C->A,S: Loss of activity.,REGION:Coenzyme A binding,REGION:Disordered,
BDH1	3-hydroxybutyrate dehydrogenase 1(BDH1)	Homo sapiens				GO:0006629~lipid metabolic process,GO:0046951~ketone body biosynthetic process,GO:0046952~ketone body catabolic process,	GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0099617~matrix side of mitochondrial inner membrane,	GO:0003858~3-hydroxybutyrate dehydrogenase activity,GO:0016491~oxidoreductase activity,	IPR002347:Glucose/ribitol dehydrogenase,IPR020904:Short-chain dehydrogenase/reductase, conserved site,	hsa00650:Butanoate metabolism,hsa01100:Metabolic pathways,				KW-0443~Lipid metabolism,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,		KW-0809~Transit peptide,	KW-0520~NAD,	KW-0021~Allosteric enzyme,KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:Substrate,CARBOHYD:O-linked (GlcNAc) serine,NP_BIND:NAD,TRANSIT:Mitochondrion,
OXCT1	3-oxoacid CoA-transferase 1(OXCT1)	Homo sapiens			Lipid metabolism,	GO:0007420~brain development,GO:0007507~heart development,GO:0007584~response to nutrient,GO:0009410~response to xenobiotic stimulus,GO:0009725~response to hormone,GO:0014823~response to activity,GO:0035774~positive regulation of insulin secretion involved in cellular response to glucose stimulus,GO:0042182~ketone catabolic process,GO:0042493~response to drug,GO:0042594~response to starvation,GO:0045471~response to ethanol,GO:0046950~cellular ketone body metabolic process,GO:0046952~ketone body catabolic process,GO:0060612~adipose tissue development,	GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,	GO:0008260~3-oxoacid CoA-transferase activity,GO:0008410~CoA-transferase activity,GO:0042802~identical protein binding,	IPR004163:Coenzyme A transferase binding site,IPR004164:Coenzyme A transferase active site,IPR004165:Coenzyme A transferase family I,IPR012791:3-oxoacid CoA-transferase, subunit B,IPR012792:3-oxoacid CoA-transferase, subunit A,IPR014388:3-oxoacid CoA-transferase,	hsa00280:Valine, leucine and isoleucine degradation,hsa00650:Butanoate metabolism,hsa01100:Metabolic pathways,	245050~Succinyl CoA:3-oxoacid CoA transferase deficiency,	PIRSF000858:3-oxoacid CoA-transferase,	SM00882:SM00882,		KW-0496~Mitochondrion,	KW-0225~Disease variant,	KW-0732~Signal,KW-0809~Transit peptide,		KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:5-glutamyl coenzyme A thioester intermediate,TRANSIT:Mitochondrion,
ALAS1	5'-aminolevulinate synthase 1(ALAS1)	Homo sapiens		h_ahspPathway:Hemoglobin's Chaperone,		GO:0001666~response to hypoxia,GO:0006782~protoporphyrinogen IX biosynthetic process,GO:0006783~heme biosynthetic process,GO:0007005~mitochondrion organization,GO:0009058~biosynthetic process,GO:0019222~regulation of metabolic process,GO:0042541~hemoglobin biosynthetic process,GO:0048821~erythrocyte development,	GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005829~cytosol,	GO:0003824~catalytic activity,GO:0003870~5-aminolevulinate synthase activity,GO:0005515~protein binding,GO:0030170~pyridoxal phosphate binding,GO:0042802~identical protein binding,	IPR001917:Aminotransferase, class-II, pyridoxal-phosphate binding site,IPR004839:Aminotransferase, class I/classII,IPR010961:Tetrapyrrole biosynthesis, 5-aminolevulinic acid synthase,IPR015118:5-aminolevulinate synthase presequence,IPR015421:Pyridoxal phosphate-dependent transferase, major region, subdomain 1,IPR015422:Pyridoxal phosphate-dependent transferase, major region, subdomain 2,IPR015424:Pyridoxal phosphate-dependent transferase,	hsa00260:Glycine, serine and threonine metabolism,hsa00860:Porphyrin metabolism,hsa01100:Metabolic pathways,hsa01240:Biosynthesis of cofactors,				KW-0350~Heme biosynthesis,	KW-0496~Mitochondrion,		KW-0809~Transit peptide,	KW-0663~Pyridoxal phosphate,	KW-0012~Acyltransferase,KW-0808~Transferase,		BINDING:Pyridoxal phosphate,BINDING:Pyridoxal phosphate; shared with dimeric partner,BINDING:Substrate,COMPBIAS:Polar residues,DOMAIN:Aminotran_1_2,DOMAIN:Preseq_ALAS,REGION:Disordered,TRANSIT:Mitochondrion,
NT5DC2	5'-nucleotidase domain containing 2(NT5DC2)	Homo sapiens				GO:0016311~dephosphorylation,		GO:0008253~5'-nucleotidase activity,GO:0016787~hydrolase activity,GO:0046872~metal ion binding,	IPR008380:HAD-superfamily hydrolase, subfamily IG, 5'-nucleotidase,IPR016695:Purine 5'-nucleotidase,IPR023214:HAD-like domain,			PIRSF017434:cytosolic purine 5'-nucleotidase,						KW-0460~Magnesium,KW-0479~Metal-binding,	KW-0378~Hydrolase,		ACT_SITE:Nucleophile,ACT_SITE:Proton donor,METAL:Magnesium,METAL:Magnesium; via carbonyl oxygen,REGION:Disordered,
AKAP8L	A-kinase anchoring protein 8 like(AKAP8L)	Homo sapiens				GO:0006397~mRNA processing,GO:0007076~mitotic chromosome condensation,GO:0008380~RNA splicing,GO:0010793~regulation of mRNA export from nucleus,GO:0016032~viral process,GO:0031065~positive regulation of histone deacetylation,GO:0033127~regulation of histone phosphorylation,GO:0044839~cell cycle G2/M phase transition,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051081~nuclear envelope disassembly,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0016363~nuclear matrix,GO:0016605~PML body,GO:0016607~nuclear speck,GO:1990904~ribonucleoprotein complex,	GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0005521~lamin binding,GO:0016301~kinase activity,GO:0017151~DEAD/H-box RNA helicase binding,GO:0034237~protein kinase A regulatory subunit binding,GO:0042826~histone deacetylase binding,GO:0046872~metal ion binding,	IPR007071:A-kinase anchoring protein 95 (AKAP95),					KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0418~Kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DOMAIN:C2H2 AKAP95-type,MOTIF:Nuclear export signal (NES),MOTIF:Nuclear localization signal,REGION:Disordered,REGION:Sufficient for activation of CTE-mediated expression,ZN_FING:C2H2 AKAP95-type 1,ZN_FING:C2H2 AKAP95-type 2,
AKAP8	A-kinase anchoring protein 8(AKAP8)	Homo sapiens		h_akap95Pathway:AKAP95 role in mitosis and chromosome dynamics,		GO:0000278~mitotic cell cycle,GO:0007076~mitotic chromosome condensation,GO:0007165~signal transduction,GO:0015031~protein transport,GO:0031065~positive regulation of histone deacetylation,GO:0032720~negative regulation of tumor necrosis factor production,GO:0033127~regulation of histone phosphorylation,GO:0044839~cell cycle G2/M phase transition,GO:0045087~innate immune response,GO:0071222~cellular response to lipopolysaccharide,GO:0071380~cellular response to prostaglandin E stimulus,	GO:0000793~condensed chromosome,GO:0001939~female pronucleus,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005739~mitochondrion,GO:0005794~Golgi apparatus,GO:0016020~membrane,GO:0016363~nuclear matrix,	GO:0003677~DNA binding,GO:0003690~double-stranded DNA binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0034237~protein kinase A regulatory subunit binding,GO:0042826~histone deacetylase binding,GO:0051059~NF-kappaB binding,	IPR007071:A-kinase anchoring protein 95 (AKAP95),					KW-0391~Immunity,KW-0399~Innate immunity,KW-0653~Protein transport,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0813~Transport,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:C2H2 AKAP95-type,MOTIF:Bipartite nuclear localization signal,MUTAGEN:C->S: Abolishes chromosome-condensation activity and recruitment of condensin complex; when associated with S-481.,MUTAGEN:C->S: Abolishes chromosome-condensation activity and recruitment of condensin complex; when associated with S-484.,MUTAGEN:C->S: Abolishes chromosome-condensation activity; when associated with S-392.,MUTAGEN:C->S: Abolishes chromosome-condensation activity; when associated with S-395.,MUTAGEN:I->P: No effect on activity to regulate DNA replication and on condensin complex recruitment.,MUTAGEN:KR->NS: No nuclear localization; when associated with S-290.,MUTAGEN:R->S: No nuclear localization; when associated with 304-N-S-305.,REGION:Disordered,REGION:Interaction with DDX5,REGION:Interaction with DPY30,REGION:Interaction with MCM2,REGION:Involved in chromatin-binding,REGION:Involved in condensin complex recruitment,REGION:RII-binding,REGION:Required for interaction with MYCBP,ZN_FING:C2H2 AKAP95-type 1,ZN_FING:C2H2 AKAP95-type 2,
ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase(ABL1)	Homo sapiens		h_arfPathway:Tumor Suppressor Arf Inhibits Ribosomal Biogenesis,h_atmPathway:ATM Signaling Pathway,h_g1Pathway:Cell Cycle: G1/S Check Point ,h_Lis1Pathway:Lissencephaly gene (LIS1) in neuronal migration and development,		GO:0000278~mitotic cell cycle,GO:0001843~neural tube closure,GO:0001922~B-1 B cell homeostasis,GO:0001934~positive regulation of protein phosphorylation,GO:0002322~B cell proliferation involved in immune response,GO:0002333~transitional one stage B cell differentiation,GO:0006298~mismatch repair,GO:0006355~regulation of transcription, DNA-templated,GO:0006464~cellular protein modification process,GO:0006468~protein phosphorylation,GO:0006897~endocytosis,GO:0006914~autophagy,GO:0006974~cellular response to DNA damage stimulus,GO:0006975~DNA damage induced protein phosphorylation,GO:0006979~response to oxidative stress,GO:0007050~cell cycle arrest,GO:0007173~epidermal growth factor receptor signaling pathway,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007229~integrin-mediated signaling pathway,GO:0008306~associative learning,GO:0008630~intrinsic apoptotic signaling pathway in response to DNA damage,GO:0009410~response to xenobiotic stimulus,GO:0009791~post-embryonic development,GO:0010506~regulation of autophagy,GO:0010595~positive regulation of endothelial cell migration,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0021587~cerebellum morphogenesis,GO:0022408~negative regulation of cell-cell adhesion,GO:0030035~microspike assembly,GO:0030036~actin cytoskeleton organization,GO:0030041~actin filament polymerization,GO:0030100~regulation of endocytosis,GO:0030155~regulation of cell adhesion,GO:0030514~negative regulation of BMP signaling pathway,GO:0030516~regulation of axon extension,GO:0031113~regulation of microtubule polymerization,GO:0032489~regulation of Cdc42 protein signal transduction,GO:0032729~positive regulation of interferon-gamma production,GO:0032743~positive regulation of interleukin-2 production,GO:0032956~regulation of actin cytoskeleton organization,GO:0033690~positive regulation of osteoblast proliferation,GO:0034446~substrate adhesion-dependent cell spreading,GO:0034599~cellular response to oxidative stress,GO:0034976~response to endoplasmic reticulum stress,GO:0035791~platelet-derived growth factor receptor-beta signaling pathway,GO:0038083~peptidyl-tyrosine autophosphorylation,GO:0038096~Fc-gamma receptor signaling pathway involved in phagocytosis,GO:0038189~neuropilin signaling pathway,GO:0042770~signal transduction in response to DNA damage,GO:0042981~regulation of apoptotic process,GO:0043065~positive regulation of apoptotic process,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043124~negative regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043525~positive regulation of neuron apoptotic process,GO:0043542~endothelial cell migration,GO:0045184~establishment of protein localization,GO:0045580~regulation of T cell differentiation,GO:0045907~positive regulation of vasoconstriction,GO:0045930~negative regulation of mitotic cell cycle,GO:0045931~positive regulation of mitotic cell cycle,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046632~alpha-beta T cell differentiation,GO:0046777~protein autophosphorylation,GO:0048146~positive regulation of fibroblast proliferation,GO:0048536~spleen development,GO:0048538~thymus development,GO:0048668~collateral sprouting,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0050798~activated T cell proliferation,GO:0050852~T cell receptor signaling pathway,GO:0050853~B cell receptor signaling pathway,GO:0050885~neuromuscular process controlling balance,GO:0051149~positive regulation of muscle cell differentiation,GO:0051281~positive regulation of release of sequestered calcium ion into cytosol,GO:0051353~positive regulation of oxidoreductase activity,GO:0051444~negative regulation of ubiquitin-protein transferase activity,GO:0051496~positive regulation of stress fiber assembly,GO:0051726~regulation of cell cycle,GO:0051882~mitochondrial depolarization,GO:0051894~positive regulation of focal adhesion assembly,GO:0060020~Bergmann glial cell differentiation,GO:0060563~neuroepithelial cell differentiation,GO:0070301~cellular response to hydrogen peroxide,GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071103~DNA conformation change,GO:0071222~cellular response to lipopolysaccharide,GO:0071560~cellular response to transforming growth factor beta stimulus,GO:0071871~response to epinephrine,GO:0071901~negative regulation of protein serine/threonine kinase activity,GO:0072359~circulatory system development,GO:0090050~positive regulation of cell migration involved in sprouting angiogenesis,GO:0090135~actin filament branching,GO:1900006~positive regulation of dendrite development,GO:1900026~positive regulation of substrate adhesion-dependent cell spreading,GO:1900272~negative regulation of long-term synaptic potentiation,GO:1900275~negative regulation of phospholipase C activity,GO:1901216~positive regulation of neuron death,GO:1901300~positive regulation of hydrogen peroxide-mediated programmed cell death,GO:1902036~regulation of hematopoietic stem cell differentiation,GO:1903053~regulation of extracellular matrix organization,GO:1903055~positive regulation of extracellular matrix organization,GO:1903210~glomerular visceral epithelial cell apoptotic process,GO:1903351~cellular response to dopamine,GO:1904528~positive regulation of microtubule binding,GO:1904531~positive regulation of actin filament binding,GO:1905244~regulation of modification of synaptic structure,GO:1905555~positive regulation blood vessel branching,GO:1990051~activation of protein kinase C activity,GO:2000096~positive regulation of Wnt signaling pathway, planar cell polarity pathway,GO:2000145~regulation of cell motility,GO:2000249~regulation of actin cytoskeleton reorganization,GO:2000251~positive regulation of actin cytoskeleton reorganization,GO:2000352~negative regulation of endothelial cell apoptotic process,GO:2000773~negative regulation of cellular senescence,GO:2001020~regulation of response to DNA damage stimulus,	GO:0001726~ruffle,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0015629~actin cytoskeleton,GO:0016604~nuclear body,GO:0030425~dendrite,GO:0030426~growth cone,GO:0031252~cell leading edge,GO:0031965~nuclear membrane,GO:0032991~macromolecular complex,GO:0043025~neuronal cell body,GO:0048471~perinuclear region of cytoplasm,GO:0098794~postsynapse,	GO:0000287~magnesium ion binding,GO:0000400~four-way junction DNA binding,GO:0000405~bubble DNA binding,GO:0001784~phosphotyrosine binding,GO:0003677~DNA binding,GO:0003713~transcription coactivator activity,GO:0003785~actin monomer binding,GO:0004515~nicotinate-nucleotide adenylyltransferase activity,GO:0004672~protein kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0004715~non-membrane spanning protein tyrosine kinase activity,GO:0005080~protein kinase C binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008022~protein C-terminus binding,GO:0016301~kinase activity,GO:0017124~SH3 domain binding,GO:0019905~syntaxin binding,GO:0030145~manganese ion binding,GO:0038191~neuropilin binding,GO:0042169~SH2 domain binding,GO:0046875~ephrin receptor binding,GO:0051015~actin filament binding,GO:0051019~mitogen-activated protein kinase binding,GO:0070064~proline-rich region binding,GO:0070097~delta-catenin binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000719:Protein kinase, catalytic domain,IPR000980:SH2 domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR001452:Src homology-3 domain,IPR008266:Tyrosine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR015015:F-actin binding,IPR017441:Protein kinase, ATP binding site,IPR020635:Tyrosine-protein kinase, catalytic domain,	hsa04012:ErbB signaling pathway,hsa04014:Ras signaling pathway,hsa04110:Cell cycle,hsa04360:Axon guidance,hsa04722:Neurotrophin signaling pathway,hsa05130:Pathogenic Escherichia coli infection,hsa05200:Pathways in cancer,hsa05206:MicroRNAs in cancer,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05220:Chronic myeloid leukemia,hsa05416:Viral myocarditis,	608232~Leukemia, Philadelphia chromosome-positive, resistant to imatinib,617602~Congenital heart defects and skeletal malformations syndrome,		SM00219:TyrKc,SM00252:SH2,SM00326:SH3,SM00808:FABD,	KW-0053~Apoptosis,KW-0072~Autophagy,KW-0130~Cell adhesion,KW-0227~DNA damage,KW-0234~DNA repair,KW-0254~Endocytosis,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0656~Proto-oncogene,	KW-0727~SH2 domain,KW-0728~SH3 domain,	KW-0067~ATP-binding,KW-0460~Magnesium,KW-0464~Manganese,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0238~DNA-binding,KW-0418~Kinase,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0519~Myristate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Proton acceptor,BINDING:ATP,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:FABD,DOMAIN:Protein kinase,DOMAIN:SH2,DOMAIN:SH3,LIPID:N-myristoyl glycine,MOTIF:Kinase activation loop,MOTIF:Nuclear export signal,MOTIF:Nuclear localization signal 1,MOTIF:Nuclear localization signal 2,MOTIF:Nuclear localization signal 3,MUTAGEN:T->A: Abolishes phosphorylation. Loss of binding YWHAS and YWHAZ. Localizes to the nucleus. No effect on kinase activity.,NP_BIND:ATP,REGION:CAP,REGION:DNA-binding,REGION:Disordered,REGION:F-actin-binding,SITE:Breakpoint for translocation to form BCR-ABL and NUP214-ABL1 fusion proteins,
ACD	ACD shelterin complex subunit and telomerase recruitment factor(ACD)	Homo sapiens				GO:0000723~telomere maintenance,GO:0001501~skeletal system development,GO:0001655~urogenital system development,GO:0006886~intracellular protein transport,GO:0007004~telomere maintenance via telomerase,GO:0016233~telomere capping,GO:0030326~embryonic limb morphogenesis,GO:0031848~protection from non-homologous end joining at telomere,GO:0032201~telomere maintenance via semi-conservative replication,GO:0032202~telomere assembly,GO:0032211~negative regulation of telomere maintenance via telomerase,GO:0032212~positive regulation of telomere maintenance via telomerase,GO:0035282~segmentation,GO:0045007~depurination,GO:0048239~negative regulation of DNA recombination at telomere,GO:0051973~positive regulation of telomerase activity,GO:0060381~positive regulation of single-stranded telomeric DNA binding,GO:0070198~protein localization to chromosome, telomeric region,GO:0070200~establishment of protein localization to telomere,GO:1900051~positive regulation of histone exchange,	GO:0000781~chromosome, telomeric region,GO:0000783~nuclear telomere cap complex,GO:0005654~nucleoplasm,GO:0005697~telomerase holoenzyme complex,GO:0016604~nuclear body,GO:0070187~shelterin complex,	GO:0005515~protein binding,GO:0042162~telomeric DNA binding,GO:0044877~macromolecular complex binding,GO:0070182~DNA polymerase binding,	IPR019437:Telomerase holoenzyme, Est3 subunit,		616553~Dyskeratosis congenita, autosomal dominant 6,616553~Dyskeratosis congenita, autosomal recessive 7,				KW-0158~Chromosome,KW-0539~Nucleus,KW-0779~Telomere,	KW-0225~Disease variant,KW-1011~Dyskeratosis congenita,			KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:TPP1,MOTIF:PWI,REGION:Disordered,REGION:Interaction with POT1,
ADAM10	ADAM metallopeptidase domain 10(ADAM10)	Homo sapiens		h_appPathway:Generation of amyloid b-peptide by PS1,		GO:0001701~in utero embryonic development,GO:0006468~protein phosphorylation,GO:0006509~membrane protein ectodomain proteolysis,GO:0007162~negative regulation of cell adhesion,GO:0007219~Notch signaling pathway,GO:0007229~integrin-mediated signaling pathway,GO:0007267~cell-cell signaling,GO:0007283~spermatogenesis,GO:0008284~positive regulation of cell proliferation,GO:0008593~regulation of Notch signaling pathway,GO:0010629~negative regulation of gene expression,GO:0010820~positive regulation of T cell chemotaxis,GO:0016485~protein processing,GO:0022617~extracellular matrix disassembly,GO:0030307~positive regulation of cell growth,GO:0030335~positive regulation of cell migration,GO:0034205~beta-amyloid formation,GO:0034332~adherens junction organization,GO:0034612~response to tumor necrosis factor,GO:0035333~Notch receptor processing, ligand-dependent,GO:0042117~monocyte activation,GO:0042987~amyloid precursor protein catabolic process,GO:0043065~positive regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043312~neutrophil degranulation,GO:0043687~post-translational protein modification,GO:0044267~cellular protein metabolic process,GO:0046931~pore complex assembly,GO:0051089~constitutive protein ectodomain proteolysis,GO:0061001~regulation of dendritic spine morphogenesis,GO:0071157~negative regulation of cell cycle arrest,GO:0090102~cochlea development,GO:0097327~response to antineoplastic agent,GO:1901342~regulation of vasculature development,GO:1901998~toxin transport,GO:1990000~amyloid fibril formation,	GO:0000139~Golgi membrane,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005788~endoplasmic reticulum lumen,GO:0005794~Golgi apparatus,GO:0005798~Golgi-associated vesicle,GO:0005802~trans-Golgi network,GO:0005886~plasma membrane,GO:0005912~adherens junction,GO:0005925~focal adhesion,GO:0008021~synaptic vesicle,GO:0009986~cell surface,GO:0014069~postsynaptic density,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030136~clathrin-coated vesicle,GO:0030424~axon,GO:0030425~dendrite,GO:0035579~specific granule membrane,GO:0043025~neuronal cell body,GO:0043197~dendritic spine,GO:0043231~intracellular membrane-bounded organelle,GO:0045211~postsynaptic membrane,GO:0046930~pore complex,GO:0070062~extracellular exosome,GO:0070821~tertiary granule membrane,GO:0097038~perinuclear endoplasmic reticulum,GO:0097060~synaptic membrane,GO:0097197~tetraspanin-enriched microdomain,GO:0098978~glutamatergic synapse,	GO:0004175~endopeptidase activity,GO:0004222~metalloendopeptidase activity,GO:0005102~receptor binding,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0008237~metallopeptidase activity,GO:0017124~SH3 domain binding,GO:0019901~protein kinase binding,GO:0042803~protein homodimerization activity,GO:0046872~metal ion binding,GO:1902945~metalloendopeptidase activity involved in amyloid precursor protein catabolic process,	IPR001590:Peptidase M12B, ADAM/reprolysin,IPR001762:Blood coagulation inhibitor, Disintegrin,IPR002870:Peptidase M12B, propeptide,IPR024079:Metallopeptidase, catalytic domain,IPR027053:Disintegrin and metalloproteinase domain-containing protein 10,	hsa05010:Alzheimer disease,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,	615537~Reticulate acropigmentation of Kitamura,615590~Alzheimer disease 18, susceptibility to,		SM00050:DISIN,	KW-0914~Notch signaling pathway,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-0966~Cell projection,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,	KW-0026~Alzheimer disease,KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-1008~Amyloidosis,	KW-0729~SH3-binding,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Pro residues,DOMAIN:Disintegrin,DOMAIN:Pep_M12B_propep,DOMAIN:Peptidase M12B,METAL:Zinc; in inhibited form,METAL:Zinc; via tele nitrogen; catalytic,MOTIF:Cysteine switch,MOTIF:SH3-binding,MUTAGEN:E->A: Abrogates APP cleavage. Reduces Notch signaling. Loss of proteolytic activity.,REGION:Disordered,REGION:Interaction with AP2A1, AP2A2 and AP2M1,SITE:Cleavage; by furin and PCSK7,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ARFIP2	ADP ribosylation factor interacting protein 2(ARFIP2)	Homo sapiens		h_rac1Pathway:Rac 1 cell motility signaling pathway,		GO:0000423~macromitophagy,GO:0006886~intracellular protein transport,GO:0006914~autophagy,GO:0007264~small GTPase mediated signal transduction,GO:0030032~lamellipodium assembly,GO:0030036~actin cytoskeleton organization,GO:0031529~ruffle organization,GO:0034315~regulation of Arp2/3 complex-mediated actin nucleation,GO:0034497~protein localization to pre-autophagosomal structure,	GO:0001726~ruffle,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005938~cell cortex,GO:0032588~trans-Golgi network membrane,	GO:0005515~protein binding,GO:0005525~GTP binding,GO:0005543~phospholipid binding,GO:0019904~protein domain specific binding,GO:0030742~GTP-dependent protein binding,GO:0031267~small GTPase binding,GO:0042802~identical protein binding,GO:0045296~cadherin binding,GO:0070273~phosphatidylinositol-4-phosphate binding,	IPR010504:Arfaptin homology (AH) domain,IPR027267:Arfaptin homology (AH) domain/BAR domain,				SM01015:SM01015,	KW-0072~Autophagy,	KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:AH,MUTAGEN:W->A: Abolished ability to regulate ATG9A trafficking.,REGION:Disordered,
ARL4C	ADP ribosylation factor like GTPase 4C(ARL4C)	Homo sapiens				GO:0006886~intracellular protein transport,GO:0016192~vesicle-mediated transport,GO:0030522~intracellular receptor signaling pathway,GO:0032456~endocytic recycling,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0030175~filopodium,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0043014~alpha-tubulin binding,	IPR005225:Small GTP-binding protein domain,IPR006689:Small GTPase superfamily, ARF/SAR type,IPR027417:P-loop containing nucleoside triphosphate hydrolase,					KW-0813~Transport,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0175~Coiled coil,	KW-0342~GTP-binding,KW-0547~Nucleotide-binding,		KW-0449~Lipoprotein,KW-0519~Myristate,	LIPID:N-myristoyl glycine,MUTAGEN:G->A: Cytoplasmic localization.,MUTAGEN:K->N: Cytoplasmic localization. Increases GDP-form.,MUTAGEN:Q->L: Does not interact with alpha tubulin. Activates transferrin transport from early endosome to recycling endosome.,MUTAGEN:T->N: Does not interact with alpha tubulin.,NP_BIND:GTP,
AKT1	AKT serine/threonine kinase 1(AKT1)	Homo sapiens	104.Insulin_signaling,105.Signaling_glucose_uptake,106.Glycogen_synthase-synthesis,107.mRNA_translation-protein_synthesis,108.Regulating_glucose_transport,37.Akt-PKB_Effector_of_P13K_in_Vivo,83.Growth_factors_Survival_factors_Mitogens,	h_achPathway:Role of nicotinic acetylcholine receptors in the regulation of apoptosis,h_aktPathway:AKT Signaling Pathway,h_badPathway:Regulation of BAD phosphorylation,h_bcellsurvivalPathway:B Cell Survival Pathway,h_chemicalPathway:Apoptotic Signaling in Response to DNA Damage,h_crebPathway:Transcription factor CREB and its extracellular signals,h_edg1Pathway:Phospholipids as signalling intermediaries,h_eif4Pathway:Regulation of eIF4e and p70 S6 Kinase,h_erk5Pathway:Role of Erk5 in Neuronal Survival,h_gcrpathway:Corticosteroids and cardioprotection,h_gleevecPathway:Inhibition of Cellular Proliferation by Gleevec,H_gsk3Pathway:Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar Macrophages,h_hcmvPathway:Human Cytomegalovirus and Map Kinase Pathways,h_hdacPathway:Control of skeletal myogenesis by HDAC & calcium/calmodulin-dependent kinase (CaMK),h_igf1mtorPathway:Skeletal muscle hypertrophy is regulated via AKT/mTOR pathway,h_igf1rPathway:Multiple antiapoptotic pathways from IGF-1R signaling lead to BAD phosphorylation,h_il2rbPathway:IL-2 Receptor Beta Chain in T cell Activation,h_il4Pathway:IL 4 signaling pathway,h_longevityPathway:The IGF-1 Receptor and Longevity,h_mtorPathway:mTOR Signaling Pathway,h_nfatPathway:NFAT and Hypertrophy of the heart (Transcription in the broken heart),h_no1Pathway:Actions of Nitric Oxide in the Heart,h_p53hypoxiaPathway:Hypoxia and p53 in the Cardiovascular system,h_plcPathway:Phospholipase C Signaling Pathway,h_ptdinsPathway:Phosphoinositides and their downstream targets.,h_ptenPathway:PTEN dependent cell cycle arrest and apoptosis,h_raccycdPathway:Influence of Ras and Rho proteins on G1 to S Transition,h_rasPathway:Ras Signaling Pathway,h_telPathway:Telomeres, Telomerase, Cellular Aging, and  Immortality,h_tffPathway:Trefoil Factors Initiate  Mucosal Healing,h_trkaPathway:Trka Receptor Signaling Pathway,		GO:0001649~osteoblast differentiation,GO:0001893~maternal placenta development,GO:0001934~positive regulation of protein phosphorylation,GO:0001938~positive regulation of endothelial cell proliferation,GO:0002042~cell migration involved in sprouting angiogenesis,GO:0002931~response to ischemia,GO:0003376~sphingosine-1-phosphate signaling pathway,GO:0005978~glycogen biosynthetic process,GO:0005979~regulation of glycogen biosynthetic process,GO:0006006~glucose metabolic process,GO:0006412~translation,GO:0006417~regulation of translation,GO:0006468~protein phosphorylation,GO:0006469~negative regulation of protein kinase activity,GO:0006606~protein import into nucleus,GO:0006809~nitric oxide biosynthetic process,GO:0006924~activation-induced cell death of T cells,GO:0006954~inflammatory response,GO:0006974~cellular response to DNA damage stimulus,GO:0006979~response to oxidative stress,GO:0007165~signal transduction,GO:0007173~epidermal growth factor receptor signaling pathway,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007249~I-kappaB kinase/NF-kappaB signaling,GO:0007281~germ cell development,GO:0007568~aging,GO:0008283~cell proliferation,GO:0008284~positive regulation of cell proliferation,GO:0008286~insulin receptor signaling pathway,GO:0008637~apoptotic mitochondrial changes,GO:0008643~carbohydrate transport,GO:0009408~response to heat,GO:0010467~gene expression,GO:0010507~negative regulation of autophagy,GO:0010595~positive regulation of endothelial cell migration,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0010748~negative regulation of plasma membrane long-chain fatty acid transport,GO:0010761~fibroblast migration,GO:0010763~positive regulation of fibroblast migration,GO:0010765~positive regulation of sodium ion transport,GO:0010907~positive regulation of glucose metabolic process,GO:0010918~positive regulation of mitochondrial membrane potential,GO:0010951~negative regulation of endopeptidase activity,GO:0010975~regulation of neuron projection development,GO:0014065~phosphatidylinositol 3-kinase signaling,GO:0016242~negative regulation of macroautophagy,GO:0016310~phosphorylation,GO:0016567~protein ubiquitination,GO:0018105~peptidyl-serine phosphorylation,GO:0018107~peptidyl-threonine phosphorylation,GO:0019221~cytokine-mediated signaling pathway,GO:0021510~spinal cord development,GO:0030030~cell projection organization,GO:0030154~cell differentiation,GO:0030163~protein catabolic process,GO:0030212~hyaluronan metabolic process,GO:0030307~positive regulation of cell growth,GO:0030334~regulation of cell migration,GO:0031295~T cell costimulation,GO:0031397~negative regulation of protein ubiquitination,GO:0031641~regulation of myelination,GO:0031663~lipopolysaccharide-mediated signaling pathway,GO:0031929~TOR signaling,GO:0031999~negative regulation of fatty acid beta-oxidation,GO:0032079~positive regulation of endodeoxyribonuclease activity,GO:0032091~negative regulation of protein binding,GO:0032094~response to food,GO:0032148~activation of protein kinase B activity,GO:0032270~positive regulation of cellular protein metabolic process,GO:0032287~peripheral nervous system myelin maintenance,GO:0032436~positive regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0032869~cellular response to insulin stimulus,GO:0032929~negative regulation of superoxide anion generation,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0034405~response to fluid shear stress,GO:0034614~cellular response to reactive oxygen species,GO:0035556~intracellular signal transduction,GO:0035655~interleukin-18-mediated signaling pathway,GO:0035924~cellular response to vascular endothelial growth factor stimulus,GO:0036294~cellular response to decreased oxygen levels,GO:0038061~NIK/NF-kappaB signaling,GO:0042593~glucose homeostasis,GO:0042981~regulation of apoptotic process,GO:0043065~positive regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043154~negative regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0043276~anoikis,GO:0043488~regulation of mRNA stability,GO:0043491~protein kinase B signaling,GO:0043536~positive regulation of blood vessel endothelial cell migration,GO:0045429~positive regulation of nitric oxide biosynthetic process,GO:0045600~positive regulation of fat cell differentiation,GO:0045725~positive regulation of glycogen biosynthetic process,GO:0045737~positive regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0045742~positive regulation of epidermal growth factor receptor signaling pathway,GO:0045746~negative regulation of Notch signaling pathway,GO:0045792~negative regulation of cell size,GO:0045861~negative regulation of proteolysis,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045907~positive regulation of vasoconstriction,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046146~tetrahydrobiopterin metabolic process,GO:0046326~positive regulation of glucose import,GO:0046329~negative regulation of JNK cascade,GO:0046622~positive regulation of organ growth,GO:0046777~protein autophosphorylation,GO:0046889~positive regulation of lipid biosynthetic process,GO:0048009~insulin-like growth factor receptor signaling pathway,GO:0048266~behavioral response to pain,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0050999~regulation of nitric-oxide synthase activity,GO:0051000~positive regulation of nitric-oxide synthase activity,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0051146~striated muscle cell differentiation,GO:0051898~negative regulation of protein kinase B signaling,GO:0060079~excitatory postsynaptic potential,GO:0060416~response to growth hormone,GO:0060644~mammary gland epithelial cell differentiation,GO:0060709~glycogen cell differentiation involved in embryonic placenta development,GO:0060716~labyrinthine layer blood vessel development,GO:0070141~response to UV-A,GO:0070848~response to growth factor,GO:0071260~cellular response to mechanical stimulus,GO:0071276~cellular response to cadmium ion,GO:0071356~cellular response to tumor necrosis factor,GO:0071364~cellular response to epidermal growth factor stimulus,GO:0071380~cellular response to prostaglandin E stimulus,GO:0071407~cellular response to organic cyclic compound,GO:0071456~cellular response to hypoxia,GO:0071901~negative regulation of protein serine/threonine kinase activity,GO:0072655~establishment of protein localization to mitochondrion,GO:0072656~maintenance of protein location in mitochondrion,GO:0090201~negative regulation of release of cytochrome c from mitochondria,GO:0097011~cellular response to granulocyte macrophage colony-stimulating factor stimulus,GO:0097194~execution phase of apoptosis,GO:0100002~negative regulation of protein kinase activity by protein phosphorylation,GO:1900087~positive regulation of G1/S transition of mitotic cell cycle,GO:1900182~positive regulation of protein localization to nucleus,GO:1901215~negative regulation of neuron death,GO:1901796~regulation of signal transduction by p53 class mediator,GO:1902176~negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway,GO:1903038~negative regulation of leukocyte cell-cell adhesion,GO:1903078~positive regulation of protein localization to plasma membrane,GO:1903715~regulation of aerobic respiration,GO:1903721~positive regulation of I-kappaB phosphorylation,GO:1990090~cellular response to nerve growth factor stimulus,GO:1990418~response to insulin-like growth factor stimulus,GO:2000010~positive regulation of protein localization to cell surface,GO:2000074~regulation of type B pancreatic cell development,GO:2000402~negative regulation of lymphocyte migration,GO:2001240~negative regulation of extrinsic apoptotic signaling pathway in absence of ligand,GO:2001243~negative regulation of intrinsic apoptotic signaling pathway,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005819~spindle,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0015630~microtubule cytoskeleton,GO:0030027~lamellipodium,GO:0031234~extrinsic component of cytoplasmic side of plasma membrane,GO:0031982~vesicle,GO:0032991~macromolecular complex,GO:0036064~ciliary basal body,GO:0098794~postsynapse,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005080~protein kinase C binding,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0005524~ATP binding,GO:0005547~phosphatidylinositol-3,4,5-trisphosphate binding,GO:0016301~kinase activity,GO:0019899~enzyme binding,GO:0019901~protein kinase binding,GO:0030235~nitric-oxide synthase regulator activity,GO:0032794~GTPase activating protein binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0043325~phosphatidylinositol-3,4-bisphosphate binding,GO:0051721~protein phosphatase 2A binding,GO:0071889~14-3-3 protein binding,GO:0099104~potassium channel activator activity,	IPR000719:Protein kinase, catalytic domain,IPR000961:AGC-kinase, C-terminal,IPR001849:Pleckstrin homology domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR011993:Pleckstrin homology-like domain,IPR017441:Protein kinase, ATP binding site,IPR017892:Protein kinase, C-terminal,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa01522:Endocrine resistance,hsa01524:Platinum drug resistance,hsa04010:MAPK signaling pathway,hsa04012:ErbB signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04062:Chemokine signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04068:FoxO signaling pathway,hsa04071:Sphingolipid signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04140:Autophagy - animal,hsa04150:mTOR signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04152:AMPK signaling pathway,hsa04210:Apoptosis,hsa04211:Longevity regulating pathway,hsa04213:Longevity regulating pathway - multiple species,hsa04218:Cellular senescence,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04370:VEGF signaling pathway,hsa04371:Apelin signaling pathway,hsa04380:Osteoclast differentiation,hsa04510:Focal adhesion,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04611:Platelet activation,hsa04613:Neutrophil extracellular trap formation,hsa04620:Toll-like receptor signaling pathway,hsa04625:C-type lectin receptor signaling pathway,hsa04630:JAK-STAT signaling pathway,hsa04660:T cell receptor signaling pathway,hsa04662:B cell receptor signaling pathway,hsa04664:Fc epsilon RI signaling pathway,hsa04666:Fc gamma R-mediated phagocytosis,hsa04668:TNF signaling pathway,hsa04722:Neurotrophin signaling pathway,hsa04725:Cholinergic synapse,hsa04728:Dopaminergic synapse,hsa04910:Insulin signaling pathway,hsa04914:Progesterone-mediated oocyte maturation,hsa04915:Estrogen signaling pathway,hsa04917:Prolactin signaling pathway,hsa04919:Thyroid hormone signaling pathway,hsa04920:Adipocytokine signaling pathway,hsa04922:Glucagon signaling pathway,hsa04923:Regulation of lipolysis in adipocytes,hsa04926:Relaxin signaling pathway,hsa04929:GnRH secretion,hsa04931:Insulin resistance,hsa04932:Non-alcoholic fatty liver disease,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04935:Growth hormone synthesis, secretion and action,hsa04936:Alcoholic liver disease,hsa04973:Carbohydrate digestion and absorption,hsa05010:Alzheimer disease,hsa05017:Spinocerebellar ataxia,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05135:Yersinia infection,hsa05142:Chagas disease,hsa05145:Toxoplasmosis,hsa05152:Tuberculosis,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05210:Colorectal cancer,hsa05211:Renal cell carcinoma,hsa05212:Pancreatic cancer,hsa05213:Endometrial cancer,hsa05214:Glioma,hsa05215:Prostate cancer,hsa05218:Melanoma,hsa05220:Chronic myeloid leukemia,hsa05221:Acute myeloid leukemia,hsa05222:Small cell lung cancer,hsa05223:Non-small cell lung cancer,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,hsa05230:Central carbon metabolism in cancer,hsa05231:Choline metabolism in cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05415:Diabetic cardiomyopathy,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,	114480~Breast cancer, somatic,114500~Colorectal cancer, somatic,167000~Ovarian cancer, somatic,176920~Proteus syndrome, somatic,615109~Cowden syndrome 6,		SM00133:S_TK_X,SM00220:S_TKc,SM00233:PH,	KW-0053~Apoptosis,KW-0119~Carbohydrate metabolism,KW-0313~Glucose metabolism,KW-0320~Glycogen biosynthesis,KW-0321~Glycogen metabolism,KW-0524~Neurogenesis,KW-0762~Sugar transport,KW-0810~Translation regulation,KW-0813~Transport,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0656~Proto-oncogene,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0217~Developmental protein,KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	ACT_SITE:Proton acceptor,BINDING:(2S)-2-(4-chlorobenzyl)-3-oxo-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperazin-1-yl]propan-1-amine; inhibitor,BINDING:(2S)-2-(4-chlorobenzyl)-3-oxo-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperazin-1-yl]propan-1-amine; inhibitor; via carbonyl oxygen,BINDING:5-(5-chloro-1H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine; inhibitor,BINDING:ATP,BINDING:Inositol-(1,3,4,5)-tetrakisphosphate,CARBOHYD:O-linked (GlcNAc) serine; alternate,CARBOHYD:O-linked (GlcNAc) threonine,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:AGC-kinase C-terminal,DOMAIN:PH,DOMAIN:Protein kinase,MUTAGEN:E->K: No effect on membrane localization. Loss of membrane localization; when associated with Q-20.,MUTAGEN:K->A: Impairs interaction with PtdIns(3,4,5)P3 and PtdIns(3,4)P2.,MUTAGEN:K->Q: Substantial reduction of phosphorylation at T-308 and S-473, loss of AKT activation, and loss of binding to PIP3 as well as IGF1-induced membrane recruitment.,MUTAGEN:K->Q: Substantial reduction of phosphorylation at T-308 and S-473, reduced AKT activation, and reduced binding to PIP3 as well as IGF1-induced membrane recruitment. Loss of membrane localization; when associated with K-17.,MUTAGEN:K->R: Slight increase of phosphorylation at T-308 and S-473.,MUTAGEN:K->R: Substantial reduction of ubiquitination, phosphorylation at T-308 and S-473, AKT activation as well as IGF1-induced membrane recruitment. Decrease in ubiquitination and phosphorylation at T-308 as well as impaired association with the membrane; when associated with K-17.,MUTAGEN:K->R: Substantial reduction of ubiquitination, phosphorylation at T-308 and S-473, AKT activation, loss of binding to PIP3 as well as IGF1-induced membrane recruitment.,MUTAGEN:R->A,C: Impairs interaction with PtdIns(3,4,5)P3 and PtdIns(3,4)P2.,MUTAGEN:R->A: Impairs interaction with PtdIns(3,4,5)P3 and PtdIns(3,4)P2.,MUTAGEN:S->D: 7-fold activation and 25-fold activation; when associated with D-308.,MUTAGEN:T->A: Reduces O-GlcNAc levels; Reduces O-GlcNAc levels even more; when associated with A-305.,MUTAGEN:T->A: Reduces O-GlcNAc levels; Reduces O-GlcNAc levels even more; when associated with A-312.,MUTAGEN:T->D: 5-fold activation and 18-fold activation; when associated with D-473.,MUTAGEN:T->Y: Abolishes phosphorylation at Thr-308.,MUTAGEN:Y->F: 55% inhibition of activation.,MUTAGEN:Y->F: Significant loss of interaction with TNK2. Loss of membrane localization. Significant reduction in phosphorylation on Ser-473.,NP_BIND:ATP,REGION:(2S)-2-(4-chlorobenzyl)-3-oxo-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperazin-1-yl]propan-1-amine binding; inhibitor,REGION:5-(5-chloro-1H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine binding; inhibitor,REGION:Disordered,REGION:Inositol-(1,3,4,5)-tetrakisphosphate binding,SITE:Cleavage; by caspase-3,
ARID4B	AT-rich interaction domain 4B(ARID4B)	Homo sapiens				GO:0006325~chromatin organization,GO:0006349~regulation of gene expression by genetic imprinting,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007283~spermatogenesis,GO:0034773~histone H4-K20 trimethylation,GO:0036124~histone H3-K9 trimethylation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0097368~establishment of Sertoli cell barrier,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0003677~DNA binding,GO:0005515~protein binding,	IPR001606:ARID/BRIGHT DNA-binding domain,IPR002999:Tudor domain,IPR012603:RBB1NT,IPR016197:Chromo domain-like,IPR025995:RNA binding activity-knot of a chromodomain,				SM00333:TUDOR,SM00501:BRIGHT,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,		KW-0156~Chromatin regulator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:ARID,REGION:Antigenic epitope,REGION:Disordered,
ARID5B	AT-rich interaction domain 5B(ARID5B)	Homo sapiens				GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001822~kidney development,GO:0001889~liver development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006807~nitrogen compound metabolic process,GO:0008584~male gonad development,GO:0008585~female gonad development,GO:0009791~post-embryonic development,GO:0010761~fibroblast migration,GO:0030325~adrenal gland development,GO:0035264~multicellular organism growth,GO:0045444~fat cell differentiation,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0048008~platelet-derived growth factor receptor signaling pathway,GO:0048468~cell development,GO:0048644~muscle organ morphogenesis,GO:0048705~skeletal system morphogenesis,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0060021~palate development,GO:0060325~face morphogenesis,GO:0060612~adipose tissue development,GO:0060613~fat pad development,GO:1990830~cellular response to leukemia inhibitory factor,	GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003713~transcription coactivator activity,GO:0005515~protein binding,	IPR001606:ARID/BRIGHT DNA-binding domain,				SM00501:BRIGHT,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,KW-0238~DNA-binding,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:ARID,MUTAGEN:K->A,R: Abolishes methylation and FSK-dependent DNA-binding of the PHF2-ARID5B complex to promoters.,REGION:Disordered,
ATMIN	ATM interactor(ATMIN)	Homo sapiens				GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006974~cellular response to DNA damage stimulus,GO:0010628~positive regulation of gene expression,GO:0044458~motile cilium assembly,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:1902857~positive regulation of non-motile cilium assembly,	GO:0005634~nucleus,GO:0016604~nuclear body,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0005515~protein binding,GO:0046872~metal ion binding,GO:0070840~dynein complex binding,	IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,				SM00355:ZnF_C2H2,	KW-0227~DNA damage,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,REGION:Required for formation of RAD51 foci,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2; degenerate,
ABCB6	ATP binding cassette subfamily B member 6 (Langereis blood group)(ABCB6)	Homo sapiens			Posttranslational modification, protein turnover, chaperones,	GO:0006778~porphyrin-containing compound metabolic process,GO:0006779~porphyrin-containing compound biosynthetic process,GO:0006878~cellular copper ion homeostasis,GO:0006879~cellular iron ion homeostasis,GO:0007420~brain development,GO:0015886~heme transport,GO:0033013~tetrapyrrole metabolic process,GO:0035351~heme transmembrane transport,GO:0042168~heme metabolic process,GO:0043588~skin development,GO:0055085~transmembrane transport,GO:0098849~cellular detoxification of cadmium ion,GO:1903232~melanosome assembly,	GO:0000139~Golgi membrane,GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0005740~mitochondrial envelope,GO:0005741~mitochondrial outer membrane,GO:0005765~lysosomal membrane,GO:0005768~endosome,GO:0005774~vacuolar membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0031307~integral component of mitochondrial outer membrane,GO:0031901~early endosome membrane,GO:0032585~multivesicular body membrane,GO:0033162~melanosome membrane,GO:0036020~endolysosome membrane,GO:0043190~ATP-binding cassette (ABC) transporter complex,GO:0070062~extracellular exosome,	GO:0005524~ATP binding,GO:0015439~heme-transporting ATPase activity,GO:0015562~efflux transmembrane transporter activity,GO:0016887~ATPase activity,GO:0020037~heme binding,GO:0042626~ATPase activity, coupled to transmembrane movement of substances,GO:0046906~tetrapyrrole binding,	IPR003439:ABC transporter-like,IPR003593:AAA+ ATPase domain,IPR011527:ABC transporter, transmembrane domain, type 1,IPR017871:ABC transporter, conserved site,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa02010:ABC transporters,	111600~Blood group, Langereis system,609153~Pseudohyperkalemia, familial, 2, due to red cell leak,614497~Microphthalmia, isolated, with coloboma 7,615402~Dyschromatosis universalis hereditaria 3,		SM00382:AAA,	KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0458~Lysosome,KW-0472~Membrane,KW-0496~Mitochondrion,KW-0964~Secreted,KW-0967~Endosome,KW-1000~Mitochondrion outer membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-1011~Dyskeratosis congenita,KW-1013~Microphthalmia,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-1278~Translocase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	BINDING:ATP,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:ABC transmembrane type-1,DOMAIN:ABC transporter,DOMAIN:MTABC_N,MUTAGEN:C->A: Decreases protein expression. Affects protein stability. Loss of ability to stimulate porphyrin synthesis.,MUTAGEN:C->A: Increases migration in the absence of DTT; when associated with A-120. Reduces migration in with the presence of DTT; when associated with A-120.,MUTAGEN:C->A: Increases migration in the absence of DTT; when associated with A-50. Reduces migration in with the presence of DTT; when associated with A-50.,MUTAGEN:C->G: Loss of N-glycosylation.,MUTAGEN:C->S: Decreases protein expression. Impairs endoplasmic reticulum exit; when associated with C-8. Affects protein stability.,MUTAGEN:C->S: Does not affect subtrate binding. Does not affect N-glycosylation. Impairs endoplasmic reticulum exit. Impairs endoplasmic reticulum exit; when associated with C-8. Increases ABCB6 proteasomal degradation. Affects protein stability. Does not affect migration in the presence of DTT; when associated with A-50 and A-120.,MUTAGEN:K->A: Abolishes ATP hydrolysis. Abolishes coproporphyrin III transport.,MUTAGEN:K->M: Does not affect sucellular location in early melanosome and lysosome. Does not rescue the normal amyloid fibril formation and normal maturation of pigmented melanosomes. Does not influence trafficking of melanosomal proteins. Fails to rescue vacuolar sequestration of cadmium in Schizosaccharomyces pombe and Caenorhabditis elegans strains defective for HMT-1. Fails to rescue the cadmium tolerance in Schizosaccharomyces pombe and Caenorhabditis elegans strains defective for HMT-1. Does not rescue vacuolar cadmium levels in hmt-1 mutant S. pombe.,MUTAGEN:M->A: Loss of substrate-stimulate ATPase activity.,MUTAGEN:N->Q: Does not affect N-glycosylation. Does not affect N-glycosylation; when associated with Q-447; Q-498 and Q-677. Does not affect trafficking from endoplasmic reticulum; when associated with Q-447; Q-498 and Q-677.,MUTAGEN:N->Q: Does not affect N-glycosylation. Does not affect N-glycosylation; when associated with Q-447; Q-498; and Q-775. Does not affect trafficking from endoplasmic reticulum; when associated with Q-447; Q-498; and Q-775.,MUTAGEN:N->Q: Does not affect N-glycosylation. Does not affect N-glycosylation; when associated with Q-447; Q-677 and Q-775. Does not affect trafficking from endoplasmic reticulum; when associated with Q-447; Q-677 and Q-775.,MUTAGEN:N->Q: Does not affect N-glycosylation. Does not affect N-glycosylation; when associated with Q-498; Q-677 and Q-775. Does not affect trafficking from endoplasmic reticulum; when associated with Q-498; Q-677 and Q-775.,MUTAGEN:N->Q: Loss of N-glycosylation. Loss of N-glycosylation; when associated with Q-447; Q-498; Q-677 and Q-775. Does not affect subtrate binding.,MUTAGEN:V->A: Loss of substrate-stimulate ATPase activity. Impairs protein expression.,MUTAGEN:W->A: Loss of substrate-stimulate ATPase activity. Impairs protein expression.,MUTAGEN:W->F: Does not affect substrate-stimulate ATPase activity.,MUTAGEN:W->V: Loss of substrate-stimulate ATPase activity. Impairs protein expression.,MUTAGEN:Y->A: Loss of substrate-stimulate ATPase activity. Impairs protein expression.,NP_BIND:ATP,REGION:Required for ATPase activity,REGION:Required for the lysosomal targeting,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
ABCC5	ATP binding cassette subfamily C member 5(ABCC5)	Homo sapiens			Defense mechanisms,	GO:0015698~inorganic anion transport,GO:0015865~purine nucleotide transport,GO:0030213~hyaluronan biosynthetic process,GO:0034775~glutathione transmembrane transport,GO:0035351~heme transmembrane transport,GO:0042908~xenobiotic transport,GO:0055085~transmembrane transport,GO:0070730~cAMP transport,GO:0070731~cGMP transport,GO:0098838~reduced folate transmembrane transport,	GO:0005796~Golgi lumen,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,	GO:0005524~ATP binding,GO:0008514~organic anion transmembrane transporter activity,GO:0008559~xenobiotic-transporting ATPase activity,GO:0015216~purine nucleotide transmembrane transporter activity,GO:0015232~heme transporter activity,GO:0015562~efflux transmembrane transporter activity,GO:0034634~glutathione transmembrane transporter activity,GO:0042626~ATPase activity, coupled to transmembrane movement of substances,GO:0042910~xenobiotic transporter activity,GO:0043225~ATPase-coupled anion transmembrane transporter activity,	IPR003439:ABC transporter-like,IPR003593:AAA+ ATPase domain,IPR011527:ABC transporter, transmembrane domain, type 1,IPR017871:ABC transporter, conserved site,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa01523:Antifolate resistance,hsa02010:ABC transporters,			SM00382:AAA,	KW-0813~Transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-1278~Translocase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:ABC transmembrane type-1,DOMAIN:ABC transmembrane type-1 1,DOMAIN:ABC transmembrane type-1 2,DOMAIN:ABC transporter 1,DOMAIN:ABC transporter 2,NP_BIND:ATP 1,NP_BIND:ATP 2,REGION:Disordered,TRANSMEM:Helical,
ABCF1	ATP binding cassette subfamily F member 1(ABCF1)	Homo sapiens			General function prediction only,	GO:0006412~translation,GO:0006413~translational initiation,GO:0006954~inflammatory response,GO:0045727~positive regulation of translation,GO:0055085~transmembrane transport,	GO:0005635~nuclear envelope,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0016020~membrane,GO:0042788~polysomal ribosome,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008135~translation factor activity, RNA binding,GO:0008494~translation activator activity,GO:0042626~ATPase activity, coupled to transmembrane movement of substances,GO:0043022~ribosome binding,	IPR003439:ABC transporter-like,IPR003593:AAA+ ATPase domain,IPR017871:ABC transporter, conserved site,IPR027417:P-loop containing nucleoside triphosphate hydrolase,				SM00382:AAA,		KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0010~Activator,	KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,DOMAIN:ABC transporter,DOMAIN:ABC transporter 1,DOMAIN:ABC transporter 2,MUTAGEN:E->Q: Does not inhibit ribosome binding. Reduces protein synthesis; when associated with Q-477.,MUTAGEN:E->Q: Does not inhibit ribosome binding. Reduces protein synthesis; when associated with Q-768.,MUTAGEN:G->D: Does not inhibit ribosome binding.,MUTAGEN:H->L: Does not inhibit ribosome binding.,MUTAGEN:K->M: Does not inhibit ribosome binding. Reduces ATP-binding. Inhibits ATP-binding and reduces protein synthesis; when associated with M-342. Shows a reduced association with polyribosomes; when associated with M-664. Does not inhibit IRES-mediated protein synthesis; when associated with M-664.,MUTAGEN:K->M: Does not inhibit ribosome binding. Reduces ATP-binding. Inhibits ATP-binding and reduces protein synthesis; when associated with M-664. Shows an enhanced association with polyribosomes; when associated with M-664. Does not inhibit IRES-mediated protein synthesis; when associated with M-664.,MUTAGEN:Q->E: Does not inhibit ribosome binding.,MUTAGEN:S->A: Reduces phosphorylation. Inhibits strongly phosphorylation by CK2; when associated with S-109. Does not inhibits interaction with EIF2; when associated with S-109. Does not inhibit association with ribosomes; when associated with S-109. Reduces EIF2 interaction with ribosomes; when associated with S-109. Does not inhibit protein synthesis; when associated with A-109.,MUTAGEN:S->A: Reduces phosphorylation. Inhibits strongly phosphorylation by CK2; when associated with S-140. Does not inhibit interaction with EIF2; when associated with S-140. Does not inhibit association with ribosomes; when associated with S-140. Reduces EIF2 interaction with ribosomes; when associated with S-140. Does not inhibit protein synthesis; when associated with A-140.,NP_BIND:ATP,NP_BIND:ATP 1,NP_BIND:ATP 2,REGION:Disordered,
ABCF3	ATP binding cassette subfamily F member 3(ABCF3)	Homo sapiens			General function prediction only,	GO:0051607~defense response to virus,	GO:0016020~membrane,	GO:0005515~protein binding,GO:0005524~ATP binding,GO:0042626~ATPase activity, coupled to transmembrane movement of substances,GO:0045296~cadherin binding,	IPR003439:ABC transporter-like,IPR003593:AAA+ ATPase domain,IPR017871:ABC transporter, conserved site,IPR027417:P-loop containing nucleoside triphosphate hydrolase,				SM00382:AAA,	KW-0051~Antiviral defense,			KW-0677~Repeat,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:ABC transporter,DOMAIN:ABC transporter 1,DOMAIN:ABC transporter 2,NP_BIND:ATP,NP_BIND:ATP 1,NP_BIND:ATP 2,REGION:Disordered,
ACLY	ATP citrate lyase(ACLY)	Homo sapiens		h_malatexPathway:Shuttle for transfer of acetyl groups from mitochondria to the cytosol,	Energy production and conversion,	GO:0006085~acetyl-CoA biosynthetic process,GO:0006101~citrate metabolic process,GO:0006107~oxaloacetate metabolic process,GO:0006629~lipid metabolic process,GO:0006633~fatty acid biosynthetic process,GO:0006695~cholesterol biosynthetic process,GO:0008610~lipid biosynthetic process,GO:0015936~coenzyme A metabolic process,GO:0031325~positive regulation of cellular metabolic process,GO:0043312~neutrophil degranulation,GO:0046949~fatty-acyl-CoA biosynthetic process,	GO:0005576~extracellular region,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0035578~azurophil granule lumen,GO:0070062~extracellular exosome,GO:1904813~ficolin-1-rich granule lumen,	GO:0003878~ATP citrate synthase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016829~lyase activity,GO:0046872~metal ion binding,	IPR002020:Citrate synthase-like,IPR003781:CoA-binding,IPR005811:ATP-citrate lyase/succinyl-CoA ligase,IPR014608:ATP-citrate synthase,IPR016102:Succinyl-CoA synthetase-like,IPR016142:Citrate synthase-like, large alpha subdomain,IPR016143:Citrate synthase-like, small alpha subdomain,IPR017440:ATP-citrate lyase/succinyl-CoA ligase, active site,IPR017866:Succinyl-CoA synthetase, beta subunit, conserved site,	hsa00020:Citrate cycle (TCA cycle),hsa01100:Metabolic pathways,		PIRSF036511:ATP citrate synthase, fused large and small subunits,	SM00881:SM00881,	KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,	KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0456~Lyase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Tele-phosphohistidine intermediate,BINDING:ATP,BINDING:Citrate,BINDING:Citrate; via amide nitrogen,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate,DOMAIN:ATP-grasp,DOMAIN:Citrate_bind,DOMAIN:CoA_binding,METAL:Magnesium,MUTAGEN:H->A: Reduced enzyme activity.,MUTAGEN:K->R,Q: Decreased acetylation and increased de novo lipid synthesis; when associated with R,Q-540 and R,Q-546.,MUTAGEN:K->R,Q: Decreased acetylation and increased de novo lipid synthesis; when associated with R,Q-540 and R,Q-554.,MUTAGEN:K->R,Q: Decreased acetylation and increased de novo lipid synthesis; when associated with R,Q-546 and R,Q-554.,NP_BIND:ATP,REGION:CoA-binding,REGION:Disordered,
ATP6V0B	ATPase H+ transporting V0 subunit b(ATP6V0B)	Homo sapiens				GO:0008286~insulin receptor signaling pathway,GO:0016241~regulation of macroautophagy,GO:0033572~transferrin transport,GO:0034198~cellular response to amino acid starvation,GO:0034220~ion transmembrane transport,GO:0090383~phagosome acidification,GO:1902600~hydrogen ion transmembrane transport,	GO:0000220~vacuolar proton-transporting V-type ATPase, V0 domain,GO:0005765~lysosomal membrane,GO:0005768~endosome,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030670~phagocytic vesicle membrane,GO:0033179~proton-transporting V-type ATPase, V0 domain,	GO:0005215~transporter activity,GO:0005515~protein binding,GO:0015078~hydrogen ion transmembrane transporter activity,GO:0046961~proton-transporting ATPase activity, rotational mechanism,	IPR000245:V-ATPase proteolipid subunit,IPR002379:V-ATPase proteolipid subunit C-like domain,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04142:Lysosome,hsa04145:Phagosome,hsa04721:Synaptic vesicle cycle,hsa05110:Vibrio cholerae infection,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05152:Tuberculosis,hsa05165:Human papillomavirus infection,hsa05323:Rheumatoid arthritis,				KW-0375~Hydrogen ion transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-0926~Vacuole,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				DOMAIN:ATP-synt_C,REGION:Disordered,SITE:Essential for proton translocation,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
ATP6V1D	ATPase H+ transporting V1 subunit D(ATP6V1D)	Homo sapiens				GO:0006811~ion transport,GO:0008286~insulin receptor signaling pathway,GO:0016241~regulation of macroautophagy,GO:0030030~cell projection organization,GO:0033572~transferrin transport,GO:0034198~cellular response to amino acid starvation,GO:0034220~ion transmembrane transport,GO:0043312~neutrophil degranulation,GO:0060271~cilium assembly,GO:0061512~protein localization to cilium,GO:0090383~phagosome acidification,	GO:0000221~vacuolar proton-transporting V-type ATPase, V1 domain,GO:0005765~lysosomal membrane,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005929~cilium,GO:0016020~membrane,GO:0033176~proton-transporting V-type ATPase complex,GO:0035579~specific granule membrane,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0042626~ATPase activity, coupled to transmembrane movement of substances,GO:0046961~proton-transporting ATPase activity, rotational mechanism,	IPR002699:ATPase, V1 complex, subunit D,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04145:Phagosome,hsa04150:mTOR signaling pathway,hsa04721:Synaptic vesicle cycle,hsa04966:Collecting duct acid secretion,hsa05110:Vibrio cholerae infection,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05165:Human papillomavirus infection,hsa05323:Rheumatoid arthritis,				KW-0375~Hydrogen ion transport,KW-0406~Ion transport,KW-0813~Transport,KW-0970~Cilium biogenesis/degradation,	KW-0472~Membrane,		KW-0175~Coiled coil,
ATP1B1	ATPase Na+/K+ transporting subunit beta 1(ATP1B1)	Homo sapiens				GO:0001666~response to hypoxia,GO:0006813~potassium ion transport,GO:0006814~sodium ion transport,GO:0006874~cellular calcium ion homeostasis,GO:0006883~cellular sodium ion homeostasis,GO:0007155~cell adhesion,GO:0010248~establishment or maintenance of transmembrane electrochemical gradient,GO:0010468~regulation of gene expression,GO:0010882~regulation of cardiac muscle contraction by calcium ion signaling,GO:0030007~cellular potassium ion homeostasis,GO:0032781~positive regulation of ATPase activity,GO:0034220~ion transmembrane transport,GO:0035725~sodium ion transmembrane transport,GO:0036376~sodium ion export from cell,GO:0044861~protein transport into plasma membrane raft,GO:0046034~ATP metabolic process,GO:0050821~protein stabilization,GO:0050900~leukocyte migration,GO:0055119~relaxation of cardiac muscle,GO:0060048~cardiac muscle contraction,GO:0072659~protein localization to plasma membrane,GO:0086009~membrane repolarization,GO:0086013~membrane repolarization during cardiac muscle cell action potential,GO:0086064~cell communication by electrical coupling involved in cardiac conduction,GO:0098655~cation transmembrane transport,GO:1901018~positive regulation of potassium ion transmembrane transporter activity,GO:1903278~positive regulation of sodium ion export from cell,GO:1903281~positive regulation of calcium:sodium antiporter activity,GO:1903288~positive regulation of potassium ion import,GO:1903408~positive regulation of sodium:potassium-exchanging ATPase activity,GO:1903779~regulation of cardiac conduction,GO:1990573~potassium ion import across plasma membrane,	GO:0005886~plasma membrane,GO:0005890~sodium:potassium-exchanging ATPase complex,GO:0005901~caveola,GO:0014704~intercalated disc,GO:0016020~membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0016328~lateral plasma membrane,GO:0030315~T-tubule,GO:0031090~organelle membrane,GO:0036126~sperm flagellum,GO:0042383~sarcolemma,GO:0070062~extracellular exosome,GO:1903561~extracellular vesicle,	GO:0001671~ATPase activator activity,GO:0005391~sodium:potassium-exchanging ATPase activity,GO:0005515~protein binding,GO:0008022~protein C-terminus binding,GO:0019901~protein kinase binding,GO:0023026~MHC class II protein complex binding,GO:0030674~protein binding, bridging,GO:0046982~protein heterodimerization activity,GO:0051117~ATPase binding,	IPR000402:Sodium/potassium-transporting ATPase subunit beta,IPR015565:Sodium/potassium-transporting ATPase subunit beta, chordates,	hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04260:Cardiac muscle contraction,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04911:Insulin secretion,hsa04918:Thyroid hormone synthesis,hsa04919:Thyroid hormone signaling pathway,hsa04925:Aldosterone synthesis and secretion,hsa04960:Aldosterone-regulated sodium reabsorption,hsa04961:Endocrine and other factor-regulated calcium reabsorption,hsa04964:Proximal tubule bicarbonate reclamation,hsa04970:Salivary secretion,hsa04971:Gastric acid secretion,hsa04972:Pancreatic secretion,hsa04973:Carbohydrate digestion and absorption,hsa04974:Protein digestion and absorption,hsa04976:Bile secretion,hsa04978:Mineral absorption,	145500~Blood pressure regulation QTL,			KW-0130~Cell adhesion,KW-0406~Ion transport,KW-0633~Potassium transport,KW-0739~Sodium transport,KW-0740~Sodium/potassium transport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0630~Potassium,KW-0915~Sodium,		KW-0318~Glutathionylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:immunoglobulin-like,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
ATP11B	ATPase phospholipid transporting 11B (putative)(ATP11B)	Homo sapiens				GO:0006811~ion transport,GO:0015914~phospholipid transport,GO:0015917~aminophospholipid transport,GO:0034220~ion transmembrane transport,GO:0043312~neutrophil degranulation,GO:0045332~phospholipid translocation,	GO:0005637~nuclear inner membrane,GO:0005769~early endosome,GO:0005783~endoplasmic reticulum,GO:0005802~trans-Golgi network,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0031901~early endosome membrane,GO:0035577~azurophil granule membrane,GO:0055037~recycling endosome,GO:0055038~recycling endosome membrane,GO:1990531~Lem3p-Dnf1p complex,	GO:0000287~magnesium ion binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0015075~ion transmembrane transporter activity,GO:0090555~phosphatidylethanolamine-translocating ATPase activity,GO:0090556~phosphatidylserine-translocating ATPase activity,	IPR001757:Cation-transporting P-type ATPase,IPR006539:Phospholipid-transporting  P-type ATPase, subfamily IV,IPR008250:P-type ATPase, A  domain,IPR018303:P-type ATPase, phosphorylation site,IPR023214:HAD-like domain,IPR023298:P-type ATPase,  transmembrane domain,IPR023299:P-type ATPase, cytoplasmic domain N,					KW-0445~Lipid transport,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0967~Endosome,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-1278~Translocase,	KW-0597~Phosphoprotein,	ACT_SITE:4-aspartylphosphate intermediate,DOMAIN:PhoLip_ATPase_C,DOMAIN:PhoLip_ATPase_N,METAL:Magnesium,MUTAGEN:E->Q: Impairs ATPase activity.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ATP2C1	ATPase secretory pathway Ca2+ transporting 1(ATP2C1)	Homo sapiens				GO:0006816~calcium ion transport,GO:0006828~manganese ion transport,GO:0006874~cellular calcium ion homeostasis,GO:0008544~epidermis development,GO:0016339~calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules,GO:0030026~cellular manganese ion homeostasis,GO:0031532~actin cytoskeleton reorganization,GO:0032468~Golgi calcium ion homeostasis,GO:0032472~Golgi calcium ion transport,GO:0034220~ion transmembrane transport,GO:0042998~positive regulation of Golgi to plasma membrane protein transport,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0070588~calcium ion transmembrane transport,GO:0071421~manganese ion transmembrane transport,GO:0098629~trans-Golgi network membrane organization,	GO:0000139~Golgi membrane,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005802~trans-Golgi network,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030173~integral component of Golgi membrane,GO:0032580~Golgi cisterna membrane,GO:0033106~cis-Golgi network membrane,	GO:0005384~manganese ion transmembrane transporter activity,GO:0005388~calcium-transporting ATPase activity,GO:0005509~calcium ion binding,GO:0005524~ATP binding,GO:0008553~hydrogen-exporting ATPase activity, phosphorylative mechanism,GO:0015410~manganese-transporting ATPase activity,GO:0015662~ATPase activity, coupled to transmembrane movement of ions, phosphorylative mechanism,GO:0016887~ATPase activity,GO:0030145~manganese ion binding,GO:0046872~metal ion binding,	IPR001757:Cation-transporting P-type ATPase,IPR004014:Cation-transporting P-type ATPase, N-terminal,IPR006068:Cation-transporting P-type ATPase, C-terminal,IPR006413:Calcium-transporting P-type ATPase, subfamily IIA, PMR1-type,IPR008250:P-type ATPase, A  domain,IPR018303:P-type ATPase, phosphorylation site,IPR023214:HAD-like domain,IPR023298:P-type ATPase,  transmembrane domain,IPR023299:P-type ATPase, cytoplasmic domain N,		169600~Hailey-Hailey disease,		SM00831:SM00831,	KW-0109~Calcium transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,	KW-0225~Disease variant,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0106~Calcium,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-1278~Translocase,		ACT_SITE:4-aspartylphosphate intermediate,DOMAIN:Cation_ATPase_C,DOMAIN:Cation_ATPase_N,METAL:Calcium 2,METAL:Calcium 2; via carbonyl oxygen,METAL:Magnesium,MUTAGEN:D->A: Decreases calcium-dependent autophosphorylation and the ATPase activity; when associated with A-50.,MUTAGEN:D->A: Impairs pump activity.,MUTAGEN:E->A: Decreases calcium-dependent autophosphorylation and the ATPase activity; when associated with A-41.,MUTAGEN:E->S: Decreases calcium-dependent autophosphorylation.,MUTAGEN:Q->A: Increases manganese transporter activity.,MUTAGEN:Q->C: Decreases calcium-dependent autophosphorylation.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=10,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,TRANSMEM:Helical; Name=8,TRANSMEM:Helical; Name=9,
BCL7B	BAF chromatin remodeling complex subunit BCL7B(BCL7B)	Homo sapiens				GO:0006915~apoptotic process,GO:0016055~Wnt signaling pathway,GO:0030154~cell differentiation,	GO:0016514~SWI/SNF complex,	GO:0003779~actin binding,GO:0005515~protein binding,	IPR006804:BCL7,					KW-0053~Apoptosis,KW-0221~Differentiation,KW-0879~Wnt signaling pathway,		KW-0020~Allergen,KW-0856~Williams-Beuren syndrome,				KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,REGION:Disordered,
BAG3	BAG cochaperone 3(BAG3)	Homo sapiens				GO:0000045~autophagosome assembly,GO:0006457~protein folding,GO:0007420~brain development,GO:0008625~extrinsic apoptotic signaling pathway via death domain receptors,GO:0010664~negative regulation of striated muscle cell apoptotic process,GO:0021510~spinal cord development,GO:0034605~cellular response to heat,GO:0034620~cellular response to unfolded protein,GO:0042307~positive regulation of protein import into nucleus,GO:0043066~negative regulation of apoptotic process,GO:0046716~muscle cell cellular homeostasis,GO:0046827~positive regulation of protein export from nucleus,GO:0050821~protein stabilization,GO:0061684~chaperone-mediated autophagy,GO:0070842~aggresome assembly,GO:0071260~cellular response to mechanical stimulus,GO:0072321~chaperone-mediated protein transport,GO:0097192~extrinsic apoptotic signaling pathway in absence of ligand,GO:0097201~negative regulation of transcription from RNA polymerase II promoter in response to stress,GO:0098840~protein transport along microtubule,GO:1900034~regulation of cellular response to heat,GO:1903215~negative regulation of protein targeting to mitochondrion,GO:1905337~positive regulation of aggrephagy,	GO:0001725~stress fiber,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016235~aggresome,GO:0030018~Z disc,GO:0043005~neuron projection,GO:0101031~chaperone complex,	GO:0000774~adenyl-nucleotide exchange factor activity,GO:0005515~protein binding,GO:0031072~heat shock protein binding,GO:0044877~macromolecular complex binding,GO:0045296~cadherin binding,GO:0045505~dynein intermediate chain binding,GO:0051087~chaperone binding,	IPR001202:WW domain,IPR003103:BAG domain,		612954~Myopathy, myofibrillar, 6,613881~Cardiomyopathy, dilated, 1HH,		SM00264:BAG,SM00456:WW,	KW-0053~Apoptosis,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0122~Cardiomyopathy,KW-0225~Disease variant,KW-1060~Myofibrillar myopathy,	KW-0677~Repeat,		KW-0143~Chaperone,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:BAG,DOMAIN:WW 1,DOMAIN:WW 2,MUTAGEN:RR->AA: Significant loss of interaction with HSPA8.,REGION:Disordered,
BCL2	BCL2 apoptosis regulator(BCL2)	Homo sapiens	127.Mito-stress,152.altered_synaptic_signalling-neurodegenerative_disorders,38.Cell_cycle_arrest_and_apoptosis_ceramide,46.P13K_PTEN,83.Growth_factors_Survival_factors_Mitogens,86.Apoptosis_Nematode&_Vert,99.NF-kB_activation,	h_badPathway:Regulation of BAD phosphorylation,h_ceramidePathway:Ceramide Signaling Pathway,h_chemicalPathway:Apoptotic Signaling in Response to DNA Damage,h_deathPathway:Induction of apoptosis through DR3 and DR4/5 Death Receptors ,h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_hsp27Pathway:Stress Induction of HSP Regulation,h_il2rbPathway:IL-2 Receptor Beta Chain in T cell Activation,h_il7Pathway:IL-7 Signal Transduction,h_keratinocytePathway:Keratinocyte Differentiation,h_melanocytePathway:Melanocyte Development and Pigmentation Pathway,h_mitochondriaPathway:Role of Mitochondria in Apoptotic Signaling,h_p53Pathway:p53 Signaling Pathway,h_prionPathway:Prion Pathway,h_telPathway:Telomeres, Telomerase, Cellular Aging, and  Immortality,		GO:0000209~protein polyubiquitination,GO:0001503~ossification,GO:0001541~ovarian follicle development,GO:0001656~metanephros development,GO:0001658~branching involved in ureteric bud morphogenesis,GO:0001662~behavioral fear response,GO:0001782~B cell homeostasis,GO:0001836~release of cytochrome c from mitochondria,GO:0001952~regulation of cell-matrix adhesion,GO:0002320~lymphoid progenitor cell differentiation,GO:0002326~B cell lineage commitment,GO:0002931~response to ischemia,GO:0003014~renal system process,GO:0006470~protein dephosphorylation,GO:0006582~melanin metabolic process,GO:0006808~regulation of nitrogen utilization,GO:0006915~apoptotic process,GO:0006959~humoral immune response,GO:0006974~cellular response to DNA damage stimulus,GO:0007015~actin filament organization,GO:0007409~axonogenesis,GO:0007565~female pregnancy,GO:0007569~cell aging,GO:0008283~cell proliferation,GO:0008284~positive regulation of cell proliferation,GO:0008584~male gonad development,GO:0008625~extrinsic apoptotic signaling pathway via death domain receptors,GO:0008630~intrinsic apoptotic signaling pathway in response to DNA damage,GO:0008631~intrinsic apoptotic signaling pathway in response to oxidative stress,GO:0009314~response to radiation,GO:0009410~response to xenobiotic stimulus,GO:0009636~response to toxic substance,GO:0009791~post-embryonic development,GO:0010039~response to iron ion,GO:0010224~response to UV-B,GO:0010332~response to gamma radiation,GO:0010468~regulation of gene expression,GO:0010507~negative regulation of autophagy,GO:0010523~negative regulation of calcium ion transport into cytosol,GO:0010559~regulation of glycoprotein biosynthetic process,GO:0014031~mesenchymal cell development,GO:0014042~positive regulation of neuron maturation,GO:0014911~positive regulation of smooth muscle cell migration,GO:0018105~peptidyl-serine phosphorylation,GO:0018107~peptidyl-threonine phosphorylation,GO:0019221~cytokine-mediated signaling pathway,GO:0021747~cochlear nucleus development,GO:0022612~gland morphogenesis,GO:0022898~regulation of transmembrane transporter activity,GO:0030279~negative regulation of ossification,GO:0030307~positive regulation of cell growth,GO:0030308~negative regulation of cell growth,GO:0030318~melanocyte differentiation,GO:0030336~negative regulation of cell migration,GO:0030890~positive regulation of B cell proliferation,GO:0031069~hair follicle morphogenesis,GO:0031103~axon regeneration,GO:0031647~regulation of protein stability,GO:0032469~endoplasmic reticulum calcium ion homeostasis,GO:0032835~glomerulus development,GO:0032848~negative regulation of cellular pH reduction,GO:0032880~regulation of protein localization,GO:0033033~negative regulation of myeloid cell apoptotic process,GO:0033077~T cell differentiation in thymus,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0033689~negative regulation of osteoblast proliferation,GO:0034097~response to cytokine,GO:0035094~response to nicotine,GO:0035265~organ growth,GO:0040018~positive regulation of multicellular organism growth,GO:0042100~B cell proliferation,GO:0042149~cellular response to glucose starvation,GO:0042493~response to drug,GO:0042542~response to hydrogen peroxide,GO:0043029~T cell homeostasis,GO:0043066~negative regulation of apoptotic process,GO:0043085~positive regulation of catalytic activity,GO:0043375~CD8-positive, alpha-beta T cell lineage commitment,GO:0043524~negative regulation of neuron apoptotic process,GO:0043583~ear development,GO:0045069~regulation of viral genome replication,GO:0045636~positive regulation of melanocyte differentiation,GO:0046671~negative regulation of retinal cell programmed cell death,GO:0046902~regulation of mitochondrial membrane permeability,GO:0048041~focal adhesion assembly,GO:0048536~spleen development,GO:0048538~thymus development,GO:0048546~digestive tract morphogenesis,GO:0048599~oocyte development,GO:0048743~positive regulation of skeletal muscle fiber development,GO:0048753~pigment granule organization,GO:0048873~homeostasis of number of cells within a tissue,GO:0050853~B cell receptor signaling pathway,GO:0051384~response to glucocorticoid,GO:0051402~neuron apoptotic process,GO:0051607~defense response to virus,GO:0051881~regulation of mitochondrial membrane potential,GO:0051902~negative regulation of mitochondrial depolarization,GO:0051924~regulation of calcium ion transport,GO:0055085~transmembrane transport,GO:0070059~intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress,GO:0071310~cellular response to organic substance,GO:0071456~cellular response to hypoxia,GO:0072593~reactive oxygen species metabolic process,GO:0097192~extrinsic apoptotic signaling pathway in absence of ligand,GO:0098609~cell-cell adhesion,GO:1900740~positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway,GO:1902166~negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator,GO:2000134~negative regulation of G1/S transition of mitotic cell cycle,GO:2000378~negative regulation of reactive oxygen species metabolic process,GO:2000811~negative regulation of anoikis,GO:2001234~negative regulation of apoptotic signaling pathway,GO:2001240~negative regulation of extrinsic apoptotic signaling pathway in absence of ligand,GO:2001243~negative regulation of intrinsic apoptotic signaling pathway,GO:2001244~positive regulation of intrinsic apoptotic signaling pathway,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0031965~nuclear membrane,GO:0032991~macromolecular complex,GO:0043209~myelin sheath,GO:0046930~pore complex,	GO:0002020~protease binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0015267~channel activity,GO:0016248~channel inhibitor activity,GO:0031625~ubiquitin protein ligase binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0043565~sequence-specific DNA binding,GO:0046982~protein heterodimerization activity,GO:0051434~BH3 domain binding,GO:0051721~protein phosphatase 2A binding,GO:0070491~repressing transcription factor binding,	IPR002475:Bcl2-like,IPR003093:Apoptosis regulator, Bcl-2 protein, BH4,IPR004725:Apoptosis regulator, Bcl-2/ BclX,IPR013278:Apoptosis regulator, Bcl-2,IPR020717:Apoptosis regulator, Bcl-2, BH1 motif, conserved site,IPR020726:Apoptosis regulator, Bcl-2, BH2 motif, conserved site,IPR020728:Apoptosis regulator, Bcl-2, BH3 motif, conserved site,IPR020731:Apoptosis regulator, Bcl-2, BH4 motif, conserved site,IPR026298:Blc2 family,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa01522:Endocrine resistance,hsa01524:Platinum drug resistance,hsa04064:NF-kappa B signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04071:Sphingolipid signaling pathway,hsa04115:p53 signaling pathway,hsa04140:Autophagy - animal,hsa04141:Protein processing in endoplasmic reticulum,hsa04151:PI3K-Akt signaling pathway,hsa04210:Apoptosis,hsa04215:Apoptosis - multiple species,hsa04217:Necroptosis,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04340:Hedgehog signaling pathway,hsa04510:Focal adhesion,hsa04621:NOD-like receptor signaling pathway,hsa04630:JAK-STAT signaling pathway,hsa04722:Neurotrophin signaling pathway,hsa04725:Cholinergic synapse,hsa04915:Estrogen signaling pathway,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa05014:Amyotrophic lateral sclerosis,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05145:Toxoplasmosis,hsa05152:Tuberculosis,hsa05161:Hepatitis B,hsa05162:Measles,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,hsa05206:MicroRNAs in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05210:Colorectal cancer,hsa05215:Prostate cancer,hsa05222:Small cell lung cancer,hsa05226:Gastric cancer,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,	Leukemia/lymphoma, B-cell, 2~Leukemia/lymphoma, B-cell, 2,		SM00265:BH4,	KW-0053~Apoptosis,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-1000~Mitochondrion outer membrane,	KW-0225~Disease variant,KW-0656~Proto-oncogene,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	DOMAIN:BH4_2,MOTIF:BH1,MOTIF:BH2,MOTIF:BH3,MOTIF:BH4,MUTAGEN:D->A: Abolishes cleavage by caspase-3.,MUTAGEN:D->A: No effect on BAX-binding, nor on anti-apoptotic activity. Partial loss of BAX-binding and 50% decrease in anti-apoptotic activity; when associated with L-190 and A-192. No effect on homodimerization; when associated with L-190 and A-191.,MUTAGEN:D->A: No effect on cleavage by caspase-3.,MUTAGEN:E->A: Partial loss of BAX-binding and 50% decrease in anti-apoptotic activity.,MUTAGEN:FRDG->AAAA: Loss of BAX-binding and of anti-apoptotic activity.,MUTAGEN:G->A: Loss of BAX-binding and of anti-apoptotic activity. No effect on NLRP1-induced IL1B release, nor on homodimerization. Loss of BAX-binding and of anti-apoptotic activity; when associated with A-145 and A146.,MUTAGEN:G->E: Loss of BAX-binding and of anti-apoptotic activity. No effect on homodimerization.,MUTAGEN:Missing: Loss of BAX-binding and of anti-apoptotic activity. May also affect protein stability.,MUTAGEN:N->A: Partial loss of BAX-binding and 50% decrease in anti-apoptotic activity; when associated with L-190 and A-191. No effect on homodimerization; when associated with L-190 and A-191.,MUTAGEN:Q->L: Partial loss of BAX-binding and 50% decrease in anti-apoptotic activity; when associated with A-191 and A-192. No effect on homodimerization; when associated with L-190 and A-191.,MUTAGEN:R->A: Loss of BAX-binding and of anti-apoptotic activity; when associated with A-144 and A145.,MUTAGEN:W->A: Loss of BAX-binding and of anti-apoptotic activity. No effect on homodimerization.,MUTAGEN:W->A: Loss of BAX-binding and of anti-apoptotic activity; when associated with A-145 and A146.,REGION:Disordered,SITE:Cleavage; by caspase-3,TRANSMEM:Helical,
BAX	BCL2 associated X, apoptosis regulator(BAX)	Homo sapiens	127.Mito-stress,152.altered_synaptic_signalling-neurodegenerative_disorders,46.P13K_PTEN,	h_badPathway:Regulation of BAD phosphorylation,h_ceramidePathway:Ceramide Signaling Pathway,h_chemicalPathway:Apoptotic Signaling in Response to DNA Damage,h_mitochondriaPathway:Role of Mitochondria in Apoptotic Signaling,h_p53hypoxiaPathway:Hypoxia and p53 in the Cardiovascular system,h_p53Pathway:p53 Signaling Pathway,		GO:0001541~ovarian follicle development,GO:0001764~neuron migration,GO:0001777~T cell homeostatic proliferation,GO:0001782~B cell homeostasis,GO:0001783~B cell apoptotic process,GO:0001822~kidney development,GO:0001836~release of cytochrome c from mitochondria,GO:0001844~protein insertion into mitochondrial membrane involved in apoptotic signaling pathway,GO:0001974~blood vessel remodeling,GO:0002262~myeloid cell homeostasis,GO:0002352~B cell negative selection,GO:0002358~B cell homeostatic proliferation,GO:0002904~positive regulation of B cell apoptotic process,GO:0006687~glycosphingolipid metabolic process,GO:0006808~regulation of nitrogen utilization,GO:0006915~apoptotic process,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0006977~DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest,GO:0007281~germ cell development,GO:0008053~mitochondrial fusion,GO:0008625~extrinsic apoptotic signaling pathway via death domain receptors,GO:0008630~intrinsic apoptotic signaling pathway in response to DNA damage,GO:0008635~activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c,GO:0008637~apoptotic mitochondrial changes,GO:0009566~fertilization,GO:0009636~response to toxic substance,GO:0009651~response to salt stress,GO:0010248~establishment or maintenance of transmembrane electrochemical gradient,GO:0010332~response to gamma radiation,GO:0010917~negative regulation of mitochondrial membrane potential,GO:0016032~viral process,GO:0021854~hypothalamus development,GO:0021987~cerebral cortex development,GO:0031334~positive regulation of protein complex assembly,GO:0032091~negative regulation of protein binding,GO:0032469~endoplasmic reticulum calcium ion homeostasis,GO:0032471~negative regulation of endoplasmic reticulum calcium ion concentration,GO:0032976~release of matrix enzymes from mitochondria,GO:0033137~negative regulation of peptidyl-serine phosphorylation,GO:0033599~regulation of mammary gland epithelial cell proliferation,GO:0034620~cellular response to unfolded protein,GO:0034644~cellular response to UV,GO:0035234~ectopic germ cell programmed cell death,GO:0042475~odontogenesis of dentin-containing tooth,GO:0042981~regulation of apoptotic process,GO:0043065~positive regulation of apoptotic process,GO:0043524~negative regulation of neuron apoptotic process,GO:0043525~positive regulation of neuron apoptotic process,GO:0043653~mitochondrial fragmentation involved in apoptotic process,GO:0045136~development of secondary sexual characteristics,GO:0046666~retinal cell programmed cell death,GO:0048087~positive regulation of developmental pigmentation,GO:0048147~negative regulation of fibroblast proliferation,GO:0048515~spermatid differentiation,GO:0048597~post-embryonic camera-type eye morphogenesis,GO:0048678~response to axon injury,GO:0048873~homeostasis of number of cells within a tissue,GO:0051281~positive regulation of release of sequestered calcium ion into cytosol,GO:0051402~neuron apoptotic process,GO:0051726~regulation of cell cycle,GO:0051881~regulation of mitochondrial membrane potential,GO:0060011~Sertoli cell proliferation,GO:0060041~retina development in camera-type eye,GO:0060058~positive regulation of apoptotic process involved in mammary gland involution,GO:0060068~vagina development,GO:0060260~regulation of transcription initiation from RNA polymerase II promoter,GO:0070059~intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress,GO:0070242~thymocyte apoptotic process,GO:0070584~mitochondrion morphogenesis,GO:0072332~intrinsic apoptotic signaling pathway by p53 class mediator,GO:0090200~positive regulation of release of cytochrome c from mitochondria,GO:0097190~apoptotic signaling pathway,GO:0097191~extrinsic apoptotic signaling pathway,GO:0097192~extrinsic apoptotic signaling pathway in absence of ligand,GO:0097193~intrinsic apoptotic signaling pathway,GO:0097296~activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway,GO:0097435~supramolecular fiber organization,GO:0098586~cellular response to virus,GO:1900103~positive regulation of endoplasmic reticulum unfolded protein response,GO:1901030~positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway,GO:1902262~apoptotic process involved in blood vessel morphogenesis,GO:1902263~apoptotic process involved in embryonic digit morphogenesis,GO:1902445~regulation of mitochondrial membrane permeability involved in programmed necrotic cell death,GO:1902512~positive regulation of apoptotic DNA fragmentation,GO:1903896~positive regulation of IRE1-mediated unfolded protein response,GO:1990117~B cell receptor apoptotic signaling pathway,GO:2001234~negative regulation of apoptotic signaling pathway,GO:2001244~positive regulation of intrinsic apoptotic signaling pathway,	GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005757~mitochondrial permeability transition pore complex,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0046930~pore complex,GO:0070062~extracellular exosome,GO:0071944~cell periphery,GO:0097136~Bcl-2 family protein complex,GO:0097144~BAX complex,GO:0097145~BAK complex,	GO:0005515~protein binding,GO:0008289~lipid binding,GO:0015267~channel activity,GO:0030544~Hsp70 protein binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0046982~protein heterodimerization activity,GO:0051087~chaperone binding,GO:0051434~BH3 domain binding,	IPR002475:Bcl2-like,IPR020717:Apoptosis regulator, Bcl-2, BH1 motif, conserved site,IPR020726:Apoptosis regulator, Bcl-2, BH2 motif, conserved site,IPR020728:Apoptosis regulator, Bcl-2, BH3 motif, conserved site,IPR026298:Blc2 family,IPR026304:Apoptosis regulator BAX,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa01522:Endocrine resistance,hsa01524:Platinum drug resistance,hsa04071:Sphingolipid signaling pathway,hsa04115:p53 signaling pathway,hsa04141:Protein processing in endoplasmic reticulum,hsa04210:Apoptosis,hsa04211:Longevity regulating pathway,hsa04215:Apoptosis - multiple species,hsa04217:Necroptosis,hsa04722:Neurotrophin signaling pathway,hsa04932:Non-alcoholic fatty liver disease,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05152:Tuberculosis,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05203:Viral carcinogenesis,hsa05210:Colorectal cancer,hsa05212:Pancreatic cancer,hsa05213:Endometrial cancer,hsa05214:Glioma,hsa05216:Thyroid cancer,hsa05217:Basal cell carcinoma,hsa05218:Melanoma,hsa05220:Chronic myeloid leukemia,hsa05222:Small cell lung cancer,hsa05223:Non-small cell lung cancer,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,hsa05417:Lipid and atherosclerosis,	114500~Colorectal cancer, somatic,613065~T-cell acute lymphoblastic leukemia, somatic,			KW-0053~Apoptosis,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0963~Cytoplasm,KW-1000~Mitochondrion outer membrane,	KW-0043~Tumor suppressor,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,MOTIF:BH1,MOTIF:BH2,MOTIF:BH3,MUTAGEN:K->E: Reduces interaction with BCL2L11, homooligomerization and triggering of apoptosis.,MUTAGEN:M->D,E: Strongly reduced interaction with MCL1, BCL2, BCL2L1 and BCL2L2. No effect on cytochrome c release and subsequent apoptosis triggered by etoposide.,MUTAGEN:Missing: Enhanced fiber formation with humanin.,MUTAGEN:S->D,E,H,K: Constitutive cytoplasmic location.,MUTAGEN:S->V: Constitutive mitochondrial location. Enhanced fiber formation with humanin.,REGION:Disordered,TRANSMEM:Helical,
BAD	BCL2 associated agonist of cell death(BAD)	Homo sapiens	103.Ca2-calmodulin_PK_cascade,159.14-3-3_Apoptosis,46.P13K_PTEN,69.Survival_signaling_BH3-Bad,83.Growth_factors_Survival_factors_Mitogens,86.Apoptosis_Nematode&_Vert,	h_achPathway:Role of nicotinic acetylcholine receptors in the regulation of apoptosis,h_aktPathway:AKT Signaling Pathway,h_badPathway:Regulation of BAD phosphorylation,h_ceramidePathway:Ceramide Signaling Pathway,h_chemicalPathway:Apoptotic Signaling in Response to DNA Damage,h_gleevecPathway:Inhibition of Cellular Proliferation by Gleevec,h_igf1rPathway:Multiple antiapoptotic pathways from IGF-1R signaling lead to BAD phosphorylation,h_il2rbPathway:IL-2 Receptor Beta Chain in T cell Activation,h_ptdinsPathway:Phosphoinositides and their downstream targets.,h_rasPathway:Ras Signaling Pathway,h_tffPathway:Trefoil Factors Initiate  Mucosal Healing,		GO:0001666~response to hypoxia,GO:0001836~release of cytochrome c from mitochondria,GO:0001844~protein insertion into mitochondrial membrane involved in apoptotic signaling pathway,GO:0006007~glucose catabolic process,GO:0006915~apoptotic process,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0007283~spermatogenesis,GO:0008625~extrinsic apoptotic signaling pathway via death domain receptors,GO:0008630~intrinsic apoptotic signaling pathway in response to DNA damage,GO:0009410~response to xenobiotic stimulus,GO:0009749~response to glucose,GO:0010508~positive regulation of autophagy,GO:0010918~positive regulation of mitochondrial membrane potential,GO:0019050~suppression by virus of host apoptotic process,GO:0019221~cytokine-mediated signaling pathway,GO:0021987~cerebral cortex development,GO:0032024~positive regulation of insulin secretion,GO:0032355~response to estradiol,GO:0032570~response to progesterone,GO:0033133~positive regulation of glucokinase activity,GO:0033574~response to testosterone,GO:0034201~response to oleic acid,GO:0035774~positive regulation of insulin secretion involved in cellular response to glucose stimulus,GO:0042493~response to drug,GO:0042542~response to hydrogen peroxide,GO:0042593~glucose homeostasis,GO:0043065~positive regulation of apoptotic process,GO:0043200~response to amino acid,GO:0043280~positive regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0044342~type B pancreatic cell proliferation,GO:0045471~response to ethanol,GO:0045579~positive regulation of B cell differentiation,GO:0045582~positive regulation of T cell differentiation,GO:0045862~positive regulation of proteolysis,GO:0046031~ADP metabolic process,GO:0046034~ATP metabolic process,GO:0046902~regulation of mitochondrial membrane permeability,GO:0046931~pore complex assembly,GO:0050679~positive regulation of epithelial cell proliferation,GO:0051384~response to glucocorticoid,GO:0051592~response to calcium ion,GO:0060139~positive regulation of apoptotic process by virus,GO:0071247~cellular response to chromate,GO:0071260~cellular response to mechanical stimulus,GO:0071316~cellular response to nicotine,GO:0071396~cellular response to lipid,GO:0071456~cellular response to hypoxia,GO:0090200~positive regulation of release of cytochrome c from mitochondria,GO:0097191~extrinsic apoptotic signaling pathway,GO:0097192~extrinsic apoptotic signaling pathway in absence of ligand,GO:0097193~intrinsic apoptotic signaling pathway,GO:0097202~activation of cysteine-type endopeptidase activity,GO:1900740~positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway,GO:1901216~positive regulation of neuron death,GO:1901423~response to benzene,GO:1902220~positive regulation of intrinsic apoptotic signaling pathway in response to osmotic stress,GO:1904710~positive regulation of granulosa cell apoptotic process,GO:2000078~positive regulation of type B pancreatic cell development,GO:2001244~positive regulation of intrinsic apoptotic signaling pathway,	GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0005543~phospholipid binding,GO:0008289~lipid binding,GO:0008656~cysteine-type endopeptidase activator activity involved in apoptotic process,GO:0019901~protein kinase binding,GO:0019903~protein phosphatase binding,GO:0030346~protein phosphatase 2B binding,GO:0043422~protein kinase B binding,GO:0071889~14-3-3 protein binding,	IPR018868:Pro-apoptotic Bcl-2 protein, BAD,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa01522:Endocrine resistance,hsa01524:Platinum drug resistance,hsa04012:ErbB signaling pathway,hsa04014:Ras signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04062:Chemokine signaling pathway,hsa04140:Autophagy - animal,hsa04151:PI3K-Akt signaling pathway,hsa04210:Apoptosis,hsa04370:VEGF signaling pathway,hsa04510:Focal adhesion,hsa04722:Neurotrophin signaling pathway,hsa04910:Insulin signaling pathway,hsa04919:Thyroid hormone signaling pathway,hsa05010:Alzheimer disease,hsa05014:Amyotrophic lateral sclerosis,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05145:Toxoplasmosis,hsa05152:Tuberculosis,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05165:Human papillomavirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05207:Chemical carcinogenesis - receptor activation,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05210:Colorectal cancer,hsa05211:Renal cell carcinoma,hsa05212:Pancreatic cancer,hsa05213:Endometrial cancer,hsa05215:Prostate cancer,hsa05218:Melanoma,hsa05220:Chronic myeloid leukemia,hsa05221:Acute myeloid leukemia,hsa05223:Non-small cell lung cancer,hsa05225:Hepatocellular carcinoma,hsa05417:Lipid and atherosclerosis,				KW-0053~Apoptosis,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0963~Cytoplasm,KW-1000~Mitochondrion outer membrane,					KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,MOTIF:BH3,MUTAGEN:R->K: Decreased methylation; when associated with K-94.,MUTAGEN:R->K: Decreased methylation; when associated with K-96.,REGION:Disordered,
BNIP3L	BCL2 interacting protein 3 like(BNIP3L)	Homo sapiens				GO:0010917~negative regulation of mitochondrial membrane potential,GO:0016032~viral process,GO:0016239~positive regulation of macroautophagy,GO:0035694~mitochondrial protein catabolic process,GO:0035794~positive regulation of mitochondrial membrane permeability,GO:0042981~regulation of apoptotic process,GO:0043065~positive regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043067~regulation of programmed cell death,GO:0051607~defense response to virus,GO:0060548~negative regulation of cell death,GO:0071456~cellular response to hypoxia,GO:0097345~mitochondrial outer membrane permeabilization,GO:1903146~regulation of mitophagy,GO:1903214~regulation of protein targeting to mitochondrion,	GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005739~mitochondrion,GO:0005740~mitochondrial envelope,GO:0005741~mitochondrial outer membrane,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0016021~integral component of membrane,GO:0016607~nuclear speck,GO:0031224~intrinsic component of membrane,	GO:0005515~protein binding,GO:0005521~lamin binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,	IPR010548:BNIP3,	hsa04137:Mitophagy - animal,				KW-0053~Apoptosis,KW-0945~Host-virus interaction,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-1000~Mitochondrion outer membrane,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,MOTIF:BH3,REGION:Disordered,TRANSMEM:Helical,
BNIP3	BCL2 interacting protein 3(BNIP3)	Homo sapiens				GO:0000422~mitophagy,GO:0001666~response to hypoxia,GO:0006915~apoptotic process,GO:0008219~cell death,GO:0009617~response to bacterium,GO:0010508~positive regulation of autophagy,GO:0010637~negative regulation of mitochondrial fusion,GO:0010659~cardiac muscle cell apoptotic process,GO:0010666~positive regulation of cardiac muscle cell apoptotic process,GO:0010917~negative regulation of mitochondrial membrane potential,GO:0010940~positive regulation of necrotic cell death,GO:0016032~viral process,GO:0016239~positive regulation of macroautophagy,GO:0021987~cerebral cortex development,GO:0035694~mitochondrial protein catabolic process,GO:0043065~positive regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043067~regulation of programmed cell death,GO:0043068~positive regulation of programmed cell death,GO:0043243~positive regulation of protein complex disassembly,GO:0043653~mitochondrial fragmentation involved in apoptotic process,GO:0045837~negative regulation of membrane potential,GO:0046902~regulation of mitochondrial membrane permeability,GO:0048102~autophagic cell death,GO:0048678~response to axon injury,GO:0048709~oligodendrocyte differentiation,GO:0050873~brown fat cell differentiation,GO:0051402~neuron apoptotic process,GO:0051561~positive regulation of mitochondrial calcium ion concentration,GO:0051607~defense response to virus,GO:0055093~response to hyperoxia,GO:0060548~negative regulation of cell death,GO:0070301~cellular response to hydrogen peroxide,GO:0071260~cellular response to mechanical stimulus,GO:0071279~cellular response to cobalt ion,GO:0071456~cellular response to hypoxia,GO:0072593~reactive oxygen species metabolic process,GO:0090141~positive regulation of mitochondrial fission,GO:0090200~positive regulation of release of cytochrome c from mitochondria,GO:0090649~response to oxygen-glucose deprivation,GO:0097345~mitochondrial outer membrane permeabilization,GO:1901998~toxin transport,GO:1902109~negative regulation of mitochondrial membrane permeability involved in apoptotic process,GO:1903599~positive regulation of mitophagy,GO:1903715~regulation of aerobic respiration,GO:1990144~intrinsic apoptotic signaling pathway in response to hypoxia,GO:2000378~negative regulation of reactive oxygen species metabolic process,	GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005740~mitochondrial envelope,GO:0005741~mitochondrial outer membrane,GO:0005783~endoplasmic reticulum,GO:0014069~postsynaptic density,GO:0016021~integral component of membrane,GO:0030425~dendrite,GO:0031307~integral component of mitochondrial outer membrane,GO:0031966~mitochondrial membrane,	GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0051020~GTPase binding,	IPR010548:BNIP3,	hsa04068:FoxO signaling pathway,hsa04137:Mitophagy - animal,hsa04140:Autophagy - animal,hsa05131:Shigellosis,hsa05134:Legionellosis,				KW-0053~Apoptosis,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-1000~Mitochondrion outer membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,MOTIF:BH3,REGION:Disordered,TRANSMEM:Helical,
BID	BH3 interacting domain death agonist(BID)	Homo sapiens	127.Mito-stress,150.caspase_and_NFKB_activation,46.P13K_PTEN,	h_chemicalPathway:Apoptotic Signaling in Response to DNA Damage,h_deathPathway:Induction of apoptosis through DR3 and DR4/5 Death Receptors ,h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_mitochondriaPathway:Role of Mitochondria in Apoptotic Signaling,		GO:0001836~release of cytochrome c from mitochondria,GO:0006626~protein targeting to mitochondrion,GO:0006915~apoptotic process,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0008625~extrinsic apoptotic signaling pathway via death domain receptors,GO:0008637~apoptotic mitochondrial changes,GO:0010918~positive regulation of mitochondrial membrane potential,GO:0031334~positive regulation of protein complex assembly,GO:0042127~regulation of cell proliferation,GO:0042770~signal transduction in response to DNA damage,GO:0042775~mitochondrial ATP synthesis coupled electron transport,GO:0042981~regulation of apoptotic process,GO:0043065~positive regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0051402~neuron apoptotic process,GO:0065003~macromolecular complex assembly,GO:0090150~establishment of protein localization to membrane,GO:0090200~positive regulation of release of cytochrome c from mitochondria,GO:0097284~hepatocyte apoptotic process,GO:0097345~mitochondrial outer membrane permeabilization,GO:0097435~supramolecular fiber organization,GO:1900740~positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway,GO:1901030~positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway,GO:1902230~negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage,GO:2000045~regulation of G1/S transition of mitotic cell cycle,GO:2000271~positive regulation of fibroblast apoptotic process,GO:2001238~positive regulation of extrinsic apoptotic signaling pathway,GO:2001244~positive regulation of intrinsic apoptotic signaling pathway,	GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005829~cytosol,GO:0016020~membrane,GO:0032592~integral component of mitochondrial membrane,	GO:0005123~death receptor binding,GO:0005515~protein binding,GO:0031625~ubiquitin protein ligase binding,	IPR010479:BH3 interacting,IPR020728:Apoptosis regulator, Bcl-2, BH3 motif, conserved site,	hsa01524:Platinum drug resistance,hsa04071:Sphingolipid signaling pathway,hsa04115:p53 signaling pathway,hsa04210:Apoptosis,hsa04215:Apoptosis - multiple species,hsa04217:Necroptosis,hsa04650:Natural killer cell mediated cytotoxicity,hsa04932:Non-alcoholic fatty liver disease,hsa05010:Alzheimer disease,hsa05014:Amyotrophic lateral sclerosis,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05152:Tuberculosis,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,hsa05416:Viral myocarditis,hsa05417:Lipid and atherosclerosis,		PIRSF038018:BH3-interacting domain death agonist,		KW-0053~Apoptosis,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0963~Cytoplasm,KW-1000~Mitochondrion outer membrane,					KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,MOTIF:BH3,REGION:Disordered,SITE:Cleavage,
BLCAP	BLCAP apoptosis inducing factor(BLCAP)	Homo sapiens				GO:0007049~cell cycle,GO:0030262~apoptotic nuclear changes,	GO:0016021~integral component of membrane,	GO:0005515~protein binding,	IPR009598:Bladder cancer-related BC10,				SM01396:SM01396,	KW-0053~Apoptosis,KW-0131~Cell cycle,	KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				TRANSMEM:Helical,
BAMBI	BMP and activin membrane bound inhibitor(BAMBI)	Homo sapiens				GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0008284~positive regulation of cell proliferation,GO:0008360~regulation of cell shape,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0016477~cell migration,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0030514~negative regulation of BMP signaling pathway,GO:0032092~positive regulation of protein binding,GO:0045668~negative regulation of osteoblast differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0090263~positive regulation of canonical Wnt signaling pathway,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,	GO:0005109~frizzled binding,GO:0005114~type II transforming growth factor beta receptor binding,GO:0005515~protein binding,	IPR009345:BMP/activin membrane-bound inhibitor,	hsa04310:Wnt signaling pathway,hsa04350:TGF-beta signaling pathway,		PIRSF037456:BMP and activin membrane-bound inhibitor,			KW-0472~Membrane,		KW-0175~Coiled coil,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
BRCA1	BRCA1 DNA repair associated(BRCA1)	Homo sapiens		h_atmPathway:ATM Signaling Pathway,h_atrbrcaPathway:Role of BRCA1,  BRCA2 and ATR in Cancer Susceptibility,h_bard1Pathway:BRCA1-dependent Ub-ligase activity,h_carm-erPathway:CARM1 and Regulation of the Estrogen Receptor,h_g2Pathway:Cell Cycle: G2/M Checkpoint,	Signal transduction mechanisms,	GO:0000209~protein polyubiquitination,GO:0000724~double-strand break repair via homologous recombination,GO:0000729~DNA double-strand break processing,GO:0006260~DNA replication,GO:0006281~DNA repair,GO:0006301~postreplication repair,GO:0006302~double-strand break repair,GO:0006303~double-strand break repair via nonhomologous end joining,GO:0006310~DNA recombination,GO:0006349~regulation of gene expression by genetic imprinting,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006633~fatty acid biosynthetic process,GO:0006974~cellular response to DNA damage stimulus,GO:0007049~cell cycle,GO:0007059~chromosome segregation,GO:0007095~mitotic G2 DNA damage checkpoint,GO:0007098~centrosome cycle,GO:0008630~intrinsic apoptotic signaling pathway in response to DNA damage,GO:0009048~dosage compensation by inactivation of X chromosome,GO:0010212~response to ionizing radiation,GO:0010575~positive regulation of vascular endothelial growth factor production,GO:0010628~positive regulation of gene expression,GO:0016567~protein ubiquitination,GO:0016579~protein deubiquitination,GO:0031398~positive regulation of protein ubiquitination,GO:0033147~negative regulation of intracellular estrogen receptor signaling pathway,GO:0035066~positive regulation of histone acetylation,GO:0035067~negative regulation of histone acetylation,GO:0043009~chordate embryonic development,GO:0043627~response to estrogen,GO:0044030~regulation of DNA methylation,GO:0044818~mitotic G2/M transition checkpoint,GO:0045717~negative regulation of fatty acid biosynthetic process,GO:0045739~positive regulation of DNA repair,GO:0045766~positive regulation of angiogenesis,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046600~negative regulation of centriole replication,GO:0051571~positive regulation of histone H3-K4 methylation,GO:0051572~negative regulation of histone H3-K4 methylation,GO:0051573~negative regulation of histone H3-K9 methylation,GO:0051574~positive regulation of histone H3-K9 methylation,GO:0051726~regulation of cell cycle,GO:0051865~protein autoubiquitination,GO:0070317~negative regulation of G0 to G1 transition,GO:0070512~positive regulation of histone H4-K20 methylation,GO:0071158~positive regulation of cell cycle arrest,GO:0071356~cellular response to tumor necrosis factor,GO:0071479~cellular response to ionizing radiation,GO:0071681~cellular response to indole-3-methanol,GO:0072425~signal transduction involved in G2 DNA damage checkpoint,GO:0085020~protein K6-linked ubiquitination,GO:1901796~regulation of signal transduction by p53 class mediator,GO:1902042~negative regulation of extrinsic apoptotic signaling pathway via death domain receptors,GO:2000378~negative regulation of reactive oxygen species metabolic process,GO:2000617~positive regulation of histone H3-K9 acetylation,GO:2000620~positive regulation of histone H4-K16 acetylation,	GO:0000151~ubiquitin ligase complex,GO:0000152~nuclear ubiquitin ligase complex,GO:0000800~lateral element,GO:0000931~gamma-tubulin large complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0008274~gamma-tubulin ring complex,GO:0016021~integral component of membrane,GO:0016604~nuclear body,GO:0031436~BRCA1-BARD1 complex,GO:0032991~macromolecular complex,GO:0070531~BRCA1-A complex,GO:0070532~BRCA1-B complex,GO:0070533~BRCA1-C complex,GO:1990391~DNA repair complex,GO:1990904~ribonucleoprotein complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003684~damaged DNA binding,GO:0003713~transcription coactivator activity,GO:0003723~RNA binding,GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0015631~tubulin binding,GO:0016746~transferase activity, transferring acyl groups,GO:0016874~ligase activity,GO:0019899~enzyme binding,GO:0031625~ubiquitin protein ligase binding,GO:0046872~metal ion binding,GO:0070063~RNA polymerase binding,	IPR001357:BRCT domain,IPR001841:Zinc finger, RING-type,IPR011364:Breast cancer type 1 susceptibility protein (BRCA1),IPR013083:Zinc finger, RING/FYVE/PHD-type,IPR017907:Zinc finger, RING-type, conserved site,IPR018957:Zinc finger, C3HC4 RING-type,IPR025994:BRCA1, serine-rich domain,IPR027370:RING-type zinc-finger, LisH dimerisation motif,	hsa01524:Platinum drug resistance,hsa03440:Homologous recombination,hsa03460:Fanconi anemia pathway,hsa04120:Ubiquitin mediated proteolysis,hsa04151:PI3K-Akt signaling pathway,hsa05206:MicroRNAs in cancer,hsa05224:Breast cancer,	604370~Breast-ovarian cancer, familial, 1,614320~Pancreatic cancer, susceptibility to, 4,617883~Fanconi anemia, complementation group S,	PIRSF001734:transcriptional regulator, BRCA1 type,	SM00184:RING,SM00292:BRCT,	KW-0131~Cell cycle,KW-0227~DNA damage,KW-0233~DNA recombination,KW-0234~DNA repair,KW-0275~Fatty acid biosynthesis,KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0833~Ubl conjugation pathway,	KW-0158~Chromosome,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0043~Tumor suppressor,KW-0225~Disease variant,KW-0923~Fanconi anemia,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0812~Transmembrane,KW-0863~Zinc-finger,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0012~Acyltransferase,KW-0238~DNA-binding,KW-0436~Ligase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:BRCT,DOMAIN:BRCT 1,DOMAIN:BRCT 2,DOMAIN:BRCT_assoc,DOMAIN:RING-type,DOMAIN:zf-C3HC4,DOMAIN:zf-RING_UBOX,MUTAGEN:E->K: Slightly reduces affinity for a BRIP1 phosphopeptide.,MUTAGEN:F->S: Does not abolish ABRAXAS1 binding, but abolishes formation of a heterotetramer with ABRAXAS1.,MUTAGEN:G->D: No effect on affinity for a BRIP1 phosphopeptide.,MUTAGEN:G->E: Abolishes interaction with BRIP1.,MUTAGEN:I->A: Disrupts the interaction with E2 enzymes, thereby abolishing the E3 ubiquitin-protein ligase activity.,MUTAGEN:I->E: No ubiquitination of RBBP8. No restoration RBBP8-mediated focus formation or G2/M checkpoint control upon DNA damage.,MUTAGEN:K->E: Impairs formation of a heterotetramer with ABRAXAS1.,MUTAGEN:K->M: Abolishes interaction with BRIP1.,MUTAGEN:M->K: Does not abolish ABRAXAS1 binding, but abolishes formation of a heterotetramer with ABRAXAS1.,MUTAGEN:R->E: Impairs formation of a heterotetramer with ABRAXAS1.,MUTAGEN:R->G: No effect on interaction with BAP1.,MUTAGEN:R->P: Mildly reduces affinity for a BRIP1 phosphopeptide.,MUTAGEN:S->A: Abolishes interaction with BRIP1.,MUTAGEN:S->A: Inhibition of the infrared-induced G2 arrest. Reduces phosphorylation by ATR.,MUTAGEN:S->A: Loss of IR-induced S-phase checkpoint. Reduces in vitro phosphorylation by ATR.,MUTAGEN:S->A: No change in infrared S-phase delay; when associated with A-1387. No effect on in vitro phosphorylation by ATR.,MUTAGEN:S->A: No effect on in vitro phosphorylation by ATR.,MUTAGEN:S->A: Reduces in vitro phosphorylation by ATR.,MUTAGEN:T->A: Reduces in vitro phosphorylation by ATR.,MUTAGEN:T->A: Strongly reduces affinity for a BRIP1 phosphopeptide.,MUTAGEN:Y->A: Does not abolish ABRAXAS1 binding, but impairs formation of a heterotetramer with ABRAXAS1.,REGION:Disordered,REGION:Interaction with PALB2,TRANSMEM:Helical,ZN_FING:RING-type,
BUB1B	BUB1 mitotic checkpoint serine/threonine kinase B(BUB1B)	Homo sapiens			General function prediction only / Signal transduction mechanisms / Transcription / DNA replication, recombination, and repair,	GO:0000278~mitotic cell cycle,GO:0006468~protein phosphorylation,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0006915~apoptotic process,GO:0007052~mitotic spindle organization,GO:0007091~metaphase/anaphase transition of mitotic cell cycle,GO:0007093~mitotic cell cycle checkpoint,GO:0007094~mitotic spindle assembly checkpoint,GO:0007096~regulation of exit from mitosis,GO:0031145~anaphase-promoting complex-dependent catabolic process,GO:0051301~cell division,GO:0051444~negative regulation of ubiquitin-protein transferase activity,GO:0051754~meiotic sister chromatid cohesion, centromeric,GO:0071459~protein localization to chromosome, centromeric region,GO:1901990~regulation of mitotic cell cycle phase transition,	GO:0000776~kinetochore,GO:0000777~condensed chromosome kinetochore,GO:0000778~condensed nuclear chromosome kinetochore,GO:0000940~condensed chromosome outer kinetochore,GO:0005680~anaphase-promoting complex,GO:0005737~cytoplasm,GO:0005815~microtubule organizing center,GO:0005819~spindle,GO:0005829~cytosol,GO:0033597~mitotic checkpoint complex,GO:0048471~perinuclear region of cytoplasm,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,	IPR011009:Protein kinase-like domain,IPR013212:Mad3/BUB1 homology region 1,IPR015661:Mitotic checkpoint serine/threonine protein kinase Bub1/Mitotic spindle checkpoint component Mad3,	hsa04110:Cell cycle,hsa05166:Human T-cell leukemia virus 1 infection,	114500~Colorectal cancer, somatic,176430~Premature chromatid separation trait,257300~Mosaic variegated aneuploidy syndrome 1,		SM00777:Mad3_BUB1_I,	KW-0053~Apoptosis,KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0137~Centromere,KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0995~Kinetochore,	KW-0043~Tumor suppressor,KW-0225~Disease variant,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Proton acceptor,BINDING:ATP,DOMAIN:BUB1 N-terminal,DOMAIN:Protein kinase,MOTIF:D-box,MOTIF:Nuclear localization signal,MUTAGEN:A->W: Loss of interaction with KNL1.,MUTAGEN:D->E: Abolishes the cleavage by caspase-3.,MUTAGEN:F->A: Loss of interaction with KNL1.,MUTAGEN:K->A: Does not abolish the capacity to inhibit APC/CDC20.,MUTAGEN:K->R: Inhibits kinase activity.,MUTAGEN:T->A: Induces chromosome congression defects and mitotic delay.,NP_BIND:ATP,REGION:Disordered,REGION:Necessary for interaction with KNL1,SITE:Cleavage; by caspase-3,
BTK	Bruton tyrosine kinase(BTK)	Homo sapiens	101.Gprot_coupled_Rec_MAP_Kinase,	h_bcrPathway:BCR Signaling Pathway,h_fcer1Pathway:Fc Epsilon Receptor I Signaling in Mast Cells,h_ptdinsPathway:Phosphoinositides and their downstream targets.,		GO:0001805~positive regulation of type III hypersensitivity,GO:0001812~positive regulation of type I hypersensitivity,GO:0001818~negative regulation of cytokine production,GO:0002250~adaptive immune response,GO:0002344~B cell affinity maturation,GO:0002553~histamine secretion by mast cell,GO:0002721~regulation of B cell cytokine production,GO:0002755~MyD88-dependent toll-like receptor signaling pathway,GO:0002902~regulation of B cell apoptotic process,GO:0006468~protein phosphorylation,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007249~I-kappaB kinase/NF-kappaB signaling,GO:0007498~mesoderm development,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0019722~calcium-mediated signaling,GO:0030889~negative regulation of B cell proliferation,GO:0034614~cellular response to reactive oxygen species,GO:0035556~intracellular signal transduction,GO:0038095~Fc-epsilon receptor signaling pathway,GO:0042113~B cell activation,GO:0045087~innate immune response,GO:0045579~positive regulation of B cell differentiation,GO:0046777~protein autophosphorylation,GO:0048469~cell maturation,GO:0050790~regulation of catalytic activity,GO:0050853~B cell receptor signaling pathway,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0071226~cellular response to molecule of fungal origin,GO:0097190~apoptotic signaling pathway,GO:0098761~cellular response to interleukin-7,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0031410~cytoplasmic vesicle,GO:0045121~membrane raft,GO:0048471~perinuclear region of cytoplasm,	GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0004715~non-membrane spanning protein tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0005547~phosphatidylinositol-3,4,5-trisphosphate binding,GO:0016004~phospholipase activator activity,GO:0016301~kinase activity,GO:0042802~identical protein binding,GO:0043274~phospholipase binding,GO:0046872~metal ion binding,	IPR000719:Protein kinase, catalytic domain,IPR000980:SH2 domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR001452:Src homology-3 domain,IPR001562:Zinc finger, Btk motif,IPR001849:Pleckstrin homology domain,IPR008266:Tyrosine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR011993:Pleckstrin homology-like domain,IPR017441:Protein kinase, ATP binding site,IPR020635:Tyrosine-protein kinase, catalytic domain,	hsa04064:NF-kappa B signaling pathway,hsa04380:Osteoclast differentiation,hsa04611:Platelet activation,hsa04662:B cell receptor signaling pathway,hsa04664:Fc epsilon RI signaling pathway,hsa05169:Epstein-Barr virus infection,hsa05340:Primary immunodeficiency,	300755~Agammaglobulinemia, X-linked 1,307200~Isolated growth hormone deficiency, type III, with agammaglobulinemia,		SM00107:BTK,SM00219:TyrKc,SM00233:PH,SM00252:SH2,SM00326:SH3,	KW-0053~Apoptosis,KW-0391~Immunity,KW-0399~Innate immunity,KW-0804~Transcription,KW-0805~Transcription regulation,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0242~Dwarfism,	KW-0727~SH2 domain,KW-0728~SH3 domain,KW-0863~Zinc-finger,	KW-0067~ATP-binding,KW-0446~Lipid-binding,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0862~Zinc,	KW-0418~Kinase,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:ATP,BINDING:Clofedanol; inhibitor; via carbonyl oxygen,BINDING:Inositol-(1,3,4,5)-tetrakisphosphate,BINDING:Inositol-(1,3,4,5)-tetrakisphosphate; via carbonyl oxygen,DOMAIN:PH,DOMAIN:Protein kinase,DOMAIN:SH2,DOMAIN:SH3,METAL:Zinc,MOTIF:CAV1-binding,MUTAGEN:E->K: No effect on phosphorylation of GTF2I.,MUTAGEN:P->A: No effect on phosphorylation of GTF2I.,MUTAGEN:R->K: Loss of phosphorylation of GTF2I.,MUTAGEN:W->L: No effect on phosphorylation of GTF2I.,MUTAGEN:WW->LL: Large decrease in binding by SH3BP5.,MUTAGEN:Y->E: Defective in mediating calcium response.,MUTAGEN:Y->F: Loss of phosphorylation of GTF2I.,NP_BIND:ATP,REGION:Clofedanol binding; inhibitor,REGION:Dasatinib binding; inhibitor,REGION:Disordered,REGION:Inositol-(1,3,4,5)-tetrakisphosphate 1-binding,ZN_FING:Btk-type,
CCL2	C-C motif chemokine ligand 2(CCL2)	Homo sapiens	109.Chemokine_families,18.Cytokine_astocytes,19.Cytokine_microglia,33.GProt-coupled_Rec_T_Cell_med_Inflamm,34.Chemokines_in_EAE,35.Chemokines_EAE_Autoreactive_T_Cells,	h_ccr5Pathway:Pertussis toxin-insensitive CCR5 Signaling in Macrophage,h_LDLpathway:Low-density lipoprotein (LDL) pathway during atherogenesis,h_mspPathway:Msp/Ron Receptor Signaling Pathway,		GO:0000165~MAPK cascade,GO:0001525~angiogenesis,GO:0002548~monocyte chemotaxis,GO:0006468~protein phosphorylation,GO:0006935~chemotaxis,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0006959~humoral immune response,GO:0007010~cytoskeleton organization,GO:0007155~cell adhesion,GO:0007165~signal transduction,GO:0007166~cell surface receptor signaling pathway,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007187~G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger,GO:0007259~JAK-STAT cascade,GO:0008360~regulation of cell shape,GO:0009617~response to bacterium,GO:0009887~animal organ morphogenesis,GO:0019079~viral genome replication,GO:0019221~cytokine-mediated signaling pathway,GO:0019233~sensory perception of pain,GO:0019725~cellular homeostasis,GO:0030593~neutrophil chemotaxis,GO:0031663~lipopolysaccharide-mediated signaling pathway,GO:0034351~negative regulation of glial cell apoptotic process,GO:0035684~helper T cell extravasation,GO:0036499~PERK-mediated unfolded protein response,GO:0043491~protein kinase B signaling,GO:0043524~negative regulation of neuron apoptotic process,GO:0043547~positive regulation of GTPase activity,GO:0043615~astrocyte cell migration,GO:0044344~cellular response to fibroblast growth factor stimulus,GO:0048245~eosinophil chemotaxis,GO:0048246~macrophage chemotaxis,GO:0048247~lymphocyte chemotaxis,GO:0050870~positive regulation of T cell activation,GO:0051770~positive regulation of nitric-oxide synthase biosynthetic process,GO:0051968~positive regulation of synaptic transmission, glutamatergic,GO:0070098~chemokine-mediated signaling pathway,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071222~cellular response to lipopolysaccharide,GO:0071346~cellular response to interferon-gamma,GO:0071347~cellular response to interleukin-1,GO:0071356~cellular response to tumor necrosis factor,GO:0071407~cellular response to organic cyclic compound,GO:0090280~positive regulation of calcium ion import,GO:1904783~positive regulation of NMDA glutamate receptor activity,GO:1905563~negative regulation of vascular endothelial cell proliferation,GO:2000134~negative regulation of G1/S transition of mitotic cell cycle,GO:2000353~positive regulation of endothelial cell apoptotic process,GO:2000427~positive regulation of apoptotic cell clearance,GO:2000502~negative regulation of natural killer cell chemotaxis,	GO:0005576~extracellular region,GO:0005615~extracellular space,	GO:0004672~protein kinase activity,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0008009~chemokine activity,GO:0031727~CCR2 chemokine receptor binding,GO:0048020~CCR chemokine receptor binding,	IPR000827:CC chemokine, conserved site,IPR001811:Chemokine interleukin-8-like domain,	hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa04062:Chemokine signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04657:IL-17 signaling pathway,hsa04668:TNF signaling pathway,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa05135:Yersinia infection,hsa05142:Chagas disease,hsa05144:Malaria,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05168:Herpes simplex virus 1 infection,hsa05171:Coronavirus disease - COVID-19,hsa05323:Rheumatoid arthritis,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,	182940~Spina bifida, susceptibility to,607948~Mycobacterium tuberculosis, susceptibility to,609423~HIV-1, resistance to,Coronary artery disease, modifier of~Coronary artery disease, modifier of,		SM00199:SCY,	KW-0145~Chemotaxis,KW-0395~Inflammatory response,	KW-0964~Secreted,		KW-0732~Signal,		KW-0202~Cytokine,	KW-0325~Glycoprotein,KW-0873~Pyrrolidone carboxylic acid,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:SCY,MUTAGEN:D->A: Reduction in activity.,MUTAGEN:D->L: 90% reduction in activity.,MUTAGEN:H->A: Strongly reduces heparin binding.,MUTAGEN:I->A: Slight reduction in activity.,MUTAGEN:K->A: No effect on heparin binding.,MUTAGEN:K->A: Strongly reduces heparin binding.,MUTAGEN:Missing: 83% reduction in activity.,MUTAGEN:Missing: 90% reduction in activity.,MUTAGEN:Missing: Loss of activity.,MUTAGEN:Missing: Loss of signaling.,MUTAGEN:Missing: No effect on heparin binding.,MUTAGEN:N->A: 50% reduction in activity.,MUTAGEN:P->A: Loss of dimerization; slight reduction of activity.,MUTAGEN:R->F: 95% reduction in activity; strong reduction of receptor binding.,MUTAGEN:R->L: Loss of activity.,MUTAGEN:S->Q: 40% reduction in activity.,MUTAGEN:T->A: Slight reduction in activity.,MUTAGEN:T->E: Slight reduction in affinity.,MUTAGEN:V->A: Slight reduction in activity.,MUTAGEN:V->E: Slight reduction in affinity.,MUTAGEN:Y->A: Loss of activity.,MUTAGEN:Y->D: Loss of activity.,SITE:Involved in GAG binding,SITE:Involved in GAG binding and receptor binding,SITE:Involved in dimerization,SITE:Involved in dimerization, receptor binding and signaling,
CXCL2	C-X-C motif chemokine ligand 2(CXCL2)	Homo sapiens				GO:0002237~response to molecule of bacterial origin,GO:0006935~chemotaxis,GO:0006952~defense response,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0007186~G-protein coupled receptor signaling pathway,GO:0019221~cytokine-mediated signaling pathway,GO:0030593~neutrophil chemotaxis,GO:0031640~killing of cells of other organism,GO:0061844~antimicrobial humoral immune response mediated by antimicrobial peptide,GO:0070098~chemokine-mediated signaling pathway,GO:0071222~cellular response to lipopolysaccharide,	GO:0005576~extracellular region,GO:0005615~extracellular space,	GO:0005515~protein binding,GO:0008009~chemokine activity,GO:0045236~CXCR chemokine receptor binding,	IPR001089:CXC chemokine,IPR001811:Chemokine interleukin-8-like domain,IPR018048:CXC chemokine, conserved site,	hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa04062:Chemokine signaling pathway,hsa04064:NF-kappa B signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04657:IL-17 signaling pathway,hsa04668:TNF signaling pathway,hsa04936:Alcoholic liver disease,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05134:Legionellosis,hsa05146:Amoebiasis,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05323:Rheumatoid arthritis,hsa05417:Lipid and atherosclerosis,			SM00199:SCY,	KW-0145~Chemotaxis,KW-0395~Inflammatory response,	KW-0964~Secreted,		KW-0732~Signal,		KW-0202~Cytokine,	KW-1015~Disulfide bond,	DOMAIN:SCY,
CXCR4	C-X-C motif chemokine receptor 4(CXCR4)	Homo sapiens	14.chemokine_receptor-ligand,15.T-cell_polarization-chemokine_receptors,	h_ccr5Pathway:Pertussis toxin-insensitive CCR5 Signaling in Macrophage,h_cxcr4Pathway:CXCR4 Signaling Pathway,h_nktPathway:Selective expression of chemokine receptors during T-cell polarization,h_vifPathway:HIV-1 defeats host-mediated resistance by CEM15,		GO:0000187~activation of MAPK activity,GO:0001666~response to hypoxia,GO:0001764~neuron migration,GO:0002064~epithelial cell development,GO:0002407~dendritic cell chemotaxis,GO:0006915~apoptotic process,GO:0006935~chemotaxis,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007411~axon guidance,GO:0007420~brain development,GO:0008038~neuron recognition,GO:0009615~response to virus,GO:0014823~response to activity,GO:0019064~fusion of virus membrane with host plasma membrane,GO:0019722~calcium-mediated signaling,GO:0022008~neurogenesis,GO:0022029~telencephalon cell migration,GO:0030155~regulation of cell adhesion,GO:0035470~positive regulation of vascular wound healing,GO:0035690~cellular response to drug,GO:0038160~CXCL12-activated CXCR4 signaling pathway,GO:0043067~regulation of programmed cell death,GO:0043217~myelin maintenance,GO:0043278~response to morphine,GO:0044409~entry into host,GO:0045446~endothelial cell differentiation,GO:0046718~viral entry into host cell,GO:0048714~positive regulation of oligodendrocyte differentiation,GO:0050792~regulation of viral process,GO:0050920~regulation of chemotaxis,GO:0050921~positive regulation of chemotaxis,GO:0050965~detection of temperature stimulus involved in sensory perception of pain,GO:0050966~detection of mechanical stimulus involved in sensory perception of pain,GO:0051924~regulation of calcium ion transport,GO:0060048~cardiac muscle contraction,GO:0060326~cell chemotaxis,GO:0061154~endothelial tube morphogenesis,GO:0071345~cellular response to cytokine stimulus,GO:0071466~cellular response to xenobiotic stimulus,GO:1903861~positive regulation of dendrite extension,GO:1905322~positive regulation of mesenchymal stem cell migration,GO:1990478~response to ultrasound,GO:2000448~positive regulation of macrophage migration inhibitory factor signaling pathway,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005764~lysosome,GO:0005769~early endosome,GO:0005770~late endosome,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0030054~cell junction,GO:0031252~cell leading edge,GO:0031410~cytoplasmic vesicle,GO:0032991~macromolecular complex,GO:0070062~extracellular exosome,	GO:0001618~virus receptor activity,GO:0003779~actin binding,GO:0004930~G-protein coupled receptor activity,GO:0004950~chemokine receptor activity,GO:0005515~protein binding,GO:0015026~coreceptor activity,GO:0016493~C-C chemokine receptor activity,GO:0016494~C-X-C chemokine receptor activity,GO:0019955~cytokine binding,GO:0019957~C-C chemokine binding,GO:0031625~ubiquitin protein ligase binding,GO:0032027~myosin light chain binding,GO:0036094~small molecule binding,GO:0038147~C-X-C motif chemokine 12 receptor activity,GO:0043130~ubiquitin binding,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR000355:Chemokine receptor family,IPR001277:CXC chemokine receptor 4,IPR017452:GPCR, rhodopsin-like, 7TM,IPR022726:CXC chemokine receptor 4 N-terminal domain,	hsa04020:Calcium signaling pathway,hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa04062:Chemokine signaling pathway,hsa04144:Endocytosis,hsa04360:Axon guidance,hsa04670:Leukocyte transendothelial migration,hsa04672:Intestinal immune network for IgA production,hsa04810:Regulation of actin cytoskeleton,hsa05163:Human cytomegalovirus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,	193670~Myelokathexis, isolated,193670~WHIM syndrome 1,			KW-0945~Host-virus interaction,	KW-0458~Lysosome,KW-0472~Membrane,KW-0965~Cell junction,KW-0967~Endosome,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,KW-1183~Host cell receptor for virus entry,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0654~Proteoglycan,KW-0765~Sulfation,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (Xyl...) (chondroitin sulfate) serine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:G_PROTEIN_RECEP_F1_2,MOTIF:Important for signaling,MUTAGEN:D->A,S,N: Greatly reduced coreceptor activity for HIV-1 isolate NDK. Reduced coreceptor activity for several other HIV-1 isolates.,MUTAGEN:D->A: Markedly reduced coreceptor activity for HIV-1 isolate LAI.,MUTAGEN:D->A: Reduced CXCL12 binding. Abolishes signaling.,MUTAGEN:D->N: No reduction of agonist-induced G-protein activation.,MUTAGEN:D->N: Reduced CXCL12 binding. Abolishes signaling. Markedly reduced coreceptor activity for HIV-1 isolate LAI.,MUTAGEN:D->N: Reduced coreceptor activity for HIV-1 isolate NDK.,MUTAGEN:D->R: Abolishes coreceptor activity for HIV-1 isolate NDK. Reduced coreceptor activity for several other HIV-1 isolates.,MUTAGEN:E->A: Markedly reduced coreceptor activity for HIV-1 isolate NDK. Less effect for HIV-1 isolate LAI.,MUTAGEN:E->Q: Reduced CXCL12 binding. Impaired signaling. Reduced coreceptor activity for HIV-1 isolate LAI. Enhanced coreceptor activity for HIV-1 isolate NDK.,MUTAGEN:EE->AA: Reduced CXCL12 binding. Reduced coreceptor activity for HIV-1 isolate NDK.,MUTAGEN:K->R: Loss of ubiquitination by RNF113A.,MUTAGEN:K->R: No effect on ubiquitination by RNF113A.,MUTAGEN:L->W: Increased thermostability.,MUTAGEN:Missing: Reduced CXCL12 binding. Abolishes signaling.,MUTAGEN:Missing: Reduced CXCL12 binding. Impaired signaling. Reduced coreceptor activity for HIV-1 isolates LAI and NDK.,MUTAGEN:Missing: Reduced CXCL12 binding. No effect on signaling.,MUTAGEN:N->A: Enhanced coreceptor activity on R5 HIV-1 isolate Envs; when associated with A-11.,MUTAGEN:N->A: Reduced molecular weight. Enhanced coreceptor activity on R5 HIV-1 isolate Envs. Slight further enhancement of coreceptor activity; when associated with A-13.,MUTAGEN:N->D: No reduction of agonist-induced G-protein activation.,MUTAGEN:N->K: Loss of agonist-induced G-protein activation.,MUTAGEN:N->S: Constitutive G-protein activation, with further activation induced by agonist.,MUTAGEN:R->A: Loss of agonist-induced G-protein activation.,MUTAGEN:R->A: Reduced coreceptor activity for several HIV-1 isolates.,MUTAGEN:S->A: Moderate degradation. About 60% reduction in binding ITCH and no ubiquitination nor protein degradation; when associated with A-324.,MUTAGEN:S->A: Moderate degradation. About 60% reduction in binding ITCH and no ubiquitination nor protein degradation; when associated with A-325.,MUTAGEN:S->A: No effect on binding to ITCH.,MUTAGEN:S->A: No effect on sulfate incorporation; when associated with A-8 and A-13.,MUTAGEN:S->A: Sulfate incorporation greatly reduced; when associated with F-21. Moderate reduction in sulfate incorporation; when associated with F-7 and F-12. No sulfate incorporation and binding SDF-1alpha greatly reduced; when associated with F-7; F-12; and F-21.,MUTAGEN:S->D: Enhanced binding to ITCH. Enhanced binding to ITCH and greatly increased protein degradation; when associated with D-324.,MUTAGEN:S->D: Enhanced binding to ITCH. Enhanced binding to ITCH and greatly increased protein degradation; when associated with D-325.,MUTAGEN:T->A: Enhanced coreceptor activity on R5 HIV-1 isolate Envs. No effect on sulfate incorporation; when associated with A-8 and A-9.,MUTAGEN:T->A: No effect on sulfate incorporation; when associated with A-9 and A-13.,MUTAGEN:T->P: Retains ligand-binding affinity but abolishes signaling.,MUTAGEN:Y->A: Greatly reduced coreceptor activity for HIV-1 isolates LAI and NDK; when associated with A-7.,MUTAGEN:Y->A: No reduction of agonist-induced G-protein activation.,MUTAGEN:Y->A: Reduced CXCL12 binding. Reduced coreceptor activity for HIV-1 isolates LAI and NDk.,MUTAGEN:Y->A: Reduced coreceptor activity for HIV-1 isolates LAI and NDK. Greatly reduced coreceptor activity for HIV-1 isolates LAI and NDK; when associated with A-12.,MUTAGEN:Y->F: Sulfate incorporation greatly reduced; when associated with F-12 and F-21. Moderate reduction in sulfate incorporation; when associated with F-12 and A-18. No sulfate incorporation and binding SDF-1alpha greatly reduced; when associated with F-12; A-18 and F-21.,MUTAGEN:Y->F: Sulfate incorporation greatly reduced; when associated with F-7 and F-12. Sulfate incorporation greatly reduced; when associated with A-18. No sulfate incorporation and binding SDF-1alpha greatly reduced; when associated with F-7; F-12 and A-18.,MUTAGEN:Y->F: Sulfate incorporation greatly reduced; when associated with F-7 and F-21. Moderate reduction in sulfate incorporation; when associated with F-7 and A-18. No sulfate incorporation and binding SDF-1alpha greatly reduced; when associated with F-7; A-18 and F-21.,REGION:Chemokine binding,REGION:Chemokine binding, important for signaling and HIV-1 coreceptor activity,REGION:Disordered,REGION:Important for chemokine binding, signaling and HIV-1 coreceptor activity,REGION:Involved in dimerization,REGION:Involved in dimerization; when bound to chemokine,SITE:Chemokine binding,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
CSK	C-terminal Src kinase(CSK)	Homo sapiens		h_cell2cellPathway:Cell to Cell Adhesion Signaling,h_cskPathway:Activation of Csk by cAMP-dependent Protein Kinase Inhibits Signaling through the T Cell Receptor,h_integrinPathway:Integrin Signaling Pathway,h_srcRPTPPathway:Activation of Src by Protein-tyrosine phosphatase alpha,		GO:0002250~adaptive immune response,GO:0006468~protein phosphorylation,GO:0007420~brain development,GO:0008285~negative regulation of cell proliferation,GO:0010989~negative regulation of low-density lipoprotein particle clearance,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0019221~cytokine-mediated signaling pathway,GO:0031295~T cell costimulation,GO:0032715~negative regulation of interleukin-6 production,GO:0033673~negative regulation of kinase activity,GO:0034332~adherens junction organization,GO:0042997~negative regulation of Golgi to plasma membrane protein transport,GO:0043406~positive regulation of MAP kinase activity,GO:0045779~negative regulation of bone resorption,GO:0046777~protein autophosphorylation,GO:0048709~oligodendrocyte differentiation,GO:0050765~negative regulation of phagocytosis,GO:0050852~T cell receptor signaling pathway,GO:0060368~regulation of Fc receptor mediated stimulatory signaling pathway,GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:0071375~cellular response to peptide hormone stimulus,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0045121~membrane raft,GO:0070062~extracellular exosome,	GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0004715~non-membrane spanning protein tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008022~protein C-terminus binding,GO:0019903~protein phosphatase binding,GO:0034236~protein kinase A catalytic subunit binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,GO:0070064~proline-rich region binding,	IPR000719:Protein kinase, catalytic domain,IPR000980:SH2 domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR001452:Src homology-3 domain,IPR008266:Tyrosine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,IPR020635:Tyrosine-protein kinase, catalytic domain,	hsa05120:Epithelial cell signaling in Helicobacter pylori infection,			SM00219:TyrKc,SM00252:SH2,SM00326:SH3,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0727~SH2 domain,KW-0728~SH3 domain,	KW-0067~ATP-binding,KW-0460~Magnesium,KW-0464~Manganese,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:ATP,DOMAIN:Protein kinase,DOMAIN:SH2,DOMAIN:SH3,MUTAGEN:S->A: Strong decrease of phosphorylation by PRKACA (catalytic subunit of PKA).,MUTAGEN:Y->F: Abolishes phosphorylation.,MUTAGEN:Y->F: Decreases activity by two-thirds and alters conformation.,NP_BIND:ATP,REGION:Interaction with PTPN22,
C2CD2	C2 calcium dependent domain containing 2(C2CD2)	Homo sapiens					GO:0005634~nucleus,GO:0005829~cytosol,GO:0016021~integral component of membrane,		IPR000008:C2 calcium-dependent membrane targeting,						KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	DOMAIN:C2,DOMAIN:SMP-LBD,REGION:Disordered,TRANSMEM:Helical,
C2CD2L	C2CD2 like(C2CD2L)	Homo sapiens				GO:0015914~phospholipid transport,GO:0035774~positive regulation of insulin secretion involved in cellular response to glucose stimulus,	GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0032541~cortical endoplasmic reticulum,GO:0098592~cytoplasmic side of apical plasma membrane,	GO:0005515~protein binding,GO:0008526~phosphatidylinositol transporter activity,GO:0035091~phosphatidylinositol binding,GO:0043559~insulin binding,						KW-0445~Lipid transport,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0446~Lipid-binding,		KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:C2,DOMAIN:SMP-LBD,REGION:Association with the cell membrane,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
CASC3	CASC3 exon junction complex subunit(CASC3)	Homo sapiens				GO:0000184~nuclear-transcribed mRNA catabolic process, nonsense-mediated decay,GO:0000398~mRNA splicing, via spliceosome,GO:0006397~mRNA processing,GO:0006405~RNA export from nucleus,GO:0006406~mRNA export from nucleus,GO:0006417~regulation of translation,GO:0008298~intracellular mRNA localization,GO:0008380~RNA splicing,GO:0031124~mRNA 3'-end processing,GO:0051028~mRNA transport,GO:2000622~regulation of nuclear-transcribed mRNA catabolic process, nonsense-mediated decay,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0010494~cytoplasmic stress granule,GO:0016607~nuclear speck,GO:0030425~dendrite,GO:0031965~nuclear membrane,GO:0035145~exon-exon junction complex,GO:0048471~perinuclear region of cytoplasm,GO:0071006~U2-type catalytic step 1 spliceosome,	GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0031625~ubiquitin protein ligase binding,GO:0042802~identical protein binding,	IPR018545:Btz domain,	hsa03013:Nucleocytoplasmic transport,hsa03015:mRNA surveillance pathway,			SM01044:SM01044,	KW-0346~Stress response,KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0509~mRNA transport,KW-0810~Translation regulation,KW-0813~Transport,KW-0866~Nonsense-mediated mRNA decay,	KW-0539~Nucleus,KW-0747~Spliceosome,KW-0963~Cytoplasm,KW-0966~Cell projection,		KW-0175~Coiled coil,		KW-0694~RNA-binding,	KW-0013~ADP-ribosylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Btz,MOTIF:Nuclear export signal,MOTIF:Nuclear localization signal 1,MOTIF:Nuclear localization signal 2,MUTAGEN:F->A: Does not affect EJC formation.,MUTAGEN:HD->AA: Abolishes interaction with EIF4A3, EJC formation and localization in nucleus speckles.,MUTAGEN:RK->AA: Does not affect EJC formation.,MUTAGEN:W->A: Abolishes interaction with EIF4A3, EJC formation and localization in nucleus speckles.,MUTAGEN:Y->A: Does not affect EJC formation.,MUTAGEN:YG->AA: Abolishes interaction with EIF4A3, EJC formation and localization in nucleus speckles.,REGION:Disordered,REGION:Necessary for RNA-binding, interaction with MAGOH and localization in nucleus speckles,REGION:Necessary for localization in cytoplasmic stress granules,REGION:Sufficient to form the EJC,
CFLAR	CASP8 and FADD like apoptosis regulator(CFLAR)	Homo sapiens	36.Death_of_Key_Intracellular_Targets,86.Apoptosis_Nematode&_Vert,	h_deathPathway:Induction of apoptosis through DR3 and DR4/5 Death Receptors ,h_fasPathway:FAS signaling pathway ( CD95 ),h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_il2rbPathway:IL-2 Receptor Beta Chain in T cell Activation,		GO:0006508~proteolysis,GO:0006915~apoptotic process,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0007519~skeletal muscle tissue development,GO:0010667~negative regulation of cardiac muscle cell apoptotic process,GO:0010803~regulation of tumor necrosis factor-mediated signaling pathway,GO:0010976~positive regulation of neuron projection development,GO:0014732~skeletal muscle atrophy,GO:0014842~regulation of skeletal muscle satellite cell proliferation,GO:0014866~skeletal myofibril assembly,GO:0016032~viral process,GO:0032869~cellular response to insulin stimulus,GO:0033574~response to testosterone,GO:0042060~wound healing,GO:0042981~regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043403~skeletal muscle tissue regeneration,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0060544~regulation of necroptotic process,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071364~cellular response to epidermal growth factor stimulus,GO:0071392~cellular response to estradiol stimulus,GO:0071456~cellular response to hypoxia,GO:0071549~cellular response to dexamethasone stimulus,GO:0071732~cellular response to nitric oxide,GO:0072126~positive regulation of glomerular mesangial cell proliferation,GO:0097190~apoptotic signaling pathway,GO:0097194~execution phase of apoptosis,GO:1901740~negative regulation of myoblast fusion,GO:1902041~regulation of extrinsic apoptotic signaling pathway via death domain receptors,GO:1902042~negative regulation of extrinsic apoptotic signaling pathway via death domain receptors,GO:1903055~positive regulation of extracellular matrix organization,GO:1903427~negative regulation of reactive oxygen species biosynthetic process,GO:1903845~negative regulation of cellular response to transforming growth factor beta stimulus,GO:1903944~negative regulation of hepatocyte apoptotic process,GO:2000347~positive regulation of hepatocyte proliferation,GO:2001237~negative regulation of extrinsic apoptotic signaling pathway,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0031264~death-inducing signaling complex,GO:0031265~CD95 death-inducing signaling complex,GO:0045121~membrane raft,GO:0097342~ripoptosome,	GO:0002020~protease binding,GO:0004197~cysteine-type endopeptidase activity,GO:0005123~death receptor binding,GO:0005515~protein binding,GO:0008047~enzyme activator activity,GO:0044877~macromolecular complex binding,GO:0097153~cysteine-type endopeptidase activity involved in apoptotic process,GO:0097199~cysteine-type endopeptidase activity involved in apoptotic signaling pathway,GO:0097200~cysteine-type endopeptidase activity involved in execution phase of apoptosis,	IPR001309:Peptidase C14, ICE, catalytic subunit p20,IPR001875:Death effector domain,IPR002398:Peptidase C14, caspase precursor p45,IPR011029:Death-like domain,IPR015917:Peptidase C14, caspase precursor p45, core,	hsa04064:NF-kappa B signaling pathway,hsa04140:Autophagy - animal,hsa04210:Apoptosis,hsa04217:Necroptosis,hsa04668:TNF signaling pathway,hsa05142:Chagas disease,hsa05160:Hepatitis C,			SM00031:DED,SM00115:CASc,	KW-0053~Apoptosis,KW-0945~Host-virus interaction,			KW-0677~Repeat,				DOMAIN:CASPASE_P20,DOMAIN:DED,DOMAIN:DED 1,DOMAIN:DED 2,MUTAGEN:D->N,A: Abolishes proteolytic processing.,MUTAGEN:Y->F: Decreases apoptosis-inducing activity. Reduces interaction with caspase-3 and proteolytic processing.,REGION:Caspase,REGION:Interaction with CASP3,REGION:Interaction with CASP8,REGION:Interaction with CASP8 propeptide,REGION:Interaction with CASP8 subunits p18 and p10,REGION:Interaction with FADD,REGION:Interaction with TRAF1 and TRAF2,REGION:Not proteolytically processed and involved in apoptosis inhibition,SITE:Cleavage; by CASP8,
CEBPA	CCAAT enhancer binding protein alpha(CEBPA)	Homo sapiens		h_keratinocytePathway:Keratinocyte Differentiation,h_mapkPathway:MAPKinase Signaling Pathway,		GO:0000050~urea cycle,GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001889~liver development,GO:0001892~embryonic placenta development,GO:0006091~generation of precursor metabolites and energy,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006360~transcription from RNA polymerase I promoter,GO:0007005~mitochondrion organization,GO:0007219~Notch signaling pathway,GO:0008203~cholesterol metabolic process,GO:0008285~negative regulation of cell proliferation,GO:0010628~positive regulation of gene expression,GO:0016032~viral process,GO:0019221~cytokine-mediated signaling pathway,GO:0030099~myeloid cell differentiation,GO:0030225~macrophage differentiation,GO:0030324~lung development,GO:0030851~granulocyte differentiation,GO:0032436~positive regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0042593~glucose homeostasis,GO:0043032~positive regulation of macrophage activation,GO:0045444~fat cell differentiation,GO:0045600~positive regulation of fat cell differentiation,GO:0045669~positive regulation of osteoblast differentiation,GO:0045736~negative regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0045945~positive regulation of transcription from RNA polymerase III promoter,GO:0048469~cell maturation,GO:0048839~inner ear development,GO:0050729~positive regulation of inflammatory response,GO:0050872~white fat cell differentiation,GO:0050873~brown fat cell differentiation,GO:0055088~lipid homeostasis,GO:0070102~interleukin-6-mediated signaling pathway,GO:0071285~cellular response to lithium ion,GO:0071356~cellular response to tumor necrosis factor,GO:0071407~cellular response to organic cyclic compound,GO:2000144~positive regulation of DNA-templated transcription, initiation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005730~nucleolus,GO:0036488~CHOP-C/EBP complex,GO:0043231~intracellular membrane-bounded organelle,GO:0090575~RNA polymerase II transcription factor complex,GO:1990647~C/EBP complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001163~RNA polymerase I regulatory region sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0019900~kinase binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0097677~STAT family protein binding,	IPR004827:Basic-leucine zipper domain,IPR016468:CCAAT/enhancer-binding,	hsa04932:Non-alcoholic fatty liver disease,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05221:Acute myeloid leukemia,	601626~Leukemia, acute myeloid,601626~Leukemia, acute myeloid, somatic,	PIRSF005879:CCAAT/enhancer-binding protein,	SM00338:BRLZ,	KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,	KW-0225~Disease variant,			KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:bZIP,MUTAGEN:D->A: No effect on interaction with TRIB1.,MUTAGEN:E->A: Decreased interaction with TRIB1.,MUTAGEN:E->T: No effect on interaction with TRIB1.,MUTAGEN:H->D: No effect on interaction with TRIB1.,MUTAGEN:I->A: Decreased interaction with TRIB1.,MUTAGEN:S->A: Decreased interaction with TRIB1.,MUTAGEN:S->A: No effect on interaction with TRIB1.,MUTAGEN:Y->A: Decreased interaction with TRIB1.,MUTAGEN:Y->F: No effect on interaction with TRIB1.,REGION:Basic motif,REGION:Disordered,REGION:Interaction with FOXO1,REGION:Leucine-zipper,REGION:Required for interaction with TRIB1,REGION:Required to functionally cooperate with SREBF1 in promoter activation,REGION:Required to induce adipocyte differentiation,REGION:Required to repress E2F1:TFDP1-mediated transcription, to inhibit cell cycle and to induce adipocyte differentiation,
CEBPD	CCAAT enhancer binding protein delta(CEBPD)	Homo sapiens				GO:0002244~hematopoietic progenitor cell differentiation,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0019058~viral life cycle,GO:0019221~cytokine-mediated signaling pathway,GO:0045444~fat cell differentiation,GO:0045595~regulation of cell differentiation,GO:0045669~positive regulation of osteoblast differentiation,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048839~inner ear development,	GO:0000785~chromatin,GO:0005654~nucleoplasm,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR004827:Basic-leucine zipper domain,IPR016468:CCAAT/enhancer-binding,			PIRSF005879:CCAAT/enhancer-binding protein,	SM00338:BRLZ,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),DOMAIN:bZIP,MUTAGEN:K->A: Loss of sumoylation.,REGION:Basic motif,REGION:Disordered,REGION:Leucine-zipper,
CEBPZ	CCAAT enhancer binding protein zeta(CEBPZ)	Homo sapiens				GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,GO:0016602~CCAAT-binding factor complex,	GO:0003713~transcription coactivator activity,GO:0003723~RNA binding,	IPR005612:CCAAT-binding factor,IPR016024:Armadillo-type fold,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,REGION:Disordered,
CNOT4	CCR4-NOT transcription complex subunit 4(CNOT4)	Homo sapiens			Transcription,	GO:0000289~nuclear-transcribed mRNA poly(A) tail shortening,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0006977~DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest,GO:0016567~protein ubiquitination,GO:0045652~regulation of megakaryocyte differentiation,GO:0051865~protein autoubiquitination,	GO:0005634~nucleus,GO:0005829~cytosol,GO:0030014~CCR4-NOT complex,	GO:0003723~RNA binding,GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR000504:RNA recognition motif domain,IPR000571:Zinc finger, CCCH-type,IPR001841:Zinc finger, RING-type,IPR003954:RNA recognition motif domain, eukaryote,IPR012677:Nucleotide-binding, alpha-beta plait,IPR013083:Zinc finger, RING/FYVE/PHD-type,	hsa03018:RNA degradation,			SM00361:RRM_1,	KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0694~RNA-binding,KW-0808~Transferase,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:C3H1-type,DOMAIN:RING-type,DOMAIN:RRM,MUTAGEN:C->A: Abolishes interaction with E2 ubiquitin ligases.,MUTAGEN:C->R: Abolishes interaction with E2 ubiquitin ligases.,MUTAGEN:E->A: Strongly reduces interaction with E2 ubiquitin ligases.,MUTAGEN:E->K: Strongly reduced interaction with UBE2D2.,MUTAGEN:I->A,W: Strongly reduces interaction with E2 ubiquitin ligases.,MUTAGEN:L->A,E: Abolishes interaction with E2 ubiquitin ligases.,MUTAGEN:M->A: Strongly reduces interaction with E2 ubiquitin ligases.,MUTAGEN:P->A: Strongly reduces interaction with E2 ubiquitin ligases.,MUTAGEN:R->A,E: Strongly reduces interaction with E2 ubiquitin ligases.,MUTAGEN:W->A: Strongly reduces interaction with E2 ubiquitin ligases.,REGION:Disordered,ZN_FING:C3H1-type,ZN_FING:RING-type; degenerate,
CD320	CD320 molecule(CD320)	Homo sapiens				GO:0006897~endocytosis,GO:0007165~signal transduction,GO:0009235~cobalamin metabolic process,GO:0015889~cobalamin transport,GO:0030656~regulation of vitamin metabolic process,GO:0030890~positive regulation of B cell proliferation,GO:0031296~B cell costimulation,	GO:0005783~endoplasmic reticulum,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0010008~endosome membrane,GO:0016020~membrane,	GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008083~growth factor activity,GO:0031419~cobalamin binding,GO:0038024~cargo receptor activity,	IPR002172:Low-density lipoprotein (LDL) receptor class A repeat,IPR023415:Low-density lipoprotein (LDL) receptor class A, conserved site,		613646~Methylmalonic aciduria, transient, due to transcobalamin receptor defect,		SM00192:LDLa,		KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0339~Growth factor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:LDL-receptor class A 1,DOMAIN:LDL-receptor class A 2,METAL:Calcium 1,METAL:Calcium 1; via carbonyl oxygen,METAL:Calcium 2,METAL:Calcium 2; via carbonyl oxygen,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD40	CD40 molecule(CD40)	Homo sapiens	125.T_Cells_CNS-APCs,15.T-cell_polarization-chemokine_receptors,19.Cytokine_microglia,5.B7_CD40_B-cell_activa,50.Hypothesis_of_bronchial_asthma,55.Allergen_recognition_by_Th2_or_Th0_cell,58.(CD40L)_immnosurveillance,99.NF-kB_activation,	h_asbcellPathway:Antigen Dependent B Cell Activation,h_bbcellPathway:Bystander B Cell Activation,h_blymphocytePathway:B Lymphocyte Cell Surface Molecules,h_cd40Pathway:CD40L Signaling Pathway,h_dcPathway:Dendritic cells in regulating TH1 and TH2 Development,h_th1th2Pathway:Th1/Th2 Differentiation,		GO:0001934~positive regulation of protein phosphorylation,GO:0002768~immune response-regulating cell surface receptor signaling pathway,GO:0006874~cellular calcium ion homeostasis,GO:0006954~inflammatory response,GO:0019724~B cell mediated immunity,GO:0023035~CD40 signaling pathway,GO:0030168~platelet activation,GO:0030890~positive regulation of B cell proliferation,GO:0032735~positive regulation of interleukin-12 production,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0033590~response to cobalamin,GO:0034341~response to interferon-gamma,GO:0035666~TRIF-dependent toll-like receptor signaling pathway,GO:0036018~cellular response to erythropoietin,GO:0042100~B cell proliferation,GO:0042113~B cell activation,GO:0042531~positive regulation of tyrosine phosphorylation of STAT protein,GO:0042832~defense response to protozoan,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043406~positive regulation of MAP kinase activity,GO:0043491~protein kinase B signaling,GO:0043536~positive regulation of blood vessel endothelial cell migration,GO:0043547~positive regulation of GTPase activity,GO:0045766~positive regulation of angiogenesis,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048304~positive regulation of isotype switching to IgG isotypes,GO:0050776~regulation of immune response,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051607~defense response to virus,GO:0065003~macromolecular complex assembly,GO:0071222~cellular response to lipopolysaccharide,GO:0071260~cellular response to mechanical stimulus,GO:0071347~cellular response to interleukin-1,GO:0071356~cellular response to tumor necrosis factor,GO:0090037~positive regulation of protein kinase C signaling,GO:1901652~response to peptide,GO:2000353~positive regulation of endothelial cell apoptotic process,	GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0035631~CD40 receptor complex,GO:0043025~neuronal cell body,GO:0043196~varicosity,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,	GO:0003823~antigen binding,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0019904~protein domain specific binding,GO:0031625~ubiquitin protein ligase binding,GO:0038023~signaling receptor activity,	IPR001368:TNFR/NGFR cysteine-rich region,IPR020435:Tumour necrosis factor receptor 5,	hsa04060:Cytokine-cytokine receptor interaction,hsa04064:NF-kappa B signaling pathway,hsa04514:Cell adhesion molecules,hsa04620:Toll-like receptor signaling pathway,hsa04672:Intestinal immune network for IgA production,hsa05144:Malaria,hsa05145:Toxoplasmosis,hsa05166:Human T-cell leukemia virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05202:Transcriptional misregulation in cancer,hsa05310:Asthma,hsa05320:Autoimmune thyroid disease,hsa05322:Systemic lupus erythematosus,hsa05330:Allograft rejection,hsa05340:Primary immunodeficiency,hsa05416:Viral myocarditis,hsa05417:Lipid and atherosclerosis,	606843~Immunodeficiency with hyper-IgM, type 3,		SM00208:TNFR,	KW-0391~Immunity,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:TNFR-Cys,REGION:Disordered,REPEAT:TNFR-Cys,REPEAT:TNFR-Cys 1,REPEAT:TNFR-Cys 2,REPEAT:TNFR-Cys 3,REPEAT:TNFR-Cys 4,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD44	CD44 molecule (Indian blood group)(CD44)	Homo sapiens	124.GH-IGF1_thymopoiesis,160.abT-cell_development,	h_lymphocytePathway:Adhesion Molecules on Lymphocyte,h_monocytePathway:Monocyte and its Surface Molecules,h_neutrophilPathway:Neutrophil and Its Surface Molecules,		GO:0006954~inflammatory response,GO:0007155~cell adhesion,GO:0007160~cell-matrix adhesion,GO:0016477~cell migration,GO:0019221~cytokine-mediated signaling pathway,GO:0022617~extracellular matrix disassembly,GO:0030198~extracellular matrix organization,GO:0030214~hyaluronan catabolic process,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0033674~positive regulation of kinase activity,GO:0034116~positive regulation of heterotypic cell-cell adhesion,GO:0042110~T cell activation,GO:0043066~negative regulation of apoptotic process,GO:0043154~negative regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0043312~neutrophil degranulation,GO:0043518~negative regulation of DNA damage response, signal transduction by p53 class mediator,GO:0044319~wound healing, spreading of cells,GO:0044344~cellular response to fibroblast growth factor stimulus,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0050900~leukocyte migration,GO:0051216~cartilage development,GO:0060333~interferon-gamma-mediated signaling pathway,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0070487~monocyte aggregation,GO:0098609~cell-cell adhesion,GO:1900625~positive regulation of monocyte aggregation,GO:1902166~negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator,GO:2000392~regulation of lamellipodium morphogenesis,	GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005902~microvillus,GO:0005925~focal adhesion,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0030667~secretory granule membrane,GO:0031258~lamellipodium membrane,GO:0035692~macrophage migration inhibitory factor receptor complex,GO:0042995~cell projection,GO:0070062~extracellular exosome,	GO:0004888~transmembrane signaling receptor activity,GO:0004896~cytokine receptor activity,GO:0005515~protein binding,GO:0005518~collagen binding,GO:0005540~hyaluronic acid binding,	IPR000538:Link,IPR001231:CD44 antigen,IPR016186:C-type lectin-like,IPR016187:C-type lectin fold,	hsa04512:ECM-receptor interaction,hsa04640:Hematopoietic cell lineage,hsa05131:Shigellosis,hsa05169:Epstein-Barr virus infection,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,	609027~Blood group, Indian system,		SM00445:LINK,	KW-0130~Cell adhesion,	KW-0472~Membrane,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0095~Blood group antigen,KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0654~Proteoglycan,KW-1015~Disulfide bond,	BINDING:Hyaluronan,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Link,REGION:Disordered,REGION:Required for interaction with EZR, MSN and RDX and for co-localization to microvilli,REGION:Stem,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD58	CD58 molecule(CD58)	Homo sapiens	7.IL17_hematopoesis,	h_il17Pathway:IL 17 Signaling Pathway,		GO:0032757~positive regulation of interleukin-8 production,GO:0034113~heterotypic cell-cell adhesion,GO:0043312~neutrophil degranulation,GO:0050900~leukocyte migration,GO:0071346~cellular response to interferon-gamma,GO:0071356~cellular response to tumor necrosis factor,GO:0098609~cell-cell adhesion,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030667~secretory granule membrane,GO:0070062~extracellular exosome,GO:0101003~ficolin-1-rich granule membrane,	GO:0005102~receptor binding,GO:0005515~protein binding,	IPR013783:Immunoglobulin-like fold,IPR015714:Lymphocyte function associated antigen 3,	hsa04514:Cell adhesion molecules,hsa05169:Epstein-Barr virus infection,					KW-0472~Membrane,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,MUTAGEN:F->S: No effect on CD2-binding.,MUTAGEN:L->G: No effect on CD2-binding.,MUTAGEN:T->S: No effect on CD2-binding.,MUTAGEN:V->K: No effect on CD2-binding.,MUTAGEN:V->Q: No effect on CD2-binding.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CISD1	CDGSH iron sulfur domain 1(CISD1)	Homo sapiens				GO:0010506~regulation of autophagy,GO:0043457~regulation of cellular respiration,	GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0016021~integral component of membrane,GO:0032473~cytoplasmic side of mitochondrial outer membrane,	GO:0042802~identical protein binding,GO:0046872~metal ion binding,GO:0051537~2 iron, 2 sulfur cluster binding,	IPR018967:Iron sulphur-containing domain, CDGSH-type,IPR019610:Iron sulphur domain-containing, mitoNEET, N-terminal,				SM00704:ZnF_CDGSH,		KW-0472~Membrane,KW-0496~Mitochondrion,KW-1000~Mitochondrion outer membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0001~2Fe-2S,KW-0408~Iron,KW-0411~Iron-sulfur,KW-0479~Metal-binding,		KW-0007~Acetylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate,DOMAIN:ZnF_CDGSH,METAL:Iron-sulfur (2Fe-2S),METAL:Iron-sulfur (2Fe-2S); via pros nitrogen,MUTAGEN:C->S: Abolishes absorption in the 300-500 nm range.,MUTAGEN:D->N: Does not affect absorption in the 300-500 nm range.,MUTAGEN:H->C: Affects absorption in the 300-500 nm range but it is not reduced. Increased stability of the 2Fe-2S cluster at low pH.,MUTAGEN:H->Q: Abolishes absorption in the 300-500 nm range.,TOPO_DOM:Cytoplasmic,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type III membrane protein,
COPS7A	COP9 signalosome subunit 7A(COPS7A)	Homo sapiens				GO:0000338~protein deneddylation,GO:0000715~nucleotide-excision repair, DNA damage recognition,GO:0006283~transcription-coupled nucleotide-excision repair,GO:0010387~COP9 signalosome assembly,GO:0016032~viral process,GO:0043687~post-translational protein modification,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0008180~COP9 signalosome,	GO:0005515~protein binding,	IPR000717:Proteasome component (PCI) domain,				SM00088:PINT,	KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0736~Signalosome,KW-0963~Cytoplasm,		KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:PCI,REGION:Disordered,
COPB2	COPI coat complex subunit beta 2(COPB2)	Homo sapiens			General function prediction only,	GO:0006886~intracellular protein transport,GO:0006888~ER to Golgi vesicle-mediated transport,GO:0006890~retrograde vesicle-mediated transport, Golgi to ER,GO:0006891~intra-Golgi vesicle-mediated transport,GO:0016192~vesicle-mediated transport,GO:1901998~toxin transport,	GO:0000139~Golgi membrane,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0030117~membrane coat,GO:0030126~COPI vesicle coat,GO:0030133~transport vesicle,	GO:0005198~structural molecule activity,GO:0005515~protein binding,	IPR001680:WD40 repeat,IPR006692:Coatomer, WD associated region,IPR011044:Quinoprotein amine dehydrogenase, beta chain-like,IPR015943:WD40/YVTN repeat-like-containing domain,IPR016453:Coatomer beta' subunit (COPB2),IPR017986:WD40-repeat-containing domain,IPR020472:G-protein beta WD-40 repeat,		617800~Microcephaly 19, primary, autosomal recessive,	PIRSF005567:coatomer, beta' subunit,	SM00320:WD40,	KW-0653~Protein transport,KW-0813~Transport,KW-0931~ER-Golgi transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,	KW-0225~Disease variant,KW-0905~Primary microcephaly,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0853~WD repeat,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:Coatomer_WDAD,REGION:Disordered,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,
CRKL	CRK like proto-oncogene, adaptor protein(CRKL)	Homo sapiens		h_gleevecPathway:Inhibition of Cellular Proliferation by Gleevec,h_il2rbPathway:IL-2 Receptor Beta Chain in T cell Activation,h_integrinPathway:Integrin Signaling Pathway,h_metPathway:Signaling of Hepatocyte Growth Factor Receptor,h_pyk2Pathway:Links between Pyk2 and Map Kinases,		GO:0000186~activation of MAPKK activity,GO:0000187~activation of MAPK activity,GO:0001558~regulation of cell growth,GO:0001568~blood vessel development,GO:0001655~urogenital system development,GO:0001764~neuron migration,GO:0001783~B cell apoptotic process,GO:0001933~negative regulation of protein phosphorylation,GO:0001934~positive regulation of protein phosphorylation,GO:0003151~outflow tract morphogenesis,GO:0006629~lipid metabolic process,GO:0007165~signal transduction,GO:0007254~JNK cascade,GO:0007265~Ras protein signal transduction,GO:0007283~spermatogenesis,GO:0007338~single fertilization,GO:0007416~synapse assembly,GO:0008284~positive regulation of cell proliferation,GO:0008543~fibroblast growth factor receptor signaling pathway,GO:0008584~male gonad development,GO:0009952~anterior/posterior pattern specification,GO:0010629~negative regulation of gene expression,GO:0016358~dendrite development,GO:0016477~cell migration,GO:0019221~cytokine-mediated signaling pathway,GO:0021766~hippocampus development,GO:0021987~cerebral cortex development,GO:0030010~establishment of cell polarity,GO:0033628~regulation of cell adhesion mediated by integrin,GO:0035556~intracellular signal transduction,GO:0035685~helper T cell diapedesis,GO:0035690~cellular response to drug,GO:0038026~reelin-mediated signaling pathway,GO:0046579~positive regulation of Ras protein signal transduction,GO:0048384~retinoic acid receptor signaling pathway,GO:0048538~thymus development,GO:0050773~regulation of dendrite development,GO:0050852~T cell receptor signaling pathway,GO:0060017~parathyroid gland development,GO:0060326~cell chemotaxis,GO:0060465~pharynx development,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071466~cellular response to xenobiotic stimulus,GO:0071560~cellular response to transforming growth factor beta stimulus,GO:0086100~endothelin receptor signaling pathway,GO:0090630~activation of GTPase activity,GO:0095500~acetylcholine receptor signaling pathway,GO:0098749~cerebellar neuron development,GO:0098761~cellular response to interleukin-7,GO:1900026~positive regulation of substrate adhesion-dependent cell spreading,GO:1903977~positive regulation of glial cell migration,GO:1904393~regulation of skeletal muscle acetylcholine-gated channel clustering,GO:1904888~cranial skeletal system development,GO:2000404~regulation of T cell migration,	GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0031594~neuromuscular junction,GO:0032991~macromolecular complex,GO:0098890~extrinsic component of postsynaptic membrane,	GO:0001784~phosphotyrosine binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0030971~receptor tyrosine kinase binding,GO:0035591~signaling adaptor activity,GO:0042802~identical protein binding,GO:0045296~cadherin binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,	IPR000980:SH2 domain,IPR001452:Src homology-3 domain,	hsa04010:MAPK signaling pathway,hsa04012:ErbB signaling pathway,hsa04015:Rap1 signaling pathway,hsa04062:Chemokine signaling pathway,hsa04510:Focal adhesion,hsa04666:Fc gamma R-mediated phagocytosis,hsa04722:Neurotrophin signaling pathway,hsa04810:Regulation of actin cytoskeleton,hsa04910:Insulin signaling pathway,hsa04935:Growth hormone synthesis, secretion and action,hsa05100:Bacterial invasion of epithelial cells,hsa05131:Shigellosis,hsa05135:Yersinia infection,hsa05163:Human cytomegalovirus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,hsa05206:MicroRNAs in cancer,hsa05211:Renal cell carcinoma,hsa05220:Chronic myeloid leukemia,			SM00252:SH2,SM00326:SH3,				KW-0677~Repeat,KW-0727~SH2 domain,KW-0728~SH3 domain,			KW-0597~Phosphoprotein,	DOMAIN:SH2,DOMAIN:SH3 1,DOMAIN:SH3 2,MUTAGEN:W->L: Abolishes interaction with DOCK5.,REGION:Disordered,
CRK	CRK proto-oncogene, adaptor protein(CRK)	Homo sapiens		h_cxcr4Pathway:CXCR4 Signaling Pathway,h_metPathway:Signaling of Hepatocyte Growth Factor Receptor,		GO:0000186~activation of MAPKK activity,GO:0001764~neuron migration,GO:0001878~response to yeast,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006629~lipid metabolic process,GO:0007165~signal transduction,GO:0008360~regulation of cell shape,GO:0009966~regulation of signal transduction,GO:0014911~positive regulation of smooth muscle cell migration,GO:0016358~dendrite development,GO:0016477~cell migration,GO:0019221~cytokine-mediated signaling pathway,GO:0021766~hippocampus development,GO:0021987~cerebral cortex development,GO:0030010~establishment of cell polarity,GO:0030036~actin cytoskeleton organization,GO:0030307~positive regulation of cell growth,GO:0032956~regulation of actin cytoskeleton organization,GO:0033628~regulation of cell adhesion mediated by integrin,GO:0035020~regulation of Rac protein signal transduction,GO:0035685~helper T cell diapedesis,GO:0035728~response to hepatocyte growth factor,GO:0038026~reelin-mediated signaling pathway,GO:0038096~Fc-gamma receptor signaling pathway involved in phagocytosis,GO:0042542~response to hydrogen peroxide,GO:0043087~regulation of GTPase activity,GO:0043393~regulation of protein binding,GO:0045953~negative regulation of natural killer cell mediated cytotoxicity,GO:0048010~vascular endothelial growth factor receptor signaling pathway,GO:0048013~ephrin receptor signaling pathway,GO:0050773~regulation of dendrite development,GO:0060326~cell chemotaxis,GO:0061045~negative regulation of wound healing,GO:0061847~response to cholecystokinin,GO:0071560~cellular response to transforming growth factor beta stimulus,GO:0071732~cellular response to nitric oxide,GO:0090630~activation of GTPase activity,GO:0098749~cerebellar neuron development,GO:1900026~positive regulation of substrate adhesion-dependent cell spreading,GO:1902531~regulation of intracellular signal transduction,GO:1990090~cellular response to nerve growth factor stimulus,GO:1990314~cellular response to insulin-like growth factor stimulus,GO:1990859~cellular response to endothelin,GO:2000146~negative regulation of cell motility,GO:2000404~regulation of T cell migration,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0015629~actin cytoskeleton,GO:0016020~membrane,GO:0032991~macromolecular complex,GO:0045121~membrane raft,GO:0070062~extracellular exosome,	GO:0001784~phosphotyrosine binding,GO:0005159~insulin-like growth factor receptor binding,GO:0005515~protein binding,GO:0008092~cytoskeletal protein binding,GO:0017124~SH3 domain binding,GO:0019900~kinase binding,GO:0019904~protein domain specific binding,GO:0030159~receptor signaling complex scaffold activity,GO:0030971~receptor tyrosine kinase binding,GO:0031625~ubiquitin protein ligase binding,GO:0035591~signaling adaptor activity,GO:0042169~SH2 domain binding,GO:0043621~protein self-association,GO:0045309~protein phosphorylated amino acid binding,GO:0046875~ephrin receptor binding,GO:0097110~scaffold protein binding,GO:1990782~protein tyrosine kinase binding,	IPR000980:SH2 domain,IPR001452:Src homology-3 domain,	hsa04010:MAPK signaling pathway,hsa04012:ErbB signaling pathway,hsa04015:Rap1 signaling pathway,hsa04062:Chemokine signaling pathway,hsa04510:Focal adhesion,hsa04666:Fc gamma R-mediated phagocytosis,hsa04722:Neurotrophin signaling pathway,hsa04810:Regulation of actin cytoskeleton,hsa04910:Insulin signaling pathway,hsa04935:Growth hormone synthesis, secretion and action,hsa05100:Bacterial invasion of epithelial cells,hsa05131:Shigellosis,hsa05135:Yersinia infection,hsa05163:Human cytomegalovirus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,hsa05206:MicroRNAs in cancer,hsa05211:Renal cell carcinoma,hsa05220:Chronic myeloid leukemia,			SM00252:SH2,SM00326:SH3,		KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0656~Proto-oncogene,	KW-0677~Repeat,KW-0727~SH2 domain,KW-0728~SH3 domain,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Pro residues,DOMAIN:SH2,DOMAIN:SH3,DOMAIN:SH3 1,DOMAIN:SH3 2,MUTAGEN:D->K: Abolishes interaction with DOCK1.,MUTAGEN:W->K: Abolishes interaction with PEAK3.,MUTAGEN:W->K: No effect on interaction with PEAK3.,MUTAGEN:W->L: Abolishes interaction with DOCK5. Abolishes RAP1 activation.,REGION:Disordered,SITE:Proline switch,
CBLB	Cbl proto-oncogene B(CBLB)	Homo sapiens				GO:0002669~positive regulation of T cell anergy,GO:0006607~NLS-bearing protein import into nucleus,GO:0006955~immune response,GO:0007165~signal transduction,GO:0007166~cell surface receptor signaling pathway,GO:0007175~negative regulation of epidermal growth factor-activated receptor activity,GO:0016567~protein ubiquitination,GO:0018193~peptidyl-amino acid modification,GO:0023051~regulation of signaling,GO:0031398~positive regulation of protein ubiquitination,GO:0035556~intracellular signal transduction,GO:0042110~T cell activation,GO:0043087~regulation of GTPase activity,GO:0043393~regulation of protein binding,GO:0045732~positive regulation of protein catabolic process,GO:0046642~negative regulation of alpha-beta T cell proliferation,GO:0050852~T cell receptor signaling pathway,GO:0050860~negative regulation of T cell receptor signaling pathway,GO:2000583~regulation of platelet-derived growth factor receptor-alpha signaling pathway,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0045121~membrane raft,	GO:0001784~phosphotyrosine binding,GO:0004842~ubiquitin-protein transferase activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0017124~SH3 domain binding,GO:0030971~receptor tyrosine kinase binding,GO:0047690~aspartyltransferase activity,GO:0061630~ubiquitin protein ligase activity,	IPR001841:Zinc finger, RING-type,IPR003153:Adaptor protein Cbl, N-terminal helical,IPR009060:UBA-like,IPR011992:EF-hand-like domain,IPR013083:Zinc finger, RING/FYVE/PHD-type,IPR014741:Adaptor protein Cbl, EF hand-like,IPR014742:Adaptor protein Cbl, SH2-like,IPR015940:Ubiquitin-associated/translation elongation factor EF1B, N-terminal, eukaryote,IPR017907:Zinc finger, RING-type, conserved site,IPR024159:Adaptor protein Cbl, PTB domain,IPR024162:Adaptor protein Cbl,	hsa04012:ErbB signaling pathway,hsa04120:Ubiquitin mediated proteolysis,hsa04144:Endocytosis,hsa04625:C-type lectin receptor signaling pathway,hsa04660:T cell receptor signaling pathway,hsa04910:Insulin signaling pathway,hsa05162:Measles,			SM00165:UBA,SM00184:RING,	KW-0833~Ubl conjugation pathway,	KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0106~Calcium,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	BINDING:Phosphotyrosine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Cbl-PTB,DOMAIN:RING-type,DOMAIN:UBA,MUTAGEN:A->E: Loss of ubiquitin binding. Reduced levels of tyrosine phosphorylation.,MUTAGEN:C->A: Abolishes E3 activity but does not affect binding to substrates.,MUTAGEN:F->A: Loss of ubiquitin binding. Reduced levels of tyrosine phosphorylation.,MUTAGEN:G->E: Inhibits interaction with SYK. No effect on E3 activity.,MUTAGEN:GY->AQ: Abolishes interaction with ubiquitinated proteins.,MUTAGEN:I->E: Interferes with dimerization. Reduced E3 ubiquitin-protein ligase activity. Reduced levels of tyrosine phosphorylation.,MUTAGEN:K->A: No effect on interaction with SH3KBP1. Reduced interaction with CD2AP. Strongly reduced interaction with CD2AP; when associated with A-911.,MUTAGEN:L->A: No effect on interaction with ubiquitinated proteins.,MUTAGEN:M->A: Loss of ubiquitin binding. Reduced levels of tyrosine phosphorylation.,MUTAGEN:R->A: No effect on interaction with CD2AP. Reduced interaction with SH3KBP1. Strongly reduced interaction with SH3KBP1; when associated with A-911.,MUTAGEN:R->A: Reduced interaction with CD2AP and with SH3KBP1. Strongly reduced interaction with CD2AP; when associated with A-907. Strongly reduced interaction with SH3KBP1; when associated with A-904.,MUTAGEN:Y->E: Decreases affinity for E2 ubiquitin-conjugating enzymes.,MUTAGEN:Y->F: Inhibits interaction with CRKL. Abolishes interaction with CRKL; when associated with F-665.,MUTAGEN:Y->F: Slightly inhibits interaction with CRKL. Abolishes interaction with CRKL; when associated with F-709.,REGION:4H,REGION:Disordered,REGION:EF-hand-like,REGION:Interaction with SH3KBP1,REGION:Interaction with VAV1,REGION:Linker,REGION:SH2-like,ZN_FING:RING-type,
CHAC1	ChaC glutathione specific gamma-glutamylcyclotransferase 1(CHAC1)	Homo sapiens				GO:0006750~glutathione biosynthetic process,GO:0006751~glutathione catabolic process,GO:0006986~response to unfolded protein,GO:0007219~Notch signaling pathway,GO:0010955~negative regulation of protein processing,GO:0022008~neurogenesis,GO:0045746~negative regulation of Notch signaling pathway,GO:0070059~intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress,	GO:0005737~cytoplasm,GO:0005802~trans-Golgi network,GO:0005829~cytosol,	GO:0003839~gamma-glutamylcyclotransferase activity,GO:0005112~Notch binding,GO:0005515~protein binding,	IPR006840:ChaC-like protein,IPR013024:Butirosin biosynthesis, BtrG-like,	hsa00480:Glutathione metabolism,hsa01100:Metabolic pathways,				KW-0053~Apoptosis,KW-0524~Neurogenesis,KW-0834~Unfolded protein response,KW-0914~Notch signaling pathway,	KW-0333~Golgi apparatus,KW-0963~Cytoplasm,				KW-0456~Lyase,		ACT_SITE:Proton acceptor,REGION:Disordered,REGION:Substrate binding,
COASY	Coenzyme A synthase(COASY)	Homo sapiens			Coenzyme metabolism,	GO:0015937~coenzyme A biosynthetic process,GO:0016310~phosphorylation,	GO:0005741~mitochondrial outer membrane,GO:0005759~mitochondrial matrix,GO:0070062~extracellular exosome,	GO:0004140~dephospho-CoA kinase activity,GO:0004595~pantetheine-phosphate adenylyltransferase activity,GO:0005515~protein binding,GO:0005524~ATP binding,	IPR001977:Dephospho-CoA kinase,IPR004821:Cytidyltransferase-like domain,IPR014729:Rossmann-like alpha/beta/alpha sandwich fold,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa00770:Pantothenate and CoA biosynthesis,hsa01100:Metabolic pathways,hsa01240:Biosynthesis of cofactors,	615643~Neurodegeneration with brain iron accumulation 6,618266~Pontocerebellar hypoplasia, type 12,			KW-0173~Coenzyme A biosynthesis,	KW-0496~Mitochondrion,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0523~Neurodegeneration,	KW-0732~Signal,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0511~Multifunctional enzyme,KW-0548~Nucleotidyltransferase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	DOMAIN:DPCK,NP_BIND:ATP,REGION:Disordered,REGION:Phosphopantetheine adenylyltransferase,
DDX10	DEAD-box helicase 10(DDX10)	Homo sapiens			DNA replication, recombination, and repair / Transcription / Translation, ribosomal structure and biogenesis,	GO:0006364~rRNA processing,GO:0097065~anterior head development,	GO:0005634~nucleus,	GO:0003723~RNA binding,GO:0003724~RNA helicase activity,GO:0005524~ATP binding,GO:0016787~hydrolase activity,GO:0016887~ATPase activity,	IPR000629:RNA helicase, ATP-dependent, DEAD-box, conserved site,IPR001650:Helicase, C-terminal,IPR011545:DNA/RNA helicase, DEAD/DEAH box type, N-terminal,IPR014001:Helicase, superfamily 1/2, ATP-binding domain,IPR014014:RNA helicase, DEAD-box type, Q motif,IPR025313:Domain of unknown function DUF4217,IPR027417:P-loop containing nucleoside triphosphate hydrolase,				SM00487:DEXDc,SM00490:HELICc,SM01178:SM01178,					KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0347~Helicase,KW-0378~Hydrolase,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	BINDING:ATP,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Helicase ATP-binding,DOMAIN:Helicase C-terminal,DOMAIN:Q_MOTIF,MOTIF:DEAD box,MOTIF:Q motif,NP_BIND:ATP,REGION:Disordered,
DDX42	DEAD-box helicase 42(DDX42)	Homo sapiens				GO:0000398~mRNA splicing, via spliceosome,GO:0008104~protein localization,GO:0042981~regulation of apoptotic process,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0015030~Cajal body,GO:0016020~membrane,GO:0016607~nuclear speck,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0003724~RNA helicase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016787~hydrolase activity,GO:0016887~ATPase activity,	IPR000629:RNA helicase, ATP-dependent, DEAD-box, conserved site,IPR001650:Helicase, C-terminal,IPR011545:DNA/RNA helicase, DEAD/DEAH box type, N-terminal,IPR014001:Helicase, superfamily 1/2, ATP-binding domain,IPR014014:RNA helicase, DEAD-box type, Q motif,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa03040:Spliceosome,			SM00487:DEXDc,SM00490:HELICc,		KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0347~Helicase,KW-0378~Hydrolase,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Helicase ATP-binding,DOMAIN:Helicase C-terminal,DOMAIN:Q_MOTIF,MOTIF:DEAD box,MOTIF:Q motif,NP_BIND:ATP,REGION:Disordered,REGION:Necessary for interaction with TP53BP2,
DENND2D	DENN domain containing 2D(DENND2D)	Homo sapiens				GO:0050790~regulation of catalytic activity,	GO:0005654~nucleoplasm,GO:0005829~cytosol,	GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,	IPR001194:DENN domain,IPR005112:dDENN domain,IPR005113:uDENN domain,				SM00799:DENN,SM00800:uDENN,SM00801:dDENN,		KW-0963~Cytoplasm,				KW-0344~Guanine-nucleotide releasing factor,		DOMAIN:UDENN,DOMAIN:cDENN,DOMAIN:dDENN,DOMAIN:uDENN,REGION:Disordered,
DHX29	DExH-box helicase 29(DHX29)	Homo sapiens				GO:0001731~formation of translation preinitiation complex,GO:0042255~ribosome assembly,GO:0045948~positive regulation of translational initiation,	GO:0005622~intracellular,GO:0005737~cytoplasm,GO:0016282~eukaryotic 43S preinitiation complex,GO:0022627~cytosolic small ribosomal subunit,	GO:0003723~RNA binding,GO:0003724~RNA helicase activity,GO:0003743~translation initiation factor activity,GO:0005524~ATP binding,GO:0008494~translation activator activity,GO:0016818~hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides,GO:0016887~ATPase activity,GO:0017111~nucleoside-triphosphatase activity,GO:0043024~ribosomal small subunit binding,GO:0045296~cadherin binding,	IPR001650:Helicase, C-terminal,IPR002464:DNA/RNA helicase, ATP-dependent, DEAH-box type, conserved site,IPR007502:Helicase-associated domain,IPR011545:DNA/RNA helicase, DEAD/DEAH box type, N-terminal,IPR011709:Domain of unknown function DUF1605,IPR014001:Helicase, superfamily 1/2, ATP-binding domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,				SM00487:DEXDc,SM00490:HELICc,SM00847:SM00847,	KW-0648~Protein biosynthesis,	KW-0963~Cytoplasm,		KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0347~Helicase,KW-0378~Hydrolase,KW-0396~Initiation factor,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Helicase ATP-binding,DOMAIN:Helicase C-terminal,MOTIF:DEAH box,NP_BIND:ATP,REGION:Disordered,
DDIT4	DNA damage inducible transcript 4(DDIT4)	Homo sapiens				GO:0001666~response to hypoxia,GO:0001764~neuron migration,GO:0006915~apoptotic process,GO:0007420~brain development,GO:0010801~negative regulation of peptidyl-threonine phosphorylation,GO:0030182~neuron differentiation,GO:0032006~regulation of TOR signaling,GO:0032007~negative regulation of TOR signaling,GO:0032984~macromolecular complex disassembly,GO:0033137~negative regulation of peptidyl-serine phosphorylation,GO:0042771~intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator,GO:0045820~negative regulation of glycolytic process,GO:0048011~neurotrophin TRK receptor signaling pathway,GO:0051607~defense response to virus,GO:0071549~cellular response to dexamethasone stimulus,GO:0072593~reactive oxygen species metabolic process,GO:1901216~positive regulation of neuron death,GO:1902532~negative regulation of intracellular signal transduction,	GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0071889~14-3-3 protein binding,	IPR012918:RTP801-like,	hsa04140:Autophagy - animal,hsa04150:mTOR signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa05206:MicroRNAs in cancer,				KW-0051~Antiviral defense,KW-0053~Apoptosis,	KW-0496~Mitochondrion,KW-0963~Cytoplasm,					KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,MUTAGEN:C->S: Mildly reduces inhibition of mTORC1.,MUTAGEN:K->A: Reduces inhibition of mTORC1. Abolishes inhibition of mTORC1; when associated with A-222.,MUTAGEN:L->A: Reduces inhibition of mTORC1.,MUTAGEN:P->A: Abolishes inhibition of mTORC1.,MUTAGEN:R->A: No effect on inhibition of mTORC1.,MUTAGEN:S->A,D: No effect on inhibition of mTORC1.,MUTAGEN:S->A: Strongly inhibits proteasomal degradation.,MUTAGEN:S->L,W: No effect on inhibition of mTORC1.,MUTAGEN:T->A: Strongly inhibits proteasomal degradation. Strongly inhibits proteasomal degradation; when associated with A-25.,MUTAGEN:T->A: Strongly inhibits proteasomal degradation; when associated with A-23.,MUTAGEN:Y->A: Reduces inhibition of mTORC1. Abolishes inhibition of mTORC1; when associated with A-219.,REGION:Disordered,
DFFA	DNA fragmentation factor subunit alpha(DFFA)	Homo sapiens		h_caspasePathway:Caspase Cascade in Apoptosis,h_deathPathway:Induction of apoptosis through DR3 and DR4/5 Death Receptors ,h_DNAfragmentPathway:Apoptotic DNA fragmentation and tissue homeostasis,h_fasPathway:FAS signaling pathway ( CD95 ),h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_mitochondriaPathway:Role of Mitochondria in Apoptotic Signaling,h_setPathway:Granzyme A mediated Apoptosis Pathway,h_tnfr1Pathway:TNFR1 Signaling Pathway,		GO:0006309~apoptotic DNA fragmentation,GO:0007165~signal transduction,GO:0032076~negative regulation of deoxyribonuclease activity,GO:0042981~regulation of apoptotic process,GO:0043065~positive regulation of apoptotic process,GO:0061077~chaperone-mediated protein folding,GO:0070242~thymocyte apoptotic process,GO:1900118~negative regulation of execution phase of apoptosis,GO:1902511~negative regulation of apoptotic DNA fragmentation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0032991~macromolecular complex,	GO:0005515~protein binding,GO:0019904~protein domain specific binding,GO:0044183~protein binding involved in protein folding,GO:0060703~deoxyribonuclease inhibitor activity,	IPR000488:Death domain,IPR003508:Caspase-activated nuclease CIDE-N,IPR015121:DNA fragmentation factor 45kDa, middle domain,IPR017299:DNA fragmentation factor, alpha subunit,IPR027296:DNA fragmentation factor 45kDa C-terminal domain,	hsa04210:Apoptosis,		PIRSF037865:DNA fragmentation factor, alpha subunit,	SM00266:CAD,	KW-0053~Apoptosis,	KW-0963~Cytoplasm,		KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:CIDE-N,DOMAIN:Death,REGION:Disordered,SITE:Cleavage; by caspase-3,
DFFB	DNA fragmentation factor subunit beta(DFFB)	Homo sapiens		h_caspasePathway:Caspase Cascade in Apoptosis,h_deathPathway:Induction of apoptosis through DR3 and DR4/5 Death Receptors ,h_DNAfragmentPathway:Apoptotic DNA fragmentation and tissue homeostasis,h_fasPathway:FAS signaling pathway ( CD95 ),h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_mitochondriaPathway:Role of Mitochondria in Apoptotic Signaling,h_setPathway:Granzyme A mediated Apoptosis Pathway,h_tnfr1Pathway:TNFR1 Signaling Pathway,		GO:0006308~DNA catabolic process,GO:0006309~apoptotic DNA fragmentation,GO:0030263~apoptotic chromosome condensation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0032991~macromolecular complex,	GO:0003677~DNA binding,GO:0004520~endodeoxyribonuclease activity,GO:0004536~deoxyribonuclease activity,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0019904~protein domain specific binding,GO:0042802~identical protein binding,GO:0097718~disordered domain specific binding,	IPR003508:Caspase-activated nuclease CIDE-N,IPR015311:Apoptosis, DNA fragmentation factor 40kDa,	hsa04210:Apoptosis,			SM00266:CAD,	KW-0053~Apoptosis,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0378~Hydrolase,KW-0540~Nuclease,		DOMAIN:CIDE-N,DOMAIN:DFF40,
LIG1	DNA ligase 1(LIG1)	Homo sapiens				GO:0006260~DNA replication,GO:0006266~DNA ligation,GO:0006273~lagging strand elongation,GO:0006281~DNA repair,GO:0006283~transcription-coupled nucleotide-excision repair,GO:0006284~base-excision repair,GO:0006287~base-excision repair, gap-filling,GO:0006297~nucleotide-excision repair, DNA gap filling,GO:0006298~mismatch repair,GO:0006310~DNA recombination,GO:0009653~anatomical structure morphogenesis,GO:0051301~cell division,GO:0071897~DNA biosynthetic process,GO:1903461~Okazaki fragment processing involved in mitotic DNA replication,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0043231~intracellular membrane-bounded organelle,	GO:0003677~DNA binding,GO:0003909~DNA ligase activity,GO:0003910~DNA ligase (ATP) activity,GO:0005524~ATP binding,GO:0016874~ligase activity,GO:0046872~metal ion binding,	IPR000977:DNA ligase, ATP-dependent,IPR012308:DNA ligase, ATP-dependent, N-terminal,IPR012309:DNA ligase, ATP-dependent, C-terminal,IPR012310:DNA ligase, ATP-dependent, central,IPR012340:Nucleic acid-binding, OB-fold,IPR016059:DNA ligase, ATP-dependent, conserved site,	hsa03030:DNA replication,hsa03410:Base excision repair,hsa03420:Nucleotide excision repair,hsa03430:Mismatch repair,				KW-0131~Cell cycle,KW-0132~Cell division,KW-0227~DNA damage,KW-0233~DNA recombination,KW-0234~DNA repair,KW-0235~DNA replication,	KW-0539~Nucleus,			KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0436~Ligase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:N6-AMP-lysine intermediate,BINDING:ATP,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:DNA_LIGASE_A3,DOMAIN:DNA_ligase_A_N,METAL:Magnesium 1,METAL:Magnesium 2,REGION:Disordered,REGION:Interaction with target DNA,SITE:Interaction with target DNA,
DNMT1	DNA methyltransferase 1(DNMT1)	Homo sapiens				GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006306~DNA methylation,GO:0006325~chromatin organization,GO:0006346~methylation-dependent chromatin silencing,GO:0007265~Ras protein signal transduction,GO:0010216~maintenance of DNA methylation,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0032259~methylation,GO:0043045~DNA methylation involved in embryo development,GO:0045814~negative regulation of gene expression, epigenetic,GO:0051571~positive regulation of histone H3-K4 methylation,GO:0051573~negative regulation of histone H3-K9 methylation,GO:0071230~cellular response to amino acid stimulus,GO:0090116~C-5 methylation of cytosine,GO:0090309~positive regulation of methylation-dependent chromatin silencing,GO:1903926~cellular response to bisphenol A,GO:1904707~positive regulation of vascular smooth muscle cell proliferation,GO:1905460~negative regulation of vascular associated smooth muscle cell apoptotic process,GO:1905931~negative regulation of vascular smooth muscle cell differentiation involved in phenotypic switching,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005657~replication fork,GO:0005721~pericentric heterochromatin,	GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003723~RNA binding,GO:0003886~DNA (cytosine-5-)-methyltransferase activity,GO:0005515~protein binding,GO:0008168~methyltransferase activity,GO:0008270~zinc ion binding,GO:0008327~methyl-CpG binding,GO:0009008~DNA-methyltransferase activity,GO:1990841~promoter-specific chromatin binding,	IPR001025:Bromo adjacent homology (BAH) domain,IPR001525:C-5 cytosine methyltransferase,IPR002857:Zinc finger, CXXC-type,IPR010506:DMAP1-binding,IPR017198:DNA (cytosine-5)-methyltransferase 1, eukaryote,IPR018117:DNA methylase, C-5 cytosine-specific, active site,IPR022702:DNA (cytosine-5)-methyltransferase 1, replication foci domain,	hsa00270:Cysteine and methionine metabolism,hsa01100:Metabolic pathways,hsa05206:MicroRNAs in cancer,	604121~Cerebellar ataxia, deafness, and narcolepsy, autosomal dominant,614116~Neuropathy, hereditary sensory, type IE,	PIRSF037404:DNA (cytosine-5)-methyltransferase 1, DNMT1 type,	SM00439:BAH,SM01137:SM01137,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0209~Deafness,KW-0225~Disease variant,KW-0622~Neuropathy,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,KW-0949~S-adenosyl-L-methionine,	KW-0010~Activator,KW-0156~Chromatin regulator,KW-0238~DNA-binding,KW-0489~Methyltransferase,KW-0678~Repressor,KW-0808~Transferase,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	BINDING:S-adenosyl-L-methionine,BINDING:S-adenosyl-L-methionine; via amide nitrogen,BINDING:S-adenosyl-L-methionine; via carbonyl oxygen,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:BAH,DOMAIN:BAH 1,DOMAIN:BAH 2,DOMAIN:CXXC-type,DOMAIN:DMAP1-binding,DOMAIN:SAM-dependent MTase C5-type,METAL:Zinc,METAL:Zinc 1,METAL:Zinc 2,MOTIF:Nuclear localization signal,MUTAGEN:A->S: No loss of interaction with PCNA.,MUTAGEN:C->A: Loss of activity.,MUTAGEN:C->F: Reduces activity about 10-fold; when associated with G-653; G-656; G-659; G-667 and G-670.,MUTAGEN:C->G: Reduces activity about 10-fold; when associated with G-653; G-656; G-659; G-664 and G-667.,MUTAGEN:C->G: Reduces activity about 10-fold; when associated with G-653; G-656; G-659; G-664 and G-670.,MUTAGEN:C->G: Reduces activity about 10-fold; when associated with G-653; G-656; G-664; G-667 and G-670.,MUTAGEN:C->G: Reduces activity about 10-fold; when associated with G-653; G-659; G-664; G-667 and G-670.,MUTAGEN:C->G: Reduces activity about 10-fold; when associated with G-656; G-659; G-664; G-667 and G-670.,MUTAGEN:F->V: Abolishes interaction with PCNA.,MUTAGEN:H->V: Abolishes interaction with PCNA.,MUTAGEN:I->A: Abolishes interaction with PCNA.,MUTAGEN:K->A: No loss of interaction with PCNA.,MUTAGEN:Q->A: Abolishes interaction with PCNA.,MUTAGEN:R->A: Abolishes interaction with PCNA.,MUTAGEN:S->A: No loss of interaction with PCNA.,MUTAGEN:T->A: Abolishes interaction with PCNA.,REGION:6 X 2 AA tandem repeats of K-G,REGION:Autoinhibitory linker,REGION:Catalytic,REGION:DNA replication foci-targeting sequence,REGION:Disordered,REGION:Homodimerization,REGION:Interaction with DMAP1,REGION:Interaction with DNMT3A,REGION:Interaction with DNMT3B,REGION:Interaction with PCNA,REGION:Interaction with the PRC2/EED-EZH2 complex,REGION:Required for activity,REGION:S-adenosyl-L-methionine binding,REPEAT:1,REPEAT:2,REPEAT:3,REPEAT:4,REPEAT:5,REPEAT:6; approximate,SITE:Important for activity,ZN_FING:CXXC-type,
DNMT3A	DNA methyltransferase 3 alpha(DNMT3A)	Homo sapiens				GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000278~mitotic cell cycle,GO:0006306~DNA methylation,GO:0006346~methylation-dependent chromatin silencing,GO:0006349~regulation of gene expression by genetic imprinting,GO:0006479~protein methylation,GO:0007283~spermatogenesis,GO:0007568~aging,GO:0009410~response to xenobiotic stimulus,GO:0009636~response to toxic substance,GO:0010212~response to ionizing radiation,GO:0010288~response to lead ion,GO:0010468~regulation of gene expression,GO:0010942~positive regulation of cell death,GO:0030182~neuron differentiation,GO:0032355~response to estradiol,GO:0032776~DNA methylation on cytosine,GO:0033189~response to vitamin A,GO:0042220~response to cocaine,GO:0042493~response to drug,GO:0043045~DNA methylation involved in embryo development,GO:0043046~DNA methylation involved in gamete generation,GO:0045814~negative regulation of gene expression, epigenetic,GO:0045892~negative regulation of transcription, DNA-templated,GO:0071230~cellular response to amino acid stimulus,GO:0071361~cellular response to ethanol,GO:0071456~cellular response to hypoxia,GO:0090116~C-5 methylation of cytosine,GO:0097284~hepatocyte apoptotic process,GO:1903926~cellular response to bisphenol A,	GO:0000775~chromosome, centromeric region,GO:0000791~euchromatin,GO:0000792~heterochromatin,GO:0001741~XY body,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016363~nuclear matrix,GO:1902494~catalytic complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003714~transcription corepressor activity,GO:0003886~DNA (cytosine-5-)-methyltransferase activity,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0009008~DNA-methyltransferase activity,GO:0042802~identical protein binding,GO:0046872~metal ion binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,	IPR000313:PWWP,IPR001525:C-5 cytosine methyltransferase,IPR018117:DNA methylase, C-5 cytosine-specific, active site,IPR025766:ADD domain,	hsa00270:Cysteine and methionine metabolism,hsa01100:Metabolic pathways,hsa05206:MicroRNAs in cancer,	601626~Acute myeloid leukemia, somatic,615879~Tatton-Brown-Rahman syndrome,618724~Heyn-Sproul-Jackson syndrome,		SM00293:PWWP,		KW-0158~Chromosome,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0242~Dwarfism,KW-0991~Mental retardation,	KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,KW-0949~S-adenosyl-L-methionine,	KW-0156~Chromatin regulator,KW-0238~DNA-binding,KW-0489~Methyltransferase,KW-0678~Repressor,KW-0808~Transferase,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	BINDING:S-adenosyl-L-methionine,COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:ADD,DOMAIN:PHD-type,DOMAIN:PWWP,DOMAIN:SAM-dependent MTase C5-type,MUTAGEN:F->A: Loss of activity due to the incapacity to bind the regulatory subunit DNMT3L.,REGION:Disordered,REGION:Interaction with DNMT1 and DNMT3B,REGION:Interaction with the PRC2/EED-EZH2 complex,REGION:S-adenosyl-L-methionine binding,ZN_FING:GATA-type; atypical,ZN_FING:PHD-type; atypical,
POLB	DNA polymerase beta(POLB)	Homo sapiens				GO:0001701~in utero embryonic development,GO:0006260~DNA replication,GO:0006261~DNA-dependent DNA replication,GO:0006281~DNA repair,GO:0006284~base-excision repair,GO:0006286~base-excision repair, base-free sugar-phosphate removal,GO:0006287~base-excision repair, gap-filling,GO:0006288~base-excision repair, DNA ligation,GO:0006290~pyrimidine dimer repair,GO:0006303~double-strand break repair via nonhomologous end joining,GO:0006954~inflammatory response,GO:0006974~cellular response to DNA damage stimulus,GO:0007435~salivary gland morphogenesis,GO:0007568~aging,GO:0008630~intrinsic apoptotic signaling pathway in response to DNA damage,GO:0010332~response to gamma radiation,GO:0016446~somatic hypermutation of immunoglobulin genes,GO:0016579~protein deubiquitination,GO:0045471~response to ethanol,GO:0048535~lymph node development,GO:0048536~spleen development,GO:0048872~homeostasis of number of cells,GO:0051402~neuron apoptotic process,GO:0055093~response to hyperoxia,GO:0071707~immunoglobulin heavy chain V-D-J recombination,GO:0071897~DNA biosynthetic process,GO:0090305~nucleic acid phosphodiester bond hydrolysis,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005874~microtubule,GO:0005876~spindle microtubule,GO:0032991~macromolecular complex,	GO:0003677~DNA binding,GO:0003684~damaged DNA binding,GO:0003887~DNA-directed DNA polymerase activity,GO:0003906~DNA-(apurinic or apyrimidinic site) lyase activity,GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0016779~nucleotidyltransferase activity,GO:0016829~lyase activity,GO:0019899~enzyme binding,GO:0034061~DNA polymerase activity,GO:0046872~metal ion binding,	IPR002008:DNA polymerase, family X, beta-like,IPR002054:DNA-directed DNA polymerase X,IPR003583:Helix-hairpin-helix DNA-binding motif, class 1,IPR010996:DNA polymerase beta-like, N-terminal domain,IPR018944:DNA polymerase lambda, fingers domain,IPR019843:DNA polymerase family X, binding site,IPR022312:DNA polymerase family X,IPR027421:DNA polymerase family X lyase domain,	hsa03410:Base excision repair,hsa05166:Human T-cell leukemia virus 1 infection,hsa05203:Viral carcinogenesis,			SM00278:HhH1,SM00483:POLXc,	KW-0227~DNA damage,KW-0234~DNA repair,KW-0235~DNA replication,KW-0237~DNA synthesis,	KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0460~Magnesium,KW-0479~Metal-binding,KW-0915~Sodium,	KW-0238~DNA-binding,KW-0239~DNA-directed DNA polymerase,KW-0456~Lyase,KW-0548~Nucleotidyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0488~Methylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Schiff-base intermediate with DNA,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:DNA_pol_B_palm,DOMAIN:DNA_pol_B_thumb,DOMAIN:DNA_pol_lambd_f,DOMAIN:HhH1,DOMAIN:POLXc,METAL:Magnesium 1,METAL:Magnesium 2,METAL:Sodium; via carbonyl oxygen,MUTAGEN:K->Q,R: Abolishes DNA lyase activity. No effect on DNA polymerase activity.,MUTAGEN:K->Q,R: Reduces DNA lyase activity slightly.,MUTAGEN:K->R: Abolishes ubiquitination; when associated with R-41 and R-61.,MUTAGEN:K->R: Abolishes ubiquitination; when associated with R-41 and R-81.,MUTAGEN:K->R: Abolishes ubiquitination; when associated with R-61 and R-81.,MUTAGEN:K->R: No effect.,MUTAGEN:R->K: Slight effect. Abolishes methylation by PRMT6 and impairs the polymerase activity; when associated with K-152.,MUTAGEN:R->K: Slight effect. Abolishes methylation by PRMT6 and impairs the polymerase activity; when associated with K-83.,MUTAGEN:Y->Q: Abolishes DNA polymerase and DNA lyase activity.,REGION:DNA binding,
POLD4	DNA polymerase delta 4, accessory subunit(POLD4)	Homo sapiens				GO:0000723~telomere maintenance,GO:0000731~DNA synthesis involved in DNA repair,GO:0006260~DNA replication,GO:0006261~DNA-dependent DNA replication,GO:0006283~transcription-coupled nucleotide-excision repair,GO:0006287~base-excision repair, gap-filling,GO:0006296~nucleotide-excision repair, DNA incision, 5'-to lesion,GO:0006297~nucleotide-excision repair, DNA gap filling,GO:0006298~mismatch repair,GO:0019985~translesion synthesis,GO:0032201~telomere maintenance via semi-conservative replication,GO:0033683~nucleotide-excision repair, DNA incision,GO:0042769~DNA damage response, detection of DNA damage,	GO:0005654~nucleoplasm,GO:0043625~delta DNA polymerase complex,	GO:0003887~DNA-directed DNA polymerase activity,GO:0005515~protein binding,	IPR007218:DNA polymerase delta, subunit 4,	hsa03030:DNA replication,hsa03410:Base excision repair,hsa03420:Nucleotide excision repair,hsa03430:Mismatch repair,hsa03440:Homologous recombination,				KW-0227~DNA damage,KW-0228~DNA excision,KW-0234~DNA repair,KW-0235~DNA replication,	KW-0539~Nucleus,					KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,MOTIF:PCNA-interaction protein motif (PIP box),MUTAGEN:D->A: Strongly increased stability following UV irradiation; when associated with A-8.,MUTAGEN:I->A: Complete loss of PCNA binding; when associated with 10-AA-11.,MUTAGEN:K->A: Decreased PCNA binding. No effect on PCNA binding, but normal degradation after UV irradiation; when associated with Q-4 and Y-10. Increased stability following UV irradiation and no trough during S phase; when associated with A-16 and A-17.,MUTAGEN:K->A: No effect on PCNA binding.,MUTAGEN:K->Q: No effect on PCNA binding, nor on degradation after UV irradiation; when associated with Y-10. No effect on PCNA binding, but normal degradation after UV irradiation; when associated with Y-10 and A-15.,MUTAGEN:K->R: No effect on ubiquitination. Loss of ubiquitination, when associated with R-15, R-25, R-74 and R-89.,MUTAGEN:K->R: No effect on ubiquitination. Loss of ubiquitination; when associated with R-4, R-15, R-25 and R-74.,MUTAGEN:K->R: No effect on ubiquitination. Loss of ubiquitination; when associated with R-4, R-15, R-25 and R-89.,MUTAGEN:K->R: No effect on ubiquitination. Loss of ubiquitination; when associated with R-4, R-15, R-74 and R-89.,MUTAGEN:K->R: No effect on ubiquitination. Loss of ubiquitination; when associated with R-4, R-25, R-74 and R-89.,MUTAGEN:Missing: Complete loss of PCNA binding and of degradation after UV irradiation.,MUTAGEN:R->A: Increased stability following UV irradiation and no trough during S phase; when associated with A-15 and A-16.,MUTAGEN:R->A: Increased stability following UV irradiation and no trough during S phase; when associated with A-15 and A-17.,MUTAGEN:S->Y: No effect on PCNA binding, nor on degradation after UV irradiation; when associated with Q-4. No effect on PCNA binding, but normal degradation after UV irradiation with Q-4 and A-15.,MUTAGEN:SY->AA: Complete loss of PCNA binding; when associated with A-7.,MUTAGEN:T->A: Strongly increased stability following UV irradiation; when associated with A-9.,MUTAGEN:T->D: Complete loss of PCNA binding.,REGION:Disordered,
POLE2	DNA polymerase epsilon 2, accessory subunit(POLE2)	Homo sapiens				GO:0006260~DNA replication,GO:0006261~DNA-dependent DNA replication,GO:0006270~DNA replication initiation,GO:0006281~DNA repair,GO:0042276~error-prone translesion synthesis,	GO:0005654~nucleoplasm,GO:0008622~epsilon DNA polymerase complex,GO:0016604~nuclear body,GO:0043231~intracellular membrane-bounded organelle,	GO:0003677~DNA binding,GO:0003887~DNA-directed DNA polymerase activity,GO:0005515~protein binding,	IPR007185:DNA polymerase alpha/epsilon, subunit B,IPR016266:DNA polymerase epsilon, subunit B,IPR024639:DNA polymerase epsilon subunit B, N-terminal,	hsa03030:DNA replication,hsa03410:Base excision repair,hsa03420:Nucleotide excision repair,		PIRSF000799:DNA polymerase epsilon, subunit B,		KW-0235~DNA replication,	KW-0539~Nucleus,				KW-0238~DNA-binding,		DOMAIN:Dpoe2NT,
POLG2	DNA polymerase gamma 2, accessory subunit(POLG2)	Homo sapiens				GO:0001701~in utero embryonic development,GO:0006260~DNA replication,GO:0006261~DNA-dependent DNA replication,GO:0006264~mitochondrial DNA replication,GO:0006281~DNA repair,GO:0007005~mitochondrion organization,GO:0022904~respiratory electron transport chain,GO:0032042~mitochondrial DNA metabolic process,GO:0070584~mitochondrion morphogenesis,GO:0071897~DNA biosynthetic process,GO:1900264~positive regulation of DNA-directed DNA polymerase activity,	GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005760~gamma DNA polymerase complex,GO:0042645~mitochondrial nucleoid,	GO:0003690~double-stranded DNA binding,GO:0003887~DNA-directed DNA polymerase activity,GO:0005515~protein binding,GO:0030337~DNA polymerase processivity factor activity,GO:0042802~identical protein binding,GO:0070182~DNA polymerase binding,	IPR004154:Anticodon-binding,IPR027030:DNA polymerase subunit gamma-2, mitochondrial,IPR027031:Glycyl-tRNA synthetase/DNA polymerase subunit gamma-2,		610131~Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 4,618528~Mitochondrial DNA depletion syndrome 16 (hepatic type),619425~Mitochondrial DNA depletion syndrome 16B (neuroophthalmic type),			KW-0235~DNA replication,	KW-0496~Mitochondrion,	KW-0225~Disease variant,KW-0935~Progressive external ophthalmoplegia,KW-1274~Primary mitochondrial disease,	KW-0809~Transit peptide,		KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:HGTP_anticodon,REGION:Disordered,TRANSIT:Mitochondrion,
TOP2A	DNA topoisomerase II alpha(TOP2A)	Homo sapiens		h_DNAfragmentPathway:Apoptotic DNA fragmentation and tissue homeostasis,		GO:0000712~resolution of meiotic recombination intermediates,GO:0000819~sister chromatid segregation,GO:0002244~hematopoietic progenitor cell differentiation,GO:0006265~DNA topological change,GO:0006266~DNA ligation,GO:0006974~cellular response to DNA damage stimulus,GO:0007059~chromosome segregation,GO:0007143~female meiotic division,GO:0030263~apoptotic chromosome condensation,GO:0040016~embryonic cleavage,GO:0042752~regulation of circadian rhythm,GO:0043065~positive regulation of apoptotic process,GO:0045870~positive regulation of single stranded viral RNA replication via double stranded DNA intermediate,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048511~rhythmic process,GO:1905463~negative regulation of DNA duplex unwinding,	GO:0000228~nuclear chromosome,GO:0000775~chromosome, centromeric region,GO:0000793~condensed chromosome,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005814~centriole,GO:0009330~DNA topoisomerase complex (ATP-hydrolyzing),GO:0032991~macromolecular complex,GO:1990904~ribonucleoprotein complex,	GO:0000287~magnesium ion binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003723~RNA binding,GO:0003918~DNA topoisomerase type II (ATP-hydrolyzing) activity,GO:0005080~protein kinase C binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008022~protein C-terminus binding,GO:0008094~DNA-dependent ATPase activity,GO:0008301~DNA binding, bending,GO:0019899~enzyme binding,GO:0042803~protein homodimerization activity,GO:0042826~histone deacetylase binding,GO:0043130~ubiquitin binding,GO:0046872~metal ion binding,GO:0046982~protein heterodimerization activity,	IPR001241:DNA topoisomerase, type IIA,IPR002205:DNA topoisomerase, type IIA, subunit A/C-terminal,IPR003594:Histidine kinase-like ATPase, ATP-binding domain,IPR006171:Toprim domain,IPR012542:DTHCT,IPR013506:DNA topoisomerase, type IIA, subunit B, domain 2,IPR013758:DNA topoisomerase, type IIA, subunit A/ C-terminal, alpha-beta,IPR013759:DNA topoisomerase, type IIA, central domain,IPR013760:DNA topoisomerase, type IIA-like domain,IPR014721:Ribosomal protein S5 domain 2-type fold, subgroup,IPR018522:DNA topoisomerase, type IIA, conserved site,IPR020568:Ribosomal protein S5 domain 2-type fold,	hsa01524:Platinum drug resistance,	DNA topoisomerase II, resistance to inhibition of, by amsacrine~DNA topoisomerase II, resistance to inhibition of, by amsacrine,		SM00433:TOP2c,SM00434:TOP4c,	KW-0090~Biological rhythms,	KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0238~DNA-binding,KW-0413~Isomerase,KW-0799~Topoisomerase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:O-(5'-phospho-DNA)-tyrosine intermediate,BINDING:ATP,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:HATPase_c,DOMAIN:Toprim,METAL:Magnesium 1; catalytic,METAL:Magnesium 2,MOTIF:Nuclear export signal,MUTAGEN:D->A,C: Impairs bending of target DNA. Strongly reduced DNA cleavage.,MUTAGEN:D->A,C: Strongly reduced DNA cleavage.,MUTAGEN:E->A,C: Impairs bending of target DNA. Strongly reduced DNA cleavage.,MUTAGEN:KKK->AAA: Reduced enzyme activity; abolishes stimulation of ATPase activity upon DNA binding.,MUTAGEN:KKK->EEE: Strongly reduced enzyme activity; abolishes stimulation of ATPase activity upon DNA binding.,MUTAGEN:S->A: Abolishes binding to the antibody MPM2.,NP_BIND:ATP,REGION:Disordered,REGION:Interaction with DNA,REGION:Interaction with PLSCR1,SITE:Important for DNA bending; intercalates between base pairs of target DNA,SITE:Interaction with DNA,SITE:Transition state stabilizer,
TOPBP1	DNA topoisomerase II binding protein 1(TOPBP1)	Homo sapiens				GO:0006259~DNA metabolic process,GO:0006260~DNA replication,GO:0006270~DNA replication initiation,GO:0006281~DNA repair,GO:0006974~cellular response to DNA damage stimulus,GO:0007095~mitotic G2 DNA damage checkpoint,GO:0010212~response to ionizing radiation,GO:0033314~mitotic DNA replication checkpoint,GO:1901796~regulation of signal transduction by p53 class mediator,	GO:0000794~condensed nuclear chromosome,GO:0000922~spindle pole,GO:0001673~male germ cell nucleus,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005737~cytoplasm,GO:0005815~microtubule organizing center,GO:0005886~plasma membrane,GO:0015629~actin cytoskeleton,GO:0016604~nuclear body,GO:0016605~PML body,GO:0043231~intracellular membrane-bounded organelle,GO:0070532~BRCA1-B complex,	GO:0003677~DNA binding,GO:0005515~protein binding,GO:0008022~protein C-terminus binding,GO:0016853~isomerase activity,GO:0042802~identical protein binding,	IPR001357:BRCT domain,	hsa03440:Homologous recombination,			SM00292:BRCT,	KW-0227~DNA damage,KW-0234~DNA repair,	KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0238~DNA-binding,KW-0413~Isomerase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:BRCT,DOMAIN:BRCT 1,DOMAIN:BRCT 2,DOMAIN:BRCT 3,DOMAIN:BRCT 4,DOMAIN:BRCT 5,DOMAIN:BRCT 6,DOMAIN:BRCT 7,DOMAIN:BRCT 8,MOTIF:Nuclear localization signal,REGION:Disordered,
DRAP1	DR1 associated protein 1(DRAP1)	Homo sapiens				GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006355~regulation of transcription, DNA-templated,GO:0006366~transcription from RNA polymerase II promoter,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,GO:0017054~negative cofactor 2 complex,GO:0090575~RNA polymerase II transcription factor complex,	GO:0001046~core promoter sequence-specific DNA binding,GO:0001091~RNA polymerase II basal transcription factor binding,GO:0003677~DNA binding,GO:0003713~transcription coactivator activity,GO:0003714~transcription corepressor activity,GO:0005515~protein binding,GO:0017025~TBP-class protein binding,GO:0042802~identical protein binding,GO:0046982~protein heterodimerization activity,	IPR003958:Transcription factor CBF/NF-Y/archaeal histone,IPR009072:Histone-fold,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0238~DNA-binding,KW-0678~Repressor,	KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:CBFD_NFYB_HMF,DOMAIN:Histone-fold,REGION:Disordered,
DNAJA3	DnaJ heat shock protein family (Hsp40) member A3(DNAJA3)	Homo sapiens		h_tidPathway:Chaperones modulate interferon Signaling Pathway,		GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006264~mitochondrial DNA replication,GO:0006457~protein folding,GO:0006469~negative regulation of protein kinase activity,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0006924~activation-induced cell death of T cells,GO:0007005~mitochondrion organization,GO:0007264~small GTPase mediated signal transduction,GO:0007528~neuromuscular junction development,GO:0007569~cell aging,GO:0008285~negative regulation of cell proliferation,GO:0009408~response to heat,GO:0031398~positive regulation of protein ubiquitination,GO:0032088~negative regulation of NF-kappaB transcription factor activity,GO:0033077~T cell differentiation in thymus,GO:0034341~response to interferon-gamma,GO:0042102~positive regulation of T cell proliferation,GO:0042981~regulation of apoptotic process,GO:0043065~positive regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043069~negative regulation of programmed cell death,GO:0043124~negative regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043154~negative regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0050790~regulation of catalytic activity,GO:0050821~protein stabilization,GO:0060336~negative regulation of interferon-gamma-mediated signaling pathway,GO:0071340~skeletal muscle acetylcholine-gated channel clustering,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005829~cytosol,GO:0005884~actin filament,GO:0016020~membrane,GO:0019897~extrinsic component of plasma membrane,GO:0031594~neuromuscular junction,GO:0042645~mitochondrial nucleoid,GO:0043231~intracellular membrane-bounded organelle,GO:0045211~postsynaptic membrane,	GO:0005133~interferon-gamma receptor binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008134~transcription factor binding,GO:0019901~protein kinase binding,GO:0030544~Hsp70 protein binding,GO:0030695~GTPase regulator activity,GO:0031072~heat shock protein binding,GO:0044877~macromolecular complex binding,GO:0046872~metal ion binding,GO:0051059~NF-kappaB binding,GO:0051082~unfolded protein binding,	IPR001305:Heat shock protein DnaJ, cysteine-rich domain,IPR001623:DnaJ domain,IPR002939:Chaperone DnaJ, C-terminal,IPR008971:HSP40/DnaJ peptide-binding,IPR012724:Chaperone DnaJ,IPR018253:DnaJ domain, conserved site,	hsa05203:Viral carcinogenesis,			SM00271:DnaJ,	KW-0053~Apoptosis,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0809~Transit peptide,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0143~Chaperone,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	DOMAIN:CR-type,DOMAIN:J,METAL:Zinc 1,METAL:Zinc 2,MUTAGEN:H->Q: Loss of modulation of apoptosis.,REGION:Disordered,REPEAT:CXXCXGXG motif,TRANSIT:Mitochondrion,ZN_FING:CR-type,
DNAJB1	DnaJ heat shock protein family (Hsp40) member B1(DNAJB1)	Homo sapiens		h_p53hypoxiaPathway:Hypoxia and p53 in the Cardiovascular system,h_prionPathway:Prion Pathway,	Posttranslational modification, protein turnover, chaperones,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006457~protein folding,GO:0006986~response to unfolded protein,GO:0030900~forebrain development,GO:0032781~positive regulation of ATPase activity,GO:0051085~chaperone mediated protein folding requiring cofactor,GO:0090084~negative regulation of inclusion body assembly,GO:0097201~negative regulation of transcription from RNA polymerase II promoter in response to stress,GO:1900034~regulation of cellular response to heat,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0014069~postsynaptic density,GO:0043025~neuronal cell body,GO:0043197~dendritic spine,GO:0061827~sperm head,GO:0070062~extracellular exosome,GO:0098978~glutamatergic synapse,	GO:0001671~ATPase activator activity,GO:0003714~transcription corepressor activity,GO:0005515~protein binding,GO:0030544~Hsp70 protein binding,GO:0044183~protein binding involved in protein folding,GO:0045296~cadherin binding,GO:0051082~unfolded protein binding,GO:0051087~chaperone binding,GO:0051117~ATPase binding,	IPR001623:DnaJ domain,IPR002939:Chaperone DnaJ, C-terminal,IPR008971:HSP40/DnaJ peptide-binding,IPR018253:DnaJ domain, conserved site,	hsa04141:Protein processing in endoplasmic reticulum,hsa05164:Influenza A,			SM00271:DnaJ,	KW-0346~Stress response,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0143~Chaperone,	KW-0597~Phosphoprotein,	DOMAIN:DnaJ_C,DOMAIN:J,REGION:Disordered,
DNAJB2	DnaJ heat shock protein family (Hsp40) member B2(DNAJB2)	Homo sapiens				GO:0006986~response to unfolded protein,GO:0008285~negative regulation of cell proliferation,GO:0030308~negative regulation of cell growth,GO:0030433~ubiquitin-dependent ERAD pathway,GO:0031396~regulation of protein ubiquitination,GO:0031398~positive regulation of protein ubiquitination,GO:0032091~negative regulation of protein binding,GO:0032436~positive regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0032781~positive regulation of ATPase activity,GO:0032880~regulation of protein localization,GO:0042026~protein refolding,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0061077~chaperone-mediated protein folding,GO:0070050~neuron cellular homeostasis,GO:0090084~negative regulation of inclusion body assembly,GO:0090086~negative regulation of protein deubiquitination,GO:1903644~regulation of chaperone-mediated protein folding,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016234~inclusion body,GO:0031227~intrinsic component of endoplasmic reticulum membrane,GO:0031965~nuclear membrane,GO:0042406~extrinsic component of endoplasmic reticulum membrane,GO:0048471~perinuclear region of cytoplasm,GO:0098554~cytoplasmic side of endoplasmic reticulum membrane,	GO:0001671~ATPase activator activity,GO:0005515~protein binding,GO:0030544~Hsp70 protein binding,GO:0031593~polyubiquitin binding,GO:0031625~ubiquitin protein ligase binding,GO:0043130~ubiquitin binding,GO:0051082~unfolded protein binding,GO:0051087~chaperone binding,GO:0070628~proteasome binding,	IPR001623:DnaJ domain,IPR003903:Ubiquitin interacting motif,IPR018253:DnaJ domain, conserved site,	hsa04141:Protein processing in endoplasmic reticulum,	614881~Spinal muscular atrophy, distal, autosomal recessive, 5,		SM00271:DnaJ,SM00726:UIM,		KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0523~Neurodegeneration,	KW-0175~Coiled coil,KW-0677~Repeat,		KW-0143~Chaperone,	KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0636~Prenylation,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:J,DOMAIN:UIM 1,DOMAIN:UIM 2,LIPID:S-geranylgeranyl cysteine,MOTIF:CAAX motif,MUTAGEN:C->S: Loss of localization to the endoplasmic reticulum and relocalization to cytoplasm and nucleus.,MUTAGEN:E->A: Loss of interaction with polyubiquitin chains, loss of interaction with PSMA3, and loss of the ability to protect ATXN3 from proteasomal degradation; when associated with A-219; A-222 and A-262.,MUTAGEN:E->A: Loss of interaction with polyubiquitin chains, loss of interaction with PSMA3, and loss of the ability to protect ATXN3 from proteasomal degradation; when associated with A-219; A-262 and A-265.,MUTAGEN:H->Q: Probable loss of interaction with HSP70 and loss of the ability to reduce PRKN aggregation.,MUTAGEN:HPD->QPN: Loss of interaction with HSP70 and loss of the ability to promote ATXN3 proteasomal degradation.,MUTAGEN:L->M: No effect on localization to the endoplasmic reticulum membrane.,MUTAGEN:S->A: Loss of interaction with polyubiquitin chains, loss of interaction with PSMA3, and loss of the ability to protect ATXN3 from proteasomal degradation; when associated with A-219; A-222 and A-265.,MUTAGEN:S->A: Loss of interaction with polyubiquitin chains, loss of interaction with PSMA3, and loss of the ability to protect ATXN3 from proteasomal degradation; when associated with A-222; A-262 and A-265.,PROPEP:Removed in mature form,REGION:Disordered,
DNAJB6	DnaJ heat shock protein family (Hsp40) member B6(DNAJB6)	Homo sapiens		h_prionPathway:Prion Pathway,		GO:0006457~protein folding,GO:0030036~actin cytoskeleton organization,GO:0030198~extracellular matrix organization,GO:0032880~regulation of protein localization,GO:0034504~protein localization to nucleus,GO:0043154~negative regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0045109~intermediate filament organization,GO:0045892~negative regulation of transcription, DNA-templated,GO:0060710~chorio-allantoic fusion,GO:0060715~syncytiotrophoblast cell differentiation involved in labyrinthine layer development,GO:0060717~chorion development,GO:0061077~chaperone-mediated protein folding,GO:0090084~negative regulation of inclusion body assembly,GO:1900034~regulation of cellular response to heat,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0030018~Z disc,GO:0048471~perinuclear region of cytoplasm,	GO:0001671~ATPase activator activity,GO:0003677~DNA binding,GO:0005515~protein binding,GO:0031072~heat shock protein binding,GO:0042802~identical protein binding,GO:0044183~protein binding involved in protein folding,GO:0051082~unfolded protein binding,GO:0051087~chaperone binding,	IPR001623:DnaJ domain,IPR018253:DnaJ domain, conserved site,IPR026901:DnaJ homologue subfamily C member 3,		603511~Muscular dystrophy, limb-girdle, autosomal dominant 1,		SM00271:DnaJ,		KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0947~Limb-girdle muscular dystrophy,	KW-0175~Coiled coil,		KW-0143~Chaperone,	KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:J,REGION:Disordered,REGION:Interaction with HSP70,REGION:Interaction with KRT18,
DNAJC15	DnaJ heat shock protein family (Hsp40) member C15(DNAJC15)	Homo sapiens				GO:0009267~cellular response to starvation,GO:0019216~regulation of lipid metabolic process,GO:0030150~protein import into mitochondrial matrix,GO:0031333~negative regulation of protein complex assembly,GO:1902957~negative regulation of mitochondrial electron transport, NADH to ubiquinone,	GO:0001405~presequence translocase-associated import motor,GO:0016021~integral component of membrane,	GO:0001671~ATPase activator activity,GO:0005515~protein binding,	IPR001623:DnaJ domain,				SM00271:DnaJ,	KW-0653~Protein transport,KW-0811~Translocation,KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0143~Chaperone,	KW-0597~Phosphoprotein,	DOMAIN:J,TOPO_DOM:Mitochondrial intermembrane,TOPO_DOM:Mitochondrial matrix,TRANSMEM:Helical,
EAPP	E2F associated phosphoprotein(EAPP)	Homo sapiens				GO:0008284~positive regulation of cell proliferation,GO:0032968~positive regulation of transcription elongation from RNA polymerase II promoter,GO:0034244~negative regulation of transcription elongation from RNA polymerase II promoter,	GO:0005634~nucleus,GO:0005737~cytoplasm,	GO:0005515~protein binding,	IPR019370:E2F-associated phosphoprotein,						KW-0539~Nucleus,KW-0963~Cytoplasm,					KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
E2F2	E2F transcription factor 2(E2F2)	Homo sapiens				GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006367~transcription initiation from RNA polymerase II promoter,GO:0007049~cell cycle,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051726~regulation of cell cycle,GO:0072332~intrinsic apoptotic signaling pathway by p53 class mediator,GO:1903671~negative regulation of sprouting angiogenesis,GO:1990086~lens fiber cell apoptotic process,	GO:0000785~chromatin,GO:0005654~nucleoplasm,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0000987~core promoter proximal region sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0043565~sequence-specific DNA binding,GO:0046983~protein dimerization activity,GO:1990837~sequence-specific double-stranded DNA binding,	IPR003316:Transcription factor E2F/dimerisation partner (TDP),IPR015633:E2F Family,	hsa01522:Endocrine resistance,hsa04110:Cell cycle,hsa04218:Cellular senescence,hsa04934:Cushing syndrome,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05163:Human cytomegalovirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05169:Epstein-Barr virus infection,hsa05200:Pathways in cancer,hsa05206:MicroRNAs in cancer,hsa05212:Pancreatic cancer,hsa05214:Glioma,hsa05215:Prostate cancer,hsa05218:Melanoma,hsa05219:Bladder cancer,hsa05220:Chronic myeloid leukemia,hsa05222:Small cell lung cancer,hsa05223:Non-small cell lung cancer,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,			SM01372:SM01372,	KW-0131~Cell cycle,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,MOTIF:DEF box,REGION:Cyclin A/CDK2 binding,REGION:Dimerization,REGION:Disordered,REGION:Leucine-zipper,REGION:Retinoblastoma protein binding,REGION:Transactivation,
EBNA1BP2	EBNA1 binding protein 2(EBNA1BP2)	Homo sapiens				GO:0006364~rRNA processing,GO:0042254~ribosome biogenesis,GO:0042273~ribosomal large subunit biogenesis,	GO:0005694~chromosome,GO:0005730~nucleolus,GO:0030687~preribosome, large subunit precursor,GO:0034399~nuclear periphery,	GO:0003723~RNA binding,GO:0005515~protein binding,	IPR008610:Eukaryotic rRNA processing,					KW-0690~Ribosome biogenesis,	KW-0539~Nucleus,		KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,
EBP	EBP cholestenol delta-isomerase(EBP)	Homo sapiens				GO:0001501~skeletal system development,GO:0006695~cholesterol biosynthetic process,GO:0008203~cholesterol metabolic process,GO:0016125~sterol metabolic process,GO:0016126~sterol biosynthetic process,GO:0033489~cholesterol biosynthetic process via desmosterol,GO:0033490~cholesterol biosynthetic process via lathosterol,GO:0043931~ossification involved in bone maturation,	GO:0005635~nuclear envelope,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0030176~integral component of endoplasmic reticulum membrane,GO:0031410~cytoplasmic vesicle,	GO:0000247~C-8 sterol isomerase activity,GO:0004769~steroid delta-isomerase activity,GO:0004888~transmembrane signaling receptor activity,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0042910~xenobiotic transporter activity,GO:0047750~cholestenol delta-isomerase activity,	IPR007905:Emopamil-binding,	hsa00100:Steroid biosynthesis,hsa01100:Metabolic pathways,	300960~MEND syndrome,302960~Chondrodysplasia punctata, X-linked dominant,			KW-0152~Cholesterol biosynthesis,KW-0153~Cholesterol metabolism,KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,KW-0752~Steroid biosynthesis,KW-0753~Steroid metabolism,KW-0756~Sterol biosynthesis,KW-1207~Sterol metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,KW-0968~Cytoplasmic vesicle,	KW-0225~Disease variant,KW-0242~Dwarfism,KW-0898~Cataract,KW-0977~Ichthyosis,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0413~Isomerase,	KW-0007~Acetylation,	DOMAIN:EXPERA,MUTAGEN:E->A: Reduces catalytic activity to less than 10% of wild-type.,MUTAGEN:F->A: Reduces catalytic activity to less than 35% of wild-type.,MUTAGEN:F->L: No effect on catalytic activity.,MUTAGEN:H->A: Reduces catalytic activity to less than 10% of wild-type.,MUTAGEN:I->A: Reduces catalytic activity to less than 35% of wild-type.,MUTAGEN:M->A: Reduces catalytic activity to less than 35% of wild-type.,MUTAGEN:M->V: No effect on catalytic activity.,MUTAGEN:N->A: Reduces catalytic activity to less than 10% of wild-type.,MUTAGEN:T->A: Reduces catalytic activity to less than 10% of wild-type.,MUTAGEN:W->A: Reduces catalytic activity to less than 10% of wild-type.,MUTAGEN:W->A: Reduces catalytic activity to less than 35% of wild-type.,MUTAGEN:Y->A: Reduces catalytic activity to less than 35% of wild-type.,MUTAGEN:Y->W: Reduces catalytic activity to less than 2% of wild-type.,TRANSMEM:Helical,
ELAVL1	ELAV like RNA binding protein 1(ELAVL1)	Homo sapiens		h_vegfPathway:VEGF, Hypoxia, and Angiogenesis,		GO:0000398~mRNA splicing, via spliceosome,GO:0006606~protein import into nucleus,GO:0016441~posttranscriptional gene silencing,GO:0043488~regulation of mRNA stability,GO:0045727~positive regulation of translation,GO:0048255~mRNA stabilization,GO:0051260~protein homooligomerization,GO:0060965~negative regulation of gene silencing by miRNA,GO:0070935~3'-UTR-mediated mRNA stabilization,GO:2000036~regulation of stem cell population maintenance,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0010494~cytoplasmic stress granule,GO:0016020~membrane,GO:0031410~cytoplasmic vesicle,GO:0098794~postsynapse,GO:0098978~glutamatergic synapse,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003725~double-stranded RNA binding,GO:0003729~mRNA binding,GO:0003730~mRNA 3'-UTR binding,GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0035198~miRNA binding,GO:0035925~mRNA 3'-UTR AU-rich region binding,GO:0042803~protein homodimerization activity,	IPR000504:RNA recognition motif domain,IPR002343:Paraneoplastic encephalomyelitis antigen,IPR006548:Splicing factor ELAV/HuD,IPR012677:Nucleotide-binding, alpha-beta plait,	hsa04152:AMPK signaling pathway,hsa04657:IL-17 signaling pathway,			SM00360:RRM,		KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,DOMAIN:RRM 3,MUTAGEN:S->A: Decreases phosphorylation by PRKCD.,MUTAGEN:S->A: Decreases phosphorylation by PRKCD. Nearly abolishes phosphorylation by PRKCD and translocation from the nucleus into the cytoplasm; when associated with A-221.,MUTAGEN:S->A: Decreases phosphorylation by PRKCD. Nearly abolishes phosphorylation by PRKCD and translocation from the nucleus into the cytoplasm; when associated with A-318.,REGION:Disordered,
ELOVL6	ELOVL fatty acid elongase 6(ELOVL6)	Homo sapiens				GO:0006633~fatty acid biosynthetic process,GO:0006636~unsaturated fatty acid biosynthetic process,GO:0019216~regulation of lipid metabolic process,GO:0019367~fatty acid elongation, saturated fatty acid,GO:0030148~sphingolipid biosynthetic process,GO:0034625~fatty acid elongation, monounsaturated fatty acid,GO:0034626~fatty acid elongation, polyunsaturated fatty acid,GO:0035338~long-chain fatty-acyl-CoA biosynthetic process,GO:0042759~long-chain fatty acid biosynthetic process,GO:0042761~very long-chain fatty acid biosynthetic process,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0009923~fatty acid elongase complex,GO:0016021~integral component of membrane,GO:0030176~integral component of endoplasmic reticulum membrane,	GO:0005515~protein binding,GO:0009922~fatty acid elongase activity,GO:0102336~3-oxo-arachidoyl-CoA synthase activity,GO:0102337~3-oxo-cerotoyl-CoA synthase activity,GO:0102338~3-oxo-lignoceronyl-CoA synthase activity,	IPR002076:GNS1/SUR4 membrane protein,	hsa00062:Fatty acid elongation,hsa01040:Biosynthesis of unsaturated fatty acids,hsa01100:Metabolic pathways,hsa01212:Fatty acid metabolism,				KW-0275~Fatty acid biosynthesis,KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0808~Transferase,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,TRANSMEM:Helical,
EML3	EMAP like 3(EML3)	Homo sapiens				GO:0000226~microtubule cytoskeleton organization,GO:0007080~mitotic metaphase plate congression,GO:0051301~cell division,GO:1901673~regulation of mitotic spindle assembly,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005819~spindle,GO:0005856~cytoskeleton,GO:0005876~spindle microtubule,GO:0015630~microtubule cytoskeleton,GO:0030496~midbody,GO:0072686~mitotic spindle,GO:1990498~mitotic spindle microtubule,	GO:0005515~protein binding,GO:0008017~microtubule binding,	IPR001680:WD40 repeat,IPR005108:HELP,IPR011047:Quinonprotein alcohol dehydrogenase-like superfamily,IPR015943:WD40/YVTN repeat-like-containing domain,IPR017986:WD40-repeat-containing domain,				SM00320:WD40,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0853~WD repeat,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:HELP,MUTAGEN:S->A: No loss of phosphorylation.,MUTAGEN:T->A: Loss of phosphorylation and impaired interaction with TUBG1, HAUS2, HAUS3, HAUS4, HAUS5, HAUS6, HAUS7 and HAUS8.,REGION:Disordered,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 10,REPEAT:WD 11,REPEAT:WD 12,REPEAT:WD 13,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,REPEAT:WD 8,REPEAT:WD 9,
EPHA3	EPH receptor A3(EPHA3)	Homo sapiens				GO:0007155~cell adhesion,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007275~multicellular organism development,GO:0007411~axon guidance,GO:0010717~regulation of epithelial to mesenchymal transition,GO:0010976~positive regulation of neuron projection development,GO:0016477~cell migration,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0032956~regulation of actin cytoskeleton organization,GO:0033674~positive regulation of kinase activity,GO:0043087~regulation of GTPase activity,GO:0045806~negative regulation of endocytosis,GO:0048013~ephrin receptor signaling pathway,GO:0051893~regulation of focal adhesion assembly,GO:0070507~regulation of microtubule cytoskeleton organization,GO:0071300~cellular response to retinoic acid,GO:0097155~fasciculation of sensory neuron axon,GO:0097156~fasciculation of motor neuron axon,GO:1903078~positive regulation of protein localization to plasma membrane,	GO:0005576~extracellular region,GO:0005654~nucleoplasm,GO:0005769~early endosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0015629~actin cytoskeleton,GO:0016021~integral component of membrane,GO:0031965~nuclear membrane,GO:0043005~neuron projection,GO:0043235~receptor complex,	GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0005003~ephrin receptor activity,GO:0005004~GPI-linked ephrin receptor activity,GO:0005005~transmembrane-ephrin receptor activity,GO:0005515~protein binding,GO:0005524~ATP binding,	IPR000719:Protein kinase, catalytic domain,IPR001090:Ephrin receptor ligand binding domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR001426:Tyrosine-protein kinase, receptor class V, conserved site,IPR001660:Sterile alpha motif domain,IPR003961:Fibronectin, type III,IPR008266:Tyrosine-protein kinase, active site,IPR008979:Galactose-binding domain-like,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR011009:Protein kinase-like domain,IPR011641:Tyrosine-protein kinase ephrin type A/B receptor-like,IPR013761:Sterile alpha motif/pointed domain,IPR013783:Immunoglobulin-like fold,IPR016257:Tyrosine-protein kinase, ephrin receptor,IPR017441:Protein kinase, ATP binding site,IPR020635:Tyrosine-protein kinase, catalytic domain,	hsa04360:Axon guidance,		PIRSF000666:tyrosine-protein kinase, ephrin receptor type,	SM00060:FN3,SM00219:TyrKc,SM00454:SAM,SM00615:EPH_lbd,	KW-0130~Cell adhesion,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0675~Receptor,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:ATP,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Eph LBD,DOMAIN:Fibronectin type-III,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,DOMAIN:Protein kinase,DOMAIN:SAM,MOTIF:PDZ-binding,MUTAGEN:F->L: Loss of EFNA5-binding ability and function.,MUTAGEN:S->A: Full kinase activity; when associated with F-596 and F-602.,MUTAGEN:V->E: Loss of EFNA5-binding ability and function.,MUTAGEN:Y->F: 10-fold suppression of kinase activity; when associated with F-596. Full kinase activity; when associated with F-596 and F-742. Full kinase activity; when associated with F-596 and A-768.,MUTAGEN:Y->F: 10-fold suppression of kinase activity; when associated with F-602. Full kinase activity; when associated with F-602 and F-742. Full kinase activity; when associated with F-602 and A-768.,MUTAGEN:Y->F: Full kinase activity; when associated with F-596 and F-602.,NP_BIND:ATP,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
EPHB2	EPH receptor B2(EPHB2)	Homo sapiens				GO:0001525~angiogenesis,GO:0001655~urogenital system development,GO:0001933~negative regulation of protein phosphorylation,GO:0002639~positive regulation of immunoglobulin production,GO:0006469~negative regulation of protein kinase activity,GO:0007162~negative regulation of cell adhesion,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007275~multicellular organism development,GO:0007399~nervous system development,GO:0007411~axon guidance,GO:0007413~axonal fasciculation,GO:0007611~learning or memory,GO:0007612~learning,GO:0010628~positive regulation of gene expression,GO:0016310~phosphorylation,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0021631~optic nerve morphogenesis,GO:0021934~hindbrain tangential cell migration,GO:0021952~central nervous system projection neuron axonogenesis,GO:0022038~corpus callosum development,GO:0030193~regulation of blood coagulation,GO:0030335~positive regulation of cell migration,GO:0030890~positive regulation of B cell proliferation,GO:0031290~retinal ganglion cell axon guidance,GO:0031915~positive regulation of synaptic plasticity,GO:0032760~positive regulation of tumor necrosis factor production,GO:0033674~positive regulation of kinase activity,GO:0042113~B cell activation,GO:0042472~inner ear morphogenesis,GO:0046425~regulation of JAK-STAT cascade,GO:0046580~negative regulation of Ras protein signal transduction,GO:0048013~ephrin receptor signaling pathway,GO:0048168~regulation of neuronal synaptic plasticity,GO:0048170~positive regulation of long-term neuronal synaptic plasticity,GO:0048593~camera-type eye morphogenesis,GO:0050771~negative regulation of axonogenesis,GO:0050878~regulation of body fluid levels,GO:0051389~inactivation of MAPKK activity,GO:0051489~regulation of filopodium assembly,GO:0051965~positive regulation of synapse assembly,GO:0060021~palate development,GO:0060996~dendritic spine development,GO:0060997~dendritic spine morphogenesis,GO:0061003~positive regulation of dendritic spine morphogenesis,GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:0071222~cellular response to lipopolysaccharide,GO:0071679~commissural neuron axon guidance,GO:0097104~postsynaptic membrane assembly,GO:0099557~trans-synaptic signaling by trans-synaptic complex, modulating synaptic transmission,GO:1900016~negative regulation of cytokine production involved in inflammatory response,GO:1900273~positive regulation of long-term synaptic potentiation,GO:1903078~positive regulation of protein localization to plasma membrane,GO:1904646~cellular response to beta-amyloid,GO:1904782~negative regulation of NMDA glutamate receptor activity,GO:1904783~positive regulation of NMDA glutamate receptor activity,GO:2000316~regulation of T-helper 17 type immune response,GO:2000822~regulation of behavioral fear response,	GO:0005576~extracellular region,GO:0005654~nucleoplasm,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0030424~axon,GO:0030425~dendrite,GO:0043005~neuron projection,GO:0043025~neuronal cell body,GO:0043197~dendritic spine,GO:0043235~receptor complex,GO:0098794~postsynapse,GO:0098978~glutamatergic synapse,GO:0099055~integral component of postsynaptic membrane,GO:0099056~integral component of presynaptic membrane,	GO:0001540~beta-amyloid binding,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0005003~ephrin receptor activity,GO:0005005~transmembrane-ephrin receptor activity,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008046~axon guidance receptor activity,GO:0042802~identical protein binding,GO:0044877~macromolecular complex binding,	IPR000719:Protein kinase, catalytic domain,IPR001090:Ephrin receptor ligand binding domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR001426:Tyrosine-protein kinase, receptor class V, conserved site,IPR001660:Sterile alpha motif domain,IPR003961:Fibronectin, type III,IPR008266:Tyrosine-protein kinase, active site,IPR008979:Galactose-binding domain-like,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR011009:Protein kinase-like domain,IPR011641:Tyrosine-protein kinase ephrin type A/B receptor-like,IPR013761:Sterile alpha motif/pointed domain,IPR013783:Immunoglobulin-like fold,IPR016257:Tyrosine-protein kinase, ephrin receptor,IPR017441:Protein kinase, ATP binding site,IPR020635:Tyrosine-protein kinase, catalytic domain,	hsa04360:Axon guidance,	603688~Prostate cancer/brain cancer susceptibility, somatic,618462~Bleeding disorder, platelet-type, 22,	PIRSF000666:tyrosine-protein kinase, ephrin receptor type,	SM00060:FN3,SM00219:TyrKc,SM00454:SAM,SM00615:EPH_lbd,	KW-0524~Neurogenesis,	KW-0472~Membrane,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0043~Tumor suppressor,KW-0225~Disease variant,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0217~Developmental protein,KW-0418~Kinase,KW-0675~Receptor,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,BINDING:ATP,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:Eph LBD,DOMAIN:Fibronectin type-III,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,DOMAIN:Protein kinase,DOMAIN:SAM,MOTIF:PDZ-binding (in isoform 2),NP_BIND:ATP,REGION:Disordered,SITE:Cleavage; by a metalloproteinase,SITE:Cleavage; by gamma-secretase/PS1,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
EDEM1	ER degradation enhancing alpha-mannosidase like protein 1(EDEM1)	Homo sapiens		h_eradPathway:ERï¿½associated degradation (ERAD) Pathway,		GO:0005975~carbohydrate metabolic process,GO:0006986~response to unfolded protein,GO:0030433~ubiquitin-dependent ERAD pathway,GO:0036498~IRE1-mediated unfolded protein response,GO:0036510~trimming of terminal mannose on C branch,GO:0045047~protein targeting to ER,GO:0097466~ubiquitin-dependent glycoprotein ERAD pathway,GO:1904154~positive regulation of retrograde protein transport, ER to cytosol,GO:1904380~endoplasmic reticulum mannose trimming,GO:1904382~mannose trimming involved in glycoprotein ERAD pathway,	GO:0005783~endoplasmic reticulum,GO:0016020~membrane,GO:0016235~aggresome,GO:0030176~integral component of endoplasmic reticulum membrane,GO:0044322~endoplasmic reticulum quality control compartment,	GO:0004571~mannosyl-oligosaccharide 1,2-alpha-mannosidase activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0051787~misfolded protein binding,	IPR001382:Glycoside hydrolase, family 47,IPR012341:Six-hairpin glycosidase,	hsa04141:Protein processing in endoplasmic reticulum,				KW-0834~Unfolded protein response,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0326~Glycosidase,KW-0378~Hydrolase,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,MUTAGEN:D->N: Normal affinity for misfolded glycoproteins, but impaired SEL1L binding.,MUTAGEN:E->Q: Normal affinity for misfolded glycoproteins, but impaired SEL1L binding.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
ETS1	ETS proto-oncogene 1, transcription factor(ETS1)	Homo sapiens		h_etsPathway:METS affect on Macrophage Differentiation,h_keratinocytePathway:Keratinocyte Differentiation,		GO:0001666~response to hypoxia,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0006955~immune response,GO:0007565~female pregnancy,GO:0008284~positive regulation of cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0009612~response to mechanical stimulus,GO:0010595~positive regulation of endothelial cell migration,GO:0010628~positive regulation of gene expression,GO:0010715~regulation of extracellular matrix disassembly,GO:0021854~hypothalamus development,GO:0021983~pituitary gland development,GO:0030154~cell differentiation,GO:0030578~PML body organization,GO:0032355~response to estradiol,GO:0034616~response to laminar fluid shear stress,GO:0042981~regulation of apoptotic process,GO:0043536~positive regulation of blood vessel endothelial cell migration,GO:0044849~estrous cycle,GO:0045648~positive regulation of erythrocyte differentiation,GO:0045765~regulation of angiogenesis,GO:0045766~positive regulation of angiogenesis,GO:0045786~negative regulation of cell cycle,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046677~response to antibiotic,GO:0048870~cell motility,GO:0050729~positive regulation of inflammatory response,GO:0051272~positive regulation of cellular component movement,GO:0060055~angiogenesis involved in wound healing,GO:0070301~cellular response to hydrogen peroxide,GO:0070555~response to interleukin-1,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1904996~positive regulation of leukocyte adhesion to vascular endothelial cell,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001222~transcription corepressor binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0030374~ligand-dependent nuclear receptor transcription coactivator activity,GO:0035035~histone acetyltransferase binding,GO:0042802~identical protein binding,GO:0043565~sequence-specific DNA binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,	IPR000418:Ets domain,IPR003118:Pointed domain,IPR013761:Sterile alpha motif/pointed domain,IPR016311:Transforming protein C-ets,	hsa04014:Ras signaling pathway,hsa04218:Cellular senescence,hsa05166:Human T-cell leukemia virus 1 infection,hsa05200:Pathways in cancer,hsa05211:Renal cell carcinoma,		PIRSF001698:transforming factor C-ets,	SM00251:SAM_PNT,SM00413:ETS,	KW-0391~Immunity,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0656~Proto-oncogene,			KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DNA_BIND:ETS,DOMAIN:ETS,DOMAIN:PNT,REGION:Activation domain; required for transcription activation,REGION:Disordered,
ETV1	ETS variant transcription factor 1(ETV1)	Homo sapiens				GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0007411~axon guidance,GO:0007517~muscle organ development,GO:0007638~mechanosensory behavior,GO:0030154~cell differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048935~peripheral nervous system neuron development,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000418:Ets domain,IPR006715:PEA3-type ETS-domain transcription factor, N-terminal,	hsa05202:Transcriptional misregulation in cancer,			SM00413:ETS,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0656~Proto-oncogene,			KW-0010~Activator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DNA_BIND:ETS,DOMAIN:ETS,DOMAIN:ETS_PEA3_N,MUTAGEN:S->A: Loss of phosphorylation by RPS6KA5.,REGION:Disordered,
EVL	Enah/Vasp-like(EVL)	Homo sapiens				GO:0007015~actin filament organization,GO:0007166~cell surface receptor signaling pathway,GO:0007399~nervous system development,GO:0007411~axon guidance,GO:0008154~actin polymerization or depolymerization,GO:0009887~animal organ morphogenesis,GO:0010633~negative regulation of epithelial cell migration,GO:0030838~positive regulation of actin filament polymerization,GO:0045010~actin nucleation,GO:0051289~protein homotetramerization,GO:0051496~positive regulation of stress fiber assembly,GO:1900028~negative regulation of ruffle assembly,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0030027~lamellipodium,	GO:0003779~actin binding,GO:0005515~protein binding,GO:0005522~profilin binding,GO:0017124~SH3 domain binding,	IPR000697:EVH1,IPR011993:Pleckstrin homology-like domain,IPR014885:VASP tetramerisation,IPR017354:Vasodilator-stimulated phosphoprotein,	hsa04015:Rap1 signaling pathway,		PIRSF038010:vasodilator-stimulated phosphoprotein,	SM00461:WH1,		KW-0206~Cytoskeleton,KW-0963~Cytoplasm,KW-0966~Cell projection,		KW-0175~Coiled coil,KW-0729~SH3-binding,		KW-0009~Actin-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:VASP_tetra,DOMAIN:WH1,MOTIF:KLKR,REGION:Disordered,REGION:EVH2,REGION:EVH2 block A,REGION:EVH2 block B,REGION:EVH2 block C,REGION:Required for interaction with ZDHHC17,
FBXL12	F-box and leucine rich repeat protein 12(FBXL12)	Homo sapiens				GO:0000086~G2/M transition of mitotic cell cycle,GO:0000209~protein polyubiquitination,GO:0016567~protein ubiquitination,GO:0031146~SCF-dependent proteasomal ubiquitin-dependent protein catabolic process,GO:0043153~entrainment of circadian clock by photoperiod,GO:0043687~post-translational protein modification,GO:0051726~regulation of cell cycle,	GO:0005634~nucleus,GO:0005829~cytosol,GO:0016021~integral component of membrane,GO:0019005~SCF ubiquitin ligase complex,	GO:0005515~protein binding,	IPR001810:F-box domain, cyclin-like,				SM00256:FBOX,	KW-0833~Ubl conjugation pathway,	KW-0472~Membrane,		KW-0433~Leucine-rich repeat,KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				COMPBIAS:Polar residues,DOMAIN:F-box,REGION:Disordered,REPEAT:LRR 1,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,REPEAT:LRR 8,TRANSMEM:Helical,
FBXO11	F-box protein 11(FBXO11)	Homo sapiens			Inorganic ion transport and metabolism,	GO:0000209~protein polyubiquitination,GO:0006464~cellular protein modification process,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0007605~sensory perception of sound,GO:0016567~protein ubiquitination,GO:0035246~peptidyl-arginine N-methylation,GO:0042981~regulation of apoptotic process,GO:0043687~post-translational protein modification,	GO:0000151~ubiquitin ligase complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0016274~protein-arginine N-methyltransferase activity,	IPR001810:F-box domain, cyclin-like,IPR003126:Zinc finger, N-recognin,IPR006626:Parallel beta-helix repeat,IPR006633:Carbohydrate-binding/sugar hydrolysis domain,IPR007742:Periplasmic copper-binding protein NosD, beta helix domain,IPR011050:Pectin lyase fold/virulence factor,IPR012334:Pectin lyase fold,IPR022441:Parallel beta-helix repeat-2,		618089~Intellectual developmental disorder with dysmorphic facies and behavioral abnormalities,		SM00256:FBOX,SM00396:ZnF_UBR1,SM00710:PbH1,SM00722:CASH,	KW-0833~Ubl conjugation pathway,	KW-0158~Chromosome,KW-0539~Nucleus,	KW-0225~Disease variant,KW-0991~Mental retardation,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,			COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:CASH,DOMAIN:F-box,DOMAIN:UBR-type,MUTAGEN:Q->L: Greatly reduced ability to bind PRDM1 and reduced proteolysis of PRDM1.,REGION:Disordered,REPEAT:PbH1 1,REPEAT:PbH1 10,REPEAT:PbH1 11,REPEAT:PbH1 12,REPEAT:PbH1 13,REPEAT:PbH1 14,REPEAT:PbH1 15,REPEAT:PbH1 16,REPEAT:PbH1 17,REPEAT:PbH1 18,REPEAT:PbH1 19,REPEAT:PbH1 2,REPEAT:PbH1 3,REPEAT:PbH1 4,REPEAT:PbH1 5,REPEAT:PbH1 6,REPEAT:PbH1 7,REPEAT:PbH1 8,REPEAT:PbH1 9,ZN_FING:UBR-type,
FBXO21	F-box protein 21(FBXO21)	Homo sapiens			Function unknown,	GO:0000209~protein polyubiquitination,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0016567~protein ubiquitination,GO:0043687~post-translational protein modification,	GO:0000151~ubiquitin ligase complex,GO:0005829~cytosol,	GO:0003677~DNA binding,GO:0004842~ubiquitin-protein transferase activity,	IPR011722:Hemimethylated DNA-binding domain,				SM00992:SM00992,	KW-0833~Ubl conjugation pathway,							DOMAIN:F-box,DOMAIN:YccV-like,
FBXO7	F-box protein 7(FBXO7)	Homo sapiens				GO:0000209~protein polyubiquitination,GO:0000422~mitophagy,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0006626~protein targeting to mitochondrion,GO:0010975~regulation of neuron projection development,GO:0016567~protein ubiquitination,GO:0031647~regulation of protein stability,GO:0040012~regulation of locomotion,GO:0043687~post-translational protein modification,GO:0045620~negative regulation of lymphocyte differentiation,GO:0045736~negative regulation of cyclin-dependent protein serine/threonine kinase activity,GO:1903204~negative regulation of oxidative stress-induced neuron death,GO:1903208~negative regulation of hydrogen peroxide-induced neuron death,GO:1903599~positive regulation of mitophagy,GO:2000134~negative regulation of G1/S transition of mitotic cell cycle,	GO:0000151~ubiquitin ligase complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0019005~SCF ubiquitin ligase complex,GO:0032991~macromolecular complex,GO:0097409~glial cytoplasmic inclusion,GO:0097414~classical Lewy body,GO:0097462~Lewy neurite,GO:1990037~Lewy body core,GO:1990038~Lewy body corona,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0031625~ubiquitin protein ligase binding,GO:0043130~ubiquitin binding,GO:0046982~protein heterodimerization activity,GO:1990756~protein binding, bridging involved in substrate recognition for ubiquitination,	IPR001810:F-box domain, cyclin-like,IPR021625:Proteasome Inhibitor PI31,		260300~Parkinson disease 15, autosomal recessive,		SM00256:FBOX,	KW-0833~Ubl conjugation pathway,	KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0907~Parkinson disease,KW-0908~Parkinsonism,				KW-0488~Methylation,	COMPBIAS:Polar residues,DOMAIN:F-box,MOTIF:RFDP motif,MUTAGEN:T->M: Impairs interaction with PRKN.,MUTAGEN:V->E: Abolishes interaction with PSMF1.,REGION:Disordered,REGION:Important for dimerization and interaction with PSMF1,REGION:Important for interaction with CDK6,REGION:Important for interaction with PINK1,REGION:Ubiquitin-like,
FAM20B	FAM20B glycosaminoglycan xylosylkinase(FAM20B)	Homo sapiens				GO:0030166~proteoglycan biosynthetic process,	GO:0000139~Golgi membrane,GO:0005654~nucleoplasm,GO:0005794~Golgi apparatus,GO:0016021~integral component of membrane,	GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016301~kinase activity,GO:0016773~phosphotransferase activity, alcohol group as acceptor,GO:0046872~metal ion binding,	IPR009581:Domain of unknown function DUF1193,IPR024869:FAM20,						KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0464~Manganese,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	BINDING:ATP,BINDING:ATP; via amide nitrogen,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Fam20C,METAL:Manganese,NP_BIND:ATP,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
FASTKD5	FAST kinase domains 5(FASTKD5)	Homo sapiens				GO:0000963~mitochondrial RNA processing,GO:0006397~mRNA processing,GO:0044528~regulation of mitochondrial mRNA stability,	GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0035770~ribonucleoprotein granule,GO:0042645~mitochondrial nucleoid,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0019843~rRNA binding,	IPR010622:FAST kinase leucine-rich,IPR013579:FAST kinase-like protein, subdomain 2,IPR013584:RAP domain,				SM00952:SM00952,	KW-0507~mRNA processing,	KW-0496~Mitochondrion,KW-1135~Mitochondrion nucleoid,		KW-0809~Transit peptide,		KW-0694~RNA-binding,KW-0699~rRNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:RAP,TRANSIT:Mitochondrion,
FAT1	FAT atypical cadherin 1(FAT1)	Homo sapiens				GO:0002088~lens development in camera-type eye,GO:0003382~epithelial cell morphogenesis,GO:0003412~establishment of epithelial cell apical/basal polarity involved in camera-type eye morphogenesis,GO:0007015~actin filament organization,GO:0007155~cell adhesion,GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules,GO:0007163~establishment or maintenance of cell polarity,GO:0007267~cell-cell signaling,GO:0009653~anatomical structure morphogenesis,GO:0016477~cell migration,GO:0098609~cell-cell adhesion,	GO:0005634~nucleus,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005911~cell-cell junction,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0030027~lamellipodium,GO:0030054~cell junction,GO:0030175~filopodium,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0005509~calcium ion binding,GO:0005515~protein binding,	IPR000152:EGF-type aspartate/asparagine hydroxylation site,IPR000742:Epidermal growth factor-like domain,IPR001791:Laminin G domain,IPR001881:EGF-like calcium-binding,IPR002126:Cadherin,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,IPR015919:Cadherin-like,IPR018097:EGF-like calcium-binding, conserved site,IPR020894:Cadherin conserved site,				SM00112:CA,SM00179:EGF_CA,SM00181:EGF,SM00282:LamG,	KW-0130~Cell adhesion,	KW-0472~Membrane,KW-0539~Nucleus,KW-1003~Cell membrane,		KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Cadherin,DOMAIN:Cadherin 1,DOMAIN:Cadherin 10,DOMAIN:Cadherin 11,DOMAIN:Cadherin 12,DOMAIN:Cadherin 13,DOMAIN:Cadherin 14,DOMAIN:Cadherin 15,DOMAIN:Cadherin 16,DOMAIN:Cadherin 17,DOMAIN:Cadherin 18,DOMAIN:Cadherin 19,DOMAIN:Cadherin 2,DOMAIN:Cadherin 20,DOMAIN:Cadherin 21,DOMAIN:Cadherin 22,DOMAIN:Cadherin 23,DOMAIN:Cadherin 24,DOMAIN:Cadherin 25,DOMAIN:Cadherin 26,DOMAIN:Cadherin 27,DOMAIN:Cadherin 28,DOMAIN:Cadherin 29,DOMAIN:Cadherin 3,DOMAIN:Cadherin 30,DOMAIN:Cadherin 31,DOMAIN:Cadherin 32,DOMAIN:Cadherin 33,DOMAIN:Cadherin 4,DOMAIN:Cadherin 5,DOMAIN:Cadherin 6,DOMAIN:Cadherin 7,DOMAIN:Cadherin 8,DOMAIN:Cadherin 9,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 2,DOMAIN:EGF-like 3,DOMAIN:EGF-like 4,DOMAIN:EGF-like 5; calcium-binding,DOMAIN:LAM_G_DOMAIN,DOMAIN:Laminin G-like,MOTIF:Nuclear localization signal,MOTIF:PTB-like motif,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
FCHO1	FCH and mu domain containing endocytic adaptor 1(FCHO1)	Homo sapiens				GO:0048268~clathrin coat assembly,GO:0050852~T cell receptor signaling pathway,GO:0050870~positive regulation of T cell activation,GO:0061024~membrane organization,GO:0072583~clathrin-dependent endocytosis,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0005905~clathrin-coated pit,	GO:0005515~protein binding,GO:0035612~AP-2 adaptor complex binding,	IPR001060:FCH domain,IPR018808:Muniscin C-terminal mu homology domain,IPR022023:U1 small nuclear ribonucleoprotein of 70kDa N-terminal,IPR027267:Arfaptin homology (AH) domain/BAR domain,		619164~Immunodeficiency 76,		SM00055:FCH,	KW-0254~Endocytosis,	KW-0168~Coated pit,KW-0472~Membrane,		KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:F-BAR,DOMAIN:MHD,REGION:Disordered,REGION:Mediates interaction with AGFG1, CALM, DAB2, EPS15, EPS15R, ITSN1 and clathrin,REGION:Mediates interaction with the adaptor protein complex AP-2,REGION:Mediates membrane-binding,
FKBP14	FKBP prolyl isomerase 14(FKBP14)	Homo sapiens				GO:0000413~protein peptidyl-prolyl isomerization,GO:0036498~IRE1-mediated unfolded protein response,	GO:0005788~endoplasmic reticulum lumen,	GO:0003755~peptidyl-prolyl cis-trans isomerase activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,	IPR001179:Peptidyl-prolyl cis-trans isomerase, FKBP-type, domain,IPR002048:EF-hand domain,IPR011992:EF-hand-like domain,IPR018247:EF-Hand 1, calcium-binding site,		614557~Ehlers-Danlos syndrome, kyphoscoliotic type, 2,				KW-0256~Endoplasmic reticulum,	KW-0209~Deafness,KW-0248~Ehlers-Danlos syndrome,	KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0413~Isomerase,KW-0697~Rotamase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CA_BIND:1,CA_BIND:2,DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:PPIase FKBP-type,MOTIF:Prevents secretion from ER,
FKBP4	FKBP prolyl isomerase 4(FKBP4)	Homo sapiens				GO:0000413~protein peptidyl-prolyl isomerization,GO:0006457~protein folding,GO:0006463~steroid hormone receptor complex assembly,GO:0006825~copper ion transport,GO:0007566~embryo implantation,GO:0010977~negative regulation of neuron projection development,GO:0030521~androgen receptor signaling pathway,GO:0030850~prostate gland development,GO:0031111~negative regulation of microtubule polymerization or depolymerization,GO:0031115~negative regulation of microtubule polymerization,GO:0031503~protein complex localization,GO:0046661~male sex differentiation,GO:0061077~chaperone-mediated protein folding,GO:1900034~regulation of cellular response to heat,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0005874~microtubule,GO:0032991~macromolecular complex,GO:0043025~neuronal cell body,GO:0044295~axonal growth cone,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0003755~peptidyl-prolyl cis-trans isomerase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0005525~GTP binding,GO:0005528~FK506 binding,GO:0030674~protein binding, bridging,GO:0031072~heat shock protein binding,GO:0032767~copper-dependent protein binding,GO:0035259~glucocorticoid receptor binding,GO:0048156~tau protein binding,GO:0051219~phosphoprotein binding,	IPR001179:Peptidyl-prolyl cis-trans isomerase, FKBP-type, domain,IPR001440:Tetratricopeptide TPR-1,IPR011990:Tetratricopeptide-like helical,IPR013026:Tetratricopeptide repeat-containing domain,IPR013105:Tetratricopeptide TPR2,IPR019734:Tetratricopeptide repeat,	hsa04915:Estrogen signaling pathway,			SM00028:TPR,		KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0802~TPR repeat,		KW-0143~Chaperone,KW-0413~Isomerase,KW-0697~Rotamase,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),DOMAIN:PPIase FKBP-type,DOMAIN:PPIase FKBP-type 1,DOMAIN:PPIase FKBP-type 2,MUTAGEN:FD->DV: Decreased catalytic activity toward TRPC1.,REGION:Disordered,REGION:Interaction with tubulin,REPEAT:TPR,REPEAT:TPR 1,REPEAT:TPR 2,REPEAT:TPR 3,
FOSL1	FOS like 1, AP-1 transcription factor subunit(FOSL1)	Homo sapiens		h_ranklPathway:Bone Remodelling,		GO:0001701~in utero embryonic development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006935~chemotaxis,GO:0006968~cellular defense response,GO:0007296~vitellogenesis,GO:0007565~female pregnancy,GO:0007612~learning,GO:0008284~positive regulation of cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0009410~response to xenobiotic stimulus,GO:0009612~response to mechanical stimulus,GO:0009615~response to virus,GO:0009629~response to gravity,GO:0031668~cellular response to extracellular stimulus,GO:0032570~response to progesterone,GO:0034097~response to cytokine,GO:0042493~response to drug,GO:0042542~response to hydrogen peroxide,GO:0043065~positive regulation of apoptotic process,GO:0045787~positive regulation of cell cycle,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0051412~response to corticosterone,GO:0051591~response to cAMP,GO:0060674~placenta blood vessel development,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:2000144~positive regulation of DNA-templated transcription, initiation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0042734~presynaptic membrane,GO:0043005~neuron projection,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000837:Fos transforming protein,IPR004827:Basic-leucine zipper domain,	hsa04310:Wnt signaling pathway,hsa04380:Osteoclast differentiation,hsa04657:IL-17 signaling pathway,hsa05166:Human T-cell leukemia virus 1 infection,			SM00338:BRLZ,		KW-0539~Nucleus,		KW-0175~Coiled coil,		KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:BZIP,DOMAIN:bZIP,REGION:Basic motif,REGION:Disordered,REGION:Leucine-zipper,
FYN	FYN proto-oncogene, Src family tyrosine kinase(FYN)	Homo sapiens	67.Ikaros_and_signaling_inhibitors,81.Structure_of_Caps_and_SMACs,	h_biopeptidesPathway:Bioactive Peptide Induced Signaling Pathway,h_ecmPathway:Erk and PI-3 Kinase Are Necessary for Collagen Binding in Corneal Epithelia,h_ephA4Pathway:Eph Kinases and ephrins support platelet aggregation,h_il7Pathway:IL-7 Signal Transduction,h_integrinPathway:Integrin Signaling Pathway,h_reelinPathway:Reelin Signaling Pathway,h_tcraPathway:Lck and Fyn tyrosine kinases in initiation of TCR Activation,h_tcrPathway:T Cell Receptor Signaling Pathway,h_tsp1Pathway:TSP-1 Induced Apoptosis in Microvascular Endothelial Cell ,		GO:0000165~MAPK cascade,GO:0000304~response to singlet oxygen,GO:0001764~neuron migration,GO:0002223~stimulatory C-type lectin receptor signaling pathway,GO:0002250~adaptive immune response,GO:0002862~negative regulation of inflammatory response to antigenic stimulus,GO:0003015~heart process,GO:0006468~protein phosphorylation,GO:0006816~calcium ion transport,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007411~axon guidance,GO:0007596~blood coagulation,GO:0007612~learning,GO:0007631~feeding behavior,GO:0008360~regulation of cell shape,GO:0010629~negative regulation of gene expression,GO:0010730~negative regulation of hydrogen peroxide biosynthetic process,GO:0010976~positive regulation of neuron projection development,GO:0014068~positive regulation of phosphatidylinositol 3-kinase signaling,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0019221~cytokine-mediated signaling pathway,GO:0030154~cell differentiation,GO:0030168~platelet activation,GO:0030900~forebrain development,GO:0031295~T cell costimulation,GO:0031397~negative regulation of protein ubiquitination,GO:0035556~intracellular signal transduction,GO:0036120~cellular response to platelet-derived growth factor stimulus,GO:0038096~Fc-gamma receptor signaling pathway involved in phagocytosis,GO:0042177~negative regulation of protein catabolic process,GO:0042493~response to drug,GO:0042531~positive regulation of tyrosine phosphorylation of STAT protein,GO:0042542~response to hydrogen peroxide,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043524~negative regulation of neuron apoptotic process,GO:0045087~innate immune response,GO:0045471~response to ethanol,GO:0046777~protein autophosphorylation,GO:0048010~vascular endothelial growth factor receptor signaling pathway,GO:0048013~ephrin receptor signaling pathway,GO:0048813~dendrite morphogenesis,GO:0050690~regulation of defense response to virus by virus,GO:0050730~regulation of peptidyl-tyrosine phosphorylation,GO:0050798~activated T cell proliferation,GO:0050804~modulation of synaptic transmission,GO:0050852~T cell receptor signaling pathway,GO:0050900~leukocyte migration,GO:0050966~detection of mechanical stimulus involved in sensory perception of pain,GO:0051897~positive regulation of protein kinase B signaling,GO:0071375~cellular response to peptide hormone stimulus,GO:0071560~cellular response to transforming growth factor beta stimulus,GO:0090314~positive regulation of protein targeting to membrane,GO:0097062~dendritic spine maintenance,GO:1900182~positive regulation of protein localization to nucleus,GO:1900449~regulation of glutamate receptor signaling pathway,GO:1901216~positive regulation of neuron death,GO:1902951~negative regulation of dendritic spine maintenance,GO:1903202~negative regulation of oxidative stress-induced cell death,GO:1903997~positive regulation of non-membrane spanning protein tyrosine kinase activity,GO:1904645~response to beta-amyloid,GO:1904646~cellular response to beta-amyloid,GO:1905232~cellular response to L-glutamate,GO:1905430~cellular response to glycine,GO:1905477~positive regulation of protein localization to membrane,GO:1905664~regulation of calcium ion import across plasma membrane,GO:2001056~positive regulation of cysteine-type endopeptidase activity,GO:2001240~negative regulation of extrinsic apoptotic signaling pathway in absence of ligand,	GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0005768~endosome,GO:0005829~cytosol,GO:0005884~actin filament,GO:0005886~plasma membrane,GO:0014069~postsynaptic density,GO:0030425~dendrite,GO:0031234~extrinsic component of cytoplasmic side of plasma membrane,GO:0044297~cell body,GO:0045121~membrane raft,GO:0048471~perinuclear region of cytoplasm,GO:0097038~perinuclear endoplasmic reticulum,GO:0097386~glial cell projection,GO:0098685~Schaffer collateral - CA1 synapse,GO:0098978~glutamatergic synapse,GO:0099092~postsynaptic density, intracellular component,	GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0004715~non-membrane spanning protein tyrosine kinase activity,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016004~phospholipase activator activity,GO:0019899~enzyme binding,GO:0031802~type 5 metabotropic glutamate receptor binding,GO:0042608~T cell receptor binding,GO:0042609~CD4 receptor binding,GO:0042610~CD8 receptor binding,GO:0042802~identical protein binding,GO:0043014~alpha-tubulin binding,GO:0043274~phospholipase binding,GO:0043548~phosphatidylinositol 3-kinase binding,GO:0044325~ion channel binding,GO:0046872~metal ion binding,GO:0046875~ephrin receptor binding,GO:0048156~tau protein binding,GO:0050321~tau-protein kinase activity,GO:0051428~peptide hormone receptor binding,GO:0070851~growth factor receptor binding,GO:0097110~scaffold protein binding,GO:0097718~disordered domain specific binding,	IPR000719:Protein kinase, catalytic domain,IPR000980:SH2 domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR001452:Src homology-3 domain,IPR008266:Tyrosine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,IPR020635:Tyrosine-protein kinase, catalytic domain,	hsa04071:Sphingolipid signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04360:Axon guidance,hsa04380:Osteoclast differentiation,hsa04510:Focal adhesion,hsa04520:Adherens junction,hsa04611:Platelet activation,hsa04650:Natural killer cell mediated cytotoxicity,hsa04660:T cell receptor signaling pathway,hsa04664:Fc epsilon RI signaling pathway,hsa04725:Cholinergic synapse,hsa05020:Prion disease,hsa05130:Pathogenic Escherichia coli infection,hsa05416:Viral myocarditis,			SM00219:TyrKc,SM00252:SH2,SM00326:SH3,	KW-0391~Immunity,KW-0945~Host-virus interaction,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0656~Proto-oncogene,	KW-0727~SH2 domain,KW-0728~SH3 domain,	KW-0067~ATP-binding,KW-0464~Manganese,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0217~Developmental protein,KW-0418~Kinase,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,KW-9996~Developmental protein,	KW-0449~Lipoprotein,KW-0519~Myristate,KW-0564~Palmitate,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:ATP,COMPBIAS:Polar residues,DOMAIN:Protein kinase,DOMAIN:SH2,DOMAIN:SH3,LIPID:N-myristoyl glycine,LIPID:S-palmitoyl cysteine,NP_BIND:ATP,REGION:Disordered,
FAIM	Fas apoptotic inhibitory molecule(FAIM)	Homo sapiens				GO:0006915~apoptotic process,GO:0007249~I-kappaB kinase/NF-kappaB signaling,GO:0043066~negative regulation of apoptotic process,GO:0050769~positive regulation of neurogenesis,GO:1902042~negative regulation of extrinsic apoptotic signaling pathway via death domain receptors,	GO:0005737~cytoplasm,	GO:0005515~protein binding,	IPR010695:Fas apoptotic inhibitory molecule,					KW-0053~Apoptosis,	KW-0963~Cytoplasm,					KW-0007~Acetylation,
FAS	Fas cell surface death receptor(FAS)	Homo sapiens	38.Cell_cycle_arrest_and_apoptosis_ceramide,39.Deg_of_Chromosomal_DNA,46.P13K_PTEN,58.(CD40L)_immnosurveillance,72.IAP_interaction_with_cell_death_pathways,97.Immune_injury_MS-lesions_MS_antigen,	h_asbcellPathway:Antigen Dependent B Cell Activation,h_bbcellPathway:Bystander B Cell Activation,h_ctlPathway:CTL mediated immune response against target cells ,h_fasPathway:FAS signaling pathway ( CD95 ),h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_hsp27Pathway:Stress Induction of HSP Regulation,h_il2rbPathway:IL-2 Receptor Beta Chain in T cell Activation,h_keratinocytePathway:Keratinocyte Differentiation,h_pmlPathway:Regulation of transcriptional activity by PML,h_tcapoptosisPathway:HIV Induced T Cell Apoptosis,		GO:0001934~positive regulation of protein phosphorylation,GO:0006915~apoptotic process,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0006924~activation-induced cell death of T cells,GO:0006955~immune response,GO:0007165~signal transduction,GO:0032872~regulation of stress-activated MAPK cascade,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0034198~cellular response to amino acid starvation,GO:0036337~Fas signaling pathway,GO:0042981~regulation of apoptotic process,GO:0043065~positive regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0065003~macromolecular complex assembly,GO:0071260~cellular response to mechanical stimulus,GO:0071455~cellular response to hyperoxia,GO:0097049~motor neuron apoptotic process,GO:0097190~apoptotic signaling pathway,GO:0097191~extrinsic apoptotic signaling pathway,GO:0097192~extrinsic apoptotic signaling pathway in absence of ligand,GO:0097527~necroptotic signaling pathway,GO:1902041~regulation of extrinsic apoptotic signaling pathway via death domain receptors,GO:1902042~negative regulation of extrinsic apoptotic signaling pathway via death domain receptors,GO:2001235~positive regulation of apoptotic signaling pathway,GO:2001269~positive regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016604~nuclear body,GO:0031264~death-inducing signaling complex,GO:0031265~CD95 death-inducing signaling complex,GO:0045121~membrane raft,GO:0070062~extracellular exosome,	GO:0004888~transmembrane signaling receptor activity,GO:0005031~tumor necrosis factor-activated receptor activity,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0019900~kinase binding,GO:0038023~signaling receptor activity,GO:0042802~identical protein binding,	IPR000488:Death domain,IPR001368:TNFR/NGFR cysteine-rich region,IPR008063:Fas receptor,IPR011029:Death-like domain,	hsa01524:Platinum drug resistance,hsa04010:MAPK signaling pathway,hsa04060:Cytokine-cytokine receptor interaction,hsa04115:p53 signaling pathway,hsa04210:Apoptosis,hsa04217:Necroptosis,hsa04650:Natural killer cell mediated cytotoxicity,hsa04668:TNF signaling pathway,hsa04932:Non-alcoholic fatty liver disease,hsa04936:Alcoholic liver disease,hsa04940:Type I diabetes mellitus,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05130:Pathogenic Escherichia coli infection,hsa05142:Chagas disease,hsa05143:African trypanosomiasis,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05320:Autoimmune thyroid disease,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05417:Lipid and atherosclerosis,	601859~Autoimmune lymphoproliferative syndrome,601859~Autoimmune lymphoproliferative syndrome, type IA,Squamous cell carcinoma, burn scar-related, somatic~Squamous cell carcinoma, burn scar-related, somatic,		SM00005:DEATH,SM00208:TNFR,	KW-0053~Apoptosis,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0112~Calmodulin-binding,KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:(Microbial infection) N-beta-linked (GlcNAc) arginine,CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GalNAc...) threonine,DOMAIN:Death,DOMAIN:TNFR-Cys,LIPID:S-palmitoyl cysteine,MUTAGEN:C->V: Loss of palmitoylation.,MUTAGEN:E->K: Loss of interaction with FADD.,MUTAGEN:I->D: Constitutive activation. Promotes apoptosis, both in the presence and in the absence of stimulation by a ligand.,MUTAGEN:K->D: Strongly decreased interaction with FADD.,MUTAGEN:Q->K: Loss of interaction with FADD.,MUTAGEN:R->A: Abolished GlcNAcylation by E.coli NleB1.,MUTAGEN:R->E: Strongly decreased interaction with FADD.,MUTAGEN:Y->D: Decreased interaction with FADD.,REGION:Interaction with CALM,REGION:Interaction with HIPK3,REPEAT:TNFR-Cys,REPEAT:TNFR-Cys 1,REPEAT:TNFR-Cys 2,REPEAT:TNFR-Cys 3,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
FOS	Fos proto-oncogene, AP-1 transcription factor subunit(FOS)	Homo sapiens	3.T_cell_receptor,67.Ikaros_and_signaling_inhibitors,92.Ancient_Host_Defense_Pathways,	h_arenrf2Pathway:Oxidative Stress Induced Gene Expression Via Nrf2,h_bcellsurvivalPathway:B Cell Survival Pathway,h_bcrPathway:BCR Signaling Pathway,h_cardiacEGFPathway:Role of EGF Receptor Transactivation by GPCRs in Cardiac Hypertrophy,h_ccr5Pathway:Pertussis toxin-insensitive CCR5 Signaling in Macrophage,h_cdmacPathway:Cadmium induces DNA synthesis and proliferation in macrophages,h_dreamPathway:Repression of Pain Sensation by the Transcriptional Regulator DREAM,h_egfPathway:EGF Signaling Pathway,h_epoPathway:EPO Signaling Pathway,h_etsPathway:METS affect on Macrophage Differentiation,h_fcer1Pathway:Fc Epsilon Receptor I Signaling in Mast Cells,h_gleevecPathway:Inhibition of Cellular Proliferation by Gleevec,h_gpcrPathway:Signaling Pathway from G-Protein Families,h_igf1Pathway:IGF-1 Signaling Pathway,h_il2Pathway:IL 2 signaling pathway,h_il2rbPathway:IL-2 Receptor Beta Chain in T cell Activation,h_il3Pathway:IL 3 signaling pathway,h_il6Pathway:IL 6 signaling pathway,h_insulinPathway:Insulin Signaling Pathway,h_keratinocytePathway:Keratinocyte Differentiation,h_mapkPathway:MAPKinase Signaling Pathway,h_metPathway:Signaling of Hepatocyte Growth Factor Receptor,h_ngfPathway:Nerve growth factor pathway (NGF),h_pdgfPathway:PDGF Signaling Pathway,h_ranklPathway:Bone Remodelling,h_tcrPathway:T Cell Receptor Signaling Pathway,h_tollPathway:Toll-Like Receptor Pathway,h_tpoPathway:TPO Signaling Pathway,h_tsp1Pathway:TSP-1 Induced Apoptosis in Microvascular Endothelial Cell ,		GO:0001661~conditioned taste aversion,GO:0006306~DNA methylation,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0006954~inflammatory response,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0007399~nervous system development,GO:0007565~female pregnancy,GO:0007568~aging,GO:0009409~response to cold,GO:0009410~response to xenobiotic stimulus,GO:0009416~response to light stimulus,GO:0009629~response to gravity,GO:0009636~response to toxic substance,GO:0019221~cytokine-mediated signaling pathway,GO:0030431~sleep,GO:0031668~cellular response to extracellular stimulus,GO:0032496~response to lipopolysaccharide,GO:0032570~response to progesterone,GO:0032870~cellular response to hormone stimulus,GO:0034097~response to cytokine,GO:0034614~cellular response to reactive oxygen species,GO:0035902~response to immobilization stress,GO:0035914~skeletal muscle cell differentiation,GO:0035994~response to muscle stretch,GO:0038095~Fc-epsilon receptor signaling pathway,GO:0042493~response to drug,GO:0045672~positive regulation of osteoclast differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051090~regulation of sequence-specific DNA binding transcription factor activity,GO:0051412~response to corticosterone,GO:0051591~response to cAMP,GO:0060395~SMAD protein signal transduction,GO:0071276~cellular response to cadmium ion,GO:0071277~cellular response to calcium ion,GO:1901216~positive regulation of neuron death,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0016020~membrane,GO:0032993~protein-DNA complex,GO:0035976~transcription factor AP-1 complex,GO:0043005~neuron projection,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000979~RNA polymerase II core promoter sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001102~RNA polymerase II activating transcription factor binding,GO:0001221~transcription cofactor binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0042802~identical protein binding,GO:0044877~macromolecular complex binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0070412~R-SMAD binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000837:Fos transforming protein,IPR004827:Basic-leucine zipper domain,	hsa01522:Endocrine resistance,hsa04010:MAPK signaling pathway,hsa04024:cAMP signaling pathway,hsa04210:Apoptosis,hsa04380:Osteoclast differentiation,hsa04620:Toll-like receptor signaling pathway,hsa04657:IL-17 signaling pathway,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04660:T cell receptor signaling pathway,hsa04662:B cell receptor signaling pathway,hsa04668:TNF signaling pathway,hsa04713:Circadian entrainment,hsa04725:Cholinergic synapse,hsa04728:Dopaminergic synapse,hsa04915:Estrogen signaling pathway,hsa04917:Prolactin signaling pathway,hsa04921:Oxytocin signaling pathway,hsa04926:Relaxin signaling pathway,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04932:Non-alcoholic fatty liver disease,hsa04935:Growth hormone synthesis, secretion and action,hsa05031:Amphetamine addiction,hsa05130:Pathogenic Escherichia coli infection,hsa05132:Salmonella infection,hsa05133:Pertussis,hsa05135:Yersinia infection,hsa05140:Leishmaniasis,hsa05142:Chagas disease,hsa05161:Hepatitis B,hsa05162:Measles,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05210:Colorectal cancer,hsa05224:Breast cancer,hsa05231:Choline metabolism in cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05323:Rheumatoid arthritis,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,			SM00338:BRLZ,		KW-0256~Endoplasmic reticulum,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0656~Proto-oncogene,	KW-0175~Coiled coil,		KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:BZIP,DOMAIN:bZIP,MUTAGEN:K->R: Abolishes sumoylation. No change in nuclear location nor on protein stability. Increased AP1 transactivation activity when heterodimerized with cJUN.,MUTAGEN:K->R: No change in sumoylation.,MUTAGEN:S->A: Loss of protein stability. Reduced MOS/MAPK-mediated transforming ability; when associated with A-374.,MUTAGEN:S->A: No change in sumoylation levels. Loss of protein stability. Reduced MOS/MAPK-mediated transforming ability; when associated with A-362.,MUTAGEN:S->D: Increased protein stability. Increased MOS/MAPK-mediated transforming ability and no change in sumoylation levels; when associated with D-362.,MUTAGEN:S->D: Increased protein stability. Increased MOS/MAPK-mediated transforming ability and no change in sumoylation levels; when associated with D-374.,MUTAGEN:T->D: Decreased sumoylation levels.,MUTAGEN:T->D: No change in sumoylation levels.,MUTAGEN:Y->E: Loss of activation of phospholipid synthesis; when associated with E-10.,MUTAGEN:Y->E: Loss of activation of phospholipid synthesis; when associated with E-30.,MUTAGEN:Y->F: No effect on Tyr-phosphorylation. Loss of endoplasmic reticulum localization in quiescent cells.,MUTAGEN:Y->F: Overall loss of Tyr-phosphorylation, including that of Y-10 phosphorylation. Localizes to the endoplasmic reticulum in quiescent cells. Activates phospholipid synthesis in growing cells.,MUTAGEN:Y->F: Overall loss of Tyr-phosphorylation, including that of Y-30 phosphorylation. Localizes to the endoplasmic reticulum in quiescent cells. Activates phospholipid synthesis in growing cells.,REGION:Basic motif; required for the activation of phospholipid synthesis, but not for CDS1-binding,REGION:Disordered,REGION:Leucine-zipper,
GNA11	G protein subunit alpha 11(GNA11)	Homo sapiens		h_biopeptidesPathway:Bioactive Peptide Induced Signaling Pathway,		GO:0001501~skeletal system development,GO:0001508~action potential,GO:0007165~signal transduction,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007188~adenylate cyclase-modulating G-protein coupled receptor signaling pathway,GO:0007213~G-protein coupled acetylcholine receptor signaling pathway,GO:0007507~heart development,GO:0007603~phototransduction, visible light,GO:0008217~regulation of blood pressure,GO:0009649~entrainment of circadian clock,GO:0010259~multicellular organism aging,GO:0030168~platelet activation,GO:0045634~regulation of melanocyte differentiation,GO:0048066~developmental pigmentation,GO:0060158~phospholipase C-activating dopamine receptor signaling pathway,GO:0071467~cellular response to pH,GO:0086100~endothelin receptor signaling pathway,GO:1904888~cranial skeletal system development,	GO:0001750~photoreceptor outer segment,GO:0005737~cytoplasm,GO:0005765~lysosomal membrane,GO:0005834~heterotrimeric G-protein complex,GO:0005886~plasma membrane,GO:0045202~synapse,GO:0070062~extracellular exosome,	GO:0001664~G-protein coupled receptor binding,GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019001~guanyl nucleotide binding,GO:0031683~G-protein beta/gamma-subunit complex binding,GO:0031826~type 2A serotonin receptor binding,GO:0046872~metal ion binding,	IPR000654:G-protein alpha subunit, group Q,IPR001019:Guanine nucleotide binding protein (G-protein), alpha subunit,IPR011025:G protein alpha subunit, helical insertion,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04020:Calcium signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04270:Vascular smooth muscle contraction,hsa04540:Gap junction,hsa04725:Cholinergic synapse,hsa04730:Long-term depression,hsa04911:Insulin secretion,hsa04912:GnRH signaling pathway,hsa04925:Aldosterone synthesis and secretion,hsa04927:Cortisol synthesis and secretion,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04929:GnRH secretion,hsa04934:Cushing syndrome,hsa04935:Growth hormone synthesis, secretion and action,hsa05142:Chagas disease,hsa05146:Amoebiasis,hsa05163:Human cytomegalovirus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,	145981~Hypocalciuric hypercalcemia, type II,615361~Hypocalcemia, autosomal dominant 2,		SM00275:SM00275,		KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0225~Disease variant,		KW-0342~GTP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0807~Transducer,	KW-0013~ADP-ribosylation,KW-0449~Lipoprotein,KW-0564~Palmitate,	BINDING:GTP; via amide nitrogen,DOMAIN:G-alpha,LIPID:S-palmitoyl cysteine,METAL:Magnesium,NP_BIND:GTP,REGION:G1 motif,REGION:G2 motif,REGION:G3 motif,REGION:G4 motif,REGION:G5 motif,
GNA15	G protein subunit alpha 15(GNA15)	Homo sapiens		h_fmlpPathway:fMLP induced chemokine gene expression in HMC-1 cells,		GO:0001508~action potential,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007188~adenylate cyclase-modulating G-protein coupled receptor signaling pathway,GO:0007202~activation of phospholipase C activity,GO:0007207~phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway,GO:0030168~platelet activation,GO:0051482~positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway,GO:0060158~phospholipase C-activating dopamine receptor signaling pathway,	GO:0005834~heterotrimeric G-protein complex,GO:0005886~plasma membrane,GO:0045202~synapse,	GO:0001664~G-protein coupled receptor binding,GO:0003924~GTPase activity,GO:0005525~GTP binding,GO:0031683~G-protein beta/gamma-subunit complex binding,GO:0031826~type 2A serotonin receptor binding,GO:0046872~metal ion binding,	IPR000654:G-protein alpha subunit, group Q,IPR001019:Guanine nucleotide binding protein (G-protein), alpha subunit,IPR011025:G protein alpha subunit, helical insertion,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04020:Calcium signaling pathway,hsa04926:Relaxin signaling pathway,hsa05142:Chagas disease,hsa05146:Amoebiasis,			SM00275:SM00275,					KW-0342~GTP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0807~Transducer,	KW-0013~ADP-ribosylation,	BINDING:GTP; via amide nitrogen,DOMAIN:G-alpha,METAL:Magnesium,NP_BIND:GTP,REGION:G1 motif,REGION:G2 motif,REGION:G3 motif,REGION:G4 motif,REGION:G5 motif,
GNAI1	G protein subunit alpha i1(GNAI1)	Homo sapiens		h_biopeptidesPathway:Bioactive Peptide Induced Signaling Pathway,h_cxcr4Pathway:CXCR4 Signaling Pathway,h_edg1Pathway:Phospholipids as signalling intermediaries,h_gpcrPathway:Signaling Pathway from G-Protein Families,H_gsk3Pathway:Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar Macrophages,h_mPRPathway:How Progesterone Initiates the Oocyte Maturation,h_par1pathway:Thrombin signaling and protease-activated receptors,h_sppaPathway:Aspirin Blocks Signaling Pathway Involved in Platelet Activation,		GO:0006457~protein folding,GO:0007049~cell cycle,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007188~adenylate cyclase-modulating G-protein coupled receptor signaling pathway,GO:0007193~adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway,GO:0030168~platelet activation,GO:0043434~response to peptide hormone,GO:0043949~regulation of cAMP-mediated signaling,GO:0050805~negative regulation of synaptic transmission,GO:0051301~cell division,GO:0060236~regulation of mitotic spindle organization,GO:1904322~cellular response to forskolin,GO:1904778~positive regulation of protein localization to cell cortex,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005765~lysosomal membrane,GO:0005813~centrosome,GO:0005834~heterotrimeric G-protein complex,GO:0005886~plasma membrane,GO:0005938~cell cortex,GO:0030496~midbody,GO:0045121~membrane raft,GO:0070062~extracellular exosome,GO:0099738~cell cortex region,	GO:0000287~magnesium ion binding,GO:0001664~G-protein coupled receptor binding,GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019001~guanyl nucleotide binding,GO:0019003~GDP binding,GO:0031683~G-protein beta/gamma-subunit complex binding,GO:0031821~G-protein coupled serotonin receptor binding,GO:0032794~GTPase activating protein binding,	IPR001019:Guanine nucleotide binding protein (G-protein), alpha subunit,IPR001408:G-protein alpha subunit, group I,IPR011025:G protein alpha subunit, helical insertion,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04015:Rap1 signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04062:Chemokine signaling pathway,hsa04071:Sphingolipid signaling pathway,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04360:Axon guidance,hsa04371:Apelin signaling pathway,hsa04540:Gap junction,hsa04611:Platelet activation,hsa04670:Leukocyte transendothelial migration,hsa04713:Circadian entrainment,hsa04723:Retrograde endocannabinoid signaling,hsa04724:Glutamatergic synapse,hsa04725:Cholinergic synapse,hsa04726:Serotonergic synapse,hsa04727:GABAergic synapse,hsa04728:Dopaminergic synapse,hsa04730:Long-term depression,hsa04914:Progesterone-mediated oocyte maturation,hsa04915:Estrogen signaling pathway,hsa04916:Melanogenesis,hsa04921:Oxytocin signaling pathway,hsa04923:Regulation of lipolysis in adipocytes,hsa04924:Renin secretion,hsa04926:Relaxin signaling pathway,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04934:Cushing syndrome,hsa04935:Growth hormone synthesis, secretion and action,hsa04971:Gastric acid secretion,hsa05012:Parkinson disease,hsa05030:Cocaine addiction,hsa05032:Morphine addiction,hsa05034:Alcoholism,hsa05133:Pertussis,hsa05142:Chagas disease,hsa05145:Toxoplasmosis,hsa05163:Human cytomegalovirus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,hsa05207:Chemical carcinogenesis - receptor activation,			SM00275:SM00275,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,KW-0813~Transport,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,			KW-0342~GTP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0807~Transducer,	KW-0013~ADP-ribosylation,KW-0449~Lipoprotein,KW-0519~Myristate,KW-0564~Palmitate,	BINDING:GTP,BINDING:GTP; via amide nitrogen,DOMAIN:G-alpha,LIPID:N-myristoyl glycine,LIPID:S-palmitoyl cysteine,METAL:Magnesium,MUTAGEN:E->L: Enhances interaction (inactive GDP-bound) with RGS14.,MUTAGEN:G->R: Abolishes switch to an activated conformation and dissociation from beta and gamma subunits upon GTP binding. Abolishes interaction with RGS family members.,MUTAGEN:Q->L: Enhances interaction (inactive GDP-bound) with RGS14.,NP_BIND:GTP,REGION:G1 motif,REGION:G2 motif,REGION:G3 motif,REGION:G4 motif,REGION:G5 motif,
GNAI2	G protein subunit alpha i2(GNAI2)	Homo sapiens				GO:0001973~adenosine receptor signaling pathway,GO:0006457~protein folding,GO:0007049~cell cycle,GO:0007165~signal transduction,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007188~adenylate cyclase-modulating G-protein coupled receptor signaling pathway,GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0007193~adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway,GO:0007194~negative regulation of adenylate cyclase activity,GO:0007213~G-protein coupled acetylcholine receptor signaling pathway,GO:0007214~gamma-aminobutyric acid signaling pathway,GO:0007584~response to nutrient,GO:0008283~cell proliferation,GO:0008284~positive regulation of cell proliferation,GO:0030168~platelet activation,GO:0030335~positive regulation of cell migration,GO:0032930~positive regulation of superoxide anion generation,GO:0033864~positive regulation of NAD(P)H oxidase activity,GO:0035810~positive regulation of urine volume,GO:0035815~positive regulation of renal sodium excretion,GO:0043434~response to peptide hormone,GO:0045955~negative regulation of calcium ion-dependent exocytosis,GO:0046628~positive regulation of insulin receptor signaling pathway,GO:0050805~negative regulation of synaptic transmission,GO:0051301~cell division,GO:0051924~regulation of calcium ion transport,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:1903614~negative regulation of protein tyrosine phosphatase activity,GO:1904707~positive regulation of vascular smooth muscle cell proliferation,GO:2000179~positive regulation of neural precursor cell proliferation,GO:2001234~negative regulation of apoptotic signaling pathway,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005834~heterotrimeric G-protein complex,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0030425~dendrite,GO:0030496~midbody,GO:0044297~cell body,GO:0045121~membrane raft,GO:0045202~synapse,GO:0070062~extracellular exosome,GO:1903561~extracellular vesicle,	GO:0001664~G-protein coupled receptor binding,GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019001~guanyl nucleotide binding,GO:0031683~G-protein beta/gamma-subunit complex binding,GO:0046872~metal ion binding,	IPR001019:Guanine nucleotide binding protein (G-protein), alpha subunit,IPR001408:G-protein alpha subunit, group I,IPR011025:G protein alpha subunit, helical insertion,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04015:Rap1 signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04062:Chemokine signaling pathway,hsa04071:Sphingolipid signaling pathway,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04360:Axon guidance,hsa04371:Apelin signaling pathway,hsa04540:Gap junction,hsa04611:Platelet activation,hsa04670:Leukocyte transendothelial migration,hsa04713:Circadian entrainment,hsa04723:Retrograde endocannabinoid signaling,hsa04724:Glutamatergic synapse,hsa04725:Cholinergic synapse,hsa04726:Serotonergic synapse,hsa04727:GABAergic synapse,hsa04728:Dopaminergic synapse,hsa04730:Long-term depression,hsa04914:Progesterone-mediated oocyte maturation,hsa04915:Estrogen signaling pathway,hsa04916:Melanogenesis,hsa04921:Oxytocin signaling pathway,hsa04923:Regulation of lipolysis in adipocytes,hsa04924:Renin secretion,hsa04926:Relaxin signaling pathway,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04934:Cushing syndrome,hsa04935:Growth hormone synthesis, secretion and action,hsa04971:Gastric acid secretion,hsa05012:Parkinson disease,hsa05030:Cocaine addiction,hsa05032:Morphine addiction,hsa05034:Alcoholism,hsa05133:Pertussis,hsa05142:Chagas disease,hsa05145:Toxoplasmosis,hsa05163:Human cytomegalovirus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,hsa05207:Chemical carcinogenesis - receptor activation,	192605~Ventricular tachycardia, idiopathic,Pituitary adenoma, ACTH-secreting, somatic~Pituitary adenoma, ACTH-secreting, somatic,		SM00275:SM00275,	KW-0131~Cell cycle,KW-0132~Cell division,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,			KW-0342~GTP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0807~Transducer,	KW-0013~ADP-ribosylation,KW-0449~Lipoprotein,KW-0519~Myristate,KW-0564~Palmitate,	BINDING:GTP; via amide nitrogen,COMPBIAS:Polar residues,DOMAIN:G-alpha,LIPID:N-myristoyl glycine,LIPID:S-palmitoyl cysteine,METAL:Magnesium,NP_BIND:GTP,REGION:Disordered,REGION:G1 motif,REGION:G2 motif,REGION:G3 motif,REGION:G4 motif,REGION:G5 motif,
GNB5	G protein subunit beta 5(GNB5)	Homo sapiens				GO:0006457~protein folding,GO:0007165~signal transduction,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007212~dopamine receptor signaling pathway,GO:0036367~light adaption,GO:0043547~positive regulation of GTPase activity,GO:1901386~negative regulation of voltage-gated calcium channel activity,GO:1990603~dark adaptation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005834~heterotrimeric G-protein complex,GO:0005886~plasma membrane,GO:0098793~presynapse,GO:1902773~GTPase activator complex,	GO:0003924~GTPase activity,GO:0005096~GTPase activator activity,GO:0005515~protein binding,GO:0030159~receptor signaling complex scaffold activity,GO:0031682~G-protein gamma-subunit binding,GO:0051087~chaperone binding,	IPR001632:G-protein, beta subunit,IPR001680:WD40 repeat,IPR015943:WD40/YVTN repeat-like-containing domain,IPR016346:Guanine nucleotide-binding protein, beta subunit,IPR017986:WD40-repeat-containing domain,IPR019775:WD40 repeat, conserved site,IPR020472:G-protein beta WD-40 repeat,	hsa04014:Ras signaling pathway,hsa04062:Chemokine signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04371:Apelin signaling pathway,hsa04713:Circadian entrainment,hsa04723:Retrograde endocannabinoid signaling,hsa04724:Glutamatergic synapse,hsa04725:Cholinergic synapse,hsa04726:Serotonergic synapse,hsa04727:GABAergic synapse,hsa04728:Dopaminergic synapse,hsa04926:Relaxin signaling pathway,hsa05032:Morphine addiction,hsa05034:Alcoholism,hsa05163:Human cytomegalovirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,	617173~Intellectual developmental disorder with cardiac arrhythmia,617182~Language delay and ADHD/cognitive impairment with or without cardiac arrhythmia,		SM00320:WD40,		KW-0472~Membrane,	KW-0225~Disease variant,KW-0991~Mental retardation,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0853~WD repeat,		KW-0807~Transducer,		REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
GPATCH8	G-patch domain containing 8(GPATCH8)	Homo sapiens			DNA replication, recombination, and repair,		GO:0005634~nucleus,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR000467:G-patch domain,IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,IPR022755:Zinc finger, double-stranded RNA binding,				SM00443:G_patch,				KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:C2H2-type,DOMAIN:G-patch,REGION:Disordered,ZN_FING:C2H2-type,
G3BP1	G3BP stress granule assembly factor 1(G3BP1)	Homo sapiens				GO:0007265~Ras protein signal transduction,GO:0016032~viral process,GO:0032481~positive regulation of type I interferon production,GO:0032508~DNA duplex unwinding,GO:0034063~stress granule assembly,GO:0045087~innate immune response,GO:0051607~defense response to virus,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:0090305~nucleic acid phosphodiester bond hydrolysis,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005925~focal adhesion,GO:0010494~cytoplasmic stress granule,GO:0043204~perikaryon,GO:1990904~ribonucleoprotein complex,	GO:0003677~DNA binding,GO:0003678~DNA helicase activity,GO:0003723~RNA binding,GO:0003724~RNA helicase activity,GO:0003729~mRNA binding,GO:0004519~endonuclease activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0033677~DNA/RNA helicase activity,	IPR000504:RNA recognition motif domain,IPR002075:Nuclear transport factor 2,IPR012677:Nucleotide-binding, alpha-beta plait,IPR018222:Nuclear transport factor 2, Eukaryote,				SM00360:RRM,	KW-0391~Immunity,KW-0399~Innate immunity,KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0238~DNA-binding,KW-0255~Endonuclease,KW-0347~Helicase,KW-0378~Hydrolase,KW-0540~Nuclease,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:NTF2,DOMAIN:RRM,MUTAGEN:Q->G: Loss of cleavage by human enterovirus 71 protease 3C.,MUTAGEN:S->A: Cytoplasmic. Partially nuclear; when associated with E-149.,MUTAGEN:S->A: Cytoplasmic; no effect on stress granule assembly.,MUTAGEN:S->E: Cytoplasmic and nuclear; no assembly of stress granules; no homo-oligomerization.,MUTAGEN:S->E: Cytoplasmic. Partially nuclear; when associated with E-149.,REGION:Disordered,SITE:Cleavage; by human enterovirus 71 protease 3C,TRANSMEM:Helical,
GABPB1	GA binding protein transcription factor subunit beta 1(GABPB1)	Homo sapiens				GO:0007005~mitochondrion organization,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0036464~cytoplasmic ribonucleoprotein granule,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0005515~protein binding,	IPR002110:Ankyrin repeat,IPR020683:Ankyrin repeat-containing domain,				SM00248:ANK,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0040~ANK repeat,KW-0175~Coiled coil,KW-0677~Repeat,			KW-0007~Acetylation,	DOMAIN:Ankyrin_rpt-contain_dom,MUTAGEN:IIV->AAA: Strongly reduces interaction with HCFC1 and transcriptional activation. Loss of activity; when associated with A-264 and A-265, or A-273 and A-275.,MUTAGEN:ITI->ATA: Strongly reduces interaction with HCFC1 and transcriptional activation. Loss of activity; when associated with A-297; A-298 and A-299, or with A-307 and A-310.,MUTAGEN:Q->A: No effect on transcriptional activation. Minor reduction in activity; when associated with A-270 and A-271.,MUTAGEN:QQ->AA: Minor reduction in transcriptional activation. Moderate reduction in activity; when associated with A-270 and A-271.,MUTAGEN:QQ->AA: Minor reduction in transcriptional activation. Moderate reduction in activity; when associated with A-305 and A-306.,MUTAGEN:QQ->AA: Minor reduction in transcriptional activation; when associated with A-295 or A-305 and A-306.,MUTAGEN:VLTV->ALTA: Moderately reduces interaction with HCFC1 and transcriptional activation. Loss of activity; when associated with A-273 and A-275.,MUTAGEN:VV->AA: Minor effect upon interaction with HCFC1 and transcriptional activation. Loss of activity; when associated with A-297; A-298 and A-299, or with A-307 and A-310.,REGION:Transcription activation and HCFC1 interaction,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,REPEAT:ANK 5,
GATA2	GATA binding protein 2(GATA2)	Homo sapiens			Transcription,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001655~urogenital system development,GO:0001709~cell fate determination,GO:0001764~neuron migration,GO:0001892~embryonic placenta development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006909~phagocytosis,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007596~blood coagulation,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0010725~regulation of primitive erythrocyte differentiation,GO:0021514~ventral spinal cord interneuron differentiation,GO:0021533~cell differentiation in hindbrain,GO:0021902~commitment of neuronal cell to specific neuron type in forebrain,GO:0021954~central nervous system neuron development,GO:0021983~pituitary gland development,GO:0030097~hemopoiesis,GO:0033993~response to lipid,GO:0035019~somatic stem cell population maintenance,GO:0035065~regulation of histone acetylation,GO:0035854~eosinophil fate commitment,GO:0042472~inner ear morphogenesis,GO:0043306~positive regulation of mast cell degranulation,GO:0043536~positive regulation of blood vessel endothelial cell migration,GO:0045165~cell fate commitment,GO:0045599~negative regulation of fat cell differentiation,GO:0045648~positive regulation of erythrocyte differentiation,GO:0045650~negative regulation of macrophage differentiation,GO:0045654~positive regulation of megakaryocyte differentiation,GO:0045666~positive regulation of neuron differentiation,GO:0045746~negative regulation of Notch signaling pathway,GO:0045766~positive regulation of angiogenesis,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048469~cell maturation,GO:0048873~homeostasis of number of cells within a tissue,GO:0050766~positive regulation of phagocytosis,GO:0060100~positive regulation of phagocytosis, engulfment,GO:0060216~definitive hemopoiesis,GO:0060872~semicircular canal development,GO:0061042~vascular wound healing,GO:0070345~negative regulation of fat cell proliferation,GO:0090050~positive regulation of cell migration involved in sprouting angiogenesis,GO:0090102~cochlea development,GO:0097154~GABAergic neuron differentiation,GO:1902036~regulation of hematopoietic stem cell differentiation,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1903589~positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis,GO:2000178~negative regulation of neural precursor cell proliferation,GO:2000352~negative regulation of endothelial cell apoptotic process,GO:2000977~regulation of forebrain neuron differentiation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001221~transcription cofactor binding,GO:0001223~transcription coactivator binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003682~chromatin binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0008270~zinc ion binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0070742~C2H2 zinc finger domain binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000679:Zinc finger, GATA-type,IPR013088:Zinc finger, NHR/GATA-type,IPR016374:Transcription factor, GATA-1/2/3,		601626~Leukemia, acute myeloid, susceptibility to,614038~Emberger syndrome,614172~Immunodeficiency 21,614286~Myelodysplastic syndrome, susceptibility to,	PIRSF003027:transcription factor, GATA-1/2/3 types,	SM00401:ZnF_GATA,	KW-0581~Phagocytosis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0238~DNA-binding,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,ZN_FING:GATA-type 1,ZN_FING:GATA-type 2,
GATA3	GATA binding protein 3(GATA3)	Homo sapiens	78.B_Cell_Development,80.T_cell_Activation,89.CD4_T_Cell_Differentiation,	h_gata3Pathway:GATA3 participate in activating the Th2 cytokine genes expression,		GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001701~in utero embryonic development,GO:0001709~cell fate determination,GO:0001764~neuron migration,GO:0001806~type IV hypersensitivity,GO:0001817~regulation of cytokine production,GO:0001822~kidney development,GO:0001823~mesonephros development,GO:0002088~lens development in camera-type eye,GO:0002520~immune system development,GO:0002572~pro-T cell differentiation,GO:0003180~aortic valve morphogenesis,GO:0003215~cardiac right ventricle morphogenesis,GO:0003281~ventricular septum development,GO:0006338~chromatin remodeling,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006952~defense response,GO:0006959~humoral immune response,GO:0007165~signal transduction,GO:0007411~axon guidance,GO:0007596~blood coagulation,GO:0008285~negative regulation of cell proliferation,GO:0008584~male gonad development,GO:0009410~response to xenobiotic stimulus,GO:0009615~response to virus,GO:0009653~anatomical structure morphogenesis,GO:0009791~post-embryonic development,GO:0009967~positive regulation of signal transduction,GO:0010332~response to gamma radiation,GO:0010595~positive regulation of endothelial cell migration,GO:0010719~negative regulation of epithelial to mesenchymal transition,GO:0010975~regulation of neuron projection development,GO:0014065~phosphatidylinositol 3-kinase signaling,GO:0016579~protein deubiquitination,GO:0019221~cytokine-mediated signaling pathway,GO:0030217~T cell differentiation,GO:0030218~erythrocyte differentiation,GO:0030856~regulation of epithelial cell differentiation,GO:0031929~TOR signaling,GO:0032689~negative regulation of interferon-gamma production,GO:0032703~negative regulation of interleukin-2 production,GO:0032736~positive regulation of interleukin-13 production,GO:0032753~positive regulation of interleukin-4 production,GO:0032754~positive regulation of interleukin-5 production,GO:0033600~negative regulation of mammary gland epithelial cell proliferation,GO:0035162~embryonic hemopoiesis,GO:0035457~cellular response to interferon-alpha,GO:0035799~ureter maturation,GO:0035898~parathyroid hormone secretion,GO:0042421~norepinephrine biosynthetic process,GO:0042472~inner ear morphogenesis,GO:0042493~response to drug,GO:0043370~regulation of CD4-positive, alpha-beta T cell differentiation,GO:0043523~regulation of neuron apoptotic process,GO:0043583~ear development,GO:0043627~response to estrogen,GO:0045061~thymic T cell selection,GO:0045064~T-helper 2 cell differentiation,GO:0045087~innate immune response,GO:0045165~cell fate commitment,GO:0045471~response to ethanol,GO:0045582~positive regulation of T cell differentiation,GO:0045599~negative regulation of fat cell differentiation,GO:0045786~negative regulation of cell cycle,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048469~cell maturation,GO:0048485~sympathetic nervous system development,GO:0048538~thymus development,GO:0048568~embryonic organ development,GO:0048589~developmental growth,GO:0048646~anatomical structure formation involved in morphogenesis,GO:0050728~negative regulation of inflammatory response,GO:0050852~T cell receptor signaling pathway,GO:0051569~regulation of histone H3-K4 methylation,GO:0051897~positive regulation of protein kinase B signaling,GO:0060017~parathyroid gland development,GO:0060037~pharyngeal system development,GO:0060065~uterus development,GO:0060231~mesenchymal to epithelial transition,GO:0060374~mast cell differentiation,GO:0060676~ureteric bud formation,GO:0061085~regulation of histone H3-K27 methylation,GO:0061290~canonical Wnt signaling pathway involved in metanephric kidney development,GO:0071353~cellular response to interleukin-4,GO:0071356~cellular response to tumor necrosis factor,GO:0071442~positive regulation of histone H3-K14 acetylation,GO:0071599~otic vesicle development,GO:0071773~cellular response to BMP stimulus,GO:0072107~positive regulation of ureteric bud formation,GO:0072178~nephric duct morphogenesis,GO:0072179~nephric duct formation,GO:0072182~regulation of nephron tubule epithelial cell differentiation,GO:0072197~ureter morphogenesis,GO:0072676~lymphocyte migration,GO:0090102~cochlea development,GO:1901536~negative regulation of DNA demethylation,GO:1902036~regulation of hematopoietic stem cell differentiation,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:2000114~regulation of establishment of cell polarity,GO:2000146~negative regulation of cell motility,GO:2000352~negative regulation of endothelial cell apoptotic process,GO:2000553~positive regulation of T-helper 2 cell cytokine production,GO:2000607~negative regulation of cell proliferation involved in mesonephros development,GO:2000611~positive regulation of thyroid hormone generation,GO:2000617~positive regulation of histone H3-K9 acetylation,GO:2000679~positive regulation of transcription regulatory region DNA binding,GO:2000683~regulation of cellular response to X-ray,GO:2000703~negative regulation of fibroblast growth factor receptor signaling pathway involved in ureteric bud formation,GO:2000734~negative regulation of glial cell-derived neurotrophic factor receptor signaling pathway involved in ureteric bud formation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0000987~core promoter proximal region sequence-specific DNA binding,GO:0001223~transcription coactivator binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005134~interleukin-2 receptor binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0008270~zinc ion binding,GO:0042802~identical protein binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0070888~E-box binding,GO:0071837~HMG box domain binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000679:Zinc finger, GATA-type,IPR013088:Zinc finger, NHR/GATA-type,IPR016374:Transcription factor, GATA-1/2/3,	hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa05321:Inflammatory bowel disease,	146255~Hypoparathyroidism, sensorineural deafness, and renal dysplasia,	PIRSF003027:transcription factor, GATA-1/2/3 types,	SM00401:ZnF_GATA,	KW-0391~Immunity,KW-0399~Innate immunity,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0209~Deafness,KW-0225~Disease variant,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,MOTIF:YxKxHxxxRP,REGION:Disordered,REGION:Flexible linker,REGION:Interaction with TBX21,ZN_FING:GATA-type 1,ZN_FING:GATA-type 2,
GLI2	GLI family zinc finger 2(GLI2)	Homo sapiens		h_shhPathway:Sonic Hedgehog (Shh) Pathway,	Transcription / Cell division and chromosome partitioning,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001501~skeletal system development,GO:0001649~osteoblast differentiation,GO:0001701~in utero embryonic development,GO:0001822~kidney development,GO:0002062~chondrocyte differentiation,GO:0002076~osteoblast development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007224~smoothened signaling pathway,GO:0007389~pattern specification process,GO:0007411~axon guidance,GO:0007418~ventral midline development,GO:0007442~hindgut morphogenesis,GO:0007507~heart development,GO:0009913~epidermal cell differentiation,GO:0009952~anterior/posterior pattern specification,GO:0009954~proximal/distal pattern formation,GO:0021508~floor plate formation,GO:0021513~spinal cord dorsal/ventral patterning,GO:0021517~ventral spinal cord development,GO:0021696~cerebellar cortex morphogenesis,GO:0021775~smoothened signaling pathway involved in ventral spinal cord interneuron specification,GO:0021776~smoothened signaling pathway involved in spinal cord motor neuron cell fate specification,GO:0021938~smoothened signaling pathway involved in regulation of cerebellar granule cell precursor cell proliferation,GO:0021965~spinal cord ventral commissure morphogenesis,GO:0021983~pituitary gland development,GO:0030324~lung development,GO:0030879~mammary gland development,GO:0030902~hindbrain development,GO:0031069~hair follicle morphogenesis,GO:0032331~negative regulation of chondrocyte differentiation,GO:0033089~positive regulation of T cell differentiation in thymus,GO:0035295~tube development,GO:0042475~odontogenesis of dentin-containing tooth,GO:0042733~embryonic digit morphogenesis,GO:0043066~negative regulation of apoptotic process,GO:0045666~positive regulation of neuron differentiation,GO:0045740~positive regulation of DNA replication,GO:0045879~negative regulation of smoothened signaling pathway,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048566~embryonic digestive tract development,GO:0048589~developmental growth,GO:0048666~neuron development,GO:0048754~branching morphogenesis of an epithelial tube,GO:0060032~notochord regression,GO:0060513~prostatic bud formation,GO:0060603~mammary gland duct morphogenesis,GO:0060831~smoothened signaling pathway involved in dorsal/ventral neural tube patterning,GO:0071407~cellular response to organic cyclic compound,GO:0090103~cochlea morphogenesis,GO:0098586~cellular response to virus,GO:1901620~regulation of smoothened signaling pathway involved in dorsal/ventral neural tube patterning,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005829~cytosol,GO:0005929~cilium,GO:0005930~axoneme,GO:0016020~membrane,GO:0016607~nuclear speck,GO:0031514~motile cilium,GO:0097542~ciliary tip,GO:0097546~ciliary base,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0008270~zinc ion binding,GO:0043565~sequence-specific DNA binding,GO:0046872~metal ion binding,GO:1990837~sequence-specific double-stranded DNA binding,GO:1990841~promoter-specific chromatin binding,	IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,	hsa04340:Hedgehog signaling pathway,hsa04390:Hippo signaling pathway,hsa05200:Pathways in cancer,hsa05217:Basal cell carcinoma,	610829~Holoprosencephaly 9,615849~Culler-Jones syndrome,		SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0969~Cilium,	KW-0225~Disease variant,KW-0370~Holoprosencephaly,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0678~Repressor,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:C2H2-type,REGION:Disordered,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2; degenerate,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,
GNAS	GNAS complex locus(GNAS)	Homo sapiens		h_agpcrPathway:Attenuation of GPCR Signaling,h_bArr-mapkPathway:Role of ï¿½-arrestins in the activation and targeting of MAP kinases,h_bArrestin-srcPathway:Roles of ï¿½-arrestin-dependent Recruitment of Src Kinases in GPCR Signaling,h_bArrestinPathway:ï¿½-arrestins in GPCR Desensitization,h_ccr3Pathway:CCR3 signaling in Eosinophils,h_cftrPathway:Cystic fibrosis transmembrane conductance regulator (CFTR) and beta 2 adrenergic receptor (b2AR) pathway,h_chrebpPathway:ChREBP regulation by carbohydrates and cAMP,h_crebPathway:Transcription factor CREB and its extracellular signals,h_cremPathway:Regulation of Spermatogenesis by CREM,h_cskPathway:Activation of Csk by cAMP-dependent Protein Kinase Inhibits Signaling through the T Cell Receptor,h_erkPathway:Erk1/Erk2 Mapk Signaling pathway,h_gcrpathway:Corticosteroids and cardioprotection,h_gpcrPathway:Signaling Pathway from G-Protein Families,h_gsPathway:Activation of cAMP-dependent protein kinase, PKA,h_mPRPathway:How Progesterone Initiates the Oocyte Maturation,h_plcePathway:Phospholipase C-epsilon pathway,h_raccPathway:Ion Channels and Their Functional Role in Vascular Endothelium,		GO:0001894~tissue homeostasis,GO:0001958~endochondral ossification,GO:0002862~negative regulation of inflammatory response to antigenic stimulus,GO:0003091~renal water homeostasis,GO:0006112~energy reserve metabolic process,GO:0006306~DNA methylation,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007188~adenylate cyclase-modulating G-protein coupled receptor signaling pathway,GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0007190~activation of adenylate cyclase activity,GO:0007191~adenylate cyclase-activating dopamine receptor signaling pathway,GO:0007565~female pregnancy,GO:0007606~sensory perception of chemical stimulus,GO:0007608~sensory perception of smell,GO:0009306~protein secretion,GO:0009966~regulation of signal transduction,GO:0031279~regulation of cyclase activity,GO:0035116~embryonic hindlimb morphogenesis,GO:0035264~multicellular organism growth,GO:0040015~negative regulation of multicellular organism growth,GO:0040032~post-embryonic body morphogenesis,GO:0042493~response to drug,GO:0043547~positive regulation of GTPase activity,GO:0043588~skin development,GO:0043950~positive regulation of cAMP-mediated signaling,GO:0045669~positive regulation of osteoblast differentiation,GO:0045672~positive regulation of osteoclast differentiation,GO:0046907~intracellular transport,GO:0048589~developmental growth,GO:0048701~embryonic cranial skeleton morphogenesis,GO:0050796~regulation of insulin secretion,GO:0050890~cognition,GO:0051216~cartilage development,GO:0060348~bone development,GO:0060789~hair follicle placode formation,GO:0070527~platelet aggregation,GO:0071107~response to parathyroid hormone,GO:0071377~cellular response to glucagon stimulus,GO:0071380~cellular response to prostaglandin E stimulus,GO:0071514~genetic imprinting,GO:0071870~cellular response to catecholamine stimulus,GO:0071880~adenylate cyclase-activating adrenergic receptor signaling pathway,GO:2000828~regulation of parathyroid hormone secretion,	GO:0001726~ruffle,GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005834~heterotrimeric G-protein complex,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0030133~transport vesicle,GO:0030425~dendrite,GO:0031224~intrinsic component of membrane,GO:0032588~trans-Golgi network membrane,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0001664~G-protein coupled receptor binding,GO:0003924~GTPase activity,GO:0005159~insulin-like growth factor receptor binding,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0010856~adenylate cyclase activator activity,GO:0019001~guanyl nucleotide binding,GO:0031683~G-protein beta/gamma-subunit complex binding,GO:0031698~beta-2 adrenergic receptor binding,GO:0031748~D1 dopamine receptor binding,GO:0031852~mu-type opioid receptor binding,GO:0035255~ionotropic glutamate receptor binding,GO:0046872~metal ion binding,GO:0051430~corticotropin-releasing hormone receptor 1 binding,	IPR000367:G-protein alpha subunit, group S,IPR001019:Guanine nucleotide binding protein (G-protein), alpha subunit,IPR009434:Neuroendocrine-specific golgi P55,IPR011025:G protein alpha subunit, helical insertion,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa01522:Endocrine resistance,hsa04015:Rap1 signaling pathway,hsa04020:Calcium signaling pathway,hsa04024:cAMP signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04270:Vascular smooth muscle contraction,hsa04540:Gap junction,hsa04611:Platelet activation,hsa04713:Circadian entrainment,hsa04714:Thermogenesis,hsa04724:Glutamatergic synapse,hsa04726:Serotonergic synapse,hsa04728:Dopaminergic synapse,hsa04730:Long-term depression,hsa04750:Inflammatory mediator regulation of TRP channels,hsa04911:Insulin secretion,hsa04912:GnRH signaling pathway,hsa04913:Ovarian steroidogenesis,hsa04915:Estrogen signaling pathway,hsa04916:Melanogenesis,hsa04918:Thyroid hormone synthesis,hsa04921:Oxytocin signaling pathway,hsa04922:Glucagon signaling pathway,hsa04923:Regulation of lipolysis in adipocytes,hsa04924:Renin secretion,hsa04925:Aldosterone synthesis and secretion,hsa04926:Relaxin signaling pathway,hsa04927:Cortisol synthesis and secretion,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04934:Cushing syndrome,hsa04935:Growth hormone synthesis, secretion and action,hsa04961:Endocrine and other factor-regulated calcium reabsorption,hsa04962:Vasopressin-regulated water reabsorption,hsa04970:Salivary secretion,hsa04971:Gastric acid secretion,hsa04972:Pancreatic secretion,hsa04976:Bile secretion,hsa05012:Parkinson disease,hsa05030:Cocaine addiction,hsa05031:Amphetamine addiction,hsa05032:Morphine addiction,hsa05034:Alcoholism,hsa05110:Vibrio cholerae infection,hsa05142:Chagas disease,hsa05146:Amoebiasis,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05200:Pathways in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05414:Dilated cardiomyopathy,	103580~Pseudohypoparathyroidism Ia,166350~Osseous heteroplasia, progressive,219080~ACTH-independent macronodular adrenal hyperplasia,603233~Pseudohypoparathyroidism Ib,612462~Pseudohypoparathyroidism Ic,612463~Pseudopseudohypoparathyroidism,617686~Pituitary adenoma 3, multiple types, somatic,McCune-Albright syndrome, somatic, mosaic 174800~McCune-Albright syndrome, somatic, mosaic 174800,		SM00275:SM00275,		KW-0472~Membrane,KW-0964~Secreted,KW-0966~Cell projection,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0242~Dwarfism,KW-0550~Obesity,KW-0656~Proto-oncogene,KW-1062~Cushing syndrome,	KW-0175~Coiled coil,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0342~GTP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0807~Transducer,	KW-0013~ADP-ribosylation,KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0654~Proteoglycan,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	BINDING:GTP; via amide nitrogen,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:G-alpha,LIPID:N-palmitoyl glycine,LIPID:S-palmitoyl cysteine,METAL:Magnesium,MUTAGEN:D->N: Increases binding to GAS2L2; when associated with L-227.,MUTAGEN:Q->A: Increases GDP release but does not affect receptor-mediated activation.,MUTAGEN:Q->L: Increases binding to GAS2L2; when associated with N-295.,MUTAGEN:R->A: Increases GDP release and impairs receptor-mediated activation; markedly elevated intrinsic GTPase rate which will lead to more rapid inactivation.,NP_BIND:GTP,PEPTIDE:GPIPIRRH peptide,PEPTIDE:LHAL tetrapeptide,REGION:Disordered,REGION:G1 motif,REGION:G2 motif,REGION:G3 motif,REGION:G4 motif,REGION:G5 motif,TRANSMEM:Helical,
GTPBP8	GTP binding protein 8 (putative)(GTPBP8)	Homo sapiens					GO:0005739~mitochondrion,	GO:0005515~protein binding,GO:0005525~GTP binding,GO:0046872~metal ion binding,	IPR006073:GTP binding domain,IPR019987:GTP-binding protein, ribosome biogenesis, YsxC,IPR027417:P-loop containing nucleoside triphosphate hydrolase,									KW-0342~GTP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,			DOMAIN:EngB-type G,DOMAIN:G,METAL:Magnesium,NP_BIND:GTP,
HEATR1	HEAT repeat containing 1(HEATR1)	Homo sapiens				GO:0000462~maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA),GO:0006364~rRNA processing,GO:0045943~positive regulation of transcription from RNA polymerase I promoter,GO:2000234~positive regulation of rRNA processing,	GO:0001650~fibrillar center,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005739~mitochondrion,GO:0016020~membrane,GO:0030686~90S preribosome,GO:0032040~small-subunit processome,GO:0034455~t-UTP complex,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0030515~snoRNA binding,	IPR011989:Armadillo-like helical,IPR012954:BP28, C-terminal domain,IPR016024:Armadillo-type fold,IPR022125:U3 small nucleolar RNA-associated protein 10,	hsa03008:Ribosome biogenesis in eukaryotes,			SM01036:SM01036,	KW-0690~Ribosome biogenesis,KW-0698~rRNA processing,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0175~Coiled coil,		KW-0687~Ribonucleoprotein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:BP28CT,REGION:Disordered,REPEAT:HEAT,
HERC6	HECT and RLD domain containing E3 ubiquitin protein ligase family member 6(HERC6)	Homo sapiens			Cell division and chromosome partitioning / Cytoskeleton,	GO:0000209~protein polyubiquitination,GO:0002244~hematopoietic progenitor cell differentiation,GO:0009617~response to bacterium,GO:0016567~protein ubiquitination,	GO:0005654~nucleoplasm,GO:0005829~cytosol,	GO:0004842~ubiquitin-protein transferase activity,	IPR000408:Regulator of chromosome condensation, RCC1,IPR000569:HECT,IPR009091:Regulator of chromosome condensation 1/beta-lactamase-inhibitor protein II,				SM00119:HECTc,	KW-0833~Ubl conjugation pathway,	KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0808~Transferase,		ACT_SITE:Glycyl thioester intermediate,DOMAIN:HECT,REGION:Disordered,REPEAT:RCC1,REPEAT:RCC1 1,REPEAT:RCC1 2,REPEAT:RCC1 3,REPEAT:RCC1 4,REPEAT:RCC1 5,
HTATSF1	HIV-1 Tat specific factor 1(HTATSF1)	Homo sapiens				GO:0000398~mRNA splicing, via spliceosome,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0019079~viral genome replication,GO:0032784~regulation of DNA-templated transcription, elongation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005684~U2-type spliceosomal complex,GO:0005686~U2 snRNP,	GO:0003723~RNA binding,	IPR000504:RNA recognition motif domain,IPR012677:Nucleotide-binding, alpha-beta plait,				SM00360:RRM,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,		KW-0010~Activator,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,MUTAGEN:Y->D: Loss of interaction with U snRNPs.,REGION:Disordered,REGION:Mediates interaction with the P-TEFb complex,
HTRA1	HtrA serine peptidase 1(HTRA1)	Homo sapiens			Posttranslational modification, protein turnover, chaperones,	GO:0001890~placenta development,GO:0006508~proteolysis,GO:0012501~programmed cell death,GO:0022617~extracellular matrix disassembly,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0030514~negative regulation of BMP signaling pathway,GO:0043065~positive regulation of apoptotic process,GO:0050679~positive regulation of epithelial cell proliferation,GO:0050687~negative regulation of defense response to virus,GO:0060718~chorionic trophoblast cell differentiation,GO:0097187~dentinogenesis,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0070062~extracellular exosome,	GO:0004252~serine-type endopeptidase activity,GO:0005515~protein binding,GO:0005520~insulin-like growth factor binding,GO:0008236~serine-type peptidase activity,GO:0042802~identical protein binding,	IPR000867:Insulin-like growth factor-binding protein, IGFBP,IPR001478:PDZ domain,IPR001940:Peptidase S1C,IPR002350:Kazal domain,IPR009003:Trypsin-like cysteine/serine peptidase domain,IPR009030:Insulin-like growth factor binding protein, N-terminal,		600142~CARASIL syndrome,610149~Macular degeneration, age-related, 7,610149~Macular degeneration, age-related, neovascular type,616779~Cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 2,		SM00121:IB,SM00228:PDZ,SM00280:KAZAL,		KW-0472~Membrane,KW-0963~Cytoplasm,KW-0964~Secreted,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0913~Age-related macular degeneration,	KW-0732~Signal,		KW-0340~Growth factor binding,KW-0378~Hydrolase,KW-0645~Protease,KW-0720~Serine protease,	KW-1015~Disulfide bond,	ACT_SITE:Charge relay system,COMPBIAS:Basic residues,DOMAIN:IGFBP N-terminal,DOMAIN:Kazal-like,DOMAIN:PDZ,MUTAGEN:S->A: Loss of activity.,REGION:Disordered,REGION:Serine protease,SITE:Involved in trimer stabilization,
IKZF1	IKAROS family zinc finger 1(IKZF1)	Homo sapiens			General function prediction only,	GO:0006325~chromatin organization,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007049~cell cycle,GO:0007498~mesoderm development,GO:0030098~lymphocyte differentiation,GO:0030218~erythrocyte differentiation,GO:0045892~negative regulation of transcription, DNA-templated,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005721~pericentric heterochromatin,GO:0005829~cytosol,GO:0032991~macromolecular complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0019904~protein domain specific binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,	IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,		616873~Immunodeficiency, common variable, 13,		SM00355:ZnF_C2H2,	KW-0131~Cell cycle,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0156~Chromatin regulator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0678~Repressor,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),DOMAIN:C2H2-type,MUTAGEN:H->R: Abolishes binding to DNA and has diffuse nuclear localization.,MUTAGEN:N->A: Abolishes binding to DNA and has diffuse nuclear localization.,REGION:Disordered,REGION:Required for binding PP1CC,REGION:Required for both high-affinity DNA binding and pericentromeric heterochromatin localization,SITE:Required for both pericentromeric heterochromatin localization and DNA binding,SITE:Required for both pericentromeric heterochromatin localization and complete DNA binding,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6,
IQGAP1	IQ motif containing GTPase activating protein 1(IQGAP1)	Homo sapiens			Cell division and chromosome partitioning / Signal transduction mechanisms,	GO:0001817~regulation of cytokine production,GO:0007165~signal transduction,GO:0007173~epidermal growth factor receptor signaling pathway,GO:0007346~regulation of mitotic cell cycle,GO:0008543~fibroblast growth factor receptor signaling pathway,GO:0010761~fibroblast migration,GO:0016032~viral process,GO:0016477~cell migration,GO:0032956~regulation of actin cytoskeleton organization,GO:0035305~negative regulation of dephosphorylation,GO:0036120~cellular response to platelet-derived growth factor stimulus,GO:0043086~negative regulation of catalytic activity,GO:0043087~regulation of GTPase activity,GO:0043312~neutrophil degranulation,GO:0043406~positive regulation of MAP kinase activity,GO:0043410~positive regulation of MAPK cascade,GO:0045860~positive regulation of protein kinase activity,GO:0048008~platelet-derived growth factor receptor signaling pathway,GO:0051894~positive regulation of focal adhesion assembly,GO:0071277~cellular response to calcium ion,GO:0071364~cellular response to epidermal growth factor stimulus,GO:0071902~positive regulation of protein serine/threonine kinase activity,GO:0072015~glomerular visceral epithelial cell development,GO:1900006~positive regulation of dendrite development,GO:1900086~positive regulation of peptidyl-tyrosine autophosphorylation,GO:1903829~positive regulation of cellular protein localization,GO:1904754~positive regulation of vascular associated smooth muscle cell migration,GO:1990138~neuron projection extension,GO:1990776~response to angiotensin,	GO:0001726~ruffle,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005874~microtubule,GO:0005884~actin filament,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0015629~actin cytoskeleton,GO:0015630~microtubule cytoskeleton,GO:0016328~lateral plasma membrane,GO:0030424~axon,GO:0030426~growth cone,GO:0030496~midbody,GO:0030667~secretory granule membrane,GO:0030864~cortical actin cytoskeleton,GO:0031234~extrinsic component of cytoplasmic side of plasma membrane,GO:0032991~macromolecular complex,GO:0036057~slit diaphragm,GO:0036464~cytoplasmic ribonucleoprotein granule,GO:0043005~neuron projection,GO:0045121~membrane raft,GO:0070062~extracellular exosome,GO:1990904~ribonucleoprotein complex,	GO:0005078~MAP-kinase scaffold activity,GO:0005095~GTPase inhibitor activity,GO:0005096~GTPase activator activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0005547~phosphatidylinositol-3,4,5-trisphosphate binding,GO:0019901~protein kinase binding,GO:0019903~protein phosphatase binding,GO:0019904~protein domain specific binding,GO:0031267~small GTPase binding,GO:0043539~protein serine/threonine kinase activator activity,GO:0044548~S100 protein binding,GO:0044877~macromolecular complex binding,GO:0045296~cadherin binding,GO:0051015~actin filament binding,GO:0051019~mitogen-activated protein kinase binding,GO:0060090~binding, bridging,	IPR000048:IQ motif, EF-hand binding site,IPR000593:RasGAP protein, C-terminal,IPR001202:WW domain,IPR001715:Calponin homology domain,IPR001936:Ras GTPase-activating protein,IPR008936:Rho GTPase activation protein,IPR023152:Ras GTPase-activating protein, conserved site,IPR027401:Myosin-like IQ motif-containing domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04520:Adherens junction,hsa04810:Regulation of actin cytoskeleton,hsa05205:Proteoglycans in cancer,			SM00015:IQ,SM00033:CH,SM00323:RasGAP,SM00456:WW,	KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0732~Signal,		KW-0112~Calmodulin-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:Calponin-homology (CH),DOMAIN:IQ 1,DOMAIN:IQ 2,DOMAIN:IQ 3,DOMAIN:IQ 4,DOMAIN:Ras-GAP,DOMAIN:WW,MUTAGEN:S->A: Abolishes neurite outgrowth promoting activity; when associated with A-1441.,MUTAGEN:S->A: Abolishes neurite outgrowth promoting activity; when associated with A-1443.,MUTAGEN:S->D: Strongly enhances neurite outgrowth promoting activity; when associated with A-1441.,MUTAGEN:S->E: Strongly enhances neurite outgrowth promoting activity; when associated with A-1443.,REGION:C1,REGION:C2,REGION:Disordered,
JUN	Jun proto-oncogene, AP-1 transcription factor subunit(JUN)	Homo sapiens	114.Genomic_reformatting_Brain_Ischemia,3.T_cell_receptor,67.Ikaros_and_signaling_inhibitors,77.IkBa_Kinase_JNK_MEKK1,92.Ancient_Host_Defense_Pathways,	h_41BBPathway:The 4-1BB-dependent immune response,h_agrPathway:Agrin in Postsynaptic Differentiation,h_arenrf2Pathway:Oxidative Stress Induced Gene Expression Via Nrf2,h_at1rPathway:Angiotensin II mediated activation of JNK Pathway via Pyk2 dependent signaling,h_atmPathway:ATM Signaling Pathway,h_bcrPathway:BCR Signaling Pathway,h_cardiacEGFPathway:Role of EGF Receptor Transactivation by GPCRs in Cardiac Hypertrophy,h_ccr5Pathway:Pertussis toxin-insensitive CCR5 Signaling in Macrophage,h_cdmacPathway:Cadmium induces DNA synthesis and proliferation in macrophages,h_d4gdiPathway:D4-GDI Signaling Pathway,h_dreamPathway:Repression of Pain Sensation by the Transcriptional Regulator DREAM,h_egfPathway:EGF Signaling Pathway,h_epoPathway:EPO Signaling Pathway,h_etsPathway:METS affect on Macrophage Differentiation,h_fasPathway:FAS signaling pathway ( CD95 ),h_fcer1Pathway:Fc Epsilon Receptor I Signaling in Mast Cells,h_gleevecPathway:Inhibition of Cellular Proliferation by Gleevec,h_gpcrPathway:Signaling Pathway from G-Protein Families,h_hifPathway:Hypoxia-Inducible Factor in the Cardiovascular System,h_igf1Pathway:IGF-1 Signaling Pathway,h_il12Pathway:IL12 and Stat4 Dependent Signaling Pathway in Th1 Development,h_il1rPathway:Signal transduction through IL1R,h_il2Pathway:IL 2 signaling pathway,h_il6Pathway:IL 6 signaling pathway,h_insulinPathway:Insulin Signaling Pathway,h_integrinPathway:Integrin Signaling Pathway,h_keratinocytePathway:Keratinocyte Differentiation,h_mapkPathway:MAPKinase Signaling Pathway,h_metPathway:Signaling of Hepatocyte Growth Factor Receptor,h_ngfPathway:Nerve growth factor pathway (NGF),h_pcafPathway:The information-processing pathway at the IFN-beta enhancer,h_pdgfPathway:PDGF Signaling Pathway,h_PparaPathway:Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha),h_pyk2Pathway:Links between Pyk2 and Map Kinases,h_stressPathway:TNF/Stress Related Signaling,h_tcrPathway:T Cell Receptor Signaling Pathway,h_tnfr1Pathway:TNFR1 Signaling Pathway,h_tollPathway:Toll-Like Receptor Pathway,h_tpoPathway:TPO Signaling Pathway,h_tsp1Pathway:TSP-1 Induced Apoptosis in Microvascular Endothelial Cell ,		GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001525~angiogenesis,GO:0001774~microglial cell activation,GO:0001836~release of cytochrome c from mitochondria,GO:0001889~liver development,GO:0001938~positive regulation of endothelial cell proliferation,GO:0003151~outflow tract morphogenesis,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0007265~Ras protein signal transduction,GO:0007568~aging,GO:0007612~learning,GO:0007623~circadian rhythm,GO:0008285~negative regulation of cell proliferation,GO:0009314~response to radiation,GO:0009410~response to xenobiotic stimulus,GO:0009612~response to mechanical stimulus,GO:0010634~positive regulation of epithelial cell migration,GO:0030224~monocyte differentiation,GO:0031103~axon regeneration,GO:0031953~negative regulation of protein autophosphorylation,GO:0032496~response to lipopolysaccharide,GO:0034097~response to cytokine,GO:0034614~cellular response to reactive oxygen species,GO:0035026~leading edge cell differentiation,GO:0035994~response to muscle stretch,GO:0038095~Fc-epsilon receptor signaling pathway,GO:0042127~regulation of cell proliferation,GO:0042493~response to drug,GO:0042542~response to hydrogen peroxide,GO:0043065~positive regulation of apoptotic process,GO:0043392~negative regulation of DNA binding,GO:0043524~negative regulation of neuron apoptotic process,GO:0043525~positive regulation of neuron apoptotic process,GO:0043922~negative regulation by host of viral transcription,GO:0043923~positive regulation by host of viral transcription,GO:0045657~positive regulation of monocyte differentiation,GO:0045740~positive regulation of DNA replication,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048146~positive regulation of fibroblast proliferation,GO:0050790~regulation of catalytic activity,GO:0051090~regulation of sequence-specific DNA binding transcription factor activity,GO:0051365~cellular response to potassium ion starvation,GO:0051591~response to cAMP,GO:0051726~regulation of cell cycle,GO:0051899~membrane depolarization,GO:0060395~SMAD protein signal transduction,GO:0061029~eyelid development in camera-type eye,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071276~cellular response to cadmium ion,GO:0071277~cellular response to calcium ion,GO:0072740~cellular response to anisomycin,GO:1901522~positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1904707~positive regulation of vascular smooth muscle cell proliferation,GO:1990441~negative regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress,GO:2000144~positive regulation of DNA-templated transcription, initiation,	GO:0000228~nuclear chromosome,GO:0000785~chromatin,GO:0000791~euchromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0017053~transcriptional repressor complex,GO:0035976~transcription factor AP-1 complex,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001102~RNA polymerase II activating transcription factor binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0003723~RNA binding,GO:0005096~GTPase activator activity,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0019899~enzyme binding,GO:0031625~ubiquitin protein ligase binding,GO:0035497~cAMP response element binding,GO:0042802~identical protein binding,GO:0044389~ubiquitin-like protein ligase binding,GO:0044877~macromolecular complex binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0070412~R-SMAD binding,GO:0071837~HMG box domain binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR002112:Transcription factor Jun,IPR004827:Basic-leucine zipper domain,IPR005643:Jun-like transcription factor,IPR008917:Eukaryotic transcription factor, Skn-1-like, DNA-binding,IPR015558:c-Jun Transcription Factor,	hsa01522:Endocrine resistance,hsa04010:MAPK signaling pathway,hsa04012:ErbB signaling pathway,hsa04024:cAMP signaling pathway,hsa04137:Mitophagy - animal,hsa04210:Apoptosis,hsa04310:Wnt signaling pathway,hsa04380:Osteoclast differentiation,hsa04510:Focal adhesion,hsa04530:Tight junction,hsa04620:Toll-like receptor signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04625:C-type lectin receptor signaling pathway,hsa04657:IL-17 signaling pathway,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04660:T cell receptor signaling pathway,hsa04662:B cell receptor signaling pathway,hsa04668:TNF signaling pathway,hsa04722:Neurotrophin signaling pathway,hsa04912:GnRH signaling pathway,hsa04915:Estrogen signaling pathway,hsa04921:Oxytocin signaling pathway,hsa04926:Relaxin signaling pathway,hsa04932:Non-alcoholic fatty liver disease,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa05030:Cocaine addiction,hsa05031:Amphetamine addiction,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05133:Pertussis,hsa05135:Yersinia infection,hsa05140:Leishmaniasis,hsa05142:Chagas disease,hsa05161:Hepatitis B,hsa05162:Measles,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05207:Chemical carcinogenesis - receptor activation,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05210:Colorectal cancer,hsa05211:Renal cell carcinoma,hsa05224:Breast cancer,hsa05231:Choline metabolism in cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05321:Inflammatory bowel disease,hsa05323:Rheumatoid arthritis,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,			SM00338:BRLZ,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0656~Proto-oncogene,	KW-0175~Coiled coil,		KW-0010~Activator,KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:BZIP,DOMAIN:bZIP,MUTAGEN:R->V: Abolishes the synergistic activity with SMAD3 to activate TGF-beta-mediated transcription.,MUTAGEN:S->A: Abolishes phosphorylation by DYRK2. Abolishes phosphorylation by GSK3B at Thr-239.,MUTAGEN:S->A: Greatly reduced ATF7-mediated transcriptional activity; when associated with A-63. Abolishes interaction with FBXW7; when associated with A-63; A-91 and A-93.,MUTAGEN:S->A: Greatly reduced ATF7-mediated transcriptional activity; when associated with A-73. Abolishes interaction with FBXW7; when associated with A-73; A-91 and A-93.,MUTAGEN:T->A: Abolishes interaction with FBXW7; when associated with A-63; A-73 and A-91.,MUTAGEN:T->A: Abolishes interaction with FBXW7; when associated with A-63; A-73 and A-93.,MUTAGEN:T->A: Complete loss of PAK2-mediated phosphorylation; when associated with A-2; A-89; A-93; and A-286.,MUTAGEN:T->A: Complete loss of PAK2-mediated phosphorylation; when associated with A-2; A-8; A-89; and A-286.,MUTAGEN:T->A: Complete loss of PAK2-mediated phosphorylation; when associated with A-2; A-8; A-89; and A-93.,MUTAGEN:T->A: Complete loss of PAK2-mediated phosphorylation; when associated with A-2; A-8; A-93; and A-286.,MUTAGEN:T->A: Complete loss of PAK2-mediated phosphorylation; when associated with A-8; A-89; A-93; and A-286.,REGION:Basic motif,REGION:Interaction with PAGE4,REGION:Leucine-zipper,SITE:Necessary for synergistic transcriptional activity with SMAD3,
KDELR2	KDEL endoplasmic reticulum protein retention receptor 2(KDELR2)	Homo sapiens		h_arapPathway:ADP-Ribosylation Factor,		GO:0006621~protein retention in ER lumen,GO:0006888~ER to Golgi vesicle-mediated transport,GO:0006890~retrograde vesicle-mediated transport, Golgi to ER,GO:0015031~protein transport,GO:0035437~maintenance of protein localization in endoplasmic reticulum,	GO:0000139~Golgi membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005801~cis-Golgi network,GO:0016021~integral component of membrane,GO:0030133~transport vesicle,GO:0030663~COPI-coated vesicle membrane,	GO:0005046~KDEL sequence binding,GO:0046923~ER retention sequence binding,	IPR000133:ER lumen protein retaining receptor,	hsa05110:Vibrio cholerae infection,	619131~Osteogenesis imperfecta 21,			KW-0653~Protein transport,KW-0813~Transport,KW-0931~ER-Golgi transport,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,		REGION:Important for recycling of cargo proteins with the sequence motif K-D-E-L from the Golgi to the endoplasmic reticulum,REGION:Interaction with the K-D-E-L motif on target proteins,SITE:Important for recycling of cargo proteins with the sequence motif K-D-E-L from the Golgi to the endoplasmic reticulum,SITE:Interaction with the K-D-E-L motif on target proteins,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
KIAA0100	KIAA0100(KIAA0100)	Homo sapiens					GO:0005576~extracellular region,		IPR019439:FMP27, N-terminal,IPR019441:FMP27, GFWDK domain,IPR019443:FMP27,  C-terminal,				SM01214:SM01214,		KW-0964~Secreted,		KW-0175~Coiled coil,KW-0732~Signal,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Fmp27,DOMAIN:Fmp27_GFWDK,REGION:Disordered,
KIAA0753	KIAA0753(KIAA0753)	Homo sapiens				GO:0007099~centriole replication,GO:0071539~protein localization to centrosome,	GO:0005813~centrosome,GO:0005814~centriole,GO:0005829~cytosol,GO:0034451~centriolar satellite,	GO:0005515~protein binding,			617127~Orofaciodigital syndrome XV,619476~Joubert syndrome 38,619479~Short-rib thoracic dysplasia 21 without polydactyly,				KW-0206~Cytoskeleton,KW-0963~Cytoplasm,	KW-1186~Ciliopathy,	KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,REGION:Necessary and sufficient for CEP20-binding,
KIT	KIT proto-oncogene, receptor tyrosine kinase(KIT)	Homo sapiens		h_badPathway:Regulation of BAD phosphorylation,h_melanocytePathway:Melanocyte Development and Pigmentation Pathway,		GO:0000165~MAPK cascade,GO:0000187~activation of MAPK activity,GO:0001541~ovarian follicle development,GO:0002244~hematopoietic progenitor cell differentiation,GO:0002318~myeloid progenitor cell differentiation,GO:0002320~lymphoid progenitor cell differentiation,GO:0002327~immature B cell differentiation,GO:0002551~mast cell chemotaxis,GO:0002732~positive regulation of dendritic cell cytokine production,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006687~glycosphingolipid metabolic process,GO:0006954~inflammatory response,GO:0007165~signal transduction,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007275~multicellular organism development,GO:0007283~spermatogenesis,GO:0007286~spermatid development,GO:0008284~positive regulation of cell proliferation,GO:0008354~germ cell migration,GO:0008360~regulation of cell shape,GO:0008542~visual learning,GO:0008584~male gonad development,GO:0010863~positive regulation of phospholipase C activity,GO:0014068~positive regulation of phosphatidylinositol 3-kinase signaling,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0019221~cytokine-mediated signaling pathway,GO:0019827~stem cell population maintenance,GO:0030032~lamellipodium assembly,GO:0030097~hemopoiesis,GO:0030183~B cell differentiation,GO:0030217~T cell differentiation,GO:0030218~erythrocyte differentiation,GO:0030318~melanocyte differentiation,GO:0030335~positive regulation of cell migration,GO:0031274~positive regulation of pseudopodium assembly,GO:0031532~actin cytoskeleton reorganization,GO:0032765~positive regulation of mast cell cytokine production,GO:0033674~positive regulation of kinase activity,GO:0035019~somatic stem cell population maintenance,GO:0035162~embryonic hemopoiesis,GO:0035234~ectopic germ cell programmed cell death,GO:0035556~intracellular signal transduction,GO:0035701~hematopoietic stem cell migration,GO:0035855~megakaryocyte development,GO:0038093~Fc receptor signaling pathway,GO:0038109~Kit signaling pathway,GO:0038162~erythropoietin-mediated signaling pathway,GO:0042127~regulation of cell proliferation,GO:0042531~positive regulation of tyrosine phosphorylation of STAT protein,GO:0043069~negative regulation of programmed cell death,GO:0043303~mast cell degranulation,GO:0043406~positive regulation of MAP kinase activity,GO:0043410~positive regulation of MAPK cascade,GO:0043473~pigmentation,GO:0043552~positive regulation of phosphatidylinositol 3-kinase activity,GO:0043586~tongue development,GO:0045747~positive regulation of Notch signaling pathway,GO:0046427~positive regulation of JAK-STAT cascade,GO:0046686~response to cadmium ion,GO:0046777~protein autophosphorylation,GO:0048103~somatic stem cell division,GO:0048170~positive regulation of long-term neuronal synaptic plasticity,GO:0048565~digestive tract development,GO:0048863~stem cell differentiation,GO:0050673~epithelial cell proliferation,GO:0050910~detection of mechanical stimulus involved in sensory perception of sound,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0051897~positive regulation of protein kinase B signaling,GO:0060326~cell chemotaxis,GO:0060374~mast cell differentiation,GO:0070662~mast cell proliferation,GO:0097067~cellular response to thyroid hormone stimulus,GO:0097324~melanocyte migration,GO:0097326~melanocyte adhesion,GO:1904251~regulation of bile acid metabolic process,GO:1904343~positive regulation of colon smooth muscle contraction,GO:1904349~positive regulation of small intestine smooth muscle contraction,GO:1905065~positive regulation of vascular smooth muscle cell differentiation,	GO:0001650~fibrillar center,GO:0001669~acrosomal vesicle,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005911~cell-cell junction,GO:0009897~external side of plasma membrane,GO:0009898~cytoplasmic side of plasma membrane,GO:0016021~integral component of membrane,GO:0043235~receptor complex,	GO:0002020~protease binding,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0005020~stem cell factor receptor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0019955~cytokine binding,GO:0042169~SH2 domain binding,GO:0042803~protein homodimerization activity,GO:0046872~metal ion binding,	IPR000719:Protein kinase, catalytic domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR001824:Tyrosine-protein kinase, receptor class III, conserved site,IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR008266:Tyrosine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR013151:Immunoglobulin,IPR013783:Immunoglobulin-like fold,IPR017441:Protein kinase, ATP binding site,IPR020635:Tyrosine-protein kinase, catalytic domain,IPR027263:Mast/stem cell growth factor receptor,	hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04640:Hematopoietic cell lineage,hsa04916:Melanogenesis,hsa05200:Pathways in cancer,hsa05221:Acute myeloid leukemia,hsa05224:Breast cancer,hsa05230:Central carbon metabolism in cancer,	154800~Mastocytosis, cutaneous,154800~Mastocytosis, systemic, somatic,172800~Piebaldism,273300~Germ cell tumors, somatic,601626~Leukemia, acute myeloid, somatic,606764~Gastrointestinal stromal tumor, familial,	PIRSF500951:mast/stem cell growth factor receptor [Parent=PIRSF000615],	SM00219:TyrKc,SM00408:IGc2,SM00409:IG,		KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0656~Proto-oncogene,	KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0675~Receptor,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,BINDING:ATP,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,DOMAIN:Ig-like C2-type 4,DOMAIN:Ig-like C2-type 5,DOMAIN:PK_Tyr_Ser-Thr,DOMAIN:Protein kinase,METAL:Magnesium,MUTAGEN:E->A: Reduces autophosphorylation in response to KITLG/SCF.,MUTAGEN:I->A: Reduction in SH2B2/APS binding. Abolishes SH2B2/APS binding; when associated with A-939.,MUTAGEN:K->M: Stronger interaction with MPDZ.,MUTAGEN:L->A: Reduction in SH2B2/APS binding. Abolishes SH2B2/APS binding; when associated with A-571.,MUTAGEN:R->A: Reduces autophosphorylation in response to KITLG/SCF.,MUTAGEN:S->A: Abolishes down-regulation of kinase activity by PKC/PRKCA-mediated phosphorylation; when associated with A-741.,MUTAGEN:S->A: Abolishes down-regulation of kinase activity by PKC/PRKCA-mediated phosphorylation; when associated with A-746.,MUTAGEN:Y->F: No decrease in activity. Leads to autophosphorylation at Tyr-900.,NP_BIND:ATP,REGION:Disordered,REGION:Important for interaction with phosphotyrosine-binding proteins,SITE:Important for interaction with phosphotyrosine-binding proteins,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
LAGE3	L antigen family member 3(LAGE3)	Homo sapiens				GO:0008033~tRNA processing,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0070525~tRNA threonylcarbamoyladenosine metabolic process,	GO:0000408~EKC/KEOPS complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016604~nuclear body,	GO:0005515~protein binding,	IPR015419:EKC/KEOPS complex, subunit Pcc1,		301006~Galloway-Mowat syndrome 2, X-linked,			KW-0819~tRNA processing,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0887~Epilepsy,KW-0991~Mental retardation,					REGION:Disordered,
LRP10	LDL receptor related protein 10(LRP10)	Homo sapiens				GO:0006629~lipid metabolic process,GO:0006869~lipid transport,GO:0006897~endocytosis,GO:0048839~inner ear development,	GO:0005886~plasma membrane,GO:0005905~clathrin-coated pit,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0005041~low-density lipoprotein receptor activity,GO:0005515~protein binding,	IPR000859:CUB domain,IPR002172:Low-density lipoprotein (LDL) receptor class A repeat,IPR023415:Low-density lipoprotein (LDL) receptor class A, conserved site,				SM00042:CUB,SM00192:LDLa,	KW-0254~Endocytosis,	KW-0168~Coated pit,KW-0472~Membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:CUB,DOMAIN:CUB 1,DOMAIN:CUB 2,DOMAIN:LDL-receptor class A 1,DOMAIN:LDL-receptor class A 2,DOMAIN:LDL-receptor class A 3,DOMAIN:LDL-receptor class A 4,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
LRPAP1	LDL receptor related protein associated protein 1(LRPAP1)	Homo sapiens				GO:0002091~negative regulation of receptor internalization,GO:0007165~signal transduction,GO:0010916~negative regulation of very-low-density lipoprotein particle clearance,GO:0032091~negative regulation of protein binding,GO:0048259~regulation of receptor-mediated endocytosis,GO:0060548~negative regulation of cell death,GO:1900116~extracellular negative regulation of signal transduction,GO:1900222~negative regulation of beta-amyloid clearance,GO:1900223~positive regulation of beta-amyloid clearance,GO:2000272~negative regulation of receptor activity,	GO:0005576~extracellular region,GO:0005768~endosome,GO:0005783~endoplasmic reticulum,GO:0005793~endoplasmic reticulum-Golgi intermediate compartment,GO:0005794~Golgi apparatus,GO:0005796~Golgi lumen,GO:0005801~cis-Golgi network,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0012505~endomembrane system,GO:0031904~endosome lumen,GO:0048237~rough endoplasmic reticulum lumen,	GO:0001540~beta-amyloid binding,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0008201~heparin binding,GO:0035473~lipase binding,GO:0048018~receptor agonist activity,GO:0048019~receptor antagonist activity,GO:0050750~low-density lipoprotein particle receptor binding,GO:0070326~very-low-density lipoprotein particle receptor binding,	IPR009066:Alpha-2-macroglobulin receptor-associated protein, domain 1,IPR010483:Alpha-2-macroglobulin RAP, C-terminal,	hsa04979:Cholesterol metabolism,	615431~Myopia 23, autosomal recessive,				KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0967~Endosome,		KW-0175~Coiled coil,KW-0732~Signal,		KW-0358~Heparin-binding,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:Alpha-2-MRAP_C,DOMAIN:Alpha-2-MRAP_N,MOTIF:Prevents secretion from ER,MUTAGEN:H->A: Strongly reduced interaction with LRP1; when associated with A-283; A-291; A-293; A-302 and A-307.,MUTAGEN:H->A: Strongly reduced interaction with LRP1; when associated with A-283; A-291; A-293; A-302 and A-341.,MUTAGEN:H->A: Strongly reduced interaction with LRP1; when associated with A-283; A-291; A-293; A-307 and A-341.,MUTAGEN:H->A: Strongly reduced interaction with LRP1; when associated with A-283; A-291; A-302; A-307 and A-341.,MUTAGEN:H->A: Strongly reduced interaction with LRP1; when associated with A-283; A-293; A-302; A-307 and A-341.,MUTAGEN:H->A: Strongly reduced interaction with LRP1; when associated with A-291; A-293; A-302; A-307 and A-341.,MUTAGEN:K->A: Reduces competition with MAPT for binding to LRP1; when associated with A-290.,MUTAGEN:K->A: Reduces competition with MAPT for binding to LRP1; when associated with A-304.,REGION:Disordered,REGION:LDL receptor binding,
LSM5	LSM5 homolog, U6 small nuclear RNA and mRNA degradation associated(LSM5)	Homo sapiens				GO:0000398~mRNA splicing, via spliceosome,GO:0006397~mRNA processing,GO:0006402~mRNA catabolic process,GO:0008380~RNA splicing,GO:0009617~response to bacterium,GO:0043928~exonucleolytic nuclear-transcribed mRNA catabolic process involved in deadenylation-dependent decay,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:0005688~U6 snRNP,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0046540~U4/U6 x U5 tri-snRNP complex,GO:0071005~U2-type precatalytic spliceosome,GO:1990726~Lsm1-7-Pat1 complex,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0046982~protein heterodimerization activity,	IPR001163:Ribonucleoprotein LSM domain,IPR010920:Like-Sm (LSM) domain,	hsa03018:RNA degradation,hsa03040:Spliceosome,			SM00651:Sm,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0747~Spliceosome,				KW-0687~Ribonucleoprotein,KW-0694~RNA-binding,	KW-0007~Acetylation,	DOMAIN:Sm,REGION:Disordered,
LSM6	LSM6 homolog, U6 small nuclear RNA and mRNA degradation associated(LSM6)	Homo sapiens				GO:0000398~mRNA splicing, via spliceosome,GO:0006402~mRNA catabolic process,GO:0008033~tRNA processing,GO:0008380~RNA splicing,GO:0030490~maturation of SSU-rRNA,GO:0043928~exonucleolytic nuclear-transcribed mRNA catabolic process involved in deadenylation-dependent decay,	GO:0000932~P-body,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005688~U6 snRNP,GO:0005730~nucleolus,GO:0005732~small nucleolar ribonucleoprotein complex,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0030532~small nuclear ribonucleoprotein complex,GO:0046540~U4/U6 x U5 tri-snRNP complex,GO:0071005~U2-type precatalytic spliceosome,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0046982~protein heterodimerization activity,	IPR001163:Ribonucleoprotein LSM domain,IPR010920:Like-Sm (LSM) domain,IPR016487:Small nuclear ribonucleoprotein SmF,	hsa03018:RNA degradation,hsa03040:Spliceosome,			SM00651:Sm,	KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0698~rRNA processing,KW-0819~tRNA processing,	KW-0539~Nucleus,KW-0747~Spliceosome,KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0694~RNA-binding,	KW-0007~Acetylation,
LYN	LYN proto-oncogene, Src family tyrosine kinase(LYN)	Homo sapiens	74.CD47-IAP_with_avB3,	h_bcrPathway:BCR Signaling Pathway,h_ephA4Pathway:Eph Kinases and ephrins support platelet aggregation,h_fcer1Pathway:Fc Epsilon Receptor I Signaling in Mast Cells,h_ptdinsPathway:Phosphoinositides and their downstream targets.,		GO:0001782~B cell homeostasis,GO:0001817~regulation of cytokine production,GO:0001932~regulation of protein phosphorylation,GO:0001933~negative regulation of protein phosphorylation,GO:0001934~positive regulation of protein phosphorylation,GO:0002223~stimulatory C-type lectin receptor signaling pathway,GO:0002250~adaptive immune response,GO:0002431~Fc receptor mediated stimulatory signaling pathway,GO:0002513~tolerance induction to self antigen,GO:0002553~histamine secretion by mast cell,GO:0002576~platelet degranulation,GO:0002762~negative regulation of myeloid leukocyte differentiation,GO:0002768~immune response-regulating cell surface receptor signaling pathway,GO:0002774~Fc receptor mediated inhibitory signaling pathway,GO:0002862~negative regulation of inflammatory response to antigenic stimulus,GO:0002902~regulation of B cell apoptotic process,GO:0006468~protein phosphorylation,GO:0006974~cellular response to DNA damage stimulus,GO:0006991~response to sterol depletion,GO:0007165~signal transduction,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007596~blood coagulation,GO:0008284~positive regulation of cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0009410~response to xenobiotic stimulus,GO:0009636~response to toxic substance,GO:0009725~response to hormone,GO:0009743~response to carbohydrate,GO:0010976~positive regulation of neuron projection development,GO:0014003~oligodendrocyte development,GO:0014068~positive regulation of phosphatidylinositol 3-kinase signaling,GO:0014070~response to organic cyclic compound,GO:0016032~viral process,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0030154~cell differentiation,GO:0030168~platelet activation,GO:0030218~erythrocyte differentiation,GO:0030335~positive regulation of cell migration,GO:0030889~negative regulation of B cell proliferation,GO:0031175~neuron projection development,GO:0031295~T cell costimulation,GO:0031663~lipopolysaccharide-mediated signaling pathway,GO:0031668~cellular response to extracellular stimulus,GO:0032868~response to insulin,GO:0033003~regulation of mast cell activation,GO:0033628~regulation of cell adhesion mediated by integrin,GO:0034136~negative regulation of toll-like receptor 2 signaling pathway,GO:0034142~toll-like receptor 4 signaling pathway,GO:0034144~negative regulation of toll-like receptor 4 signaling pathway,GO:0034605~cellular response to heat,GO:0035556~intracellular signal transduction,GO:0038095~Fc-epsilon receptor signaling pathway,GO:0038096~Fc-gamma receptor signaling pathway involved in phagocytosis,GO:0042493~response to drug,GO:0042531~positive regulation of tyrosine phosphorylation of STAT protein,GO:0043200~response to amino acid,GO:0043304~regulation of mast cell degranulation,GO:0043407~negative regulation of MAP kinase activity,GO:0043552~positive regulation of phosphatidylinositol 3-kinase activity,GO:0045087~innate immune response,GO:0045646~regulation of erythrocyte differentiation,GO:0046579~positive regulation of Ras protein signal transduction,GO:0046777~protein autophosphorylation,GO:0048013~ephrin receptor signaling pathway,GO:0048678~response to axon injury,GO:0050777~negative regulation of immune response,GO:0050853~B cell receptor signaling pathway,GO:0050855~regulation of B cell receptor signaling pathway,GO:0050900~leukocyte migration,GO:0051272~positive regulation of cellular component movement,GO:0051279~regulation of release of sequestered calcium ion into cytosol,GO:0060252~positive regulation of glial cell proliferation,GO:0060369~positive regulation of Fc receptor mediated stimulatory signaling pathway,GO:0060397~JAK-STAT cascade involved in growth hormone signaling pathway,GO:0070304~positive regulation of stress-activated protein kinase signaling cascade,GO:0070372~regulation of ERK1 and ERK2 cascade,GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:0070447~positive regulation of oligodendrocyte progenitor proliferation,GO:0070667~negative regulation of mast cell proliferation,GO:0070668~positive regulation of mast cell proliferation,GO:0071300~cellular response to retinoic acid,GO:0090025~regulation of monocyte chemotaxis,GO:0090330~regulation of platelet aggregation,GO:0097028~dendritic cell differentiation,GO:1902532~negative regulation of intracellular signal transduction,GO:1902961~positive regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic process,GO:2000670~positive regulation of dendritic cell apoptotic process,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005758~mitochondrial intermembrane space,GO:0005765~lysosomal membrane,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005912~adherens junction,GO:0014069~postsynaptic density,GO:0030061~mitochondrial crista,GO:0030666~endocytic vesicle membrane,GO:0031234~extrinsic component of cytoplasmic side of plasma membrane,GO:0034666~integrin alpha2-beta1 complex,GO:0043231~intracellular membrane-bounded organelle,GO:0045121~membrane raft,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:0098978~glutamatergic synapse,GO:0099091~postsynaptic specialization, intracellular component,	GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0004715~non-membrane spanning protein tyrosine kinase activity,GO:0005102~receptor binding,GO:0005161~platelet-derived growth factor receptor binding,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016301~kinase activity,GO:0017124~SH3 domain binding,GO:0019899~enzyme binding,GO:0031625~ubiquitin protein ligase binding,GO:0043015~gamma-tubulin binding,GO:0043208~glycosphingolipid binding,GO:0044325~ion channel binding,GO:0046875~ephrin receptor binding,GO:0051219~phosphoprotein binding,GO:0097110~scaffold protein binding,	IPR000719:Protein kinase, catalytic domain,IPR000980:SH2 domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR001452:Src homology-3 domain,IPR008266:Tyrosine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,IPR020635:Tyrosine-protein kinase, catalytic domain,	hsa04062:Chemokine signaling pathway,hsa04064:NF-kappa B signaling pathway,hsa04611:Platelet activation,hsa04662:B cell receptor signaling pathway,hsa04664:Fc epsilon RI signaling pathway,hsa04666:Fc gamma R-mediated phagocytosis,hsa04730:Long-term depression,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05169:Epstein-Barr virus infection,hsa05203:Viral carcinogenesis,hsa05417:Lipid and atherosclerosis,			SM00219:TyrKc,SM00252:SH2,SM00326:SH3,	KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,KW-0945~Host-virus interaction,KW-1064~Adaptive immunity,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0656~Proto-oncogene,	KW-0727~SH2 domain,KW-0728~SH3 domain,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0449~Lipoprotein,KW-0519~Myristate,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Proton acceptor,BINDING:ATP,COMPBIAS:Polar residues,DOMAIN:Protein kinase,DOMAIN:SH2,DOMAIN:SH3,LIPID:N-myristoyl glycine,LIPID:S-palmitoyl cysteine,MUTAGEN:C->A: Loss of localization to the cell membrane; when associated with A-2.,MUTAGEN:D->A: Impedes the trafficking from the Golgi apparatus toward the cell membrane; when associated with A-346; A-353 and A-498.,MUTAGEN:D->A: Impedes the trafficking from the Golgi apparatus toward the cell membrane; when associated with A-346; A-353 and A-499.,MUTAGEN:D->A: Impedes the trafficking from the Golgi apparatus toward the cell membrane; when associated with A-353; A-498 and A-499.,MUTAGEN:E->A: Impedes the trafficking from the Golgi apparatus toward the cell membrane; when associated with A-346; A-498 and A-499.,MUTAGEN:G->A: Loss of localization to the cell membrane; when associated with A-3.,MUTAGEN:K->A: Loss of activity and no effect on localization to the cell membrane. Abundant localization in the nucleus; when associated with A-2 and A-3.,MUTAGEN:K->L,R: Loss of kinase activity.,MUTAGEN:Y->F: Abolishes autoinhibition and thereby increases kinase activity.,MUTAGEN:Y->F: Strongly reduced kinase activity.,NP_BIND:ATP,REGION:Disordered,
LYRM1	LYR motif containing 1(LYRM1)	Homo sapiens					GO:0005654~nucleoplasm,GO:0030496~midbody,		IPR008011:Complex 1 LYR protein,						KW-0539~Nucleus,
MALT1	MALT1 paracaspase(MALT1)	Homo sapiens				GO:0001923~B-1 B cell differentiation,GO:0002223~stimulatory C-type lectin receptor signaling pathway,GO:0002726~positive regulation of T cell cytokine production,GO:0006508~proteolysis,GO:0006952~defense response,GO:0007250~activation of NF-kappaB-inducing kinase activity,GO:0009620~response to fungus,GO:0016567~protein ubiquitination,GO:0031398~positive regulation of protein ubiquitination,GO:0031663~lipopolysaccharide-mediated signaling pathway,GO:0032731~positive regulation of interleukin-1 beta production,GO:0032743~positive regulation of interleukin-2 production,GO:0038095~Fc-epsilon receptor signaling pathway,GO:0042098~T cell proliferation,GO:0042113~B cell activation,GO:0042981~regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043280~positive regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0045087~innate immune response,GO:0050852~T cell receptor signaling pathway,GO:0050856~regulation of T cell receptor signaling pathway,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051168~nuclear export,GO:0051603~proteolysis involved in cellular protein catabolic process,GO:2000321~positive regulation of T-helper 17 cell differentiation,	GO:0001650~fibrillar center,GO:0002096~polkadots,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0032449~CBM complex,GO:0032991~macromolecular complex,GO:0048471~perinuclear region of cytoplasm,	GO:0002020~protease binding,GO:0004175~endopeptidase activity,GO:0004197~cysteine-type endopeptidase activity,GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0008233~peptidase activity,GO:0019209~kinase activator activity,GO:0042802~identical protein binding,GO:0043621~protein self-association,	IPR001309:Peptidase C14, ICE, catalytic subunit p20,IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR011029:Death-like domain,IPR013783:Immunoglobulin-like fold,	hsa04064:NF-kappa B signaling pathway,hsa04625:C-type lectin receptor signaling pathway,hsa04660:T cell receptor signaling pathway,hsa04662:B cell receptor signaling pathway,hsa05131:Shigellosis,hsa05152:Tuberculosis,	615468~Immunodeficiency 12,		SM00408:IGc2,SM00409:IG,	KW-0391~Immunity,KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0393~Immunoglobulin domain,KW-0677~Repeat,		KW-0378~Hydrolase,KW-0645~Protease,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	DOMAIN:CASPASE_P20,DOMAIN:Death,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,MOTIF:Nuclear export signal,MUTAGEN:C->A: Slight decrease in NF-kappa-B activation.,MUTAGEN:E->A: Abolishes binding to TRAF6.,REGION:Caspase-like,REGION:Disordered,SITE:Breakpoint for translocation to form BIRC2-MALT1,
MAPKAPK2	MAPK activated protein kinase 2(MAPKAPK2)	Homo sapiens	37.Akt-PKB_Effector_of_P13K_in_Vivo,	h_hsp27Pathway:Stress Induction of HSP Regulation,h_mapkPathway:MAPKinase Signaling Pathway,h_p38mapkPathway:p38 MAPK Signaling Pathway ,		GO:0000165~MAPK cascade,GO:0000187~activation of MAPK activity,GO:0002224~toll-like receptor signaling pathway,GO:0006468~protein phosphorylation,GO:0006691~leukotriene metabolic process,GO:0006954~inflammatory response,GO:0006974~cellular response to DNA damage stimulus,GO:0018105~peptidyl-serine phosphorylation,GO:0032496~response to lipopolysaccharide,GO:0032675~regulation of interleukin-6 production,GO:0032680~regulation of tumor necrosis factor production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0034097~response to cytokine,GO:0035556~intracellular signal transduction,GO:0035924~cellular response to vascular endothelial growth factor stimulus,GO:0038066~p38MAPK cascade,GO:0043488~regulation of mRNA stability,GO:0044351~macropinocytosis,GO:0046777~protein autophosphorylation,GO:0048010~vascular endothelial growth factor receptor signaling pathway,GO:0048839~inner ear development,GO:0070935~3'-UTR-mediated mRNA stabilization,GO:1900034~regulation of cellular response to heat,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004683~calmodulin-dependent protein kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0005524~ATP binding,GO:0009931~calcium-dependent protein serine/threonine kinase activity,GO:0051019~mitogen-activated protein kinase binding,	IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,IPR027442:MAP kinase activated protein kinase, C-terminal domain,	hsa04010:MAPK signaling pathway,hsa04218:Cellular senescence,hsa04370:VEGF signaling pathway,hsa04625:C-type lectin receptor signaling pathway,hsa04722:Neurotrophin signaling pathway,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05203:Viral carcinogenesis,			SM00220:S_TKc,	KW-0227~DNA damage,	KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Proton acceptor,BINDING:ATP,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),DOMAIN:Protein kinase,MOTIF:Bipartite nuclear localization signal 1,MOTIF:Bipartite nuclear localization signal 2,MOTIF:Nuclear export signal (NES),MUTAGEN:D->A: Kinase defective mutant, abolishes activity.,MUTAGEN:K->R: Induces decreased sumoylation and increase in protein kinase activity.,MUTAGEN:K->R: Kinase defective mutant, abolishes activity.,MUTAGEN:S->A: Strong decrease in kinase activity.,MUTAGEN:S->D: Mimicks phosphorylation state, leading to slight increase of basal kinase activity.,MUTAGEN:T->A: Slight decrease in kinase activity.,MUTAGEN:T->A: Strong decrease in kinase activity.,MUTAGEN:T->D,E: Mimicks phosphorylation state, leading to elevated basal kinase activity.,MUTAGEN:T->D: Mimicks phosphorylation state, leading to slight increase of basal kinase activity.,MUTAGEN:T->E: Mimicks phosphorylation state and constitutive protein kinase activity; when associated with E-222.,MUTAGEN:T->E: Mimicks phosphorylation state and constitutive protein kinase activity; when associated with E-334.,NP_BIND:ATP,REGION:Autoinhibitory helix,REGION:Disordered,REGION:Staurosporine binding,REGION:p38 MAPK-binding site,
MAPKAPK3	MAPK activated protein kinase 3(MAPKAPK3)	Homo sapiens		h_hsp27Pathway:Stress Induction of HSP Regulation,h_mapkPathway:MAPKinase Signaling Pathway,		GO:0000165~MAPK cascade,GO:0000187~activation of MAPK activity,GO:0002224~toll-like receptor signaling pathway,GO:0007165~signal transduction,GO:0018105~peptidyl-serine phosphorylation,GO:0032496~response to lipopolysaccharide,GO:0034097~response to cytokine,GO:0035556~intracellular signal transduction,GO:0044351~macropinocytosis,GO:0046777~protein autophosphorylation,GO:0048010~vascular endothelial growth factor receptor signaling pathway,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0004674~protein serine/threonine kinase activity,GO:0004683~calmodulin-dependent protein kinase activity,GO:0004708~MAP kinase kinase activity,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0005524~ATP binding,GO:0009931~calcium-dependent protein serine/threonine kinase activity,GO:0051019~mitogen-activated protein kinase binding,	IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,IPR027442:MAP kinase activated protein kinase, C-terminal domain,	hsa04010:MAPK signaling pathway,hsa04370:VEGF signaling pathway,	617111~Macular dystrophy, patterned, 3,		SM00220:S_TKc,		KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:ATP,COMPBIAS:Polar residues,DOMAIN:Protein kinase,MOTIF:Bipartite nuclear localization signal 1,MOTIF:Bipartite nuclear localization signal 2,MOTIF:Nuclear export signal (NES),MUTAGEN:K->M: Higher affinity toward PCH2.,NP_BIND:ATP,REGION:Autoinhibitory helix,REGION:Disordered,REGION:p38 MAPK-binding site,
MAPKAPK5	MAPK activated protein kinase 5(MAPKAPK5)	Homo sapiens		h_mapkPathway:MAPKinase Signaling Pathway,h_p38mapkPathway:p38 MAPK Signaling Pathway ,		GO:0000165~MAPK cascade,GO:0006417~regulation of translation,GO:0007165~signal transduction,GO:0007265~Ras protein signal transduction,GO:0018105~peptidyl-serine phosphorylation,GO:0032007~negative regulation of TOR signaling,GO:0032212~positive regulation of telomere maintenance via telomerase,GO:0035556~intracellular signal transduction,GO:0046777~protein autophosphorylation,GO:0051973~positive regulation of telomerase activity,GO:0090398~cellular senescence,GO:0090400~stress-induced premature senescence,GO:1901796~regulation of signal transduction by p53 class mediator,GO:1904355~positive regulation of telomere capping,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0002039~p53 binding,GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004683~calmodulin-dependent protein kinase activity,GO:0004708~MAP kinase kinase activity,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0005524~ATP binding,GO:0009931~calcium-dependent protein serine/threonine kinase activity,GO:0051019~mitogen-activated protein kinase binding,	IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,	hsa04010:MAPK signaling pathway,			SM00220:S_TKc,		KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0043~Tumor suppressor,	KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:ATP,COMPBIAS:Polar residues,DOMAIN:Protein kinase,MUTAGEN:K->M: Kinase defective mutant, abolishes activity.,MUTAGEN:L->G: Induces constitutive protein kinase activity.,MUTAGEN:S->D: Mimicks phosphorylation state and displays a slightly higher protein kinase activity.,MUTAGEN:T->A: No p38-beta/MAPK11-induced activation.,MUTAGEN:T->D: Mimicks phosphorylation state and induces constitutive protein kinase activity.,NP_BIND:ATP,REGION:Disordered,
MKNK1	MAPK interacting serine/threonine kinase 1(MKNK1)	Homo sapiens	107.mRNA_translation-protein_synthesis,	h_eif4Pathway:Regulation of eIF4e and p70 S6 Kinase,h_erkPathway:Erk1/Erk2 Mapk Signaling pathway,h_mapkPathway:MAPKinase Signaling Pathway,h_mtorPathway:mTOR Signaling Pathway,h_p38mapkPathway:p38 MAPK Signaling Pathway ,		GO:0006417~regulation of translation,GO:0006468~protein phosphorylation,GO:0018105~peptidyl-serine phosphorylation,GO:0035556~intracellular signal transduction,GO:0046777~protein autophosphorylation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004683~calmodulin-dependent protein kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0005524~ATP binding,GO:0009931~calcium-dependent protein serine/threonine kinase activity,GO:0046872~metal ion binding,	IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,	hsa04010:MAPK signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04910:Insulin signaling pathway,			SM00220:S_TKc,	KW-0810~Translation regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:ATP,COMPBIAS:Basic and acidic residues,DOMAIN:Protein kinase,MUTAGEN:D->A: Loss of kinase activity; when associated with K-78.,MUTAGEN:K->M: Loss of kinase activity; when associated with D-232.,MUTAGEN:T->A: Loss of kinase activity; when associated with T-250.,MUTAGEN:T->A: Loss of kinase activity; when associated with T-255.,MUTAGEN:T->D: Constitutively active.,NP_BIND:ATP,REGION:Disordered,
MICALL1	MICAL like 1(MICALL1)	Homo sapiens				GO:0006612~protein targeting to membrane,GO:0006897~endocytosis,GO:0006898~receptor-mediated endocytosis,GO:0031175~neuron projection development,GO:0032456~endocytic recycling,GO:0032458~slow endocytic recycling,GO:0036010~protein localization to endosome,GO:0097320~plasma membrane tubulation,	GO:0005770~late endosome,GO:0019898~extrinsic component of membrane,GO:0031902~late endosome membrane,GO:0055038~recycling endosome membrane,	GO:0005515~protein binding,GO:0031267~small GTPase binding,GO:0042802~identical protein binding,GO:0045296~cadherin binding,GO:0046872~metal ion binding,GO:0070300~phosphatidic acid binding,	IPR001715:Calponin homology domain,IPR001781:Zinc finger, LIM-type,IPR022735:Domain of unknown function DUF3585,				SM00033:CH,SM00132:LIM,	KW-0254~Endocytosis,KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,KW-0967~Endosome,		KW-0175~Coiled coil,KW-0440~LIM domain,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:BMERB,DOMAIN:Calponin-homology (CH),DOMAIN:LIM zinc-binding,DOMAIN:bMERB,MOTIF:NPF1,MOTIF:NPF2,MUTAGEN:EEE->AAA: Strongly reduces interaction with EHD1.,MUTAGEN:MLVDWF->AAAAAA: Altered association with membranes.,MUTAGEN:NPF->APA: No effect on interaction with EHD1. Complete loss of interaction with EHD1; when associated with 425-A--A-427.,MUTAGEN:NPF->APA: Partial loss of interaction with EHD1. Complete loss of interaction with EHD1; when associated with 633-A--A-635.,MUTAGEN:PLP->ALA: No effect on interaction with PACSIN2. Loss of interaction with PACSIN2; when associated with 480-A--A-483.,MUTAGEN:PRAP->ARAA: No effect on interaction with PACSIN2. Loss of interaction with PACSIN2; when associated with 385-A--A-387.,REGION:Disordered,REGION:Mediates the interaction with RAB13 and RAB35 and intramolecular interaction with the CH domain,REGION:Necessary and sufficient to associate with tubular recycling endosome membranes, mediate phosphatidic acid-binding and membrane tubulation,
MLLT11	MLLT11 transcription factor 7 cofactor(MLLT11)	Homo sapiens				GO:0043065~positive regulation of apoptotic process,GO:0045893~positive regulation of transcription, DNA-templated,GO:0051901~positive regulation of mitochondrial depolarization,GO:0090200~positive regulation of release of cytochrome c from mitochondria,GO:0097190~apoptotic signaling pathway,GO:0097191~extrinsic apoptotic signaling pathway,GO:0097193~intrinsic apoptotic signaling pathway,	GO:0005654~nucleoplasm,GO:0005815~microtubule organizing center,GO:0005829~cytosol,	GO:0005515~protein binding,	IPR026778:MLLT11 family,						KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0656~Proto-oncogene,				KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	DOMAIN:WRNPLPNID,MOTIF:Nuclear export signal,MUTAGEN:LSELEGLGL->ASEAEGAGA: Constitutive nuclear sequestration.,
MNAT1	MNAT1 component of CDK activating kinase(MNAT1)	Homo sapiens		h_ptc1Pathway:Sonic Hedgehog (SHH) Receptor Ptc1 Regulates cell cycle,		GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0000082~G1/S transition of mitotic cell cycle,GO:0000086~G2/M transition of mitotic cell cycle,GO:0006281~DNA repair,GO:0006283~transcription-coupled nucleotide-excision repair,GO:0006289~nucleotide-excision repair,GO:0006294~nucleotide-excision repair, preincision complex assembly,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006361~transcription initiation from RNA polymerase I promoter,GO:0006363~termination of RNA polymerase I transcription,GO:0006366~transcription from RNA polymerase II promoter,GO:0006367~transcription initiation from RNA polymerase II promoter,GO:0006368~transcription elongation from RNA polymerase II promoter,GO:0006370~7-methylguanosine mRNA capping,GO:0007049~cell cycle,GO:0007512~adult heart development,GO:0021591~ventricular system development,GO:0043066~negative regulation of apoptotic process,GO:0045737~positive regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0051592~response to calcium ion,GO:0065003~macromolecular complex assembly,GO:1905775~negative regulation of DNA helicase activity,GO:2000045~regulation of G1/S transition of mitotic cell cycle,	GO:0000439~core TFIIH complex,GO:0005654~nucleoplasm,GO:0005675~holo TFIIH complex,GO:0005694~chromosome,GO:0019907~cyclin-dependent protein kinase activating kinase holoenzyme complex,GO:0070516~CAK-ERCC2 complex,GO:0070985~TFIIK complex,	GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0046872~metal ion binding,GO:0047485~protein N-terminus binding,GO:0061575~cyclin-dependent protein serine/threonine kinase activator activity,	IPR001841:Zinc finger, RING-type,IPR003511:DNA-binding HORMA,IPR003903:Ubiquitin interacting motif,IPR004575:Cdk-activating kinase assembly factor MAT1/Tfb3,IPR013083:Zinc finger, RING/FYVE/PHD-type,IPR015877:Cdk-activating kinase assembly factor MAT1, centre,IPR017907:Zinc finger, RING-type, conserved site,	hsa03022:Basal transcription factors,hsa03420:Nucleotide excision repair,		PIRSF003338:CDK-activating kinase assembly factor MAT1,	SM00184:RING,	KW-0131~Cell cycle,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0158~Chromosome,KW-0539~Nucleus,		KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:HORMA,DOMAIN:MAT1,DOMAIN:RING-type,DOMAIN:UIM,ZN_FING:RING-type,
MYBL2	MYB proto-oncogene like 2(MYBL2)	Homo sapiens				GO:0000278~mitotic cell cycle,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0043525~positive regulation of neuron apoptotic process,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051726~regulation of cell cycle,GO:0090307~mitotic spindle assembly,GO:1990830~cellular response to leukemia inhibitory factor,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0031523~Myb complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001005:SANT/Myb domain,IPR009057:Homeodomain-like,IPR015395:C-myb, C-terminal,IPR017930:Myb domain,	hsa04218:Cellular senescence,			SM00717:SANT,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,		KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DNA_BIND:H-T-H motif,DOMAIN:HTH myb-type 1,DOMAIN:HTH myb-type 2,DOMAIN:HTH myb-type 3,MOTIF:Bipartite nuclear localization signal,MOTIF:Nuclear localization signal,REGION:Disordered,
MYCBP2	MYC binding protein 2(MYCBP2)	Homo sapiens			Cell division and chromosome partitioning / Cytoskeleton,	GO:0016567~protein ubiquitination,GO:0021785~branchiomotor neuron axon guidance,GO:0021952~central nervous system projection neuron axonogenesis,GO:0031398~positive regulation of protein ubiquitination,GO:0032880~regulation of protein localization,GO:0032922~circadian regulation of gene expression,GO:0042177~negative regulation of protein catabolic process,GO:0050790~regulation of catalytic activity,GO:0050905~neuromuscular process,GO:0051493~regulation of cytoskeleton organization,GO:1902667~regulation of axon guidance,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0015630~microtubule cytoskeleton,GO:0016020~membrane,GO:0030424~axon,GO:0043231~intracellular membrane-bounded organelle,	GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0031267~small GTPase binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,GO:0061630~ubiquitin protein ligase activity,	IPR000408:Regulator of chromosome condensation, RCC1,IPR001841:Zinc finger, RING-type,IPR003646:SH3-like domain, bacterial,IPR004939:Anaphase-promoting complex, subunit 10/DOC domain,IPR008979:Galactose-binding domain-like,IPR009091:Regulator of chromosome condensation 1/beta-lactamase-inhibitor protein II,IPR012983:PHR,IPR013083:Zinc finger, RING/FYVE/PHD-type,IPR014756:Immunoglobulin E-set,IPR017868:Filamin/ABP280 repeat-like,				SM00184:RING,SM01337:SM01337,	KW-0090~Biological rhythms,KW-0833~Ubl conjugation pathway,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0344~Guanine-nucleotide releasing factor,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:DOC,DOMAIN:RING-type,METAL:Zinc 1,METAL:Zinc 2,METAL:Zinc 3,METAL:Zinc 4,METAL:Zinc 5,METAL:Zinc 6,MUTAGEN:C->A: Increased thiol-sensitive adduct formation.,MUTAGEN:C->S: Abolished E3 ubiquitin-protein ligase activity.,MUTAGEN:C->S: Retains activity while also forming a discrete monoubiquitin adduct that is resistant to thiolysis but is reversible after base treatment.,MUTAGEN:E->A,Q: Does not affect E3 ubiquitin-protein ligase activity.,MUTAGEN:F->A: Reduced E3 ubiquitin-protein ligase activity in threonine discharge assay.,MUTAGEN:H->N: Abolished E3 ubiquitin-protein ligase activity in threonine discharge assay, associated with enhanced thiol-sensitive ubiquitin adduct formation.,REGION:Disordered,REGION:PHR domain 1,REGION:PHR domain 2,REGION:RAE1 binding,REGION:Tandem cysteine domain,REPEAT:Filamin,REPEAT:RCC1 1,REPEAT:RCC1 2,REPEAT:RCC1 3,REPEAT:RCC1 4,REPEAT:RCC1 5,SITE:Important for catalysis,ZN_FING:RING-type; atypical,
MYCBP	MYC binding protein(MYCBP)	Homo sapiens				GO:0006355~regulation of transcription, DNA-templated,GO:0007283~spermatogenesis,GO:0045893~positive regulation of transcription, DNA-templated,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,	GO:0003713~transcription coactivator activity,GO:0005515~protein binding,	IPR026060:Associate of Myc 1,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,				REGION:Disordered,
MYC	MYC proto-oncogene, bHLH transcription factor(MYC)	Homo sapiens	61.Myc_network,62.G1-phase_progression_by_Myc,99.NF-kB_activation,	h_arfPathway:Tumor Suppressor Arf Inhibits Ribosomal Biogenesis,h_cardiacEGFPathway:Role of EGF Receptor Transactivation by GPCRs in Cardiac Hypertrophy,h_cdmacPathway:Cadmium induces DNA synthesis and proliferation in macrophages,h_ctcfPathway:CTCF: First Multivalent Nuclear Factor,h_erkPathway:Erk1/Erk2 Mapk Signaling pathway,h_gleevecPathway:Inhibition of Cellular Proliferation by Gleevec,h_il2rbPathway:IL-2 Receptor Beta Chain in T cell Activation,h_mapkPathway:MAPKinase Signaling Pathway,h_p38mapkPathway:p38 MAPK Signaling Pathway ,h_PparaPathway:Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha),h_telPathway:Telomeres, Telomerase, Cellular Aging, and  Immortality,h_tertPathway:Overview of telomerase protein component gene hTert Transcriptional Regulation ,h_vipPathway:Neuropeptides VIP and PACAP inhibit the apoptosis of activated T cells,h_wntPathway:WNT Signaling Pathway,		GO:0000082~G1/S transition of mitotic cell cycle,GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000165~MAPK cascade,GO:0000320~re-entry into mitotic cell cycle,GO:0001541~ovarian follicle development,GO:0001658~branching involved in ureteric bud morphogenesis,GO:0001701~in utero embryonic development,GO:0002053~positive regulation of mesenchymal cell proliferation,GO:0006006~glucose metabolic process,GO:0006112~energy reserve metabolic process,GO:0006338~chromatin remodeling,GO:0006352~DNA-templated transcription, initiation,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0006848~pyruvate transport,GO:0006865~amino acid transport,GO:0006879~cellular iron ion homeostasis,GO:0006974~cellular response to DNA damage stimulus,GO:0007007~inner mitochondrial membrane organization,GO:0007050~cell cycle arrest,GO:0007219~Notch signaling pathway,GO:0007346~regulation of mitotic cell cycle,GO:0008283~cell proliferation,GO:0008284~positive regulation of cell proliferation,GO:0009410~response to xenobiotic stimulus,GO:0009611~response to wounding,GO:0010332~response to gamma radiation,GO:0010468~regulation of gene expression,GO:0010564~regulation of cell cycle process,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0010918~positive regulation of mitochondrial membrane potential,GO:0014911~positive regulation of smooth muscle cell migration,GO:0015671~oxygen transport,GO:0016579~protein deubiquitination,GO:0019221~cytokine-mediated signaling pathway,GO:0021854~hypothalamus development,GO:0030728~ovulation,GO:0032204~regulation of telomere maintenance,GO:0032355~response to estradiol,GO:0032869~cellular response to insulin stimulus,GO:0032873~negative regulation of stress-activated MAPK cascade,GO:0032986~protein-DNA complex disassembly,GO:0034644~cellular response to UV,GO:0035690~cellular response to drug,GO:0036120~cellular response to platelet-derived growth factor stimulus,GO:0042493~response to drug,GO:0043066~negative regulation of apoptotic process,GO:0043280~positive regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0043388~positive regulation of DNA binding,GO:0044344~cellular response to fibroblast growth factor stimulus,GO:0044346~fibroblast apoptotic process,GO:0044752~response to human chorionic gonadotropin,GO:0045023~G0 to G1 transition,GO:0045471~response to ethanol,GO:0045656~negative regulation of monocyte differentiation,GO:0045727~positive regulation of translation,GO:0045787~positive regulation of cell cycle,GO:0045821~positive regulation of glycolytic process,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046325~negative regulation of glucose import,GO:0046722~lactic acid secretion,GO:0048146~positive regulation of fibroblast proliferation,GO:0048147~negative regulation of fibroblast proliferation,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0050679~positive regulation of epithelial cell proliferation,GO:0051276~chromosome organization,GO:0051782~negative regulation of cell division,GO:0051973~positive regulation of telomerase activity,GO:0060252~positive regulation of glial cell proliferation,GO:0070371~ERK1 and ERK2 cascade,GO:0070848~response to growth factor,GO:0071300~cellular response to retinoic acid,GO:0071322~cellular response to carbohydrate stimulus,GO:0071346~cellular response to interferon-gamma,GO:0071347~cellular response to interleukin-1,GO:0071364~cellular response to epidermal growth factor stimulus,GO:0071378~cellular response to growth hormone stimulus,GO:0071391~cellular response to estrogen stimulus,GO:0071394~cellular response to testosterone stimulus,GO:0071409~cellular response to cycloheximide,GO:0071456~cellular response to hypoxia,GO:0071464~cellular response to hydrostatic pressure,GO:0071466~cellular response to xenobiotic stimulus,GO:0090096~positive regulation of metanephric cap mesenchymal cell proliferation,GO:0097421~liver regeneration,GO:1902255~positive regulation of intrinsic apoptotic signaling pathway by p53 class mediator,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1903841~cellular response to arsenite(3-),GO:1903862~positive regulation of oxidative phosphorylation,GO:1904385~cellular response to angiotensin,GO:1904586~cellular response to putrescine,GO:1904620~cellular response to dimethyl sulfoxide,GO:1904628~cellular response to phorbol 13-acetate 12-myristate,GO:1904672~regulation of somatic stem cell population maintenance,GO:1904837~beta-catenin-TCF complex assembly,GO:1905643~positive regulation of DNA methylation,GO:1990646~cellular response to prolactin,GO:1990858~cellular response to lectin,GO:1990859~cellular response to endothelin,GO:2000573~positive regulation of DNA biosynthetic process,GO:2001022~positive regulation of response to DNA damage stimulus,GO:2001171~positive regulation of ATP biosynthetic process,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005739~mitochondrion,GO:0005791~rough endoplasmic reticulum,GO:0016021~integral component of membrane,GO:0032991~macromolecular complex,GO:0044195~nucleoplasmic reticulum,GO:0071943~Myc-Max complex,GO:0090571~RNA polymerase II transcription repressor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001046~core promoter sequence-specific DNA binding,GO:0001221~transcription cofactor binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0033613~activating transcription factor binding,GO:0044877~macromolecular complex binding,GO:0046983~protein dimerization activity,GO:0070491~repressing transcription factor binding,GO:0070888~E-box binding,GO:0071074~eukaryotic initiation factor eIF2 binding,	IPR002418:Transcription regulator Myc,IPR003327:Leucine zipper, Myc,IPR011598:Myc-type, basic helix-loop-helix (bHLH) domain,IPR012682:Transcription regulator Myc, N-terminal,	hsa04010:MAPK signaling pathway,hsa04012:ErbB signaling pathway,hsa04110:Cell cycle,hsa04151:PI3K-Akt signaling pathway,hsa04218:Cellular senescence,hsa04310:Wnt signaling pathway,hsa04350:TGF-beta signaling pathway,hsa04390:Hippo signaling pathway,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04630:JAK-STAT signaling pathway,hsa04919:Thyroid hormone signaling pathway,hsa05132:Salmonella infection,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05163:Human cytomegalovirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05169:Epstein-Barr virus infection,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05210:Colorectal cancer,hsa05213:Endometrial cancer,hsa05216:Thyroid cancer,hsa05219:Bladder cancer,hsa05220:Chronic myeloid leukemia,hsa05221:Acute myeloid leukemia,hsa05222:Small cell lung cancer,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,hsa05230:Central carbon metabolism in cancer,	113970~Burkitt lymphoma, somatic,	PIRSF001705:myc protein,	SM00353:HLH,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0472~Membrane,KW-0539~Nucleus,	KW-0656~Proto-oncogene,	KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0010~Activator,KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CARBOHYD:O-linked (GlcNAc) threonine; alternate,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:BHLH,DOMAIN:Myc_N,DOMAIN:bHLH,MUTAGEN:R->K: Abolished ubiquitination and degradation by the DCX(TRPC4AP) complex.,MUTAGEN:S->A: Impairs interaction with FBXW7 and subsequent degradation by the proteasome. Impaired inhibition of Ras-induced senescence. Abolishes phosphorylation by DYRK2, and subsequent phosphorylation by GSK3B at Thr-58.,MUTAGEN:S->D: Phospho-mimetic mutant; abolished regulation by AMBRA1.,MUTAGEN:T->A: Impairs interaction with FBXW7 and subsequent degradation by the proteasome. Normal inhibition of Ras-induced senescence.,REGION:Disordered,REGION:Leucine-zipper,TRANSMEM:Helical,
ASAH1	N-acylsphingosine amidohydrolase 1(ASAH1)	Homo sapiens		h_edg1Pathway:Phospholipids as signalling intermediaries,		GO:0006631~fatty acid metabolic process,GO:0006687~glycosphingolipid metabolic process,GO:0030216~keratinocyte differentiation,GO:0043312~neutrophil degranulation,GO:0046512~sphingosine biosynthetic process,GO:0046513~ceramide biosynthetic process,GO:0046514~ceramide catabolic process,GO:0050810~regulation of steroid biosynthetic process,GO:0071356~cellular response to tumor necrosis factor,GO:1903507~negative regulation of nucleic acid-templated transcription,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005764~lysosome,GO:0016021~integral component of membrane,GO:0043202~lysosomal lumen,GO:0070062~extracellular exosome,GO:1904724~tertiary granule lumen,GO:1904813~ficolin-1-rich granule lumen,	GO:0003714~transcription corepressor activity,GO:0016787~hydrolase activity,GO:0016810~hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds,GO:0016811~hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amides,GO:0016922~ligand-dependent nuclear receptor binding,GO:0017040~ceramidase activity,GO:0017064~fatty acid amide hydrolase activity,	IPR016699:Acid ceramidase-like,	hsa00600:Sphingolipid metabolism,hsa01100:Metabolic pathways,hsa04071:Sphingolipid signaling pathway,hsa04142:Lysosome,	159950~Spinal muscular atrophy with progressive myoclonic epilepsy,228000~Farber lipogranulomatosis,	PIRSF017632:acid ceramidase,		KW-0443~Lipid metabolism,KW-0746~Sphingolipid metabolism,	KW-0458~Lysosome,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0964~Secreted,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0887~Epilepsy,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	ACT_SITE:Nucleophile,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DISULFID:Interchain (between alpha and beta subunits),DOMAIN:CBAH,DOMAIN:NAAA-beta,MUTAGEN:C->A: Loss of autocatalytic processing. Loss of ceramidase activity.,MUTAGEN:D->N: Strongly decreased autocatalytic processing. Strongly decreased ceramidase activity.,MUTAGEN:FFL->QQQ: No effect on autocatalytic processing, but strongly decreased ceramidase activity.,MUTAGEN:L->Q: No effect on autocatalytic processing, but loss of ceramidase activity, when associated with 165-Q--Q-167.,MUTAGEN:N->A: Strongly decreased autocatalytic processing. Mildly decreased ceramidase activity.,MUTAGEN:N->Q: Loss of ceramide catabolic process.,MUTAGEN:N->Q: No effect on ceramide catabolic process.,MUTAGEN:R->Q: Mildly decreased autocatalytic processing. Loss of ceramidase activity.,MUTAGEN:R->Q: Strongly decreased autocatalytic processing. Moderately decreased ceramidase activity.,MUTAGEN:T->A: Decreased rate of autocatalytic processing.,MUTAGEN:VFL->QFQ: No effect on autocatalytic processing, but loss of ceramidase activity, when associated with Q-80.,MUTAGEN:W->Q: Moderately decreased autocatalytic processing, but loss of ceramidase activity, when associated with 169-Q--Q-171.,MUTAGEN:WNI->QNQ: Moderately decreased autocatalytic processing, but loss of ceramidase activity, when associated with Q-176.,REGION:Disordered,SITE:Important for catalytic activity,TRANSMEM:Helical,
NMT1	N-myristoyltransferase 1(NMT1)	Homo sapiens			Lipid metabolism,	GO:0001701~in utero embryonic development,GO:0006499~N-terminal protein myristoylation,GO:0018008~N-terminal peptidyl-glycine N-myristoylation,GO:0022400~regulation of rhodopsin mediated signaling pathway,GO:0042180~cellular ketone metabolic process,GO:1900740~positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway,	GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0019898~extrinsic component of membrane,	GO:0004379~glycylpeptide N-tetradecanoyltransferase activity,GO:0005515~protein binding,GO:0019107~myristoyltransferase activity,	IPR000903:Myristoyl-CoA:protein N-myristoyltransferase,IPR016181:Acyl-CoA N-acyltransferase,IPR022676:Myristoyl-CoA:protein N-myristoyltransferase, N-terminal,IPR022677:Myristoyl-CoA:protein N-myristoyltransferase, C-terminal,IPR022678:Myristoyl-CoA:protein N-myristoyltransferase, conserved site,			PIRSF015892:N-myristoyl transferase,			KW-0472~Membrane,KW-0963~Cytoplasm,				KW-0012~Acyltransferase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:NMT,DOMAIN:NMT_C,MUTAGEN:G->D,K: Reduced activity.,REGION:Disordered,REGION:Myristoyl-CoA binding,
NSDHL	NAD(P) dependent steroid dehydrogenase-like(NSDHL)	Homo sapiens			Cell envelope biogenesis, outer membrane / Carbohydrate transport and metabolism,	GO:0001942~hair follicle development,GO:0006694~steroid biosynthetic process,GO:0006695~cholesterol biosynthetic process,GO:0007224~smoothened signaling pathway,GO:0008203~cholesterol metabolic process,GO:0060716~labyrinthine layer blood vessel development,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005811~lipid particle,GO:0016021~integral component of membrane,	GO:0000252~C-3 sterol dehydrogenase (C-4 sterol decarboxylase) activity,GO:0003854~3-beta-hydroxy-delta5-steroid dehydrogenase activity,GO:0005515~protein binding,GO:0016616~oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor,GO:0047012~sterol-4-alpha-carboxylate 3-dehydrogenase (decarboxylating) activity,	IPR002225:3-beta hydroxysteroid dehydrogenase/isomerase,	hsa00100:Steroid biosynthesis,hsa01100:Metabolic pathways,	300831~CK syndrome,308050~CHILD syndrome,			KW-0152~Cholesterol biosynthesis,KW-0153~Cholesterol metabolism,KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,KW-0752~Steroid biosynthesis,KW-0753~Steroid metabolism,KW-0756~Sterol biosynthesis,KW-1207~Sterol metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0551~Lipid droplet,	KW-0225~Disease variant,KW-0977~Ichthyosis,KW-0991~Mental retardation,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0520~NAD,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:NAD,DOMAIN:3Beta_HSD,MOTIF:Prevents secretion from ER,TRANSMEM:Helical,
NCK1	NCK adaptor protein 1(NCK1)	Homo sapiens		h_actinYPathway:Y branching of actin filaments,		GO:0006930~substrate-dependent cell migration, cell extension,GO:0007015~actin filament organization,GO:0007165~signal transduction,GO:0007172~signal complex assembly,GO:0010976~positive regulation of neuron projection development,GO:0016477~cell migration,GO:0030032~lamellipodium assembly,GO:0030334~regulation of cell migration,GO:0030838~positive regulation of actin filament polymerization,GO:0033137~negative regulation of peptidyl-serine phosphorylation,GO:0036493~positive regulation of translation in response to endoplasmic reticulum stress,GO:0038096~Fc-gamma receptor signaling pathway involved in phagocytosis,GO:0042102~positive regulation of T cell proliferation,GO:0042110~T cell activation,GO:0043086~negative regulation of catalytic activity,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046627~negative regulation of insulin receptor signaling pathway,GO:0048010~vascular endothelial growth factor receptor signaling pathway,GO:0048013~ephrin receptor signaling pathway,GO:0050852~T cell receptor signaling pathway,GO:0051016~barbed-end actin filament capping,GO:0051017~actin filament bundle assembly,GO:0051707~response to other organism,GO:0060548~negative regulation of cell death,GO:0070262~peptidyl-serine dephosphorylation,GO:1902237~positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway,GO:1903676~positive regulation of cap-dependent translational initiation,GO:1903679~positive regulation of cap-independent translational initiation,GO:1903898~negative regulation of PERK-mediated unfolded protein response,GO:1903912~negative regulation of endoplasmic reticulum stress-induced eIF2 alpha phosphorylation,GO:1990441~negative regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress,	GO:0000164~protein phosphatase type 1 complex,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0012506~vesicle membrane,	GO:0003779~actin binding,GO:0004860~protein kinase inhibitor activity,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0008093~cytoskeletal adaptor activity,GO:0019904~protein domain specific binding,GO:0030159~receptor signaling complex scaffold activity,GO:0030674~protein binding, bridging,GO:0030971~receptor tyrosine kinase binding,GO:0035591~signaling adaptor activity,GO:0045296~cadherin binding,GO:0046875~ephrin receptor binding,GO:0071074~eukaryotic initiation factor eIF2 binding,	IPR000980:SH2 domain,IPR001452:Src homology-3 domain,IPR017304:Cytoplasmic, NCK,	hsa04012:ErbB signaling pathway,hsa04360:Axon guidance,hsa04660:T cell receptor signaling pathway,hsa05130:Pathogenic Escherichia coli infection,		PIRSF037874:adapter protein NCK,	SM00252:SH2,SM00326:SH3,	KW-0810~Translation regulation,	KW-0256~Endoplasmic reticulum,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0727~SH2 domain,KW-0728~SH3 domain,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:SH2,DOMAIN:SH3,DOMAIN:SH3 1,DOMAIN:SH3 2,DOMAIN:SH3 3,MUTAGEN:R->K: No effect on RASA1-binding.,MUTAGEN:W->K: No effect on RASA1-binding. Almost complete loss of RASA1-binding; when associated with K-38 and K-229.,MUTAGEN:W->K: Small decrease in RASA1-binding. Almost complete loss of RASA1-binding; when associated with K-143 and K-229.,MUTAGEN:W->K: Small decrease in RASA1-binding. Almost complete loss of RASA1-binding; when associated with K-38 and K-229.,
NCK2	NCK adaptor protein 2(NCK2)	Homo sapiens				GO:0001771~immunological synapse formation,GO:0007015~actin filament organization,GO:0007165~signal transduction,GO:0007172~signal complex assembly,GO:0007173~epidermal growth factor receptor signaling pathway,GO:0007176~regulation of epidermal growth factor-activated receptor activity,GO:0008285~negative regulation of cell proliferation,GO:0016477~cell migration,GO:0030032~lamellipodium assembly,GO:0030838~positive regulation of actin filament polymerization,GO:0033137~negative regulation of peptidyl-serine phosphorylation,GO:0036493~positive regulation of translation in response to endoplasmic reticulum stress,GO:0042102~positive regulation of T cell proliferation,GO:0042110~T cell activation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048010~vascular endothelial growth factor receptor signaling pathway,GO:0048013~ephrin receptor signaling pathway,GO:0051016~barbed-end actin filament capping,GO:0051017~actin filament bundle assembly,GO:0060996~dendritic spine development,GO:1902237~positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway,GO:1903898~negative regulation of PERK-mediated unfolded protein response,GO:1903912~negative regulation of endoplasmic reticulum stress-induced eIF2 alpha phosphorylation,GO:1990441~negative regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress,	GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0012506~vesicle membrane,GO:0014069~postsynaptic density,	GO:0001784~phosphotyrosine binding,GO:0003779~actin binding,GO:0005515~protein binding,GO:0008093~cytoskeletal adaptor activity,GO:0030159~receptor signaling complex scaffold activity,GO:0030971~receptor tyrosine kinase binding,GO:0035591~signaling adaptor activity,GO:0044877~macromolecular complex binding,GO:0097110~scaffold protein binding,	IPR000980:SH2 domain,IPR001452:Src homology-3 domain,IPR017304:Cytoplasmic, NCK,	hsa04012:ErbB signaling pathway,hsa04360:Axon guidance,hsa04660:T cell receptor signaling pathway,hsa05130:Pathogenic Escherichia coli infection,		PIRSF037874:adapter protein NCK,	SM00252:SH2,SM00326:SH3,	KW-0810~Translation regulation,	KW-0256~Endoplasmic reticulum,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0727~SH2 domain,KW-0728~SH3 domain,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:SH2,DOMAIN:SH3,DOMAIN:SH3 1,DOMAIN:SH3 2,DOMAIN:SH3 3,MUTAGEN:W->K: Abolishes interaction with DOCK1.,REGION:Disordered,
NFE2L2	NFE2 like bZIP transcription factor 2(NFE2L2)	Homo sapiens		h_arenrf2Pathway:Oxidative Stress Induced Gene Expression Via Nrf2,h_prionPathway:Prion Pathway,		GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006954~inflammatory response,GO:0007568~aging,GO:0010226~response to lithium ion,GO:0010499~proteasomal ubiquitin-independent protein catabolic process,GO:0010628~positive regulation of gene expression,GO:0010667~negative regulation of cardiac muscle cell apoptotic process,GO:0010976~positive regulation of neuron projection development,GO:0016032~viral process,GO:0016567~protein ubiquitination,GO:0030194~positive regulation of blood coagulation,GO:0030968~endoplasmic reticulum unfolded protein response,GO:0034599~cellular response to oxidative stress,GO:0035690~cellular response to drug,GO:0036003~positive regulation of transcription from RNA polymerase II promoter in response to stress,GO:0036091~positive regulation of transcription from RNA polymerase II promoter in response to oxidative stress,GO:0036499~PERK-mediated unfolded protein response,GO:0042149~cellular response to glucose starvation,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0043536~positive regulation of blood vessel endothelial cell migration,GO:0045088~regulation of innate immune response,GO:0045454~cell redox homeostasis,GO:0045766~positive regulation of angiogenesis,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0045995~regulation of embryonic development,GO:0046223~aflatoxin catabolic process,GO:0046326~positive regulation of glucose import,GO:0061419~positive regulation of transcription from RNA polymerase II promoter in response to hypoxia,GO:0070301~cellular response to hydrogen peroxide,GO:0071280~cellular response to copper ion,GO:0071356~cellular response to tumor necrosis factor,GO:0071466~cellular response to xenobiotic stimulus,GO:0071498~cellular response to fluid shear stress,GO:0071499~cellular response to laminar fluid shear stress,GO:1902037~negative regulation of hematopoietic stem cell differentiation,GO:1902176~negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway,GO:1903071~positive regulation of ER-associated ubiquitin-dependent protein catabolic process,GO:1903206~negative regulation of hydrogen peroxide-induced cell death,GO:1903788~positive regulation of glutathione biosynthetic process,GO:1904385~cellular response to angiotensin,GO:1904753~negative regulation of vascular associated smooth muscle cell migration,GO:2000121~regulation of removal of superoxide radicals,GO:2000352~negative regulation of endothelial cell apoptotic process,GO:2000379~positive regulation of reactive oxygen species metabolic process,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0032993~protein-DNA complex,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001102~RNA polymerase II activating transcription factor binding,GO:0001221~transcription cofactor binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0019904~protein domain specific binding,GO:0043565~sequence-specific DNA binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,	IPR004826:Basic leucine zipper domain, Maf-type,IPR004827:Basic-leucine zipper domain,IPR008917:Eukaryotic transcription factor, Skn-1-like, DNA-binding,	hsa04141:Protein processing in endoplasmic reticulum,hsa05012:Parkinson disease,hsa05200:Pathways in cancer,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05225:Hepatocellular carcinoma,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,	617744~Immunodeficiency, developmental delay, and hypohomocysteinemia,		SM00338:BRLZ,	KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0175~Coiled coil,		KW-0010~Activator,KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-0971~Glycation,	CARBOHYD:N-linked (Glc) (glycation) arginine,CARBOHYD:N-linked (Glc) (glycation) lysine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:BZIP,DOMAIN:bZIP,MOTIF:DLG motif,MOTIF:ETGE motif,MUTAGEN:E->G: Abolished interaction with KEAP1.,MUTAGEN:K->A: Loss of function; when associated with A-462; A-472; A-499; A-569 and A-587.,MUTAGEN:K->A: Loss of function; when associated with A-462; A-487; A-499; A-569 and A-587.,MUTAGEN:K->A: Loss of function; when associated with A-472; A-487; A-499; A-569 and A-587.,MUTAGEN:Missing: Abolished interaction with KEAP1.,MUTAGEN:R->A: Loss of function; when associated with A-462; A-472; A-487; A-499 and A-569.,MUTAGEN:R->A: Loss of function; when associated with A-462; A-472; A-487; A-499 and A-587.,MUTAGEN:R->A: Loss of function; when associated with A-462; A-472; A-487; A-569 and A-587.,MUTAGEN:T->A: Loss of interaction with KEAP1.,REGION:Basic motif,REGION:Disordered,REGION:Leucine-zipper,REGION:Mediates interaction with CHD6 and is necessary to activate transcription,
NFKBIA	NFKB inhibitor alpha(NFKBIA)	Homo sapiens	17.Activators-CAM,77.IkBa_Kinase_JNK_MEKK1,90.IB_and-cat-Arm_processing_of_Ci,	h_41BBPathway:The 4-1BB-dependent immune response,h_aktPathway:AKT Signaling Pathway,h_atmPathway:ATM Signaling Pathway,h_cd40Pathway:CD40L Signaling Pathway,h_cdmacPathway:Cadmium induces DNA synthesis and proliferation in macrophages,h_deathPathway:Induction of apoptosis through DR3 and DR4/5 Death Receptors ,h_eponfkbPathway:Erythropoietin mediated neuroprotection through NF-kB,h_fmlpPathway:fMLP induced chemokine gene expression in HMC-1 cells,h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_il1rPathway:Signal transduction through IL1R,h_keratinocytePathway:Keratinocyte Differentiation,h_mapkPathway:MAPKinase Signaling Pathway,h_nfkbPathway:NF-kB Signaling Pathway,h_nthiPathway:NFkB activation by Nontypeable Hemophilus influenzae,h_pkcPathway:Activation of PKC through G protein coupled receptor,h_PparaPathway:Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha),h_raccycdPathway:Influence of Ras and Rho proteins on G1 to S Transition,h_relaPathway:Acetylation and Deacetylation of RelA in The Nucleus,h_rnaPathway:Double Stranded RNA Induced Gene Expression,h_stressPathway:TNF/Stress Related Signaling,h_tcrPathway:T Cell Receptor Signaling Pathway,h_tidPathway:Chaperones modulate interferon Signaling Pathway,h_tnfr2Pathway:TNFR2 Signaling Pathway,h_tollPathway:Toll-Like Receptor Pathway,h_vipPathway:Neuropeptides VIP and PACAP inhibit the apoptosis of activated T cells,		GO:0006606~protein import into nucleus,GO:0006915~apoptotic process,GO:0007249~I-kappaB kinase/NF-kappaB signaling,GO:0007253~cytoplasmic sequestering of NF-kappaB,GO:0010745~negative regulation of macrophage derived foam cell differentiation,GO:0010875~positive regulation of cholesterol efflux,GO:0010888~negative regulation of lipid storage,GO:0016032~viral process,GO:0016579~protein deubiquitination,GO:0031663~lipopolysaccharide-mediated signaling pathway,GO:0032088~negative regulation of NF-kappaB transcription factor activity,GO:0032270~positive regulation of cellular protein metabolic process,GO:0032495~response to muramyl dipeptide,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0034142~toll-like receptor 4 signaling pathway,GO:0035994~response to muscle stretch,GO:0042127~regulation of cell proliferation,GO:0042994~cytoplasmic sequestering of transcription factor,GO:0043066~negative regulation of apoptotic process,GO:0043330~response to exogenous dsRNA,GO:0043392~negative regulation of DNA binding,GO:0045638~negative regulation of myeloid cell differentiation,GO:0045746~negative regulation of Notch signaling pathway,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050729~positive regulation of inflammatory response,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0070417~cellular response to cold,GO:0070427~nucleotide-binding oligomerization domain containing 1 signaling pathway,GO:0070431~nucleotide-binding oligomerization domain containing 2 signaling pathway,GO:0070498~interleukin-1-mediated signaling pathway,GO:1901222~regulation of NIK/NF-kappaB signaling,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0033256~I-kappaB/NF-kappaB complex,	GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0008139~nuclear localization sequence binding,GO:0019899~enzyme binding,GO:0031625~ubiquitin protein ligase binding,GO:0042802~identical protein binding,GO:0051059~NF-kappaB binding,	IPR002110:Ankyrin repeat,IPR020683:Ankyrin repeat-containing domain,	hsa04024:cAMP signaling pathway,hsa04062:Chemokine signaling pathway,hsa04064:NF-kappa B signaling pathway,hsa04210:Apoptosis,hsa04380:Osteoclast differentiation,hsa04620:Toll-like receptor signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04622:RIG-I-like receptor signaling pathway,hsa04623:Cytosolic DNA-sensing pathway,hsa04625:C-type lectin receptor signaling pathway,hsa04657:IL-17 signaling pathway,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04660:T cell receptor signaling pathway,hsa04662:B cell receptor signaling pathway,hsa04668:TNF signaling pathway,hsa04722:Neurotrophin signaling pathway,hsa04920:Adipocytokine signaling pathway,hsa04926:Relaxin signaling pathway,hsa04931:Insulin resistance,hsa04936:Alcoholic liver disease,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05134:Legionellosis,hsa05135:Yersinia infection,hsa05140:Leishmaniasis,hsa05142:Chagas disease,hsa05145:Toxoplasmosis,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05215:Prostate cancer,hsa05220:Chronic myeloid leukemia,hsa05222:Small cell lung cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05417:Lipid and atherosclerosis,	612132~Ectodermal dysplasia and immunodeficiency 2,		SM00248:ANK,	KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0038~Ectodermal dysplasia,KW-0225~Disease variant,	KW-0040~ANK repeat,KW-0677~Repeat,			KW-0379~Hydroxylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO or ubiquitin); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate,DOMAIN:Ankyrin_rpt-contain_dom,MOTIF:Destruction motif,MOTIF:Nuclear export signal,MOTIF:Nuclear import signal,MUTAGEN:D->A: Loss in phosphorylation; when associated with A-31.,MUTAGEN:D->A: Loss of phosphorylation; when associated with A-35.,MUTAGEN:D->G: No change neither in phosphorylation, nor on degradation.,MUTAGEN:K->R: Little change in Tax-stimulated transactivation. No change in Tax-stimulated transactivation; when associated with R-38.,MUTAGEN:K->R: Little change in Tax-stimulated transactivation. No sumoylation. Greatly reduced Tax- or cytokine-stimulated transactivation and decrease in ubiquitination and degradation; when associated with R-21.,MUTAGEN:K->R: Little change in Tax-stimulated transactivation. No sumoylation. Greatly reduced Tax- or cytokine-stimulated transactivation and decrease in ubiquitination and degradation; when associated with R-22.,MUTAGEN:K->R: No change in Tax-stimulated transactivation. No change in Tax-stimulated transactivation; when associated with R-47.,MUTAGEN:LHLAVI->AHAAVA: Greatly reduced nuclear localization. Great reduction in its ability to inhibit DNA binding of RELA.,MUTAGEN:MVKELQEI->AAKEAQEA: No nuclear export.,MUTAGEN:N->A: Almost abolished ability to inhibit NF-kappa-B DNA-binding activity; when associated with A-210.,MUTAGEN:N->A: Almost abolished ability to inhibit NF-kappa-B DNA-binding activity; when associated with A-244.,MUTAGEN:S->A: Loss of phosphorylation, ubiquitination and degradation; when associated with A-36.,MUTAGEN:S->A: Loss of phosphorylation, ubiquitination, and degradation; when associated with A-32.,MUTAGEN:S->A: No inducible ubiquitination nor protein degradation.,MUTAGEN:S->T: Decrease in phosphorylation and degradation; when associated with T-32.,MUTAGEN:S->T: Decrease in phosphorylation and degradation; when associated with T-36.,MUTAGEN:T->A: No inducible ubiquitination nor protein degradation.,MUTAGEN:Y->F: No phosphorylation.,REGION:Disordered,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,REPEAT:ANK 5,
NFKBIB	NFKB inhibitor beta(NFKBIB)	Homo sapiens		h_p53hypoxiaPathway:Hypoxia and p53 in the Cardiovascular system,		GO:0006351~transcription, DNA-templated,GO:0006954~inflammatory response,GO:0007165~signal transduction,GO:0007253~cytoplasmic sequestering of NF-kappaB,GO:0043122~regulation of I-kappaB kinase/NF-kappaB signaling,GO:0045893~positive regulation of transcription, DNA-templated,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0071222~cellular response to lipopolysaccharide,	GO:0005634~nucleus,GO:0005829~cytosol,	GO:0003713~transcription coactivator activity,GO:0005515~protein binding,	IPR002110:Ankyrin repeat,IPR020683:Ankyrin repeat-containing domain,	hsa04062:Chemokine signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04622:RIG-I-like receptor signaling pathway,hsa04623:Cytosolic DNA-sensing pathway,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04660:T cell receptor signaling pathway,hsa04662:B cell receptor signaling pathway,hsa04722:Neurotrophin signaling pathway,hsa04920:Adipocytokine signaling pathway,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05140:Leishmaniasis,hsa05145:Toxoplasmosis,hsa05162:Measles,hsa05164:Influenza A,hsa05169:Epstein-Barr virus infection,hsa05171:Coronavirus disease - COVID-19,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,			SM00248:ANK,		KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0040~ANK repeat,KW-0677~Repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:Ankyrin_rpt-contain_dom,MUTAGEN:S->A: No degradation; when associated with A-19.,MUTAGEN:S->A: No degradation; when associated with A-23.,REGION:Disordered,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,REPEAT:ANK 5,REPEAT:ANK 6,
NFKBIE	NFKB inhibitor epsilon(NFKBIE)	Homo sapiens				GO:0042942~D-serine transport,GO:0042994~cytoplasmic sequestering of transcription factor,	GO:0001650~fibrillar center,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0048471~perinuclear region of cytoplasm,	GO:0005515~protein binding,	IPR002110:Ankyrin repeat,IPR020683:Ankyrin repeat-containing domain,	hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04660:T cell receptor signaling pathway,hsa04662:B cell receptor signaling pathway,hsa04722:Neurotrophin signaling pathway,hsa04920:Adipocytokine signaling pathway,hsa05169:Epstein-Barr virus infection,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,			SM00248:ANK,		KW-0963~Cytoplasm,		KW-0040~ANK repeat,KW-0677~Repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Ankyrin_rpt-contain_dom,MUTAGEN:K->R: No effect.,MUTAGEN:S->A: No degradation.,REGION:Disordered,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,REPEAT:ANK 5,REPEAT:ANK 6,
NPC1	NPC intracellular cholesterol transporter 1(NPC1)	Homo sapiens				GO:0006486~protein glycosylation,GO:0006897~endocytosis,GO:0006914~autophagy,GO:0007041~lysosomal transport,GO:0007628~adult walking behavior,GO:0008203~cholesterol metabolic process,GO:0008206~bile acid metabolic process,GO:0009410~response to xenobiotic stimulus,GO:0010467~gene expression,GO:0016242~negative regulation of macroautophagy,GO:0030301~cholesterol transport,GO:0031579~membrane raft organization,GO:0032367~intracellular cholesterol transport,GO:0033344~cholesterol efflux,GO:0034383~low-density lipoprotein particle clearance,GO:0042493~response to drug,GO:0042632~cholesterol homeostasis,GO:0046686~response to cadmium ion,GO:0046718~viral entry into host cell,GO:0060548~negative regulation of cell death,GO:0071383~cellular response to steroid hormone stimulus,GO:0071404~cellular response to low-density lipoprotein particle stimulus,GO:0090150~establishment of protein localization to membrane,	GO:0005576~extracellular region,GO:0005635~nuclear envelope,GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005887~integral component of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0031902~late endosome membrane,GO:0045121~membrane raft,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:1905103~integral component of lysosomal membrane,	GO:0001618~virus receptor activity,GO:0004888~transmembrane signaling receptor activity,GO:0005319~lipid transporter activity,GO:0005515~protein binding,GO:0015248~sterol transporter activity,GO:0015485~cholesterol binding,GO:0038023~signaling receptor activity,	IPR000731:Sterol-sensing domain,IPR003392:Patched,IPR004765:Niemann-Pick C type protein,	hsa04142:Lysosome,hsa04979:Cholesterol metabolism,	257220~Niemann-Pick disease, type C1,257220~Niemann-Pick disease, type D,			KW-0153~Cholesterol metabolism,KW-0443~Lipid metabolism,KW-0445~Lipid transport,KW-0753~Steroid metabolism,KW-0813~Transport,KW-0945~Host-virus interaction,KW-1207~Sterol metabolism,	KW-0458~Lysosome,KW-0472~Membrane,KW-0967~Endosome,	KW-0225~Disease variant,KW-1054~Niemann-Pick disease,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,KW-1183~Host cell receptor for virus entry,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	BINDING:Cholesterol,CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine; atypical,DOMAIN:SSD,MOTIF:Di-leucine motif,MUTAGEN:C->S: Loss of function.,MUTAGEN:CC->SS: Loss of function.,MUTAGEN:CGGMGCNND->A: Abolishes cholesterol transport. No effect on subcellular location.,MUTAGEN:DAD->AAA: Strongly reduces cholesterol transfer to liposomes in a NPC2-dependent manner.,MUTAGEN:DN->AA: Strongly reduces cholesterol and 25-hydroxycholesterol binding.,MUTAGEN:ELT->AAA: No effect on cholesterol and 25-hydroxycholesterol binding and transfer.,MUTAGEN:EY->AA: No effect on cholesterol or 25-hydroxycholesterol binding. Nearly abolishes cholesterol transfer to liposomes in a NPC2-dependent manner.,MUTAGEN:F->A,G: Loss of interaction with ebolavirus glycoprotein.,MUTAGEN:FY->AA: Strongly reduces 25-hydroxycholesterol binding. No effect on cholesterol binding.,MUTAGEN:G->R: Loss of function.,MUTAGEN:GQ->AA: Strongly reduces 25-hydroxycholesterol binding and cholesterol transfer to liposomes in a NPC2-dependent manner.,MUTAGEN:LL->AA: No effect on cholesterol or 25-hydroxycholesterol binding. Decreases affinity for NPC2. Strongly reduces cholesterol transfer to liposomes in a NPC2-dependent manner.,MUTAGEN:LQ->AA: Strongly reduces 25-hydroxycholesterol binding. No effect on cholesterol binding.,MUTAGEN:Missing: Decreased cholesterol transport.,MUTAGEN:Missing: Decreases affinity for NPC2. Abolishes cholesterol transfer from NPC2 to NPC1.,MUTAGEN:Missing: Loss of location in lysosomes.,MUTAGEN:N->A: Nearly abolishes cholesterol and 25-hydroxycholesterol binding.,MUTAGEN:N->Q: Reduces glycosylation; when associated with Q-122 and Q-185. No effect on cholesterol and 25-hydroxycholesterol binding.,MUTAGEN:N->Q: Reduces glycosylation; when associated with Q-70 and Q-122. No effect on cholesterol and 25-hydroxycholesterol binding. Strongly reduces cholesterol transfer to liposomes in a NPC2-dependent manner.,MUTAGEN:N->Q: Reduces glycosylation; when associated with Q-70 and Q-185. No effect on cholesterol and 25-hydroxycholesterol binding.,MUTAGEN:NK->AA: Strongly reduces 25-hydroxycholesterol binding. No effect on cholesterol binding.,MUTAGEN:NLF->AAA: Nearly abolishes cholesterol and 25-hydroxycholesterol binding.,MUTAGEN:P->S: Abolishes cholesterol transport. No effect on subcellular location.,MUTAGEN:PF->AA: Abolishes cholesterol and 25-hydroxycholesterol binding. Abolishes cholesterol transfer from NPC2 to NPC1.,MUTAGEN:Q->A: Decreased affinity for NPC2 and decreased cholesterol transfer from NPC2 to NPC1; when associated with A-88 and A-96.,MUTAGEN:Q->A: Decreased affinity for NPC2 and decreased cholesterol transfer from NPC2 to NPC1; when associated with A-92 and A-96.,MUTAGEN:R->A: Decreased affinity for NPC2 and decreased cholesterol transfer from NPC2 to NPC1; when associated with A-88 and A-92.,MUTAGEN:RYN->AAA: Strongly reduces cholesterol and 25-hydroxycholesterol binding.,MUTAGEN:TI->AA: Strongly reduces cholesterol and 25-hydroxycholesterol binding.,MUTAGEN:TL->AA: Strongly reduces cholesterol and 25-hydroxycholesterol binding.,MUTAGEN:TN->AA: Strongly reduces 25-hydroxycholesterol binding and cholesterol transfer to liposomes in a NPC2-dependent manner.,MUTAGEN:VW->AA: Nearly abolishes 25-hydroxycholesterol binding. Reduces cholesterol binding.,MUTAGEN:Y->A: Loss of interaction with ebolavirus glycoprotein.,MUTAGEN:YP->GG: Strongly reduces interaction with ebolavirus glycoprotein.,MUTAGEN:YY->AA: Strongly reduces 25-hydroxycholesterol binding. No effect on cholesterol binding.,REGION:Important for cholesterol binding and cholesterol transfer from NPC1 to liposomes,REGION:Required for location in lysosomes,SITE:Important for cholesterol binding,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
NRAS	NRAS proto-oncogene, GTPase(NRAS)	Homo sapiens	65.Integrin_affinity_modulation,			GO:0000165~MAPK cascade,GO:0001938~positive regulation of endothelial cell proliferation,GO:0002223~stimulatory C-type lectin receptor signaling pathway,GO:0007165~signal transduction,GO:0007265~Ras protein signal transduction,GO:0043312~neutrophil degranulation,	GO:0000139~Golgi membrane,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0070062~extracellular exosome,GO:0070821~tertiary granule membrane,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019003~GDP binding,GO:0044877~macromolecular complex binding,	IPR001806:Small GTPase superfamily,IPR005225:Small GTP-binding protein domain,IPR020849:Small GTPase superfamily, Ras type,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa01522:Endocrine resistance,hsa04010:MAPK signaling pathway,hsa04012:ErbB signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04062:Chemokine signaling pathway,hsa04068:FoxO signaling pathway,hsa04071:Sphingolipid signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04137:Mitophagy - animal,hsa04140:Autophagy - animal,hsa04150:mTOR signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04210:Apoptosis,hsa04211:Longevity regulating pathway,hsa04213:Longevity regulating pathway - multiple species,hsa04218:Cellular senescence,hsa04360:Axon guidance,hsa04370:VEGF signaling pathway,hsa04371:Apelin signaling pathway,hsa04540:Gap junction,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04625:C-type lectin receptor signaling pathway,hsa04650:Natural killer cell mediated cytotoxicity,hsa04660:T cell receptor signaling pathway,hsa04662:B cell receptor signaling pathway,hsa04664:Fc epsilon RI signaling pathway,hsa04714:Thermogenesis,hsa04720:Long-term potentiation,hsa04722:Neurotrophin signaling pathway,hsa04725:Cholinergic synapse,hsa04726:Serotonergic synapse,hsa04730:Long-term depression,hsa04810:Regulation of actin cytoskeleton,hsa04910:Insulin signaling pathway,hsa04912:GnRH signaling pathway,hsa04915:Estrogen signaling pathway,hsa04916:Melanogenesis,hsa04917:Prolactin signaling pathway,hsa04919:Thyroid hormone signaling pathway,hsa04921:Oxytocin signaling pathway,hsa04926:Relaxin signaling pathway,hsa04929:GnRH secretion,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04935:Growth hormone synthesis, secretion and action,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05034:Alcoholism,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05210:Colorectal cancer,hsa05211:Renal cell carcinoma,hsa05213:Endometrial cancer,hsa05214:Glioma,hsa05215:Prostate cancer,hsa05216:Thyroid cancer,hsa05218:Melanoma,hsa05219:Bladder cancer,hsa05220:Chronic myeloid leukemia,hsa05221:Acute myeloid leukemia,hsa05223:Non-small cell lung cancer,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,hsa05230:Central carbon metabolism in cancer,hsa05231:Choline metabolism in cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05417:Lipid and atherosclerosis,	114500~Colorectal cancer, somatic,137550~Melanocytic nevus syndrome, congenital, somatic,162900~Epidermal nevus, somatic,163200~Schimmelpenning-Feuerstein-Mims syndrome, somatic mosaic,188470~Thyroid carcinoma, follicular, somatic,249400~Neurocutaneous melanosis, somatic,613224~Noonan syndrome 6,614470~RAS-associated autoimmune lymphoproliferative syndrome type IV, somatic,				KW-0333~Golgi apparatus,KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0656~Proto-oncogene,		KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0636~Prenylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CARBOHYD:(Microbial infection) O-linked (Glc) threonine; by P.sordellii toxin TcsL,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),LIPID:S-farnesyl cysteine,LIPID:S-palmitoyl cysteine,MOTIF:Effector region,MUTAGEN:C->S: Loss of plasma membrane localization.,MUTAGEN:R->A: Loss of GTP-binding activity.,MUTAGEN:S->A: Abolished phosphorylation by STK19.,NP_BIND:GTP,PROPEP:Removed in mature form,REGION:Hypervariable region,
NUDCD3	NudC domain containing 3(NUDCD3)	Homo sapiens				GO:0006457~protein folding,GO:0060271~cilium assembly,GO:1905793~protein localization to pericentriolar material,	GO:0005737~cytoplasm,GO:0005868~cytoplasmic dynein complex,	GO:0005515~protein binding,GO:0051082~unfolded protein binding,	IPR007052:CS-like domain,IPR008978:HSP20-like chaperone,IPR025934:NudC N-terminal domain,											KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:CS,REGION:Disordered,
OXA1L	OXA1L mitochondrial inner membrane protein(OXA1L)	Homo sapiens				GO:0009060~aerobic respiration,GO:0032780~negative regulation of ATPase activity,GO:0032979~protein insertion into mitochondrial membrane from inner side,GO:0032981~mitochondrial respiratory chain complex I assembly,GO:0033615~mitochondrial proton-transporting ATP synthase complex assembly,GO:0033617~mitochondrial respiratory chain complex IV assembly,GO:0051205~protein insertion into membrane,GO:0051262~protein tetramerization,GO:0051354~negative regulation of oxidoreductase activity,GO:0070125~mitochondrial translational elongation,GO:0070126~mitochondrial translational termination,	GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0016021~integral component of membrane,GO:0031305~integral component of mitochondrial inner membrane,GO:0031966~mitochondrial membrane,GO:0032592~integral component of mitochondrial membrane,GO:0032991~macromolecular complex,	GO:0005515~protein binding,GO:0032977~membrane insertase activity,GO:0042803~protein homodimerization activity,GO:0097177~mitochondrial ribosome binding,	IPR001708:Membrane insertase OXA1/ALB3/YidC,	hsa03060:Protein export,					KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,		KW-0175~Coiled coil,KW-0809~Transit peptide,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,MUTAGEN:A->C: Increases strongly homooligomer formation in presence of magnesium, but weakly in absence of magnesium.,MUTAGEN:A->C: Increases weakly homooligomer formation in presence or absence of magnesium.,MUTAGEN:S->C: Increases weakly homooligomer formation in presence of magnesium, but strongly in absence of magnesium.,MUTAGEN:T->C: Increases homooligomer formation in presence or absence of magnesium.,REGION:Disordered,TOPO_DOM:Mitochondrial intermembrane,TOPO_DOM:Mitochondrial matrix,TRANSIT:Mitochondrion,TRANSMEM:Helical,
PAF1	PAF1 homolog, Paf1/RNA polymerase II complex component(PAF1)	Homo sapiens				GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001711~endodermal cell fate commitment,GO:0006366~transcription from RNA polymerase II promoter,GO:0006368~transcription elongation from RNA polymerase II promoter,GO:0006378~mRNA polyadenylation,GO:0010390~histone monoubiquitination,GO:0016055~Wnt signaling pathway,GO:0016567~protein ubiquitination,GO:0016570~histone modification,GO:0016584~nucleosome positioning,GO:0019827~stem cell population maintenance,GO:0031062~positive regulation of histone methylation,GO:0031442~positive regulation of mRNA 3'-end processing,GO:0033523~histone H2B ubiquitination,GO:0034504~protein localization to nucleus,GO:0045638~negative regulation of myeloid cell differentiation,GO:0071222~cellular response to lipopolysaccharide,GO:1902808~positive regulation of cell cycle G1/S phase transition,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016020~membrane,GO:0016593~Cdc73/Paf1 complex,GO:0030054~cell junction,GO:0035327~transcriptionally active chromatin,	GO:0000993~RNA polymerase II core binding,GO:0003682~chromatin binding,GO:0005515~protein binding,	IPR007133:RNA polymerase II-associated, Paf1,					KW-0804~Transcription,KW-0805~Transcription regulation,KW-0879~Wnt signaling pathway,	KW-0539~Nucleus,	KW-0043~Tumor suppressor,	KW-0175~Coiled coil,			KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,
PSIP1	PC4 and SFRS1 interacting protein 1(PSIP1)	Homo sapiens				GO:0000395~mRNA 5'-splice site recognition,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006979~response to oxidative stress,GO:0009408~response to heat,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051169~nuclear transport,GO:0075713~establishment of integrated proviral latency,	GO:0000792~heterochromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0034399~nuclear periphery,GO:0035327~transcriptionally active chromatin,	GO:0003682~chromatin binding,GO:0003690~double-stranded DNA binding,GO:0003712~transcription cofactor activity,GO:0003713~transcription coactivator activity,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0033613~activating transcription factor binding,GO:0097100~supercoiled DNA binding,	IPR000313:PWWP,IPR021567:Lens epithelium-derived growth factor (LEDGF),				SM00293:PWWP,	KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,		KW-0175~Coiled coil,		KW-0238~DNA-binding,	KW-0164~Citrullination,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:PWWP,MOTIF:Nuclear localization signal,MUTAGEN:D->A: Loss of interaction with human HIV-1 integrase; no effect on interaction with CDCA7L and POGZ.,MUTAGEN:D->N: Loss of interaction with human HIV-1 integrase; no effect on interaction with KMT2A.,MUTAGEN:F->A: Loss of interaction with human HIV-1 integrase and POGZ; reduced interaction with CDCA7L.,MUTAGEN:I->A: Loss of interaction with human HIV-1 integrase; reduced interaction with POGZ and CDCA7L.,MUTAGEN:K->A: Reduced interaction with POGZ, CDCA7L and human HIV-1 integrase.,MUTAGEN:K->D: Reduced interaction with KMT2A. Significant loss of interaction with KMT2A; when associated with A-368.,MUTAGEN:L->A: Reduced interaction with KMT2A. Significant loss of interaction with KMT2A; when associated with D-407.,MUTAGEN:R->D: Significant loss of interaction with KMT2A; when associated with D-404.,MUTAGEN:R->D: Significant loss of interaction with KMT2A; when associated with D-405.,MUTAGEN:V->A: Reduced interaction with POGZ, CDCA7L and human HIV-1 integrase.,MUTAGEN:V->A: Reduced interaction with human HIV-1 integrase; no effect on interaction with POGZ and CDCA7L.,REGION:Disordered,REGION:Integrase-binding domain (IBD),
PDS5A	PDS5 cohesin associated factor A(PDS5A)	Homo sapiens				GO:0006281~DNA repair,GO:0007064~mitotic sister chromatid cohesion,GO:0008156~negative regulation of DNA replication,GO:0051301~cell division,	GO:0000775~chromosome, centromeric region,GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005829~cytosol,GO:0005886~plasma membrane,	GO:0005515~protein binding,	IPR011989:Armadillo-like helical,IPR016024:Armadillo-type fold,					KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0539~Nucleus,		KW-0677~Repeat,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,REPEAT:HEAT,
PDLIM1	PDZ and LIM domain 1(PDLIM1)	Homo sapiens				GO:0001666~response to hypoxia,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006979~response to oxidative stress,GO:0007507~heart development,GO:0010761~fibroblast migration,GO:0030011~maintenance of cell polarity,GO:0030036~actin cytoskeleton organization,GO:0030950~establishment or maintenance of actin cytoskeleton polarity,GO:0043149~stress fiber assembly,GO:0045893~positive regulation of transcription, DNA-templated,GO:0061061~muscle structure development,GO:0098609~cell-cell adhesion,	GO:0001725~stress fiber,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,GO:0005856~cytoskeleton,GO:0005912~adherens junction,GO:0005925~focal adhesion,GO:0030018~Z disc,GO:0031941~filamentous actin,	GO:0003713~transcription coactivator activity,GO:0003779~actin binding,GO:0005515~protein binding,GO:0046872~metal ion binding,GO:0051371~muscle alpha-actinin binding,GO:0098641~cadherin binding involved in cell-cell adhesion,	IPR001478:PDZ domain,IPR001781:Zinc finger, LIM-type,IPR006643:ZASP,				SM00132:LIM,SM00228:PDZ,SM00735:ZM,		KW-0206~Cytoskeleton,KW-0963~Cytoplasm,		KW-0440~LIM domain,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:LIM zinc-binding,DOMAIN:PDZ,METAL:Zinc 1,METAL:Zinc 2,
PIH1D1	PIH1 domain containing 1(PIH1D1)	Homo sapiens				GO:0000492~box C/D snoRNP assembly,GO:0001188~RNA polymerase I transcriptional preinitiation complex assembly,GO:0006338~chromatin remodeling,GO:0006364~rRNA processing,GO:0030855~epithelial cell differentiation,GO:0031334~positive regulation of protein complex assembly,GO:0048254~snoRNA localization,GO:0051569~regulation of histone H3-K4 methylation,GO:0071169~establishment of protein localization to chromatin,GO:0071902~positive regulation of protein serine/threonine kinase activity,GO:0090240~positive regulation of histone H4 acetylation,GO:1900110~negative regulation of histone H3-K9 dimethylation,GO:1900113~negative regulation of histone H3-K9 trimethylation,GO:1901838~positive regulation of transcription of nuclear large rRNA transcript from RNA polymerase I promoter,GO:1902661~positive regulation of glucose mediated signaling pathway,GO:1904263~positive regulation of TORC1 signaling,GO:2000617~positive regulation of histone H3-K9 acetylation,GO:2000619~negative regulation of histone H4-K16 acetylation,GO:2001268~negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway,	GO:0005634~nucleus,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0070761~pre-snoRNP complex,GO:0097255~R2TP complex,GO:1990062~RPAP3/R2TP/prefoldin-like complex,GO:1990904~ribonucleoprotein complex,	GO:0001164~RNA polymerase I CORE element sequence-specific DNA binding,GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0042393~histone binding,GO:0051117~ATPase binding,GO:0051219~phosphoprotein binding,	IPR012981:PIH,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:PIH1,DOMAIN:PIH1_CS,MUTAGEN:C->A: No effect on binding to histone H4.,MUTAGEN:F->A: Abolishes binding to histone H4.,MUTAGEN:K->A: Abolishes binding to ECD, EFTUD2, RPB1, TELO2 and UBR5.,MUTAGEN:K->A: Abolishes binding to TELO2.,MUTAGEN:K->A: Reduces binding to TELO2.,MUTAGEN:R->A: Abolishes binding to TELO2.,MUTAGEN:R->A: Reduces binding to TELO2.,REGION:Disordered,SITE:Interacts with TELO2,
POP4	POP4 homolog, ribonuclease P/MRP subunit(POP4)	Homo sapiens				GO:0001682~tRNA 5'-leader removal,GO:0006364~rRNA processing,GO:0008033~tRNA processing,GO:0090502~RNA phosphodiester bond hydrolysis, endonucleolytic,	GO:0000172~ribonuclease MRP complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0030677~ribonuclease P complex,GO:0030681~multimeric ribonuclease P complex,	GO:0003723~RNA binding,GO:0004526~ribonuclease P activity,GO:0005515~protein binding,GO:0033204~ribonuclease P RNA binding,	IPR002730:Ribonuclease P/MRP, subunit p29,IPR016848:Ribonuclease P/MRP, p29 subunit,IPR023534:Rof/RNase P-like,	hsa03008:Ribosome biogenesis in eukaryotes,		PIRSF027081:RNase P/MRP, p29 subunit,	SM00538:POP4,	KW-0819~tRNA processing,	KW-0539~Nucleus,				KW-0378~Hydrolase,KW-0694~RNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,REGION:Disordered,
PRAF2	PRA1 domain family member 2(PRAF2)	Homo sapiens				GO:0015031~protein transport,GO:0015813~L-glutamate transport,	GO:0010008~endosome membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,	IPR004895:Prenylated rab acceptor PRA1,					KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,KW-0967~Endosome,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				COMPBIAS:Polar residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
PWP1	PWP1 homolog, endonuclein(PWP1)	Homo sapiens				GO:0006351~transcription, DNA-templated,GO:0006364~rRNA processing,GO:0033140~negative regulation of peptidyl-serine phosphorylation of STAT protein,GO:0034773~histone H4-K20 trimethylation,GO:1901838~positive regulation of transcription of nuclear large rRNA transcript from RNA polymerase I promoter,GO:2000738~positive regulation of stem cell differentiation,	GO:0005634~nucleus,GO:0005694~chromosome,GO:0005730~nucleolus,GO:0005794~Golgi apparatus,	GO:1990889~H4K20me3 modified histone binding,	IPR001680:WD40 repeat,IPR015943:WD40/YVTN repeat-like-containing domain,IPR017986:WD40-repeat-containing domain,IPR019775:WD40 repeat, conserved site,IPR020472:G-protein beta WD-40 repeat,				SM00320:WD40,	KW-0690~Ribosome biogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0158~Chromosome,KW-0539~Nucleus,		KW-0677~Repeat,KW-0853~WD repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,REGION:Disordered,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
RAB11FIP2	RAB11 family interacting protein 2(RAB11FIP2)	Homo sapiens				GO:0003091~renal water homeostasis,GO:0006909~phagocytosis,GO:0030010~establishment of cell polarity,GO:0035669~TRAM-dependent toll-like receptor 4 signaling pathway,GO:0035773~insulin secretion involved in cellular response to glucose stimulus,GO:0043547~positive regulation of GTPase activity,GO:0045055~regulated exocytosis,GO:1903078~positive regulation of protein localization to plasma membrane,	GO:0001891~phagocytic cup,GO:0005654~nucleoplasm,GO:0005768~endosome,GO:0030659~cytoplasmic vesicle membrane,GO:0042995~cell projection,GO:0043231~intracellular membrane-bounded organelle,GO:0055038~recycling endosome membrane,	GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0031267~small GTPase binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,	IPR000008:C2 calcium-dependent membrane targeting,IPR019018:Rab-binding domain FIP-RBD,	hsa04144:Endocytosis,			SM00239:C2,	KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,KW-0966~Cell projection,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0677~Repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:C2,DOMAIN:FIP-RBD,MOTIF:NPF 1,MOTIF:NPF 2,MOTIF:NPF 3,MUTAGEN:I->E: Abolishes the interaction with RAB11A and the vesicular localization.,MUTAGEN:NPF->AAA: Severe reduction of the interaction with REPS1 and AP2A1. No effects on its subcellular location. Modifies the endocytosis activity.,MUTAGEN:S->A: Abolishes phosphorylation by MARK2 and induces defects in the reestablishment of junctional complexes.,MUTAGEN:S->A: No effect.,MUTAGEN:Y->F: No effect on the interaction with RAB11A. Abolishes the vesicular localization.,MUTAGEN:YID->AAA: Abolishes the interaction with REPS1 and AP2A1. Modifies its subcellular location and the endocytosis activity. Enhances homooligomerization.,REGION:Disordered,REGION:Necessary for interaction with AP2A1, RAB11A, subcellular location, endocytosis activity and homooligomerization,REGION:Necessary for its cellular translocation to the plasma membrane,
RAB21	RAB21, member RAS oncogene family(RAB21)	Homo sapiens				GO:0006886~intracellular protein transport,GO:0008089~anterograde axonal transport,GO:0015031~protein transport,GO:0017157~regulation of exocytosis,GO:0030516~regulation of axon extension,GO:0032482~Rab protein signal transduction,GO:0048260~positive regulation of receptor-mediated endocytosis,GO:0050775~positive regulation of dendrite morphogenesis,GO:0050821~protein stabilization,GO:2000643~positive regulation of early endosome to late endosome transport,	GO:0000139~Golgi membrane,GO:0005768~endosome,GO:0005769~early endosome,GO:0005789~endoplasmic reticulum membrane,GO:0005802~trans-Golgi network,GO:0005829~cytosol,GO:0005925~focal adhesion,GO:0009898~cytoplasmic side of plasma membrane,GO:0012505~endomembrane system,GO:0012506~vesicle membrane,GO:0030659~cytoplasmic vesicle membrane,GO:0031901~early endosome membrane,GO:0032154~cleavage furrow,GO:0032580~Golgi cisterna membrane,GO:0045202~synapse,GO:0070062~extracellular exosome,GO:0098559~cytoplasmic side of early endosome membrane,GO:1904115~axon cytoplasm,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019003~GDP binding,	IPR001806:Small GTPase superfamily,IPR005225:Small GTP-binding protein domain,IPR020849:Small GTPase superfamily, Ras type,IPR027417:P-loop containing nucleoside triphosphate hydrolase,					KW-0653~Protein transport,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0966~Cell projection,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,		KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0636~Prenylation,	COMPBIAS:Polar residues,LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,MUTAGEN:Q->L: Defects in GTP hydrolysis. Does not affect the interaction with VAMP8 in response to starvation. Does not affect the interaction with TMED10.,MUTAGEN:T->N: Defects in GTP-binding. Abolishes the interaction with VAMP8 in response to starvation. Abolishes the interaction with TMED10.,NP_BIND:GTP,PROPEP:Removed in mature form,REGION:Disordered,
RAB27A	RAB27A, member RAS oncogene family(RAB27A)	Homo sapiens		h_rabPathway:Rab GTPases Mark Targets In The Endocytotic Machinery,		GO:0006605~protein targeting,GO:0006887~exocytosis,GO:0007596~blood coagulation,GO:0009306~protein secretion,GO:0010628~positive regulation of gene expression,GO:0019882~antigen processing and presentation,GO:0030318~melanocyte differentiation,GO:0032400~melanosome localization,GO:0032402~melanosome transport,GO:0036257~multivesicular body organization,GO:0043312~neutrophil degranulation,GO:0043316~cytotoxic T cell degranulation,GO:0043320~natural killer cell degranulation,GO:0045921~positive regulation of exocytosis,GO:0048489~synaptic vesicle transport,GO:0050766~positive regulation of phagocytosis,GO:0071985~multivesicular body sorting pathway,GO:0097278~complement-dependent cytotoxicity,GO:1903307~positive regulation of regulated secretory pathway,GO:1903428~positive regulation of reactive oxygen species biosynthetic process,GO:1903435~positive regulation of constitutive secretory pathway,GO:1990182~exosomal secretion,	GO:0001750~photoreceptor outer segment,GO:0005576~extracellular region,GO:0005764~lysosome,GO:0005770~late endosome,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0016020~membrane,GO:0016324~apical plasma membrane,GO:0030141~secretory granule,GO:0030425~dendrite,GO:0030667~secretory granule membrane,GO:0032585~multivesicular body membrane,GO:0033093~Weibel-Palade body,GO:0033162~melanosome membrane,GO:0035580~specific granule lumen,GO:0042470~melanosome,GO:0070062~extracellular exosome,GO:0070382~exocytic vesicle,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019003~GDP binding,GO:0019904~protein domain specific binding,GO:0031489~myosin V binding,	IPR001806:Small GTPase superfamily,IPR005225:Small GTP-binding protein domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,		607624~Griscelli syndrome, type 2,			KW-0268~Exocytosis,	KW-0458~Lysosome,KW-0472~Membrane,KW-0967~Endosome,	KW-0225~Disease variant,	KW-0175~Coiled coil,	KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0636~Prenylation,KW-1015~Disulfide bond,	LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,MUTAGEN:A->V: Abolishes interaction with SYTL2.,MUTAGEN:L->P: Abolishes interaction with SYTL2.,MUTAGEN:Q->L: GTP-locked. decreases interaction with DENND10.,MUTAGEN:T->N: GDP-locked. Abolishes interaction with UNC13D and localization to lysosomes. Increases interaction with DENND10. Disrupts late endocytic pathway homeostasis.,NP_BIND:GTP,
RAB31	RAB31, member RAS oncogene family(RAB31)	Homo sapiens				GO:0006886~intracellular protein transport,GO:0031623~receptor internalization,GO:0032869~cellular response to insulin stimulus,GO:0043001~Golgi to plasma membrane protein transport,GO:0043312~neutrophil degranulation,GO:0045055~regulated exocytosis,GO:0060100~positive regulation of phagocytosis, engulfment,GO:0090382~phagosome maturation,	GO:0001891~phagocytic cup,GO:0005769~early endosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0012505~endomembrane system,GO:0030667~secretory granule membrane,GO:0031901~early endosome membrane,GO:0032588~trans-Golgi network membrane,GO:0036186~early phagosome membrane,GO:0045335~phagocytic vesicle,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019003~GDP binding,	IPR001806:Small GTPase superfamily,IPR005225:Small GTP-binding protein domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04144:Endocytosis,					KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,		KW-0449~Lipoprotein,KW-0597~Phosphoprotein,KW-0636~Prenylation,	LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,MUTAGEN:Q->L: No change in GTPase activity.,NP_BIND:GTP,
RAB4A	RAB4A, member RAS oncogene family(RAB4A)	Homo sapiens		h_rabPathway:Rab GTPases Mark Targets In The Endocytotic Machinery,		GO:0006661~phosphatidylinositol biosynthetic process,GO:0015031~protein transport,GO:0019882~antigen processing and presentation,GO:0030100~regulation of endocytosis,GO:0032482~Rab protein signal transduction,	GO:0005768~endosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0030659~cytoplasmic vesicle membrane,GO:0031901~early endosome membrane,GO:0031982~vesicle,GO:0032593~insulin-responsive compartment,GO:0043231~intracellular membrane-bounded organelle,GO:0048471~perinuclear region of cytoplasm,GO:0055038~recycling endosome membrane,GO:0070062~extracellular exosome,GO:0098837~postsynaptic recycling endosome,GO:0098993~anchored component of synaptic vesicle membrane,	GO:0001671~ATPase activator activity,GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019003~GDP binding,GO:0019905~syntaxin binding,GO:0035255~ionotropic glutamate receptor binding,GO:0051117~ATPase binding,	IPR001806:Small GTPase superfamily,IPR005225:Small GTP-binding protein domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04144:Endocytosis,				KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-0967~Endosome,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0449~Lipoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0636~Prenylation,	LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,MUTAGEN:G->A: 10-fold decrease in ZFYVE20 binding affinity.,MUTAGEN:G->L: 10-fold decrease in ZFYVE20 binding affinity.,NP_BIND:GTP,
RAD51C	RAD51 paralog C(RAD51C)	Homo sapiens				GO:0000707~meiotic DNA recombinase assembly,GO:0000722~telomere maintenance via recombination,GO:0000724~double-strand break repair via homologous recombination,GO:0006281~DNA repair,GO:0006310~DNA recombination,GO:0007062~sister chromatid cohesion,GO:0007066~female meiosis sister chromatid cohesion,GO:0007131~reciprocal meiotic recombination,GO:0007141~male meiosis I,GO:0007283~spermatogenesis,GO:0007596~blood coagulation,GO:0010971~positive regulation of G2/M transition of mitotic cell cycle,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005657~replication fork,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0030054~cell junction,GO:0033063~Rad51B-Rad51C-Rad51D-XRCC2 complex,GO:0033065~Rad51C-XRCC3 complex,GO:0043231~intracellular membrane-bounded organelle,GO:0048471~perinuclear region of cytoplasm,	GO:0000400~four-way junction DNA binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008094~DNA-dependent ATPase activity,GO:0008821~crossover junction endodeoxyribonuclease activity,	IPR010995:DNA repair Rad51/transcription factor NusA, alpha-helical,IPR013632:DNA recombination and repair protein Rad51, C-terminal,IPR016467:DNA recombination and repair protein, RecA-like,IPR020588:DNA recombination/repair protein RecA/RadB, ATP-binding domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa03440:Homologous recombination,hsa03460:Fanconi anemia pathway,	613390~Fanconi anemia, complementation group O,613399~Breast-ovarian cancer, familial, susceptibility to, 3,	PIRSF005856:DNA repair and recombination protein, Rad51 type,		KW-0227~DNA damage,KW-0233~DNA recombination,KW-0234~DNA repair,	KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0923~Fanconi anemia,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	DOMAIN:RECA_2,MOTIF:Nuclear localization signal,MUTAGEN:K->A: Significant loss of function; abolishes Holliday junction resolution activity.,MUTAGEN:K->R: Partial loss of function.,NP_BIND:ATP,REGION:Interaction with RAD51B, RAD51D and XRCC3,REGION:Required for Holliday junction resolution activity,
RAD9A	RAD9 checkpoint clamp component A(RAD9A)	Homo sapiens		h_atrbrcaPathway:Role of BRCA1,  BRCA2 and ATR in Cancer Susceptibility,		GO:0000076~DNA replication checkpoint,GO:0000077~DNA damage checkpoint,GO:0006260~DNA replication,GO:0006281~DNA repair,GO:0006974~cellular response to DNA damage stimulus,GO:0031573~intra-S DNA damage checkpoint,GO:0071479~cellular response to ionizing radiation,GO:0090305~nucleic acid phosphodiester bond hydrolysis,GO:1901796~regulation of signal transduction by p53 class mediator,GO:1902231~positive regulation of intrinsic apoptotic signaling pathway in response to DNA damage,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0030896~checkpoint clamp complex,	GO:0005515~protein binding,GO:0008408~3'-5' exonuclease activity,GO:0008853~exodeoxyribonuclease III activity,GO:0017124~SH3 domain binding,GO:0019899~enzyme binding,GO:0019901~protein kinase binding,GO:0042826~histone deacetylase binding,	IPR007268:Rad9/Ddc1,IPR026584:Rad9,	hsa04218:Cellular senescence,		PIRSF009303:cell cycle checkpoint protein, RAD9 type,		KW-0227~DNA damage,	KW-0539~Nucleus,				KW-0269~Exonuclease,KW-0378~Hydrolase,KW-0540~Nuclease,	KW-0597~Phosphoprotein,	MUTAGEN:S->A: Complete loss of phosphorylation and no loss of interaction with the 9-1-1 complex; when associated with A-272; A-277; A-328; A-341; A-375 and A-380.,MUTAGEN:S->A: Complete loss of phosphorylation and no loss of interaction with the 9-1-1 complex; when associated with A-272; A-277; A-328; A-341; A-375 and A-387.,MUTAGEN:S->A: Complete loss of phosphorylation and no loss of interaction with the 9-1-1 complex; when associated with A-272; A-277; A-328; A-341; A-380 and A-387.,MUTAGEN:S->A: Complete loss of phosphorylation and no loss of interaction with the 9-1-1 complex; when associated with A-272; A-277; A-328; A-375; A-380 and A-387.,MUTAGEN:S->A: Complete loss of phosphorylation and no loss of interaction with the 9-1-1 complex; when associated with A-272; A-277; A-341; A-375; A-380 and A-387.,MUTAGEN:S->A: Complete loss of phosphorylation and no loss of interaction with the 9-1-1 complex; when associated with A-272; A-328; A-341; A-375; A-380 and A-387.,MUTAGEN:S->A: Complete loss of phosphorylation and no loss of interaction with the 9-1-1 complex; when associated with A-277; A-328; A-341; A-375; A-380 and A-387.,MUTAGEN:Y->F: Abolishes phosphorylation by ABL1.,REGION:Disordered,REGION:Possesses 3'-5' exonuclease activity,REGION:Sufficient for interaction with ABL1,
RAP1GAP	RAP1 GTPase activating protein(RAP1GAP)	Homo sapiens				GO:0002250~adaptive immune response,GO:0007165~signal transduction,GO:0007411~axon guidance,GO:0043087~regulation of GTPase activity,GO:0043547~positive regulation of GTPase activity,GO:0045665~negative regulation of neuron differentiation,GO:0051056~regulation of small GTPase mediated signal transduction,GO:0090630~activation of GTPase activity,GO:1903697~negative regulation of microvillus assembly,GO:1904425~negative regulation of GTP binding,GO:1904442~negative regulation of thyroid gland epithelial cell proliferation,GO:1990792~cellular response to glial cell derived neurotrophic factor,	GO:0000139~Golgi membrane,GO:0005737~cytoplasm,GO:0005769~early endosome,GO:0005829~cytosol,GO:0016020~membrane,GO:0030424~axon,GO:0030425~dendrite,GO:0043025~neuronal cell body,	GO:0003924~GTPase activity,GO:0005096~GTPase activator activity,GO:0005515~protein binding,GO:0030695~GTPase regulator activity,GO:0031267~small GTPase binding,GO:0042803~protein homodimerization activity,	IPR000331:Rap GTPase activating proteins domain,IPR003109:GoLoco motif,	hsa04015:Rap1 signaling pathway,			SM00390:GoLoco,		KW-0333~Golgi apparatus,KW-0472~Membrane,				KW-0343~GTPase activation,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:GoLoco,DOMAIN:Rap-GAP,MUTAGEN:D->A: Abolishes GTPase activation.,MUTAGEN:E->A: Reduces GTPase activation.,MUTAGEN:F->E: Impaired dimerization; when associated with E-173.,MUTAGEN:H->A: Abolishes GTPase activation.,MUTAGEN:L->E: Impaired dimerization; when associated with E-100.,MUTAGEN:N->A,K: Abolishes GTPase activation.,MUTAGEN:R->A,P: Reduces GTPase activation.,MUTAGEN:R->A: Reduces GTPase activation.,REGION:Disordered,
RALA	RAS like proto-oncogene A(RALA)	Homo sapiens		h_rasPathway:Ras Signaling Pathway,		GO:0001843~neural tube closure,GO:0006887~exocytosis,GO:0006935~chemotaxis,GO:0007049~cell cycle,GO:0007165~signal transduction,GO:0007265~Ras protein signal transduction,GO:0017157~regulation of exocytosis,GO:0031532~actin cytoskeleton reorganization,GO:0035722~interleukin-12-mediated signaling pathway,GO:0051301~cell division,GO:0051491~positive regulation of filopodium assembly,GO:0051665~membrane raft localization,GO:0072655~establishment of protein localization to mitochondrion,GO:0090141~positive regulation of mitochondrial fission,	GO:0005739~mitochondrion,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0009986~cell surface,GO:0030139~endocytic vesicle,GO:0030659~cytoplasmic vesicle membrane,GO:0032154~cleavage furrow,GO:0070062~extracellular exosome,GO:0090543~Flemming body,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0017022~myosin binding,GO:0019003~GDP binding,GO:0031625~ubiquitin protein ligase binding,GO:0031755~Edg-2 lysophosphatidic acid receptor binding,GO:0051117~ATPase binding,	IPR001806:Small GTPase superfamily,IPR005225:Small GTP-binding protein domain,IPR020849:Small GTPase superfamily, Ras type,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa05132:Salmonella infection,hsa05200:Pathways in cancer,hsa05210:Colorectal cancer,hsa05212:Pancreatic cancer,	619311~Hiatt-Neu-Cooper neurodevelopmental syndrome,			KW-0131~Cell cycle,KW-0132~Cell division,KW-0268~Exocytosis,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-1003~Cell membrane,		KW-0175~Coiled coil,	KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0636~Prenylation,	CARBOHYD:(Microbial infection) O-linked (Glc) threonine; by P.sordellii toxin TcsL,LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,MUTAGEN:A->W: Impaired cytokinesis, as shown by increased number of binucleate cells. No effect on cytokinesis; when associated with V-23. Decreased interaction with EXOC2 and EXOC8; when associated with V-23.,MUTAGEN:A->W: Strongly reduces interaction with EXOC8.,MUTAGEN:C->S: Loss of geranylgeranylation and membrane localization.,MUTAGEN:D->E: No effect on cytokinesis; when associated with L-72.,MUTAGEN:D->N: No effect on cytokinesis. Impaired cytokinesis, as shown by increased number of binucleate cells; when associated with L-72.,MUTAGEN:E->R: Impaired cytokinesis, as shown by increased number of binucleate cells. No effect on cytokinesis; when associated with V-23. Decreased interaction with EXOC2 and EXOC8; when associated with V-23.,MUTAGEN:G->V: Impaired cytokinesis, as shown by increased number of binucleate cells. No effect on interaction with EXOC2 and EXOC8. No effect on cytokinesis; when associated with R-38 or W-48. Decreased interaction with EXOC2 and EXOC8; when associated with R-38 or W-48.,MUTAGEN:K->E: Strongly reduces interaction with EXOC8.,MUTAGEN:K->I: No effect on interaction with EXOC8.,MUTAGEN:L->S: Converts geranyl-geranylation to farnesylation. No effect on membrane localization. Fails to deflect GGTI-induced apoptosis of adherent cell cultures, but rescues anchorage-independent cell proliferation.,MUTAGEN:Missing: Impaired cytokinesis, as shown by increased number of binucleate cells. Impaired cytokinesis; when associated with L-72.,MUTAGEN:N->A: No effect on interaction with EXOC8.,MUTAGEN:N->R: Strongly reduces interaction with EXOC8.,MUTAGEN:Q->L: Impaired cytokinesis, as shown by increased number of binucleate cells. Impaired cytokinesis; when associated with N-49 or 1-M--S-11. No effect on cytokinesis; when associated with E-49.,MUTAGEN:R->A: Strongly reduces interaction with EXOC8.,MUTAGEN:R->W: No effect on interaction with EXOC8.,MUTAGEN:S->A: Decreased localization to mitochondrion. Loss of function in mitochondrial fission.,MUTAGEN:S->D: Increased localization to mitochondrion.,MUTAGEN:S->W: Strongly reduces interaction with EXOC8.,MUTAGEN:T->A: Abolished monoglucosylation by P.sordellii toxin TcsL.,NP_BIND:GTP,PROPEP:Removed in mature form,
RALB	RAS like proto-oncogene B(RALB)	Homo sapiens				GO:0001928~regulation of exocyst assembly,GO:0001934~positive regulation of protein phosphorylation,GO:0006915~apoptotic process,GO:0007049~cell cycle,GO:0007165~signal transduction,GO:0007265~Ras protein signal transduction,GO:0009267~cellular response to starvation,GO:0032091~negative regulation of protein binding,GO:0032092~positive regulation of protein binding,GO:0051301~cell division,GO:0060178~regulation of exocyst localization,GO:0071360~cellular response to exogenous dsRNA,GO:0071902~positive regulation of protein serine/threonine kinase activity,GO:2000786~positive regulation of autophagosome assembly,	GO:0005886~plasma membrane,GO:0030496~midbody,GO:0070062~extracellular exosome,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019003~GDP binding,GO:0031625~ubiquitin protein ligase binding,GO:0051117~ATPase binding,	IPR001806:Small GTPase superfamily,IPR005225:Small GTP-binding protein domain,IPR020849:Small GTPase superfamily, Ras type,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa05200:Pathways in cancer,hsa05210:Colorectal cancer,hsa05212:Pancreatic cancer,				KW-0053~Apoptosis,KW-0131~Cell cycle,KW-0132~Cell division,	KW-0472~Membrane,KW-1003~Cell membrane,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0449~Lipoprotein,KW-0488~Methylation,KW-0636~Prenylation,	COMPBIAS:Basic and acidic residues,LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,MUTAGEN:A->W: Impaired abscission, the last step of cytokinesis, as shown by the accumulation of bridged cells. No effect on cytokinesis; when associated with V-23. Decreased interaction with EXOC2 and EXOC8; when associated with V-23.,MUTAGEN:C->S: Loss of geranylgeranylation and membrane localization.,MUTAGEN:D->E: Impaired abscission, the last step of cytokinesis. No effect on cytokinesis; when associated with V-23.,MUTAGEN:D->N: No effect on cytokinesis. Impaired cytokinesis, as shown by increased number of binucleate cells; when associated with V-23.,MUTAGEN:E->R: No effect on cytokinesis. No effect on cytokinesis; when associated with V-23. Decreased interaction with EXOC2 and EXOC8; when associated with V-23.,MUTAGEN:G->V: Impaired cytokinesis, as shown by increased number of binucleate cells. Impaired cytokinesis; when associated with 1-M--S-11 or N-49. No effect on cytokinesis; when associated with R-38, W-48 or E-49. No effect on interaction with EXOC2 and EXOC8. Decreased interaction with EXOC2 and EXOC8; when associated with R-38 or W-48.,MUTAGEN:L->S: Converts geranyl-geranylation to farnesylation. No effect on membrane localization. Confers resistance to GGTI-induced pancreatic cancer cell apoptosis, but not to GGTI-dependent inhibition of anchorage-independent proliferation.,MUTAGEN:Missing: No effect on cytokinesis. Impaired cytokinesis, as shown by increased number of binucleate cells; when associated with V-23.,MUTAGEN:Q->L: Loss of GTPase activity.,MUTAGEN:T->A: Reduces the binding affinity to EXOC2 effector.,MUTAGEN:T->S: Reduces the binding affinity to EXOC2 effector.,NP_BIND:GTP,PROPEP:Removed in mature form,REGION:Disordered,
RASA1	RAS p21 protein activator 1(RASA1)	Homo sapiens		h_egfPathway:EGF Signaling Pathway,h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_igf1Pathway:IGF-1 Signaling Pathway,h_insulinPathway:Insulin Signaling Pathway,h_metPathway:Signaling of Hepatocyte Growth Factor Receptor,h_pdgfPathway:PDGF Signaling Pathway,h_sam68Pathway:Regulation of Splicing through Sam68,h_spryPathway:Sprouty regulation of tyrosine kinase signals,h_tcrPathway:T Cell Receptor Signaling Pathway,h_tpoPathway:TPO Signaling Pathway,		GO:0000165~MAPK cascade,GO:0000281~mitotic cytokinesis,GO:0001570~vasculogenesis,GO:0001953~negative regulation of cell-matrix adhesion,GO:0007162~negative regulation of cell adhesion,GO:0007165~signal transduction,GO:0008360~regulation of cell shape,GO:0030833~regulation of actin filament polymerization,GO:0035556~intracellular signal transduction,GO:0043066~negative regulation of apoptotic process,GO:0043524~negative regulation of neuron apoptotic process,GO:0043547~positive regulation of GTPase activity,GO:0046580~negative regulation of Ras protein signal transduction,GO:0048013~ephrin receptor signaling pathway,GO:0048514~blood vessel morphogenesis,GO:0051252~regulation of RNA metabolic process,	GO:0001726~ruffle,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,	GO:0001784~phosphotyrosine binding,GO:0003924~GTPase activity,GO:0005096~GTPase activator activity,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0019870~potassium channel inhibitor activity,GO:0051020~GTPase binding,	IPR000008:C2 calcium-dependent membrane targeting,IPR000980:SH2 domain,IPR001452:Src homology-3 domain,IPR001849:Pleckstrin homology domain,IPR001936:Ras GTPase-activating protein,IPR008936:Rho GTPase activation protein,IPR011993:Pleckstrin homology-like domain,IPR023152:Ras GTPase-activating protein, conserved site,	hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04360:Axon guidance,	605462~Basal cell carcinoma, somatic,608354~Capillary malformation-arteriovenous malformation 1,		SM00233:PH,SM00239:C2,SM00252:SH2,SM00323:RasGAP,SM00326:SH3,		KW-0963~Cytoplasm,	KW-0043~Tumor suppressor,KW-0225~Disease variant,	KW-0677~Repeat,KW-0727~SH2 domain,KW-0728~SH3 domain,		KW-0343~GTPase activation,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:C2,DOMAIN:PH,DOMAIN:Ras-GAP,DOMAIN:SH2,DOMAIN:SH2 1,DOMAIN:SH2 2,DOMAIN:SH3,REGION:Disordered,
RB1	RB transcriptional corepressor 1(RB1)	Homo sapiens	94.E2F_transcriptional_activity_cell_cycle,	h_arfPathway:Tumor Suppressor Arf Inhibits Ribosomal Biogenesis,h_btg2Pathway:BTG family proteins and cell cycle regulation,h_cellcyclePathway:Cyclins and Cell Cycle Regulation,h_fasPathway:FAS signaling pathway ( CD95 ),h_fbw7Pathway:Cyclin E Destruction Pathway,h_g1Pathway:Cell Cycle: G1/S Check Point ,h_hcmvPathway:Human Cytomegalovirus and Map Kinase Pathways,h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_p27Pathway:Regulation of p27 Phosphorylation during Cell Cycle Progression,h_p53Pathway:p53 Signaling Pathway,h_pmlPathway:Regulation of transcriptional activity by PML,h_PparaPathway:Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha),h_raccycdPathway:Influence of Ras and Rho proteins on G1 to S Transition,h_rbPathway:RB Tumor Suppressor/Checkpoint Signaling in response to DNA damage,h_skp2e2fPathway:E2F1 Destruction Pathway,h_telPathway:Telomeres, Telomerase, Cellular Aging, and  Immortality,h_tercPathway:Overview of telomerase RNA component gene hTerc Transcriptional Regulation,h_tidPathway:Chaperones modulate interferon Signaling Pathway,h_tnfr1Pathway:TNFR1 Signaling Pathway,		GO:0000082~G1/S transition of mitotic cell cycle,GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001894~tissue homeostasis,GO:0002062~chondrocyte differentiation,GO:0003180~aortic valve morphogenesis,GO:0006338~chromatin remodeling,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006469~negative regulation of protein kinase activity,GO:0007049~cell cycle,GO:0007050~cell cycle arrest,GO:0007076~mitotic chromosome condensation,GO:0007265~Ras protein signal transduction,GO:0007283~spermatogenesis,GO:0007346~regulation of mitotic cell cycle,GO:0010629~negative regulation of gene expression,GO:0016032~viral process,GO:0030154~cell differentiation,GO:0030308~negative regulation of cell growth,GO:0031134~sister chromatid biorientation,GO:0031145~anaphase-promoting complex-dependent catabolic process,GO:0031175~neuron projection development,GO:0031507~heterochromatin assembly,GO:0032869~cellular response to insulin stimulus,GO:0034088~maintenance of mitotic sister chromatid cohesion,GO:0034349~glial cell apoptotic process,GO:0035914~skeletal muscle cell differentiation,GO:0042551~neuron maturation,GO:0043353~enucleate erythrocyte differentiation,GO:0043433~negative regulation of sequence-specific DNA binding transcription factor activity,GO:0043550~regulation of lipid kinase activity,GO:0045445~myoblast differentiation,GO:0045651~positive regulation of macrophage differentiation,GO:0045786~negative regulation of cell cycle,GO:0045842~positive regulation of mitotic metaphase/anaphase transition,GO:0045879~negative regulation of smoothened signaling pathway,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048565~digestive tract development,GO:0048667~cell morphogenesis involved in neuron differentiation,GO:0050680~negative regulation of epithelial cell proliferation,GO:0050728~negative regulation of inflammatory response,GO:0051146~striated muscle cell differentiation,GO:0051301~cell division,GO:0051402~neuron apoptotic process,GO:0051726~regulation of cell cycle,GO:0071459~protein localization to chromosome, centromeric region,GO:0071466~cellular response to xenobiotic stimulus,GO:0071901~negative regulation of protein serine/threonine kinase activity,GO:0071922~regulation of cohesin loading,GO:0071930~negative regulation of transcription involved in G1/S transition of mitotic cell cycle,GO:0090230~regulation of centromere complex assembly,GO:0097284~hepatocyte apoptotic process,GO:1902948~negative regulation of tau-protein kinase activity,GO:1903055~positive regulation of extracellular matrix organization,GO:1903944~negative regulation of hepatocyte apoptotic process,GO:1904028~positive regulation of collagen fibril organization,GO:1904761~negative regulation of myofibroblast differentiation,GO:2000134~negative regulation of G1/S transition of mitotic cell cycle,GO:2000679~positive regulation of transcription regulatory region DNA binding,GO:2001234~negative regulation of apoptotic signaling pathway,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005819~spindle,GO:0005829~cytosol,GO:0016514~SWI/SNF complex,GO:0016605~PML body,GO:0035189~Rb-E2F complex,GO:0061793~chromatin lock complex,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0001102~RNA polymerase II activating transcription factor binding,GO:0003714~transcription corepressor activity,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0019899~enzyme binding,GO:0019900~kinase binding,GO:0031625~ubiquitin protein ligase binding,GO:0042802~identical protein binding,GO:0051219~phosphoprotein binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0061676~importin-alpha family protein binding,GO:0097718~disordered domain specific binding,	IPR002719:Retinoblastoma-associated protein, B-box,IPR002720:Retinoblastoma-associated protein, A-box,IPR013763:Cyclin-like,IPR015030:Rb C-terminal,IPR024599:Domain of unknown function DUF3452, retinoblastoma-associated,	hsa01522:Endocrine resistance,hsa04110:Cell cycle,hsa04218:Cellular senescence,hsa04934:Cushing syndrome,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05169:Epstein-Barr virus infection,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05207:Chemical carcinogenesis - receptor activation,hsa05212:Pancreatic cancer,hsa05214:Glioma,hsa05215:Prostate cancer,hsa05218:Melanoma,hsa05219:Bladder cancer,hsa05220:Chronic myeloid leukemia,hsa05222:Small cell lung cancer,hsa05223:Non-small cell lung cancer,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,	109800~Bladder cancer, somatic,180200~Retinoblastoma,180200~Retinoblastoma, trilateral,182280~Small cell cancer of the lung, somatic,259500~Osteosarcoma, somatic,		SM00385:CYCLIN,SM01367:SM01367,SM01368:SM01368,SM01369:SM01369,	KW-0131~Cell cycle,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,	KW-0043~Tumor suppressor,KW-0225~Disease variant,	KW-0175~Coiled coil,		KW-0156~Chromatin regulator,KW-0238~DNA-binding,KW-0678~Repressor,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:CYCLIN,DOMAIN:DUF3452,DOMAIN:RB_A,DOMAIN:RB_B,DOMAIN:Rb_C,MOTIF:Bipartite nuclear localization signal,MUTAGEN:K->R: Abolishes monomethylation by SMYD2 and subsequent interaction with L3MBTL1.,MUTAGEN:K->R: Does not affect the ability to be methylated by SMYD2; when associated with 873-R-R-874.,MUTAGEN:KK->R: Does not affect the ability to be methylated by SMYD2; when associated with 873-R-R-874.,MUTAGEN:KK->RR: Does not alter Rb localization in cycling cells, but mislocalizes to the cytoplasm during keratinocyte differentiation. Does not affect the ability to arrest cell growth. Probable loss of acetylation by PCAF.,MUTAGEN:T->A: Abolishes interaction with Pocket domain; when associated with A-821.,MUTAGEN:T->A: Abolishes interaction with Pocket domain; when associated with A-826.,REGION:Disordered,REGION:Domain A,REGION:Domain B,REGION:Domain C; mediates interaction with E4F1,REGION:Interaction with LIMD1,REGION:Pocket; binds T and E1A,REGION:Spacer,
RELB	RELB proto-oncogene, NF-kB subunit(RELB)	Homo sapiens				GO:0002223~stimulatory C-type lectin receptor signaling pathway,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006954~inflammatory response,GO:0007249~I-kappaB kinase/NF-kappaB signaling,GO:0010628~positive regulation of gene expression,GO:0019882~antigen processing and presentation,GO:0030098~lymphocyte differentiation,GO:0032688~negative regulation of interferon-beta production,GO:0032922~circadian regulation of gene expression,GO:0033554~cellular response to stress,GO:0034097~response to cytokine,GO:0038061~NIK/NF-kappaB signaling,GO:0043011~myeloid dendritic cell differentiation,GO:0045063~T-helper 1 cell differentiation,GO:0045087~innate immune response,GO:0045892~negative regulation of transcription, DNA-templated,GO:0071470~cellular response to osmotic stress,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005815~microtubule organizing center,GO:0005829~cytosol,GO:0017053~transcriptional repressor complex,GO:0032991~macromolecular complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0042802~identical protein binding,	IPR000451:NF-kappa-B/Rel/Dorsal,IPR002909:Cell surface receptor IPT/TIG,IPR008967:p53-like transcription factor, DNA-binding,IPR011539:Rel homology domain,IPR013783:Immunoglobulin-like fold,IPR014756:Immunoglobulin E-set,	hsa04010:MAPK signaling pathway,hsa04064:NF-kappa B signaling pathway,hsa04380:Osteoclast differentiation,hsa04625:C-type lectin receptor signaling pathway,hsa05166:Human T-cell leukemia virus 1 infection,hsa05169:Epstein-Barr virus infection,	617585~Immunodeficiency 53,		SM00429:IPT,	KW-0090~Biological rhythms,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,			KW-0010~Activator,KW-0238~DNA-binding,KW-0678~Repressor,	KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:RHD,DOMAIN:RelB_leu_zip,DOMAIN:RelB_transactiv,MOTIF:Nuclear localization signal,REGION:Disordered,REGION:Leucine-zipper,
RFNG	RFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase(RFNG)	Homo sapiens				GO:0007389~pattern specification process,GO:0007399~nervous system development,GO:0008593~regulation of Notch signaling pathway,GO:0009887~animal organ morphogenesis,GO:0030154~cell differentiation,GO:0032092~positive regulation of protein binding,GO:0045747~positive regulation of Notch signaling pathway,	GO:0005576~extracellular region,GO:0016021~integral component of membrane,GO:0030173~integral component of Golgi membrane,	GO:0008375~acetylglucosaminyltransferase activity,GO:0016757~transferase activity, transferring glycosyl groups,GO:0033829~O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase activity,GO:0046872~metal ion binding,	IPR003378:Fringe-like,IPR017374:Fringe,	hsa00514:Other types of O-glycan biosynthesis,hsa04330:Notch signaling pathway,hsa05165:Human papillomavirus infection,		PIRSF038073:beta-1,3-N-acetylglucosaminyltransferase, radical fringe type,		KW-0221~Differentiation,KW-0524~Neurogenesis,	KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0732~Signal,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0464~Manganese,KW-0479~Metal-binding,	KW-0217~Developmental protein,KW-0328~Glycosyltransferase,KW-0808~Transferase,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	BINDING:Substrate,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Pro residues,METAL:Manganese,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
RBM15B	RNA binding motif protein 15B(RBM15B)	Homo sapiens			General function prediction only,	GO:0000381~regulation of alternative mRNA splicing, via spliceosome,GO:0000398~mRNA splicing, via spliceosome,GO:0001510~RNA methylation,GO:0006397~mRNA processing,GO:0006406~mRNA export from nucleus,GO:0008380~RNA splicing,GO:0009048~dosage compensation by inactivation of X chromosome,GO:0016032~viral process,	GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005654~nucleoplasm,GO:0016021~integral component of membrane,GO:0016607~nuclear speck,GO:0036396~MIS complex,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,	IPR000504:RNA recognition motif domain,IPR010912:Spen paralogue/orthologue C-terminal, metazoa,IPR012677:Nucleotide-binding, alpha-beta plait,IPR012921:Spen paralogue and orthologue SPOC, C-terminal,IPR016194:SPOC like C-terminal domain,				SM00360:RRM,	KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0539~Nucleus,		KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0694~RNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:RRM 1,DOMAIN:RRM 2,DOMAIN:RRM 3,DOMAIN:SPOC,MOTIF:Nuclear localization signal,REGION:Disordered,REGION:Interaction with Epstein-Barr virus BMLF1,TRANSMEM:Helical,
RBM34	RNA binding motif protein 34(RBM34)	Homo sapiens					GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005730~nucleolus,	GO:0003723~RNA binding,	IPR000504:RNA recognition motif domain,IPR012677:Nucleotide-binding, alpha-beta plait,				SM00360:RRM,		KW-0539~Nucleus,		KW-0677~Repeat,		KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,REGION:Disordered,
RBM6	RNA binding motif protein 6(RBM6)	Homo sapiens			Function unknown,	GO:0000398~mRNA splicing, via spliceosome,GO:0006396~RNA processing,	GO:0005634~nucleus,	GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0005515~protein binding,	IPR000467:G-patch domain,IPR000504:RNA recognition motif domain,IPR012677:Nucleotide-binding, alpha-beta plait,				SM00360:RRM,SM00443:G_patch,		KW-0539~Nucleus,		KW-0175~Coiled coil,		KW-0694~RNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:G-patch,DOMAIN:OCRE,DOMAIN:RRM,REGION:Disordered,
RNPS1	RNA binding protein with serine rich domain 1(RNPS1)	Homo sapiens				GO:0000184~nuclear-transcribed mRNA catabolic process, nonsense-mediated decay,GO:0000381~regulation of alternative mRNA splicing, via spliceosome,GO:0000398~mRNA splicing, via spliceosome,GO:0006351~transcription, DNA-templated,GO:0006405~RNA export from nucleus,GO:0006406~mRNA export from nucleus,GO:0008380~RNA splicing,GO:0031124~mRNA 3'-end processing,GO:0043065~positive regulation of apoptotic process,GO:0048025~negative regulation of mRNA splicing, via spliceosome,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016607~nuclear speck,GO:0061574~ASAP complex,	GO:0003723~RNA binding,GO:0003730~mRNA 3'-UTR binding,GO:0005515~protein binding,	IPR000504:RNA recognition motif domain,IPR012677:Nucleotide-binding, alpha-beta plait,IPR014010:Egg jelly receptor, REJ-like,	hsa03013:Nucleocytoplasmic transport,hsa03015:mRNA surveillance pathway,			SM00360:RRM,	KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0866~Nonsense-mediated mRNA decay,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:REJ,DOMAIN:RRM,MUTAGEN:N->R: Impairs interaction with SAP18.,MUTAGEN:S->A: Abolishes phosphorylation by CSNK2A1 and partially reduces splicing stimulation. Does not abolish interaction with CSNK2A1 and subcellular localization.,MUTAGEN:S->E: Partially reduces splicing stimulation. Does not abolish interaction with CSNK2A1 and subcellular localization.,MUTAGEN:Y->A: Abolishes exon-skipping.,REGION:Disordered,REGION:Interaction with SAP18 and ACIN1,REGION:Necessary for interaction with PNN and exon-skipping,REGION:Necessary for interaction with SRP54, nuclear localization and exon-skipping,REGION:Necessary for interaction with TRA2B, nuclear localization and exon-skipping,REGION:Necessary for interaction with the cleaved p110 isoform of CDC2L1,REGION:Necessary for interactions with UPF2 and UPF3B and UPF2-dependent NMD,
RNMT	RNA guanine-7 methyltransferase(RNMT)	Homo sapiens				GO:0006366~transcription from RNA polymerase II promoter,GO:0006370~7-methylguanosine mRNA capping,GO:1990830~cellular response to leukemia inhibitory factor,	GO:0001650~fibrillar center,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005845~mRNA cap binding complex,GO:0031533~mRNA cap methyltransferase complex,GO:0043235~receptor complex,	GO:0003723~RNA binding,GO:0004482~mRNA (guanine-N7-)-methyltransferase activity,GO:0005515~protein binding,	IPR004971:mRNA (guanine-N(7))-methyltransferase domain,IPR016899:mRNA (guanine-N(7))-methyltransferase,	hsa03015:mRNA surveillance pathway,		PIRSF028762:mRNA (guanine-N(7))-methyltransferase,		KW-0506~mRNA capping,KW-0507~mRNA processing,	KW-0539~Nucleus,			KW-0949~S-adenosyl-L-methionine,	KW-0489~Methyltransferase,KW-0694~RNA-binding,KW-0808~Transferase,	KW-0597~Phosphoprotein,	BINDING:S-adenosyl-L-methionine,BINDING:S-adenosyl-L-methionine; via amide nitrogen,BINDING:S-adenosyl-L-methionine; via carbonyl oxygen,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:MRNA cap 0 methyltransferase,DOMAIN:mRNA cap 0 methyltransferase,MOTIF:Nuclear localization signal,MUTAGEN:A->C: Loss of methyltransferase activity in presence or absence of RAMAC; when associated with C-178. Complete restored RAMAC-mediated methyltransferase activity under reducing conditions; when associated with C-178. Loss of methyltransferase activity in presence or absence of RAMAC; when associated with C-178. Loss of methyltransferase activity in presence or absence of RAMAC; when associated with C-178; C-393 and C-398. Partially restored RAMAC-mediated methyltransferase activity under reducing conditions; when associated with C-178; C-393 and C-398.,MUTAGEN:D->A: Loss of activity.,MUTAGEN:F->A: Loss of activity.,MUTAGEN:F->A: Strongly impairs enzyme activity.,MUTAGEN:F->C: Loss of methyltransferase activity in presence or absence of RAMAC; when associated with C-178; C-393 and C-417. Partially restored RAMAC-mediated methyltransferase activity under reducing conditions; when associated with C-178; C-393 and C-417.,MUTAGEN:K->C: Loss of methyltransferase activity in presence or absence of RAMAC; when associated with C-178; C-398 and C-417. Partially restored RAMAC-mediated methyltransferase activity under reducing conditions; when associated with C-178; C-398 and C-417.,MUTAGEN:K->E: Decreased S-adenosyl-L-methionine binding and methyltransferase activity in absence of RAMAC; when associated with E-409. Decreased interaction with RAMAC; when associated with E-409.,MUTAGEN:K->E: Decreased S-adenosyl-L-methionine binding and methyltransferase activity in absence of RAMAC; when associated with E-413. Decreased interaction with RAMAC; when associated with E-413.,MUTAGEN:KKRK->AAAA: Does not abolish nuclear localization. Abolishes nuclear localization; when associated with 103-AAAAA-107 and I-127.,MUTAGEN:KKRKR->AAAAA: Does not abolish nuclear localization. Abolishes nuclear localization; when associated with 80-AAAA-83 and I-127.,MUTAGEN:P->E: Increased S-adenosyl-L-methionine binding and methyltransferase activity in absence of RAMAC; when associated with E-450. No change in interaction with RAMAC; when associated with E-450.,MUTAGEN:R->A: Loss of activity.,MUTAGEN:R->E: Increased S-adenosyl-L-methionine binding and methyltransferase activity in absence of RAMAC; when associated with E-452. No change in interaction with RAMAC; when associated with E-452.,MUTAGEN:R->I: Does not abolish nuclear localization. Abolishes nuclear localization; when associated with 80-AAAA-83 and 103-AAAAA-107.,MUTAGEN:W->C: Loss of methyltransferase activity in presence or absence of RAMAC; when associated with C-417. Complete restored RAMAC-mediated methyltransferase activity under reducing conditions; when associated with C-417. Loss of methyltransferase activity in presence or absence of RAMAC; when associated with C-417; C-393 and C-398. Partially restored RAMAC-mediated methyltransferase activity under reducing conditions; when associated with C-417; C-393 and C-398.,MUTAGEN:Y->A: Loss of activity.,REGION:Disordered,REGION:mRNA cap binding,SITE:mRNA cap binding,
POLR1C	RNA polymerase I and III subunit C(POLR1C)	Homo sapiens		h_arfPathway:Tumor Suppressor Arf Inhibits Ribosomal Biogenesis,		GO:0006360~transcription from RNA polymerase I promoter,GO:0006361~transcription initiation from RNA polymerase I promoter,GO:0006363~termination of RNA polymerase I transcription,GO:0006383~transcription from RNA polymerase III promoter,GO:0032481~positive regulation of type I interferon production,GO:0045815~positive regulation of gene expression, epigenetic,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005666~DNA-directed RNA polymerase III complex,GO:0005736~DNA-directed RNA polymerase I complex,GO:0005829~cytosol,	GO:0001054~RNA polymerase I activity,GO:0001056~RNA polymerase III activity,GO:0003677~DNA binding,GO:0003899~DNA-directed 5'-3' RNA polymerase activity,GO:0005515~protein binding,GO:0046983~protein dimerization activity,	IPR001514:DNA-directed RNA polymerase, 30-40kDa subunit, conserved site,IPR011262:DNA-directed RNA polymerase, insert domain,IPR011263:DNA-directed RNA polymerase, RpoA/D/Rpb3-type,	hsa03020:RNA polymerase,hsa04623:Cytosolic DNA-sensing pathway,	248390~Treacher Collins syndrome 3,616494~Leukodystrophy, hypomyelinating, 11,		SM00662:RPOLD,	KW-0804~Transcription,	KW-0240~DNA-directed RNA polymerase,KW-0539~Nucleus,KW-9994~DNA-directed RNA polymerase,	KW-0225~Disease variant,KW-1026~Leukodystrophy,				KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:RPOLD,
POLR2I	RNA polymerase II subunit I(POLR2I)	Homo sapiens			Transcription,	GO:0000398~mRNA splicing, via spliceosome,GO:0001193~maintenance of transcriptional fidelity during DNA-templated transcription elongation from RNA polymerase II promoter,GO:0006283~transcription-coupled nucleotide-excision repair,GO:0006351~transcription, DNA-templated,GO:0006366~transcription from RNA polymerase II promoter,GO:0006367~transcription initiation from RNA polymerase II promoter,GO:0006368~transcription elongation from RNA polymerase II promoter,GO:0006370~7-methylguanosine mRNA capping,GO:0006379~mRNA cleavage,GO:0008543~fibroblast growth factor receptor signaling pathway,GO:0016070~RNA metabolic process,GO:0042795~snRNA transcription from RNA polymerase II promoter,GO:0048239~negative regulation of DNA recombination at telomere,GO:0050434~positive regulation of viral transcription,GO:0060964~regulation of gene silencing by miRNA,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005665~DNA-directed RNA polymerase II, core complex,GO:0005730~nucleolus,	GO:0003676~nucleic acid binding,GO:0003899~DNA-directed 5'-3' RNA polymerase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,	IPR001222:Zinc finger, TFIIS-type,IPR001529:DNA-directed RNA polymerase, M/15kDa subunit,IPR012164:DNA-directed RNA polymerase, subunit C11/M/9,IPR019761:DNA-directed RNA polymerase M, 15kDa subunit, conserved site,	hsa03020:RNA polymerase,hsa05016:Huntington disease,		PIRSF005586:DNA-directed RNA polymerase subunit, RpoM type,	SM00440:ZnF_C2C2,SM00661:RPOL9,	KW-0804~Transcription,	KW-0240~DNA-directed RNA polymerase,KW-0539~Nucleus,KW-9994~DNA-directed RNA polymerase,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0007~Acetylation,	DOMAIN:RPOL9,METAL:Zinc 1,METAL:Zinc 2,ZN_FING:C4-type,ZN_FING:TFIIS-type,
POLR2K	RNA polymerase II, I and III subunit K(POLR2K)	Homo sapiens				GO:0000398~mRNA splicing, via spliceosome,GO:0006283~transcription-coupled nucleotide-excision repair,GO:0006351~transcription, DNA-templated,GO:0006356~regulation of transcription from RNA polymerase I promoter,GO:0006361~transcription initiation from RNA polymerase I promoter,GO:0006363~termination of RNA polymerase I transcription,GO:0006366~transcription from RNA polymerase II promoter,GO:0006367~transcription initiation from RNA polymerase II promoter,GO:0006368~transcription elongation from RNA polymerase II promoter,GO:0006370~7-methylguanosine mRNA capping,GO:0006383~transcription from RNA polymerase III promoter,GO:0008543~fibroblast growth factor receptor signaling pathway,GO:0016070~RNA metabolic process,GO:0032481~positive regulation of type I interferon production,GO:0042795~snRNA transcription from RNA polymerase II promoter,GO:0045815~positive regulation of gene expression, epigenetic,GO:0048239~negative regulation of DNA recombination at telomere,GO:0050434~positive regulation of viral transcription,GO:0060964~regulation of gene silencing by miRNA,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005665~DNA-directed RNA polymerase II, core complex,GO:0005666~DNA-directed RNA polymerase III complex,GO:0005736~DNA-directed RNA polymerase I complex,GO:0005829~cytosol,	GO:0003677~DNA binding,GO:0003899~DNA-directed 5'-3' RNA polymerase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,	IPR006591:RNA polymerase archaeal subunit P/eukaryotic subunit RPC10,	hsa03020:RNA polymerase,hsa04623:Cytosolic DNA-sensing pathway,hsa05016:Huntington disease,			SM00659:RPOLCX,	KW-0804~Transcription,	KW-0240~DNA-directed RNA polymerase,KW-0539~Nucleus,KW-9994~DNA-directed RNA polymerase,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,			METAL:Zinc,ZN_FING:C4-type,
RAC2	Rac family small GTPase 2(RAC2)	Homo sapiens				GO:0006935~chemotaxis,GO:0007015~actin filament organization,GO:0007163~establishment or maintenance of cell polarity,GO:0007165~signal transduction,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007264~small GTPase mediated signal transduction,GO:0008045~motor neuron axon guidance,GO:0008284~positive regulation of cell proliferation,GO:0008360~regulation of cell shape,GO:0010310~regulation of hydrogen peroxide metabolic process,GO:0010592~positive regulation of lamellipodium assembly,GO:0010810~regulation of cell-substrate adhesion,GO:0016601~Rac protein signal transduction,GO:0030031~cell projection assembly,GO:0030036~actin cytoskeleton organization,GO:0030865~cortical cytoskeleton organization,GO:0032956~regulation of actin cytoskeleton organization,GO:0042129~regulation of T cell proliferation,GO:0043304~regulation of mast cell degranulation,GO:0043652~engulfment of apoptotic cell,GO:0045453~bone resorption,GO:0045454~cell redox homeostasis,GO:0050790~regulation of catalytic activity,GO:0051056~regulation of small GTPase mediated signal transduction,GO:0051897~positive regulation of protein kinase B signaling,GO:0060263~regulation of respiratory burst,GO:0060753~regulation of mast cell chemotaxis,GO:0071593~lymphocyte aggregation,GO:0090023~positive regulation of neutrophil chemotaxis,GO:1902622~regulation of neutrophil migration,GO:1903955~positive regulation of protein targeting to mitochondrion,	GO:0005635~nuclear envelope,GO:0005737~cytoplasm,GO:0005741~mitochondrial outer membrane,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005884~actin filament,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0005938~cell cortex,GO:0016020~membrane,GO:0030027~lamellipodium,GO:0030670~phagocytic vesicle membrane,GO:0031410~cytoplasmic vesicle,GO:0042995~cell projection,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019887~protein kinase regulator activity,GO:0019901~protein kinase binding,	IPR001806:Small GTPase superfamily,IPR003578:Small GTPase superfamily, Rho type,IPR005225:Small GTP-binding protein domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04024:cAMP signaling pathway,hsa04062:Chemokine signaling pathway,hsa04071:Sphingolipid signaling pathway,hsa04310:Wnt signaling pathway,hsa04360:Axon guidance,hsa04370:VEGF signaling pathway,hsa04510:Focal adhesion,hsa04520:Adherens junction,hsa04613:Neutrophil extracellular trap formation,hsa04650:Natural killer cell mediated cytotoxicity,hsa04662:B cell receptor signaling pathway,hsa04664:Fc epsilon RI signaling pathway,hsa04666:Fc gamma R-mediated phagocytosis,hsa04670:Leukocyte transendothelial migration,hsa04810:Regulation of actin cytoskeleton,hsa05020:Prion disease,hsa05135:Yersinia infection,hsa05163:Human cytomegalovirus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,hsa05210:Colorectal cancer,hsa05212:Pancreatic cancer,hsa05231:Choline metabolism in cancer,hsa05415:Diabetic cardiomyopathy,hsa05416:Viral myocarditis,hsa05418:Fluid shear stress and atherosclerosis,	608203~Immunodeficiency 73A with defective neutrophil chemotaxix and leukocytosis,618986~Immunodeficiency 73B with defective neutrophil chemotaxis and lymphopenia,618987~Immunodeficiency 73C with defective neutrophil chemotaxis and hypogammaglobulinemia,				KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0732~Signal,	KW-0342~GTP-binding,KW-0547~Nucleotide-binding,		KW-0007~Acetylation,KW-0013~ADP-ribosylation,KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0636~Prenylation,	CARBOHYD:O-linked (GlcNAc) tyrosine; by Photorhabdus PAU_02230,LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,MUTAGEN:C->W: Abolishes in vitro prenylation.,NP_BIND:GTP,PROPEP:Removed in mature form,REGION:Disordered,
RHEB	Ras homolog, mTORC1 binding(RHEB)	Homo sapiens		h_mtorPathway:mTOR Signaling Pathway,		GO:0007050~cell cycle arrest,GO:0007165~signal transduction,GO:0007264~small GTPase mediated signal transduction,GO:0016241~regulation of macroautophagy,GO:0032008~positive regulation of TOR signaling,GO:0034198~cellular response to amino acid starvation,GO:0048714~positive regulation of oligodendrocyte differentiation,GO:0051726~regulation of cell cycle,GO:2000074~regulation of type B pancreatic cell development,	GO:0000139~Golgi membrane,GO:0005681~spliceosomal complex,GO:0005765~lysosomal membrane,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0014069~postsynaptic density,GO:0016020~membrane,GO:0070062~extracellular exosome,	GO:0000287~magnesium ion binding,GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019003~GDP binding,GO:0019901~protein kinase binding,	IPR001806:Small GTPase superfamily,IPR005225:Small GTP-binding protein domain,IPR020849:Small GTPase superfamily, Ras type,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04072:Phospholipase D signaling pathway,hsa04140:Autophagy - animal,hsa04150:mTOR signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04152:AMPK signaling pathway,hsa04211:Longevity regulating pathway,hsa04218:Cellular senescence,hsa04714:Thermogenesis,hsa04910:Insulin signaling pathway,hsa04919:Thyroid hormone signaling pathway,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05231:Choline metabolism in cancer,					KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,			KW-0342~GTP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,		KW-0449~Lipoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0636~Prenylation,	BINDING:GTP; via amide nitrogen,LIPID:S-farnesyl cysteine,METAL:Magnesium,MOTIF:Effector region,MUTAGEN:C->S: Reduces the ability to rescue S6K1 from inactivation by amino-acid withdrawal.,MUTAGEN:D->I: Deficient in guanine nucleotide binding. Unable to rescue S6K1 from inactivation by amino-acid withdrawal.,MUTAGEN:E->A: Causes slightly reduced phosphorylation of EIF4EBP1.,MUTAGEN:E->G: No effect.,MUTAGEN:F->C: No effect.,MUTAGEN:I->K: Impairs S6K1 activation, but still binds guanine nucleotides normally.,MUTAGEN:L->A: Causes slight reduction in S6K1 activation.,MUTAGEN:L->A: Partially deficient in guanine nucleotide binding. Fully impairs EIF4EBP1 phosphorylation and S6K1 activation.,MUTAGEN:N->A: Impairs interaction with MTOR. Impairs signaling through mTORC1, but still binds guanine nucleotides normally.,MUTAGEN:Q->L: Has a higher basal GTPase level, however, is still sensitive to TSC2 GAP activity.,MUTAGEN:R->G: Partially resistant to inactivation by TSC1-TSC2.,MUTAGEN:S->N: Deficient in guanine nucleotide binding. Unable to rescue S6K1 from inactivation by amino-acid withdrawal.,MUTAGEN:T->A: Causes slightly reduced phosphorylation of EIF4EBP1.,MUTAGEN:T->M: Slightly impairs signaling through mTORC1, but still binds guanine nucleotides normally.,MUTAGEN:V->A: Causes slightly reduced phosphorylation of EIF4EBP1.,MUTAGEN:Y->A: Partially deficient in guanine nucleotide binding. Fully impairs EIF4EBP1 phosphorylation and S6K1 activation.,NP_BIND:GTP,PROPEP:Removed in mature form,
RRAGA	Ras related GTP binding A(RRAGA)	Homo sapiens				GO:0006915~apoptotic process,GO:0007050~cell cycle arrest,GO:0008219~cell death,GO:0009267~cellular response to starvation,GO:0010506~regulation of autophagy,GO:0010507~negative regulation of autophagy,GO:0016241~regulation of macroautophagy,GO:0016567~protein ubiquitination,GO:0019048~modulation by virus of host morphology or physiology,GO:0032008~positive regulation of TOR signaling,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0034198~cellular response to amino acid starvation,GO:0034613~cellular protein localization,GO:0045918~negative regulation of cytolysis,GO:0071230~cellular response to amino acid stimulus,GO:1904263~positive regulation of TORC1 signaling,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0005829~cytosol,GO:0071986~Ragulator complex,GO:1990131~Gtr1-Gtr2 GTPase complex,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0031625~ubiquitin protein ligase binding,GO:0042803~protein homodimerization activity,GO:0046982~protein heterodimerization activity,GO:0051219~phosphoprotein binding,	IPR006762:Gtr1/RagA G protein,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04140:Autophagy - animal,hsa04150:mTOR signaling pathway,hsa05131:Shigellosis,				KW-0053~Apoptosis,KW-0945~Host-virus interaction,	KW-0458~Lysosome,KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	BINDING:GTP binding; via carbonyl oxygen,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),MUTAGEN:K->R: Prevents RRAGA ubiquitination and alters interaction and regulation by GATOR1; when associated with R-142, R-230 and R-244.,MUTAGEN:K->R: Prevents RRAGA ubiquitination and alters interaction and regulation by GATOR1; when associated with R-220, R-230 and R-244.,MUTAGEN:K->R: Prevents RRAGA ubiquitination and alters interaction and regulation by GATOR1; when associated with RR-142, R-220 and R-230.,MUTAGEN:K->R: Prevents RRAGA ubiquitination and alters interaction and regulation by GATOR1; when associated with RR-142, R-220 and R-244.,MUTAGEN:T->N: Reduced affinity for all nucleotides, but with preferential binding of GDP over GTP.,NP_BIND:GTP,
RSU1	Ras suppressor protein 1(RSU1)	Homo sapiens				GO:0007165~signal transduction,GO:0010811~positive regulation of cell-substrate adhesion,GO:0043547~positive regulation of GTPase activity,	GO:0005829~cytosol,GO:0005925~focal adhesion,GO:0070062~extracellular exosome,	GO:0005515~protein binding,	IPR001611:Leucine-rich repeat,IPR003591:Leucine-rich repeat, typical subtype,				SM00369:LRR_TYP,				KW-0433~Leucine-rich repeat,KW-0677~Repeat,			KW-0007~Acetylation,	COMPBIAS:Basic and acidic residues,REGION:Disordered,REPEAT:LRR 1,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,
ARHGAP1	Rho GTPase activating protein 1(ARHGAP1)	Homo sapiens		h_rhoPathway:Rho cell motility signaling pathway,		GO:0007165~signal transduction,GO:0007264~small GTPase mediated signal transduction,GO:0007266~Rho protein signal transduction,GO:0016197~endosomal transport,GO:0033572~transferrin transport,GO:0050790~regulation of catalytic activity,GO:0051056~regulation of small GTPase mediated signal transduction,GO:2001136~negative regulation of endocytic recycling,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0010008~endosome membrane,GO:0016021~integral component of membrane,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:0097443~sorting endosome,	GO:0005096~GTPase activator activity,GO:0005515~protein binding,GO:0017124~SH3 domain binding,GO:0031267~small GTPase binding,GO:0045296~cadherin binding,	IPR000198:Rho GTPase-activating protein domain,IPR001251:CRAL-TRIO domain,IPR008936:Rho GTPase activation protein,				SM00324:RhoGAP,SM00516:SEC14,		KW-0472~Membrane,KW-0963~Cytoplasm,		KW-0729~SH3-binding,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0343~GTPase activation,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:CRAL-TRIO,DOMAIN:Rho-GAP,MOTIF:SH3-binding,REGION:Disordered,SITE:Involved in G-protein binding to GAPs,TRANSMEM:Helical,
ARHGEF12	Rho guanine nucleotide exchange factor 12(ARHGEF12)	Homo sapiens				GO:0007186~G-protein coupled receptor signaling pathway,GO:0007266~Rho protein signal transduction,GO:0043065~positive regulation of apoptotic process,GO:0043547~positive regulation of GTPase activity,GO:0050790~regulation of catalytic activity,GO:0051056~regulation of small GTPase mediated signal transduction,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0070062~extracellular exosome,	GO:0001664~G-protein coupled receptor binding,GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005096~GTPase activator activity,GO:0005515~protein binding,	IPR000219:Dbl homology (DH) domain,IPR001331:Guanine-nucleotide dissociation stimulator, CDC24, conserved site,IPR001478:PDZ domain,IPR001849:Pleckstrin homology domain,IPR011993:Pleckstrin homology-like domain,IPR015212:Regulator of G protein signalling-like fold,	hsa04270:Vascular smooth muscle contraction,hsa04360:Axon guidance,hsa04611:Platelet activation,hsa04625:C-type lectin receptor signaling pathway,hsa04810:Regulation of actin cytoskeleton,hsa05130:Pathogenic Escherichia coli infection,hsa05135:Yersinia infection,hsa05152:Tuberculosis,hsa05163:Human cytomegalovirus infection,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,			SM00228:PDZ,SM00233:PH,SM00325:RhoGEF,		KW-0472~Membrane,KW-0963~Cytoplasm,	KW-0656~Proto-oncogene,	KW-0175~Coiled coil,		KW-0343~GTPase activation,KW-0344~Guanine-nucleotide releasing factor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:DH,DOMAIN:PDZ,DOMAIN:PH,DOMAIN:RGSL,REGION:Disordered,SITE:Breakpoint for translocation to form KMT2A/MLL1-ARHGEF12 oncogene,
ARHGEF2	Rho/Rac guanine nucleotide exchange factor 2(ARHGEF2)	Homo sapiens		h_ptdinsPathway:Phosphoinositides and their downstream targets.,		GO:0000902~cell morphogenesis,GO:0006886~intracellular protein transport,GO:0007015~actin filament organization,GO:0007026~negative regulation of microtubule depolymerization,GO:0007049~cell cycle,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007399~nervous system development,GO:0030154~cell differentiation,GO:0032755~positive regulation of interleukin-6 production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0035023~regulation of Rho protein signal transduction,GO:0035556~intracellular signal transduction,GO:0042127~regulation of cell proliferation,GO:0043065~positive regulation of apoptotic process,GO:0045087~innate immune response,GO:0045666~positive regulation of neuron differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0050790~regulation of catalytic activity,GO:0051056~regulation of small GTPase mediated signal transduction,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051301~cell division,GO:0055059~asymmetric neuroblast division,GO:0060546~negative regulation of necroptotic process,GO:0071225~cellular response to muramyl dipeptide,GO:0071356~cellular response to tumor necrosis factor,GO:0071474~cellular hyperosmotic response,GO:1902042~negative regulation of extrinsic apoptotic signaling pathway via death domain receptors,GO:1902219~negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress,GO:2001224~positive regulation of neuron migration,	GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005819~spindle,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005874~microtubule,GO:0005923~bicellular tight junction,GO:0005925~focal adhesion,GO:0031410~cytoplasmic vesicle,GO:0031982~vesicle,GO:0032587~ruffle membrane,GO:0032991~macromolecular complex,GO:0098978~glutamatergic synapse,GO:0099092~postsynaptic density, intracellular component,	GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0008134~transcription factor binding,GO:0008270~zinc ion binding,GO:0031267~small GTPase binding,	IPR000219:Dbl homology (DH) domain,IPR001849:Pleckstrin homology domain,IPR002219:Protein kinase C-like, phorbol ester/diacylglycerol binding,IPR011993:Pleckstrin homology-like domain,	hsa04530:Tight junction,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05418:Fluid shear stress and atherosclerosis,	617523~Neurodevelopmental disorder with midbrain and hindbrain malformations,		SM00109:C1,SM00233:PH,SM00325:RhoGEF,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0221~Differentiation,KW-0391~Immunity,KW-0399~Innate immunity,KW-0498~Mitosis,KW-0524~Neurogenesis,	KW-0206~Cytoskeleton,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0493~Microtubule,KW-0796~Tight junction,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-0966~Cell projection,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,	KW-0991~Mental retardation,	KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0217~Developmental protein,KW-0344~Guanine-nucleotide releasing factor,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:DH,DOMAIN:PH,DOMAIN:Phorbol-ester/DAG-type,MUTAGEN:C->R: Abolishes microtubule binding, increased activity in vitro.,MUTAGEN:S->A: Abolishes phosphorylation by PAK4, self aggregation in the cytoplasm. Increases activity; when associated with A-143.,MUTAGEN:S->A: Abolishes phosphorylation by PAK4, self aggregation in the cytoplasm. Increases activity; when associated with A-896.,MUTAGEN:S->A: Normal activity.,MUTAGEN:S->D: Increases activity. Abolishes nucleotide exchange activity; when associated with D-886.,MUTAGEN:S->D: Increases activity. Abolishes nucleotide exchange activity; when associated with D-960.,MUTAGEN:T->A: Reduces phosphorylation level.,MUTAGEN:Y->A: Reduces phosphorylation level, normal microtubule localization and activity.,REGION:Disordered,REGION:Interaction with DYNLT1,ZN_FING:Phorbol-ester/DAG-type,
RUVBL1	RuvB like AAA ATPase 1(RUVBL1)	Homo sapiens			Transcription,	GO:0000492~box C/D snoRNP assembly,GO:0006275~regulation of DNA replication,GO:0006281~DNA repair,GO:0006310~DNA recombination,GO:0006338~chromatin remodeling,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007049~cell cycle,GO:0007283~spermatogenesis,GO:0016573~histone acetylation,GO:0016579~protein deubiquitination,GO:0032508~DNA duplex unwinding,GO:0033044~regulation of chromosome organization,GO:0034080~CENP-A containing nucleosome assembly,GO:0040008~regulation of growth,GO:0042766~nucleosome mobilization,GO:0043967~histone H4 acetylation,GO:0043968~histone H2A acetylation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0051301~cell division,GO:0051726~regulation of cell cycle,GO:0060382~regulation of DNA strand elongation,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:1904837~beta-catenin-TCF complex assembly,GO:1904874~positive regulation of telomerase RNA localization to Cajal body,GO:1905168~positive regulation of double-strand break repair via homologous recombination,	GO:0000786~nucleosome,GO:0000812~Swr1 complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005815~microtubule organizing center,GO:0005829~cytosol,GO:0016020~membrane,GO:0016363~nuclear matrix,GO:0031011~Ino80 complex,GO:0035267~NuA4 histone acetyltransferase complex,GO:0070062~extracellular exosome,GO:0071339~MLL1 complex,GO:0097255~R2TP complex,GO:0101031~chaperone complex,GO:1990062~RPAP3/R2TP/prefoldin-like complex,GO:1990904~ribonucleoprotein complex,	GO:0001094~TFIID-class transcription factor binding,GO:0003678~DNA helicase activity,GO:0003713~transcription coactivator activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016787~hydrolase activity,GO:0016887~ATPase activity,GO:0017025~TBP-class protein binding,GO:0043139~5'-3' DNA helicase activity,GO:0043531~ADP binding,GO:0045296~cadherin binding,GO:0051117~ATPase binding,	IPR003593:AAA+ ATPase domain,IPR010339:TIP49, C-terminal,IPR012340:Nucleic acid-binding, OB-fold,IPR027238:RuvB-like,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04310:Wnt signaling pathway,			SM00382:AAA,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0227~DNA damage,KW-0233~DNA recombination,KW-0234~DNA repair,KW-0341~Growth regulation,KW-0498~Mitosis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0010~Activator,KW-0156~Chromatin regulator,KW-0347~Helicase,KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:AAA,DOMAIN:TIP49,DOMAIN:TIP49_C,MUTAGEN:D->N: Abolishes ATPase activity; inhibition of MYC- and CTNNB1-mediated transformation.,MUTAGEN:E->Q: Decreases interaction with NOPCHAP1.,MUTAGEN:K->M: No effect on interaction with NOPCHAP1.,NP_BIND:ATP,
SKP1	S-phase kinase associated protein 1(SKP1)	Homo sapiens	84.Ubiquitination_Pathways_Cell_Cycle,	h_eradPathway:ERï¿½associated degradation (ERAD) Pathway,h_fbw7Pathway:Cyclin E Destruction Pathway,h_p27Pathway:Regulation of p27 Phosphorylation during Cell Cycle Progression,h_skp2e2fPathway:E2F1 Destruction Pathway,	Posttranslational modification, protein turnover, chaperones,	GO:0000086~G2/M transition of mitotic cell cycle,GO:0000209~protein polyubiquitination,GO:0002223~stimulatory C-type lectin receptor signaling pathway,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0006879~cellular iron ion homeostasis,GO:0010265~SCF complex assembly,GO:0010972~negative regulation of G2/M transition of mitotic cell cycle,GO:0016032~viral process,GO:0016055~Wnt signaling pathway,GO:0016567~protein ubiquitination,GO:0031146~SCF-dependent proteasomal ubiquitin-dependent protein catabolic process,GO:0035518~histone H2A monoubiquitination,GO:0038061~NIK/NF-kappaB signaling,GO:0038095~Fc-epsilon receptor signaling pathway,GO:0043687~post-translational protein modification,GO:0050852~T cell receptor signaling pathway,GO:0051403~stress-activated MAPK cascade,GO:0051457~maintenance of protein location in nucleus,GO:0070498~interleukin-1-mediated signaling pathway,GO:0070936~protein K48-linked ubiquitination,GO:1901990~regulation of mitotic cell cycle phase transition,GO:1904668~positive regulation of ubiquitin protein ligase activity,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0019005~SCF ubiquitin ligase complex,GO:0031467~Cul7-RING ubiquitin ligase complex,	GO:0005515~protein binding,GO:0008013~beta-catenin binding,GO:0019904~protein domain specific binding,GO:0097602~cullin family protein binding,GO:1990444~F-box domain binding,GO:1990756~protein binding, bridging involved in substrate recognition for ubiquitination,	IPR001232:SKP1 component,IPR011333:BTB/POZ fold,IPR016072:SKP1 component, dimerisation,IPR016073:SKP1 component, POZ,IPR016897:E3 ubiquitin ligase, SCF complex, Skp subunit,	hsa04110:Cell cycle,hsa04114:Oocyte meiosis,hsa04120:Ubiquitin mediated proteolysis,hsa04141:Protein processing in endoplasmic reticulum,hsa04310:Wnt signaling pathway,hsa04350:TGF-beta signaling pathway,hsa04710:Circadian rhythm,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,		PIRSF028729:E3 ubiquitin ligase SCF complex, Skp subunit,	SM00512:Skp1,	KW-0833~Ubl conjugation pathway,KW-0945~Host-virus interaction,						KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),DOMAIN:Skp1,DOMAIN:Skp1_POZ,REGION:Disordered,REGION:Interaction with the F-box domain of F-box proteins,
S100A13	S100 calcium binding protein A13(S100A13)	Homo sapiens				GO:0001819~positive regulation of cytokine production,GO:0008284~positive regulation of cell proliferation,GO:0008360~regulation of cell shape,GO:0015031~protein transport,GO:0032730~positive regulation of interleukin-1 alpha production,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043303~mast cell degranulation,GO:0046688~response to copper ion,GO:0051602~response to electrical stimulus,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0048471~perinuclear region of cytoplasm,	GO:0005507~copper ion binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0008289~lipid binding,GO:0017134~fibroblast growth factor binding,GO:0042803~protein homodimerization activity,GO:0048306~calcium-dependent protein binding,GO:0050786~RAGE receptor binding,	IPR011992:EF-hand-like domain,IPR013787:S100/CaBP-9k-type, calcium binding, subdomain,				SM01394:SM01394,	KW-0653~Protein transport,KW-0813~Transport,	KW-0963~Cytoplasm,KW-0964~Secreted,		KW-0677~Repeat,	KW-0106~Calcium,KW-0186~Copper,KW-0446~Lipid-binding,KW-0479~Metal-binding,		KW-0597~Phosphoprotein,	CA_BIND:1,CA_BIND:2,DOMAIN:EF-hand,DOMAIN:S_100,
S100A4	S100 calcium binding protein A4(S100A4)	Homo sapiens				GO:0001837~epithelial to mesenchymal transition,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0043005~neuron projection,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0003779~actin binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0046914~transition metal ion binding,GO:0048306~calcium-dependent protein binding,GO:0050786~RAGE receptor binding,	IPR001751:S100/Calbindin-D9k, conserved site,IPR002048:EF-hand domain,IPR011992:EF-hand-like domain,IPR013787:S100/CaBP-9k-type, calcium binding, subdomain,IPR018247:EF-Hand 1, calcium-binding site,				SM00054:EFh,SM01394:SM01394,		KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0964~Secreted,		KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0007~Acetylation,	CA_BIND:1; low affinity,CA_BIND:2; high affinity,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,
SACM1L	SAC1 like phosphatidylinositide phosphatase(SACM1L)	Homo sapiens				GO:0006661~phosphatidylinositol biosynthetic process,GO:0046856~phosphatidylinositol dephosphorylation,	GO:0000139~Golgi membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0016021~integral component of membrane,GO:0030176~integral component of endoplasmic reticulum membrane,	GO:0004438~phosphatidylinositol-3-phosphatase activity,GO:0005515~protein binding,GO:0016791~phosphatase activity,GO:0034593~phosphatidylinositol bisphosphate phosphatase activity,GO:0034596~phosphatidylinositol phosphate 4-phosphatase activity,GO:0043812~phosphatidylinositol-4-phosphate phosphatase activity,	IPR002013:Synaptojanin, N-terminal,	hsa00562:Inositol phosphate metabolism,hsa01100:Metabolic pathways,hsa04070:Phosphatidylinositol signaling system,				KW-0443~Lipid metabolism,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,	KW-0007~Acetylation,	DOMAIN:SAC,MUTAGEN:C->S: Loss of phosphatidylinositol-4-phosphate phosphatase activity.,REGION:Essential for phosphatidylinositol-4-phosphate phosphatase activity,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
SPDEF	SAM pointed domain containing ETS transcription factor(SPDEF)	Homo sapiens				GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007275~multicellular organism development,GO:0010454~negative regulation of cell fate commitment,GO:0010455~positive regulation of cell fate commitment,GO:0030154~cell differentiation,GO:0043065~positive regulation of apoptotic process,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0060480~lung goblet cell differentiation,GO:0060576~intestinal epithelial cell development,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000418:Ets domain,IPR003118:Pointed domain,IPR013761:Sterile alpha motif/pointed domain,				SM00251:SAM_PNT,SM00413:ETS,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,KW-0238~DNA-binding,		COMPBIAS:Polar residues,DNA_BIND:ETS,DOMAIN:PNT,REGION:Disordered,
SATB1	SATB homeobox 1(SATB1)	Homo sapiens				GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006325~chromatin organization,GO:0006338~chromatin remodeling,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0016032~viral process,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016363~nuclear matrix,GO:0016604~nuclear body,GO:0016605~PML body,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003690~double-stranded DNA binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,	IPR001356:Homeodomain,IPR003350:Homeodomain protein CUT,IPR009057:Homeodomain-like,IPR010982:Lambda repressor-like, DNA-binding domain,		619228~Developmental delay with dysmorphic facies and dental anomalies,619229~Kohlschutter-Tonz syndrome-like,		SM00389:HOX,SM01109:SM01109,	KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,		KW-0371~Homeobox,KW-0677~Repeat,KW-0732~Signal,		KW-0156~Chromatin regulator,KW-0238~DNA-binding,KW-0678~Repressor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	BINDING:Matrix attachment region (MAR) DNA,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DNA_BIND:CUT 1,DNA_BIND:CUT 2,DNA_BIND:Homeobox,DOMAIN:CUT,DOMAIN:CUTL,DOMAIN:Homeobox,DOMAIN:ULD,MOTIF:Nuclear localization signal,MOTIF:Protein interaction,MUTAGEN:D->A: CASP6-resistant.,MUTAGEN:E->A: Normal nuclear localization.,MUTAGEN:FQN->AAA: Reduced interaction with matrix attachment region (MAR) DNA.,MUTAGEN:G->A: Impaired MAR-DNA-binding.,MUTAGEN:K->A,Q,R: No acetylation.,MUTAGEN:K->A: Loss of nuclear localization, cytoplasmic.,MUTAGEN:K->N: Impaired MAR-DNA-binding.,MUTAGEN:K->N: Reduced MAR-DNA-binding.,MUTAGEN:K->R: Loss of sumoylation.,MUTAGEN:K->R: Normal sumoylation.,MUTAGEN:N->A: Normal nuclear localization.,MUTAGEN:Q->A: Impaired MAR-DNA-binding.,MUTAGEN:R->A: Loss of nuclear localization, cytoplasmic.,MUTAGEN:R->A: Reduced interaction with matrix attachment region (MAR) DNA; when associated with A-646.,MUTAGEN:R->A: Reduced interaction with matrix attachment region (MAR) DNA; when associated with A-648.,MUTAGEN:R->N: Impaired MAR-DNA-binding.,MUTAGEN:R->N: Reduced MAR-DNA-binding.,MUTAGEN:S->A: Impaired MAR-DNA-binding.,MUTAGEN:S->A: No phosphorylation.,MUTAGEN:S->A: Slightly reduced MAR-DNA-binding.,REGION:Disordered,REGION:Matrix attachment region (MAR) DNA-binding,REGION:Nuclear matrix targeting sequence (NMTS),REGION:PDZ-like dimerization domain,SITE:Cleavage; by caspases,
SCAND1	SCAN domain containing 1(SCAND1)	Homo sapiens				GO:0045893~positive regulation of transcription, DNA-templated,	GO:0005634~nucleus,	GO:0005515~protein binding,	IPR003309:Transcription regulator SCAN,				SM00431:SCAN,		KW-0539~Nucleus,						COMPBIAS:Pro residues,DOMAIN:SCAN box,REGION:Disordered,
SCYL3	SCY1 like pseudokinase 3(SCYL3)	Homo sapiens				GO:0006468~protein phosphorylation,GO:0006954~inflammatory response,GO:0016477~cell migration,GO:0021522~spinal cord motor neuron differentiation,GO:0034613~cellular protein localization,GO:0048666~neuron development,	GO:0000139~Golgi membrane,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0030027~lamellipodium,	GO:0004672~protein kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0042802~identical protein binding,	IPR000719:Protein kinase, catalytic domain,IPR011009:Protein kinase-like domain,IPR011989:Armadillo-like helical,IPR016024:Armadillo-type fold,IPR021133:HEAT, type 2,				SM00220:S_TKc,		KW-0333~Golgi apparatus,KW-0963~Cytoplasm,KW-0966~Cell projection,		KW-0677~Repeat,			KW-0449~Lipoprotein,KW-0519~Myristate,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,DOMAIN:Protein kinase,LIPID:N-myristoyl glycine,MUTAGEN:GSENS->M: No Golgi targeting, accumulates in the cytoplasm.,REGION:Disordered,REGION:Interaction with EZR,REPEAT:HEAT,REPEAT:HEAT 1,REPEAT:HEAT 2,REPEAT:HEAT 3,REPEAT:HEAT 4,
SHB	SH2 domain containing adaptor protein B(SHB)	Homo sapiens				GO:0001525~angiogenesis,GO:0006915~apoptotic process,GO:0007165~signal transduction,GO:0030154~cell differentiation,GO:0048010~vascular endothelial growth factor receptor signaling pathway,	GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0036464~cytoplasmic ribonucleoprotein granule,	GO:0001784~phosphotyrosine binding,GO:0005515~protein binding,	IPR000980:SH2 domain,				SM00252:SH2,	KW-0037~Angiogenesis,KW-0053~Apoptosis,KW-0221~Differentiation,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0727~SH2 domain,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:SH2,MUTAGEN:R->K: Loss of interaction with CD3Z. Alters LAT, PLCG1, VAV1 and LCP2 phosphorylation, MAP kinase signaling, Rac1 and JNK activation, intracellular calcium increase, activation of the nuclear factor for activation of T-cells and subsequent interleukin-2 expression which normally occur upon T-cells stimulation.,REGION:Disordered,REGION:Mediates interaction with LAT, PTK2/FAK1, JAK1 and JAK3,
SH3BP5	SH3 domain binding protein 5(SH3BP5)	Homo sapiens				GO:0007165~signal transduction,GO:0035556~intracellular signal transduction,GO:0061099~negative regulation of protein tyrosine kinase activity,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0016604~nuclear body,GO:0030659~cytoplasmic vesicle membrane,	GO:0004860~protein kinase inhibitor activity,GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,GO:0017124~SH3 domain binding,	IPR007940:SH3-binding 5,						KW-0472~Membrane,KW-0496~Mitochondrion,KW-0968~Cytoplasmic vesicle,		KW-0175~Coiled coil,KW-0729~SH3-binding,		KW-0344~Guanine-nucleotide releasing factor,	KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,MUTAGEN:L->A: Loss of phosphorylation and binding by phospho-JNK; when associated with A-347.,MUTAGEN:L->A: Loss of phosphorylation and binding by phospho-JNK; when associated with A-349.,MUTAGEN:L->A: No change of phosphorylation or binding by phospho-JNK; when associated with A-434.,MUTAGEN:L->A: No change of phosphorylation or binding by phospho-JNK; when associated with A-436.,MUTAGEN:LE->AK: Loss of guanine nucleotide exchange factor activity.,MUTAGEN:LNQ->AAA: Loss of guanine nucleotide exchange factor activity.,REGION:Disordered,REGION:Sufficient for interaction with RAB11A and for guanine nucleotide exchange activity,
SHC1	SHC adaptor protein 1(SHC1)	Homo sapiens	101.Gprot_coupled_Rec_MAP_Kinase,	h_at1rPathway:Angiotensin II mediated activation of JNK Pathway via Pyk2 dependent signaling,h_bcrPathway:BCR Signaling Pathway,h_biopeptidesPathway:Bioactive Peptide Induced Signaling Pathway,h_ecmPathway:Erk and PI-3 Kinase Are Necessary for Collagen Binding in Corneal Epithelia,h_egfPathway:EGF Signaling Pathway,h_epoPathway:EPO Signaling Pathway,h_erk5Pathway:Role of Erk5 in Neuronal Survival,h_erkPathway:Erk1/Erk2 Mapk Signaling pathway,h_fcer1Pathway:Fc Epsilon Receptor I Signaling in Mast Cells,h_ghPathway:Growth Hormone Signaling Pathway,h_hbxPathway:Calcium Signaling by HBx of Hepatitis B virus,h_her2Pathway:Role of ERBB2 in Signal Transduction and Oncology,h_igf1Pathway:IGF-1 Signaling Pathway,h_igf1rPathway:Multiple antiapoptotic pathways from IGF-1R signaling lead to BAD phosphorylation,h_il2Pathway:IL 2 signaling pathway,h_il2rbPathway:IL-2 Receptor Beta Chain in T cell Activation,h_il3Pathway:IL 3 signaling pathway,h_il4Pathway:IL 4 signaling pathway,h_il6Pathway:IL 6 signaling pathway,h_insulinPathway:Insulin Signaling Pathway,h_integrinPathway:Integrin Signaling Pathway,h_longevityPathway:The IGF-1 Receptor and Longevity,h_mapkPathway:MAPKinase Signaling Pathway,h_ngfPathway:Nerve growth factor pathway (NGF),h_p38mapkPathway:p38 MAPK Signaling Pathway ,h_pdgfPathway:PDGF Signaling Pathway,h_ptenPathway:PTEN dependent cell cycle arrest and apoptosis,h_pyk2Pathway:Links between Pyk2 and Map Kinases,h_spryPathway:Sprouty regulation of tyrosine kinase signals,h_tcrPathway:T Cell Receptor Signaling Pathway,h_tffPathway:Trefoil Factors Initiate  Mucosal Healing,h_tpoPathway:TPO Signaling Pathway,h_trkaPathway:Trka Receptor Signaling Pathway,h_vegfPathway:VEGF, Hypoxia, and Angiogenesis,		GO:0000165~MAPK cascade,GO:0000187~activation of MAPK activity,GO:0001525~angiogenesis,GO:0007165~signal transduction,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007173~epidermal growth factor receptor signaling pathway,GO:0007176~regulation of epidermal growth factor-activated receptor activity,GO:0007265~Ras protein signal transduction,GO:0007411~axon guidance,GO:0007507~heart development,GO:0008284~positive regulation of cell proliferation,GO:0008286~insulin receptor signaling pathway,GO:0016032~viral process,GO:0016525~negative regulation of angiogenesis,GO:0019221~cytokine-mediated signaling pathway,GO:0031532~actin cytoskeleton reorganization,GO:0035556~intracellular signal transduction,GO:0035723~interleukin-15-mediated signaling pathway,GO:0036498~IRE1-mediated unfolded protein response,GO:0038095~Fc-epsilon receptor signaling pathway,GO:0038110~interleukin-2-mediated signaling pathway,GO:0038128~ERBB2 signaling pathway,GO:0040008~regulation of growth,GO:0042742~defense response to bacterium,GO:0043066~negative regulation of apoptotic process,GO:0043410~positive regulation of MAPK cascade,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0046579~positive regulation of Ras protein signal transduction,GO:0050900~leukocyte migration,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071363~cellular response to growth factor stimulus,GO:0071864~positive regulation of cell proliferation in bone marrow,GO:0090322~regulation of superoxide metabolic process,GO:0098609~cell-cell adhesion,	GO:0005737~cytoplasm,GO:0005759~mitochondrial matrix,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0070435~Shc-EGFR complex,	GO:0001784~phosphotyrosine binding,GO:0005068~transmembrane receptor protein tyrosine kinase adaptor activity,GO:0005154~epidermal growth factor receptor binding,GO:0005158~insulin receptor binding,GO:0005159~insulin-like growth factor receptor binding,GO:0005168~neurotrophin TRKA receptor binding,GO:0005515~protein binding,GO:0005543~phospholipid binding,GO:0019901~protein kinase binding,GO:0030971~receptor tyrosine kinase binding,GO:0046875~ephrin receptor binding,GO:0048408~epidermal growth factor binding,	IPR000980:SH2 domain,IPR006019:Phosphotyrosine interaction (PID/PI),IPR006020:Phosphotyrosine interaction domain,IPR011993:Pleckstrin homology-like domain,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa01522:Endocrine resistance,hsa04012:ErbB signaling pathway,hsa04014:Ras signaling pathway,hsa04062:Chemokine signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04510:Focal adhesion,hsa04650:Natural killer cell mediated cytotoxicity,hsa04722:Neurotrophin signaling pathway,hsa04910:Insulin signaling pathway,hsa04915:Estrogen signaling pathway,hsa04917:Prolactin signaling pathway,hsa04926:Relaxin signaling pathway,hsa04935:Growth hormone synthesis, secretion and action,hsa05034:Alcoholism,hsa05100:Bacterial invasion of epithelial cells,hsa05206:MicroRNAs in cancer,hsa05214:Glioma,hsa05220:Chronic myeloid leukemia,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,			SM00252:SH2,SM00462:PTB,	KW-0037~Angiogenesis,KW-0341~Growth regulation,KW-0945~Host-virus interaction,	KW-0496~Mitochondrion,KW-0963~Cytoplasm,		KW-0727~SH2 domain,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:PID,DOMAIN:SH2,MUTAGEN:Y->F: Alters interaction with GRB2; isoform p52Shc (in vitro).,MUTAGEN:Y->F: No effect on interaction with GRB2; isoform p52Shc (in vitro).,REGION:CH1,REGION:Disordered,
SMAD3	SMAD family member 3(SMAD3)	Homo sapiens		h_g1Pathway:Cell Cycle: G1/S Check Point ,h_nthiPathway:NFkB activation by Nontypeable Hemophilus influenzae,h_tgfbPathway:TGF beta signaling pathway,h_tob1Pathway:Role of Tob in T-cell activation,		GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001657~ureteric bud development,GO:0001666~response to hypoxia,GO:0001701~in utero embryonic development,GO:0001707~mesoderm formation,GO:0001756~somitogenesis,GO:0001889~liver development,GO:0001947~heart looping,GO:0002076~osteoblast development,GO:0002520~immune system development,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0006955~immune response,GO:0007050~cell cycle arrest,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0007183~SMAD protein complex assembly,GO:0007254~JNK cascade,GO:0007492~endoderm development,GO:0008285~negative regulation of cell proliferation,GO:0009653~anatomical structure morphogenesis,GO:0009880~embryonic pattern specification,GO:0010628~positive regulation of gene expression,GO:0010694~positive regulation of alkaline phosphatase activity,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0016032~viral process,GO:0016202~regulation of striated muscle tissue development,GO:0016579~protein deubiquitination,GO:0017015~regulation of transforming growth factor beta receptor signaling pathway,GO:0023019~signal transduction involved in regulation of gene expression,GO:0030154~cell differentiation,GO:0030308~negative regulation of cell growth,GO:0030325~adrenal gland development,GO:0030335~positive regulation of cell migration,GO:0030501~positive regulation of bone mineralization,GO:0030509~BMP signaling pathway,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0030878~thyroid gland development,GO:0031053~primary miRNA processing,GO:0032332~positive regulation of chondrocyte differentiation,GO:0032731~positive regulation of interleukin-1 beta production,GO:0032909~regulation of transforming growth factor beta2 production,GO:0032916~positive regulation of transforming growth factor beta3 production,GO:0032924~activin receptor signaling pathway,GO:0033689~negative regulation of osteoblast proliferation,GO:0038092~nodal signaling pathway,GO:0042060~wound healing,GO:0042110~T cell activation,GO:0042177~negative regulation of protein catabolic process,GO:0042307~positive regulation of protein import into nucleus,GO:0043066~negative regulation of apoptotic process,GO:0045216~cell-cell junction organization,GO:0045429~positive regulation of nitric oxide biosynthetic process,GO:0045599~negative regulation of fat cell differentiation,GO:0045668~negative regulation of osteoblast differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045930~negative regulation of mitotic cell cycle,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048340~paraxial mesoderm morphogenesis,GO:0048589~developmental growth,GO:0048617~embryonic foregut morphogenesis,GO:0048701~embryonic cranial skeleton morphogenesis,GO:0050678~regulation of epithelial cell proliferation,GO:0050728~negative regulation of inflammatory response,GO:0050776~regulation of immune response,GO:0050821~protein stabilization,GO:0050927~positive regulation of positive chemotaxis,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0051098~regulation of binding,GO:0051481~negative regulation of cytosolic calcium ion concentration,GO:0051496~positive regulation of stress fiber assembly,GO:0051894~positive regulation of focal adhesion assembly,GO:0060039~pericardium development,GO:0060290~transdifferentiation,GO:0060395~SMAD protein signal transduction,GO:0061045~negative regulation of wound healing,GO:0061767~negative regulation of lung blood pressure,GO:0070306~lens fiber cell differentiation,GO:0071345~cellular response to cytokine stimulus,GO:0071560~cellular response to transforming growth factor beta stimulus,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:0097191~extrinsic apoptotic signaling pathway,GO:0097296~activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway,GO:0098586~cellular response to virus,GO:1901203~positive regulation of extracellular matrix assembly,GO:1902893~regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1903243~negative regulation of cardiac muscle hypertrophy in response to stress,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005637~nuclear inner membrane,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0043235~receptor complex,GO:0071141~SMAD protein complex,GO:0071144~SMAD2-SMAD3 protein complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0000987~core promoter proximal region sequence-specific DNA binding,GO:0001102~RNA polymerase II activating transcription factor binding,GO:0001217~bacterial-type RNA polymerase transcriptional repressor activity, sequence-specific DNA binding,GO:0001223~transcription coactivator binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005160~transforming growth factor beta receptor binding,GO:0005515~protein binding,GO:0005518~collagen binding,GO:0008013~beta-catenin binding,GO:0008134~transcription factor binding,GO:0008270~zinc ion binding,GO:0016922~ligand-dependent nuclear receptor binding,GO:0017151~DEAD/H-box RNA helicase binding,GO:0019899~enzyme binding,GO:0019901~protein kinase binding,GO:0019902~phosphatase binding,GO:0031490~chromatin DNA binding,GO:0031625~ubiquitin protein ligase binding,GO:0031962~mineralocorticoid receptor binding,GO:0032810~sterol response element binding,GO:0035259~glucocorticoid receptor binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0043130~ubiquitin binding,GO:0043425~bHLH transcription factor binding,GO:0043565~sequence-specific DNA binding,GO:0046332~SMAD binding,GO:0046872~metal ion binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0070410~co-SMAD binding,GO:0070411~I-SMAD binding,GO:0070412~R-SMAD binding,GO:1990841~promoter-specific chromatin binding,	IPR001132:SMAD domain, Dwarfin-type,IPR003619:MAD homology 1, Dwarfin-type,IPR008984:SMAD/FHA domain,IPR013019:MAD homology, MH1,IPR013790:Dwarfin,IPR017855:SMAD domain-like,	hsa04068:FoxO signaling pathway,hsa04110:Cell cycle,hsa04144:Endocytosis,hsa04218:Cellular senescence,hsa04310:Wnt signaling pathway,hsa04350:TGF-beta signaling pathway,hsa04371:Apelin signaling pathway,hsa04390:Hippo signaling pathway,hsa04520:Adherens junction,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04659:Th17 cell differentiation,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa05161:Hepatitis B,hsa05166:Human T-cell leukemia virus 1 infection,hsa05200:Pathways in cancer,hsa05210:Colorectal cancer,hsa05212:Pancreatic cancer,hsa05220:Chronic myeloid leukemia,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,hsa05321:Inflammatory bowel disease,hsa05415:Diabetic cardiomyopathy,	613795~Loeys-Dietz syndrome 3,		SM00523:DWA,SM00524:DWB,	KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0993~Aortic aneurysm,		KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0013~ADP-ribosylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:MH1,DOMAIN:MH2,METAL:Zinc,MUTAGEN:K->A: Greatly reduced interaction with DNA and JUN. Abolishes interaction with DNA and JUN; when associated with A-40; A-44 and A-43.,MUTAGEN:K->A: Little effect on interaction with DNA or JUN. Abolishes interaction with DNA and JUN; when associated with A-40; A-41 and A-44.,MUTAGEN:K->A: Little effect on interaction with DNA or JUN. Abolishes interaction with DNA and JUN; when associated with A-41; A-43 and A-44.,MUTAGEN:K->A: Little effect on interaction with DNA or JUN. Abolishes interaction with JUN; when associated with A-40; A-41 and A-43.,MUTAGEN:K->Q: Increased transcriptional activity. No further increase in transcriptional activity with EP300.,MUTAGEN:K->R: Decreased monoubiquitination.,MUTAGEN:K->R: Greatly reduced acetylation and 85% reduction in transcriptional activity. Completely abolishes acetylation and 97% reduction in transcriptional activity; when associated with R-333; R-341 and R-409.,MUTAGEN:K->R: No effect on acetylation. Completely abolishes acetylation and 97% reduction in transcriptional activity; when associated with R-333; R-341 and R-378.,MUTAGEN:K->R: No effect on acetylation. Completely abolishes acetylation and 97% reduction in transcriptional activity; when associated with R-333; R-378 and R-409.,MUTAGEN:K->R: No effect on acetylation. Completely abolishes acetylation and 97% reduction in transcriptional activity; when associated with R-341; R-378 and R-409.,MUTAGEN:K->R: Slightly decreased monoubiquitination.,MUTAGEN:R->D: Reduced interaction with JUN. Loss of transcriptional activity and cooperation with JUN.,MUTAGEN:S->A: Increased constitutive activity.,MUTAGEN:S->A: Increased transcriptional activity. Further increased transcriptional activity; when associated with S-208.,MUTAGEN:S->A: Reduced phosphorylation. Increased transcriptional and antiproliferative activities. Further increase in transcriptional and antiproliferative activities; when associated with V-8 and V-179.,MUTAGEN:S->D: Decreased activity.,MUTAGEN:SSVS->AAVA: Does not abolish protein nuclear export. Abolishes almost completely acetylation.,MUTAGEN:SSVS->EEVE: Forms heterotrimers.,MUTAGEN:SSVS->RRVR: Diminishes cargo protein export.,MUTAGEN:T->V: Reduced phosphorylation, increased transcriptional and antiproliferative activities. Further increase in transcriptional and antiproliferative activities; when associated with V-179 and A-213.,MUTAGEN:T->V: Reduced phosphorylation, increased transcriptional and increased antiproliferative activities. Further increase in transcriptional and antiproliferative activities; when associated with V-8 and A-213.,REGION:Disordered,REGION:Linker,REGION:Sufficient for interaction with XPO4,SITE:Required for interaction with DNA and JUN and for functional cooperation with JUN,SITE:Required for trimerization,
SRC	SRC proto-oncogene, non-receptor tyrosine kinase(SRC)	Homo sapiens	85.Nuc_Rec-Coact_Complex,	h_achPathway:Role of nicotinic acetylcholine receptors in the regulation of apoptosis,h_agrPathway:Agrin in Postsynaptic Differentiation,h_at1rPathway:Angiotensin II mediated activation of JNK Pathway via Pyk2 dependent signaling,h_bArrestin-srcPathway:Roles of ï¿½-arrestin-dependent Recruitment of Src Kinases in GPCR Signaling,h_cblPathway:CBL mediated ligand-induced downregulation of EGF receptors,h_cell2cellPathway:Cell to Cell Adhesion Signaling,h_ecmPathway:Erk and PI-3 Kinase Are Necessary for Collagen Binding in Corneal Epithelia,h_edg1Pathway:Phospholipids as signalling intermediaries,h_erkPathway:Erk1/Erk2 Mapk Signaling pathway,h_gabaPathway:Gamma-aminobutyric Acid Receptor Life Cycle,h_hbxPathway:Calcium Signaling by HBx of Hepatitis B virus,h_integrinPathway:Integrin Signaling Pathway,h_metPathway:Signaling of Hepatocyte Growth Factor Receptor,h_mPRPathway:How Progesterone Initiates the Oocyte Maturation,h_pelp1Pathway:Pelp1 Modulation of Estrogen Receptor Activity,h_pyk2Pathway:Links between Pyk2 and Map Kinases,h_rhoPathway:Rho cell motility signaling pathway,h_sam68Pathway:Regulation of Splicing through Sam68,h_sppaPathway:Aspirin Blocks Signaling Pathway Involved in Platelet Activation,h_spryPathway:Sprouty regulation of tyrosine kinase signals,h_srcRPTPPathway:Activation of Src by Protein-tyrosine phosphatase alpha,h_uCalpainPathway:uCalpain and friends in Cell spread,		GO:0001545~primary ovarian follicle growth,GO:0001819~positive regulation of cytokine production,GO:0002223~stimulatory C-type lectin receptor signaling pathway,GO:0002862~negative regulation of inflammatory response to antigenic stimulus,GO:0007049~cell cycle,GO:0007155~cell adhesion,GO:0007165~signal transduction,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007172~signal complex assembly,GO:0007173~epidermal growth factor receptor signaling pathway,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007229~integrin-mediated signaling pathway,GO:0007411~axon guidance,GO:0008283~cell proliferation,GO:0009410~response to xenobiotic stimulus,GO:0009612~response to mechanical stimulus,GO:0009615~response to virus,GO:0010447~response to acidic pH,GO:0010632~regulation of epithelial cell migration,GO:0010634~positive regulation of epithelial cell migration,GO:0010907~positive regulation of glucose metabolic process,GO:0010954~positive regulation of protein processing,GO:0014068~positive regulation of phosphatidylinositol 3-kinase signaling,GO:0014911~positive regulation of smooth muscle cell migration,GO:0016032~viral process,GO:0016236~macroautophagy,GO:0018105~peptidyl-serine phosphorylation,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0022407~regulation of cell-cell adhesion,GO:0030154~cell differentiation,GO:0030168~platelet activation,GO:0030900~forebrain development,GO:0031295~T cell costimulation,GO:0031333~negative regulation of protein complex assembly,GO:0031648~protein destabilization,GO:0031667~response to nutrient levels,GO:0031954~positive regulation of protein autophosphorylation,GO:0032148~activation of protein kinase B activity,GO:0032211~negative regulation of telomere maintenance via telomerase,GO:0032869~cellular response to insulin stimulus,GO:0033146~regulation of intracellular estrogen receptor signaling pathway,GO:0033625~positive regulation of integrin activation,GO:0034332~adherens junction organization,GO:0034446~substrate adhesion-dependent cell spreading,GO:0035306~positive regulation of dephosphorylation,GO:0035556~intracellular signal transduction,GO:0035635~entry of bacterium into host cell,GO:0036035~osteoclast development,GO:0036120~cellular response to platelet-derived growth factor stimulus,GO:0038083~peptidyl-tyrosine autophosphorylation,GO:0038096~Fc-gamma receptor signaling pathway involved in phagocytosis,GO:0038128~ERBB2 signaling pathway,GO:0042476~odontogenesis,GO:0042493~response to drug,GO:0043065~positive regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043114~regulation of vascular permeability,GO:0043149~stress fiber assembly,GO:0043154~negative regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0043393~regulation of protein binding,GO:0043406~positive regulation of MAP kinase activity,GO:0043552~positive regulation of phosphatidylinositol 3-kinase activity,GO:0045056~transcytosis,GO:0045087~innate immune response,GO:0045124~regulation of bone resorption,GO:0045453~bone resorption,GO:0045737~positive regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0045747~positive regulation of Notch signaling pathway,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0046628~positive regulation of insulin receptor signaling pathway,GO:0046777~protein autophosphorylation,GO:0048010~vascular endothelial growth factor receptor signaling pathway,GO:0048011~neurotrophin TRK receptor signaling pathway,GO:0048013~ephrin receptor signaling pathway,GO:0048041~focal adhesion assembly,GO:0048477~oogenesis,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0050847~progesterone receptor signaling pathway,GO:0050900~leukocyte migration,GO:0051057~positive regulation of small GTPase mediated signal transduction,GO:0051222~positive regulation of protein transport,GO:0051385~response to mineralocorticoid,GO:0051602~response to electrical stimulus,GO:0051895~negative regulation of focal adhesion assembly,GO:0051897~positive regulation of protein kinase B signaling,GO:0051902~negative regulation of mitochondrial depolarization,GO:0051974~negative regulation of telomerase activity,GO:0060065~uterus development,GO:0060444~branching involved in mammary gland duct morphogenesis,GO:0060491~regulation of cell projection assembly,GO:0060576~intestinal epithelial cell development,GO:0070102~interleukin-6-mediated signaling pathway,GO:0070301~cellular response to hydrogen peroxide,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0070555~response to interleukin-1,GO:0071222~cellular response to lipopolysaccharide,GO:0071375~cellular response to peptide hormone stimulus,GO:0071393~cellular response to progesterone stimulus,GO:0071398~cellular response to fatty acid,GO:0071456~cellular response to hypoxia,GO:0071498~cellular response to fluid shear stress,GO:0071803~positive regulation of podosome assembly,GO:0071902~positive regulation of protein serine/threonine kinase activity,GO:0086098~angiotensin-activated signaling pathway involved in heart process,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:0098609~cell-cell adhesion,GO:0098962~regulation of postsynaptic neurotransmitter receptor activity,GO:1900182~positive regulation of protein localization to nucleus,GO:1903997~positive regulation of non-membrane spanning protein tyrosine kinase activity,GO:2000386~positive regulation of ovarian follicle development,GO:2000394~positive regulation of lamellipodium morphogenesis,GO:2000573~positive regulation of DNA biosynthetic process,GO:2000588~positive regulation of platelet-derived growth factor receptor-beta signaling pathway,GO:2000641~regulation of early endosome to late endosome transport,GO:2000811~negative regulation of anoikis,GO:2001237~negative regulation of extrinsic apoptotic signaling pathway,GO:2001243~negative regulation of intrinsic apoptotic signaling pathway,GO:2001286~regulation of caveolin-mediated endocytosis,	GO:0002102~podosome,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005764~lysosome,GO:0005770~late endosome,GO:0005829~cytosol,GO:0005884~actin filament,GO:0005886~plasma membrane,GO:0005901~caveola,GO:0005925~focal adhesion,GO:0014069~postsynaptic density,GO:0030054~cell junction,GO:0031234~extrinsic component of cytoplasmic side of plasma membrane,GO:0032587~ruffle membrane,GO:0043005~neuron projection,GO:0045121~membrane raft,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:0098978~glutamatergic synapse,GO:0099091~postsynaptic specialization, intracellular component,	GO:0004672~protein kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0004715~non-membrane spanning protein tyrosine kinase activity,GO:0005080~protein kinase C binding,GO:0005102~receptor binding,GO:0005158~insulin receptor binding,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008022~protein C-terminus binding,GO:0016004~phospholipase activator activity,GO:0019899~enzyme binding,GO:0019900~kinase binding,GO:0020037~heme binding,GO:0030331~estrogen receptor binding,GO:0031625~ubiquitin protein ligase binding,GO:0042169~SH2 domain binding,GO:0043274~phospholipase binding,GO:0044325~ion channel binding,GO:0045296~cadherin binding,GO:0046875~ephrin receptor binding,GO:0051117~ATPase binding,GO:0051219~phosphoprotein binding,GO:0070700~BMP receptor binding,GO:0070851~growth factor receptor binding,GO:0071253~connexin binding,GO:0097110~scaffold protein binding,	IPR000719:Protein kinase, catalytic domain,IPR000980:SH2 domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR001452:Src homology-3 domain,IPR008266:Tyrosine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,IPR020635:Tyrosine-protein kinase, catalytic domain,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa01522:Endocrine resistance,hsa04012:ErbB signaling pathway,hsa04015:Rap1 signaling pathway,hsa04062:Chemokine signaling pathway,hsa04137:Mitophagy - animal,hsa04144:Endocytosis,hsa04360:Axon guidance,hsa04370:VEGF signaling pathway,hsa04510:Focal adhesion,hsa04520:Adherens junction,hsa04530:Tight junction,hsa04540:Gap junction,hsa04611:Platelet activation,hsa04613:Neutrophil extracellular trap formation,hsa04625:C-type lectin receptor signaling pathway,hsa04727:GABAergic synapse,hsa04750:Inflammatory mediator regulation of TRP channels,hsa04810:Regulation of actin cytoskeleton,hsa04912:GnRH signaling pathway,hsa04915:Estrogen signaling pathway,hsa04917:Prolactin signaling pathway,hsa04919:Thyroid hormone signaling pathway,hsa04921:Oxytocin signaling pathway,hsa04926:Relaxin signaling pathway,hsa05100:Bacterial invasion of epithelial cells,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05135:Yersinia infection,hsa05152:Tuberculosis,hsa05161:Hepatitis B,hsa05163:Human cytomegalovirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05203:Viral carcinogenesis,hsa05205:Proteoglycans in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05219:Bladder cancer,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,	114500~Colon cancer, advanced, somatic,616937~Thrombocytopenia 6,		SM00219:TyrKc,SM00252:SH2,SM00326:SH3,	KW-0130~Cell adhesion,KW-0131~Cell cycle,KW-0391~Immunity,KW-0945~Host-virus interaction,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-0999~Mitochondrion inner membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0656~Proto-oncogene,	KW-0727~SH2 domain,KW-0728~SH3 domain,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0449~Lipoprotein,KW-0519~Myristate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Proton acceptor,BINDING:ATP,DOMAIN:PK_Tyr_Ser-Thr,DOMAIN:Protein kinase,DOMAIN:SH2,DOMAIN:SH3,LIPID:N-myristoyl glycine,MUTAGEN:K->M: Kinase inactive. Abolishes ubiquitination promoted by CBLC.,MUTAGEN:P->E: Kinase active. Interacts with PDLIM4; when associated with E-302 and F-419.,MUTAGEN:P->E: Kinase active. Interacts with PDLIM4; when associated with E-307 and F-419.,MUTAGEN:Y->F: Loss of kinase activity. Loss of interaction with PDLIM4.,NP_BIND:ATP,REGION:Disordered,
SOX2	SRY-box transcription factor 2(SOX2)	Homo sapiens				GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001649~osteoblast differentiation,GO:0001654~eye development,GO:0001714~endodermal cell fate specification,GO:0006325~chromatin organization,GO:0006355~regulation of transcription, DNA-templated,GO:0007050~cell cycle arrest,GO:0009611~response to wounding,GO:0009653~anatomical structure morphogenesis,GO:0010468~regulation of gene expression,GO:0019221~cytokine-mediated signaling pathway,GO:0021781~glial cell fate commitment,GO:0021983~pituitary gland development,GO:0021984~adenohypophysis development,GO:0022409~positive regulation of cell-cell adhesion,GO:0030154~cell differentiation,GO:0030900~forebrain development,GO:0035019~somatic stem cell population maintenance,GO:0042246~tissue regeneration,GO:0043281~regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0043410~positive regulation of MAPK cascade,GO:0045165~cell fate commitment,GO:0045597~positive regulation of cell differentiation,GO:0045665~negative regulation of neuron differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048839~inner ear development,GO:0050680~negative regulation of epithelial cell proliferation,GO:0070848~response to growth factor,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:0097150~neuronal stem cell population maintenance,GO:1902807~negative regulation of cell cycle G1/S phase transition,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0035198~miRNA binding,GO:0043565~sequence-specific DNA binding,	IPR009071:High mobility group (HMG) box domain,IPR022097:Transcription factor SOX,	hsa04390:Hippo signaling pathway,hsa04550:Signaling pathways regulating pluripotency of stem cells,	206900~Microphthalmia, syndromic 3,206900~Optic nerve hypoplasia and abnormalities of the central nervous system,		SM00398:HMG,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-1013~Microphthalmia,			KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),DNA_BIND:HMG box,DOMAIN:HMG box,REGION:Disordered,
SOX4	SRY-box transcription factor 4(SOX4)	Homo sapiens				GO:0001501~skeletal system development,GO:0001841~neural tube formation,GO:0002328~pro-B cell differentiation,GO:0003183~mitral valve morphogenesis,GO:0003211~cardiac ventricle formation,GO:0003215~cardiac right ventricle morphogenesis,GO:0003289~atrial septum primum morphogenesis,GO:0003357~noradrenergic neuron differentiation,GO:0006355~regulation of transcription, DNA-templated,GO:0006977~DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest,GO:0007507~heart development,GO:0008284~positive regulation of cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0009653~anatomical structure morphogenesis,GO:0014009~glial cell proliferation,GO:0021510~spinal cord development,GO:0021522~spinal cord motor neuron differentiation,GO:0021782~glial cell development,GO:0030154~cell differentiation,GO:0030217~T cell differentiation,GO:0031018~endocrine pancreas development,GO:0031397~negative regulation of protein ubiquitination,GO:0031647~regulation of protein stability,GO:0032024~positive regulation of insulin secretion,GO:0035019~somatic stem cell population maintenance,GO:0035910~ascending aorta morphogenesis,GO:0042593~glucose homeostasis,GO:0042769~DNA damage response, detection of DNA damage,GO:0043065~positive regulation of apoptotic process,GO:0043516~regulation of DNA damage response, signal transduction by p53 class mediator,GO:0045588~positive regulation of gamma-delta T cell differentiation,GO:0045727~positive regulation of translation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048485~sympathetic nervous system development,GO:0050821~protein stabilization,GO:0060174~limb bud formation,GO:0060412~ventricular septum morphogenesis,GO:0060548~negative regulation of cell death,GO:0060563~neuroepithelial cell differentiation,GO:0060993~kidney morphogenesis,GO:0061484~hematopoietic stem cell homeostasis,GO:0071333~cellular response to glucose stimulus,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:2000761~positive regulation of N-terminal peptidyl-lysine acetylation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,GO:0005739~mitochondrion,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0035198~miRNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR009071:High mobility group (HMG) box domain,IPR017386:Transcription factor SOX-12/11/4a,	hsa05206:MicroRNAs in cancer,	618506~Coffin-Siris syndrome 10,	PIRSF038098:SOX-12/11/4a protein,	SM00398:HMG,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0991~Mental retardation,			KW-0010~Activator,KW-0238~DNA-binding,		COMPBIAS:Polar residues,DNA_BIND:HMG box,REGION:Disordered,
ST3GAL5	ST3 beta-galactoside alpha-2,3-sialyltransferase 5(ST3GAL5)	Homo sapiens				GO:0001574~ganglioside biosynthetic process,GO:0005975~carbohydrate metabolic process,GO:0006486~protein glycosylation,GO:0006688~glycosphingolipid biosynthetic process,GO:0097503~sialylation,	GO:0000139~Golgi membrane,GO:0005794~Golgi apparatus,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,	GO:0003836~beta-galactoside (CMP) alpha-2,3-sialyltransferase activity,GO:0004513~neolactotetraosylceramide alpha-2,3-sialyltransferase activity,GO:0008373~sialyltransferase activity,GO:0016757~transferase activity, transferring glycosyl groups,GO:0047291~lactosylceramide alpha-2,3-sialyltransferase activity,	IPR001675:Glycosyl transferase, family 29,IPR012163:Sialyltransferase,	hsa00604:Glycosphingolipid biosynthesis - ganglio series,hsa01100:Metabolic pathways,	609056~Salt and pepper developmental regression syndrome,	PIRSF005557:sialyltransferase,		KW-0443~Lipid metabolism,	KW-0333~Golgi apparatus,KW-0472~Membrane,	KW-0887~Epilepsy,KW-0991~Mental retardation,	KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
ST6GALNAC2	ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 2(ST6GALNAC2)	Homo sapiens				GO:0006486~protein glycosylation,GO:0006493~protein O-linked glycosylation,GO:0016266~O-glycan processing,GO:0019082~viral protein processing,GO:1990743~protein sialylation,	GO:0000139~Golgi membrane,GO:0005794~Golgi apparatus,GO:0016021~integral component of membrane,	GO:0001665~alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase activity,GO:0008373~sialyltransferase activity,	IPR001675:Glycosyl transferase, family 29,IPR012163:Sialyltransferase,	hsa00512:Mucin type O-glycan biosynthesis,hsa01100:Metabolic pathways,		PIRSF005557:sialyltransferase,			KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0732~Signal,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	BINDING:CMP-N-acetylneuraminate,CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
STAMBP	STAM binding protein(STAMBP)	Homo sapiens				GO:0000281~mitotic cytokinesis,GO:0007259~JAK-STAT cascade,GO:0008284~positive regulation of cell proliferation,GO:0014067~negative regulation of phosphatidylinositol 3-kinase signaling,GO:0016579~protein deubiquitination,GO:0043524~negative regulation of neuron apoptotic process,GO:0046580~negative regulation of Ras protein signal transduction,GO:0070536~protein K63-linked deubiquitination,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005768~endosome,GO:0005769~early endosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0032154~cleavage furrow,GO:0070062~extracellular exosome,	GO:0004843~thiol-dependent ubiquitin-specific protease activity,GO:0005515~protein binding,GO:0008237~metallopeptidase activity,GO:0019904~protein domain specific binding,GO:0046872~metal ion binding,GO:0061578~Lys63-specific deubiquitinase activity,GO:0070122~isopeptidase activity,GO:0101005~ubiquitinyl hydrolase activity,	IPR000555:JAB1/Mov34/MPN/PAD-1,IPR015063:Domain of unknown function DUF1873,	hsa04144:Endocytosis,	614261~Microcephaly-capillary malformation syndrome,		SM00232:JAB_MPN,	KW-0833~Ubl conjugation pathway,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0967~Endosome,	KW-0225~Disease variant,	KW-0175~Coiled coil,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	DOMAIN:MPN,METAL:Zinc 1; catalytic,METAL:Zinc 2,MOTIF:JAMM motif,MUTAGEN:D->A: Promotes accumulation of ubiquitin on endosomes, ablates enzymatic activity toward polyubiquitin substrate and allows ubiquitinated STAM stabilization.,REGION:Interaction with CHMP3,REGION:Interaction with STAM,SITE:Indirect zinc-binding,
STUB1	STIP1 homology and U-box containing protein 1(STUB1)	Homo sapiens				GO:0000209~protein polyubiquitination,GO:0002931~response to ischemia,GO:0006281~DNA repair,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0006515~misfolded or incompletely synthesized protein catabolic process,GO:0016567~protein ubiquitination,GO:0030433~ubiquitin-dependent ERAD pathway,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0030579~ubiquitin-dependent SMAD protein catabolic process,GO:0030968~endoplasmic reticulum unfolded protein response,GO:0031398~positive regulation of protein ubiquitination,GO:0031647~regulation of protein stability,GO:0031943~regulation of glucocorticoid metabolic process,GO:0032091~negative regulation of protein binding,GO:0032436~positive regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0034605~cellular response to heat,GO:0038128~ERBB2 signaling pathway,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0045862~positive regulation of proteolysis,GO:0051443~positive regulation of ubiquitin-protein transferase activity,GO:0051604~protein maturation,GO:0051865~protein autoubiquitination,GO:0060544~regulation of necroptotic process,GO:0061684~chaperone-mediated autophagy,GO:0070534~protein K63-linked ubiquitination,GO:0071218~cellular response to misfolded protein,GO:0071456~cellular response to hypoxia,GO:0090035~positive regulation of chaperone-mediated protein complex assembly,	GO:0000151~ubiquitin ligase complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0030018~Z disc,GO:0031371~ubiquitin conjugating enzyme complex,GO:0042405~nuclear inclusion body,GO:0101031~chaperone complex,	GO:0001664~G-protein coupled receptor binding,GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0019900~kinase binding,GO:0030544~Hsp70 protein binding,GO:0030674~protein binding, bridging,GO:0030911~TPR domain binding,GO:0031072~heat shock protein binding,GO:0031625~ubiquitin protein ligase binding,GO:0034450~ubiquitin-ubiquitin ligase activity,GO:0042803~protein homodimerization activity,GO:0046332~SMAD binding,GO:0048156~tau protein binding,GO:0051087~chaperone binding,GO:0051787~misfolded protein binding,GO:0051879~Hsp90 protein binding,GO:0061630~ubiquitin protein ligase activity,	IPR003613:U box domain,IPR011990:Tetratricopeptide-like helical,IPR013026:Tetratricopeptide repeat-containing domain,IPR013083:Zinc finger, RING/FYVE/PHD-type,IPR019734:Tetratricopeptide repeat,	hsa04120:Ubiquitin mediated proteolysis,hsa04141:Protein processing in endoplasmic reticulum,	615768~Spinocerebellar ataxia, autosomal recessive 16,618093~Spinocerebellar ataxia 48,		SM00028:TPR,SM00504:Ubox,	KW-0227~DNA damage,KW-0234~DNA repair,KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0950~Spinocerebellar ataxia,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0802~TPR repeat,		KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:CHIP_TPR_N,DOMAIN:U-box,MUTAGEN:H->Q: Loss of ability to ubiquitinate FOXP3.,MUTAGEN:K->A: Loss of interaction with FOXP3 and its ability to ubiquitinate FOXP3. Loss of interaction with SMAD3, HSPA8, HSP90AA1 and HSP90AB1.,MUTAGEN:P->A: Abolishes E3 ligase activity.,REGION:Disordered,REPEAT:TPR,REPEAT:TPR 1,REPEAT:TPR 2,REPEAT:TPR 3,
SENP6	SUMO specific peptidase 6(SENP6)	Homo sapiens				GO:0016925~protein sumoylation,GO:0016926~protein desumoylation,GO:0070646~protein modification by small protein removal,GO:0090169~regulation of spindle assembly,GO:0090234~regulation of kinetochore assembly,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0008234~cysteine-type peptidase activity,GO:0070139~SUMO-specific endopeptidase activity,	IPR003653:Peptidase C48, SUMO/Sentrin/Ubl1,					KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,				KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:ULP_PROTEASE,MUTAGEN:C->S: Abolishes enzymatic activity.,REGION:Disordered,REGION:Protease,
SUV39H1	SUV39H1 histone lysine methyltransferase(SUV39H1)	Homo sapiens				GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000183~chromatin silencing at rDNA,GO:0006325~chromatin organization,GO:0006364~rRNA processing,GO:0006974~cellular response to DNA damage stimulus,GO:0007049~cell cycle,GO:0016032~viral process,GO:0030154~cell differentiation,GO:0031062~positive regulation of histone methylation,GO:0031065~positive regulation of histone deacetylation,GO:0034968~histone lysine methylation,GO:0036123~histone H3-K9 dimethylation,GO:0036124~histone H3-K9 trimethylation,GO:0042149~cellular response to glucose starvation,GO:0042754~negative regulation of circadian rhythm,GO:0045786~negative regulation of cell cycle,GO:0045892~negative regulation of transcription, DNA-templated,GO:0046015~regulation of transcription by glucose,GO:0048511~rhythmic process,GO:0071456~cellular response to hypoxia,GO:0097009~energy homeostasis,	GO:0000775~chromosome, centromeric region,GO:0000792~heterochromatin,GO:0000794~condensed nuclear chromosome,GO:0005634~nucleus,GO:0005652~nuclear lamina,GO:0005654~nucleoplasm,GO:0005677~chromatin silencing complex,GO:0005730~nucleolus,GO:0033553~rDNA heterochromatin,GO:0061773~eNoSc complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0003682~chromatin binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0008757~S-adenosylmethionine-dependent methyltransferase activity,GO:0018024~histone-lysine N-methyltransferase activity,GO:0042054~histone methyltransferase activity,GO:0046974~histone methyltransferase activity (H3-K9 specific),GO:0047485~protein N-terminus binding,	IPR000953:Chromo domain/shadow,IPR001214:SET domain,IPR003616:Post-SET domain,IPR007728:Pre-SET domain,IPR011381:Histone H3-K9 methyltransferase,IPR016197:Chromo domain-like,IPR023779:Chromo domain, conserved site,IPR023780:Chromo domain,	hsa00310:Lysine degradation,hsa01100:Metabolic pathways,		PIRSF009343:histone H3-K9 methyltransferase,	SM00298:CHROMO,SM00317:SET,SM00468:PreSET,SM00508:PostSET,	KW-0090~Biological rhythms,KW-0131~Cell cycle,KW-0221~Differentiation,KW-0698~rRNA processing,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0137~Centromere,KW-0158~Chromosome,KW-0539~Nucleus,			KW-0479~Metal-binding,KW-0862~Zinc,KW-0949~S-adenosyl-L-methionine,	KW-0156~Chromatin regulator,KW-0489~Methyltransferase,KW-0678~Repressor,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	BINDING:S-adenosyl-L-methionine,DOMAIN:Chromo,DOMAIN:Post-SET,DOMAIN:Pre-SET,DOMAIN:SET,METAL:Zinc 1,METAL:Zinc 2,METAL:Zinc 3,METAL:Zinc 4,MUTAGEN:C->A: Abolishes methylation of histone H3.,MUTAGEN:H->L,K: Abolishes methylation of histone H3.,MUTAGEN:H->R: Strongly increases methylation of histone H3.,MUTAGEN:K->A: Loss of SIRT1-mediated up-regulation of enzymatic activity.,MUTAGEN:K->Q: Significant loss of enzymatic activity.,MUTAGEN:W->A: Abolishes methyltransferase activity.,MUTAGEN:Y->A: Abolishes methyltransferase activity.,REGION:Interaction with SIRT1,REGION:Mediates interaction with MECOM,REGION:S-adenosyl-L-methionine binding,
SUZ12	SUZ12 polycomb repressive complex 2 subunit(SUZ12)	Homo sapiens		h_prc2Pathway:The PRC2 Complex Sets Long-term Gene Silencing Through Modification of Histone Tails,		GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0008284~positive regulation of cell proliferation,GO:0009048~dosage compensation by inactivation of X chromosome,GO:0016571~histone methylation,GO:0016574~histone ubiquitination,GO:0019058~viral life cycle,GO:0021510~spinal cord development,GO:0032526~response to retinoic acid,GO:0032682~negative regulation of chemokine production,GO:0042532~negative regulation of tyrosine phosphorylation of STAT protein,GO:0045596~negative regulation of cell differentiation,GO:0045814~negative regulation of gene expression, epigenetic,GO:0048709~oligodendrocyte differentiation,GO:0050680~negative regulation of epithelial cell proliferation,GO:0050790~regulation of catalytic activity,GO:0070317~negative regulation of G0 to G1 transition,GO:0098532~histone H3-K27 trimethylation,	GO:0001739~sex chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005677~chromatin silencing complex,GO:0005730~nucleolus,GO:0016604~nuclear body,GO:0032993~protein-DNA complex,GO:0035098~ESC/E(Z) complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0001222~transcription corepressor binding,GO:0001226~RNA polymerase II transcription corepressor binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008047~enzyme activator activity,GO:0031490~chromatin DNA binding,GO:0035064~methylated histone binding,GO:0042054~histone methyltransferase activity,GO:0046872~metal ion binding,GO:1990841~promoter-specific chromatin binding,	IPR019135:Polycomb protein, VEFS-Box,		618786~Imagawa-Matsumoto syndrome,			KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0656~Proto-oncogene,KW-0991~Mental retardation,	KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0156~Chromatin regulator,KW-0678~Repressor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:VEFS-Box,MUTAGEN:F->A: Fails to interact with JARID2; when associated with A-86.,MUTAGEN:F->A: Fails to interact with JARID2; when associated with A-90.,MUTAGEN:G->W: No effect on interaction with PHF19. The PRC2.1 dimer forms but is unstable.,MUTAGEN:KRK->DDD: Fails to form a PRC2.1 dimer. Reduced H3K27me3 enrichment on PRC2 target genes.,MUTAGEN:R->A: Fails to form a PRC2.1 dimer.,MUTAGEN:W->A: Fails to interact with PHF19. The PRC2.1 dimer forms but is unstable.,REGION:Disordered,REGION:Interaction with AEBP2 and PHF19,REGION:Interaction with JARID2 and EPOP,REGION:VEFS-box,SITE:Breakpoint for translocation to form JAZF1-SUZ12 oncogene,ZN_FING:C2H2-type,
SMARCC1	SWI/SNF related, matrix associated, actin dependent regulator of chromatin subfamily c member 1(SMARCC1)	Homo sapiens		h_hSWI-SNFpathway:Chromatin Remodeling by hSWI/SNF ATP-dependent Complexes,h_vdrPathway:Control of Gene Expression by Vitamin D Receptor,	Chromatin structure and dynamics / Transcription,General function prediction only,	GO:0006337~nucleosome disassembly,GO:0006338~chromatin remodeling,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007399~nervous system development,GO:0008286~insulin receptor signaling pathway,GO:0009887~animal organ morphogenesis,GO:0030850~prostate gland development,GO:0032435~negative regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0043044~ATP-dependent chromatin remodeling,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0000785~chromatin,GO:0001741~XY body,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016514~SWI/SNF complex,GO:0032991~macromolecular complex,GO:0071564~npBAF complex,GO:0071565~nBAF complex,	GO:0003682~chromatin binding,GO:0003713~transcription coactivator activity,GO:0005515~protein binding,GO:0031492~nucleosomal DNA binding,GO:0042393~histone binding,GO:0047485~protein N-terminus binding,	IPR000953:Chromo domain/shadow,IPR001005:SANT/Myb domain,IPR007526:SWIRM domain,IPR009057:Homeodomain-like,IPR017884:SANT domain,	hsa04714:Thermogenesis,hsa05225:Hepatocellular carcinoma,			SM00298:CHROMO,SM00717:SANT,	KW-0524~Neurogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,		KW-0156~Chromatin regulator,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:Myb-like,DOMAIN:SANT,DOMAIN:SWIRM,DOMAIN:SWIRM-assoc_2,REGION:Disordered,
SMARCA4	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4(SMARCA4)	Homo sapiens		h_hSWI-SNFpathway:Chromatin Remodeling by hSWI/SNF ATP-dependent Complexes,h_vdrPathway:Control of Gene Expression by Vitamin D Receptor,		GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001188~RNA polymerase I transcriptional preinitiation complex assembly,GO:0003407~neural retina development,GO:0006325~chromatin organization,GO:0006337~nucleosome disassembly,GO:0006338~chromatin remodeling,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007399~nervous system development,GO:0030177~positive regulation of Wnt signaling pathway,GO:0030308~negative regulation of cell growth,GO:0038111~interleukin-7-mediated signaling pathway,GO:0043044~ATP-dependent chromatin remodeling,GO:0043923~positive regulation by host of viral transcription,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0060766~negative regulation of androgen receptor signaling pathway,GO:1901838~positive regulation of transcription of nuclear large rRNA transcript from RNA polymerase I promoter,GO:1902661~positive regulation of glucose mediated signaling pathway,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1904837~beta-catenin-TCF complex assembly,	GO:0000785~chromatin,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0016020~membrane,GO:0016514~SWI/SNF complex,GO:0032991~macromolecular complex,GO:0071564~npBAF complex,GO:0071565~nBAF complex,	GO:0001164~RNA polymerase I CORE element sequence-specific DNA binding,GO:0001221~transcription cofactor binding,GO:0002039~p53 binding,GO:0003677~DNA binding,GO:0003713~transcription coactivator activity,GO:0003714~transcription corepressor activity,GO:0003723~RNA binding,GO:0004386~helicase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008094~DNA-dependent ATPase activity,GO:0008134~transcription factor binding,GO:0016787~hydrolase activity,GO:0016887~ATPase activity,GO:0030957~Tat protein binding,GO:0031492~nucleosomal DNA binding,GO:0042393~histone binding,GO:0047485~protein N-terminus binding,GO:0050681~androgen receptor binding,GO:0070182~DNA polymerase binding,GO:0070577~lysine-acetylated histone binding,GO:0070615~nucleosome-dependent ATPase activity,	IPR000330:SNF2-related,IPR001487:Bromodomain,IPR001650:Helicase, C-terminal,IPR006576:BRK domain,IPR014001:Helicase, superfamily 1/2, ATP-binding domain,IPR014012:Helicase/SANT-associated, DNA binding,IPR014978:Glutamine-Leucine-Glutamine, QLQ,IPR018359:Bromodomain, conserved site,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04714:Thermogenesis,hsa05225:Hepatocellular carcinoma,	613325~Rhabdoid tumor predisposition syndrome 2,614609~Coffin-Siris syndrome 4,		SM00297:BROMO,SM00487:DEXDc,SM00490:HELICc,SM00573:HSA,SM00592:BRK,SM00951:SM00951,SM01314:SM01314,	KW-0524~Neurogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0991~Mental retardation,	KW-0103~Bromodomain,KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0010~Activator,KW-0156~Chromatin regulator,KW-0347~Helicase,KW-0378~Hydrolase,KW-0678~Repressor,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:BRK,DOMAIN:Bromo,DOMAIN:HSA,DOMAIN:Helicase ATP-binding,DOMAIN:Helicase C-terminal,DOMAIN:QLQ,MOTIF:DEGH box,MUTAGEN:F->A: Abolishes binding to 'Lys-15'-acetylated histone H3.,MUTAGEN:N->A: Abolishes binding to 'Lys-15'-acetylated histone H3.,MUTAGEN:V->A: No effect on binding to 'Lys-15'-acetylated histone H3.,NP_BIND:ATP,REGION:Disordered,REGION:Necessary for interaction with SS18L1/CREST,REGION:RNA-binding region which is sufficient for binding to lncRNA Evf2,REGION:Sufficient for interaction with DLX1,SITE:Required for binding to 'Lys-15'-acetylated histone 3,
SMARCD2	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 2(SMARCD2)	Homo sapiens			Chromatin structure and dynamics,	GO:0006337~nucleosome disassembly,GO:0006338~chromatin remodeling,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0043044~ATP-dependent chromatin remodeling,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016514~SWI/SNF complex,GO:0032991~macromolecular complex,	GO:0003712~transcription cofactor activity,GO:0003713~transcription coactivator activity,GO:0005515~protein binding,GO:0031492~nucleosomal DNA binding,	IPR003121:SWIB/MDM2 domain,IPR019835:SWIB domain,	hsa04714:Thermogenesis,hsa05225:Hepatocellular carcinoma,	617475~Specific granule deficiency 2,		SM00151:SWIB,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0156~Chromatin regulator,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:SWIB/MDM2,REGION:Disordered,
SKIV2L	Ski2 like RNA helicase(SKIV2L)	Homo sapiens			DNA replication, recombination, and repair,	GO:0006401~RNA catabolic process,GO:0043928~exonucleolytic nuclear-transcribed mRNA catabolic process involved in deadenylation-dependent decay,GO:0070478~nuclear-transcribed mRNA catabolic process, 3'-5' exonucleolytic nonsense-mediated decay,	GO:0005634~nucleus,GO:0005829~cytosol,GO:0055087~Ski complex,	GO:0003723~RNA binding,GO:0003724~RNA helicase activity,GO:0004386~helicase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016787~hydrolase activity,	IPR001650:Helicase, C-terminal,IPR011545:DNA/RNA helicase, DEAD/DEAH box type, N-terminal,IPR012961:DSH, C-terminal,IPR014001:Helicase, superfamily 1/2, ATP-binding domain,IPR016438:RNA helicase, ATP-dependent, SK12/DOB1,IPR025696:rRNA-processing arch domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa03018:RNA degradation,	614602~Trichohepatoenteric syndrome 2,	PIRSF005198:antiviral helicase, SKI2 type,	SM00487:DEXDc,SM00490:HELICc,SM01142:SM01142,		KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0347~Helicase,KW-0378~Hydrolase,KW-0694~RNA-binding,	KW-0597~Phosphoprotein,	DOMAIN:DSHCT,DOMAIN:Helicase ATP-binding,DOMAIN:Helicase C-terminal,DOMAIN:Ski2_N,DOMAIN:rRNA_proc-arch,MOTIF:DEVH box,NP_BIND:ATP,REGION:Disordered,
SUPV3L1	Suv3 like RNA helicase(SUPV3L1)	Homo sapiens			DNA replication, recombination, and repair / Transcription / Translation, ribosomal structure and biogenesis,	GO:0000958~mitochondrial mRNA catabolic process,GO:0000962~positive regulation of mitochondrial RNA catabolic process,GO:0000965~mitochondrial RNA 3'-end processing,GO:0006310~DNA recombination,GO:0006401~RNA catabolic process,GO:0030307~positive regulation of cell growth,GO:0032508~DNA duplex unwinding,GO:0035945~mitochondrial ncRNA surveillance,GO:0035946~mitochondrial mRNA surveillance,GO:0043066~negative regulation of apoptotic process,GO:0070584~mitochondrion morphogenesis,GO:0070827~chromatin maintenance,GO:2000827~mitochondrial RNA surveillance,	GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0042645~mitochondrial nucleoid,GO:0045025~mitochondrial degradosome,	GO:0003677~DNA binding,GO:0003678~DNA helicase activity,GO:0003723~RNA binding,GO:0003724~RNA helicase activity,GO:0003725~double-stranded RNA binding,GO:0004386~helicase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016817~hydrolase activity, acting on acid anhydrides,GO:0016887~ATPase activity,GO:0034458~3'-5' RNA helicase activity,GO:0042803~protein homodimerization activity,	IPR001650:Helicase, C-terminal,IPR022192:Mitochondrial degradasome RNA helicase subunit, C-terminal domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,				SM00490:HELICc,		KW-0496~Mitochondrion,KW-0539~Nucleus,KW-1135~Mitochondrion nucleoid,		KW-0809~Transit peptide,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0347~Helicase,KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Helicase ATP-binding,DOMAIN:Helicase C-terminal,MUTAGEN:G->V: Abolishes ATPase and dsDNA and dsRNA helicase activities.,MUTAGEN:K->A,R: Abolishes ATPase activity. Abolishes helicase activity and reduces double-stranded RNA degradation. Does not abolish formation of the mitochondrial RNA-degrading complex.,MUTAGEN:Missing: Does not abolish ATPase activity. Shows a loss of double-stranded RNA-binding, helicase and degrading activities.,NP_BIND:ATP,REGION:Disordered,REGION:Interaction with LAMTOR5, important for protein stability,TRANSIT:Mitochondrion,
TCTA	T cell leukemia translocation altered(TCTA)	Homo sapiens				GO:0045671~negative regulation of osteoclast differentiation,GO:0072675~osteoclast fusion,	GO:0016021~integral component of membrane,	GO:0005515~protein binding,	IPR016560:T-cell leukaemia translocation-associated protein,			PIRSF009935:T-cell leukemia translocation-associated protein,			KW-0472~Membrane,	KW-0656~Proto-oncogene,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TBX2	T-box transcription factor 2(TBX2)	Homo sapiens		h_arfPathway:Tumor Suppressor Arf Inhibits Ribosomal Biogenesis,		GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001708~cell fate specification,GO:0001947~heart looping,GO:0003148~outflow tract septum morphogenesis,GO:0003151~outflow tract morphogenesis,GO:0003203~endocardial cushion morphogenesis,GO:0003256~regulation of transcription from RNA polymerase II promoter involved in myocardial precursor cell differentiation,GO:0003272~endocardial cushion formation,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006915~apoptotic process,GO:0007219~Notch signaling pathway,GO:0007521~muscle cell fate determination,GO:0007569~cell aging,GO:0008016~regulation of heart contraction,GO:0008284~positive regulation of cell proliferation,GO:0008543~fibroblast growth factor receptor signaling pathway,GO:0022008~neurogenesis,GO:0032526~response to retinoic acid,GO:0035050~embryonic heart tube development,GO:0035909~aorta morphogenesis,GO:0036302~atrioventricular canal development,GO:0042733~embryonic digit morphogenesis,GO:0043474~pigment metabolic process involved in pigmentation,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048596~embryonic camera-type eye morphogenesis,GO:0048738~cardiac muscle tissue development,GO:0051145~smooth muscle cell differentiation,GO:0060021~palate development,GO:0060045~positive regulation of cardiac muscle cell proliferation,GO:0060441~epithelial tube branching involved in lung morphogenesis,GO:0060465~pharynx development,GO:0060560~developmental growth involved in morphogenesis,GO:0060596~mammary placode formation,GO:0060916~mesenchymal cell proliferation involved in lung development,GO:0072105~ureteric peristalsis,GO:0090103~cochlea morphogenesis,GO:0090398~cellular senescence,GO:0097325~melanocyte proliferation,GO:1901208~negative regulation of heart looping,GO:1901211~negative regulation of cardiac chamber formation,GO:1902808~positive regulation of cell cycle G1/S phase transition,GO:1905072~cardiac jelly development,GO:1905222~atrioventricular canal morphogenesis,GO:2000773~negative regulation of cellular senescence,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0042826~histone deacetylase binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001699:Transcription factor, T-box,IPR002070:Transcription factor, Brachyury,IPR008967:p53-like transcription factor, DNA-binding,IPR018186:Transcription factor, T-box, conserved site,IPR022582:Transcription factor, T-box, region of unknown function,		618223~Vertebral anomalies and variable endocrine and T-cell dysfunction,		SM00425:TBOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,			KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DNA_BIND:T-box,DOMAIN:TBX,MUTAGEN:A->E: Severely impairs repression of tumor suppressor ARF/p14ARF expression.,MUTAGEN:R->A: Abolishes binding to T site 5'-TTCACACCTAGGTGTGAA-3' DNA sequence.,MUTAGEN:RR->EE: Abolishes repression of tumor suppressor ARF/p14ARF expression.,REGION:Disordered,REGION:Repression domain 1 (RD1),
TARBP1	TAR (HIV-1) RNA binding protein 1(TARBP1)	Homo sapiens				GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0030488~tRNA methylation,	GO:0005634~nucleus,	GO:0003723~RNA binding,GO:0016423~tRNA (guanine) methyltransferase activity,	IPR001537:tRNA/rRNA methyltransferase, SpoU,IPR016024:Armadillo-type fold,IPR025806:Probable methyltransferase TARBP1,									KW-0949~S-adenosyl-L-methionine,	KW-0489~Methyltransferase,KW-0694~RNA-binding,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	BINDING:S-adenosyl-L-methionine,BINDING:S-adenosyl-L-methionine; via amide nitrogen,REGION:S-adenosyl-L-methionine binding,
TBPL1	TATA-box binding protein like 1(TBPL1)	Homo sapiens			Transcription,	GO:0001675~acrosome assembly,GO:0006235~dTTP biosynthetic process,GO:0006352~DNA-templated transcription, initiation,GO:0006366~transcription from RNA polymerase II promoter,GO:0007289~spermatid nucleus differentiation,	GO:0005672~transcription factor TFIIA complex,GO:0005737~cytoplasm,	GO:0000979~RNA polymerase II core promoter sequence-specific DNA binding,GO:0003677~DNA binding,GO:0005515~protein binding,	IPR000814:TATA-box binding protein,IPR012295:Beta2-adaptin/TBP, C-terminal domain,IPR015445:TATA-Box binding protein-like,	hsa03022:Basal transcription factors,hsa05016:Huntington disease,hsa05017:Spinocerebellar ataxia,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05203:Viral carcinogenesis,				KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0238~DNA-binding,
TBP	TATA-box binding protein(TBP)	Homo sapiens		h_carm-erPathway:CARM1 and Regulation of the Estrogen Receptor,h_hSWI-SNFpathway:Chromatin Remodeling by hSWI/SNF ATP-dependent Complexes,h_rarrxrPathway:Nuclear receptors coordinate the activities of chromatin remodeling complexes and coactivators to facilitate initiation of transcription in carcinoma cells,h_RNApol3Pathway:RNA polymerase III transcription,	Transcription,	GO:0006352~DNA-templated transcription, initiation,GO:0006361~transcription initiation from RNA polymerase I promoter,GO:0006363~termination of RNA polymerase I transcription,GO:0006366~transcription from RNA polymerase II promoter,GO:0006367~transcription initiation from RNA polymerase II promoter,GO:0006383~transcription from RNA polymerase III promoter,GO:0006468~protein phosphorylation,GO:0007283~spermatogenesis,GO:0016032~viral process,GO:0042789~mRNA transcription from RNA polymerase II promoter,GO:0042795~snRNA transcription from RNA polymerase II promoter,GO:0045815~positive regulation of gene expression, epigenetic,GO:0045893~positive regulation of transcription, DNA-templated,GO:0051123~RNA polymerase II transcriptional preinitiation complex assembly,GO:0060261~positive regulation of transcription initiation from RNA polymerase II promoter,GO:1901796~regulation of signal transduction by p53 class mediator,	GO:0000785~chromatin,GO:0000791~euchromatin,GO:0001939~female pronucleus,GO:0001940~male pronucleus,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005669~transcription factor TFIID complex,GO:0005672~transcription factor TFIIA complex,GO:0005737~cytoplasm,GO:0032991~macromolecular complex,GO:0097550~transcriptional preinitiation complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000979~RNA polymerase II core promoter sequence-specific DNA binding,GO:0000995~transcription factor activity, core RNA polymerase III binding,GO:0001046~core promoter sequence-specific DNA binding,GO:0001091~RNA polymerase II basal transcription factor binding,GO:0001093~TFIIB-class transcription factor binding,GO:0001103~RNA polymerase II repressing transcription factor binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0017162~aryl hydrocarbon receptor binding,GO:0019899~enzyme binding,GO:0070491~repressing transcription factor binding,	IPR000814:TATA-box binding protein,IPR012295:Beta2-adaptin/TBP, C-terminal domain,	hsa03022:Basal transcription factors,hsa05016:Huntington disease,hsa05017:Spinocerebellar ataxia,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05203:Viral carcinogenesis,	168600~Parkinson disease, susceptibility to,607136~Spinocerebellar ataxia 17,			KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0950~Spinocerebellar ataxia,	KW-0175~Coiled coil,KW-0677~Repeat,		KW-0238~DNA-binding,		COMPBIAS:Polar residues,COMPBIAS:Pro residues,REGION:Disordered,REPEAT:1,REPEAT:2,
TBC1D9B	TBC1 domain family member 9B(TBC1D9B)	Homo sapiens				GO:0006886~intracellular protein transport,GO:0043547~positive regulation of GTPase activity,GO:0090630~activation of GTPase activity,	GO:0016021~integral component of membrane,	GO:0005096~GTPase activator activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,	IPR000195:Rab-GTPase-TBC domain,IPR002048:EF-hand domain,IPR004182:GRAM,IPR011992:EF-hand-like domain,IPR011993:Pleckstrin homology-like domain,				SM00164:TBC,SM00568:GRAM,		KW-0472~Membrane,		KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,	KW-0343~GTPase activation,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:EF-hand,DOMAIN:GRAM,DOMAIN:GRAM 1,DOMAIN:GRAM 2,DOMAIN:Rab-GAP TBC,REGION:Disordered,SITE:Arginine finger,SITE:Glutamine finger,TRANSMEM:Helical,
TIPARP	TCDD inducible poly(ADP-ribose) polymerase(TIPARP)	Homo sapiens				GO:0001570~vasculogenesis,GO:0001822~kidney development,GO:0006471~protein ADP-ribosylation,GO:0008209~androgen metabolic process,GO:0008210~estrogen metabolic process,GO:0008585~female gonad development,GO:0009791~post-embryonic development,GO:0010629~negative regulation of gene expression,GO:0030097~hemopoiesis,GO:0045732~positive regulation of protein catabolic process,GO:0048008~platelet-derived growth factor receptor signaling pathway,GO:0048705~skeletal system morphogenesis,GO:0048745~smooth muscle tissue development,GO:0060021~palate development,GO:0060325~face morphogenesis,GO:0070213~protein auto-ADP-ribosylation,GO:0071407~cellular response to organic cyclic compound,GO:1904612~response to 2,3,7,8-tetrachlorodibenzodioxine,	GO:0005634~nucleus,	GO:0000987~core promoter proximal region sequence-specific DNA binding,GO:0003950~NAD+ ADP-ribosyltransferase activity,GO:0046872~metal ion binding,GO:1990404~protein ADP-ribosylase activity,	IPR000571:Zinc finger, CCCH-type,IPR004170:WWE domain,IPR012317:Poly(ADP-ribose) polymerase, catalytic domain,						KW-0539~Nucleus,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0520~NAD,KW-0862~Zinc,	KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0013~ADP-ribosylation,	DOMAIN:C3H1-type,DOMAIN:PARP catalytic,DOMAIN:WWE,MOTIF:Nuclear localization signal,MUTAGEN:C->A: Relocalization to the cytosol.,MUTAGEN:C->A: Slight reduction of auto-mono-ADP-ribosylation.,MUTAGEN:H->A: Abolishes ADP-ribosyltransferase activity.,MUTAGEN:I->A: Does not affect ADP-ribosyltransferase activity.,MUTAGEN:K->A: Partial relocalization to the cytoplasm.,MUTAGEN:Y->A: Abolishes ADP-ribosyltransferase activity.,REGION:Disordered,ZN_FING:C3H1-type,
TERF2IP	TERF2 interacting protein(TERF2IP)	Homo sapiens				GO:0000723~telomere maintenance,GO:0001933~negative regulation of protein phosphorylation,GO:0006355~regulation of transcription, DNA-templated,GO:0007004~telomere maintenance via telomerase,GO:0010569~regulation of double-strand break repair via homologous recombination,GO:0010833~telomere maintenance via telomere lengthening,GO:0016233~telomere capping,GO:0031848~protection from non-homologous end joining at telomere,GO:0032201~telomere maintenance via semi-conservative replication,GO:0032204~regulation of telomere maintenance,GO:0032205~negative regulation of telomere maintenance,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0045007~depurination,GO:0048239~negative regulation of DNA recombination at telomere,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0070198~protein localization to chromosome, telomeric region,GO:1900051~positive regulation of histone exchange,GO:1901224~positive regulation of NIK/NF-kappaB signaling,GO:1901985~positive regulation of protein acetylation,	GO:0000228~nuclear chromosome,GO:0000781~chromosome, telomeric region,GO:0000783~nuclear telomere cap complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016604~nuclear body,GO:0070187~shelterin complex,	GO:0003677~DNA binding,GO:0005515~protein binding,GO:0019902~phosphatase binding,GO:0042162~telomeric DNA binding,GO:0098505~G-rich strand telomeric DNA binding,	IPR001357:BRCT domain,IPR009057:Homeodomain-like,IPR015010:Rap1 Myb domain,IPR021661:Rap1 - C-terminal,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0158~Chromosome,KW-0539~Nucleus,KW-0779~Telomere,KW-0963~Cytoplasm,		KW-0175~Coiled coil,		KW-0010~Activator,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:BRCT,DOMAIN:Myb-like,DOMAIN:Myb_DNA-bind_2,MOTIF:Nuclear localization signal,REGION:Disordered,
THAP11	THAP domain containing 11(THAP11)	Homo sapiens				GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006357~regulation of transcription from RNA polymerase II promoter,	GO:0000785~chromatin,GO:0005654~nucleoplasm,GO:0005829~cytosol,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,	IPR006612:Zinc finger, C2CH-type,				SM00692:DM3,SM00980:SM00980,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0678~Repressor,		MOTIF:HCFC1-binding motif (HBM),REGION:Disordered,ZN_FING:THAP-type,
TIAM1	TIAM Rac1 associated GEF 1(TIAM1)	Homo sapiens				GO:0003300~cardiac muscle hypertrophy,GO:0006915~apoptotic process,GO:0007160~cell-matrix adhesion,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007264~small GTPase mediated signal transduction,GO:0008284~positive regulation of cell proliferation,GO:0010717~regulation of epithelial to mesenchymal transition,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0016477~cell migration,GO:0016601~Rac protein signal transduction,GO:0030335~positive regulation of cell migration,GO:0032092~positive regulation of protein binding,GO:0034622~cellular macromolecular complex assembly,GO:0042220~response to cocaine,GO:0043065~positive regulation of apoptotic process,GO:0043507~positive regulation of JUN kinase activity,GO:0048013~ephrin receptor signaling pathway,GO:0050772~positive regulation of axonogenesis,GO:0051056~regulation of small GTPase mediated signal transduction,GO:0060071~Wnt signaling pathway, planar cell polarity pathway,GO:0061003~positive regulation of dendritic spine morphogenesis,GO:0061178~regulation of insulin secretion involved in cellular response to glucose stimulus,GO:0070372~regulation of ERK1 and ERK2 cascade,GO:0072657~protein localization to membrane,GO:0090630~activation of GTPase activity,GO:0098989~NMDA selective glutamate receptor signaling pathway,GO:1904268~positive regulation of Schwann cell chemotaxis,GO:1904338~regulation of dopaminergic neuron differentiation,GO:1905274~regulation of modification of postsynaptic actin cytoskeleton,GO:1990138~neuron projection extension,GO:2000050~regulation of non-canonical Wnt signaling pathway,	GO:0005634~nucleus,GO:0005829~cytosol,GO:0005874~microtubule,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0016020~membrane,GO:0031234~extrinsic component of cytoplasmic side of plasma membrane,GO:0032587~ruffle membrane,GO:0043025~neuronal cell body,GO:0043197~dendritic spine,GO:0044291~cell-cell contact zone,GO:0044295~axonal growth cone,GO:0044304~main axon,GO:0045202~synapse,GO:0098978~glutamatergic synapse,	GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0008289~lipid binding,GO:0019900~kinase binding,GO:0030971~receptor tyrosine kinase binding,	IPR000219:Dbl homology (DH) domain,IPR001331:Guanine-nucleotide dissociation stimulator, CDC24, conserved site,IPR001478:PDZ domain,IPR001849:Pleckstrin homology domain,IPR003116:Raf-like Ras-binding,IPR011993:Pleckstrin homology-like domain,	hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04024:cAMP signaling pathway,hsa04062:Chemokine signaling pathway,hsa04530:Tight junction,hsa04810:Regulation of actin cytoskeleton,hsa05205:Proteoglycans in cancer,			SM00228:PDZ,SM00233:PH,SM00325:RhoGEF,SM00455:RBD,		KW-0472~Membrane,KW-0965~Cell junction,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0677~Repeat,	KW-0446~Lipid-binding,	KW-0344~Guanine-nucleotide releasing factor,	KW-0449~Lipoprotein,KW-0519~Myristate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:DH,DOMAIN:PDZ,DOMAIN:PH,DOMAIN:PH 1,DOMAIN:PH 2,DOMAIN:RBD,LIPID:N-myristoyl glycine,MUTAGEN:K->E: Strongly reduces affinity for SDC1.,MUTAGEN:K->R: Decreased ubiquitination and increased abundance.,REGION:Disordered,
TIMP2	TIMP metallopeptidase inhibitor 2(TIMP2)	Homo sapiens		h_reckPathway:Inhibition of Matrix Metalloproteinases,		GO:0007417~central nervous system development,GO:0007568~aging,GO:0008285~negative regulation of cell proliferation,GO:0009725~response to hormone,GO:0010033~response to organic substance,GO:0010951~negative regulation of endopeptidase activity,GO:0022617~extracellular matrix disassembly,GO:0032487~regulation of Rap protein signal transduction,GO:0034097~response to cytokine,GO:0042493~response to drug,GO:0043312~neutrophil degranulation,GO:0043410~positive regulation of MAPK cascade,GO:0045666~positive regulation of neuron differentiation,GO:0045762~positive regulation of adenylate cyclase activity,GO:0045930~negative regulation of mitotic cell cycle,GO:0046580~negative regulation of Ras protein signal transduction,GO:0051045~negative regulation of membrane protein ectodomain proteolysis,GO:1905049~negative regulation of metallopeptidase activity,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0009986~cell surface,GO:0030426~growth cone,GO:0031012~extracellular matrix,GO:0035580~specific granule lumen,GO:0043025~neuronal cell body,GO:1904724~tertiary granule lumen,GO:1904813~ficolin-1-rich granule lumen,	GO:0002020~protease binding,GO:0004857~enzyme inhibitor activity,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0008191~metalloendopeptidase inhibitor activity,GO:0008270~zinc ion binding,GO:0030414~peptidase inhibitor activity,GO:0046872~metal ion binding,	IPR001134:Netrin domain,IPR001820:Proteinase inhibitor I35, tissue inhibitor of metalloproteinase,IPR008993:Tissue inhibitor of metalloproteinases-like, OB-fold,IPR015613:Tissue inhibitor of metalloprotease 2,IPR027465:Proteinase inhibitor I35, tissue inhibitor of metalloproteinase, C-terminal domain,				SM00206:NTR,		KW-0964~Secreted,		KW-0732~Signal,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0481~Metalloenzyme inhibitor,KW-0483~Metalloprotease inhibitor,KW-0646~Protease inhibitor,	KW-1015~Disulfide bond,	DOMAIN:NTR,METAL:Zinc; via amino nitrogen and carbonyl oxygen; shared with metalloproteinase partner,REGION:Involved in metalloproteinase-binding,SITE:Involved in metalloproteinase-binding,
TLE1	TLE family member 1, transcriptional corepressor(TLE1)	Homo sapiens		h_wntPathway:WNT Signaling Pathway,		GO:0006355~regulation of transcription, DNA-templated,GO:0007165~signal transduction,GO:0007275~multicellular organism development,GO:0009887~animal organ morphogenesis,GO:0010628~positive regulation of gene expression,GO:0016055~Wnt signaling pathway,GO:0030178~negative regulation of Wnt signaling pathway,GO:0043124~negative regulation of I-kappaB kinase/NF-kappaB signaling,GO:0045892~negative regulation of transcription, DNA-templated,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:1904837~beta-catenin-TCF complex assembly,GO:2000811~negative regulation of anoikis,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005829~cytosol,GO:1990907~beta-catenin-TCF complex,	GO:0003714~transcription corepressor activity,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0042802~identical protein binding,GO:0070491~repressing transcription factor binding,	IPR001680:WD40 repeat,IPR005617:Groucho/TLE, N-terminal Q-rich domain,IPR009146:Groucho/transducin-like enhancer,IPR015943:WD40/YVTN repeat-like-containing domain,IPR017986:WD40-repeat-containing domain,IPR019775:WD40 repeat, conserved site,	hsa04310:Wnt signaling pathway,hsa04330:Notch signaling pathway,			SM00320:WD40,	KW-0804~Transcription,KW-0805~Transcription regulation,KW-0879~Wnt signaling pathway,	KW-0539~Nucleus,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0853~WD repeat,		KW-0678~Repressor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:TLE_N,MOTIF:Nuclear localization signal,MUTAGEN:L->S: Abolishes HESX1 binding.,MUTAGEN:S->P: Abolishes HESX1 binding.,MUTAGEN:V->S: Abolishes HESX1 binding.,MUTAGEN:Y->H: Abolishes HESX1 binding.,REGION:CcN domain,REGION:Disordered,REGION:GP domain,REGION:Q domain,REGION:SP domain,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,
TRAP1	TNF receptor associated protein 1(TRAP1)	Homo sapiens				GO:0006457~protein folding,GO:0009386~translational attenuation,GO:0061077~chaperone-mediated protein folding,GO:1901856~negative regulation of cellular respiration,GO:1903427~negative regulation of reactive oxygen species biosynthetic process,GO:1903751~negative regulation of intrinsic apoptotic signaling pathway in response to hydrogen peroxide,	GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005758~mitochondrial intermembrane space,GO:0005759~mitochondrial matrix,GO:0016020~membrane,GO:0071944~cell periphery,	GO:0003723~RNA binding,GO:0005164~tumor necrosis factor receptor binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0019901~protein kinase binding,GO:0051082~unfolded protein binding,	IPR001404:Heat shock protein Hsp90,IPR003594:Histidine kinase-like ATPase, ATP-binding domain,IPR020568:Ribosomal protein S5 domain 2-type fold,IPR020575:Heat shock protein Hsp90, N-terminal,	hsa05012:Parkinson disease,hsa05022:Pathways of neurodegeneration - multiple diseases,		PIRSF002583:heat shock protein, HSP90/HTPG types,	SM00387:HATPase_c,	KW-0346~Stress response,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,		KW-0809~Transit peptide,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0143~Chaperone,KW-0675~Receptor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	BINDING:ATP,BINDING:ATP; via amide nitrogen,DOMAIN:HATPase_c,REGION:Disordered,TRANSIT:Mitochondrion,
TNFRSF21	TNF receptor superfamily member 21(TNFRSF21)	Homo sapiens				GO:0001783~B cell apoptotic process,GO:0002250~adaptive immune response,GO:0006915~apoptotic process,GO:0006959~humoral immune response,GO:0007165~signal transduction,GO:0007413~axonal fasciculation,GO:0016032~viral process,GO:0019222~regulation of metabolic process,GO:0030889~negative regulation of B cell proliferation,GO:0031642~negative regulation of myelination,GO:0032693~negative regulation of interleukin-10 production,GO:0032696~negative regulation of interleukin-13 production,GO:0032714~negative regulation of interleukin-5 production,GO:0042130~negative regulation of T cell proliferation,GO:0042552~myelination,GO:0048713~regulation of oligodendrocyte differentiation,GO:0050852~T cell receptor signaling pathway,GO:0051402~neuron apoptotic process,GO:0071356~cellular response to tumor necrosis factor,GO:0097252~oligodendrocyte apoptotic process,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0030424~axon,GO:0031226~intrinsic component of plasma membrane,	GO:0005515~protein binding,	IPR000488:Death domain,IPR001368:TNFR/NGFR cysteine-rich region,IPR011029:Death-like domain,IPR022330:Tumour necrosis factor receptor 21,	hsa04060:Cytokine-cytokine receptor interaction,			SM00005:DEATH,SM00208:TNFR,	KW-0053~Apoptosis,KW-0391~Immunity,KW-0945~Host-virus interaction,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Death,DOMAIN:TNFR-Cys,LIPID:S-palmitoyl cysteine,MUTAGEN:C->V: Abolishes palmitoylation.,MUTAGEN:N->Q: Abolishes one glycosylation site and reduces total N-glycosylation. Abolishes one glycosylation site and reduces total N-glycosylation; when associated with Q-82; Q-141; Q-252; Q-257 and Q-289.,MUTAGEN:N->Q: Abolishes one glycosylation site and reduces total N-glycosylation; when associated with Q-252; Q-278 and Q-289.,MUTAGEN:N->Q: Abolishes one glycosylation site and reduces total N-glycosylation; when associated with Q-278 and Q-289.,MUTAGEN:N->Q: Abolishes one glycosylation site and reduces total N-glycosylation; when associated with Q-278.,MUTAGEN:N->Q: Abolishes one glycosylation site and reduces total N-glycosylation; when associated with Q-82; Q-141; Q-252; Q-278 and Q-289.,MUTAGEN:N->Q: Abolishes one glycosylation site and reduces total N-glycosylation; when associated with Q-82; Q-252; Q-278 and Q-289.,REGION:Disordered,REPEAT:TNFR-Cys,REPEAT:TNFR-Cys 1,REPEAT:TNFR-Cys 2,REPEAT:TNFR-Cys 3,REPEAT:TNFR-Cys 4,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TNIP1	TNFAIP3 interacting protein 1(TNIP1)	Homo sapiens				GO:0002755~MyD88-dependent toll-like receptor signaling pathway,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006412~translation,GO:0006952~defense response,GO:0006954~inflammatory response,GO:0007159~leukocyte cell-cell adhesion,GO:0009101~glycoprotein biosynthetic process,GO:0016579~protein deubiquitination,GO:0043124~negative regulation of I-kappaB kinase/NF-kappaB signaling,GO:0045071~negative regulation of viral genome replication,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050727~regulation of inflammatory response,GO:0050729~positive regulation of inflammatory response,GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:0071222~cellular response to lipopolysaccharide,GO:0085032~modulation by symbiont of host I-kappaB kinase/NF-kappaB cascade,GO:1903003~positive regulation of protein deubiquitination,	GO:0005654~nucleoplasm,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0031593~polyubiquitin binding,GO:0042802~identical protein binding,GO:0051019~mitogen-activated protein kinase binding,		hsa05131:Shigellosis,				KW-0395~Inflammatory response,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,			KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:CC2-LZ,MOTIF:Nuclear localization signal,MUTAGEN:D->N: Abolishes binding to polyubiquitin ('K-63'-linked and linear).,MUTAGEN:Y->F: Abolishes interaction with PI3K p85 regulatory subunit and abolishes interaction between SELPLG and PI3K p85 regulatory subunit.,REGION:Disordered,REGION:Interaction with Nef,REGION:Interaction with Shigella flexneri ipah9.8,REGION:Required for inhibitory activity of TNF-induced NF-kappa-B activation,REGION:Ubiquitin-binding domain (UBD),
TPD52L2	TPD52 like 2(TPD52L2)	Homo sapiens				GO:0005975~carbohydrate metabolic process,GO:0042127~regulation of cell proliferation,	GO:0005737~cytoplasm,GO:0048471~perinuclear region of cytoplasm,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0042803~protein homodimerization activity,	IPR007327:Tumour protein D52,IPR012341:Six-hairpin glycosidase,								KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,REGION:Disordered,
TSC22D3	TSC22 domain family member 3(TSC22D3)	Homo sapiens				GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006970~response to osmotic stress,GO:0034220~ion transmembrane transport,GO:0070236~negative regulation of activation-induced cell death of T cells,	GO:0005634~nucleus,GO:0005829~cytosol,	GO:0005515~protein binding,	IPR000580:TSC-22 / Dip / Bun,						KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,REGION:AP1-binding,REGION:Disordered,REGION:Leucine-zipper,
TATDN2	TatD DNase domain containing 2(TATDN2)	Homo sapiens				GO:0036498~IRE1-mediated unfolded protein response,GO:0090305~nucleic acid phosphodiester bond hydrolysis,	GO:0005654~nucleoplasm,	GO:0004518~nuclease activity,GO:0016888~endodeoxyribonuclease activity, producing 5'-phosphomonoesters,GO:0046872~metal ion binding,	IPR001130:TatD family,IPR018228:Deoxyribonuclease, TatD-related, conserved site,						KW-0539~Nucleus,			KW-0479~Metal-binding,	KW-0378~Hydrolase,KW-0540~Nuclease,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,METAL:Divalent metal cation 1,METAL:Divalent metal cation 2,REGION:Disordered,
GALE	UDP-galactose-4-epimerase(GALE)	Homo sapiens		h_g1pPathway:Leloir pathway of galactose metabolism,	Cell envelope biogenesis, outer membrane,	GO:0006012~galactose metabolic process,GO:0019388~galactose catabolic process,GO:0033499~galactose catabolic process via UDP-galactose,	GO:0005829~cytosol,	GO:0003974~UDP-N-acetylglucosamine 4-epimerase activity,GO:0003978~UDP-glucose 4-epimerase activity,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,	IPR001509:NAD-dependent epimerase/dehydratase,IPR005886:UDP-glucose 4-epimerase GalE,IPR016040:NAD(P)-binding domain,	hsa00052:Galactose metabolism,hsa00520:Amino sugar and nucleotide sugar metabolism,hsa01100:Metabolic pathways,hsa01250:Biosynthesis of nucleotide sugars,	230350~Galactose epimerase deficiency,			KW-0119~Carbohydrate metabolism,KW-0299~Galactose metabolism,		KW-0225~Disease variant,		KW-0520~NAD,	KW-0413~Isomerase,		ACT_SITE:Proton acceptor,BINDING:NAD,BINDING:NAD; via carbonyl oxygen,BINDING:Substrate,DOMAIN:Epimerase,DOMAIN:NAD(P)-bd_dom,MUTAGEN:C->Y: No effect on activity towards UDP-galactose. Loss of activity towards UDP-N-acetylgalactosamine.,MUTAGEN:S->A: Loss of activity.,MUTAGEN:Y->F: Loss of activity.,NP_BIND:NAD,REGION:Substrate binding,
UGDH	UDP-glucose 6-dehydrogenase(UGDH)	Homo sapiens			Cell envelope biogenesis, outer membrane,	GO:0001702~gastrulation with mouth forming second,GO:0005975~carbohydrate metabolic process,GO:0006024~glycosaminoglycan biosynthetic process,GO:0006065~UDP-glucuronate biosynthetic process,GO:0015012~heparan sulfate proteoglycan biosynthetic process,GO:0030206~chondroitin sulfate biosynthetic process,GO:0034214~protein hexamerization,GO:0048666~neuron development,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0003979~UDP-glucose 6-dehydrogenase activity,GO:0042802~identical protein binding,GO:0051287~NAD binding,	IPR001732:UDP-glucose/GDP-mannose dehydrogenase, N-terminal,IPR008927:6-phosphogluconate dehydrogenase, C-terminal-like,IPR014026:UDP-glucose/GDP-mannose dehydrogenase, dimerisation,IPR014027:UDP-glucose/GDP-mannose dehydrogenase, C-terminal,IPR017476:Nucleotide sugar dehydrogenase,	hsa00040:Pentose and glucuronate interconversions,hsa00053:Ascorbate and aldarate metabolism,hsa00520:Amino sugar and nucleotide sugar metabolism,hsa01100:Metabolic pathways,hsa01240:Biosynthesis of cofactors,hsa01250:Biosynthesis of nucleotide sugars,	618792~Developmental and epileptic encephalopathy 84,	PIRSF000124:UDP-glucose/GDP-mannose dehydrogenase,PIRSF500133:UDP-glucose 6-dehydrogenase, eukaryotic type [Parent=PIRSF000124],	SM00984:SM00984,	KW-0119~Carbohydrate metabolism,		KW-0225~Disease variant,KW-0887~Epilepsy,		KW-0520~NAD,	KW-0021~Allosteric enzyme,KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Nucleophile,ACT_SITE:Proton donor/acceptor,BINDING:NAD,BINDING:Substrate,DOMAIN:UDPG_MGDP_dh_N,MUTAGEN:A->G: Impairs protein folding. Decreases affinity for UDP-glucose. No effect on inhibition by UDP-xylose. No effect on hysteresis and cooperativity.,MUTAGEN:A->L: No significant effect on catalytic activity and on affinity for NAD and UDP-glucose. Decreases affinity for the inhibitor UDP-xylose. Disrupts hysteresis and cooperativity.,MUTAGEN:A->M: Stabilizes the active conformation of the hexamer. Decreases affinity for UDP-xylose, but not for UDP-glucose. Disrupts hysteresis and cooperativity.,MUTAGEN:C->A,S: Loss of enzyme activity.,MUTAGEN:D->A: Loss of ezyme activity.,MUTAGEN:E->Q: Abolishes hydrolysis of the covalent intermediate between substrate and the catalytic cysteine residue.,MUTAGEN:FNT->TTD: Loss of hexamer formation. Causes formation of stable dimers. Strongly decreased specific activity at pH 8.4.,MUTAGEN:K->A: Loss of ezyme activity.,MUTAGEN:K->E: Loss of hexamer formation. Causes formation of stable dimers. Strongly reduced affinity for NAD and UDP-glucose, and strongly decreased catalytic efficiency at pH 8.6.,MUTAGEN:KVSSKRIPYAPSGEIPKFSLQDPPNKKPKV->SSSSSSSSSSSSSSSSSSSS SSSSSSSSSS: No effect on the intrinsically disordered nature of the C-terminus. No effect on affinity for the inhibitor UDP-xylose.,MUTAGEN:Missing: Nearly abolishes enzyme activity. Stabilizes the enzyme in a low-activity hexameric conformation.,MUTAGEN:Missing: Strongly decreases affinity for the inhibitor UDP-xylose.,MUTAGEN:T->A: Reduced affinity for UDP-glucose, and reduced catalytic efficiency.,NP_BIND:NAD,REGION:Allosteric switch region,REGION:Disordered,REGION:Important for formation of active hexamer structure,REGION:Substrate binding,
USP6NL	USP6 N-terminal like(USP6NL)	Homo sapiens				GO:0006886~intracellular protein transport,GO:0007030~Golgi organization,GO:0019068~virion assembly,GO:0035526~retrograde transport, plasma membrane to Golgi,GO:0043547~positive regulation of GTPase activity,GO:0048227~plasma membrane to endosome transport,GO:0090630~activation of GTPase activity,GO:1903358~regulation of Golgi organization,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0031410~cytoplasmic vesicle,GO:0032588~trans-Golgi network membrane,	GO:0005096~GTPase activator activity,GO:0031267~small GTPase binding,	IPR000195:Rab-GTPase-TBC domain,				SM00164:TBC,		KW-0333~Golgi apparatus,KW-0968~Cytoplasmic vesicle,				KW-0343~GTPase activation,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Rab-GAP TBC,MUTAGEN:D->A: Loss of GAP activity on RAB5A.,MUTAGEN:R->A: Loss of GAP activity on RAB5A.,REGION:Disordered,
UTP14A	UTP14A small subunit processome component(UTP14A)	Homo sapiens				GO:0006364~rRNA processing,	GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005829~cytosol,GO:0032040~small-subunit processome,	GO:0003723~RNA binding,GO:0005515~protein binding,	IPR006709:Small-subunit processome, Utp14,	hsa03008:Ribosome biogenesis in eukaryotes,				KW-0690~Ribosome biogenesis,	KW-0539~Nucleus,		KW-0175~Coiled coil,			KW-0164~Citrullination,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,
VAPB	VAMP associated protein B and C(VAPB)	Homo sapiens				GO:0006874~cellular calcium ion homeostasis,GO:0006888~ER to Golgi vesicle-mediated transport,GO:0007029~endoplasmic reticulum organization,GO:0019048~modulation by virus of host morphology or physiology,GO:0030148~sphingolipid biosynthetic process,GO:0030968~endoplasmic reticulum unfolded protein response,GO:0036498~IRE1-mediated unfolded protein response,GO:0044790~negative regulation by host of viral release from host cell,GO:0044791~positive regulation by host of viral release from host cell,GO:0044828~negative regulation by host of viral genome replication,GO:0044829~positive regulation by host of viral genome replication,GO:0044830~modulation by host of viral RNA genome replication,GO:0045070~positive regulation of viral genome replication,GO:0046725~negative regulation by virus of viral protein levels in host cell,GO:0061817~endoplasmic reticulum-plasma membrane tethering,GO:0090114~COPII-coated vesicle budding,GO:0090158~endoplasmic reticulum membrane organization,	GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0019899~enzyme binding,GO:0033149~FFAT motif binding,GO:0042803~protein homodimerization activity,GO:0045296~cadherin binding,GO:0046982~protein heterodimerization activity,GO:0048487~beta-tubulin binding,	IPR000535:Major sperm protein,IPR008962:PapD-like,IPR013783:Immunoglobulin-like fold,IPR016763:Vesicle-associated membrane protein,	hsa04979:Cholesterol metabolism,hsa05014:Amyotrophic lateral sclerosis,hsa05022:Pathways of neurodegeneration - multiple diseases,	182980~Spinal muscular atrophy, late-onset, Finkel type,608627~Amyotrophic lateral sclerosis 8,	PIRSF019693:VAMP-associated protein,		KW-0834~Unfolded protein response,KW-0945~Host-virus interaction,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,	KW-0036~Amyotrophic lateral sclerosis,KW-0225~Disease variant,KW-0523~Neurodegeneration,	KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),DOMAIN:MSP,MUTAGEN:K->D: Prevents binding to the FFAT motif in target proteins; when associated with D-89.,MUTAGEN:M->D: Prevents binding to the FFAT motif in target proteins; when associated with D-87.,TOPO_DOM:Cytoplasmic,TRANSMEM:Helical,TRANSMEM:Helical; Anchor for type IV membrane protein,
VPS28	VPS28 subunit of ESCRT-I(VPS28)	Homo sapiens				GO:0015031~protein transport,GO:0016197~endosomal transport,GO:0016236~macroautophagy,GO:0019058~viral life cycle,GO:0031397~negative regulation of protein ubiquitination,GO:0032509~endosome transport via multivesicular body sorting pathway,GO:0036258~multivesicular body assembly,GO:0039702~viral budding via host ESCRT complex,GO:0043162~ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway,GO:0043328~protein targeting to vacuole involved in ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway,GO:0045732~positive regulation of protein catabolic process,GO:0075733~intracellular transport of virus,GO:2000397~positive regulation of ubiquitin-dependent endocytosis,	GO:0000813~ESCRT I complex,GO:0005737~cytoplasm,GO:0005768~endosome,GO:0005769~early endosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0010008~endosome membrane,GO:0031902~late endosome membrane,GO:0043657~host cell,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0043130~ubiquitin binding,GO:0044877~macromolecular complex binding,	IPR007143:Vacuolar protein sorting-associated, VPS28,IPR017898:Vacuolar protein sorting-associated, VPS28, N-terminal,IPR017899:Vacuolar protein sorting-associated, VPS28, C-terminal,	hsa04144:Endocytosis,		PIRSF017535:ESCRT-1 complex, Vps28 subunit,		KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,KW-0967~Endosome,KW-1003~Cell membrane,					KW-0007~Acetylation,	COMPBIAS:Polar residues,DOMAIN:VPS28 C-terminal,DOMAIN:VPS28 N-terminal,REGION:Disordered,
WIPF2	WAS/WASL interacting protein family member 2(WIPF2)	Homo sapiens				GO:0030048~actin filament-based movement,GO:0038096~Fc-gamma receptor signaling pathway involved in phagocytosis,	GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005884~actin filament,GO:0005886~plasma membrane,	GO:0003779~actin binding,GO:0005515~protein binding,	IPR003124:WH2 domain,	hsa04144:Endocytosis,hsa05130:Pathogenic Escherichia coli infection,hsa05135:Yersinia infection,			SM00246:WH2,		KW-0206~Cytoskeleton,KW-0963~Cytoplasm,				KW-0009~Actin-binding,	KW-0488~Methylation,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:WH2,REGION:Binds actin,REGION:Disordered,
WASF3	WASP family member 3(WASF3)	Homo sapiens		h_actinYPathway:Y branching of actin filaments,		GO:0007010~cytoskeleton organization,GO:0008360~regulation of cell shape,GO:0014003~oligodendrocyte development,GO:0030032~lamellipodium assembly,GO:0030036~actin cytoskeleton organization,GO:0030041~actin filament polymerization,GO:0031643~positive regulation of myelination,GO:0065003~macromolecular complex assembly,GO:0098885~modification of postsynaptic actin cytoskeleton,GO:2000601~positive regulation of Arp2/3 complex-mediated actin nucleation,	GO:0005737~cytoplasm,GO:0005856~cytoskeleton,GO:0030027~lamellipodium,GO:0031209~SCAR complex,GO:0070062~extracellular exosome,GO:0098794~postsynapse,GO:0098978~glutamatergic synapse,	GO:0003779~actin binding,GO:0034237~protein kinase A regulatory subunit binding,GO:0071933~Arp2/3 complex binding,	IPR003124:WH2 domain,	hsa04520:Adherens junction,hsa04666:Fc gamma R-mediated phagocytosis,hsa05130:Pathogenic Escherichia coli infection,hsa05132:Salmonella infection,hsa05231:Choline metabolism in cancer,			SM00246:WH2,		KW-0206~Cytoskeleton,KW-0963~Cytoplasm,		KW-0175~Coiled coil,		KW-0009~Actin-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:WH2,REGION:Disordered,
WDTC1	WD and tetratricopeptide repeats 1(WDTC1)	Homo sapiens				GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001701~in utero embryonic development,GO:0006006~glucose metabolic process,GO:0008361~regulation of cell size,GO:0016567~protein ubiquitination,GO:0032869~cellular response to insulin stimulus,GO:0035264~multicellular organism growth,GO:0043086~negative regulation of catalytic activity,GO:0043687~post-translational protein modification,GO:0045717~negative regulation of fatty acid biosynthetic process,GO:0055082~cellular chemical homeostasis,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0080008~Cul4-RING E3 ubiquitin ligase complex,	GO:0004857~enzyme inhibitor activity,GO:0005515~protein binding,GO:0042393~histone binding,GO:0042826~histone deacetylase binding,	IPR001680:WD40 repeat,IPR011990:Tetratricopeptide-like helical,IPR013026:Tetratricopeptide repeat-containing domain,IPR015943:WD40/YVTN repeat-like-containing domain,IPR017986:WD40-repeat-containing domain,IPR019734:Tetratricopeptide repeat,				SM00028:TPR,SM00320:WD40,	KW-0833~Ubl conjugation pathway,			KW-0677~Repeat,KW-0802~TPR repeat,KW-0853~WD repeat,			KW-0597~Phosphoprotein,	REGION:Disordered,REPEAT:TPR 1,REPEAT:TPR 2,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
WDR61	WD repeat domain 61(WDR61)	Homo sapiens				GO:0006366~transcription from RNA polymerase II promoter,GO:0006368~transcription elongation from RNA polymerase II promoter,GO:0016055~Wnt signaling pathway,GO:0016567~protein ubiquitination,GO:0043928~exonucleolytic nuclear-transcribed mRNA catabolic process involved in deadenylation-dependent decay,GO:0045638~negative regulation of myeloid cell differentiation,GO:0051568~histone H3-K4 methylation,GO:0051571~positive regulation of histone H3-K4 methylation,GO:0080182~histone H3-K4 trimethylation,GO:2001162~positive regulation of histone H3-K79 methylation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016593~Cdc73/Paf1 complex,GO:0035327~transcriptionally active chromatin,GO:0055087~Ski complex,	GO:0005515~protein binding,	IPR001680:WD40 repeat,IPR013979:Translation initiation factor, beta propellor-like domain,IPR015943:WD40/YVTN repeat-like-containing domain,IPR017986:WD40-repeat-containing domain,IPR019775:WD40 repeat, conserved site,IPR020472:G-protein beta WD-40 repeat,IPR024977:Anaphase-promoting complex subunit 4, WD40 domain,	hsa03018:RNA degradation,			SM00320:WD40,	KW-0804~Transcription,KW-0805~Transcription regulation,KW-0879~Wnt signaling pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0853~WD repeat,			KW-0007~Acetylation,	DOMAIN:ANAPC4_WD40,DOMAIN:eIF2A,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
WDR7	WD repeat domain 7(WDR7)	Homo sapiens				GO:0002244~hematopoietic progenitor cell differentiation,	GO:0005737~cytoplasm,GO:0008021~synaptic vesicle,		IPR001680:WD40 repeat,IPR011047:Quinonprotein alcohol dehydrogenase-like superfamily,IPR015943:WD40/YVTN repeat-like-containing domain,IPR016024:Armadillo-type fold,IPR017986:WD40-repeat-containing domain,IPR019775:WD40 repeat, conserved site,	hsa04142:Lysosome,			SM00320:WD40,				KW-0677~Repeat,KW-0853~WD repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,REGION:Disordered,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,REPEAT:WD 8,REPEAT:WD 9,
XBP1	X-box binding protein 1(XBP1)	Homo sapiens				GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001525~angiogenesis,GO:0001558~regulation of cell growth,GO:0001889~liver development,GO:0001934~positive regulation of protein phosphorylation,GO:0001935~endothelial cell proliferation,GO:0002639~positive regulation of immunoglobulin production,GO:0006366~transcription from RNA polymerase II promoter,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0006633~fatty acid biosynthetic process,GO:0006914~autophagy,GO:0006915~apoptotic process,GO:0006955~immune response,GO:0006990~positive regulation of transcription from RNA polymerase II promoter involved in unfolded protein response,GO:0006996~organelle organization,GO:0007517~muscle organ development,GO:0008284~positive regulation of cell proliferation,GO:0010508~positive regulation of autophagy,GO:0010832~negative regulation of myotube differentiation,GO:0014065~phosphatidylinositol 3-kinase signaling,GO:0015031~protein transport,GO:0030335~positive regulation of cell migration,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0030968~endoplasmic reticulum unfolded protein response,GO:0031062~positive regulation of histone methylation,GO:0031647~regulation of protein stability,GO:0031648~protein destabilization,GO:0031670~cellular response to nutrient,GO:0032008~positive regulation of TOR signaling,GO:0032755~positive regulation of interleukin-6 production,GO:0032869~cellular response to insulin stimulus,GO:0034599~cellular response to oxidative stress,GO:0034976~response to endoplasmic reticulum stress,GO:0035356~cellular triglyceride homeostasis,GO:0035470~positive regulation of vascular wound healing,GO:0035924~cellular response to vascular endothelial growth factor stimulus,GO:0036498~IRE1-mediated unfolded protein response,GO:0036500~ATF6-mediated unfolded protein response,GO:0042149~cellular response to glucose starvation,GO:0042307~positive regulation of protein import into nucleus,GO:0042632~cholesterol homeostasis,GO:0043066~negative regulation of apoptotic process,GO:0045348~positive regulation of MHC class II biosynthetic process,GO:0045579~positive regulation of B cell differentiation,GO:0045582~positive regulation of T cell differentiation,GO:0045600~positive regulation of fat cell differentiation,GO:0045766~positive regulation of angiogenesis,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048010~vascular endothelial growth factor receptor signaling pathway,GO:0048666~neuron development,GO:0051897~positive regulation of protein kinase B signaling,GO:0055089~fatty acid homeostasis,GO:0055092~sterol homeostasis,GO:0060394~negative regulation of pathway-restricted SMAD protein phosphorylation,GO:0060612~adipose tissue development,GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:0071073~positive regulation of phospholipid biosynthetic process,GO:0071222~cellular response to lipopolysaccharide,GO:0071230~cellular response to amino acid stimulus,GO:0071332~cellular response to fructose stimulus,GO:0071333~cellular response to glucose stimulus,GO:0071353~cellular response to interleukin-4,GO:0071375~cellular response to peptide hormone stimulus,GO:0071498~cellular response to fluid shear stress,GO:0071499~cellular response to laminar fluid shear stress,GO:1900100~positive regulation of plasma cell differentiation,GO:1900102~negative regulation of endoplasmic reticulum unfolded protein response,GO:1900103~positive regulation of endoplasmic reticulum unfolded protein response,GO:1901985~positive regulation of protein acetylation,GO:1902236~negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway,GO:1903071~positive regulation of ER-associated ubiquitin-dependent protein catabolic process,GO:1903489~positive regulation of lactation,GO:1904707~positive regulation of vascular smooth muscle cell proliferation,GO:1904754~positive regulation of vascular associated smooth muscle cell migration,GO:1990418~response to insulin-like growth factor stimulus,GO:1990440~positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress,GO:2000347~positive regulation of hepatocyte proliferation,GO:2000353~positive regulation of endothelial cell apoptotic process,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0016021~integral component of membrane,GO:0030176~integral component of endoplasmic reticulum membrane,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0000987~core promoter proximal region sequence-specific DNA binding,GO:0002020~protease binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0030331~estrogen receptor binding,GO:0031490~chromatin DNA binding,GO:0031625~ubiquitin protein ligase binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0046982~protein heterodimerization activity,GO:1990837~sequence-specific double-stranded DNA binding,	IPR004827:Basic-leucine zipper domain,	hsa04141:Protein processing in endoplasmic reticulum,hsa04932:Non-alcoholic fatty liver disease,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05017:Spinocerebellar ataxia,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05417:Lipid and atherosclerosis,	612371~Major affective disorder-7, susceptibility to,		SM00338:BRLZ,	KW-0037~Angiogenesis,KW-0053~Apoptosis,KW-0072~Autophagy,KW-0221~Differentiation,KW-0346~Stress response,KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,KW-0517~Myogenesis,KW-0653~Protein transport,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0813~Transport,KW-0834~Unfolded protein response,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0553~Oncogene,	KW-0175~Coiled coil,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0165~Cleavage on pair of basic residues,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,DOMAIN:BZIP,DOMAIN:bZIP,MUTAGEN:C->N: Induces glycosylation.,MUTAGEN:I->D: Reduces endoplasmic reticulum localization of its own mRNA; when associated with E-194 and E-205.,MUTAGEN:L->A: Reduces translational pausing, membrane targeting and cytoplasmic splicing of its own mRNA.,MUTAGEN:L->D: Reduces endoplasmic reticulum localization of its own mRNA; when associated with E-189 and E-193.,MUTAGEN:L->E: Reduces endoplasmic reticulum localization of its own mRNA; when associated with D-198 and E-205.,MUTAGEN:Q->L: Inhibits HM13/SPP-mediated degradation of XBP1; when associated with L-197; L-200 and L-203.,MUTAGEN:Q->L: Inhibits HM13/SPP-mediated degradation of XBP1; when associated with L-199; L-200 and L-203.,MUTAGEN:R->N: Induces glycosylation.,MUTAGEN:S->A: Increases translational pausing of its own mRNA.,MUTAGEN:S->L: Inhibits HM13/SPP-mediated degradation of XBP1; when associated with L-197; L-199 and L-200.,MUTAGEN:S->L: Inhibits HM13/SPP-mediated degradation of XBP1; when associated with L-197; L-199 and L-203.,MUTAGEN:T->N: Does not induce glycosylation.,MUTAGEN:V->E: Reduces endoplasmic reticulum localization of its own mRNA; when associated with E-189 and D-196.,MUTAGEN:W->A: Reduces translational pausing, membrane targeting and cytoplasmic splicing of its own mRNA.,MUTAGEN:W->E: Reduces endoplasmic reticulum localization of its own mRNA; when associated with E-193 and D-196.,MUTAGEN:W->E: Reduces endoplasmic reticulum localization of its own mRNA; when associated with E-194 and D-198.,REGION:Basic motif,REGION:Disordered,REGION:Leucine-zipper,REGION:Necessary for the translational pausing of its own mRNA,REGION:Nuclear localization signal (NLS); in isoforms 1 and isoform 2,SITE:Cleavage; by HM13/SPP,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
XPNPEP1	X-prolyl aminopeptidase 1(XPNPEP1)	Homo sapiens				GO:0006508~proteolysis,GO:0010815~bradykinin catabolic process,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0004177~aminopeptidase activity,GO:0016787~hydrolase activity,GO:0030145~manganese ion binding,GO:0042803~protein homodimerization activity,GO:0046872~metal ion binding,GO:0070006~metalloaminopeptidase activity,	IPR000587:Creatinase,IPR000994:Peptidase M24, structural domain,IPR001131:Peptidase M24B, X-Pro dipeptidase/aminopeptidase P, conserved site,						KW-0963~Cytoplasm,			KW-0464~Manganese,KW-0479~Metal-binding,	KW-0031~Aminopeptidase,KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0007~Acetylation,	BINDING:Substrate,BINDING:Substrate; via tele nitrogen,DOMAIN:Creatinase_N,DOMAIN:Peptidase_M24,DOMAIN:Peptidase_M24_C,METAL:Manganese 1,METAL:Manganese 2,METAL:Manganese 2; via tele nitrogen,MUTAGEN:E->A: Reduces activity by 10%.,MUTAGEN:W->E: Interferes with dimerization and reduces activity by 94%.,
YKT6	YKT6 v-SNARE homolog(YKT6)	Homo sapiens			Intracellular trafficking and secretion,	GO:0006888~ER to Golgi vesicle-mediated transport,GO:0006903~vesicle targeting,GO:0006904~vesicle docking involved in exocytosis,GO:0015031~protein transport,GO:0016192~vesicle-mediated transport,GO:0042147~retrograde transport, endosome to Golgi,GO:0061025~membrane fusion,	GO:0000139~Golgi membrane,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005768~endosome,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0030133~transport vesicle,GO:0030659~cytoplasmic vesicle membrane,GO:0031201~SNARE complex,GO:0033116~endoplasmic reticulum-Golgi intermediate compartment membrane,GO:0043025~neuronal cell body,GO:0097440~apical dendrite,GO:0097441~basilar dendrite,	GO:0005484~SNAP receptor activity,GO:0019706~protein-cysteine S-palmitoyltransferase activity,GO:0045296~cadherin binding,	IPR001388:Synaptobrevin,IPR010908:Longin domain,IPR011012:Longin-like domain,	hsa04130:SNARE interactions in vesicular transport,			SM01270:SM01270,	KW-0653~Protein transport,KW-0813~Transport,KW-0931~ER-Golgi transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,		KW-0175~Coiled coil,		KW-0808~Transferase,	KW-0449~Lipoprotein,KW-0488~Methylation,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0636~Prenylation,	DOMAIN:Longin,DOMAIN:V-SNARE coiled-coil homology,DOMAIN:v-SNARE coiled-coil homology,LIPID:S-farnesyl cysteine,LIPID:S-palmitoyl cysteine,MUTAGEN:C->S: Decreases palmitoylation by 55%. Prevents palmitoylation; when associated with S-195. Targeted to Golgi and cytosol; when associated with E-42.,MUTAGEN:C->S: Prevents farnesylation. Targeted to cytosol; when associated with E-42. Decreases palmitoylation by 13%. Prevents palmitoylation; when associated with S-194.,MUTAGEN:F->E: Increases palmitoylation. Targeted to Golgi membranes. Targeted to Golgi and cytosol; when associated with S-194. Targeted to cytosol; when associated with S-195.,PROPEP:Removed in mature form,
YME1L1	YME1 like 1 ATPase(YME1L1)	Homo sapiens				GO:0006508~proteolysis,GO:0006515~misfolded or incompletely synthesized protein catabolic process,GO:0006851~mitochondrial calcium ion transport,GO:0007005~mitochondrion organization,GO:0008283~cell proliferation,GO:0034214~protein hexamerization,GO:0034982~mitochondrial protein processing,GO:0035694~mitochondrial protein catabolic process,GO:0043066~negative regulation of apoptotic process,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016604~nuclear body,	GO:0004176~ATP-dependent peptidase activity,GO:0004222~metalloendopeptidase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0046872~metal ion binding,	IPR000642:Peptidase M41,IPR003593:AAA+ ATPase domain,IPR003959:ATPase, AAA-type, core,IPR003960:ATPase, AAA-type, conserved site,IPR005936:Peptidase, FtsH,IPR027417:P-loop containing nucleoside triphosphate hydrolase,		617302~Optic atrophy 11,		SM00382:AAA,		KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,	KW-0225~Disease variant,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,		DOMAIN:AAA,DOMAIN:ATPase_AAA_core,METAL:Zinc; catalytic,MUTAGEN:E->Q: Loss of ATPase and protease activity. Loss of PRELID1 degradation. Cannot restore OMA1 degradation in YME1L-depleted cells.,MUTAGEN:E->Q: Loss of protease activity. Cannot restore OMA1 degradation in YME1L-depleted cells.,NP_BIND:ATP,REGION:Disordered,TOPO_DOM:Mitochondrial intermembrane,TOPO_DOM:Mitochondrial matrix,TRANSMEM:Helical,
YTHDF1	YTH N6-methyladenosine RNA binding protein 1(YTHDF1)	Homo sapiens				GO:0002376~immune system process,GO:0002577~regulation of antigen processing and presentation,GO:0007612~learning,GO:0007613~memory,GO:0034063~stress granule assembly,GO:0043488~regulation of mRNA stability,GO:0045727~positive regulation of translation,GO:0045948~positive regulation of translational initiation,GO:0061157~mRNA destabilization,GO:0070925~organelle assembly,GO:1900271~regulation of long-term synaptic potentiation,GO:1902667~regulation of axon guidance,	GO:0000932~P-body,GO:0005737~cytoplasm,GO:0010494~cytoplasmic stress granule,	GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0043022~ribosome binding,GO:1990247~N6-methyladenosine-containing RNA binding,	IPR007275:YTH domain,					KW-0391~Immunity,	KW-0963~Cytoplasm,				KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	BINDING:N6-methyladenosine,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:YTH,MUTAGEN:D->N: Increased binding to N6-methyladenosine (m6A)-containing RNAs.,MUTAGEN:R->A: Reduced binding to N6-methyladenosine (m6A)-containing RNAs.,MUTAGEN:W->A: Abolished binding to N6-methyladenosine (m6A)-containing RNAs.,MUTAGEN:Y->A: Strongly reduced binding to N6-methyladenosine (m6A)-containing RNAs.,REGION:Disordered,REGION:N6-methyladenosine binding,
ZFP36	ZFP36 ring finger protein(ZFP36)	Homo sapiens				GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000165~MAPK cascade,GO:0000288~nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay,GO:0000289~nuclear-transcribed mRNA poly(A) tail shortening,GO:0006402~mRNA catabolic process,GO:0009611~response to wounding,GO:0010837~regulation of keratinocyte proliferation,GO:0016032~viral process,GO:0031086~nuclear-transcribed mRNA catabolic process, deadenylation-independent decay,GO:0032680~regulation of tumor necrosis factor production,GO:0032703~negative regulation of interleukin-2 production,GO:0032897~negative regulation of viral transcription,GO:0035278~miRNA mediated inhibition of translation,GO:0038066~p38MAPK cascade,GO:0042594~response to starvation,GO:0043488~regulation of mRNA stability,GO:0044344~cellular response to fibroblast growth factor stimulus,GO:0045600~positive regulation of fat cell differentiation,GO:0045616~regulation of keratinocyte differentiation,GO:0045638~negative regulation of myeloid cell differentiation,GO:0045647~negative regulation of erythrocyte differentiation,GO:0050728~negative regulation of inflammatory response,GO:0051028~mRNA transport,GO:0060213~positive regulation of nuclear-transcribed mRNA poly(A) tail shortening,GO:0061158~3'-UTR-mediated mRNA destabilization,GO:0070935~3'-UTR-mediated mRNA stabilization,GO:0071222~cellular response to lipopolysaccharide,GO:0071356~cellular response to tumor necrosis factor,GO:0071364~cellular response to epidermal growth factor stimulus,GO:0071385~cellular response to glucocorticoid stimulus,GO:0097011~cellular response to granulocyte macrophage colony-stimulating factor stimulus,GO:1900153~positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay,GO:1901835~positive regulation of deadenylation-independent decapping of nuclear-transcribed mRNA,GO:1902172~regulation of keratinocyte apoptotic process,GO:1904246~negative regulation of polynucleotide adenylyltransferase activity,GO:1904582~positive regulation of intracellular mRNA localization,GO:2000637~positive regulation of gene silencing by miRNA,	GO:0000932~P-body,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0010494~cytoplasmic stress granule,GO:0030014~CCR4-NOT complex,GO:1990904~ribonucleoprotein complex,	GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0019901~protein kinase binding,GO:0019957~C-C chemokine binding,GO:0031072~heat shock protein binding,GO:0035925~mRNA 3'-UTR AU-rich region binding,GO:0044877~macromolecular complex binding,GO:0046872~metal ion binding,GO:0070063~RNA polymerase binding,GO:0071889~14-3-3 protein binding,	IPR000571:Zinc finger, CCCH-type,	hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,			SM00356:ZnF_C3H1,	KW-0509~mRNA transport,KW-0813~Transport,KW-0943~RNA-mediated gene silencing,KW-0945~Host-virus interaction,	KW-0271~Exosome,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0687~Ribonucleoprotein,KW-0694~RNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:C3H1-type,MUTAGEN:C->R: Inhibits binding to ARE-containing transcripts. Inhibits binding to and deadenylation activities of ARE-containing mRNAs. Inhibits localization of ARE-containing mRNAs to processing bodies (PBs).,MUTAGEN:C->R: Inhibits both ARE-binding and mRNA deadenylation activities.,MUTAGEN:F->A: Abolishes interaction with CNOT1 and impairs TNF mRNA deadenylation.,MUTAGEN:F->N: Inhibits ARE-containing RNA-binding, deadenylation and RNA decapping activities.,MUTAGEN:P->V: Inhibits interaction with SH3KBP1.,MUTAGEN:R->A: Abolishes interaction with CNOT1.,MUTAGEN:S->A: Inhibits PKM-induced ZFP36 degradation through a p38 MAPK signaling pathway.,REGION:Disordered,REGION:Interaction with CNOT1,REGION:Necessary and sufficient for the association with mRNA decay enzymes and mRNA decay activation,REGION:Necessary for RNA-binding,REGION:Necessary for interaction with PABPN1,REGION:Necessary for localization of ARE-containing mRNAs to processing bodies (PBs),REGION:Necessary for mRNA decay activation,REGION:Necessary for nuclear export,REGION:Necessary for nuclear localization,REPEAT:P-P-P-P-G,ZN_FING:C3H1-type,ZN_FING:C3H1-type 1,ZN_FING:C3H1-type 2,
ABHD4	abhydrolase domain containing 4, N-acyl phospholipase B(ABHD4)	Homo sapiens			Lipid metabolism,	GO:0006654~phosphatidic acid biosynthetic process,GO:0016042~lipid catabolic process,GO:0036152~phosphatidylethanolamine acyl-chain remodeling,GO:0055088~lipid homeostasis,GO:0070292~N-acylphosphatidylethanolamine metabolic process,	GO:0005739~mitochondrion,GO:0005789~endoplasmic reticulum membrane,GO:0005811~lipid particle,	GO:0004622~lysophospholipase activity,GO:0005515~protein binding,GO:0016787~hydrolase activity,GO:0042171~lysophosphatidic acid acyltransferase activity,GO:0052689~carboxylic ester hydrolase activity,	IPR000073:Alpha/beta hydrolase fold-1,					KW-0442~Lipid degradation,KW-0443~Lipid metabolism,					KW-0378~Hydrolase,		DOMAIN:AB hydrolase-1,
ACAT2	acetyl-CoA acetyltransferase 2(ACAT2)	Homo sapiens				GO:0006629~lipid metabolic process,GO:0006635~fatty acid beta-oxidation,GO:0006695~cholesterol biosynthetic process,	GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0003985~acetyl-CoA C-acetyltransferase activity,GO:0005515~protein binding,	IPR002155:Thiolase,IPR016039:Thiolase-like,IPR020610:Thiolase, active site,IPR020613:Thiolase, conserved site,IPR020616:Thiolase, N-terminal,IPR020617:Thiolase, C-terminal,	hsa00071:Fatty acid degradation,hsa00280:Valine, leucine and isoleucine degradation,hsa00310:Lysine degradation,hsa00380:Tryptophan metabolism,hsa00620:Pyruvate metabolism,hsa00630:Glyoxylate and dicarboxylate metabolism,hsa00650:Butanoate metabolism,hsa00900:Terpenoid backbone biosynthesis,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa01212:Fatty acid metabolism,hsa04975:Fat digestion and absorption,	614055~ACAT2 deficiency,	PIRSF000429:acetyl-CoA acetyltransferase,			KW-0963~Cytoplasm,				KW-0012~Acyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,	ACT_SITE:Acyl-thioester intermediate,ACT_SITE:Proton donor/acceptor,BINDING:Coenzyme A,BINDING:Coenzyme A; via carbonyl oxygen,SITE:Increases nucleophilicity of active site Cys,
ACAA1	acetyl-CoA acyltransferase 1(ACAA1)	Homo sapiens				GO:0000038~very long-chain fatty acid metabolic process,GO:0006635~fatty acid beta-oxidation,GO:0008104~protein localization,GO:0008206~bile acid metabolic process,GO:0010124~phenylacetate catabolic process,GO:0033540~fatty acid beta-oxidation using acyl-CoA oxidase,GO:0036109~alpha-linolenic acid metabolic process,GO:0043312~neutrophil degranulation,	GO:0005576~extracellular region,GO:0005777~peroxisome,GO:0005782~peroxisomal matrix,GO:0005829~cytosol,GO:0016020~membrane,GO:0035580~specific granule lumen,	GO:0003985~acetyl-CoA C-acetyltransferase activity,GO:0003988~acetyl-CoA C-acyltransferase activity,GO:0005515~protein binding,GO:0008775~acetate CoA-transferase activity,GO:0016401~palmitoyl-CoA oxidase activity,GO:0016747~transferase activity, transferring acyl groups other than amino-acyl groups,GO:0050633~acetyl-CoA C-myristoyltransferase activity,	IPR002155:Thiolase,IPR016039:Thiolase-like,IPR020610:Thiolase, active site,IPR020613:Thiolase, conserved site,IPR020615:Thiolase, acyl-enzyme intermediate active site,IPR020616:Thiolase, N-terminal,IPR020617:Thiolase, C-terminal,	hsa00071:Fatty acid degradation,hsa00280:Valine, leucine and isoleucine degradation,hsa00592:alpha-Linolenic acid metabolism,hsa01040:Biosynthesis of unsaturated fatty acids,hsa01100:Metabolic pathways,hsa01212:Fatty acid metabolism,hsa03320:PPAR signaling pathway,hsa04146:Peroxisome,		PIRSF000429:acetyl-CoA acetyltransferase,		KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,	KW-0576~Peroxisome,		KW-0809~Transit peptide,		KW-0012~Acyltransferase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Acyl-thioester intermediate,ACT_SITE:Proton acceptor,DOMAIN:Thiolase_C,DOMAIN:Thiolase_N,TRANSIT:Peroxisome,
ADI1	acireductone dioxygenase 1(ADI1)	Homo sapiens				GO:0006555~methionine metabolic process,GO:0009086~methionine biosynthetic process,GO:0019509~L-methionine salvage from methylthioadenosine,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,	GO:0005506~iron ion binding,GO:0005515~protein binding,GO:0010309~acireductone dioxygenase [iron(II)-requiring] activity,GO:0016491~oxidoreductase activity,	IPR004313:Acireductone dioxygenase ARD family,IPR011051:RmlC-like cupin domain,IPR014710:RmlC-like jelly roll fold,IPR027496:1,2-dihydroxy-3-keto-5-methylthiopentene dioxygenase, eukaryotes,	hsa00270:Cysteine and methionine metabolism,hsa01100:Metabolic pathways,				KW-0028~Amino-acid biosynthesis,KW-0486~Methionine biosynthesis,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0732~Signal,	KW-0408~Iron,KW-0479~Metal-binding,	KW-0223~Dioxygenase,KW-0560~Oxidoreductase,		COMPBIAS:Basic and acidic residues,METAL:Iron or nickel,MUTAGEN:E->A: Loss of aci-reductone dioxygenase activity.,REGION:Disordered,
ASCC3	activating signal cointegrator 1 complex subunit 3(ASCC3)	Homo sapiens			General function prediction only,	GO:0006307~DNA dealkylation involved in DNA repair,GO:0008283~cell proliferation,GO:0032508~DNA duplex unwinding,GO:0072344~rescue of stalled ribosome,GO:1990116~ribosome-associated ubiquitin-dependent protein catabolic process,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0016607~nuclear speck,GO:0099053~activating signal cointegrator 1 complex,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0004386~helicase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0043138~3'-5' DNA helicase activity,	IPR001650:Helicase, C-terminal,IPR003593:AAA+ ATPase domain,IPR004179:Sec63 domain,IPR011545:DNA/RNA helicase, DEAD/DEAH box type, N-terminal,IPR014001:Helicase, superfamily 1/2, ATP-binding domain,IPR014756:Immunoglobulin E-set,IPR027417:P-loop containing nucleoside triphosphate hydrolase,				SM00382:AAA,SM00487:DEXDc,SM00490:HELICc,SM00973:SM00973,	KW-0227~DNA damage,KW-0234~DNA repair,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0677~Repeat,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0347~Helicase,KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Helicase ATP-binding,DOMAIN:Helicase ATP-binding 1,DOMAIN:Helicase ATP-binding 2,DOMAIN:Helicase C-terminal,DOMAIN:Helicase C-terminal 1,DOMAIN:Helicase C-terminal 2,DOMAIN:SEC63 1,DOMAIN:SEC63 2,MOTIF:DEIH box,MOTIF:DEVH box,MUTAGEN:G->D: Abolishes 3'-5' DNA helicase activity and ability to promote DNA repair.,MUTAGEN:K->R: Defective activation of the ribosome quality control (RQC) pathway. Impairs its association with ribosomes.,NP_BIND:ATP,REGION:Required for interaction with ASCC2,
ATF1	activating transcription factor 1(ATF1)	Homo sapiens		h_stressPathway:TNF/Stress Related Signaling,		GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0010976~positive regulation of neuron projection development,GO:0014070~response to organic cyclic compound,GO:0032025~response to cobalt ion,GO:0034622~cellular macromolecular complex assembly,GO:0045740~positive regulation of DNA replication,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0090575~RNA polymerase II transcription factor complex,GO:1990589~ATF4-CREB1 transcription factor complex,GO:1990590~ATF1-ATF4 transcription factor complex,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0043565~sequence-specific DNA binding,GO:0044877~macromolecular complex binding,GO:0046982~protein heterodimerization activity,	IPR001630:cAMP response element binding (CREB) protein,IPR003102:Coactivator CBP, pKID,IPR004827:Basic-leucine zipper domain,	hsa04925:Aldosterone synthesis and secretion,hsa05202:Transcriptional misregulation in cancer,			SM00338:BRLZ,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:KID,DOMAIN:bZIP,MUTAGEN:S->A: Impaired CDK3-mediated phosphorylation and altered transactivation and transcriptional activities.,REGION:Basic motif,REGION:Disordered,REGION:Leucine-zipper,SITE:Breakpoint for translocation to form chimeric EWSR1/ATF1 protein,SITE:Breakpoint for translocation to form chimeric FUS/ATF1 protein,
ATF5	activating transcription factor 5(ATF5)	Homo sapiens				GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007623~circadian rhythm,GO:0008285~negative regulation of cell proliferation,GO:0009791~post-embryonic development,GO:0021891~olfactory bulb interneuron development,GO:0021930~cerebellar granule cell precursor proliferation,GO:0035264~multicellular organism growth,GO:0043066~negative regulation of apoptotic process,GO:0045444~fat cell differentiation,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046605~regulation of centrosome cycle,GO:1902750~negative regulation of cell cycle G2/M phase transition,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005813~centrosome,GO:0005829~cytosol,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003682~chromatin binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0015631~tubulin binding,GO:0019900~kinase binding,GO:0043565~sequence-specific DNA binding,	IPR004827:Basic-leucine zipper domain,				SM00338:BRLZ,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0732~Signal,		KW-0010~Activator,KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DOMAIN:BZIP,DOMAIN:bZIP,MUTAGEN:D->A: Resistant to cleavage by CASP3.,MUTAGEN:L->A: Increases protein levels.,MUTAGEN:LEL->AEA: Increases protein levels.,MUTAGEN:LGWLV->AGWAA: Increases protein levels.,MUTAGEN:LL->AA: Increases protein levels.,MUTAGEN:LL->AA: Increases protein levels. No effect on protein stability enhanced by IL1B.,MUTAGEN:LL->II: Decreases protein levels.,MUTAGEN:LL->VV: No effect on protein levels. No effect on protein stability enhanced by IL1B.,MUTAGEN:LLATLGLELDRALLPASGLGWLV->AAATAGAEADRAAAPASGAGWAA: Highly increases protein levels. No effect on protein stability enhanced by IL1B.,MUTAGEN:S->A: Not phosphorylated; when associated with 92-A--A-94 and A-126.,MUTAGEN:S->A: Not phosphorylated; when associated with 92-A--A-94 and A-190.,MUTAGEN:SPT->APA: Not phosphorylated; when associated with A-126 and A-190.,REGION:Basic motif,REGION:Disordered,REGION:Interaction with PTP4A1,REGION:Leucine-zipper,REGION:Required for protein stabilization induced by IL1B,
ATF6	activating transcription factor 6(ATF6)	Homo sapiens				GO:0001654~eye development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006457~protein folding,GO:0007165~signal transduction,GO:0007601~visual perception,GO:0010508~positive regulation of autophagy,GO:0030968~endoplasmic reticulum unfolded protein response,GO:0036500~ATF6-mediated unfolded protein response,GO:0043065~positive regulation of apoptotic process,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:1903893~positive regulation of ATF6-mediated unfolded protein response,GO:1990440~positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress,	GO:0000139~Golgi membrane,GO:0000785~chromatin,GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005654~nucleoplasm,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0016020~membrane,GO:0030176~integral component of endoplasmic reticulum membrane,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0031625~ubiquitin protein ligase binding,GO:0035497~cAMP response element binding,GO:0042802~identical protein binding,GO:0043565~sequence-specific DNA binding,GO:0046982~protein heterodimerization activity,GO:1990837~sequence-specific double-stranded DNA binding,	IPR004827:Basic-leucine zipper domain,	hsa04141:Protein processing in endoplasmic reticulum,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05417:Lipid and atherosclerosis,	616517~Achromatopsia 7,		SM00338:BRLZ,	KW-0804~Transcription,KW-0805~Transcription regulation,KW-0834~Unfolded protein response,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0539~Nucleus,	KW-0225~Disease variant,	KW-0175~Coiled coil,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0010~Activator,KW-0238~DNA-binding,	KW-0325~Glycoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:BZIP,DOMAIN:bZIP,MUTAGEN:L->V: Reduces proteolytic cleavage.,MUTAGEN:N->F: Loss of proteolytic cleavage; when associated with L-394.,MUTAGEN:P->L: Loss of proteolytic cleavage; when associated with F-391.,MUTAGEN:RR->AA: Reduces proteolytic cleavage.,MUTAGEN:T->I: Loss of glycosylation at Asn-472 and increase of Golgi translocation rate.,MUTAGEN:T->I: Loss of glycosylation at Asn-584 and increase of Golgi translocation rate. Higher increase in Golgi translocation rate; when associated with Ile-645.,MUTAGEN:T->I: Loss of glycosylation at Asn-643 and increase of Golgi translocation rate. Higher increase in Golgi translocation rate; when associated with Ile-586.,REGION:Basic motif,REGION:Disordered,REGION:Interaction with THBS4,REGION:Leucine-zipper,REGION:Transcription activation,SITE:Cleavage; by MBTPS1,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
ACBD3	acyl-CoA binding domain containing 3(ACBD3)	Homo sapiens				GO:0006694~steroid biosynthetic process,GO:0006892~post-Golgi vesicle-mediated transport,GO:0016032~viral process,	GO:0000139~Golgi membrane,GO:0005739~mitochondrion,GO:0005794~Golgi apparatus,GO:0016020~membrane,	GO:0000062~fatty-acyl-CoA binding,GO:0005515~protein binding,GO:0034237~protein kinase A regulatory subunit binding,	IPR000582:Acyl-CoA-binding protein, ACBP,IPR009038:GOLD,IPR014352:FERM/acyl-CoA-binding protein, 3-helical bundle,IPR022408:Acyl-CoA-binding protein, ACBP, conserved site,	hsa05132:Salmonella infection,				KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,KW-0752~Steroid biosynthesis,KW-0945~Host-virus interaction,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0496~Mitochondrion,		KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Pro residues,DOMAIN:ACB,DOMAIN:GOLD,MUTAGEN:EQHY->AAAA: Loss of PI4KB-, TBC1D22A- and TBC1D22B-binding.,MUTAGEN:F->A: Differential effect on PI4KB- and TBC1D22B-binding, with PI4KB-binding being much more affected than TBC1D22B-binding.,MUTAGEN:FEW->AAA: No effect on PI4KB-, TBC1D22A- and TBC1D22B-binding.,MUTAGEN:FQ->AA: Complete loss of interaction with PI4KB.,MUTAGEN:FQ->AA: Loss of interaction with PI4KB.,MUTAGEN:FWEF->AAAA: No effect on PI4KB-, TBC1D22A- and TBC1D22B-binding.,MUTAGEN:GSH->AAA: No effect on PI4KB-, TBC1D22A- and TBC1D22B-binding.,MUTAGEN:H->A: Almost complete loss of PI4KB- and TBC1D22B-binding.,MUTAGEN:I->A: No effect on PI4KB- and TBC1D22B-binding.,MUTAGEN:I->A: Partial loss of PI4KB- and TBC1D22B-binding.,MUTAGEN:IK->AE: No effect on interaction with PI4KB but loss of interaction with Kobuviral (Aichi) 3A protein. Loss of ability to sensitize PI4KB activation by Kobuviral (Aichi) 3A protein.,MUTAGEN:K->A: No effect on PI4KB- and TBC1D22B-binding.,MUTAGEN:L->A: No effect on PI4KB- and TBC1D22B-binding.,MUTAGEN:LWR->AAA: Almost complete loss of Golgi loalization.,MUTAGEN:PGN->AAA: Loss of PI4KB-, TBC1D22A- and TBC1D22B-binding.,MUTAGEN:Q->A: No effect on PI4KB- and TBC1D22B-binding.,MUTAGEN:Q->A: Partial loss of PI4KB- and TBC1D22B-binding.,MUTAGEN:QQY->AAA: No effect on PI4KB-, TBC1D22A- and TBC1D22B-binding.,MUTAGEN:RVYYT->AAAAA: 75% reduced ability to interact with the 3A protein of enterovirus D68.,MUTAGEN:S->A: Partial loss of PI4KB- and TBC1D22B-binding.,MUTAGEN:SS->AA: No effect on PI4KB-, TBC1D22A- and TBC1D22B-binding.,MUTAGEN:SYL->AAA: No effect on PI4KB-, TBC1D22A- and TBC1D22B-binding.,MUTAGEN:SYLF->AAAA: 60% reduced ability to interact with the 3A protein of enterovirus D68.,MUTAGEN:SYS->AAA: No effect on PI4KB-, TBC1D22A- and TBC1D22B-binding.,MUTAGEN:T->A: No effect on PI4KB- and TBC1D22B-binding.,MUTAGEN:VQF->AAA: Loss of PI4KB-, TBC1D22A- and TBC1D22B-binding.,MUTAGEN:VTVRV->AAAAA: 95% reduced ability to interact with the 3A protein of enterovirus D68.,MUTAGEN:WTR->ATA: 80% reduced ability to interact with the 3A protein of enterovirus D68.,MUTAGEN:Y->A: Almost complete loss of PI4KB- and TBC1D22B-binding.,MUTAGEN:Y->A: Differential loss of PI4KB- and TBC1D22B-binding, with PI4KB-binding being much more affected than TBC1D22B-binding.,MUTAGEN:Y->A: No effect on PI4KB- and TBC1D22B-binding.,MUTAGEN:Y->A: No effect on interaction with PI4KB but loss of interaction with Kobuviral (Aichi) 3A protein. Loss of ability to sensitize PI4KB activation by Kobuviral (Aichi) 3A protein.,MUTAGEN:Y->A: No loss of interaction with PI4KB.,REGION:Charged amino-acid region (CAR),REGION:Disordered,REGION:Membrane-binding,REGION:Q domain; Interaction with PI4KB, TBC1D22A and TBC1D22B,SITE:Membrane-binding,
ACOT9	acyl-CoA thioesterase 9(ACOT9)	Homo sapiens				GO:0006637~acyl-CoA metabolic process,	GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,	GO:0003986~acetyl-CoA hydrolase activity,GO:0016290~palmitoyl-CoA hydrolase activity,GO:0016787~hydrolase activity,GO:0047617~acyl-CoA hydrolase activity,GO:0052689~carboxylic ester hydrolase activity,							KW-0496~Mitochondrion,		KW-0677~Repeat,KW-0809~Transit peptide,		KW-0378~Hydrolase,KW-0719~Serine esterase,	KW-0007~Acetylation,	DOMAIN:HotDog ACOT-type,DOMAIN:HotDog ACOT-type 1,DOMAIN:HotDog ACOT-type 2,TRANSIT:Mitochondrion,
ADAT1	adenosine deaminase tRNA specific 1(ADAT1)	Homo sapiens				GO:0006396~RNA processing,GO:0008033~tRNA processing,		GO:0003723~RNA binding,GO:0004000~adenosine deaminase activity,GO:0008251~tRNA-specific adenosine deaminase activity,GO:0046872~metal ion binding,	IPR002466:Adenosine deaminase/editase,				SM00552:ADEAMc,	KW-0819~tRNA processing,				KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton donor,BINDING:Inositol hexakisphosphate,DOMAIN:A to I editase,METAL:Zinc,REGION:Disordered,
ADRB2	adrenoceptor beta 2(ADRB2)	Homo sapiens		h_cftrPathway:Cystic fibrosis transmembrane conductance regulator (CFTR) and beta 2 adrenergic receptor (b2AR) pathway,h_gcrpathway:Corticosteroids and cardioprotection,h_plcePathway:Phospholipase C-epsilon pathway,		GO:0002024~diet induced thermogenesis,GO:0002025~norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure,GO:0002028~regulation of sodium ion transport,GO:0002032~desensitization of G-protein coupled receptor protein signaling pathway by arrestin,GO:0002862~negative regulation of inflammatory response to antigenic stimulus,GO:0006898~receptor-mediated endocytosis,GO:0006940~regulation of smooth muscle contraction,GO:0007166~cell surface receptor signaling pathway,GO:0007171~activation of transmembrane receptor protein tyrosine kinase activity,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007188~adenylate cyclase-modulating G-protein coupled receptor signaling pathway,GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0007190~activation of adenylate cyclase activity,GO:0008333~endosome to lysosome transport,GO:0009409~response to cold,GO:0010739~positive regulation of protein kinase A signaling,GO:0016579~protein deubiquitination,GO:0030501~positive regulation of bone mineralization,GO:0031649~heat generation,GO:0040015~negative regulation of multicellular organism growth,GO:0043410~positive regulation of MAPK cascade,GO:0045453~bone resorption,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0045986~negative regulation of smooth muscle contraction,GO:0050873~brown fat cell differentiation,GO:0061024~membrane organization,GO:0071875~adrenergic receptor signaling pathway,GO:0071880~adenylate cyclase-activating adrenergic receptor signaling pathway,GO:0071902~positive regulation of protein serine/threonine kinase activity,GO:0097746~regulation of blood vessel diameter,GO:1901098~positive regulation of autophagosome maturation,GO:1904504~positive regulation of lipophagy,GO:1904646~cellular response to beta-amyloid,GO:1990911~response to psychosocial stress,GO:2000481~positive regulation of cAMP-dependent protein kinase activity,GO:2000969~positive regulation of AMPA receptor activity,	GO:0005634~nucleus,GO:0005764~lysosome,GO:0005768~endosome,GO:0005769~early endosome,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0043235~receptor complex,	GO:0001540~beta-amyloid binding,GO:0004930~G-protein coupled receptor activity,GO:0004941~beta2-adrenergic receptor activity,GO:0005515~protein binding,GO:0008179~adenylate cyclase binding,GO:0015459~potassium channel regulator activity,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0044877~macromolecular complex binding,GO:0051380~norepinephrine binding,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR000332:Adrenergic receptor beta 2,IPR002233:Adrenergic receptor,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04020:Calcium signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04923:Regulation of lipolysis in adipocytes,hsa04924:Renin secretion,hsa04970:Salivary secretion,hsa05207:Chemical carcinogenesis - receptor activation,	600807~Asthma, nocturnal, susceptibility to,601665~Obesity, susceptibility to,Beta-2-adrenoreceptor agonist, reduced response to~Beta-2-adrenoreceptor agonist, reduced response to,		SM01381:SM01381,		KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0379~Hydroxylation,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	BINDING:Carazolol; inverse agonist,BINDING:Timolol; inverse agonist,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:G_PROTEIN_RECEP_F1_2,LIPID:S-palmitoyl cysteine,MOTIF:PDZ-binding,MUTAGEN:C->A: Loss of basal palmitoylation.,MUTAGEN:C->A: Loss of ligand-induced palmitoylation.,MUTAGEN:C->G: Uncoupled receptor.,MUTAGEN:D->N: Affects binding of catecholamines, and produces an uncoupling between the receptor and stimulatory G proteins.,MUTAGEN:SS->AA: Delayed agonist-promoted desensitization.,MUTAGEN:Y->A: Does not affect insulin-induced tyrosine phosphorylation or insulin-induced receptor supersensitization.,MUTAGEN:Y->F: Abolishes insulin-induced tyrosine phosphorylation and insulin-induced receptor supersensitization.,MUTAGEN:Y->F: Does not affect insulin-induced tyrosine phosphorylation or insulin-induced receptor supersensitization.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
ADH5	alcohol dehydrogenase 5 (class III), chi polypeptide(ADH5)	Homo sapiens				GO:0001523~retinoid metabolic process,GO:0003016~respiratory system process,GO:0006069~ethanol oxidation,GO:0010430~fatty acid omega-oxidation,GO:0018119~peptidyl-cysteine S-nitrosylation,GO:0022900~electron transport chain,GO:0032496~response to lipopolysaccharide,GO:0045777~positive regulation of blood pressure,GO:0046294~formaldehyde catabolic process,GO:0051409~response to nitrosative stress,GO:0051775~response to redox state,	GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0004022~alcohol dehydrogenase (NAD) activity,GO:0004024~alcohol dehydrogenase activity, zinc-dependent,GO:0005504~fatty acid binding,GO:0008270~zinc ion binding,GO:0009055~electron carrier activity,GO:0016491~oxidoreductase activity,GO:0018467~formaldehyde dehydrogenase activity,GO:0042802~identical protein binding,GO:0051903~S-(hydroxymethyl)glutathione dehydrogenase activity,	IPR002328:Alcohol dehydrogenase, zinc-type, conserved site,IPR011032:GroES-like,IPR013149:Alcohol dehydrogenase, C-terminal,IPR013154:Alcohol dehydrogenase GroES-like,IPR014183:Alcohol dehydrogenase class III/S-(hydroxymethyl)glutathione dehydrogenase,	hsa00010:Glycolysis / Gluconeogenesis,hsa00071:Fatty acid degradation,hsa00350:Tyrosine metabolism,hsa00620:Pyruvate metabolism,hsa00830:Retinol metabolism,hsa00980:Metabolism of xenobiotics by cytochrome P450,hsa00982:Drug metabolism - cytochrome P450,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa04936:Alcoholic liver disease,	619151~AMED syndrome, digenic,			KW-0443~Lipid metabolism,	KW-0963~Cytoplasm,			KW-0479~Metal-binding,KW-0520~NAD,KW-0862~Zinc,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:ADH_N,DOMAIN:ADH_zinc_N,METAL:Zinc 1; catalytic,METAL:Zinc 2,MUTAGEN:R->A,D: Loss of FDH activity and loss of activation by fatty acids.,SITE:Important for FDH activity and activation by fatty acids,
ALDH7A1	aldehyde dehydrogenase 7 family member A1(ALDH7A1)	Homo sapiens				GO:0006081~cellular aldehyde metabolic process,GO:0006554~lysine catabolic process,GO:0007605~sensory perception of sound,GO:0019285~glycine betaine biosynthetic process from choline,GO:0042426~choline catabolic process,	GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0004029~aldehyde dehydrogenase (NAD) activity,GO:0004043~L-aminoadipate-semialdehyde dehydrogenase activity,GO:0005515~protein binding,GO:0008802~betaine-aldehyde dehydrogenase activity,GO:0042802~identical protein binding,GO:0043878~glyceraldehyde-3-phosphate dehydrogenase (NAD+) (non-phosphorylating) activity,	IPR015590:Aldehyde dehydrogenase domain,IPR016161:Aldehyde/histidinol dehydrogenase,IPR016162:Aldehyde dehydrogenase, N-terminal,IPR016163:Aldehyde dehydrogenase, C-terminal,	hsa00010:Glycolysis / Gluconeogenesis,hsa00053:Ascorbate and aldarate metabolism,hsa00071:Fatty acid degradation,hsa00260:Glycine, serine and threonine metabolism,hsa00280:Valine, leucine and isoleucine degradation,hsa00310:Lysine degradation,hsa00330:Arginine and proline metabolism,hsa00340:Histidine metabolism,hsa00380:Tryptophan metabolism,hsa00410:beta-Alanine metabolism,hsa00561:Glycerolipid metabolism,hsa00620:Pyruvate metabolism,hsa01100:Metabolic pathways,hsa04936:Alcoholic liver disease,	266100~Epilepsy, pyridoxine-dependent,				KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0887~Epilepsy,	KW-0809~Transit peptide,	KW-0520~NAD,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,	ACT_SITE:Nucleophile,ACT_SITE:Proton acceptor,DOMAIN:Aldedh,NP_BIND:NAD,REGION:Disordered,SITE:Transition state stabilizer,TRANSIT:Mitochondrion,
AKR7A2	aldo-keto reductase family 7 member A2(AKR7A2)	Homo sapiens		h_arenrf2Pathway:Oxidative Stress Induced Gene Expression Via Nrf2,		GO:0005975~carbohydrate metabolic process,GO:0006081~cellular aldehyde metabolic process,GO:0006629~lipid metabolic process,GO:0022900~electron transport chain,GO:0044597~daunorubicin metabolic process,GO:0044598~doxorubicin metabolic process,GO:0046222~aflatoxin metabolic process,	GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0004032~alditol:NADP+ 1-oxidoreductase activity,GO:0004033~aldo-keto reductase (NADP) activity,GO:0005515~protein binding,GO:0009055~electron carrier activity,GO:0019119~phenanthrene-9,10-epoxide hydrolase activity,GO:0047834~D-threo-aldose 1-dehydrogenase activity,	IPR023210:NADP-dependent oxidoreductase domain,	hsa00980:Metabolism of xenobiotics by cytochrome P450,				KW-0443~Lipid metabolism,	KW-0333~Golgi apparatus,KW-0963~Cytoplasm,			KW-0521~NADP,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton donor,BINDING:NADP,BINDING:Substrate,DOMAIN:Aldo_ket_red,NP_BIND:NADP,REGION:Disordered,SITE:Lowers pKa of active site Tyr,
ALDOA	aldolase, fructose-bisphosphate A(ALDOA)	Homo sapiens		h_mta3Pathway:Downregulated of MTA-3 in ER-negative Breast Tumors,		GO:0002576~platelet degranulation,GO:0006000~fructose metabolic process,GO:0006094~gluconeogenesis,GO:0006096~glycolytic process,GO:0006754~ATP biosynthetic process,GO:0006941~striated muscle contraction,GO:0007015~actin filament organization,GO:0007339~binding of sperm to zona pellucida,GO:0008360~regulation of cell shape,GO:0030388~fructose 1,6-bisphosphate metabolic process,GO:0043312~neutrophil degranulation,GO:0046716~muscle cell cellular homeostasis,GO:0051289~protein homotetramerization,GO:0061621~canonical glycolysis,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005829~cytosol,GO:0015629~actin cytoskeleton,GO:0016020~membrane,GO:0031093~platelet alpha granule lumen,GO:0031430~M band,GO:0031674~I band,GO:0034774~secretory granule lumen,GO:0061827~sperm head,GO:0070062~extracellular exosome,GO:1904724~tertiary granule lumen,GO:1904813~ficolin-1-rich granule lumen,	GO:0003723~RNA binding,GO:0003779~actin binding,GO:0004332~fructose-bisphosphate aldolase activity,GO:0005515~protein binding,GO:0008092~cytoskeletal protein binding,GO:0015631~tubulin binding,GO:0042802~identical protein binding,GO:0045296~cadherin binding,GO:0070061~fructose binding,	IPR000741:Fructose-bisphosphate aldolase, class-I,IPR013785:Aldolase-type TIM barrel,	hsa00010:Glycolysis / Gluconeogenesis,hsa00030:Pentose phosphate pathway,hsa00051:Fructose and mannose metabolism,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa01230:Biosynthesis of amino acids,hsa04066:HIF-1 signaling pathway,	611881~Glycogen storage disease XII,			KW-0324~Glycolysis,	KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0322~Glycogen storage disease,KW-0360~Hereditary hemolytic anemia,		KW-0704~Schiff base,	KW-0456~Lyase,	KW-0007~Acetylation,KW-0379~Hydroxylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Proton acceptor,ACT_SITE:Schiff-base intermediate with dihydroxyacetone-P,BINDING:Substrate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,SITE:Necessary for preference for fructose 1,6-bisphosphate over fructose 1-phosphate,
ALDOC	aldolase, fructose-bisphosphate C(ALDOC)	Homo sapiens				GO:0006000~fructose metabolic process,GO:0006094~gluconeogenesis,GO:0006096~glycolytic process,GO:0030388~fructose 1,6-bisphosphate metabolic process,GO:0030855~epithelial cell differentiation,GO:0043312~neutrophil degranulation,GO:0061621~canonical glycolysis,	GO:0005576~extracellular region,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0034774~secretory granule lumen,GO:0070062~extracellular exosome,GO:1904724~tertiary granule lumen,GO:1904813~ficolin-1-rich granule lumen,	GO:0004332~fructose-bisphosphate aldolase activity,GO:0005515~protein binding,GO:0008092~cytoskeletal protein binding,	IPR000741:Fructose-bisphosphate aldolase, class-I,IPR013785:Aldolase-type TIM barrel,	hsa00010:Glycolysis / Gluconeogenesis,hsa00030:Pentose phosphate pathway,hsa00051:Fructose and mannose metabolism,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa01230:Biosynthesis of amino acids,hsa04066:HIF-1 signaling pathway,				KW-0324~Glycolysis,				KW-0704~Schiff base,	KW-0456~Lyase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,ACT_SITE:Schiff-base intermediate with dihydroxyacetone-P,BINDING:Substrate,SITE:Necessary for preference for fructose 1,6-bisphosphate over fructose 1-phosphate,
GAA	alpha glucosidase(GAA)	Homo sapiens				GO:0000023~maltose metabolic process,GO:0002026~regulation of the force of heart contraction,GO:0002086~diaphragm contraction,GO:0003007~heart morphogenesis,GO:0005975~carbohydrate metabolic process,GO:0005980~glycogen catabolic process,GO:0005985~sucrose metabolic process,GO:0006006~glucose metabolic process,GO:0007040~lysosome organization,GO:0007626~locomotory behavior,GO:0009888~tissue development,GO:0043181~vacuolar sequestering,GO:0043312~neutrophil degranulation,GO:0046716~muscle cell cellular homeostasis,GO:0050884~neuromuscular process controlling posture,GO:0050885~neuromuscular process controlling balance,GO:0060048~cardiac muscle contraction,	GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0035577~azurophil granule membrane,GO:0043202~lysosomal lumen,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,GO:0070821~tertiary granule membrane,GO:0101003~ficolin-1-rich granule membrane,	GO:0003824~catalytic activity,GO:0004553~hydrolase activity, hydrolyzing O-glycosyl compounds,GO:0004558~alpha-1,4-glucosidase activity,GO:0030246~carbohydrate binding,GO:0032450~maltose alpha-glucosidase activity,GO:0090599~alpha-glucosidase activity,	IPR000322:Glycoside hydrolase, family 31,IPR000519:P-type trefoil,IPR011013:Galactose mutarotase-like domain,IPR013780:Glycosyl hydrolase, family 13, all-beta,IPR017853:Glycoside hydrolase, superfamily,IPR017957:P-type trefoil, conserved site,IPR025887:Glycoside hydrolase family 31, N-terminal domain,	hsa00052:Galactose metabolism,hsa00500:Starch and sucrose metabolism,hsa01100:Metabolic pathways,hsa04142:Lysosome,	232300~Glycogen storage disease II,		SM00018:PD,		KW-0458~Lysosome,KW-0472~Membrane,	KW-0225~Disease variant,KW-0322~Glycogen storage disease,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0326~Glycosidase,KW-0378~Hydrolase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Nucleophile,BINDING:Substrate,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:P-type,MUTAGEN:D->G,N,E: Loss of activity.,MUTAGEN:W->R: Loss of activity.,REGION:Disordered,TRANSMEM:Helical,
AMDHD2	amidohydrolase domain containing 2(AMDHD2)	Homo sapiens				GO:0005975~carbohydrate metabolic process,GO:0006044~N-acetylglucosamine metabolic process,GO:0006046~N-acetylglucosamine catabolic process,GO:0006048~UDP-N-acetylglucosamine biosynthetic process,GO:0019262~N-acetylneuraminate catabolic process,	GO:0005634~nucleus,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0008448~N-acetylglucosamine-6-phosphate deacetylase activity,GO:0046872~metal ion binding,GO:0047419~N-acetylgalactosamine-6-phosphate deacetylase activity,	IPR003764:N-acetylglucosamine-6-phosphate deacetylase,IPR006680:Amidohydrolase 1,IPR011059:Metal-dependent hydrolase, composite domain,	hsa00520:Amino sugar and nucleotide sugar metabolism,hsa01100:Metabolic pathways,		PIRSF038994:N-acetylglucosamine-6-phosphate deacetylase,		KW-0119~Carbohydrate metabolism,				KW-0479~Metal-binding,	KW-0378~Hydrolase,		ACT_SITE:Proton donor/acceptor,BINDING:Substrate,DOMAIN:Amidohydro-rel,METAL:Divalent metal cation,METAL:Divalent metal cation; via tele nitrogen,REGION:Disordered,REGION:Substrate binding,
NPEPL1	aminopeptidase like 1(NPEPL1)	Homo sapiens				GO:0006508~proteolysis,	GO:0005634~nucleus,GO:0005737~cytoplasm,	GO:0008233~peptidase activity,GO:0030145~manganese ion binding,GO:0070006~metalloaminopeptidase activity,	IPR000819:Peptidase M17, leucyl aminopeptidase, C-terminal,IPR011356:Leucine aminopeptidase/peptidase B,									KW-0464~Manganese,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0031~Aminopeptidase,KW-0378~Hydrolase,KW-0645~Protease,		DOMAIN:CYTOSOL_AP,METAL:Zinc 1,METAL:Zinc 2,
AGL	amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase(AGL)	Homo sapiens				GO:0005978~glycogen biosynthetic process,GO:0005980~glycogen catabolic process,GO:0007584~response to nutrient,GO:0043312~neutrophil degranulation,GO:0051384~response to glucocorticoid,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016234~inclusion body,GO:0016529~sarcoplasmic reticulum,GO:0034774~secretory granule lumen,GO:0043033~isoamylase complex,GO:1904813~ficolin-1-rich granule lumen,	GO:0004133~glycogen debranching enzyme activity,GO:0004134~4-alpha-glucanotransferase activity,GO:0004135~amylo-alpha-1,6-glucosidase activity,GO:0005515~protein binding,GO:0030247~polysaccharide binding,GO:0031593~polyubiquitin binding,	IPR006421:Glycogen debranching enzyme, metazoa,IPR008928:Six-hairpin glycosidase-like,IPR010401:Amylo-alpha-1,6-glucosidase,IPR017853:Glycoside hydrolase, superfamily,	hsa00500:Starch and sucrose metabolism,hsa01100:Metabolic pathways,	232400~Glycogen storage disease IIIa,232400~Glycogen storage disease IIIb,			KW-0320~Glycogen biosynthesis,	KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0322~Glycogen storage disease,	KW-0175~Coiled coil,		KW-0326~Glycosidase,KW-0328~Glycosyltransferase,KW-0378~Hydrolase,KW-0511~Multifunctional enzyme,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	DOMAIN:GDE_C,DOMAIN:hDGE_amylase,DOMAIN:hGDE_N,DOMAIN:hGDE_central,REGION:4-alpha-glucanotransferase,REGION:Amylo-1,6-glucosidase,
APBB2	amyloid beta precursor protein binding family B member 2(APBB2)	Homo sapiens				GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006355~regulation of transcription, DNA-templated,GO:0006939~smooth muscle contraction,GO:0007050~cell cycle arrest,GO:0030308~negative regulation of cell growth,GO:0035556~intracellular signal transduction,GO:0036438~maintenance of lens transparency,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050808~synapse organization,GO:1901988~negative regulation of cell cycle phase transition,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005769~early endosome,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0016020~membrane,GO:0030027~lamellipodium,GO:0030426~growth cone,GO:0045202~synapse,	GO:0001540~beta-amyloid binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,	IPR001202:WW domain,IPR006020:Phosphotyrosine interaction domain,IPR011993:Pleckstrin homology-like domain,				SM00456:WW,SM00462:PTB,		KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0967~Endosome,		KW-0677~Repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:PID,DOMAIN:PID 1,DOMAIN:PID 2,DOMAIN:WW,MUTAGEN:C->V: Abolishes interaction with APP and gamma-secretase-dependent processing of the APP membrane-anchored C-terminal fragment C83.,REGION:Disordered,
APPBP2	amyloid beta precursor protein binding protein 2(APPBP2)	Homo sapiens				GO:0006886~intracellular protein transport,GO:0016567~protein ubiquitination,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0046907~intracellular transport,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005874~microtubule,GO:0005875~microtubule associated complex,GO:0030659~cytoplasmic vesicle membrane,GO:0031462~Cul2-RING ubiquitin ligase complex,	GO:0003777~microtubule motor activity,GO:0005515~protein binding,GO:1990756~protein binding, bridging involved in substrate recognition for ubiquitination,	IPR011990:Tetratricopeptide-like helical,IPR013026:Tetratricopeptide repeat-containing domain,IPR019734:Tetratricopeptide repeat,				SM00028:TPR,	KW-0653~Protein transport,KW-0813~Transport,KW-0833~Ubl conjugation pathway,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0493~Microtubule,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0802~TPR repeat,				REPEAT:TPR,REPEAT:TPR 1,REPEAT:TPR 2,REPEAT:TPR 3,REPEAT:TPR 4,REPEAT:TPR 5,REPEAT:TPR 6,REPEAT:TPR 7,REPEAT:TPR 8,
APP	amyloid beta precursor protein(APP)	Homo sapiens	12.IL-6_type_cytok-signal-transduct,151.pro-apoptotic_actions_of_altered_APP&PS1,	h_appPathway:Generation of amyloid b-peptide by PS1,h_p35AlzheimersPathway:Deregulation of CDK5 in Alzheimers Disease,h_plateletAppPathway:Platelet Amyloid Precursor Protein Pathway,		GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000185~activation of MAPKKK activity,GO:0000187~activation of MAPK activity,GO:0001774~microglial cell activation,GO:0001878~response to yeast,GO:0001934~positive regulation of protein phosphorylation,GO:0001967~suckling behavior,GO:0002265~astrocyte activation involved in immune response,GO:0002576~platelet degranulation,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006378~mRNA polyadenylation,GO:0006417~regulation of translation,GO:0006468~protein phosphorylation,GO:0006878~cellular copper ion homeostasis,GO:0006892~post-Golgi vesicle-mediated transport,GO:0006897~endocytosis,GO:0006979~response to oxidative stress,GO:0007155~cell adhesion,GO:0007176~regulation of epidermal growth factor-activated receptor activity,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0007193~adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007219~Notch signaling pathway,GO:0007399~nervous system development,GO:0007409~axonogenesis,GO:0007417~central nervous system development,GO:0007611~learning or memory,GO:0007612~learning,GO:0007613~memory,GO:0007617~mating behavior,GO:0007626~locomotory behavior,GO:0008088~axo-dendritic transport,GO:0008203~cholesterol metabolic process,GO:0008285~negative regulation of cell proliferation,GO:0008306~associative learning,GO:0008344~adult locomotory behavior,GO:0008542~visual learning,GO:0009987~cellular process,GO:0010288~response to lead ion,GO:0010468~regulation of gene expression,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0010739~positive regulation of protein kinase A signaling,GO:0010800~positive regulation of peptidyl-threonine phosphorylation,GO:0010823~negative regulation of mitochondrion organization,GO:0010951~negative regulation of endopeptidase activity,GO:0010952~positive regulation of peptidase activity,GO:0010971~positive regulation of G2/M transition of mitotic cell cycle,GO:0014005~microglia development,GO:0016199~axon midline choice point recognition,GO:0016322~neuron remodeling,GO:0016358~dendrite development,GO:0019722~calcium-mediated signaling,GO:0019731~antibacterial humoral response,GO:0019732~antifungal humoral response,GO:0030111~regulation of Wnt signaling pathway,GO:0030198~extracellular matrix organization,GO:0030900~forebrain development,GO:0031175~neuron projection development,GO:0032092~positive regulation of protein binding,GO:0032722~positive regulation of chemokine production,GO:0032729~positive regulation of interferon-gamma production,GO:0032731~positive regulation of interleukin-1 beta production,GO:0032755~positive regulation of interleukin-6 production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0032930~positive regulation of superoxide anion generation,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0034121~regulation of toll-like receptor signaling pathway,GO:0035066~positive regulation of histone acetylation,GO:0035235~ionotropic glutamate receptor signaling pathway,GO:0035590~purinergic nucleotide receptor signaling pathway,GO:0040014~regulation of multicellular organism growth,GO:0042157~lipoprotein metabolic process,GO:0042327~positive regulation of phosphorylation,GO:0043065~positive regulation of apoptotic process,GO:0043280~positive regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0043393~regulation of protein binding,GO:0043410~positive regulation of MAPK cascade,GO:0043525~positive regulation of neuron apoptotic process,GO:0043687~post-translational protein modification,GO:0044267~cellular protein metabolic process,GO:0045048~protein insertion into ER membrane,GO:0045087~innate immune response,GO:0045429~positive regulation of nitric oxide biosynthetic process,GO:0045665~negative regulation of neuron differentiation,GO:0045666~positive regulation of neuron differentiation,GO:0045745~positive regulation of G-protein coupled receptor protein signaling pathway,GO:0045821~positive regulation of glycolytic process,GO:0045931~positive regulation of mitotic cell cycle,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046330~positive regulation of JNK cascade,GO:0048143~astrocyte activation,GO:0048169~regulation of long-term neuronal synaptic plasticity,GO:0048669~collateral sprouting in absence of injury,GO:0050729~positive regulation of inflammatory response,GO:0050730~regulation of peptidyl-tyrosine phosphorylation,GO:0050803~regulation of synapse structure or activity,GO:0050808~synapse organization,GO:0050829~defense response to Gram-negative bacterium,GO:0050830~defense response to Gram-positive bacterium,GO:0050867~positive regulation of cell activation,GO:0050885~neuromuscular process controlling balance,GO:0050890~cognition,GO:0051044~positive regulation of membrane protein ectodomain proteolysis,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051124~synaptic growth at neuromuscular junction,GO:0051247~positive regulation of protein metabolic process,GO:0051260~protein homooligomerization,GO:0051262~protein tetramerization,GO:0051402~neuron apoptotic process,GO:0051563~smooth endoplasmic reticulum calcium ion homeostasis,GO:0051897~positive regulation of protein kinase B signaling,GO:0061098~positive regulation of protein tyrosine kinase activity,GO:0061844~antimicrobial humoral immune response mediated by antimicrobial peptide,GO:0070206~protein trimerization,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0070555~response to interleukin-1,GO:0071280~cellular response to copper ion,GO:0071287~cellular response to manganese ion,GO:0071320~cellular response to cAMP,GO:0071874~cellular response to norepinephrine stimulus,GO:0090026~positive regulation of monocyte chemotaxis,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:0090647~modulation of age-related behavioral decline,GO:0098815~modulation of excitatory postsynaptic potential,GO:1900122~positive regulation of receptor binding,GO:1900181~negative regulation of protein localization to nucleus,GO:1900221~regulation of beta-amyloid clearance,GO:1900272~negative regulation of long-term synaptic potentiation,GO:1900273~positive regulation of long-term synaptic potentiation,GO:1901215~negative regulation of neuron death,GO:1901216~positive regulation of neuron death,GO:1901224~positive regulation of NIK/NF-kappaB signaling,GO:1902894~negative regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1902949~positive regulation of tau-protein kinase activity,GO:1902950~regulation of dendritic spine maintenance,GO:1902961~positive regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic process,GO:1903048~regulation of acetylcholine-gated cation channel activity,GO:1903223~positive regulation of oxidative stress-induced neuron death,GO:1903523~negative regulation of blood circulation,GO:1904022~positive regulation of G-protein coupled receptor internalization,GO:1904472~positive regulation of endothelin secretion,GO:1904591~positive regulation of protein import,GO:1904646~cellular response to beta-amyloid,GO:1905606~regulation of presynapse assembly,GO:1905893~positive regulation of cellular response to thapsigargin,GO:1905896~positive regulation of cellular response to tunicamycin,GO:1905898~positive regulation of response to endoplasmic reticulum stress,GO:1905906~regulation of amyloid fibril formation,GO:1905908~positive regulation of amyloid fibril formation,GO:1905945~regulation of response to calcium ion,GO:1990000~amyloid fibril formation,GO:1990090~cellular response to nerve growth factor stimulus,GO:1990535~neuron projection maintenance,GO:2000310~regulation of NMDA receptor activity,GO:2000406~positive regulation of T cell migration,GO:2000463~positive regulation of excitatory postsynaptic potential,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005641~nuclear envelope lumen,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005768~endosome,GO:0005769~early endosome,GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0005790~smooth endoplasmic reticulum,GO:0005791~rough endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005796~Golgi lumen,GO:0005798~Golgi-associated vesicle,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005905~clathrin-coated pit,GO:0005911~cell-cell junction,GO:0008021~synaptic vesicle,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030134~ER to Golgi transport vesicle,GO:0030424~axon,GO:0030426~growth cone,GO:0031093~platelet alpha granule lumen,GO:0031594~neuromuscular junction,GO:0031904~endosome lumen,GO:0032588~trans-Golgi network membrane,GO:0032991~macromolecular complex,GO:0034363~intermediate-density lipoprotein particle,GO:0034364~high-density lipoprotein particle,GO:0035253~ciliary rootlet,GO:0043197~dendritic spine,GO:0043198~dendritic shaft,GO:0043204~perikaryon,GO:0043235~receptor complex,GO:0044304~main axon,GO:0045121~membrane raft,GO:0045177~apical part of cell,GO:0045202~synapse,GO:0048471~perinuclear region of cytoplasm,GO:0048786~presynaptic active zone,GO:0051233~spindle midzone,GO:0055037~recycling endosome,GO:0070062~extracellular exosome,GO:0070381~endosome to plasma membrane transport vesicle,GO:0097449~astrocyte projection,GO:1990761~growth cone lamellipodium,GO:1990777~lipoprotein particle,GO:1990812~growth cone filopodium,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0001664~G-protein coupled receptor binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0004867~serine-type endopeptidase inhibitor activity,GO:0005102~receptor binding,GO:0005109~frizzled binding,GO:0005158~insulin receptor binding,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0008201~heparin binding,GO:0008233~peptidase activity,GO:0016504~peptidase activator activity,GO:0019899~enzyme binding,GO:0030546~receptor activator activity,GO:0030549~acetylcholine receptor activator activity,GO:0033130~acetylcholine receptor binding,GO:0034185~apolipoprotein binding,GO:0042056~chemoattractant activity,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0043395~heparan sulfate proteoglycan binding,GO:0046875~ephrin receptor binding,GO:0046914~transition metal ion binding,GO:0046982~protein heterodimerization activity,GO:0046983~protein dimerization activity,GO:0050750~low-density lipoprotein particle receptor binding,GO:0050786~RAGE receptor binding,GO:0051087~chaperone binding,GO:0051425~PTB domain binding,GO:0070851~growth factor receptor binding,GO:0097645~amylin binding,GO:1904399~heparan sulfate binding,	IPR002223:Proteinase inhibitor I2, Kunitz metazoa,IPR008154:Amyloidogenic glycoprotein, extracellular,IPR008155:Amyloidogenic glycoprotein,IPR011178:Amyloidogenic glycoprotein, copper-binding,IPR011993:Pleckstrin homology-like domain,IPR013803:Amyloidogenic glycoprotein, amyloid-beta peptide,IPR015849:Amyloidogenic glycoprotein, heparin-binding,IPR019543:Beta-amyloid precursor protein C-terminal,IPR019744:Amyloidogenic glycoprotein, extracellular domain conserved site,IPR019745:Amyloidogenic glycoprotein, intracellular domain, conserved site,IPR020901:Proteinase inhibitor I2, Kunitz, conserved site,IPR024329:Amyloidogenic glycoprotein, E2 domain,	hsa04726:Serotonergic synapse,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,	104300~Alzheimer disease 1, familial,605714~Cerebral amyloid angiopathy, Dutch, Italian, Iowa, Flemish, Arctic variants,		SM00006:A4_EXTRA,SM00131:KU,	KW-0053~Apoptosis,KW-0130~Cell adhesion,KW-0254~Endocytosis,KW-0914~Notch signaling pathway,	KW-0034~Amyloid,KW-0168~Coated pit,KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0964~Secreted,KW-0966~Cell projection,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,	KW-0026~Alzheimer disease,KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-1008~Amyloidosis,	KW-0175~Coiled coil,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0186~Copper,KW-0408~Iron,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0358~Heparin-binding,KW-0378~Hydrolase,KW-0645~Protease,KW-0646~Protease inhibitor,KW-0722~Serine protease inhibitor,	KW-0325~Glycoprotein,KW-0558~Oxidation,KW-0597~Phosphoprotein,KW-0654~Proteoglycan,KW-0765~Sulfation,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GalNAc...) serine; partial,CARBOHYD:O-linked (GalNAc...) threonine; partial,CARBOHYD:O-linked (HexNAc...) threonine; partial,CARBOHYD:O-linked (HexNAc...) tyrosine; partial,CARBOHYD:O-linked (Xyl...) (chondroitin sulfate) serine; in L-APP isoforms,COMPBIAS:Acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:BPTI/Kunitz inhibitor,DOMAIN:Beta-APP,DOMAIN:E1,DOMAIN:E2,METAL:Cu(2+) 1,METAL:Cu(2+) 2,METAL:Zn(2+),MOTIF:Basolateral sorting signal,MOTIF:OX-2,MOTIF:YENPXY motif; contains endocytosis signal,MUTAGEN:C->S: Binds copper. No dimer formation. No copper reducing activity.,MUTAGEN:D->A: No cleavage by caspases during apoptosis.,MUTAGEN:D->N: No effect on FADD-induced apoptosis.,MUTAGEN:G->A: APP internalization unchanged. No change in amyloid-beta protein 42 secretion.,MUTAGEN:G->V: Reduced protein oxidation. No hippocampal neuron toxicity.,MUTAGEN:H->A: Loss of a copper binding site; when associated with A-147.,MUTAGEN:H->A: Loss of a copper binding site; when associated with A-151.,MUTAGEN:H->A: Loss of the copper binding site in the GFLD subdomain; when associated with A-108.,MUTAGEN:H->A: Loss of the copper binding site in the GFLD subdomain; when associated with A-110.,MUTAGEN:H->A: Some decrease in copper reducing activity.,MUTAGEN:H->K: Greatly reduced copper-mediated low-density lipoprotein oxidation.,MUTAGEN:H->N: Binds copper. Forms dimer.,MUTAGEN:H->R: Only 23% zinc-induced amyloid-beta protein 28 aggregation.,MUTAGEN:H->Y: Greatly reduced copper-mediated low-density lipoprotein oxidation.,MUTAGEN:HLH->ALA: 50% decrease in copper reducing activity.,MUTAGEN:K->A: Reduced affinity for heparin; when associated with A-499.,MUTAGEN:KRGR->NQGG: Reduced heparin-binding.,MUTAGEN:M->L: Reduced lipid peroxidation inhibition.,MUTAGEN:M->T: Binds copper. Forms dimer.,MUTAGEN:M->V: No free radical production. No hippocampal neuron toxicity.,MUTAGEN:N->A: No binding to APBA1, no effect on APBB1 binding. Little APP internalization. Reduced amyloid-beta protein 42 secretion.,MUTAGEN:P->A: Little APP internalization. Reduced amyloid-beta protein 42 secretion.,MUTAGEN:R->A: Reduced affinity for heparin; when associated with A-503.,MUTAGEN:R->G: 60-70% zinc-induced amyloid-beta protein 28 aggregation.,MUTAGEN:S->A: Abolishes chondroitin sulfate binding in L-APP733 isoform.,MUTAGEN:S->A: Greatly reduced casein kinase phosphorylation.,MUTAGEN:S->A: Reduced casein kinase phosphorylation.,MUTAGEN:T->A: Greatly reduces the binding to SHC1 and APBB family members; no effect on NGF-stimulated neurite extension. Loss of phosphorylation by LRRK2.,MUTAGEN:T->E: Reduced NGF-stimulated neurite extension. No effect on APP maturation.,MUTAGEN:V->C,S: Unchanged amyloid-beta protein 42/total amyloid-beta ratio.,MUTAGEN:V->C: Causes formation of an artifactual disulfide bond with PSEN1.,MUTAGEN:V->K: Decreased amyloid-beta protein 42/total amyloid-beta ratio.,MUTAGEN:V->M: Increased amyloid-beta protein 42/40 ratio. No change in apoptosis after caspase cleavage.,MUTAGEN:Y->A: Little APP internalization. Reduced amyloid-beta protein 42 secretion.,MUTAGEN:Y->A: Loss of binding to APBA1 and APBB1. APP internalization unchanged. No change in amyloid-beta protein 42 secretion.,MUTAGEN:Y->A: No effect on APBA1 nor APBB1 binding. Greatly reduces the binding to APPBP2. APP internalization unchanged. No change in amyloid-beta protein 42 secretion.,MUTAGEN:Y->F: 60-70% zinc-induced amyloid-beta protein 28 aggregation.,MUTAGEN:Y->G: Loss of binding to MAPK8IP1, APBA1, APBB1, APPBP2 and SHC1.,MUTAGEN:YENPTY->AENPTA: No effect on C99 interaction with SORL1.,PEPTIDE:P3(40),PEPTIDE:P3(42),REGION:Collagen-binding,REGION:CuBD subdomain,REGION:Disordered,REGION:GFLD subdomain,REGION:Heparin-binding,REGION:Interaction with G(o)-alpha,REGION:Interaction with PSEN1,REGION:Required for the interaction with KIF5B and for anterograde transport in axons,REGION:Zinc-binding,SITE:Cleavage; by alpha-secretase,SITE:Cleavage; by beta-secretase,SITE:Cleavage; by caspase-6, caspase-8 or caspase-9,SITE:Cleavage; by caspase-6; when associated with variant 670-N-L-671,SITE:Cleavage; by caspases,SITE:Cleavage; by gamma-secretase; site 1,SITE:Cleavage; by gamma-secretase; site 2,SITE:Cleavage; by gamma-secretase; site 3,SITE:Cleavage; by theta-secretase,SITE:Implicated in free radical propagation,SITE:Reactive bond,SITE:Required for Cu(2+) reduction,SITE:Susceptible to oxidation,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ANKRD10	ankyrin repeat domain 10(ANKRD10)	Homo sapiens						GO:0005515~protein binding,	IPR002110:Ankyrin repeat,IPR020683:Ankyrin repeat-containing domain,				SM00248:ANK,				KW-0040~ANK repeat,KW-0677~Repeat,				COMPBIAS:Polar residues,DOMAIN:Ankyrin_rpt-contain_dom,REGION:Disordered,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,
ANXA7	annexin A7(ANXA7)	Homo sapiens				GO:0006914~autophagy,GO:0010629~negative regulation of gene expression,GO:0014070~response to organic cyclic compound,GO:0030855~epithelial cell differentiation,GO:0051592~response to calcium ion,GO:0061025~membrane fusion,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,GO:0042584~chromaffin granule membrane,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0005178~integrin binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005544~calcium-dependent phospholipid binding,GO:0048306~calcium-dependent protein binding,	IPR001464:Annexin,IPR018252:Annexin repeat, conserved site,IPR018502:Annexin repeat,	hsa05014:Amyotrophic lateral sclerosis,			SM00335:ANX,				KW-0041~Annexin,KW-0677~Repeat,	KW-0106~Calcium,KW-0111~Calcium/phospholipid-binding,		KW-0007~Acetylation,	COMPBIAS:Pro residues,REGION:3 X 5 AA tandem repeats of G-Y-P-P-X,REGION:Disordered,REGION:Repeat-rich region,REPEAT:Annexin 1,REPEAT:Annexin 2,REPEAT:Annexin 3,REPEAT:Annexin 4,
ANO10	anoctamin 10(ANO10)	Homo sapiens				GO:0006812~cation transport,GO:0006821~chloride transport,GO:0034220~ion transmembrane transport,GO:0055085~transmembrane transport,GO:0098655~cation transmembrane transport,	GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0005227~calcium activated cation channel activity,GO:0005229~intracellular calcium activated chloride channel activity,	IPR007632:Anoctamin/TMEM 16,		613728~Spinocerebellar ataxia, autosomal recessive 10,				KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0523~Neurodegeneration,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,				TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
APOE	apolipoprotein E(APOE)	Homo sapiens				GO:0000302~response to reactive oxygen species,GO:0001523~retinoid metabolic process,GO:0001937~negative regulation of endothelial cell proliferation,GO:0002021~response to dietary excess,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006641~triglyceride metabolic process,GO:0006707~cholesterol catabolic process,GO:0006869~lipid transport,GO:0006874~cellular calcium ion homeostasis,GO:0006898~receptor-mediated endocytosis,GO:0006979~response to oxidative stress,GO:0007010~cytoskeleton organization,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007263~nitric oxide mediated signal transduction,GO:0007271~synaptic transmission, cholinergic,GO:0007616~long-term memory,GO:0008203~cholesterol metabolic process,GO:0010467~gene expression,GO:0010544~negative regulation of platelet activation,GO:0010596~negative regulation of endothelial cell migration,GO:0010629~negative regulation of gene expression,GO:0010873~positive regulation of cholesterol esterification,GO:0010875~positive regulation of cholesterol efflux,GO:0010877~lipid transport involved in lipid storage,GO:0010976~positive regulation of neuron projection development,GO:0010977~negative regulation of neuron projection development,GO:0015909~long-chain fatty acid transport,GO:0017038~protein import,GO:0019068~virion assembly,GO:0019934~cGMP-mediated signaling,GO:0030195~negative regulation of blood coagulation,GO:0030516~regulation of axon extension,GO:0030522~intracellular receptor signaling pathway,GO:0031175~neuron projection development,GO:0032269~negative regulation of cellular protein metabolic process,GO:0032489~regulation of Cdc42 protein signal transduction,GO:0032805~positive regulation of low-density lipoprotein particle receptor catabolic process,GO:0033344~cholesterol efflux,GO:0033700~phospholipid efflux,GO:0034371~chylomicron remodeling,GO:0034372~very-low-density lipoprotein particle remodeling,GO:0034374~low-density lipoprotein particle remodeling,GO:0034375~high-density lipoprotein particle remodeling,GO:0034378~chylomicron assembly,GO:0034380~high-density lipoprotein particle assembly,GO:0034382~chylomicron remnant clearance,GO:0034384~high-density lipoprotein particle clearance,GO:0034447~very-low-density lipoprotein particle clearance,GO:0035641~locomotory exploration behavior,GO:0042157~lipoprotein metabolic process,GO:0042158~lipoprotein biosynthetic process,GO:0042159~lipoprotein catabolic process,GO:0042311~vasodilation,GO:0042632~cholesterol homeostasis,GO:0042981~regulation of apoptotic process,GO:0042982~amyloid precursor protein metabolic process,GO:0043254~regulation of protein complex assembly,GO:0043407~negative regulation of MAP kinase activity,GO:0043524~negative regulation of neuron apoptotic process,GO:0043537~negative regulation of blood vessel endothelial cell migration,GO:0043687~post-translational protein modification,GO:0043691~reverse cholesterol transport,GO:0044267~cellular protein metabolic process,GO:0044794~positive regulation by host of viral process,GO:0045088~regulation of innate immune response,GO:0045541~negative regulation of cholesterol biosynthetic process,GO:0045807~positive regulation of endocytosis,GO:0045893~positive regulation of transcription, DNA-templated,GO:0046889~positive regulation of lipid biosynthetic process,GO:0046907~intracellular transport,GO:0048168~regulation of neuronal synaptic plasticity,GO:0048662~negative regulation of smooth muscle cell proliferation,GO:0048844~artery morphogenesis,GO:0050709~negative regulation of protein secretion,GO:0050728~negative regulation of inflammatory response,GO:0050807~regulation of synapse organization,GO:0051000~positive regulation of nitric-oxide synthase activity,GO:0051044~positive regulation of membrane protein ectodomain proteolysis,GO:0051055~negative regulation of lipid biosynthetic process,GO:0051246~regulation of protein metabolic process,GO:0051651~maintenance of location in cell,GO:0055089~fatty acid homeostasis,GO:0060999~positive regulation of dendritic spine development,GO:0061000~negative regulation of dendritic spine development,GO:0061136~regulation of proteasomal protein catabolic process,GO:0061771~response to caloric restriction,GO:0070328~triglyceride homeostasis,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071830~triglyceride-rich lipoprotein particle clearance,GO:0071831~intermediate-density lipoprotein particle clearance,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:0090181~regulation of cholesterol metabolic process,GO:0090209~negative regulation of triglyceride metabolic process,GO:0090370~negative regulation of cholesterol efflux,GO:0097113~AMPA glutamate receptor clustering,GO:0097114~NMDA glutamate receptor clustering,GO:0098869~cellular oxidant detoxification,GO:1900221~regulation of beta-amyloid clearance,GO:1900223~positive regulation of beta-amyloid clearance,GO:1900272~negative regulation of long-term synaptic potentiation,GO:1901214~regulation of neuron death,GO:1901215~negative regulation of neuron death,GO:1901216~positive regulation of neuron death,GO:1901627~negative regulation of postsynaptic membrane organization,GO:1901631~positive regulation of presynaptic membrane organization,GO:1902004~positive regulation of beta-amyloid formation,GO:1902430~negative regulation of beta-amyloid formation,GO:1902947~regulation of tau-protein kinase activity,GO:1902951~negative regulation of dendritic spine maintenance,GO:1902952~positive regulation of dendritic spine maintenance,GO:1902991~regulation of amyloid precursor protein catabolic process,GO:1902995~positive regulation of phospholipid efflux,GO:1902998~positive regulation of neurofibrillary tangle assembly,GO:1902999~negative regulation of phospholipid efflux,GO:1903001~negative regulation of lipid transport across blood brain barrier,GO:1903002~positive regulation of lipid transport across blood brain barrier,GO:1905855~positive regulation of heparan sulfate binding,GO:1905860~positive regulation of heparan sulfate proteoglycan binding,GO:1905890~regulation of cellular response to very-low-density lipoprotein particle stimulus,GO:1905906~regulation of amyloid fibril formation,GO:1905907~negative regulation of amyloid fibril formation,GO:1905908~positive regulation of amyloid fibril formation,GO:2000822~regulation of behavioral fear response,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005769~early endosome,GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0030425~dendrite,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0031012~extracellular matrix,GO:0034361~very-low-density lipoprotein particle,GO:0034362~low-density lipoprotein particle,GO:0034363~intermediate-density lipoprotein particle,GO:0034364~high-density lipoprotein particle,GO:0034365~discoidal high-density lipoprotein particle,GO:0042627~chylomicron,GO:0043025~neuronal cell body,GO:0043083~synaptic cleft,GO:0070062~extracellular exosome,GO:0071682~endocytic vesicle lumen,GO:0072562~blood microparticle,GO:0098978~glutamatergic synapse,GO:1903561~extracellular vesicle,GO:1990777~lipoprotein particle,	GO:0001540~beta-amyloid binding,GO:0005102~receptor binding,GO:0005198~structural molecule activity,GO:0005319~lipid transporter activity,GO:0005515~protein binding,GO:0005543~phospholipid binding,GO:0008201~heparin binding,GO:0008289~lipid binding,GO:0016209~antioxidant activity,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0043395~heparan sulfate proteoglycan binding,GO:0044877~macromolecular complex binding,GO:0046911~metal chelating activity,GO:0046983~protein dimerization activity,GO:0048156~tau protein binding,GO:0050750~low-density lipoprotein particle receptor binding,GO:0060228~phosphatidylcholine-sterol O-acyltransferase activator activity,GO:0070326~very-low-density lipoprotein particle receptor binding,GO:0071813~lipoprotein particle binding,	IPR000074:Apolipoprotein A1/A4/E,	hsa04979:Cholesterol metabolism,hsa05010:Alzheimer disease,	104310~Alzheimer disease 2,269600~Sea-blue histiocyte disease,603075~Macular degeneration, age-related,607822~Alzheimer disease, protection against, due to APOE3-Christchurch,611771~Lipoprotein glomerulopathy,617347~Coronary artery disease, severe, susceptibility to,617347~Hyperlipoproteinemia, type III,			KW-0153~Cholesterol metabolism,KW-0443~Lipid metabolism,KW-0445~Lipid transport,KW-0753~Steroid metabolism,KW-0813~Transport,KW-0945~Host-virus interaction,KW-1207~Sterol metabolism,	KW-0162~Chylomicron,KW-0272~Extracellular matrix,KW-0345~HDL,KW-0850~VLDL,KW-0964~Secreted,	KW-0026~Alzheimer disease,KW-0225~Disease variant,KW-0380~Hyperlipidemia,KW-0523~Neurodegeneration,KW-1008~Amyloidosis,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0732~Signal,	KW-0446~Lipid-binding,	KW-0358~Heparin-binding,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0558~Oxidation,KW-0597~Phosphoprotein,KW-0971~Glycation,	CARBOHYD:N-linked (Glc) (glycation) lysine,CARBOHYD:O-linked (GalNAc...) serine,CARBOHYD:O-linked (GalNAc...) threonine,MUTAGEN:D->A: Restores the LDL receptor binding activity of ApoE2.,MUTAGEN:E->A: No effect on plasma lipoprotein distribution.,MUTAGEN:H->A: Decreased binding to LDL receptor.,MUTAGEN:K->A: Decreased binding to LDL receptor.,MUTAGEN:L->A: Increased binding to LDL receptor; when associated with R-157.,MUTAGEN:L->P: Decreased binding to LDL receptor.,MUTAGEN:R->A: Decreased binding to LDL receptor.,MUTAGEN:R->T: Changes the plasma lipoprotein distribution of ApoE4 to the HDL.,MUTAGEN:S->R: Increased binding to LDL receptor; when associated with A-167.,MUTAGEN:T->A: Loss of O-glycosylation.,REGION:8 X 22 AA approximate tandem repeats,REGION:Heparin-binding,REGION:Homooligomerization,REGION:LDL and other lipoprotein receptors binding,REGION:Lipid-binding and lipoprotein association,REGION:Specificity for association with VLDL,REPEAT:1,REPEAT:2,REPEAT:3,REPEAT:4,REPEAT:5,REPEAT:6,REPEAT:7,REPEAT:8,
ARNT2	aryl hydrocarbon receptor nuclear translocator 2(ARNT2)	Homo sapiens				GO:0001666~response to hypoxia,GO:0001701~in utero embryonic development,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006805~xenobiotic metabolic process,GO:0007417~central nervous system development,GO:0007420~brain development,GO:0008284~positive regulation of cell proliferation,GO:0032355~response to estradiol,GO:0043066~negative regulation of apoptotic process,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,GO:0034751~aryl hydrocarbon receptor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0017162~aryl hydrocarbon receptor binding,GO:0044877~macromolecular complex binding,GO:0046982~protein heterodimerization activity,GO:0046983~protein dimerization activity,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000014:PAS domain,IPR001067:Nuclear translocator,IPR001610:PAC motif,IPR011598:Myc-type, basic helix-loop-helix (bHLH) domain,IPR013655:PAS fold-3,IPR013767:PAS fold,	hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05211:Renal cell carcinoma,	615926~Webb-Dattani syndrome,		SM00086:PAC,SM00091:PAS,SM00353:HLH,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,		KW-0238~DNA-binding,KW-0675~Receptor,	KW-0488~Methylation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:BHLH,DOMAIN:PAC,DOMAIN:PAS,DOMAIN:PAS 1,DOMAIN:PAS 2,DOMAIN:bHLH,REGION:Disordered,
AURKA	aurora kinase A(AURKA)	Homo sapiens		h_ranMSPathway:Role of Ran in mitotic spindle regulation,		GO:0000086~G2/M transition of mitotic cell cycle,GO:0000278~mitotic cell cycle,GO:0006468~protein phosphorylation,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0006977~DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest,GO:0007049~cell cycle,GO:0007051~spindle organization,GO:0007052~mitotic spindle organization,GO:0007057~spindle assembly involved in female meiosis I,GO:0007100~mitotic centrosome separation,GO:0009611~response to wounding,GO:0009948~anterior/posterior axis specification,GO:0010389~regulation of G2/M transition of mitotic cell cycle,GO:0010629~negative regulation of gene expression,GO:0010972~negative regulation of G2/M transition of mitotic cell cycle,GO:0018105~peptidyl-serine phosphorylation,GO:0031145~anaphase-promoting complex-dependent catabolic process,GO:0031647~regulation of protein stability,GO:0032091~negative regulation of protein binding,GO:0032436~positive regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0032465~regulation of cytokinesis,GO:0035404~histone-serine phosphorylation,GO:0043066~negative regulation of apoptotic process,GO:0045840~positive regulation of mitotic nuclear division,GO:0046605~regulation of centrosome cycle,GO:0046777~protein autophosphorylation,GO:0051301~cell division,GO:0051642~centrosome localization,GO:0071539~protein localization to centrosome,GO:0090141~positive regulation of mitochondrial fission,GO:0097421~liver regeneration,GO:1900195~positive regulation of oocyte maturation,GO:1901796~regulation of signal transduction by p53 class mediator,GO:1990138~neuron projection extension,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005813~centrosome,GO:0005814~centriole,GO:0005819~spindle,GO:0005829~cytosol,GO:0005874~microtubule,GO:0005876~spindle microtubule,GO:0005929~cilium,GO:0015630~microtubule cytoskeleton,GO:0030496~midbody,GO:0031616~spindle pole centrosome,GO:0032133~chromosome passenger complex,GO:0042585~germinal vesicle,GO:0043203~axon hillock,GO:0045120~pronucleus,GO:0048471~perinuclear region of cytoplasm,GO:0051233~spindle midzone,GO:0072687~meiotic spindle,GO:0097431~mitotic spindle pole,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0019901~protein kinase binding,GO:0031625~ubiquitin protein ligase binding,GO:0035174~histone serine kinase activity,GO:0046982~protein heterodimerization activity,	IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,	hsa04114:Oocyte meiosis,hsa04914:Progesterone-mediated oocyte maturation,	114500~Colon cancer, susceptibility to,		SM00220:S_TKc,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,KW-0970~Cilium biogenesis/degradation,	KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0969~Cilium,	KW-0656~Proto-oncogene,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Proton acceptor,BINDING:ATP,BINDING:ATP; via amide nitrogen,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Protein kinase,MUTAGEN:C->A: Enhances stability; when associated with A-290.,MUTAGEN:C->A: Enhances stability; when associated with A-393.,MUTAGEN:D->N: Abolishes autophosphorylation.,MUTAGEN:F->A: Decreases the interaction with phosphatase type 1 isoforms.,MUTAGEN:G->N: Reduces interaction with TPX2. Reduces kinase activity tenfold. Promotes interaction with the AURKB binding partners INCENP and BIRC5 that are normally not bound by AURKA.,MUTAGEN:K->R: Loss of kinase activity.,MUTAGEN:Q->A: Reduces binding to MYCN.,MUTAGEN:R->A: Reduces ubiquitination and proteasomal degradation.,MUTAGEN:T->A: No direct effect on catalytic activity.,MUTAGEN:T->D: Mimics phosphorylation state and increases kinase activity.,MUTAGEN:T->E: Enhances interaction with TPX2.,MUTAGEN:Y->A: Reduces binding to MYCN.,NP_BIND:ATP,REGION:Activation segment,REGION:Disordered,
AURKB	aurora kinase B(AURKB)	Homo sapiens				GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0002903~negative regulation of B cell apoptotic process,GO:0006468~protein phosphorylation,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0007051~spindle organization,GO:0007052~mitotic spindle organization,GO:0007094~mitotic spindle assembly checkpoint,GO:0007568~aging,GO:0008283~cell proliferation,GO:0008608~attachment of spindle microtubules to kinetochore,GO:0009838~abscission,GO:0016570~histone modification,GO:0031145~anaphase-promoting complex-dependent catabolic process,GO:0032091~negative regulation of protein binding,GO:0032212~positive regulation of telomere maintenance via telomerase,GO:0032465~regulation of cytokinesis,GO:0032466~negative regulation of cytokinesis,GO:0032467~positive regulation of cytokinesis,GO:0034501~protein localization to kinetochore,GO:0034644~cellular response to UV,GO:0036089~cleavage furrow formation,GO:0043988~histone H3-S28 phosphorylation,GO:0044878~mitotic cytokinesis checkpoint,GO:0046777~protein autophosphorylation,GO:0051256~mitotic spindle midzone assembly,GO:0051301~cell division,GO:0051973~positive regulation of telomerase activity,GO:0051983~regulation of chromosome segregation,GO:1901796~regulation of signal transduction by p53 class mediator,GO:1904355~positive regulation of telomere capping,GO:1905116~positive regulation of lateral attachment of mitotic spindle microtubules to kinetochore,	GO:0000775~chromosome, centromeric region,GO:0000776~kinetochore,GO:0000779~condensed chromosome, centromeric region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005819~spindle,GO:0005829~cytosol,GO:0005876~spindle microtubule,GO:0010369~chromocenter,GO:0015630~microtubule cytoskeleton,GO:0030496~midbody,GO:0031616~spindle pole centrosome,GO:0032133~chromosome passenger complex,GO:0051233~spindle midzone,GO:0097431~mitotic spindle pole,GO:1990023~mitotic spindle midzone,	GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0019900~kinase binding,GO:0035174~histone serine kinase activity,GO:0046872~metal ion binding,	IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,				SM00220:S_TKc,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0137~Centromere,KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Proton acceptor,BINDING:ATP,COMPBIAS:Polar residues,DOMAIN:Protein kinase,MUTAGEN:K->R: Leads to loss of kinase activity and severely impairs mitotic progression.,NP_BIND:ATP,REGION:Disordered,
ATG3	autophagy related 3(ATG3)	Homo sapiens				GO:0000045~autophagosome assembly,GO:0000422~mitophagy,GO:0006464~cellular protein modification process,GO:0006612~protein targeting to membrane,GO:0016236~macroautophagy,GO:0016567~protein ubiquitination,GO:0043653~mitochondrial fragmentation involved in apoptotic process,GO:0044804~nucleophagy,GO:0050765~negative regulation of phagocytosis,GO:1902017~regulation of cilium assembly,	GO:0000153~cytoplasmic ubiquitin ligase complex,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0019776~Atg8 ligase activity,GO:0019777~Atg12 transferase activity,GO:0019787~ubiquitin-like protein transferase activity,GO:0019899~enzyme binding,	IPR007135:Autophagy-related protein 3,	hsa04136:Autophagy - other,hsa04140:Autophagy - animal,hsa05167:Kaposi sarcoma-associated herpesvirus infection,				KW-0072~Autophagy,KW-0653~Protein transport,KW-0813~Transport,KW-0833~Ubl conjugation pathway,	KW-0963~Cytoplasm,				KW-0808~Transferase,	KW-0007~Acetylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Glycyl thioester intermediate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ATG12),DOMAIN:Autophagy_act_C,MOTIF:Caspase cleavage motif LETD,MUTAGEN:C->S: Instead of the formation of an intermediate complex with a thiol ester bond between ATG3 (E2-like enzyme) and GABARAPL1/APG8L (substrate), a stable complex with an O-ester bond is formed.,REGION:Disordered,SITE:Cleavage; by CASP8,
AXIN1	axin 1(AXIN1)	Homo sapiens		h_alkPathway:ALK in cardiac myocytes,H_gsk3Pathway:Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar Macrophages,h_pitx2Pathway:Multi-step Regulation of Transcription by Pitx2,h_ps1Pathway:Presenilin action in Notch and Wnt signaling,h_wntPathway:WNT Signaling Pathway,		GO:0000209~protein polyubiquitination,GO:0001701~in utero embryonic development,GO:0001934~positive regulation of protein phosphorylation,GO:0006913~nucleocytoplasmic transport,GO:0006915~apoptotic process,GO:0007275~multicellular organism development,GO:0007605~sensory perception of sound,GO:0009950~dorsal/ventral axis specification,GO:0010629~negative regulation of gene expression,GO:0010800~positive regulation of peptidyl-threonine phosphorylation,GO:0016055~Wnt signaling pathway,GO:0030111~regulation of Wnt signaling pathway,GO:0030511~positive regulation of transforming growth factor beta receptor signaling pathway,GO:0031122~cytoplasmic microtubule organization,GO:0031398~positive regulation of protein ubiquitination,GO:0032147~activation of protein kinase activity,GO:0032436~positive regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0033146~regulation of intracellular estrogen receptor signaling pathway,GO:0034244~negative regulation of transcription elongation from RNA polymerase II promoter,GO:0034622~cellular macromolecular complex assembly,GO:0036342~post-anal tail morphogenesis,GO:0043507~positive regulation of JUN kinase activity,GO:0045599~negative regulation of fat cell differentiation,GO:0045732~positive regulation of protein catabolic process,GO:0045893~positive regulation of transcription, DNA-templated,GO:0046330~positive regulation of JNK cascade,GO:0048320~axial mesoderm formation,GO:0051248~negative regulation of protein metabolic process,GO:0051443~positive regulation of ubiquitin-protein transferase activity,GO:0060070~canonical Wnt signaling pathway,GO:0060322~head development,GO:0071514~genetic imprinting,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:1904885~beta-catenin destruction complex assembly,GO:1904886~beta-catenin destruction complex disassembly,GO:2000060~positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005938~cell cortex,GO:0015630~microtubule cytoskeleton,GO:0016328~lateral plasma membrane,GO:0030877~beta-catenin destruction complex,GO:0031410~cytoplasmic vesicle,GO:0048471~perinuclear region of cytoplasm,GO:0071944~cell periphery,GO:1990909~Wnt signalosome,	GO:0002039~p53 binding,GO:0005515~protein binding,GO:0008013~beta-catenin binding,GO:0008022~protein C-terminus binding,GO:0019899~enzyme binding,GO:0019901~protein kinase binding,GO:0030159~receptor signaling complex scaffold activity,GO:0031625~ubiquitin protein ligase binding,GO:0035591~signaling adaptor activity,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0043621~protein self-association,GO:0046332~SMAD binding,GO:0060090~binding, bridging,GO:0070016~armadillo repeat domain binding,GO:0070411~I-SMAD binding,GO:0070412~R-SMAD binding,	IPR001158:DIX domain,IPR014936:Axin beta-catenin binding,IPR016137:Regulator of G protein signalling superfamily,IPR024066:Regulator of G-protein signaling, domain 1,	hsa04310:Wnt signaling pathway,hsa04390:Hippo signaling pathway,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04934:Cushing syndrome,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05165:Human papillomavirus infection,hsa05200:Pathways in cancer,hsa05210:Colorectal cancer,hsa05213:Endometrial cancer,hsa05217:Basal cell carcinoma,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,	114550~Hepatocellular carcinoma, somatic,607864~Caudal duplication anomaly,		SM00021:DAX,SM00315:RGS,	KW-0053~Apoptosis,KW-0879~Wnt signaling pathway,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0043~Tumor suppressor,KW-0225~Disease variant,	KW-0175~Coiled coil,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0013~ADP-ribosylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),DOMAIN:DIX,DOMAIN:RGS,MOTIF:Tankyrase-binding motif,REGION:Disordered,REGION:Interaction with CTNNB1,REGION:Interaction with GSK3B,REGION:Interaction with HIPK2,REGION:Interaction with PPP2CA,REGION:Interaction with RNF111,REGION:Interaction with TP53,
BIRC2	baculoviral IAP repeat containing 2(BIRC2)	Homo sapiens		h_caspasePathway:Caspase Cascade in Apoptosis,h_deathPathway:Induction of apoptosis through DR3 and DR4/5 Death Receptors ,h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_mitochondriaPathway:Role of Mitochondria in Apoptotic Signaling,		GO:0000209~protein polyubiquitination,GO:0001666~response to hypoxia,GO:0001890~placenta development,GO:0002756~MyD88-independent toll-like receptor signaling pathway,GO:0006915~apoptotic process,GO:0007166~cell surface receptor signaling pathway,GO:0007249~I-kappaB kinase/NF-kappaB signaling,GO:0010803~regulation of tumor necrosis factor-mediated signaling pathway,GO:0016579~protein deubiquitination,GO:0031398~positive regulation of protein ubiquitination,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0034121~regulation of toll-like receptor signaling pathway,GO:0035666~TRIF-dependent toll-like receptor signaling pathway,GO:0038061~NIK/NF-kappaB signaling,GO:0039535~regulation of RIG-I signaling pathway,GO:0042127~regulation of cell proliferation,GO:0042981~regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043154~negative regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0045088~regulation of innate immune response,GO:0045471~response to ethanol,GO:0045595~regulation of cell differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0050727~regulation of inflammatory response,GO:0051591~response to cAMP,GO:0051726~regulation of cell cycle,GO:0060544~regulation of necroptotic process,GO:0060546~negative regulation of necroptotic process,GO:0070266~necroptotic process,GO:0070424~regulation of nucleotide-binding oligomerization domain containing signaling pathway,GO:1901222~regulation of NIK/NF-kappaB signaling,GO:1902443~negative regulation of ripoptosome assembly involved in necroptotic process,GO:1902523~positive regulation of protein K63-linked ubiquitination,GO:1902524~positive regulation of protein K48-linked ubiquitination,GO:1902527~positive regulation of protein monoubiquitination,GO:2000116~regulation of cysteine-type endopeptidase activity,GO:2000377~regulation of reactive oxygen species metabolic process,	GO:0001741~XY body,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0009898~cytoplasmic side of plasma membrane,GO:0035631~CD40 receptor complex,GO:0045121~membrane raft,	GO:0003713~transcription coactivator activity,GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0016740~transferase activity,GO:0042802~identical protein binding,GO:0043027~cysteine-type endopeptidase inhibitor activity involved in apoptotic process,GO:0043130~ubiquitin binding,GO:0044877~macromolecular complex binding,GO:0046872~metal ion binding,GO:0047485~protein N-terminus binding,GO:0051087~chaperone binding,GO:0061630~ubiquitin protein ligase activity,GO:0098770~FBXO family protein binding,	IPR001315:Caspase Recruitment,IPR001370:Baculoviral inhibition of apoptosis protein repeat,IPR001841:Zinc finger, RING-type,IPR011029:Death-like domain,IPR013083:Zinc finger, RING/FYVE/PHD-type,	hsa01524:Platinum drug resistance,hsa04064:NF-kappa B signaling pathway,hsa04120:Ubiquitin mediated proteolysis,hsa04210:Apoptosis,hsa04215:Apoptosis - multiple species,hsa04217:Necroptosis,hsa04390:Hippo signaling pathway,hsa04510:Focal adhesion,hsa04621:NOD-like receptor signaling pathway,hsa04668:TNF signaling pathway,hsa05132:Salmonella infection,hsa05145:Toxoplasmosis,hsa05168:Herpes simplex virus 1 infection,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05222:Small cell lung cancer,			SM00114:CARD,SM00184:RING,SM00238:BIR,	KW-0053~Apoptosis,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0808~Transferase,	KW-0832~Ubl conjugation,	DOMAIN:CARD,DOMAIN:RING-type,METAL:Zinc,REGION:Disordered,REPEAT:BIR 1,REPEAT:BIR 2,REPEAT:BIR 3,ZN_FING:RING-type,
BIRC5	baculoviral IAP repeat containing 5(BIRC5)	Homo sapiens		h_bcellsurvivalPathway:B Cell Survival Pathway,		GO:0000086~G2/M transition of mitotic cell cycle,GO:0000226~microtubule cytoskeleton organization,GO:0000278~mitotic cell cycle,GO:0000281~mitotic cytokinesis,GO:0006468~protein phosphorylation,GO:0006915~apoptotic process,GO:0007052~mitotic spindle organization,GO:0007059~chromosome segregation,GO:0007094~mitotic spindle assembly checkpoint,GO:0007346~regulation of mitotic cell cycle,GO:0007605~sensory perception of sound,GO:0008284~positive regulation of cell proliferation,GO:0019221~cytokine-mediated signaling pathway,GO:0031503~protein complex localization,GO:0031536~positive regulation of exit from mitosis,GO:0042981~regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043154~negative regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0043524~negative regulation of neuron apoptotic process,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045931~positive regulation of mitotic cell cycle,GO:0051301~cell division,GO:0051303~establishment of chromosome localization,GO:0051726~regulation of cell cycle,GO:0061178~regulation of insulin secretion involved in cellular response to glucose stimulus,GO:0061469~regulation of type B pancreatic cell proliferation,	GO:0000228~nuclear chromosome,GO:0000775~chromosome, centromeric region,GO:0000776~kinetochore,GO:0000777~condensed chromosome kinetochore,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005814~centriole,GO:0005829~cytosol,GO:0005876~spindle microtubule,GO:0005881~cytoplasmic microtubule,GO:0015630~microtubule cytoskeleton,GO:0030496~midbody,GO:0031021~interphase microtubule organizing center,GO:0032133~chromosome passenger complex,GO:0032991~macromolecular complex,GO:1990713~survivin complex,	GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0008270~zinc ion binding,GO:0015631~tubulin binding,GO:0019899~enzyme binding,GO:0031267~small GTPase binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0043027~cysteine-type endopeptidase inhibitor activity involved in apoptotic process,GO:0046872~metal ion binding,GO:0046982~protein heterodimerization activity,GO:0050897~cobalt ion binding,GO:0051087~chaperone binding,	IPR001370:Baculoviral inhibition of apoptosis protein repeat,	hsa01524:Platinum drug resistance,hsa04210:Apoptosis,hsa04215:Apoptosis - multiple species,hsa04390:Hippo signaling pathway,hsa05161:Hepatitis B,hsa05200:Pathways in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05210:Colorectal cancer,			SM00238:BIR,	KW-0053~Apoptosis,KW-0131~Cell cycle,KW-0132~Cell division,KW-0159~Chromosome partition,KW-0498~Mitosis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0137~Centromere,KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0995~Kinetochore,		KW-0175~Coiled coil,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0646~Protease inhibitor,KW-0678~Repressor,KW-0789~Thiol protease inhibitor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	METAL:Zinc,MUTAGEN:C->A: Disrupts interaction with histone H3pT3, no effect on interaction with INCENP.,MUTAGEN:C->A: Loss of cytoprotection.,MUTAGEN:C->R: Disrupts interaction with histone H3pT3, no effect on interaction with INCENP.,MUTAGEN:D->A: No change. Loss of interaction with AURKB; when associated with A-70.,MUTAGEN:D->A: No change. Loss of interaction with AURKB; when associated with A-71.,MUTAGEN:E->A: Almost abolishes RAN-binding. Does not disrupt binding to AURKB or CDCA8. Disrupts mitotic spindle assembly. Does not disrupt nuclear export.,MUTAGEN:E->A: Loss of FBXL7 binding.,MUTAGEN:K->A,Q: Mimics acetylation. Localization primarily within the nucleus.,MUTAGEN:K->R: Increases ubiquitination and blocks dissociation from centromeres; when associated with R-23; R-62 and R-78.,MUTAGEN:K->R: Increases ubiquitination and blocks dissociation from centromeres; when associated with R-23; R-62 and R-79.,MUTAGEN:K->R: Increases ubiquitination and blocks dissociation from centromeres; when associated with R-23; R-78 and R-79.,MUTAGEN:K->R: Increases ubiquitination and blocks dissociation from centromeres; when associated with R-62; R-78 and R-79.,MUTAGEN:K->R: Loss of acetylation. Localization primarily within the cytoplasm.,MUTAGEN:KK->RR: Loss of FBXL7 mediated polyubiquitination.,MUTAGEN:R->A: Disrupts interaction with histone H3pT3, no effect on interaction with INCENP.,MUTAGEN:T->A,E: Localizes normally during mitosis but cannot support cell proliferation. Increased affinity for CDCA8/borealin.,MUTAGEN:T->A: Loss of LAMTOR5 binding.,MUTAGEN:T->A: Prevents phosphorylation by AURKB. Still able to localize correctly but prevents interaction with INCENP.,MUTAGEN:T->E: Higher affinity for LAMTOR5 binding.,MUTAGEN:T->E: Mimics phosphorylation. Disrupts subcellular localization during mitosis and prevents interaction with INCENP.,MUTAGEN:W->A: Disrupts interaction with histone H3pT3, no effect on interaction with INCENP.,REPEAT:BIR,SITE:Interaction with FBXL7,
BHLHE40	basic helix-loop-helix family member e40(BHLHE40)	Homo sapiens				GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007623~circadian rhythm,GO:0009952~anterior/posterior pattern specification,GO:0032922~circadian regulation of gene expression,GO:0042752~regulation of circadian rhythm,GO:0043153~entrainment of circadian clock by photoperiod,GO:0043433~negative regulation of sequence-specific DNA binding transcription factor activity,GO:0045892~negative regulation of transcription, DNA-templated,GO:0050767~regulation of neurogenesis,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0016604~nuclear body,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001102~RNA polymerase II activating transcription factor binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0019904~protein domain specific binding,GO:0042803~protein homodimerization activity,GO:0043425~bHLH transcription factor binding,GO:0043426~MRF binding,GO:0046982~protein heterodimerization activity,GO:0046983~protein dimerization activity,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0070888~E-box binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR003650:Orange,IPR011598:Myc-type, basic helix-loop-helix (bHLH) domain,	hsa04710:Circadian rhythm,			SM00353:HLH,SM00511:ORANGE,	KW-0090~Biological rhythms,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0238~DNA-binding,KW-0678~Repressor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1, SUMO2 and SUMO3),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1, SUMO2 and SUMO3); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:BHLH,DOMAIN:Orange,DOMAIN:bHLH,MUTAGEN:H->A: No effect on its interaction with ARNTL/BMAL1 or its repressor activity against the CLOCK-ARNTL/BMAL1 heterodimer. Significant reduction in E-box binding.,MUTAGEN:K->R: Partial loss of sumoylation. Complete loss of sumoylation; when associated with R-159.,MUTAGEN:K->R: Partial loss of sumoylation. Complete loss of sumoylation; when associated with R-279.,MUTAGEN:LL->AA: Abolishes RXRA repression.,MUTAGEN:P->A: No loss of repressor activity against NR0B2.,MUTAGEN:R->A: Loss of interaction with ARNTL/BMAL1 and E-box binding. Significant reduction in its repressor activity against the CLOCK-ARNTL/BMAL1 heterodimer.,MUTAGEN:R->A: Loss of repressor activity against NR0B2.,REGION:Disordered,REGION:Essential for interaction with ARNTL/BMAL1, E-box binding and repressor activity against the CLOCK-ARNTL/BMAL1 heterodimer,REGION:Necessary for interaction with RXRA and repressor activity against RXRA,
BZW2	basic leucine zipper and W2 domains 2(BZW2)	Homo sapiens				GO:0006446~regulation of translational initiation,GO:0007399~nervous system development,GO:0030154~cell differentiation,	GO:0005737~cytoplasm,GO:0016020~membrane,	GO:0005515~protein binding,GO:0045296~cadherin binding,	IPR003307:W2 domain,IPR016021:MIF4-like, type 1/2/3,IPR016024:Armadillo-type fold,				SM00515:eIF5C,	KW-0221~Differentiation,KW-0524~Neurogenesis,					KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:W2,REGION:Disordered,
BECN1	beclin 1(BECN1)	Homo sapiens				GO:0000045~autophagosome assembly,GO:0000422~mitophagy,GO:0000423~macromitophagy,GO:0001666~response to hypoxia,GO:0006468~protein phosphorylation,GO:0006897~endocytosis,GO:0006914~autophagy,GO:0006915~apoptotic process,GO:0006968~cellular defense response,GO:0006995~cellular response to nitrogen starvation,GO:0007040~lysosome organization,GO:0007049~cell cycle,GO:0007080~mitotic metaphase plate congression,GO:0007568~aging,GO:0008285~negative regulation of cell proliferation,GO:0009410~response to xenobiotic stimulus,GO:0010040~response to iron(II) ion,GO:0010288~response to lead ion,GO:0010506~regulation of autophagy,GO:0010508~positive regulation of autophagy,GO:0010613~positive regulation of cardiac muscle hypertrophy,GO:0014068~positive regulation of phosphatidylinositol 3-kinase signaling,GO:0016032~viral process,GO:0016236~macroautophagy,GO:0016241~regulation of macroautophagy,GO:0016579~protein deubiquitination,GO:0032465~regulation of cytokinesis,GO:0032801~receptor catabolic process,GO:0033197~response to vitamin E,GO:0034198~cellular response to amino acid starvation,GO:0036092~phosphatidylinositol-3-phosphate biosynthetic process,GO:0042149~cellular response to glucose starvation,GO:0042493~response to drug,GO:0043066~negative regulation of apoptotic process,GO:0043652~engulfment of apoptotic cell,GO:0045022~early endosome to late endosome transport,GO:0045324~late endosome to vacuole transport,GO:0048666~neuron development,GO:0050435~beta-amyloid metabolic process,GO:0050790~regulation of catalytic activity,GO:0051301~cell division,GO:0051607~defense response to virus,GO:0060548~negative regulation of cell death,GO:0070301~cellular response to hydrogen peroxide,GO:0071275~cellular response to aluminum ion,GO:0071280~cellular response to copper ion,GO:0071364~cellular response to epidermal growth factor stimulus,GO:0097352~autophagosome maturation,GO:0098780~response to mitochondrial depolarisation,GO:1902425~positive regulation of attachment of mitotic spindle microtubules to kinetochore,GO:1902902~negative regulation of autophagosome assembly,GO:1905672~negative regulation of lysosome organization,GO:2000378~negative regulation of reactive oxygen species metabolic process,GO:2000786~positive regulation of autophagosome assembly,GO:2001244~positive regulation of intrinsic apoptotic signaling pathway,	GO:0000407~pre-autophagosomal structure,GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0005768~endosome,GO:0005776~autophagosome,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005802~trans-Golgi network,GO:0005829~cytosol,GO:0010008~endosome membrane,GO:0019898~extrinsic component of membrane,GO:0030425~dendrite,GO:0031966~mitochondrial membrane,GO:0034271~phosphatidylinositol 3-kinase complex, class III, type I,GO:0034272~phosphatidylinositol 3-kinase complex, class III, type II,GO:0035032~phosphatidylinositol 3-kinase complex, class III,GO:0045335~phagocytic vesicle,	GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0031625~ubiquitin protein ligase binding,GO:0042802~identical protein binding,GO:0043548~phosphatidylinositol 3-kinase binding,GO:0051020~GTPase binding,	IPR007243:Beclin family,	hsa04136:Autophagy - other,hsa04137:Mitophagy - animal,hsa04140:Autophagy - animal,hsa04215:Apoptosis - multiple species,hsa04371:Apelin signaling pathway,hsa05010:Alzheimer disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05017:Spinocerebellar ataxia,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05131:Shigellosis,hsa05167:Kaposi sarcoma-associated herpesvirus infection,				KW-0051~Antiviral defense,KW-0053~Apoptosis,KW-0072~Autophagy,KW-0131~Cell cycle,KW-0132~Cell division,KW-0254~Endocytosis,KW-0945~Host-virus interaction,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,		KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:APG6,DOMAIN:APG6_N,DOMAIN:BH3,MOTIF:BH3,MUTAGEN:D->A: Abolishes in vitro cleavage by CASP3 and CASP8; when associated with A-133.,MUTAGEN:D->A: Abolishes in vitro cleavage by CASP3 and CASP8; when associated with A-149.,MUTAGEN:D->A: Abolishes in vitro cleavage by CASP8; when associated with A-133.,MUTAGEN:D->A: Abolishes in vitro cleavage by CASP8; when associated with A-146.,MUTAGEN:D->A: No effect on interaction with MUHV-4 M11, disrupts interaction with BCL2L1 isoform Bcl-X(L).,MUTAGEN:D->E: Abolishes in vitro cleavage by CASP3.,MUTAGEN:F->A: Weakly decreases interaction with MUHV-4 M11, disrupts interaction with BCL2 and decreases interaction with BCL2L1 isoform Bcl-X(L).,MUTAGEN:G->E: Decreases interaction with MUHV-4 M11, disrupts interaction with BCL2L1 isoform Bcl-X(L).,MUTAGEN:GD->EA: Weakly decreases interaction with MUHV-4 M11, disrupts interaction with BCL2L1 isoform Bcl-X(L).,MUTAGEN:K->A: Weakly decreases interaction with MUHV-4 M11, greatly decreases interaction with BCL2L1 isoform Bcl-X(L).,MUTAGEN:K->R: Abolished ubiquitination by the DCX(AMBRA1) complex.,MUTAGEN:K->R: Decreases K48 polyubiquitination and stabilizes BECN1.,MUTAGEN:K->R: Does not affect ubiquitination by the DCX(AMBRA1) complex.,MUTAGEN:L->A: Decreases interaction with BCL2L1 isoform Bcl-X(L).,MUTAGEN:L->A: Weakly decreases interaction with MUHV-4 M11, greatly decreases interaction with BCL2L1 isoform Bcl-X(L).,MUTAGEN:S->A: Complete loss of phosphorylation. Complete loss of phosphorylation and defective autophagic function; when associated with Ala-93.,MUTAGEN:S->A: Partial loss of phosphorylation. Complete loss of phosphorylation and defective autophagic function; when associated with Ala-90.,MUTAGEN:W->A: Decrease in membrane-association.,MUTAGEN:Y->A: Significantly reduces ubiquitination.,REGION:Disordered,REGION:Evolutionary conserved domain (ECD),REGION:Interaction with BCL2 and BCL2L1 isoform Bcl-X(L),REGION:Required for membrane-association,
BACE2	beta-secretase 2(BACE2)	Homo sapiens				GO:0006508~proteolysis,GO:0006509~membrane protein ectodomain proteolysis,GO:0016486~peptide hormone processing,GO:0042593~glucose homeostasis,GO:0042985~negative regulation of amyloid precursor protein biosynthetic process,GO:0048143~astrocyte activation,GO:0050435~beta-amyloid metabolic process,	GO:0005768~endosome,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005802~trans-Golgi network,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0031045~dense core granule,	GO:0004190~aspartic-type endopeptidase activity,GO:0005515~protein binding,	IPR001461:Peptidase A1,IPR001969:Peptidase aspartic, active site,IPR009119:Peptidase A1, beta-site APP cleaving enzyme, BACE,IPR009121:Peptidase A1, beta-site APP cleaving enzyme 2, BACE 2,IPR021109:Aspartic peptidase,	hsa05010:Alzheimer disease,					KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0064~Aspartyl protease,KW-0378~Hydrolase,KW-0645~Protease,	KW-0068~Autocatalytic cleavage,KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Peptidase A1,MUTAGEN:D->A,N: Loss of autoproteolytic cleavage.,MUTAGEN:D->A: Loss of autoproteolytic cleavage.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
BLVRA	biliverdin reductase A(BLVRA)	Homo sapiens		h_il10Pathway:IL-10 Anti-inflammatory Signaling Pathway,		GO:0042167~heme catabolic process,	GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0000166~nucleotide binding,GO:0004074~biliverdin reductase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,	IPR000683:Oxidoreductase, N-terminal,IPR015249:Biliverdin reductase, catalytic,IPR017094:Biliverdin reductase A,	hsa00860:Porphyrin metabolism,hsa01100:Metabolic pathways,	614156~Hyperbiliverdinemia,	PIRSF037032:biliverdin reductase A,			KW-0963~Cytoplasm,			KW-0479~Metal-binding,KW-0520~NAD,KW-0521~NADP,KW-0862~Zinc,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	BINDING:NAD or NADP; via carbonyl oxygen,DOMAIN:Biliv-reduc_cat,DOMAIN:GFO_IDH_MocA,METAL:Zinc,NP_BIND:NAD or NADP,
BPHL	biphenyl hydrolase like(BPHL)	Homo sapiens				GO:0006520~cellular amino acid metabolic process,GO:0006805~xenobiotic metabolic process,GO:0009636~response to toxic substance,	GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,	GO:0016787~hydrolase activity,GO:0047658~alpha-amino-acid esterase activity,	IPR000073:Alpha/beta hydrolase fold-1,								KW-0732~Signal,		KW-0378~Hydrolase,	KW-0007~Acetylation,	ACT_SITE:Charge relay system,ACT_SITE:Nucleophile,DOMAIN:AB hydrolase-1,MUTAGEN:D->N: <0.1% of wild type activity.,MUTAGEN:H->A: Complete loss of activity.,MUTAGEN:S->A: <0.1% of wild type activity.,SITE:Binding of alpha-amino group of substrate,
BLMH	bleomycin hydrolase(BLMH)	Homo sapiens				GO:0000209~protein polyubiquitination,GO:0006508~proteolysis,GO:0009410~response to xenobiotic stimulus,GO:0009636~response to toxic substance,GO:0042493~response to drug,GO:0043418~homocysteine catabolic process,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0004177~aminopeptidase activity,GO:0004180~carboxypeptidase activity,GO:0004197~cysteine-type endopeptidase activity,GO:0005515~protein binding,GO:0008234~cysteine-type peptidase activity,GO:0042802~identical protein binding,	IPR000169:Cysteine peptidase, cysteine active site,IPR004134:Peptidase C1B, bleomycin hydrolase,			PIRSF005700:aminopeptidase C (bleomycin hydrolase),			KW-0963~Cytoplasm,				KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0007~Acetylation,
BMP4	bone morphogenetic protein 4(BMP4)	Homo sapiens		h_alkPathway:ALK in cardiac myocytes,		GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000186~activation of MAPKK activity,GO:0001649~osteoblast differentiation,GO:0001657~ureteric bud development,GO:0001658~branching involved in ureteric bud morphogenesis,GO:0001759~organ induction,GO:0001822~kidney development,GO:0001823~mesonephros development,GO:0001843~neural tube closure,GO:0001934~positive regulation of protein phosphorylation,GO:0001938~positive regulation of endothelial cell proliferation,GO:0001958~endochondral ossification,GO:0002043~blood vessel endothelial cell proliferation involved in sprouting angiogenesis,GO:0002062~chondrocyte differentiation,GO:0002244~hematopoietic progenitor cell differentiation,GO:0002320~lymphoid progenitor cell differentiation,GO:0003014~renal system process,GO:0003130~BMP signaling pathway involved in heart induction,GO:0003139~secondary heart field specification,GO:0003148~outflow tract septum morphogenesis,GO:0003149~membranous septum morphogenesis,GO:0003163~sinoatrial node development,GO:0003180~aortic valve morphogenesis,GO:0003184~pulmonary valve morphogenesis,GO:0003197~endocardial cushion development,GO:0003279~cardiac septum development,GO:0003323~type B pancreatic cell development,GO:0003337~mesenchymal to epithelial transition involved in metanephros morphogenesis,GO:0007182~common-partner SMAD protein phosphorylation,GO:0007281~germ cell development,GO:0007492~endoderm development,GO:0007500~mesodermal cell fate determination,GO:0008284~positive regulation of cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0009791~post-embryonic development,GO:0009948~anterior/posterior axis specification,GO:0010159~specification of animal organ position,GO:0010453~regulation of cell fate commitment,GO:0010595~positive regulation of endothelial cell migration,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0010862~positive regulation of pathway-restricted SMAD protein phosphorylation,GO:0010942~positive regulation of cell death,GO:0021537~telencephalon development,GO:0021904~dorsal/ventral neural tube patterning,GO:0021978~telencephalon regionalization,GO:0021983~pituitary gland development,GO:0030218~erythrocyte differentiation,GO:0030224~monocyte differentiation,GO:0030225~macrophage differentiation,GO:0030501~positive regulation of bone mineralization,GO:0030509~BMP signaling pathway,GO:0030513~positive regulation of BMP signaling pathway,GO:0032092~positive regulation of protein binding,GO:0032331~negative regulation of chondrocyte differentiation,GO:0032967~positive regulation of collagen biosynthetic process,GO:0033085~negative regulation of T cell differentiation in thymus,GO:0033088~negative regulation of immature T cell proliferation in thymus,GO:0034504~protein localization to nucleus,GO:0035116~embryonic hindlimb morphogenesis,GO:0035990~tendon cell differentiation,GO:0035993~deltoid tuberosity development,GO:0042306~regulation of protein import into nucleus,GO:0042326~negative regulation of phosphorylation,GO:0042475~odontogenesis of dentin-containing tooth,GO:0042476~odontogenesis,GO:0042487~regulation of odontogenesis of dentin-containing tooth,GO:0042733~embryonic digit morphogenesis,GO:0043065~positive regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043401~steroid hormone mediated signaling pathway,GO:0043407~negative regulation of MAP kinase activity,GO:0043410~positive regulation of MAPK cascade,GO:0043687~post-translational protein modification,GO:0044267~cellular protein metabolic process,GO:0045603~positive regulation of endothelial cell differentiation,GO:0045606~positive regulation of epidermal cell differentiation,GO:0045662~negative regulation of myoblast differentiation,GO:0045666~positive regulation of neuron differentiation,GO:0045669~positive regulation of osteoblast differentiation,GO:0045778~positive regulation of ossification,GO:0045786~negative regulation of cell cycle,GO:0045839~negative regulation of mitotic nuclear division,GO:0045843~negative regulation of striated muscle tissue development,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048286~lung alveolus development,GO:0048392~intermediate mesodermal cell differentiation,GO:0048660~regulation of smooth muscle cell proliferation,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0048663~neuron fate commitment,GO:0048701~embryonic cranial skeleton morphogenesis,GO:0048745~smooth muscle tissue development,GO:0048754~branching morphogenesis of an epithelial tube,GO:0050679~positive regulation of epithelial cell proliferation,GO:0050680~negative regulation of epithelial cell proliferation,GO:0050918~positive chemotaxis,GO:0051150~regulation of smooth muscle cell differentiation,GO:0055007~cardiac muscle cell differentiation,GO:0055020~positive regulation of cardiac muscle fiber development,GO:0060113~inner ear receptor cell differentiation,GO:0060197~cloacal septation,GO:0060235~lens induction in camera-type eye,GO:0060272~embryonic skeletal joint morphogenesis,GO:0060363~cranial suture morphogenesis,GO:0060391~positive regulation of SMAD protein import into nucleus,GO:0060393~regulation of pathway-restricted SMAD protein phosphorylation,GO:0060395~SMAD protein signal transduction,GO:0060425~lung morphogenesis,GO:0060433~bronchus development,GO:0060438~trachea development,GO:0060440~trachea formation,GO:0060441~epithelial tube branching involved in lung morphogenesis,GO:0060442~branching involved in prostate gland morphogenesis,GO:0060449~bud elongation involved in lung branching,GO:0060502~epithelial cell proliferation involved in lung morphogenesis,GO:0060503~bud dilation involved in lung branching,GO:0060548~negative regulation of cell death,GO:0060592~mammary gland formation,GO:0060684~epithelial-mesenchymal cell signaling,GO:0060686~negative regulation of prostatic bud formation,GO:0060687~regulation of branching involved in prostate gland morphogenesis,GO:0060976~coronary vasculature development,GO:0061036~positive regulation of cartilage development,GO:0061047~positive regulation of branching involved in lung morphogenesis,GO:0061149~BMP signaling pathway involved in ureter morphogenesis,GO:0061151~BMP signaling pathway involved in renal system segmentation,GO:0061155~pulmonary artery endothelial tube morphogenesis,GO:0061312~BMP signaling pathway involved in heart development,GO:0061626~pharyngeal arch artery morphogenesis,GO:0070244~negative regulation of thymocyte apoptotic process,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071773~cellular response to BMP stimulus,GO:0071893~BMP signaling pathway involved in nephric duct formation,GO:0072015~glomerular visceral epithelial cell development,GO:0072097~negative regulation of branch elongation involved in ureteric bud branching by BMP signaling pathway,GO:0072101~specification of ureteric bud anterior/posterior symmetry by BMP signaling pathway,GO:0072104~glomerular capillary formation,GO:0072125~negative regulation of glomerular mesangial cell proliferation,GO:0072138~mesenchymal cell proliferation involved in ureteric bud development,GO:0072161~mesenchymal cell differentiation involved in kidney development,GO:0072192~ureter epithelial cell differentiation,GO:0072193~ureter smooth muscle cell differentiation,GO:0072198~mesenchymal cell proliferation involved in ureter development,GO:0072200~negative regulation of mesenchymal cell proliferation involved in ureter development,GO:0072205~metanephric collecting duct development,GO:0090184~positive regulation of kidney development,GO:0090191~negative regulation of branching involved in ureteric bud morphogenesis,GO:0090194~negative regulation of glomerulus development,GO:1900745~positive regulation of p38MAPK cascade,GO:1901964~positive regulation of cell proliferation involved in outflow tract morphogenesis,GO:1902894~negative regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1903800~positive regulation of production of miRNAs involved in gene silencing by miRNA,GO:1905312~positive regulation of cardiac neural crest cell migration involved in outflow tract morphogenesis,GO:2000005~negative regulation of metanephric S-shaped body morphogenesis,GO:2000007~negative regulation of metanephric comma-shaped body morphogenesis,GO:2000137~negative regulation of cell proliferation involved in heart morphogenesis,GO:2001237~negative regulation of extrinsic apoptotic signaling pathway,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,	GO:0005125~cytokine activity,GO:0005515~protein binding,GO:0008083~growth factor activity,GO:0008201~heparin binding,GO:0039706~co-receptor binding,GO:0042056~chemoattractant activity,GO:0070700~BMP receptor binding,	IPR001111:Transforming growth factor-beta, N-terminal,IPR001839:Transforming growth factor-beta, C-terminal,IPR015615:Transforming growth factor-beta-related,IPR017948:Transforming growth factor beta, conserved site,	hsa04060:Cytokine-cytokine receptor interaction,hsa04350:TGF-beta signaling pathway,hsa04390:Hippo signaling pathway,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04919:Thyroid hormone signaling pathway,hsa05200:Pathways in cancer,hsa05217:Basal cell carcinoma,hsa05418:Fluid shear stress and atherosclerosis,	600625~Orofacial cleft 11,607932~Microphthalmia, syndromic 6,		SM00204:TGFB,	KW-0221~Differentiation,KW-0891~Chondrogenesis,KW-0892~Osteogenesis,	KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,KW-1013~Microphthalmia,	KW-0732~Signal,		KW-0202~Cytokine,KW-0217~Developmental protein,KW-0339~Growth factor,KW-9996~Developmental protein,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic residues,DISULFID:Interchain,DOMAIN:TGF_BETA_2,DOMAIN:TGFb_propeptide,REGION:Disordered,
CREB1	cAMP responsive element binding protein 1(CREB1)	Homo sapiens		h_arenrf2Pathway:Oxidative Stress Induced Gene Expression Via Nrf2,h_CaCaMPathway:Ca++/ Calmodulin-dependent Protein Kinase Activation,h_carm1Pathway:Transcription Regulation by Methyltransferase of CARM1,h_crebPathway:Transcription factor CREB and its extracellular signals,h_dreamPathway:Repression of Pain Sensation by the Transcriptional Regulator DREAM,h_erk5Pathway:Role of Erk5 in Neuronal Survival,h_gpcrPathway:Signaling Pathway from G-Protein Families,h_hbxPathway:Calcium Signaling by HBx of Hepatitis B virus,h_hcmvPathway:Human Cytomegalovirus and Map Kinase Pathways,h_hifPathway:Hypoxia-Inducible Factor in the Cardiovascular System,h_huntingtonPathway:Inhibition of Huntington's disease neurodegeneration by histone deacetylase inhibitors,h_mapkPathway:MAPKinase Signaling Pathway,h_melanocytePathway:Melanocyte Development and Pigmentation Pathway,h_p38mapkPathway:p38 MAPK Signaling Pathway ,		GO:0001666~response to hypoxia,GO:0002862~negative regulation of inflammatory response to antigenic stimulus,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0006468~protein phosphorylation,GO:0007165~signal transduction,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0007409~axonogenesis,GO:0007568~aging,GO:0007595~lactation,GO:0007613~memory,GO:0007623~circadian rhythm,GO:0008361~regulation of cell size,GO:0008542~visual learning,GO:0009410~response to xenobiotic stimulus,GO:0010033~response to organic substance,GO:0010629~negative regulation of gene expression,GO:0010944~negative regulation of transcription by competitive promoter binding,GO:0014823~response to activity,GO:0016032~viral process,GO:0021983~pituitary gland development,GO:0032916~positive regulation of transforming growth factor beta3 production,GO:0033363~secretory granule organization,GO:0033762~response to glucagon,GO:0034670~chemotaxis to arachidonic acid,GO:0035094~response to nicotine,GO:0035729~cellular response to hepatocyte growth factor stimulus,GO:0036120~cellular response to platelet-derived growth factor stimulus,GO:0040018~positive regulation of multicellular organism growth,GO:0042493~response to drug,GO:0042752~regulation of circadian rhythm,GO:0043065~positive regulation of apoptotic process,GO:0045600~positive regulation of fat cell differentiation,GO:0045672~positive regulation of osteoclast differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045899~positive regulation of RNA polymerase II transcriptional preinitiation complex assembly,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046887~positive regulation of hormone secretion,GO:0046889~positive regulation of lipid biosynthetic process,GO:0048145~regulation of fibroblast proliferation,GO:0050821~protein stabilization,GO:0055025~positive regulation of cardiac muscle tissue development,GO:0060251~regulation of glial cell proliferation,GO:0060430~lung saccule development,GO:0060509~Type I pneumocyte differentiation,GO:0071294~cellular response to zinc ion,GO:0071300~cellular response to retinoic acid,GO:0071398~cellular response to fatty acid,GO:1900273~positive regulation of long-term synaptic potentiation,GO:1901215~negative regulation of neuron death,GO:1902065~response to L-glutamate,GO:1990090~cellular response to nerve growth factor stimulus,GO:1990314~cellular response to insulin-like growth factor stimulus,GO:1990830~cellular response to leukemia inhibitory factor,	GO:0000785~chromatin,GO:0000791~euchromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005759~mitochondrial matrix,GO:0030424~axon,GO:0090575~RNA polymerase II transcription factor complex,GO:1990589~ATF4-CREB1 transcription factor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001102~RNA polymerase II activating transcription factor binding,GO:0001225~RNA polymerase II transcription coactivator binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0030544~Hsp70 protein binding,GO:0035035~histone acetyltransferase binding,GO:0035497~cAMP response element binding,GO:0042802~identical protein binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:1990763~arrestin family protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001630:cAMP response element binding (CREB) protein,IPR003102:Coactivator CBP, pKID,IPR004827:Basic-leucine zipper domain,	hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04152:AMPK signaling pathway,hsa04211:Longevity regulating pathway,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04380:Osteoclast differentiation,hsa04612:Antigen processing and presentation,hsa04668:TNF signaling pathway,hsa04710:Circadian rhythm,hsa04713:Circadian entrainment,hsa04714:Thermogenesis,hsa04725:Cholinergic synapse,hsa04728:Dopaminergic synapse,hsa04911:Insulin secretion,hsa04915:Estrogen signaling pathway,hsa04916:Melanogenesis,hsa04918:Thyroid hormone synthesis,hsa04922:Glucagon signaling pathway,hsa04924:Renin secretion,hsa04925:Aldosterone synthesis and secretion,hsa04926:Relaxin signaling pathway,hsa04927:Cortisol synthesis and secretion,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04931:Insulin resistance,hsa04934:Cushing syndrome,hsa04935:Growth hormone synthesis, secretion and action,hsa04962:Vasopressin-regulated water reabsorption,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05030:Cocaine addiction,hsa05031:Amphetamine addiction,hsa05034:Alcoholism,hsa05152:Tuberculosis,hsa05161:Hepatitis B,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05203:Viral carcinogenesis,hsa05207:Chemical carcinogenesis - receptor activation,hsa05215:Prostate cancer,	612160~Histiocytoma, angiomatoid fibrous, somatic,		SM00338:BRLZ,	KW-0090~Biological rhythms,KW-0221~Differentiation,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,		KW-0175~Coiled coil,		KW-0010~Activator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:BZIP,DOMAIN:KID,DOMAIN:bZIP,MUTAGEN:K->R: Decreased sumoylation, in vivo and in vitro.,MUTAGEN:K->R: Decreased sumoylation, in vivo and in vitro. Loss of nuclear localization.,MUTAGEN:K->R: No effect on sumoylation.,MUTAGEN:S->A: Does not interact with TOX3 and inhibits induction of transcription by TOX3. Loss of phosphorylation by CaMK4. Loss of phosphorylation by TSSK4.,MUTAGEN:S->A: Impaired phosphorylation by HIPK2 and subsequent transactivation.,MUTAGEN:S->E: Potentiated transactivation.,REGION:Basic motif,REGION:Disordered,REGION:Leucine-zipper,SITE:Required for binding TORCs,
PKIG	cAMP-dependent protein kinase inhibitor gamma(PKIG)	Homo sapiens				GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0007165~signal transduction,GO:0042308~negative regulation of protein import into nucleus,GO:2000480~negative regulation of cAMP-dependent protein kinase activity,	GO:0005634~nucleus,GO:0005737~cytoplasm,	GO:0004860~protein kinase inhibitor activity,GO:0004862~cAMP-dependent protein kinase inhibitor activity,GO:0005515~protein binding,GO:0016301~kinase activity,	IPR004171:cAMP-dependent protein kinase inhibitor,			PIRSF001667:cAMP-dependent protein kinase inhibitor,							KW-0418~Kinase,KW-0649~Protein kinase inhibitor,KW-0808~Transferase,		COMPBIAS:Polar residues,REGION:Disordered,SITE:Important for inhibition,
CDH3	cadherin 3(CDH3)	Homo sapiens				GO:0001895~retina homeostasis,GO:0007155~cell adhesion,GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules,GO:0007601~visual perception,GO:0009410~response to xenobiotic stimulus,GO:0010628~positive regulation of gene expression,GO:0010838~positive regulation of keratinocyte proliferation,GO:0022405~hair cycle process,GO:0031424~keratinization,GO:0032773~positive regulation of monophenol monooxygenase activity,GO:0032912~negative regulation of transforming growth factor beta2 production,GO:0034332~adherens junction organization,GO:0042060~wound healing,GO:0042493~response to drug,GO:0043568~positive regulation of insulin-like growth factor receptor signaling pathway,GO:0048023~positive regulation of melanin biosynthetic process,GO:0051796~negative regulation of timing of catagen,GO:0060901~regulation of hair cycle by canonical Wnt signaling pathway,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:0098609~cell-cell adhesion,GO:0098742~cell-cell adhesion via plasma-membrane adhesion molecules,GO:1902910~positive regulation of melanosome transport,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005912~adherens junction,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016342~catenin complex,GO:0030054~cell junction,	GO:0005509~calcium ion binding,GO:0045296~cadherin binding,	IPR000233:Cadherin, cytoplasmic domain,IPR002126:Cadherin,IPR014868:Cadherin prodomain,IPR015919:Cadherin-like,IPR020894:Cadherin conserved site,IPR027397:Catenin binding domain,	hsa04514:Cell adhesion molecules,	225280~Ectodermal dysplasia, ectrodactyly, and macular dystrophy,601553~Hypotrichosis, congenital, with juvenile macular dystrophy,		SM00112:CA,SM01055:SM01055,	KW-0130~Cell adhesion,KW-0716~Sensory transduction,KW-0844~Vision,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0038~Ectodermal dysplasia,KW-0225~Disease variant,KW-1063~Hypotrichosis,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Cadherin,DOMAIN:Cadherin 1,DOMAIN:Cadherin 2,DOMAIN:Cadherin 3,DOMAIN:Cadherin 4,DOMAIN:Cadherin 5,DOMAIN:Cadherin_C,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CANT1	calcium activated nucleotidase 1(CANT1)	Homo sapiens				GO:0030166~proteoglycan biosynthetic process,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043312~neutrophil degranulation,	GO:0005576~extracellular region,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0032580~Golgi cisterna membrane,GO:0035580~specific granule lumen,GO:0070062~extracellular exosome,GO:1904724~tertiary granule lumen,GO:1904813~ficolin-1-rich granule lumen,	GO:0004382~guanosine-diphosphatase activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0017110~nucleoside-diphosphatase activity,GO:0042803~protein homodimerization activity,GO:0043262~adenosine-diphosphatase activity,GO:0045134~uridine-diphosphatase activity,	IPR009283:Apyrase,	hsa00230:Purine metabolism,hsa00240:Pyrimidine metabolism,hsa01100:Metabolic pathways,	251450~Desbuquois dysplasia 1,617719~Epiphyseal dysplasia, multiple, 7,				KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0242~Dwarfism,	KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0378~Hydrolase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain,METAL:Calcium,METAL:Calcium; via carbonyl oxygen,MUTAGEN:A->C: Reduces GDPase activity 1.7-fold and ADPase activity 1.5-fold. Severe loss of dimer formation; when associated with S-287.,MUTAGEN:C->S: Loss of dimer formation.,MUTAGEN:C->S: Reduces GDPase and ADPase activities 1.3-fold.,MUTAGEN:D->A: Loss of activity.,MUTAGEN:D->A: Reduces activity by 99%.,MUTAGEN:D->A: Slightly reduced activity.,MUTAGEN:D->N: Reduces activity by 96%.,MUTAGEN:D->N: Reduces activity by over 99.9%.,MUTAGEN:E->M: Increases activity 5-fold.,MUTAGEN:E->Q: Reduces activity by 95%.,MUTAGEN:E->Q: Reduces activity by 99%.,MUTAGEN:E->Y: Increases GDPase activity 2-fold and ADPase activity 5-fold. Forms dimer even at suboptimal Ca(2+) concentrations.,MUTAGEN:G->E: Slightly reduced activity.,MUTAGEN:I->C: Reduces GDPase activity 2-fold and ADPase activity 2.5-fold. No effect on dimer formation; when associated with S-287.,MUTAGEN:R->A: Reduces activity by 98%.,MUTAGEN:R->A: Reduces activity by 99%.,MUTAGEN:S->A: Reduces activity by over 99.9%.,MUTAGEN:S->C: No effect on GDPase and ADPase activities. No effect on dimer formation; when associated with S-287.,MUTAGEN:S->C: Reduces GDPase activity 1.3-fold and ADPase activity 2-fold. Severe loss of dimer formation; when associated with S-287.,MUTAGEN:S->C: Reduces GDPase activity 1.7-fold and ADPase activity 1.5-fold. No effect on dimer formation; when associated with S-287.,MUTAGEN:S->C: Reduces GDPase and ADPase activities 1.7-fold. Severe loss of dimer formation; when associated with S-287.,REGION:Disordered,SITE:Important for dimer formation,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
CAB39	calcium binding protein 39(CAB39)	Homo sapiens				GO:0007050~cell cycle arrest,GO:0007165~signal transduction,GO:0010800~positive regulation of peptidyl-threonine phosphorylation,GO:0014823~response to activity,GO:0018105~peptidyl-serine phosphorylation,GO:0032147~activation of protein kinase activity,GO:0035556~intracellular signal transduction,GO:0043312~neutrophil degranulation,GO:0071476~cellular hypotonic response,GO:0071902~positive regulation of protein serine/threonine kinase activity,GO:0097066~response to thyroid hormone,GO:1901017~negative regulation of potassium ion transmembrane transporter activity,GO:1901380~negative regulation of potassium ion transmembrane transport,	GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0030018~Z disc,GO:0032991~macromolecular complex,GO:0034774~secretory granule lumen,GO:0070062~extracellular exosome,GO:1902554~serine/threonine protein kinase complex,GO:1904813~ficolin-1-rich granule lumen,	GO:0005515~protein binding,GO:0019900~kinase binding,GO:0030295~protein kinase activator activity,GO:0043539~protein serine/threonine kinase activator activity,	IPR011989:Armadillo-like helical,IPR013878:Mo25-like,IPR016024:Armadillo-type fold,	hsa04150:mTOR signaling pathway,hsa04152:AMPK signaling pathway,					KW-0963~Cytoplasm,						MUTAGEN:F->A: Abolishes activation of STK11/LKB1; when associated with A-240.,MUTAGEN:R->A: Abolishes activation of STK11/LKB1; when associated with A-243.,
CHERP	calcium homeostasis endoplasmic reticulum protein(CHERP)	Homo sapiens				GO:0000398~mRNA splicing, via spliceosome,GO:0006396~RNA processing,GO:0006874~cellular calcium ion homeostasis,GO:0007399~nervous system development,GO:0008285~negative regulation of cell proliferation,GO:0051209~release of sequestered calcium ion into cytosol,GO:0070886~positive regulation of calcineurin-NFAT signaling cascade,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016020~membrane,GO:0033017~sarcoplasmic reticulum membrane,GO:0048471~perinuclear region of cytoplasm,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0044325~ion channel binding,	IPR000061:SWAP/Surp,IPR000467:G-patch domain,IPR006569:CID domain,IPR008942:ENTH/VHS,	hsa03040:Spliceosome,			SM00443:G_patch,SM00648:SWAP,		KW-0256~Endoplasmic reticulum,KW-0963~Cytoplasm,		KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:CID,DOMAIN:G-patch,DOMAIN:SURP motif,REGION:Disordered,REPEAT:SURP motif,
CASK	calcium/calmodulin dependent serine protein kinase(CASK)	Homo sapiens		h_PDZsPathway:Synaptic Proteins at the Synaptic Junction,		GO:0001953~negative regulation of cell-matrix adhesion,GO:0006468~protein phosphorylation,GO:0006836~neurotransmitter transport,GO:0007155~cell adhesion,GO:0010839~negative regulation of keratinocyte proliferation,GO:0034613~cellular protein localization,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046037~GMP metabolic process,GO:0046710~GDP metabolic process,GO:0046928~regulation of neurotransmitter secretion,GO:0061045~negative regulation of wound healing,GO:0070509~calcium ion import,GO:0090280~positive regulation of calcium ion import,GO:0090288~negative regulation of cellular response to growth factor stimulus,GO:2000300~regulation of synaptic vesicle exocytosis,	GO:0005604~basement membrane,GO:0005634~nucleus,GO:0005652~nuclear lamina,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0005925~focal adhesion,GO:0015629~actin cytoskeleton,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0016363~nuclear matrix,GO:0031982~vesicle,GO:0042734~presynaptic membrane,GO:0060170~ciliary membrane,GO:0098685~Schaffer collateral - CA1 synapse,	GO:0004385~guanylate kinase activity,GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0005524~ATP binding,GO:0016301~kinase activity,GO:0042043~neurexin family protein binding,	IPR000719:Protein kinase, catalytic domain,IPR001452:Src homology-3 domain,IPR001478:PDZ domain,IPR004172:L27,IPR008144:Guanylate kinase,IPR008145:Guanylate kinase/L-type calcium channel,IPR011009:Protein kinase-like domain,IPR014775:L27, C-terminal,IPR020590:Guanylate kinase, conserved site,IPR027417:P-loop containing nucleoside triphosphate hydrolase,		300422~FG syndrome 4,300422~Mental retardation, with or without nystagmus,300749~Intellectual developmental disorder and microcephaly with pontine and cerebellar hypoplasia,		SM00072:GuKc,SM00220:S_TKc,SM00228:PDZ,SM00326:SH3,SM00569:L27,		KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0991~Mental retardation,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0728~SH3 domain,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0112~Calmodulin-binding,KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	BINDING:ATP,DOMAIN:Guanylate kinase-like,DOMAIN:L27,DOMAIN:L27 1,DOMAIN:L27 2,DOMAIN:PDZ,DOMAIN:Protein kinase,DOMAIN:SH3,NP_BIND:ATP,REGION:Calmodulin-binding,REGION:Disordered,REGION:Required for interaction with NRXN1 (via C-terminal tail),TRANSMEM:Helical,
CAPN1	calpain 1(CAPN1)	Homo sapiens		h_integrinPathway:Integrin Signaling Pathway,h_mCalpainPathway:mCalpain and friends in Cell motility,h_p35AlzheimersPathway:Deregulation of CDK5 in Alzheimers Disease,h_uCalpainPathway:uCalpain and friends in Cell spread,		GO:0006508~proteolysis,GO:0008284~positive regulation of cell proliferation,GO:0016241~regulation of macroautophagy,GO:0022617~extracellular matrix disassembly,GO:0032801~receptor catabolic process,GO:0043312~neutrophil degranulation,GO:0050790~regulation of catalytic activity,GO:0060056~mammary gland involution,GO:0070268~cornification,GO:0097264~self proteolysis,GO:2000310~regulation of NMDA receptor activity,	GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005764~lysosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0070062~extracellular exosome,GO:1904813~ficolin-1-rich granule lumen,	GO:0004198~calcium-dependent cysteine-type endopeptidase activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008233~peptidase activity,	IPR000169:Cysteine peptidase, cysteine active site,IPR001300:Peptidase C2, calpain, catalytic domain,IPR002048:EF-hand domain,IPR011992:EF-hand-like domain,IPR018247:EF-Hand 1, calcium-binding site,IPR022682:Peptidase C2, calpain, large subunit, domain III,IPR022683:Peptidase C2, calpain, domain III,IPR022684:Peptidase C2, calpain family,	hsa04141:Protein processing in endoplasmic reticulum,hsa04210:Apoptosis,hsa04217:Necroptosis,hsa04218:Cellular senescence,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05131:Shigellosis,	616907~Spastic paraplegia 76, autosomal recessive,		SM00230:CysPc,SM00720:calpain_III,		KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0890~Hereditary spastic paraplegia,	KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0007~Acetylation,KW-0068~Autocatalytic cleavage,KW-0597~Phosphoprotein,	CA_BIND:1,CA_BIND:2,CA_BIND:3,CA_BIND:4,DOMAIN:Calpain catalytic,DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:EF-hand 3,DOMAIN:EF-hand 4,REGION:Domain III,REGION:Domain IV,REGION:Linker,SITE:Cleavage; for 75 kDa form,SITE:Cleavage; for 78 kDa form,
CAST	calpastatin(CAST)	Homo sapiens				GO:0097340~inhibition of cysteine-type endopeptidase activity,GO:1990709~presynaptic active zone organization,GO:2000675~negative regulation of type B pancreatic cell apoptotic process,	GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0016020~membrane,	GO:0003723~RNA binding,GO:0004866~endopeptidase inhibitor activity,GO:0005515~protein binding,GO:0010859~calcium-dependent cysteine-type endopeptidase inhibitor activity,GO:0045296~cadherin binding,	IPR001259:Proteinase inhibitor I27, calpastatin,IPR026998:Calpastatin,	hsa05131:Shigellosis,	616295~Peeling skin with leukonychia, acral punctate keratoses, cheilitis, and knuckle pads,					KW-1007~Palmoplantar keratoderma,	KW-0677~Repeat,		KW-0646~Protease inhibitor,KW-0789~Thiol protease inhibitor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,REPEAT:Inhibitory domain 1,REPEAT:Inhibitory domain 2,REPEAT:Inhibitory domain 3,REPEAT:Inhibitory domain 4,
CLSTN1	calsyntenin 1(CLSTN1)	Homo sapiens				GO:0001558~regulation of cell growth,GO:0007155~cell adhesion,GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules,GO:0050806~positive regulation of synaptic transmission,GO:0051965~positive regulation of synapse assembly,GO:0090128~regulation of synapse maturation,GO:0098969~neurotransmitter receptor transport to postsynaptic membrane,GO:0099003~vesicle-mediated transport in synapse,	GO:0000139~Golgi membrane,GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005789~endoplasmic reticulum membrane,GO:0009986~cell surface,GO:0014069~postsynaptic density,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0042995~cell projection,GO:0043005~neuron projection,GO:0045211~postsynaptic membrane,GO:0098845~postsynaptic endosome,GO:0098978~glutamatergic synapse,GO:0098982~GABA-ergic synapse,GO:0099061~integral component of postsynaptic density membrane,GO:0099065~integral component of spine apparatus membrane,	GO:0001540~beta-amyloid binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0019894~kinesin binding,GO:0042988~X11-like protein binding,	IPR002126:Cadherin,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,IPR015919:Cadherin-like,IPR026914:Calsyntenin,				SM00112:CA,	KW-0130~Cell adhesion,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0539~Nucleus,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-0965~Cell junction,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,		KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Acidic residues,COMPBIAS:Polar residues,DOMAIN:Cadherin,DOMAIN:Cadherin 1,DOMAIN:Cadherin 2,MUTAGEN:NP->AA: Abolishes interaction with APBA2.,MUTAGEN:Y->A: No effect on APBA2-binding.,REGION:Disordered,SITE:Cleavage,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CALU	calumenin(CALU)	Homo sapiens				GO:0043687~post-translational protein modification,GO:0044267~cellular protein metabolic process,	GO:0005576~extracellular region,GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0016020~membrane,GO:0033018~sarcoplasmic reticulum lumen,GO:0042470~melanosome,	GO:0005509~calcium ion binding,GO:0005515~protein binding,	IPR002048:EF-hand domain,IPR011992:EF-hand-like domain,IPR018247:EF-Hand 1, calcium-binding site,IPR027239:Calumenin,				SM00054:EFh,		KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0703~Sarcoplasmic reticulum,KW-0964~Secreted,		KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CA_BIND:1,CA_BIND:2,CA_BIND:3; possibly ancestral,CA_BIND:4,CA_BIND:5,CA_BIND:6,DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:EF-hand 3,DOMAIN:EF-hand 4,DOMAIN:EF-hand 5,DOMAIN:EF-hand 6,MOTIF:Prevents secretion from ER,
CNPY3	canopy FGF signaling regulator 3(CNPY3)	Homo sapiens				GO:0002224~toll-like receptor signaling pathway,GO:0045087~innate immune response,	GO:0005788~endoplasmic reticulum lumen,	GO:0005102~receptor binding,GO:0005515~protein binding,	IPR021852:Domain of unknown function DUF3456,		617929~Developmental and epileptic encephalopathy 60,			KW-0391~Immunity,KW-0399~Innate immunity,	KW-0256~Endoplasmic reticulum,	KW-0225~Disease variant,KW-0887~Epilepsy,	KW-0175~Coiled coil,KW-0732~Signal,		KW-0143~Chaperone,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:DUF3456,DOMAIN:Saposin B-type,REGION:Disordered,
CBR1	carbonyl reductase 1(CBR1)	Homo sapiens				GO:0006805~xenobiotic metabolic process,GO:0017144~drug metabolic process,GO:0019371~cyclooxygenase pathway,GO:0030855~epithelial cell differentiation,GO:0042373~vitamin K metabolic process,GO:2000379~positive regulation of reactive oxygen species metabolic process,	GO:0005829~cytosol,GO:0070062~extracellular exosome,GO:1903561~extracellular vesicle,	GO:0004090~carbonyl reductase (NADPH) activity,GO:0016491~oxidoreductase activity,GO:0016655~oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor,GO:0047020~15-hydroxyprostaglandin-D dehydrogenase (NADP+) activity,GO:0047021~15-hydroxyprostaglandin dehydrogenase (NADP+) activity,GO:0050221~prostaglandin-E2 9-reductase activity,	IPR002347:Glucose/ribitol dehydrogenase,IPR020904:Short-chain dehydrogenase/reductase, conserved site,	hsa00590:Arachidonic acid metabolism,hsa00790:Folate biosynthesis,hsa00980:Metabolism of xenobiotics by cytochrome P450,hsa01100:Metabolic pathways,hsa05204:Chemical carcinogenesis - DNA adducts,hsa05208:Chemical carcinogenesis - reactive oxygen species,				KW-0443~Lipid metabolism,	KW-0963~Cytoplasm,			KW-0521~NADP,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:Glutathione,BINDING:NADP; via carbonyl oxygen,BINDING:Substrate,NP_BIND:NADP,REGION:Glutathione binding,
CBR3	carbonyl reductase 3(CBR3)	Homo sapiens				GO:0006805~xenobiotic metabolic process,GO:0042376~phylloquinone catabolic process,GO:0050890~cognition,	GO:0005615~extracellular space,GO:0005654~nucleoplasm,GO:0005829~cytosol,	GO:0000253~3-keto sterol reductase activity,GO:0004090~carbonyl reductase (NADPH) activity,GO:0005515~protein binding,GO:0016491~oxidoreductase activity,GO:0070402~NADPH binding,	IPR002347:Glucose/ribitol dehydrogenase,IPR020904:Short-chain dehydrogenase/reductase, conserved site,	hsa00590:Arachidonic acid metabolism,hsa00980:Metabolism of xenobiotics by cytochrome P450,hsa01100:Metabolic pathways,					KW-0963~Cytoplasm,			KW-0521~NADP,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:NADP,BINDING:NADP; via carbonyl oxygen,BINDING:Substrate,NP_BIND:NADP,
CNDP2	carnosine dipeptidase 2(CNDP2)	Homo sapiens			Amino acid transport and metabolism,	GO:0006508~proteolysis,GO:0006750~glutathione biosynthetic process,	GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0004180~carboxypeptidase activity,GO:0008233~peptidase activity,GO:0016787~hydrolase activity,GO:0016805~dipeptidase activity,GO:0046872~metal ion binding,GO:0070573~metallodipeptidase activity,GO:0103046~alanylglutamate dipeptidase activity,	IPR001261:ArgE/DapE/ACY1/CPG2/YscS, conserved site,IPR002933:Peptidase M20,IPR011650:Peptidase M20, dimerisation domain,IPR017153:Glutathione degradosome, DUG1,	hsa00330:Arginine and proline metabolism,hsa00340:Histidine metabolism,hsa00410:beta-Alanine metabolism,hsa01100:Metabolic pathways,		PIRSF037242:CNDP dipeptidase,			KW-0963~Cytoplasm,			KW-0464~Manganese,KW-0479~Metal-binding,	KW-0121~Carboxypeptidase,KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:Substrate,BINDING:Substrate; shared with homodimeric partner,BINDING:Substrate; via amide nitrogen and carbonyl oxygen,BINDING:Substrate; via carbonyl oxygen,DOMAIN:M20_dimer,METAL:Manganese 1,METAL:Manganese 1; via tele nitrogen,METAL:Manganese 2,METAL:Manganese 2; via tele nitrogen,REGION:Disordered,REGION:Substrate binding,SITE:Important for catalytic activity,
CRTAP	cartilage associated protein(CRTAP)	Homo sapiens				GO:0007283~spermatogenesis,GO:0018400~peptidyl-proline hydroxylation to 3-hydroxy-L-proline,GO:0030199~collagen fibril organization,GO:0050821~protein stabilization,GO:0061077~chaperone-mediated protein folding,GO:1901874~negative regulation of post-translational protein modification,	GO:0005615~extracellular space,GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0032991~macromolecular complex,	GO:0005515~protein binding,GO:0005518~collagen binding,	IPR011990:Tetratricopeptide-like helical,		610682~Osteogenesis imperfecta, type VII,				KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,KW-0242~Dwarfism,KW-1065~Osteogenesis imperfecta,	KW-0732~Signal,			KW-0325~Glycoprotein,KW-0379~Hydroxylation,	CARBOHYD:N-linked (GlcNAc...) asparagine,
CSNK1A1	casein kinase 1 alpha 1(CSNK1A1)	Homo sapiens		h_nfatPathway:NFAT and Hypertrophy of the heart (Transcription in the broken heart),h_p35AlzheimersPathway:Deregulation of CDK5 in Alzheimers Disease,h_p53hypoxiaPathway:Hypoxia and p53 in the Cardiovascular system,h_wntPathway:WNT Signaling Pathway,		GO:0006468~protein phosphorylation,GO:0007030~Golgi organization,GO:0007049~cell cycle,GO:0007165~signal transduction,GO:0007166~cell surface receptor signaling pathway,GO:0016055~Wnt signaling pathway,GO:0018105~peptidyl-serine phosphorylation,GO:0019082~viral protein processing,GO:0032436~positive regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0045104~intermediate filament cytoskeleton organization,GO:0051301~cell division,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:1904424~regulation of GTP binding,GO:1904885~beta-catenin destruction complex assembly,GO:1904886~beta-catenin destruction complex disassembly,	GO:0000776~kinetochore,GO:0000777~condensed chromosome kinetochore,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005819~spindle,GO:0005829~cytosol,GO:0005929~cilium,GO:0016020~membrane,GO:0016607~nuclear speck,GO:0030877~beta-catenin destruction complex,GO:0036064~ciliary basal body,GO:0045095~keratin filament,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,	IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,	hsa04310:Wnt signaling pathway,hsa04340:Hedgehog signaling pathway,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05165:Human papillomavirus infection,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,			SM00220:S_TKc,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,KW-0879~Wnt signaling pathway,	KW-0137~Centromere,KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0995~Kinetochore,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:ATP,COMPBIAS:Polar residues,DOMAIN:Protein kinase,NP_BIND:ATP,REGION:Disordered,
CSNK1E	casein kinase 1 epsilon(CSNK1E)	Homo sapiens		h_circadianPathway:Circadian Rhythms,		GO:0000086~G2/M transition of mitotic cell cycle,GO:0006281~DNA repair,GO:0006468~protein phosphorylation,GO:0006897~endocytosis,GO:0007165~signal transduction,GO:0010389~regulation of G2/M transition of mitotic cell cycle,GO:0016055~Wnt signaling pathway,GO:0018105~peptidyl-serine phosphorylation,GO:0032091~negative regulation of protein binding,GO:0032436~positive regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0032880~regulation of protein localization,GO:0032922~circadian regulation of gene expression,GO:0042752~regulation of circadian rhythm,GO:0060070~canonical Wnt signaling pathway,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:0097711~ciliary basal body docking,GO:1903827~regulation of cellular protein localization,GO:1905426~positive regulation of Wnt-mediated midbrain dopaminergic neuron differentiation,GO:2000052~positive regulation of non-canonical Wnt signaling pathway,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016021~integral component of membrane,	GO:0003723~RNA binding,GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,	IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,	hsa04068:FoxO signaling pathway,hsa04310:Wnt signaling pathway,hsa04340:Hedgehog signaling pathway,hsa04390:Hippo signaling pathway,hsa04392:Hippo signaling pathway - multiple species,hsa04710:Circadian rhythm,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,			SM00220:S_TKc,	KW-0090~Biological rhythms,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0488~Methylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:ATP,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Protein kinase,MUTAGEN:K->R: Loss of kinase activity.,NP_BIND:ATP,REGION:Disordered,TRANSMEM:Helical,
CSNK2A2	casein kinase 2 alpha 2(CSNK2A2)	Homo sapiens				GO:0006457~protein folding,GO:0006656~phosphatidylcholine biosynthetic process,GO:0006915~apoptotic process,GO:0007049~cell cycle,GO:0007076~mitotic chromosome condensation,GO:0007283~spermatogenesis,GO:0016055~Wnt signaling pathway,GO:0016236~macroautophagy,GO:0018105~peptidyl-serine phosphorylation,GO:0018107~peptidyl-threonine phosphorylation,GO:0021987~cerebral cortex development,GO:0051726~regulation of cell cycle,GO:0097421~liver regeneration,GO:1901796~regulation of signal transduction by p53 class mediator,GO:1903146~regulation of mitophagy,GO:1903955~positive regulation of protein targeting to mitochondrion,GO:1905818~regulation of chromosome separation,GO:2000059~negative regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process,GO:2001234~negative regulation of apoptotic signaling pathway,	GO:0000785~chromatin,GO:0001669~acrosomal vesicle,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005956~protein kinase CK2 complex,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0047485~protein N-terminus binding,	IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,	hsa03008:Ribosome biogenesis in eukaryotes,hsa04064:NF-kappa B signaling pathway,hsa04137:Mitophagy - animal,hsa04310:Wnt signaling pathway,hsa04520:Adherens junction,hsa05010:Alzheimer disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05162:Measles,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,			SM00220:S_TKc,	KW-0053~Apoptosis,KW-0131~Cell cycle,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0879~Wnt signaling pathway,				KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:ATP,DOMAIN:Protein kinase,NP_BIND:ATP,
CLPX	caseinolytic mitochondrial matrix peptidase chaperone subunit X(CLPX)	Homo sapiens				GO:0006457~protein folding,GO:0006508~proteolysis,GO:0010952~positive regulation of peptidase activity,GO:0030163~protein catabolic process,GO:0046034~ATP metabolic process,GO:0051603~proteolysis involved in cellular protein catabolic process,	GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005759~mitochondrial matrix,GO:0005829~cytosol,GO:0009368~endopeptidase Clp complex,GO:0009841~mitochondrial endopeptidase Clp complex,GO:0042645~mitochondrial nucleoid,	GO:0004176~ATP-dependent peptidase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008270~zinc ion binding,GO:0016504~peptidase activator activity,GO:0016887~ATPase activity,GO:0046983~protein dimerization activity,GO:0051082~unfolded protein binding,	IPR003593:AAA+ ATPase domain,IPR003959:ATPase, AAA-type, core,IPR004487:Clp protease, ATP-binding subunit ClpX,IPR010603:Zinc finger, ClpX C4-type,IPR019489:Clp ATPase, C-terminal,IPR027417:P-loop containing nucleoside triphosphate hydrolase,		618015~Protoporphyria, erythropoietic, 2,		SM00382:AAA,SM01086:SM01086,		KW-0496~Mitochondrion,KW-1135~Mitochondrion nucleoid,	KW-0225~Disease variant,	KW-0809~Transit peptide,	KW-0067~ATP-binding,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0862~Zinc,	KW-0143~Chaperone,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:ClpX-type ZB,METAL:Zinc,MUTAGEN:E->A: Abolishes ATP hydrolysis.,NP_BIND:ATP,REGION:Disordered,TRANSIT:Mitochondrion,
CASP10	caspase 10(CASP10)	Homo sapiens		h_caspasePathway:Caspase Cascade in Apoptosis,h_d4gdiPathway:D4-GDI Signaling Pathway,h_deathPathway:Induction of apoptosis through DR3 and DR4/5 Death Receptors ,h_fasPathway:FAS signaling pathway ( CD95 ),		GO:0006508~proteolysis,GO:0006915~apoptotic process,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0007166~cell surface receptor signaling pathway,GO:0042981~regulation of apoptotic process,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0097190~apoptotic signaling pathway,GO:0097194~execution phase of apoptosis,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0031265~CD95 death-inducing signaling complex,GO:0097342~ripoptosome,	GO:0004197~cysteine-type endopeptidase activity,GO:0005515~protein binding,GO:0031625~ubiquitin protein ligase binding,GO:0035877~death effector domain binding,GO:0097153~cysteine-type endopeptidase activity involved in apoptotic process,GO:0097199~cysteine-type endopeptidase activity involved in apoptotic signaling pathway,GO:0097200~cysteine-type endopeptidase activity involved in execution phase of apoptosis,	IPR001309:Peptidase C14, ICE, catalytic subunit p20,IPR001875:Death effector domain,IPR002138:Peptidase C14, caspase non-catalytic subunit p10,IPR002398:Peptidase C14, caspase precursor p45,IPR011029:Death-like domain,IPR015917:Peptidase C14, caspase precursor p45, core,IPR016129:Peptidase C14, ICE, catalytic subunit p20, active site,	hsa04210:Apoptosis,hsa04622:RIG-I-like receptor signaling pathway,hsa04668:TNF signaling pathway,hsa05152:Tuberculosis,hsa05161:Hepatitis B,	603909~Autoimmune lymphoproliferative syndrome, type II,605027~Lymphoma, non-Hodgkin, somatic,613659~Gastric cancer, somatic,		SM00031:DED,SM00115:CASc,	KW-0053~Apoptosis,		KW-0225~Disease variant,	KW-0677~Repeat,		KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0865~Zymogen,	DOMAIN:CASPASE_P10,DOMAIN:CASPASE_P20,DOMAIN:DED,DOMAIN:DED 1,DOMAIN:DED 2,MUTAGEN:C->A: Abolishes proteolytic activity.,REGION:Disordered,
CASP2	caspase 2(CASP2)	Homo sapiens		h_caspasePathway:Caspase Cascade in Apoptosis,h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_stressPathway:TNF/Stress Related Signaling,h_tnfr1Pathway:TNFR1 Signaling Pathway,		GO:0001554~luteolysis,GO:0003407~neural retina development,GO:0006915~apoptotic process,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0006977~DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest,GO:0007420~brain development,GO:0007568~aging,GO:0008630~intrinsic apoptotic signaling pathway in response to DNA damage,GO:0016485~protein processing,GO:0035234~ectopic germ cell programmed cell death,GO:0042981~regulation of apoptotic process,GO:0043065~positive regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043525~positive regulation of neuron apoptotic process,GO:0071260~cellular response to mechanical stimulus,GO:0097190~apoptotic signaling pathway,GO:0097192~extrinsic apoptotic signaling pathway in absence of ligand,GO:0097194~execution phase of apoptosis,GO:2001235~positive regulation of apoptotic signaling pathway,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0016020~membrane,GO:1905369~endopeptidase complex,	GO:0004197~cysteine-type endopeptidase activity,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0019904~protein domain specific binding,GO:0042802~identical protein binding,GO:0097153~cysteine-type endopeptidase activity involved in apoptotic process,GO:0097199~cysteine-type endopeptidase activity involved in apoptotic signaling pathway,GO:0097200~cysteine-type endopeptidase activity involved in execution phase of apoptosis,	IPR001309:Peptidase C14, ICE, catalytic subunit p20,IPR001315:Caspase Recruitment,IPR002138:Peptidase C14, caspase non-catalytic subunit p10,IPR002398:Peptidase C14, caspase precursor p45,IPR011029:Death-like domain,IPR015917:Peptidase C14, caspase precursor p45, core,IPR016129:Peptidase C14, ICE, catalytic subunit p20, active site,	hsa04210:Apoptosis,			SM00114:CARD,SM00115:CASc,	KW-0053~Apoptosis,					KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0865~Zymogen,	DOMAIN:CARD,DOMAIN:CASPASE_P10,DOMAIN:CASPASE_P20,MUTAGEN:A->T: Loss of function.,MUTAGEN:C->S: Loss of function.,MUTAGEN:D->A: No effect on interaction with CRADD. Loss of interaction with CRADD; when associated A-104.,MUTAGEN:E->A: No effect on interaction with CRADD. Loss of interaction with CRADD; when associated A-100.,MUTAGEN:F->A: Loss of interaction with CRADD.,MUTAGEN:G->R: Loss of interaction with CRADD.,MUTAGEN:L->A: Loss of interaction with CRADD.,MUTAGEN:L->F: Loss of interaction with CRADD.,REGION:Disordered,
CASP3	caspase 3(CASP3)	Homo sapiens	126.Apoptosis-Bcl-2,127.Mito-stress,150.caspase_and_NFKB_activation,38.Cell_cycle_arrest_and_apoptosis_ceramide,46.P13K_PTEN,72.IAP_interaction_with_cell_death_pathways,86.Apoptosis_Nematode&_Vert,	h_bcellsurvivalPathway:B Cell Survival Pathway,h_caspasePathway:Caspase Cascade in Apoptosis,h_chemicalPathway:Apoptotic Signaling in Response to DNA Damage,h_d4gdiPathway:D4-GDI Signaling Pathway,h_deathPathway:Induction of apoptosis through DR3 and DR4/5 Death Receptors ,h_DNAfragmentPathway:Apoptotic DNA fragmentation and tissue homeostasis,h_fasPathway:FAS signaling pathway ( CD95 ),h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_hsp27Pathway:Stress Induction of HSP Regulation,h_mitochondriaPathway:Role of Mitochondria in Apoptotic Signaling,h_tnfr1Pathway:TNFR1 Signaling Pathway,h_tsp1Pathway:TSP-1 Induced Apoptosis in Microvascular Endothelial Cell ,		GO:0001554~luteolysis,GO:0001666~response to hypoxia,GO:0001782~B cell homeostasis,GO:0006309~apoptotic DNA fragmentation,GO:0006508~proteolysis,GO:0006915~apoptotic process,GO:0006974~cellular response to DNA damage stimulus,GO:0007413~axonal fasciculation,GO:0007507~heart development,GO:0007605~sensory perception of sound,GO:0007611~learning or memory,GO:0008627~intrinsic apoptotic signaling pathway in response to osmotic stress,GO:0009410~response to xenobiotic stimulus,GO:0009411~response to UV,GO:0009749~response to glucose,GO:0010165~response to X-ray,GO:0016241~regulation of macroautophagy,GO:0016485~protein processing,GO:0019221~cytokine-mediated signaling pathway,GO:0021766~hippocampus development,GO:0030182~neuron differentiation,GO:0030216~keratinocyte differentiation,GO:0030218~erythrocyte differentiation,GO:0030220~platelet formation,GO:0030889~negative regulation of B cell proliferation,GO:0031647~regulation of protein stability,GO:0032025~response to cobalt ion,GO:0032355~response to estradiol,GO:0032496~response to lipopolysaccharide,GO:0034349~glial cell apoptotic process,GO:0034612~response to tumor necrosis factor,GO:0035094~response to nicotine,GO:0035329~hippo signaling,GO:0042060~wound healing,GO:0042493~response to drug,GO:0042542~response to hydrogen peroxide,GO:0043029~T cell homeostasis,GO:0043065~positive regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043200~response to amino acid,GO:0043525~positive regulation of neuron apoptotic process,GO:0045165~cell fate commitment,GO:0045736~negative regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0046007~negative regulation of activated T cell proliferation,GO:0046677~response to antibiotic,GO:0048011~neurotrophin TRK receptor signaling pathway,GO:0051146~striated muscle cell differentiation,GO:0051384~response to glucocorticoid,GO:0051402~neuron apoptotic process,GO:0061713~anterior neural tube closure,GO:0071887~leukocyte apoptotic process,GO:0072734~cellular response to staurosporine,GO:0097190~apoptotic signaling pathway,GO:0097192~extrinsic apoptotic signaling pathway in absence of ligand,GO:0097194~execution phase of apoptosis,GO:1902004~positive regulation of beta-amyloid formation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0031264~death-inducing signaling complex,GO:0043025~neuronal cell body,GO:0045121~membrane raft,	GO:0002020~protease binding,GO:0004190~aspartic-type endopeptidase activity,GO:0004197~cysteine-type endopeptidase activity,GO:0004861~cyclin-dependent protein serine/threonine kinase inhibitor activity,GO:0005123~death receptor binding,GO:0005515~protein binding,GO:0008233~peptidase activity,GO:0016005~phospholipase A2 activator activity,GO:0044877~macromolecular complex binding,GO:0097153~cysteine-type endopeptidase activity involved in apoptotic process,GO:0097199~cysteine-type endopeptidase activity involved in apoptotic signaling pathway,GO:0097200~cysteine-type endopeptidase activity involved in execution phase of apoptosis,	IPR001309:Peptidase C14, ICE, catalytic subunit p20,IPR002138:Peptidase C14, caspase non-catalytic subunit p10,IPR002398:Peptidase C14, caspase precursor p45,IPR015471:Caspase-7,IPR015917:Peptidase C14, caspase precursor p45, core,IPR016129:Peptidase C14, ICE, catalytic subunit p20, active site,	hsa01524:Platinum drug resistance,hsa04010:MAPK signaling pathway,hsa04115:p53 signaling pathway,hsa04210:Apoptosis,hsa04215:Apoptosis - multiple species,hsa04650:Natural killer cell mediated cytotoxicity,hsa04657:IL-17 signaling pathway,hsa04668:TNF signaling pathway,hsa04726:Serotonergic synapse,hsa04932:Non-alcoholic fatty liver disease,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04936:Alcoholic liver disease,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05130:Pathogenic Escherichia coli infection,hsa05132:Salmonella infection,hsa05133:Pertussis,hsa05134:Legionellosis,hsa05145:Toxoplasmosis,hsa05146:Amoebiasis,hsa05152:Tuberculosis,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,hsa05210:Colorectal cancer,hsa05222:Small cell lung cancer,hsa05416:Viral myocarditis,hsa05417:Lipid and atherosclerosis,			SM00115:CASc,	KW-0053~Apoptosis,	KW-0963~Cytoplasm,				KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0702~S-nitrosylation,KW-0865~Zymogen,	DOMAIN:CASPASE_P20,REGION:Disordered,
CASP7	caspase 7(CASP7)	Homo sapiens	46.P13K_PTEN,72.IAP_interaction_with_cell_death_pathways,	h_bcellsurvivalPathway:B Cell Survival Pathway,h_caspasePathway:Caspase Cascade in Apoptosis,h_chemicalPathway:Apoptotic Signaling in Response to DNA Damage,h_deathPathway:Induction of apoptosis through DR3 and DR4/5 Death Receptors ,h_DNAfragmentPathway:Apoptotic DNA fragmentation and tissue homeostasis,h_fasPathway:FAS signaling pathway ( CD95 ),h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_mitochondriaPathway:Role of Mitochondria in Apoptotic Signaling,		GO:0006508~proteolysis,GO:0006915~apoptotic process,GO:0007507~heart development,GO:0007568~aging,GO:0009411~response to UV,GO:0016485~protein processing,GO:0051146~striated muscle cell differentiation,GO:0051402~neuron apoptotic process,GO:0071887~leukocyte apoptotic process,GO:0072734~cellular response to staurosporine,GO:0097194~execution phase of apoptosis,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0043231~intracellular membrane-bounded organelle,	GO:0004190~aspartic-type endopeptidase activity,GO:0004197~cysteine-type endopeptidase activity,GO:0005515~protein binding,GO:0008233~peptidase activity,GO:0008234~cysteine-type peptidase activity,GO:0097153~cysteine-type endopeptidase activity involved in apoptotic process,GO:0097200~cysteine-type endopeptidase activity involved in execution phase of apoptosis,	IPR001309:Peptidase C14, ICE, catalytic subunit p20,IPR002138:Peptidase C14, caspase non-catalytic subunit p10,IPR002398:Peptidase C14, caspase precursor p45,IPR015471:Caspase-7,IPR015917:Peptidase C14, caspase precursor p45, core,IPR016129:Peptidase C14, ICE, catalytic subunit p20, active site,	hsa04210:Apoptosis,hsa04215:Apoptosis - multiple species,hsa04668:TNF signaling pathway,hsa04932:Non-alcoholic fatty liver disease,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05130:Pathogenic Escherichia coli infection,hsa05132:Salmonella infection,hsa05133:Pertussis,hsa05134:Legionellosis,hsa05200:Pathways in cancer,hsa05417:Lipid and atherosclerosis,			SM00115:CASc,	KW-0053~Apoptosis,	KW-0963~Cytoplasm,				KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0865~Zymogen,	COMPBIAS:Acidic residues,DOMAIN:CASPASE_P10,DOMAIN:CASPASE_P20,MUTAGEN:C->A: No apoptotic activity. Loss of autocatalytic cleavage.,PROPEP:N-terminally processed,REGION:Disordered,
CAT	catalase(CAT)	Homo sapiens		h_longevityPathway:The IGF-1 Receptor and Longevity,	Inorganic ion transport and metabolism,	GO:0000302~response to reactive oxygen species,GO:0001649~osteoblast differentiation,GO:0001657~ureteric bud development,GO:0001666~response to hypoxia,GO:0006641~triglyceride metabolic process,GO:0007568~aging,GO:0008104~protein localization,GO:0008203~cholesterol metabolic process,GO:0009060~aerobic respiration,GO:0009410~response to xenobiotic stimulus,GO:0009411~response to UV,GO:0009642~response to light intensity,GO:0009650~UV protection,GO:0010193~response to ozone,GO:0010288~response to lead ion,GO:0014068~positive regulation of phosphatidylinositol 3-kinase signaling,GO:0014823~response to activity,GO:0014854~response to inactivity,GO:0020027~hemoglobin metabolic process,GO:0032088~negative regulation of NF-kappaB transcription factor activity,GO:0032355~response to estradiol,GO:0032868~response to insulin,GO:0033189~response to vitamin A,GO:0033197~response to vitamin E,GO:0033591~response to L-ascorbic acid,GO:0034599~cellular response to oxidative stress,GO:0042493~response to drug,GO:0042542~response to hydrogen peroxide,GO:0042744~hydrogen peroxide catabolic process,GO:0043066~negative regulation of apoptotic process,GO:0043312~neutrophil degranulation,GO:0045471~response to ethanol,GO:0046686~response to cadmium ion,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051781~positive regulation of cell division,GO:0055093~response to hyperoxia,GO:0061692~cellular detoxification of hydrogen peroxide,GO:0070542~response to fatty acid,GO:0071363~cellular response to growth factor stimulus,GO:0080184~response to phenylpropanoid,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005758~mitochondrial intermembrane space,GO:0005764~lysosome,GO:0005777~peroxisome,GO:0005778~peroxisomal membrane,GO:0005782~peroxisomal matrix,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0032991~macromolecular complex,GO:0034774~secretory granule lumen,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,GO:1904813~ficolin-1-rich granule lumen,	GO:0000268~peroxisome targeting sequence binding,GO:0004046~aminoacylase activity,GO:0004096~catalase activity,GO:0016209~antioxidant activity,GO:0016684~oxidoreductase activity, acting on peroxide as acceptor,GO:0019899~enzyme binding,GO:0020037~heme binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0046872~metal ion binding,GO:0050661~NADP binding,	IPR002226:Catalase haem-binding site,IPR010582:Catalase immune-responsive domain,IPR011614:Catalase core domain,IPR018028:Catalase, mono-functional, haem-containing,IPR020835:Catalase-like domain,IPR024708:Catalase active site,IPR024711:Catalase, mono-functional, haem-containing, clades 1 and 3,	hsa00380:Tryptophan metabolism,hsa00630:Glyoxylate and dicarboxylate metabolism,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa04068:FoxO signaling pathway,hsa04146:Peroxisome,hsa04211:Longevity regulating pathway,hsa04213:Longevity regulating pathway - multiple species,hsa05014:Amyotrophic lateral sclerosis,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05208:Chemical carcinogenesis - reactive oxygen species,	614097~Acatalasemia,	PIRSF038928:monofunctional catalase, clades 1 and 3 type,	SM01060:SM01060,	KW-0376~Hydrogen peroxide,	KW-0576~Peroxisome,			KW-0349~Heme,KW-0408~Iron,KW-0479~Metal-binding,KW-0521~NADP,	KW-0497~Mitogen,KW-0560~Oxidoreductase,KW-0575~Peroxidase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Catalase,METAL:Iron (heme axial ligand),REGION:Disordered,
CTNNAL1	catenin alpha like 1(CTNNAL1)	Homo sapiens				GO:0007155~cell adhesion,GO:0007266~Rho protein signal transduction,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,	GO:0005515~protein binding,GO:0045296~cadherin binding,GO:0051015~actin filament binding,	IPR001033:Alpha-catenin,IPR006077:Vinculin/alpha-catenin,						KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0175~Coiled coil,			KW-0597~Phosphoprotein,
CTNND1	catenin delta 1(CTNND1)	Homo sapiens				GO:0007043~cell-cell junction assembly,GO:0007420~brain development,GO:0016055~Wnt signaling pathway,GO:0034332~adherens junction organization,GO:0035635~entry of bacterium into host cell,GO:0044331~cell-cell adhesion mediated by cadherin,GO:0050821~protein stabilization,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:0098609~cell-cell adhesion,GO:0099072~regulation of postsynaptic specialization membrane neurotransmitter receptor levels,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0005912~adherens junction,GO:0005915~zonula adherens,GO:0016342~catenin complex,GO:0030027~lamellipodium,GO:0030054~cell junction,GO:0030426~growth cone,GO:0030496~midbody,GO:0043197~dendritic spine,GO:0070062~extracellular exosome,GO:0098685~Schaffer collateral - CA1 synapse,GO:0098686~hippocampal mossy fiber to CA3 synapse,GO:0098831~presynaptic active zone cytoplasmic component,GO:0098978~glutamatergic synapse,GO:0099092~postsynaptic density, intracellular component,	GO:0005102~receptor binding,GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0045296~cadherin binding,	IPR000225:Armadillo,IPR011989:Armadillo-like helical,IPR016024:Armadillo-type fold,	hsa04015:Rap1 signaling pathway,hsa04520:Adherens junction,hsa04670:Leukocyte transendothelial migration,	617681~Blepharocheilodontic syndrome 2,		SM00185:ARM,	KW-0130~Cell adhesion,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0879~Wnt signaling pathway,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-1003~Cell membrane,	KW-0038~Ectodermal dysplasia,KW-0225~Disease variant,	KW-0175~Coiled coil,KW-0677~Repeat,			KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),MOTIF:Nuclear localization signal (NLS),MUTAGEN:K->M: Complete loss of cadherin interaction.,MUTAGEN:K->M: Severely disrupts cadherin interaction.,MUTAGEN:N->A: Complete loss of cadherin interaction.,MUTAGEN:W->A: Severely disrupts cadherin interaction.,REGION:Disordered,REGION:Necessary and sufficient for interaction with CCDC85B,REPEAT:ARM,REPEAT:ARM 1,REPEAT:ARM 10,REPEAT:ARM 2,REPEAT:ARM 3,REPEAT:ARM 4,REPEAT:ARM 5,REPEAT:ARM 6,REPEAT:ARM 7,REPEAT:ARM 8,REPEAT:ARM 9,SITE:Essential for interaction with cadherins,
CTSD	cathepsin D(CTSD)	Homo sapiens		h_mta3Pathway:Downregulated of MTA-3 in ER-negative Breast Tumors,		GO:0006508~proteolysis,GO:0019886~antigen processing and presentation of exogenous peptide antigen via MHC class II,GO:0030574~collagen catabolic process,GO:0042159~lipoprotein catabolic process,GO:0043065~positive regulation of apoptotic process,GO:0043280~positive regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0043312~neutrophil degranulation,GO:0070201~regulation of establishment of protein localization,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0010008~endosome membrane,GO:0035580~specific granule lumen,GO:0042470~melanosome,GO:0043202~lysosomal lumen,GO:0045121~membrane raft,GO:0070062~extracellular exosome,GO:1904724~tertiary granule lumen,GO:1904813~ficolin-1-rich granule lumen,	GO:0004190~aspartic-type endopeptidase activity,GO:0004197~cysteine-type endopeptidase activity,GO:0005515~protein binding,GO:0008233~peptidase activity,GO:0070001~aspartic-type peptidase activity,	IPR001461:Peptidase A1,IPR001969:Peptidase aspartic, active site,IPR012848:Propeptide, peptidase A1,IPR021109:Aspartic peptidase,	hsa04071:Sphingolipid signaling pathway,hsa04140:Autophagy - animal,hsa04142:Lysosome,hsa04210:Apoptosis,hsa04915:Estrogen signaling pathway,hsa05152:Tuberculosis,hsa05415:Diabetic cardiomyopathy,	610127~Ceroid lipofuscinosis, neuronal, 10,				KW-0458~Lysosome,KW-0964~Secreted,	KW-0026~Alzheimer disease,KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0525~Neuronal ceroid lipofuscinosis,	KW-0732~Signal,		KW-0064~Aspartyl protease,KW-0378~Hydrolase,KW-0645~Protease,	KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GalNAc...) threonine,COMPBIAS:Polar residues,DOMAIN:Peptidase A1,PROPEP:Activation peptide,REGION:Disordered,
CDC20	cell division cycle 20(CDC20)	Homo sapiens	84.Ubiquitination_Pathways_Cell_Cycle,			GO:0006511~ubiquitin-dependent protein catabolic process,GO:0007052~mitotic spindle organization,GO:0007064~mitotic sister chromatid cohesion,GO:0007094~mitotic spindle assembly checkpoint,GO:0007096~regulation of exit from mitosis,GO:0007399~nervous system development,GO:0008284~positive regulation of cell proliferation,GO:0016567~protein ubiquitination,GO:0016579~protein deubiquitination,GO:0030154~cell differentiation,GO:0031145~anaphase-promoting complex-dependent catabolic process,GO:0031915~positive regulation of synaptic plasticity,GO:0040020~regulation of meiotic nuclear division,GO:0050773~regulation of dendrite development,GO:0051301~cell division,GO:0051444~negative regulation of ubiquitin-protein transferase activity,GO:0090129~positive regulation of synapse maturation,GO:0090307~mitotic spindle assembly,GO:1901990~regulation of mitotic cell cycle phase transition,GO:1904668~positive regulation of ubiquitin protein ligase activity,GO:1905786~positive regulation of anaphase-promoting complex-dependent catabolic process,	GO:0000922~spindle pole,GO:0005654~nucleoplasm,GO:0005680~anaphase-promoting complex,GO:0005813~centrosome,GO:0005819~spindle,GO:0005829~cytosol,GO:0032991~macromolecular complex,GO:0033597~mitotic checkpoint complex,GO:0048471~perinuclear region of cytoplasm,	GO:0005515~protein binding,GO:0008022~protein C-terminus binding,GO:0010997~anaphase-promoting complex binding,GO:0019899~enzyme binding,GO:0042826~histone deacetylase binding,GO:1990757~ubiquitin ligase activator activity,	IPR001680:WD40 repeat,IPR015943:WD40/YVTN repeat-like-containing domain,IPR017986:WD40-repeat-containing domain,IPR019775:WD40 repeat, conserved site,IPR024977:Anaphase-promoting complex subunit 4, WD40 domain,	hsa04110:Cell cycle,hsa04114:Oocyte meiosis,hsa04120:Ubiquitin mediated proteolysis,hsa05166:Human T-cell leukemia virus 1 infection,hsa05203:Viral carcinogenesis,			SM00320:WD40,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0221~Differentiation,KW-0498~Mitosis,KW-0524~Neurogenesis,KW-0833~Ubl conjugation pathway,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0853~WD repeat,			KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),MUTAGEN:K->R: Does not affect its ability to bind the APC/C complex; when associated with R-485.,MUTAGEN:K->R: Does not affect its ability to bind the APC/C complex; when associated with R-490.,MUTAGEN:R->A: Loss of interaction with MAD2L1.,MUTAGEN:S->A: Loss of BUB1-mediated phosphorylation and inhibition and partially defective spindle-assembly checkpoint; when associated with A-41; A-72; A-153; A-157 and A-161.,MUTAGEN:S->A: Loss of BUB1-mediated phosphorylation and inhibition and partially defective spindle-assembly checkpoint; when associated with A-41; A-92; A-153; A-157 and A-161.,MUTAGEN:S->A: Loss of BUB1-mediated phosphorylation and inhibition and partially defective spindle-assembly checkpoint; when associated with A-42; A-72; A-92; A-157 and A-161.,MUTAGEN:S->A: Loss of BUB1-mediated phosphorylation and inhibition and partially defective spindle-assembly checkpoint; when associated with A-72; A-92; A-153; A-157 and A-161.,MUTAGEN:T->A: Loss of BUB1-mediated phosphorylation and inhibition and partially defective spindle-assembly checkpoint; when associated with A-42; A-72; A-92; A-153 and A-161.,REGION:Disordered,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
CDC25A	cell division cycle 25A(CDC25A)	Homo sapiens	62.G1-phase_progression_by_Myc,	H_cdc25Pathway:cdc25 and chk1 Regulatory Pathway in response to DNA damage,h_cellcyclePathway:Cyclins and Cell Cycle Regulation,h_g1Pathway:Cell Cycle: G1/S Check Point ,h_g2Pathway:Cell Cycle: G2/M Checkpoint,h_ptc1Pathway:Sonic Hedgehog (SHH) Receptor Ptc1 Regulates cell cycle,h_rbPathway:RB Tumor Suppressor/Checkpoint Signaling in response to DNA damage,h_srcRPTPPathway:Activation of Src by Protein-tyrosine phosphatase alpha,		GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0000082~G1/S transition of mitotic cell cycle,GO:0000086~G2/M transition of mitotic cell cycle,GO:0007049~cell cycle,GO:0008283~cell proliferation,GO:0009314~response to radiation,GO:0010971~positive regulation of G2/M transition of mitotic cell cycle,GO:0016579~protein deubiquitination,GO:0034644~cellular response to UV,GO:0035335~peptidyl-tyrosine dephosphorylation,GO:0051301~cell division,GO:0051726~regulation of cell cycle,GO:1902751~positive regulation of cell cycle G2/M phase transition,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0004721~phosphoprotein phosphatase activity,GO:0004725~protein tyrosine phosphatase activity,GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0051087~chaperone binding,	IPR000751:M-phase inducer phosphatase,IPR001763:Rhodanese-like domain,	hsa04110:Cell cycle,hsa04218:Cellular senescence,hsa04914:Progesterone-mediated oocyte maturation,hsa05206:MicroRNAs in cancer,hsa05207:Chemical carcinogenesis - receptor activation,			SM00450:RHOD,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,					KW-0378~Hydrolase,KW-0904~Protein phosphatase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Rhodanese,MOTIF:KEN box,MOTIF:Phosphodegron,MUTAGEN:C->S: Abolishes phosphatase activity.,MUTAGEN:D->A: Abrogates interactions with BTRC and FBXW11 and prevents ubiquitination.,MUTAGEN:K->L: Abrogates binding to CCNB1; when associated with L-520.,MUTAGEN:KEN->AAA: Prevents ubiquitination and subsequent degradation by the APC/C ubiquitin ligase complex.,MUTAGEN:R->L: Abrogates binding to CCNB1; when associated with L-514.,MUTAGEN:S->A: Abolishes ubiquitination and impairs CHEK1-dependent degradation following checkpoint activation.,MUTAGEN:S->A: Abrogates interactions with BTRC and FBXW11 and prevents ubiquitination.,MUTAGEN:S->A: Abrogates phosphorylation by CHEK2 and infrared-induced degradation. Increases basal stability and impairs CHEK1-dependent degradation following checkpoint activation; when associated with A-178; A-279 and A-293.,MUTAGEN:S->A: Increased stability following IR treatment.,MUTAGEN:S->A: Increases basal stability and impairs CHEK1-dependent degradation following checkpoint activation; when associated with A-124; A-178 and A-279.,MUTAGEN:S->A: Increases basal stability and impairs CHEK1-dependent degradation following checkpoint activation; when associated with A-124; A-178 and A-293.,MUTAGEN:S->A: Increases basal stability and impairs CHEK1-dependent degradation following checkpoint activation; when associated with A-124; A-279 and A-293. Abrogates 14-3-3 protein binding.,MUTAGEN:S->D: Mimicks phosphorylation state, leading to promote degradation following IR treatment.,MUTAGEN:T->A: Abrogates 14-3-3 protein binding; increases binding to cyclin B1.,REGION:Disordered,
CDC25B	cell division cycle 25B(CDC25B)	Homo sapiens		H_cdc25Pathway:cdc25 and chk1 Regulatory Pathway in response to DNA damage,h_g2Pathway:Cell Cycle: G2/M Checkpoint,h_ptc1Pathway:Sonic Hedgehog (SHH) Receptor Ptc1 Regulates cell cycle,h_rbPathway:RB Tumor Suppressor/Checkpoint Signaling in response to DNA damage,h_srcRPTPPathway:Activation of Src by Protein-tyrosine phosphatase alpha,		GO:0000086~G2/M transition of mitotic cell cycle,GO:0000278~mitotic cell cycle,GO:0001556~oocyte maturation,GO:0006468~protein phosphorylation,GO:0007049~cell cycle,GO:0007144~female meiosis I,GO:0008284~positive regulation of cell proliferation,GO:0010971~positive regulation of G2/M transition of mitotic cell cycle,GO:0032467~positive regulation of cytokinesis,GO:0035335~peptidyl-tyrosine dephosphorylation,GO:0045860~positive regulation of protein kinase activity,GO:0045931~positive regulation of mitotic cell cycle,GO:0051301~cell division,GO:1902751~positive regulation of cell cycle G2/M phase transition,	GO:0000922~spindle pole,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,	GO:0004721~phosphoprotein phosphatase activity,GO:0004725~protein tyrosine phosphatase activity,GO:0005515~protein binding,GO:0019901~protein kinase binding,	IPR000751:M-phase inducer phosphatase,IPR001763:Rhodanese-like domain,	hsa04010:MAPK signaling pathway,hsa04110:Cell cycle,hsa04914:Progesterone-mediated oocyte maturation,hsa05206:MicroRNAs in cancer,			SM00450:RHOD,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,				KW-0378~Hydrolase,KW-0904~Protein phosphatase,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Rhodanese,REGION:Disordered,
CDC42	cell division cycle 42(CDC42)	Homo sapiens	101.Gprot_coupled_Rec_MAP_Kinase,82.TCR_and_Cap_or_SMAC,	h_agrPathway:Agrin in Postsynaptic Differentiation,h_cdc42racPathway:Role of PI3K subunit p85 in regulation of Actin Organization and Cell Migration,h_malPathway:Role of MAL in Rho-Mediated Activation of SRF,h_p38mapkPathway:p38 MAPK Signaling Pathway ,h_rasPathway:Ras Signaling Pathway,h_salmonellaPathway:How does salmonella hijack a cell,		GO:0002040~sprouting angiogenesis,GO:0003161~cardiac conduction system development,GO:0003253~cardiac neural crest cell migration involved in outflow tract morphogenesis,GO:0006468~protein phosphorylation,GO:0006897~endocytosis,GO:0006911~phagocytosis, engulfment,GO:0007015~actin filament organization,GO:0007030~Golgi organization,GO:0007088~regulation of mitotic nuclear division,GO:0007097~nuclear migration,GO:0007163~establishment or maintenance of cell polarity,GO:0007229~integrin-mediated signaling pathway,GO:0007264~small GTPase mediated signal transduction,GO:0007596~blood coagulation,GO:0010591~regulation of lamellipodium assembly,GO:0010592~positive regulation of lamellipodium assembly,GO:0016477~cell migration,GO:0016567~protein ubiquitination,GO:0021762~substantia nigra development,GO:0030031~cell projection assembly,GO:0030036~actin cytoskeleton organization,GO:0030225~macrophage differentiation,GO:0030307~positive regulation of cell growth,GO:0031274~positive regulation of pseudopodium assembly,GO:0031295~T cell costimulation,GO:0031333~negative regulation of protein complex assembly,GO:0032467~positive regulation of cytokinesis,GO:0032488~Cdc42 protein signal transduction,GO:0034329~cell junction assembly,GO:0034332~adherens junction organization,GO:0034613~cellular protein localization,GO:0035050~embryonic heart tube development,GO:0035088~establishment or maintenance of apical/basal cell polarity,GO:0035722~interleukin-12-mediated signaling pathway,GO:0036336~dendritic cell migration,GO:0038096~Fc-gamma receptor signaling pathway involved in phagocytosis,GO:0038189~neuropilin signaling pathway,GO:0039694~viral RNA genome replication,GO:0042059~negative regulation of epidermal growth factor receptor signaling pathway,GO:0043393~regulation of protein binding,GO:0043525~positive regulation of neuron apoptotic process,GO:0043552~positive regulation of phosphatidylinositol 3-kinase activity,GO:0045198~establishment of epithelial cell apical/basal polarity,GO:0045740~positive regulation of DNA replication,GO:0046330~positive regulation of JNK cascade,GO:0046847~filopodium assembly,GO:0048010~vascular endothelial growth factor receptor signaling pathway,GO:0048013~ephrin receptor signaling pathway,GO:0048549~positive regulation of pinocytosis,GO:0048664~neuron fate determination,GO:0051056~regulation of small GTPase mediated signal transduction,GO:0051149~positive regulation of muscle cell differentiation,GO:0051301~cell division,GO:0051489~regulation of filopodium assembly,GO:0051491~positive regulation of filopodium assembly,GO:0051492~regulation of stress fiber assembly,GO:0051496~positive regulation of stress fiber assembly,GO:0051683~establishment of Golgi localization,GO:0051835~positive regulation of synapse structural plasticity,GO:0051988~regulation of attachment of spindle microtubules to kinetochore,GO:0060047~heart contraction,GO:0060071~Wnt signaling pathway, planar cell polarity pathway,GO:0060501~positive regulation of epithelial cell proliferation involved in lung morphogenesis,GO:0060661~submandibular salivary gland formation,GO:0060997~dendritic spine morphogenesis,GO:0071346~cellular response to interferon-gamma,GO:0072384~organelle transport along microtubule,GO:0086101~endothelin receptor signaling pathway involved in heart process,GO:0090135~actin filament branching,GO:0090316~positive regulation of intracellular protein transport,GO:0099563~modification of synaptic structure,GO:1900026~positive regulation of substrate adhesion-dependent cell spreading,GO:2000251~positive regulation of actin cytoskeleton reorganization,	GO:0000139~Golgi membrane,GO:0000322~storage vacuole,GO:0005737~cytoplasm,GO:0005789~endoplasmic reticulum membrane,GO:0005813~centrosome,GO:0005815~microtubule organizing center,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0017119~Golgi transport complex,GO:0030141~secretory granule,GO:0030175~filopodium,GO:0030496~midbody,GO:0031256~leading edge membrane,GO:0032991~macromolecular complex,GO:0036464~cytoplasmic ribonucleoprotein granule,GO:0042995~cell projection,GO:0043005~neuron projection,GO:0043025~neuronal cell body,GO:0043197~dendritic spine,GO:0045177~apical part of cell,GO:0045335~phagocytic vesicle,GO:0051233~spindle midzone,GO:0070062~extracellular exosome,GO:0072686~mitotic spindle,GO:0098685~Schaffer collateral - CA1 synapse,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019901~protein kinase binding,GO:0030742~GTP-dependent protein binding,GO:0031435~mitogen-activated protein kinase kinase kinase binding,GO:0031996~thioesterase binding,GO:0032427~GBD domain binding,GO:0034191~apolipoprotein A-I receptor binding,GO:0042802~identical protein binding,GO:0061630~ubiquitin protein ligase activity,	IPR001806:Small GTPase superfamily,IPR003578:Small GTPase superfamily, Rho type,IPR005225:Small GTP-binding protein domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04062:Chemokine signaling pathway,hsa04144:Endocytosis,hsa04360:Axon guidance,hsa04370:VEGF signaling pathway,hsa04510:Focal adhesion,hsa04520:Adherens junction,hsa04530:Tight junction,hsa04660:T cell receptor signaling pathway,hsa04666:Fc gamma R-mediated phagocytosis,hsa04670:Leukocyte transendothelial migration,hsa04722:Neurotrophin signaling pathway,hsa04810:Regulation of actin cytoskeleton,hsa04912:GnRH signaling pathway,hsa04932:Non-alcoholic fatty liver disease,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa05100:Bacterial invasion of epithelial cells,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05135:Yersinia infection,hsa05165:Human papillomavirus infection,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05205:Proteoglycans in cancer,hsa05211:Renal cell carcinoma,hsa05212:Pancreatic cancer,hsa05417:Lipid and atherosclerosis,	616737~Takenouchi-Kosaki syndrome,			KW-0131~Cell cycle,KW-0132~Cell division,KW-0221~Differentiation,KW-0524~Neurogenesis,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0991~Mental retardation,		KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0636~Prenylation,	CARBOHYD:(Microbial infection) O-alpha-linked (GlcNAc) threonine; by C.novyi toxin TcdA; alternate,CARBOHYD:(Microbial infection) O-linked (Glc) threonine; by C.difficile toxins TcdA and TcdB; alternate,CARBOHYD:(Microbial infection) O-linked (GlcNAc) tyrosine; by Photorhabdus PAU_02230; alternate,LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,MUTAGEN:G->V: Constitutively active. Interacts with PARD6 proteins. Does not inhibit filopodia formation. No effect on NR3C2 transcriptional activity.,MUTAGEN:Q->L: Constitutively active. Interacts with PARD6 proteins.,MUTAGEN:T->N: Constitutively inactive. Does not interact with PARD6 proteins. Inhibits filopodia formation. No effect on NR3C2 transcriptional activity.,MUTAGEN:Y->F: Abolishes AMPylation by Haemophilus IbpA.,NP_BIND:GTP,PROPEP:Removed in mature form,
CDCA4	cell division cycle associated 4(CDCA4)	Homo sapiens				GO:0048096~chromatin-mediated maintenance of transcription,GO:0051301~cell division,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,	GO:0005515~protein binding,	IPR009263:SERTA,					KW-0131~Cell cycle,KW-0132~Cell division,	KW-0539~Nucleus,						DOMAIN:SERTA,
CGRRF1	cell growth regulator with ring finger domain 1(CGRRF1)	Homo sapiens				GO:0007049~cell cycle,GO:0007050~cell cycle arrest,GO:0008285~negative regulation of cell proliferation,GO:0030308~negative regulation of cell growth,	GO:0005654~nucleoplasm,GO:0005783~endoplasmic reticulum,GO:0016021~integral component of membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR001841:Zinc finger, RING-type,IPR013083:Zinc finger, RING/FYVE/PHD-type,				SM00184:RING,	KW-0131~Cell cycle,KW-0338~Growth arrest,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,		KW-0812~Transmembrane,KW-0863~Zinc-finger,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,			TRANSMEM:Helical,ZN_FING:RING-type,
CREG1	cellular repressor of E1A stimulated genes 1(CREG1)	Homo sapiens				GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007275~multicellular organism development,GO:0040008~regulation of growth,GO:0043312~neutrophil degranulation,GO:0045892~negative regulation of transcription, DNA-templated,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005667~transcription factor complex,GO:0035578~azurophil granule lumen,GO:0070062~extracellular exosome,	GO:0003714~transcription corepressor activity,GO:0008134~transcription factor binding,	IPR012349:FMN-binding split barrel,IPR014631:Cellular repressor of E1A-stimulated genes (CREG),			PIRSF036911:cellular repressor of E1A-stimulated protein,		KW-0341~Growth regulation,	KW-0964~Secreted,		KW-0732~Signal,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,
CETN3	centrin 3(CETN3)	Homo sapiens			Signal transduction mechanisms / Cytoskeleton / Cell division and chromosome partitioning / General function prediction only,	GO:0007098~centrosome cycle,GO:0015031~protein transport,GO:0051028~mRNA transport,GO:0051301~cell division,	GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005814~centriole,GO:0005815~microtubule organizing center,GO:0032391~photoreceptor connecting cilium,GO:0036064~ciliary basal body,GO:0044615~nuclear pore nuclear basket,GO:0070390~transcription export complex 2,	GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0031683~G-protein beta/gamma-subunit complex binding,	IPR002048:EF-hand domain,IPR011992:EF-hand-like domain,IPR018247:EF-Hand 1, calcium-binding site,				SM00054:EFh,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,KW-0509~mRNA transport,KW-0653~Protein transport,KW-0811~Translocation,KW-0813~Transport,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0906~Nuclear pore complex,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0597~Phosphoprotein,	CA_BIND:1,CA_BIND:2,COMPBIAS:Basic and acidic residues,DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:EF-hand 3,DOMAIN:EF-hand 4,REGION:Disordered,
CENPE	centromere protein E(CENPE)	Homo sapiens			Cell division and chromosome partitioning,	GO:0000278~mitotic cell cycle,GO:0006890~retrograde vesicle-mediated transport, Golgi to ER,GO:0007018~microtubule-based movement,GO:0007052~mitotic spindle organization,GO:0007059~chromosome segregation,GO:0007079~mitotic chromosome movement towards spindle pole,GO:0007080~mitotic metaphase plate congression,GO:0007275~multicellular organism development,GO:0019886~antigen processing and presentation of exogenous peptide antigen via MHC class II,GO:0030071~regulation of mitotic metaphase/anaphase transition,GO:0045860~positive regulation of protein kinase activity,GO:0051301~cell division,GO:0051310~metaphase plate congression,GO:0051315~attachment of mitotic spindle microtubules to kinetochore,GO:0051382~kinetochore assembly,GO:0099606~microtubule plus-end directed mitotic chromosome migration,GO:0099607~lateral attachment of mitotic spindle microtubules to kinetochore,	GO:0000775~chromosome, centromeric region,GO:0000776~kinetochore,GO:0000777~condensed chromosome kinetochore,GO:0000779~condensed chromosome, centromeric region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005828~kinetochore microtubule,GO:0005829~cytosol,GO:0005874~microtubule,GO:0015630~microtubule cytoskeleton,GO:0016020~membrane,GO:0030496~midbody,GO:0051233~spindle midzone,GO:1990023~mitotic spindle midzone,	GO:0003777~microtubule motor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008017~microtubule binding,GO:0008574~ATP-dependent microtubule motor activity, plus-end-directed,GO:0043515~kinetochore binding,GO:1990939~ATP-dependent microtubule motor activity,	IPR001752:Kinesin, motor domain,IPR019821:Kinesin, motor region, conserved site,IPR027417:P-loop containing nucleoside triphosphate hydrolase,		616051~Microcephaly 13, primary, autosomal recessive,		SM00129:KISc,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0137~Centromere,KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0963~Cytoplasm,KW-0995~Kinetochore,	KW-0225~Disease variant,KW-0905~Primary microcephaly,	KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0217~Developmental protein,KW-0505~Motor protein,KW-9996~Developmental protein,	KW-0449~Lipoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0636~Prenylation,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:Kinesin motor,LIPID:S-farnesyl cysteine,NP_BIND:ATP,PROPEP:Removed in mature form,REGION:Disordered,REGION:Globular autoinhibitory domain,REGION:Kinetochore-binding domain,
CEP57	centrosomal protein 57(CEP57)	Homo sapiens				GO:0000086~G2/M transition of mitotic cell cycle,GO:0007286~spermatid development,GO:0008543~fibroblast growth factor receptor signaling pathway,GO:0010389~regulation of G2/M transition of mitotic cell cycle,GO:0034453~microtubule anchoring,GO:0051260~protein homooligomerization,GO:0097711~ciliary basal body docking,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005874~microtubule,	GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0017134~fibroblast growth factor binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0043015~gamma-tubulin binding,	IPR010597:Centrosomal protein 57kDa,IPR024957:Cep57 centrosome microtubule-binding domain,IPR025913:Cep57 centrosome localisation domain,		614114~Mosaic variegated aneuploidy syndrome 2,				KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Cep57_CLD,DOMAIN:Cep57_MT_bd,REGION:Disordered,REGION:Mediates interaction with microtubules,REGION:centrosome localization domain (CLD),
CERK	ceramide kinase(CERK)	Homo sapiens				GO:0006665~sphingolipid metabolic process,GO:0006672~ceramide metabolic process,GO:0006687~glycosphingolipid metabolic process,GO:0016310~phosphorylation,GO:0046834~lipid phosphorylation,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,	GO:0000287~magnesium ion binding,GO:0001727~lipid kinase activity,GO:0001729~ceramide kinase activity,GO:0003951~NAD+ kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016301~kinase activity,	IPR001206:Diacylglycerol kinase, catalytic domain,IPR016064:ATP-NAD kinase-like domain,IPR017438:Inorganic polyphosphate/ATP-NAD kinase, domain 1,	hsa00600:Sphingolipid metabolism,hsa01100:Metabolic pathways,			SM00046:DAGKc,	KW-0443~Lipid metabolism,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,			KW-0067~ATP-binding,KW-0106~Calcium,KW-0460~Magnesium,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton donor/acceptor,BINDING:ATP,DOMAIN:DAGKc,MUTAGEN:L->A: 99% decrease in catalytic activity but no effect on substrate affinity.,MUTAGEN:L->I: 71% decrease in catalytic activity but no effect on substrate affinity.,MUTAGEN:S->A: 15% decrease in catalytic activity and decreased stability.,NP_BIND:ATP,REGION:Essential for enzyme activity,REGION:Required for binding to sulfatide and phosphoinositides,REGION:Substrate binding,
CHMP4A	charged multivesicular body protein 4A(CHMP4A)	Homo sapiens				GO:0001778~plasma membrane repair,GO:0006620~posttranslational protein targeting to membrane,GO:0006900~membrane budding,GO:0006914~autophagy,GO:0006997~nucleus organization,GO:0007034~vacuolar transport,GO:0007080~mitotic metaphase plate congression,GO:0007084~mitotic nuclear envelope reassembly,GO:0010324~membrane invagination,GO:0016197~endosomal transport,GO:0016236~macroautophagy,GO:0019058~viral life cycle,GO:0031468~nuclear envelope reassembly,GO:0032511~late endosome to vacuole transport via multivesicular body sorting pathway,GO:0036258~multivesicular body assembly,GO:0039702~viral budding via host ESCRT complex,GO:0043162~ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway,GO:0046761~viral budding from plasma membrane,GO:0051258~protein polymerization,GO:0060548~negative regulation of cell death,GO:0071985~multivesicular body sorting pathway,GO:0097320~plasma membrane tubulation,GO:0097352~autophagosome maturation,GO:1901215~negative regulation of neuron death,GO:1901673~regulation of mitotic spindle assembly,GO:1902774~late endosome to lysosome transport,GO:1902902~negative regulation of autophagosome assembly,	GO:0000421~autophagosome membrane,GO:0000776~kinetochore,GO:0000815~ESCRT III complex,GO:0005634~nucleus,GO:0005643~nuclear pore,GO:0005737~cytoplasm,GO:0005765~lysosomal membrane,GO:0005768~endosome,GO:0005771~multivesicular body,GO:0005828~kinetochore microtubule,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0009898~cytoplasmic side of plasma membrane,GO:0030117~membrane coat,GO:0030496~midbody,GO:0030659~cytoplasmic vesicle membrane,GO:0031902~late endosome membrane,GO:0032585~multivesicular body membrane,GO:1904930~amphisome membrane,	GO:0005515~protein binding,GO:0008289~lipid binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0051117~ATPase binding,	IPR005024:Snf7,	hsa04144:Endocytosis,hsa04217:Necroptosis,				KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,		KW-0175~Coiled coil,	KW-0446~Lipid-binding,		KW-0597~Phosphoprotein,	MUTAGEN:E->A: Reduces interaction with PDCD6IP.,MUTAGEN:L->A: Abolishes interaction with PDCD6IP.,MUTAGEN:Missing: Membrane association; releases autoinhibition.,MUTAGEN:W->A: Abolishes interaction with PDCD6IP.,REGION:Disordered,REGION:Interaction with phosphoinosides,REGION:Intramolecular interaction with C-terminus,REGION:Intramolecular interaction with N-terminus,
CHMP6	charged multivesicular body protein 6(CHMP6)	Homo sapiens				GO:0001778~plasma membrane repair,GO:0006900~membrane budding,GO:0006914~autophagy,GO:0006997~nucleus organization,GO:0007034~vacuolar transport,GO:0007080~mitotic metaphase plate congression,GO:0007084~mitotic nuclear envelope reassembly,GO:0007175~negative regulation of epidermal growth factor-activated receptor activity,GO:0015031~protein transport,GO:0016197~endosomal transport,GO:0016236~macroautophagy,GO:0019058~viral life cycle,GO:0031468~nuclear envelope reassembly,GO:0032511~late endosome to vacuole transport via multivesicular body sorting pathway,GO:0036258~multivesicular body assembly,GO:0039702~viral budding via host ESCRT complex,GO:0042176~regulation of protein catabolic process,GO:0043162~ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway,GO:0046761~viral budding from plasma membrane,GO:0060548~negative regulation of cell death,GO:0071985~multivesicular body sorting pathway,GO:0097352~autophagosome maturation,GO:1901673~regulation of mitotic spindle assembly,GO:1902774~late endosome to lysosome transport,GO:1904902~ESCRT III complex assembly,	GO:0000421~autophagosome membrane,GO:0000776~kinetochore,GO:0000815~ESCRT III complex,GO:0005643~nuclear pore,GO:0005765~lysosomal membrane,GO:0005771~multivesicular body,GO:0005828~kinetochore microtubule,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0030496~midbody,GO:0031902~late endosome membrane,GO:0032585~multivesicular body membrane,GO:0070062~extracellular exosome,GO:1904930~amphisome membrane,	GO:0005515~protein binding,GO:0044877~macromolecular complex binding,GO:0047485~protein N-terminus binding,	IPR005024:Snf7,	hsa04144:Endocytosis,hsa04217:Necroptosis,				KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,KW-0967~Endosome,		KW-0175~Coiled coil,			KW-0449~Lipoprotein,KW-0519~Myristate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	LIPID:N-myristoyl glycine,MOTIF:Type-2 MIT-interacting motif,MUTAGEN:G->A: Abolishes myristoylation.,MUTAGEN:L->D: Abolishes interaction with VPS4A.,MUTAGEN:L->D: Reduces interaction with VPS4A.,MUTAGEN:Missing: Membrane association; releases autoinhibition.,MUTAGEN:R->E: Does not affect the subcellular location.,MUTAGEN:V->D: Abolishes interaction with VPS4A.,REGION:Disordered,REGION:Interaction with VPS4A,
CHEK1	checkpoint kinase 1(CHEK1)	Homo sapiens		h_atmPathway:ATM Signaling Pathway,h_atrbrcaPathway:Role of BRCA1,  BRCA2 and ATR in Cancer Susceptibility,H_cdc25Pathway:cdc25 and chk1 Regulatory Pathway in response to DNA damage,h_g2Pathway:Cell Cycle: G2/M Checkpoint,h_plk3Pathway:Regulation of cell cycle progression by Plk3,h_rbPathway:RB Tumor Suppressor/Checkpoint Signaling in response to DNA damage,		GO:0000077~DNA damage checkpoint,GO:0000086~G2/M transition of mitotic cell cycle,GO:0001833~inner cell mass cell proliferation,GO:0006260~DNA replication,GO:0006281~DNA repair,GO:0006468~protein phosphorylation,GO:0006915~apoptotic process,GO:0006974~cellular response to DNA damage stimulus,GO:0006975~DNA damage induced protein phosphorylation,GO:0006997~nucleus organization,GO:0007095~mitotic G2 DNA damage checkpoint,GO:0010569~regulation of double-strand break repair via homologous recombination,GO:0010767~regulation of transcription from RNA polymerase II promoter in response to UV-induced DNA damage,GO:0018107~peptidyl-threonine phosphorylation,GO:0035407~histone H3-T11 phosphorylation,GO:0035556~intracellular signal transduction,GO:0042127~regulation of cell proliferation,GO:0044818~mitotic G2/M transition checkpoint,GO:0045787~positive regulation of cell cycle,GO:0045815~positive regulation of gene expression, epigenetic,GO:0045839~negative regulation of mitotic nuclear division,GO:0046602~regulation of mitotic centrosome separation,GO:0048096~chromatin-mediated maintenance of transcription,GO:0070317~negative regulation of G0 to G1 transition,GO:0071260~cellular response to mechanical stimulus,GO:0071313~cellular response to caffeine,GO:0072425~signal transduction involved in G2 DNA damage checkpoint,GO:0090399~replicative senescence,GO:1901796~regulation of signal transduction by p53 class mediator,GO:1902742~apoptotic process involved in development,GO:2000279~negative regulation of DNA biosynthetic process,GO:2000615~regulation of histone H3-K9 acetylation,	GO:0000781~chromosome, telomeric region,GO:0000785~chromatin,GO:0000794~condensed nuclear chromosome,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005657~replication fork,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0032991~macromolecular complex,GO:0043231~intracellular membrane-bounded organelle,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0019904~protein domain specific binding,GO:0035402~histone kinase activity (H3-T11 specific),	IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,	hsa04110:Cell cycle,hsa04115:p53 signaling pathway,hsa04218:Cellular senescence,hsa05166:Human T-cell leukemia virus 1 infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05203:Viral carcinogenesis,			SM00220:S_TKc,	KW-0131~Cell cycle,KW-0227~DNA damage,KW-0234~DNA repair,	KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Proton acceptor,BINDING:ATP,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:Protein kinase,MUTAGEN:D->A: Abolishes kinase activity.,MUTAGEN:F->A: Impairs nuclear export.,MUTAGEN:K->R: Abolishes kinase activity.,MUTAGEN:K->R: Enhances stability of the protein, probably by preventing ubiquitination at this site.,MUTAGEN:K->R: Strong reduction of chromatin-associated CHK1 ubiquitination.,MUTAGEN:M->A: Impairs nuclear export.,MUTAGEN:R->E: In 3RE mutant. Disrupts the folding and/or conformation, allowing increased accessibility to FBXO6 component of SCF-type E3 ubiquitin ligase complex; when associated with E-372 and E-376.,MUTAGEN:R->E: In 3RE mutant. Disrupts the folding and/or conformation, allowing increased accessibility to FBXO6 component of SCF-type E3 ubiquitin ligase complex; when associated with E-372 and E-379.,MUTAGEN:R->E: In 3RE mutant. Disrupts the folding and/or conformation, allowing increased accessibility to FBXO6 component of SCF-type E3 ubiquitin ligase complex; when associated with E-376 and E-379.,MUTAGEN:S->A: Abrogates interaction with RAD51; when associated with A-317. Reduces phosphorylation and impairs activation by hydroxyurea and ionizing radiation. Impairs interaction with YWHAZ which is required for nuclear retention after checkpoint activation.,MUTAGEN:S->A: Abrogates interaction with RAD51; when associated with A-345. Reduces phosphorylation and impairs activation by hydroxyurea and ionizing radiation. Abrogates nuclear retention upon checkpoint activation. Impairs interaction with FBXO6.,MUTAGEN:S->A: No effect on phosphorylation induced by hydroxyurea.,MUTAGEN:S->E: Enhances interaction with RAD51; when associated with E-317.,MUTAGEN:S->E: Enhances interaction with RAD51; when associated with E-345.,NP_BIND:ATP,REGION:Autoinhibitory region,REGION:Disordered,REGION:Interaction with CLSPN,
CHEK2	checkpoint kinase 2(CHEK2)	Homo sapiens		h_atmPathway:ATM Signaling Pathway,h_atrbrcaPathway:Role of BRCA1,  BRCA2 and ATR in Cancer Susceptibility,h_g2Pathway:Cell Cycle: G2/M Checkpoint,h_plk3Pathway:Regulation of cell cycle progression by Plk3,		GO:0000077~DNA damage checkpoint,GO:0000086~G2/M transition of mitotic cell cycle,GO:0001934~positive regulation of protein phosphorylation,GO:0006302~double-strand break repair,GO:0006355~regulation of transcription, DNA-templated,GO:0006468~protein phosphorylation,GO:0006974~cellular response to DNA damage stimulus,GO:0006975~DNA damage induced protein phosphorylation,GO:0006977~DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest,GO:0006978~DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator,GO:0008630~intrinsic apoptotic signaling pathway in response to DNA damage,GO:0018105~peptidyl-serine phosphorylation,GO:0031573~intra-S DNA damage checkpoint,GO:0035690~cellular response to drug,GO:0042176~regulation of protein catabolic process,GO:0042770~signal transduction in response to DNA damage,GO:0042771~intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator,GO:0044257~cellular protein catabolic process,GO:0044773~mitotic DNA damage checkpoint,GO:0045893~positive regulation of transcription, DNA-templated,GO:0046777~protein autophosphorylation,GO:0050821~protein stabilization,GO:0051301~cell division,GO:0071466~cellular response to xenobiotic stimulus,GO:0071480~cellular response to gamma radiation,GO:0072428~signal transduction involved in intra-S DNA damage checkpoint,GO:0090307~mitotic spindle assembly,GO:0090399~replicative senescence,GO:1901796~regulation of signal transduction by p53 class mediator,GO:1903416~response to glycoside,GO:1903926~cellular response to bisphenol A,GO:2000002~negative regulation of DNA damage checkpoint,GO:2000210~positive regulation of anoikis,	GO:0000781~chromosome, telomeric region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0016605~PML body,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016301~kinase activity,GO:0019901~protein kinase binding,GO:0031625~ubiquitin protein ligase binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0046872~metal ion binding,	IPR000253:Forkhead-associated (FHA) domain,IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR008984:SMAD/FHA domain,IPR011009:Protein kinase-like domain,	hsa04110:Cell cycle,hsa04115:p53 signaling pathway,hsa04218:Cellular senescence,hsa05166:Human T-cell leukemia virus 1 infection,	114480~Breast cancer, susceptibility to,114500~Colorectal cancer, susceptibility to,176807~Prostate cancer, familial, susceptibility to,259500~Osteosarcoma, somatic,609265~Li-Fraumeni syndrome 2,		SM00220:S_TKc,SM00240:FHA,	KW-0053~Apoptosis,KW-0131~Cell cycle,KW-0132~Cell division,KW-0227~DNA damage,KW-0234~DNA repair,KW-0498~Mitosis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0043~Tumor suppressor,KW-0225~Disease variant,KW-0435~Li-Fraumeni syndrome,KW-9993~Li-Fraumeni syndrome,		KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Proton acceptor,BINDING:ATP,COMPBIAS:Polar residues,DOMAIN:FHA,DOMAIN:Protein kinase,MUTAGEN:D->A: Loss of kinase activity and of the ability to phosphorylate CDC25A.,MUTAGEN:D->N: Loss of autophosphorylation activity.,MUTAGEN:S->A: Abrogates autophosphorylation at Ser-379 and prevents ubiquitination.,MUTAGEN:S->A: Impaired activation, phosphorylation by ATM and G2/M transition checkpoint.,MUTAGEN:S->A: Increased ubiquitination and degradation by the proteasome.,MUTAGEN:T->A: Loss of activation and phosphorylation.,MUTAGEN:T->A: Loss of phosphorylation in response to ionizing radiation.,NP_BIND:ATP,REGION:Disordered,REGION:T-loop/activation segment,
CHN1	chimerin 1(CHN1)	Homo sapiens		h_rac1Pathway:Rac 1 cell motility signaling pathway,		GO:0007165~signal transduction,GO:0008045~motor neuron axon guidance,GO:0035556~intracellular signal transduction,GO:0043087~regulation of GTPase activity,GO:0043547~positive regulation of GTPase activity,GO:0048013~ephrin receptor signaling pathway,GO:0050770~regulation of axonogenesis,GO:0051056~regulation of small GTPase mediated signal transduction,	GO:0005829~cytosol,	GO:0005096~GTPase activator activity,GO:0005515~protein binding,GO:0046872~metal ion binding,GO:0046875~ephrin receptor binding,	IPR000198:Rho GTPase-activating protein domain,IPR000980:SH2 domain,IPR002219:Protein kinase C-like, phorbol ester/diacylglycerol binding,IPR008936:Rho GTPase activation protein,IPR017356:N-chimaerin,IPR020454:Diacylglycerol/phorbol-ester binding,		604356~Duane retraction syndrome 2,	PIRSF038015:chimaerin,	SM00109:C1,SM00252:SH2,SM00324:RhoGAP,	KW-0524~Neurogenesis,		KW-0225~Disease variant,	KW-0727~SH2 domain,KW-0732~Signal,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0343~GTPase activation,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Phorbol-ester/DAG-type,DOMAIN:Rho-GAP,DOMAIN:SH2,REGION:Disordered,ZN_FING:Phorbol-ester/DAG-type,
CLIC4	chloride intracellular channel 4(CLIC4)	Homo sapiens				GO:0001525~angiogenesis,GO:0001886~endothelial cell morphogenesis,GO:0006821~chloride transport,GO:0007035~vacuolar acidification,GO:0009566~fertilization,GO:0030154~cell differentiation,GO:0030216~keratinocyte differentiation,GO:0030336~negative regulation of cell migration,GO:0034220~ion transmembrane transport,GO:0034765~regulation of ion transmembrane transport,GO:0035088~establishment or maintenance of apical/basal cell polarity,GO:0035264~multicellular organism growth,GO:0048754~branching morphogenesis of an epithelial tube,GO:0051493~regulation of cytoskeleton organization,GO:0061299~retina vasculature morphogenesis in camera-type eye,GO:0071277~cellular response to calcium ion,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005902~microvillus,GO:0005911~cell-cell junction,GO:0009986~cell surface,GO:0015629~actin cytoskeleton,GO:0015630~microtubule cytoskeleton,GO:0016020~membrane,GO:0016363~nuclear matrix,GO:0030496~midbody,GO:0030659~cytoplasmic vesicle membrane,GO:0034707~chloride channel complex,GO:0045177~apical part of cell,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0005244~voltage-gated ion channel activity,GO:0005254~chloride channel activity,GO:0005515~protein binding,	IPR002946:Intracellular chloride channel,IPR010987:Glutathione S-transferase, C-terminal-like,					KW-0406~Ion transport,KW-0813~Transport,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0868~Chloride,	KW-0407~Ion channel,KW-0851~Voltage-gated channel,KW-0869~Chloride channel,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:GST C-terminal,REGION:Required for insertion into the membrane,TRANSMEM:Helical; Note=After insertion into the membrane,
CLTC	clathrin heavy chain(CLTC)	Homo sapiens				GO:0000278~mitotic cell cycle,GO:0001649~osteoblast differentiation,GO:0006886~intracellular protein transport,GO:0006892~post-Golgi vesicle-mediated transport,GO:0006898~receptor-mediated endocytosis,GO:0006914~autophagy,GO:0016192~vesicle-mediated transport,GO:0019886~antigen processing and presentation of exogenous peptide antigen via MHC class II,GO:0031623~receptor internalization,GO:0032802~low-density lipoprotein particle receptor catabolic process,GO:0033572~transferrin transport,GO:0034383~low-density lipoprotein particle clearance,GO:0042147~retrograde transport, endosome to Golgi,GO:0048268~clathrin coat assembly,GO:0051301~cell division,GO:0060071~Wnt signaling pathway, planar cell polarity pathway,GO:0060236~regulation of mitotic spindle organization,GO:0061024~membrane organization,GO:0072583~clathrin-dependent endocytosis,GO:0090307~mitotic spindle assembly,GO:1900126~negative regulation of hyaluronan biosynthetic process,GO:1903077~negative regulation of protein localization to plasma membrane,	GO:0005764~lysosome,GO:0005768~endosome,GO:0005819~spindle,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0030118~clathrin coat,GO:0030130~clathrin coat of trans-Golgi network vesicle,GO:0030132~clathrin coat of coated pit,GO:0030136~clathrin-coated vesicle,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0031523~Myb complex,GO:0032588~trans-Golgi network membrane,GO:0032991~macromolecular complex,GO:0036020~endolysosome membrane,GO:0042470~melanosome,GO:0045334~clathrin-coated endocytic vesicle,GO:0070062~extracellular exosome,GO:0071439~clathrin complex,GO:0072686~mitotic spindle,GO:1903561~extracellular vesicle,GO:1990498~mitotic spindle microtubule,	GO:0003723~RNA binding,GO:0003725~double-stranded RNA binding,GO:0005198~structural molecule activity,GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0032051~clathrin light chain binding,GO:0050750~low-density lipoprotein particle receptor binding,GO:0097718~disordered domain specific binding,GO:1990381~ubiquitin-specific protease binding,	IPR000547:Clathrin, heavy chain/VPS, 7-fold repeat,IPR011990:Tetratricopeptide-like helical,IPR015348:Clathrin, heavy chain, linker, core motif,IPR016024:Armadillo-type fold,IPR016025:Clathrin, heavy chain, linker/propeller domain,IPR016341:Clathrin, heavy chain,IPR022365:Clathrin, heavy chain, propeller repeat,	hsa04142:Lysosome,hsa04144:Endocytosis,hsa04721:Synaptic vesicle cycle,hsa04961:Endocrine and other factor-regulated calcium reabsorption,hsa05016:Huntington disease,hsa05100:Bacterial invasion of epithelial cells,	617854~Mental retardation, autosomal dominant 56,	PIRSF002290:clathrin heavy chain,	SM00299:CLH,	KW-0072~Autophagy,KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0168~Coated pit,KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,	KW-0225~Disease variant,KW-0991~Mental retardation,	KW-0175~Coiled coil,KW-0677~Repeat,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Clathrin-link,MUTAGEN:K->E: Disrupts spindle localization.,MUTAGEN:K->E: Disrupts spindle localization; when associated with E-444, E-445, E-500 and E-506.,MUTAGEN:K->E: Disrupts spindle localization; when associated with E-444, E-445, E-500 and E-507.,MUTAGEN:K->E: Disrupts spindle localization; when associated with E-444, E-445, E-506 and E-507.,MUTAGEN:K->E: Disrupts spindle localization; when associated with E-444, E-500, E-506 and E-507.,MUTAGEN:K->E: Disrupts spindle localization; when associated with E-481, E-487, E-500 and E-506.,MUTAGEN:K->E: Disrupts spindle localization; when associated with E-481, E-487, E-500 and E-507.,MUTAGEN:K->E: Disrupts spindle localization; when associated with E-481, E-487, E-506 and E-507.,MUTAGEN:K->E: Disrupts spindle localization; when associated with E-481, E-500, E-506 and E-507.,MUTAGEN:LRANV->ERGQC: Disrupts spindle localization and interaction with TACC3.,MUTAGEN:P->N: Disrupts spindle localization.,MUTAGEN:Q->A: Disrupts spindle localization.,MUTAGEN:R->E: Disrupts spindle localization; when associated with E-445, E-500 E-506 and E-507.,MUTAGEN:R->E: Disrupts spindle localization; when associated with E-487, E-500, E-506 and E-507.,MUTAGEN:S->G: Disrupts spindle localization.,MUTAGEN:T->A: Disrupts spindle localization.,REGION:Binding site for the uncoating ATPase, involved in lattice disassembly,REGION:Distal segment,REGION:Flexible linker,REGION:Globular terminal domain,REGION:Heavy chain arm,REGION:Involved in binding clathrin light chain,REGION:Involved in spindle localization and interaction with TACC3,REGION:Proximal segment,REGION:Trimerization,REGION:WD40-like repeat 1,REGION:WD40-like repeat 2,REGION:WD40-like repeat 3,REGION:WD40-like repeat 4,REGION:WD40-like repeat 5,REGION:WD40-like repeat 6,REGION:WD40-like repeat 7,REPEAT:CHCR,REPEAT:CHCR 1,REPEAT:CHCR 2,REPEAT:CHCR 3,REPEAT:CHCR 4,REPEAT:CHCR 5,REPEAT:CHCR 6,REPEAT:CHCR 7,
CLTB	clathrin light chain B(CLTB)	Homo sapiens		h_arapPathway:ADP-Ribosylation Factor,		GO:0006886~intracellular protein transport,GO:0016192~vesicle-mediated transport,GO:0048268~clathrin coat assembly,GO:0061024~membrane organization,GO:0072583~clathrin-dependent endocytosis,	GO:0005802~trans-Golgi network,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0030118~clathrin coat,GO:0030125~clathrin vesicle coat,GO:0030130~clathrin coat of trans-Golgi network vesicle,GO:0030132~clathrin coat of coated pit,GO:0030672~synaptic vesicle membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0045334~clathrin-coated endocytic vesicle,GO:0060170~ciliary membrane,GO:0098835~presynaptic endocytic zone membrane,GO:0099631~postsynaptic endocytic zone cytoplasmic component,	GO:0005198~structural molecule activity,GO:0005515~protein binding,GO:0032050~clathrin heavy chain binding,GO:0042277~peptide binding,	IPR000996:Clathrin light chain,	hsa04142:Lysosome,hsa04144:Endocytosis,hsa04721:Synaptic vesicle cycle,hsa04961:Endocrine and other factor-regulated calcium reabsorption,hsa05016:Huntington disease,hsa05100:Bacterial invasion of epithelial cells,					KW-0168~Coated pit,KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,		KW-0175~Coiled coil,	KW-0106~Calcium,		KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,REGION:Involved in binding clathrin heavy chain,
CPSF4	cleavage and polyadenylation specific factor 4(CPSF4)	Homo sapiens		h_cpsfPathway:Polyadenylation of mRNA,	General function prediction only,	GO:0000398~mRNA splicing, via spliceosome,GO:0006369~termination of RNA polymerase II transcription,GO:0006388~tRNA splicing, via endonucleolytic cleavage and ligation,GO:0006406~mRNA export from nucleus,GO:0031124~mRNA 3'-end processing,GO:0046778~modification by virus of host mRNA processing,GO:0098789~pre-mRNA cleavage required for polyadenylation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005847~mRNA cleavage and polyadenylation specificity factor complex,GO:0043231~intracellular membrane-bounded organelle,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0046872~metal ion binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000571:Zinc finger, CCCH-type,IPR001878:Zinc finger, CCHC-type,	hsa03015:mRNA surveillance pathway,hsa05164:Influenza A,			SM00343:ZnF_C2HC,SM00356:ZnF_C3H1,	KW-0507~mRNA processing,KW-0945~Host-virus interaction,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0694~RNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:C3H1-type,DOMAIN:CCHC-type,REGION:Disordered,ZN_FING:C3H1-type,ZN_FING:C3H1-type 1,ZN_FING:C3H1-type 2,ZN_FING:C3H1-type 3,ZN_FING:C3H1-type 4,ZN_FING:C3H1-type 5,ZN_FING:CCHC-type,
CCDC85B	coiled-coil domain containing 85B(CCDC85B)	Homo sapiens				GO:0016032~viral process,GO:0030154~cell differentiation,GO:0030308~negative regulation of cell growth,GO:0045599~negative regulation of fat cell differentiation,GO:0045892~negative regulation of transcription, DNA-templated,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005912~adherens junction,	GO:0005515~protein binding,GO:0070097~delta-catenin binding,	IPR019359:Protein of unknown function DUF2216, coiled-coil,					KW-0221~Differentiation,KW-0341~Growth regulation,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0965~Cell junction,		KW-0175~Coiled coil,		KW-0678~Repressor,	KW-0007~Acetylation,	MUTAGEN:L->A: Loss of interaction with TCF7L2 and loss of suppression of CTNNB1 activity. Loss of cell growth inhibition.,REGION:Disordered,
CCDC86	coiled-coil domain containing 86(CCDC86)	Homo sapiens				GO:0016032~viral process,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005730~nucleolus,	GO:0003723~RNA binding,GO:0005515~protein binding,	IPR005579:Cgr1,IPR026570:Coiled-coil domain-containing protein 86,					KW-0945~Host-virus interaction,	KW-0539~Nucleus,		KW-0175~Coiled coil,			KW-0164~Citrullination,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,REGION:Disordered,
CCDC92	coiled-coil domain containing 92(CCDC92)	Homo sapiens				GO:0045087~innate immune response,GO:0050688~regulation of defense response to virus,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005814~centriole,GO:0043231~intracellular membrane-bounded organelle,	GO:0005515~protein binding,GO:0042802~identical protein binding,						KW-0391~Immunity,KW-0399~Innate immunity,KW-0945~Host-virus interaction,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,		KW-0175~Coiled coil,		KW-0930~Antiviral protein,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:CCDC92,REGION:Disordered,
CIRBP	cold inducible RNA binding protein(CIRBP)	Homo sapiens				GO:0009409~response to cold,GO:0009411~response to UV,GO:0017148~negative regulation of translation,GO:0034063~stress granule assembly,GO:0045727~positive regulation of translation,GO:0048026~positive regulation of mRNA splicing, via spliceosome,GO:0048255~mRNA stabilization,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:0005737~cytoplasm,GO:0010494~cytoplasmic stress granule,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0003730~mRNA 3'-UTR binding,GO:0005515~protein binding,GO:0030371~translation repressor activity,GO:0070181~small ribosomal subunit rRNA binding,	IPR000504:RNA recognition motif domain,IPR003954:RNA recognition motif domain, eukaryote,IPR012677:Nucleotide-binding, alpha-beta plait,				SM00360:RRM,SM00361:RRM_1,	KW-0346~Stress response,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0010~Activator,KW-0678~Repressor,KW-0694~RNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:RRM,REGION:Disordered,
COL1A1	collagen type I alpha 1 chain(COL1A1)	Homo sapiens				GO:0001501~skeletal system development,GO:0001503~ossification,GO:0001568~blood vessel development,GO:0001649~osteoblast differentiation,GO:0001957~intramembranous ossification,GO:0001958~endochondral ossification,GO:0007155~cell adhesion,GO:0007596~blood coagulation,GO:0007601~visual perception,GO:0007605~sensory perception of sound,GO:0009410~response to xenobiotic stimulus,GO:0009612~response to mechanical stimulus,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0010812~negative regulation of cell-substrate adhesion,GO:0015031~protein transport,GO:0030168~platelet activation,GO:0030198~extracellular matrix organization,GO:0030199~collagen fibril organization,GO:0030335~positive regulation of cell migration,GO:0031960~response to corticosteroid,GO:0032355~response to estradiol,GO:0032964~collagen biosynthetic process,GO:0034504~protein localization to nucleus,GO:0034505~tooth mineralization,GO:0038063~collagen-activated tyrosine kinase receptor signaling pathway,GO:0042060~wound healing,GO:0042493~response to drug,GO:0042542~response to hydrogen peroxide,GO:0043434~response to peptide hormone,GO:0043588~skin development,GO:0043589~skin morphogenesis,GO:0044344~cellular response to fibroblast growth factor stimulus,GO:0044691~tooth eruption,GO:0045893~positive regulation of transcription, DNA-templated,GO:0048706~embryonic skeletal system development,GO:0050776~regulation of immune response,GO:0050900~leukocyte migration,GO:0051591~response to cAMP,GO:0055093~response to hyperoxia,GO:0060325~face morphogenesis,GO:0060346~bone trabecula formation,GO:0060351~cartilage development involved in endochondral bone morphogenesis,GO:0071230~cellular response to amino acid stimulus,GO:0071260~cellular response to mechanical stimulus,GO:0071300~cellular response to retinoic acid,GO:0071306~cellular response to vitamin E,GO:0071356~cellular response to tumor necrosis factor,GO:0071364~cellular response to epidermal growth factor stimulus,GO:0071560~cellular response to transforming growth factor beta stimulus,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:1902618~cellular response to fluoride,	GO:0005576~extracellular region,GO:0005581~collagen trimer,GO:0005584~collagen type I trimer,GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005788~endoplasmic reticulum lumen,GO:0005794~Golgi apparatus,GO:0016021~integral component of membrane,GO:0030141~secretory granule,GO:0031012~extracellular matrix,	GO:0002020~protease binding,GO:0005201~extracellular matrix structural constituent,GO:0005515~protein binding,GO:0030020~extracellular matrix structural constituent conferring tensile strength,GO:0042802~identical protein binding,GO:0046872~metal ion binding,GO:0048407~platelet-derived growth factor binding,	IPR000885:Fibrillar collagen, C-terminal,IPR001007:von Willebrand factor, type C,IPR008160:Collagen triple helix repeat,	hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04512:ECM-receptor interaction,hsa04611:Platelet activation,hsa04926:Relaxin signaling pathway,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04974:Protein digestion and absorption,hsa05146:Amoebiasis,hsa05165:Human papillomavirus infection,hsa05205:Proteoglycans in cancer,hsa05415:Diabetic cardiomyopathy,	114000~Caffey disease,130060~Ehlers-Danlos syndrome, arthrochalasia type, 1,166200~Osteogenesis imperfecta, type I,166210~Osteogenesis imperfecta, type II,166220~Osteogenesis imperfecta, type IV,166710~Bone mineral density variation QTL, osteoporosis,259420~Osteogenesis imperfecta, type III,619115~Combined osteogenesis imperfecta and Ehlers-Danlos syndrome 1,		SM00038:COLFI,SM00214:VWC,		KW-0272~Extracellular matrix,KW-0472~Membrane,KW-0964~Secreted,	KW-0225~Disease variant,KW-0242~Dwarfism,KW-0248~Ehlers-Danlos syndrome,KW-1065~Osteogenesis imperfecta,	KW-0176~Collagen,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0325~Glycoprotein,KW-0379~Hydroxylation,KW-0597~Phosphoprotein,KW-0873~Pyrrolidone carboxylic acid,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (Gal...) hydroxylysine; alternate,COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DISULFID:Interchain,DOMAIN:Fibrillar collagen NC1,DOMAIN:VWFC,METAL:Calcium,METAL:Calcium; via carbonyl oxygen,MOTIF:Cell attachment site,PROPEP:C-terminal propeptide,PROPEP:N-terminal propeptide,REGION:Disordered,REGION:Nonhelical region (C-terminal),REGION:Nonhelical region (N-terminal),REGION:Triple-helical region,SITE:Cleavage; by collagenase,SITE:Cleavage; by procollagen C-endopeptidase,SITE:Cleavage; by procollagen N-endopeptidase,TRANSMEM:Helical,
COL4A1	collagen type IV alpha 1 chain(COL4A1)	Homo sapiens		h_ace2Pathway:Angiotensin-converting enzyme 2 regulates heart function,h_amiPathway:Acute Myocardial Infarction,h_intrinsicPathway:Intrinsic Prothrombin Activation Pathway,h_npp1Pathway:Regulators of Bone Mineralization,h_plateletAppPathway:Platelet Amyloid Precursor Protein Pathway,h_vitCBPathway:Vitamin C in the Brain,		GO:0001569~branching involved in blood vessel morphogenesis,GO:0007420~brain development,GO:0007528~neuromuscular junction development,GO:0030198~extracellular matrix organization,GO:0030199~collagen fibril organization,GO:0030855~epithelial cell differentiation,GO:0038063~collagen-activated tyrosine kinase receptor signaling pathway,GO:0048514~blood vessel morphogenesis,GO:0061304~retinal blood vessel morphogenesis,GO:0061333~renal tubule morphogenesis,GO:0071230~cellular response to amino acid stimulus,GO:0071711~basement membrane organization,	GO:0005576~extracellular region,GO:0005581~collagen trimer,GO:0005587~collagen type IV trimer,GO:0005604~basement membrane,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0016020~membrane,GO:0031012~extracellular matrix,	GO:0005201~extracellular matrix structural constituent,GO:0005515~protein binding,GO:0030020~extracellular matrix structural constituent conferring tensile strength,GO:0048407~platelet-derived growth factor binding,	IPR001442:Collagen IV, non-collagenous,IPR008160:Collagen triple helix repeat,IPR016187:C-type lectin fold,	hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04512:ECM-receptor interaction,hsa04926:Relaxin signaling pathway,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04974:Protein digestion and absorption,hsa05146:Amoebiasis,hsa05165:Human papillomavirus infection,hsa05200:Pathways in cancer,hsa05222:Small cell lung cancer,	175780~Brain small vessel disease with or without ocular anomalies,180000~Retinal arteries, tortuosity of,611773~Angiopathy, hereditary, with nephropathy, aneurysms, and muscle cramps,614519~Hemorrhage, intracerebral, susceptibility to,618564~Microangiopathy and leukoencephalopathy, pontine, autosomal dominant,		SM00111:C4,	KW-0037~Angiogenesis,	KW-0084~Basement membrane,KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,	KW-0176~Collagen,KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,KW-0379~Hydroxylation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:S-Lysyl-methionine sulfilimine (Lys-Met) (interchain with M-1533),CROSSLNK:S-Lysyl-methionine sulfilimine (Met-Lys) (interchain with K-1651),DOMAIN:Collagen IV NC1,PROPEP:N-terminal propeptide (7S domain),REGION:Disordered,REGION:Triple-helical region,
C5	complement C5(C5)	Homo sapiens		h_alternativePathway:Alternative Complement Pathway,h_classicPathway:Classical Complement Pathway,h_compPathway:Complement Pathway,h_granulocytesPathway:Adhesion and Diapedesis of Granulocytes,h_LairPathway:Cells and Molecules involved in local acute inflammatory response,h_lectinPathway:Lectin Induced Complement Pathway,		GO:0000187~activation of MAPK activity,GO:0001701~in utero embryonic development,GO:0006935~chemotaxis,GO:0006954~inflammatory response,GO:0006956~complement activation,GO:0006957~complement activation, alternative pathway,GO:0006958~complement activation, classical pathway,GO:0007166~cell surface receptor signaling pathway,GO:0007186~G-protein coupled receptor signaling pathway,GO:0010575~positive regulation of vascular endothelial growth factor production,GO:0010760~negative regulation of macrophage chemotaxis,GO:0010951~negative regulation of endopeptidase activity,GO:0019835~cytolysis,GO:0030449~regulation of complement activation,GO:0032722~positive regulation of chemokine production,GO:0045766~positive regulation of angiogenesis,GO:0060326~cell chemotaxis,	GO:0005576~extracellular region,GO:0005579~membrane attack complex,GO:0005615~extracellular space,GO:0070062~extracellular exosome,	GO:0004866~endopeptidase inhibitor activity,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0008009~chemokine activity,	IPR000020:Anaphylatoxin/fibulin,IPR001134:Netrin domain,IPR001599:Alpha-2-macroglobulin,IPR001840:Complement C3a/C4a/C5a anaphylatoxin,IPR002890:Alpha-2-macroglobulin, N-terminal,IPR008930:Terpenoid cyclases/protein prenyltransferase alpha-alpha toroid,IPR008993:Tissue inhibitor of metalloproteinases-like, OB-fold,IPR009048:Alpha-macroglobulin, receptor-binding,IPR011625:Alpha-2-macroglobulin, N-terminal 2,IPR011626:A-macroglobulin complement component,IPR013783:Immunoglobulin-like fold,IPR018081:Anaphylatoxin,IPR018933:Netrin module, non-TIMP type,	hsa04080:Neuroactive ligand-receptor interaction,hsa04610:Complement and coagulation cascades,hsa04613:Neutrophil extracellular trap formation,hsa04936:Alcoholic liver disease,hsa05020:Prion disease,hsa05133:Pertussis,hsa05150:Staphylococcus aureus infection,hsa05168:Herpes simplex virus 1 infection,hsa05171:Coronavirus disease - COVID-19,hsa05322:Systemic lupus erythematosus,	609536~C5 deficiency,615749~Eculizumab, poor response to,		SM00104:ANATO,SM00643:C345C,SM01359:SM01359,SM01360:SM01360,SM01361:SM01361,	KW-0179~Complement alternate pathway,KW-0180~Complement pathway,KW-0204~Cytolysis,KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,	KW-0473~Membrane attack complex,KW-0964~Secreted,		KW-0732~Signal,			KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Anaphylatoxin-like,DOMAIN:NTR,REGION:Involved in C5AR1 binding,
COG2	component of oligomeric golgi complex 2(COG2)	Homo sapiens				GO:0000301~retrograde transport, vesicle recycling within Golgi,GO:0006888~ER to Golgi vesicle-mediated transport,GO:0006891~intra-Golgi vesicle-mediated transport,GO:0007030~Golgi organization,GO:0015031~protein transport,GO:0070085~glycosylation,	GO:0000139~Golgi membrane,GO:0005794~Golgi apparatus,GO:0005795~Golgi stack,GO:0005829~cytosol,GO:0016020~membrane,GO:0017119~Golgi transport complex,GO:0032588~trans-Golgi network membrane,	GO:0005515~protein binding,GO:0044877~macromolecular complex binding,	IPR009316:COG complex component, COG2,IPR024602:Conserved oligomeric Golgi complex, subunit 2, N-terminal,IPR024603:COG complex component, COG2, C-terminal,		617395~Congenital disorder of glycosylation, type IIq,			KW-0653~Protein transport,KW-0813~Transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,	KW-0225~Disease variant,KW-0900~Congenital disorder of glycosylation,	KW-0175~Coiled coil,				COMPBIAS:Polar residues,DOMAIN:COG2,DOMAIN:DUF3510,REGION:Disordered,
COG4	component of oligomeric golgi complex 4(COG4)	Homo sapiens				GO:0000301~retrograde transport, vesicle recycling within Golgi,GO:0006888~ER to Golgi vesicle-mediated transport,GO:0006890~retrograde vesicle-mediated transport, Golgi to ER,GO:0007030~Golgi organization,GO:0015031~protein transport,GO:0048213~Golgi vesicle prefusion complex stabilization,GO:0070085~glycosylation,	GO:0000139~Golgi membrane,GO:0005829~cytosol,GO:0017119~Golgi transport complex,GO:0032588~trans-Golgi network membrane,	GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR013167:Conserved oligomeric Golgi complex, subunit 4,		613489~Congenital disorder of glycosylation, type IIj,618150~Saul-Wilson syndrome,		SM00762:Cog4,	KW-0653~Protein transport,KW-0813~Transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0242~Dwarfism,KW-0900~Congenital disorder of glycosylation,	KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Cog4,MUTAGEN:E->A: Severe defects in glycosylation.,MUTAGEN:R->A: Severe defects in glycosylation.,REGION:D domain,REGION:Disordered,REGION:E domain; essential for proper cell surface glycosylation,REGION:Interaction with SCFD1,REGION:Interaction with STX5,
COG7	component of oligomeric golgi complex 7(COG7)	Homo sapiens				GO:0000301~retrograde transport, vesicle recycling within Golgi,GO:0006486~protein glycosylation,GO:0006886~intracellular protein transport,GO:0006888~ER to Golgi vesicle-mediated transport,GO:0006890~retrograde vesicle-mediated transport, Golgi to ER,GO:0007030~Golgi organization,GO:0033365~protein localization to organelle,GO:0034067~protein localization to Golgi apparatus,GO:0050821~protein stabilization,GO:0070085~glycosylation,	GO:0000139~Golgi membrane,GO:0005730~nucleolus,GO:0005794~Golgi apparatus,GO:0017119~Golgi transport complex,GO:0032588~trans-Golgi network membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0005515~protein binding,	IPR019335:Conserved oligomeric Golgi complex subunit 7,		608779~Congenital disorder of glycosylation, type IIe,			KW-0653~Protein transport,KW-0813~Transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,	KW-0900~Congenital disorder of glycosylation,	KW-0175~Coiled coil,				REGION:Disordered,
CPNE3	copine 3(CPNE3)	Homo sapiens				GO:0006468~protein phosphorylation,GO:0030335~positive regulation of cell migration,GO:0038128~ERBB2 signaling pathway,GO:0043312~neutrophil degranulation,GO:0046474~glycerophospholipid biosynthetic process,GO:0071277~cellular response to calcium ion,GO:0071363~cellular response to growth factor stimulus,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0030054~cell junction,GO:0035577~azurophil granule membrane,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0004674~protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0005544~calcium-dependent phospholipid binding,GO:0030971~receptor tyrosine kinase binding,GO:0046872~metal ion binding,GO:0048306~calcium-dependent protein binding,	IPR000008:C2 calcium-dependent membrane targeting,IPR002035:von Willebrand factor, type A,IPR010734:Copine,				SM00239:C2,SM00327:VWA,		KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-1003~Cell membrane,		KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0597~Phosphoprotein,	DOMAIN:C2,DOMAIN:C2 1,DOMAIN:C2 2,DOMAIN:VWFA,METAL:Calcium 1,METAL:Calcium 2,METAL:Calcium 3,METAL:Calcium 4,
CORO1A	coronin 1A(CORO1A)	Homo sapiens				GO:0001845~phagolysosome assembly,GO:0006816~calcium ion transport,GO:0006909~phagocytosis,GO:0007015~actin filament organization,GO:0008360~regulation of cell shape,GO:0016477~cell migration,GO:0030036~actin cytoskeleton organization,GO:0030335~positive regulation of cell migration,GO:0030595~leukocyte chemotaxis,GO:0030833~regulation of actin filament polymerization,GO:0031339~negative regulation of vesicle fusion,GO:0031589~cell-substrate adhesion,GO:0032796~uropod organization,GO:0032956~regulation of actin cytoskeleton organization,GO:0038180~nerve growth factor signaling pathway,GO:0042102~positive regulation of T cell proliferation,GO:0043029~T cell homeostasis,GO:0043320~natural killer cell degranulation,GO:0043524~negative regulation of neuron apoptotic process,GO:0045087~innate immune response,GO:0048873~homeostasis of number of cells within a tissue,GO:0050918~positive chemotaxis,GO:0051126~negative regulation of actin nucleation,GO:0051279~regulation of release of sequestered calcium ion into cytosol,GO:0061502~early endosome to recycling endosome transport,GO:0071353~cellular response to interleukin-4,	GO:0001772~immunological synapse,GO:0001891~phagocytic cup,GO:0005737~cytoplasm,GO:0005769~early endosome,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005884~actin filament,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0005938~cell cortex,GO:0015629~actin cytoskeleton,GO:0016020~membrane,GO:0030027~lamellipodium,GO:0030424~axon,GO:0030670~phagocytic vesicle membrane,GO:0030864~cortical actin cytoskeleton,GO:0031252~cell leading edge,GO:0032991~macromolecular complex,GO:0045335~phagocytic vesicle,GO:0070062~extracellular exosome,GO:0098978~glutamatergic synapse,	GO:0003723~RNA binding,GO:0003779~actin binding,GO:0003785~actin monomer binding,GO:0005515~protein binding,GO:0008022~protein C-terminus binding,GO:0008092~cytoskeletal protein binding,GO:0032036~myosin heavy chain binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0043548~phosphatidylinositol 3-kinase binding,GO:0051015~actin filament binding,	IPR001680:WD40 repeat,IPR015048:Domain of unknown function DUF1899,IPR015049:Domain of unknown function DUF1900,IPR015505:Coronin,IPR015943:WD40/YVTN repeat-like-containing domain,IPR017986:WD40-repeat-containing domain,IPR019775:WD40 repeat, conserved site,	hsa04145:Phagosome,hsa05152:Tuberculosis,	615401~Immunodeficiency 8,		SM00320:WD40,SM01166:SM01166,		KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,	KW-0225~Disease variant,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0853~WD repeat,		KW-0009~Actin-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	DOMAIN:DUF1899,REGION:Disordered,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
CTTN	cortactin(CTTN)	Homo sapiens		h_agrPathway:Agrin in Postsynaptic Differentiation,		GO:0006886~intracellular protein transport,GO:0006898~receptor-mediated endocytosis,GO:0006930~substrate-dependent cell migration, cell extension,GO:0030041~actin filament polymerization,GO:0030516~regulation of axon extension,GO:0030833~regulation of actin filament polymerization,GO:0030838~positive regulation of actin filament polymerization,GO:0031532~actin cytoskeleton reorganization,GO:0045987~positive regulation of smooth muscle contraction,GO:0048041~focal adhesion assembly,GO:0048812~neuron projection morphogenesis,GO:0048870~cell motility,GO:0061024~membrane organization,GO:0097062~dendritic spine maintenance,GO:0097581~lamellipodium organization,GO:1903146~regulation of mitophagy,GO:2001237~negative regulation of extrinsic apoptotic signaling pathway,	GO:0001726~ruffle,GO:0002102~podosome,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005884~actin filament,GO:0005886~plasma membrane,GO:0005905~clathrin-coated pit,GO:0005925~focal adhesion,GO:0005938~cell cortex,GO:0008076~voltage-gated potassium channel complex,GO:0030027~lamellipodium,GO:0030426~growth cone,GO:0030427~site of polarized growth,GO:0030863~cortical cytoskeleton,GO:0030864~cortical actin cytoskeleton,GO:0043197~dendritic spine,GO:0043231~intracellular membrane-bounded organelle,GO:1990023~mitotic spindle midzone,	GO:0005515~protein binding,GO:0005522~profilin binding,GO:0045296~cadherin binding,GO:0051015~actin filament binding,	IPR001452:Src homology-3 domain,IPR003134:Hs1/Cortactin,IPR015503:Cortactin,	hsa04530:Tight junction,hsa05100:Bacterial invasion of epithelial cells,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05205:Proteoglycans in cancer,			SM00326:SH3,	KW-0254~Endocytosis,	KW-0168~Coated pit,KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0728~SH3 domain,			KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:SH3,REGION:Disordered,REPEAT:Cortactin 1,REPEAT:Cortactin 2,REPEAT:Cortactin 3,REPEAT:Cortactin 4,REPEAT:Cortactin 5,REPEAT:Cortactin 6,REPEAT:Cortactin 7; truncated,
CRYZ	crystallin zeta(CRYZ)	Homo sapiens		h_arenrf2Pathway:Oxidative Stress Induced Gene Expression Via Nrf2,	Energy production and conversion / General function prediction only,	GO:0007601~visual perception,GO:0042178~xenobiotic catabolic process,GO:0051289~protein homotetramerization,	GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0003730~mRNA 3'-UTR binding,GO:0003960~NADPH:quinone reductase activity,GO:0008270~zinc ion binding,GO:0016491~oxidoreductase activity,GO:0042802~identical protein binding,GO:0070402~NADPH binding,	IPR002364:Quinone oxidoreductase/zeta-crystallin, conserved site,IPR011032:GroES-like,IPR013149:Alcohol dehydrogenase, C-terminal,IPR013154:Alcohol dehydrogenase GroES-like,IPR020843:Polyketide synthase, enoylreductase,				SM00829:SM00829,		KW-0963~Cytoplasm,			KW-0521~NADP,	KW-0560~Oxidoreductase,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	BINDING:NADP,BINDING:NADP; via amide nitrogen,DOMAIN:PKS_ER,NP_BIND:NADP,
CCNA1	cyclin A1(CCNA1)	Homo sapiens		h_cellcyclePathway:Cyclins and Cell Cycle Regulation,h_g1Pathway:Cell Cycle: G1/S Check Point ,h_skp2e2fPathway:E2F1 Destruction Pathway,		GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0000083~regulation of transcription involved in G1/S transition of mitotic cell cycle,GO:0007141~male meiosis I,GO:0007283~spermatogenesis,GO:0016579~protein deubiquitination,GO:0044772~mitotic cell cycle phase transition,GO:0051301~cell division,	GO:0000307~cyclin-dependent protein kinase holoenzyme complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0015630~microtubule cytoskeleton,GO:0097123~cyclin A1-CDK2 complex,GO:0097124~cyclin A2-CDK2 complex,	GO:0005515~protein binding,GO:0016538~cyclin-dependent protein serine/threonine kinase regulator activity,	IPR004367:Cyclin, C-terminal domain,IPR006671:Cyclin, N-terminal,IPR013763:Cyclin-like,	hsa04110:Cell cycle,hsa04152:AMPK signaling pathway,hsa04218:Cellular senescence,hsa04914:Progesterone-mediated oocyte maturation,hsa05161:Hepatitis B,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05203:Viral carcinogenesis,hsa05221:Acute myeloid leukemia,			SM00385:CYCLIN,SM01332:SM01332,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0539~Nucleus,				KW-0195~Cyclin,	KW-0832~Ubl conjugation,	DOMAIN:Cyclin N-terminal,
CCNA2	cyclin A2(CCNA2)	Homo sapiens			Cell division and chromosome partitioning / Transcription / DNA replication, recombination, and repair,	GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0000086~G2/M transition of mitotic cell cycle,GO:0006275~regulation of DNA replication,GO:0007265~Ras protein signal transduction,GO:0016032~viral process,GO:0016572~histone phosphorylation,GO:0016579~protein deubiquitination,GO:0031100~animal organ regeneration,GO:0033762~response to glucagon,GO:0036120~cellular response to platelet-derived growth factor stimulus,GO:0044320~cellular response to leptin stimulus,GO:0044772~mitotic cell cycle phase transition,GO:0044843~cell cycle G1/S phase transition,GO:0045893~positive regulation of transcription, DNA-templated,GO:0048146~positive regulation of fibroblast proliferation,GO:0051301~cell division,GO:0071314~cellular response to cocaine,GO:0071373~cellular response to luteinizing hormone stimulus,GO:0071392~cellular response to estradiol stimulus,GO:0071456~cellular response to hypoxia,GO:0071732~cellular response to nitric oxide,GO:0090102~cochlea development,GO:1990314~cellular response to insulin-like growth factor stimulus,	GO:0000307~cyclin-dependent protein kinase holoenzyme complex,GO:0001939~female pronucleus,GO:0001940~male pronucleus,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0097124~cyclin A2-CDK2 complex,	GO:0005515~protein binding,GO:0016538~cyclin-dependent protein serine/threonine kinase regulator activity,GO:0019901~protein kinase binding,GO:0019904~protein domain specific binding,	IPR004367:Cyclin, C-terminal domain,IPR006671:Cyclin, N-terminal,IPR013763:Cyclin-like,	hsa04110:Cell cycle,hsa04152:AMPK signaling pathway,hsa04218:Cellular senescence,hsa04914:Progesterone-mediated oocyte maturation,hsa05161:Hepatitis B,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05203:Viral carcinogenesis,hsa05221:Acute myeloid leukemia,		PIRSF001771:cyclin, A/B/D/E types,	SM00385:CYCLIN,SM01332:SM01332,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0195~Cyclin,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	REGION:Disordered,
CCNB1	cyclin B1(CCNB1)	Homo sapiens		h_akap95Pathway:AKAP95 role in mitosis and chromosome dynamics,h_cellcyclePathway:Cyclins and Cell Cycle Regulation,h_EfpPathway:Estrogen-responsive protein Efp controls cell cycle and breast tumors growth,h_g2Pathway:Cell Cycle: G2/M Checkpoint,h_mPRPathway:How Progesterone Initiates the Oocyte Maturation,h_ptc1Pathway:Sonic Hedgehog (SHH) Receptor Ptc1 Regulates cell cycle,h_srcRPTPPathway:Activation of Src by Protein-tyrosine phosphatase alpha,h_stathminPathway:Stathmin and breast cancer resistance to antimicrotubule agents,		GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0000086~G2/M transition of mitotic cell cycle,GO:0001556~oocyte maturation,GO:0001701~in utero embryonic development,GO:0001933~negative regulation of protein phosphorylation,GO:0006468~protein phosphorylation,GO:0006977~DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest,GO:0007052~mitotic spindle organization,GO:0007076~mitotic chromosome condensation,GO:0007077~mitotic nuclear envelope disassembly,GO:0007080~mitotic metaphase plate congression,GO:0007084~mitotic nuclear envelope reassembly,GO:0007283~spermatogenesis,GO:0009612~response to mechanical stimulus,GO:0010629~negative regulation of gene expression,GO:0010971~positive regulation of G2/M transition of mitotic cell cycle,GO:0031145~anaphase-promoting complex-dependent catabolic process,GO:0031442~positive regulation of mRNA 3'-end processing,GO:0033129~positive regulation of histone phosphorylation,GO:0042246~tissue regeneration,GO:0042493~response to drug,GO:0044772~mitotic cell cycle phase transition,GO:0045737~positive regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0045931~positive regulation of mitotic cell cycle,GO:0046680~response to DDT,GO:0048146~positive regulation of fibroblast proliferation,GO:0048565~digestive tract development,GO:0051301~cell division,GO:0051726~regulation of cell cycle,GO:0051987~positive regulation of attachment of spindle microtubules to kinetochore,GO:0055015~ventricular cardiac muscle cell development,GO:0060045~positive regulation of cardiac muscle cell proliferation,GO:0060260~regulation of transcription initiation from RNA polymerase II promoter,GO:0060623~regulation of chromosome condensation,GO:0065003~macromolecular complex assembly,GO:0071283~cellular response to iron(III) ion,GO:0071398~cellular response to fatty acid,GO:0071407~cellular response to organic cyclic compound,GO:0071456~cellular response to hypoxia,GO:0090266~regulation of mitotic cell cycle spindle assembly checkpoint,GO:1901990~regulation of mitotic cell cycle phase transition,GO:1905448~positive regulation of mitochondrial ATP synthesis coupled electron transport,GO:2000775~histone H3-S10 phosphorylation involved in chromosome condensation,	GO:0000307~cyclin-dependent protein kinase holoenzyme complex,GO:0000922~spindle pole,GO:0000940~condensed chromosome outer kinetochore,GO:0000942~condensed nuclear chromosome outer kinetochore,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005759~mitochondrial matrix,GO:0005813~centrosome,GO:0005829~cytosol,GO:0016020~membrane,GO:0097125~cyclin B1-CDK1 complex,	GO:0005113~patched binding,GO:0005515~protein binding,GO:0016538~cyclin-dependent protein serine/threonine kinase regulator activity,GO:0019901~protein kinase binding,GO:0044389~ubiquitin-like protein ligase binding,GO:0061575~cyclin-dependent protein serine/threonine kinase activator activity,	IPR004367:Cyclin, C-terminal domain,IPR006671:Cyclin, N-terminal,IPR013763:Cyclin-like,	hsa04068:FoxO signaling pathway,hsa04110:Cell cycle,hsa04114:Oocyte meiosis,hsa04115:p53 signaling pathway,hsa04218:Cellular senescence,hsa04914:Progesterone-mediated oocyte maturation,hsa05170:Human immunodeficiency virus 1 infection,		PIRSF001771:cyclin, A/B/D/E types,	SM00385:CYCLIN,SM01332:SM01332,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0195~Cyclin,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	DOMAIN:CYCLIN,DOMAIN:Cyclin N-terminal,MUTAGEN:S->A: Does not affect phosphorylation by PLK1.,MUTAGEN:S->A: Strongly impairs phosphorylation by PLK1.,REGION:Disordered,REGION:Interaction with CDK2,
CCNB2	cyclin B2(CCNB2)	Homo sapiens		h_EfpPathway:Estrogen-responsive protein Efp controls cell cycle and breast tumors growth,		GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0000086~G2/M transition of mitotic cell cycle,GO:0001701~in utero embryonic development,GO:0007057~spindle assembly involved in female meiosis I,GO:0007077~mitotic nuclear envelope disassembly,GO:0007084~mitotic nuclear envelope reassembly,GO:0008315~meiotic G2/MI transition,GO:0040008~regulation of growth,GO:0043029~T cell homeostasis,GO:0044772~mitotic cell cycle phase transition,GO:0048538~thymus development,GO:0051301~cell division,GO:0051726~regulation of cell cycle,	GO:0000307~cyclin-dependent protein kinase holoenzyme complex,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0015630~microtubule cytoskeleton,GO:0016020~membrane,	GO:0005515~protein binding,GO:0016538~cyclin-dependent protein serine/threonine kinase regulator activity,GO:0045296~cadherin binding,	IPR004367:Cyclin, C-terminal domain,IPR006671:Cyclin, N-terminal,IPR013763:Cyclin-like,	hsa04068:FoxO signaling pathway,hsa04110:Cell cycle,hsa04114:Oocyte meiosis,hsa04115:p53 signaling pathway,hsa04218:Cellular senescence,hsa04914:Progesterone-mediated oocyte maturation,hsa05166:Human T-cell leukemia virus 1 infection,hsa05170:Human immunodeficiency virus 1 infection,		PIRSF001771:cyclin, A/B/D/E types,	SM00385:CYCLIN,SM01332:SM01332,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,					KW-0195~Cyclin,	KW-0597~Phosphoprotein,	DOMAIN:Cyclin N-terminal,
DMTF1	cyclin D binding myb like transcription factor 1(DMTF1)	Homo sapiens			Transcription / RNA processing and modification / Cell division and chromosome partitioning,	GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007049~cell cycle,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,	IPR001005:SANT/Myb domain,IPR009057:Homeodomain-like,IPR017877:Myb-like domain,IPR017930:Myb domain,				SM00717:SANT,	KW-0131~Cell cycle,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0043~Tumor suppressor,	KW-0677~Repeat,		KW-0010~Activator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DNA_BIND:H-T-H motif,DOMAIN:HTH myb-type,DOMAIN:Myb-like,DOMAIN:Myb-like 1,DOMAIN:Myb-like 2,REGION:Disordered,REGION:Interaction with CCND1, CCND2 and CCND3,REGION:Interaction with CCND2,REGION:Required for DNA-binding,REGION:Required for transcriptional activation,
CCND1	cyclin D1(CCND1)	Homo sapiens		h_btg2Pathway:BTG family proteins and cell cycle regulation,h_carm-erPathway:CARM1 and Regulation of the Estrogen Receptor,h_cellcyclePathway:Cyclins and Cell Cycle Regulation,h_g1Pathway:Cell Cycle: G1/S Check Point ,H_gsk3Pathway:Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar Macrophages,h_p53Pathway:p53 Signaling Pathway,h_raccycdPathway:Influence of Ras and Rho proteins on G1 to S Transition,h_wntPathway:WNT Signaling Pathway,		GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0000082~G1/S transition of mitotic cell cycle,GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000320~re-entry into mitotic cell cycle,GO:0001934~positive regulation of protein phosphorylation,GO:0006468~protein phosphorylation,GO:0006974~cellular response to DNA damage stimulus,GO:0007595~lactation,GO:0009410~response to xenobiotic stimulus,GO:0010039~response to iron ion,GO:0010165~response to X-ray,GO:0010243~response to organonitrogen compound,GO:0010971~positive regulation of G2/M transition of mitotic cell cycle,GO:0016055~Wnt signaling pathway,GO:0019221~cytokine-mediated signaling pathway,GO:0030857~negative regulation of epithelial cell differentiation,GO:0030968~endoplasmic reticulum unfolded protein response,GO:0031571~mitotic G1 DNA damage checkpoint,GO:0032026~response to magnesium ion,GO:0032355~response to estradiol,GO:0033197~response to vitamin E,GO:0033327~Leydig cell differentiation,GO:0033598~mammary gland epithelial cell proliferation,GO:0033601~positive regulation of mammary gland epithelial cell proliferation,GO:0042493~response to drug,GO:0043627~response to estrogen,GO:0044321~response to leptin,GO:0044772~mitotic cell cycle phase transition,GO:0045444~fat cell differentiation,GO:0045471~response to ethanol,GO:0045737~positive regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0045787~positive regulation of cell cycle,GO:0051301~cell division,GO:0051412~response to corticosterone,GO:0051592~response to calcium ion,GO:0060260~regulation of transcription initiation from RNA polymerase II promoter,GO:0060749~mammary gland alveolus development,GO:0070141~response to UV-A,GO:0071157~negative regulation of cell cycle arrest,GO:0097421~liver regeneration,GO:1900087~positive regulation of G1/S transition of mitotic cell cycle,GO:2000045~regulation of G1/S transition of mitotic cell cycle,	GO:0000307~cyclin-dependent protein kinase holoenzyme complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005923~bicellular tight junction,GO:0016020~membrane,GO:0017053~transcriptional repressor complex,GO:0031965~nuclear membrane,GO:0097128~cyclin D1-CDK4 complex,	GO:0003714~transcription corepressor activity,GO:0004672~protein kinase activity,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0016538~cyclin-dependent protein serine/threonine kinase regulator activity,GO:0019899~enzyme binding,GO:0019901~protein kinase binding,GO:0042826~histone deacetylase binding,GO:0044877~macromolecular complex binding,GO:0070064~proline-rich region binding,	IPR004367:Cyclin, C-terminal domain,IPR006671:Cyclin, N-terminal,IPR013763:Cyclin-like,IPR015451:Cyclin D,	hsa01522:Endocrine resistance,hsa04068:FoxO signaling pathway,hsa04110:Cell cycle,hsa04115:p53 signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04152:AMPK signaling pathway,hsa04218:Cellular senescence,hsa04310:Wnt signaling pathway,hsa04340:Hedgehog signaling pathway,hsa04371:Apelin signaling pathway,hsa04390:Hippo signaling pathway,hsa04510:Focal adhesion,hsa04530:Tight junction,hsa04630:JAK-STAT signaling pathway,hsa04917:Prolactin signaling pathway,hsa04919:Thyroid hormone signaling pathway,hsa04921:Oxytocin signaling pathway,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04934:Cushing syndrome,hsa04936:Alcoholic liver disease,hsa05160:Hepatitis C,hsa05162:Measles,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05169:Epstein-Barr virus infection,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05210:Colorectal cancer,hsa05212:Pancreatic cancer,hsa05213:Endometrial cancer,hsa05214:Glioma,hsa05215:Prostate cancer,hsa05216:Thyroid cancer,hsa05218:Melanoma,hsa05219:Bladder cancer,hsa05220:Chronic myeloid leukemia,hsa05221:Acute myeloid leukemia,hsa05222:Small cell lung cancer,hsa05223:Non-small cell lung cancer,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,hsa05416:Viral myocarditis,	114500~Colorectal cancer, susceptibility to,193300~von Hippel-Lindau syndrome, modifier of,254500~Multiple myeloma, susceptibility to,		SM00385:CYCLIN,SM01332:SM01332,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0227~DNA damage,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0656~Proto-oncogene,			KW-0195~Cyclin,KW-0678~Repressor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:Cyclin N-terminal,MUTAGEN:P->A,L,S: Reduced interaction with the DCX(AMBRA1) complex, and subsequent ubiquitination and degradation by the proteasome.,MUTAGEN:T->A: Reduced interaction with the DCX(AMBRA1) complex, and subsequent ubiquitination and degradation by the proteasome. Abolished ubiquitination and subsequent degradation following DNA damage.,MUTAGEN:TPT->ATA: Reduced ubiquitination and subsequent degradation by the proteasome.,REGION:Disordered,
CCND3	cyclin D3(CCND3)	Homo sapiens		h_cellcyclePathway:Cyclins and Cell Cycle Regulation,		GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001934~positive regulation of protein phosphorylation,GO:0007165~signal transduction,GO:0042098~T cell proliferation,GO:0042127~regulation of cell proliferation,GO:0044772~mitotic cell cycle phase transition,GO:0045737~positive regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0046626~regulation of insulin receptor signaling pathway,GO:0051301~cell division,GO:1900087~positive regulation of G1/S transition of mitotic cell cycle,	GO:0000307~cyclin-dependent protein kinase holoenzyme complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016020~membrane,GO:0097130~cyclin D3-CDK4 complex,	GO:0004693~cyclin-dependent protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0016538~cyclin-dependent protein serine/threonine kinase regulator activity,GO:0019901~protein kinase binding,	IPR004367:Cyclin, C-terminal domain,IPR006671:Cyclin, N-terminal,IPR013763:Cyclin-like,IPR015451:Cyclin D,	hsa04110:Cell cycle,hsa04115:p53 signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04218:Cellular senescence,hsa04310:Wnt signaling pathway,hsa04390:Hippo signaling pathway,hsa04510:Focal adhesion,hsa04630:JAK-STAT signaling pathway,hsa05162:Measles,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05207:Chemical carcinogenesis - receptor activation,			SM00385:CYCLIN,SM01332:SM01332,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0195~Cyclin,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:CYCLIN,DOMAIN:Cyclin N-terminal,DOMAIN:Cyclin_C,REGION:Disordered,
CCNE2	cyclin E2(CCNE2)	Homo sapiens				GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0000082~G1/S transition of mitotic cell cycle,GO:0000723~telomere maintenance,GO:0006270~DNA replication initiation,GO:0007129~synapsis,GO:0032880~regulation of protein localization,GO:0044772~mitotic cell cycle phase transition,GO:0051301~cell division,GO:0051726~regulation of cell cycle,GO:1903827~regulation of cellular protein localization,	GO:0000307~cyclin-dependent protein kinase holoenzyme complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0097134~cyclin E1-CDK2 complex,GO:0097135~cyclin E2-CDK2 complex,	GO:0005515~protein binding,GO:0016538~cyclin-dependent protein serine/threonine kinase regulator activity,GO:0019901~protein kinase binding,	IPR004367:Cyclin, C-terminal domain,IPR006671:Cyclin, N-terminal,IPR013763:Cyclin-like,	hsa04110:Cell cycle,hsa04114:Oocyte meiosis,hsa04115:p53 signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04218:Cellular senescence,hsa04934:Cushing syndrome,hsa05161:Hepatitis B,hsa05162:Measles,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05206:MicroRNAs in cancer,hsa05215:Prostate cancer,hsa05222:Small cell lung cancer,hsa05226:Gastric cancer,			SM00385:CYCLIN,SM01332:SM01332,	KW-0131~Cell cycle,KW-0132~Cell division,	KW-0539~Nucleus,				KW-0195~Cyclin,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Cyclin N-terminal,MUTAGEN:T->A: Increase of steady state level.,REGION:Disordered,
CCNF	cyclin F(CCNF)	Homo sapiens				GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0000209~protein polyubiquitination,GO:0000320~re-entry into mitotic cell cycle,GO:0001890~placenta development,GO:0010826~negative regulation of centrosome duplication,GO:0016567~protein ubiquitination,GO:0031146~SCF-dependent proteasomal ubiquitin-dependent protein catabolic process,GO:0043687~post-translational protein modification,GO:0044772~mitotic cell cycle phase transition,GO:0051301~cell division,GO:0051726~regulation of cell cycle,	GO:0000307~cyclin-dependent protein kinase holoenzyme complex,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005814~centriole,GO:0005829~cytosol,GO:0019005~SCF ubiquitin ligase complex,GO:0030054~cell junction,GO:0048471~perinuclear region of cytoplasm,	GO:0005515~protein binding,GO:0010997~anaphase-promoting complex binding,GO:0016538~cyclin-dependent protein serine/threonine kinase regulator activity,	IPR001810:F-box domain, cyclin-like,IPR004367:Cyclin, C-terminal domain,IPR006671:Cyclin, N-terminal,IPR011990:Tetratricopeptide-like helical,IPR013763:Cyclin-like,		619141~Frontotemporal dementia and/or amyotrophic lateral sclerosis 5,		SM00256:FBOX,SM00385:CYCLIN,SM01332:SM01332,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,KW-0833~Ubl conjugation pathway,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0036~Amyotrophic lateral sclerosis,KW-0225~Disease variant,KW-0523~Neurodegeneration,			KW-0195~Cyclin,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:Cyclin N-terminal,DOMAIN:F-box,MOTIF:D box 1,MOTIF:D box 2,MOTIF:D box 3,MOTIF:D box 4,MOTIF:D box 5,MOTIF:Nuclear localization signal 1,MOTIF:Nuclear localization signal 2,MUTAGEN:L->A: Abolishes the interaction with CP110 and RRM2; when associated with A-309.,MUTAGEN:LP->AA: Impairs interaction with SKP1 and CUL1 and prevents degradation of CP110, leading to promote the formation of micronuclei. Increased interaction with RRM2 and lack of RRM2 ubiquitination.,MUTAGEN:M->A: Reduced degradation of RRM2 after UV-induced DNA-damage. Abolishes the interaction with CP110 and RRM2; when associated with A-352.,MUTAGEN:MR->AA: Reduces the interaction with MYBL2/BMYB. Disrupts the interaction with CDC6. Does not dirupt interaction with CUL1.,MUTAGEN:RINL->AINA: Reduces the interaction with FZR1/CDH1.,MUTAGEN:RLQL->ALQA: Reduces the interaction with FZR1/CDH1. Abolishes the interaction with FZR1/CDH1; when associated with 310-R--L-313. Loss of ubiquitination and impaired degradation; when associated with 310-R--L-313.,MUTAGEN:RRRL->ARRA: Reduces the interaction with FZR1/CDH1.,MUTAGEN:RYIL->AYIA: Reduces the interaction with FZR1/CDH1. Reduced ubiquitination. Abolishes the interaction with FZR1/CDH1; when associated with 351-R--L-354. Loss of ubiquitination and impaired degradation; when associated with 351-R--L-354.,MUTAGEN:RYRL->AYRA: Reduces the interaction with FZR1/CDH1.,REGION:Disordered,REGION:PEST,
CCNH	cyclin H(CCNH)	Homo sapiens		h_cellcyclePathway:Cyclins and Cell Cycle Regulation,h_ptc1Pathway:Sonic Hedgehog (SHH) Receptor Ptc1 Regulates cell cycle,		GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0000082~G1/S transition of mitotic cell cycle,GO:0000086~G2/M transition of mitotic cell cycle,GO:0006283~transcription-coupled nucleotide-excision repair,GO:0006294~nucleotide-excision repair, preincision complex assembly,GO:0006351~transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006361~transcription initiation from RNA polymerase I promoter,GO:0006363~termination of RNA polymerase I transcription,GO:0006366~transcription from RNA polymerase II promoter,GO:0006367~transcription initiation from RNA polymerase II promoter,GO:0006368~transcription elongation from RNA polymerase II promoter,GO:0006370~7-methylguanosine mRNA capping,GO:0007049~cell cycle,GO:0050821~protein stabilization,GO:0070816~phosphorylation of RNA polymerase II C-terminal domain,GO:2000045~regulation of G1/S transition of mitotic cell cycle,	GO:0000439~core TFIIH complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005675~holo TFIIH complex,GO:0019907~cyclin-dependent protein kinase activating kinase holoenzyme complex,GO:0070516~CAK-ERCC2 complex,GO:0070985~TFIIK complex,	GO:0005515~protein binding,GO:0016538~cyclin-dependent protein serine/threonine kinase regulator activity,	IPR006671:Cyclin, N-terminal,IPR013763:Cyclin-like,IPR027081:CyclinH/Ccl1,	hsa03022:Basal transcription factors,hsa03420:Nucleotide excision repair,hsa04110:Cell cycle,			SM00385:CYCLIN,	KW-0131~Cell cycle,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0195~Cyclin,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:CYCLIN,MUTAGEN:S->A: No effect on the transcriptional activity of the reconstituted TFIIH complex.,REGION:Disordered,
CDK2	cyclin dependent kinase 2(CDK2)	Homo sapiens	157.14-3-3_Cell_Cycle,26.cyclin-CDK_complexes,4.cyclins_&_p27_cell_cycle,71.Id_proteins_G0-to-S_cell_cycle,94.E2F_transcriptional_activity_cell_cycle,	h_cellcyclePathway:Cyclins and Cell Cycle Regulation,h_EfpPathway:Estrogen-responsive protein Efp controls cell cycle and breast tumors growth,h_fbw7Pathway:Cyclin E Destruction Pathway,h_g1Pathway:Cell Cycle: G1/S Check Point ,h_mcmPathway:CDK Regulation of DNA Replication,h_p27Pathway:Regulation of p27 Phosphorylation during Cell Cycle Progression,h_p53Pathway:p53 Signaling Pathway,h_raccycdPathway:Influence of Ras and Rho proteins on G1 to S Transition,h_rbPathway:RB Tumor Suppressor/Checkpoint Signaling in response to DNA damage,h_skp2e2fPathway:E2F1 Destruction Pathway,		GO:0000082~G1/S transition of mitotic cell cycle,GO:0000086~G2/M transition of mitotic cell cycle,GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006260~DNA replication,GO:0006270~DNA replication initiation,GO:0006281~DNA repair,GO:0006468~protein phosphorylation,GO:0006813~potassium ion transport,GO:0007004~telomere maintenance via telomerase,GO:0007099~centriole replication,GO:0007165~signal transduction,GO:0007265~Ras protein signal transduction,GO:0008284~positive regulation of cell proliferation,GO:0010389~regulation of G2/M transition of mitotic cell cycle,GO:0010468~regulation of gene expression,GO:0016572~histone phosphorylation,GO:0018105~peptidyl-serine phosphorylation,GO:0030851~granulocyte differentiation,GO:0031145~anaphase-promoting complex-dependent catabolic process,GO:0031453~positive regulation of heterochromatin assembly,GO:0031571~mitotic G1 DNA damage checkpoint,GO:0032298~positive regulation of DNA-dependent DNA replication initiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0051298~centrosome duplication,GO:0051301~cell division,GO:0051321~meiotic cell cycle,GO:0060968~regulation of gene silencing,GO:0071732~cellular response to nitric oxide,GO:0090398~cellular senescence,GO:1901796~regulation of signal transduction by p53 class mediator,GO:1905784~regulation of anaphase-promoting complex-dependent catabolic process,	GO:0000307~cyclin-dependent protein kinase holoenzyme complex,GO:0000781~chromosome, telomeric region,GO:0000793~condensed chromosome,GO:0000805~X chromosome,GO:0000806~Y chromosome,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,GO:0005768~endosome,GO:0005813~centrosome,GO:0005829~cytosol,GO:0015030~Cajal body,GO:0097123~cyclin A1-CDK2 complex,GO:0097124~cyclin A2-CDK2 complex,GO:0097134~cyclin E1-CDK2 complex,GO:0097135~cyclin E2-CDK2 complex,	GO:0000287~magnesium ion binding,GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004693~cyclin-dependent protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0019904~protein domain specific binding,GO:0030332~cyclin binding,GO:0035173~histone kinase activity,GO:0046872~metal ion binding,GO:0097472~cyclin-dependent protein kinase activity,	IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,	hsa04068:FoxO signaling pathway,hsa04110:Cell cycle,hsa04114:Oocyte meiosis,hsa04115:p53 signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04218:Cellular senescence,hsa04914:Progesterone-mediated oocyte maturation,hsa04934:Cushing syndrome,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05215:Prostate cancer,hsa05222:Small cell lung cancer,hsa05226:Gastric cancer,			SM00220:S_TKc,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0227~DNA damage,KW-0234~DNA repair,KW-0469~Meiosis,KW-0498~Mitosis,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0967~Endosome,			KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0702~S-nitrosylation,	ACT_SITE:Proton acceptor,BINDING:ATP,DOMAIN:Protein kinase,METAL:Magnesium,MUTAGEN:K->F: Reduced phosphorylation by CAK.,MUTAGEN:KK->EV: Reduced phosphorylation by CAK.,MUTAGEN:L->R: Reduced phosphorylation by CAK and reduced kinase activity.,MUTAGEN:T->A: 2-fold increase in activity.,MUTAGEN:T->A: Abolishes activity.,MUTAGEN:Y->F: 2-fold increase in activity.,NP_BIND:ATP,SITE:CDK7 binding,
CDK4	cyclin dependent kinase 4(CDK4)	Homo sapiens	26.cyclin-CDK_complexes,4.cyclins_&_p27_cell_cycle,83.Growth_factors_Survival_factors_Mitogens,94.E2F_transcriptional_activity_cell_cycle,	h_cellcyclePathway:Cyclins and Cell Cycle Regulation,h_EfpPathway:Estrogen-responsive protein Efp controls cell cycle and breast tumors growth,h_g1Pathway:Cell Cycle: G1/S Check Point ,h_p53Pathway:p53 Signaling Pathway,h_raccycdPathway:Influence of Ras and Rho proteins on G1 to S Transition,h_rbPathway:RB Tumor Suppressor/Checkpoint Signaling in response to DNA damage,		GO:0000082~G1/S transition of mitotic cell cycle,GO:0002088~lens development in camera-type eye,GO:0006468~protein phosphorylation,GO:0007165~signal transduction,GO:0007623~circadian rhythm,GO:0008284~positive regulation of cell proliferation,GO:0009410~response to xenobiotic stimulus,GO:0009636~response to toxic substance,GO:0010288~response to lead ion,GO:0010468~regulation of gene expression,GO:0010971~positive regulation of G2/M transition of mitotic cell cycle,GO:0030851~granulocyte differentiation,GO:0031100~animal organ regeneration,GO:0032869~cellular response to insulin stimulus,GO:0033574~response to testosterone,GO:0040014~regulation of multicellular organism growth,GO:0042493~response to drug,GO:0043065~positive regulation of apoptotic process,GO:0045727~positive regulation of translation,GO:0045787~positive regulation of cell cycle,GO:0045793~positive regulation of cell size,GO:0046626~regulation of insulin receptor signaling pathway,GO:0046890~regulation of lipid biosynthetic process,GO:0048146~positive regulation of fibroblast proliferation,GO:0050790~regulation of catalytic activity,GO:0050994~regulation of lipid catabolic process,GO:0051301~cell division,GO:0051726~regulation of cell cycle,GO:0055093~response to hyperoxia,GO:0060260~regulation of transcription initiation from RNA polymerase II promoter,GO:0060612~adipose tissue development,GO:0071157~negative regulation of cell cycle arrest,GO:0071222~cellular response to lipopolysaccharide,GO:0071353~cellular response to interleukin-4,GO:1904628~cellular response to phorbol 13-acetate 12-myristate,GO:1904637~cellular response to ionomycin,GO:2000134~negative regulation of G1/S transition of mitotic cell cycle,	GO:0000307~cyclin-dependent protein kinase holoenzyme complex,GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005730~nucleolus,GO:0005829~cytosol,GO:0005923~bicellular tight junction,GO:0016592~mediator complex,GO:0031965~nuclear membrane,GO:0048471~perinuclear region of cytoplasm,GO:0097128~cyclin D1-CDK4 complex,GO:0097129~cyclin D2-CDK4 complex,GO:0097130~cyclin D3-CDK4 complex,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004693~cyclin-dependent protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008353~RNA polymerase II carboxy-terminal domain kinase activity,GO:0016301~kinase activity,GO:0016538~cyclin-dependent protein serine/threonine kinase regulator activity,GO:0030332~cyclin binding,GO:0044877~macromolecular complex binding,	IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,	hsa01522:Endocrine resistance,hsa04110:Cell cycle,hsa04115:p53 signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04218:Cellular senescence,hsa04530:Tight junction,hsa04660:T cell receptor signaling pathway,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04934:Cushing syndrome,hsa05160:Hepatitis C,hsa05162:Measles,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05169:Epstein-Barr virus infection,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05212:Pancreatic cancer,hsa05214:Glioma,hsa05218:Melanoma,hsa05219:Bladder cancer,hsa05220:Chronic myeloid leukemia,hsa05222:Small cell lung cancer,hsa05223:Non-small cell lung cancer,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,	609048~Melanoma, cutaneous malignant, 3,		SM00220:S_TKc,	KW-0131~Cell cycle,KW-0132~Cell division,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0195~Cyclin,KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:ATP,DOMAIN:Protein kinase,MUTAGEN:P->S: No effect on in vitro phosphorylation by CDK7. Greatly reduced T-172 phosphorylation and enzyme activity.,MUTAGEN:T->A: Weak enzyme activity towards RB1, but no effect on binding of CCDN1 nor CCDN3.,MUTAGEN:T->E: Retains moderate enzyme activity.,NP_BIND:ATP,REGION:Required for binding D-type cyclins,
CDK5R1	cyclin dependent kinase 5 regulatory subunit 1(CDK5R1)	Homo sapiens		h_cdk5Pathway:Phosphorylation of MEK1 by cdk5/p35 down regulates the MAP kinase pathway,h_ck1Pathway:Regulation of ck1/cdk5 by type 1 glutamate receptors,h_Lis1Pathway:Lissencephaly gene (LIS1) in neuronal migration and development,h_p35AlzheimersPathway:Deregulation of CDK5 in Alzheimers Disease,h_rac1Pathway:Rac 1 cell motility signaling pathway,h_reelinPathway:Reelin Signaling Pathway,		GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0000226~microtubule cytoskeleton organization,GO:0001764~neuron migration,GO:0007158~neuron cell-cell adhesion,GO:0007213~G-protein coupled acetylcholine receptor signaling pathway,GO:0007411~axon guidance,GO:0007413~axonal fasciculation,GO:0007420~brain development,GO:0009792~embryo development ending in birth or egg hatching,GO:0016241~regulation of macroautophagy,GO:0018105~peptidyl-serine phosphorylation,GO:0018107~peptidyl-threonine phosphorylation,GO:0021549~cerebellum development,GO:0021722~superior olivary nucleus maturation,GO:0021766~hippocampus development,GO:0021819~layer formation in cerebral cortex,GO:0030182~neuron differentiation,GO:0030517~negative regulation of axon extension,GO:0031116~positive regulation of microtubule polymerization,GO:0031175~neuron projection development,GO:0032147~activation of protein kinase activity,GO:0032956~regulation of actin cytoskeleton organization,GO:0035235~ionotropic glutamate receptor signaling pathway,GO:0042501~serine phosphorylation of STAT protein,GO:0043525~positive regulation of neuron apoptotic process,GO:0045348~positive regulation of MHC class II biosynthetic process,GO:0045664~regulation of neuron differentiation,GO:0045737~positive regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0045892~negative regulation of transcription, DNA-templated,GO:0048013~ephrin receptor signaling pathway,GO:0048511~rhythmic process,GO:0061001~regulation of dendritic spine morphogenesis,GO:0070315~G1 to G0 transition involved in cell differentiation,GO:0071158~positive regulation of cell cycle arrest,GO:0090314~positive regulation of protein targeting to membrane,GO:1901796~regulation of signal transduction by p53 class mediator,GO:2000273~positive regulation of receptor activity,	GO:0000307~cyclin-dependent protein kinase holoenzyme complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0014069~postsynaptic density,GO:0016020~membrane,GO:0016533~cyclin-dependent protein kinase 5 holoenzyme complex,GO:0030424~axon,GO:0030425~dendrite,GO:0030426~growth cone,GO:0031594~neuromuscular junction,GO:0043005~neuron projection,GO:0043025~neuronal cell body,GO:0043197~dendritic spine,GO:0043204~perikaryon,GO:0043231~intracellular membrane-bounded organelle,GO:0043292~contractile fiber,GO:0048471~perinuclear region of cytoplasm,GO:0098793~presynapse,	GO:0002020~protease binding,GO:0004672~protein kinase activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0016301~kinase activity,GO:0019901~protein kinase binding,GO:0030295~protein kinase activator activity,GO:0035255~ionotropic glutamate receptor binding,GO:0043014~alpha-tubulin binding,GO:0043539~protein serine/threonine kinase activator activity,GO:0045296~cadherin binding,GO:0046875~ephrin receptor binding,GO:0048487~beta-tubulin binding,GO:0051015~actin filament binding,GO:0061575~cyclin-dependent protein serine/threonine kinase activator activity,	IPR004944:Cyclin-dependent kinase 5 activator,	hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05030:Cocaine addiction,		PIRSF009324:cyclin-dependent kinase 5, regulatory subunit (activating),		KW-0090~Biological rhythms,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,				KW-0418~Kinase,KW-0808~Transferase,	KW-0449~Lipoprotein,KW-0519~Myristate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,LIPID:N-myristoyl glycine,MUTAGEN:G->A: Absent from the cell periphery.,MUTAGEN:L->A: In L-3A mutant; abolished recognition and ubiquitination by the CRL2(FEM1B) complex.,MUTAGEN:L->R: In L-3R mutant; abolished recognition and ubiquitination by the CRL2(FEM1B) complex, while promoting recognition and ubiquitination by the CRL2(FEM1B) complex.,MUTAGEN:S->A: Increased susceptibility to calpain.,MUTAGEN:S->E: Reduced susceptibility to calpain.,MUTAGEN:T->A: Increased susceptibility to calpain.,MUTAGEN:T->E: Reduced susceptibility to calpain.,REGION:Disordered,SITE:Cleavage; by calpain,
CDK6	cyclin dependent kinase 6(CDK6)	Homo sapiens	26.cyclin-CDK_complexes,4.cyclins_&_p27_cell_cycle,71.Id_proteins_G0-to-S_cell_cycle,83.Growth_factors_Survival_factors_Mitogens,94.E2F_transcriptional_activity_cell_cycle,	h_cellcyclePathway:Cyclins and Cell Cycle Regulation,h_EfpPathway:Estrogen-responsive protein Efp controls cell cycle and breast tumors growth,h_g1Pathway:Cell Cycle: G1/S Check Point ,h_raccycdPathway:Influence of Ras and Rho proteins on G1 to S Transition,		GO:0000082~G1/S transition of mitotic cell cycle,GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001954~positive regulation of cell-matrix adhesion,GO:0003323~type B pancreatic cell development,GO:0006468~protein phosphorylation,GO:0007050~cell cycle arrest,GO:0007219~Notch signaling pathway,GO:0008285~negative regulation of cell proliferation,GO:0009615~response to virus,GO:0010468~regulation of gene expression,GO:0010628~positive regulation of gene expression,GO:0014002~astrocyte development,GO:0021542~dentate gyrus development,GO:0021670~lateral ventricle development,GO:0033077~T cell differentiation in thymus,GO:0042063~gliogenesis,GO:0043697~cell dedifferentiation,GO:0045596~negative regulation of cell differentiation,GO:0045638~negative regulation of myeloid cell differentiation,GO:0045646~regulation of erythrocyte differentiation,GO:0045656~negative regulation of monocyte differentiation,GO:0045668~negative regulation of osteoblast differentiation,GO:0045786~negative regulation of cell cycle,GO:0048146~positive regulation of fibroblast proliferation,GO:0048699~generation of neurons,GO:0050680~negative regulation of epithelial cell proliferation,GO:0051301~cell division,GO:0051726~regulation of cell cycle,GO:0060218~hematopoietic stem cell differentiation,GO:1902036~regulation of hematopoietic stem cell differentiation,GO:2000134~negative regulation of G1/S transition of mitotic cell cycle,GO:2000145~regulation of cell motility,GO:2000773~negative regulation of cellular senescence,	GO:0000307~cyclin-dependent protein kinase holoenzyme complex,GO:0001726~ruffle,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0016592~mediator complex,GO:0097132~cyclin D2-CDK6 complex,	GO:0004693~cyclin-dependent protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008353~RNA polymerase II carboxy-terminal domain kinase activity,GO:0030332~cyclin binding,GO:0098770~FBXO family protein binding,	IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,	hsa04110:Cell cycle,hsa04115:p53 signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04218:Cellular senescence,hsa04934:Cushing syndrome,hsa05160:Hepatitis C,hsa05162:Measles,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05169:Epstein-Barr virus infection,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05206:MicroRNAs in cancer,hsa05212:Pancreatic cancer,hsa05214:Glioma,hsa05218:Melanoma,hsa05220:Chronic myeloid leukemia,hsa05222:Small cell lung cancer,hsa05223:Non-small cell lung cancer,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,	616080~Microcephaly 12, primary, autosomal recessive,		SM00220:S_TKc,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0221~Differentiation,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,	KW-0225~Disease variant,KW-0905~Primary microcephaly,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:ATP,DOMAIN:Protein kinase,NP_BIND:ATP,
CDK7	cyclin dependent kinase 7(CDK7)	Homo sapiens		h_cellcyclePathway:Cyclins and Cell Cycle Regulation,h_EfpPathway:Estrogen-responsive protein Efp controls cell cycle and breast tumors growth,h_ptc1Pathway:Sonic Hedgehog (SHH) Receptor Ptc1 Regulates cell cycle,h_rarPathway:Degradation of the RAR and RXR by the proteasome,		GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0000082~G1/S transition of mitotic cell cycle,GO:0000086~G2/M transition of mitotic cell cycle,GO:0006281~DNA repair,GO:0006283~transcription-coupled nucleotide-excision repair,GO:0006294~nucleotide-excision repair, preincision complex assembly,GO:0006361~transcription initiation from RNA polymerase I promoter,GO:0006363~termination of RNA polymerase I transcription,GO:0006366~transcription from RNA polymerase II promoter,GO:0006367~transcription initiation from RNA polymerase II promoter,GO:0006368~transcription elongation from RNA polymerase II promoter,GO:0006370~7-methylguanosine mRNA capping,GO:0006468~protein phosphorylation,GO:0007049~cell cycle,GO:0007050~cell cycle arrest,GO:0042795~snRNA transcription from RNA polymerase II promoter,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050821~protein stabilization,GO:0051301~cell division,GO:0051726~regulation of cell cycle,GO:0070816~phosphorylation of RNA polymerase II C-terminal domain,GO:2000045~regulation of G1/S transition of mitotic cell cycle,	GO:0000439~core TFIIH complex,GO:0001650~fibrillar center,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005675~holo TFIIH complex,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0019907~cyclin-dependent protein kinase activating kinase holoenzyme complex,GO:0048471~perinuclear region of cytoplasm,GO:0070516~CAK-ERCC2 complex,GO:0070985~TFIIK complex,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004693~cyclin-dependent protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008022~protein C-terminus binding,GO:0008094~DNA-dependent ATPase activity,GO:0008353~RNA polymerase II carboxy-terminal domain kinase activity,	IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,	hsa03022:Basal transcription factors,hsa03420:Nucleotide excision repair,hsa04110:Cell cycle,			SM00220:S_TKc,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0227~DNA damage,KW-0234~DNA repair,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:ATP,DOMAIN:Protein kinase,MUTAGEN:F->G: Enhanced capacity to bind ATP analogs.,MUTAGEN:K->A: Total loss of activity.,MUTAGEN:K->M: No effect on interaction with HINT1.,MUTAGEN:S->A: No mitotic repression of transcriptional activity of the reconstituted TFIIH complex.,MUTAGEN:T->A: Total loss of activity. Total loss of transcriptional activity of the reconstituted TFIIH complex.,MUTAGEN:T->E: No effect on interaction with HINT1.,NP_BIND:ATP,
CDKN1A	cyclin dependent kinase inhibitor 1A(CDKN1A)	Homo sapiens	1.RBphosphoE2F,108.Regulating_glucose_transport,157.14-3-3_Cell_Cycle,26.cyclin-CDK_complexes,94.E2F_transcriptional_activity_cell_cycle,	h_atmPathway:ATM Signaling Pathway,h_calcineurinPathway:Effects of calcineurin in Keratinocyte Differentiation,h_cellcyclePathway:Cyclins and Cell Cycle Regulation,h_eponfkbPathway:Erythropoietin mediated neuroprotection through NF-kB,h_g1Pathway:Cell Cycle: G1/S Check Point ,h_g2Pathway:Cell Cycle: G2/M Checkpoint,h_p53hypoxiaPathway:Hypoxia and p53 in the Cardiovascular system,h_p53Pathway:p53 Signaling Pathway,h_raccycdPathway:Influence of Ras and Rho proteins on G1 to S Transition,		GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0000082~G1/S transition of mitotic cell cycle,GO:0000086~G2/M transition of mitotic cell cycle,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006606~protein import into nucleus,GO:0006974~cellular response to DNA damage stimulus,GO:0006977~DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest,GO:0006978~DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator,GO:0007050~cell cycle arrest,GO:0007095~mitotic G2 DNA damage checkpoint,GO:0007265~Ras protein signal transduction,GO:0007507~heart development,GO:0008285~negative regulation of cell proliferation,GO:0009636~response to toxic substance,GO:0010165~response to X-ray,GO:0010243~response to organonitrogen compound,GO:0010389~regulation of G2/M transition of mitotic cell cycle,GO:0010629~negative regulation of gene expression,GO:0019221~cytokine-mediated signaling pathway,GO:0030308~negative regulation of cell growth,GO:0030851~granulocyte differentiation,GO:0030890~positive regulation of B cell proliferation,GO:0031100~animal organ regeneration,GO:0031668~cellular response to extracellular stimulus,GO:0032091~negative regulation of protein binding,GO:0034198~cellular response to amino acid starvation,GO:0034605~cellular response to heat,GO:0042060~wound healing,GO:0042246~tissue regeneration,GO:0042326~negative regulation of phosphorylation,GO:0042493~response to drug,GO:0042771~intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator,GO:0043066~negative regulation of apoptotic process,GO:0043068~positive regulation of programmed cell death,GO:0045736~negative regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0045860~positive regulation of protein kinase activity,GO:0046685~response to arsenic-containing substance,GO:0048146~positive regulation of fibroblast proliferation,GO:0050821~protein stabilization,GO:0051412~response to corticosterone,GO:0051726~regulation of cell cycle,GO:0055093~response to hyperoxia,GO:0060260~regulation of transcription initiation from RNA polymerase II promoter,GO:0060574~intestinal epithelial cell maturation,GO:0071479~cellular response to ionizing radiation,GO:0071480~cellular response to gamma radiation,GO:0071493~cellular response to UV-B,GO:0071850~mitotic cell cycle arrest,GO:0090398~cellular senescence,GO:0090399~replicative senescence,GO:0090400~stress-induced premature senescence,GO:0097193~intrinsic apoptotic signaling pathway,GO:1902806~regulation of cell cycle G1/S phase transition,GO:1904030~negative regulation of cyclin-dependent protein kinase activity,GO:1904031~positive regulation of cyclin-dependent protein kinase activity,GO:1904706~negative regulation of vascular smooth muscle cell proliferation,GO:1905179~negative regulation of cardiac muscle tissue regeneration,GO:2000045~regulation of G1/S transition of mitotic cell cycle,GO:2000134~negative regulation of G1/S transition of mitotic cell cycle,GO:2000278~regulation of DNA biosynthetic process,GO:2000279~negative regulation of DNA biosynthetic process,GO:2000379~positive regulation of reactive oxygen species metabolic process,	GO:0000307~cyclin-dependent protein kinase holoenzyme complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005829~cytosol,GO:0016604~nuclear body,GO:0032991~macromolecular complex,GO:0048471~perinuclear region of cytoplasm,GO:0070557~PCNA-p21 complex,	GO:0004860~protein kinase inhibitor activity,GO:0004861~cyclin-dependent protein serine/threonine kinase inhibitor activity,GO:0005515~protein binding,GO:0016301~kinase activity,GO:0019901~protein kinase binding,GO:0019912~cyclin-dependent protein kinase activating kinase activity,GO:0030332~cyclin binding,GO:0031625~ubiquitin protein ligase binding,GO:0044877~macromolecular complex binding,GO:0046872~metal ion binding,	IPR003175:Cyclin-dependent kinase inhibitor,	hsa01522:Endocrine resistance,hsa01524:Platinum drug resistance,hsa04012:ErbB signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04068:FoxO signaling pathway,hsa04110:Cell cycle,hsa04115:p53 signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04218:Cellular senescence,hsa04630:JAK-STAT signaling pathway,hsa04921:Oxytocin signaling pathway,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04934:Cushing syndrome,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05169:Epstein-Barr virus infection,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05203:Viral carcinogenesis,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,hsa05210:Colorectal cancer,hsa05211:Renal cell carcinoma,hsa05212:Pancreatic cancer,hsa05213:Endometrial cancer,hsa05214:Glioma,hsa05215:Prostate cancer,hsa05216:Thyroid cancer,hsa05217:Basal cell carcinoma,hsa05218:Melanoma,hsa05219:Bladder cancer,hsa05220:Chronic myeloid leukemia,hsa05222:Small cell lung cancer,hsa05223:Non-small cell lung cancer,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,				KW-0131~Cell cycle,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0418~Kinase,KW-0649~Protein kinase inhibitor,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	CROSSLNK:Glycyl serine ester (Ser-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:CDI,MOTIF:Nuclear localization signal,MOTIF:PIP-box K+4 motif,MUTAGEN:K->A: Loss of interaction with TRIM39.,MUTAGEN:KRR->AAA: Abolishes degradation by the proteasome without affecting the interaction with PCNA.,MUTAGEN:MTDFY->ATDAAA: Abolishes interaction with PCNA and subsequent degradation by the proteasome.,MUTAGEN:QTSMTDF->ATSATDA: Abolishes interaction with PCNA and subsequent degradation by the proteasome.,MUTAGEN:S->A: No change in interaction with PCNA. Abolishes UV radiation-induced phosphorylation and subsequent degradation.,MUTAGEN:S->D: Reduces interaction with PCNA.,MUTAGEN:S->E: Phosphomimetic mutant, increases ubiquitination by the DCX(DTL) complex.,MUTAGEN:T->A: Abolishes UV radiation-induced phosphorylation and subsequent degradation.,MUTAGEN:T->A: Reduces phosphorylation by Akt; no change in interaction with PCNA, CDK2 or CDK4; no change in subcellular location.,MUTAGEN:T->D: No interaction with PCNA; 59% inhibition of CDK2 binding; modest inhibition of CDK4 binding; no change in subcellular location.,REGION:Disordered,REGION:Interaction with TRIM39,REGION:Required for binding CDKs,REGION:Required for binding cyclins,ZN_FING:C4-type,
CDKN1B	cyclin dependent kinase inhibitor 1B(CDKN1B)	Homo sapiens	1.RBphosphoE2F,26.cyclin-CDK_complexes,4.cyclins_&_p27_cell_cycle,62.G1-phase_progression_by_Myc,84.Ubiquitination_Pathways_Cell_Cycle,	h_cellcyclePathway:Cyclins and Cell Cycle Regulation,h_ctcfPathway:CTCF: First Multivalent Nuclear Factor,h_g1Pathway:Cell Cycle: G1/S Check Point ,h_mcmPathway:CDK Regulation of DNA Replication,h_p27Pathway:Regulation of p27 Phosphorylation during Cell Cycle Progression,h_ptenPathway:PTEN dependent cell cycle arrest and apoptosis,h_raccycdPathway:Influence of Ras and Rho proteins on G1 to S Transition,		GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0000082~G1/S transition of mitotic cell cycle,GO:0001666~response to hypoxia,GO:0001890~placenta development,GO:0006813~potassium ion transport,GO:0006977~DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest,GO:0007050~cell cycle arrest,GO:0007096~regulation of exit from mitosis,GO:0007219~Notch signaling pathway,GO:0007507~heart development,GO:0007605~sensory perception of sound,GO:0008219~cell death,GO:0008284~positive regulation of cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0009410~response to xenobiotic stimulus,GO:0009749~response to glucose,GO:0010942~positive regulation of cell death,GO:0019221~cytokine-mediated signaling pathway,GO:0030308~negative regulation of cell growth,GO:0031116~positive regulation of microtubule polymerization,GO:0032355~response to estradiol,GO:0033673~negative regulation of kinase activity,GO:0042127~regulation of cell proliferation,GO:0042326~negative regulation of phosphorylation,GO:0042493~response to drug,GO:0043066~negative regulation of apoptotic process,GO:0043200~response to amino acid,GO:0043434~response to peptide hormone,GO:0045732~positive regulation of protein catabolic process,GO:0045736~negative regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0045737~positive regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0045786~negative regulation of cell cycle,GO:0045787~positive regulation of cell cycle,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045930~negative regulation of mitotic cell cycle,GO:0046686~response to cadmium ion,GO:0048102~autophagic cell death,GO:0048839~inner ear development,GO:0051271~negative regulation of cellular component movement,GO:0051726~regulation of cell cycle,GO:0060770~negative regulation of epithelial cell proliferation involved in prostate gland development,GO:0071236~cellular response to antibiotic,GO:0071285~cellular response to lithium ion,GO:0071407~cellular response to organic cyclic compound,GO:0071850~mitotic cell cycle arrest,GO:0090398~cellular senescence,GO:1902746~regulation of lens fiber cell differentiation,GO:1902806~regulation of cell cycle G1/S phase transition,GO:1902807~negative regulation of cell cycle G1/S phase transition,GO:1904030~negative regulation of cyclin-dependent protein kinase activity,GO:1904706~negative regulation of vascular smooth muscle cell proliferation,GO:1905179~negative regulation of cardiac muscle tissue regeneration,GO:2000045~regulation of G1/S transition of mitotic cell cycle,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005768~endosome,GO:0005829~cytosol,GO:0031464~Cul4A-RING E3 ubiquitin ligase complex,GO:0032991~macromolecular complex,GO:0043231~intracellular membrane-bounded organelle,	GO:0004860~protein kinase inhibitor activity,GO:0004861~cyclin-dependent protein serine/threonine kinase inhibitor activity,GO:0005515~protein binding,GO:0016301~kinase activity,GO:0019901~protein kinase binding,GO:0019903~protein phosphatase binding,GO:0030332~cyclin binding,GO:0030544~Hsp70 protein binding,GO:0044877~macromolecular complex binding,GO:0051087~chaperone binding,	IPR003175:Cyclin-dependent kinase inhibitor,	hsa01522:Endocrine resistance,hsa04012:ErbB signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04068:FoxO signaling pathway,hsa04110:Cell cycle,hsa04151:PI3K-Akt signaling pathway,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04934:Cushing syndrome,hsa05162:Measles,hsa05165:Human papillomavirus infection,hsa05169:Epstein-Barr virus infection,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05203:Viral carcinogenesis,hsa05206:MicroRNAs in cancer,hsa05215:Prostate cancer,hsa05220:Chronic myeloid leukemia,hsa05222:Small cell lung cancer,hsa05226:Gastric cancer,	610755~Multiple endocrine neoplasia, type IV,			KW-0131~Cell cycle,	KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0967~Endosome,	KW-0043~Tumor suppressor,	KW-0175~Coiled coil,		KW-0195~Cyclin,KW-0418~Kinase,KW-0649~Protein kinase inhibitor,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,DOMAIN:CDI,MOTIF:Nuclear localization signal,MUTAGEN:E->A,D,Q: Strongly reduced ubiquitination by a TRIM21-containing SCF(SKP2) complex.,MUTAGEN:S->A: Loss of phosphorylation by UHMK1. No translocation to the cytoplasm. Greater cell cycle arrest.,MUTAGEN:S->A: No change in PKB/AKT1-mediated phosphorylation.,MUTAGEN:S->D: Exported to the cytoplasm. Inhibits cell cycle arrest.,MUTAGEN:S->E: Increased stability in vivo and in vitro.,MUTAGEN:T->A,D: Abolishes PKB/AKT1-mediated phosphorylation. 46% cytoplasmic location. Greatly reduced binding to YWHAQ. Equally reduced binding; when associated with A-10 and A-187. No nuclear import; when associated with A-157. Completely abolishes PKB/AKT1-mediated phosphorylation and no cytoplasmic translocation; when associated with A-157.,MUTAGEN:T->A,D: No change in PKB/AKT1- nor UHMK1-mediated phosphorylation.,MUTAGEN:T->A: Abolishes phosphorylation-dependent ubiquitination.,MUTAGEN:T->A: Greatly reduced PKB/AKT1-mediated phosphorylation. Nuclear location. Inhibits cyclin E/CDK2 cell cycle progression. No effect on binding AKT1. Completely abolishes PKB/AKT1-mediated phosphorylation and no cytoplasmic translocation; when associated with A-198.,MUTAGEN:T->A: No change in PKB/AKT1-mediated phosphorylation.,MUTAGEN:Y->F: Abolishes LYN-mediated phosphorylation, reduces CDK2-mediated phosphorylation on T-187, has greater cell cycle arrest into S-phase, no effect on binding CDK2 complexes, reduced CDK4 binding and inhibits CDK4 enzyme activity. No nuclear translocation. No effect on in vitro phosphorylation of CDK4 by CCNH-CDK7. Completely abolishes CDK4 binding; when associated with F-89.,MUTAGEN:Y->F: No change in binding CDK4 and no inhibition of CDK4 activity. Translocates to nucleus. No effect on in vitro phosphorylation of CDK4 by CCNH-CDK7.,MUTAGEN:Y->F: No effect on binding CDK2 complexes, reduced CDK4 binding and greatly inhibits CDK4 enzyme activity. No nuclear translocation. Inhibits in vitro phosphorylation of CDK4 by CCNH-CDK7. Completely abolishes CDK4 binding; when associated with F-88.,REGION:Disordered,REGION:Interaction with CDK2,
CDKN2A	cyclin dependent kinase inhibitor 2A(CDKN2A)	Homo sapiens	1.RBphosphoE2F,26.cyclin-CDK_complexes,94.E2F_transcriptional_activity_cell_cycle,	h_arfPathway:Tumor Suppressor Arf Inhibits Ribosomal Biogenesis,h_cellcyclePathway:Cyclins and Cell Cycle Regulation,h_ctcfPathway:CTCF: First Multivalent Nuclear Factor,h_g1Pathway:Cell Cycle: G1/S Check Point ,		GO:0000082~G1/S transition of mitotic cell cycle,GO:0000209~protein polyubiquitination,GO:0000422~mitophagy,GO:0001953~negative regulation of cell-matrix adhesion,GO:0006364~rRNA processing,GO:0006469~negative regulation of protein kinase activity,GO:0006915~apoptotic process,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0007049~cell cycle,GO:0007050~cell cycle arrest,GO:0007265~Ras protein signal transduction,GO:0008285~negative regulation of cell proliferation,GO:0008637~apoptotic mitochondrial changes,GO:0010389~regulation of G2/M transition of mitotic cell cycle,GO:0010628~positive regulation of gene expression,GO:0030308~negative regulation of cell growth,GO:0030889~negative regulation of B cell proliferation,GO:0031647~regulation of protein stability,GO:0031648~protein destabilization,GO:0032088~negative regulation of NF-kappaB transcription factor activity,GO:0033088~negative regulation of immature T cell proliferation in thymus,GO:0033235~positive regulation of protein sumoylation,GO:0034393~positive regulation of smooth muscle cell apoptotic process,GO:0035986~senescence-associated heterochromatin focus assembly,GO:0042326~negative regulation of phosphorylation,GO:0043065~positive regulation of apoptotic process,GO:0043517~positive regulation of DNA damage response, signal transduction by p53 class mediator,GO:0045736~negative regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046825~regulation of protein export from nucleus,GO:0048103~somatic stem cell division,GO:0050821~protein stabilization,GO:0051444~negative regulation of ubiquitin-protein transferase activity,GO:0051726~regulation of cell cycle,GO:0051882~mitochondrial depolarization,GO:0060260~regulation of transcription initiation from RNA polymerase II promoter,GO:0070534~protein K63-linked ubiquitination,GO:0071158~positive regulation of cell cycle arrest,GO:0090398~cellular senescence,GO:0090399~replicative senescence,GO:0097193~intrinsic apoptotic signaling pathway,GO:1900182~positive regulation of protein localization to nucleus,GO:1901796~regulation of signal transduction by p53 class mediator,GO:1901798~positive regulation of signal transduction by p53 class mediator,GO:1902510~regulation of apoptotic DNA fragmentation,GO:1903051~negative regulation of proteolysis involved in cellular protein catabolic process,GO:1903214~regulation of protein targeting to mitochondrion,GO:1904667~negative regulation of ubiquitin protein ligase activity,GO:1990000~amyloid fibril formation,GO:2000045~regulation of G1/S transition of mitotic cell cycle,GO:2000059~negative regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process,GO:2000111~positive regulation of macrophage apoptotic process,GO:2000134~negative regulation of G1/S transition of mitotic cell cycle,GO:2000435~negative regulation of protein neddylation,GO:2000774~positive regulation of cellular senescence,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005829~cytosol,GO:0032991~macromolecular complex,GO:0035985~senescence-associated heterochromatin focus,	GO:0002039~p53 binding,GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0004861~cyclin-dependent protein serine/threonine kinase inhibitor activity,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0016301~kinase activity,GO:0019789~SUMO transferase activity,GO:0019901~protein kinase binding,GO:0051059~NF-kappaB binding,GO:0055105~ubiquitin-protein transferase inhibitor activity,GO:0097371~MDM2/MDM4 family protein binding,GO:0097718~disordered domain specific binding,GO:1990948~ubiquitin ligase inhibitor activity,	IPR010868:Cyclin-dependent kinase inhibitor 2A,IPR020683:Ankyrin repeat-containing domain,	hsa01522:Endocrine resistance,hsa01524:Platinum drug resistance,hsa04110:Cell cycle,hsa04115:p53 signaling pathway,hsa04218:Cellular senescence,hsa04934:Cushing syndrome,hsa05163:Human cytomegalovirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05206:MicroRNAs in cancer,hsa05212:Pancreatic cancer,hsa05214:Glioma,hsa05218:Melanoma,hsa05219:Bladder cancer,hsa05220:Chronic myeloid leukemia,hsa05223:Non-small cell lung cancer,hsa05225:Hepatocellular carcinoma,	155601~Melanoma, cutaneous malignant, 2,155755~Melanoma and neural system tumor syndrome,606719~Melanoma-pancreatic cancer syndrome,			KW-0053~Apoptosis,KW-0131~Cell cycle,KW-0698~rRNA processing,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0833~Ubl conjugation pathway,	KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0043~Tumor suppressor,KW-0225~Disease variant,KW-0435~Li-Fraumeni syndrome,KW-9993~Li-Fraumeni syndrome,	KW-0040~ANK repeat,KW-0677~Repeat,		KW-0195~Cyclin,KW-0238~DNA-binding,KW-0418~Kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	REGION:Disordered,REGION:Interaction with CDK5RAP3 and MDM2,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,
CSRP1	cysteine and glycine rich protein 1(CSRP1)	Homo sapiens				GO:0030036~actin cytoskeleton organization,GO:0045214~sarcomere organization,GO:0060537~muscle tissue development,GO:0070527~platelet aggregation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005925~focal adhesion,GO:0030018~Z disc,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0008307~structural constituent of muscle,GO:0042805~actinin binding,GO:0046872~metal ion binding,	IPR001781:Zinc finger, LIM-type,				SM00132:LIM,		KW-0539~Nucleus,		KW-0440~LIM domain,KW-0677~Repeat,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:LIM zinc-binding,DOMAIN:LIM zinc-binding 1,DOMAIN:LIM zinc-binding 2,MOTIF:Nuclear localization signal,
CHIC2	cysteine rich hydrophobic domain 2(CHIC2)	Homo sapiens					GO:0005794~Golgi apparatus,GO:0005798~Golgi-associated vesicle,GO:0005886~plasma membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0005515~protein binding,	IPR019383:Golgin subfamily A member 7/ERF4,		601626~Leukemia, acute myeloid,				KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0175~Coiled coil,			KW-0449~Lipoprotein,KW-0564~Palmitate,	MOTIF:CHIC motif (Cys-rich),MUTAGEN:CGCLCCCC->SGSLSSSS: Loss of palmitoylation. Abolishes membrane association.,SITE:Breakpoint for translocation to form CHIC2-ETV6 in AML,
CRELD2	cysteine rich with EGF like domains 2(CRELD2)	Homo sapiens					GO:0005615~extracellular space,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,	GO:0003756~protein disulfide isomerase activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,	IPR000152:EGF-type aspartate/asparagine hydroxylation site,IPR000742:Epidermal growth factor-like domain,IPR001881:EGF-like calcium-binding,IPR002049:EGF-like, laminin,IPR006212:Furin-like repeat,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR018097:EGF-like calcium-binding, conserved site,IPR021852:Domain of unknown function DUF3456,				SM00179:EGF_CA,SM00181:EGF,SM00261:FU,		KW-0256~Endoplasmic reticulum,		KW-0245~EGF-like domain,KW-0676~Redox-active center,KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,	KW-0413~Isomerase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Redox-active,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 2; calcium-binding,MOTIF:CXXC,REGION:Disordered,REPEAT:FU 1,REPEAT:FU 2,
CYB561	cytochrome b561(CYB561)	Homo sapiens				GO:0006879~cellular iron ion homeostasis,GO:0022900~electron transport chain,	GO:0005765~lysosomal membrane,GO:0016021~integral component of membrane,GO:0030658~transport vesicle membrane,GO:0042584~chromaffin granule membrane,	GO:0000293~ferric-chelate reductase activity,GO:0005515~protein binding,GO:0016491~oxidoreductase activity,GO:0046872~metal ion binding,	IPR006593:Cytochrome b561/ferric reductase transmembrane,		618182~Orthostatic hypotension 2,		SM00665:B561,	KW-0249~Electron transport,KW-0813~Transport,	KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,	KW-0225~Disease variant,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0349~Heme,KW-0408~Iron,KW-0479~Metal-binding,	KW-1278~Translocase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	BINDING:Ascorbate,BINDING:Heme b 1,BINDING:Heme b 2,DOMAIN:Cytochrome b561,METAL:Iron 1 (heme b 1 axial ligand); via tele nitrogen,METAL:Iron 2 (heme b 2 axial ligand); via tele nitrogen,REGION:Heme b 1 binding,TOPO_DOM:Cytoplasmic,TOPO_DOM:Vesicular,TRANSMEM:Helical,
CYCS	cytochrome c, somatic(CYCS)	Homo sapiens		h_aifPathway:Opposing roles of AIF in Apoptosis and Cell Survival,h_caspasePathway:Caspase Cascade in Apoptosis,h_ceramidePathway:Ceramide Signaling Pathway,h_chemicalPathway:Apoptotic Signaling in Response to DNA Damage,h_d4gdiPathway:D4-GDI Signaling Pathway,h_deathPathway:Induction of apoptosis through DR3 and DR4/5 Death Receptors ,h_etcPathway:Electron Transport Reaction in Mitochondria,h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_hsp27Pathway:Stress Induction of HSP Regulation,h_mitochondriaPathway:Role of Mitochondria in Apoptotic Signaling,h_tffPathway:Trefoil Factors Initiate  Mucosal Healing,		GO:0006122~mitochondrial electron transport, ubiquinol to cytochrome c,GO:0006123~mitochondrial electron transport, cytochrome c to oxygen,GO:0006915~apoptotic process,GO:0007005~mitochondrion organization,GO:0008635~activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c,GO:0034599~cellular response to oxidative stress,GO:0043280~positive regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0045333~cellular respiration,GO:0097202~activation of cysteine-type endopeptidase activity,	GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005758~mitochondrial intermembrane space,GO:0005829~cytosol,GO:0043293~apoptosome,GO:0070469~respiratory chain,	GO:0005515~protein binding,GO:0009055~electron carrier activity,GO:0020037~heme binding,GO:0046872~metal ion binding,	IPR002327:Cytochrome c, class IA/ IB,IPR009056:Cytochrome c domain,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa01524:Platinum drug resistance,hsa04115:p53 signaling pathway,hsa04210:Apoptosis,hsa04215:Apoptosis - multiple species,hsa04932:Non-alcoholic fatty liver disease,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05017:Spinocerebellar ataxia,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05134:Legionellosis,hsa05145:Toxoplasmosis,hsa05152:Tuberculosis,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,hsa05210:Colorectal cancer,hsa05222:Small cell lung cancer,hsa05416:Viral myocarditis,hsa05417:Lipid and atherosclerosis,	612004~Thrombocytopenia 4,			KW-0053~Apoptosis,KW-0249~Electron transport,KW-0679~Respiratory chain,KW-0813~Transport,	KW-0496~Mitochondrion,	KW-0225~Disease variant,		KW-0349~Heme,KW-0408~Iron,KW-0479~Metal-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	BINDING:Heme; covalent,DOMAIN:Cytochrome c,METAL:Iron (heme axial ligand),MUTAGEN:C->A: Decreased covalent heme attachment.,MUTAGEN:C->S: Decreased covalent heme attachment.,MUTAGEN:F->A: Decreased covalent heme attachment.,MUTAGEN:F->Y: No effect on covalent heme attachment.,MUTAGEN:H->A: Loss of covalent heme attachment.,MUTAGEN:K->A,D,R: No effect on covalent heme attachment.,
CYTH1	cytohesin 1(CYTH1)	Homo sapiens		h_arapPathway:ADP-Ribosylation Factor,		GO:0016192~vesicle-mediated transport,GO:0030155~regulation of cell adhesion,GO:0032012~regulation of ARF protein signal transduction,GO:0050790~regulation of catalytic activity,GO:0090162~establishment of epithelial cell polarity,	GO:0000139~Golgi membrane,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005912~adherens junction,GO:0005923~bicellular tight junction,GO:0031234~extrinsic component of cytoplasmic side of plasma membrane,	GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,GO:0008289~lipid binding,	IPR000904:SEC7-like,IPR001849:Pleckstrin homology domain,IPR011993:Pleckstrin homology-like domain,IPR023394:SEC7-like, alpha orthogonal bundle,	hsa04072:Phospholipase D signaling pathway,hsa04144:Endocytosis,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,			SM00222:Sec7,SM00233:PH,		KW-0472~Membrane,KW-0796~Tight junction,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-1003~Cell membrane,		KW-0175~Coiled coil,	KW-0446~Lipid-binding,	KW-0344~Guanine-nucleotide releasing factor,	KW-0007~Acetylation,KW-0832~Ubl conjugation,	BINDING:Phosphatidylinositol 3,4,5-trisphosphate,DOMAIN:PH,DOMAIN:SEC7,MUTAGEN:E->A,K: Reduces guanine exchange factor activity by over 90%.,MUTAGEN:M->A: Reduces guanine exchange factor activity by over 90%.,MUTAGEN:Y->A: Reduces guanine exchange factor activity by over 90%.,REGION:C-terminal autoinhibitory region,REGION:Phosphatidylinositol 3,4,5-trisphosphate binding,
CIAPIN1	cytokine induced apoptosis inhibitor 1(CIAPIN1)	Homo sapiens			Function unknown,	GO:0006915~apoptotic process,GO:0016226~iron-sulfur cluster assembly,GO:0022900~electron transport chain,GO:0030097~hemopoiesis,GO:0043066~negative regulation of apoptotic process,	GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005758~mitochondrial intermembrane space,	GO:0005515~protein binding,GO:0008168~methyltransferase activity,GO:0009055~electron carrier activity,GO:0046872~metal ion binding,GO:0051537~2 iron, 2 sulfur cluster binding,GO:0051539~4 iron, 4 sulfur cluster binding,	IPR007785:Anamorsin,IPR013216:Methyltransferase type 11,					KW-0053~Apoptosis,	KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0001~2Fe-2S,KW-0004~4Fe-4S,KW-0408~Iron,KW-0411~Iron-sulfur,KW-0479~Metal-binding,		KW-0597~Phosphoprotein,	DOMAIN:Methyltransf_11,METAL:Iron-sulfur (2Fe-2S),METAL:Iron-sulfur (4Fe-4S),MOTIF:Cx2C motif 1,MOTIF:Cx2C motif 2,REGION:Disordered,REGION:Fe-S binding site A,REGION:Fe-S binding site B,REGION:Linker,REGION:N-terminal SAM-like domain,
DCTD	dCMP deaminase(DCTD)	Homo sapiens				GO:0006220~pyrimidine nucleotide metabolic process,GO:0006226~dUMP biosynthetic process,GO:0006231~dTMP biosynthetic process,GO:0015949~nucleobase-containing small molecule interconversion,	GO:0005829~cytosol,	GO:0003824~catalytic activity,GO:0004132~dCMP deaminase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0042802~identical protein binding,	IPR002125:CMP/dCMP deaminase, zinc-binding,IPR015517:Cytidine deaminase,IPR016192:APOBEC/CMP deaminase, zinc-binding,IPR016193:Cytidine deaminase-like,IPR016473:dCMP deaminase,	hsa00240:Pyrimidine metabolism,hsa01100:Metabolic pathways,		PIRSF006019:dCMP deaminase,		KW-0545~Nucleotide biosynthesis,				KW-0479~Metal-binding,KW-0862~Zinc,	KW-0021~Allosteric enzyme,KW-0378~Hydrolase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton donor,DOMAIN:CMP/dCMP-type deaminase,METAL:Zinc; catalytic,
DDB2	damage specific DNA binding protein 2(DDB2)	Homo sapiens				GO:0000209~protein polyubiquitination,GO:0000715~nucleotide-excision repair, DNA damage recognition,GO:0000717~nucleotide-excision repair, DNA duplex unwinding,GO:0006281~DNA repair,GO:0006289~nucleotide-excision repair,GO:0006290~pyrimidine dimer repair,GO:0006293~nucleotide-excision repair, preincision complex stabilization,GO:0006294~nucleotide-excision repair, preincision complex assembly,GO:0006295~nucleotide-excision repair, DNA incision, 3'-to lesion,GO:0006296~nucleotide-excision repair, DNA incision, 5'-to lesion,GO:0009411~response to UV,GO:0016579~protein deubiquitination,GO:0033683~nucleotide-excision repair, DNA incision,GO:0035518~histone H2A monoubiquitination,GO:0043687~post-translational protein modification,GO:0051865~protein autoubiquitination,GO:0070911~global genome nucleotide-excision repair,GO:0070914~UV-damage excision repair,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0030054~cell junction,GO:0031465~Cul4B-RING E3 ubiquitin ligase complex,GO:0032991~macromolecular complex,GO:0080008~Cul4-RING E3 ubiquitin ligase complex,	GO:0003677~DNA binding,GO:0003684~damaged DNA binding,GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0044877~macromolecular complex binding,	IPR001680:WD40 repeat,IPR015943:WD40/YVTN repeat-like-containing domain,IPR017986:WD40-repeat-containing domain,IPR019775:WD40 repeat, conserved site,	hsa03420:Nucleotide excision repair,hsa04115:p53 signaling pathway,hsa04120:Ubiquitin mediated proteolysis,hsa05161:Hepatitis B,hsa05169:Epstein-Barr virus infection,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05210:Colorectal cancer,hsa05212:Pancreatic cancer,hsa05213:Endometrial cancer,hsa05214:Glioma,hsa05216:Thyroid cancer,hsa05217:Basal cell carcinoma,hsa05218:Melanoma,hsa05220:Chronic myeloid leukemia,hsa05222:Small cell lung cancer,hsa05223:Non-small cell lung cancer,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,	278740~Xeroderma pigmentosum, group E, DDB-negative subtype,		SM00320:WD40,	KW-0227~DNA damage,KW-0234~DNA repair,KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0857~Xeroderma pigmentosum,	KW-0677~Repeat,KW-0853~WD repeat,		KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	MOTIF:DWD box,MUTAGEN:D->A: Impairs interaction with DDB1.,MUTAGEN:I->A: Impairs interaction with DDB1.,MUTAGEN:L->A: Impairs interaction with DDB1.,MUTAGEN:L->P: Impairs interaction with DDB1.,MUTAGEN:R->A: Impairs interaction with DDB1.,MUTAGEN:S->A: Impairs interaction with DDB1.,MUTAGEN:W->A: Impairs interaction with DDB1.,REGION:Disordered,REGION:Photolesion recognition,REGION:Required for interaction with DDB1,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
DAXX	death domain associated protein(DAXX)	Homo sapiens		h_fasPathway:FAS signaling pathway ( CD95 ),h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_hsp27Pathway:Stress Induction of HSP Regulation,h_keratinocytePathway:Keratinocyte Differentiation,h_mapkPathway:MAPKinase Signaling Pathway,h_p38mapkPathway:p38 MAPK Signaling Pathway ,h_pmlPathway:Regulation of transcriptional activity by PML,		GO:0001934~positive regulation of protein phosphorylation,GO:0006325~chromatin organization,GO:0006334~nucleosome assembly,GO:0006338~chromatin remodeling,GO:0006355~regulation of transcription, DNA-templated,GO:0006915~apoptotic process,GO:0007254~JNK cascade,GO:0007257~activation of JUN kinase activity,GO:0008625~extrinsic apoptotic signaling pathway via death domain receptors,GO:0010468~regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0019058~viral life cycle,GO:0030521~androgen receptor signaling pathway,GO:0031396~regulation of protein ubiquitination,GO:0032147~activation of protein kinase activity,GO:0034605~cellular response to heat,GO:0034620~cellular response to unfolded protein,GO:0042981~regulation of apoptotic process,GO:0045860~positive regulation of protein kinase activity,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0048239~negative regulation of DNA recombination at telomere,GO:0071276~cellular response to cadmium ion,GO:0071280~cellular response to copper ion,GO:0072738~cellular response to diamide,GO:1900051~positive regulation of histone exchange,GO:1901216~positive regulation of neuron death,GO:1901796~regulation of signal transduction by p53 class mediator,GO:1903936~cellular response to sodium arsenite,	GO:0000775~chromosome, centromeric region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016604~nuclear body,GO:0016605~PML body,	GO:0002039~p53 binding,GO:0003713~transcription coactivator activity,GO:0003714~transcription corepressor activity,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0019899~enzyme binding,GO:0019901~protein kinase binding,GO:0030295~protein kinase activator activity,GO:0031072~heat shock protein binding,GO:0031625~ubiquitin protein ligase binding,GO:0042393~histone binding,GO:0042803~protein homodimerization activity,GO:0047485~protein N-terminus binding,GO:0050681~androgen receptor binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,	IPR005012:Daxx protein,	hsa04010:MAPK signaling pathway,hsa04210:Apoptosis,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05168:Herpes simplex virus 1 infection,				KW-0053~Apoptosis,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0137~Centromere,KW-0158~Chromosome,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,		KW-0143~Chaperone,KW-0156~Chromatin regulator,KW-0678~Repressor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Daxx,MOTIF:Nuclear localization signal,MUTAGEN:D->A: Abolishes interaction with histones H3 and H4.,MUTAGEN:E->L: Impairs interaction with histones H3 and H4.,MUTAGEN:F->A: Abolishes interaction with histones H3 and H4.,MUTAGEN:K->A,L: Impairs interaction with histones H3 and H4.,MUTAGEN:K->A: Abolishes sumoylation; when associated with A-630.,MUTAGEN:K->A: Abolishes sumoylation; when associated with A-631.,MUTAGEN:Missing: Abolishes sumoylation.,MUTAGEN:Q->L: Impairs interaction with histones H3 and H4.,MUTAGEN:R->A: Abolishes interaction with histones H3 and H4.,MUTAGEN:S->A: Abolishes interaction with histones H3 and H4.,MUTAGEN:S->A: No effect on cytosol translocation. upon glucose deprivation.,MUTAGEN:S->A: No translocation to the cytosol upon glucose deprivation.,MUTAGEN:Y->A,S: Abolishes interaction with histones H3 and H4.,MUTAGEN:Y->E: Abolishes interaction with histone H3.3.,REGION:Disordered,REGION:Interaction with MAP3K5,REGION:Interaction with SPOP,REGION:Interaction with histone H3.3,REGION:Necessary for interaction with USP7,REGION:Necessary for interaction with USP7 and ATRX,REGION:Sumo interaction motif (SIM),
DCUN1D4	defective in cullin neddylation 1 domain containing 4(DCUN1D4)	Homo sapiens				GO:0045116~protein neddylation,GO:0051443~positive regulation of ubiquitin-protein transferase activity,GO:2000436~positive regulation of protein neddylation,	GO:0000151~ubiquitin ligase complex,GO:0005634~nucleus,	GO:0005515~protein binding,GO:0031624~ubiquitin conjugating enzyme binding,GO:0032182~ubiquitin-like protein binding,GO:0097602~cullin family protein binding,	IPR005176:Potentiating neddylation domain,IPR014764:Defective-in-cullin neddylation protein,						KW-0539~Nucleus,		KW-0732~Signal,			KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:DCUN1,MUTAGEN:A->R: Does not affect localization at nucleus; when associated with A-250 and A-280.,MUTAGEN:D->A: Does not affect localization at nucleus; when associated with A-250 and R-274.,MUTAGEN:D->A: Does not affect localization at nucleus; when associated with R-274 and A-280.,REGION:Disordered,
DHDDS	dehydrodolichyl diphosphate synthase subunit(DHDDS)	Homo sapiens				GO:0006489~dolichyl diphosphate biosynthetic process,GO:0016094~polyprenol biosynthetic process,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:1904423~dehydrodolichyl diphosphate synthase complex,	GO:0002094~polyprenyltransferase activity,GO:0005515~protein binding,GO:0016765~transferase activity, transferring alkyl or aryl (other than methyl) groups,GO:0045547~dehydrodolichyl diphosphate synthase activity,GO:0046872~metal ion binding,	IPR001441:Decaprenyl diphosphate synthase-like,IPR018520:Di-trans-poly-cis-decaprenylcistransferase-like, conserved site,	hsa00900:Terpenoid backbone biosynthesis,	613861~Congenital disorder of glycosylation, type 1bb,613861~Retinitis pigmentosa 59,617836~Developmental delay and seizures with or without movement abnormalities,			KW-0443~Lipid metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,	KW-0225~Disease variant,KW-0682~Retinitis pigmentosa,KW-0887~Epilepsy,KW-0991~Mental retardation,	KW-0175~Coiled coil,	KW-0460~Magnesium,KW-0479~Metal-binding,	KW-0808~Transferase,		BINDING:Isopentenyl diphosphate,METAL:Magnesium,MUTAGEN:F->A: Delays cell growth; when associated with A-306 and A-317.,MUTAGEN:F->A: Markedly decreases phosphatidylinositol-mediated activation of cis-prenyltransferase activity resulting in products with longer chain length; when associated with A-12 and A-19.,MUTAGEN:I->A: Markedly decreases phosphatidylinositol-mediated activation of cis-prenyltransferase activity resulting in products with longer chain length; when associated with A-12 and A-15.,MUTAGEN:L->A: Delays cell growth; when associated with A-306 and A-313.,MUTAGEN:Missing: Affects chain elongation resulting in shorter products.,MUTAGEN:R->A: Delays cell growth; when associated with A-313 and A-317.,MUTAGEN:W->A: Markedly decreases phosphatidylinositol-mediated activation of cis-prenyltransferase activity resulting in products with longer chain length; when associated with A-15 and A-19.,
DHRS7	dehydrogenase/reductase 7(DHRS7)	Homo sapiens			General function prediction only,	GO:0042572~retinol metabolic process,	GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,	GO:0004090~carbonyl reductase (NADPH) activity,GO:0005515~protein binding,GO:0016491~oxidoreductase activity,GO:0016616~oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor,GO:0052650~NADP-retinol dehydrogenase activity,	IPR002347:Glucose/ribitol dehydrogenase,IPR020904:Short-chain dehydrogenase/reductase, conserved site,								KW-0732~Signal,	KW-0520~NAD,	KW-0560~Oxidoreductase,		ACT_SITE:Proton acceptor,BINDING:Substrate,NP_BIND:NAD,
DCK	deoxycytidine kinase(DCK)	Homo sapiens			Nucleotide transport and metabolism,	GO:0006220~pyrimidine nucleotide metabolic process,GO:0016310~phosphorylation,GO:0043097~pyrimidine nucleoside salvage,GO:0043101~purine-containing compound salvage,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,	GO:0004136~deoxyadenosine kinase activity,GO:0004137~deoxycytidine kinase activity,GO:0004138~deoxyguanosine kinase activity,GO:0005524~ATP binding,GO:0008144~drug binding,GO:0019136~deoxynucleoside kinase activity,GO:0042803~protein homodimerization activity,	IPR002624:Deoxynucleoside kinase,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa00230:Purine metabolism,hsa00240:Pyrimidine metabolism,hsa01100:Metabolic pathways,		PIRSF000705:deoxynucleoside kinase,			KW-0539~Nucleus,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:Substrate,DOMAIN:dNK,MUTAGEN:A->V: Strongly increased catalytic efficiency towards deoxycytidine; when associated with M-104 and A-133.,MUTAGEN:D->A: Strongly increased catalytic efficiency towards deoxycytidine; when associated with V-100 and M-104. Strongly increased catalytic efficiency towards deoxythymidine; when associated with L-104.,MUTAGEN:R->L: Strongly increased catalytic efficiency towards deoxythymidine; when associated with A-133.,MUTAGEN:R->M: Strongly increased catalytic efficiency towards deoxycytidine; when associated with V-100 and A-133.,NP_BIND:ATP,REGION:Disordered,
DNTTIP2	deoxynucleotidyltransferase terminal interacting protein 2(DNTTIP2)	Homo sapiens				GO:0006396~RNA processing,	GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005730~nucleolus,	GO:0003723~RNA binding,GO:0005515~protein binding,	IPR014810:Fcf2 pre-rRNA processing,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0175~Coiled coil,			KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,REGION:TdBR region; mediates interaction with DNTT,
DERA	deoxyribose-phosphate aldolase(DERA)	Homo sapiens				GO:0006098~pentose-phosphate shunt,GO:0009264~deoxyribonucleotide catabolic process,GO:0016052~carbohydrate catabolic process,GO:0043312~neutrophil degranulation,GO:0046121~deoxyribonucleoside catabolic process,GO:0046386~deoxyribose phosphate catabolic process,	GO:0005576~extracellular region,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0034774~secretory granule lumen,GO:1904813~ficolin-1-rich granule lumen,	GO:0004139~deoxyribose-phosphate aldolase activity,GO:0005515~protein binding,	IPR002915:DeoC/FbaB/ lacD aldolase,IPR011343:Deoxyribose-phosphate aldolase,IPR013785:Aldolase-type TIM barrel,	hsa00030:Pentose phosphate pathway,hsa01100:Metabolic pathways,		PIRSF001357:deoxyribose-phosphate aldolase,	SM01133:SM01133,		KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0704~Schiff base,	KW-0456~Lyase,		ACT_SITE:Proton donor/acceptor,ACT_SITE:Schiff-base intermediate with acetaldehyde,COMPBIAS:Polar residues,MUTAGEN:K->A: Abolishes deoxyribose-phosphate aldolase activity.,REGION:Disordered,
DSG2	desmoglein 2(DSG2)	Homo sapiens				GO:0002934~desmosome organization,GO:0003165~Purkinje myocyte development,GO:0007155~cell adhesion,GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules,GO:0031424~keratinization,GO:0032570~response to progesterone,GO:0060135~maternal process involved in female pregnancy,GO:0070268~cornification,GO:0086073~bundle of His cell-Purkinje myocyte adhesion involved in cell communication,GO:0086091~regulation of heart rate by cardiac conduction,GO:0098609~cell-cell adhesion,GO:0098911~regulation of ventricular cardiac muscle cell action potential,	GO:0001533~cornified envelope,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0009986~cell surface,GO:0014704~intercalated disc,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0016328~lateral plasma membrane,GO:0030054~cell junction,GO:0030057~desmosome,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,	GO:0005509~calcium ion binding,GO:0050839~cell adhesion molecule binding,GO:0086083~cell adhesive protein binding involved in bundle of His cell-Purkinje myocyte communication,	IPR002126:Cadherin,IPR009122:Desmosomal cadherin,IPR009123:Desmoglein,IPR015919:Cadherin-like,IPR020894:Cadherin conserved site,IPR027397:Catenin binding domain,	hsa05412:Arrhythmogenic right ventricular cardiomyopathy,	610193~Arrhythmogenic right ventricular dysplasia 10,612877~Cardiomyopathy, dilated, 1BB,		SM00112:CA,	KW-0130~Cell adhesion,	KW-0472~Membrane,KW-0965~Cell junction,KW-1003~Cell membrane,	KW-0122~Cardiomyopathy,KW-0225~Disease variant,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Cadherin,DOMAIN:Cadherin 1,DOMAIN:Cadherin 2,DOMAIN:Cadherin 3,DOMAIN:Cadherin 4,REGION:Disordered,REPEAT:Desmoglein repeat 1,REPEAT:Desmoglein repeat 2,REPEAT:Desmoglein repeat 3,REPEAT:Desmoglein repeat 4,REPEAT:Desmoglein repeat 5,REPEAT:Desmoglein repeat 6,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
DLD	dihydrolipoamide dehydrogenase(DLD)	Homo sapiens				GO:0006086~acetyl-CoA biosynthetic process from pyruvate,GO:0006090~pyruvate metabolic process,GO:0006099~tricarboxylic acid cycle,GO:0006103~2-oxoglutarate metabolic process,GO:0006120~mitochondrial electron transport, NADH to ubiquinone,GO:0006508~proteolysis,GO:0006546~glycine catabolic process,GO:0006554~lysine catabolic process,GO:0007369~gastrulation,GO:0007568~aging,GO:0009083~branched-chain amino acid catabolic process,GO:0009106~lipoate metabolic process,GO:0042391~regulation of membrane potential,GO:0045454~cell redox homeostasis,GO:0048240~sperm capacitation,GO:0051068~dihydrolipoamide metabolic process,GO:0061732~mitochondrial acetyl-CoA biosynthetic process from pyruvate,	GO:0001669~acrosomal vesicle,GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005947~mitochondrial alpha-ketoglutarate dehydrogenase complex,GO:0005967~mitochondrial pyruvate dehydrogenase complex,GO:0031514~motile cilium,GO:0043159~acrosomal matrix,GO:0045252~oxoglutarate dehydrogenase complex,GO:0045254~pyruvate dehydrogenase complex,	GO:0004148~dihydrolipoyl dehydrogenase activity,GO:0005515~protein binding,GO:0016668~oxidoreductase activity, acting on a sulfur group of donors, NAD(P) as acceptor,GO:0034604~pyruvate dehydrogenase (NAD+) activity,GO:0043544~lipoamide binding,GO:0050660~flavin adenine dinucleotide binding,GO:0051287~NAD binding,	IPR004099:Pyridine nucleotide-disulphide oxidoreductase, dimerisation,IPR006258:Dihydrolipoamide dehydrogenase,IPR012999:Pyridine nucleotide-disulphide oxidoreductase, class I, active site,IPR016156:FAD/NAD-linked reductase, dimerisation,IPR023753:Pyridine nucleotide-disulphide oxidoreductase, FAD/NAD(P)-binding domain,	hsa00010:Glycolysis / Gluconeogenesis,hsa00020:Citrate cycle (TCA cycle),hsa00260:Glycine, serine and threonine metabolism,hsa00280:Valine, leucine and isoleucine degradation,hsa00310:Lysine degradation,hsa00380:Tryptophan metabolism,hsa00620:Pyruvate metabolism,hsa00630:Glyoxylate and dicarboxylate metabolism,hsa00640:Propanoate metabolism,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa01240:Biosynthesis of cofactors,	246900~Dihydrolipoamide dehydrogenase deficiency,	PIRSF000350:mercury(II) reductase, MerA type,			KW-0282~Flagellum,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0966~Cell projection,KW-0968~Cytoplasmic vesicle,KW-0969~Cilium,	KW-0225~Disease variant,	KW-0676~Redox-active center,KW-0809~Transit peptide,	KW-0274~FAD,KW-0285~Flavoprotein,KW-0520~NAD,KW-0547~Nucleotide-binding,KW-0670~Pyruvate,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,BINDING:FAD,BINDING:FAD; via amide nitrogen and carbonyl oxygen,BINDING:NAD,BINDING:NAD; via amide nitrogen,BINDING:NAD; via amide nitrogen and carbonyl oxygen,DISULFID:Redox-active,DOMAIN:Pyr_redox_2,DOMAIN:Pyr_redox_dim,MUTAGEN:D->A: Reduces interaction with PDHX. Inhibits multienzyme pyruvate dehydrogenase complex activity. Does not affect dihydrolipoyl dehydrogenase activity.,MUTAGEN:D->N: Does not affect dihydrolipoyl dehydrogenase activity.,MUTAGEN:E->A: Decreases dehydrogenase activity. Loss of proteolytic activity.,MUTAGEN:E->Q: Reduces dihydrolipoyl dehydrogenase activity. Does not affect interaction with PDHX.,MUTAGEN:H->A: Loss of dehydrogenase activity. Increases proteolytic activity.,MUTAGEN:H->A: Reduces dihydrolipoyl dehydrogenase activity.,MUTAGEN:H->L: Reduces dihydrolipoyl dehydrogenase activity.,MUTAGEN:K->E: Abolishes dihydrolipoyl dehydrogenase activity. Does not affect interaction with PDHX.,MUTAGEN:K->M: Reduces dihydrolipoyl dehydrogenase activity. Does not affect interaction with PDHX.,MUTAGEN:R->A: Does not affect dihydrolipoyl dehydrogenase activity.,MUTAGEN:R->M: Does not affect interaction with PDHX.,MUTAGEN:S->A: Loss of proteolytic activity. Does not affect dehydrogenase activity.,MUTAGEN:Y->A: Reduces interaction with PDHX. Inhibits multienzyme pyruvate dehydrogenase complex activity. Does not affect dihydrolipoyl dehydrogenase activity.,MUTAGEN:Y->F: Does not affect dihydrolipoyl dehydrogenase activity.,MUTAGEN:Y->H: Reduces interaction with PDHX. Inhibits multienzyme pyruvate dehydrogenase complex activity. Does not affect dihydrolipoyl dehydrogenase activity.,NP_BIND:FAD,NP_BIND:NAD,SITE:Important for interaction with PDHX and activity of multienzyme pyruvate dehydrogenase complex,TRANSIT:Mitochondrion,
DPH2	diphthamide biosynthesis 2(DPH2)	Homo sapiens				GO:0017183~peptidyl-diphthamide biosynthetic process from peptidyl-histidine,	GO:0005829~cytosol,	GO:0005515~protein binding,GO:0090560~2-(3-amino-3-carboxypropyl)histidine synthase activity,	IPR010014:Diphthamide synthesis DHP2, eukaryotic,IPR016435:Diphthamide synthesis, eukaryotic DPH1/archaeal DPH2,									KW-0949~S-adenosyl-L-methionine,	KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	REGION:Disordered,
DDR1	discoidin domain receptor tyrosine kinase 1(DDR1)	Homo sapiens				GO:0001558~regulation of cell growth,GO:0001952~regulation of cell-matrix adhesion,GO:0007155~cell adhesion,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007275~multicellular organism development,GO:0007566~embryo implantation,GO:0007595~lactation,GO:0008285~negative regulation of cell proliferation,GO:0010715~regulation of extracellular matrix disassembly,GO:0014909~smooth muscle cell migration,GO:0030198~extracellular matrix organization,GO:0033674~positive regulation of kinase activity,GO:0038063~collagen-activated tyrosine kinase receptor signaling pathway,GO:0038083~peptidyl-tyrosine autophosphorylation,GO:0043583~ear development,GO:0044319~wound healing, spreading of cells,GO:0046777~protein autophosphorylation,GO:0060444~branching involved in mammary gland duct morphogenesis,GO:0060749~mammary gland alveolus development,GO:0061302~smooth muscle cell-matrix adhesion,GO:0061564~axon development,GO:1990138~neuron projection extension,	GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0043235~receptor complex,GO:0070062~extracellular exosome,	GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0005515~protein binding,GO:0005518~collagen binding,GO:0005524~ATP binding,GO:0038062~protein tyrosine kinase collagen receptor activity,GO:0046872~metal ion binding,	IPR000421:Coagulation factor 5/8 C-terminal type domain,IPR000719:Protein kinase, catalytic domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR002011:Tyrosine-protein kinase, receptor class II, conserved site,IPR008266:Tyrosine-protein kinase, active site,IPR008979:Galactose-binding domain-like,IPR011009:Protein kinase-like domain,IPR020635:Tyrosine-protein kinase, catalytic domain,				SM00219:TyrKc,SM00231:FA58C,	KW-0421~Lactation,KW-0635~Pregnancy,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0106~Calcium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0675~Receptor,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,BINDING:ATP,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:F5/8 type C,DOMAIN:Protein kinase,METAL:Calcium 1,METAL:Calcium 1; via carbonyl oxygen,METAL:Calcium 2,METAL:Calcium 2; via carbonyl oxygen,MOTIF:PPxY motif,MUTAGEN:G->A: Confers over 20-fold resistance to the ability of an inhibitor to inhibit autophosphorylation.,MUTAGEN:K->A: Loss of kinase activity. Complete loss of the collagen-independent constitutive activation; when associated with Q-211.,MUTAGEN:N->A: Phosphorylates regardless of collagen presence, collagen addition does not alter significantly the levels of constitutive phosphorylation.,MUTAGEN:N->Q: Phosphorylates in response to collagen, but at lower levels compared to wild-type. No activation in the absence of collagen.,MUTAGEN:N->Q: Sustained phosphorylation regardless of collagen presence, collagen addition does not alter significantly the levels of constitutive phosphorylation. Located intracellularly and at the cell surface. Displays a reduced rate of receptor internalization, which is not altered in the presence of collagen. Able to bind collagen as wild-type. Exhibits enhanced collagen-independent receptor dimerization. Complete loss of the collagen-independent constitutive activation; when associated with A-655.,MUTAGEN:R->A: Inhibits collagen-induced phosphorylation.,MUTAGEN:S->A: Phosphorylates regardless of collagen presence, collagen addition does not alter significantly the levels of constitutive phosphorylation.,MUTAGEN:T->A: Phosphorylates in response to collagen, but at lower levels compared to wild-type. Phosphorylates in response to collagen, but at lower levels compared to wild-type; when associated with A-379.,MUTAGEN:T->A: Phosphorylates in response to collagen, but at lower levels compared to wild-type. Phosphorylates in response to collagen, but at lower levels compared to wild-type; when associated with A-393.,MUTAGEN:Y->F: Abolishes interaction with PTPN11.,NP_BIND:ATP,REGION:DS-like domain,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
DUSP11	dual specificity phosphatase 11(DUSP11)	Homo sapiens				GO:0006396~RNA processing,GO:0006470~protein dephosphorylation,GO:0016070~RNA metabolic process,GO:0035335~peptidyl-tyrosine dephosphorylation,GO:0098507~polynucleotide 5' dephosphorylation,	GO:0001650~fibrillar center,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016607~nuclear speck,GO:0045171~intercellular bridge,	GO:0003723~RNA binding,GO:0004651~polynucleotide 5'-phosphatase activity,GO:0004725~protein tyrosine phosphatase activity,GO:0008138~protein tyrosine/serine/threonine phosphatase activity,GO:0016791~phosphatase activity,GO:0098519~nucleotide phosphatase activity, acting on free nucleotides,	IPR000387:Protein-tyrosine/Dual specificity phosphatase,IPR016130:Protein-tyrosine phosphatase, active site,IPR020422:Dual specificity phosphatase, subgroup, catalytic domain,				SM00195:DSPc,		KW-0539~Nucleus,				KW-0378~Hydrolase,KW-0694~RNA-binding,KW-0904~Protein phosphatase,		ACT_SITE:Phosphocysteine intermediate,ACT_SITE:Proton donor/acceptor,COMPBIAS:Basic and acidic residues,DOMAIN:Tyrosine-protein phosphatase,MUTAGEN:C->S: Loss of activity. No effect in RNA-binding.,MUTAGEN:H->A: Strongly decreases phosphatase activity with ATP and ADP.,MUTAGEN:H->G: No effect on phosphatase activity with ATP and ADP.,MUTAGEN:N->A: Strongly decreases phosphatase activity with ATP and ADP.,MUTAGEN:R->K: Slightly decreases phosphatase activity with ATP. Strongly decreases phosphatase activity with ADP.,REGION:Disordered,REGION:Substrate binding,
DUSP14	dual specificity phosphatase 14(DUSP14)	Homo sapiens				GO:0035335~peptidyl-tyrosine dephosphorylation,		GO:0003723~RNA binding,GO:0004725~protein tyrosine phosphatase activity,GO:0005515~protein binding,GO:0017017~MAP kinase tyrosine/serine/threonine phosphatase activity,	IPR000387:Protein-tyrosine/Dual specificity phosphatase,IPR016130:Protein-tyrosine phosphatase, active site,IPR020420:Atypical dual specificity phosphatase, subfamily B,IPR020422:Dual specificity phosphatase, subgroup, catalytic domain,				SM00195:DSPc,						KW-0378~Hydrolase,KW-0904~Protein phosphatase,		ACT_SITE:Phosphocysteine intermediate,DOMAIN:TYR_PHOSPHATASE_2,DOMAIN:Tyrosine-protein phosphatase,
DUSP22	dual specificity phosphatase 22(DUSP22)	Homo sapiens				GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0002710~negative regulation of T cell mediated immunity,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0030336~negative regulation of cell migration,GO:0035335~peptidyl-tyrosine dephosphorylation,GO:0042127~regulation of cell proliferation,GO:0046330~positive regulation of JNK cascade,GO:0050860~negative regulation of T cell receptor signaling pathway,GO:0050868~negative regulation of T cell activation,GO:0051895~negative regulation of focal adhesion assembly,GO:0071364~cellular response to epidermal growth factor stimulus,GO:1903996~negative regulation of non-membrane spanning protein tyrosine kinase activity,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0031941~filamentous actin,GO:0061851~leading edge of lamellipodium,	GO:0004725~protein tyrosine phosphatase activity,GO:0004726~non-membrane spanning protein tyrosine phosphatase activity,GO:0008138~protein tyrosine/serine/threonine phosphatase activity,GO:1990782~protein tyrosine kinase binding,	IPR000387:Protein-tyrosine/Dual specificity phosphatase,IPR020422:Dual specificity phosphatase, subgroup, catalytic domain,				SM00195:DSPc,		KW-0963~Cytoplasm,				KW-0378~Hydrolase,KW-0904~Protein phosphatase,	KW-0449~Lipoprotein,KW-0519~Myristate,KW-0597~Phosphoprotein,	ACT_SITE:Phosphocysteine intermediate,DOMAIN:TYR_PHOSPHATASE_2,DOMAIN:Tyrosine-protein phosphatase,LIPID:N-myristoyl glycine,
DUSP3	dual specificity phosphatase 3(DUSP3)	Homo sapiens				GO:0000188~inactivation of MAPK activity,GO:0016311~dephosphorylation,GO:0030336~negative regulation of cell migration,GO:0035335~peptidyl-tyrosine dephosphorylation,GO:0042059~negative regulation of epidermal growth factor receptor signaling pathway,GO:0043409~negative regulation of MAPK cascade,GO:0045931~positive regulation of mitotic cell cycle,GO:0046329~negative regulation of JNK cascade,GO:0050860~negative regulation of T cell receptor signaling pathway,GO:0050868~negative regulation of T cell activation,GO:0050922~negative regulation of chemotaxis,GO:0051893~regulation of focal adhesion assembly,GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:0071364~cellular response to epidermal growth factor stimulus,GO:1990264~peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activity,	GO:0001772~immunological synapse,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0004725~protein tyrosine phosphatase activity,GO:0005515~protein binding,GO:0008092~cytoskeletal protein binding,GO:0008138~protein tyrosine/serine/threonine phosphatase activity,GO:0016791~phosphatase activity,GO:0019901~protein kinase binding,GO:0030971~receptor tyrosine kinase binding,GO:0033549~MAP kinase phosphatase activity,GO:1990782~protein tyrosine kinase binding,	IPR000387:Protein-tyrosine/Dual specificity phosphatase,IPR016130:Protein-tyrosine phosphatase, active site,IPR020405:Atypical dual specificity phosphatase, subfamily A,IPR020422:Dual specificity phosphatase, subgroup, catalytic domain,	hsa04010:MAPK signaling pathway,			SM00195:DSPc,		KW-0539~Nucleus,				KW-0378~Hydrolase,KW-0904~Protein phosphatase,		ACT_SITE:Phosphocysteine intermediate,DOMAIN:TYR_PHOSPHATASE_2,DOMAIN:Tyrosine-protein phosphatase,
DUSP4	dual specificity phosphatase 4(DUSP4)	Homo sapiens		h_dspPathway:Regulation of MAP Kinase Pathways Through Dual Specificity Phosphatases,		GO:0000188~inactivation of MAPK activity,GO:0001706~endoderm formation,GO:0006470~protein dephosphorylation,GO:0016311~dephosphorylation,GO:0035335~peptidyl-tyrosine dephosphorylation,GO:0035970~peptidyl-threonine dephosphorylation,GO:0043409~negative regulation of MAPK cascade,GO:0070373~negative regulation of ERK1 and ERK2 cascade,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,	GO:0004721~phosphoprotein phosphatase activity,GO:0004725~protein tyrosine phosphatase activity,GO:0005515~protein binding,GO:0008330~protein tyrosine/threonine phosphatase activity,GO:0016791~phosphatase activity,GO:0017017~MAP kinase tyrosine/serine/threonine phosphatase activity,GO:0051019~mitogen-activated protein kinase binding,GO:1990439~MAP kinase threonine phosphatase activity,	IPR000387:Protein-tyrosine/Dual specificity phosphatase,IPR001763:Rhodanese-like domain,IPR003595:Protein-tyrosine phosphatase, catalytic,IPR008343:Mitogen-activated protein (MAP) kinase phosphatase,IPR016130:Protein-tyrosine phosphatase, active site,IPR020422:Dual specificity phosphatase, subgroup, catalytic domain,	hsa04010:MAPK signaling pathway,		PIRSF000939:dual specificity protein phosphatase (MAP kinase phosphatase),	SM00195:DSPc,SM00404:PTPc_motif,SM00450:RHOD,		KW-0539~Nucleus,				KW-0378~Hydrolase,KW-0904~Protein phosphatase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Phosphocysteine intermediate,DOMAIN:Rhodanese,DOMAIN:Tyrosine-protein phosphatase,
DUSP6	dual specificity phosphatase 6(DUSP6)	Homo sapiens		h_dspPathway:Regulation of MAP Kinase Pathways Through Dual Specificity Phosphatases,		GO:0000165~MAPK cascade,GO:0000187~activation of MAPK activity,GO:0000188~inactivation of MAPK activity,GO:0001933~negative regulation of protein phosphorylation,GO:0006470~protein dephosphorylation,GO:0009410~response to xenobiotic stimulus,GO:0010942~positive regulation of cell death,GO:0014070~response to organic cyclic compound,GO:0030154~cell differentiation,GO:0035335~peptidyl-tyrosine dephosphorylation,GO:0035970~peptidyl-threonine dephosphorylation,GO:0042493~response to drug,GO:0043065~positive regulation of apoptotic process,GO:0043409~negative regulation of MAPK cascade,GO:0051409~response to nitrosative stress,GO:0060420~regulation of heart growth,GO:0070371~ERK1 and ERK2 cascade,GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:0070848~response to growth factor,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0004721~phosphoprotein phosphatase activity,GO:0004725~protein tyrosine phosphatase activity,GO:0005515~protein binding,GO:0008138~protein tyrosine/serine/threonine phosphatase activity,GO:0008330~protein tyrosine/threonine phosphatase activity,GO:0017017~MAP kinase tyrosine/serine/threonine phosphatase activity,GO:0051019~mitogen-activated protein kinase binding,	IPR000387:Protein-tyrosine/Dual specificity phosphatase,IPR001763:Rhodanese-like domain,IPR008343:Mitogen-activated protein (MAP) kinase phosphatase,IPR020422:Dual specificity phosphatase, subgroup, catalytic domain,	hsa04010:MAPK signaling pathway,hsa05202:Transcriptional misregulation in cancer,hsa05221:Acute myeloid leukemia,	615269~Hypogonadotropic hypogonadism 19 with or without anosmia,	PIRSF000939:dual specificity protein phosphatase (MAP kinase phosphatase),	SM00195:DSPc,SM00450:RHOD,		KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0956~Kallmann syndrome,KW-1016~Hypogonadotropic hypogonadism,			KW-0378~Hydrolase,KW-0904~Protein phosphatase,		ACT_SITE:Phosphocysteine intermediate,DOMAIN:Rhodanese,DOMAIN:TYR_PHOSPHATASE_2,DOMAIN:Tyrosine-protein phosphatase,REGION:Disordered,
DYRK3	dual specificity tyrosine phosphorylation regulated kinase 3(DYRK3)	Homo sapiens				GO:0006468~protein phosphorylation,GO:0007049~cell cycle,GO:0018105~peptidyl-serine phosphorylation,GO:0018107~peptidyl-threonine phosphorylation,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0030218~erythrocyte differentiation,GO:0035063~nuclear speck organization,GO:0035617~stress granule disassembly,GO:0043066~negative regulation of apoptotic process,GO:0043518~negative regulation of DNA damage response, signal transduction by p53 class mediator,GO:0051301~cell division,GO:0080135~regulation of cellular response to stress,GO:1902751~positive regulation of cell cycle G2/M phase transition,GO:1903008~organelle disassembly,GO:1903432~regulation of TORC1 signaling,	GO:0000242~pericentriolar material,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0010494~cytoplasmic stress granule,GO:0016607~nuclear speck,GO:0043231~intracellular membrane-bounded organelle,	GO:0000287~magnesium ion binding,GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0005524~ATP binding,	IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,				SM00220:S_TKc,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Proton acceptor,BINDING:ATP,DOMAIN:Protein kinase,MOTIF:Nuclear localization signal,MUTAGEN:K->M: Kinase dead; Induces formation of stress granules-like in absence of stress. Impaired dissolution of membraneless organelles during mitosis, such as stress granules, nuclear speckles and pericentriolar material.,MUTAGEN:RRGKK->AAGAA: Abolishes localization to the nucleus, leading to impaired dissolution of nuclear speckles during mitosis.,MUTAGEN:S->A: Decreased stability of the protein.,MUTAGEN:S->E,D: Phosphomimetic mutant; increased stability of the protein.,NP_BIND:ATP,REGION:Disordered,
DNM1L	dynamin 1 like(DNM1L)	Homo sapiens			General function prediction only,	GO:0000266~mitochondrial fission,GO:0001836~release of cytochrome c from mitochondria,GO:0003374~dynamin family protein polymerization involved in mitochondrial fission,GO:0006816~calcium ion transport,GO:0006897~endocytosis,GO:0007005~mitochondrion organization,GO:0010468~regulation of gene expression,GO:0010637~negative regulation of mitochondrial fusion,GO:0010821~regulation of mitochondrion organization,GO:0016559~peroxisome fission,GO:0036466~synaptic vesicle recycling via endosome,GO:0043065~positive regulation of apoptotic process,GO:0043653~mitochondrial fragmentation involved in apoptotic process,GO:0048312~intracellular distribution of mitochondria,GO:0048488~synaptic vesicle endocytosis,GO:0048511~rhythmic process,GO:0050714~positive regulation of protein secretion,GO:0051259~protein oligomerization,GO:0060047~heart contraction,GO:0061003~positive regulation of dendritic spine morphogenesis,GO:0061025~membrane fusion,GO:0065003~macromolecular complex assembly,GO:0070266~necroptotic process,GO:0070584~mitochondrion morphogenesis,GO:0070585~protein localization to mitochondrion,GO:0090023~positive regulation of neutrophil chemotaxis,GO:0090141~positive regulation of mitochondrial fission,GO:0090149~mitochondrial membrane fission,GO:0090200~positive regulation of release of cytochrome c from mitochondria,GO:0090650~cellular response to oxygen-glucose deprivation,GO:0097194~execution phase of apoptosis,GO:1900063~regulation of peroxisome organization,GO:1900244~positive regulation of synaptic vesicle endocytosis,GO:1903146~regulation of mitophagy,GO:1903578~regulation of ATP metabolic process,GO:1904579~cellular response to thapsigargin,GO:1904666~regulation of ubiquitin protein ligase activity,GO:1905395~response to flavonoid,GO:1990910~response to hypobaric hypoxia,GO:2000302~positive regulation of synaptic vesicle exocytosis,GO:2001244~positive regulation of intrinsic apoptotic signaling pathway,	GO:0000139~Golgi membrane,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005777~peroxisome,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005874~microtubule,GO:0005903~brush border,GO:0005905~clathrin-coated pit,GO:0016020~membrane,GO:0030672~synaptic vesicle membrane,GO:0031966~mitochondrial membrane,GO:0032991~macromolecular complex,GO:0043231~intracellular membrane-bounded organelle,GO:0048471~perinuclear region of cytoplasm,GO:0098835~presynaptic endocytic zone membrane,GO:0099073~mitochondrion-derived vesicle,	GO:0003924~GTPase activity,GO:0005096~GTPase activator activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0008017~microtubule binding,GO:0008289~lipid binding,GO:0030276~clathrin binding,GO:0030742~GTP-dependent protein binding,GO:0031267~small GTPase binding,GO:0031625~ubiquitin protein ligase binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0044877~macromolecular complex binding,GO:0051433~BH2 domain binding,	IPR000375:Dynamin central domain,IPR001401:Dynamin, GTPase domain,IPR003130:Dynamin GTPase effector,IPR011993:Pleckstrin homology-like domain,IPR019762:Dynamin, GTPase region, conserved site,IPR020850:GTPase effector domain, GED,IPR022812:Dynamin,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04217:Necroptosis,hsa04621:NOD-like receptor signaling pathway,hsa04668:TNF signaling pathway,	610708~Optic atrophy 5,614388~Encephalopathy, lethal, due to defective mitochondrial peroxisomal fission 1,		SM00053:DYNc,SM00302:GED,	KW-0090~Biological rhythms,KW-0254~Endocytosis,KW-1210~Necrosis,	KW-0168~Coated pit,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0496~Mitochondrion,KW-0576~Peroxisome,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-0968~Cytoplasmic vesicle,KW-1000~Mitochondrion outer membrane,	KW-0225~Disease variant,	KW-0175~Coiled coil,	KW-0342~GTP-binding,KW-0446~Lipid-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0702~S-nitrosylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CARBOHYD:O-linked (GlcNAc) threonine,COMPBIAS:Basic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO); alternate,DOMAIN:Dynamin-type G,DOMAIN:GED,MUTAGEN:C->A: Abolishes S-nitrosylation. Reduced dimerization and no enhancement of GTPase activity.,MUTAGEN:C->A: No effect on S-nitrosylation.,MUTAGEN:D->A: Abolishes GTP hydrolysis.,MUTAGEN:D->A: Unable to homooligomerize. Unable to associate with MIEF2 into filaments forming the tubular structures that wrap around the scission site.,MUTAGEN:E->A: Does not impair homodimerization and formation of higher order oligomers.,MUTAGEN:E->R: Impairs homodimerization and formation of higher order oligomers.,MUTAGEN:G->A: Abolishes GTP hydrolysis.,MUTAGEN:G->D: Temperature-sensitive. Impairs mitochondrial division.,MUTAGEN:GPRP->AAAA: Impairs formation of higher order oligomers, but not homodimerization.,MUTAGEN:K->A: Abolishes GTP hydrolysis.,MUTAGEN:K->A: Diminishes intramolecular interaction between GTP-middle domain and GED domain but no effect on homooligomerization. Marked reduction in GTPase activity, in vitro. Decreased mitochondrial division.,MUTAGEN:K->A: Loss of GTPase activity. Impairs mitochondrial division and induces changes in peroxisome morphology. No effect on oligomerization. Increase in sumoylation by SUMO3.,MUTAGEN:K->E: Abolishes homodimerization and formation of higher order oligomers.,MUTAGEN:K->E: Overexpression delays protein secretion. Rescues fragmented or truncated mitochondria in PRKN- or PINK1-depleted cells.,MUTAGEN:K->R: Some loss of sumoylation in B domain. Complete loss of sumoylation in B domain; when associated with R-532; R-535 and R-558.,MUTAGEN:K->R: Some loss of sumoylation in B domain. Complete loss of sumoylation in B domain; when associated with R-532; R-535 and R-568.,MUTAGEN:K->R: Some loss of sumoylation in B domain. Complete loss of sumoylation in B domain; when associated with R-532; R-558 and R-568.,MUTAGEN:K->R: Some loss of sumoylation in B domain. Complete loss of sumoylation in B domain; when associated with R-535; R-558 and R-568.,MUTAGEN:K->R: Some loss of sumoylation in the GED domain; Complete loss of sumoylation in the GED domain; when associated with R-594; R-597 and R-606.,MUTAGEN:K->R: Some loss of sumoylation in the GED domain; Complete loss of sumoylation in the GED domain; when associated with R-594; R-597 and R-608.,MUTAGEN:K->R: Some loss of sumoylation in the GED domain; Complete loss of sumoylation in the GED domain; when associated with R-594; R-606 and R-608.,MUTAGEN:K->R: Some loss of sumoylation in the GED domain; Complete loss of sumoylation in the GED domain; when associated with R-597; R-606 and R-608.,MUTAGEN:Q->A: Abolishes GTP hydrolysis.,MUTAGEN:S->A: Abolishes GTP hydrolysis.,MUTAGEN:S->A: Abolishes phosphorylation. Reduces interaction with MIEF1 and MIEF2. Promotes mitochondrial fission and cell vulnerability to apoptotic insults. Mostly mitochondrial. Disrupts, in vitro, binding to FIS1.,MUTAGEN:S->A: Loss of activity. Little effect on mitochondrial morphology. Translocated to mitochondria.,MUTAGEN:S->D: Impairs intramolecular interactions but not homooligomerization. Does not reduce interaction with MIEF1 and MIEF2. Impairs formation of higher order oligomers but not homodimerization. Unable to associate with MIEF2 into filaments forming the tubular structures that wrap around the scission site. Slight reduction in GTPase activity. Inhibits mitochondrial fission. Retained in the cytoplasm.,MUTAGEN:S->I: Decreased localization to the perinuclear region.,MUTAGEN:S->N: Reduces peroxisomal abundance.,MUTAGEN:T->A: Abolishes GTP hydrolysis. Impairs mitochondrial division. Reduces peroxisomal abundance.,MUTAGEN:V->F: Temperature-sensitive. Impairs mitochondrial division.,NP_BIND:GTP,REGION:B domain,REGION:Disordered,REGION:G1 motif,REGION:G2 motif,REGION:G3 motif,REGION:G4 motif,REGION:G5 motif,REGION:Important for homodimerization,REGION:Interaction with GSK3B,REGION:Middle domain,
DNM1	dynamin 1(DNM1)	Homo sapiens		h_bArr-mapkPathway:Role of ï¿½-arrestins in the activation and targeting of MAP kinases,h_bArrestin-srcPathway:Roles of ï¿½-arrestin-dependent Recruitment of Src Kinases in GPCR Signaling,h_bArrestinPathway:ï¿½-arrestins in GPCR Desensitization,h_ndkDynaminPathway:Endocytotic role of NDK, Phosphins and Dynamin,		GO:0000266~mitochondrial fission,GO:0002031~G-protein coupled receptor internalization,GO:0003374~dynamin family protein polymerization involved in mitochondrial fission,GO:0006897~endocytosis,GO:0006898~receptor-mediated endocytosis,GO:0007032~endosome organization,GO:0016185~synaptic vesicle budding from presynaptic endocytic zone membrane,GO:0031623~receptor internalization,GO:0048013~ephrin receptor signaling pathway,GO:0048488~synaptic vesicle endocytosis,GO:0050803~regulation of synapse structure or activity,GO:0050804~modulation of synaptic transmission,GO:0061025~membrane fusion,GO:0098884~postsynaptic neurotransmitter receptor internalization,GO:1900244~positive regulation of synaptic vesicle endocytosis,GO:1901998~toxin transport,GO:1904645~response to beta-amyloid,	GO:0001917~photoreceptor inner segment,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005874~microtubule,GO:0005886~plasma membrane,GO:0008021~synaptic vesicle,GO:0014069~postsynaptic density,GO:0015630~microtubule cytoskeleton,GO:0016020~membrane,GO:0030117~membrane coat,GO:0030424~axon,GO:0031410~cytoplasmic vesicle,GO:0031966~mitochondrial membrane,GO:0043196~varicosity,GO:0044327~dendritic spine head,GO:0045202~synapse,GO:0070062~extracellular exosome,GO:0098684~photoreceptor ribbon synapse,GO:0098793~presynapse,GO:0098835~presynaptic endocytic zone membrane,GO:0098844~postsynaptic endocytic zone membrane,GO:0098978~glutamatergic synapse,	GO:0003723~RNA binding,GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0008017~microtubule binding,GO:0008022~protein C-terminus binding,GO:0017124~SH3 domain binding,GO:0019901~protein kinase binding,GO:0031749~D2 dopamine receptor binding,GO:0042802~identical protein binding,GO:0044877~macromolecular complex binding,GO:0050998~nitric-oxide synthase binding,	IPR000375:Dynamin central domain,IPR001401:Dynamin, GTPase domain,IPR001849:Pleckstrin homology domain,IPR003130:Dynamin GTPase effector,IPR011993:Pleckstrin homology-like domain,IPR019762:Dynamin, GTPase region, conserved site,IPR020850:GTPase effector domain, GED,IPR022812:Dynamin,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04072:Phospholipase D signaling pathway,hsa04144:Endocytosis,hsa04721:Synaptic vesicle cycle,hsa04961:Endocrine and other factor-regulated calcium reabsorption,hsa05100:Bacterial invasion of epithelial cells,	616346~Developmental and epileptic encephalopathy 31,		SM00053:DYNc,SM00233:PH,SM00302:GED,	KW-0254~Endocytosis,	KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0887~Epilepsy,	KW-0175~Coiled coil,	KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,KW-0505~Motor protein,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0944~Nitration,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Dynamin-type G,DOMAIN:Dynamin_M,DOMAIN:GED,DOMAIN:PH,MUTAGEN:K->A: Inhibits receptor-mediated endocytosis.,NP_BIND:GTP,REGION:Disordered,REGION:G1 motif,REGION:G2 motif,REGION:G3 motif,REGION:G4 motif,REGION:G5 motif,
DYNLT3	dynein light chain Tctex-type 3(DYNLT3)	Homo sapiens				GO:0007018~microtubule-based movement,GO:0007049~cell cycle,GO:0007346~regulation of mitotic cell cycle,GO:0045931~positive regulation of mitotic cell cycle,GO:0051301~cell division,	GO:0000776~kinetochore,GO:0000777~condensed chromosome kinetochore,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005868~cytoplasmic dynein complex,GO:0005874~microtubule,GO:0061673~mitotic spindle astral microtubule,	GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0045505~dynein intermediate chain binding,	IPR005334:Tctex-1,	hsa05132:Salmonella infection,				KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,KW-0813~Transport,	KW-0137~Centromere,KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0243~Dynein,KW-0493~Microtubule,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0995~Kinetochore,		KW-0732~Signal,		KW-0505~Motor protein,	KW-0944~Nitration,
DAG1	dystroglycan 1(DAG1)	Homo sapiens	10.Dysdap,63.LAT_couples_T-cell_receptor,82.TCR_and_Cap_or_SMAC,	h_agrPathway:Agrin in Postsynaptic Differentiation,		GO:0001954~positive regulation of cell-matrix adhesion,GO:0002009~morphogenesis of an epithelium,GO:0002011~morphogenesis of an epithelial sheet,GO:0006509~membrane protein ectodomain proteolysis,GO:0007411~axon guidance,GO:0007568~aging,GO:0010470~regulation of gastrulation,GO:0010717~regulation of epithelial to mesenchymal transition,GO:0014894~response to denervation involved in regulation of muscle adaptation,GO:0016203~muscle attachment,GO:0016340~calcium-dependent cell-matrix adhesion,GO:0016476~regulation of embryonic cell shape,GO:0019048~modulation by virus of host morphology or physiology,GO:0021675~nerve development,GO:0021682~nerve maturation,GO:0022011~myelination in peripheral nervous system,GO:0030198~extracellular matrix organization,GO:0030336~negative regulation of cell migration,GO:0031103~axon regeneration,GO:0031643~positive regulation of myelination,GO:0034453~microtubule anchoring,GO:0043403~skeletal muscle tissue regeneration,GO:0043409~negative regulation of MAPK cascade,GO:0043434~response to peptide hormone,GO:0045860~positive regulation of protein kinase activity,GO:0046718~viral entry into host cell,GO:0048714~positive regulation of oligodendrocyte differentiation,GO:0050807~regulation of synapse organization,GO:0051898~negative regulation of protein kinase B signaling,GO:0060055~angiogenesis involved in wound healing,GO:0060441~epithelial tube branching involved in lung morphogenesis,GO:0060445~branching involved in salivary gland morphogenesis,GO:0071260~cellular response to mechanical stimulus,GO:0071397~cellular response to cholesterol,GO:0071679~commissural neuron axon guidance,GO:0071711~basement membrane organization,GO:0098942~retrograde trans-synaptic signaling by trans-synaptic protein complex,GO:1904261~positive regulation of basement membrane assembly involved in embryonic body morphogenesis,	GO:0005576~extracellular region,GO:0005604~basement membrane,GO:0005615~extracellular space,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005788~endoplasmic reticulum lumen,GO:0005796~Golgi lumen,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0005912~adherens junction,GO:0005925~focal adhesion,GO:0009897~external side of plasma membrane,GO:0016010~dystrophin-associated glycoprotein complex,GO:0016011~dystroglycan complex,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0030027~lamellipodium,GO:0030175~filopodium,GO:0033268~node of Ranvier,GO:0034399~nuclear periphery,GO:0042383~sarcolemma,GO:0043034~costamere,GO:0043231~intracellular membrane-bounded organelle,GO:0044853~plasma membrane raft,GO:0045211~postsynaptic membrane,GO:0070062~extracellular exosome,GO:0070938~contractile ring,GO:0098978~glutamatergic synapse,GO:0098982~GABA-ergic synapse,GO:0099524~postsynaptic cytosol,	GO:0001618~virus receptor activity,GO:0002162~dystroglycan binding,GO:0003779~actin binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008307~structural constituent of muscle,GO:0015631~tubulin binding,GO:0017166~vinculin binding,GO:0042169~SH2 domain binding,GO:0043236~laminin binding,GO:0043237~laminin-1 binding,GO:0051393~alpha-actinin binding,	IPR006644:Dystroglycan-type cadherin-like,IPR008465:Dystroglycan,IPR013783:Immunoglobulin-like fold,IPR015919:Cadherin-like,IPR027468:Alpha-dystroglycan domain 2,	hsa04512:ECM-receptor interaction,hsa05410:Hypertrophic cardiomyopathy,hsa05412:Arrhythmogenic right ventricular cardiomyopathy,hsa05414:Dilated cardiomyopathy,hsa05416:Viral myocarditis,	613818~Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 9,616538~Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 9,		SM00736:CADG,	KW-0945~Host-virus interaction,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0539~Nucleus,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0964~Secreted,KW-0965~Cell junction,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0451~Lissencephaly,KW-0912~Congenital muscular dystrophy,KW-0947~Limb-girdle muscular dystrophy,KW-1215~Dystroglycanopathy,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,KW-1183~Host cell receptor for virus entry,	KW-0068~Autocatalytic cleavage,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GalNAc...) threonine,CARBOHYD:O-linked (Hex...) threonine,CARBOHYD:O-linked (Man6P...) threonine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:CADG,DOMAIN:Peptidase S72,MOTIF:Nuclear localization signal,MOTIF:PPXY motif,MUTAGEN:K->A: No change in nuclear location.,MUTAGEN:K->A: Significant reduction in nuclear accumulation.,MUTAGEN:KK->TA: Abolishes nuclear translocation.,MUTAGEN:KKRK->NPGE: Abolishes nuclear translocation.,MUTAGEN:KKRKGK->AARKGA: About 50% reduction in nuclear accumulation.,MUTAGEN:KKRKGK->RKKAAGA: Drastic reduction in nuclear accumulation.,MUTAGEN:PP->AA: No change in nuclear location.,MUTAGEN:R->A: Significant reduction in nuclear accumulation.,MUTAGEN:RKKRKGK->AKKRKGA: Moderate reduction in nuclear accumulation.,MUTAGEN:S->A: Abolishes autoproteolysis and enhances laminin-binding.,MUTAGEN:T->A: Reduced N-linked glycosylation. No change in nuclear translocation.,MUTAGEN:TPT->APA: Impaired laminin-binding.,MUTAGEN:TT->AA: Does not affect laminin-binding.,MUTAGEN:Y->A: Abolishes phosphorylation. No change in plasma membrane location.,MUTAGEN:Y->A: No change in nuclear location.,MUTAGEN:Y->E: Redistributes to a vesicular internal membrane compartment.,MUTAGEN:Y->F: Abolishes phosphorylation. Increase in nuclear location.,REGION:Disordered,REGION:Mucin-like domain,REGION:O-glycosylated at one site,REGION:O-glycosylated at seven sites with GalNAc,REGION:Required for binding DMD and UTRN,REGION:Required for interaction with CAV3,REGION:Required for laminin recognition,SITE:Cleavage; by MMP9,SITE:Cleavage; by autolysis,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
EGR1	early growth response 1(EGR1)	Homo sapiens	114.Genomic_reformatting_Brain_Ischemia,	h_cdk5Pathway:Phosphorylation of MEK1 by cdk5/p35 down regulates the MAP kinase pathway,	Transcription / Cell division and chromosome partitioning,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001666~response to hypoxia,GO:0002931~response to ischemia,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0009749~response to glucose,GO:0010628~positive regulation of gene expression,GO:0030217~T cell differentiation,GO:0030509~BMP signaling pathway,GO:0032722~positive regulation of chemokine production,GO:0032731~positive regulation of interleukin-1 beta production,GO:0032868~response to insulin,GO:0032922~circadian regulation of gene expression,GO:0033233~regulation of protein sumoylation,GO:0035914~skeletal muscle cell differentiation,GO:0042981~regulation of apoptotic process,GO:0044849~estrous cycle,GO:0045475~locomotor rhythm,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046886~positive regulation of hormone biosynthetic process,GO:0060086~circadian temperature homeostasis,GO:0060337~type I interferon signaling pathway,GO:0061418~regulation of transcription from RNA polymerase II promoter in response to hypoxia,GO:0070498~interleukin-1-mediated signaling pathway,GO:0071480~cellular response to gamma radiation,GO:0071504~cellular response to heparin,GO:0071506~cellular response to mycophenolic acid,GO:0072110~glomerular mesangial cell proliferation,GO:0072303~positive regulation of glomerular metanephric mesangial cell proliferation,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:0098759~cellular response to interleukin-8,GO:1901216~positive regulation of neuron death,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1902949~positive regulation of tau-protein kinase activity,GO:2000182~regulation of progesterone biosynthetic process,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0010385~double-stranded methylated DNA binding,GO:0035035~histone acetyltransferase binding,GO:0043565~sequence-specific DNA binding,GO:0044729~hemi-methylated DNA-binding,GO:0046872~metal ion binding,GO:1990837~sequence-specific double-stranded DNA binding,GO:1990841~promoter-specific chromatin binding,	IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,IPR021839:Protein of unknown function DUF3432,IPR021849:Protein of unknown function DUF3446,	hsa04371:Apelin signaling pathway,hsa04912:GnRH signaling pathway,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa05020:Prion disease,hsa05166:Human T-cell leukemia virus 1 infection,			SM00355:ZnF_C2H2,	KW-0090~Biological rhythms,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0238~DNA-binding,	KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:C2H2-type,REGION:Disordered,SITE:Interaction with DNA,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,
ECD	ecdysoneless cell cycle regulator(ECD)	Homo sapiens				GO:0006397~mRNA processing,GO:0008283~cell proliferation,GO:0008380~RNA splicing,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:2000045~regulation of G1/S transition of mitotic cell cycle,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0035035~histone acetyltransferase binding,	IPR010770:SGT1,					KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0010~Activator,	KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,MUTAGEN:D->F: Decreases transactivation activity.,MUTAGEN:D->P: Increases transactivation activity.,MUTAGEN:D->R: Increases transactivation activity.,MUTAGEN:I->A: Decreases transactivation activity.,MUTAGEN:L->A: Decreases transactivation activity.,MUTAGEN:S->A: Greatly impairs in vitro phosphorylation by CK2 and impairs cell cycle regulation activity; when associated with A-503, A-505, A-518, A-572 and A-579.,MUTAGEN:S->A: Greatly impairs in vitro phosphorylation by CK2 and impairs cell cycle regulation activity; when associated with A-503, A-505, A-518, A-572 and A-584.,MUTAGEN:S->A: Greatly impairs in vitro phosphorylation by CK2 and impairs cell cycle regulation activity; when associated with A-503, A-505, A-518, A-579 and A-584.,MUTAGEN:S->A: Greatly impairs in vitro phosphorylation by CK2 and impairs cell cycle regulation activity; when associated with A-503, A-505, A-572, A-579 and A-584.,MUTAGEN:S->A: Greatly impairs in vitro phosphorylation by CK2 and impairs cell cycle regulation activity; when associated with A-503, A-518, A-572, A-579 and A-584.,MUTAGEN:S->A: Greatly impairs in vitro phosphorylation by CK2 and impairs cell cycle regulation activity; when associated with A-505, A-518, A-572, A-579 and A-584.,REGION:Acidic region required for transactivation activity,REGION:Disordered,REGION:Involved in nuclear export,REGION:Transcription activation,
ELAC2	elaC ribonuclease Z 2(ELAC2)	Homo sapiens				GO:0008033~tRNA processing,GO:0016078~tRNA catabolic process,GO:0042780~tRNA 3'-end processing,GO:0072684~mitochondrial tRNA 3'-trailer cleavage, endonucleolytic,GO:0090646~mitochondrial tRNA processing,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005829~cytosol,GO:0042645~mitochondrial nucleoid,	GO:0003723~RNA binding,GO:0004521~endoribonuclease activity,GO:0004549~tRNA-specific ribonuclease activity,GO:0016787~hydrolase activity,GO:0042781~3'-tRNA processing endoribonuclease activity,GO:0046872~metal ion binding,	IPR001279:Beta-lactamase-like,		614731~Prostate cancer, hereditary, 2, susceptibility to,615440~Combined oxidative phosphorylation deficiency 17,			KW-0819~tRNA processing,	KW-0496~Mitochondrion,KW-0539~Nucleus,KW-1135~Mitochondrion nucleoid,	KW-0225~Disease variant,KW-0656~Proto-oncogene,KW-1274~Primary mitochondrial disease,	KW-0809~Transit peptide,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0255~Endonuclease,KW-0378~Hydrolase,KW-0540~Nuclease,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:Lactamase_B,DOMAIN:Lactamase_B_4,REGION:Disordered,TRANSIT:Mitochondrion,
ETFB	electron transfer flavoprotein subunit beta(ETFB)	Homo sapiens				GO:0009063~cellular amino acid catabolic process,GO:0022904~respiratory electron transport chain,GO:0033539~fatty acid beta-oxidation using acyl-CoA dehydrogenase,	GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0045251~electron transfer flavoprotein complex,	GO:0005515~protein binding,GO:0009055~electron carrier activity,	IPR000049:Electron transfer flavoprotein, beta-subunit, conserved site,IPR012255:Electron transfer flavoprotein, beta subunit,IPR014729:Rossmann-like alpha/beta/alpha sandwich fold,IPR014730:Electron transfer flavoprotein, alpha/beta-subunit, N-terminal,		231680~Glutaric acidemia IIB,	PIRSF000090:electron transfer flavoprotein, beta subunit,	SM00893:SM00893,	KW-0249~Electron transport,KW-0813~Transport,	KW-0496~Mitochondrion,	KW-0225~Disease variant,KW-0316~Glutaricaciduria,				KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	BINDING:AMP; via amide nitrogen and carbonyl oxygen,BINDING:AMP; via carbonyl oxygen,DOMAIN:ETF,MUTAGEN:E->A,Q: Drastically increases interprotein electron transfer rates.,MUTAGEN:K->R: Does not abolish electron transfer activity. Decreases sensitivity to inhibition by lysine methyltransferase ETFBKMT.,MUTAGEN:KAK->RAR: Does not abolish methylation by ETFBKMT.,MUTAGEN:KAKK->RAKR: Does not abolish electron transfer activity. Abolishes sensitivity to inhibition by lysine methyltransferase ETFBKMT.,MUTAGEN:L->A: Severely impaired in complex formation with ACADM.,NP_BIND:AMP,REGION:Recognition loop,
EED	embryonic ectoderm development(EED)	Homo sapiens		h_prc2Pathway:The PRC2 Complex Sets Long-term Gene Silencing Through Modification of Histone Tails,		GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006342~chromatin silencing,GO:0016571~histone methylation,GO:0019058~viral life cycle,GO:0021510~spinal cord development,GO:0045814~negative regulation of gene expression, epigenetic,GO:0045892~negative regulation of transcription, DNA-templated,GO:0050790~regulation of catalytic activity,GO:0070317~negative regulation of G0 to G1 transition,GO:0070734~histone H3-K27 methylation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005829~cytosol,GO:0016021~integral component of membrane,GO:0035098~ESC/E(Z) complex,	GO:0001222~transcription corepressor binding,GO:0001226~RNA polymerase II transcription corepressor binding,GO:0003682~chromatin binding,GO:0005515~protein binding,GO:0008047~enzyme activator activity,GO:0031491~nucleosome binding,GO:0042054~histone methyltransferase activity,GO:0042802~identical protein binding,	IPR001680:WD40 repeat,IPR015943:WD40/YVTN repeat-like-containing domain,IPR017986:WD40-repeat-containing domain,IPR019775:WD40 repeat, conserved site,		617561~Cohen-Gibson syndrome,		SM00320:WD40,	KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0158~Chromosome,KW-0472~Membrane,KW-0539~Nucleus,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0812~Transmembrane,KW-0853~WD repeat,KW-1133~Transmembrane helix,		KW-0156~Chromatin regulator,KW-0678~Repressor,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,MUTAGEN:F->A: Abolishes binding to H3K27me3.,MUTAGEN:HRNY->AAAA: Impairs interaction with the matrix protein MA of HIV-1.,MUTAGEN:I->N: Impairs interaction with EZH2.,MUTAGEN:L->P: Impairs interaction with EZH2.,MUTAGEN:ST->AA: Impairs interaction with the matrix protein MA of HIV-1.,MUTAGEN:W->A: Abolishes binding to H3K27me3.,MUTAGEN:W->L: Abolishes binding to H3K27me3.,MUTAGEN:Y->A: Abolishes binding to H3K27me3.,REGION:Disordered,REGION:Interaction with EZH2,REGION:Required for interaction with the matrix protein MA of HIV-1,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,TRANSMEM:Helical,
EDN1	endothelin 1(EDN1)	Homo sapiens		h_cardiacEGFPathway:Role of EGF Receptor Transactivation by GPCRs in Cardiac Hypertrophy,h_hifPathway:Hypoxia-Inducible Factor in the Cardiovascular System,h_nfatPathway:NFAT and Hypertrophy of the heart (Transcription in the broken heart),		GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001516~prostaglandin biosynthetic process,GO:0001569~branching involved in blood vessel morphogenesis,GO:0001701~in utero embryonic development,GO:0001821~histamine secretion,GO:0001975~response to amphetamine,GO:0003100~regulation of systemic arterial blood pressure by endothelin,GO:0003253~cardiac neural crest cell migration involved in outflow tract morphogenesis,GO:0003357~noradrenergic neuron differentiation,GO:0006366~transcription from RNA polymerase II promoter,GO:0006468~protein phosphorylation,GO:0006874~cellular calcium ion homeostasis,GO:0006885~regulation of pH,GO:0007005~mitochondrion organization,GO:0007166~cell surface receptor signaling pathway,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007193~adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007205~protein kinase C-activating G-protein coupled receptor signaling pathway,GO:0007249~I-kappaB kinase/NF-kappaB signaling,GO:0007267~cell-cell signaling,GO:0007507~heart development,GO:0007585~respiratory gaseous exchange,GO:0007589~body fluid secretion,GO:0008217~regulation of blood pressure,GO:0008284~positive regulation of cell proliferation,GO:0009953~dorsal/ventral pattern formation,GO:0010193~response to ozone,GO:0010259~multicellular organism aging,GO:0010460~positive regulation of heart rate,GO:0010595~positive regulation of endothelial cell migration,GO:0010613~positive regulation of cardiac muscle hypertrophy,GO:0010629~negative regulation of gene expression,GO:0010737~protein kinase A signaling,GO:0010827~regulation of glucose transport,GO:0014032~neural crest cell development,GO:0014034~neural crest cell fate commitment,GO:0014065~phosphatidylinositol 3-kinase signaling,GO:0014823~response to activity,GO:0014824~artery smooth muscle contraction,GO:0014826~vein smooth muscle contraction,GO:0019229~regulation of vasoconstriction,GO:0019233~sensory perception of pain,GO:0019722~calcium-mediated signaling,GO:0030072~peptide hormone secretion,GO:0030185~nitric oxide transport,GO:0030195~negative regulation of blood coagulation,GO:0030335~positive regulation of cell migration,GO:0030878~thyroid gland development,GO:0031583~phospholipase D-activating G-protein coupled receptor signaling pathway,GO:0032269~negative regulation of cellular protein metabolic process,GO:0032308~positive regulation of prostaglandin secretion,GO:0032496~response to lipopolysaccharide,GO:0033574~response to testosterone,GO:0034392~negative regulation of smooth muscle cell apoptotic process,GO:0034696~response to prostaglandin F,GO:0035050~embryonic heart tube development,GO:0035094~response to nicotine,GO:0035556~intracellular signal transduction,GO:0035690~cellular response to drug,GO:0035810~positive regulation of urine volume,GO:0035815~positive regulation of renal sodium excretion,GO:0035994~response to muscle stretch,GO:0042045~epithelial fluid transport,GO:0042310~vasoconstriction,GO:0042313~protein kinase C deactivation,GO:0042474~middle ear morphogenesis,GO:0042482~positive regulation of odontogenesis,GO:0042554~superoxide anion generation,GO:0043179~rhythmic excitation,GO:0043200~response to amino acid,GO:0043406~positive regulation of MAP kinase activity,GO:0043507~positive regulation of JUN kinase activity,GO:0044321~response to leptin,GO:0044751~cellular response to human chorionic gonadotropin stimulus,GO:0045321~leukocyte activation,GO:0045429~positive regulation of nitric oxide biosynthetic process,GO:0045793~positive regulation of cell size,GO:0045840~positive regulation of mitotic nuclear division,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0045987~positive regulation of smooth muscle contraction,GO:0046887~positive regulation of hormone secretion,GO:0046888~negative regulation of hormone secretion,GO:0048016~inositol phosphate-mediated signaling,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0048675~axon extension,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0051216~cartilage development,GO:0051482~positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway,GO:0051771~negative regulation of nitric-oxide synthase biosynthetic process,GO:0051899~membrane depolarization,GO:0051930~regulation of sensory perception of pain,GO:0060070~canonical Wnt signaling pathway,GO:0060137~maternal process involved in parturition,GO:0060298~positive regulation of sarcomere organization,GO:0060385~axonogenesis involved in innervation,GO:0060585~positive regulation of prostaglandin-endoperoxide synthase activity,GO:0061051~positive regulation of cell growth involved in cardiac muscle cell development,GO:0061626~pharyngeal arch artery morphogenesis,GO:0070101~positive regulation of chemokine-mediated signaling pathway,GO:0070294~renal sodium ion absorption,GO:0070301~cellular response to hydrogen peroxide,GO:0070371~ERK1 and ERK2 cascade,GO:0070588~calcium ion transmembrane transport,GO:0071277~cellular response to calcium ion,GO:0071310~cellular response to organic substance,GO:0071346~cellular response to interferon-gamma,GO:0071347~cellular response to interleukin-1,GO:0071356~cellular response to tumor necrosis factor,GO:0071372~cellular response to follicle-stimulating hormone stimulus,GO:0071373~cellular response to luteinizing hormone stimulus,GO:0071375~cellular response to peptide hormone stimulus,GO:0071385~cellular response to glucocorticoid stimulus,GO:0071389~cellular response to mineralocorticoid stimulus,GO:0071398~cellular response to fatty acid,GO:0071456~cellular response to hypoxia,GO:0071466~cellular response to xenobiotic stimulus,GO:0071548~response to dexamethasone,GO:0071560~cellular response to transforming growth factor beta stimulus,GO:0086100~endothelin receptor signaling pathway,GO:0086101~endothelin receptor signaling pathway involved in heart process,GO:0090023~positive regulation of neutrophil chemotaxis,GO:0097492~sympathetic neuron axon guidance,GO:1901224~positive regulation of NIK/NF-kappaB signaling,GO:1902074~response to salt,GO:1902287~semaphorin-plexin signaling pathway involved in axon guidance,GO:1903537~meiotic cell cycle process involved in oocyte maturation,GO:1904707~positive regulation of vascular smooth muscle cell proliferation,GO:2000273~positive regulation of receptor activity,GO:2001259~positive regulation of cation channel activity,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0030133~transport vesicle,GO:0033093~Weibel-Palade body,GO:0045178~basal part of cell,GO:0048237~rough endoplasmic reticulum lumen,	GO:0005125~cytokine activity,GO:0005179~hormone activity,GO:0005515~protein binding,GO:0031707~endothelin A receptor binding,GO:0031708~endothelin B receptor binding,	IPR001928:Endothelin-like toxin,IPR019764:Endothelin-like toxin, conserved site,IPR020475:Bibrotoxin/Sarafotoxin-D,	hsa04024:cAMP signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04270:Vascular smooth muscle contraction,hsa04668:TNF signaling pathway,hsa04916:Melanogenesis,hsa04924:Renin secretion,hsa04926:Relaxin signaling pathway,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa05200:Pathways in cancer,hsa05410:Hypertrophic cardiomyopathy,hsa05418:Fluid shear stress and atherosclerosis,	612798~Question mark ears, isolated,615706~Auriculocondylar syndrome 3,High density lipoprotein cholesterol level QTL 7~High density lipoprotein cholesterol level QTL 7,		SM00272:END,		KW-0964~Secreted,	KW-0225~Disease variant,	KW-0732~Signal,		KW-0838~Vasoactive,KW-0839~Vasoconstrictor,	KW-0165~Cleavage on pair of basic residues,KW-1015~Disulfide bond,	DOMAIN:END,PEPTIDE:Big endothelin-1,PEPTIDE:Endothelin-1,REGION:Disordered,REGION:Endothelin-like,SITE:Cleavage; by KEL,
EZH2	enhancer of zeste 2 polycomb repressive complex 2 subunit(EZH2)	Homo sapiens		h_prc2Pathway:The PRC2 Complex Sets Long-term Gene Silencing Through Modification of Histone Tails,		GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001932~regulation of protein phosphorylation,GO:0006306~DNA methylation,GO:0006325~chromatin organization,GO:0006348~chromatin silencing at telomere,GO:0006355~regulation of transcription, DNA-templated,GO:0008284~positive regulation of cell proliferation,GO:0010629~negative regulation of gene expression,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0014013~regulation of gliogenesis,GO:0014834~skeletal muscle satellite cell maintenance involved in skeletal muscle regeneration,GO:0014898~cardiac muscle hypertrophy in response to stress,GO:0016571~histone methylation,GO:0019058~viral life cycle,GO:0021695~cerebellar cortex development,GO:0021766~hippocampus development,GO:0030183~B cell differentiation,GO:0031509~telomeric heterochromatin assembly,GO:0032355~response to estradiol,GO:0034244~negative regulation of transcription elongation from RNA polymerase II promoter,GO:0035984~cellular response to trichostatin A,GO:0036333~hepatocyte homeostasis,GO:0042127~regulation of cell proliferation,GO:0042752~regulation of circadian rhythm,GO:0043406~positive regulation of MAP kinase activity,GO:0043433~negative regulation of sequence-specific DNA binding transcription factor activity,GO:0043547~positive regulation of GTPase activity,GO:0045605~negative regulation of epidermal cell differentiation,GO:0045814~negative regulation of gene expression, epigenetic,GO:0045892~negative regulation of transcription, DNA-templated,GO:0048387~negative regulation of retinoic acid receptor signaling pathway,GO:0048468~cell development,GO:0048511~rhythmic process,GO:0051154~negative regulation of striated muscle cell differentiation,GO:0051932~synaptic transmission, GABAergic,GO:0070301~cellular response to hydrogen peroxide,GO:0070314~G1 to G0 transition,GO:0070317~negative regulation of G0 to G1 transition,GO:0070734~histone H3-K27 methylation,GO:0071168~protein localization to chromatin,GO:0071902~positive regulation of protein serine/threonine kinase activity,GO:0097421~liver regeneration,GO:0098532~histone H3-K27 trimethylation,GO:1900006~positive regulation of dendrite development,GO:1900016~negative regulation of cytokine production involved in inflammatory response,GO:1902808~positive regulation of cell cycle G1/S phase transition,GO:1904772~response to tetrachloromethane,GO:2000134~negative regulation of G1/S transition of mitotic cell cycle,	GO:0000781~chromosome, telomeric region,GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005677~chromatin silencing complex,GO:0005721~pericentric heterochromatin,GO:0005737~cytoplasm,GO:0035098~ESC/E(Z) complex,GO:0045120~pronucleus,GO:0045202~synapse,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000979~RNA polymerase II core promoter sequence-specific DNA binding,GO:0001222~transcription corepressor binding,GO:0001226~RNA polymerase II transcription corepressor binding,GO:0003682~chromatin binding,GO:0003714~transcription corepressor activity,GO:0005515~protein binding,GO:0016279~protein-lysine N-methyltransferase activity,GO:0018024~histone-lysine N-methyltransferase activity,GO:0031490~chromatin DNA binding,GO:0042054~histone methyltransferase activity,GO:0043021~ribonucleoprotein complex binding,GO:0046976~histone methyltransferase activity (H3-K27 specific),GO:0070878~primary miRNA binding,GO:1990841~promoter-specific chromatin binding,	IPR001005:SANT/Myb domain,IPR001214:SET domain,IPR021654:WD repeat binding protein EZH2,IPR026489:CXC domain,	hsa00310:Lysine degradation,hsa01100:Metabolic pathways,hsa05206:MicroRNAs in cancer,	277590~Weaver syndrome,		SM00317:SET,SM00717:SANT,SM01114:SM01114,	KW-0090~Biological rhythms,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,		KW-0949~S-adenosyl-L-methionine,	KW-0156~Chromatin regulator,KW-0489~Methyltransferase,KW-0678~Repressor,KW-0808~Transferase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CARBOHYD:O-linked (GlcNAc) serine,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:CXC,DOMAIN:Myb-like,DOMAIN:SET,MUTAGEN:C->Y: Strongly impairs methyltransferase activity towards 'Lys-27' of histone H3.,MUTAGEN:F->I: Strongly decreases histone methyltransferase activity.,MUTAGEN:H->A: Abrogates methyltransferase activity.,MUTAGEN:S->A: Enhances methyltransferase activity towards 'Lys-27' of histone H3 and abrogates phosphorylation by PKB/AKT1.,MUTAGEN:S->A: Reduced protein stability.,MUTAGEN:S->D: Reduces methyltransferase activity towards 'Lys-27' of histone H3 and abrogates phosphorylation by PKB/AKT1.,MUTAGEN:T->A: Impaired CDK1- and CDK-2 mediated phosphorylation and subsequent gene silencing. Altered EZH2-mediated cell proliferation and migration.,REGION:Disordered,REGION:Interaction with CDYL,REGION:Interaction with DNMT1, DNMT3A and DNMT3B,REGION:Interaction with EED,
ENOSF1	enolase superfamily member 1(ENOSF1)	Homo sapiens			Cell envelope biogenesis, outer membrane / General function prediction only,	GO:0009063~cellular amino acid catabolic process,GO:0016052~carbohydrate catabolic process,GO:0044275~cellular carbohydrate catabolic process,	GO:0005739~mitochondrion,	GO:0000287~magnesium ion binding,GO:0016836~hydro-lyase activity,GO:0016853~isomerase activity,GO:0046872~metal ion binding,GO:0050023~L-fuconate dehydratase activity,	IPR013341:Mandelate racemase/muconate lactonizing enzyme, N-terminal,IPR013342:Mandelate racemase/muconate lactonizing enzyme, C-terminal,IPR018110:Mandelate racemase/muconate lactonizing enzyme, conserved site,	hsa00051:Fructose and mannose metabolism,hsa01100:Metabolic pathways,			SM00922:SM00922,		KW-0496~Mitochondrion,			KW-0460~Magnesium,KW-0479~Metal-binding,	KW-0413~Isomerase,KW-0456~Lyase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Proton donor/acceptor,BINDING:Substrate,DOMAIN:MR_MLE,DOMAIN:MR_MLE_N,METAL:Magnesium,MUTAGEN:Missing: Impairs protein solubility. Abolishes catalytic activity.,REGION:Disordered,REGION:Substrate binding,
ENOPH1	enolase-phosphatase 1(ENOPH1)	Homo sapiens				GO:0016311~dephosphorylation,GO:0019284~L-methionine salvage from S-adenosylmethionine,GO:0019509~L-methionine salvage from methylthioadenosine,	GO:0005634~nucleus,GO:0005829~cytosol,	GO:0000287~magnesium ion binding,GO:0005515~protein binding,GO:0043715~2,3-diketo-5-methylthiopentyl-1-phosphate enolase activity,GO:0043716~2-hydroxy-3-keto-5-methylthiopentenyl-1-phosphate phosphatase activity,GO:0043874~acireductone synthase activity,	IPR006439:HAD-superfamily hydrolase, subfamily IA, variant 1,IPR023214:HAD-like domain,IPR023943:Enolase-phosphatase E1,IPR027511:Enolase-phosphatase E1, eukaryotes,	hsa00270:Cysteine and methionine metabolism,hsa01100:Metabolic pathways,				KW-0028~Amino-acid biosynthesis,KW-0486~Methionine biosynthesis,	KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0460~Magnesium,KW-0479~Metal-binding,	KW-0378~Hydrolase,		BINDING:Substrate,METAL:Magnesium,METAL:Magnesium; via carbonyl oxygen,REGION:Substrate binding,
ECH1	enoyl-CoA hydratase 1(ECH1)	Homo sapiens			Lipid metabolism,	GO:0006635~fatty acid beta-oxidation,GO:0008104~protein localization,	GO:0005739~mitochondrion,GO:0005777~peroxisome,GO:0005782~peroxisomal matrix,GO:0005829~cytosol,GO:0016020~membrane,GO:0070062~extracellular exosome,	GO:0003824~catalytic activity,GO:0005515~protein binding,GO:0051750~delta3,5-delta2,4-dienoyl-CoA isomerase activity,	IPR001753:Crotonase superfamily,IPR014748:Crontonase, C-terminal,IPR018376:Enoyl-CoA hydratase/isomerase, conserved site,	hsa04146:Peroxisome,				KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,	KW-0496~Mitochondrion,KW-0576~Peroxisome,		KW-0809~Transit peptide,		KW-0413~Isomerase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	BINDING:Substrate; via amide nitrogen,MOTIF:Microbody targeting signal,REGION:Substrate binding,SITE:Important for catalytic activity,TRANSIT:Mitochondrion,
EGFR	epidermal growth factor receptor(EGFR)	Homo sapiens		h_agrPathway:Agrin in Postsynaptic Differentiation,h_at1rPathway:Angiotensin II mediated activation of JNK Pathway via Pyk2 dependent signaling,h_cardiacEGFPathway:Role of EGF Receptor Transactivation by GPCRs in Cardiac Hypertrophy,h_cblPathway:CBL mediated ligand-induced downregulation of EGF receptors,h_eea1Pathway:The role of FYVE-finger proteins in vesicle transport,h_egfPathway:EGF Signaling Pathway,h_egfr_smrtePathway:Map Kinase Inactivation of SMRT Corepressor,h_ErbB3Pathway:Neuroregulin receptor degredation protein-1 Controls ErbB3 receptor recycling,h_erkPathway:Erk1/Erk2 Mapk Signaling pathway,h_her2Pathway:Role of ERBB2 in Signal Transduction and Oncology,h_keratinocytePathway:Keratinocyte Differentiation,h_mCalpainPathway:mCalpain and friends in Cell motility,h_spryPathway:Sprouty regulation of tyrosine kinase signals,h_telPathway:Telomeres, Telomerase, Cellular Aging, and  Immortality,h_tffPathway:Trefoil Factors Initiate  Mucosal Healing,		GO:0000165~MAPK cascade,GO:0000902~cell morphogenesis,GO:0001503~ossification,GO:0001892~embryonic placenta development,GO:0001934~positive regulation of protein phosphorylation,GO:0001942~hair follicle development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006412~translation,GO:0006898~receptor-mediated endocytosis,GO:0006970~response to osmotic stress,GO:0007165~signal transduction,GO:0007166~cell surface receptor signaling pathway,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007173~epidermal growth factor receptor signaling pathway,GO:0007202~activation of phospholipase C activity,GO:0007275~multicellular organism development,GO:0007435~salivary gland morphogenesis,GO:0007494~midgut development,GO:0007611~learning or memory,GO:0007623~circadian rhythm,GO:0008284~positive regulation of cell proliferation,GO:0010750~positive regulation of nitric oxide mediated signal transduction,GO:0010960~magnesium ion homeostasis,GO:0014066~regulation of phosphatidylinositol 3-kinase signaling,GO:0016101~diterpenoid metabolic process,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0019058~viral life cycle,GO:0021795~cerebral cortex cell migration,GO:0030154~cell differentiation,GO:0030307~positive regulation of cell growth,GO:0030324~lung development,GO:0030335~positive regulation of cell migration,GO:0032930~positive regulation of superoxide anion generation,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0033590~response to cobalamin,GO:0033594~response to hydroxyisoflavone,GO:0033674~positive regulation of kinase activity,GO:0034614~cellular response to reactive oxygen species,GO:0035690~cellular response to drug,GO:0038083~peptidyl-tyrosine autophosphorylation,GO:0038128~ERBB2 signaling pathway,GO:0042059~negative regulation of epidermal growth factor receptor signaling pathway,GO:0042060~wound healing,GO:0042177~negative regulation of protein catabolic process,GO:0042327~positive regulation of phosphorylation,GO:0042698~ovulation cycle,GO:0042743~hydrogen peroxide metabolic process,GO:0043006~activation of phospholipase A2 activity by calcium-mediated signaling,GO:0043066~negative regulation of apoptotic process,GO:0043406~positive regulation of MAP kinase activity,GO:0043586~tongue development,GO:0045737~positive regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0045739~positive regulation of DNA repair,GO:0045740~positive regulation of DNA replication,GO:0045746~negative regulation of Notch signaling pathway,GO:0045780~positive regulation of bone resorption,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045907~positive regulation of vasoconstriction,GO:0045930~negative regulation of mitotic cell cycle,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046328~regulation of JNK cascade,GO:0046718~viral entry into host cell,GO:0046777~protein autophosphorylation,GO:0048143~astrocyte activation,GO:0048146~positive regulation of fibroblast proliferation,GO:0048546~digestive tract morphogenesis,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0048812~neuron projection morphogenesis,GO:0050679~positive regulation of epithelial cell proliferation,GO:0050729~positive regulation of inflammatory response,GO:0050730~regulation of peptidyl-tyrosine phosphorylation,GO:0050999~regulation of nitric-oxide synthase activity,GO:0051205~protein insertion into membrane,GO:0051592~response to calcium ion,GO:0051897~positive regulation of protein kinase B signaling,GO:0051968~positive regulation of synaptic transmission, glutamatergic,GO:0060252~positive regulation of glial cell proliferation,GO:0060571~morphogenesis of an epithelial fold,GO:0061024~membrane organization,GO:0061029~eyelid development in camera-type eye,GO:0070141~response to UV-A,GO:0070257~positive regulation of mucus secretion,GO:0070372~regulation of ERK1 and ERK2 cascade,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071230~cellular response to amino acid stimulus,GO:0071260~cellular response to mechanical stimulus,GO:0071276~cellular response to cadmium ion,GO:0071364~cellular response to epidermal growth factor stimulus,GO:0071392~cellular response to estradiol stimulus,GO:0071549~cellular response to dexamethasone stimulus,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:0097421~liver regeneration,GO:0098609~cell-cell adhesion,GO:1900020~positive regulation of protein kinase C activity,GO:1900087~positive regulation of G1/S transition of mitotic cell cycle,GO:1901185~negative regulation of ERBB signaling pathway,GO:1901224~positive regulation of NIK/NF-kappaB signaling,GO:1902722~positive regulation of prolactin secretion,GO:1903078~positive regulation of protein localization to plasma membrane,GO:1903800~positive regulation of production of miRNAs involved in gene silencing by miRNA,GO:1905208~negative regulation of cardiocyte differentiation,GO:2000145~regulation of cell motility,	GO:0000139~Golgi membrane,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005768~endosome,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005925~focal adhesion,GO:0009925~basal plasma membrane,GO:0009986~cell surface,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0030054~cell junction,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0031901~early endosome membrane,GO:0031965~nuclear membrane,GO:0032587~ruffle membrane,GO:0032991~macromolecular complex,GO:0043235~receptor complex,GO:0045121~membrane raft,GO:0045202~synapse,GO:0048471~perinuclear region of cytoplasm,GO:0070435~Shc-EGFR complex,GO:0097489~multivesicular body, internal vesicle lumen,GO:0097708~intracellular vesicle,	GO:0001618~virus receptor activity,GO:0003682~chromatin binding,GO:0003690~double-stranded DNA binding,GO:0004672~protein kinase activity,GO:0004709~MAP kinase kinase kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0004888~transmembrane signaling receptor activity,GO:0005006~epidermal growth factor-activated receptor activity,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0005524~ATP binding,GO:0016301~kinase activity,GO:0019899~enzyme binding,GO:0019900~kinase binding,GO:0019901~protein kinase binding,GO:0019903~protein phosphatase binding,GO:0030235~nitric-oxide synthase regulator activity,GO:0031625~ubiquitin protein ligase binding,GO:0042802~identical protein binding,GO:0045296~cadherin binding,GO:0048408~epidermal growth factor binding,GO:0051015~actin filament binding,GO:0051117~ATPase binding,	IPR000494:EGF receptor, L domain,IPR000719:Protein kinase, catalytic domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR006211:Furin-like cysteine-rich domain,IPR006212:Furin-like repeat,IPR008266:Tyrosine-protein kinase, active site,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR011009:Protein kinase-like domain,IPR016245:Tyrosine protein kinase, EGF/ERB/XmrK receptor,IPR017441:Protein kinase, ATP binding site,IPR020635:Tyrosine-protein kinase, catalytic domain,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa01522:Endocrine resistance,hsa04010:MAPK signaling pathway,hsa04012:ErbB signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04020:Calcium signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04068:FoxO signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04144:Endocytosis,hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04520:Adherens junction,hsa04540:Gap junction,hsa04630:JAK-STAT signaling pathway,hsa04810:Regulation of actin cytoskeleton,hsa04912:GnRH signaling pathway,hsa04915:Estrogen signaling pathway,hsa04921:Oxytocin signaling pathway,hsa04926:Relaxin signaling pathway,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04934:Cushing syndrome,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05131:Shigellosis,hsa05160:Hepatitis C,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05210:Colorectal cancer,hsa05212:Pancreatic cancer,hsa05213:Endometrial cancer,hsa05214:Glioma,hsa05215:Prostate cancer,hsa05218:Melanoma,hsa05219:Bladder cancer,hsa05223:Non-small cell lung cancer,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,hsa05230:Central carbon metabolism in cancer,hsa05231:Choline metabolism in cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,	211980~Adenocarcinoma of lung, response to tyrosine kinase inhibitor in,211980~Nonsmall cell lung cancer, response to tyrosine kinase inhibitor in,211980~Nonsmall cell lung cancer, susceptibility to,616069~Inflammatory skin and bowel disease, neonatal, 2,	PIRSF000619:tyrosine-protein kinase, EGF receptor type,	SM00219:TyrKc,SM00261:FU,	KW-0945~Host-virus interaction,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0539~Nucleus,KW-0964~Secreted,KW-0967~Endosome,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0656~Proto-oncogene,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0217~Developmental protein,KW-0418~Kinase,KW-0675~Receptor,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,KW-1183~Host cell receptor for virus entry,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	ACT_SITE:Proton acceptor,BINDING:ATP,CARBOHYD:N-linked (GlcNAc...) (complex) asparagine; atypical; partial,CARBOHYD:N-linked (GlcNAc...) (high mannose) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine; atypical,CARBOHYD:N-linked (GlcNAc...) asparagine; partial,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:Furin-like,DOMAIN:GF_recep_IV,DOMAIN:PK_Tyr_Ser-Thr,DOMAIN:Protein kinase,DOMAIN:Recep_L_domain,LIPID:S-palmitoyl cysteine,MUTAGEN:C->A: Decreased palmitoylation.,MUTAGEN:D->A: Increased EGF binding; when associated with A-590 and A-609.,MUTAGEN:D->A: Strongly reduced phosphorylation.,MUTAGEN:DGPH->AGPA: Decreases intramolecular interactions and facilitates EGF binding.,MUTAGEN:E->A: Reduced phosphorylation.,MUTAGEN:ED->RK: Constitutively activated kinase.,MUTAGEN:F->A: Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A-309.,MUTAGEN:H->A: Increased EGF binding; when associated with A-587; A-590 and A-609.,MUTAGEN:I->A: Abolishes phosphorylation.,MUTAGEN:K->A,M: Abolishes kinase activity.,MUTAGEN:K->A: Decreases intramolecular interactions and facilitates EGF binding. Increased EGF binding; when associated with A-587; A-590 and A-609.,MUTAGEN:L->A,P: Strongly reduced phosphorylation.,MUTAGEN:L->A: Abolishes phosphorylation.,MUTAGEN:L->A: Strongly reduced phosphorylation.,MUTAGEN:Missing: Abolishes palmitoylation.,MUTAGEN:Missing: Increased EGF binding.,MUTAGEN:N->A: Abolishes phosphorylation.,MUTAGEN:P->A: Reduced phosphorylation.,MUTAGEN:P->A: Strongly reduced phosphorylation.,MUTAGEN:Q->G: No effect on interaction with CBLC.,MUTAGEN:R->A: Abolishes phosphorylation.,MUTAGEN:R->A: Reduced phosphorylation.,MUTAGEN:R->E: Abolishes autophosphorylation and activation of downstream kinases.,MUTAGEN:R->G: Strongly decreases interaction with CBLC.,MUTAGEN:R->S: Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A-275. Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A-287.,MUTAGEN:T->A: Increased phosphorylation.,MUTAGEN:T->D: Strongly reduced phosphorylation.,MUTAGEN:V->A: Reduced autophosphorylation.,MUTAGEN:V->M: Constitutively activated kinase.,MUTAGEN:Y->A: Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A-309.,MUTAGEN:Y->F: 50% decrease in interaction with PIK3C2B. 65% decrease in interaction with PIK3C2B; when associated with F-1197. Abolishes interaction with PIK3C2B; when associated with F-1197 and F-1092.,MUTAGEN:Y->F: Abolishes interaction with CBLC.,MUTAGEN:Y->F: No change in interaction with PIK3C2B.,MUTAGEN:Y->F: No change in interaction with PIK3C2B. 65% decrease in interaction with PIK3C2B; when associated with F-1016. Abolishes interaction with PIK3C2B; when associated with F-1092 and F-1016.,MUTAGEN:Y->F: No change in interaction with PIK3C2B. Abolishes interaction with PIK3C2B; when associated with F-1197 and F-1016.,NP_BIND:ATP,REGION:Disordered,REGION:Important for dimerization, phosphorylation and activation,REPEAT:Approximate,SITE:Important for interaction with PIK3C2B,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
EGF	epidermal growth factor(EGF)	Homo sapiens		h_cardiacEGFPathway:Role of EGF Receptor Transactivation by GPCRs in Cardiac Hypertrophy,h_cblPathway:CBL mediated ligand-induced downregulation of EGF receptors,h_eea1Pathway:The role of FYVE-finger proteins in vesicle transport,h_egfPathway:EGF Signaling Pathway,h_egfr_smrtePathway:Map Kinase Inactivation of SMRT Corepressor,h_ErbB3Pathway:Neuroregulin receptor degredation protein-1 Controls ErbB3 receptor recycling,h_keratinocytePathway:Keratinocyte Differentiation,h_mCalpainPathway:mCalpain and friends in Cell motility,h_spryPathway:Sprouty regulation of tyrosine kinase signals,		GO:0000165~MAPK cascade,GO:0000186~activation of MAPKK activity,GO:0000187~activation of MAPK activity,GO:0001525~angiogenesis,GO:0001938~positive regulation of endothelial cell proliferation,GO:0002092~positive regulation of receptor internalization,GO:0002576~platelet degranulation,GO:0007165~signal transduction,GO:0007171~activation of transmembrane receptor protein tyrosine kinase activity,GO:0007173~epidermal growth factor receptor signaling pathway,GO:0008284~positive regulation of cell proliferation,GO:0010595~positive regulation of endothelial cell migration,GO:0010628~positive regulation of gene expression,GO:0010800~positive regulation of peptidyl-threonine phosphorylation,GO:0014068~positive regulation of phosphatidylinositol 3-kinase signaling,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0021940~positive regulation of cerebellar granule cell precursor proliferation,GO:0030335~positive regulation of cell migration,GO:0038029~epidermal growth factor receptor signaling pathway via MAPK cascade,GO:0038128~ERBB2 signaling pathway,GO:0042059~negative regulation of epidermal growth factor receptor signaling pathway,GO:0042327~positive regulation of phosphorylation,GO:0043388~positive regulation of DNA binding,GO:0043406~positive regulation of MAP kinase activity,GO:0043410~positive regulation of MAPK cascade,GO:0045740~positive regulation of DNA replication,GO:0045741~positive regulation of epidermal growth factor-activated receptor activity,GO:0045746~negative regulation of Notch signaling pathway,GO:0045840~positive regulation of mitotic nuclear division,GO:0045893~positive regulation of transcription, DNA-templated,GO:0046425~regulation of JAK-STAT cascade,GO:0048754~branching morphogenesis of an epithelial tube,GO:0051048~negative regulation of secretion,GO:0051897~positive regulation of protein kinase B signaling,GO:0060749~mammary gland alveolus development,GO:0061024~membrane organization,GO:0070371~ERK1 and ERK2 cascade,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:0090279~regulation of calcium ion import,GO:0090370~negative regulation of cholesterol efflux,GO:1900127~positive regulation of hyaluronan biosynthetic process,GO:1901185~negative regulation of ERBB signaling pathway,GO:1902966~positive regulation of protein localization to early endosome,GO:1905278~positive regulation of epithelial tube formation,GO:2000008~regulation of protein localization to cell surface,GO:2000060~positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process,GO:2000145~regulation of cell motility,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005765~lysosomal membrane,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0031093~platelet alpha granule lumen,GO:0070062~extracellular exosome,	GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005154~epidermal growth factor receptor binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008083~growth factor activity,GO:0030297~transmembrane receptor protein tyrosine kinase activator activity,	IPR000033:LDLR class B repeat,IPR000152:EGF-type aspartate/asparagine hydroxylation site,IPR000742:Epidermal growth factor-like domain,IPR001881:EGF-like calcium-binding,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR011042:Six-bladed beta-propeller, TolB-like,IPR016317:Pro-epidermal growth factor,IPR018097:EGF-like calcium-binding, conserved site,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa04010:MAPK signaling pathway,hsa04012:ErbB signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04020:Calcium signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04068:FoxO signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04540:Gap junction,hsa04630:JAK-STAT signaling pathway,hsa04810:Regulation of actin cytoskeleton,hsa05160:Hepatitis C,hsa05165:Human papillomavirus infection,hsa05200:Pathways in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05210:Colorectal cancer,hsa05212:Pancreatic cancer,hsa05213:Endometrial cancer,hsa05214:Glioma,hsa05215:Prostate cancer,hsa05218:Melanoma,hsa05219:Bladder cancer,hsa05223:Non-small cell lung cancer,hsa05224:Breast cancer,hsa05226:Gastric cancer,hsa05231:Choline metabolism in cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,	611718~Hypomagnesemia 4, renal,	PIRSF001778:pro-epidermal growth factor,	SM00135:LY,SM00179:EGF_CA,SM00181:EGF,		KW-0472~Membrane,	KW-0225~Disease variant,KW-0982~Primary hypomagnesemia,	KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0339~Growth factor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 2; calcium-binding,DOMAIN:EGF-like 3,DOMAIN:EGF-like 4,DOMAIN:EGF-like 5,DOMAIN:EGF-like 6,DOMAIN:EGF-like 7; calcium-binding,DOMAIN:EGF-like 8; calcium-binding,DOMAIN:EGF-like 9,REGION:Disordered,REGION:O-glycosylated at one site,REPEAT:LDL-receptor class B,REPEAT:LDL-receptor class B 1,REPEAT:LDL-receptor class B 2,REPEAT:LDL-receptor class B 3,REPEAT:LDL-receptor class B 4,REPEAT:LDL-receptor class B 5,REPEAT:LDL-receptor class B 6,REPEAT:LDL-receptor class B 7,REPEAT:LDL-receptor class B 8,REPEAT:LDL-receptor class B 9,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
EPN2	epsin 2(EPN2)	Homo sapiens				GO:0006897~endocytosis,GO:0030948~negative regulation of vascular endothelial growth factor receptor signaling pathway,GO:0045747~positive regulation of Notch signaling pathway,GO:0061024~membrane organization,GO:1903671~negative regulation of sprouting angiogenesis,	GO:0005768~endosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0030125~clathrin vesicle coat,GO:0030128~clathrin coat of endocytic vesicle,GO:0043231~intracellular membrane-bounded organelle,	GO:0005515~protein binding,GO:0005543~phospholipid binding,GO:0008289~lipid binding,GO:0030276~clathrin binding,GO:0045296~cadherin binding,	IPR003903:Ubiquitin interacting motif,IPR008942:ENTH/VHS,IPR013809:Epsin-like, N-terminal,IPR027319:Epsin-2, metazoa,	hsa04144:Endocytosis,			SM00273:ENTH,SM00726:UIM,	KW-0254~Endocytosis,	KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,		KW-0175~Coiled coil,KW-0677~Repeat,	KW-0446~Lipid-binding,		KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	BINDING:Phosphatidylinositol 4,5-bisphosphate,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:ENTH,DOMAIN:UIM 1,DOMAIN:UIM 2,REGION:3 X 3 AA repeats of N-P-F,REGION:6 X 3 AA repeats of [DE]-P-W,REGION:Disordered,REPEAT:1,REPEAT:2,REPEAT:3,REPEAT:4,REPEAT:5,REPEAT:6,
ERBB2	erb-b2 receptor tyrosine kinase 2(ERBB2)	Homo sapiens		h_her2Pathway:Role of ERBB2 in Signal Transduction and Oncology,h_tffPathway:Trefoil Factors Initiate  Mucosal Healing,		GO:0000165~MAPK cascade,GO:0001934~positive regulation of protein phosphorylation,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006468~protein phosphorylation,GO:0007165~signal transduction,GO:0007166~cell surface receptor signaling pathway,GO:0007167~enzyme linked receptor protein signaling pathway,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007275~multicellular organism development,GO:0007422~peripheral nervous system development,GO:0007507~heart development,GO:0007528~neuromuscular junction development,GO:0008045~motor neuron axon guidance,GO:0008284~positive regulation of cell proliferation,GO:0010628~positive regulation of gene expression,GO:0014065~phosphatidylinositol 3-kinase signaling,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0030182~neuron differentiation,GO:0030307~positive regulation of cell growth,GO:0032886~regulation of microtubule-based process,GO:0033088~negative regulation of immature T cell proliferation in thymus,GO:0033674~positive regulation of kinase activity,GO:0035556~intracellular signal transduction,GO:0038128~ERBB2 signaling pathway,GO:0042060~wound healing,GO:0042552~myelination,GO:0043406~positive regulation of MAP kinase activity,GO:0043410~positive regulation of MAPK cascade,GO:0043547~positive regulation of GTPase activity,GO:0045727~positive regulation of translation,GO:0045765~regulation of angiogenesis,GO:0045785~positive regulation of cell adhesion,GO:0045943~positive regulation of transcription from RNA polymerase I promoter,GO:0046777~protein autophosphorylation,GO:0048709~oligodendrocyte differentiation,GO:0050679~positive regulation of epithelial cell proliferation,GO:0051897~positive regulation of protein kinase B signaling,GO:0070372~regulation of ERK1 and ERK2 cascade,GO:0071363~cellular response to growth factor stimulus,GO:0071364~cellular response to epidermal growth factor stimulus,GO:0090314~positive regulation of protein targeting to membrane,GO:1901185~negative regulation of ERBB signaling pathway,GO:2000145~regulation of cell motility,	GO:0005634~nucleus,GO:0005769~early endosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009925~basal plasma membrane,GO:0010008~endosome membrane,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0031410~cytoplasmic vesicle,GO:0038143~ERBB3:ERBB2 complex,GO:0043209~myelin sheath,GO:0043235~receptor complex,GO:0048471~perinuclear region of cytoplasm,	GO:0001042~RNA polymerase I core binding,GO:0004672~protein kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0004888~transmembrane signaling receptor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008022~protein C-terminus binding,GO:0016301~kinase activity,GO:0019838~growth factor binding,GO:0019903~protein phosphatase binding,GO:0042802~identical protein binding,GO:0043125~ErbB-3 class receptor binding,GO:0046982~protein heterodimerization activity,	IPR000494:EGF receptor, L domain,IPR000719:Protein kinase, catalytic domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR006211:Furin-like cysteine-rich domain,IPR006212:Furin-like repeat,IPR008266:Tyrosine-protein kinase, active site,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR011009:Protein kinase-like domain,IPR016245:Tyrosine protein kinase, EGF/ERB/XmrK receptor,IPR017441:Protein kinase, ATP binding site,IPR020635:Tyrosine-protein kinase, catalytic domain,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa01522:Endocrine resistance,hsa01524:Platinum drug resistance,hsa04010:MAPK signaling pathway,hsa04012:ErbB signaling pathway,hsa04020:Calcium signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04520:Adherens junction,hsa04530:Tight junction,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,hsa05212:Pancreatic cancer,hsa05213:Endometrial cancer,hsa05215:Prostate cancer,hsa05219:Bladder cancer,hsa05223:Non-small cell lung cancer,hsa05224:Breast cancer,hsa05226:Gastric cancer,hsa05230:Central carbon metabolism in cancer,	137800~Glioblastoma, somatic,167000~Ovarian cancer, somatic,211980~Adenocarcinoma of lung, somatic,613659~Gastric cancer, somatic,619465~Visceral neuropathy, familial, 2, autosomal recessive,	PIRSF000619:tyrosine-protein kinase, EGF receptor type,	SM00219:TyrKc,SM00261:FU,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0010~Activator,KW-0418~Kinase,KW-0675~Receptor,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,BINDING:ATP,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Pro residues,DOMAIN:Furin-like,DOMAIN:GF_recep_IV,DOMAIN:PK_Tyr_Ser-Thr,DOMAIN:Protein kinase,DOMAIN:Recep_L_domain,MOTIF:Nuclear localization signal,MUTAGEN:LH->AA: Reduces dimerization with ERBB3.,MUTAGEN:M->A: No effect on isoform production.,MUTAGEN:M->A: Prevents synthesis of isoform 2.,MUTAGEN:M->A: Prevents synthesis of isoform 3.,NP_BIND:ATP,REGION:Disordered,REGION:Interaction with PIK3C2B,REGION:Required for interaction with KPNB1 and EEA1,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ERBB3	erb-b2 receptor tyrosine kinase 3(ERBB3)	Homo sapiens		h_ErbB3Pathway:Neuroregulin receptor degredation protein-1 Controls ErbB3 receptor recycling,h_her2Pathway:Role of ERBB2 in Signal Transduction and Oncology,		GO:0000165~MAPK cascade,GO:0003197~endocardial cushion development,GO:0007162~negative regulation of cell adhesion,GO:0007165~signal transduction,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007275~multicellular organism development,GO:0007399~nervous system development,GO:0007422~peripheral nervous system development,GO:0007507~heart development,GO:0008284~positive regulation of cell proliferation,GO:0009968~negative regulation of signal transduction,GO:0010628~positive regulation of gene expression,GO:0014037~Schwann cell differentiation,GO:0014065~phosphatidylinositol 3-kinase signaling,GO:0014068~positive regulation of phosphatidylinositol 3-kinase signaling,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0021545~cranial nerve development,GO:0033674~positive regulation of kinase activity,GO:0038128~ERBB2 signaling pathway,GO:0042060~wound healing,GO:0042127~regulation of cell proliferation,GO:0043524~negative regulation of neuron apoptotic process,GO:0051048~negative regulation of secretion,GO:0051402~neuron apoptotic process,GO:0051897~positive regulation of protein kinase B signaling,GO:0055025~positive regulation of cardiac muscle tissue development,GO:0061098~positive regulation of protein tyrosine kinase activity,GO:0070886~positive regulation of calcineurin-NFAT signaling cascade,GO:0097192~extrinsic apoptotic signaling pathway in absence of ligand,GO:2000145~regulation of cell motility,	GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009925~basal plasma membrane,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0016328~lateral plasma membrane,GO:0038143~ERBB3:ERBB2 complex,GO:0043235~receptor complex,	GO:0004672~protein kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0004888~transmembrane signaling receptor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0019838~growth factor binding,GO:0030296~protein tyrosine kinase activator activity,GO:0031625~ubiquitin protein ligase binding,GO:0038131~neuregulin receptor activity,GO:0038132~neuregulin binding,GO:0042802~identical protein binding,GO:0043125~ErbB-3 class receptor binding,GO:0046982~protein heterodimerization activity,	IPR000494:EGF receptor, L domain,IPR000719:Protein kinase, catalytic domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR006211:Furin-like cysteine-rich domain,IPR006212:Furin-like repeat,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR011009:Protein kinase-like domain,IPR016245:Tyrosine protein kinase, EGF/ERB/XmrK receptor,IPR020635:Tyrosine-protein kinase, catalytic domain,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa04010:MAPK signaling pathway,hsa04012:ErbB signaling pathway,hsa04020:Calcium signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,	133180~Erythroleukemia, familial, susceptibility to,243180~Visceral neuropathy, familial, 1, autosomal recessive,607598~Lethal congenital contractural syndrome 2,	PIRSF000619:tyrosine-protein kinase, EGF receptor type,	SM00219:TyrKc,SM00261:FU,		KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0675~Receptor,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,BINDING:ATP,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:GF_recep_IV,DOMAIN:PK_Tyr_Ser-Thr,DOMAIN:Protein kinase,DOMAIN:Recep_L_domain,DOMAIN:TyrKc,MUTAGEN:K->M: Strongly reduced autophosphorylation.,MUTAGEN:Y->E: Strongly reduced tyrosine phosphorylation.,NP_BIND:ATP,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
EPB41L2	erythrocyte membrane protein band 4.1 like 2(EPB41L2)	Homo sapiens				GO:0007049~cell cycle,GO:0030866~cortical actin cytoskeleton organization,GO:0031032~actomyosin structure organization,GO:0051301~cell division,GO:1904778~positive regulation of protein localization to cell cortex,	GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0005938~cell cortex,GO:0008091~spectrin,GO:0030054~cell junction,GO:0070062~extracellular exosome,GO:0099738~cell cortex region,	GO:0003779~actin binding,GO:0005198~structural molecule activity,GO:0005515~protein binding,GO:0008092~cytoskeletal protein binding,GO:0030507~spectrin binding,GO:0042731~PH domain binding,	IPR000299:FERM domain,IPR000798:Ezrin/radixin/moesin like,IPR007477:SAB domain,IPR008379:Band 4.1, C-terminal,IPR011993:Pleckstrin homology-like domain,IPR014352:FERM/acyl-CoA-binding protein, 3-helical bundle,IPR014847:FERM adjacent (FA),IPR018979:FERM, N-terminal,IPR018980:FERM, C-terminal PH-like domain,IPR019747:FERM conserved site,IPR019748:FERM central domain,IPR019749:Band 4.1 domain,				SM00295:B41,SM01195:SM01195,SM01196:SM01196,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,KW-0813~Transport,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0175~Coiled coil,		KW-0009~Actin-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:4_1_CTD,DOMAIN:FA,DOMAIN:FERM,DOMAIN:SAB,REGION:C-terminal (CTD),REGION:Disordered,REGION:Hydrophilic,REGION:Spectrin--actin-binding,
EIF4G1	eukaryotic translation initiation factor 4 gamma 1(EIF4G1)	Homo sapiens		h_eif4Pathway:Regulation of eIF4e and p70 S6 Kinase,h_eifPathway:Eukaryotic protein translation,h_iresPathway:Internal Ribosome entry pathway,h_mtorPathway:mTOR Signaling Pathway,		GO:0000184~nuclear-transcribed mRNA catabolic process, nonsense-mediated decay,GO:0001662~behavioral fear response,GO:0002191~cap-dependent translational initiation,GO:0006412~translation,GO:0006413~translational initiation,GO:0006446~regulation of translational initiation,GO:0010507~negative regulation of autophagy,GO:0010801~negative regulation of peptidyl-threonine phosphorylation,GO:0010942~positive regulation of cell death,GO:0016032~viral process,GO:0030307~positive regulation of cell growth,GO:0031669~cellular response to nutrient levels,GO:0032270~positive regulation of cellular protein metabolic process,GO:0032502~developmental process,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0034645~cellular macromolecule biosynthetic process,GO:0036493~positive regulation of translation in response to endoplasmic reticulum stress,GO:0043488~regulation of mRNA stability,GO:0045666~positive regulation of neuron differentiation,GO:0060964~regulation of gene silencing by miRNA,GO:0080135~regulation of cellular response to stress,GO:0097009~energy homeostasis,GO:1900087~positive regulation of G1/S transition of mitotic cell cycle,GO:1901215~negative regulation of neuron death,GO:1905537~positive regulation of eukaryotic translation initiation factor 4F complex assembly,GO:1905606~regulation of presynapse assembly,GO:1905612~positive regulation of mRNA cap binding,GO:1905618~positive regulation of miRNA mediated inhibition of translation,GO:1905696~regulation of polysome binding,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005844~polysome,GO:0010494~cytoplasmic stress granule,GO:0016020~membrane,GO:0016281~eukaryotic translation initiation factor 4F complex,	GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0003743~translation initiation factor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008135~translation factor activity, RNA binding,GO:0008190~eukaryotic initiation factor 4E binding,GO:0031369~translation initiation factor binding,GO:0042802~identical protein binding,GO:0060090~binding, bridging,	IPR003307:W2 domain,IPR003890:MIF4G-like, type 3,IPR003891:Initiation factor eIF-4 gamma, MA3,IPR016021:MIF4-like, type 1/2/3,IPR016024:Armadillo-type fold,	hsa05416:Viral myocarditis,	614251~Parkinson disease 18,		SM00515:eIF5C,SM00543:MIF4G,SM00544:MA3,	KW-0648~Protein biosynthesis,KW-0810~Translation regulation,KW-0945~Host-virus interaction,	KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0907~Parkinson disease,KW-0908~Parkinsonism,			KW-0396~Initiation factor,KW-0694~RNA-binding,KW-1155~Translational shunt,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:MI,DOMAIN:MIF4G,DOMAIN:W2,MUTAGEN:DPNQ->AAAA: Loss of PABPC1 binding; when associated with 174-AAAAA-178.,MUTAGEN:F->A: Abolishes binding to EIF4A; when associated with A-767 and A-770.,MUTAGEN:F->A: Abolishes binding to EIF4A; when associated with A-973.,MUTAGEN:FE->AK: Abolishes binding to EIF4A; when associated with A-841 and A-842.,MUTAGEN:G->A,V,W,R,E: Reduced cleavage by protease 2A from human rhinovirus 2.,MUTAGEN:I->A: Abolishes binding to EIF4A; when associated with A-895 and A-95.,MUTAGEN:I->A: Loss of PABPC1 binding.,MUTAGEN:KRERK->AAAAA: Loss of PABPC1 binding; when associated with 184-AAAA-187.,MUTAGEN:L->A: Abolishes binding to EIF4A; when associated with A-767 and A-775.,MUTAGEN:L->A: Abolishes binding to EIF4A; when associated with A-770 and A-775.,MUTAGEN:L->A: Abolishes binding to EIF4A; when associated with A-895 and A-92.,MUTAGEN:L->A: Abolishes binding to EIF4A; when associated with A-92 and A-95.,MUTAGEN:L->A: Slightly reduced binding to EIF4A; when associated with A-989.,MUTAGEN:LL->AA: Abolishes binding to EIF4A; when associated with A-850 and K-851.,MUTAGEN:LL->AA: Abolishes binding to EIF4E.,MUTAGEN:R->A: Abolishes binding to EIF4A; when associated with A-976.,MUTAGEN:W->A: Slightly reduced binding to EIF4A; when associated with A-984.,MUTAGEN:Y->A,F: Abolishes binding to EIF4E.,REGION:Disordered,REGION:EIF4A-binding,REGION:EIF4E-binding,REGION:Necessary but not sufficient for MKNK1-binding,REGION:PABPC1-binding,REGION:eIF3/EIF4A-binding,SITE:Cleavage; by enterovirus/rhinovirus protease 2A,SITE:Cleavage; by foot-and-mouth disease virus leader protease,
EIF4EBP1	eukaryotic translation initiation factor 4E binding protein 1(EIF4EBP1)	Homo sapiens	107.mRNA_translation-protein_synthesis,	h_eif4Pathway:Regulation of eIF4e and p70 S6 Kinase,h_igf1mtorPathway:Skeletal muscle hypertrophy is regulated via AKT/mTOR pathway,h_mtorPathway:mTOR Signaling Pathway,		GO:0000082~G1/S transition of mitotic cell cycle,GO:0002931~response to ischemia,GO:0030324~lung development,GO:0031333~negative regulation of protein complex assembly,GO:0031929~TOR signaling,GO:0045471~response to ethanol,GO:0045931~positive regulation of mitotic cell cycle,GO:0045947~negative regulation of translational initiation,GO:0071456~cellular response to hypoxia,GO:1990928~response to amino acid starvation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0032991~macromolecular complex,GO:0098978~glutamatergic synapse,GO:0099524~postsynaptic cytosol,	GO:0005515~protein binding,GO:0008190~eukaryotic initiation factor 4E binding,GO:0030371~translation repressor activity,GO:0051721~protein phosphatase 2A binding,	IPR008606:Eukaryotic translation initiation factor 4E binding,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa04012:ErbB signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04150:mTOR signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04152:AMPK signaling pathway,hsa04211:Longevity regulating pathway,hsa04218:Cellular senescence,hsa04910:Insulin signaling pathway,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05207:Chemical carcinogenesis - receptor activation,hsa05221:Acute myeloid leukemia,hsa05231:Choline metabolism in cancer,				KW-0810~Translation regulation,					KW-0652~Protein synthesis inhibitor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),MOTIF:TOS motif,MOTIF:YXXXXLphi motif,MUTAGEN:K->R: Does not affect ubiquitination by the BCR(KLHL25) complex.,MUTAGEN:K->R: Impaired ubiquitination by the BCR(KLHL25) complex.,MUTAGEN:LM->AA: Abolishes eIF4E-binding. Increased ubiquitination by the BCR(KLHL25) complex.,MUTAGEN:S->A: Abolishes phosphorylation by MTOR and increased ubiquitination by the BCR(KLHL25) complex; when associated with A-37; A-46 and A-70.,MUTAGEN:T->A: Abolishes phosphorylation by MTOR and increased ubiquitination by the BCR(KLHL25) complex; when associated with A-37; A-46 and A-65.,MUTAGEN:T->A: Abolishes phosphorylation by MTOR and increased ubiquitination by the BCR(KLHL25) complex; when associated with A-37; A-65 and A-70.,MUTAGEN:T->A: Abolishes phosphorylation by MTOR and increased ubiquitination by the BCR(KLHL25) complex; when associated with A-46; A-65 and A-70.,REGION:Disordered,
EIF5	eukaryotic translation initiation factor 5(EIF5)	Homo sapiens		h_eif2Pathway:Regulation of eIF2,h_eifPathway:Eukaryotic protein translation,		GO:0001731~formation of translation preinitiation complex,GO:0001732~formation of cytoplasmic translation initiation complex,GO:0006446~regulation of translational initiation,GO:0050790~regulation of catalytic activity,GO:0090630~activation of GTPase activity,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,	GO:0003723~RNA binding,GO:0003743~translation initiation factor activity,GO:0005092~GDP-dissociation inhibitor activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0045296~cadherin binding,GO:0071074~eukaryotic initiation factor eIF2 binding,	IPR002735:Translation initiation factor IF2/IF5,IPR003307:W2 domain,IPR016021:MIF4-like, type 1/2/3,IPR016024:Armadillo-type fold,IPR016189:Translation initiation factor IF2/IF5, N-terminal,IPR016190:Translation initiation factor IF2/IF5, zinc-binding,				SM00515:eIF5C,SM00653:eIF2B_5,	KW-0648~Protein biosynthesis,				KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0396~Initiation factor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:W2,DOMAIN:eIF2B_5,NP_BIND:GTP,REGION:Disordered,
EXOSC4	exosome component 4(EXOSC4)	Homo sapiens				GO:0000460~maturation of 5.8S rRNA,GO:0000956~nuclear-transcribed mRNA catabolic process,GO:0006364~rRNA processing,GO:0006396~RNA processing,GO:0006401~RNA catabolic process,GO:0016075~rRNA catabolic process,GO:0030307~positive regulation of cell growth,GO:0034427~nuclear-transcribed mRNA catabolic process, exonucleolytic, 3'-5',GO:0034475~U4 snRNA 3'-end processing,GO:0043488~regulation of mRNA stability,GO:0043928~exonucleolytic nuclear-transcribed mRNA catabolic process involved in deadenylation-dependent decay,GO:0045006~DNA deamination,GO:0051607~defense response to virus,GO:0071028~nuclear mRNA surveillance,GO:0071044~histone mRNA catabolic process,GO:0071051~polyadenylation-dependent snoRNA 3'-end processing,GO:0090503~RNA phosphodiester bond hydrolysis, exonucleolytic,	GO:0000176~nuclear exosome (RNase complex),GO:0000177~cytoplasmic exosome (RNase complex),GO:0000178~exosome (RNase complex),GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0035327~transcriptionally active chromatin,GO:0043231~intracellular membrane-bounded organelle,	GO:0000175~3'-5'-exoribonuclease activity,GO:0005515~protein binding,GO:0035925~mRNA 3'-UTR AU-rich region binding,	IPR001247:Exoribonuclease, phosphorolytic domain 1,IPR015847:Exoribonuclease, phosphorolytic domain 2,IPR020568:Ribosomal protein S5 domain 2-type fold,IPR027408:PNPase/RNase PH domain,	hsa03018:RNA degradation,				KW-0698~rRNA processing,	KW-0271~Exosome,KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0694~RNA-binding,	KW-0007~Acetylation,	DOMAIN:RNase_PH,DOMAIN:RNase_PH_C,
EXT1	exostosin glycosyltransferase 1(EXT1)	Homo sapiens				GO:0001501~skeletal system development,GO:0001503~ossification,GO:0001958~endochondral ossification,GO:0001974~blood vessel remodeling,GO:0002062~chondrocyte differentiation,GO:0002067~glandular epithelial cell differentiation,GO:0002524~hypersensitivity,GO:0003128~heart field specification,GO:0003415~chondrocyte hypertrophy,GO:0003416~endochondral bone growth,GO:0006024~glycosaminoglycan biosynthetic process,GO:0006486~protein glycosylation,GO:0007033~vacuole organization,GO:0007165~signal transduction,GO:0007369~gastrulation,GO:0007411~axon guidance,GO:0007492~endoderm development,GO:0007498~mesoderm development,GO:0008217~regulation of blood pressure,GO:0008543~fibroblast growth factor receptor signaling pathway,GO:0009615~response to virus,GO:0009642~response to light intensity,GO:0010467~gene expression,GO:0014033~neural crest cell differentiation,GO:0015012~heparan sulfate proteoglycan biosynthetic process,GO:0015014~heparan sulfate proteoglycan biosynthetic process, polysaccharide chain biosynthetic process,GO:0017145~stem cell division,GO:0019882~antigen processing and presentation,GO:0021554~optic nerve development,GO:0021772~olfactory bulb development,GO:0030163~protein catabolic process,GO:0030199~collagen fibril organization,GO:0030204~chondroitin sulfate metabolic process,GO:0030210~heparin biosynthetic process,GO:0030509~BMP signaling pathway,GO:0031069~hair follicle morphogenesis,GO:0032836~glomerular basement membrane development,GO:0033627~cell adhesion mediated by integrin,GO:0033692~cellular polysaccharide biosynthetic process,GO:0035176~social behavior,GO:0035249~synaptic transmission, glutamatergic,GO:0035264~multicellular organism growth,GO:0035988~chondrocyte proliferation,GO:0036022~limb joint morphogenesis,GO:0036336~dendritic cell migration,GO:0036339~lymphocyte adhesion to endothelial cell of high endothelial venule,GO:0042044~fluid transport,GO:0042060~wound healing,GO:0042311~vasodilation,GO:0042596~fear response,GO:0043931~ossification involved in bone maturation,GO:0045165~cell fate commitment,GO:0045453~bone resorption,GO:0048733~sebaceous gland development,GO:0050891~multicellular organismal water homeostasis,GO:0050901~leukocyte tethering or rolling,GO:0051923~sulfation,GO:0055078~sodium ion homeostasis,GO:0060047~heart contraction,GO:0060070~canonical Wnt signaling pathway,GO:0060218~hematopoietic stem cell differentiation,GO:0060351~cartilage development involved in endochondral bone morphogenesis,GO:0060441~epithelial tube branching involved in lung morphogenesis,GO:0060506~smoothened signaling pathway involved in lung development,GO:0060560~developmental growth involved in morphogenesis,GO:0060792~sweat gland development,GO:0061484~hematopoietic stem cell homeostasis,GO:0061744~motor behavior,GO:0065003~macromolecular complex assembly,GO:0070593~dendrite self-avoidance,GO:0071503~response to heparin,GO:0071625~vocalization behavior,GO:0071711~basement membrane organization,GO:0071847~TNFSF11-mediated signaling pathway,GO:0072112~glomerular visceral epithelial cell differentiation,GO:0072498~embryonic skeletal joint development,GO:0097021~lymphocyte migration into lymphoid organs,GO:0097241~hematopoietic stem cell migration to bone marrow,GO:0098586~cellular response to virus,GO:1901706~mesenchymal cell differentiation involved in bone development,GO:1904888~cranial skeletal system development,GO:1990823~response to leukemia inhibitory factor,	GO:0000139~Golgi membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0016021~integral component of membrane,GO:0030176~integral component of endoplasmic reticulum membrane,GO:0045202~synapse,	GO:0008375~acetylglucosaminyltransferase activity,GO:0015020~glucuronosyltransferase activity,GO:0016757~transferase activity, transferring glycosyl groups,GO:0042328~heparan sulfate N-acetylglucosaminyltransferase activity,GO:0042803~protein homodimerization activity,GO:0046872~metal ion binding,GO:0046982~protein heterodimerization activity,GO:0050508~glucuronosyl-N-acetylglucosaminyl-proteoglycan 4-alpha-N-acetylglucosaminyltransferase activity,GO:0050509~N-acetylglucosaminyl-proteoglycan 4-beta-glucuronosyltransferase activity,	IPR004263:Exostosin-like,IPR015338:EXTL2, alpha-1,4-N-acetylhexosaminyltransferase,	hsa00534:Glycosaminoglycan biosynthesis - heparan sulfate / heparin,hsa01100:Metabolic pathways,	133700~Exostoses, multiple, type 1,215300~Chondrosarcoma,				KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,	KW-0043~Tumor suppressor,KW-0225~Disease variant,KW-0361~Hereditary multiple exostoses,	KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0464~Manganese,KW-0479~Metal-binding,	KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	BINDING:Substrate,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Exostosin,METAL:Manganese; catalytic,MUTAGEN:A->H: No effect on heparan-sulfate biosynthesis.,MUTAGEN:D->E: Abolishes heparan-sulfate biosynthesis.,MUTAGEN:Missing: Abolishes heparan-sulfate biosynthesis.,MUTAGEN:Missing: No effect on heparan-sulfate biosynthesis.,MUTAGEN:N->A: No effect on heparan-sulfate biosynthesis.,MUTAGEN:P->H: No effect on heparan-sulfate biosynthesis.,MUTAGEN:Q->A,P: No effect on heparan-sulfate biosynthesis.,REGION:Substrate binding,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
XPO7	exportin 7(XPO7)	Homo sapiens			Nuclear structure / Intracellular trafficking and secretion,	GO:0006611~protein export from nucleus,GO:0006886~intracellular protein transport,	GO:0005634~nucleus,GO:0005643~nuclear pore,GO:0005737~cytoplasm,	GO:0005049~nuclear export signal receptor activity,GO:0005515~protein binding,GO:0031267~small GTPase binding,	IPR001494:Importin-beta, N-terminal,IPR011989:Armadillo-like helical,IPR016024:Armadillo-type fold,	hsa03013:Nucleocytoplasmic transport,			SM00913:SM00913,	KW-0653~Protein transport,KW-0813~Transport,	KW-0539~Nucleus,KW-0963~Cytoplasm,					KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Importin N-terminal,
FDFT1	farnesyl-diphosphate farnesyltransferase 1(FDFT1)	Homo sapiens				GO:0006694~steroid biosynthetic process,GO:0006695~cholesterol biosynthetic process,GO:0008610~lipid biosynthetic process,GO:0016126~sterol biosynthetic process,GO:0019216~regulation of lipid metabolic process,GO:0019222~regulation of metabolic process,GO:0045338~farnesyl diphosphate metabolic process,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016021~integral component of membrane,	GO:0004310~farnesyl-diphosphate farnesyltransferase activity,GO:0005515~protein binding,GO:0046872~metal ion binding,GO:0051996~squalene synthase activity,	IPR002060:Squalene/phytoene synthase,IPR006449:Farnesyl-diphosphate farnesyltransferase,IPR008949:Terpenoid synthase,IPR019845:Squalene/phytoene synthase, conserved site,	hsa00100:Steroid biosynthesis,hsa01100:Metabolic pathways,	618156~Squalene synthase deficiency,			KW-0152~Cholesterol biosynthesis,KW-0153~Cholesterol metabolism,KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,KW-0752~Steroid biosynthesis,KW-0753~Steroid metabolism,KW-0756~Sterol biosynthesis,KW-1207~Sterol metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0460~Magnesium,KW-0479~Metal-binding,KW-0520~NAD,KW-0521~NADP,	KW-0511~Multifunctional enzyme,KW-0808~Transferase,		BINDING:NADP,COMPBIAS:Polar residues,METAL:Magnesium,REGION:Disordered,TRANSMEM:Helical,
FEZ2	fasciculation and elongation protein zeta 2(FEZ2)	Homo sapiens				GO:0007165~signal transduction,GO:0007399~nervous system development,GO:0007411~axon guidance,GO:1902902~negative regulation of autophagosome assembly,	GO:0005737~cytoplasm,GO:0030424~axon,	GO:0005515~protein binding,	IPR011680:FEZ-like,								KW-0175~Coiled coil,			KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	COMPBIAS:Polar residues,DISULFID:Interchain,REGION:Disordered,
FGFR2	fibroblast growth factor receptor 2(FGFR2)	Homo sapiens				GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000165~MAPK cascade,GO:0001525~angiogenesis,GO:0001657~ureteric bud development,GO:0001701~in utero embryonic development,GO:0001837~epithelial to mesenchymal transition,GO:0002053~positive regulation of mesenchymal cell proliferation,GO:0003148~outflow tract septum morphogenesis,GO:0003149~membranous septum morphogenesis,GO:0003416~endochondral bone growth,GO:0006915~apoptotic process,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007267~cell-cell signaling,GO:0007275~multicellular organism development,GO:0007409~axonogenesis,GO:0008284~positive regulation of cell proliferation,GO:0008543~fibroblast growth factor receptor signaling pathway,GO:0008589~regulation of smoothened signaling pathway,GO:0009791~post-embryonic development,GO:0009880~embryonic pattern specification,GO:0009887~animal organ morphogenesis,GO:0010518~positive regulation of phospholipase activity,GO:0010839~negative regulation of keratinocyte proliferation,GO:0016331~morphogenesis of embryonic epithelium,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0021769~orbitofrontal cortex development,GO:0021847~ventricular zone neuroblast division,GO:0021860~pyramidal neuron development,GO:0022612~gland morphogenesis,GO:0030177~positive regulation of Wnt signaling pathway,GO:0030282~bone mineralization,GO:0030324~lung development,GO:0030855~epithelial cell differentiation,GO:0030901~midbrain development,GO:0030916~otic vesicle formation,GO:0031069~hair follicle morphogenesis,GO:0032496~response to lipopolysaccharide,GO:0032808~lacrimal gland development,GO:0033674~positive regulation of kinase activity,GO:0033688~regulation of osteoblast proliferation,GO:0035265~organ growth,GO:0035602~fibroblast growth factor receptor signaling pathway involved in negative regulation of apoptotic process in bone marrow,GO:0035603~fibroblast growth factor receptor signaling pathway involved in hemopoiesis,GO:0035604~fibroblast growth factor receptor signaling pathway involved in positive regulation of cell proliferation in bone marrow,GO:0035607~fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development,GO:0042060~wound healing,GO:0042472~inner ear morphogenesis,GO:0042476~odontogenesis,GO:0043410~positive regulation of MAPK cascade,GO:0045165~cell fate commitment,GO:0045471~response to ethanol,GO:0045667~regulation of osteoblast differentiation,GO:0045787~positive regulation of cell cycle,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046777~protein autophosphorylation,GO:0048286~lung alveolus development,GO:0048333~mesodermal cell differentiation,GO:0048557~embryonic digestive tract morphogenesis,GO:0048562~embryonic organ morphogenesis,GO:0048565~digestive tract development,GO:0048568~embryonic organ development,GO:0048608~reproductive structure development,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0048701~embryonic cranial skeleton morphogenesis,GO:0048705~skeletal system morphogenesis,GO:0048730~epidermis morphogenesis,GO:0048755~branching morphogenesis of a nerve,GO:0048762~mesenchymal cell differentiation,GO:0050679~positive regulation of epithelial cell proliferation,GO:0051150~regulation of smooth muscle cell differentiation,GO:0051781~positive regulation of cell division,GO:0051897~positive regulation of protein kinase B signaling,GO:0055010~ventricular cardiac muscle tissue morphogenesis,GO:0060045~positive regulation of cardiac muscle cell proliferation,GO:0060174~limb bud formation,GO:0060348~bone development,GO:0060349~bone morphogenesis,GO:0060442~branching involved in prostate gland morphogenesis,GO:0060445~branching involved in salivary gland morphogenesis,GO:0060449~bud elongation involved in lung branching,GO:0060463~lung lobe morphogenesis,GO:0060484~lung-associated mesenchyme development,GO:0060501~positive regulation of epithelial cell proliferation involved in lung morphogenesis,GO:0060512~prostate gland morphogenesis,GO:0060523~prostate epithelial cord elongation,GO:0060527~prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis,GO:0060529~squamous basal epithelial stem cell differentiation involved in prostate gland acinus development,GO:0060595~fibroblast growth factor receptor signaling pathway involved in mammary gland specification,GO:0060601~lateral sprouting from an epithelium,GO:0060615~mammary gland bud formation,GO:0060664~epithelial cell proliferation involved in salivary gland morphogenesis,GO:0060667~branch elongation involved in salivary gland morphogenesis,GO:0060670~branching involved in labyrinthine layer morphogenesis,GO:0060688~regulation of morphogenesis of a branching structure,GO:0060915~mesenchymal cell differentiation involved in lung development,GO:0060916~mesenchymal cell proliferation involved in lung development,GO:0070372~regulation of ERK1 and ERK2 cascade,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071300~cellular response to retinoic acid,GO:0071560~cellular response to transforming growth factor beta stimulus,GO:0090263~positive regulation of canonical Wnt signaling pathway,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005938~cell cortex,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0031410~cytoplasmic vesicle,GO:0043235~receptor complex,GO:0060076~excitatory synapse,	GO:0004672~protein kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0005007~fibroblast growth factor-activated receptor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008201~heparin binding,GO:0017134~fibroblast growth factor binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,	IPR000719:Protein kinase, catalytic domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR008266:Tyrosine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR013098:Immunoglobulin I-set,IPR013783:Immunoglobulin-like fold,IPR016248:Tyrosine-protein kinase, fibroblast growth factor receptor,IPR017441:Protein kinase, ATP binding site,IPR020635:Tyrosine-protein kinase, catalytic domain,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04020:Calcium signaling pathway,hsa04144:Endocytosis,hsa04151:PI3K-Akt signaling pathway,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04810:Regulation of actin cytoskeleton,hsa05200:Pathways in cancer,hsa05215:Prostate cancer,hsa05226:Gastric cancer,hsa05230:Central carbon metabolism in cancer,	101200~Apert syndrome,101400~Saethre-Chotzen syndrome,101600~Craniofacial-skeletal-dermatologic dysplasia,101600~Pfeiffer syndrome,123150~Jackson-Weiss syndrome,123500~Crouzon syndrome,123790~Beare-Stevenson cutis gyrata syndrome,149730~LADD syndrome,207410~Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis,609579~Scaphocephaly, maxillary retrusion, and mental retardation,613659~Gastric cancer, somatic,614592~Bent bone dysplasia syndrome,Craniosynostosis, nonspecific~Craniosynostosis, nonspecific,Scaphocephaly and Axenfeld-Rieger anomaly~Scaphocephaly and Axenfeld-Rieger anomaly,	PIRSF000628:fibroblast growth factor receptor,	SM00219:TyrKc,SM00408:IGc2,SM00409:IG,	KW-0053~Apoptosis,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0964~Secreted,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,	KW-0038~Ectodermal dysplasia,KW-0225~Disease variant,KW-0656~Proto-oncogene,KW-0953~Lacrimo-auriculo-dento-digital syndrome,KW-0989~Craniosynostosis,KW-0991~Mental retardation,	KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0358~Heparin-binding,KW-0418~Kinase,KW-0675~Receptor,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,BINDING:ATP,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Acidic residues,COMPBIAS:Polar residues,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,DOMAIN:Protein kinase,MUTAGEN:E->A: Constitutive kinase activity.,MUTAGEN:Missing: Loss of kinase activity.,MUTAGEN:N->Q: Reduced N-glycosylation. Reduced expression at the cell surface.,MUTAGEN:N->T: Constitutive kinase activity.,MUTAGEN:Y->F: Increases fibroblast proliferation. Decreases phosphorylation of PLCG1 and FRS2. Decreases activation of MAP kinases.,NP_BIND:ATP,REGION:Disordered,REGION:Heparin-binding,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
FGFR4	fibroblast growth factor receptor 4(FGFR4)	Homo sapiens				GO:0000165~MAPK cascade,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007275~multicellular organism development,GO:0008284~positive regulation of cell proliferation,GO:0008543~fibroblast growth factor receptor signaling pathway,GO:0010628~positive regulation of gene expression,GO:0010715~regulation of extracellular matrix disassembly,GO:0016477~cell migration,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0019216~regulation of lipid metabolic process,GO:0033674~positive regulation of kinase activity,GO:0042593~glucose homeostasis,GO:0042632~cholesterol homeostasis,GO:0043085~positive regulation of catalytic activity,GO:0045862~positive regulation of proteolysis,GO:0046777~protein autophosphorylation,GO:0051897~positive regulation of protein kinase B signaling,GO:0055062~phosphate ion homeostasis,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0070857~regulation of bile acid biosynthetic process,GO:2000573~positive regulation of DNA biosynthetic process,	GO:0005576~extracellular region,GO:0005768~endosome,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005911~cell-cell junction,GO:0016021~integral component of membrane,GO:0030133~transport vesicle,GO:0043235~receptor complex,	GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0005007~fibroblast growth factor-activated receptor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008201~heparin binding,GO:0017134~fibroblast growth factor binding,	IPR000719:Protein kinase, catalytic domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR008266:Tyrosine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR013098:Immunoglobulin I-set,IPR013783:Immunoglobulin-like fold,IPR016248:Tyrosine-protein kinase, fibroblast growth factor receptor,IPR017441:Protein kinase, ATP binding site,IPR020635:Tyrosine-protein kinase, catalytic domain,	hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04020:Calcium signaling pathway,hsa04144:Endocytosis,hsa04151:PI3K-Akt signaling pathway,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04810:Regulation of actin cytoskeleton,hsa05200:Pathways in cancer,	Cancer progression/metastasis~Cancer progression/metastasis,	PIRSF000628:fibroblast growth factor receptor,	SM00219:TyrKc,SM00408:IGc2,SM00409:IG,		KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0964~Secreted,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0675~Receptor,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,BINDING:ATP,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:IGc2,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,DOMAIN:Protein kinase,MUTAGEN:K->R: Loss of kinase activity.,MUTAGEN:Y->F: Loss of interaction with PLCG1.,NP_BIND:ATP,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
FRS2	fibroblast growth factor receptor substrate 2(FRS2)	Homo sapiens				GO:0000165~MAPK cascade,GO:0000186~activation of MAPKK activity,GO:0000187~activation of MAPK activity,GO:0001702~gastrulation with mouth forming second,GO:0001759~organ induction,GO:0003281~ventricular septum development,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007185~transmembrane receptor protein tyrosine phosphatase signaling pathway,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007405~neuroblast proliferation,GO:0007411~axon guidance,GO:0008543~fibroblast growth factor receptor signaling pathway,GO:0008595~anterior/posterior axis specification, embryo,GO:0030900~forebrain development,GO:0042981~regulation of apoptotic process,GO:0043410~positive regulation of MAPK cascade,GO:0046619~optic placode formation involved in camera-type eye formation,GO:0048011~neurotrophin TRK receptor signaling pathway,GO:0050678~regulation of epithelial cell proliferation,GO:0050790~regulation of catalytic activity,GO:0051897~positive regulation of protein kinase B signaling,GO:0060527~prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis,GO:0070307~lens fiber cell development,GO:0070372~regulation of ERK1 and ERK2 cascade,GO:1904707~positive regulation of vascular smooth muscle cell proliferation,GO:2000726~negative regulation of cardiac muscle cell differentiation,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005911~cell-cell junction,GO:0005912~adherens junction,GO:0012505~endomembrane system,GO:0016020~membrane,	GO:0005068~transmembrane receptor protein tyrosine kinase adaptor activity,GO:0005104~fibroblast growth factor receptor binding,GO:0005168~neurotrophin TRKA receptor binding,GO:0005515~protein binding,GO:0019211~phosphatase activator activity,	IPR002404:Insulin receptor substrate-1, PTB,	hsa04714:Thermogenesis,hsa04722:Neurotrophin signaling pathway,hsa05205:Proteoglycans in cancer,			SM00310:PTBI,		KW-0472~Membrane,				KW-0675~Receptor,	KW-0449~Lipoprotein,KW-0519~Myristate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:IRS-type PTB,LIPID:N-myristoyl glycine,REGION:Disordered,
FSD1	fibronectin type III and SPRY domain containing 1(FSD1)	Homo sapiens				GO:0007049~cell cycle,GO:0031122~cytoplasmic microtubule organization,GO:0032465~regulation of cytokinesis,GO:0051301~cell division,GO:0051302~regulation of cell division,GO:0060236~regulation of mitotic spindle organization,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005874~microtubule,GO:0032154~cleavage furrow,	GO:0008017~microtubule binding,GO:0042802~identical protein binding,	IPR001870:B30.2/SPRY domain,IPR003649:B-box, C-terminal,IPR003877:SPla/RYanodine receptor SPRY,IPR003961:Fibronectin, type III,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,IPR013783:Immunoglobulin-like fold,IPR017903:COS domain,				SM00060:FN3,SM00449:SPRY,SM00502:BBC,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,			KW-0488~Methylation,	DOMAIN:B30.2/SPRY,DOMAIN:COS,DOMAIN:Fibronectin type-III,MUTAGEN:S->A: In mitosis, remained associated with microtubules; when associated with A-313; A-317 and A-322.,MUTAGEN:S->A: In mitosis, remained associated with microtubules; when associated with A-313; A-322 and A-324.,MUTAGEN:S->A: In mitosis, remained associated with microtubules; when associated with A-317; A-322 and A-324.,MUTAGEN:S->D: Reduced ability to associate with microtubules; when associated with D-313; D-317 and E-322.,MUTAGEN:S->D: Reduced ability to associate with microtubules; when associated with D-313; E-322 and D-324.,MUTAGEN:S->D: Reduced ability to associate with microtubules; when associated with D-317; E-322 and D-324.,MUTAGEN:T->A: In mitosis, remained associated with microtubules; when associated with A-313; A-317 and A-324.,MUTAGEN:T->E: Reduced ability to associate with microtubules; when associated with D-313; D-317 and D-324.,REGION:Disordered,
FIS1	fission, mitochondrial 1(FIS1)	Homo sapiens				GO:0000266~mitochondrial fission,GO:0000422~mitophagy,GO:0001836~release of cytochrome c from mitochondria,GO:0006626~protein targeting to mitochondrion,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0008053~mitochondrial fusion,GO:0010821~regulation of mitochondrion organization,GO:0016559~peroxisome fission,GO:0032471~negative regulation of endoplasmic reticulum calcium ion concentration,GO:0035584~calcium-mediated signaling using intracellular calcium source,GO:0043280~positive regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0043653~mitochondrial fragmentation involved in apoptotic process,GO:0045046~protein import into peroxisome membrane,GO:0051561~positive regulation of mitochondrial calcium ion concentration,GO:0070584~mitochondrion morphogenesis,GO:0090141~positive regulation of mitochondrial fission,GO:0090314~positive regulation of protein targeting to membrane,GO:1903579~negative regulation of ATP metabolic process,GO:2000192~negative regulation of fatty acid transport,GO:2001244~positive regulation of intrinsic apoptotic signaling pathway,	GO:0005739~mitochondrion,GO:0005777~peroxisome,GO:0005778~peroxisomal membrane,GO:0005779~integral component of peroxisomal membrane,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0016020~membrane,GO:0031307~integral component of mitochondrial outer membrane,GO:0032991~macromolecular complex,	GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR011990:Tetratricopeptide-like helical,IPR016543:Tetratricopeptide repeat 11 Fission 1 protein,	hsa04137:Mitophagy - animal,		PIRSF008835:mitochondrial fission 1 protein,		KW-0053~Apoptosis,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0576~Peroxisome,KW-1000~Mitochondrion outer membrane,		KW-0802~TPR repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,MUTAGEN:K->A: Protein localizes to both mitochondrion and endoplasmic reticulum. Protein localizes to endoplasmic reticulum only; when associated with A-149.,MUTAGEN:K->A: Protein localizes to both mitochondrion and endoplasmic reticulum. Protein localizes to endoplasmic reticulum only; when associated with A-151.,MUTAGEN:L->P: Approximately 40% of cells display fragmented mitochondria.,MUTAGEN:L->P: Approximately 40% of cells display fragmented mitochondria. No change in binding to DNM1L.,MUTAGEN:L->P: Less than 15% of cells display fragmented mitochondria.,MUTAGEN:L->P: Less than 15% of cells display fragmented mitochondria. Shows greatly reduced binding to DNM1L.,REGION:Disordered,REPEAT:TPR,TOPO_DOM:Cytoplasmic,TOPO_DOM:Mitochondrial intermembrane,TRANSMEM:Helical,
FPGS	folylpolyglutamate synthase(FPGS)	Homo sapiens				GO:0001889~liver development,GO:0006139~nucleobase-containing compound metabolic process,GO:0006536~glutamate metabolic process,GO:0006544~glycine metabolic process,GO:0006730~one-carbon metabolic process,GO:0006760~folic acid-containing compound metabolic process,GO:0007420~brain development,GO:0008283~cell proliferation,GO:0009116~nucleoside metabolic process,GO:0009396~folic acid-containing compound biosynthetic process,GO:0017144~drug metabolic process,GO:0031100~animal organ regeneration,GO:0042493~response to drug,GO:0046655~folic acid metabolic process,GO:0046901~tetrahydrofolylpolyglutamate biosynthetic process,	GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005759~mitochondrial matrix,GO:0005829~cytosol,	GO:0004326~tetrahydrofolylpolyglutamate synthase activity,GO:0005524~ATP binding,GO:0046872~metal ion binding,	IPR001645:Folylpolyglutamate synthetase,IPR018109:Folylpolyglutamate synthetase, conserved site,IPR023600:Folylpolyglutamate synthase, eukaryota,	hsa00790:Folate biosynthesis,hsa01100:Metabolic pathways,hsa01240:Biosynthesis of cofactors,hsa01523:Antifolate resistance,		PIRSF038895:folylpolyglutamate synthase,		KW-0554~One-carbon metabolism,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0963~Cytoplasm,KW-0999~Mitochondrion inner membrane,		KW-0732~Signal,KW-0809~Transit peptide,	KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0436~Ligase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	BINDING:ATP,METAL:Magnesium 1,METAL:Magnesium 2,NP_BIND:ATP,REGION:Disordered,TRANSIT:Mitochondrion,
FOXJ3	forkhead box J3(FOXJ3)	Homo sapiens			Transcription,	GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007141~male meiosis I,GO:0007283~spermatogenesis,GO:0030154~cell differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001766:Transcription factor, fork head,IPR018122:Transcription factor, fork head, conserved site,				SM00339:FH,	KW-0221~Differentiation,KW-0469~Meiosis,KW-0744~Spermatogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DNA_BIND:Fork-head,DOMAIN:Fork-head,REGION:Disordered,
FOXO3	forkhead box O3(FOXO3)	Homo sapiens		h_achPathway:Role of nicotinic acetylcholine receptors in the regulation of apoptosis,h_aktPathway:AKT Signaling Pathway,h_longevityPathway:The IGF-1 Receptor and Longevity,h_ptenPathway:PTEN dependent cell cycle arrest and apoptosis,		GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001542~ovulation from ovarian follicle,GO:0001544~initiation of primordial ovarian follicle growth,GO:0001547~antral ovarian follicle growth,GO:0001556~oocyte maturation,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006390~transcription from mitochondrial promoter,GO:0006417~regulation of translation,GO:0006915~apoptotic process,GO:0007568~aging,GO:0009410~response to xenobiotic stimulus,GO:0010508~positive regulation of autophagy,GO:0014737~positive regulation of muscle atrophy,GO:0019221~cytokine-mediated signaling pathway,GO:0030330~DNA damage response, signal transduction by p53 class mediator,GO:0030336~negative regulation of cell migration,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0034599~cellular response to oxidative stress,GO:0042149~cellular response to glucose starvation,GO:0042594~response to starvation,GO:0043065~positive regulation of apoptotic process,GO:0043525~positive regulation of neuron apoptotic process,GO:0045591~positive regulation of regulatory T cell differentiation,GO:0045648~positive regulation of erythrocyte differentiation,GO:0045665~negative regulation of neuron differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048854~brain morphogenesis,GO:0070542~response to fatty acid,GO:0071333~cellular response to glucose stimulus,GO:0071386~cellular response to corticosterone stimulus,GO:0071456~cellular response to hypoxia,GO:0071548~response to dexamethasone,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:0097150~neuronal stem cell population maintenance,GO:0097192~extrinsic apoptotic signaling pathway in absence of ligand,GO:1901300~positive regulation of hydrogen peroxide-mediated programmed cell death,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1903428~positive regulation of reactive oxygen species biosynthetic process,GO:1904646~cellular response to beta-amyloid,GO:1990090~cellular response to nerve growth factor stimulus,GO:1990785~response to water-immersion restraint stress,GO:2000177~regulation of neural precursor cell proliferation,GO:2000353~positive regulation of endothelial cell apoptotic process,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005759~mitochondrial matrix,GO:0005829~cytosol,GO:0032991~macromolecular complex,GO:0090571~RNA polymerase II transcription repressor complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001221~transcription cofactor binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0008013~beta-catenin binding,GO:0019901~protein kinase binding,GO:0031490~chromatin DNA binding,GO:0034246~mitochondrial RNA polymerase binding promoter specificity activity,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001766:Transcription factor, fork head,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa04062:Chemokine signaling pathway,hsa04068:FoxO signaling pathway,hsa04137:Mitophagy - animal,hsa04151:PI3K-Akt signaling pathway,hsa04152:AMPK signaling pathway,hsa04211:Longevity regulating pathway,hsa04213:Longevity regulating pathway - multiple species,hsa04218:Cellular senescence,hsa04722:Neurotrophin signaling pathway,hsa04917:Prolactin signaling pathway,hsa04936:Alcoholic liver disease,hsa05131:Shigellosis,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05213:Endometrial cancer,hsa05223:Non-small cell lung cancer,			SM00339:FH,	KW-0053~Apoptosis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1000~Mitochondrion outer membrane,	KW-0656~Proto-oncogene,			KW-0010~Activator,KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Acidic residues,COMPBIAS:Polar residues,DNA_BIND:Fork-head,MOTIF:Nuclear localization signal,MUTAGEN:K->A: Decreases DNA affinity.,MUTAGEN:K->A: Slightly decreases DNA affinity.,MUTAGEN:K->R: Methylation levels similar to wild-type; when associated with ARG-269.,MUTAGEN:K->R: Methylation levels similar to wild-type; when associated with ARG-270.,MUTAGEN:K->R: Methylation levels strongly reduced.,MUTAGEN:K->R: Reduces acetylation, increases interaction with SKP2 and inhibits FOXO3 ubiquitination and degradation; when associated with R-242; R-259 and R-290.,MUTAGEN:K->R: Reduces acetylation, increases interaction with SKP2 and inhibits FOXO3 ubiquitination and degradation; when associated with R-242; R-259 and R-569.,MUTAGEN:K->R: Reduces acetylation, increases interaction with SKP2 and inhibits FOXO3 ubiquitination and degradation; when associated with R-242; R-290 and R-569.,MUTAGEN:K->R: Reduces acetylation, increases interaction with SKP2 and inhibits FOXO3 ubiquitination and degradation; when associated with R-259; R-290 and R-569.,MUTAGEN:Missing: Loss of localization to the mitochondrion outer membrane and loss of translocation into the mitochondrion following metabolic stress.,MUTAGEN:Missing: Loss of nuclear import.,MUTAGEN:Missing: Loss of translocation into the mitochondrion following metabolic stress.,MUTAGEN:S->A: Abolishes YWHAZ-binding; when associated with A-32. Exclusively nuclear, induces transcription and promotes apoptosis; when associated with A-32 and A-315.,MUTAGEN:S->A: Abolishes phosphorylation. Loss of localization to the mitochondrion outer membrane and loss of translocation into the mitochondrion following metabolic stress.,MUTAGEN:S->A: Decreased phosphorylation by AMPK and impaired ability to transactivate a reporter gene; when associated with A-179; A-399; A-413; A-555 and A-588.,MUTAGEN:S->A: Decreased phosphorylation by AMPK and impaired ability to transactivate a reporter gene; when associated with A-179; A-399; A-413; A-555 and A-626.,MUTAGEN:S->A: Decreased phosphorylation by AMPK and impaired ability to transactivate a reporter gene; when associated with A-179; A-399; A-413; A-588 and A-626.,MUTAGEN:S->A: Decreased phosphorylation by AMPK and impaired ability to transactivate a reporter gene; when associated with A-179; A-399; A-555; A-588 and A-626.,MUTAGEN:S->A: Decreased phosphorylation by AMPK and impaired ability to transactivate a reporter gene; when associated with A-179; A-413; A-555; A-588 and A-626.,MUTAGEN:S->A: Impairs nuclear translocation upon oxidative stress.,MUTAGEN:S->A: In normal cells, no defect in mitochondrion import following metabolic stress. In cancer cells, defective mitochondrion import following metabolic stress and abolition of ERK-mediated phosphorylation.,MUTAGEN:S->A: Loss of phosphorylation by IKKB.,MUTAGEN:S->A: No effect on YWHAZ-binding. Promotes nuclear translocation. Exclusively nuclear, induces transcription and promotes apoptosis; when associated with A-32 and A-253.,MUTAGEN:T->A: Abolishes YWHAZ-binding; when associated with A-253. Exclusively nuclear, induces transcription and promotes apoptosis; when associated with A-253 and A-315.,MUTAGEN:T->A: Decreased phosphorylation by AMPK and impaired ability to transactivate a reporter gene; when associated with A-399; A-413; A-555; A-588 and A-626.,REGION:Disordered,REGION:Mediates interaction with CHUK/IKKA and IKBKB/IKKB,REGION:Required for mitochondrial import,
FOXO4	forkhead box O4(FOXO4)	Homo sapiens		h_aktPathway:AKT Signaling Pathway,h_rasPathway:Ras Signaling Pathway,		GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007050~cell cycle arrest,GO:0007095~mitotic G2 DNA damage checkpoint,GO:0007517~muscle organ development,GO:0007568~aging,GO:0008285~negative regulation of cell proliferation,GO:0008286~insulin receptor signaling pathway,GO:0014911~positive regulation of smooth muscle cell migration,GO:0016525~negative regulation of angiogenesis,GO:0016579~protein deubiquitination,GO:0031667~response to nutrient levels,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048863~stem cell differentiation,GO:0051151~negative regulation of smooth muscle cell differentiation,GO:0070317~negative regulation of G0 to G1 transition,GO:0071158~positive regulation of cell cycle arrest,GO:1990785~response to water-immersion restraint stress,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016607~nuclear speck,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0008013~beta-catenin binding,GO:0008134~transcription factor binding,GO:0019899~enzyme binding,GO:0042802~identical protein binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,GO:1990841~promoter-specific chromatin binding,	IPR001766:Transcription factor, fork head,	hsa04014:Ras signaling pathway,hsa04068:FoxO signaling pathway,hsa05131:Shigellosis,			SM00339:FH,	KW-0131~Cell cycle,KW-0221~Differentiation,KW-0517~Myogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0656~Proto-oncogene,			KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	DNA_BIND:Fork-head,MUTAGEN:S->A: Abolishes phosphorylation. No effect on cellular location or transcriptional activity. Increased transcriptional and proteasome activities in embryonic stem cells; when associated with A-32 and A-197.,MUTAGEN:S->A: Abolishes phosphorylation. Protein is located mainly in nucleus and shows increased transcriptional activity. Increased transcriptional and proteasome activities in embryonic stem cells; when associated with A-32 and A-262.,MUTAGEN:T->A: Abolishes phosphorylation. Protein is located mainly in nucleus and shows increased transcriptional activity. Increased transcriptional and proteasome activities in embryonic stem cells; when associated with A-197 and A-262.,REGION:Disordered,
FHL2	four and a half LIM domains 2(FHL2)	Homo sapiens		h_p53hypoxiaPathway:Hypoxia and p53 in the Cardiovascular system,		GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001649~osteoblast differentiation,GO:0009725~response to hormone,GO:0019222~regulation of metabolic process,GO:0043066~negative regulation of apoptotic process,GO:0055014~atrial cardiac muscle cell development,GO:0055015~ventricular cardiac muscle cell development,GO:0060347~heart trabecula formation,GO:0070885~negative regulation of calcineurin-NFAT signaling cascade,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005925~focal adhesion,GO:0030018~Z disc,GO:0031430~M band,	GO:0003712~transcription cofactor activity,GO:0003714~transcription corepressor activity,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0042802~identical protein binding,GO:0043425~bHLH transcription factor binding,GO:0046872~metal ion binding,	IPR001781:Zinc finger, LIM-type,	hsa04380:Osteoclast differentiation,			SM00132:LIM,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0440~LIM domain,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:LIM zinc-binding,DOMAIN:LIM zinc-binding 1,DOMAIN:LIM zinc-binding 2,DOMAIN:LIM zinc-binding 3,DOMAIN:LIM zinc-binding 4,REGION:Disordered,ZN_FING:C4-type,
FZD1	frizzled class receptor 1(FZD1)	Homo sapiens		h_alkPathway:ALK in cardiac myocytes,H_gsk3Pathway:Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar Macrophages,h_hesPathway:Segmentation Clock,h_pitx2Pathway:Multi-step Regulation of Transcription by Pitx2,h_ps1Pathway:Presenilin action in Notch and Wnt signaling,h_wnt-Lrp6Pathway:Wnt/LRP6 Signalling,h_wntPathway:WNT Signaling Pathway,		GO:0001934~positive regulation of protein phosphorylation,GO:0003149~membranous septum morphogenesis,GO:0003150~muscular septum morphogenesis,GO:0003151~outflow tract morphogenesis,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007267~cell-cell signaling,GO:0009410~response to xenobiotic stimulus,GO:0010976~positive regulation of neuron projection development,GO:0030182~neuron differentiation,GO:0030514~negative regulation of BMP signaling pathway,GO:0030855~epithelial cell differentiation,GO:0035425~autocrine signaling,GO:0035567~non-canonical Wnt signaling pathway,GO:0036520~astrocyte-dopaminergic neuron signaling,GO:0042493~response to drug,GO:0044338~canonical Wnt signaling pathway involved in mesenchymal stem cell differentiation,GO:0044339~canonical Wnt signaling pathway involved in osteoblast differentiation,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0060022~hard palate development,GO:0060070~canonical Wnt signaling pathway,GO:0060071~Wnt signaling pathway, planar cell polarity pathway,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:0090179~planar cell polarity pathway involved in neural tube closure,GO:0099054~presynapse assembly,GO:1903204~negative regulation of oxidative stress-induced neuron death,GO:1904886~beta-catenin destruction complex disassembly,GO:1904953~Wnt signaling pathway involved in midbrain dopaminergic neuron differentiation,GO:1905606~regulation of presynapse assembly,	GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:1990909~Wnt signalosome,	GO:0004930~G-protein coupled receptor activity,GO:0005102~receptor binding,GO:0005109~frizzled binding,GO:0005515~protein binding,GO:0017147~Wnt-protein binding,GO:0030165~PDZ domain binding,GO:0042813~Wnt-activated receptor activity,	IPR000539:Frizzled protein,IPR015526:Frizzled/secreted frizzled-related protein,IPR017981:GPCR, family 2-like,IPR020067:Frizzled domain,IPR026550:Frizzled-2,	hsa04150:mTOR signaling pathway,hsa04310:Wnt signaling pathway,hsa04390:Hippo signaling pathway,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04916:Melanogenesis,hsa04934:Cushing syndrome,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05165:Human papillomavirus infection,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05217:Basal cell carcinoma,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,			SM00063:FRI,SM01330:SM01330,	KW-0879~Wnt signaling pathway,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0217~Developmental protein,KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:FZ,MOTIF:Lys-Thr-X-X-X-Trp motif, mediates interaction with the PDZ domain of Dvl family members,MOTIF:PDZ-binding,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
FZD7	frizzled class receptor 7(FZD7)	Homo sapiens				GO:0006355~regulation of transcription, DNA-templated,GO:0007186~G-protein coupled receptor signaling pathway,GO:0010812~negative regulation of cell-substrate adhesion,GO:0014834~skeletal muscle satellite cell maintenance involved in skeletal muscle regeneration,GO:0019827~stem cell population maintenance,GO:0030182~neuron differentiation,GO:0031343~positive regulation of cell killing,GO:0033077~T cell differentiation in thymus,GO:0034446~substrate adhesion-dependent cell spreading,GO:0035567~non-canonical Wnt signaling pathway,GO:0038031~non-canonical Wnt signaling pathway via JNK cascade,GO:0042327~positive regulation of phosphorylation,GO:0042666~negative regulation of ectodermal cell fate specification,GO:0045893~positive regulation of transcription, DNA-templated,GO:0046330~positive regulation of JNK cascade,GO:0048103~somatic stem cell division,GO:0060054~positive regulation of epithelial cell proliferation involved in wound healing,GO:0060070~canonical Wnt signaling pathway,GO:0060071~Wnt signaling pathway, planar cell polarity pathway,GO:0060231~mesenchymal to epithelial transition,GO:0060828~regulation of canonical Wnt signaling pathway,GO:0071300~cellular response to retinoic acid,GO:2000726~negative regulation of cardiac muscle cell differentiation,	GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0055038~recycling endosome membrane,	GO:0004930~G-protein coupled receptor activity,GO:0005109~frizzled binding,GO:0005515~protein binding,GO:0005546~phosphatidylinositol-4,5-bisphosphate binding,GO:0017147~Wnt-protein binding,GO:0030165~PDZ domain binding,GO:0042813~Wnt-activated receptor activity,	IPR000539:Frizzled protein,IPR015526:Frizzled/secreted frizzled-related protein,IPR017981:GPCR, family 2-like,IPR020067:Frizzled domain,IPR026552:Frizzled-7,	hsa04150:mTOR signaling pathway,hsa04310:Wnt signaling pathway,hsa04390:Hippo signaling pathway,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04916:Melanogenesis,hsa04934:Cushing syndrome,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05165:Human papillomavirus infection,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05217:Basal cell carcinoma,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,			SM00063:FRI,SM01330:SM01330,	KW-0879~Wnt signaling pathway,	KW-0472~Membrane,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0217~Developmental protein,KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:FZ,MOTIF:Lys-Thr-X-X-X-Trp motif, mediates interaction with the PDZ domain of Dvl family members,MOTIF:PDZ-binding,MUTAGEN:K->A: Impaired SDCBP-mediated interaction with phosphatidylinositol-4,5-bisphosphate.,SITE:Essential for SDCBP-mediated plasma membrane phosphatidylinositol-4,5-bisphosphate recognition,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
FUT1	fucosyltransferase 1 (H blood group)(FUT1)	Homo sapiens				GO:0001936~regulation of endothelial cell proliferation,GO:0001954~positive regulation of cell-matrix adhesion,GO:0005975~carbohydrate metabolic process,GO:0006486~protein glycosylation,GO:0006629~lipid metabolic process,GO:0009312~oligosaccharide biosynthetic process,GO:0010595~positive regulation of endothelial cell migration,GO:0021772~olfactory bulb development,GO:0030155~regulation of cell adhesion,GO:0036065~fucosylation,GO:0042355~L-fucose catabolic process,GO:1903672~positive regulation of sprouting angiogenesis,GO:1904906~positive regulation of endothelial cell-matrix adhesion via fibronectin,	GO:0000139~Golgi membrane,GO:0005794~Golgi apparatus,GO:0005887~integral component of plasma membrane,GO:0016020~membrane,GO:0032580~Golgi cisterna membrane,	GO:0008107~galactoside 2-alpha-L-fucosyltransferase activity,GO:0008417~fucosyltransferase activity,GO:0016757~transferase activity, transferring glycosyl groups,GO:0031127~alpha-(1,2)-fucosyltransferase activity,	IPR002516:Glycosyl transferase, family 11,	hsa00601:Glycosphingolipid biosynthesis - lacto and neolacto series,hsa00603:Glycosphingolipid biosynthesis - globo and isoglobo series,hsa01100:Metabolic pathways,	616754~Bombay phenotype,			KW-0443~Lipid metabolism,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0934~Plastid,		KW-0732~Signal,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0095~Blood group antigen,KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
FAH	fumarylacetoacetate hydrolase(FAH)	Homo sapiens				GO:0006527~arginine catabolic process,GO:0006559~L-phenylalanine catabolic process,GO:0006572~tyrosine catabolic process,GO:0006629~lipid metabolic process,GO:0009072~aromatic amino acid family metabolic process,GO:1902000~homogentisate catabolic process,	GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0004334~fumarylacetoacetase activity,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR005959:Fumarylacetoacetase,IPR011234:Fumarylacetoacetase, C-terminal-related,IPR015377:Fumarylacetoacetase, N-terminal,	hsa00350:Tyrosine metabolism,hsa01100:Metabolic pathways,	276700~Tyrosinemia, type I,			KW-0443~Lipid metabolism,KW-0585~Phenylalanine catabolism,KW-0828~Tyrosine catabolism,		KW-0225~Disease variant,		KW-0106~Calcium,KW-0460~Magnesium,KW-0479~Metal-binding,	KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:Substrate,DOMAIN:FAA_hydrolase,DOMAIN:FAA_hydrolase_N,METAL:Calcium,METAL:Magnesium,
LGALS8	galectin 8(LGALS8)	Homo sapiens				GO:0098586~cellular response to virus,GO:0098792~xenophagy,GO:1904977~lymphatic endothelial cell migration,	GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0031410~cytoplasmic vesicle,	GO:0005178~integrin binding,GO:0005515~protein binding,GO:0030246~carbohydrate binding,	IPR001079:Galectin, carbohydrate recognition domain,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,				SM00276:GLECT,SM00908:SM00908,	KW-0072~Autophagy,	KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,		KW-0677~Repeat,	KW-0430~Lectin,			BINDING:Carbohydrate,COMPBIAS:Polar residues,DOMAIN:Galectin,DOMAIN:Galectin 1,DOMAIN:Galectin 2,MUTAGEN:R->H: Abolishes localization to cytoplasmic vesicles in case of infection by S.typhimurium.,MUTAGEN:R->H: Does not affect localization to cytoplasmic vesicles in case of infection by S.typhimurium.,REGION:Beta-galactoside binding,REGION:Disordered,SITE:Critical for binding to sialylated and sulfated oligosaccharides,
GMNN	geminin DNA replication inhibitor(GMNN)	Homo sapiens				GO:0006270~DNA replication initiation,GO:0006275~regulation of DNA replication,GO:0007346~regulation of mitotic cell cycle,GO:0008156~negative regulation of DNA replication,GO:0009887~animal organ morphogenesis,GO:0030174~regulation of DNA-dependent DNA replication initiation,GO:0035563~positive regulation of chromatin binding,GO:0036388~pre-replicative complex assembly,GO:0045786~negative regulation of cell cycle,GO:0045892~negative regulation of transcription, DNA-templated,GO:0065003~macromolecular complex assembly,GO:0071163~DNA replication preinitiation complex assembly,GO:2000104~negative regulation of DNA-dependent DNA replication,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0017053~transcriptional repressor complex,	GO:0003682~chromatin binding,GO:0003714~transcription corepressor activity,GO:0005515~protein binding,GO:0042826~histone deacetylase binding,GO:0070491~repressing transcription factor binding,	IPR022786:Geminin family,		616835~Meier-Gorlin syndrome 6,			KW-0131~Cell cycle,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0242~Dwarfism,	KW-0175~Coiled coil,		KW-0236~DNA replication inhibitor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Polar residues,REGION:Disordered,REGION:Homeodomain binding,REGION:Necessary and sufficient for interaction with IDAS and CDT1,
GTF2A2	general transcription factor IIA subunit 2(GTF2A2)	Homo sapiens			Transcription,	GO:0006366~transcription from RNA polymerase II promoter,GO:0006367~transcription initiation from RNA polymerase II promoter,GO:0016032~viral process,GO:0042795~snRNA transcription from RNA polymerase II promoter,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051123~RNA polymerase II transcriptional preinitiation complex assembly,GO:0060261~positive regulation of transcription initiation from RNA polymerase II promoter,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005669~transcription factor TFIID complex,GO:0005672~transcription factor TFIIA complex,GO:0030054~cell junction,	GO:0001091~RNA polymerase II basal transcription factor binding,GO:0001103~RNA polymerase II repressing transcription factor binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0017025~TBP-class protein binding,GO:0042803~protein homodimerization activity,GO:0046982~protein heterodimerization activity,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,	IPR003194:Transcription initiation factor IIA, gamma subunit,IPR009083:Transcription factor IIA, helical,IPR009088:Transcription factor IIA, beta-barrel,IPR015871:Transcription initiation factor IIA, gamma subunit, C-terminal,IPR015872:Transcription initiation factor IIA, gamma subunit, N-terminal,	hsa03022:Basal transcription factors,hsa05203:Viral carcinogenesis,		PIRSF009415:transcription initiation factor IIA, gamma subunit,		KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,						DOMAIN:TFIIA_gamma_C,DOMAIN:TFIIA_gamma_N,
GTF2E2	general transcription factor IIE subunit 2(GTF2E2)	Homo sapiens				GO:0006366~transcription from RNA polymerase II promoter,GO:0006367~transcription initiation from RNA polymerase II promoter,GO:0042795~snRNA transcription from RNA polymerase II promoter,	GO:0005654~nucleoplasm,GO:0005669~transcription factor TFIID complex,GO:0005673~transcription factor TFIIE complex,GO:0005829~cytosol,GO:0016607~nuclear speck,	GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0005515~protein binding,	IPR003166:Transcription factor TFIIE beta subunit, DNA-binding domain,IPR016656:Transcription initiation factor TFIIE, beta subunit,	hsa03022:Basal transcription factors,hsa05203:Viral carcinogenesis,	616943~Trichothiodystrophy 6, nonphotosensitive,	PIRSF016398:transcription initiation factor IIE, beta subunit,		KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,			KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DNA_BIND:TFIIE beta,DOMAIN:TFIIE beta,REGION:Disordered,
GNPDA1	glucosamine-6-phosphate deaminase 1(GNPDA1)	Homo sapiens				GO:0005975~carbohydrate metabolic process,GO:0006043~glucosamine catabolic process,GO:0006044~N-acetylglucosamine metabolic process,GO:0006046~N-acetylglucosamine catabolic process,GO:0006048~UDP-N-acetylglucosamine biosynthetic process,GO:0006091~generation of precursor metabolites and energy,GO:0007338~single fertilization,GO:0019262~N-acetylneuraminate catabolic process,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0004342~glucosamine-6-phosphate deaminase activity,GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR004547:Glucosamine-6-phosphate isomerase,IPR006148:Glucosamine/galactosamine-6-phosphate isomerase,IPR018321:Glucosamine-6-phosphate isomerase, conserved site,	hsa00520:Amino sugar and nucleotide sugar metabolism,hsa01100:Metabolic pathways,				KW-0119~Carbohydrate metabolism,	KW-0963~Cytoplasm,				KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:For ring-opening step,ACT_SITE:Proton acceptor; for enolization step,ACT_SITE:Proton acceptor; for ring-opening step,DOMAIN:Glucosamine_iso,
GFOD1	glucose-fructose oxidoreductase domain containing 1(GFOD1)	Homo sapiens			General function prediction only,		GO:0005576~extracellular region,	GO:0000166~nucleotide binding,GO:0005515~protein binding,GO:0016491~oxidoreductase activity,	IPR000683:Oxidoreductase, N-terminal,IPR004104:Oxidoreductase, C-terminal,						KW-0964~Secreted,		KW-0732~Signal,		KW-0560~Oxidoreductase,		COMPBIAS:Basic and acidic residues,DOMAIN:GFO_IDH_MocA,REGION:Disordered,
GRWD1	glutamate rich WD repeat containing 1(GRWD1)	Homo sapiens				GO:0006260~DNA replication,GO:0006334~nucleosome assembly,GO:0006337~nucleosome disassembly,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005730~nucleolus,GO:0005829~cytosol,GO:0032991~macromolecular complex,	GO:0003682~chromatin binding,GO:0003688~DNA replication origin binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0042393~histone binding,	IPR001680:WD40 repeat,IPR015943:WD40/YVTN repeat-like-containing domain,IPR017986:WD40-repeat-containing domain,IPR019775:WD40 repeat, conserved site,IPR020472:G-protein beta WD-40 repeat,IPR022052:Histone-binding protein RBBP4,				SM00320:WD40,	KW-0235~DNA replication,	KW-0158~Chromosome,KW-0539~Nucleus,		KW-0677~Repeat,KW-0853~WD repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
GFPT1	glutamine--fructose-6-phosphate transaminase 1(GFPT1)	Homo sapiens				GO:0006002~fructose 6-phosphate metabolic process,GO:0006047~UDP-N-acetylglucosamine metabolic process,GO:0006048~UDP-N-acetylglucosamine biosynthetic process,GO:0006112~energy reserve metabolic process,GO:0006487~protein N-linked glycosylation,GO:0006541~glutamine metabolic process,GO:0032922~circadian regulation of gene expression,GO:0036498~IRE1-mediated unfolded protein response,GO:1901135~carbohydrate derivative metabolic process,	GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0004360~glutamine-fructose-6-phosphate transaminase (isomerizing) activity,GO:0097367~carbohydrate derivative binding,	IPR001347:Sugar isomerase (SIS),IPR005855:Glucosamine-fructose-6-phosphate aminotransferase, isomerising,IPR017932:Glutamine amidotransferase type 2 domain,	hsa00250:Alanine, aspartate and glutamate metabolism,hsa00520:Amino sugar and nucleotide sugar metabolism,hsa01100:Metabolic pathways,hsa01250:Biosynthesis of nucleotide sugars,hsa04931:Insulin resistance,hsa05415:Diabetic cardiomyopathy,	610542~Myasthenia, congenital, 12, with tubular aggregates,			KW-0090~Biological rhythms,		KW-0225~Disease variant,KW-1004~Congenital myasthenic syndrome,	KW-0315~Glutamine amidotransferase,KW-0677~Repeat,		KW-0032~Aminotransferase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:For GATase activity,BINDING:Substrate,DOMAIN:Glutamine amidotransferase type-2,DOMAIN:SIS,DOMAIN:SIS 1,DOMAIN:SIS 2,REGION:Isomerase,REGION:Substrate-binding,
GLRX	glutaredoxin(GLRX)	Homo sapiens				GO:0015949~nucleobase-containing small molecule interconversion,GO:0045838~positive regulation of membrane potential,GO:0080058~protein deglutathionylation,GO:0098869~cellular oxidant detoxification,GO:2000651~positive regulation of sodium ion transmembrane transporter activity,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0004362~glutathione-disulfide reductase activity,GO:0005515~protein binding,GO:0009055~electron carrier activity,GO:0015035~protein disulfide oxidoreductase activity,GO:0015038~glutathione disulfide oxidoreductase activity,GO:0016740~transferase activity,GO:0047485~protein N-terminus binding,GO:0097573~glutathione oxidoreductase activity,	IPR002109:Glutaredoxin,IPR011767:Glutaredoxin active site,IPR011899:Glutaredoxin, eukaryotic/virial,IPR014025:Glutaredoxin subgroup,					KW-0249~Electron transport,KW-0813~Transport,	KW-0963~Cytoplasm,		KW-0676~Redox-active center,		KW-0808~Transferase,	KW-0007~Acetylation,KW-1015~Disulfide bond,	DISULFID:Redox-active,DOMAIN:Glutaredoxin,
GSTM2	glutathione S-transferase mu 2(GSTM2)	Homo sapiens			Posttranslational modification, protein turnover, chaperones,	GO:0006749~glutathione metabolic process,GO:0010880~regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum,GO:0010881~regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion,GO:0014809~regulation of skeletal muscle contraction by regulation of release of sequestered calcium ion,GO:0018916~nitrobenzene metabolic process,GO:0042178~xenobiotic catabolic process,GO:0043651~linoleic acid metabolic process,GO:0051122~hepoxilin biosynthetic process,GO:0055119~relaxation of cardiac muscle,GO:0060315~negative regulation of ryanodine-sensitive calcium-release channel activity,GO:0060316~positive regulation of ryanodine-sensitive calcium-release channel activity,GO:0070458~cellular detoxification of nitrogen compound,GO:0071313~cellular response to caffeine,GO:0098869~cellular oxidant detoxification,GO:1901687~glutathione derivative biosynthetic process,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016529~sarcoplasmic reticulum,GO:0045171~intercellular bridge,GO:0070062~extracellular exosome,	GO:0004364~glutathione transferase activity,GO:0004602~glutathione peroxidase activity,GO:0005102~receptor binding,GO:0005504~fatty acid binding,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0042803~protein homodimerization activity,GO:0043295~glutathione binding,	IPR003081:Glutathione S-transferase, Mu class,IPR004045:Glutathione S-transferase, N-terminal,IPR004046:Glutathione S-transferase, C-terminal,IPR010987:Glutathione S-transferase, C-terminal-like,	hsa00480:Glutathione metabolism,hsa00980:Metabolism of xenobiotics by cytochrome P450,hsa00982:Drug metabolism - cytochrome P450,hsa00983:Drug metabolism - other enzymes,hsa01100:Metabolic pathways,hsa01524:Platinum drug resistance,hsa05200:Pathways in cancer,hsa05204:Chemical carcinogenesis - DNA adducts,hsa05207:Chemical carcinogenesis - receptor activation,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05225:Hepatocellular carcinoma,hsa05418:Fluid shear stress and atherosclerosis,				KW-0443~Lipid metabolism,	KW-0963~Cytoplasm,				KW-0808~Transferase,	KW-0597~Phosphoprotein,	BINDING:Glutathione,BINDING:Substrate,DOMAIN:GST C-terminal,DOMAIN:GST N-terminal,MUTAGEN:T->C,F,H,I,K,L,R,Y,W: Reduced enzyme activity.,REGION:Glutathione binding,SITE:Important for substrate specificity,
GSTZ1	glutathione S-transferase zeta 1(GSTZ1)	Homo sapiens				GO:0006559~L-phenylalanine catabolic process,GO:0006572~tyrosine catabolic process,GO:0006749~glutathione metabolic process,GO:0010510~regulation of acetyl-CoA biosynthetic process from pyruvate,GO:0098869~cellular oxidant detoxification,GO:1901687~glutathione derivative biosynthetic process,	GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005829~cytosol,	GO:0004364~glutathione transferase activity,GO:0004602~glutathione peroxidase activity,GO:0005515~protein binding,GO:0016034~maleylacetoacetate isomerase activity,GO:0016740~transferase activity,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,	IPR004045:Glutathione S-transferase, N-terminal,IPR004046:Glutathione S-transferase, C-terminal,IPR005955:Maleylacetoacetate isomerase,IPR010987:Glutathione S-transferase, C-terminal-like,	hsa00350:Tyrosine metabolism,hsa01100:Metabolic pathways,	617596~Maleylacetoacetate isomerase deficiency,			KW-0585~Phenylalanine catabolism,KW-0828~Tyrosine catabolism,	KW-0963~Cytoplasm,	KW-0225~Disease variant,			KW-0413~Isomerase,KW-0511~Multifunctional enzyme,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	BINDING:Glutathione,BINDING:Glutathione; via amide nitrogen and carbonyl oxygen,DOMAIN:GST C-terminal,DOMAIN:GST N-terminal,REGION:Glutathione binding,
GAPDH	glyceraldehyde-3-phosphate dehydrogenase(GAPDH)	Homo sapiens		h_glycolysisPathway:Glycolysis Pathway,h_mta3Pathway:Downregulated of MTA-3 in ER-negative Breast Tumors,		GO:0000226~microtubule cytoskeleton organization,GO:0001819~positive regulation of cytokine production,GO:0006006~glucose metabolic process,GO:0006094~gluconeogenesis,GO:0006096~glycolytic process,GO:0010951~negative regulation of endopeptidase activity,GO:0016241~regulation of macroautophagy,GO:0017148~negative regulation of translation,GO:0031640~killing of cells of other organism,GO:0032481~positive regulation of type I interferon production,GO:0035606~peptidyl-cysteine S-trans-nitrosylation,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0050821~protein stabilization,GO:0050832~defense response to fungus,GO:0051402~neuron apoptotic process,GO:0051873~killing by host of symbiont cells,GO:0061621~canonical glycolysis,GO:0061844~antimicrobial humoral immune response mediated by antimicrobial peptide,GO:0071346~cellular response to interferon-gamma,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005811~lipid particle,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0015630~microtubule cytoskeleton,GO:0016020~membrane,GO:0031965~nuclear membrane,GO:0031982~vesicle,GO:0043231~intracellular membrane-bounded organelle,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:0097452~GAIT complex,GO:1990904~ribonucleoprotein complex,	GO:0004365~glyceraldehyde-3-phosphate dehydrogenase (NAD+) (phosphorylating) activity,GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0016620~oxidoreductase activity, acting on the aldehyde or oxo group of donors, NAD or NADP as acceptor,GO:0019828~aspartic-type endopeptidase inhibitor activity,GO:0035605~peptidyl-cysteine S-nitrosylase activity,GO:0042802~identical protein binding,GO:0050661~NADP binding,GO:0051287~NAD binding,GO:0097718~disordered domain specific binding,	IPR006424:Glyceraldehyde-3-phosphate dehydrogenase, type I,IPR020828:Glyceraldehyde 3-phosphate dehydrogenase, NAD(P) binding domain,IPR020829:Glyceraldehyde 3-phosphate dehydrogenase, catalytic domain,IPR020830:Glyceraldehyde 3-phosphate dehydrogenase, active site,IPR020831:Glyceraldehyde/Erythrose phosphate dehydrogenase family,	hsa00010:Glycolysis / Gluconeogenesis,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa01230:Biosynthesis of amino acids,hsa04066:HIF-1 signaling pathway,hsa05010:Alzheimer disease,hsa05130:Pathogenic Escherichia coli infection,hsa05132:Salmonella infection,hsa05415:Diabetic cardiomyopathy,		PIRSF000149:glyceraldehyde-3-phosphate dehydrogenase,	SM00846:SM00846,	KW-0053~Apoptosis,KW-0324~Glycolysis,KW-0391~Immunity,KW-0399~Innate immunity,KW-0810~Translation regulation,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0520~NAD,KW-0547~Nucleotide-binding,	KW-0560~Oxidoreductase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0013~ADP-ribosylation,KW-0325~Glycoprotein,KW-0488~Methylation,KW-0558~Oxidation,KW-0597~Phosphoprotein,KW-0702~S-nitrosylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Nucleophile,BINDING:Glyceraldehyde 3-phosphate,BINDING:NAD,BINDING:NAD; via carbonyl oxygen,CARBOHYD:(Microbial infection) N-beta-linked (GlcNAc) arginine,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Gp_dh_N,MOTIF:[IL]-x-C-x-x-[DE] motif,MUTAGEN:C->S: Markedly reduced glycolytic activity; when associated with S-152 and S-156. Forms free radical-induced aggregates, but to a lesser extent than wild-type protein; when associated with S-156 and S-247.,MUTAGEN:C->S: Markedly reduced glycolytic activity; when associated with S-152 and S-247. Forms free radical-induced aggregates, but to a lesser extent than wild-type protein; when associated with S-156 and S-247.,MUTAGEN:C->S: Markedly reduced glycolytic activity; when associated with S-156 and S-247. Forms free radical-induced aggregates, but to a lesser extent than wild-type protein; when associated with S-156 and S-247. Abolished interaction with TRAF2 and TRAF3.,MUTAGEN:E->M: Inhibits S-nitrosylation of Cys-247; when associated with M-245.,MUTAGEN:L->M: Inhibits S-nitrosylation of Cys-247; when associated with M-250.,MUTAGEN:M->L: Drastic reduction of the extent and significant prolongation of the lag phase of free radical-induced aggregation.,MUTAGEN:M->L: Increased resistance to free radical-induced aggregation.,MUTAGEN:S->A: Does not affect glycosylation by C.rodentium protein NleB.,MUTAGEN:T->A: Does not affect glycosylation by C.rodentium protein NleB.,MUTAGEN:W->F: Increased free radical-induced aggregation.,MUTAGEN:Y->F: No effect on free radical-induced aggregation.,NP_BIND:NAD,REGION:Glyceraldehyde 3-phosphate binding,REGION:Interaction with WARS1,SITE:Activates thiol group during catalysis,
GDPD5	glycerophosphodiester phosphodiesterase domain containing 5(GDPD5)	Homo sapiens				GO:0006629~lipid metabolic process,GO:0007399~nervous system development,GO:0045666~positive regulation of neuron differentiation,	GO:0005886~plasma membrane,GO:0012505~endomembrane system,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030426~growth cone,GO:0048471~perinuclear region of cytoplasm,	GO:0004435~phosphatidylinositol phospholipase C activity,GO:0005515~protein binding,GO:0008081~phosphoric diester hydrolase activity,GO:0008889~glycerophosphodiester phosphodiesterase activity,GO:0047389~glycerophosphocholine phosphodiesterase activity,	IPR017946:PLC-like phosphodiesterase, TIM beta/alpha-barrel domain,					KW-0443~Lipid metabolism,KW-0524~Neurogenesis,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:GP-PDE,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
PYGL	glycogen phosphorylase L(PYGL)	Homo sapiens				GO:0005975~carbohydrate metabolic process,GO:0005977~glycogen metabolic process,GO:0005980~glycogen catabolic process,GO:0006015~5-phosphoribose 1-diphosphate biosynthetic process,GO:0009617~response to bacterium,GO:0042593~glucose homeostasis,GO:0043312~neutrophil degranulation,GO:0070266~necroptotic process,	GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0034774~secretory granule lumen,GO:0070062~extracellular exosome,GO:1904813~ficolin-1-rich granule lumen,	GO:0002060~purine nucleobase binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0005536~glucose binding,GO:0008184~glycogen phosphorylase activity,GO:0016208~AMP binding,GO:0019842~vitamin binding,GO:0030170~pyridoxal phosphate binding,GO:0032052~bile acid binding,GO:0042802~identical protein binding,	IPR000811:Glycosyl transferase, family 35,IPR011833:Glycogen/starch/alpha-glucan phosphorylase,	hsa00500:Starch and sucrose metabolism,hsa01100:Metabolic pathways,hsa04217:Necroptosis,hsa04910:Insulin signaling pathway,hsa04922:Glucagon signaling pathway,hsa04931:Insulin resistance,	232700~Glycogen storage disease VI,	PIRSF000460:glucan phosphorylase,		KW-0119~Carbohydrate metabolism,KW-0321~Glycogen metabolism,	KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0322~Glycogen storage disease,		KW-0547~Nucleotide-binding,KW-0663~Pyridoxal phosphate,	KW-0021~Allosteric enzyme,KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	BINDING:AMP,MUTAGEN:K->Q: Decreased glycogen phosphorylase activity.,MUTAGEN:K->R: Decreased acetylation; when associated with R-470.,MUTAGEN:K->R: Decreased acetylation; when associated with R-796.,NP_BIND:AMP,REGION:Disordered,SITE:Involved in the association of subunits,SITE:May be involved in allosteric control,
GLOD4	glyoxalase domain containing 4(GLOD4)	Homo sapiens					GO:0005739~mitochondrion,GO:0070062~extracellular exosome,	GO:0045296~cadherin binding,							KW-0496~Mitochondrion,		KW-0677~Repeat,			KW-0597~Phosphoprotein,	DOMAIN:VOC,DOMAIN:VOC 1,DOMAIN:VOC 2,REGION:Disordered,
GPC1	glypican 1(GPC1)	Homo sapiens				GO:0001523~retinoid metabolic process,GO:0006024~glycosaminoglycan biosynthetic process,GO:0006027~glycosaminoglycan catabolic process,GO:0007411~axon guidance,GO:0009966~regulation of signal transduction,GO:0014037~Schwann cell differentiation,GO:0016477~cell migration,GO:0030200~heparan sulfate proteoglycan catabolic process,GO:0032288~myelin assembly,GO:0040037~negative regulation of fibroblast growth factor receptor signaling pathway,GO:0050900~leukocyte migration,GO:1905475~regulation of protein localization to membrane,GO:2001016~positive regulation of skeletal muscle cell differentiation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005654~nucleoplasm,GO:0005768~endosome,GO:0005796~Golgi lumen,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0031012~extracellular matrix,GO:0031226~intrinsic component of plasma membrane,GO:0043202~lysosomal lumen,GO:0045121~membrane raft,GO:0045202~synapse,GO:0046658~anchored component of plasma membrane,GO:0070062~extracellular exosome,	GO:0005507~copper ion binding,GO:0005515~protein binding,GO:0017134~fibroblast growth factor binding,GO:0043236~laminin binding,	IPR001863:Glypican,IPR015502:Glypican-1,IPR019803:Glypican, conserved site,	hsa05205:Proteoglycans in cancer,hsa05418:Fluid shear stress and atherosclerosis,					KW-0472~Membrane,KW-0964~Secreted,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0732~Signal,	KW-0186~Copper,KW-0862~Zinc,		KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0357~Heparan sulfate,KW-0449~Lipoprotein,KW-0654~Proteoglycan,KW-0702~S-nitrosylation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (Xyl...) (heparan sulfate) serine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,LIPID:GPI-anchor amidated serine,MUTAGEN:N->Q: No effect on protein yield. Protein yield reduced by 90%, abolishes N-glycosylation but no effect on secondary structure; when associated with Q-79.,MUTAGEN:N->Q: Protein yield reduced by half. Protein yield reduced by 90%, abolishes N-glycosylation but no effect on secondary structure; when associated with Q-116.,PROPEP:Removed in mature form,REGION:Disordered,
GOLT1B	golgi transport 1B(GOLT1B)	Homo sapiens				GO:0015031~protein transport,GO:0016192~vesicle-mediated transport,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,	GO:0000139~Golgi membrane,GO:0005783~endoplasmic reticulum,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0032991~macromolecular complex,	GO:0005515~protein binding,	IPR007305:Vesicle transport protein, Got1/SFT2-like,					KW-0653~Protein transport,KW-0813~Transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,	TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,
GRN	granulin precursor(GRN)	Homo sapiens		h_pepiPathway:Proepithelin Conversion to Epithelin and Wound Repair Control,		GO:0002265~astrocyte activation involved in immune response,GO:0002282~microglial cell activation involved in immune response,GO:0007040~lysosome organization,GO:0007041~lysosomal transport,GO:0007042~lysosomal lumen acidification,GO:0007165~signal transduction,GO:0010595~positive regulation of endothelial cell migration,GO:0030335~positive regulation of cell migration,GO:0043312~neutrophil degranulation,GO:0043524~negative regulation of neuron apoptotic process,GO:0043525~positive regulation of neuron apoptotic process,GO:0045766~positive regulation of angiogenesis,GO:0048680~positive regulation of axon regeneration,GO:0050679~positive regulation of epithelial cell proliferation,GO:0050727~regulation of inflammatory response,GO:0050821~protein stabilization,GO:0060266~negative regulation of respiratory burst involved in inflammatory response,GO:1900426~positive regulation of defense response to bacterium,GO:1902564~negative regulation of neutrophil activation,GO:1903334~positive regulation of protein folding,GO:1903979~negative regulation of microglial cell activation,GO:1905247~positive regulation of aspartic-type peptidase activity,GO:1905673~positive regulation of lysosome organization,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0005768~endosome,GO:0005770~late endosome,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005802~trans-Golgi network,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0035578~azurophil granule lumen,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0005125~cytokine activity,GO:0005515~protein binding,GO:0008083~growth factor activity,GO:0051087~chaperone binding,	IPR000118:Granulin,		607485~Aphasia, primary progressive,607485~Frontotemporal lobar degeneration with ubiquitin-positive inclusions,614706~Ceroid lipofuscinosis, neuronal, 11,		SM00277:GRAN,		KW-0458~Lysosome,KW-0964~Secreted,	KW-0523~Neurodegeneration,KW-0525~Neuronal ceroid lipofuscinosis,	KW-0677~Repeat,KW-0732~Signal,		KW-0202~Cytokine,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:GRANULINS,PEPTIDE:Granulin-1,PEPTIDE:Granulin-2,PEPTIDE:Granulin-3,PEPTIDE:Granulin-4,PEPTIDE:Granulin-5,PEPTIDE:Granulin-6,PEPTIDE:Granulin-7,PEPTIDE:Paragranulin,REGION:Disordered,
GADD45A	growth arrest and DNA damage inducible alpha(GADD45A)	Homo sapiens		h_atmPathway:ATM Signaling Pathway,h_g2Pathway:Cell Cycle: G2/M Checkpoint,h_p53hypoxiaPathway:Hypoxia and p53 in the Cardiovascular system,h_p53Pathway:p53 Signaling Pathway,		GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000185~activation of MAPKKK activity,GO:0006281~DNA repair,GO:0006915~apoptotic process,GO:0006977~DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest,GO:0007050~cell cycle arrest,GO:0007098~centrosome cycle,GO:0016525~negative regulation of angiogenesis,GO:0033140~negative regulation of peptidyl-serine phosphorylation of STAT protein,GO:0042770~signal transduction in response to DNA damage,GO:0043065~positive regulation of apoptotic process,GO:0043537~negative regulation of blood vessel endothelial cell migration,GO:0046330~positive regulation of JNK cascade,GO:0051726~regulation of cell cycle,GO:0071260~cellular response to mechanical stimulus,GO:0071479~cellular response to ionizing radiation,GO:0071850~mitotic cell cycle arrest,GO:0071901~negative regulation of protein serine/threonine kinase activity,GO:1900745~positive regulation of p38MAPK cascade,GO:2000379~positive regulation of reactive oxygen species metabolic process,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016607~nuclear speck,	GO:0005515~protein binding,GO:0019900~kinase binding,GO:0042803~protein homodimerization activity,GO:0046982~protein heterodimerization activity,GO:0047485~protein N-terminus binding,GO:1990841~promoter-specific chromatin binding,	IPR004038:Ribosomal protein L7Ae/L30e/S12e/Gadd45,IPR024824:Growth arrest and DNA damage-inducible protein GADD45,	hsa04010:MAPK signaling pathway,hsa04064:NF-kappa B signaling pathway,hsa04068:FoxO signaling pathway,hsa04110:Cell cycle,hsa04115:p53 signaling pathway,hsa04210:Apoptosis,hsa04218:Cellular senescence,hsa05169:Epstein-Barr virus infection,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05210:Colorectal cancer,hsa05212:Pancreatic cancer,hsa05213:Endometrial cancer,hsa05214:Glioma,hsa05216:Thyroid cancer,hsa05217:Basal cell carcinoma,hsa05218:Melanoma,hsa05220:Chronic myeloid leukemia,hsa05222:Small cell lung cancer,hsa05223:Non-small cell lung cancer,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,				KW-0131~Cell cycle,KW-0227~DNA damage,KW-0338~Growth arrest,	KW-0539~Nucleus,					KW-0597~Phosphoprotein,	DOMAIN:Ribosomal_L7Ae,MUTAGEN:L->E: Abolishes dimerization.,
GADD45B	growth arrest and DNA damage inducible beta(GADD45B)	Homo sapiens				GO:0000185~activation of MAPKKK activity,GO:0000186~activation of MAPKK activity,GO:0006469~negative regulation of protein kinase activity,GO:0006915~apoptotic process,GO:0007275~multicellular organism development,GO:0030154~cell differentiation,GO:0043065~positive regulation of apoptotic process,GO:0046330~positive regulation of JNK cascade,GO:0051726~regulation of cell cycle,GO:1900745~positive regulation of p38MAPK cascade,	GO:0005634~nucleus,GO:0005737~cytoplasm,	GO:0005515~protein binding,	IPR004038:Ribosomal protein L7Ae/L30e/S12e/Gadd45,IPR024824:Growth arrest and DNA damage-inducible protein GADD45,	hsa04010:MAPK signaling pathway,hsa04064:NF-kappa B signaling pathway,hsa04068:FoxO signaling pathway,hsa04110:Cell cycle,hsa04115:p53 signaling pathway,hsa04210:Apoptosis,hsa04218:Cellular senescence,hsa05169:Epstein-Barr virus infection,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05210:Colorectal cancer,hsa05212:Pancreatic cancer,hsa05213:Endometrial cancer,hsa05214:Glioma,hsa05216:Thyroid cancer,hsa05217:Basal cell carcinoma,hsa05218:Melanoma,hsa05220:Chronic myeloid leukemia,hsa05222:Small cell lung cancer,hsa05223:Non-small cell lung cancer,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,				KW-0053~Apoptosis,KW-0221~Differentiation,					KW-0217~Developmental protein,KW-9996~Developmental protein,		DOMAIN:Ribosomal_L7Ae,
GRB10	growth factor receptor bound protein 10(GRB10)	Homo sapiens				GO:0007165~signal transduction,GO:0007411~axon guidance,GO:0008286~insulin receptor signaling pathway,GO:0010467~gene expression,GO:0019221~cytokine-mediated signaling pathway,GO:0030178~negative regulation of Wnt signaling pathway,GO:0030949~positive regulation of vascular endothelial growth factor receptor signaling pathway,GO:0032868~response to insulin,GO:0042326~negative regulation of phosphorylation,GO:0042327~positive regulation of phosphorylation,GO:0045719~negative regulation of glycogen biosynthetic process,GO:0046325~negative regulation of glucose import,GO:0046627~negative regulation of insulin receptor signaling pathway,GO:0048009~insulin-like growth factor receptor signaling pathway,GO:0070371~ERK1 and ERK2 cascade,GO:1904738~vascular associated smooth muscle cell migration,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0032991~macromolecular complex,	GO:0005158~insulin receptor binding,GO:0005515~protein binding,GO:0030159~receptor signaling complex scaffold activity,GO:0042802~identical protein binding,	IPR000159:Ras-association,IPR000980:SH2 domain,IPR001849:Pleckstrin homology domain,IPR011993:Pleckstrin homology-like domain,IPR015042:BPS (Between PH and SH2) domain,	hsa04150:mTOR signaling pathway,			SM00233:PH,SM00252:SH2,SM00314:RA,		KW-0963~Cytoplasm,		KW-0727~SH2 domain,			KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:PH,DOMAIN:Ras-associating,DOMAIN:SH2,MUTAGEN:K->A: 2-fold loss of inositide-binding.,MUTAGEN:K->A: 5-fold loss of inositide-binding.,MUTAGEN:N->G: 5-fold loss of inositide-binding.,MUTAGEN:P->A: No effect on NEDD4-binding; when associated with A-136 and A-141.,MUTAGEN:P->A: No effect on NEDD4-binding; when associated with A-139 and A-141.,MUTAGEN:P->S: No effect on NEDD4-binding; when associated with A-136 and A-139.,MUTAGEN:R->K: No effect on NEDD4-binding. No effect on the disruption of the interaction between INSR and IRS1 and IRS2.,MUTAGEN:S->A: Impairs YWHAE-binding.,MUTAGEN:S->A: Loss of phosphorylation.,MUTAGEN:S->A: No effect on YWHAE-binding.,MUTAGEN:S->A: No net loss of phosphorylation, this may be due to a compensatory phosphorylation of T-422 in vitro.,MUTAGEN:S->G: No effect on phosphorylation.,MUTAGEN:S->I: Loss of phosphorylation.,REGION:Disordered,
GRB7	growth factor receptor bound protein 7(GRB7)	Homo sapiens				GO:0007165~signal transduction,GO:0007173~epidermal growth factor receptor signaling pathway,GO:0007411~axon guidance,GO:0017148~negative regulation of translation,GO:0030335~positive regulation of cell migration,GO:0034063~stress granule assembly,GO:0038128~ERBB2 signaling pathway,GO:0050900~leukocyte migration,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0010494~cytoplasmic stress granule,GO:0042995~cell projection,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0035091~phosphatidylinositol binding,GO:0042802~identical protein binding,	IPR000159:Ras-association,IPR000980:SH2 domain,IPR001849:Pleckstrin homology domain,IPR011993:Pleckstrin homology-like domain,IPR015042:BPS (Between PH and SH2) domain,				SM00233:PH,SM00252:SH2,SM00314:RA,		KW-0472~Membrane,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0727~SH2 domain,	KW-0446~Lipid-binding,	KW-0675~Receptor,KW-0678~Repressor,KW-0694~RNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Pro residues,DOMAIN:PH,DOMAIN:Ras-associating,DOMAIN:SH2,MUTAGEN:F->R: Abolishes dimerization. Abolishes activation of HRAS.,MUTAGEN:R->L: Abolishes phosphoinositide binding.,MUTAGEN:R->L: Impairs phosphotyrosine binding by SH2 domain.,MUTAGEN:Y->F: Abolishes Ras activity increase and ERK1/2 phosphorylation.,MUTAGEN:Y->F: Global loss of tyrosine phosphorylation. Abolishes interaction with FHL2 and HAX1.,REGION:Disordered,SITE:Important for dimerization and for HRAS activation,SITE:Important for lipid binding and for stimulation of cell migration,
GHR	growth hormone receptor(GHR)	Homo sapiens		h_aktPathway:AKT Signaling Pathway,h_eif4Pathway:Regulation of eIF4e and p70 S6 Kinase,h_ghPathway:Growth Hormone Signaling Pathway,h_longevityPathway:The IGF-1 Receptor and Longevity,h_tffPathway:Trefoil Factors Initiate  Mucosal Healing,		GO:0000187~activation of MAPK activity,GO:0006897~endocytosis,GO:0007259~JAK-STAT cascade,GO:0009755~hormone-mediated signaling pathway,GO:0019221~cytokine-mediated signaling pathway,GO:0019530~taurine metabolic process,GO:0031623~receptor internalization,GO:0032094~response to food,GO:0032355~response to estradiol,GO:0032869~cellular response to insulin stimulus,GO:0032870~cellular response to hormone stimulus,GO:0040014~regulation of multicellular organism growth,GO:0040018~positive regulation of multicellular organism growth,GO:0042445~hormone metabolic process,GO:0042531~positive regulation of tyrosine phosphorylation of STAT protein,GO:0042976~activation of Janus kinase activity,GO:0043278~response to morphine,GO:0043406~positive regulation of MAP kinase activity,GO:0045597~positive regulation of cell differentiation,GO:0046427~positive regulation of JAK-STAT cascade,GO:0046898~response to cycloheximide,GO:0048009~insulin-like growth factor receptor signaling pathway,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0051384~response to glucocorticoid,GO:0060351~cartilage development involved in endochondral bone morphogenesis,GO:0060396~growth hormone receptor signaling pathway,GO:0060397~JAK-STAT cascade involved in growth hormone signaling pathway,GO:0070555~response to interleukin-1,GO:1901215~negative regulation of neuron death,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0036464~cytoplasmic ribonucleoprotein granule,GO:0043025~neuronal cell body,GO:0043235~receptor complex,GO:0070195~growth hormone receptor complex,	GO:0004896~cytokine receptor activity,GO:0004903~growth hormone receptor activity,GO:0005515~protein binding,GO:0017046~peptide hormone binding,GO:0019838~growth factor binding,GO:0019901~protein kinase binding,GO:0019903~protein phosphatase binding,GO:0019955~cytokine binding,GO:0042169~SH2 domain binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0070064~proline-rich region binding,	IPR003528:Long hematopoietin receptor, single chain, conserved site,IPR003961:Fibronectin, type III,IPR013783:Immunoglobulin-like fold,IPR015152:Growth hormone/erythropoietin receptor, ligand binding,IPR025871:Growth hormone-binding protein,	hsa04060:Cytokine-cytokine receptor interaction,hsa04080:Neuroactive ligand-receptor interaction,hsa04151:PI3K-Akt signaling pathway,hsa04630:JAK-STAT signaling pathway,hsa04935:Growth hormone synthesis, secretion and action,	143890~Hypercholesterolemia, familial, modifier of,262500~Laron dwarfism,604271~Growth hormone insensitivity, partial,604271~Increased responsiveness to growth hormone,			KW-0254~Endocytosis,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0242~Dwarfism,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:Fibronectin type-III,MOTIF:Box 1 motif,MOTIF:UbE motif,MOTIF:WSXWS motif,MUTAGEN:D->A: No change in shedding activity: No change in hormone binding.,MUTAGEN:E->A: No change in shedding activity: No change in hormone binding.,REGION:Disordered,REGION:Required for ADAM17-mediated proteolysis,SITE:Required for endocytosis and down-regulation,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
HSPA4	heat shock protein family A (Hsp70) member 4(HSPA4)	Homo sapiens				GO:0006986~response to unfolded protein,GO:0045040~protein import into mitochondrial outer membrane,GO:0051131~chaperone-mediated protein complex assembly,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,	IPR013126:Heat shock protein 70 family,IPR018181:Heat shock protein 70, conserved site,	hsa04530:Tight junction,hsa04612:Antigen processing and presentation,hsa05417:Lipid and atherosclerosis,				KW-0346~Stress response,	KW-0963~Cytoplasm,		KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,		KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,REGION:Disordered,
HSPA8	heat shock protein family A (Hsp70) member 8(HSPA8)	Homo sapiens				GO:0000398~mRNA splicing, via spliceosome,GO:0006457~protein folding,GO:0006892~post-Golgi vesicle-mediated transport,GO:0006986~response to unfolded protein,GO:0007269~neurotransmitter secretion,GO:0009267~cellular response to starvation,GO:0016032~viral process,GO:0016192~vesicle-mediated transport,GO:0019221~cytokine-mediated signaling pathway,GO:0031647~regulation of protein stability,GO:0034620~cellular response to unfolded protein,GO:0042026~protein refolding,GO:0043254~regulation of protein complex assembly,GO:0043312~neutrophil degranulation,GO:0043488~regulation of mRNA stability,GO:0044829~positive regulation by host of viral genome replication,GO:0045892~negative regulation of transcription, DNA-templated,GO:0046034~ATP metabolic process,GO:0048026~positive regulation of mRNA splicing, via spliceosome,GO:0051085~chaperone mediated protein folding requiring cofactor,GO:0051726~regulation of cell cycle,GO:0061024~membrane organization,GO:0061635~regulation of protein complex stability,GO:0061684~chaperone-mediated autophagy,GO:0061738~late endosomal microautophagy,GO:0061740~protein targeting to lysosome involved in chaperone-mediated autophagy,GO:0061741~chaperone-mediated protein transport involved in chaperone-mediated autophagy,GO:0071383~cellular response to steroid hormone stimulus,GO:0072318~clathrin coat disassembly,GO:1900034~regulation of cellular response to heat,GO:1902904~negative regulation of supramolecular fiber organization,GO:1904589~regulation of protein import,GO:1904764~chaperone-mediated autophagy translocation complex disassembly,GO:1990832~slow axonal transport,	GO:0000974~Prp19 complex,GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0005770~late endosome,GO:0005776~autophagosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0030425~dendrite,GO:0034774~secretory granule lumen,GO:0042470~melanosome,GO:0043195~terminal bouton,GO:0043202~lysosomal lumen,GO:0048471~perinuclear region of cytoplasm,GO:0061202~clathrin-sculpted gamma-aminobutyric acid transport vesicle membrane,GO:0070062~extracellular exosome,GO:0072562~blood microparticle,GO:0098575~lumenal side of lysosomal membrane,GO:0098684~photoreceptor ribbon synapse,GO:0098793~presynapse,GO:0098978~glutamatergic synapse,GO:0099523~presynaptic cytosol,GO:0099524~postsynaptic cytosol,GO:0099634~postsynaptic specialization membrane,GO:0101031~chaperone complex,GO:1904813~ficolin-1-rich granule lumen,GO:1990904~ribonucleoprotein complex,	GO:0001664~G-protein coupled receptor binding,GO:0001786~phosphatidylserine binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0019899~enzyme binding,GO:0023026~MHC class II protein complex binding,GO:0030674~protein binding, bridging,GO:0031072~heat shock protein binding,GO:0031625~ubiquitin protein ligase binding,GO:0044183~protein binding involved in protein folding,GO:0045296~cadherin binding,GO:0051082~unfolded protein binding,GO:0051087~chaperone binding,GO:0051787~misfolded protein binding,GO:0055131~C3HC4-type RING finger domain binding,GO:1990833~clathrin-uncoating ATPase activity,	IPR013126:Heat shock protein 70 family,IPR018181:Heat shock protein 70, conserved site,	hsa03040:Spliceosome,hsa04010:MAPK signaling pathway,hsa04141:Protein processing in endoplasmic reticulum,hsa04144:Endocytosis,hsa04213:Longevity regulating pathway - multiple species,hsa04612:Antigen processing and presentation,hsa04915:Estrogen signaling pathway,hsa05020:Prion disease,hsa05134:Legionellosis,hsa05145:Toxoplasmosis,hsa05162:Measles,hsa05417:Lipid and atherosclerosis,				KW-0346~Stress response,KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0539~Nucleus,KW-0747~Spliceosome,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0143~Chaperone,KW-0378~Hydrolase,KW-0678~Repressor,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	BINDING:ATP,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,MUTAGEN:K->R: Complete loss of in vitro methylation by METTL21A.,NP_BIND:ATP,REGION:Disordered,REGION:Interaction with BAG1,REGION:Nucleotide-binding domain (NBD),REGION:Substrate-binding domain (SBD),
HSPB1	heat shock protein family B (small) member 1(HSPB1)	Homo sapiens	114.Genomic_reformatting_Brain_Ischemia,	h_hsp27Pathway:Stress Induction of HSP Regulation,h_mta3Pathway:Downregulated of MTA-3 in ER-negative Breast Tumors,h_p38mapkPathway:p38 MAPK Signaling Pathway ,		GO:0001895~retina homeostasis,GO:0001932~regulation of protein phosphorylation,GO:0006446~regulation of translational initiation,GO:0006469~negative regulation of protein kinase activity,GO:0006986~response to unfolded protein,GO:0009615~response to virus,GO:0010506~regulation of autophagy,GO:0016032~viral process,GO:0032731~positive regulation of interleukin-1 beta production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0035556~intracellular signal transduction,GO:0035924~cellular response to vascular endothelial growth factor stimulus,GO:0038033~positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway,GO:0043066~negative regulation of apoptotic process,GO:0043122~regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043488~regulation of mRNA stability,GO:0043536~positive regulation of blood vessel endothelial cell migration,GO:0045766~positive regulation of angiogenesis,GO:0061077~chaperone-mediated protein folding,GO:0070527~platelet aggregation,GO:0099641~anterograde axonal protein transport,GO:1902176~negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway,GO:2001028~positive regulation of endothelial cell chemotaxis,	GO:0000502~proteasome complex,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005819~spindle,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0030018~Z disc,GO:0070062~extracellular exosome,GO:1904115~axon cytoplasm,	GO:0003723~RNA binding,GO:0005080~protein kinase C binding,GO:0005515~protein binding,GO:0008426~protein kinase C inhibitor activity,GO:0019901~protein kinase binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0043130~ubiquitin binding,GO:0044183~protein binding involved in protein folding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,	IPR001436:Alpha crystallin/Heat shock protein,IPR002068:Alpha crystallin/Hsp20 domain,IPR008978:HSP20-like chaperone,	hsa04010:MAPK signaling pathway,hsa04370:VEGF signaling pathway,hsa05146:Amoebiasis,	606595~Charcot-Marie-Tooth disease, axonal, type 2F,608634~Neuronopathy, distal hereditary motor, type IIB,			KW-0346~Stress response,KW-0945~Host-virus interaction,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0144~Charcot-Marie-Tooth disease,KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0622~Neuropathy,			KW-0143~Chaperone,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:SHSP,DOMAIN:sHSP,MUTAGEN:S->D: Mimicks phosphorylation state, leading to dreased ability to act as molecular chaperones; when associated with D-15 and D-78.,MUTAGEN:S->D: Mimicks phosphorylation state, leading to dreased ability to act as molecular chaperones; when associated with D-15 and D-82.,MUTAGEN:S->D: Mimicks phosphorylation state, leading to dreased ability to act as molecular chaperones; when associated with D-78 and D-82.,REGION:Disordered,REGION:Interaction with TGFB1I1,
HSPD1	heat shock protein family D (Hsp60) member 1(HSPD1)	Homo sapiens				GO:0001666~response to hypoxia,GO:0002755~MyD88-dependent toll-like receptor signaling pathway,GO:0002842~positive regulation of T cell mediated immune response to tumor cell,GO:0002931~response to ischemia,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006457~protein folding,GO:0006458~'de novo' protein folding,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0006986~response to unfolded protein,GO:0008637~apoptotic mitochondrial changes,GO:0009409~response to cold,GO:0014823~response to activity,GO:0016032~viral process,GO:0032496~response to lipopolysaccharide,GO:0032727~positive regulation of interferon-alpha production,GO:0032729~positive regulation of interferon-gamma production,GO:0032733~positive regulation of interleukin-10 production,GO:0032735~positive regulation of interleukin-12 production,GO:0032755~positive regulation of interleukin-6 production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0033198~response to ATP,GO:0034514~mitochondrial unfolded protein response,GO:0034605~cellular response to heat,GO:0042026~protein refolding,GO:0042100~B cell proliferation,GO:0042110~T cell activation,GO:0042113~B cell activation,GO:0042220~response to cocaine,GO:0042493~response to drug,GO:0042542~response to hydrogen peroxide,GO:0043032~positive regulation of macrophage activation,GO:0043065~positive regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043524~negative regulation of neuron apoptotic process,GO:0043627~response to estrogen,GO:0045041~protein import into mitochondrial intermembrane space,GO:0048291~isotype switching to IgG isotypes,GO:0050729~positive regulation of inflammatory response,GO:0050821~protein stabilization,GO:0050870~positive regulation of T cell activation,GO:0051131~chaperone-mediated protein complex assembly,GO:0051384~response to glucocorticoid,GO:0051604~protein maturation,GO:0051702~interaction with symbiont,GO:0071866~negative regulation of apoptotic process in bone marrow,GO:0098761~cellular response to interleukin-7,GO:1903427~negative regulation of reactive oxygen species biosynthetic process,	GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005759~mitochondrial matrix,GO:0005769~early endosome,GO:0005782~peroxisomal matrix,GO:0005791~rough endoplasmic reticulum,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005905~clathrin-coated pit,GO:0009986~cell surface,GO:0016020~membrane,GO:0030061~mitochondrial crista,GO:0030135~coated vesicle,GO:0030141~secretory granule,GO:0031985~Golgi cisterna,GO:0032991~macromolecular complex,GO:0042588~zymogen granule,GO:0045121~membrane raft,GO:0046696~lipopolysaccharide receptor complex,GO:0070062~extracellular exosome,GO:0097225~sperm midpiece,	GO:0001530~lipopolysaccharide binding,GO:0002039~p53 binding,GO:0003688~DNA replication origin binding,GO:0003697~single-stranded DNA binding,GO:0003723~RNA binding,GO:0003725~double-stranded RNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008035~high-density lipoprotein particle binding,GO:0016853~isomerase activity,GO:0016887~ATPase activity,GO:0019899~enzyme binding,GO:0031625~ubiquitin protein ligase binding,GO:0034185~apolipoprotein binding,GO:0034186~apolipoprotein A-I binding,GO:0044877~macromolecular complex binding,GO:0051082~unfolded protein binding,GO:0051087~chaperone binding,	IPR001844:Chaperonin Cpn60,IPR002423:Chaperonin Cpn60/TCP-1,IPR017998:Chaperone tailless complex polypeptide 1 (TCP-1),IPR018370:Chaperonin Cpn60, conserved site,IPR027409:GroEL-like apical domain,IPR027410:TCP-1-like chaperonin intermediate domain,IPR027413:GroEL-like equatorial domain,	hsa03018:RNA degradation,hsa04940:Type I diabetes mellitus,hsa05134:Legionellosis,hsa05152:Tuberculosis,hsa05417:Lipid and atherosclerosis,	605280~Spastic paraplegia 13, autosomal dominant,612233~Leukodystrophy, hypomyelinating, 4,			KW-0346~Stress response,KW-0945~Host-virus interaction,	KW-0496~Mitochondrion,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0890~Hereditary spastic paraplegia,KW-1026~Leukodystrophy,	KW-0175~Coiled coil,KW-0809~Transit peptide,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0143~Chaperone,KW-0413~Isomerase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	BINDING:ATP,BINDING:ATP; via amide nitrogen and carbonyl oxygen,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),NP_BIND:ATP,TRANSIT:Mitochondrion,
HEBP1	heme binding protein 1(HEBP1)	Homo sapiens				GO:0007186~G-protein coupled receptor signaling pathway,GO:0007623~circadian rhythm,	GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0070062~extracellular exosome,	GO:0020037~heme binding,	IPR006917:SOUL haem-binding protein,IPR011256:Regulatory factor, effector, bacterial,						KW-0963~Cytoplasm,						REGION:Disordered,
HMOX1	heme oxygenase 1(HMOX1)	Homo sapiens		h_arenrf2Pathway:Oxidative Stress Induced Gene Expression Via Nrf2,h_il10Pathway:IL-10 Anti-inflammatory Signaling Pathway,		GO:0001525~angiogenesis,GO:0001666~response to hypoxia,GO:0001935~endothelial cell proliferation,GO:0002246~wound healing involved in inflammatory response,GO:0002686~negative regulation of leukocyte migration,GO:0006788~heme oxidation,GO:0006879~cellular iron ion homeostasis,GO:0006979~response to oxidative stress,GO:0007264~small GTPase mediated signal transduction,GO:0007588~excretion,GO:0008217~regulation of blood pressure,GO:0008219~cell death,GO:0008630~intrinsic apoptotic signaling pathway in response to DNA damage,GO:0009410~response to xenobiotic stimulus,GO:0010656~negative regulation of muscle cell apoptotic process,GO:0014806~smooth muscle hyperplasia,GO:0016239~positive regulation of macroautophagy,GO:0016242~negative regulation of macroautophagy,GO:0019221~cytokine-mediated signaling pathway,GO:0031670~cellular response to nutrient,GO:0032722~positive regulation of chemokine production,GO:0032764~negative regulation of mast cell cytokine production,GO:0034101~erythrocyte homeostasis,GO:0034383~low-density lipoprotein particle clearance,GO:0034395~regulation of transcription from RNA polymerase II promoter in response to iron,GO:0034605~cellular response to heat,GO:0035094~response to nicotine,GO:0035556~intracellular signal transduction,GO:0042167~heme catabolic process,GO:0042493~response to drug,GO:0042542~response to hydrogen peroxide,GO:0043065~positive regulation of apoptotic process,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043305~negative regulation of mast cell degranulation,GO:0043392~negative regulation of DNA binding,GO:0043433~negative regulation of sequence-specific DNA binding transcription factor activity,GO:0043524~negative regulation of neuron apoptotic process,GO:0043619~regulation of transcription from RNA polymerase II promoter in response to oxidative stress,GO:0043627~response to estrogen,GO:0045048~protein insertion into ER membrane,GO:0045765~regulation of angiogenesis,GO:0045766~positive regulation of angiogenesis,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0048662~negative regulation of smooth muscle cell proliferation,GO:0051090~regulation of sequence-specific DNA binding transcription factor activity,GO:0055072~iron ion homeostasis,GO:0071243~cellular response to arsenic-containing substance,GO:0071276~cellular response to cadmium ion,GO:0071456~cellular response to hypoxia,GO:0072719~cellular response to cisplatin,GO:0090050~positive regulation of cell migration involved in sprouting angiogenesis,GO:0097421~liver regeneration,GO:1902042~negative regulation of extrinsic apoptotic signaling pathway via death domain receptors,GO:1903589~positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis,GO:1904036~negative regulation of epithelial cell apoptotic process,GO:1904706~negative regulation of vascular smooth muscle cell proliferation,	GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005741~mitochondrial outer membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0005901~caveola,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0048471~perinuclear region of cytoplasm,	GO:0004392~heme oxygenase (decyclizing) activity,GO:0004630~phospholipase D activity,GO:0005198~structural molecule activity,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0020037~heme binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0046872~metal ion binding,	IPR002051:Haem oxygenase,IPR016053:Haem oxygenase-like,IPR016084:Haem oxygenase-like, multi-helical,IPR018207:Haem oxygenase conserved site,	hsa00860:Porphyrin metabolism,hsa01100:Metabolic pathways,hsa04066:HIF-1 signaling pathway,hsa04216:Ferroptosis,hsa04978:Mineral absorption,hsa05200:Pathways in cancer,hsa05206:MicroRNAs in cancer,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05225:Hepatocellular carcinoma,hsa05418:Fluid shear stress and atherosclerosis,	606963~Pulmonary disease, chronic obstructive, susceptibility to,614034~Heme oxygenase-1 deficiency,	PIRSF000343:heme oxygenase (decyclizing),		KW-0053~Apoptosis,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0492~Microsome,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0349~Heme,KW-0408~Iron,KW-0479~Metal-binding,	KW-0195~Cyclin,KW-0560~Oxidoreductase,	KW-0597~Phosphoprotein,	BINDING:Heme,COMPBIAS:Polar residues,METAL:Iron (heme axial ligand),MUTAGEN:D->A: Inactive as a heme oxygenase but active as a peroxidase.,REGION:Disordered,TRANSMEM:Helical,
HS2ST1	heparan sulfate 2-O-sulfotransferase 1(HS2ST1)	Homo sapiens				GO:0006024~glycosaminoglycan biosynthetic process,GO:0015014~heparan sulfate proteoglycan biosynthetic process, polysaccharide chain biosynthetic process,GO:0015015~heparan sulfate proteoglycan biosynthetic process, enzymatic modification,	GO:0000139~Golgi membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0004394~heparan sulfate 2-O-sulfotransferase activity,GO:0008146~sulfotransferase activity,	IPR005331:Sulfotransferase,IPR007734:Heparan sulphate 2-O-sulfotransferase,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa00534:Glycosaminoglycan biosynthesis - heparan sulfate / heparin,	619194~Neurofacioskeletal syndrome with or without renal agenesis,				KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0808~Transferase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
HES1	hes family bHLH transcription factor 1(HES1)	Homo sapiens		h_hesPathway:Segmentation Clock,		GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001889~liver development,GO:0003143~embryonic heart tube morphogenesis,GO:0003151~outflow tract morphogenesis,GO:0003266~regulation of secondary heart field cardioblast proliferation,GO:0003281~ventricular septum development,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007155~cell adhesion,GO:0007219~Notch signaling pathway,GO:0007224~smoothened signaling pathway,GO:0007399~nervous system development,GO:0008284~positive regulation of cell proliferation,GO:0009952~anterior/posterior pattern specification,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0010977~negative regulation of neuron projection development,GO:0014070~response to organic cyclic compound,GO:0016477~cell migration,GO:0021537~telencephalon development,GO:0021555~midbrain-hindbrain boundary morphogenesis,GO:0021557~oculomotor nerve development,GO:0021558~trochlear nerve development,GO:0021575~hindbrain morphogenesis,GO:0021861~forebrain radial glial cell differentiation,GO:0021984~adenohypophysis development,GO:0030324~lung development,GO:0030513~positive regulation of BMP signaling pathway,GO:0030901~midbrain development,GO:0031016~pancreas development,GO:0035019~somatic stem cell population maintenance,GO:0035315~hair cell differentiation,GO:0035910~ascending aorta morphogenesis,GO:0042102~positive regulation of T cell proliferation,GO:0042531~positive regulation of tyrosine phosphorylation of STAT protein,GO:0043254~regulation of protein complex assembly,GO:0043279~response to alkaloid,GO:0043388~positive regulation of DNA binding,GO:0043433~negative regulation of sequence-specific DNA binding transcription factor activity,GO:0045598~regulation of fat cell differentiation,GO:0045608~negative regulation of auditory receptor cell differentiation,GO:0045665~negative regulation of neuron differentiation,GO:0045747~positive regulation of Notch signaling pathway,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0045977~positive regulation of mitotic cell cycle, embryonic,GO:0046331~lateral inhibition,GO:0046425~regulation of JAK-STAT cascade,GO:0046427~positive regulation of JAK-STAT cascade,GO:0048469~cell maturation,GO:0048538~thymus development,GO:0048667~cell morphogenesis involved in neuron differentiation,GO:0048711~positive regulation of astrocyte differentiation,GO:0048715~negative regulation of oligodendrocyte differentiation,GO:0048844~artery morphogenesis,GO:0050678~regulation of epithelial cell proliferation,GO:0050767~regulation of neurogenesis,GO:0060122~inner ear receptor stereocilium organization,GO:0060164~regulation of timing of neuron differentiation,GO:0060253~negative regulation of glial cell proliferation,GO:0060412~ventricular septum morphogenesis,GO:0060675~ureteric bud morphogenesis,GO:0060716~labyrinthine layer blood vessel development,GO:0061009~common bile duct development,GO:0061106~negative regulation of stomach neuroendocrine cell differentiation,GO:0061309~cardiac neural crest cell development involved in outflow tract morphogenesis,GO:0061626~pharyngeal arch artery morphogenesis,GO:0065003~macromolecular complex assembly,GO:0071347~cellular response to interleukin-1,GO:0071356~cellular response to tumor necrosis factor,GO:0071398~cellular response to fatty acid,GO:0072012~glomerulus vasculature development,GO:0072049~comma-shaped body morphogenesis,GO:0072050~S-shaped body morphogenesis,GO:0072141~renal interstitial fibroblast development,GO:0072282~metanephric nephron tubule morphogenesis,GO:0090102~cochlea development,GO:0090162~establishment of epithelial cell polarity,GO:0090281~negative regulation of calcium ion import,GO:0097066~response to thyroid hormone,GO:0097084~vascular smooth muscle cell development,GO:0097150~neuronal stem cell population maintenance,GO:1905934~negative regulation of cell fate determination,GO:1990090~cellular response to nerve growth factor stimulus,GO:2000227~negative regulation of pancreatic A cell differentiation,GO:2000737~negative regulation of stem cell differentiation,GO:2000974~negative regulation of pro-B cell differentiation,GO:2000978~negative regulation of forebrain neuron differentiation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016363~nuclear matrix,GO:0032991~macromolecular complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001085~RNA polymerase II transcription factor binding,GO:0001222~transcription corepressor binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0008432~JUN kinase binding,GO:0042803~protein homodimerization activity,GO:0042826~histone deacetylase binding,GO:0043398~HLH domain binding,GO:0043565~sequence-specific DNA binding,GO:0044877~macromolecular complex binding,GO:0046983~protein dimerization activity,GO:0051087~chaperone binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0070888~E-box binding,GO:0071820~N-box binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR003650:Orange,IPR011598:Myc-type, basic helix-loop-helix (bHLH) domain,	hsa03460:Fanconi anemia pathway,hsa04330:Notch signaling pathway,hsa04950:Maturity onset diabetes of the young,hsa05165:Human papillomavirus infection,hsa05169:Epstein-Barr virus infection,hsa05200:Pathways in cancer,hsa05224:Breast cancer,			SM00353:HLH,SM00511:ORANGE,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0238~DNA-binding,KW-0678~Repressor,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:BHLH,DOMAIN:Orange,DOMAIN:bHLH,MOTIF:WRPW motif,REGION:Disordered,
HK1	hexokinase 1(HK1)	Homo sapiens		h_glycolysisPathway:Glycolysis Pathway,	Carbohydrate transport and metabolism,	GO:0001678~cellular glucose homeostasis,GO:0002720~positive regulation of cytokine production involved in immune response,GO:0006002~fructose 6-phosphate metabolic process,GO:0006013~mannose metabolic process,GO:0006096~glycolytic process,GO:0006954~inflammatory response,GO:0019318~hexose metabolic process,GO:0032731~positive regulation of interleukin-1 beta production,GO:0045087~innate immune response,GO:0046835~carbohydrate phosphorylation,GO:0051156~glucose 6-phosphate metabolic process,GO:0061621~canonical glycolysis,GO:0072655~establishment of protein localization to mitochondrion,GO:0072656~maintenance of protein location in mitochondrion,	GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005829~cytosol,GO:0045121~membrane raft,	GO:0004340~glucokinase activity,GO:0004396~hexokinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0005536~glucose binding,GO:0008865~fructokinase activity,GO:0019158~mannokinase activity,GO:0042834~peptidoglycan binding,GO:0047931~glucosamine kinase activity,	IPR001312:Hexokinase,IPR019807:Hexokinase, conserved site,IPR022672:Hexokinase, N-terminal,IPR022673:Hexokinase, C-terminal,	hsa00010:Glycolysis / Gluconeogenesis,hsa00051:Fructose and mannose metabolism,hsa00052:Galactose metabolism,hsa00500:Starch and sucrose metabolism,hsa00520:Amino sugar and nucleotide sugar metabolism,hsa00524:Neomycin, kanamycin and gentamicin biosynthesis,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa01250:Biosynthesis of nucleotide sugars,hsa04066:HIF-1 signaling pathway,hsa04910:Insulin signaling pathway,hsa04930:Type II diabetes mellitus,hsa04973:Carbohydrate digestion and absorption,hsa05131:Shigellosis,hsa05230:Central carbon metabolism in cancer,	235700~Hemolytic anemia due to hexokinase deficiency,605285~Neuropathy, hereditary motor and sensory, Russe type,617460~Retinitis pigmentosa 79,618547~Neurodevelopmental disorder with visual defects and brain anomalies,			KW-0324~Glycolysis,KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0963~Cytoplasm,KW-1000~Mitochondrion outer membrane,	KW-0144~Charcot-Marie-Tooth disease,KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0622~Neuropathy,KW-0682~Retinitis pigmentosa,KW-0991~Mental retardation,	KW-0677~Repeat,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0021~Allosteric enzyme,KW-0418~Kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	BINDING:ATP 1,BINDING:ATP 2,BINDING:Glucose-6-phosphate 1,BINDING:Glucose-6-phosphate 2,BINDING:Substrate 1,BINDING:Substrate 2,DOMAIN:Hexokinase 1,DOMAIN:Hexokinase 2,DOMAIN:Hexokinase_1,DOMAIN:Hexokinase_2,NP_BIND:ATP 1,NP_BIND:ATP 2,REGION:Disordered,REGION:Glucose-6-phosphate 1 binding,REGION:Glucose-6-phosphate 2 binding,REGION:Hexokinase large subdomain 1,REGION:Hexokinase large subdomain 2,REGION:Hexokinase small subdomain 1,REGION:Hexokinase small subdomain 2,REGION:Mitochondrial-binding peptide (MBP),REGION:Substrate 1 binding,REGION:Substrate 2 binding,
HMG20B	high mobility group 20B(HMG20B)	Homo sapiens				GO:0006325~chromatin organization,GO:0007049~cell cycle,GO:0007596~blood coagulation,GO:0010468~regulation of gene expression,GO:0033234~negative regulation of protein sumoylation,GO:0035914~skeletal muscle cell differentiation,GO:0045666~positive regulation of neuron differentiation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0016604~nuclear body,	GO:0003677~DNA binding,GO:0005515~protein binding,	IPR009071:High mobility group (HMG) box domain,				SM00398:HMG,	KW-0131~Cell cycle,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0158~Chromosome,KW-0539~Nucleus,		KW-0175~Coiled coil,		KW-0156~Chromatin regulator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DNA_BIND:HMG box,DOMAIN:HMG box,MUTAGEN:K->I: Loss of DNA binding activity of the BHC histone deacetylase complex.,REGION:Disordered,
HMGA2	high mobility group AT-hook 2(HMGA2)	Homo sapiens				GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001837~epithelial to mesenchymal transition,GO:0002062~chondrocyte differentiation,GO:0003131~mesodermal-endodermal cell signaling,GO:0006284~base-excision repair,GO:0006325~chromatin organization,GO:0006355~regulation of transcription, DNA-templated,GO:0007095~mitotic G2 DNA damage checkpoint,GO:0007275~multicellular organism development,GO:0009615~response to virus,GO:0010564~regulation of cell cycle process,GO:0010628~positive regulation of gene expression,GO:0030261~chromosome condensation,GO:0031052~chromosome breakage,GO:0031507~heterochromatin assembly,GO:0035978~histone H2A-S139 phosphorylation,GO:0035986~senescence-associated heterochromatin focus assembly,GO:0035987~endodermal cell differentiation,GO:0035988~chondrocyte proliferation,GO:0040008~regulation of growth,GO:0042769~DNA damage response, detection of DNA damage,GO:0043065~positive regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043392~negative regulation of DNA binding,GO:0043922~negative regulation by host of viral transcription,GO:0045444~fat cell differentiation,GO:0045766~positive regulation of angiogenesis,GO:0045869~negative regulation of single stranded viral RNA replication via double stranded DNA intermediate,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048333~mesodermal cell differentiation,GO:0048762~mesenchymal cell differentiation,GO:0048863~stem cell differentiation,GO:0051301~cell division,GO:0071158~positive regulation of cell cycle arrest,GO:0071864~positive regulation of cell proliferation in bone marrow,GO:0071902~positive regulation of protein serine/threonine kinase activity,GO:0090305~nucleic acid phosphodiester bond hydrolysis,GO:0090402~oncogene-induced cell senescence,GO:2000036~regulation of stem cell population maintenance,GO:2000648~positive regulation of stem cell proliferation,GO:2000685~positive regulation of cellular response to X-ray,GO:2000773~negative regulation of cellular senescence,GO:2000774~positive regulation of cellular senescence,GO:2001022~positive regulation of response to DNA damage stimulus,GO:2001033~negative regulation of double-strand break repair via nonhomologous end joining,GO:2001038~regulation of cellular response to drug,	GO:0000228~nuclear chromosome,GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0032993~protein-DNA complex,GO:0035985~senescence-associated heterochromatin focus,GO:0071141~SMAD protein complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003680~AT DNA binding,GO:0003712~transcription cofactor activity,GO:0003714~transcription corepressor activity,GO:0003906~DNA-(apurinic or apyrimidinic site) lyase activity,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0008301~DNA binding, bending,GO:0031492~nucleosomal DNA binding,GO:0035497~cAMP response element binding,GO:0035500~MH2 domain binding,GO:0035501~MH1 domain binding,GO:0046332~SMAD binding,GO:0051575~5'-deoxyribose-5-phosphate lyase activity,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0070742~C2H2 zinc finger domain binding,	IPR000116:High mobility group, HMG-I/HMG-Y,IPR000637:HMG-I/HMG-Y, DNA-binding, conserved site,IPR017956:AT hook, DNA-binding motif,	hsa05202:Transcriptional misregulation in cancer,hsa05206:MicroRNAs in cancer,	618908~Silver-Russell syndrome 5,		SM00384:AT_hook,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0226~DNA condensation,KW-0341~Growth regulation,KW-0498~Mitosis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0242~Dwarfism,KW-0656~Proto-oncogene,	KW-0677~Repeat,		KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DNA_BIND:A.T hook 1,DNA_BIND:A.T hook 2,DNA_BIND:A.T hook 3,REGION:Disordered,REGION:Interaction with E4F1,
HAT1	histone acetyltransferase 1(HAT1)	Homo sapiens				GO:0006323~DNA packaging,GO:0006325~chromatin organization,GO:0006335~DNA replication-dependent nucleosome assembly,GO:0006336~DNA replication-independent nucleosome assembly,GO:0006348~chromatin silencing at telomere,GO:0006475~internal protein amino acid acetylation,GO:0007584~response to nutrient,GO:0043967~histone H4 acetylation,	GO:0000781~chromosome, telomeric region,GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0016363~nuclear matrix,GO:0032991~macromolecular complex,	GO:0004402~histone acetyltransferase activity,GO:0005515~protein binding,GO:0010485~H4 histone acetyltransferase activity,GO:0042393~histone binding,	IPR013523:Histone acetyltransferase HAT1, C-terminal,IPR016181:Acyl-CoA N-acyltransferase,IPR017380:Histone acetyltransferase type B, catalytic subunit,IPR019467:Histone acetyl transferase HAT1 N-terminal,	hsa04613:Neutrophil extracellular trap formation,hsa05034:Alcoholism,		PIRSF038084:histone acetyltransferase type B, catalytic subunit,			KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0012~Acyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton donor/acceptor,DOMAIN:Hat1_N,MUTAGEN:D->A: Strongly reduces HAT activity.,MUTAGEN:D->N: Strongly reduces HAT activity.,MUTAGEN:E->A: Strongly reduces HAT activity.,MUTAGEN:E->Q: Strongly reduces HAT activity.,MUTAGEN:S->A: Complete loss of activity after pulsatile shear stress.,MUTAGEN:S->D: No loss of activity after pulsatile shear stress.,MUTAGEN:W->A: Strongly reduces HAT activity.,REGION:Acetyl-CoA binding,REGION:Interaction with histone H4 N-terminus,SITE:Interaction with histone H4 N-terminus,
HDAC2	histone deacetylase 2(HDAC2)	Homo sapiens		h_carm-erPathway:CARM1 and Regulation of the Estrogen Receptor,h_etsPathway:METS affect on Macrophage Differentiation,h_mef2dPathway:Role of MEF2D in T-cell Apoptosis,h_prc2Pathway:The PRC2 Complex Sets Long-term Gene Silencing Through Modification of Histone Tails,	Chromatin structure and dynamics / Secondary metabolites biosynthesis, transport, and catabolism,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001975~response to amphetamine,GO:0003300~cardiac muscle hypertrophy,GO:0006338~chromatin remodeling,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007596~blood coagulation,GO:0008284~positive regulation of cell proliferation,GO:0009410~response to xenobiotic stimulus,GO:0009913~epidermal cell differentiation,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0010977~negative regulation of neuron projection development,GO:0016358~dendrite development,GO:0016575~histone deacetylation,GO:0031000~response to caffeine,GO:0032496~response to lipopolysaccharide,GO:0032732~positive regulation of interleukin-1 production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0032922~circadian regulation of gene expression,GO:0032967~positive regulation of collagen biosynthetic process,GO:0034605~cellular response to heat,GO:0035094~response to nicotine,GO:0042220~response to cocaine,GO:0042475~odontogenesis of dentin-containing tooth,GO:0042493~response to drug,GO:0042531~positive regulation of tyrosine phosphorylation of STAT protein,GO:0042733~embryonic digit morphogenesis,GO:0043044~ATP-dependent chromatin remodeling,GO:0043066~negative regulation of apoptotic process,GO:0043392~negative regulation of DNA binding,GO:0043433~negative regulation of sequence-specific DNA binding transcription factor activity,GO:0045347~negative regulation of MHC class II biosynthetic process,GO:0045862~positive regulation of proteolysis,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048149~behavioral response to ethanol,GO:0048714~positive regulation of oligodendrocyte differentiation,GO:0055093~response to hyperoxia,GO:0060789~hair follicle placode formation,GO:0061000~negative regulation of dendritic spine development,GO:0061029~eyelid development in camera-type eye,GO:0061198~fungiform papilla formation,GO:0070301~cellular response to hydrogen peroxide,GO:0070828~heterochromatin organization,GO:0070829~heterochromatin maintenance,GO:0070932~histone H3 deacetylation,GO:0070933~histone H4 deacetylation,GO:0071300~cellular response to retinoic acid,GO:0071560~cellular response to transforming growth factor beta stimulus,GO:1901796~regulation of signal transduction by p53 class mediator,GO:1902437~positive regulation of male mating behavior,GO:1903351~cellular response to dopamine,GO:2000273~positive regulation of receptor activity,GO:2000757~negative regulation of peptidyl-lysine acetylation,	GO:0000118~histone deacetylase complex,GO:0000781~chromosome, telomeric region,GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016021~integral component of membrane,GO:0016580~Sin3 complex,GO:0016581~NuRD complex,GO:0032991~macromolecular complex,GO:0035098~ESC/E(Z) complex,	GO:0001103~RNA polymerase II repressing transcription factor binding,GO:0003682~chromatin binding,GO:0003723~RNA binding,GO:0004407~histone deacetylase activity,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0019213~deacetylase activity,GO:0019899~enzyme binding,GO:0031072~heat shock protein binding,GO:0031492~nucleosomal DNA binding,GO:0032041~NAD-dependent histone deacetylase activity (H3-K14 specific),GO:0033558~protein deacetylase activity,GO:0042826~histone deacetylase binding,GO:0043565~sequence-specific DNA binding,GO:0051059~NF-kappaB binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:1990841~promoter-specific chromatin binding,	IPR000286:Histone deacetylase superfamily,IPR003084:Histone deacetylase,IPR023696:Ureohydrolase domain,IPR023801:Histone deacetylase domain,	hsa04110:Cell cycle,hsa04213:Longevity regulating pathway - multiple species,hsa04330:Notch signaling pathway,hsa04613:Neutrophil extracellular trap formation,hsa04919:Thyroid hormone signaling pathway,hsa05016:Huntington disease,hsa05031:Amphetamine addiction,hsa05034:Alcoholism,hsa05165:Human papillomavirus infection,hsa05169:Epstein-Barr virus infection,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05203:Viral carcinogenesis,hsa05206:MicroRNAs in cancer,hsa05220:Chronic myeloid leukemia,		PIRSF037913:histone deacetylase class I, eukaryotic type,		KW-0090~Biological rhythms,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0156~Chromatin regulator,KW-0378~Hydrolase,KW-0678~Repressor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0702~S-nitrosylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:Hist_deacetyl,REGION:Disordered,REGION:Histone deacetylase,TRANSMEM:Helical,
HDAC6	histone deacetylase 6(HDAC6)	Homo sapiens		h_carm-erPathway:CARM1 and Regulation of the Estrogen Receptor,h_ranbp2Pathway:Sumoylation by RanBP2 Regulates Transcriptional Repression,		GO:0000209~protein polyubiquitination,GO:0006476~protein deacetylation,GO:0006515~misfolded or incompletely synthesized protein catabolic process,GO:0006886~intracellular protein transport,GO:0006914~autophagy,GO:0007026~negative regulation of microtubule depolymerization,GO:0010506~regulation of autophagy,GO:0010634~positive regulation of epithelial cell migration,GO:0010727~negative regulation of hydrogen peroxide metabolic process,GO:0016241~regulation of macroautophagy,GO:0016575~histone deacetylation,GO:0019896~axonal transport of mitochondrion,GO:0031333~negative regulation of protein complex assembly,GO:0031647~regulation of protein stability,GO:0031648~protein destabilization,GO:0032418~lysosome localization,GO:0032984~macromolecular complex disassembly,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0034983~peptidyl-lysine deacetylation,GO:0035967~cellular response to topologically incorrect protein,GO:0035973~aggrephagy,GO:0040029~regulation of gene expression, epigenetic,GO:0043162~ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway,GO:0043242~negative regulation of protein complex disassembly,GO:0045598~regulation of fat cell differentiation,GO:0045861~negative regulation of proteolysis,GO:0045892~negative regulation of transcription, DNA-templated,GO:0048668~collateral sprouting,GO:0051354~negative regulation of oxidoreductase activity,GO:0051646~mitochondrion localization,GO:0051788~response to misfolded protein,GO:0060271~cilium assembly,GO:0060632~regulation of microtubule-based movement,GO:0060765~regulation of androgen receptor signaling pathway,GO:0060997~dendritic spine morphogenesis,GO:0061734~parkin-mediated stimulation of mitophagy in response to mitochondrial depolarization,GO:0070201~regulation of establishment of protein localization,GO:0070301~cellular response to hydrogen peroxide,GO:0070842~aggresome assembly,GO:0070845~polyubiquitinated misfolded protein transport,GO:0070846~Hsp90 deacetylation,GO:0070848~response to growth factor,GO:0070932~histone H3 deacetylation,GO:0071218~cellular response to misfolded protein,GO:0090042~tubulin deacetylation,GO:0098779~positive regulation of macromitophagy in response to mitochondrial depolarization,GO:1901300~positive regulation of hydrogen peroxide-mediated programmed cell death,GO:1903146~regulation of mitophagy,GO:2000273~positive regulation of receptor activity,	GO:0000118~histone deacetylase complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005771~multivesicular body,GO:0005829~cytosol,GO:0005874~microtubule,GO:0005875~microtubule associated complex,GO:0005901~caveola,GO:0015630~microtubule cytoskeleton,GO:0016021~integral component of membrane,GO:0016234~inclusion body,GO:0016235~aggresome,GO:0030424~axon,GO:0030425~dendrite,GO:0031252~cell leading edge,GO:0032991~macromolecular complex,GO:0043204~perikaryon,GO:0048471~perinuclear region of cytoplasm,GO:1904115~axon cytoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0001222~transcription corepressor binding,GO:0001226~RNA polymerase II transcription corepressor binding,GO:0003779~actin binding,GO:0004407~histone deacetylase activity,GO:0005515~protein binding,GO:0008013~beta-catenin binding,GO:0008017~microtubule binding,GO:0008270~zinc ion binding,GO:0016787~hydrolase activity,GO:0019899~enzyme binding,GO:0031593~polyubiquitin binding,GO:0031625~ubiquitin protein ligase binding,GO:0032041~NAD-dependent histone deacetylase activity (H3-K14 specific),GO:0033558~protein deacetylase activity,GO:0042826~histone deacetylase binding,GO:0042903~tubulin deacetylase activity,GO:0043014~alpha-tubulin binding,GO:0043130~ubiquitin binding,GO:0048156~tau protein binding,GO:0048487~beta-tubulin binding,GO:0051787~misfolded protein binding,GO:0051879~Hsp90 protein binding,GO:0070840~dynein complex binding,	IPR000286:Histone deacetylase superfamily,IPR001607:Zinc finger, UBP-type,IPR013083:Zinc finger, RING/FYVE/PHD-type,IPR023696:Ureohydrolase domain,IPR023801:Histone deacetylase domain,	hsa04613:Neutrophil extracellular trap formation,hsa05014:Amyotrophic lateral sclerosis,hsa05034:Alcoholism,hsa05203:Viral carcinogenesis,	300863~Chondrodysplasia with platyspondyly, distinctive brachydactyly, hydrocephaly, and microphthalmia,		SM00290:ZnF_UBP,	KW-0072~Autophagy,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,		KW-0677~Repeat,KW-0812~Transmembrane,KW-0863~Zinc-finger,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0009~Actin-binding,KW-0156~Chromatin regulator,KW-0378~Hydrolase,KW-0678~Repressor,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:1,ACT_SITE:2,COMPBIAS:Acidic residues,COMPBIAS:Polar residues,DOMAIN:Hist_deacetyl,DOMAIN:UBP-type,METAL:Zinc 1,METAL:Zinc 2,METAL:Zinc 3,MUTAGEN:H->A: Reduces histone deacetylase activity.,REGION:Disordered,REGION:Histone deacetylase 1,REGION:Histone deacetylase 2,REGION:Ubiquitin binding,TRANSMEM:Helical,ZN_FING:UBP-type,
HOXA10	homeobox A10(HOXA10)	Homo sapiens				GO:0001501~skeletal system development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007275~multicellular organism development,GO:0007283~spermatogenesis,GO:0007338~single fertilization,GO:0008584~male gonad development,GO:0009952~anterior/posterior pattern specification,GO:0009954~proximal/distal pattern formation,GO:0030326~embryonic limb morphogenesis,GO:0030850~prostate gland development,GO:0033574~response to testosterone,GO:0043627~response to estrogen,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0060065~uterus development,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:0042826~histone deacetylase binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,	hsa05202:Transcriptional misregulation in cancer,			SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0175~Coiled coil,KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Polar residues,COMPBIAS:Pro residues,DNA_BIND:Homeobox,DOMAIN:Homeobox,REGION:Disordered,
HOXA5	homeobox A5(HOXA5)	Homo sapiens				GO:0003016~respiratory system process,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007275~multicellular organism development,GO:0009952~anterior/posterior pattern specification,GO:0010628~positive regulation of gene expression,GO:0016477~cell migration,GO:0016525~negative regulation of angiogenesis,GO:0030878~thyroid gland development,GO:0033599~regulation of mammary gland epithelial cell proliferation,GO:0035264~multicellular organism growth,GO:0043065~positive regulation of apoptotic process,GO:0045639~positive regulation of myeloid cell differentiation,GO:0045647~negative regulation of erythrocyte differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048286~lung alveolus development,GO:0048704~embryonic skeletal system morphogenesis,GO:0060435~bronchiole development,GO:0060441~epithelial tube branching involved in lung morphogenesis,GO:0060480~lung goblet cell differentiation,GO:0060484~lung-associated mesenchyme development,GO:0060535~trachea cartilage morphogenesis,GO:0060574~intestinal epithelial cell maturation,GO:0060638~mesenchymal-epithelial cell signaling,GO:0060644~mammary gland epithelial cell differentiation,GO:0060749~mammary gland alveolus development,GO:0060764~cell-cell signaling involved in mammary gland development,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR001827:Homeobox protein, antennapedia type, conserved site,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR017995:Homeobox protein, antennapedia type,IPR020479:Homeodomain, metazoa,				SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Polar residues,DNA_BIND:Homeobox,DOMAIN:Homeobox,MOTIF:Antp-type hexapeptide,REGION:Disordered,
HOMER2	homer scaffold protein 2(HOMER2)	Homo sapiens				GO:0007216~G-protein coupled glutamate receptor signaling pathway,GO:0007605~sensory perception of sound,GO:0008277~regulation of G-protein coupled receptor protein signaling pathway,GO:0032703~negative regulation of interleukin-2 production,GO:0035584~calcium-mediated signaling using intracellular calcium source,GO:0048148~behavioral response to cocaine,GO:0048875~chemical homeostasis within a tissue,GO:0070885~negative regulation of calcineurin-NFAT signaling cascade,GO:2001256~regulation of store-operated calcium entry,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0014069~postsynaptic density,GO:0030425~dendrite,GO:0032426~stereocilium tip,GO:0043025~neuronal cell body,GO:0043229~intracellular organelle,GO:0045177~apical part of cell,GO:0098978~glutamatergic synapse,	GO:0003779~actin binding,GO:0005515~protein binding,GO:0019904~protein domain specific binding,GO:0030160~GKAP/Homer scaffold activity,GO:0035256~G-protein coupled glutamate receptor binding,GO:0042802~identical protein binding,GO:0044877~macromolecular complex binding,	IPR000697:EVH1,IPR011993:Pleckstrin homology-like domain,	hsa04068:FoxO signaling pathway,hsa04724:Glutamatergic synapse,	616707~Deafness, autosomal dominant 68,		SM00461:WH1,	KW-1009~Hearing,	KW-0472~Membrane,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0209~Deafness,KW-0225~Disease variant,KW-1010~Non-syndromic deafness,	KW-0175~Coiled coil,				COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:WH1,REGION:Disordered,
HERPUD1	homocysteine inducible ER protein with ubiquitin like domain 1(HERPUD1)	Homo sapiens				GO:0006511~ubiquitin-dependent protein catabolic process,GO:0006986~response to unfolded protein,GO:0016567~protein ubiquitination,GO:0030433~ubiquitin-dependent ERAD pathway,GO:0030968~endoplasmic reticulum unfolded protein response,GO:0030970~retrograde protein transport, ER to cytosol,GO:0031396~regulation of protein ubiquitination,GO:0032469~endoplasmic reticulum calcium ion homeostasis,GO:0034976~response to endoplasmic reticulum stress,GO:0036499~PERK-mediated unfolded protein response,GO:0043154~negative regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0045047~protein targeting to ER,GO:1902236~negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway,GO:1903069~regulation of ER-associated ubiquitin-dependent protein catabolic process,GO:1903071~positive regulation of ER-associated ubiquitin-dependent protein catabolic process,GO:2001243~negative regulation of intrinsic apoptotic signaling pathway,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0044322~endoplasmic reticulum quality control compartment,GO:1990037~Lewy body core,	GO:0005515~protein binding,GO:0044325~ion channel binding,GO:1990756~protein binding, bridging involved in substrate recognition for ubiquitination,	IPR000626:Ubiquitin,	hsa04141:Protein processing in endoplasmic reticulum,			SM00213:UBQ,	KW-0834~Unfolded protein response,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Ubiquitin-like,REGION:Disordered,REGION:Interaction with SYVN1,REGION:Interaction with UBQLN1,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
HOOK2	hook microtubule tethering protein 2(HOOK2)	Homo sapiens				GO:0001678~cellular glucose homeostasis,GO:0006096~glycolytic process,GO:0006897~endocytosis,GO:0007032~endosome organization,GO:0007040~lysosome organization,GO:0008333~endosome to lysosome transport,GO:0015031~protein transport,GO:0019318~hexose metabolic process,GO:0030705~cytoskeleton-dependent intracellular transport,GO:0031122~cytoplasmic microtubule organization,GO:0045022~early endosome to late endosome transport,GO:1905719~protein localization to perinuclear region of cytoplasm,	GO:0005737~cytoplasm,GO:0005802~trans-Golgi network,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005874~microtubule,GO:0043231~intracellular membrane-bounded organelle,GO:0070695~FHF complex,	GO:0004340~glucokinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0005536~glucose binding,GO:0008017~microtubule binding,GO:0042802~identical protein binding,GO:0051959~dynein light intermediate chain binding,	IPR001312:Hexokinase,IPR001715:Calponin homology domain,IPR008636:HOOK/CCDC88,IPR019807:Hexokinase, conserved site,IPR022672:Hexokinase, N-terminal,IPR022673:Hexokinase, C-terminal,					KW-0324~Glycolysis,KW-0653~Protein transport,KW-0813~Transport,	KW-0206~Cytoskeleton,KW-0333~Golgi apparatus,KW-0493~Microtubule,KW-0963~Cytoplasm,		KW-0175~Coiled coil,	KW-0067~ATP-binding,	KW-0418~Kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	DOMAIN:Calponin-homology (CH),DOMAIN:HOOK,DOMAIN:HOOK_N,DOMAIN:Hexokinase_1,DOMAIN:Hexokinase_2,REGION:Disordered,REGION:Required for localization to the centrosome and induction of aggresome formation,REGION:Sufficient for interaction with CNTRL,REGION:Sufficient for interaction with microtubules,
HADH	hydroxyacyl-CoA dehydrogenase(HADH)	Homo sapiens			Lipid metabolism,	GO:0006631~fatty acid metabolic process,GO:0006635~fatty acid beta-oxidation,GO:0009410~response to xenobiotic stimulus,GO:0014823~response to activity,GO:0032868~response to insulin,GO:0042493~response to drug,GO:0046676~negative regulation of insulin secretion,GO:0050796~regulation of insulin secretion,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,	GO:0003857~3-hydroxyacyl-CoA dehydrogenase activity,GO:0016616~oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor,GO:0016740~transferase activity,GO:0042802~identical protein binding,GO:0070403~NAD+ binding,	IPR006108:3-hydroxyacyl-CoA dehydrogenase, C-terminal,IPR006176:3-hydroxyacyl-CoA dehydrogenase, NAD binding,IPR006180:3-hydroxyacyl-CoA dehydrogenase, conserved site,IPR008927:6-phosphogluconate dehydrogenase, C-terminal-like,IPR013328:Dehydrogenase, multihelical,IPR022694:3-hydroxyacyl-CoA dehydrogenase,	hsa00062:Fatty acid elongation,hsa00071:Fatty acid degradation,hsa00280:Valine, leucine and isoleucine degradation,hsa00310:Lysine degradation,hsa00380:Tryptophan metabolism,hsa00650:Butanoate metabolism,hsa01100:Metabolic pathways,hsa01212:Fatty acid metabolism,	231530~3-hydroxyacyl-CoA dehydrogenase deficiency,609975~Hyperinsulinemic hypoglycemia, familial, 4,	PIRSF000105:3-hydroxyacyl-CoA dehydrogenase,		KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,	KW-0496~Mitochondrion,	KW-0225~Disease variant,	KW-0809~Transit peptide,	KW-0520~NAD,	KW-0560~Oxidoreductase,KW-0808~Transferase,	KW-0007~Acetylation,	BINDING:Coenzyme A,BINDING:NAD,DOMAIN:3HCDH,DOMAIN:3HCDH_N,NP_BIND:NAD,REGION:Disordered,SITE:Important for catalytic activity,TRANSIT:Mitochondrion,
HSD17B10	hydroxysteroid 17-beta dehydrogenase 10(HSD17B10)	Homo sapiens				GO:0006550~isoleucine catabolic process,GO:0006629~lipid metabolic process,GO:0006631~fatty acid metabolic process,GO:0006635~fatty acid beta-oxidation,GO:0006699~bile acid biosynthetic process,GO:0007005~mitochondrion organization,GO:0008207~C21-steroid hormone metabolic process,GO:0008209~androgen metabolic process,GO:0008210~estrogen metabolic process,GO:0009083~branched-chain amino acid catabolic process,GO:0051289~protein homotetramerization,GO:0070901~mitochondrial tRNA methylation,GO:0097745~mitochondrial tRNA 5'-end processing,GO:1990180~mitochondrial tRNA 3'-end processing,	GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005886~plasma membrane,GO:0030678~mitochondrial ribonuclease P complex,GO:0042645~mitochondrial nucleoid,GO:0043527~tRNA methyltransferase complex,	GO:0000049~tRNA binding,GO:0003723~RNA binding,GO:0003857~3-hydroxyacyl-CoA dehydrogenase activity,GO:0004303~estradiol 17-beta-dehydrogenase activity,GO:0005515~protein binding,GO:0008709~cholate 7-alpha-dehydrogenase activity,GO:0016491~oxidoreductase activity,GO:0030283~testosterone dehydrogenase [NAD(P)] activity,GO:0044594~17-beta-hydroxysteroid dehydrogenase (NAD+) activity,GO:0047015~3-hydroxy-2-methylbutyryl-CoA dehydrogenase activity,GO:0047035~testosterone dehydrogenase (NAD+) activity,GO:0047044~androstan-3-alpha,17-beta-diol dehydrogenase activity,	IPR002347:Glucose/ribitol dehydrogenase,IPR020904:Short-chain dehydrogenase/reductase, conserved site,	hsa00280:Valine, leucine and isoleucine degradation,hsa01100:Metabolic pathways,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,	300438~HSD10 mitochondrial disease,			KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,KW-0753~Steroid metabolism,KW-0819~tRNA processing,	KW-0496~Mitochondrion,KW-1135~Mitochondrion nucleoid,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0991~Mental retardation,		KW-0520~NAD,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,	ACT_SITE:Proton acceptor,BINDING:NAD,BINDING:Substrate,MUTAGEN:K->A: Abolishes dehydrogenase activity. Does not affect mitochondrial tRNA 5'-end processing. Does not affect tRNA methylation. Does not affect homotetramerization.,MUTAGEN:S->F: Decreased dehydrogenase activity. Does not affect mitochondrial tRNA 5'-end processing. Does not affect tRNA methylation.,NP_BIND:NAD,REGION:Disordered,
HSD17B11	hydroxysteroid 17-beta dehydrogenase 11(HSD17B11)	Homo sapiens			General function prediction only,	GO:0006703~estrogen biosynthetic process,GO:0006710~androgen catabolic process,	GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005811~lipid particle,GO:0005829~cytosol,	GO:0004303~estradiol 17-beta-dehydrogenase activity,GO:0005515~protein binding,GO:0016229~steroid dehydrogenase activity,GO:0016491~oxidoreductase activity,GO:0016616~oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor,GO:0044594~17-beta-hydroxysteroid dehydrogenase (NAD+) activity,GO:0072582~17-beta-hydroxysteroid dehydrogenase (NADP+) activity,	IPR002347:Glucose/ribitol dehydrogenase,					KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,KW-0752~Steroid biosynthesis,	KW-0256~Endoplasmic reticulum,KW-0551~Lipid droplet,		KW-0732~Signal,	KW-0521~NADP,	KW-0560~Oxidoreductase,		ACT_SITE:Proton acceptor,BINDING:Substrate,NP_BIND:NADP,
HPRT1	hypoxanthine phosphoribosyltransferase 1(HPRT1)	Homo sapiens				GO:0001913~T cell mediated cytotoxicity,GO:0001975~response to amphetamine,GO:0006164~purine nucleotide biosynthetic process,GO:0006166~purine ribonucleoside salvage,GO:0006168~adenine salvage,GO:0006178~guanine salvage,GO:0007625~grooming behavior,GO:0007626~locomotory behavior,GO:0021756~striatum development,GO:0021895~cerebral cortex neuron differentiation,GO:0021954~central nervous system neuron development,GO:0032263~GMP salvage,GO:0032264~IMP salvage,GO:0042417~dopamine metabolic process,GO:0043101~purine-containing compound salvage,GO:0043103~hypoxanthine salvage,GO:0044209~AMP salvage,GO:0045964~positive regulation of dopamine metabolic process,GO:0046038~GMP catabolic process,GO:0046040~IMP metabolic process,GO:0046083~adenine metabolic process,GO:0046100~hypoxanthine metabolic process,GO:0046651~lymphocyte proliferation,GO:0048813~dendrite morphogenesis,GO:0051289~protein homotetramerization,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0000166~nucleotide binding,GO:0000287~magnesium ion binding,GO:0004422~hypoxanthine phosphoribosyltransferase activity,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,GO:0052657~guanine phosphoribosyltransferase activity,	IPR000836:Phosphoribosyltransferase domain,IPR005904:Hypoxanthine phosphoribosyl transferase,	hsa00230:Purine metabolism,hsa00983:Drug metabolism - other enzymes,hsa01100:Metabolic pathways,	300322~Lesch-Nyhan syndrome,300323~Hyperuricemia, HRPT-related,			KW-0660~Purine salvage,	KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0335~Gout,		KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Proton acceptor,BINDING:GMP,BINDING:GMP; via carbonyl oxygen,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:Pribosyltran,METAL:Magnesium,MUTAGEN:K->A: Reduced affinity for hypoxanthine, phosphoribosylpyrophosphate and IMP. Reduced catalytic activity.,NP_BIND:GMP,
HIF1A	hypoxia inducible factor 1 subunit alpha(HIF1A)	Homo sapiens		h_eponfkbPathway:Erythropoietin mediated neuroprotection through NF-kB,h_hifPathway:Hypoxia-Inducible Factor in the Cardiovascular System,h_p53hypoxiaPathway:Hypoxia and p53 in the Cardiovascular system,h_vegfPathway:VEGF, Hypoxia, and Angiogenesis,		GO:0000302~response to reactive oxygen species,GO:0001525~angiogenesis,GO:0001666~response to hypoxia,GO:0001678~cellular glucose homeostasis,GO:0001755~neural crest cell migration,GO:0001837~epithelial to mesenchymal transition,GO:0001892~embryonic placenta development,GO:0001922~B-1 B cell homeostasis,GO:0001938~positive regulation of endothelial cell proliferation,GO:0001947~heart looping,GO:0002052~positive regulation of neuroblast proliferation,GO:0002248~connective tissue replacement involved in inflammatory response wound healing,GO:0003151~outflow tract morphogenesis,GO:0003208~cardiac ventricle morphogenesis,GO:0006089~lactate metabolic process,GO:0006110~regulation of glycolytic process,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006879~cellular iron ion homeostasis,GO:0007165~signal transduction,GO:0007595~lactation,GO:0008542~visual learning,GO:0010039~response to iron ion,GO:0010468~regulation of gene expression,GO:0010573~vascular endothelial growth factor production,GO:0010575~positive regulation of vascular endothelial growth factor production,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0010634~positive regulation of epithelial cell migration,GO:0014850~response to muscle activity,GO:0016239~positive regulation of macroautophagy,GO:0016567~protein ubiquitination,GO:0016579~protein deubiquitination,GO:0019221~cytokine-mediated signaling pathway,GO:0019896~axonal transport of mitochondrion,GO:0021502~neural fold elevation formation,GO:0021987~cerebral cortex development,GO:0030502~negative regulation of bone mineralization,GO:0030949~positive regulation of vascular endothelial growth factor receptor signaling pathway,GO:0032007~negative regulation of TOR signaling,GO:0032364~oxygen homeostasis,GO:0032722~positive regulation of chemokine production,GO:0032909~regulation of transforming growth factor beta2 production,GO:0032963~collagen metabolic process,GO:0035162~embryonic hemopoiesis,GO:0035774~positive regulation of insulin secretion involved in cellular response to glucose stimulus,GO:0042541~hemoglobin biosynthetic process,GO:0042593~glucose homeostasis,GO:0043536~positive regulation of blood vessel endothelial cell migration,GO:0043619~regulation of transcription from RNA polymerase II promoter in response to oxidative stress,GO:0043687~post-translational protein modification,GO:0045648~positive regulation of erythrocyte differentiation,GO:0045766~positive regulation of angiogenesis,GO:0045821~positive regulation of glycolytic process,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045926~negative regulation of growth,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046716~muscle cell cellular homeostasis,GO:0046886~positive regulation of hormone biosynthetic process,GO:0048546~digestive tract morphogenesis,GO:0051000~positive regulation of nitric-oxide synthase activity,GO:0051216~cartilage development,GO:0051541~elastin metabolic process,GO:0060574~intestinal epithelial cell maturation,GO:0061030~epithelial cell differentiation involved in mammary gland alveolus development,GO:0061072~iris morphogenesis,GO:0061298~retina vasculature development in camera-type eye,GO:0061418~regulation of transcription from RNA polymerase II promoter in response to hypoxia,GO:0061419~positive regulation of transcription from RNA polymerase II promoter in response to hypoxia,GO:0070101~positive regulation of chemokine-mediated signaling pathway,GO:0070244~negative regulation of thymocyte apoptotic process,GO:0071347~cellular response to interleukin-1,GO:0071456~cellular response to hypoxia,GO:0071542~dopaminergic neuron differentiation,GO:0097411~hypoxia-inducible factor-1alpha signaling pathway,GO:0098586~cellular response to virus,GO:1900017~positive regulation of cytokine production involved in inflammatory response,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1903377~negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway,GO:1903599~positive regulation of mitophagy,GO:1903715~regulation of aerobic respiration,GO:2000273~positive regulation of receptor activity,GO:2000378~negative regulation of reactive oxygen species metabolic process,GO:2000434~regulation of protein neddylation,GO:2001054~negative regulation of mesenchymal cell apoptotic process,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016604~nuclear body,GO:0016607~nuclear speck,GO:0031514~motile cilium,GO:0032991~macromolecular complex,GO:0090575~RNA polymerase II transcription factor complex,GO:1904115~axon cytoplasm,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001216~bacterial-type RNA polymerase transcriptional activator activity, sequence-specific DNA binding,GO:0001223~transcription coactivator binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0002039~p53 binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0016922~ligand-dependent nuclear receptor binding,GO:0019899~enzyme binding,GO:0019901~protein kinase binding,GO:0019904~protein domain specific binding,GO:0031625~ubiquitin protein ligase binding,GO:0035035~histone acetyltransferase binding,GO:0035257~nuclear hormone receptor binding,GO:0042826~histone deacetylase binding,GO:0043565~sequence-specific DNA binding,GO:0046982~protein heterodimerization activity,GO:0046983~protein dimerization activity,GO:0051879~Hsp90 protein binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0070888~E-box binding,	IPR000014:PAS domain,IPR001321:Hypoxia-inducible factor-1 alpha,IPR001610:PAC motif,IPR011598:Myc-type, basic helix-loop-helix (bHLH) domain,IPR013655:PAS fold-3,IPR013767:PAS fold,IPR014887:HIF-1 alpha, transactivation domain, C-terminal,IPR021537:Hypoxia-inducible factor, alpha subunit,	hsa04066:HIF-1 signaling pathway,hsa04137:Mitophagy - animal,hsa04140:Autophagy - animal,hsa04659:Th17 cell differentiation,hsa04919:Thyroid hormone signaling pathway,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05211:Renal cell carcinoma,hsa05230:Central carbon metabolism in cancer,hsa05231:Choline metabolism in cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,			SM00086:PAC,SM00091:PAS,SM00353:HLH,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0010~Activator,KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0379~Hydroxylation,KW-0597~Phosphoprotein,KW-0702~S-nitrosylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CARBOHYD:(Microbial infection) N-beta-linked (GlcNAc) arginine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:BHLH,DOMAIN:PAC,DOMAIN:PAS,DOMAIN:PAS 1,DOMAIN:PAS 2,DOMAIN:bHLH,MOTIF:Nuclear localization signal,MUTAGEN:C->A: Blocks increase in transcriptional activation caused by nitrosylation.,MUTAGEN:C->S: Abolishes hypoxia-inducible transcriptional activation of ctaD.,MUTAGEN:K->R: Abolishes 1 sumoylation. Abolishes 1 sumoylation; when associated with R-532. Abolishes 2 sumoylations; when associated with R-477. No change in HIF1A protein turnover rate but increased transcriptional activity; when associated with R-377; R-477 and R-532.,MUTAGEN:K->R: Abolishes 1 sumoylation. Abolishes 2 sumoylations; when associated with R-391. No change in HIF1A protein turnover rate but increased transcriptional activity; when associated with R-377; R-391 and R-532.,MUTAGEN:K->R: Abolishes SIRT2-mediated deacetylation, increases HIF1A instability and reduces HIF1A-induced target gene transcriptional activation. Increases interaction with EGLN1.,MUTAGEN:K->R: No change in HIF1A protein turnover rate but increased transcriptional activity; when associated with R-391; R-477 and R-532.,MUTAGEN:K->R: No change in sumoylation nor in ARD1-mediated acetylation.,MUTAGEN:K->R: No change in sumoylation, but reduced ubiquitination. Complete loss of ubiquitination, but no change in VHL binding; when associated with K-532 and K-538.,MUTAGEN:K->R: No change in sumoylation, but reduced ubiquitination. Complete loss of ubiquitination, but no change in VHL binding; when associated with K-532 and K-547.,MUTAGEN:K->R: No change in sumoylation.,MUTAGEN:K->R: Reduced ubiquitination. No change in sumoylation nor on interaction with NAA10. No change in HIF1A protein turnover rate but increased transcriptional activity; when associated with R-377; R-391 and R-477. Complete loss of ubiquitination, but no change in VHL binding; when associated with K-538 and K-547.,MUTAGEN:K->T: Dramatic reduction of accumulation in the nucleus in response to hypoxia.,MUTAGEN:L->A: Abolishes VHLE3-dependent ubiquitination; when associated with A-397.,MUTAGEN:L->A: Abolishes VHLE3-dependent ubiquitination; when associated with A-400.,MUTAGEN:L->A: Inhibits interaction with EP300 and transactivation activity.,MUTAGEN:N->A: Recruits CREBBP. No enhancement of CREBBP by Clioquinol in the presence of FIH1. No change in nuclear location nor on repression of transcriptional activity in the presence of histone deacetylase inhibitor.,MUTAGEN:P->A: Abolishes in VHLE3-dependent ubiquitination, abolishes oxygen-dependent regulation of VP16, partially reduced VHLE target site ubiquitination and no interaction with VHL. No VHLE target site ubiquitination; when associated with G-564. Increases HIF1A instability and reduces HIF1A-induced target gene transcriptional activation; when associated with A-564.,MUTAGEN:P->A: Increases HIF1A instability and reduces HIF1A-induced target gene transcriptional activation; when associated with A-402.,MUTAGEN:P->A: No change in VHLE3-dependent ubiquitination.,MUTAGEN:P->G: No change in VHL-dependent ubiquitination. Partially reduced VHLE target site ubiquitination. No VHLE target site ubiquitination; when associated with A-402.,MUTAGEN:R->K: Strongly reduced GlcNAcylation by E.coli NleB1.,MUTAGEN:S->A: Constitutive kinase activity.,MUTAGEN:S->A: Induces stabilization of the protein.,MUTAGEN:S->D: Impaired kinase activity.,MUTAGEN:S->G: Constitutive expression under nonhypoxic conditions by decreasing ubiquitination.,MUTAGEN:T->A: Constitutive expression under nonhypoxic conditions by decreasing ubiquitination.,REGION:C-terminal VHL recognition site,REGION:CTAD,REGION:DNA-binding,REGION:Disordered,REGION:ID,REGION:Interaction with TSGA10,REGION:N-terminal VHL recognition site,REGION:NTAD,REGION:ODD,REGION:Required for heterodimer formation with ARNT,
HYOU1	hypoxia up-regulated 1(HYOU1)	Homo sapiens				GO:0002931~response to ischemia,GO:0006888~ER to Golgi vesicle-mediated transport,GO:0006898~receptor-mediated endocytosis,GO:0034976~response to endoplasmic reticulum stress,GO:0036498~IRE1-mediated unfolded protein response,GO:0071456~cellular response to hypoxia,GO:1903298~negative regulation of hypoxia-induced intrinsic apoptotic signaling pathway,GO:1903382~negative regulation of endoplasmic reticulum stress-induced neuron intrinsic apoptotic signaling pathway,	GO:0005576~extracellular region,GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0005790~smooth endoplasmic reticulum,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0034663~endoplasmic reticulum chaperone complex,GO:0070062~extracellular exosome,GO:0071682~endocytic vesicle lumen,	GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0051082~unfolded protein binding,GO:0051087~chaperone binding,	IPR013126:Heat shock protein 70 family,IPR018181:Heat shock protein 70, conserved site,	hsa04141:Protein processing in endoplasmic reticulum,	233600~Immunodeficiency 59 and hypoglycemia,			KW-0346~Stress response,	KW-0256~Endoplasmic reticulum,	KW-0225~Disease variant,	KW-0732~Signal,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0143~Chaperone,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,MOTIF:Prevents secretion from ER,REGION:Disordered,
IER3	immediate early response 3(IER3)	Homo sapiens				GO:0006915~apoptotic process,GO:0009653~anatomical structure morphogenesis,GO:0014066~regulation of phosphatidylinositol 3-kinase signaling,GO:0043066~negative regulation of apoptotic process,GO:2001020~regulation of response to DNA damage stimulus,	GO:0005634~nucleus,GO:0005829~cytosol,GO:0016021~integral component of membrane,	GO:0005515~protein binding,	IPR024829:Radiation-inducible immediate-early gene IEX-1,						KW-0472~Membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
IGHMBP2	immunoglobulin mu DNA binding protein 2(IGHMBP2)	Homo sapiens				GO:0006260~DNA replication,GO:0006281~DNA repair,GO:0006310~DNA recombination,GO:0006412~translation,GO:0032508~DNA duplex unwinding,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016020~membrane,GO:0016604~nuclear body,GO:0030424~axon,GO:0030426~growth cone,GO:1990904~ribonucleoprotein complex,	GO:0000049~tRNA binding,GO:0003676~nucleic acid binding,GO:0003677~DNA binding,GO:0003678~DNA helicase activity,GO:0003697~single-stranded DNA binding,GO:0003723~RNA binding,GO:0003727~single-stranded RNA binding,GO:0004386~helicase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008094~DNA-dependent ATPase activity,GO:0008134~transcription factor binding,GO:0008186~RNA-dependent ATPase activity,GO:0008270~zinc ion binding,GO:0016887~ATPase activity,GO:0032574~5'-3' RNA helicase activity,GO:0036121~double-stranded DNA-dependent ATP-dependent DNA helicase activity,GO:0042802~identical protein binding,GO:0043022~ribosome binding,GO:0043139~5'-3' DNA helicase activity,	IPR000058:Zinc finger, AN1-type,IPR001374:Single-stranded nucleic acid binding R3H,IPR003593:AAA+ ATPase domain,IPR004483:DNA helicase, putative,IPR014001:Helicase, superfamily 1/2, ATP-binding domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,		604320~Neuronopathy, distal hereditary motor, type VI,616155~Charcot-Marie-Tooth disease, axonal, type 2S,		SM00154:ZnF_AN1,SM00382:AAA,SM00393:R3H,SM00487:DEXDc,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,	KW-0144~Charcot-Marie-Tooth disease,KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0622~Neuropathy,	KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0067~ATP-binding,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0238~DNA-binding,KW-0347~Helicase,KW-0378~Hydrolase,KW-0687~Ribonucleoprotein,KW-0694~RNA-binding,KW-0820~tRNA-binding,	KW-0007~Acetylation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:AAA,DOMAIN:AAA_11,DOMAIN:Helicase ATP-binding,DOMAIN:R3H,METAL:Zinc 1,METAL:Zinc 2,MOTIF:Nuclear localization signal,NP_BIND:ATP,REGION:Disordered,REGION:SS DNA-binding,ZN_FING:AN1-type,
IPO13	importin 13(IPO13)	Homo sapiens				GO:0006606~protein import into nucleus,GO:0006886~intracellular protein transport,	GO:0005634~nucleus,GO:0005737~cytoplasm,	GO:0005515~protein binding,GO:0031267~small GTPase binding,	IPR001494:Importin-beta, N-terminal,IPR011989:Armadillo-like helical,IPR013598:Exportin-1/Importin-beta-like,IPR016024:Armadillo-type fold,	hsa03013:Nucleocytoplasmic transport,			SM00913:SM00913,	KW-0653~Protein transport,KW-0813~Transport,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,				DOMAIN:Importin N-terminal,REGION:Disordered,REPEAT:HEAT 1,REPEAT:HEAT 10,REPEAT:HEAT 11,REPEAT:HEAT 12,REPEAT:HEAT 13,REPEAT:HEAT 14,REPEAT:HEAT 15,REPEAT:HEAT 16,REPEAT:HEAT 17,REPEAT:HEAT 18,REPEAT:HEAT 19,REPEAT:HEAT 2,REPEAT:HEAT 20,REPEAT:HEAT 3,REPEAT:HEAT 4,REPEAT:HEAT 5,REPEAT:HEAT 6,REPEAT:HEAT 7,REPEAT:HEAT 8,REPEAT:HEAT 9,
ID2	inhibitor of DNA binding 2(ID2)	Homo sapiens	71.Id_proteins_G0-to-S_cell_cycle,			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0003166~bundle of His development,GO:0007507~heart development,GO:0007623~circadian rhythm,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0019216~regulation of lipid metabolic process,GO:0021772~olfactory bulb development,GO:0030154~cell differentiation,GO:0032922~circadian regulation of gene expression,GO:0033598~mammary gland epithelial cell proliferation,GO:0042752~regulation of circadian rhythm,GO:0043153~entrainment of circadian clock by photoperiod,GO:0043353~enucleate erythrocyte differentiation,GO:0043433~negative regulation of sequence-specific DNA binding transcription factor activity,GO:0045475~locomotor rhythm,GO:0045578~negative regulation of B cell differentiation,GO:0045600~positive regulation of fat cell differentiation,GO:0045651~positive regulation of macrophage differentiation,GO:0045664~regulation of neuron differentiation,GO:0045777~positive regulation of blood pressure,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0048557~embryonic digestive tract morphogenesis,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0048663~neuron fate commitment,GO:0048711~positive regulation of astrocyte differentiation,GO:0051148~negative regulation of muscle cell differentiation,GO:0060749~mammary gland alveolus development,GO:0061030~epithelial cell differentiation involved in mammary gland alveolus development,GO:0061031~endodermal digestive tract morphogenesis,GO:0071158~positive regulation of cell cycle arrest,GO:0071931~positive regulation of transcription involved in G1/S transition of mitotic cell cycle,GO:0090398~cellular senescence,GO:2000045~regulation of G1/S transition of mitotic cell cycle,GO:2000177~regulation of neural precursor cell proliferation,	GO:0000791~euchromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0032991~macromolecular complex,	GO:0001102~RNA polymerase II activating transcription factor binding,GO:0005515~protein binding,GO:0044325~ion channel binding,GO:0046983~protein dimerization activity,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,	IPR011598:Myc-type, basic helix-loop-helix (bHLH) domain,IPR026052:DNA-binding protein inhibitor,	hsa04350:TGF-beta signaling pathway,hsa04390:Hippo signaling pathway,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa05202:Transcriptional misregulation in cancer,			SM00353:HLH,	KW-0090~Biological rhythms,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0217~Developmental protein,KW-0678~Repressor,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	DOMAIN:BHLH,DOMAIN:bHLH,MOTIF:Nuclear export signal,
IKBKB	inhibitor of nuclear factor kappa B kinase subunit beta(IKBKB)	Homo sapiens		h_41BBPathway:The 4-1BB-dependent immune response,h_aktPathway:AKT Signaling Pathway,h_cd40Pathway:CD40L Signaling Pathway,h_il1rPathway:Signal transduction through IL1R,h_keratinocytePathway:Keratinocyte Differentiation,h_mapkPathway:MAPKinase Signaling Pathway,h_nfkbPathway:NF-kB Signaling Pathway,h_nthiPathway:NFkB activation by Nontypeable Hemophilus influenzae,h_raccycdPathway:Influence of Ras and Rho proteins on G1 to S Transition,h_relaPathway:Acetylation and Deacetylation of RelA in The Nucleus,h_stressPathway:TNF/Stress Related Signaling,h_tidPathway:Chaperones modulate interferon Signaling Pathway,h_tnfr2Pathway:TNFR2 Signaling Pathway,h_tollPathway:Toll-Like Receptor Pathway,		GO:0002223~stimulatory C-type lectin receptor signaling pathway,GO:0002479~antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent,GO:0002756~MyD88-independent toll-like receptor signaling pathway,GO:0006468~protein phosphorylation,GO:0006954~inflammatory response,GO:0007249~I-kappaB kinase/NF-kappaB signaling,GO:0007252~I-kappaB phosphorylation,GO:0009615~response to virus,GO:0010803~regulation of tumor necrosis factor-mediated signaling pathway,GO:0016032~viral process,GO:0018105~peptidyl-serine phosphorylation,GO:0030866~cortical actin cytoskeleton organization,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0035509~negative regulation of myosin-light-chain-phosphatase activity,GO:0035666~TRIF-dependent toll-like receptor signaling pathway,GO:0038095~Fc-epsilon receptor signaling pathway,GO:0042325~regulation of phosphorylation,GO:0043066~negative regulation of apoptotic process,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0045087~innate immune response,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050852~T cell receptor signaling pathway,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051403~stress-activated MAPK cascade,GO:0070498~interleukin-1-mediated signaling pathway,GO:0071356~cellular response to tumor necrosis factor,GO:0072659~protein localization to plasma membrane,GO:1903140~regulation of establishment of endothelial barrier,GO:1903347~negative regulation of bicellular tight junction assembly,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0008385~IkappaB kinase complex,GO:0009898~cytoplasmic side of plasma membrane,GO:0035631~CD40 receptor complex,GO:0045121~membrane raft,	GO:0000166~nucleotide binding,GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008384~IkappaB kinase activity,GO:0019901~protein kinase binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0046982~protein heterodimerization activity,GO:0097110~scaffold protein binding,GO:1990459~transferrin receptor binding,	IPR000626:Ubiquitin,IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR022007:I-kappa-kinase-beta NEMO binding domain,	hsa01523:Antifolate resistance,hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04062:Chemokine signaling pathway,hsa04064:NF-kappa B signaling pathway,hsa04068:FoxO signaling pathway,hsa04150:mTOR signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04210:Apoptosis,hsa04380:Osteoclast differentiation,hsa04620:Toll-like receptor signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04622:RIG-I-like receptor signaling pathway,hsa04623:Cytosolic DNA-sensing pathway,hsa04625:C-type lectin receptor signaling pathway,hsa04657:IL-17 signaling pathway,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04660:T cell receptor signaling pathway,hsa04662:B cell receptor signaling pathway,hsa04668:TNF signaling pathway,hsa04722:Neurotrophin signaling pathway,hsa04910:Insulin signaling pathway,hsa04920:Adipocytokine signaling pathway,hsa04930:Type II diabetes mellitus,hsa04931:Insulin resistance,hsa04932:Non-alcoholic fatty liver disease,hsa04936:Alcoholic liver disease,hsa05010:Alzheimer disease,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05135:Yersinia infection,hsa05142:Chagas disease,hsa05145:Toxoplasmosis,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,hsa05206:MicroRNAs in cancer,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05212:Pancreatic cancer,hsa05215:Prostate cancer,hsa05220:Chronic myeloid leukemia,hsa05221:Acute myeloid leukemia,hsa05222:Small cell lung cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,	615592~Immunodeficiency 15B,618204~Immunodeficiency 15A,		SM00220:S_TKc,SM01239:SM01239,	KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0705~SCID,	KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0379~Hydroxylation,KW-0597~Phosphoprotein,KW-0702~S-nitrosylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Proton acceptor,BINDING:ATP,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:IKKbetaNEMObind,DOMAIN:Protein kinase,DOMAIN:Ubiquitin-like,MUTAGEN:D->A: Loss of protein kinase activity.,MUTAGEN:K->A: Loss of kinase activity and no effect on binding to NIK.,MUTAGEN:K->E: Increased activation of NF-kappa-B signaling.,MUTAGEN:K->R: Monoubiquitinated; when associated with E-177 and E-181.,MUTAGEN:Missing: Loss of activation of NF-kappa-B signaling.,MUTAGEN:P->A: Loss of hypoxic inducibility.,MUTAGEN:S->A: Decrease of activity.,MUTAGEN:S->E: Full activation. Interaction with TRIM21 is enhanced; when associated with E-177. Monoubiquitinated; when associated with R-163 and E-177. Strongly promoted NF-kappa-B gene expression; when associated with E-177.,MUTAGEN:S->E: Full activation. Interaction with TRIM21 is enhanced; when associated with E-181. Monoubiquitinated; when associated with R-163 and E-181. Strongly promoted NF-kappa-B gene expression; when associated with E-181.,MUTAGEN:SLCTS->ALCTA: COmplete loss of TBK1-mediated phosphorylation.,NP_BIND:ATP,REGION:Disordered,REGION:Leucine-zipper,REGION:NEMO-binding,
IKBKE	inhibitor of nuclear factor kappa B kinase subunit epsilon(IKBKE)	Homo sapiens				GO:0000187~activation of MAPK activity,GO:0006468~protein phosphorylation,GO:0006955~immune response,GO:0007252~I-kappaB phosphorylation,GO:0008630~intrinsic apoptotic signaling pathway in response to DNA damage,GO:0010467~gene expression,GO:0010884~positive regulation of lipid storage,GO:0016032~viral process,GO:0018105~peptidyl-serine phosphorylation,GO:0032480~negative regulation of type I interferon production,GO:0034340~response to type I interferon,GO:0035456~response to interferon-beta,GO:0035666~TRIF-dependent toll-like receptor signaling pathway,GO:0038061~NIK/NF-kappaB signaling,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043254~regulation of protein complex assembly,GO:0048255~mRNA stabilization,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0060340~positive regulation of type I interferon-mediated signaling pathway,GO:0097400~interleukin-17-mediated signaling pathway,GO:0098586~cellular response to virus,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016605~PML body,GO:0031966~mitochondrial membrane,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004704~NF-kappaB-inducing kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008384~IkappaB kinase activity,GO:0019903~protein phosphatase binding,GO:0031625~ubiquitin protein ligase binding,GO:0036435~K48-linked polyubiquitin binding,GO:0042802~identical protein binding,	IPR000719:Protein kinase, catalytic domain,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,	hsa04620:Toll-like receptor signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04622:RIG-I-like receptor signaling pathway,hsa04623:Cytosolic DNA-sensing pathway,hsa04625:C-type lectin receptor signaling pathway,hsa04657:IL-17 signaling pathway,hsa04936:Alcoholic liver disease,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05171:Coronavirus disease - COVID-19,hsa05207:Chemical carcinogenesis - receptor activation,hsa05417:Lipid and atherosclerosis,			SM00220:S_TKc,	KW-0227~DNA damage,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Proton acceptor,BINDING:ATP,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:Protein kinase,MUTAGEN:E->A: Slight decrease of kinase activity.,MUTAGEN:K->A: Loss of kinase activity and loss of nuclear import.,MUTAGEN:K->A: Loss of ubiquitination and decreased kinase activity. No effect on homodimerization.,MUTAGEN:K->A: No effect on ubiquitination.,MUTAGEN:K->R: Loss of sumoylation and loss of targeting to nuclear bodies.,MUTAGEN:K->R: Loss of ubiquitination and decreased kinase activity. Decreases interaction with IKBKB, IKBKG and MYD88. No effect on homodimerization.,MUTAGEN:K->R: No effect on ubiquitination.,MUTAGEN:S->A: Loss of autophosphorylation and of kinase activity.,MUTAGEN:S->E: Decrease in kinase activity.,NP_BIND:ATP,REGION:Interaction with DDX3X,REGION:Leucine-zipper,
INPP1	inositol polyphosphate-1-phosphatase(INPP1)	Homo sapiens				GO:0006796~phosphate-containing compound metabolic process,GO:0007165~signal transduction,GO:0043647~inositol phosphate metabolic process,GO:0046854~phosphatidylinositol phosphorylation,GO:0046855~inositol phosphate dephosphorylation,	GO:0005829~cytosol,	GO:0004441~inositol-1,4-bisphosphate 1-phosphatase activity,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR000760:Inositol monophosphatase,IPR020550:Inositol monophosphatase, conserved site,IPR020583:Inositol monophosphatase, metal-binding site,	hsa00562:Inositol phosphate metabolism,hsa01100:Metabolic pathways,hsa04070:Phosphatidylinositol signaling system,								KW-0452~Lithium,KW-0460~Magnesium,KW-0479~Metal-binding,	KW-0378~Hydrolase,	KW-0597~Phosphoprotein,	BINDING:Substrate,METAL:Magnesium 1,METAL:Magnesium 1; via carbonyl oxygen,METAL:Magnesium 2,REGION:Substrate binding,
INPP4B	inositol polyphosphate-4-phosphatase type II B(INPP4B)	Homo sapiens				GO:0006661~phosphatidylinositol biosynthetic process,GO:0007165~signal transduction,GO:0036092~phosphatidylinositol-3-phosphate biosynthetic process,GO:0043647~inositol phosphate metabolic process,GO:0046855~inositol phosphate dephosphorylation,GO:0046856~phosphatidylinositol dephosphorylation,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016021~integral component of membrane,	GO:0005515~protein binding,GO:0016316~phosphatidylinositol-3,4-bisphosphate 4-phosphatase activity,GO:0017161~inositol-1,3,4-trisphosphate 4-phosphatase activity,GO:0034597~phosphatidylinositol-4,5-bisphosphate 4-phosphatase activity,GO:0052828~inositol-3,4-bisphosphate 4-phosphatase activity,		hsa00562:Inositol phosphate metabolism,hsa01100:Metabolic pathways,hsa04070:Phosphatidylinositol signaling system,				KW-0443~Lipid metabolism,	KW-0472~Membrane,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,		COMPBIAS:Polar residues,DOMAIN:C2,MUTAGEN:C->S: Abolished phosphotyrosine phosphatase activity.,MUTAGEN:D->E: Significantly reduces phosphotyrosine phosphatase activity. Not able to dephosphorylate phosphatidylinositol(3,4)P2 but retains approximately 35% of activity towards Inosotol(1,3,4)P3.,MUTAGEN:K->M: Does not alter phosphotyrosine phosphatase activity. Abolished lipid phosphatase activity.,MUTAGEN:K->M: Increased phosphotyrosine phosphatase activity. Does not alter lipid phosphatase activity for the substrate phosphatidylinositol(3,4)P2, but reduced hydrolysis of inositol(1,3,4)P3 by about 70%.,REGION:Disordered,TRANSMEM:Helical,
IDE	insulin degrading enzyme(IDE)	Homo sapiens			Posttranslational modification, protein turnover, chaperones,	GO:0006508~proteolysis,GO:0008104~protein localization,GO:0008286~insulin receptor signaling pathway,GO:0008340~determination of adult lifespan,GO:0010815~bradykinin catabolic process,GO:0010992~ubiquitin homeostasis,GO:0019885~antigen processing and presentation of endogenous peptide antigen via MHC class I,GO:0030163~protein catabolic process,GO:0032092~positive regulation of protein binding,GO:0042447~hormone catabolic process,GO:0043171~peptide catabolic process,GO:0044257~cellular protein catabolic process,GO:0045732~positive regulation of protein catabolic process,GO:0045861~negative regulation of proteolysis,GO:0046718~viral entry into host cell,GO:0050435~beta-amyloid metabolic process,GO:0051603~proteolysis involved in cellular protein catabolic process,GO:0097242~beta-amyloid clearance,GO:1901142~insulin metabolic process,GO:1901143~insulin catabolic process,GO:1903715~regulation of aerobic respiration,	GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005777~peroxisome,GO:0005782~peroxisomal matrix,GO:0005829~cytosol,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016323~basolateral plasma membrane,GO:0031597~cytosolic proteasome complex,GO:0070062~extracellular exosome,	GO:0001540~beta-amyloid binding,GO:0001618~virus receptor activity,GO:0004175~endopeptidase activity,GO:0004222~metalloendopeptidase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008237~metallopeptidase activity,GO:0008270~zinc ion binding,GO:0016887~ATPase activity,GO:0031626~beta-endorphin binding,GO:0042277~peptide binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0043559~insulin binding,GO:0044877~macromolecular complex binding,GO:0046872~metal ion binding,	IPR001431:Peptidase M16, zinc-binding site,IPR007863:Peptidase M16, C-terminal domain,IPR011249:Metalloenzyme, LuxS/M16 peptidase-like,IPR011765:Peptidase M16, N-terminal,	hsa05010:Alzheimer disease,				KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-0964~Secreted,KW-1003~Cell membrane,			KW-0067~ATP-binding,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0862~Zinc,	KW-0021~Allosteric enzyme,KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,KW-0675~Receptor,KW-1183~Host cell receptor for virus entry,		ACT_SITE:Proton acceptor,BINDING:ATP,DOMAIN:Peptidase_M16,DOMAIN:Peptidase_M16_C,DOMAIN:Peptidase_M16_M,METAL:Zinc,MOTIF:SlyX motif,MUTAGEN:D->C: Increases catalytic rate towards INS and amyloid; when associated with C-899.,MUTAGEN:E->C: Increases catalytic rate towards INS and amyloid; when associated with C-132.,MUTAGEN:E->Q: Loss of catalytic activity.,MUTAGEN:F->A: Strongly increased enzyme activity.,MUTAGEN:GARG->AARA: Reduced enzyme activity.,MUTAGEN:K->C: Increases catalytic rate towards INS and amyloid; when associated with C-426.,MUTAGEN:N->C: Increases catalytic rate towards INS and amyloid; when associated with C-828.,MUTAGEN:P->G: Reduced enzyme activity.,MUTAGEN:Q->C: Increases catalytic rate towards INS and amyloid; when associated with C-184.,MUTAGEN:R->A: Decreases dimerization. No effect on degradation of ANP. Retains the ability to degrade an aberrant form of ANP, when in the presence of both ANP and the aberrant ANP.,MUTAGEN:S->C: Increases catalytic rate towards INS and amyloid; when associated with C-817.,MUTAGEN:Y->A: Strongly reduced enzyme activity.,MUTAGEN:Y->F: No effect on catalytic activity.,NP_BIND:ATP,REGION:Substrate binding,REGION:Substrate binding exosite,
INSIG1	insulin induced gene 1(INSIG1)	Homo sapiens				GO:0006641~triglyceride metabolic process,GO:0006695~cholesterol biosynthetic process,GO:0006991~response to sterol depletion,GO:0008203~cholesterol metabolic process,GO:0010894~negative regulation of steroid biosynthetic process,GO:0016126~sterol biosynthetic process,GO:0032869~cellular response to insulin stimulus,GO:0032933~SREBP signaling pathway,GO:0036315~cellular response to sterol,GO:0036316~SREBP-SCAP complex retention in endoplasmic reticulum,GO:0042472~inner ear morphogenesis,GO:0042474~middle ear morphogenesis,GO:0042632~cholesterol homeostasis,GO:0045599~negative regulation of fat cell differentiation,GO:0045717~negative regulation of fatty acid biosynthetic process,GO:0060021~palate development,GO:0060363~cranial suture morphogenesis,GO:0070862~negative regulation of protein exit from endoplasmic reticulum,GO:1901303~negative regulation of cargo loading into COPII-coated vesicle,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016021~integral component of membrane,GO:0032937~SREBP-SCAP-Insig complex,	GO:0005515~protein binding,GO:0008142~oxysterol binding,GO:0008289~lipid binding,	IPR009904:Insulin-induced protein,IPR025929:Insulin-induced protein family,					KW-0153~Cholesterol metabolism,KW-0443~Lipid metabolism,KW-0753~Steroid metabolism,KW-1207~Sterol metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0446~Lipid-binding,		KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),MOTIF:KxHxx,MUTAGEN:D->A: Loss of ability to suppress the cleavage of SREBP2 and to accelerate the degradation of HMGCR.,MUTAGEN:K->R: Loss of ubiquitination and degradation.,MUTAGEN:S->A: Abolished phosphorylation by PCK1, does not affect oxysterol-binding, does not affect the interaction with SCAP.,MUTAGEN:S->E: Phosphomimetic mutant, reduced binding to oxysterol.,REGION:Disordered,SITE:Required for the recognition of 25-hydroxycholesterol,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,
IGF1R	insulin like growth factor 1 receptor(IGF1R)	Homo sapiens		h_badPathway:Regulation of BAD phosphorylation,h_erkPathway:Erk1/Erk2 Mapk Signaling pathway,h_hdacPathway:Control of skeletal myogenesis by HDAC & calcium/calmodulin-dependent kinase (CaMK),h_igf1mtorPathway:Skeletal muscle hypertrophy is regulated via AKT/mTOR pathway,h_igf1Pathway:IGF-1 Signaling Pathway,h_igf1rPathway:Multiple antiapoptotic pathways from IGF-1R signaling lead to BAD phosphorylation,h_longevityPathway:The IGF-1 Receptor and Longevity,h_telPathway:Telomeres, Telomerase, Cellular Aging, and  Immortality,		GO:0003230~cardiac atrium development,GO:0006955~immune response,GO:0007165~signal transduction,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007275~multicellular organism development,GO:0007409~axonogenesis,GO:0008284~positive regulation of cell proliferation,GO:0008286~insulin receptor signaling pathway,GO:0010656~negative regulation of muscle cell apoptotic process,GO:0014065~phosphatidylinositol 3-kinase signaling,GO:0014068~positive regulation of phosphatidylinositol 3-kinase signaling,GO:0016032~viral process,GO:0021549~cerebellum development,GO:0021766~hippocampus development,GO:0030010~establishment of cell polarity,GO:0030335~positive regulation of cell migration,GO:0032467~positive regulation of cytokinesis,GO:0033197~response to vitamin E,GO:0033674~positive regulation of kinase activity,GO:0033690~positive regulation of osteoblast proliferation,GO:0035094~response to nicotine,GO:0038083~peptidyl-tyrosine autophosphorylation,GO:0042593~glucose homeostasis,GO:0043066~negative regulation of apoptotic process,GO:0043243~positive regulation of protein complex disassembly,GO:0043409~negative regulation of MAPK cascade,GO:0043410~positive regulation of MAPK cascade,GO:0044849~estrous cycle,GO:0045056~transcytosis,GO:0045471~response to ethanol,GO:0046328~regulation of JNK cascade,GO:0046777~protein autophosphorylation,GO:0048009~insulin-like growth factor receptor signaling pathway,GO:0048015~phosphatidylinositol-mediated signaling,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0048680~positive regulation of axon regeneration,GO:0051054~positive regulation of DNA metabolic process,GO:0051389~inactivation of MAPKK activity,GO:0051897~positive regulation of protein kinase B signaling,GO:0071260~cellular response to mechanical stimulus,GO:0071333~cellular response to glucose stimulus,GO:0071392~cellular response to estradiol stimulus,GO:0071393~cellular response to progesterone stimulus,GO:0071394~cellular response to testosterone stimulus,GO:0071549~cellular response to dexamethasone stimulus,GO:0071560~cellular response to transforming growth factor beta stimulus,GO:0090031~positive regulation of steroid hormone biosynthetic process,GO:0090398~cellular senescence,GO:0097062~dendritic spine maintenance,GO:0097242~beta-amyloid clearance,GO:1902065~response to L-glutamate,GO:1903944~negative regulation of hepatocyte apoptotic process,GO:1904045~cellular response to aldosterone,GO:1904193~negative regulation of cholangiocyte apoptotic process,GO:1904385~cellular response to angiotensin,GO:1904646~cellular response to beta-amyloid,GO:1990314~cellular response to insulin-like growth factor stimulus,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005899~insulin receptor complex,GO:0005901~caveola,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030315~T-tubule,GO:0030424~axon,GO:0035867~alphav-beta3 integrin-IGF-1-IGF1R complex,GO:0043025~neuronal cell body,GO:0043231~intracellular membrane-bounded organelle,GO:0043235~receptor complex,GO:1902911~protein kinase complex,	GO:0001965~G-protein alpha-subunit binding,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0005009~insulin-activated receptor activity,GO:0005010~insulin-like growth factor-activated receptor activity,GO:0005158~insulin receptor binding,GO:0005198~structural molecule activity,GO:0005515~protein binding,GO:0005520~insulin-like growth factor binding,GO:0005524~ATP binding,GO:0031994~insulin-like growth factor I binding,GO:0042802~identical protein binding,GO:0043548~phosphatidylinositol 3-kinase binding,GO:0043559~insulin binding,GO:0043560~insulin receptor substrate binding,	IPR000494:EGF receptor, L domain,IPR000719:Protein kinase, catalytic domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR002011:Tyrosine-protein kinase, receptor class II, conserved site,IPR003961:Fibronectin, type III,IPR006211:Furin-like cysteine-rich domain,IPR006212:Furin-like repeat,IPR008266:Tyrosine-protein kinase, active site,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR011009:Protein kinase-like domain,IPR013783:Immunoglobulin-like fold,IPR016246:Tyrosine-protein kinase, insulin-like receptor,IPR017441:Protein kinase, ATP binding site,IPR020635:Tyrosine-protein kinase, catalytic domain,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa01522:Endocrine resistance,hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04068:FoxO signaling pathway,hsa04114:Oocyte meiosis,hsa04140:Autophagy - animal,hsa04144:Endocytosis,hsa04150:mTOR signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04152:AMPK signaling pathway,hsa04211:Longevity regulating pathway,hsa04213:Longevity regulating pathway - multiple species,hsa04510:Focal adhesion,hsa04520:Adherens junction,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04730:Long-term depression,hsa04913:Ovarian steroidogenesis,hsa04914:Progesterone-mediated oocyte maturation,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05205:Proteoglycans in cancer,hsa05214:Glioma,hsa05215:Prostate cancer,hsa05218:Melanoma,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,	270450~Insulin-like growth factor I, resistance to,	PIRSF000620:insulin receptor,	SM00060:FN3,SM00219:TyrKc,SM00261:FU,	KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0675~Receptor,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	ACT_SITE:Proton acceptor,BINDING:ATP,CARBOHYD:N-linked (GlcNAc...) asparagine,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:Fibronectin type-III,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,DOMAIN:Fibronectin type-III 3,DOMAIN:Fibronectin type-III 4,DOMAIN:Furin-like,DOMAIN:Protein kinase,DOMAIN:Recep_L_domain,MOTIF:IRS1- and SHC1-binding,MUTAGEN:K->A: Kinase inactive. Abolishes tyrosine phosphorylation and abolishes interaction with IRS1, SHC1 and PIK3R1.,MUTAGEN:Y->F: Loss of GRB10-binding.,MUTAGEN:Y->F: No effect on GRB10-binding.,MUTAGEN:Y->F: Reduces tyrosine phosphorylation. Abolishes interaction with IRS1 and SHC1. Does not abolish interaction with PIK3R1, nor with GRB10.,NP_BIND:ATP,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
IGF2BP2	insulin like growth factor 2 mRNA binding protein 2(IGF2BP2)	Homo sapiens				GO:0001817~regulation of cytokine production,GO:0007399~nervous system development,GO:0009653~anatomical structure morphogenesis,GO:0010468~regulation of gene expression,GO:0017148~negative regulation of translation,GO:0043488~regulation of mRNA stability,GO:0051028~mRNA transport,GO:0051252~regulation of RNA metabolic process,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0003730~mRNA 3'-UTR binding,GO:0005515~protein binding,GO:0045182~translation regulator activity,GO:0048027~mRNA 5'-UTR binding,	IPR000504:RNA recognition motif domain,IPR004087:K Homology domain,IPR004088:K Homology domain, type 1,IPR012677:Nucleotide-binding, alpha-beta plait,		125853~Diabetes mellitus, noninsulin-dependent, susceptibility to,		SM00322:KH,SM00360:RRM,	KW-0509~mRNA transport,KW-0810~Translation regulation,KW-0813~Transport,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0677~Repeat,		KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:KH,DOMAIN:KH 1,DOMAIN:KH 2,DOMAIN:KH 3,DOMAIN:KH 4,DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,MUTAGEN:K->E: Significantly impaired binding to ACTB transcript, but little effect on MYC transcript binding, accumulation in the nucleus; when associated with E-211. Loss of homo- and heterooligomerization with IGF2BP1 and IGF2BP2, almost complete loss of ACTB and MYC transcript binding, almost complete loss of ELAVL1-, DHX9- and HNRNPU-binding and perturbed subcellular location, including accumulation in the nucleus and loss of localization to stress granules; when associated with E-211; 445-E-E-445 and 526-E-E-527.,MUTAGEN:K->E: Significantly impaired binding to ACTB transcript, but little effect on MYC transcript binding, accumulation in the nucleus; when associated with E-292. Loss of homo- and heterooligomerization with IGF2BP1 and IGF2BP2, almost complete loss of ACTB and MYC transcript binding, almost complete loss of ELAVL1-, DHX9- and HNRNPU-binding and perturbed subcellular location, including accumulation in the nucleus and loss of localization to stress granules; when associated with E-292; 445-E-E-446 and 526-E-E-527.,MUTAGEN:KG->EE: Significantly impaired binding to ACTB and MYC transcripts; when associated with 445-E-E-446. Loss of homo- and heterooligomerization with IGF2BP1 and IGF2BP2, almost complete loss of ACTB and MYC transcript binding, almost complete loss of ELAVL1-, DHX9- and HNRNPU-binding and perturbed subcellular location, including accumulation in the nucleus and loss of localization to stress granules; when associated with E-211; E-292 and 445-E-E-446.,MUTAGEN:KK->EE: Significantly impaired binding to ACTB and MYC transcripts; when associated with 527-E-E-528. Loss of homo- and heterooligomerization with IGF2BP1 and IGF2BP2, almost complete loss of ACTB and MYC transcript binding, almost complete loss of ELAVL1-, DHX9- and HNRNPU-binding and perturbed subcellular location, including accumulation in the nucleus and loss of localization to stress granules; when associated with E-211; E-292 and 527-E-E-528.,REGION:Disordered,
IGF2R	insulin like growth factor 2 receptor(IGF2R)	Homo sapiens				GO:0001889~liver development,GO:0006898~receptor-mediated endocytosis,GO:0007041~lysosomal transport,GO:0007165~signal transduction,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007283~spermatogenesis,GO:0009791~post-embryonic development,GO:0031100~animal organ regeneration,GO:0032526~response to retinoic acid,GO:0043065~positive regulation of apoptotic process,GO:0043312~neutrophil degranulation,GO:0044794~positive regulation by host of viral process,GO:0048009~insulin-like growth factor receptor signaling pathway,GO:0061024~membrane organization,GO:1904772~response to tetrachloromethane,	GO:0000139~Golgi membrane,GO:0005641~nuclear envelope lumen,GO:0005768~endosome,GO:0005769~early endosome,GO:0005770~late endosome,GO:0005794~Golgi apparatus,GO:0005802~trans-Golgi network,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005925~focal adhesion,GO:0009986~cell surface,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0030118~clathrin coat,GO:0030133~transport vesicle,GO:0030139~endocytic vesicle,GO:0030140~trans-Golgi network transport vesicle,GO:0030667~secretory granule membrane,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0032588~trans-Golgi network membrane,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0001965~G-protein alpha-subunit binding,GO:0001972~retinoic acid binding,GO:0005010~insulin-like growth factor-activated receptor activity,GO:0005515~protein binding,GO:0005520~insulin-like growth factor binding,GO:0005537~mannose binding,GO:0019899~enzyme binding,GO:0031995~insulin-like growth factor II binding,GO:0038023~signaling receptor activity,GO:0042802~identical protein binding,GO:0051219~phosphoprotein binding,GO:1905394~retromer complex binding,	IPR000479:Cation-independent mannose-6-phosphate receptor,IPR000562:Fibronectin, type II, collagen-binding,IPR009011:Mannose-6-phosphate receptor binding domain,IPR013806:Kringle-like fold,	hsa04142:Lysosome,hsa04144:Endocytosis,	114550~Hepatocellular carcinoma, somatic,		SM00059:FN2,	KW-0813~Transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0967~Endosome,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:Fibronectin type-II,DOMAIN:MRH,DOMAIN:MRH 1,DOMAIN:MRH 10,DOMAIN:MRH 11,DOMAIN:MRH 12,DOMAIN:MRH 14,DOMAIN:MRH 15,DOMAIN:MRH 2,DOMAIN:MRH 3,DOMAIN:MRH 4,DOMAIN:MRH 5,DOMAIN:MRH 6,DOMAIN:MRH 7,DOMAIN:MRH 8,DOMAIN:MRH 9,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
IGFBP3	insulin like growth factor binding protein 3(IGFBP3)	Homo sapiens		h_ghrelinPathway:Ghrelin: Regulation of Food Intake and Energy Homeostasis,h_p53hypoxiaPathway:Hypoxia and p53 in the Cardiovascular system,		GO:0001558~regulation of cell growth,GO:0001649~osteoblast differentiation,GO:0001933~negative regulation of protein phosphorylation,GO:0006468~protein phosphorylation,GO:0006915~apoptotic process,GO:0008285~negative regulation of cell proliferation,GO:0009968~negative regulation of signal transduction,GO:0010906~regulation of glucose metabolic process,GO:0014912~negative regulation of smooth muscle cell migration,GO:0042981~regulation of apoptotic process,GO:0043065~positive regulation of apoptotic process,GO:0043410~positive regulation of MAPK cascade,GO:0043567~regulation of insulin-like growth factor receptor signaling pathway,GO:0043568~positive regulation of insulin-like growth factor receptor signaling pathway,GO:0043687~post-translational protein modification,GO:0044267~cellular protein metabolic process,GO:0044342~type B pancreatic cell proliferation,GO:0045663~positive regulation of myoblast differentiation,GO:0048662~negative regulation of smooth muscle cell proliferation,GO:0050790~regulation of catalytic activity,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005788~endoplasmic reticulum lumen,GO:0016942~insulin-like growth factor binding protein complex,GO:0042567~insulin-like growth factor ternary complex,	GO:0001968~fibronectin binding,GO:0005515~protein binding,GO:0005520~insulin-like growth factor binding,GO:0008160~protein tyrosine phosphatase activator activity,GO:0031994~insulin-like growth factor I binding,GO:0031995~insulin-like growth factor II binding,GO:0046872~metal ion binding,	IPR000716:Thyroglobulin type-1,IPR000867:Insulin-like growth factor-binding protein, IGFBP,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR012211:Insulin-like growth factor binding protein 3,IPR017891:Insulin-like growth factor binding protein, N-terminal, Cys-rich conserved site,IPR022321:Insulin-like growth factor-binding protein family 1-6, chordata,	hsa04115:p53 signaling pathway,hsa04218:Cellular senescence,hsa04935:Growth hormone synthesis, secretion and action,hsa05202:Transcriptional misregulation in cancer,			SM00121:IB,SM00211:TY,	KW-0053~Apoptosis,	KW-0964~Secreted,		KW-0732~Signal,		KW-0340~Growth factor binding,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:IGFBP N-terminal,DOMAIN:Thyroglobulin type-1,REGION:Disordered,REGION:IGF-binding,
INTS3	integrator complex subunit 3(INTS3)	Homo sapiens				GO:0000724~double-strand break repair via homologous recombination,GO:0006281~DNA repair,GO:0006974~cellular response to DNA damage stimulus,GO:0010212~response to ionizing radiation,GO:0016180~snRNA processing,GO:0042795~snRNA transcription from RNA polymerase II promoter,GO:0044818~mitotic G2/M transition checkpoint,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0032039~integrator complex,GO:0035861~site of double-strand break,GO:0070876~SOSS complex,	GO:0005515~protein binding,	IPR019333:Integrator complex subunit 3,					KW-0227~DNA damage,KW-0234~DNA repair,	KW-0539~Nucleus,KW-0963~Cytoplasm,					KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
ITFG1	integrin alpha FG-GAP repeat containing 1(ITFG1)	Homo sapiens					GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0070062~extracellular exosome,		IPR013517:FG-GAP repeat,IPR024881:T-cell immunomodulatory protein,						KW-0472~Membrane,KW-0964~Secreted,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,REPEAT:FG-GAP; atypical,TRANSMEM:Helical,
ILK	integrin linked kinase(ILK)	Homo sapiens	66.Prot_Interac_w_integrin_domains,	h_ptenPathway:PTEN dependent cell cycle arrest and apoptosis,		GO:0000902~cell morphogenesis,GO:0001658~branching involved in ureteric bud morphogenesis,GO:0001934~positive regulation of protein phosphorylation,GO:0001954~positive regulation of cell-matrix adhesion,GO:0003151~outflow tract morphogenesis,GO:0006468~protein phosphorylation,GO:0006469~negative regulation of protein kinase activity,GO:0007050~cell cycle arrest,GO:0007160~cell-matrix adhesion,GO:0007229~integrin-mediated signaling pathway,GO:0007569~cell aging,GO:0008284~positive regulation of cell proliferation,GO:0009967~positive regulation of signal transduction,GO:0010667~negative regulation of cardiac muscle cell apoptotic process,GO:0010761~fibroblast migration,GO:0014912~negative regulation of smooth muscle cell migration,GO:0018105~peptidyl-serine phosphorylation,GO:0021675~nerve development,GO:0022011~myelination in peripheral nervous system,GO:0030030~cell projection organization,GO:0030335~positive regulation of cell migration,GO:0030513~positive regulation of BMP signaling pathway,GO:0032288~myelin assembly,GO:0032956~regulation of actin cytoskeleton organization,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0034329~cell junction assembly,GO:0034446~substrate adhesion-dependent cell spreading,GO:0042327~positive regulation of phosphorylation,GO:0043406~positive regulation of MAP kinase activity,GO:0043491~protein kinase B signaling,GO:0043524~negative regulation of neuron apoptotic process,GO:0045197~establishment or maintenance of epithelial cell apical/basal polarity,GO:0045663~positive regulation of myoblast differentiation,GO:0045669~positive regulation of osteoblast differentiation,GO:0045773~positive regulation of axon extension,GO:0045893~positive regulation of transcription, DNA-templated,GO:0048662~negative regulation of smooth muscle cell proliferation,GO:0048812~neuron projection morphogenesis,GO:0050775~positive regulation of dendrite morphogenesis,GO:0051897~positive regulation of protein kinase B signaling,GO:0070527~platelet aggregation,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:0097435~supramolecular fiber organization,GO:1900026~positive regulation of substrate adhesion-dependent cell spreading,GO:1901224~positive regulation of NIK/NF-kappaB signaling,GO:2000178~negative regulation of neural precursor cell proliferation,	GO:0001725~stress fiber,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0030017~sarcomere,GO:0030027~lamellipodium,GO:0032991~macromolecular complex,GO:0043025~neuronal cell body,GO:0043034~costamere,GO:0043195~terminal bouton,GO:0043198~dendritic shaft,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0017124~SH3 domain binding,GO:0019901~protein kinase binding,	IPR000719:Protein kinase, catalytic domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR002110:Ankyrin repeat,IPR011009:Protein kinase-like domain,IPR020683:Ankyrin repeat-containing domain,	hsa03320:PPAR signaling pathway,hsa04360:Axon guidance,hsa04510:Focal adhesion,hsa05100:Bacterial invasion of epithelial cells,hsa05131:Shigellosis,hsa05213:Endometrial cancer,			SM00248:ANK,		KW-0472~Membrane,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0040~ANK repeat,KW-0677~Repeat,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	BINDING:ATP,DOMAIN:Protein kinase,MUTAGEN:E->K: Inactivation of ILK.,MUTAGEN:H->D: Alters interaction with LIMS1.,NP_BIND:ATP,REGION:Interaction with LIMS1,REGION:PH-like; mediates interaction with TGFB1I1,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,REPEAT:ANK 5,
ITGAE	integrin subunit alpha E(ITGAE)	Homo sapiens				GO:0007155~cell adhesion,GO:0007160~cell-matrix adhesion,GO:0007229~integrin-mediated signaling pathway,GO:0030198~extracellular matrix organization,GO:0033627~cell adhesion mediated by integrin,GO:0098609~cell-cell adhesion,	GO:0005886~plasma membrane,GO:0008305~integrin complex,GO:0009897~external side of plasma membrane,GO:0016020~membrane,	GO:0005178~integrin binding,GO:0046872~metal ion binding,	IPR000413:Integrin alpha chain,IPR002035:von Willebrand factor, type A,IPR013517:FG-GAP repeat,IPR013519:Integrin alpha beta-propellor,IPR013649:Integrin alpha-2,IPR018184:Integrin alpha chain, C-terminal cytoplasmic region, conserved site,	hsa04810:Regulation of actin cytoskeleton,			SM00191:Int_alpha,SM00327:VWA,	KW-0130~Cell adhesion,	KW-0472~Membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0460~Magnesium,KW-0479~Metal-binding,	KW-0401~Integrin,KW-0675~Receptor,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,DOMAIN:Integrin_alpha2,DOMAIN:VWFA,MOTIF:GFFKR motif,MUTAGEN:D->A: Loss of E-cadherin binding.,MUTAGEN:F->A: Loss of E-cadherin binding.,REGION:Disordered,REGION:X-domain (extra domain),REPEAT:FG-GAP 1,REPEAT:FG-GAP 2,REPEAT:FG-GAP 3,REPEAT:FG-GAP 4,REPEAT:FG-GAP 5,REPEAT:FG-GAP 6,REPEAT:FG-GAP 7,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ITGB1BP1	integrin subunit beta 1 binding protein 1(ITGB1BP1)	Homo sapiens	66.Prot_Interac_w_integrin_domains,			GO:0002043~blood vessel endothelial cell proliferation involved in sprouting angiogenesis,GO:0006469~negative regulation of protein kinase activity,GO:0006933~negative regulation of cell adhesion involved in substrate-bound cell migration,GO:0007160~cell-matrix adhesion,GO:0007219~Notch signaling pathway,GO:0007229~integrin-mediated signaling pathway,GO:0008284~positive regulation of cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0010595~positive regulation of endothelial cell migration,GO:0010764~negative regulation of fibroblast migration,GO:0016477~cell migration,GO:0030154~cell differentiation,GO:0031214~biomineral tissue development,GO:0032091~negative regulation of protein binding,GO:0032148~activation of protein kinase B activity,GO:0033622~integrin activation,GO:0033628~regulation of cell adhesion mediated by integrin,GO:0035148~tube formation,GO:0035556~intracellular signal transduction,GO:0035924~cellular response to vascular endothelial growth factor stimulus,GO:0043087~regulation of GTPase activity,GO:0043113~receptor clustering,GO:0044344~cellular response to fibroblast growth factor stimulus,GO:0045747~positive regulation of Notch signaling pathway,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051451~myoblast migration,GO:0051496~positive regulation of stress fiber assembly,GO:0051781~positive regulation of cell division,GO:0051894~positive regulation of focal adhesion assembly,GO:0051895~negative regulation of focal adhesion assembly,GO:0051897~positive regulation of protein kinase B signaling,GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:0072659~protein localization to plasma membrane,GO:0090051~negative regulation of cell migration involved in sprouting angiogenesis,GO:0090314~positive regulation of protein targeting to membrane,GO:0090315~negative regulation of protein targeting to membrane,GO:0097746~regulation of blood vessel diameter,GO:1900025~negative regulation of substrate adhesion-dependent cell spreading,GO:2001044~regulation of integrin-mediated signaling pathway,	GO:0001726~ruffle,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016604~nuclear body,GO:0030027~lamellipodium,GO:0034451~centriolar satellite,GO:0048471~perinuclear region of cytoplasm,GO:0071944~cell periphery,	GO:0005092~GDP-dissociation inhibitor activity,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0019901~protein kinase binding,	IPR006020:Phosphotyrosine interaction domain,IPR011993:Pleckstrin homology-like domain,IPR019517:Integrin binding protein, ICAP-1,				SM00462:PTB,	KW-0037~Angiogenesis,KW-0091~Biomineralization,KW-0130~Cell adhesion,KW-0221~Differentiation,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0914~Notch signaling pathway,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,				KW-0401~Integrin,KW-0497~Mitogen,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:PID,MOTIF:Nuclear localization signal,MUTAGEN:C->D: Reduces KRIT1 and ITGB1 binding.,MUTAGEN:D->A: Abolishes KRIT1 binding; when associated with A-96.,MUTAGEN:I->A: Abolishes ITGB1 binding.,MUTAGEN:I->R: Reduces KRIT1 binding. No effect on ITGB1 binding.,MUTAGEN:KK->AA: Abolishes nuclear import and transcriptional activity.,MUTAGEN:L->A: Abolishes ITGB1 binding.,MUTAGEN:L->A: Reduces ITGB1 binding.,MUTAGEN:L->Q: No effect on ITGB1 binding.,MUTAGEN:LYLII->AYAA: Reduces KRIT1 and ITGB1 binding.,MUTAGEN:Q->A: Abolishes KRIT1 binding; when associated with A-93.,MUTAGEN:T->A: Stimulates cell spreading on fibronectin to a similar extent as inhibition of CaMKII.,MUTAGEN:T->D: Changes in cell spreading.,MUTAGEN:T->D: Strong defect in cell spreading.,MUTAGEN:Y->T: Abolishes ITGB1 binding.,REGION:Disordered,REGION:Interaction with ITGB1,REGION:Interaction with KRIT1,
ITGB5	integrin subunit beta 5(ITGB5)	Homo sapiens				GO:0002479~antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent,GO:0006936~muscle contraction,GO:0007155~cell adhesion,GO:0007160~cell-matrix adhesion,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0007229~integrin-mediated signaling pathway,GO:0016477~cell migration,GO:0030198~extracellular matrix organization,GO:0033627~cell adhesion mediated by integrin,GO:0035987~endodermal cell differentiation,GO:0043149~stress fiber assembly,GO:0046718~viral entry into host cell,GO:0090136~epithelial cell-cell adhesion,	GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0008305~integrin complex,GO:0009986~cell surface,GO:0030054~cell junction,GO:0034684~integrin alphav-beta5 complex,GO:0043235~receptor complex,GO:0045335~phagocytic vesicle,GO:0070062~extracellular exosome,	GO:0001618~virus receptor activity,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0038023~signaling receptor activity,	IPR002035:von Willebrand factor, type A,IPR002369:Integrin beta subunit, N-terminal,IPR012896:Integrin beta subunit, tail,IPR013111:EGF, extracellular,IPR014836:Integrin beta subunit, cytoplasmic domain,IPR015812:Integrin beta subunit,IPR016201:Plexin-like fold,IPR027067:Integrin beta-5 subunit,	hsa04145:Phagosome,hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04512:ECM-receptor interaction,hsa04810:Regulation of actin cytoskeleton,hsa05165:Human papillomavirus infection,hsa05205:Proteoglycans in cancer,hsa05410:Hypertrophic cardiomyopathy,hsa05412:Arrhythmogenic right ventricular cardiomyopathy,hsa05414:Dilated cardiomyopathy,		PIRSF002512:integrin, beta subunit,	SM00187:INB,SM00327:VWA,SM00423:PSI,SM01241:SM01241,SM01242:SM01242,	KW-0130~Cell adhesion,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0965~Cell junction,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0401~Integrin,KW-0675~Receptor,KW-1183~Host cell receptor for virus entry,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:INB,DOMAIN:Integrin_B_tail,DOMAIN:Integrin_b_cyt,DOMAIN:PSI,DOMAIN:VWFA,REGION:Cysteine-rich tandem repeats,REPEAT:I,REPEAT:II,REPEAT:III,REPEAT:IV,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ICAM1	intercellular adhesion molecule 1(ICAM1)	Homo sapiens	125.T_Cells_CNS-APCs,18.Cytokine_astocytes,55.Allergen_recognition_by_Th2_or_Th0_cell,58.(CD40L)_immnosurveillance,60.IL-15_rheumatoid-arthritis_synovitis,8.MonocytesIFNF_IL4,81.Structure_of_Caps_and_SMACs,96.Immune_injury_MS-lesions_genetic_environ,	h_blymphocytePathway:B Lymphocyte Cell Surface Molecules,h_ctlPathway:CTL mediated immune response against target cells ,h_granulocytesPathway:Adhesion and Diapedesis of Granulocytes,h_LairPathway:Cells and Molecules involved in local acute inflammatory response,h_lymPathway:Adhesion and Diapedesis of Lymphocytes,h_lymphocytePathway:Adhesion Molecules on Lymphocyte,h_monocytePathway:Monocyte and its Surface Molecules,h_neutrophilPathway:Neutrophil and Its Surface Molecules,h_tcytotoxicPathway:T Cytotoxic Cell Surface Molecules,h_thelperPathway:T Helper Cell Surface Molecules,		GO:0001541~ovarian follicle development,GO:0001910~regulation of leukocyte mediated cytotoxicity,GO:0001975~response to amphetamine,GO:0002291~T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell,GO:0002438~acute inflammatory response to antigenic stimulus,GO:0002457~T cell antigen processing and presentation,GO:0002693~positive regulation of cellular extravasation,GO:0007155~cell adhesion,GO:0007157~heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules,GO:0007159~leukocyte cell-cell adhesion,GO:0007569~cell aging,GO:0007605~sensory perception of sound,GO:0008360~regulation of cell shape,GO:0010212~response to ionizing radiation,GO:0010477~response to sulfur dioxide,GO:0019221~cytokine-mediated signaling pathway,GO:0022614~membrane to membrane docking,GO:0030198~extracellular matrix organization,GO:0030838~positive regulation of actin filament polymerization,GO:0031669~cellular response to nutrient levels,GO:0032868~response to insulin,GO:0033627~cell adhesion mediated by integrin,GO:0034698~response to gonadotropin,GO:0042493~response to drug,GO:0043200~response to amino acid,GO:0043547~positive regulation of GTPase activity,GO:0044406~adhesion of symbiont to host,GO:0045429~positive regulation of nitric oxide biosynthetic process,GO:0045471~response to ethanol,GO:0045907~positive regulation of vasoconstriction,GO:0046688~response to copper ion,GO:0046718~viral entry into host cell,GO:0046813~receptor-mediated virion attachment to host cell,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0050776~regulation of immune response,GO:0050900~leukocyte migration,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051926~negative regulation of calcium ion transport,GO:0060333~interferon-gamma-mediated signaling pathway,GO:0061028~establishment of endothelial barrier,GO:0070234~positive regulation of T cell apoptotic process,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071222~cellular response to lipopolysaccharide,GO:0071312~cellular response to alkaloid,GO:0071333~cellular response to glucose stimulus,GO:0071346~cellular response to interferon-gamma,GO:0071347~cellular response to interleukin-1,GO:0071354~cellular response to interleukin-6,GO:0071356~cellular response to tumor necrosis factor,GO:0071456~cellular response to hypoxia,GO:0071549~cellular response to dexamethasone stimulus,GO:0072683~T cell extravasation,GO:0090557~establishment of endothelial intestinal barrier,GO:0097368~establishment of Sertoli cell barrier,GO:0098609~cell-cell adhesion,GO:1900027~regulation of ruffle assembly,GO:1902042~negative regulation of extrinsic apoptotic signaling pathway via death domain receptors,GO:1904646~cellular response to beta-amyloid,GO:1904996~positive regulation of leukocyte adhesion to vascular endothelial cell,GO:1990830~cellular response to leukemia inhibitory factor,GO:2000352~negative regulation of endothelial cell apoptotic process,	GO:0001772~immunological synapse,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005925~focal adhesion,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0045121~membrane raft,GO:0070062~extracellular exosome,	GO:0001618~virus receptor activity,GO:0004888~transmembrane signaling receptor activity,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0038023~signaling receptor activity,	IPR003599:Immunoglobulin subtype,IPR003987:Intercellular adhesion molecule/vascular cell adhesion molecule, N-terminal,IPR003988:Intercellular adhesion molecule,IPR013768:Intercellular adhesion molecule, N-terminal,IPR013783:Immunoglobulin-like fold,	hsa04064:NF-kappa B signaling pathway,hsa04514:Cell adhesion molecules,hsa04650:Natural killer cell mediated cytotoxicity,hsa04668:TNF signaling pathway,hsa04670:Leukocyte transendothelial migration,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa05143:African trypanosomiasis,hsa05144:Malaria,hsa05150:Staphylococcus aureus infection,hsa05164:Influenza A,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05169:Epstein-Barr virus infection,hsa05323:Rheumatoid arthritis,hsa05416:Viral myocarditis,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,	611162~Malaria, cerebral, susceptibility to,		SM00409:IG,	KW-0130~Cell adhesion,KW-0945~Host-virus interaction,	KW-0472~Membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,KW-1183~Host cell receptor for virus entry,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:ICAM_N,DOMAIN:IG,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,DOMAIN:Ig-like C2-type 4,DOMAIN:Ig-like C2-type 5,MOTIF:Cell attachment site; atypical,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ICAM3	intercellular adhesion molecule 3(ICAM3)	Homo sapiens				GO:0002223~stimulatory C-type lectin receptor signaling pathway,GO:0006909~phagocytosis,GO:0007155~cell adhesion,GO:0030198~extracellular matrix organization,GO:0050776~regulation of immune response,GO:0098609~cell-cell adhesion,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0070062~extracellular exosome,	GO:0005102~receptor binding,GO:0005178~integrin binding,GO:0005515~protein binding,	IPR003599:Immunoglobulin subtype,IPR003987:Intercellular adhesion molecule/vascular cell adhesion molecule, N-terminal,IPR003988:Intercellular adhesion molecule,IPR007110:Immunoglobulin-like domain,IPR013768:Intercellular adhesion molecule, N-terminal,IPR013783:Immunoglobulin-like fold,	hsa04514:Cell adhesion molecules,			SM00409:IG,	KW-0130~Cell adhesion,KW-0581~Phagocytosis,	KW-0472~Membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:ICAM_N,DOMAIN:IG,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,DOMAIN:Ig-like C2-type 4,DOMAIN:Ig-like C2-type 5,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
IFNAR1	interferon alpha and beta receptor subunit 1(IFNAR1)	Homo sapiens		h_ifnaPathway:IFN alpha signaling pathway,h_ranklPathway:Bone Remodelling,		GO:0007259~JAK-STAT cascade,GO:0009615~response to virus,GO:0019221~cytokine-mediated signaling pathway,GO:0032496~response to lipopolysaccharide,GO:0035457~cellular response to interferon-alpha,GO:0060337~type I interferon signaling pathway,GO:1901857~positive regulation of cellular respiration,	GO:0005764~lysosome,GO:0005770~late endosome,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,	GO:0004896~cytokine receptor activity,GO:0004905~type I interferon receptor activity,GO:0005515~protein binding,GO:0019962~type I interferon binding,	IPR003961:Fibronectin, type III,IPR013783:Immunoglobulin-like fold,IPR015373:Interferon alpha/beta receptor, beta chain,IPR016669:Interferon alpha/beta receptor 1,	hsa04060:Cytokine-cytokine receptor interaction,hsa04151:PI3K-Akt signaling pathway,hsa04217:Necroptosis,hsa04380:Osteoclast differentiation,hsa04620:Toll-like receptor signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04630:JAK-STAT signaling pathway,hsa04650:Natural killer cell mediated cytotoxicity,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,		PIRSF016567:interferon-alpha/beta receptor 1,			KW-0458~Lysosome,KW-0472~Membrane,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:Fibronectin type-III,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,DOMAIN:Fibronectin type-III 3,DOMAIN:Fibronectin type-III 4,DOMAIN:Interfer-bind,LIPID:S-palmitoyl cysteine,MUTAGEN:E->A: Impairs interaction with TYK2.,MUTAGEN:EE->AA: Impairs interaction with TYK2.,MUTAGEN:K->R: Mildly reduces ubiquitination. Nearly abolishes ubiquitination and subsequent degradation; when associated with 525-R-R-526.,MUTAGEN:KK->RR: Reduces ubiquitination. Nearly abolishes ubiquitination and subsequent degradation; when associated with R-501.,MUTAGEN:LL->AA: Impairs interaction with TYK2.,MUTAGEN:S->A: Abolishes interaction with FBXW11 and decreases ubiquitination.,MUTAGEN:S->A: Abolishes phosphorylation at this site and interaction with SHMT2.,MUTAGEN:Y->F: Impairs internalization in response to interferon.,REGION:Disordered,REGION:Important for interaction with TYK2,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
IFRD2	interferon related developmental regulator 2(IFRD2)	Homo sapiens					GO:0005634~nucleus,	GO:0005515~protein binding,	IPR006921:Interferon-related developmental regulator, C-terminal,IPR007701:Interferon-related developmental regulator, N-terminal,IPR011989:Armadillo-like helical,IPR016024:Armadillo-type fold,												COMPBIAS:Polar residues,DOMAIN:IFRD,DOMAIN:IFRD_C,REGION:Disordered,
IL1B	interleukin 1 beta(IL1B)	Homo sapiens		h_il1rPathway:Signal transduction through IL1R,h_il5Pathway:IL 5 Signaling Pathway,h_mspPathway:Msp/Ron Receptor Signaling Pathway,h_nthiPathway:NFkB activation by Nontypeable Hemophilus influenzae,		GO:0000165~MAPK cascade,GO:0000187~activation of MAPK activity,GO:0001660~fever generation,GO:0001934~positive regulation of protein phosphorylation,GO:0002711~positive regulation of T cell mediated immunity,GO:0006915~apoptotic process,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0007165~signal transduction,GO:0007267~cell-cell signaling,GO:0007566~embryo implantation,GO:0008284~positive regulation of cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0009743~response to carbohydrate,GO:0010573~vascular endothelial growth factor production,GO:0010575~positive regulation of vascular endothelial growth factor production,GO:0010628~positive regulation of gene expression,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0010829~negative regulation of glucose transport,GO:0014805~smooth muscle adaptation,GO:0019221~cytokine-mediated signaling pathway,GO:0030213~hyaluronan biosynthetic process,GO:0030335~positive regulation of cell migration,GO:0030593~neutrophil chemotaxis,GO:0030730~sequestering of triglyceride,GO:0030949~positive regulation of vascular endothelial growth factor receptor signaling pathway,GO:0031394~positive regulation of prostaglandin biosynthetic process,GO:0031622~positive regulation of fever generation,GO:0031663~lipopolysaccharide-mediated signaling pathway,GO:0032308~positive regulation of prostaglandin secretion,GO:0032496~response to lipopolysaccharide,GO:0032725~positive regulation of granulocyte macrophage colony-stimulating factor production,GO:0032729~positive regulation of interferon-gamma production,GO:0032743~positive regulation of interleukin-2 production,GO:0032755~positive regulation of interleukin-6 production,GO:0032757~positive regulation of interleukin-8 production,GO:0033092~positive regulation of immature T cell proliferation in thymus,GO:0033129~positive regulation of histone phosphorylation,GO:0033198~response to ATP,GO:0034116~positive regulation of heterotypic cell-cell adhesion,GO:0035066~positive regulation of histone acetylation,GO:0035234~ectopic germ cell programmed cell death,GO:0035505~positive regulation of myosin light chain kinase activity,GO:0035590~purinergic nucleotide receptor signaling pathway,GO:0035690~cellular response to drug,GO:0042102~positive regulation of T cell proliferation,GO:0043122~regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043406~positive regulation of MAP kinase activity,GO:0043407~negative regulation of MAP kinase activity,GO:0043491~protein kinase B signaling,GO:0045429~positive regulation of nitric oxide biosynthetic process,GO:0045766~positive regulation of angiogenesis,GO:0045833~negative regulation of lipid metabolic process,GO:0045840~positive regulation of mitotic nuclear division,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045917~positive regulation of complement activation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046330~positive regulation of JNK cascade,GO:0046627~negative regulation of insulin receptor signaling pathway,GO:0046827~positive regulation of protein export from nucleus,GO:0048143~astrocyte activation,GO:0050691~regulation of defense response to virus by host,GO:0050729~positive regulation of inflammatory response,GO:0050766~positive regulation of phagocytosis,GO:0050767~regulation of neurogenesis,GO:0050768~negative regulation of neurogenesis,GO:0050796~regulation of insulin secretion,GO:0050805~negative regulation of synaptic transmission,GO:0050995~negative regulation of lipid catabolic process,GO:0050996~positive regulation of lipid catabolic process,GO:0050999~regulation of nitric-oxide synthase activity,GO:0051044~positive regulation of membrane protein ectodomain proteolysis,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051781~positive regulation of cell division,GO:0060252~positive regulation of glial cell proliferation,GO:0060355~positive regulation of cell adhesion molecule production,GO:0060559~positive regulation of calcidiol 1-monooxygenase activity,GO:0070164~negative regulation of adiponectin secretion,GO:0070372~regulation of ERK1 and ERK2 cascade,GO:0070487~monocyte aggregation,GO:0070498~interleukin-1-mediated signaling pathway,GO:0070555~response to interleukin-1,GO:0071222~cellular response to lipopolysaccharide,GO:0071260~cellular response to mechanical stimulus,GO:0071310~cellular response to organic substance,GO:0071407~cellular response to organic cyclic compound,GO:0071466~cellular response to xenobiotic stimulus,GO:0071639~positive regulation of monocyte chemotactic protein-1 production,GO:0097192~extrinsic apoptotic signaling pathway in absence of ligand,GO:1900745~positive regulation of p38MAPK cascade,GO:1901224~positive regulation of NIK/NF-kappaB signaling,GO:1902680~positive regulation of RNA biosynthetic process,GO:1903140~regulation of establishment of endothelial barrier,GO:1903597~negative regulation of gap junction assembly,GO:2000556~positive regulation of T-helper 1 cell cytokine production,GO:2001240~negative regulation of extrinsic apoptotic signaling pathway in absence of ligand,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005764~lysosome,GO:0005829~cytosol,GO:0030141~secretory granule,	GO:0005125~cytokine activity,GO:0005149~interleukin-1 receptor binding,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0019904~protein domain specific binding,	IPR000975:Interleukin-1,IPR003296:Interleukin-1, beta IL1B,IPR003502:Interleukin-1 propeptide,IPR008996:Cytokine, IL-1-like,IPR020877:Interleukin-1 conserved site,	hsa01523:Antifolate resistance,hsa04010:MAPK signaling pathway,hsa04060:Cytokine-cytokine receptor interaction,hsa04064:NF-kappa B signaling pathway,hsa04217:Necroptosis,hsa04380:Osteoclast differentiation,hsa04620:Toll-like receptor signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04623:Cytosolic DNA-sensing pathway,hsa04625:C-type lectin receptor signaling pathway,hsa04640:Hematopoietic cell lineage,hsa04657:IL-17 signaling pathway,hsa04659:Th17 cell differentiation,hsa04668:TNF signaling pathway,hsa04750:Inflammatory mediator regulation of TRP channels,hsa04932:Non-alcoholic fatty liver disease,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04936:Alcoholic liver disease,hsa04940:Type I diabetes mellitus,hsa05010:Alzheimer disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05133:Pertussis,hsa05134:Legionellosis,hsa05135:Yersinia infection,hsa05140:Leishmaniasis,hsa05142:Chagas disease,hsa05143:African trypanosomiasis,hsa05144:Malaria,hsa05146:Amoebiasis,hsa05152:Tuberculosis,hsa05162:Measles,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05168:Herpes simplex virus 1 infection,hsa05171:Coronavirus disease - COVID-19,hsa05321:Inflammatory bowel disease,hsa05323:Rheumatoid arthritis,hsa05332:Graft-versus-host disease,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,	613659~Gastric cancer risk after H. pylori infection,			KW-0395~Inflammatory response,	KW-0458~Lysosome,KW-0963~Cytoplasm,KW-0964~Secreted,				KW-0202~Cytokine,KW-0497~Mitogen,KW-0666~Pyrogen,		DOMAIN:IL1_propep,MOTIF:Involved in interaction with TMED10 C-terminus,MUTAGEN:D->A: Loss of activation by CASP1; when associated with A-116.,MUTAGEN:D->A: Loss of activation by CASP1; when associated with A-27.,MUTAGEN:E->K: Enhanced integrin binding.,MUTAGEN:E->K: Increased affinity for integrin ITGAV:ITGB3. Suppression of integrin binding; when associated with E-171; E-190 or E-204. Suppression of integrin binding; when associated with E-179 and E-181.,MUTAGEN:F->C: No effect on binding to IL1R or on IL1B activity. Markedly reduced activity; when associated with E-171; E-190 and E-204. Markedly reduced activity; when associated with E-179; E-181; E-190 and E-204.,MUTAGEN:K->E: Suppression of integrin binding; when associated with E-179 and K-244. Markedly reduced activity; when associated with E-179; E-190; E-204 and C-233.,MUTAGEN:K->E: Suppression of integrin binding; when associated with E-181 and K-244. Markedly reduced activity; when associated with E-181; E-190; E-204 and C-233.,MUTAGEN:K->E: Suppression of integrin binding; when associated with K-244. Markedly reduced activity; when associated with E-171; E-190 and C-233. Markedly reduced activity; when associated with E-179; E-181; E-190 and C-233.,MUTAGEN:K->E: Suppression of integrin binding; when associated with K-244. Markedly reduced activity; when associated with E-171; E-204 and C-233. Markedly reduced activity; when associated with E-179; E-181; E-204 and C-233.,MUTAGEN:K->E: Suppression of integrin binding; when associated with K-244. Markedly reduced activity; when associated with E-190; E-204 and C-233.,PROPEP:Removed in mature form; by CASP1,SITE:Important for interaction with integrin,SITE:Involved in receptor binding,
IL13RA1	interleukin 13 receptor subunit alpha 1(IL13RA1)	Homo sapiens				GO:0007166~cell surface receptor signaling pathway,GO:0008284~positive regulation of cell proliferation,GO:0019221~cytokine-mediated signaling pathway,GO:0038165~oncostatin-M-mediated signaling pathway,GO:0048861~leukemia inhibitory factor signaling pathway,	GO:0005886~plasma membrane,GO:0005898~interleukin-13 receptor complex,GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,GO:0043235~receptor complex,	GO:0004896~cytokine receptor activity,GO:0004923~leukemia inhibitory factor receptor activity,GO:0004924~oncostatin-M receptor activity,GO:0005127~ciliary neurotrophic factor receptor binding,GO:0005515~protein binding,GO:0019955~cytokine binding,	IPR003532:Short hematopoietin receptor, family 2, conserved site,IPR003961:Fibronectin, type III,IPR013783:Immunoglobulin-like fold,IPR015321:Interleukin-6 receptor alpha chain, binding,	hsa04060:Cytokine-cytokine receptor interaction,hsa04630:JAK-STAT signaling pathway,hsa05200:Pathways in cancer,					KW-0472~Membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Fibronectin type-III,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,DOMAIN:Fibronectin type-III 3,MOTIF:Box 1 motif,MOTIF:WSXWS motif,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
IL4R	interleukin 4 receptor(IL4R)	Homo sapiens	55.Allergen_recognition_by_Th2_or_Th0_cell,80.T_cell_Activation,	h_il4Pathway:IL 4 signaling pathway,h_nktPathway:Selective expression of chemokine receptors during T-cell polarization,h_th1th2Pathway:Th1/Th2 Differentiation,		GO:0002532~production of molecular mediator involved in inflammatory response,GO:0002639~positive regulation of immunoglobulin production,GO:0006955~immune response,GO:0007165~signal transduction,GO:0016064~immunoglobulin mediated immune response,GO:0019221~cytokine-mediated signaling pathway,GO:0030728~ovulation,GO:0032722~positive regulation of chemokine production,GO:0035771~interleukin-4-mediated signaling pathway,GO:0042127~regulation of cell proliferation,GO:0042832~defense response to protozoan,GO:0043032~positive regulation of macrophage activation,GO:0043306~positive regulation of mast cell degranulation,GO:0043627~response to estrogen,GO:0045626~negative regulation of T-helper 1 cell differentiation,GO:0045630~positive regulation of T-helper 2 cell differentiation,GO:1901741~positive regulation of myoblast fusion,GO:1990834~response to odorant,	GO:0005615~extracellular space,GO:0005654~nucleoplasm,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,GO:0034451~centriolar satellite,GO:0043235~receptor complex,	GO:0004896~cytokine receptor activity,GO:0004913~interleukin-4 receptor activity,GO:0005515~protein binding,	IPR003531:Short hematopoietin receptor, family 1, conserved site,IPR003961:Fibronectin, type III,IPR013783:Immunoglobulin-like fold,IPR015319:Interleukin-4 receptor alpha chain, N-terminal,	hsa04060:Cytokine-cytokine receptor interaction,hsa04151:PI3K-Akt signaling pathway,hsa04630:JAK-STAT signaling pathway,hsa04640:Hematopoietic cell lineage,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa05200:Pathways in cancer,hsa05321:Inflammatory bowel disease,	147050~Atopy, susceptibility to,609423~AIDS, slow progression to,			KW-0391~Immunity,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Fibronectin type-III,DOMAIN:IL4Ra_N,MOTIF:Box 1 motif,MOTIF:ITIM motif,MOTIF:WSXWS motif,MUTAGEN:D->A,N: >150-fold reduction in IL4 binding.,MUTAGEN:D->A: 50-fold reduction in IL4 binding.,MUTAGEN:D->A: Little effect on IL4 binding.,MUTAGEN:E->A: No effect on IL4 binding.,MUTAGEN:F->A: 45-fold reduction in IL4 binding.,MUTAGEN:K->A: Little effect on IL4 binding.,MUTAGEN:L->A: 100-fold reduction in IL4 binding.,MUTAGEN:L->A: Little effect on IL4 binding.,MUTAGEN:L->A: No effect on IL4 binding.,MUTAGEN:M->A: No effect on IL4 binding.,MUTAGEN:N->A: Little effect on IL4 binding.,MUTAGEN:N->A: No effect on IL4 binding.,MUTAGEN:P->A: Little effect on IL4 binding.,MUTAGEN:S->A: No effect on IL4 binding.,MUTAGEN:V->A: 35-fold reduction in IL4 binding.,MUTAGEN:V->A: Little effect on IL4 binding.,MUTAGEN:Y->A: 10-fold reduction in IL4 binding.,MUTAGEN:Y->A: 40-fold reduction in IL4 binding.,MUTAGEN:Y->A: 500-fold reduction in IL4 binding.,MUTAGEN:Y->A: 700-fold reduction in IL4 binding.,MUTAGEN:Y->A: Little effect on IL4 binding.,MUTAGEN:Y->F: 200-fold reduction in IL4 binding.,MUTAGEN:Y->F: 25-fold reduction in IL4 binding.,MUTAGEN:Y->F: Abolishes IRS1 tyrosine phosphorylation. No cell proliferation.,MUTAGEN:Y->F: Increased IL4-induced cell proliferation and STAT6 activation.,MUTAGEN:Y->F: Loss of CD23 gene induction; when associated with F-575 and F-603.,MUTAGEN:Y->F: Loss of CD23 gene induction; when associated with F-575 and F-631.,MUTAGEN:Y->F: Loss of CD23 gene induction; when associated with F-603 and F-631.,MUTAGEN:Y->F: No effect on IL4 binding.,REGION:Disordered,REGION:Required for IL4-induced gene expression,REGION:Required for IRS1 activation and IL4-induced cell growth,SITE:Major IL4 binding determinant,SITE:Minor IL4 binding determinant,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ISOC1	isochorismatase domain containing 1(ISOC1)	Homo sapiens					GO:0005737~cytoplasm,GO:0005777~peroxisome,	GO:0005515~protein binding,	IPR000868:Isochorismatase-like,											KW-0597~Phosphoprotein,	DOMAIN:Isochorismatase,
IARS2	isoleucyl-tRNA synthetase 2, mitochondrial(IARS2)	Homo sapiens				GO:0006418~tRNA aminoacylation for protein translation,GO:0006428~isoleucyl-tRNA aminoacylation,GO:0032543~mitochondrial translation,	GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0016021~integral component of membrane,	GO:0000049~tRNA binding,GO:0002161~aminoacyl-tRNA editing activity,GO:0004822~isoleucine-tRNA ligase activity,GO:0005524~ATP binding,	IPR001412:Aminoacyl-tRNA synthetase, class I, conserved site,IPR002300:Aminoacyl-tRNA synthetase, class Ia,IPR002301:Isoleucine-tRNA ligase,IPR009008:Valyl/Leucyl/Isoleucyl-tRNA synthetase, class Ia, editing domain,IPR009080:Aminoacyl-tRNA synthetase, class 1a, anticodon-binding,IPR010663:Zinc finger, DNA glycosylase/AP lyase/isoleucyl tRNA synthetase,IPR013155:Valyl/Leucyl/Isoleucyl-tRNA synthetase, class I, anticodon-binding,IPR014729:Rossmann-like alpha/beta/alpha sandwich fold,IPR023585:Isoleucine-tRNA ligase, type 1,	hsa00970:Aminoacyl-tRNA biosynthesis,	616007~Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia,			KW-0648~Protein biosynthesis,	KW-0472~Membrane,KW-0496~Mitochondrion,	KW-0209~Deafness,KW-0225~Disease variant,KW-0622~Neuropathy,KW-0898~Cataract,	KW-0809~Transit peptide,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0030~Aminoacyl-tRNA synthetase,KW-0436~Ligase,	KW-0007~Acetylation,	BINDING:ATP,MOTIF:'HIGH' region,MOTIF:'KMSKS' region,TRANSIT:Mitochondrion,TRANSMEM:Helical,
ICMT	isoprenylcysteine carboxyl methyltransferase(ICMT)	Homo sapiens				GO:0000165~MAPK cascade,GO:0006464~cellular protein modification process,GO:0006481~C-terminal protein methylation,GO:0006612~protein targeting to membrane,GO:0043687~post-translational protein modification,GO:0046498~S-adenosylhomocysteine metabolic process,GO:0046499~S-adenosylmethioninamine metabolic process,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0003880~protein C-terminal carboxyl O-methyltransferase activity,GO:0004671~protein C-terminal S-isoprenylcysteine carboxyl O-methyltransferase activity,GO:0005515~protein binding,	IPR007269:Isoprenylcysteine carboxyl methyltransferase,IPR025770:Protein-S-isoprenylcysteine O-methyltransferase,	hsa00900:Terpenoid backbone biosynthesis,					KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0949~S-adenosyl-L-methionine,	KW-0489~Methyltransferase,KW-0808~Transferase,		BINDING:S-adenosyl-L-methionine,BINDING:Substrate,REGION:S-adenosyl-L-methionine binding,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
JMJD6	jumonji domain containing 6, arginine demethylase and lysine hydroxylase(JMJD6)	Homo sapiens				GO:0001822~kidney development,GO:0002040~sprouting angiogenesis,GO:0006325~chromatin organization,GO:0006397~mRNA processing,GO:0006482~protein demethylation,GO:0006909~phagocytosis,GO:0007166~cell surface receptor signaling pathway,GO:0007507~heart development,GO:0008380~RNA splicing,GO:0018395~peptidyl-lysine hydroxylation to 5-hydroxy-L-lysine,GO:0030324~lung development,GO:0032259~methylation,GO:0033077~T cell differentiation in thymus,GO:0035513~oxidative RNA demethylation,GO:0042116~macrophage activation,GO:0043654~recognition of apoptotic cell,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048024~regulation of mRNA splicing, via spliceosome,GO:0048821~erythrocyte development,GO:0051260~protein homooligomerization,GO:0060041~retina development in camera-type eye,GO:0070078~histone H3-R2 demethylation,GO:0070079~histone H4-R3 demethylation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003727~single-stranded RNA binding,GO:0005506~iron ion binding,GO:0005515~protein binding,GO:0008168~methyltransferase activity,GO:0032451~demethylase activity,GO:0032452~histone demethylase activity,GO:0033746~histone demethylase activity (H3-R2 specific),GO:0033749~histone demethylase activity (H4-R3 specific),GO:0035515~oxidative RNA demethylase activity,GO:0038023~signaling receptor activity,GO:0042802~identical protein binding,GO:0070815~peptidyl-lysine 5-dioxygenase activity,	IPR003347:JmjC domain,				SM00558:JmjC,	KW-0221~Differentiation,KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0408~Iron,KW-0479~Metal-binding,	KW-0156~Chromatin regulator,KW-0217~Developmental protein,KW-0223~Dioxygenase,KW-0489~Methyltransferase,KW-0560~Oxidoreductase,KW-0675~Receptor,KW-0694~RNA-binding,KW-0808~Transferase,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	BINDING:2-oxoglutarate,BINDING:Substrate,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:JmjC,METAL:Iron; catalytic,MOTIF:Nuclear localization signal 1,MOTIF:Nuclear localization signal 2,MOTIF:Nuclear localization signal 3,MOTIF:Nuclear localization signal 4,MOTIF:Nuclear localization signal 5,MUTAGEN:D->A: Loss of arginine demethylase and a lysyl-hydroxylase activities; when associated with A-187 and A-273.,MUTAGEN:E->A: Impairs both hydroxylation activity and 2-oxoglutarate turnover assays.,MUTAGEN:H->A: Loss of arginine demethylase and a lysyl-hydroxylase activities; when associated with A-187 and A-189.,MUTAGEN:H->A: Loss of histone arginine demethylase and lysyl-hydroxylase activities. Abolishes homooligomerisation. Loss of arginine demethylase and a lysyl-hydroxylase activities; when associated with A-189 and A-273.,MUTAGEN:K->A: Impairs enzyme activity without affecting 2-oxoglutarate-binding.,MUTAGEN:K->A: Nearly abolishes the interaction with the NET domain of BRD4.,MUTAGEN:L->A: Nearly abolishes the interaction with the NET domain of BRD4.,MUTAGEN:N->A: Impairs enzyme activity.,MUTAGEN:R->A: Nearly abolishes the interaction with the NET domain of BRD4.,MUTAGEN:T->A: Impairs enzyme activity and 2-oxoglutarate-binding.,MUTAGEN:W->A: Decreases interaction with the NET domain of BRD4.,MUTAGEN:Y->F: Abolishes 2-oxoglutarate-binding and enzyme activity.,REGION:Disordered,
KLHDC2	kelch domain containing 2(KLHDC2)	Homo sapiens				GO:0016567~protein ubiquitination,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016604~nuclear body,GO:0031462~Cul2-RING ubiquitin ligase complex,GO:0031965~nuclear membrane,	GO:0005515~protein binding,GO:1990756~protein binding, bridging involved in substrate recognition for ubiquitination,	IPR011043:Galactose oxidase/kelch, beta-propeller,IPR015915:Kelch-type beta propeller,					KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0880~Kelch repeat,				MUTAGEN:K->A: Strongly impaired ability to recognize truncated SELENOK or cleaved USP1 with a diglycine (Gly-Gly) at the C-terminus.,MUTAGEN:R->A,L,E: Abolished ability to recognize truncated SELENOK or cleaved USP1 with a diglycine (Gly-Gly) at the C-terminus.,MUTAGEN:R->A: Does not affect ability to recognize truncated SELENOK or cleaved USP1 with a diglycine (Gly-Gly) at the C-terminus.,MUTAGEN:R->A: Does not affect ability to recognize truncated SELENOK with a diglycine (Gly-Gly) at the C-terminus. Abolished ability to recognize cleaved USP1 with a diglycine (Gly-Gly) at the C-terminus.,MUTAGEN:R->E: Abolished ability to recognize truncated SELENOK with a diglycine (Gly-Gly) at the C-terminus.,MUTAGEN:R->K: Does not affect ability to recognize truncated SELENOK with a diglycine (Gly-Gly) at the C-terminus. Abolished ability to recognize cleaved USP1 with a diglycine (Gly-Gly) at the C-terminus.,MUTAGEN:S->A: Does not affect ability to recognize truncated SELENOK with a diglycine (Gly-Gly) at the C-terminus.,MUTAGEN:S->E,L: Abolished ability to recognize truncated SELENOK with a diglycine (Gly-Gly) at the C-terminus.,REPEAT:Kelch 1,REPEAT:Kelch 2,REPEAT:Kelch 3,REPEAT:Kelch 4,REPEAT:Kelch 5,REPEAT:Kelch 6,
KEAP1	kelch like ECH associated protein 1(KEAP1)	Homo sapiens		h_arenrf2Pathway:Oxidative Stress Induced Gene Expression Via Nrf2,		GO:0001701~in utero embryonic development,GO:0006355~regulation of transcription, DNA-templated,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0010506~regulation of autophagy,GO:0016032~viral process,GO:0016567~protein ubiquitination,GO:0016579~protein deubiquitination,GO:0032436~positive regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0034599~cellular response to oxidative stress,GO:0042994~cytoplasmic sequestering of transcription factor,GO:0043433~negative regulation of sequence-specific DNA binding transcription factor activity,GO:0043687~post-translational protein modification,GO:0045604~regulation of epidermal cell differentiation,GO:0071353~cellular response to interleukin-4,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005884~actin filament,GO:0016234~inclusion body,GO:0030496~midbody,GO:0031463~Cul3-RING ubiquitin ligase complex,GO:0034451~centriolar satellite,	GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0042802~identical protein binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0097718~disordered domain specific binding,	IPR000210:BTB/POZ-like,IPR006652:Kelch repeat type 1,IPR011333:BTB/POZ fold,IPR011705:BTB/Kelch-associated,IPR015915:Kelch-type beta propeller,IPR017096:Kelch-like protein, gigaxonin,	hsa04120:Ubiquitin mediated proteolysis,hsa05012:Parkinson disease,hsa05200:Pathways in cancer,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05225:Hepatocellular carcinoma,hsa05418:Fluid shear stress and atherosclerosis,		PIRSF037037:kelch-like protein, gigaxonin type,	SM00225:BTB,SM00612:Kelch,SM00875:SM00875,	KW-0833~Ubl conjugation pathway,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0880~Kelch repeat,			KW-0702~S-nitrosylation,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,CROSSLNK:N5-[4-(S-L-cysteinyl)-5-methyl-1H-imidazol-2-yl]-L-ornithine (Arg-Cys) (interchain with C-151 in KEAP1),CROSSLNK:N5-[4-(S-L-cysteinyl)-5-methyl-1H-imidazol-2-yl]-L-ornithine (Cys-Arg) (interchain with R-135 in KEAP1),DOMAIN:BACK,DOMAIN:BTB,MUTAGEN:C->S,N,D,L: Substitution with a small side chain that prevents covalent modification by an electrophile; promotes constitutive ubiquitination of NFE2L2/NRF2 and subsequent repression of phase 2 detoxifying enzymes. Resistance of ubiquitination of PGAM5 to inhibition by oxidative stress and sulforaphane. Impaired interaction with CUL3. Reduced formation of a high-molecular mass KEAP1 molecule when methylglyoxal accumulates.,MUTAGEN:C->S: Abolishes repression of NFE2L2/NRF2-dependent gene expression. Slows down degradation of NFE2L2/NRF2.,MUTAGEN:C->W,Y: Substitution with a bulky side chain that mimicks covalent modification by an electrophile; prevents ubiquitination and degradation of NFE2L2/NRF2, leading to constitutive activation of NFE2L2/NRF2 and subsequent expression of phase 2 detoxifying enzymes.,MUTAGEN:F->A: Abolishes repression of NFE2L2/NRF2-dependent gene expression.,MUTAGEN:H->A: Loss of interaction with NFE2L2/NRF2. Abolishes repression of NFE2L2/NRF2-dependent gene expression. Does not affect interaction with SQSTM1/p62.,MUTAGEN:IEG->AAA: Increases ubiquitination and proteolytic degradation.,MUTAGEN:L->A: Loss of export from nucleus; when associated with A-308.,MUTAGEN:L->A: Loss of export from nucleus; when associated with A-310.,MUTAGEN:MY->AA: Abolished interaction with NFE2L2/NRF2; when associated with 123-A--A-127.,MUTAGEN:N->A: Loss of interaction with NFE2L2/NRF2. Strongly reduces repression of NFE2L2/NRF2-dependent gene expression. Impaired interaction with SQSTM1/p62.,MUTAGEN:R->A: Loss of interaction with NFE2L2/NRF2. Abolishes repression of NFE2L2/NRF2-dependent gene expression. Impaired interaction with SQSTM1/p62.,MUTAGEN:R->A: Loss of interaction with NFE2L2/NRF2. Abolishes repression of NFE2L2/NRF2-dependent gene expression. Loss of interaction with PGAM5. Does not affect interaction with SQSTM1/p62.,MUTAGEN:R->A: Reduced formation of a high-molecular mass KEAP1 molecule when methylglyoxal accumulates.,MUTAGEN:VSIEG->ASAEA: Abolished interaction with NFE2L2/NRF2; when associated with 161-A-A-162.,MUTAGEN:Y->A: Loss of interaction with NFE2L2/NRF2. Strongly reduces repression of NFE2L2/NRF2-dependent gene expression. Abolishes interaction with SQSTM1/p62.,MUTAGEN:Y->A: Loss of interaction with NFE2L2/NRF2. Strongly reduces repression of NFE2L2/NRF2-dependent gene expression. Loss of interaction with PGAM5.,MUTAGEN:Y->A: Loss of interaction with NFE2L2/NRF2. Strongly reduces repression of NFE2L2/NRF2-dependent gene expression. Loss of interaction with PGAM5. Abolishes interaction with SQSTM1/p62.,MUTAGEN:YQI->AAA: Increases ubiquitination and proteolytic degradation.,REGION:Disordered,REPEAT:Kelch 1,REPEAT:Kelch 2,REPEAT:Kelch 3,REPEAT:Kelch 4,REPEAT:Kelch 5,REPEAT:Kelch 6,SITE:Sensor for electrophilic agents,
KLHL21	kelch like family member 21(KLHL21)	Homo sapiens				GO:0007049~cell cycle,GO:0016567~protein ubiquitination,GO:0032465~regulation of cytokinesis,GO:0035853~chromosome passenger complex localization to spindle midzone,GO:0043687~post-translational protein modification,GO:0051301~cell division,	GO:0005827~polar microtubule,GO:0005829~cytosol,GO:0031463~Cul3-RING ubiquitin ligase complex,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0097602~cullin family protein binding,	IPR000210:BTB/POZ-like,IPR006652:Kelch repeat type 1,IPR011333:BTB/POZ fold,IPR011705:BTB/Kelch-associated,IPR015915:Kelch-type beta propeller,IPR017096:Kelch-like protein, gigaxonin,			PIRSF037037:kelch-like protein, gigaxonin type,	SM00225:BTB,SM00612:Kelch,SM00875:SM00875,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,KW-0833~Ubl conjugation pathway,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0880~Kelch repeat,				COMPBIAS:Basic and acidic residues,DOMAIN:BACK,DOMAIN:BTB,MUTAGEN:DLLQ->AALA: Abolishes interaction with CUL3.,REGION:Disordered,REPEAT:Kelch 1,REPEAT:Kelch 2,REPEAT:Kelch 3,REPEAT:Kelch 4,REPEAT:Kelch 5,REPEAT:Kelch 6,
KLHL9	kelch like family member 9(KLHL9)	Homo sapiens				GO:0007049~cell cycle,GO:0016567~protein ubiquitination,GO:0032465~regulation of cytokinesis,GO:0043687~post-translational protein modification,GO:0051301~cell division,	GO:0005829~cytosol,GO:0030496~midbody,GO:0031463~Cul3-RING ubiquitin ligase complex,	GO:0004842~ubiquitin-protein transferase activity,GO:0097602~cullin family protein binding,	IPR000210:BTB/POZ-like,IPR006652:Kelch repeat type 1,IPR011333:BTB/POZ fold,IPR011705:BTB/Kelch-associated,IPR015915:Kelch-type beta propeller,IPR017096:Kelch-like protein, gigaxonin,	hsa04120:Ubiquitin mediated proteolysis,		PIRSF037037:kelch-like protein, gigaxonin type,	SM00225:BTB,SM00612:Kelch,SM00875:SM00875,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,KW-0833~Ubl conjugation pathway,			KW-0677~Repeat,KW-0880~Kelch repeat,				DOMAIN:BACK,DOMAIN:BTB,REGION:Disordered,REPEAT:Kelch 1,REPEAT:Kelch 2,REPEAT:Kelch 3,REPEAT:Kelch 4,REPEAT:Kelch 5,REPEAT:Kelch 6,
KTN1	kinectin 1(KTN1)	Homo sapiens				GO:0007018~microtubule-based movement,GO:0015031~protein transport,GO:0043687~post-translational protein modification,GO:0044267~cellular protein metabolic process,	GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0005789~endoplasmic reticulum membrane,GO:0005887~integral component of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030176~integral component of endoplasmic reticulum membrane,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0019894~kinesin binding,GO:0045296~cadherin binding,	IPR007794:Ribosome receptor lysine/proline rich,IPR024854:Kinectin,						KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0175~Coiled coil,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Rib_recp_KP_reg,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
KIF14	kinesin family member 14(KIF14)	Homo sapiens				GO:0001558~regulation of cell growth,GO:0007018~microtubule-based movement,GO:0007080~mitotic metaphase plate congression,GO:0008284~positive regulation of cell proliferation,GO:0010389~regulation of G2/M transition of mitotic cell cycle,GO:0021685~cerebellar granular layer structural organization,GO:0021693~cerebellar Purkinje cell layer structural organization,GO:0021695~cerebellar cortex development,GO:0021766~hippocampus development,GO:0021772~olfactory bulb development,GO:0021846~cell proliferation in forebrain,GO:0021987~cerebral cortex development,GO:0030155~regulation of cell adhesion,GO:0030334~regulation of cell migration,GO:0031146~SCF-dependent proteasomal ubiquitin-dependent protein catabolic process,GO:0031641~regulation of myelination,GO:0032147~activation of protein kinase activity,GO:0032467~positive regulation of cytokinesis,GO:0032487~regulation of Rap protein signal transduction,GO:0033624~negative regulation of integrin activation,GO:0034446~substrate adhesion-dependent cell spreading,GO:0043066~negative regulation of apoptotic process,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0043523~regulation of neuron apoptotic process,GO:0043524~negative regulation of neuron apoptotic process,GO:0045184~establishment of protein localization,GO:0051301~cell division,GO:1903429~regulation of cell maturation,GO:2000045~regulation of G1/S transition of mitotic cell cycle,	GO:0005634~nucleus,GO:0005829~cytosol,GO:0005871~kinesin complex,GO:0005874~microtubule,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0030496~midbody,GO:0051233~spindle midzone,GO:0090543~Flemming body,	GO:0003777~microtubule motor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008017~microtubule binding,GO:0008574~ATP-dependent microtubule motor activity, plus-end-directed,GO:0015631~tubulin binding,GO:0016887~ATPase activity,GO:0019901~protein kinase binding,GO:0030165~PDZ domain binding,	IPR000253:Forkhead-associated (FHA) domain,IPR001752:Kinesin, motor domain,IPR008984:SMAD/FHA domain,IPR019821:Kinesin, motor region, conserved site,IPR027417:P-loop containing nucleoside triphosphate hydrolase,		616258~Meckel syndrome 12,617914~Microcephaly 20, primary, autosomal recessive,		SM00129:KISc,SM00240:FHA,		KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0905~Primary microcephaly,KW-0981~Meckel syndrome,KW-1186~Ciliopathy,	KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0505~Motor protein,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:FHA,DOMAIN:Kinesin motor,NP_BIND:ATP,REGION:Disordered,REGION:Required for CIT-binding,REGION:Required for PRC1-binding,REGION:Required for microtubule-binding with high affinity,
KIF20A	kinesin family member 20A(KIF20A)	Homo sapiens				GO:0000281~mitotic cytokinesis,GO:0001578~microtubule bundle formation,GO:0007018~microtubule-based movement,GO:0015031~protein transport,GO:0032465~regulation of cytokinesis,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005794~Golgi apparatus,GO:0005819~spindle,GO:0005871~kinesin complex,GO:0005874~microtubule,GO:0030496~midbody,GO:0032154~cleavage furrow,GO:0045171~intercellular bridge,	GO:0003777~microtubule motor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008017~microtubule binding,GO:0016887~ATPase activity,GO:0019901~protein kinase binding,GO:1990939~ATP-dependent microtubule motor activity,	IPR001752:Kinesin, motor domain,IPR019821:Kinesin, motor region, conserved site,IPR027326:Kinesin-like protein KIF20A,IPR027417:P-loop containing nucleoside triphosphate hydrolase,		619433~Cardiomyopathy, familial restrictive, 6,		SM00129:KISc,	KW-0653~Protein transport,KW-0813~Transport,	KW-0206~Cytoskeleton,KW-0333~Golgi apparatus,KW-0493~Microtubule,KW-0963~Cytoplasm,		KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0505~Motor protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Kinesin motor,MUTAGEN:S->A: Impairs phosphorylation by PLK1 and recruitment of PLK1 to the spindle.,NP_BIND:ATP,REGION:Disordered,REGION:Globular,
KIF2C	kinesin family member 2C(KIF2C)	Homo sapiens				GO:0006890~retrograde vesicle-mediated transport, Golgi to ER,GO:0007018~microtubule-based movement,GO:0007019~microtubule depolymerization,GO:0007052~mitotic spindle organization,GO:0007080~mitotic metaphase plate congression,GO:0019886~antigen processing and presentation of exogenous peptide antigen via MHC class II,GO:0030951~establishment or maintenance of microtubule cytoskeleton polarity,GO:0051301~cell division,GO:0051310~metaphase plate congression,GO:0051315~attachment of mitotic spindle microtubules to kinetochore,GO:0051983~regulation of chromosome segregation,	GO:0000775~chromosome, centromeric region,GO:0000776~kinetochore,GO:0000777~condensed chromosome kinetochore,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005819~spindle,GO:0005829~cytosol,GO:0005871~kinesin complex,GO:0005874~microtubule,GO:0005881~cytoplasmic microtubule,GO:0015630~microtubule cytoskeleton,GO:0016020~membrane,GO:0035371~microtubule plus-end,	GO:0003777~microtubule motor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008017~microtubule binding,GO:0016887~ATPase activity,GO:0019237~centromeric DNA binding,GO:0051010~microtubule plus-end binding,GO:1990939~ATP-dependent microtubule motor activity,	IPR001752:Kinesin, motor domain,IPR019821:Kinesin, motor region, conserved site,IPR027417:P-loop containing nucleoside triphosphate hydrolase,				SM00129:KISc,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0159~Chromosome partition,KW-0498~Mitosis,	KW-0137~Centromere,KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0995~Kinetochore,		KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0505~Motor protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	BINDING:ATP,DOMAIN:Kinesin motor,MOTIF:Microtubule tip localization signal,MOTIF:Nuclear localization signal,MUTAGEN:IP->NN: Loss of interaction with MAPRE1 and association with microtubule growing ends.,MUTAGEN:S->E: Alters interaction with MAPRE1 and association with microtubule growing ends; when associated with E-109 and E-111.,MUTAGEN:S->E: Alters interaction with MAPRE1 and association with microtubule growing ends; when associated with E-95 and E-109.,MUTAGEN:S->E: Alters interaction with MAPRE1 and association with microtubule growing ends; when associated with E-95 and E-111.,NP_BIND:ATP,REGION:Disordered,REGION:Globular,REGION:Negative regulator of microtubule-binding,
KIF5C	kinesin family member 5C(KIF5C)	Homo sapiens			Cell division and chromosome partitioning,	GO:0006996~organelle organization,GO:0007018~microtubule-based movement,GO:0007411~axon guidance,GO:0008045~motor neuron axon guidance,GO:0030705~cytoskeleton-dependent intracellular transport,GO:0048489~synaptic vesicle transport,GO:0051028~mRNA transport,GO:0098971~anterograde dendritic transport of neurotransmitter receptor complex,GO:0099641~anterograde axonal protein transport,	GO:0005737~cytoplasm,GO:0005871~kinesin complex,GO:0005874~microtubule,GO:0032839~dendrite cytoplasm,GO:0035253~ciliary rootlet,GO:0043025~neuronal cell body,GO:0044295~axonal growth cone,GO:1904115~axon cytoplasm,	GO:0003777~microtubule motor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008017~microtubule binding,GO:0008574~ATP-dependent microtubule motor activity, plus-end-directed,GO:0016887~ATPase activity,GO:1990939~ATP-dependent microtubule motor activity,	IPR001752:Kinesin, motor domain,IPR019821:Kinesin, motor region, conserved site,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04144:Endocytosis,hsa04728:Dopaminergic synapse,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05132:Salmonella infection,hsa05223:Non-small cell lung cancer,	615282~Cortical dysplasia, complex, with other brain malformations 2,		SM00129:KISc,	KW-0813~Transport,	KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0963~Cytoplasm,KW-0966~Cell projection,	KW-0225~Disease variant,	KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0505~Motor protein,		COMPBIAS:Basic and acidic residues,DOMAIN:Kinesin motor,NP_BIND:ATP,REGION:Disordered,REGION:Globular,REGION:Microtubule-binding,
LBR	lamin B receptor(LBR)	Homo sapiens				GO:0006695~cholesterol biosynthetic process,GO:0007084~mitotic nuclear envelope reassembly,GO:0016126~sterol biosynthetic process,GO:0030223~neutrophil differentiation,	GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005637~nuclear inner membrane,GO:0005639~integral component of nuclear inner membrane,GO:0005737~cytoplasm,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0031965~nuclear membrane,	GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0005521~lamin binding,GO:0016627~oxidoreductase activity, acting on the CH-CH group of donors,GO:0050613~delta14-sterol reductase activity,GO:0070087~chromo shadow domain binding,GO:0070402~NADPH binding,	IPR001171:Ergosterol biosynthesis ERG4/ERG24,IPR002999:Tudor domain,IPR018083:Sterol reductase, conserved site,IPR019023:Lamin-B receptor of TUDOR domain,	hsa00100:Steroid biosynthesis,hsa01100:Metabolic pathways,	169400~Pelger-Huet anomaly,215140~Greenberg skeletal dysplasia,613471~Reynolds syndrome,618019~Pelger-Huet anomaly with mild skeletal anomalies,		SM00333:TUDOR,	KW-0152~Cholesterol biosynthesis,KW-0153~Cholesterol metabolism,KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,KW-0752~Steroid biosynthesis,KW-0753~Steroid metabolism,KW-0756~Sterol biosynthesis,KW-1207~Sterol metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0242~Dwarfism,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0238~DNA-binding,KW-0560~Oxidoreductase,KW-0675~Receptor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:LBR_tudor,DOMAIN:Tudor,REGION:Disordered,TOPO_DOM:Nuclear,TRANSMEM:Helical,
LAMA3	laminin subunit alpha 3(LAMA3)	Homo sapiens		h_agrPathway:Agrin in Postsynaptic Differentiation,		GO:0001738~morphogenesis of a polarized epithelium,GO:0007155~cell adhesion,GO:0007229~integrin-mediated signaling pathway,GO:0007411~axon guidance,GO:0008544~epidermis development,GO:0009887~animal organ morphogenesis,GO:0009888~tissue development,GO:0016477~cell migration,GO:0030155~regulation of cell adhesion,GO:0030198~extracellular matrix organization,GO:0030199~collagen fibril organization,GO:0030334~regulation of cell migration,GO:0031581~hemidesmosome assembly,GO:0035987~endodermal cell differentiation,GO:0045995~regulation of embryonic development,GO:0098609~cell-cell adhesion,	GO:0005576~extracellular region,GO:0005604~basement membrane,GO:0005610~laminin-5 complex,GO:0005783~endoplasmic reticulum,GO:0016020~membrane,GO:0070062~extracellular exosome,	GO:0005102~receptor binding,GO:0005178~integrin binding,GO:0005198~structural molecule activity,GO:0005201~extracellular matrix structural constituent,	IPR000034:Laminin B type IV,IPR000742:Epidermal growth factor-like domain,IPR001791:Laminin G domain,IPR002049:EGF-like, laminin,IPR008211:Laminin, N-terminal,IPR009254:Laminin I,IPR010307:Laminin II,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,	hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04512:ECM-receptor interaction,hsa05145:Toxoplasmosis,hsa05146:Amoebiasis,hsa05165:Human papillomavirus infection,hsa05200:Pathways in cancer,hsa05222:Small cell lung cancer,	226650~Epidermolysis bullosa, generalized atrophic benign,226700~Epidermolysis bullosa, junctional, Herlitz type,245660~Laryngoonychocutaneous syndrome,		SM00136:LamNT,SM00180:EGF_Lam,SM00181:EGF,SM00281:LamB,SM00282:LamG,	KW-0130~Cell adhesion,	KW-0084~Basement membrane,KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0263~Epidermolysis bullosa,	KW-0175~Coiled coil,KW-0424~Laminin EGF-like domain,KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain,DOMAIN:LAM_G_DOMAIN,DOMAIN:Laminin EGF-like,DOMAIN:Laminin EGF-like 1,DOMAIN:Laminin EGF-like 10,DOMAIN:Laminin EGF-like 11,DOMAIN:Laminin EGF-like 12,DOMAIN:Laminin EGF-like 13,DOMAIN:Laminin EGF-like 14,DOMAIN:Laminin EGF-like 15; truncated,DOMAIN:Laminin EGF-like 2,DOMAIN:Laminin EGF-like 3,DOMAIN:Laminin EGF-like 4,DOMAIN:Laminin EGF-like 5,DOMAIN:Laminin EGF-like 6,DOMAIN:Laminin EGF-like 7,DOMAIN:Laminin EGF-like 8,DOMAIN:Laminin EGF-like 9,DOMAIN:Laminin G-like 1,DOMAIN:Laminin G-like 2,DOMAIN:Laminin G-like 3,DOMAIN:Laminin G-like 4,DOMAIN:Laminin G-like 5,DOMAIN:Laminin IV type A,DOMAIN:Laminin N-terminal,MOTIF:Cell attachment site,REGION:Disordered,REGION:Domain II and I,REGION:Domain III A,REGION:Domain III B,REGION:Domain IV 1 (domain IV B),REGION:Domain V,
LGMN	legumain(LGMN)	Homo sapiens				GO:0002224~toll-like receptor signaling pathway,GO:0003014~renal system process,GO:0006508~proteolysis,GO:0006624~vacuolar protein processing,GO:0007613~memory,GO:0008284~positive regulation of cell proliferation,GO:0008306~associative learning,GO:0010447~response to acidic pH,GO:0010629~negative regulation of gene expression,GO:0019886~antigen processing and presentation of exogenous peptide antigen via MHC class II,GO:0032801~receptor catabolic process,GO:0035729~cellular response to hepatocyte growth factor stimulus,GO:0040015~negative regulation of multicellular organism growth,GO:0042359~vitamin D metabolic process,GO:0043524~negative regulation of neuron apoptotic process,GO:0045931~positive regulation of mitotic cell cycle,GO:0051603~proteolysis involved in cellular protein catabolic process,GO:0071277~cellular response to calcium ion,GO:0090026~positive regulation of monocyte chemotaxis,GO:0097061~dendritic spine organization,GO:0097202~activation of cysteine-type endopeptidase activity,GO:0097264~self proteolysis,GO:1900273~positive regulation of long-term synaptic potentiation,GO:1901185~negative regulation of ERBB signaling pathway,GO:1904646~cellular response to beta-amyloid,GO:2001028~positive regulation of endothelial cell chemotaxis,	GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005764~lysosome,GO:0005770~late endosome,GO:0036021~endolysosome lumen,GO:0043202~lysosomal lumen,GO:0045177~apical part of cell,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0004197~cysteine-type endopeptidase activity,GO:0008233~peptidase activity,GO:0048156~tau protein binding,	IPR001096:Peptidase C13, legumain,	hsa04142:Lysosome,hsa04612:Antigen processing and presentation,		PIRSF019663:transamidase/peptidase, legumain type,PIRSF500139:asparaginyl endopeptidase [Parent=PIRSF019663],			KW-0458~Lysosome,		KW-0732~Signal,		KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	ACT_SITE:Nucleophile,CARBOHYD:N-linked (GlcNAc...) asparagine,MUTAGEN:E->K: Increases catalytic activity at pH 5.5.,MUTAGEN:N->D,Q,S: Loss of autoactivation.,SITE:Cleavage; by autolysis,
LAP3	leucine aminopeptidase 3(LAP3)	Homo sapiens				GO:0006508~proteolysis,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005802~trans-Golgi network,GO:0005829~cytosol,GO:0005925~focal adhesion,GO:0030496~midbody,GO:0070062~extracellular exosome,	GO:0004177~aminopeptidase activity,GO:0004180~carboxypeptidase activity,GO:0005515~protein binding,GO:0008233~peptidase activity,GO:0008235~metalloexopeptidase activity,GO:0030145~manganese ion binding,GO:0070006~metalloaminopeptidase activity,	IPR000819:Peptidase M17, leucyl aminopeptidase, C-terminal,IPR008283:Peptidase M17, leucyl aminopeptidase, N-terminal,IPR011356:Leucine aminopeptidase/peptidase B,IPR023042:Peptidase M17, leucine aminopeptidase,	hsa00330:Arginine and proline metabolism,hsa00480:Glutathione metabolism,hsa01100:Metabolic pathways,					KW-0963~Cytoplasm,			KW-0460~Magnesium,KW-0464~Manganese,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0031~Aminopeptidase,KW-0378~Hydrolase,KW-0645~Protease,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	BINDING:Substrate,DOMAIN:CYTOSOL_AP,METAL:Magnesium; catalytic,METAL:Zinc 1; catalytic,METAL:Zinc 2; catalytic,METAL:Zinc 3; via carbonyl oxygen; structural,
LRRC41	leucine rich repeat containing 41(LRRC41)	Homo sapiens				GO:0016567~protein ubiquitination,GO:0043687~post-translational protein modification,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,	GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR026137:Leucine-rich repeat-containing  41,					KW-0833~Ubl conjugation pathway,			KW-0433~Leucine-rich repeat,KW-0677~Repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,REGION:Disordered,REGION:Interaction with Elongin BC complex,REPEAT:LRR 1,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,
LIPA	lipase A, lysosomal acid type(LIPA)	Homo sapiens				GO:0000902~cell morphogenesis,GO:0006629~lipid metabolic process,GO:0006954~inflammatory response,GO:0008283~cell proliferation,GO:0016042~lipid catabolic process,GO:0016125~sterol metabolic process,GO:0030324~lung development,GO:0034383~low-density lipoprotein particle clearance,GO:0048771~tissue remodeling,GO:0048873~homeostasis of number of cells within a tissue,	GO:0001650~fibrillar center,GO:0005654~nucleoplasm,GO:0005764~lysosome,GO:0005829~cytosol,GO:0043202~lysosomal lumen,GO:0043231~intracellular membrane-bounded organelle,	GO:0004771~sterol esterase activity,GO:0016298~lipase activity,	IPR000073:Alpha/beta hydrolase fold-1,IPR006693:Partial AB-hydrolase lipase domain,IPR025483:Lipase, eukaryotic,	hsa00100:Steroid biosynthesis,hsa04142:Lysosome,hsa04979:Cholesterol metabolism,	278000~Cholesteryl ester storage disease,278000~Wolman disease,	PIRSF000862:lipase, eukaryotic type,		KW-0442~Lipid degradation,KW-0443~Lipid metabolism,	KW-0458~Lysosome,	KW-0225~Disease variant,	KW-0732~Signal,		KW-0378~Hydrolase,	KW-0325~Glycoprotein,	ACT_SITE:Charge relay system,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:AB hydrolase-1,DOMAIN:Abhydro_lipase,MUTAGEN:G->A: Significant loss of enzyme activity.,MUTAGEN:K->R: No effect on enzyme activity.,PROPEP:Removed in mature form,
LSR	lipolysis stimulated lipoprotein receptor(LSR)	Homo sapiens				GO:0001889~liver development,GO:0010669~epithelial structure maintenance,GO:0019216~regulation of lipid metabolic process,GO:0035633~maintenance of permeability of blood-brain barrier,GO:0060856~establishment of blood-brain barrier,GO:0061436~establishment of skin barrier,GO:0061833~protein localization to tricellular tight junction,GO:1904274~tricellular tight junction assembly,	GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0034361~very-low-density lipoprotein particle,GO:0034362~low-density lipoprotein particle,GO:0042627~chylomicron,GO:0061689~tricellular tight junction,GO:0070062~extracellular exosome,GO:0070160~occluding junction,		IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR008664:LISCH7,IPR013783:Immunoglobulin-like fold,				SM00409:IG,		KW-0162~Chylomicron,KW-0427~LDL,KW-0472~Membrane,KW-0850~VLDL,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Ig-like,DOMAIN:Ig-like V-type,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
LPAR2	lysophosphatidic acid receptor 2(LPAR2)	Homo sapiens		h_akap13Pathway:Rho-Selective Guanine Exchange Factor AKAP13 Mediates Stress Fiber Formation,		GO:0007186~G-protein coupled receptor signaling pathway,GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0007202~activation of phospholipase C activity,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0019222~regulation of metabolic process,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0030139~endocytic vesicle,	GO:0004930~G-protein coupled receptor activity,GO:0005515~protein binding,GO:0008289~lipid binding,GO:0070915~lysophosphatidic acid receptor activity,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR004065:Lysophosphatidic acid receptor,IPR004066:Lysophosphatidic acid receptor EDG-4,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04015:Rap1 signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04151:PI3K-Akt signaling pathway,hsa04810:Regulation of actin cytoskeleton,hsa05130:Pathogenic Escherichia coli infection,hsa05200:Pathways in cancer,			SM01381:SM01381,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G_PROTEIN_RECEP_F1_2,LIPID:S-palmitoyl cysteine,MOTIF:PDZ-binding,MUTAGEN:D->A: Abolishes interaction with MAGI3.,MUTAGEN:L->A: Abolishes interaction with MAGI3.,MUTAGEN:S->A: Abolishes interaction with MAGI3.,MUTAGEN:T->A: Does not affect interaction with MAGI3.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
LPGAT1	lysophosphatidylglycerol acyltransferase 1(LPGAT1)	Homo sapiens				GO:0008654~phospholipid biosynthetic process,GO:0019432~triglyceride biosynthetic process,GO:0036148~phosphatidylglycerol acyl-chain remodeling,GO:0036149~phosphatidylinositol acyl-chain remodeling,GO:0045723~positive regulation of fatty acid biosynthetic process,	GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0012505~endomembrane system,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0003841~1-acylglycerol-3-phosphate O-acyltransferase activity,GO:0003846~2-acylglycerol O-acyltransferase activity,GO:0016746~transferase activity, transferring acyl groups,GO:0047144~2-acylglycerol-3-phosphate O-acyltransferase activity,GO:0071617~lysophospholipid acyltransferase activity,	IPR002123:Phospholipid/glycerol acyltransferase,	hsa00564:Glycerophospholipid metabolism,			SM00563:PlsC,	KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,KW-0594~Phospholipid biosynthesis,KW-1208~Phospholipid metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0012~Acyltransferase,KW-0808~Transferase,		MOTIF:HXXXXD motif,TRANSMEM:Helical,
LYPLA1	lysophospholipase 1(LYPLA1)	Homo sapiens				GO:0000165~MAPK cascade,GO:0002084~protein depalmitoylation,GO:0006631~fatty acid metabolic process,GO:0042997~negative regulation of Golgi to plasma membrane protein transport,GO:0050999~regulation of nitric-oxide synthase activity,	GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0031965~nuclear membrane,GO:0070062~extracellular exosome,	GO:0004620~phospholipase activity,GO:0004622~lysophospholipase activity,GO:0005515~protein binding,GO:0008474~palmitoyl-(protein) hydrolase activity,GO:0016298~lipase activity,GO:0016787~hydrolase activity,GO:0052689~carboxylic ester hydrolase activity,	IPR003140:Phospholipase/carboxylesterase/thioesterase,	hsa00564:Glycerophospholipid metabolism,hsa05231:Choline metabolism in cancer,				KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,	KW-0007~Acetylation,	ACT_SITE:Charge relay system,DOMAIN:Abhydrolase_2,MUTAGEN:S->A: Loss of thioesterase and lysophospholipase activity.,TRANSMEM:Helical,
LOXL1	lysyl oxidase like 1(LOXL1)	Homo sapiens				GO:0018057~peptidyl-lysine oxidation,GO:0018277~protein deamination,GO:0030198~extracellular matrix organization,GO:0030199~collagen fibril organization,GO:0032496~response to lipopolysaccharide,GO:0035904~aorta development,	GO:0001669~acrosomal vesicle,GO:0005576~extracellular region,GO:0005604~basement membrane,GO:0005615~extracellular space,	GO:0004720~protein-lysine 6-oxidase activity,GO:0005507~copper ion binding,GO:0005515~protein binding,	IPR001695:Lysyl oxidase,IPR019828:Lysyl oxidase, conserved site,		177650~Exfoliation syndrome, susceptibility to,				KW-0964~Secreted,	KW-0955~Glaucoma,	KW-0732~Signal,	KW-0186~Copper,KW-0479~Metal-binding,	KW-0560~Oxidoreductase,	KW-0165~Cleavage on pair of basic residues,KW-0801~TPQ,KW-0886~LTQ,KW-1015~Disulfide bond,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Lysine tyrosylquinone (Lys-Tyr); alternate,METAL:Copper,REGION:Disordered,REGION:Lysyl-oxidase like,
MFSD10	major facilitator superfamily domain containing 10(MFSD10)	Homo sapiens				GO:0006915~apoptotic process,GO:0015904~tetracycline transport,GO:0043252~sodium-independent organic anion transport,	GO:0005637~nuclear inner membrane,GO:0016021~integral component of membrane,GO:0030659~cytoplasmic vesicle membrane,GO:0031526~brush border membrane,	GO:0005515~protein binding,GO:0008493~tetracycline transporter activity,GO:0008514~organic anion transmembrane transporter activity,GO:0022857~transmembrane transporter activity,	IPR011701:Major facilitator superfamily,IPR020846:Major facilitator superfamily domain,					KW-0053~Apoptosis,KW-0813~Transport,	KW-0472~Membrane,KW-0539~Nucleus,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				DOMAIN:MFS,REGION:Disordered,TRANSMEM:Helical,
HLA-DMA	major histocompatibility complex, class II, DM alpha(HLA-DMA)	Homo sapiens				GO:0002250~adaptive immune response,GO:0002381~immunoglobulin production involved in immunoglobulin mediated immune response,GO:0002503~peptide antigen assembly with MHC class II protein complex,GO:0002504~antigen processing and presentation of peptide or polysaccharide antigen via MHC class II,GO:0006955~immune response,GO:0019882~antigen processing and presentation,GO:0019886~antigen processing and presentation of exogenous peptide antigen via MHC class II,GO:0050870~positive regulation of T cell activation,	GO:0005765~lysosomal membrane,GO:0009986~cell surface,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0031902~late endosome membrane,GO:0042613~MHC class II protein complex,GO:0043231~intracellular membrane-bounded organelle,	GO:0005515~protein binding,GO:0023026~MHC class II protein complex binding,GO:0032395~MHC class II receptor activity,	IPR001003:MHC class II, alpha chain, N-terminal,IPR003006:Immunoglobulin/major histocompatibility complex, conserved site,IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR011162:MHC classes I/II-like antigen recognition protein,IPR013783:Immunoglobulin-like fold,IPR014745:MHC class II, alpha/beta chain, N-terminal,	hsa04145:Phagosome,hsa04514:Cell adhesion molecules,hsa04612:Antigen processing and presentation,hsa04640:Hematopoietic cell lineage,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04672:Intestinal immune network for IgA production,hsa04940:Type I diabetes mellitus,hsa05140:Leishmaniasis,hsa05145:Toxoplasmosis,hsa05150:Staphylococcus aureus infection,hsa05152:Tuberculosis,hsa05164:Influenza A,hsa05166:Human T-cell leukemia virus 1 infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05310:Asthma,hsa05320:Autoimmune thyroid disease,hsa05321:Inflammatory bowel disease,hsa05322:Systemic lupus erythematosus,hsa05323:Rheumatoid arthritis,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05416:Viral myocarditis,			SM00407:IGc1,SM00920:SM00920,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0458~Lysosome,KW-0472~Membrane,KW-0491~MHC II,KW-0967~Endosome,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:IGc1,DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,DOMAIN:MHC_II_alpha,MUTAGEN:F->A: Decreases the interaction with MHCII and peptide exchange.,MUTAGEN:I->N: Decreases the interaction with MHCII and peptide exchange.,MUTAGEN:N->A,R: Abrogates the interaction with MHCII and peptide exchange.,MUTAGEN:R->A: Decreases the interaction with MHCII and peptide exchange; when associated with A-124.,MUTAGEN:R->A: Decreases the interaction with MHCII and peptide exchange; when associated with A-220.,REGION:Alpha-1,REGION:Alpha-2,REGION:Connecting peptide,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
HLA-DRA	major histocompatibility complex, class II, DR alpha(HLA-DRA)	Homo sapiens		h_asbcellPathway:Antigen Dependent B Cell Activation,h_bbcellPathway:Bystander B Cell Activation,h_blymphocytePathway:B Lymphocyte Cell Surface Molecules,h_cskPathway:Activation of Csk by cAMP-dependent Protein Kinase Inhibits Signaling through the T Cell Receptor,h_ctla4Pathway:The Co-Stimulatory Signal During T-cell Activation,h_eosinophilsPathway:The Role of Eosinophils in the Chemokine Network of Allergy,h_il5Pathway:IL 5 Signaling Pathway,h_inflamPathway:Cytokines and Inflammatory Response,h_mhcPathway:Antigen Processing and Presentation,h_tcraPathway:Lck and Fyn tyrosine kinases in initiation of TCR Activation,h_th1th2Pathway:Th1/Th2 Differentiation,		GO:0001916~positive regulation of T cell mediated cytotoxicity,GO:0002250~adaptive immune response,GO:0002381~immunoglobulin production involved in immunoglobulin mediated immune response,GO:0002469~myeloid dendritic cell antigen processing and presentation,GO:0002491~antigen processing and presentation of endogenous peptide antigen via MHC class II,GO:0002503~peptide antigen assembly with MHC class II protein complex,GO:0002504~antigen processing and presentation of peptide or polysaccharide antigen via MHC class II,GO:0006955~immune response,GO:0016032~viral process,GO:0019882~antigen processing and presentation,GO:0019886~antigen processing and presentation of exogenous peptide antigen via MHC class II,GO:0032831~positive regulation of CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation,GO:0043382~positive regulation of memory T cell differentiation,GO:0045622~regulation of T-helper cell differentiation,GO:0050852~T cell receptor signaling pathway,GO:0050870~positive regulation of T cell activation,GO:0050890~cognition,GO:0060333~interferon-gamma-mediated signaling pathway,GO:2000516~positive regulation of CD4-positive, alpha-beta T cell activation,	GO:0000139~Golgi membrane,GO:0001772~immunological synapse,GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0010008~endosome membrane,GO:0012507~ER to Golgi transport vesicle membrane,GO:0016021~integral component of membrane,GO:0030658~transport vesicle membrane,GO:0030666~endocytic vesicle membrane,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0031901~early endosome membrane,GO:0031902~late endosome membrane,GO:0032588~trans-Golgi network membrane,GO:0042613~MHC class II protein complex,GO:0070062~extracellular exosome,GO:0071556~integral component of lumenal side of endoplasmic reticulum membrane,	GO:0005515~protein binding,GO:0023026~MHC class II protein complex binding,GO:0030247~polysaccharide binding,GO:0032395~MHC class II receptor activity,GO:0042605~peptide antigen binding,GO:0042608~T cell receptor binding,	IPR001003:MHC class II, alpha chain, N-terminal,IPR003006:Immunoglobulin/major histocompatibility complex, conserved site,IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR011162:MHC classes I/II-like antigen recognition protein,IPR013783:Immunoglobulin-like fold,IPR014745:MHC class II, alpha/beta chain, N-terminal,	hsa04145:Phagosome,hsa04514:Cell adhesion molecules,hsa04612:Antigen processing and presentation,hsa04640:Hematopoietic cell lineage,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04672:Intestinal immune network for IgA production,hsa04940:Type I diabetes mellitus,hsa05140:Leishmaniasis,hsa05145:Toxoplasmosis,hsa05150:Staphylococcus aureus infection,hsa05152:Tuberculosis,hsa05164:Influenza A,hsa05166:Human T-cell leukemia virus 1 infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05310:Asthma,hsa05320:Autoimmune thyroid disease,hsa05321:Inflammatory bowel disease,hsa05322:Systemic lupus erythematosus,hsa05323:Rheumatoid arthritis,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05416:Viral myocarditis,			SM00407:IGc1,SM00920:SM00920,	KW-0391~Immunity,KW-0945~Host-virus interaction,KW-1064~Adaptive immunity,	KW-0256~Endoplasmic reticulum,KW-0458~Lysosome,KW-0472~Membrane,KW-0491~MHC II,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:IGc1,DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,DOMAIN:MHC_II_alpha,MUTAGEN:A->L: Decreases the affinity of the interaction with TCR by more than five-fold.,MUTAGEN:E->A: Increases the interaction with HLA-DM complex and peptide exchange. Decreases the affinity of the interaction with TCR by more than five-fold.,MUTAGEN:E->K: Impairs the interaction with HLA-DM complex, CLIP dissociation and peptide exchange.,MUTAGEN:F->A,C: Increases the interaction with HLA-DM complex and peptide exchange.,MUTAGEN:F->A,S,V,L: Impairs the interaction with HLA-DM complex, CLIP dissociation and peptide exchange.,MUTAGEN:F->W: Increases the interaction with HLA-DM complex and peptide exchange.,MUTAGEN:G->S: Increases the interaction with HLA-DM complex and peptide exchange.,MUTAGEN:K->R: Almost no change in down-regulation of MHCII. No ubiquitination and complete loss of down-regulation of MHCII; when associated with 'R-254' of HLA-DRB.,MUTAGEN:L->R: Decreases the interaction with CD4.,MUTAGEN:P->S: Decreases the interaction with HLA-DM complex and peptide exchange.,MUTAGEN:Q->A: Decreases the interaction with HLA-DM complex and peptide exchange.,MUTAGEN:R->A: Impairs the interaction with HLA-DM complex and peptide exchange.,MUTAGEN:S->D,H: Decreases the interaction with HLA-DM complex and peptide exchange.,MUTAGEN:T->R: Decreases the interaction with CD4.,MUTAGEN:W->F: Decreases the interaction with HLA-DM complex and peptide exchange.,REGION:Alpha-1,REGION:Alpha-2,REGION:Connecting peptide,SITE:Pathogen-derived peptide antigen,SITE:Self- and pathogen-derived peptide antigen,SITE:Self-peptide antigen,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
MVP	major vault protein(MVP)	Homo sapiens				GO:0015031~protein transport,GO:0031953~negative regulation of protein autophosphorylation,GO:0038127~ERBB signaling pathway,GO:0042059~negative regulation of epidermal growth factor receptor signaling pathway,GO:0043312~neutrophil degranulation,GO:0051028~mRNA transport,GO:0061099~negative regulation of protein tyrosine kinase activity,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005643~nuclear pore,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0016020~membrane,GO:0034774~secretory granule lumen,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:1904813~ficolin-1-rich granule lumen,	GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0019903~protein phosphatase binding,GO:0042802~identical protein binding,	IPR002499:Major vault protein, N-terminal,IPR021870:Shoulder domain,					KW-0509~mRNA transport,KW-0653~Protein transport,KW-0811~Translocation,KW-0813~Transport,	KW-0539~Nucleus,KW-0906~Nuclear pore complex,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0677~Repeat,		KW-0687~Ribonucleoprotein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:MVP_shoulder,DOMAIN:Vault,DOMAIN:Vault_2,DOMAIN:Vault_3,DOMAIN:Vault_4,REGION:Disordered,REPEAT:MVP 1,REPEAT:MVP 2,REPEAT:MVP 3,REPEAT:MVP 4,REPEAT:MVP 5,REPEAT:MVP 6,REPEAT:MVP 7,REPEAT:MVP 8,REPEAT:MVP 9,
MLEC	malectin(MLEC)	Homo sapiens				GO:0005975~carbohydrate metabolic process,GO:0006457~protein folding,GO:0006487~protein N-linked glycosylation,GO:0043312~neutrophil degranulation,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0008250~oligosaccharyltransferase complex,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0035579~specific granule membrane,	GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0030246~carbohydrate binding,	IPR021720:Malectin,					KW-0119~Carbohydrate metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	BINDING:Carbohydrate,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Malectin,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
ME2	malic enzyme 2(ME2)	Homo sapiens				GO:0006090~pyruvate metabolic process,GO:0006099~tricarboxylic acid cycle,GO:0006108~malate metabolic process,GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules,GO:0016339~calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules,GO:0022900~electron transport chain,GO:1902031~regulation of NADP metabolic process,	GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0004470~malic enzyme activity,GO:0004471~malate dehydrogenase (decarboxylating) (NAD+) activity,GO:0004473~malate dehydrogenase (decarboxylating) (NADP+) activity,GO:0005509~calcium ion binding,GO:0008948~oxaloacetate decarboxylase activity,GO:0009055~electron carrier activity,GO:0046872~metal ion binding,GO:0051287~NAD binding,	IPR001891:Malic oxidoreductase,IPR002126:Cadherin,IPR012301:Malic enzyme, N-terminal,IPR012302:Malic enzyme, NAD-binding,IPR015884:Malic enzyme, conserved site,IPR015919:Cadherin-like,IPR020894:Cadherin conserved site,	hsa00620:Pyruvate metabolism,hsa01200:Carbon metabolism,		PIRSF000106:malic enzyme,	SM00919:SM00919,SM01274:SM01274,		KW-0472~Membrane,KW-0496~Mitochondrion,		KW-0677~Repeat,KW-0809~Transit peptide,	KW-0479~Metal-binding,KW-0520~NAD,	KW-0021~Allosteric enzyme,KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0325~Glycoprotein,	ACT_SITE:Proton acceptor,ACT_SITE:Proton donor,BINDING:Fumarate; allosteric activator,BINDING:NAD,BINDING:Substrate,DOMAIN:Cadherin,DOMAIN:Malic_M,DOMAIN:malic,METAL:Divalent metal cation,MUTAGEN:R->S: Abolishes activation by fumarate.,MUTAGEN:R->T: Abolishes activation by fumarate.,NP_BIND:NAD,SITE:Important for activity,TRANSIT:Mitochondrion,
MAN2B1	mannosidase alpha class 2B member 1(MAN2B1)	Homo sapiens		h_aMANpathway:Steps in the Glycosylation of Mammalian N-linked Oligosaccarides,h_eradPathway:ERï¿½associated degradation (ERAD) Pathway,		GO:0005975~carbohydrate metabolic process,GO:0006013~mannose metabolic process,GO:0006464~cellular protein modification process,GO:0006517~protein deglycosylation,GO:0009313~oligosaccharide catabolic process,GO:0043312~neutrophil degranulation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005654~nucleoplasm,GO:0005764~lysosome,GO:0005774~vacuolar membrane,GO:0035578~azurophil granule lumen,GO:0043202~lysosomal lumen,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,	GO:0003824~catalytic activity,GO:0004559~alpha-mannosidase activity,GO:0030246~carbohydrate binding,GO:0046872~metal ion binding,	IPR000602:Glycoside hydrolase family 38, N-terminal domain,IPR011013:Galactose mutarotase-like domain,IPR011330:Glycoside hydrolase/deacetylase, beta/alpha-barrel,IPR011682:Glycosyl hydrolase family 38, C-terminal,IPR013780:Glycosyl hydrolase, family 13, all-beta,IPR015341:Glycoside hydrolase, family 38, central domain,IPR027291:Glycoside hydrolase 38/57, N-terminal domain,	hsa00511:Other glycan degradation,hsa04142:Lysosome,	248500~Mannosidosis, alpha-, types I and II,		SM00872:SM00872,		KW-0458~Lysosome,	KW-0225~Disease variant,	KW-0732~Signal,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0326~Glycosidase,KW-0378~Hydrolase,	KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	ACT_SITE:Nucleophile,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Alpha-mann_mid,DOMAIN:Glyco_hydro_38N,METAL:Zinc,REGION:Disordered,
MAMLD1	mastermind like domain containing 1(MAMLD1)	Homo sapiens				GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0008584~male gonad development,	GO:0005654~nucleoplasm,GO:0005794~Golgi apparatus,GO:0005813~centrosome,GO:0016604~nuclear body,		IPR026131:Mastermind-like domain-containing protein 1,		300758~Hypospadias 2, X-linked,			KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,MUTAGEN:L->P: Reduces transcriptional activation of the HES3 promoter.,REGION:Disordered,
MELK	maternal embryonic leucine zipper kinase(MELK)	Homo sapiens				GO:0000086~G2/M transition of mitotic cell cycle,GO:0006468~protein phosphorylation,GO:0006915~apoptotic process,GO:0008283~cell proliferation,GO:0008631~intrinsic apoptotic signaling pathway in response to oxidative stress,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0030097~hemopoiesis,GO:0035556~intracellular signal transduction,GO:0043065~positive regulation of apoptotic process,GO:0046777~protein autophosphorylation,GO:0061351~neural precursor cell proliferation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005938~cell cortex,GO:0016020~membrane,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0004715~non-membrane spanning protein tyrosine kinase activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008289~lipid binding,	IPR000719:Protein kinase, catalytic domain,IPR001772:Kinase associated domain 1 (KA1),IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,				SM00220:S_TKc,	KW-0053~Apoptosis,KW-0131~Cell cycle,	KW-0472~Membrane,KW-1003~Cell membrane,			KW-0067~ATP-binding,KW-0106~Calcium,KW-0446~Lipid-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:ATP,DOMAIN:KA1,DOMAIN:Protein kinase,MUTAGEN:C->A: Abolishes dependence to reducing agents; when associated with V-29; V-70; A-154; A-168; A-169; A-204; A-286 and A-339.,MUTAGEN:C->A: Abolishes dependence to reducing agents; when associated with V-29; V-70; A-89; A-154; A-168; A-169; A-204 and A-286.,MUTAGEN:C->A: Abolishes dependence to reducing agents; when associated with V-29; V-70; A-89; A-154; A-168; A-169; A-204; and A-339.,MUTAGEN:C->A: Abolishes dependence to reducing agents; when associated with V-29; V-70; A-89; A-154; A-168; A-169; A-286 and A-339.,MUTAGEN:C->A: Abolishes dependence to reducing agents; when associated with V-29; V-70; A-89; A-154; A-168; A-204; A-286 and A-339.,MUTAGEN:C->A: Abolishes dependence to reducing agents; when associated with V-29; V-70; A-89; A-154; A-169; A-204; A-286 and A-339.,MUTAGEN:C->A: Abolishes dependence to reducing agents; when associated with V-29; V-70; A-89; A-168; A-169; A-204; A-286 and A-339.,MUTAGEN:C->V: Abolishes dependence to reducing agents; when associated with V-29; A-89; A-154; A-168; A-169; A-204; A-286 and A-339.,MUTAGEN:C->V: Abolishes dependence to reducing agents; when associated with V-70; A-89; A-154; A-168; A-169; A-204; A-286 and A-339.,MUTAGEN:D->A: Abolishes enzymatic activity.,MUTAGEN:DDD->KKK: Inactive.,MUTAGEN:S->A: Abolishes activation of serine/threonine-protein kinase activity and has only weak activity.,MUTAGEN:S->D: Inactive.,MUTAGEN:T->A: Abolishes activation of serine/threonine-protein kinase activity and has only weak activity.,MUTAGEN:T->A: Inhibits interaction with PPP1R8.,MUTAGEN:T->A: No effect on interaction with PPP1R8.,MUTAGEN:T->A: Strongly inhibits interaction with PPP1R8. Enhances enzymatic activity.,MUTAGEN:T->D,E: Phosphomimetic mutant that has similar kinase activity as wild-type.,MUTAGEN:Y->F: Abolishes autophosphorylation on tyrosine but still active on exogenous substrates.,NP_BIND:ATP,REGION:Autoinhibitory region,REGION:UBA-like,
MMP1	matrix metallopeptidase 1(MMP1)	Homo sapiens				GO:0006508~proteolysis,GO:0016032~viral process,GO:0019221~cytokine-mediated signaling pathway,GO:0022617~extracellular matrix disassembly,GO:0030198~extracellular matrix organization,GO:0030574~collagen catabolic process,GO:0031334~positive regulation of protein complex assembly,GO:0044267~cellular protein metabolic process,GO:0050900~leukocyte migration,GO:0071492~cellular response to UV-A,	GO:0005576~extracellular region,GO:0005581~collagen trimer,GO:0031012~extracellular matrix,	GO:0004175~endopeptidase activity,GO:0004222~metalloendopeptidase activity,GO:0004252~serine-type endopeptidase activity,GO:0008233~peptidase activity,GO:0008270~zinc ion binding,	IPR000585:Hemopexin-like domain,IPR001818:Peptidase M10, metallopeptidase,IPR002477:Peptidoglycan binding-like,IPR006026:Peptidase, metallopeptidase,IPR018486:Hemopexin, conserved site,IPR018487:Hemopexin-like repeats,IPR021158:Peptidase M10A, cysteine switch, zinc binding site,IPR021190:Peptidase M10A,IPR024079:Metallopeptidase, catalytic domain,	hsa03320:PPAR signaling pathway,hsa04657:IL-17 signaling pathway,hsa04926:Relaxin signaling pathway,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,hsa05219:Bladder cancer,hsa05323:Rheumatoid arthritis,hsa05417:Lipid and atherosclerosis,	226600~Epidermolysis bullosa dystrophica, autosomal recessive, modifier of,606963~COPD, rate of decline of lung function in,	PIRSF001191:matrix metalloproteinase, stromelysin type,	SM00120:HX,SM00235:ZnMc,	KW-0177~Collagen degradation,KW-0945~Host-virus interaction,	KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0176~Collagen,KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0068~Autocatalytic cleavage,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Peptidase_M10,DOMAIN:ZnMc,METAL:Calcium 1,METAL:Calcium 2,METAL:Calcium 2; via carbonyl oxygen,METAL:Calcium 3,METAL:Calcium 3; via carbonyl oxygen,METAL:Calcium 4; via carbonyl oxygen,METAL:Zinc 1,METAL:Zinc 2; catalytic,METAL:Zinc 2; in inhibited form,MOTIF:Cysteine switch,MUTAGEN:Y->F: Partial reduction of tyrosine phosphorylation in the presence of PKDCC/VLK.,PROPEP:Activation peptide,REGION:Metalloprotease,REPEAT:Hemopexin,REPEAT:Hemopexin 1,REPEAT:Hemopexin 2,REPEAT:Hemopexin 3,REPEAT:Hemopexin 4,SITE:Cleavage; by autolysis,SITE:Not glycosylated,
MMP2	matrix metallopeptidase 2(MMP2)	Homo sapiens		h_reckPathway:Inhibition of Matrix Metalloproteinases,		GO:0001525~angiogenesis,GO:0001541~ovarian follicle development,GO:0001542~ovulation from ovarian follicle,GO:0001553~luteinization,GO:0001666~response to hypoxia,GO:0001955~blood vessel maturation,GO:0001957~intramembranous ossification,GO:0006508~proteolysis,GO:0007162~negative regulation of cell adhesion,GO:0007507~heart development,GO:0007566~embryo implantation,GO:0007567~parturition,GO:0007568~aging,GO:0009410~response to xenobiotic stimulus,GO:0009612~response to mechanical stimulus,GO:0014012~peripheral nervous system axon regeneration,GO:0014823~response to activity,GO:0016477~cell migration,GO:0019221~cytokine-mediated signaling pathway,GO:0022617~extracellular matrix disassembly,GO:0030198~extracellular matrix organization,GO:0030335~positive regulation of cell migration,GO:0030574~collagen catabolic process,GO:0032526~response to retinoic acid,GO:0034614~cellular response to reactive oxygen species,GO:0035094~response to nicotine,GO:0035987~endodermal cell differentiation,GO:0042542~response to hydrogen peroxide,GO:0043065~positive regulation of apoptotic process,GO:0043627~response to estrogen,GO:0044267~cellular protein metabolic process,GO:0045906~negative regulation of vasoconstriction,GO:0048013~ephrin receptor signaling pathway,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0048771~tissue remodeling,GO:0051602~response to electrical stimulus,GO:0055093~response to hyperoxia,GO:0060325~face morphogenesis,GO:0060346~bone trabecula formation,GO:0060740~prostate gland epithelium morphogenesis,GO:0071230~cellular response to amino acid stimulus,GO:0071347~cellular response to interleukin-1,GO:0071392~cellular response to estradiol stimulus,GO:0071492~cellular response to UV-A,GO:0071498~cellular response to fluid shear stress,GO:1904645~response to beta-amyloid,GO:1904707~positive regulation of vascular smooth muscle cell proliferation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0005886~plasma membrane,GO:0030017~sarcomere,GO:0031012~extracellular matrix,	GO:0001968~fibronectin binding,GO:0004175~endopeptidase activity,GO:0004222~metalloendopeptidase activity,GO:0004252~serine-type endopeptidase activity,GO:0005515~protein binding,GO:0008237~metallopeptidase activity,GO:0008270~zinc ion binding,	IPR000562:Fibronectin, type II, collagen-binding,IPR000585:Hemopexin-like domain,IPR001818:Peptidase M10, metallopeptidase,IPR002477:Peptidoglycan binding-like,IPR006026:Peptidase, metallopeptidase,IPR013806:Kringle-like fold,IPR018486:Hemopexin, conserved site,IPR018487:Hemopexin-like repeats,IPR021158:Peptidase M10A, cysteine switch, zinc binding site,IPR021190:Peptidase M10A,IPR024079:Metallopeptidase, catalytic domain,	hsa01522:Endocrine resistance,hsa04670:Leukocyte transendothelial migration,hsa04912:GnRH signaling pathway,hsa04915:Estrogen signaling pathway,hsa04926:Relaxin signaling pathway,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05219:Bladder cancer,hsa05415:Diabetic cardiomyopathy,hsa05418:Fluid shear stress and atherosclerosis,	259600~Multicentric osteolysis, nodulosis, and arthropathy,	PIRSF001191:matrix metalloproteinase, stromelysin type,	SM00059:FN2,SM00120:HX,SM00235:ZnMc,	KW-0037~Angiogenesis,KW-0177~Collagen degradation,	KW-0272~Extracellular matrix,KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0964~Secreted,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0068~Autocatalytic cleavage,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Fibronectin type-II,DOMAIN:Fibronectin type-II 1,DOMAIN:Fibronectin type-II 2,DOMAIN:Fibronectin type-II 3,DOMAIN:Peptidase_M10,DOMAIN:ZnMc,METAL:Calcium 1,METAL:Calcium 1; via carbonyl oxygen,METAL:Calcium 2,METAL:Calcium 2; via carbonyl oxygen,METAL:Calcium 3,METAL:Calcium 3; via carbonyl oxygen,METAL:Calcium 4; via carbonyl oxygen,METAL:Zinc 1; catalytic,METAL:Zinc 1; in inhibited form,METAL:Zinc 2,MOTIF:Cysteine switch,PROPEP:Activation peptide,REGION:Collagen-binding,REGION:Collagenase-like 1,REGION:Collagenase-like 2,REGION:Required for inhibitor TIMP2 binding,REPEAT:Hemopexin,REPEAT:Hemopexin 1,REPEAT:Hemopexin 2,REPEAT:Hemopexin 3,REPEAT:Hemopexin 4,
MBOAT7	membrane bound O-acyltransferase domain containing 7(MBOAT7)	Homo sapiens				GO:0006661~phosphatidylinositol biosynthetic process,GO:0021591~ventricular system development,GO:0021819~layer formation in cerebral cortex,GO:0030258~lipid modification,GO:0036149~phosphatidylinositol acyl-chain remodeling,GO:0036151~phosphatidylcholine acyl-chain remodeling,GO:0090207~regulation of triglyceride metabolic process,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0044233~ER-mitochondrion membrane contact site,	GO:0003841~1-acylglycerol-3-phosphate O-acyltransferase activity,GO:0005515~protein binding,GO:0008374~O-acyltransferase activity,GO:0016746~transferase activity, transferring acyl groups,GO:0047144~2-acylglycerol-3-phosphate O-acyltransferase activity,GO:0071617~lysophospholipid acyltransferase activity,	IPR004299:Membrane bound O-acyl transferase, MBOAT,	hsa00564:Glycerophospholipid metabolism,	617188~Mental retardation, autosomal recessive 57,			KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,KW-0594~Phospholipid biosynthesis,KW-1208~Phospholipid metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,	KW-0225~Disease variant,KW-0991~Mental retardation,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0012~Acyltransferase,KW-0808~Transferase,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
MBTPS1	membrane bound transcription factor peptidase, site 1(MBTPS1)	Homo sapiens		h_s1pPathway:SREBP control of lipid synthesis,		GO:0006508~proteolysis,GO:0006606~protein import into nucleus,GO:0007040~lysosome organization,GO:0008203~cholesterol metabolic process,GO:0030968~endoplasmic reticulum unfolded protein response,GO:0031293~membrane protein intracellular domain proteolysis,GO:0034976~response to endoplasmic reticulum stress,GO:0036500~ATF6-mediated unfolded protein response,GO:0043687~post-translational protein modification,GO:0044267~cellular protein metabolic process,GO:0045540~regulation of cholesterol biosynthetic process,GO:0060627~regulation of vesicle-mediated transport,	GO:0000139~Golgi membrane,GO:0005788~endoplasmic reticulum lumen,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005795~Golgi stack,GO:0016021~integral component of membrane,	GO:0004252~serine-type endopeptidase activity,	IPR000209:Peptidase S8/S53 domain,IPR015500:Peptidase S8, subtilisin-related,IPR022398:Peptidase S8, subtilisin, His-active site,IPR023828:Peptidase S8, subtilisin, Ser-active site,	hsa04141:Protein processing in endoplasmic reticulum,	618392~Spondyloepiphyseal dysplasia, Kondo-Fu type,			KW-0153~Cholesterol metabolism,KW-0443~Lipid metabolism,KW-0753~Steroid metabolism,KW-1207~Sterol metabolism,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,	KW-0225~Disease variant,KW-0242~Dwarfism,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,	KW-0378~Hydrolase,KW-0645~Protease,KW-0720~Serine protease,	KW-0068~Autocatalytic cleavage,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0865~Zymogen,	ACT_SITE:Charge relay system,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Peptidase S8,DOMAIN:Peptidase_S8,MUTAGEN:H->A: Abolished serine protease activity.,MUTAGEN:S->A: Abolished serine protease activity.,REGION:Disordered,SITE:Cleavage; by autolysis,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
MEST	mesoderm specific transcript(MEST)	Homo sapiens				GO:0007498~mesoderm development,GO:0010883~regulation of lipid storage,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016021~integral component of membrane,GO:0070062~extracellular exosome,	GO:0003824~catalytic activity,GO:0005515~protein binding,GO:0016787~hydrolase activity,	IPR000073:Alpha/beta hydrolase fold-1,IPR000639:Epoxide hydrolase-like,						KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:AB hydrolase-1,MOTIF:RVIALD,TRANSMEM:Helical,
MTF2	metal response element binding transcription factor 2(MTF2)	Homo sapiens				GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006325~chromatin organization,GO:0006355~regulation of transcription, DNA-templated,GO:0007379~segment specification,GO:0019827~stem cell population maintenance,GO:0045814~negative regulation of gene expression, epigenetic,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048863~stem cell differentiation,GO:0061086~negative regulation of histone H3-K27 methylation,GO:0061087~positive regulation of histone H3-K27 methylation,GO:1990830~cellular response to leukemia inhibitory factor,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005925~focal adhesion,GO:0035098~ESC/E(Z) complex,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0001222~transcription corepressor binding,GO:0001226~RNA polymerase II transcription corepressor binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0035064~methylated histone binding,GO:0046872~metal ion binding,	IPR001965:Zinc finger, PHD-type,IPR002999:Tudor domain,IPR011011:Zinc finger, FYVE/PHD-type,IPR013083:Zinc finger, RING/FYVE/PHD-type,IPR019786:Zinc finger, PHD-type, conserved site,IPR019787:Zinc finger, PHD-finger,IPR025894:Polycomb-like MTF2 factor 2, C-terminal domain,				SM00249:PHD,SM00333:TUDOR,		KW-0539~Nucleus,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0156~Chromatin regulator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:PHD-type,DOMAIN:Tudor,MUTAGEN:KK->AA: Abolishes chromatin binding activity of the PRC2.1 complex.,MUTAGEN:Missing: Reduced chromatin binding activity of the PRC2.1 complex, probably due to loss of dimer stability.,REGION:Disordered,ZN_FING:PHD-type 1,ZN_FING:PHD-type 2,
MTA1	metastasis associated 1(MTA1)	Homo sapiens		h_mta3Pathway:Downregulated of MTA-3 in ER-negative Breast Tumors,		GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006302~double-strand break repair,GO:0006338~chromatin remodeling,GO:0006355~regulation of transcription, DNA-templated,GO:0007165~signal transduction,GO:0010212~response to ionizing radiation,GO:0016575~histone deacetylation,GO:0032922~circadian regulation of gene expression,GO:0040029~regulation of gene expression, epigenetic,GO:0043153~entrainment of circadian clock by photoperiod,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0045475~locomotor rhythm,GO:1902499~positive regulation of protein autoubiquitination,	GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005874~microtubule,GO:0016581~NuRD complex,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0001103~RNA polymerase II repressing transcription factor binding,GO:0003682~chromatin binding,GO:0003713~transcription coactivator activity,GO:0003714~transcription corepressor activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0042826~histone deacetylase binding,GO:0043565~sequence-specific DNA binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,	IPR000679:Zinc finger, GATA-type,IPR000949:ELM2 domain,IPR001005:SANT/Myb domain,IPR001025:Bromo adjacent homology (BAH) domain,IPR009057:Homeodomain-like,IPR017884:SANT domain,				SM00401:ZnF_GATA,SM00439:BAH,SM00717:SANT,SM01189:SM01189,	KW-0090~Biological rhythms,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0238~DNA-binding,KW-0678~Repressor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2 and SUMO3),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate,DOMAIN:BAH,DOMAIN:ELM2,DOMAIN:MTA_R1,DOMAIN:SANT,MOTIF:SH3-binding,MOTIF:SUMO interaction motif 1 (SIM); crucial for efficient sumoylation,MUTAGEN:IVI->AAA: Significant loss of interaction with SUMO1 and SUMO2 and reduced transcriptional corepressor activity.,MUTAGEN:K->A: Loss of acetylation and transcriptional coactivator activity. Reduced ubiquitination. Significant reduction in ubiquitination; when associated with A-182.,MUTAGEN:K->A: Reduced ubiquitination. Significant reduction in ubiquitination; when associated with A-626.,MUTAGEN:K->R: Reduced sumoylation and transcriptional corepressor activity.,REGION:Disordered,ZN_FING:GATA-type; atypical,
METRN	meteorin, glial cell differentiation regulator(METRN)	Homo sapiens				GO:0007165~signal transduction,GO:0010001~glial cell differentiation,GO:0050772~positive regulation of axonogenesis,	GO:0005615~extracellular space,	GO:0005179~hormone activity,						KW-0221~Differentiation,KW-0524~Neurogenesis,	KW-0964~Secreted,		KW-0732~Signal,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-1015~Disulfide bond,
MAT2A	methionine adenosyltransferase 2A(MAT2A)	Homo sapiens				GO:0006556~S-adenosylmethionine biosynthetic process,GO:0006730~one-carbon metabolic process,GO:0032259~methylation,GO:0034214~protein hexamerization,GO:0051291~protein heterooligomerization,GO:1990830~cellular response to leukemia inhibitory factor,	GO:0005829~cytosol,GO:0048269~methionine adenosyltransferase complex,	GO:0004478~methionine adenosyltransferase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,	IPR002133:S-adenosylmethionine synthetase,IPR022628:S-adenosylmethionine synthetase, N-terminal,IPR022629:S-adenosylmethionine synthetase, central domain,IPR022630:S-adenosylmethionine synthetase, C-terminal,IPR022631:S-adenosylmethionine synthetase, conserved site,IPR022636:S-adenosylmethionine synthetase superfamily,	hsa00270:Cysteine and methionine metabolism,hsa01100:Metabolic pathways,hsa01230:Biosynthesis of amino acids,hsa01240:Biosynthesis of cofactors,		PIRSF000497:methionine adenosyltransferase,		KW-0554~One-carbon metabolism,				KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0630~Potassium,	KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	BINDING:ATP,BINDING:ATP; shared with neighboring subunit,BINDING:ATP; via amide nitrogen; shared with neighboring subunit,BINDING:Methionine,BINDING:Methionine; shared with neighboring subunit,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:S-AdoMet_synt_C,DOMAIN:S-AdoMet_synt_M,DOMAIN:S-AdoMet_synt_N,METAL:Magnesium,METAL:Potassium,NP_BIND:ATP,REGION:Flexible loop,
MSRA	methionine sulfoxide reductase A(MSRA)	Homo sapiens				GO:0006464~cellular protein modification process,GO:0006555~methionine metabolic process,GO:0006979~response to oxidative stress,GO:0030091~protein repair,GO:0034599~cellular response to oxidative stress,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0015629~actin cytoskeleton,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0008113~peptide-methionine (S)-S-oxide reductase activity,GO:0036456~L-methionine-(S)-S-oxide reductase activity,	IPR002569:Peptide methionine sulphoxide reductase MsrA,						KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0676~Redox-active center,KW-0732~Signal,KW-0809~Transit peptide,		KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0519~Myristate,KW-1015~Disulfide bond,	ACT_SITE:Cysteine sulfenic acid (-SOH) intermediate,DISULFID:Redox-active; alternate,DOMAIN:PMSR,LIPID:N-myristoyl glycine,MUTAGEN:Missing: Impaired subcellular location.,MUTAGEN:R->A: Impaired subcellular location.,REGION:Disordered,TRANSIT:Mitochondrion,
MTHFD2	methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase(MTHFD2)	Homo sapiens			Coenzyme metabolism,	GO:0035999~tetrahydrofolate interconversion,GO:0046653~tetrahydrofolate metabolic process,GO:0046655~folic acid metabolic process,	GO:0005615~extracellular space,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,	GO:0000287~magnesium ion binding,GO:0004477~methenyltetrahydrofolate cyclohydrolase activity,GO:0004487~methylenetetrahydrofolate dehydrogenase (NAD+) activity,GO:0004488~methylenetetrahydrofolate dehydrogenase (NADP+) activity,GO:0005515~protein binding,GO:0042301~phosphate ion binding,	IPR000672:Tetrahydrofolate dehydrogenase/cyclohydrolase,IPR020630:Tetrahydrofolate dehydrogenase/cyclohydrolase, catalytic domain,IPR020631:Tetrahydrofolate dehydrogenase/cyclohydrolase, NAD(P)-binding domain,IPR020867:Tetrahydrofolate dehydrogenase/cyclohydrolase, conserved site,	hsa00670:One carbon pool by folate,hsa01100:Metabolic pathways,hsa01240:Biosynthesis of cofactors,				KW-0554~One-carbon metabolism,	KW-0496~Mitochondrion,		KW-0809~Transit peptide,	KW-0460~Magnesium,KW-0520~NAD,KW-0521~NADP,	KW-0378~Hydrolase,KW-0511~Multifunctional enzyme,KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	BINDING:NAD,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:THF_DHG_CYH,DOMAIN:THF_DHG_CYH_C,MUTAGEN:D->A,S,E: Complete loss of NAD and NADP-dependent dehydrogenase specific activity.,MUTAGEN:D->A: Significant loss of NAD and NADP-dependent dehydrogenase specific activity.,MUTAGEN:D->E: Complete loss of NAD and NADP-dependent dehydrogenase specific activity.,MUTAGEN:D->N: 80% decrease in NAD-dependent dehydrogenase specific activity. 18% decrease in NADP-dependent dehydrogenase specific activity. Reduced affinity for magnesium.,MUTAGEN:D->N: 84% decrease in NAD-dependent dehydrogenase specific activity. 36% increase in NADP-dependent dehydrogenase specific activity. Reduced affinity for magnesium.,MUTAGEN:D->S: 82% decrease in NAD-dependent dehydrogenase specific activity. 65% decrease in NADP-dependent dehydrogenase specific activity. Reduced affinity for magnesium.,MUTAGEN:R->A,S,K: Complete loss of NAD and NADP-dependent dehydrogenase specific activity.,MUTAGEN:R->A: Significant loss of NAD and NADP-dependent dehydrogenase specific activity.,MUTAGEN:R->K: 50% decrease in NAD and NADP-dependent dehydrogenase specific activity. Reduced affinity for magnesium.,MUTAGEN:R->S: Almost complete loss of NAD-dependent dehydrogenase specific activity. 50% decrease in NADP-dependent dehydrogenase specific activity.,NP_BIND:NAD,REGION:Substrate binding,TRANSIT:Mitochondrion,
MACF1	microtubule actin crosslinking factor 1(MACF1)	Homo sapiens				GO:0010632~regulation of epithelial cell migration,GO:0016055~Wnt signaling pathway,GO:0030177~positive regulation of Wnt signaling pathway,GO:0030334~regulation of cell migration,GO:0032886~regulation of microtubule-based process,GO:0042060~wound healing,GO:0043001~Golgi to plasma membrane protein transport,GO:0045104~intermediate filament cytoskeleton organization,GO:0045773~positive regulation of axon extension,GO:0051893~regulation of focal adhesion assembly,	GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005856~cytoskeleton,GO:0005874~microtubule,GO:0005882~intermediate filament,GO:0005886~plasma membrane,GO:0015629~actin cytoskeleton,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030054~cell junction,GO:0032587~ruffle membrane,GO:0042995~cell projection,	GO:0003723~RNA binding,GO:0003779~actin binding,GO:0005198~structural molecule activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0008092~cytoskeletal protein binding,GO:0016887~ATPase activity,GO:0045296~cadherin binding,GO:0051011~microtubule minus-end binding,GO:0051015~actin filament binding,	IPR001101:Plectin repeat,IPR001452:Src homology-3 domain,IPR001589:Actinin-type, actin-binding, conserved site,IPR001715:Calponin homology domain,IPR002017:Spectrin repeat,IPR002048:EF-hand domain,IPR003108:Growth-arrest-specific protein 2 domain,IPR011992:EF-hand-like domain,IPR018159:Spectrin/alpha-actinin,IPR018247:EF-Hand 1, calcium-binding site,		618325~Lissencephaly 9 with complex brainstem malformation,		SM00033:CH,SM00054:EFh,SM00150:SPEC,SM00243:GAS2,SM00250:PLEC,	KW-0879~Wnt signaling pathway,	KW-0206~Cytoskeleton,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0493~Microtubule,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0451~Lissencephaly,	KW-0175~Coiled coil,KW-0433~Leucine-rich repeat,KW-0677~Repeat,KW-0728~SH3 domain,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0009~Actin-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	CA_BIND:1,CA_BIND:2,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Calponin-homology (CH),DOMAIN:Calponin-homology (CH) 1,DOMAIN:Calponin-homology (CH) 2,DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:GAR,DOMAIN:SH3,REGION:13 X 13 AA approximate tandem repeat of P-T-S-P-A-A-A-V-P-T-P-E-E,REGION:4 X 4 AA tandem repeats of [GS]-S-R-[AR],REGION:Actin-binding,REGION:C-terminal tail,REGION:Disordered,REPEAT:1,REPEAT:10,REPEAT:11,REPEAT:12,REPEAT:13,REPEAT:2,REPEAT:3,REPEAT:4,REPEAT:5,REPEAT:6,REPEAT:7,REPEAT:8,REPEAT:9,REPEAT:LRR 1,REPEAT:LRR 10,REPEAT:LRR 11,REPEAT:LRR 12,REPEAT:LRR 13,REPEAT:LRR 14,REPEAT:LRR 15,REPEAT:LRR 16,REPEAT:LRR 17,REPEAT:LRR 18,REPEAT:LRR 19,REPEAT:LRR 2,REPEAT:LRR 20,REPEAT:LRR 21,REPEAT:LRR 22,REPEAT:LRR 23,REPEAT:LRR 24,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,REPEAT:LRR 8,REPEAT:LRR 9,REPEAT:Plectin 1,REPEAT:Plectin 10,REPEAT:Plectin 11,REPEAT:Plectin 2,REPEAT:Plectin 3,REPEAT:Plectin 4,REPEAT:Plectin 5,REPEAT:Plectin 6,REPEAT:Plectin 7,REPEAT:Plectin 8,REPEAT:Plectin 9,REPEAT:Spectrin 1,REPEAT:Spectrin 10,REPEAT:Spectrin 11,REPEAT:Spectrin 12,REPEAT:Spectrin 13,REPEAT:Spectrin 14,REPEAT:Spectrin 15,REPEAT:Spectrin 16,REPEAT:Spectrin 17,REPEAT:Spectrin 2,REPEAT:Spectrin 3,REPEAT:Spectrin 4,REPEAT:Spectrin 5,REPEAT:Spectrin 6,REPEAT:Spectrin 7,REPEAT:Spectrin 8,REPEAT:Spectrin 9,TRANSMEM:Helical,
MAP7	microtubule associated protein 7(MAP7)	Homo sapiens				GO:0000226~microtubule cytoskeleton organization,GO:0006970~response to osmotic stress,GO:0007163~establishment or maintenance of cell polarity,GO:0072659~protein localization to plasma membrane,	GO:0005829~cytosol,GO:0005874~microtubule,GO:0005875~microtubule associated complex,GO:0015630~microtubule cytoskeleton,GO:0016323~basolateral plasma membrane,GO:0030424~axon,GO:0048471~perinuclear region of cytoplasm,	GO:0005102~receptor binding,GO:0005198~structural molecule activity,GO:0005515~protein binding,	IPR008604:E-MAP-115,						KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0493~Microtubule,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,
MAST2	microtubule associated serine/threonine kinase 2(MAST2)	Homo sapiens				GO:0006468~protein phosphorylation,GO:0007010~cytoskeleton organization,GO:0018105~peptidyl-serine phosphorylation,GO:0032655~regulation of interleukin-12 production,GO:0035556~intracellular signal transduction,GO:0048515~spermatid differentiation,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0015630~microtubule cytoskeleton,	GO:0000287~magnesium ion binding,GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008017~microtubule binding,GO:0019902~phosphatase binding,	IPR000719:Protein kinase, catalytic domain,IPR000961:AGC-kinase, C-terminal,IPR001478:PDZ domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR015022:Microtubule-associated serine/threonine-protein kinase, domain,IPR023142:Microtubule-associated serine/threonine-protein kinase, pre-PK domain,				SM00220:S_TKc,SM00228:PDZ,		KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,			KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Proton acceptor,BINDING:ATP,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:AGC-kinase C-terminal,DOMAIN:PDZ,DOMAIN:Protein kinase,NP_BIND:ATP,REGION:Disordered,
MCM3	minichromosome maintenance complex component 3(MCM3)	Homo sapiens		h_mcmPathway:CDK Regulation of DNA Replication,		GO:0000727~double-strand break repair via break-induced replication,GO:0006260~DNA replication,GO:0006267~pre-replicative complex assembly involved in nuclear cell cycle DNA replication,GO:0006268~DNA unwinding involved in DNA replication,GO:0006270~DNA replication initiation,GO:0006271~DNA strand elongation involved in DNA replication,GO:0007049~cell cycle,GO:0032508~DNA duplex unwinding,GO:0036388~pre-replicative complex assembly,GO:1902975~mitotic DNA replication initiation,	GO:0000781~chromosome, telomeric region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005658~alpha DNA polymerase:primase complex,GO:0005694~chromosome,GO:0005813~centrosome,GO:0016020~membrane,GO:0042555~MCM complex,GO:0048471~perinuclear region of cytoplasm,GO:0071162~CMG complex,	GO:0003677~DNA binding,GO:0003678~DNA helicase activity,GO:0003688~DNA replication origin binding,GO:0003697~single-stranded DNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016787~hydrolase activity,GO:0016887~ATPase activity,GO:0017116~single-stranded DNA-dependent ATP-dependent DNA helicase activity,	IPR001208:Mini-chromosome maintenance, DNA-dependent ATPase,IPR003593:AAA+ ATPase domain,IPR008046:DNA replication licensing factor Mcm3,IPR012340:Nucleic acid-binding, OB-fold,IPR018525:Mini-chromosome maintenance, conserved site,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa03030:DNA replication,hsa04110:Cell cycle,			SM00350:MCM,SM00382:AAA,	KW-0131~Cell cycle,KW-0235~DNA replication,	KW-0158~Chromosome,KW-0539~Nucleus,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0238~DNA-binding,KW-0347~Helicase,KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:MCM,DOMAIN:MCM_lid,MOTIF:Arginine finger,MUTAGEN:S->A: 50% reduction in phosphorylation by ATM or ATR.,NP_BIND:ATP,REGION:Disordered,
MTFR1	mitochondrial fission regulator 1(MTFR1)	Homo sapiens				GO:0000266~mitochondrial fission,GO:0007005~mitochondrion organization,GO:0009060~aerobic respiration,	GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0005886~plasma membrane,	GO:0005515~protein binding,	IPR007972:Mitochondrial fission regulator 1,						KW-0496~Mitochondrion,		KW-0175~Coiled coil,KW-0809~Transit peptide,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,REGION:Disordered,REGION:Necessary and sufficient to promote mitochondrial fission,TRANSIT:Mitochondrion,
MRPL12	mitochondrial ribosomal protein L12(MRPL12)	Homo sapiens				GO:0006390~transcription from mitochondrial promoter,GO:0045893~positive regulation of transcription, DNA-templated,GO:0070125~mitochondrial translational elongation,GO:0070126~mitochondrial translational termination,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005762~mitochondrial large ribosomal subunit,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR000206:Ribosomal protein L7/L12,IPR008932:Ribosomal protein L7/L12, oligomerisation,IPR013823:Ribosomal protein L7/L12, C-terminal,IPR014719:Ribosomal protein L7/L12, C-terminal/adaptor protein ClpS-like,	hsa03010:Ribosome,	618951~Combined oxidative phosphorylation deficiency 45,				KW-0496~Mitochondrion,	KW-0225~Disease variant,KW-1274~Primary mitochondrial disease,	KW-0809~Transit peptide,		KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,	TRANSIT:Mitochondrion,
MRPL19	mitochondrial ribosomal protein L19(MRPL19)	Homo sapiens				GO:0006412~translation,GO:0070125~mitochondrial translational elongation,GO:0070126~mitochondrial translational termination,	GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005762~mitochondrial large ribosomal subunit,GO:0005840~ribosome,GO:0031965~nuclear membrane,	GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR001857:Ribosomal protein L19,IPR008991:Translation protein SH3-like domain,	hsa03010:Ribosome,					KW-0496~Mitochondrion,		KW-0809~Transit peptide,		KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0597~Phosphoprotein,	REGION:Disordered,TRANSIT:Mitochondrion,
MRPS16	mitochondrial ribosomal protein S16(MRPS16)	Homo sapiens				GO:0006412~translation,GO:0032543~mitochondrial translation,GO:0070125~mitochondrial translational elongation,GO:0070126~mitochondrial translational termination,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005763~mitochondrial small ribosomal subunit,GO:0005829~cytosol,GO:0005840~ribosome,GO:0015935~small ribosomal subunit,	GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR000307:Ribosomal protein S16,IPR023803:Ribosomal protein S16 domain,	hsa03010:Ribosome,	610498~Combined oxidative phosphorylation deficiency 2,				KW-0496~Mitochondrion,	KW-1274~Primary mitochondrial disease,	KW-0809~Transit peptide,		KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0597~Phosphoprotein,	TRANSIT:Mitochondrion,
MRPS2	mitochondrial ribosomal protein S2(MRPS2)	Homo sapiens				GO:0006412~translation,GO:0032543~mitochondrial translation,GO:0061668~mitochondrial ribosome assembly,GO:0070125~mitochondrial translational elongation,GO:0070126~mitochondrial translational termination,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005763~mitochondrial small ribosomal subunit,GO:0005840~ribosome,GO:0015935~small ribosomal subunit,	GO:0003735~structural constituent of ribosome,	IPR001865:Ribosomal protein S2,IPR005706:Ribosomal protein S2, bacteria/mitochondria/plastid,IPR018130:Ribosomal protein S2, conserved site,IPR023591:Ribosomal protein S2, flavodoxin-like domain,	hsa03010:Ribosome,	617950~Combined oxidative phosphorylation deficiency 36,				KW-0496~Mitochondrion,	KW-0225~Disease variant,KW-1274~Primary mitochondrial disease,			KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,		REGION:Disordered,
MAPK1IP1L	mitogen-activated protein kinase 1 interacting protein 1 like(MAPK1IP1L)	Homo sapiens						GO:0005515~protein binding,												KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,REGION:Disordered,
MAPK13	mitogen-activated protein kinase 13(MAPK13)	Homo sapiens		h_keratinocytePathway:Keratinocyte Differentiation,h_mapkPathway:MAPKinase Signaling Pathway,h_stathminPathway:Stathmin and breast cancer resistance to antimicrotubule agents,		GO:0006970~response to osmotic stress,GO:0007049~cell cycle,GO:0018105~peptidyl-serine phosphorylation,GO:0032755~positive regulation of interleukin-6 production,GO:0034644~cellular response to UV,GO:0035556~intracellular signal transduction,GO:0050729~positive regulation of inflammatory response,GO:0051403~stress-activated MAPK cascade,GO:0070301~cellular response to hydrogen peroxide,GO:0071347~cellular response to interleukin-1,GO:0072709~cellular response to sorbitol,GO:0072740~cellular response to anisomycin,GO:1903936~cellular response to sodium arsenite,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004707~MAP kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,	IPR000719:Protein kinase, catalytic domain,IPR003527:Mitogen-activated protein (MAP) kinase, conserved site,IPR008352:Mitogen-activated protein (MAP) kinase, p38,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,	hsa01522:Endocrine resistance,hsa04010:MAPK signaling pathway,hsa04015:Rap1 signaling pathway,hsa04068:FoxO signaling pathway,hsa04071:Sphingolipid signaling pathway,hsa04114:Oocyte meiosis,hsa04218:Cellular senescence,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04370:VEGF signaling pathway,hsa04380:Osteoclast differentiation,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04611:Platelet activation,hsa04613:Neutrophil extracellular trap formation,hsa04620:Toll-like receptor signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04622:RIG-I-like receptor signaling pathway,hsa04625:C-type lectin receptor signaling pathway,hsa04657:IL-17 signaling pathway,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04660:T cell receptor signaling pathway,hsa04664:Fc epsilon RI signaling pathway,hsa04668:TNF signaling pathway,hsa04670:Leukocyte transendothelial migration,hsa04714:Thermogenesis,hsa04722:Neurotrophin signaling pathway,hsa04723:Retrograde endocannabinoid signaling,hsa04728:Dopaminergic synapse,hsa04750:Inflammatory mediator regulation of TRP channels,hsa04912:GnRH signaling pathway,hsa04914:Progesterone-mediated oocyte maturation,hsa04917:Prolactin signaling pathway,hsa04926:Relaxin signaling pathway,hsa04932:Non-alcoholic fatty liver disease,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04935:Growth hormone synthesis, secretion and action,hsa04936:Alcoholic liver disease,hsa05014:Amyotrophic lateral sclerosis,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05133:Pertussis,hsa05135:Yersinia infection,hsa05140:Leishmaniasis,hsa05142:Chagas disease,hsa05145:Toxoplasmosis,hsa05152:Tuberculosis,hsa05161:Hepatitis B,hsa05163:Human cytomegalovirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05171:Coronavirus disease - COVID-19,hsa05205:Proteoglycans in cancer,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05415:Diabetic cardiomyopathy,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,			SM00220:S_TKc,	KW-0131~Cell cycle,KW-0346~Stress response,KW-0804~Transcription,KW-0805~Transcription regulation,				KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:ATP,DOMAIN:Protein kinase,MOTIF:TXY,MUTAGEN:T->A: Loss of kinase activity.,MUTAGEN:Y->A: Loss of kinase activity.,NP_BIND:ATP,
MAPK9	mitogen-activated protein kinase 9(MAPK9)	Homo sapiens	80.T_cell_Activation,	h_mapkPathway:MAPKinase Signaling Pathway,		GO:0006468~protein phosphorylation,GO:0007254~JNK cascade,GO:0010628~positive regulation of gene expression,GO:0010744~positive regulation of macrophage derived foam cell differentiation,GO:0018105~peptidyl-serine phosphorylation,GO:0031398~positive regulation of protein ubiquitination,GO:0034614~cellular response to reactive oxygen species,GO:0035556~intracellular signal transduction,GO:0038095~Fc-epsilon receptor signaling pathway,GO:0042752~regulation of circadian rhythm,GO:0048511~rhythmic process,GO:0051090~regulation of sequence-specific DNA binding transcription factor activity,GO:0061833~protein localization to tricellular tight junction,GO:0071276~cellular response to cadmium ion,GO:0071803~positive regulation of podosome assembly,GO:0090398~cellular senescence,GO:1901485~positive regulation of transcription factor catabolic process,GO:2001235~positive regulation of apoptotic signaling pathway,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004705~JUN kinase activity,GO:0004707~MAP kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008134~transcription factor binding,GO:0016301~kinase activity,	IPR000719:Protein kinase, catalytic domain,IPR003527:Mitogen-activated protein (MAP) kinase, conserved site,IPR008271:Serine/threonine-protein kinase, active site,IPR008351:Mitogen-activated protein (MAP) kinase, JNK,IPR011009:Protein kinase-like domain,	hsa01522:Endocrine resistance,hsa04010:MAPK signaling pathway,hsa04012:ErbB signaling pathway,hsa04014:Ras signaling pathway,hsa04024:cAMP signaling pathway,hsa04068:FoxO signaling pathway,hsa04071:Sphingolipid signaling pathway,hsa04137:Mitophagy - animal,hsa04140:Autophagy - animal,hsa04141:Protein processing in endoplasmic reticulum,hsa04210:Apoptosis,hsa04215:Apoptosis - multiple species,hsa04217:Necroptosis,hsa04310:Wnt signaling pathway,hsa04380:Osteoclast differentiation,hsa04510:Focal adhesion,hsa04530:Tight junction,hsa04620:Toll-like receptor signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04622:RIG-I-like receptor signaling pathway,hsa04625:C-type lectin receptor signaling pathway,hsa04657:IL-17 signaling pathway,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04660:T cell receptor signaling pathway,hsa04664:Fc epsilon RI signaling pathway,hsa04668:TNF signaling pathway,hsa04722:Neurotrophin signaling pathway,hsa04723:Retrograde endocannabinoid signaling,hsa04728:Dopaminergic synapse,hsa04750:Inflammatory mediator regulation of TRP channels,hsa04910:Insulin signaling pathway,hsa04912:GnRH signaling pathway,hsa04914:Progesterone-mediated oocyte maturation,hsa04917:Prolactin signaling pathway,hsa04920:Adipocytokine signaling pathway,hsa04926:Relaxin signaling pathway,hsa04930:Type II diabetes mellitus,hsa04931:Insulin resistance,hsa04932:Non-alcoholic fatty liver disease,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04935:Growth hormone synthesis, secretion and action,hsa04936:Alcoholic liver disease,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05016:Huntington disease,hsa05017:Spinocerebellar ataxia,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05133:Pertussis,hsa05135:Yersinia infection,hsa05142:Chagas disease,hsa05145:Toxoplasmosis,hsa05152:Tuberculosis,hsa05161:Hepatitis B,hsa05162:Measles,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05210:Colorectal cancer,hsa05212:Pancreatic cancer,hsa05231:Choline metabolism in cancer,hsa05415:Diabetic cardiomyopathy,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,			SM00220:S_TKc,	KW-0090~Biological rhythms,	KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0460~Magnesium,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:ATP,COMPBIAS:Polar residues,DOMAIN:Protein kinase,MOTIF:TXY,NP_BIND:ATP,REGION:Disordered,
MAP2K5	mitogen-activated protein kinase kinase 5(MAP2K5)	Homo sapiens	100.MAPK_signaling_cascades,	h_mapkPathway:MAPKinase Signaling Pathway,		GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000165~MAPK cascade,GO:0000187~activation of MAPK activity,GO:0007165~signal transduction,GO:0007507~heart development,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0030307~positive regulation of cell growth,GO:0032088~negative regulation of NF-kappaB transcription factor activity,GO:0032717~negative regulation of interleukin-8 production,GO:0034115~negative regulation of heterotypic cell-cell adhesion,GO:0043154~negative regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0043406~positive regulation of MAP kinase activity,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050679~positive regulation of epithelial cell proliferation,GO:0051247~positive regulation of protein metabolic process,GO:0060761~negative regulation of response to cytokine stimulus,GO:0070375~ERK5 cascade,GO:0071363~cellular response to growth factor stimulus,GO:0071499~cellular response to laminar fluid shear stress,GO:0090051~negative regulation of cell migration involved in sprouting angiogenesis,GO:2000342~negative regulation of chemokine (C-X-C motif) ligand 2 production,GO:2001240~negative regulation of extrinsic apoptotic signaling pathway in absence of ligand,	GO:0005634~nucleus,GO:0005819~spindle,GO:0005829~cytosol,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004708~MAP kinase kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0046872~metal ion binding,	IPR000270:Phox/Bem1p,IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,	hsa04010:MAPK signaling pathway,hsa04540:Gap junction,hsa04722:Neurotrophin signaling pathway,hsa04921:Oxytocin signaling pathway,hsa05418:Fluid shear stress and atherosclerosis,			SM00220:S_TKc,SM00666:PB1,					KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:ATP,COMPBIAS:Polar residues,DOMAIN:PB1,DOMAIN:Protein kinase,MUTAGEN:K->M: Inactivation.,MUTAGEN:S->A: Inactivation.,MUTAGEN:T->A: Inactivation.,NP_BIND:ATP,REGION:Disordered,REGION:Interaction with MAP3K2/MAP3K3,REGION:Interaction with MAPK7,
MAP3K4	mitogen-activated protein kinase kinase kinase 4(MAP3K4)	Homo sapiens	100.MAPK_signaling_cascades,	h_mapkPathway:MAPKinase Signaling Pathway,		GO:0000165~MAPK cascade,GO:0000186~activation of MAPKK activity,GO:0001890~placenta development,GO:0006468~protein phosphorylation,GO:0010225~response to UV-C,GO:0010468~regulation of gene expression,GO:0019100~male germ-line sex determination,GO:0032212~positive regulation of telomere maintenance via telomerase,GO:0035556~intracellular signal transduction,GO:0043507~positive regulation of JUN kinase activity,GO:0051973~positive regulation of telomerase activity,GO:0060718~chorionic trophoblast cell differentiation,GO:1900745~positive regulation of p38MAPK cascade,GO:1904355~positive regulation of telomere capping,	GO:0005737~cytoplasm,GO:0048471~perinuclear region of cytoplasm,	GO:0004672~protein kinase activity,GO:0004709~MAP kinase kinase kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0046872~metal ion binding,	IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,	hsa04010:MAPK signaling pathway,hsa04912:GnRH signaling pathway,			SM00220:S_TKc,		KW-0963~Cytoplasm,		KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:ATP,COMPBIAS:Acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Protein kinase,MUTAGEN:K->R: Loss of activity.,NP_BIND:ATP,REGION:Disordered,
MAP4K4	mitogen-activated protein kinase kinase kinase kinase 4(MAP4K4)	Homo sapiens		h_mapkPathway:MAPKinase Signaling Pathway,		GO:0000165~MAPK cascade,GO:0001953~negative regulation of cell-matrix adhesion,GO:0006468~protein phosphorylation,GO:0030335~positive regulation of cell migration,GO:0031098~stress-activated protein kinase signaling cascade,GO:0032014~positive regulation of ARF protein signal transduction,GO:0032147~activation of protein kinase activity,GO:0035556~intracellular signal transduction,GO:0043066~negative regulation of apoptotic process,GO:0043408~regulation of MAPK cascade,GO:0043547~positive regulation of GTPase activity,GO:0046328~regulation of JNK cascade,GO:0048812~neuron projection morphogenesis,GO:0051549~positive regulation of keratinocyte migration,GO:0051894~positive regulation of focal adhesion assembly,GO:0061179~negative regulation of insulin secretion involved in cellular response to glucose stimulus,GO:0070571~negative regulation of neuron projection regeneration,	GO:0005737~cytoplasm,GO:0005925~focal adhesion,	GO:0004111~creatine kinase activity,GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008017~microtubule binding,	IPR000719:Protein kinase, catalytic domain,IPR001180:Citron-like,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,	hsa04010:MAPK signaling pathway,			SM00036:CNH,SM00220:S_TKc,		KW-0963~Cytoplasm,		KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:ATP,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:CNH,DOMAIN:Protein kinase,NP_BIND:ATP,REGION:Disordered,REGION:Mediates interaction with RAP2A,
MUC1	mucin 1, cell surface associated(MUC1)	Homo sapiens				GO:0002223~stimulatory C-type lectin receptor signaling pathway,GO:0006977~DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest,GO:0006978~DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator,GO:0010944~negative regulation of transcription by competitive promoter binding,GO:0016266~O-glycan processing,GO:0019221~cytokine-mediated signaling pathway,GO:0033629~negative regulation of cell adhesion mediated by integrin,GO:0036003~positive regulation of transcription from RNA polymerase II promoter in response to stress,GO:0043618~regulation of transcription from RNA polymerase II promoter in response to stress,GO:0090240~positive regulation of histone H4 acetylation,GO:1902166~negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator,	GO:0000785~chromatin,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005796~Golgi lumen,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0031982~vesicle,GO:0070062~extracellular exosome,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0002039~p53 binding,GO:0003712~transcription cofactor activity,GO:0005515~protein binding,	IPR000082:SEA domain,		174000~Tubulointerstitial kidney disease, autosomal dominant, 2,		SM00200:SEA,		KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0964~Secreted,KW-1003~Cell membrane,	KW-0043~Tumor suppressor,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0068~Autocatalytic cleavage,KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GalNAc...) serine,CARBOHYD:O-linked (GalNAc...) threonine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:SEA,LIPID:S-palmitoyl cysteine,MOTIF:Interaction with GRB2,MOTIF:Interaction with SRC and ESR1,MOTIF:Required for interaction with AP1S2,MUTAGEN:C->A: S-palmitoylation reduced by 50%. Complete loss of palmitoylation, no effect on endocytosis, recycling inhibited and AP1S1 binding reduced by 30%; when associated with C-1186. Accumulates in intracellular compartments; when associated with C-1186 and N-1203.,MUTAGEN:C->A: S-palmitoylation reduced by 50%. Complete loss of palmitoylation, no effect on endocytosis, recycling inhibited, and AP1S1 binding reduced by 30%; when associated with C-1184. Accumulates in intracellular compartments; when associated with C-1184 and N-1203.,MUTAGEN:D->A: Greatly reduced formation of isoform 5/isoform Y complex.,MUTAGEN:D->E: No effect on formation of isoform 5/isoform Y complex.,MUTAGEN:RRK->AAA: No nuclear targeting of HRG-stimulated MUC1 C-terminal nor JUP/gamma-catenin. No effect on interaction with JUP/gamma-catenin.,MUTAGEN:RRK->QQQ: No effect on palmitoylation.,MUTAGEN:S->A,D,E,F,G,H,I,K,L,M,N,P,Q,R,V,W,Y: Completely abrogates cleavage.,MUTAGEN:S->A: No change in PRKCD- nor GSK3B-mediated phosphorylation.,MUTAGEN:S->A: No change in PRKCD-mediated phosphorylation. Loss of GSK3B-mediated phosphorylation. CTNNB1.,MUTAGEN:S->C,T: Almost complete cleavage.,MUTAGEN:T->A: Loss of PRKCD-mediated phosphorylation. Decreased PRKCD binding. No increased binding to CTNNB1 in the presence of autophosphorylated PRKCD. Increases formation of E-cadherin/beta-catenin complex.,MUTAGEN:Y->E: No effect on nuclear colocalization of MUC1CT and CTNNB1. No effect on in vitro PDFGR-induced cell invasiveness.,MUTAGEN:Y->F: Greatly reduced EGFR- and Src-mediated phosphorylation. No nuclear localization of MUC1CT. Reduced in vitro PDGFR-mediated phosphorylation. Decreased Src-binding.,MUTAGEN:Y->F: No effect on EGFR-mediated phosphorylation.,MUTAGEN:Y->F: No effect on EGFR-mediated phosphorylation. No nuclear colocalization of MUC1CT and CTNNB1.,MUTAGEN:Y->F: No effect on EGFR-mediated phosphorylation. No nuclear localization of MUC1CT. Reduced in vitro PDGFR-induced cell invasiveness.,MUTAGEN:Y->F: Some reduction in EGFR-mediated phosphorylation.,MUTAGEN:Y->N: No effect on endocytosis.,MUTAGEN:Y->N: Reduced endocytosis by 30%. Greatly reduced binding to AP1S2 and GRB2. Binding AP1S1 reduced by 25%. Reduced endocytosis by 77%; when associated with N-1243. Accumulates in intracellular compartments; when associated with C-1184 and C-1186.,MUTAGEN:Y->N: Reduces binding to AP1S2 by 33%. Greatly reduced binding to GRB2. Reduced endocytosis by 50%. Reduced endocytosis by 77%; when associated with N-1203.,REGION:42 X 20 AA approximate tandem repeats of P-A-P-G-S-T-A-P-P-A-H-G-V-T-S-A-P-D-T-R,REGION:Disordered,REGION:Interaction with P53,REGION:Required for interaction with GSK3B,REGION:Required for interaction with beta- and gamma-catenins,REPEAT:10,REPEAT:11,REPEAT:12,REPEAT:13,REPEAT:14,REPEAT:15,REPEAT:16,REPEAT:17,REPEAT:18,REPEAT:19,REPEAT:1; approximate,REPEAT:20,REPEAT:21,REPEAT:22,REPEAT:23,REPEAT:24,REPEAT:25,REPEAT:26,REPEAT:27,REPEAT:28,REPEAT:29,REPEAT:2; approximate,REPEAT:3,REPEAT:30,REPEAT:31,REPEAT:32,REPEAT:33,REPEAT:34,REPEAT:35,REPEAT:36,REPEAT:37,REPEAT:38,REPEAT:39,REPEAT:4,REPEAT:40,REPEAT:41,REPEAT:42,REPEAT:43,REPEAT:44,REPEAT:45,REPEAT:46; approximate,REPEAT:47; approximate,REPEAT:48; approximate,REPEAT:5,REPEAT:6,REPEAT:7,REPEAT:8,REPEAT:9,SITE:Cleavage; by autolysis,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
MCOLN1	mucolipin TRP cation channel 1(MCOLN1)	Homo sapiens				GO:0002250~adaptive immune response,GO:0006812~cation transport,GO:0019722~calcium-mediated signaling,GO:0033572~transferrin transport,GO:0034755~iron ion transmembrane transport,GO:0051209~release of sequestered calcium ion into cytosol,GO:0051289~protein homotetramerization,GO:0070588~calcium ion transmembrane transport,GO:0071277~cellular response to calcium ion,GO:0071467~cellular response to pH,GO:0090382~phagosome maturation,GO:0097352~autophagosome maturation,	GO:0001891~phagocytic cup,GO:0005654~nucleoplasm,GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0005770~late endosome,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030670~phagocytic vesicle membrane,GO:0031902~late endosome membrane,GO:0042995~cell projection,GO:0043231~intracellular membrane-bounded organelle,GO:0043235~receptor complex,	GO:0005261~cation channel activity,GO:0005262~calcium channel activity,GO:0005381~iron ion transmembrane transporter activity,GO:0005515~protein binding,GO:0008289~lipid binding,GO:0042802~identical protein binding,GO:0072345~NAADP-sensitive calcium-release channel activity,GO:0097682~intracellular phosphatidylinositol-3,5-bisphosphate-sensitive cation channel activity,GO:0099604~ligand-gated calcium channel activity,	IPR013122:Polycystin cation channel, PKD1/PKD2,	hsa04020:Calcium signaling pathway,hsa04142:Lysosome,	252650~Mucolipidosis IV,			KW-0109~Calcium transport,KW-0391~Immunity,KW-0406~Ion transport,KW-0813~Transport,KW-1064~Adaptive immunity,	KW-0458~Lysosome,KW-0472~Membrane,KW-0966~Cell projection,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0942~Mucolipidosis,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0446~Lipid-binding,	KW-0407~Ion channel,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic residues,DOMAIN:PKD_channel,INTRAMEM:Pore-forming,MOTIF:Dileucine internalization motif; mediates AP2 complex-dependent internalization,MOTIF:Dileucine motif; mediates targeting to lysosomes,MOTIF:Selectivity filter,MUTAGEN:A->C: Modulates ion conduction; when associoated with C-110 and C-112.,MUTAGEN:CCC->AAA: Abolishes association with membranes.,MUTAGEN:D->A: Fails to rescue defect of lactosylceramide traffic through the late endocytic pathway in ML4 patient cells.,MUTAGEN:D->Q: Modulates inhibition by Ca(2+) at different pH levels but does not abolish channel inward rectification; when associated with Q-111 and Q-114.,MUTAGEN:D->Q: Modulates inhibition by Ca(2+) at different pH levels but does not abolish channel inward rectification; when associated with Q-111 and Q-115.,MUTAGEN:D->Q: Modulates inhibition by Ca(2+) at different pH levels but does not abolish channel inward rectification; when associated with Q-114 and Q-115.,MUTAGEN:G->C: Modulates ion conduction; when associoated with C-110 and C-113.,MUTAGEN:L->A: Abolishes interaction with PDCD6.,MUTAGEN:L->A: Abolishes localization to lysosomes and leads to expression at the cell membrane; when associated with A-15.,MUTAGEN:L->A: Abolishes localization to lysosomes and leads to expression at the cell membrane; when associated with A-577.,MUTAGEN:L->K: Disrupts tetrameric assembly and abolishes lysosomal localization; when associated with S-146.,MUTAGEN:LL->AA: No effect on localization to lysosomes.,MUTAGEN:R->A: Abolishes interaction with PDCD6.,MUTAGEN:R->H: Does not prevent proteolytic cleavage but changes cleavage pattern.,MUTAGEN:R->S: Disrupts tetrameric assembly and abolishes lysosomal localization; when associated with K-144.,MUTAGEN:RK->AA: Reduces PtdIns(3,5)P2 sensitivity.,MUTAGEN:RLK->AAA: Abolishes interaction with PDCD6 and decreases formation of aberrant endosomes upon overexpression.,MUTAGEN:RRR->AAA: Reduces PtdIns(4,5)P2 sensitivity.,MUTAGEN:S->C: Modulates ion conduction; when associoated with C-112 and C-113.,MUTAGEN:V->P: Mediates localization to the plasma membrane and strong inwardly rectifying current.,MUTAGEN:Y->G: Abolishes formation and extrusion of tubulo-vesicular structures and decreases lysosomal exocytosis when overexpressed.,MUTAGEN:YFF->AAA: Abolishes interaction with PDCD6.,REGION:Disordered,REGION:Extracellular/lumenal pore loop,REGION:Interaction with phosphoinositides,REGION:Required for palmitoylation and association with membranes,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,
MBNL1	muscleblind like splicing regulator 1(MBNL1)	Homo sapiens				GO:0000381~regulation of alternative mRNA splicing, via spliceosome,GO:0001701~in utero embryonic development,GO:0006397~mRNA processing,GO:0007399~nervous system development,GO:0008380~RNA splicing,GO:0030326~embryonic limb morphogenesis,GO:0043484~regulation of RNA splicing,GO:0045445~myoblast differentiation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0010494~cytoplasmic stress granule,	GO:0001069~regulatory region RNA binding,GO:0003723~RNA binding,GO:0003725~double-stranded RNA binding,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR000571:Zinc finger, CCCH-type,				SM00356:ZnF_C3H1,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-1212~Corneal dystrophy,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0694~RNA-binding,	KW-0597~Phosphoprotein,	DOMAIN:C3H1-type,ZN_FING:C3H1-type,ZN_FING:C3H1-type 1,ZN_FING:C3H1-type 2,ZN_FING:C3H1-type 3,ZN_FING:C3H1-type 4,
MBNL2	muscleblind like splicing regulator 2(MBNL2)	Homo sapiens				GO:0000381~regulation of alternative mRNA splicing, via spliceosome,GO:0006397~mRNA processing,GO:0008380~RNA splicing,GO:0043484~regulation of RNA splicing,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,	GO:0003723~RNA binding,GO:0046872~metal ion binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000571:Zinc finger, CCCH-type,				SM00356:ZnF_C3H1,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0694~RNA-binding,		DOMAIN:C3H1-type,ZN_FING:C3H1-type,ZN_FING:C3H1-type 1,ZN_FING:C3H1-type 2,ZN_FING:C3H1-type 3,ZN_FING:C3H1-type 4,
MSH6	mutS homolog 6(MSH6)	Homo sapiens			DNA replication, recombination, and repair,	GO:0000710~meiotic mismatch repair,GO:0006281~DNA repair,GO:0006290~pyrimidine dimer repair,GO:0006298~mismatch repair,GO:0007283~spermatogenesis,GO:0008340~determination of adult lifespan,GO:0008630~intrinsic apoptotic signaling pathway in response to DNA damage,GO:0009411~response to UV,GO:0016032~viral process,GO:0016446~somatic hypermutation of immunoglobulin genes,GO:0016447~somatic recombination of immunoglobulin gene segments,GO:0036297~interstrand cross-link repair,GO:0045190~isotype switching,GO:0045910~negative regulation of DNA recombination,GO:0051096~positive regulation of helicase activity,GO:0097193~intrinsic apoptotic signaling pathway,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0032300~mismatch repair complex,GO:0032301~MutSalpha complex,GO:0043231~intracellular membrane-bounded organelle,	GO:0000287~magnesium ion binding,GO:0000400~four-way junction DNA binding,GO:0003682~chromatin binding,GO:0003684~damaged DNA binding,GO:0003690~double-stranded DNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008094~DNA-dependent ATPase activity,GO:0019899~enzyme binding,GO:0030983~mismatched DNA binding,GO:0032137~guanine/thymine mispair binding,GO:0032142~single guanine insertion binding,GO:0032143~single thymine insertion binding,GO:0032357~oxidized purine DNA binding,GO:0032405~MutLalpha complex binding,GO:0035064~methylated histone binding,GO:0043531~ADP binding,	IPR000313:PWWP,IPR000432:DNA mismatch repair protein MutS, C-terminal,IPR007695:DNA mismatch repair protein MutS-like, N-terminal,IPR007696:DNA mismatch repair protein MutS, core,IPR007860:DNA mismatch repair protein MutS, connector domain,IPR007861:DNA mismatch repair protein MutS, clamp,IPR016151:DNA mismatch repair protein MutS, N-terminal,IPR017261:DNA mismatch repair protein Msh6,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa01524:Platinum drug resistance,hsa03430:Mismatch repair,hsa05200:Pathways in cancer,hsa05210:Colorectal cancer,	608089~Endometrial cancer, familial,614350~Colorectal cancer, hereditary nonpolyposis, type 5,619097~Mismatch repair cancer syndrome 3,	PIRSF037677:DNA mismatch repair protein Msh6,	SM00293:PWWP,SM00533:MUTSd,SM00534:MUTSac,	KW-0227~DNA damage,KW-0234~DNA repair,KW-0945~Host-virus interaction,	KW-0158~Chromosome,KW-0539~Nucleus,	KW-0225~Disease variant,KW-0362~Hereditary nonpolyposis colorectal cancer,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:DNA_MISMATCH_REPAIR_2,DOMAIN:PWWP,MUTAGEN:K->R: No effect on mismatch binding, complete loss of DNA repair function when associated with MSH2 mutant R-675.,MUTAGEN:WW->AA: Abolishes binding to H3K36me3 and DNA mismatch repair activity.,MUTAGEN:Y->A: Abolishes binding to H3K36me3 and DNA mismatch repair activity.,NP_BIND:ATP,REGION:Disordered,
MPZL1	myelin protein zero like 1(MPZL1)	Homo sapiens				GO:0007165~signal transduction,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007267~cell-cell signaling,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005925~focal adhesion,GO:0009986~cell surface,	GO:0005198~structural molecule activity,GO:0005515~protein binding,	IPR000920:Myelin P0 protein,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,	hsa04514:Cell adhesion molecules,			SM00406:IGv,SM00409:IG,		KW-0472~Membrane,		KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:IGv,DOMAIN:Ig-like,DOMAIN:Ig-like V-type,MOTIF:ITIM motif 1,MOTIF:ITIM motif 2,MUTAGEN:Y->F: Significantly decreases phosphorylation. Complete loss of phosphorylation; when associated with F-241.,MUTAGEN:Y->F: Significantly decreases phosphorylation. Complete loss of phosphorylation; when associated with F-263.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
MEF2C	myocyte enhancer factor 2C(MEF2C)	Homo sapiens		h_alkPathway:ALK in cardiac myocytes,h_at1rPathway:Angiotensin II mediated activation of JNK Pathway via Pyk2 dependent signaling,h_carm-erPathway:CARM1 and Regulation of the Estrogen Receptor,h_erk5Pathway:Role of Erk5 in Neuronal Survival,h_hdacPathway:Control of skeletal myogenesis by HDAC & calcium/calmodulin-dependent kinase (CaMK),h_mapkPathway:MAPKinase Signaling Pathway,h_mitrPathway:Signal Dependent Regulation of Myogenesis by Corepressor MITR,h_nfatPathway:NFAT and Hypertrophy of the heart (Transcription in the broken heart),h_p38mapkPathway:p38 MAPK Signaling Pathway ,h_pgc1aPathway:Regulation of PGC-1a,	Transcription,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000165~MAPK cascade,GO:0001568~blood vessel development,GO:0001649~osteoblast differentiation,GO:0001764~neuron migration,GO:0001782~B cell homeostasis,GO:0001947~heart looping,GO:0001958~endochondral ossification,GO:0001974~blood vessel remodeling,GO:0002062~chondrocyte differentiation,GO:0002467~germinal center formation,GO:0002634~regulation of germinal center formation,GO:0002931~response to ischemia,GO:0003138~primary heart field specification,GO:0003139~secondary heart field specification,GO:0003151~outflow tract morphogenesis,GO:0003185~sinoatrial valve morphogenesis,GO:0003211~cardiac ventricle formation,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006915~apoptotic process,GO:0006959~humoral immune response,GO:0007399~nervous system development,GO:0007507~heart development,GO:0007517~muscle organ development,GO:0007519~skeletal muscle tissue development,GO:0007521~muscle cell fate determination,GO:0007611~learning or memory,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0010694~positive regulation of alkaline phosphatase activity,GO:0014033~neural crest cell differentiation,GO:0014902~myotube differentiation,GO:0030154~cell differentiation,GO:0030182~neuron differentiation,GO:0030220~platelet formation,GO:0030279~negative regulation of ossification,GO:0030318~melanocyte differentiation,GO:0030501~positive regulation of bone mineralization,GO:0030890~positive regulation of B cell proliferation,GO:0035690~cellular response to drug,GO:0035984~cellular response to trichostatin A,GO:0042100~B cell proliferation,GO:0043406~positive regulation of MAP kinase activity,GO:0043523~regulation of neuron apoptotic process,GO:0043524~negative regulation of neuron apoptotic process,GO:0043537~negative regulation of blood vessel endothelial cell migration,GO:0045652~regulation of megakaryocyte differentiation,GO:0045663~positive regulation of myoblast differentiation,GO:0045666~positive regulation of neuron differentiation,GO:0045669~positive regulation of osteoblast differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046928~regulation of neurotransmitter secretion,GO:0048167~regulation of synaptic plasticity,GO:0048643~positive regulation of skeletal muscle tissue development,GO:0048666~neuron development,GO:0048667~cell morphogenesis involved in neuron differentiation,GO:0050853~B cell receptor signaling pathway,GO:0051145~smooth muscle cell differentiation,GO:0051149~positive regulation of muscle cell differentiation,GO:0051963~regulation of synapse assembly,GO:0051966~regulation of synaptic transmission, glutamatergic,GO:0055012~ventricular cardiac muscle cell differentiation,GO:0060025~regulation of synaptic activity,GO:0060045~positive regulation of cardiac muscle cell proliferation,GO:0060079~excitatory postsynaptic potential,GO:0060998~regulation of dendritic spine development,GO:0061333~renal tubule morphogenesis,GO:0071222~cellular response to lipopolysaccharide,GO:0071277~cellular response to calcium ion,GO:0071374~cellular response to parathyroid hormone stimulus,GO:0071466~cellular response to xenobiotic stimulus,GO:0071498~cellular response to fluid shear stress,GO:0071560~cellular response to transforming growth factor beta stimulus,GO:0072102~glomerulus morphogenesis,GO:0072160~nephron tubule epithelial cell differentiation,GO:1904706~negative regulation of vascular smooth muscle cell proliferation,GO:1904753~negative regulation of vascular associated smooth muscle cell migration,GO:1905563~negative regulation of vascular endothelial cell proliferation,GO:2000111~positive regulation of macrophage apoptotic process,GO:2000310~regulation of NMDA receptor activity,GO:2000311~regulation of AMPA receptor activity,GO:2000727~positive regulation of cardiac muscle cell differentiation,GO:2000987~positive regulation of behavioral fear response,GO:2001013~epithelial cell proliferation involved in renal tubule morphogenesis,GO:2001016~positive regulation of skeletal muscle cell differentiation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016528~sarcoplasm,GO:0016607~nuclear speck,GO:0032991~macromolecular complex,GO:0043231~intracellular membrane-bounded organelle,GO:0098794~postsynapse,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003680~AT DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0033613~activating transcription factor binding,GO:0042826~histone deacetylase binding,GO:0046982~protein heterodimerization activity,GO:0046983~protein dimerization activity,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR002100:Transcription factor, MADS-box,IPR022102:Holliday junction regulator protein family C-terminal,	hsa04010:MAPK signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04371:Apelin signaling pathway,hsa04921:Oxytocin signaling pathway,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa05202:Transcriptional misregulation in cancer,hsa05418:Fluid shear stress and atherosclerosis,	613443~Chromosome 5q14.3 deletion syndrome,613443~Neurodevelopmental disorder with hypotonia, stereotypic hand movements, and impaired language,		SM00432:MADS,	KW-0053~Apoptosis,KW-0221~Differentiation,KW-0524~Neurogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0887~Epilepsy,KW-0991~Mental retardation,			KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),DNA_BIND:Mef2-type,DOMAIN:MADS-box,MUTAGEN:D->A: Abolishes cleavage by caspase 7.,MUTAGEN:D->N: Reduced transcriptional activation. Completely abolishes transcriptional activation; when associated with Q-272 and N-273.,MUTAGEN:D->N: Reduced transcriptional activation. Completely abolishes transcriptional activation; when associated with Q-272 and N-275.,MUTAGEN:E->Q: Reduced transcriptional activation. Completely abolishes transcriptional activation; when associated with N-273 and N-275.,MUTAGEN:K->R: Abolishes sumoylation.,MUTAGEN:K->R: Reduced acetylation. Complete loss of acetylation, 15% less transactivation activity and slightly reduced DNA binding; when associated with R-116; R-119; R-234; R-239 and R-252.,MUTAGEN:K->R: Reduced acetylation. Complete loss of acetylation, 15% less transactivation activity and slightly reduced DNA binding; when associated with R-116; R-119; R-234; R-239 and R-264.,MUTAGEN:K->R: Reduced acetylation. Complete loss of acetylation, 15% less transactivation activity and slightly reduced DNA binding; when associated with R-116; R-119; R-234; R-252 and R-264.,MUTAGEN:K->R: Reduced acetylation. Complete loss of acetylation, 15% less transactivation activity and slightly reduced DNA binding; when associated with R-116; R-119; R-239; R-252 and R-264.,MUTAGEN:K->R: Reduced acetylation. Further reduction in acetylation; when associated with R-119. Complete loss of acetylation, 15% less transactivation activity and slightly reduced DNA binding; when associated with R-116; R-234; R-239; R-252 and R-262.,MUTAGEN:K->R: Reduced acetylation. Further reduction in acetylation; when associated with R-119. Complete loss of acetylation, 15% less transactivation activity and slightly reduced DNA binding; when associated with R-119; R-234; R-239; R-252 and R-262.,MUTAGEN:S->A,C: Abolishes sumoylation. Enhanced transcriptional activity.,MUTAGEN:S->A: No change in transactivational activation for isoforms with or without the beta domain.,MUTAGEN:S->A: No effect on MAPK14-mediated phosphorylation. Abolishes MAPK7-mediated phosphorylation and reduces transactivation activity.,MUTAGEN:S->A: No effect on transcriptional activation.,MUTAGEN:S->E: No effect on sumoylation. No effect on transcriptional activity.,MUTAGEN:T->A: Abolishes MAPK14-mediated phosphorylation. No effect on MAPK7-mediated phosphorylation; when associated with A-293.,MUTAGEN:T->A: Abolishes MAPK14-mediated phosphorylation. No effect on MAPK7-mediated phosphorylation; when associated with A-300.,REGION:Beta domain,REGION:Disordered,REGION:Transcription repressor,SITE:Cleavage,
MYO10	myosin X(MYO10)	Homo sapiens				GO:0007165~signal transduction,GO:0008360~regulation of cell shape,GO:0022409~positive regulation of cell-cell adhesion,GO:0030705~cytoskeleton-dependent intracellular transport,GO:0038096~Fc-gamma receptor signaling pathway involved in phagocytosis,GO:0051489~regulation of filopodium assembly,	GO:0001726~ruffle,GO:0005730~nucleolus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005938~cell cortex,GO:0016459~myosin complex,GO:0030027~lamellipodium,GO:0030175~filopodium,GO:0031527~filopodium membrane,GO:0032433~filopodium tip,GO:0043005~neuron projection,GO:0043025~neuronal cell body,	GO:0000146~microfilament motor activity,GO:0003774~motor activity,GO:0003779~actin binding,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0005524~ATP binding,GO:0005547~phosphatidylinositol-3,4,5-trisphosphate binding,GO:0030507~spectrin binding,GO:0030898~actin-dependent ATPase activity,GO:0051015~actin filament binding,GO:0060002~plus-end directed microfilament motor activity,	IPR000048:IQ motif, EF-hand binding site,IPR000159:Ras-association,IPR000299:FERM domain,IPR000857:MyTH4 domain,IPR001609:Myosin head, motor domain,IPR001849:Pleckstrin homology domain,IPR011993:Pleckstrin homology-like domain,IPR014352:FERM/acyl-CoA-binding protein, 3-helical bundle,IPR019748:FERM central domain,IPR019749:Band 4.1 domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04666:Fc gamma R-mediated phagocytosis,hsa05130:Pathogenic Escherichia coli infection,			SM00015:IQ,SM00139:MyTH4,SM00233:PH,SM00242:MYSc,SM00295:B41,	KW-0813~Transport,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0677~Repeat,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0009~Actin-binding,KW-0112~Calmodulin-binding,KW-0505~Motor protein,KW-0518~Myosin,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:FERM,DOMAIN:IQ 1,DOMAIN:IQ 2,DOMAIN:IQ 3,DOMAIN:MyTH4,DOMAIN:Myosin motor,DOMAIN:PH,DOMAIN:PH 1,DOMAIN:PH 2,DOMAIN:Ras-associating,MUTAGEN:F->A: Abolishes interaction with CALM3.,MUTAGEN:F->K: Abolishes interaction with DCC.,MUTAGEN:K->A: Abolishes dimerization.,MUTAGEN:K->D: Abolishes interaction with tubulin; when associated with D-1647.,MUTAGEN:K->D: Abolishes interaction with tubulin; when associated with D-1650.,MUTAGEN:L->Q: Abolishes dimerization.,MUTAGEN:SH->AA: Almost abolishes interaction with DCC.,NP_BIND:ATP,REGION:Actin-binding,REGION:Disordered,REGION:Mediates antiparallel dimerization,REGION:SAH,
MYL9	myosin light chain 9(MYL9)	Homo sapiens			Signal transduction mechanisms / Cytoskeleton / Cell division and chromosome partitioning / General function prediction only,	GO:0006936~muscle contraction,GO:0006937~regulation of muscle contraction,GO:0030239~myofibril assembly,GO:0045652~regulation of megakaryocyte differentiation,GO:0070527~platelet aggregation,	GO:0001725~stress fiber,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005859~muscle myosin complex,GO:0005938~cell cortex,GO:0016460~myosin II complex,GO:0030016~myofibril,GO:0030018~Z disc,	GO:0005509~calcium ion binding,GO:0008307~structural constituent of muscle,GO:0032036~myosin heavy chain binding,	IPR002048:EF-hand domain,IPR011992:EF-hand-like domain,IPR018247:EF-Hand 1, calcium-binding site,	hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04270:Vascular smooth muscle contraction,hsa04360:Axon guidance,hsa04510:Focal adhesion,hsa04530:Tight junction,hsa04670:Leukocyte transendothelial migration,hsa04810:Regulation of actin cytoskeleton,hsa04921:Oxytocin signaling pathway,hsa05131:Shigellosis,hsa05132:Salmonella infection,	619365~Megacystis-microcolon-intestinal hypoperistalsis syndrome 4,		SM00054:EFh,		KW-0206~Cytoskeleton,KW-0963~Cytoplasm,		KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0505~Motor protein,KW-0514~Muscle protein,KW-0518~Myosin,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:EF-hand 3,REGION:Disordered,
MYLK	myosin light chain kinase(MYLK)	Homo sapiens	68.Mitogen_signaling_in_growth_control,	h_biopeptidesPathway:Bioactive Peptide Induced Signaling Pathway,h_ecmPathway:Erk and PI-3 Kinase Are Necessary for Collagen Binding in Corneal Epithelia,h_mCalpainPathway:mCalpain and friends in Cell motility,h_myosinPathway:PKC-catalyzed phosphorylation of inhibitory phosphoprotein of myosin phosphatase,h_rac1Pathway:Rac 1 cell motility signaling pathway,h_rhoPathway:Rho cell motility signaling pathway,	General function prediction only / Signal transduction mechanisms / Transcription / DNA replication, recombination, and repair,	GO:0006468~protein phosphorylation,GO:0006936~muscle contraction,GO:0006939~smooth muscle contraction,GO:0014820~tonic smooth muscle contraction,GO:0030335~positive regulation of cell migration,GO:0032060~bleb assembly,GO:0051928~positive regulation of calcium ion transport,GO:0060414~aorta smooth muscle tissue morphogenesis,GO:0071476~cellular hypotonic response,GO:0090303~positive regulation of wound healing,	GO:0001725~stress fiber,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0015629~actin cytoskeleton,GO:0030027~lamellipodium,GO:0032154~cleavage furrow,	GO:0003779~actin binding,GO:0004672~protein kinase activity,GO:0004687~myosin light chain kinase activity,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0005524~ATP binding,GO:0016301~kinase activity,GO:0046872~metal ion binding,	IPR000719:Protein kinase, catalytic domain,IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR003961:Fibronectin, type III,IPR007110:Immunoglobulin-like domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR013098:Immunoglobulin I-set,IPR013783:Immunoglobulin-like fold,IPR017441:Protein kinase, ATP binding site,	hsa04020:Calcium signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04270:Vascular smooth muscle contraction,hsa04371:Apelin signaling pathway,hsa04510:Focal adhesion,hsa04611:Platelet activation,hsa04810:Regulation of actin cytoskeleton,hsa04921:Oxytocin signaling pathway,hsa04971:Gastric acid secretion,	249210~Megacystis-microcolon-intestinal hypoperistalsis syndrome 1,613780~Aortic aneurysm, familial thoracic 7,		SM00060:FN3,SM00220:S_TKc,SM00408:IGc2,SM00409:IG,		KW-0206~Cytoskeleton,KW-0963~Cytoplasm,KW-0966~Cell projection,	KW-0225~Disease variant,KW-0993~Aortic aneurysm,	KW-0393~Immunoglobulin domain,KW-0677~Repeat,	KW-0067~ATP-binding,KW-0106~Calcium,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0009~Actin-binding,KW-0112~Calmodulin-binding,KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,BINDING:ATP,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Fibronectin type-III,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,DOMAIN:Ig-like C2-type 4,DOMAIN:Ig-like C2-type 5,DOMAIN:Ig-like C2-type 6,DOMAIN:Ig-like C2-type 7,DOMAIN:Ig-like C2-type 8,DOMAIN:Ig-like C2-type 9,DOMAIN:Protein kinase,MUTAGEN:K->A: Loss of acetylation and no kinase activity repression by NAA10/ARD1.,NP_BIND:ATP,REGION:5 X 28 AA approximate tandem repeats,REGION:6 X 12 AA approximate tandem repeats,REGION:Actin-binding (calcium/calmodulin-insensitive),REGION:Actin-binding (calcium/calmodulin-sensitive),REGION:Calmodulin-binding,REGION:Disordered,REPEAT:1-1,REPEAT:1-2,REPEAT:1-3,REPEAT:1-4,REPEAT:1-5; truncated,REPEAT:2-1; truncated,REPEAT:2-2,REPEAT:2-3,REPEAT:2-4,REPEAT:2-5,REPEAT:2-6,
NENF	neudesin neurotrophic factor(NENF)	Homo sapiens				GO:0007165~signal transduction,GO:0032099~negative regulation of appetite,GO:0043410~positive regulation of MAPK cascade,GO:1901215~negative regulation of neuron death,	GO:0005615~extracellular space,GO:0005739~mitochondrion,GO:0005783~endoplasmic reticulum,GO:0012505~endomembrane system,GO:0016020~membrane,	GO:0005515~protein binding,GO:0008083~growth factor activity,GO:0046872~metal ion binding,	IPR001199:Cytochrome b5-like heme/steroid binding domain,				SM01117:SM01117,		KW-0256~Endoplasmic reticulum,KW-0496~Mitochondrion,KW-0964~Secreted,		KW-0732~Signal,	KW-0349~Heme,KW-0408~Iron,KW-0479~Metal-binding,		KW-0007~Acetylation,	COMPBIAS:Basic and acidic residues,DOMAIN:Cytochrome b5 heme-binding,REGION:Disordered,
NGRN	neugrin, neurite outgrowth associated(NGRN)	Homo sapiens				GO:0030182~neuron differentiation,GO:0061668~mitochondrial ribosome assembly,GO:0070131~positive regulation of mitochondrial translation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0016604~nuclear body,GO:0031966~mitochondrial membrane,GO:0045171~intercellular bridge,GO:0072686~mitotic spindle,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0019843~rRNA binding,	IPR010487:Neugrin-related,					KW-0221~Differentiation,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0964~Secreted,		KW-0732~Signal,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
NPDC1	neural proliferation, differentiation and control 1(NPDC1)	Homo sapiens				GO:0050776~regulation of immune response,	GO:0005886~plasma membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,	IPR009635:Neural proliferation differentiation control-1,						KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	REGION:Disordered,TRANSMEM:Helical,
NET1	neuroepithelial cell transforming 1(NET1)	Homo sapiens				GO:0001558~regulation of cell growth,GO:0007165~signal transduction,GO:0007186~G-protein coupled receptor signaling pathway,GO:0035025~positive regulation of Rho protein signal transduction,GO:0035556~intracellular signal transduction,GO:0043065~positive regulation of apoptotic process,GO:0043547~positive regulation of GTPase activity,GO:0051056~regulation of small GTPase mediated signal transduction,GO:0051451~myoblast migration,GO:0070301~cellular response to hydrogen peroxide,GO:0071479~cellular response to ionizing radiation,	GO:0005634~nucleus,GO:0005829~cytosol,	GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,	IPR000219:Dbl homology (DH) domain,IPR001331:Guanine-nucleotide dissociation stimulator, CDC24, conserved site,IPR001849:Pleckstrin homology domain,IPR011993:Pleckstrin homology-like domain,				SM00233:PH,SM00325:RhoGEF,		KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0656~Proto-oncogene,			KW-0344~Guanine-nucleotide releasing factor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:DH,DOMAIN:PH,MOTIF:Nuclear localization signal,REGION:Disordered,REGION:Necessary for nuclear localization,
NNT	nicotinamide nucleotide transhydrogenase(NNT)	Homo sapiens				GO:0001933~negative regulation of protein phosphorylation,GO:0006099~tricarboxylic acid cycle,GO:0006740~NADPH regeneration,GO:0010918~positive regulation of mitochondrial membrane potential,GO:0032364~oxygen homeostasis,GO:0033273~response to vitamin,GO:0043066~negative regulation of apoptotic process,GO:0045454~cell redox homeostasis,GO:0072593~reactive oxygen species metabolic process,GO:0098869~cellular oxidant detoxification,GO:1902600~hydrogen ion transmembrane transport,GO:1903285~positive regulation of hydrogen peroxide catabolic process,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005746~mitochondrial respiratory chain,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0003957~NAD(P)+ transhydrogenase (B-specific) activity,GO:0008746~NAD(P)+ transhydrogenase activity,GO:0016491~oxidoreductase activity,GO:0050661~NADP binding,GO:0051287~NAD binding,	IPR007698:Alanine dehydrogenase/PNT, NAD(H)-binding domain,IPR007886:Alanine dehydrogenase/pyridine nucleotide transhydrogenase, N-terminal,IPR008142:Alanine dehydrogenase/pyridine nucleotide transhydrogenase, conserved site-1,IPR008143:Alanine dehydrogenase/pyridine nucleotide transhydrogenase, conserved site-2,IPR024605:NAD(P) transhydrogenase, alpha subunit, C-terminal,IPR026255:NAD(P) transhydrogenase, alpha subunit,	hsa00760:Nicotinate and nicotinamide metabolism,hsa01100:Metabolic pathways,	614736~Glucocorticoid deficiency 4, with or without mineralocorticoid deficiency,	PIRSF000203:NAD(P) transhydrogenase, alpha subunit,	SM01002:SM01002,SM01003:SM01003,		KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,	KW-0225~Disease variant,	KW-0809~Transit peptide,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0520~NAD,KW-0521~NADP,KW-0547~Nucleotide-binding,	KW-1278~Translocase,	KW-0007~Acetylation,	BINDING:NAD,BINDING:NAD; via amide nitrogen,BINDING:NAD; via carbonyl oxygen,BINDING:NADP; via amide nitrogen,DOMAIN:AlaDh_PNT_C,DOMAIN:AlaDh_PNT_N,DOMAIN:PNTB,NP_BIND:NAD,NP_BIND:NADP,TOPO_DOM:Cytoplasmic,TOPO_DOM:Mitochondrial matrix,TRANSIT:Mitochondrion,TRANSMEM:Helical,
NIPSNAP1	nipsnap homolog 1(NIPSNAP1)	Homo sapiens				GO:0019233~sensory perception of pain,	GO:0005739~mitochondrion,GO:0097060~synaptic membrane,	GO:0005515~protein binding,GO:0042165~neurotransmitter binding,	IPR011008:Dimeric alpha-beta barrel,IPR012577:NIPSNAP,											KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:NIPSNAP,
NISCH	nischarin(NISCH)	Homo sapiens			Function unknown,	GO:0006006~glucose metabolic process,GO:0006915~apoptotic process,GO:0008217~regulation of blood pressure,GO:0016601~Rac protein signal transduction,GO:0030036~actin cytoskeleton organization,GO:0030336~negative regulation of cell migration,GO:0032228~regulation of synaptic transmission, GABAergic,GO:0048243~norepinephrine secretion,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005769~early endosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0015630~microtubule cytoskeleton,GO:0016020~membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0045171~intercellular bridge,GO:0055037~recycling endosome,	GO:0005178~integrin binding,GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0035091~phosphatidylinositol binding,GO:0042802~identical protein binding,	IPR001611:Leucine-rich repeat,IPR001683:Phox homologous domain,				SM00312:PX,	KW-0053~Apoptosis,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0433~Leucine-rich repeat,KW-0677~Repeat,		KW-0675~Receptor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:PX,MUTAGEN:R->A: Inhibits targeting to endosomes.,MUTAGEN:Y->A: Inhibits targeting to endosomes.,REGION:Disordered,REGION:Interaction with ITGA5,REGION:Interaction with LIMK,REGION:Interaction with PAK1,REGION:Necessary for binding to phosphoinositide-3-P; not sufficient for targeting to endosomes,REGION:Necessary for homooligomerization and targeting to endosomes,REPEAT:LRR 1,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,
NOS3	nitric oxide synthase 3(NOS3)	Homo sapiens		h_gcrpathway:Corticosteroids and cardioprotection,h_hifPathway:Hypoxia-Inducible Factor in the Cardiovascular System,h_no1Pathway:Actions of Nitric Oxide in the Heart,h_raccPathway:Ion Channels and Their Functional Role in Vascular Endothelium,h_vegfPathway:VEGF, Hypoxia, and Angiogenesis,	Inorganic ion transport and metabolism,	GO:0001525~angiogenesis,GO:0001542~ovulation from ovarian follicle,GO:0001701~in utero embryonic development,GO:0001974~blood vessel remodeling,GO:0002028~regulation of sodium ion transport,GO:0003057~regulation of the force of heart contraction by chemical signal,GO:0003100~regulation of systemic arterial blood pressure by endothelin,GO:0003180~aortic valve morphogenesis,GO:0003184~pulmonary valve morphogenesis,GO:0003203~endocardial cushion morphogenesis,GO:0006527~arginine catabolic process,GO:0006809~nitric oxide biosynthetic process,GO:0007005~mitochondrion organization,GO:0007263~nitric oxide mediated signal transduction,GO:0008217~regulation of blood pressure,GO:0008285~negative regulation of cell proliferation,GO:0009408~response to heat,GO:0009725~response to hormone,GO:0010544~negative regulation of platelet activation,GO:0010628~positive regulation of gene expression,GO:0014740~negative regulation of muscle hyperplasia,GO:0014806~smooth muscle hyperplasia,GO:0019430~removal of superoxide radicals,GO:0030324~lung development,GO:0031284~positive regulation of guanylate cyclase activity,GO:0031644~regulation of neurological system process,GO:0031663~lipopolysaccharide-mediated signaling pathway,GO:0032496~response to lipopolysaccharide,GO:0034405~response to fluid shear stress,GO:0042311~vasodilation,GO:0043267~negative regulation of potassium ion transport,GO:0043536~positive regulation of blood vessel endothelial cell migration,GO:0043542~endothelial cell migration,GO:0045454~cell redox homeostasis,GO:0045747~positive regulation of Notch signaling pathway,GO:0045766~positive regulation of angiogenesis,GO:0045776~negative regulation of blood pressure,GO:0046146~tetrahydrobiopterin metabolic process,GO:0048662~negative regulation of smooth muscle cell proliferation,GO:0048873~homeostasis of number of cells within a tissue,GO:0050999~regulation of nitric-oxide synthase activity,GO:0051346~negative regulation of hydrolase activity,GO:0051926~negative regulation of calcium ion transport,GO:0060412~ventricular septum morphogenesis,GO:0070168~negative regulation of biomineral tissue development,GO:0097746~regulation of blood vessel diameter,GO:1902042~negative regulation of extrinsic apoptotic signaling pathway via death domain receptors,	GO:0000139~Golgi membrane,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0005901~caveola,GO:0012506~vesicle membrane,GO:0030666~endocytic vesicle membrane,	GO:0003785~actin monomer binding,GO:0004517~nitric-oxide synthase activity,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0010181~FMN binding,GO:0016491~oxidoreductase activity,GO:0016709~oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen,GO:0020037~heme binding,GO:0034617~tetrahydrobiopterin binding,GO:0034618~arginine binding,GO:0046870~cadmium ion binding,GO:0046872~metal ion binding,GO:0050660~flavin adenine dinucleotide binding,GO:0050661~NADP binding,GO:0097110~scaffold protein binding,	IPR001094:Flavodoxin,IPR001433:Oxidoreductase FAD/NAD(P)-binding,IPR001709:Flavoprotein pyridine nucleotide cytochrome reductase,IPR003097:FAD-binding, type 1,IPR004030:Nitric oxide synthase, oxygenase domain,IPR008254:Flavodoxin/nitric oxide synthase,IPR012144:Nitric-oxide synthase, metazoa,IPR017927:Ferredoxin reductase-type FAD-binding domain,IPR017938:Riboflavin synthase-like beta-barrel,IPR023173:NADPH-cytochrome p450 reductase, FAD-binding, alpha-helical domain-3,	hsa00220:Arginine biosynthesis,hsa00330:Arginine and proline metabolism,hsa01100:Metabolic pathways,hsa04020:Calcium signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04071:Sphingolipid signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04370:VEGF signaling pathway,hsa04371:Apelin signaling pathway,hsa04611:Platelet activation,hsa04915:Estrogen signaling pathway,hsa04921:Oxytocin signaling pathway,hsa04926:Relaxin signaling pathway,hsa04931:Insulin resistance,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa05415:Diabetic cardiomyopathy,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,	104300~Alzheimer disease, late-onset, susceptibility to,145500~Hypertension, susceptibility to,189800~Hypertension, pregnancy-induced,601367~Ischemic stroke, susceptibility to,Coronary artery spasm 1, susceptibility to~Coronary artery spasm 1, susceptibility to,Placental abruption~Placental abruption,	PIRSF000333:nitric-oxide synthase, inducible,			KW-0206~Cytoskeleton,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,			KW-0106~Calcium,KW-0274~FAD,KW-0285~Flavoprotein,KW-0288~FMN,KW-0349~Heme,KW-0408~Iron,KW-0479~Metal-binding,KW-0521~NADP,KW-0862~Zinc,	KW-0112~Calmodulin-binding,KW-0560~Oxidoreductase,	KW-0449~Lipoprotein,KW-0519~Myristate,KW-0564~Palmitate,KW-0597~Phosphoprotein,	COMPBIAS:Pro residues,DOMAIN:FAD-binding FR-type,DOMAIN:Flavodoxin-like,LIPID:N-myristoyl glycine,LIPID:S-palmitoyl cysteine,METAL:Iron (heme axial ligand),METAL:Zinc,MUTAGEN:S->A: Reduced nitrite (NO) production.,NP_BIND:FAD,NP_BIND:FMN,NP_BIND:NADP,REGION:Calmodulin-binding,REGION:Disordered,REGION:Interaction with NOSIP,
NOSIP	nitric oxide synthase interacting protein(NOSIP)	Homo sapiens				GO:0007275~multicellular organism development,GO:0016567~protein ubiquitination,GO:0043086~negative regulation of catalytic activity,GO:0050999~regulation of nitric-oxide synthase activity,GO:0051001~negative regulation of nitric-oxide synthase activity,	GO:0000139~Golgi membrane,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0061630~ubiquitin protein ligase activity,	IPR003613:U box domain,IPR013083:Zinc finger, RING/FYVE/PHD-type,IPR016818:Nitric oxide synthase-interacting,			PIRSF023577:eNOS interacting protein,		KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,		KW-0217~Developmental protein,KW-0808~Transferase,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:U-box,DOMAIN:zf-NOSIP,MOTIF:Nuclear localization signal,REGION:Disordered,REGION:U-box-like,
NIT1	nitrilase 1(NIT1)	Homo sapiens			General function prediction only,	GO:0006807~nitrogen compound metabolic process,GO:0043605~cellular amide catabolic process,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,		IPR001110:Uncharacterised protein family UPF0012, conserved site,IPR003010:Carbon-nitrogen hydrolase,						KW-0496~Mitochondrion,KW-0963~Cytoplasm,		KW-0809~Transit peptide,		KW-0378~Hydrolase,		ACT_SITE:Nucleophile,ACT_SITE:Proton acceptor,ACT_SITE:Proton donor,DOMAIN:CN hydrolase,TRANSIT:Mitochondrion,
NCAPD2	non-SMC condensin I complex subunit D2(NCAPD2)	Homo sapiens		h_akap95Pathway:AKAP95 role in mitosis and chromosome dynamics,	Chromatin structure and dynamics / Cell division and chromosome partitioning,	GO:0007076~mitotic chromosome condensation,GO:0010032~meiotic chromosome condensation,GO:0051301~cell division,GO:1905821~positive regulation of chromosome condensation,	GO:0000228~nuclear chromosome,GO:0000779~condensed chromosome, centromeric region,GO:0000793~condensed chromosome,GO:0000796~condensin complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,	GO:0003682~chromatin binding,GO:0005515~protein binding,GO:0042393~histone binding,	IPR007673:Condensin subunit 1,IPR011989:Armadillo-like helical,IPR016024:Armadillo-type fold,IPR024324:Condensin complex, subunit 1, N-terminal,IPR026971:Condensin subunit 1/Condensin-2 complex subunit D3,		617983~Microcephaly 21, primary, autosomal recessive,	PIRSF017127:chromosome condensation complex condensin, subunit D2,		KW-0131~Cell cycle,KW-0132~Cell division,KW-0226~DNA condensation,KW-0498~Mitosis,	KW-0158~Chromosome,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0905~Primary microcephaly,	KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Cnd1,DOMAIN:Cnd1_N,MOTIF:Bipartite nuclear localization signal,MUTAGEN:KKK->AAA: Abolishes localization to the nucleus, while it only reduces chromosome binding.,MUTAGEN:RRTTRR->AATTAA: Abolishes localization to the nucleus, while it only reduces chromosome binding.,REGION:Disordered,REGION:Interactions with SMC2 and SMC4,
NOTCH1	notch receptor 1(NOTCH1)	Homo sapiens		h_hesPathway:Segmentation Clock,h_notchPathway:Proteolysis and Signaling Pathway of Notch ,h_ps1Pathway:Presenilin action in Notch and Wnt signaling,		GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001701~in utero embryonic development,GO:0001708~cell fate specification,GO:0001837~epithelial to mesenchymal transition,GO:0001889~liver development,GO:0001947~heart looping,GO:0002040~sprouting angiogenesis,GO:0002052~positive regulation of neuroblast proliferation,GO:0002437~inflammatory response to antigenic stimulus,GO:0003151~outflow tract morphogenesis,GO:0003157~endocardium development,GO:0003160~endocardium morphogenesis,GO:0003162~atrioventricular node development,GO:0003169~coronary vein morphogenesis,GO:0003180~aortic valve morphogenesis,GO:0003181~atrioventricular valve morphogenesis,GO:0003182~coronary sinus valve morphogenesis,GO:0003184~pulmonary valve morphogenesis,GO:0003192~mitral valve formation,GO:0003198~epithelial to mesenchymal transition involved in endocardial cushion formation,GO:0003203~endocardial cushion morphogenesis,GO:0003207~cardiac chamber formation,GO:0003208~cardiac ventricle morphogenesis,GO:0003209~cardiac atrium morphogenesis,GO:0003213~cardiac right atrium morphogenesis,GO:0003214~cardiac left ventricle morphogenesis,GO:0003219~cardiac right ventricle formation,GO:0003222~ventricular trabecula myocardium morphogenesis,GO:0003241~growth involved in heart morphogenesis,GO:0003252~negative regulation of cell proliferation involved in heart valve morphogenesis,GO:0003256~regulation of transcription from RNA polymerase II promoter involved in myocardial precursor cell differentiation,GO:0003270~Notch signaling pathway involved in regulation of secondary heart field cardioblast proliferation,GO:0003273~cell migration involved in endocardial cushion formation,GO:0003332~negative regulation of extracellular matrix constituent secretion,GO:0003344~pericardium morphogenesis,GO:0006355~regulation of transcription, DNA-templated,GO:0006367~transcription initiation from RNA polymerase II promoter,GO:0006606~protein import into nucleus,GO:0006955~immune response,GO:0006959~humoral immune response,GO:0007050~cell cycle arrest,GO:0007219~Notch signaling pathway,GO:0007221~positive regulation of transcription of Notch receptor target,GO:0007275~multicellular organism development,GO:0007283~spermatogenesis,GO:0007368~determination of left/right symmetry,GO:0007386~compartment pattern specification,GO:0007411~axon guidance,GO:0007440~foregut morphogenesis,GO:0007492~endoderm development,GO:0007507~heart development,GO:0008284~positive regulation of cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0009912~auditory receptor cell fate commitment,GO:0010467~gene expression,GO:0010614~negative regulation of cardiac muscle hypertrophy,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0010812~negative regulation of cell-substrate adhesion,GO:0010832~negative regulation of myotube differentiation,GO:0014031~mesenchymal cell development,GO:0014807~regulation of somitogenesis,GO:0021515~cell differentiation in spinal cord,GO:0021915~neural tube development,GO:0030154~cell differentiation,GO:0030163~protein catabolic process,GO:0030216~keratinocyte differentiation,GO:0030279~negative regulation of ossification,GO:0030324~lung development,GO:0030335~positive regulation of cell migration,GO:0030513~positive regulation of BMP signaling pathway,GO:0030514~negative regulation of BMP signaling pathway,GO:0030900~forebrain development,GO:0031069~hair follicle morphogenesis,GO:0031100~animal organ regeneration,GO:0031960~response to corticosteroid,GO:0032495~response to muramyl dipeptide,GO:0032496~response to lipopolysaccharide,GO:0035116~embryonic hindlimb morphogenesis,GO:0035148~tube formation,GO:0035914~skeletal muscle cell differentiation,GO:0035924~cellular response to vascular endothelial growth factor stimulus,GO:0042246~tissue regeneration,GO:0043086~negative regulation of catalytic activity,GO:0045070~positive regulation of viral genome replication,GO:0045603~positive regulation of endothelial cell differentiation,GO:0045608~negative regulation of auditory receptor cell differentiation,GO:0045618~positive regulation of keratinocyte differentiation,GO:0045662~negative regulation of myoblast differentiation,GO:0045668~negative regulation of osteoblast differentiation,GO:0045747~positive regulation of Notch signaling pathway,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0045955~negative regulation of calcium ion-dependent exocytosis,GO:0045967~negative regulation of growth rate,GO:0046427~positive regulation of JAK-STAT cascade,GO:0046533~negative regulation of photoreceptor cell differentiation,GO:0046579~positive regulation of Ras protein signal transduction,GO:0048103~somatic stem cell division,GO:0048708~astrocyte differentiation,GO:0048709~oligodendrocyte differentiation,GO:0048711~positive regulation of astrocyte differentiation,GO:0048715~negative regulation of oligodendrocyte differentiation,GO:0048754~branching morphogenesis of an epithelial tube,GO:0048873~homeostasis of number of cells within a tissue,GO:0050679~positive regulation of epithelial cell proliferation,GO:0050768~negative regulation of neurogenesis,GO:0055008~cardiac muscle tissue morphogenesis,GO:0060038~cardiac muscle cell proliferation,GO:0060045~positive regulation of cardiac muscle cell proliferation,GO:0060253~negative regulation of glial cell proliferation,GO:0060271~cilium assembly,GO:0060317~cardiac epithelial to mesenchymal transition,GO:0060354~negative regulation of cell adhesion molecule production,GO:0060411~cardiac septum morphogenesis,GO:0060412~ventricular septum morphogenesis,GO:0060528~secretory columnal luminar epithelial cell differentiation involved in prostate glandular acinus development,GO:0060740~prostate gland epithelium morphogenesis,GO:0060768~regulation of epithelial cell proliferation involved in prostate gland development,GO:0060842~arterial endothelial cell differentiation,GO:0060843~venous endothelial cell differentiation,GO:0060948~cardiac vascular smooth muscle cell development,GO:0060956~endocardial cell differentiation,GO:0060979~vasculogenesis involved in coronary vascular morphogenesis,GO:0060982~coronary artery morphogenesis,GO:0061314~Notch signaling involved in heart development,GO:0061384~heart trabecula morphogenesis,GO:0061419~positive regulation of transcription from RNA polymerase II promoter in response to hypoxia,GO:0070168~negative regulation of biomineral tissue development,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0070986~left/right axis specification,GO:0071228~cellular response to tumor cell,GO:0071372~cellular response to follicle-stimulating hormone stimulus,GO:0072017~distal tubule development,GO:0072044~collecting duct development,GO:0072144~glomerular mesangial cell development,GO:0072538~T-helper 17 type immune response,GO:0090051~negative regulation of cell migration involved in sprouting angiogenesis,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:0097150~neuronal stem cell population maintenance,GO:0097400~interleukin-17-mediated signaling pathway,GO:1901201~regulation of extracellular matrix assembly,GO:1902263~apoptotic process involved in embryonic digit morphogenesis,GO:1902339~positive regulation of apoptotic process involved in morphogenesis,GO:1903849~positive regulation of aorta morphogenesis,GO:2000048~negative regulation of cell-cell adhesion mediated by cadherin,GO:2000737~negative regulation of stem cell differentiation,GO:2000811~negative regulation of anoikis,GO:2000974~negative regulation of pro-B cell differentiation,GO:2001027~negative regulation of endothelial cell chemotaxis,	GO:0000139~Golgi membrane,GO:0001669~acrosomal vesicle,GO:0002193~MAML1-RBP-Jkappa- ICN1 complex,GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005912~adherens junction,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0043235~receptor complex,	GO:0003713~transcription coactivator activity,GO:0004857~enzyme inhibitor activity,GO:0004888~transmembrane signaling receptor activity,GO:0005112~Notch binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0031490~chromatin DNA binding,GO:0042802~identical protein binding,	IPR000152:EGF-type aspartate/asparagine hydroxylation site,IPR000742:Epidermal growth factor-like domain,IPR000800:Notch domain,IPR001881:EGF-like calcium-binding,IPR002110:Ankyrin repeat,IPR008297:Notch,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR010660:Notch, NOD domain,IPR011656:Notch, NODP domain,IPR013032:EGF-like, conserved site,IPR018097:EGF-like calcium-binding, conserved site,IPR020683:Ankyrin repeat-containing domain,IPR022362:Neurogenic locus Notch 1,IPR024600:Domain of unknown function DUF3454, notch,	hsa01522:Endocrine resistance,hsa04330:Notch signaling pathway,hsa04658:Th1 and Th2 cell differentiation,hsa04919:Thyroid hormone signaling pathway,hsa05020:Prion disease,hsa05165:Human papillomavirus infection,hsa05200:Pathways in cancer,hsa05206:MicroRNAs in cancer,hsa05224:Breast cancer,	109730~Aortic valve disease 1,616028~Adams-Oliver syndrome 5,	PIRSF002279:notch protein,	SM00004:NL,SM00179:EGF_CA,SM00181:EGF,SM00248:ANK,SM01334:SM01334,SM01338:SM01338,SM01339:SM01339,	KW-0037~Angiogenesis,KW-0221~Differentiation,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0914~Notch signaling pathway,	KW-0472~Membrane,KW-0539~Nucleus,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0040~ANK repeat,KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0010~Activator,KW-0217~Developmental protein,KW-0675~Receptor,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-0379~Hydroxylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (Fuc) serine,CARBOHYD:O-linked (Fuc...) threonine,CARBOHYD:O-linked (Fuc...) threonine; alternate,CARBOHYD:O-linked (GalNAc...) threonine,CARBOHYD:O-linked (GalNAc...) threonine; alternate,CARBOHYD:O-linked (Glc...) serine,CARBOHYD:O-linked (GlcNAc) serine,CARBOHYD:O-linked (GlcNAc...) threonine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:DUF3454,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 10,DOMAIN:EGF-like 11; calcium-binding,DOMAIN:EGF-like 12; calcium-binding,DOMAIN:EGF-like 13; calcium-binding,DOMAIN:EGF-like 14; calcium-binding,DOMAIN:EGF-like 15; calcium-binding,DOMAIN:EGF-like 16; calcium-binding,DOMAIN:EGF-like 17; calcium-binding,DOMAIN:EGF-like 18; calcium-binding,DOMAIN:EGF-like 19; calcium-binding,DOMAIN:EGF-like 2,DOMAIN:EGF-like 20,DOMAIN:EGF-like 21; calcium-binding,DOMAIN:EGF-like 22,DOMAIN:EGF-like 23; calcium-binding,DOMAIN:EGF-like 24,DOMAIN:EGF-like 25; calcium-binding,DOMAIN:EGF-like 26,DOMAIN:EGF-like 27,DOMAIN:EGF-like 28,DOMAIN:EGF-like 29,DOMAIN:EGF-like 3,DOMAIN:EGF-like 30,DOMAIN:EGF-like 31; calcium-binding,DOMAIN:EGF-like 32; calcium-binding,DOMAIN:EGF-like 33,DOMAIN:EGF-like 34,DOMAIN:EGF-like 35,DOMAIN:EGF-like 36,DOMAIN:EGF-like 4,DOMAIN:EGF-like 5; calcium-binding,DOMAIN:EGF-like 6,DOMAIN:EGF-like 7; calcium-binding,DOMAIN:EGF-like 8; calcium-binding,DOMAIN:EGF-like 9; calcium-binding,DOMAIN:LNR,DOMAIN:NODP,METAL:Calcium 1; via amide nitrogen,METAL:Calcium 1; via carbonyl oxygen,METAL:Calcium 2,METAL:Calcium 2; via carbonyl oxygen,METAL:Calcium 3,METAL:Calcium 3; via carbonyl oxygen,METAL:Calcium 4,METAL:Calcium 4; via carbonyl oxygen,MUTAGEN:Missing: Loss of proteolytic cleavage by gamma-secretase.,MUTAGEN:P->C: Formation of an artifactual disulfide bond with PSEN1.,REGION:Disordered,REGION:HIF1AN-binding,REGION:Interaction with DLL4,REGION:Interaction with PSEN1,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,REPEAT:ANK 5,REPEAT:ANK 6,REPEAT:LNR 1,REPEAT:LNR 2,REPEAT:LNR 3,SITE:Cleavage; by ADAM17,SITE:Cleavage; by furin-like protease,SITE:Interaction with DLL4,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
NVL	nuclear VCP like(NVL)	Homo sapiens				GO:0006364~rRNA processing,GO:0032092~positive regulation of protein binding,GO:0042254~ribosome biogenesis,GO:0042273~ribosomal large subunit biogenesis,GO:0051973~positive regulation of telomerase activity,GO:1904749~regulation of protein localization to nucleolus,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005697~telomerase holoenzyme complex,GO:0005730~nucleolus,GO:0016020~membrane,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:1990275~preribosome binding,	IPR003593:AAA+ ATPase domain,IPR003959:ATPase, AAA-type, core,IPR003960:ATPase, AAA-type, conserved site,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa03008:Ribosome biogenesis in eukaryotes,			SM00382:AAA,	KW-0690~Ribosome biogenesis,	KW-0539~Nucleus,		KW-0677~Repeat,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:AAA_lid_3,DOMAIN:Nucleolin_bd,MOTIF:Nuclear localization signal,MOTIF:Nucleolar localization signal,MUTAGEN:D->A: Impairs the binding of MTREX.,MUTAGEN:E->Q: Decreases 60S ribosomes synthesis. Strongly decreases 60S ribosomal subunit synthesis, enhances interaction with WDR74 and increases association of WDR74 and MTREX as well as induces partial migration of WDR74 to the nucleoplasm; when associated with Q-365.,MUTAGEN:E->Q: Decreases 60S ribosomes synthesis. Strongly decreases 60S ribosomal subunit synthesis, enhances interaction with WDR74 and increases association of WDR74 and MTREX as well as induces partial migration of WDR74 to the nucleoplasm; when associated with Q-682.,MUTAGEN:I->E: Impairs binding to MTREX.,MUTAGEN:K->M: Loss of ATP-binding. No effect on interaction with TERT, MTREX and RPL5 and on telomerase activity. Significant reduction in the level of the 60S ribosomal subunit.,MUTAGEN:K->M: Loss of ATP-binding. Significant reduction in interaction with TERT and in telomerase activity. Loss of interaction with MTREX.,MUTAGEN:KR->AA: Decreased nuclear localization. Complete loss of nuclear localization; when associated with 218-A--A-220 and 230-A--A-232.,MUTAGEN:KR->AA: Loss of nucleolar localization and interaction with RPL5.,MUTAGEN:KRK->AAA: Decreased nuclear localization; when associated with 230-A--A-232. Complete loss of nuclear localization; when associated with 85-A-A-86 and 230-A--A-232.,MUTAGEN:RKK->AAA: Decreased nuclear localization when associated with 218-A--A-220. Complete loss of nuclear localization; when associated with 85-A-A-86 and 218-A--A-220.,MUTAGEN:W->A: Abolishes binding to MTREX.,NP_BIND:ATP,REGION:Disordered,REGION:Interaction with RPL5,REGION:Interaction with WDR74,
NFKB2	nuclear factor kappa B subunit 2(NFKB2)	Homo sapiens				GO:0002268~follicular dendritic cell differentiation,GO:0002467~germinal center formation,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007165~signal transduction,GO:0007568~aging,GO:0030198~extracellular matrix organization,GO:0032481~positive regulation of type I interferon production,GO:0032496~response to lipopolysaccharide,GO:0034097~response to cytokine,GO:0038061~NIK/NF-kappaB signaling,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048511~rhythmic process,GO:0048536~spleen development,GO:0051092~positive regulation of NF-kappaB transcription factor activity,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0033257~Bcl3/NF-kappaB2 complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000451:NF-kappa-B/Rel/Dorsal,IPR000488:Death domain,IPR002110:Ankyrin repeat,IPR002909:Cell surface receptor IPT/TIG,IPR008967:p53-like transcription factor, DNA-binding,IPR011029:Death-like domain,IPR011539:Rel homology domain,IPR013783:Immunoglobulin-like fold,IPR014756:Immunoglobulin E-set,IPR020683:Ankyrin repeat-containing domain,	hsa04010:MAPK signaling pathway,hsa04064:NF-kappa B signaling pathway,hsa04380:Osteoclast differentiation,hsa04625:C-type lectin receptor signaling pathway,hsa05134:Legionellosis,hsa05166:Human T-cell leukemia virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05224:Breast cancer,	615577~Immunodeficiency, common variable, 10,		SM00005:DEATH,SM00248:ANK,SM00429:IPT,	KW-0090~Biological rhythms,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0656~Proto-oncogene,	KW-0040~ANK repeat,KW-0175~Coiled coil,KW-0677~Repeat,		KW-0010~Activator,KW-0238~DNA-binding,KW-0678~Repressor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:Death,DOMAIN:RHD,MOTIF:Nuclear localization signal,MUTAGEN:A->P: No change in cleavage rate or products.,MUTAGEN:G->A: No change in cleavage rate or products.,MUTAGEN:P->A: No change in cleavage rate or products.,MUTAGEN:Q->N: No change in cleavage rate or products.,MUTAGEN:S->A: Decrease in MAP3K14-induced phosphorylation; no inducible processing occurs; when associated with A-865.,MUTAGEN:S->A: Decrease in MAP3K14-induced phosphorylation; no inducible processing occurs; when associated with A-869.,MUTAGEN:S->A: Loss of phosphorylation; when associated with G-713 and A-715.,MUTAGEN:S->A: Loss of phosphorylation; when associated with G-713 and A-717.,MUTAGEN:S->G: Loss of phosphorylation; when associated with A-715 and A-717.,MUTAGEN:YLL->AAA: Two-fold reduction in heterodimerization with RelA.,REGION:Disordered,REGION:GRR,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,REPEAT:ANK 5,REPEAT:ANK 6,REPEAT:ANK 7,SITE:Breakpoint for translocation to form NFKB2-IGHA1 oncogene,SITE:Cleavage (when cotranslationally processed),
NFATC3	nuclear factor of activated T cells 3(NFATC3)	Homo sapiens	80.T_cell_Activation,	h_bcrPathway:BCR Signaling Pathway,h_calcineurinPathway:Effects of calcineurin in Keratinocyte Differentiation,h_fcer1Pathway:Fc Epsilon Receptor I Signaling in Mast Cells,h_fmlpPathway:fMLP induced chemokine gene expression in HMC-1 cells,h_gpcrPathway:Signaling Pathway from G-Protein Families,h_nfatPathway:NFAT and Hypertrophy of the heart (Transcription in the broken heart),h_tcrPathway:T Cell Receptor Signaling Pathway,		GO:0001816~cytokine production,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006954~inflammatory response,GO:0007275~multicellular organism development,GO:0033173~calcineurin-NFAT signaling cascade,GO:0038095~Fc-epsilon receptor signaling pathway,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:1902894~negative regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1905064~negative regulation of vascular smooth muscle cell differentiation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR002909:Cell surface receptor IPT/TIG,IPR008366:Nuclear factor of activated T cells (NFAT),IPR008967:p53-like transcription factor, DNA-binding,IPR011539:Rel homology domain,IPR013783:Immunoglobulin-like fold,IPR014756:Immunoglobulin E-set,	hsa04010:MAPK signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04218:Cellular senescence,hsa04310:Wnt signaling pathway,hsa04360:Axon guidance,hsa04625:C-type lectin receptor signaling pathway,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04660:T cell receptor signaling pathway,hsa04662:B cell receptor signaling pathway,hsa04921:Oxytocin signaling pathway,hsa05135:Yersinia infection,hsa05161:Hepatitis B,hsa05163:Human cytomegalovirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05417:Lipid and atherosclerosis,			SM00429:IPT,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:RHD,MOTIF:Nuclear export signal,MOTIF:Nuclear localization signal,REGION:3 X SP repeats,REGION:Calcineurin-binding,REGION:Disordered,REPEAT:1,REPEAT:2,REPEAT:3,
NFATC4	nuclear factor of activated T cells 4(NFATC4)	Homo sapiens		h_bcrPathway:BCR Signaling Pathway,h_calcineurinPathway:Effects of calcineurin in Keratinocyte Differentiation,h_fcer1Pathway:Fc Epsilon Receptor I Signaling in Mast Cells,h_fmlpPathway:fMLP induced chemokine gene expression in HMC-1 cells,h_gpcrPathway:Signaling Pathway from G-Protein Families,h_nfatPathway:NFAT and Hypertrophy of the heart (Transcription in the broken heart),h_tcrPathway:T Cell Receptor Signaling Pathway,		GO:0001569~branching involved in blood vessel morphogenesis,GO:0001816~cytokine production,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006954~inflammatory response,GO:0007507~heart development,GO:0007616~long-term memory,GO:0008630~intrinsic apoptotic signaling pathway in response to DNA damage,GO:0030178~negative regulation of Wnt signaling pathway,GO:0031547~brain-derived neurotrophic factor receptor signaling pathway,GO:0032091~negative regulation of protein binding,GO:0032760~positive regulation of tumor necrosis factor production,GO:0033173~calcineurin-NFAT signaling cascade,GO:0034644~cellular response to UV,GO:0035562~negative regulation of chromatin binding,GO:0043524~negative regulation of neuron apoptotic process,GO:0045333~cellular respiration,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050774~negative regulation of dendrite morphogenesis,GO:0051145~smooth muscle cell differentiation,GO:0055001~muscle cell development,GO:0060291~long-term synaptic potentiation,GO:0071285~cellular response to lithium ion,GO:1902894~negative regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:2000297~negative regulation of synapse maturation,GO:2001235~positive regulation of apoptotic signaling pathway,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005667~transcription factor complex,GO:0005829~cytosol,GO:0016607~nuclear speck,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0042975~peroxisome proliferator activated receptor binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR002909:Cell surface receptor IPT/TIG,IPR008366:Nuclear factor of activated T cells (NFAT),IPR008967:p53-like transcription factor, DNA-binding,IPR011539:Rel homology domain,IPR013783:Immunoglobulin-like fold,IPR014756:Immunoglobulin E-set,	hsa04022:cGMP-PKG signaling pathway,hsa04218:Cellular senescence,hsa04310:Wnt signaling pathway,hsa04360:Axon guidance,hsa04625:C-type lectin receptor signaling pathway,hsa04921:Oxytocin signaling pathway,hsa05161:Hepatitis B,hsa05163:Human cytomegalovirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05170:Human immunodeficiency virus 1 infection,			SM00429:IPT,	KW-0221~Differentiation,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:IPT/TIG,DOMAIN:RHD,MOTIF:Nuclear localization signal,MUTAGEN:S->A: Marked decrease in phosphorylation by MAPK8 or MAPK9. Complete loss of phosphorylation by MAPK8 or MAPK9, but no effect on MAPK8/9-binding; when associated with A-213. Decreased transcriptional activity; when associated with A-213.,MUTAGEN:S->A: Marked decrease in phosphorylation by MAPK8 or MAPK9. Complete loss of phosphorylation by MAPK8 or MAPK9, but no effect on MAPK8/9-binding; when associated with A-217. Decreased transcriptional activity; when associated with A-217.,MUTAGEN:S->A: Promotes nuclear localization and increases transcriptional activity; when associated with A-168.,MUTAGEN:S->A: Promotes nuclear localization and increases transcriptional activity; when associated with A-170.,REGION:2 approximate SP repeats,REGION:Calcineurin-binding,REGION:Disordered,REPEAT:SP 1,REPEAT:SP 2; approximate,
NFIL3	nuclear factor, interleukin 3 regulated(NFIL3)	Homo sapiens				GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001779~natural killer cell differentiation,GO:0006355~regulation of transcription, DNA-templated,GO:0006366~transcription from RNA polymerase II promoter,GO:0006955~immune response,GO:0007623~circadian rhythm,GO:0010628~positive regulation of gene expression,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0071353~cellular response to interleukin-4,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR004827:Basic-leucine zipper domain,IPR010533:Vertebrate interleukin-3 regulated transcription factor,IPR016743:Transcription factor, basic leucine zipper, E4BP4,			PIRSF019029:basic leucine zipper (bZIP) transcription factor E4BP4,	SM00338:BRLZ,	KW-0090~Biological rhythms,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,KW-0238~DNA-binding,KW-0678~Repressor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:BZIP,DOMAIN:bZIP,MUTAGEN:K->A: Interacts with DR1 and partially affects transcriptional repression; when associated with E-330.,MUTAGEN:K->A: Interacts with DR1 and partially affects transcriptional repression; when associated with E-332.,MUTAGEN:K->E: Does not interact with DR1 and drastically affects transcriptional repression; when associated with E-330.,MUTAGEN:K->E: Does not interact with DR1 and drastically affects transcriptional repression; when associated with E-332.,REGION:Basic motif,REGION:Disordered,REGION:Leucine-zipper,REGION:Necessary for transcriptional repression and sufficient for interaction with DR1,
NCOA3	nuclear receptor coactivator 3(NCOA3)	Homo sapiens		h_rarrxrPathway:Nuclear receptors coordinate the activities of chromatin remodeling complexes and coactivators to facilitate initiation of transcription in carcinoma cells,h_vdrPathway:Control of Gene Expression by Vitamin D Receptor,		GO:0016573~histone acetylation,GO:0032870~cellular response to hormone stimulus,GO:0035624~receptor transactivation,GO:0043697~cell dedifferentiation,GO:0045618~positive regulation of keratinocyte differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0071392~cellular response to estradiol stimulus,GO:1902459~positive regulation of stem cell population maintenance,GO:2000035~regulation of stem cell division,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0032991~macromolecular complex,GO:0070062~extracellular exosome,	GO:0000993~RNA polymerase II core binding,GO:0003713~transcription coactivator activity,GO:0004402~histone acetyltransferase activity,GO:0005515~protein binding,GO:0016922~ligand-dependent nuclear receptor binding,GO:0030374~ligand-dependent nuclear receptor transcription coactivator activity,GO:0035257~nuclear hormone receptor binding,GO:0046966~thyroid hormone receptor binding,GO:0046983~protein dimerization activity,GO:0047485~protein N-terminus binding,GO:0097718~disordered domain specific binding,	IPR000014:PAS domain,IPR009110:Nuclear receptor coactivator, interlocking,IPR010011:Domain of unknown function DUF1518,IPR011598:Myc-type, basic helix-loop-helix (bHLH) domain,IPR013767:PAS fold,IPR014920:Nuclear receptor coactivator, Ncoa-type, interlocking,IPR014935:Steroid receptor coactivator,IPR017426:Nuclear receptor coactivator,	hsa01522:Endocrine resistance,hsa04915:Estrogen signaling pathway,hsa04919:Thyroid hormone signaling pathway,hsa05200:Pathways in cancer,hsa05224:Breast cancer,		PIRSF038181:nuclear receptor coactivator,	SM00091:PAS,SM00353:HLH,SM01151:SM01151,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0010~Activator,KW-0012~Acyltransferase,KW-0675~Receptor,KW-0808~Transferase,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:BHLH,DOMAIN:PAS,DOMAIN:bHLH,MOTIF:LXXLL motif 1,MOTIF:LXXLL motif 2,MOTIF:LXXLL motif 3,MUTAGEN:K->Q: Does not affect acetylation by CREBBP.,MUTAGEN:K->Q: Strongly reduces acetylation by CREBBP.,MUTAGEN:KK->QQ: Abolishes acetylation by CREBBP.,REGION:Acetyltransferase,REGION:Disordered,REGION:Interaction with CREBBP,
NRIP1	nuclear receptor interacting protein 1(NRIP1)	Homo sapiens		h_carm-erPathway:CARM1 and Regulation of the Estrogen Receptor,h_PparaPathway:Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha),		GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001543~ovarian follicle rupture,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007623~circadian rhythm,GO:0019915~lipid storage,GO:0030522~intracellular receptor signaling pathway,GO:0032922~circadian regulation of gene expression,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0071392~cellular response to estradiol stimulus,	GO:0000118~histone deacetylase complex,GO:0000785~chromatin,GO:0001650~fibrillar center,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005829~cytosol,GO:0016607~nuclear speck,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0003712~transcription cofactor activity,GO:0003713~transcription coactivator activity,GO:0003714~transcription corepressor activity,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0016922~ligand-dependent nuclear receptor binding,GO:0030331~estrogen receptor binding,GO:0035257~nuclear hormone receptor binding,GO:0035259~glucocorticoid receptor binding,GO:0042826~histone deacetylase binding,GO:0046965~retinoid X receptor binding,	IPR026649:Nuclear receptor-interacting protein 1,		618270~Congenital anomalies of kidney and urinary tract 3,			KW-0090~Biological rhythms,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,		KW-0010~Activator,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:NRIP1_repr_1,DOMAIN:NRIP1_repr_2,DOMAIN:NRIP1_repr_4,MOTIF:CTBP-binding,MOTIF:CTBP-binding; principal site,MOTIF:LXXLL motif 1,MOTIF:LXXLL motif 2,MOTIF:LXXLL motif 3,MOTIF:LXXLL motif 4,MOTIF:LXXLL motif 5,MOTIF:LXXLL motif 6,MOTIF:LXXLL motif 7,MOTIF:LXXLL motif 8,MOTIF:LXXLL motif 9,MOTIF:Ligand-dependent nuclear receptor binding,MUTAGEN:DL->AA: Abolishes CTBP binding but retains transcriptional repressor activity.,MUTAGEN:DL->AA: Reduces, but does not completely abolish, interaction with CTBP. Reduces transcriptional repression.,MUTAGEN:DL->AS: Disrupts interaction with CTBP1, and CTBP2 to a lesser extent. Disrupts transcriptional repression; when associated with 567-AS-568.,MUTAGEN:K->Q: Disrupts interaction with CTBP1. Decreases lysine acetylation. Disrupts nuclear hormone receptor-dependent transcription repression.,MUTAGEN:K->R: Does not disrupt nuclear hormone receptor-dependent transcription repression.,MUTAGEN:NL->AA: Disrupts transcriptional repression.,MUTAGEN:NL->AS: Disrupts interaction with CTBP1 and CTBP2. Disrupts transcriptional repression; when associated with 442-AS-443.,MUTAGEN:PID->AIA: Abolishes interaction with CTBP1 and attenuates nuclear hormone receptor-dependent transcription repression.,MUTAGEN:PIDL->AAAA: Abolishes interaction with CTBP1.,MUTAGEN:SMDLT->PIAAS: Does not further disrupt transcriptional repression; when associated with 442-AA-443 and 567-AA-568.,REGION:Disordered,REGION:Interaction with ZNF366,REGION:Repression domain 1,REGION:Repression domain 2,REGION:Repression domain 3,REGION:Repression domain 4,REGION:Required for targeting to small nuclear foci,
NR1H2	nuclear receptor subfamily 1 group H member 2(NR1H2)	Homo sapiens				GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006367~transcription initiation from RNA polymerase II promoter,GO:0006629~lipid metabolic process,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0010745~negative regulation of macrophage derived foam cell differentiation,GO:0010867~positive regulation of triglyceride biosynthetic process,GO:0010875~positive regulation of cholesterol efflux,GO:0010884~positive regulation of lipid storage,GO:0010887~negative regulation of cholesterol storage,GO:0030154~cell differentiation,GO:0030522~intracellular receptor signaling pathway,GO:0031667~response to nutrient levels,GO:0032270~positive regulation of cellular protein metabolic process,GO:0032369~negative regulation of lipid transport,GO:0032376~positive regulation of cholesterol transport,GO:0036151~phosphatidylcholine acyl-chain remodeling,GO:0042632~cholesterol homeostasis,GO:0045723~positive regulation of fatty acid biosynthetic process,GO:0045861~negative regulation of proteolysis,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048384~retinoic acid receptor signaling pathway,GO:0048550~negative regulation of pinocytosis,GO:0051006~positive regulation of lipoprotein lipase activity,GO:0060336~negative regulation of interferon-gamma-mediated signaling pathway,GO:0090108~positive regulation of high-density lipoprotein particle assembly,GO:0090187~positive regulation of pancreatic juice secretion,GO:0090340~positive regulation of secretion of lysosomal enzymes,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1903573~negative regulation of response to endoplasmic reticulum stress,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0004879~RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0034191~apolipoprotein A-I receptor binding,GO:0043565~sequence-specific DNA binding,GO:0046965~retinoid X receptor binding,GO:0051117~ATPase binding,	IPR000536:Nuclear hormone receptor, ligand-binding, core,IPR001628:Zinc finger, nuclear hormone receptor-type,IPR001723:Steroid hormone receptor,IPR013088:Zinc finger, NHR/GATA-type,IPR023257:Liver X receptor,	hsa04931:Insulin resistance,			SM00399:ZnF_C4,SM00430:HOLI,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0238~DNA-binding,KW-0675~Receptor,	KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DNA_BIND:Nuclear receptor,DOMAIN:NR LBD,DOMAIN:Nuclear receptor,MUTAGEN:K->R: Impaired ability to act as an anti-inflammatory role during the hepatic acute phase response; when associated with R-409.,MUTAGEN:K->R: Impaired ability to act as an anti-inflammatory role during the hepatic acute phase response; when associated with R-447.,REGION:Disordered,REGION:Transactivation AF-1; required for ligand-independent transactivation function,REGION:Transactivation AF-2; required for ligand-dependent transactivation function; mediates interaction with CCAR2,ZN_FING:NR C4-type,
NR2F6	nuclear receptor subfamily 2 group F member 6(NR2F6)	Homo sapiens				GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006367~transcription initiation from RNA polymerase II promoter,GO:0030154~cell differentiation,GO:0030522~intracellular receptor signaling pathway,GO:0043153~entrainment of circadian clock by photoperiod,GO:0048666~neuron development,GO:0048856~anatomical structure development,GO:0050965~detection of temperature stimulus involved in sensory perception of pain,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0004879~RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000536:Nuclear hormone receptor, ligand-binding, core,IPR001628:Zinc finger, nuclear hormone receptor-type,IPR001723:Steroid hormone receptor,IPR013088:Zinc finger, NHR/GATA-type,				SM00399:ZnF_C4,SM00430:HOLI,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0675~Receptor,KW-0678~Repressor,	KW-0597~Phosphoprotein,	DNA_BIND:Nuclear receptor,DOMAIN:NR LBD,DOMAIN:Nuclear receptor,MUTAGEN:EGCKS->GSCKV: Loss of DNA (TRE) binding. Reduces the corepressor activity towards THRB.,REGION:Disordered,REGION:Important for dimerization,ZN_FING:NR C4-type,
NR3C1	nuclear receptor subfamily 3 group C member 1(NR3C1)	Homo sapiens		h_gcrpathway:Corticosteroids and cardioprotection,h_hSWI-SNFpathway:Chromatin Remodeling by hSWI/SNF ATP-dependent Complexes,h_nthiPathway:NFkB activation by Nontypeable Hemophilus influenzae,h_vobesityPathway:Visceral Fat Deposits and the Metabolic Syndrome,		GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006325~chromatin organization,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006367~transcription initiation from RNA polymerase II promoter,GO:0006915~apoptotic process,GO:0007049~cell cycle,GO:0007059~chromosome segregation,GO:0007165~signal transduction,GO:0030518~intracellular steroid hormone receptor signaling pathway,GO:0042921~glucocorticoid receptor signaling pathway,GO:0043402~glucocorticoid mediated signaling pathway,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051301~cell division,GO:0071383~cellular response to steroid hormone stimulus,GO:0071385~cellular response to glucocorticoid stimulus,GO:0071549~cellular response to dexamethasone stimulus,GO:0071560~cellular response to transforming growth factor beta stimulus,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005815~microtubule organizing center,GO:0005819~spindle,GO:0005829~cytosol,GO:0016607~nuclear speck,GO:0032991~macromolecular complex,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001046~core promoter sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0003723~RNA binding,GO:0004879~RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding,GO:0004883~glucocorticoid receptor activity,GO:0005496~steroid binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0019901~protein kinase binding,GO:0043565~sequence-specific DNA binding,GO:0051879~Hsp90 protein binding,GO:1990239~steroid hormone binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000536:Nuclear hormone receptor, ligand-binding, core,IPR001409:Glucocorticoid receptor,IPR001628:Zinc finger, nuclear hormone receptor-type,IPR001723:Steroid hormone receptor,IPR013088:Zinc finger, NHR/GATA-type,	hsa04080:Neuroactive ligand-receptor interaction,	615962~Glucocorticoid resistance,		SM00399:ZnF_C4,SM00430:HOLI,	KW-0053~Apoptosis,KW-0131~Cell cycle,KW-0132~Cell division,KW-0159~Chromosome partition,KW-0498~Mitosis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0206~Cytoskeleton,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0657~Pseudohermaphroditism,KW-9991~Pseudohermaphroditism,	KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0446~Lipid-binding,KW-0479~Metal-binding,KW-0754~Steroid-binding,KW-0862~Zinc,	KW-0156~Chromatin regulator,KW-0238~DNA-binding,KW-0675~Receptor,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DNA_BIND:Nuclear receptor,DOMAIN:NR LBD,DOMAIN:Nuclear receptor,MUTAGEN:D->A: Reduces activation mediated by ligand binding domain; when associated with A-585.,MUTAGEN:D->A: Reduces transcription activation activity of isoform Alpha-C3 by half.,MUTAGEN:D->K: Reduces transcription activation activity of isoform Alpha-C3 by half. Suppresses apoptosis-inducing activity of isoform Alpha-C3. Impairs recruitment of selected coregulators onto DNA binding sites.,MUTAGEN:F->D: Reduces transactivation by the ADA complex.,MUTAGEN:F->L: Strongly reduces transactivation by the ADA complex; when associated with V-236.,MUTAGEN:F->S: Increases solubility. No effect on transactivation by dexamethasone.,MUTAGEN:I->A: Decreases dimerization and transactivation by dexamethasone; when associated with S-602.,MUTAGEN:I->D: Reduces transactivation by the ADA complex.,MUTAGEN:K->A: Decrease in acetylation and in repression of its transcriptional activity by CLOCK-ARNTL/BMAL1 heterodimer. Complete loss in acetylation and in repression of its transcriptional activity by CLOCK-ARNTL/BMAL1 heterodimer; when associated with A-480; A-494 and A-495.,MUTAGEN:K->A: Decrease in acetylation and in repression of its transcriptional activity by CLOCK-ARNTL/BMAL1 heterodimer. Complete loss in acetylation and in repression of its transcriptional activity by CLOCK-ARNTL/BMAL1 heterodimer; when associated with A-492; A-494 and A-495.,MUTAGEN:K->A: Decrease in acetylation and in repression of its transcriptional activity by CLOCK-ARNTL/BMAL1 heterodimer; when associated with A-494. Complete loss in acetylation and in repression of its transcriptional activity by CLOCK-ARNTL/BMAL1 heterodimer; when associated with A-480; A-492 and A-494.,MUTAGEN:K->A: Decrease in acetylation and in repression of its transcriptional activity by CLOCK-ARNTL/BMAL1 heterodimer; when associated with A-495. Complete loss in acetylation and in repression of its transcriptional activity by CLOCK-ARNTL/BMAL1 heterodimer; when associated with A-480; A-492 and A-495.,MUTAGEN:K->R: Slightly reduces sumoylation. Inhibits the stimulatory effect of RWDD3 on its transcriptional activity.,MUTAGEN:K->R: Strongly reduces sumoylation. Almost complete loss of sumoylation; when associated with R-277.,MUTAGEN:K->R: Strongly reduces sumoylation. Almost complete loss of sumoylation; when associated with R-293.,MUTAGEN:L->A: Strongly reduces transactivation by the ADA complex; when associated with V-224 and F-225.,MUTAGEN:L->E: Reduces transactivation by the ADA complex.,MUTAGEN:L->F: Strongly reduces transactivation by the ADA complex; when associated with A-194 and V-224.,MUTAGEN:L->V: Strongly reduces transactivation by the ADA complex; when associated with A-194 and F-225.,MUTAGEN:L->V: Strongly reduces transactivation by the ADA complex; when associated with L-235.,MUTAGEN:M->I: Abolishes expression of C-type isoforms; when associated with I-86 and I-90.,MUTAGEN:M->I: Abolishes expression of C-type isoforms; when associated with I-86 and I-98.,MUTAGEN:M->I: Abolishes expression of C-type isoforms; when associated with I-90 and I-98.,MUTAGEN:M->I: Abolishes expression of D-type isoforms; when associated with I-316 and I-331.,MUTAGEN:M->I: Abolishes expression of D-type isoforms; when associated with I-316 and I-336.,MUTAGEN:M->I: Abolishes expression of D-type isoforms; when associated with I-331 and I-336.,MUTAGEN:M->T: Abolishes expression of A-type isoforms.,MUTAGEN:M->T: Abolishes expression of B-type isoforms.,MUTAGEN:P->A: Decreases transactivation by dexamethasone by 95%.,MUTAGEN:QQ->LL: Reduces activity of isoform Alpha-C3 by half.,MUTAGEN:R->A: Reduces activation mediated by ligand binding domain; when associated with A-590.,MUTAGEN:S->A: Abolishes phosphorylation and enhances transcriptional activation.,MUTAGEN:S->A: Abolishes phosphorylation. Does not affect translocation to the nucleus following ligand stimulation. Increases protein half-life and transcriptional repressor activity. Alters repertoire of regulated genes. Increases cell death.,MUTAGEN:S->A: Reduces expression of target genes IGFBP1 and IRF8.,MUTAGEN:S->D: Does not affect translocation to the nucleus following ligand stimulation.,MUTAGEN:SS->AA: Does not affect the activity of isoform Alpha-C3.,MUTAGEN:W->A: Strongly reduces transactivation by the ADA complex.,REGION:Disordered,REGION:Hinge,REGION:Interaction with CLOCK,REGION:Interaction with CRY1,REGION:Modulating,REGION:Required for high transcriptional activity of isoform Alpha-C3,ZN_FING:NR C4-type,
NUCB2	nucleobindin 2(NUCB2)	Homo sapiens				GO:0007264~small GTPase mediated signal transduction,GO:0032099~negative regulation of appetite,GO:0050790~regulation of catalytic activity,	GO:0005615~extracellular space,GO:0005635~nuclear envelope,GO:0005783~endoplasmic reticulum,GO:0005793~endoplasmic reticulum-Golgi intermediate compartment,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0070062~extracellular exosome,	GO:0001965~G-protein alpha-subunit binding,GO:0003677~DNA binding,GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,	IPR002048:EF-hand domain,IPR011992:EF-hand-like domain,IPR018247:EF-Hand 1, calcium-binding site,				SM00054:EFh,		KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0964~Secreted,		KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0238~DNA-binding,KW-0344~Guanine-nucleotide releasing factor,	KW-0165~Cleavage on pair of basic residues,KW-0597~Phosphoprotein,	CA_BIND:1,CA_BIND:2,DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,MOTIF:GBA,REGION:Binds to necdin,REGION:Disordered,
NOLC1	nucleolar and coiled-body phosphoprotein 1(NOLC1)	Homo sapiens	1.RBphosphoE2F,158.14-3-3_signal_transduction,			GO:0000278~mitotic cell cycle,GO:0006364~rRNA processing,GO:0006417~regulation of translation,GO:0006970~response to osmotic stress,GO:0007000~nucleolus organization,GO:0007409~axonogenesis,GO:0008284~positive regulation of cell proliferation,GO:0014029~neural crest formation,GO:0014032~neural crest cell development,GO:0033979~box H/ACA snoRNA metabolic process,GO:0042306~regulation of protein import into nucleus,GO:0045893~positive regulation of transcription, DNA-templated,GO:0048167~regulation of synaptic plasticity,	GO:0001650~fibrillar center,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0015030~Cajal body,GO:0031428~box C/D snoRNP complex,GO:0031429~box H/ACA snoRNP complex,	GO:0001093~TFIIB-class transcription factor binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0005525~GTP binding,GO:0008139~nuclear localization sequence binding,GO:0019904~protein domain specific binding,GO:0030674~protein binding, bridging,GO:0034512~box C/D snoRNA binding,GO:0034513~box H/ACA snoRNA binding,GO:0046982~protein heterodimerization activity,	IPR006594:LisH dimerisation motif,IPR007718:SRP40, C-terminal,						KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,	KW-0067~ATP-binding,KW-0342~GTP-binding,KW-0547~Nucleotide-binding,		KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:LisH,DOMAIN:SRP40_C,MOTIF:Nuclear localization signal,REGION:11 X 12 AA approximate repeats of an acidic serine cluster,REGION:Disordered,REGION:Interaction with RPA194,REPEAT:Acidic serine cluster 1,REPEAT:Acidic serine cluster 10,REPEAT:Acidic serine cluster 11,REPEAT:Acidic serine cluster 2,REPEAT:Acidic serine cluster 3,REPEAT:Acidic serine cluster 4,REPEAT:Acidic serine cluster 5,REPEAT:Acidic serine cluster 6,REPEAT:Acidic serine cluster 7,REPEAT:Acidic serine cluster 8,REPEAT:Acidic serine cluster 9,
NUSAP1	nucleolar and spindle associated protein 1(NUSAP1)	Homo sapiens				GO:0000070~mitotic sister chromatid segregation,GO:0000281~mitotic cytokinesis,GO:0007076~mitotic chromosome condensation,GO:0040001~establishment of mitotic spindle localization,GO:0045840~positive regulation of mitotic nuclear division,	GO:0005634~nucleus,GO:0005694~chromosome,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005819~spindle,GO:0005874~microtubule,GO:0072686~mitotic spindle,	GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008017~microtubule binding,	IPR026756:Nucleolar and spindle-associated protein 1,					KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,		KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,MOTIF:KEN box,REGION:Disordered,REGION:Interaction with microtubules,
NOL3	nucleolar protein 3(NOL3)	Homo sapiens				GO:0001666~response to hypoxia,GO:0001974~blood vessel remodeling,GO:0002931~response to ischemia,GO:0006376~mRNA splice site selection,GO:0008380~RNA splicing,GO:0010659~cardiac muscle cell apoptotic process,GO:0010667~negative regulation of cardiac muscle cell apoptotic process,GO:0010804~negative regulation of tumor necrosis factor-mediated signaling pathway,GO:0014736~negative regulation of muscle atrophy,GO:0014808~release of sequestered calcium ion into cytosol by sarcoplasmic reticulum,GO:0014876~response to injury involved in regulation of muscle adaptation,GO:0042981~regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0051259~protein oligomerization,GO:0060547~negative regulation of necrotic cell death,GO:0090201~negative regulation of release of cytochrome c from mitochondria,GO:0097193~intrinsic apoptotic signaling pathway,GO:1901222~regulation of NIK/NF-kappaB signaling,GO:1902109~negative regulation of mitochondrial membrane permeability involved in apoptotic process,GO:1902176~negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway,GO:1903298~negative regulation of hypoxia-induced intrinsic apoptotic signaling pathway,GO:1990001~inhibition of cysteine-type endopeptidase activity involved in apoptotic process,GO:2001237~negative regulation of extrinsic apoptotic signaling pathway,GO:2001243~negative regulation of intrinsic apoptotic signaling pathway,	GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0016020~membrane,GO:0016529~sarcoplasmic reticulum,	GO:0003723~RNA binding,GO:0005123~death receptor binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0035877~death effector domain binding,GO:0042802~identical protein binding,GO:0043027~cysteine-type endopeptidase inhibitor activity involved in apoptotic process,GO:0089720~caspase binding,	IPR001315:Caspase Recruitment,IPR011029:Death-like domain,		614937~Myoclonus, familial, 1,		SM00114:CARD,	KW-0053~Apoptosis,KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0703~Sarcoplasmic reticulum,KW-0963~Cytoplasm,	KW-0225~Disease variant,		KW-0106~Calcium,KW-0479~Metal-binding,		KW-0449~Lipoprotein,KW-0519~Myristate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Acidic residues,COMPBIAS:Polar residues,DOMAIN:CARD,LIPID:N-myristoyl glycine,MUTAGEN:K->R: Abolished ubiquitination in response to an apoptotic stimulus; when associated with R-17 and R-163.,MUTAGEN:K->R: Abolished ubiquitination in response to an apoptotic stimulus; when associated with R-17 and R-68.,MUTAGEN:K->R: Abolished ubiquitination in response to an apoptotic stimulus; when associated with R-68 and R-163.,MUTAGEN:L->F: Did not reduce creatine kinase release or infarct size after myocardial ischemia/reperfusion. Causes loss of mitochondrial membrane potential and nuclear condensation. Failes to prevent the increase in Bax. Interacts with BAX.,REGION:Disordered,
NUP133	nucleoporin 133(NUP133)	Homo sapiens				GO:0000972~transcription-dependent tethering of RNA polymerase II gene DNA at nuclear periphery,GO:0006110~regulation of glycolytic process,GO:0006406~mRNA export from nucleus,GO:0006409~tRNA export from nucleus,GO:0006606~protein import into nucleus,GO:0006999~nuclear pore organization,GO:0007052~mitotic spindle organization,GO:0007084~mitotic nuclear envelope reassembly,GO:0016032~viral process,GO:0016925~protein sumoylation,GO:0016973~poly(A)+ mRNA export from nucleus,GO:0019058~viral life cycle,GO:0019083~viral transcription,GO:0021915~neural tube development,GO:0022008~neurogenesis,GO:0048339~paraxial mesoderm development,GO:0060964~regulation of gene silencing by miRNA,GO:0061053~somite development,GO:0072006~nephron development,GO:0075733~intracellular transport of virus,GO:1900034~regulation of cellular response to heat,	GO:0000776~kinetochore,GO:0000777~condensed chromosome kinetochore,GO:0005635~nuclear envelope,GO:0005643~nuclear pore,GO:0005829~cytosol,GO:0016020~membrane,GO:0031080~nuclear pore outer ring,GO:0031965~nuclear membrane,GO:0043657~host cell,	GO:0005515~protein binding,GO:0017056~structural constituent of nuclear pore,	IPR007187:Nucleoporin, Nup133/Nup155-like, C-terminal,IPR015943:WD40/YVTN repeat-like-containing domain,	hsa03013:Nucleocytoplasmic transport,hsa05014:Amyotrophic lateral sclerosis,	618177~Nephrotic syndrome, type 18,618349~Galloway-Mowat syndrome 8,			KW-0509~mRNA transport,KW-0653~Protein transport,KW-0811~Translocation,KW-0813~Transport,	KW-0137~Centromere,KW-0158~Chromosome,KW-0539~Nucleus,KW-0906~Nuclear pore complex,KW-0995~Kinetochore,	KW-0225~Disease variant,KW-0887~Epilepsy,KW-0991~Mental retardation,	KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	DOMAIN:Nucleoporin_C,REGION:Disordered,
NUP62	nucleoporin 62(NUP62)	Homo sapiens		h_npcPathway:Mechanism of Protein Import into the Nucleus,		GO:0000278~mitotic cell cycle,GO:0006110~regulation of glycolytic process,GO:0006405~RNA export from nucleus,GO:0006406~mRNA export from nucleus,GO:0006409~tRNA export from nucleus,GO:0006606~protein import into nucleus,GO:0007080~mitotic metaphase plate congression,GO:0007098~centrosome cycle,GO:0007100~mitotic centrosome separation,GO:0007166~cell surface receptor signaling pathway,GO:0007283~spermatogenesis,GO:0007569~cell aging,GO:0008219~cell death,GO:0008285~negative regulation of cell proliferation,GO:0009966~regulation of signal transduction,GO:0015031~protein transport,GO:0016032~viral process,GO:0016925~protein sumoylation,GO:0019058~viral life cycle,GO:0019083~viral transcription,GO:0042059~negative regulation of epidermal growth factor receptor signaling pathway,GO:0042306~regulation of protein import into nucleus,GO:0043066~negative regulation of apoptotic process,GO:0043069~negative regulation of programmed cell death,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043407~negative regulation of MAP kinase activity,GO:0045742~positive regulation of epidermal growth factor receptor signaling pathway,GO:0045840~positive regulation of mitotic nuclear division,GO:0045893~positive regulation of transcription, DNA-templated,GO:0046578~regulation of Ras protein signal transduction,GO:0046580~negative regulation of Ras protein signal transduction,GO:0046601~positive regulation of centriole replication,GO:0051028~mRNA transport,GO:0060236~regulation of mitotic spindle organization,GO:0060964~regulation of gene silencing by miRNA,GO:0075733~intracellular transport of virus,GO:0098534~centriole assembly,GO:1900034~regulation of cellular response to heat,GO:1903438~positive regulation of mitotic cytokinetic process,GO:1904781~positive regulation of protein localization to centrosome,	GO:0000922~spindle pole,GO:0005635~nuclear envelope,GO:0005642~annulate lamellae,GO:0005643~nuclear pore,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0031965~nuclear membrane,GO:0043657~host cell,GO:0044613~nuclear pore central transport channel,GO:0072686~mitotic spindle,GO:0090543~Flemming body,GO:1990904~ribonucleoprotein complex,	GO:0003682~chromatin binding,GO:0005515~protein binding,GO:0005543~phospholipid binding,GO:0017056~structural constituent of nuclear pore,GO:0019894~kinesin binding,GO:0030159~receptor signaling complex scaffold activity,GO:0030544~Hsp70 protein binding,GO:0042169~SH2 domain binding,GO:0043130~ubiquitin binding,GO:0044877~macromolecular complex binding,GO:0051425~PTB domain binding,GO:0051879~Hsp90 protein binding,	IPR007758:Nucleoporin, NSP1-like, C-terminal,IPR026010:Nucleoporin NSP1/NUP62,	hsa03013:Nucleocytoplasmic transport,hsa05014:Amyotrophic lateral sclerosis,	271930~Striatonigral degeneration, infantile,			KW-0509~mRNA transport,KW-0653~Protein transport,KW-0811~Translocation,KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0906~Nuclear pore complex,KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0175~Coiled coil,KW-0677~Repeat,			KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:O-linked (GlcNAc) serine,CARBOHYD:O-linked (GlcNAc) threonine,COMPBIAS:Polar residues,DISULFID:Interchain (with NUP155),DOMAIN:Nsp1_C,REGION:5 X 2 AA repeats of F-G,REGION:Disordered,REGION:Required for centrosome localization,REPEAT:1,REPEAT:2,REPEAT:3,REPEAT:4,REPEAT:5,
NUP85	nucleoporin 85(NUP85)	Homo sapiens		h_akapcentrosomePathway:Protein Kinase A at the Centrosome,		GO:0006110~regulation of glycolytic process,GO:0006406~mRNA export from nucleus,GO:0006409~tRNA export from nucleus,GO:0006606~protein import into nucleus,GO:0007052~mitotic spindle organization,GO:0007084~mitotic nuclear envelope reassembly,GO:0015031~protein transport,GO:0016032~viral process,GO:0016925~protein sumoylation,GO:0019058~viral life cycle,GO:0019083~viral transcription,GO:0030032~lamellipodium assembly,GO:0045893~positive regulation of transcription, DNA-templated,GO:0048246~macrophage chemotaxis,GO:0051028~mRNA transport,GO:0060964~regulation of gene silencing by miRNA,GO:0072006~nephron development,GO:0075733~intracellular transport of virus,GO:1900034~regulation of cellular response to heat,	GO:0000776~kinetochore,GO:0000777~condensed chromosome kinetochore,GO:0005635~nuclear envelope,GO:0005654~nucleoplasm,GO:0005819~spindle,GO:0005829~cytosol,GO:0016020~membrane,GO:0031080~nuclear pore outer ring,GO:0031965~nuclear membrane,GO:0043657~host cell,	GO:0005515~protein binding,GO:0017056~structural constituent of nuclear pore,	IPR011502:Nucleoporin Nup85-like,	hsa03013:Nucleocytoplasmic transport,hsa05014:Amyotrophic lateral sclerosis,	618176~Nephrotic syndrome, type 17,			KW-0509~mRNA transport,KW-0653~Protein transport,KW-0811~Translocation,KW-0813~Transport,	KW-0137~Centromere,KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0539~Nucleus,KW-0906~Nuclear pore complex,KW-0963~Cytoplasm,KW-0995~Kinetochore,	KW-0225~Disease variant,				KW-0007~Acetylation,KW-0597~Phosphoprotein,
NUP88	nucleoporin 88(NUP88)	Homo sapiens				GO:0000055~ribosomal large subunit export from nucleus,GO:0000056~ribosomal small subunit export from nucleus,GO:0000278~mitotic cell cycle,GO:0006110~regulation of glycolytic process,GO:0006406~mRNA export from nucleus,GO:0006409~tRNA export from nucleus,GO:0006606~protein import into nucleus,GO:0016032~viral process,GO:0016925~protein sumoylation,GO:0019058~viral life cycle,GO:0019083~viral transcription,GO:0051028~mRNA transport,GO:0060964~regulation of gene silencing by miRNA,GO:0075733~intracellular transport of virus,GO:1900034~regulation of cellular response to heat,	GO:0005635~nuclear envelope,GO:0005643~nuclear pore,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0043657~host cell,	GO:0005215~transporter activity,GO:0005515~protein binding,GO:0017056~structural constituent of nuclear pore,	IPR019321:Nucleoporin Nup88,	hsa03013:Nucleocytoplasmic transport,hsa05014:Amyotrophic lateral sclerosis,	618393~Fetal akinesia deformation sequence 4,			KW-0509~mRNA transport,KW-0653~Protein transport,KW-0811~Translocation,KW-0813~Transport,	KW-0539~Nucleus,KW-0906~Nuclear pore complex,	KW-0225~Disease variant,	KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,REGION:Disordered,
NUP93	nucleoporin 93(NUP93)	Homo sapiens				GO:0006110~regulation of glycolytic process,GO:0006406~mRNA export from nucleus,GO:0006409~tRNA export from nucleus,GO:0006606~protein import into nucleus,GO:0006998~nuclear envelope organization,GO:0007084~mitotic nuclear envelope reassembly,GO:0015031~protein transport,GO:0016032~viral process,GO:0016925~protein sumoylation,GO:0016973~poly(A)+ mRNA export from nucleus,GO:0019058~viral life cycle,GO:0019083~viral transcription,GO:0051028~mRNA transport,GO:0051292~nuclear pore complex assembly,GO:0060391~positive regulation of SMAD protein import into nucleus,GO:0060395~SMAD protein signal transduction,GO:0060964~regulation of gene silencing by miRNA,GO:0075733~intracellular transport of virus,GO:1900034~regulation of cellular response to heat,	GO:0005635~nuclear envelope,GO:0005643~nuclear pore,GO:0005813~centrosome,GO:0005829~cytosol,GO:0016020~membrane,GO:0031965~nuclear membrane,GO:0034399~nuclear periphery,GO:0043657~host cell,	GO:0005515~protein binding,GO:0017056~structural constituent of nuclear pore,	IPR007231:Nucleoporin interacting component Nup93/Nic96,	hsa03013:Nucleocytoplasmic transport,hsa05014:Amyotrophic lateral sclerosis,	616892~Nephrotic syndrome, type 12,			KW-0509~mRNA transport,KW-0653~Protein transport,KW-0811~Translocation,KW-0813~Transport,	KW-0472~Membrane,KW-0539~Nucleus,KW-0906~Nuclear pore complex,	KW-0225~Disease variant,				KW-0597~Phosphoprotein,
NUDT9	nudix hydrolase 9(NUDT9)	Homo sapiens				GO:0006812~cation transport,GO:0034656~nucleobase-containing small molecule catabolic process,GO:0046032~ADP catabolic process,GO:0046709~IDP catabolic process,GO:0055086~nucleobase-containing small molecule metabolic process,	GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0016604~nuclear body,GO:0030054~cell junction,GO:0031965~nuclear membrane,GO:0070062~extracellular exosome,	GO:0005227~calcium activated cation channel activity,GO:0005515~protein binding,GO:0016829~lyase activity,GO:0019144~ADP-sugar diphosphatase activity,GO:0047631~ADP-ribose diphosphatase activity,	IPR000086:NUDIX hydrolase domain,IPR015797:NUDIX hydrolase domain-like,	hsa00230:Purine metabolism,hsa01100:Metabolic pathways,					KW-0496~Mitochondrion,		KW-0175~Coiled coil,KW-0732~Signal,KW-0809~Transit peptide,	KW-0460~Magnesium,KW-0464~Manganese,	KW-0378~Hydrolase,KW-0456~Lyase,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:Nudix hydrolase,MOTIF:Nudix box,REGION:Disordered,TRANSIT:Mitochondrion,
OXSR1	oxidative stress responsive kinase 1(OXSR1)	Homo sapiens				GO:0006468~protein phosphorylation,GO:0006979~response to oxidative stress,GO:0007165~signal transduction,GO:0007231~osmosensory signaling pathway,GO:0010820~positive regulation of T cell chemotaxis,GO:0018107~peptidyl-threonine phosphorylation,GO:0035556~intracellular signal transduction,GO:0038116~chemokine (C-C motif) ligand 21 signaling pathway,GO:0038146~chemokine (C-X-C motif) ligand 12 signaling pathway,GO:0046777~protein autophosphorylation,GO:0071476~cellular hypotonic response,GO:1901017~negative regulation of potassium ion transmembrane transporter activity,GO:1990869~cellular response to chemokine,	GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0000287~magnesium ion binding,GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0019901~protein kinase binding,GO:0042802~identical protein binding,	IPR000719:Protein kinase, catalytic domain,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,IPR024678:Serine/threonine-protein kinase OSR1/WNK, CCT domain,				SM00220:S_TKc,		KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:ATP,COMPBIAS:Basic and acidic residues,DOMAIN:Protein kinase,MUTAGEN:K->A: Loss of autophosphorylation and kinase activity.,MUTAGEN:K->M: Loss of RELT, RELL1 and RELL2 phosphorylation. Retention of some autophosphorylation activity may be due to complex formation with other endogenous kinases in the assay.,NP_BIND:ATP,REGION:Disordered,
PAK1	p21 (RAC1) activated kinase 1(PAK1)	Homo sapiens		h_agrPathway:Agrin in Postsynaptic Differentiation,h_at1rPathway:Angiotensin II mediated activation of JNK Pathway via Pyk2 dependent signaling,h_cdc42racPathway:Role of PI3K subunit p85 in regulation of Actin Organization and Cell Migration,h_fasPathway:FAS signaling pathway ( CD95 ),h_fmlpPathway:fMLP induced chemokine gene expression in HMC-1 cells,h_mapkPathway:MAPKinase Signaling Pathway,h_metPathway:Signaling of Hepatocyte Growth Factor Receptor,h_nkcellsPathway:Ras-Independent pathway in NK cell-mediated cytotoxicity,h_pyk2Pathway:Links between Pyk2 and Map Kinases,h_rac1Pathway:Rac 1 cell motility signaling pathway,h_raccycdPathway:Influence of Ras and Rho proteins on G1 to S Transition,h_tnfr1Pathway:TNFR1 Signaling Pathway,		GO:0001666~response to hypoxia,GO:0001934~positive regulation of protein phosphorylation,GO:0002223~stimulatory C-type lectin receptor signaling pathway,GO:0006338~chromatin remodeling,GO:0006468~protein phosphorylation,GO:0006887~exocytosis,GO:0006915~apoptotic process,GO:0006974~cellular response to DNA damage stimulus,GO:0008284~positive regulation of cell proliferation,GO:0010763~positive regulation of fibroblast migration,GO:0016310~phosphorylation,GO:0016477~cell migration,GO:0021549~cerebellum development,GO:0030010~establishment of cell polarity,GO:0030335~positive regulation of cell migration,GO:0031098~stress-activated protein kinase signaling cascade,GO:0031116~positive regulation of microtubule polymerization,GO:0031295~T cell costimulation,GO:0031532~actin cytoskeleton reorganization,GO:0032147~activation of protein kinase activity,GO:0032869~cellular response to insulin stimulus,GO:0032956~regulation of actin cytoskeleton organization,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0033148~positive regulation of intracellular estrogen receptor signaling pathway,GO:0035556~intracellular signal transduction,GO:0038095~Fc-epsilon receptor signaling pathway,GO:0038096~Fc-gamma receptor signaling pathway involved in phagocytosis,GO:0042060~wound healing,GO:0043408~regulation of MAPK cascade,GO:0043507~positive regulation of JUN kinase activity,GO:0045773~positive regulation of axon extension,GO:0046628~positive regulation of insulin receptor signaling pathway,GO:0046777~protein autophosphorylation,GO:0048012~hepatocyte growth factor receptor signaling pathway,GO:0048013~ephrin receptor signaling pathway,GO:0048754~branching morphogenesis of an epithelial tube,GO:0048812~neuron projection morphogenesis,GO:0050770~regulation of axonogenesis,GO:0050852~T cell receptor signaling pathway,GO:0051496~positive regulation of stress fiber assembly,GO:0060244~negative regulation of cell proliferation involved in contact inhibition,GO:0061052~negative regulation of cell growth involved in cardiac muscle cell development,GO:0090063~positive regulation of microtubule nucleation,GO:0090314~positive regulation of protein targeting to membrane,GO:1904707~positive regulation of vascular smooth muscle cell proliferation,GO:1904754~positive regulation of vascular associated smooth muscle cell migration,	GO:0001726~ruffle,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005737~cytoplasm,GO:0005815~microtubule organizing center,GO:0005829~cytosol,GO:0005884~actin filament,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0005925~focal adhesion,GO:0014704~intercalated disc,GO:0030018~Z disc,GO:0030027~lamellipodium,GO:0030424~axon,GO:0030425~dendrite,GO:0031965~nuclear membrane,GO:0032587~ruffle membrane,GO:0032991~macromolecular complex,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005518~collagen binding,GO:0005524~ATP binding,GO:0019901~protein kinase binding,GO:0031267~small GTPase binding,GO:0042802~identical protein binding,GO:0043015~gamma-tubulin binding,	IPR000095:PAK-box/P21-Rho-binding,IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,	hsa04010:MAPK signaling pathway,hsa04012:ErbB signaling pathway,hsa04014:Ras signaling pathway,hsa04024:cAMP signaling pathway,hsa04062:Chemokine signaling pathway,hsa04360:Axon guidance,hsa04392:Hippo signaling pathway - multiple species,hsa04510:Focal adhesion,hsa04625:C-type lectin receptor signaling pathway,hsa04650:Natural killer cell mediated cytotoxicity,hsa04660:T cell receptor signaling pathway,hsa04666:Fc gamma R-mediated phagocytosis,hsa04810:Regulation of actin cytoskeleton,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05130:Pathogenic Escherichia coli infection,hsa05132:Salmonella infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05205:Proteoglycans in cancer,hsa05211:Renal cell carcinoma,	618158~Intellectual developmental disorder with macrocephaly, seizures, and speech delay,		SM00220:S_TKc,SM00285:PBD,	KW-0053~Apoptosis,KW-0268~Exocytosis,	KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0887~Epilepsy,KW-0991~Mental retardation,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0021~Allosteric enzyme,KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:ATP,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:CRIB,DOMAIN:Protein kinase,MUTAGEN:D->A: Abolishes autophosphorylation at Thr-423.,MUTAGEN:D->N: Abolishes kinase activity; when associated with R-299.,MUTAGEN:H->L: Abolishes interaction with CDC42, leading to strongly decreased activity; when associated with L-83.,MUTAGEN:H->L: Abolishes interaction with CDC42, leading to strongly decreased activity; when associated with L-86.,MUTAGEN:K->R: Strongly decreases activity. Abolishes kinase activity; when associated with N-389.,MUTAGEN:L->F: Abolishes autoinhibition, leading to constitutive kinase activity.,MUTAGEN:T->A: Decreases CDC42-stimulated activity and autophosphorylation.,MUTAGEN:T->E: Constitutive kinase activity.,NP_BIND:ATP,REGION:Autoregulatory region,REGION:Disordered,REGION:GTPase-binding,REGION:Interaction with CRIPAK,
PAK4	p21 (RAC1) activated kinase 4(PAK4)	Homo sapiens		h_agrPathway:Agrin in Postsynaptic Differentiation,		GO:0001558~regulation of cell growth,GO:0006468~protein phosphorylation,GO:0006915~apoptotic process,GO:0007010~cytoskeleton organization,GO:0007049~cell cycle,GO:0007165~signal transduction,GO:0016477~cell migration,GO:0031098~stress-activated protein kinase signaling cascade,GO:0032147~activation of protein kinase activity,GO:0035556~intracellular signal transduction,GO:0043408~regulation of MAPK cascade,GO:0045766~positive regulation of angiogenesis,GO:0060996~dendritic spine development,GO:0071407~cellular response to organic cyclic compound,GO:0098609~cell-cell adhesion,GO:2000352~negative regulation of endothelial cell apoptotic process,	GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005912~adherens junction,GO:0005925~focal adhesion,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0098641~cadherin binding involved in cell-cell adhesion,	IPR000095:PAK-box/P21-Rho-binding,IPR000719:Protein kinase, catalytic domain,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,	hsa04012:ErbB signaling pathway,hsa04014:Ras signaling pathway,hsa04360:Axon guidance,hsa04510:Focal adhesion,hsa04660:T cell receptor signaling pathway,hsa04810:Regulation of actin cytoskeleton,hsa05170:Human immunodeficiency virus 1 infection,hsa05206:MicroRNAs in cancer,hsa05211:Renal cell carcinoma,			SM00220:S_TKc,SM00285:PBD,	KW-0053~Apoptosis,KW-0131~Cell cycle,	KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Proton acceptor,BINDING:ATP,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:CRIB,DOMAIN:Protein kinase,MUTAGEN:S->E: Approximately 3-fold increased autophosphorylation.,MUTAGEN:S->N: Approximately 30-fold increased autophosphorylation (constitutively active mutant).,NP_BIND:ATP,REGION:Disordered,REGION:GEF-interaction domain (GID),REGION:Linker,
PAK6	p21 (RAC1) activated kinase 6(PAK6)	Homo sapiens		h_agrPathway:Agrin in Postsynaptic Differentiation,		GO:0006355~regulation of transcription, DNA-templated,GO:0006468~protein phosphorylation,GO:0006915~apoptotic process,GO:0007010~cytoskeleton organization,GO:0007612~learning,GO:0007613~memory,GO:0007626~locomotory behavior,GO:0031098~stress-activated protein kinase signaling cascade,GO:0032147~activation of protein kinase activity,GO:0035556~intracellular signal transduction,GO:0043408~regulation of MAPK cascade,GO:1990138~neuron projection extension,	GO:0001650~fibrillar center,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0030054~cell junction,	GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0045296~cadherin binding,	IPR000095:PAK-box/P21-Rho-binding,IPR000719:Protein kinase, catalytic domain,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,	hsa04012:ErbB signaling pathway,hsa04014:Ras signaling pathway,hsa04360:Axon guidance,hsa04510:Focal adhesion,hsa04660:T cell receptor signaling pathway,hsa04810:Regulation of actin cytoskeleton,hsa05170:Human immunodeficiency virus 1 infection,hsa05211:Renal cell carcinoma,			SM00285:PBD,		KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:ATP,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:CRIB,DOMAIN:Protein kinase,MUTAGEN:S->A: Almost complete loss of PAK6 activation by MAP2K6/MAPKK6; when associated with F-566.,MUTAGEN:S->A: Complete loss of PAK6 activation by MAP2K6/MAPKK6; when associated with A-165.,MUTAGEN:Y->F: Complete loss of PAK6 activation by MAP2K6/MAPKK6; when associated with A-165.,NP_BIND:ATP,REGION:Disordered,REGION:Linker,
PAX8	paired box 8(PAX8)	Homo sapiens				GO:0001655~urogenital system development,GO:0001658~branching involved in ureteric bud morphogenesis,GO:0001822~kidney development,GO:0001823~mesonephros development,GO:0003281~ventricular septum development,GO:0003337~mesenchymal to epithelial transition involved in metanephros morphogenesis,GO:0006351~transcription, DNA-templated,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006790~sulfur compound metabolic process,GO:0007275~multicellular organism development,GO:0007417~central nervous system development,GO:0009653~anatomical structure morphogenesis,GO:0010667~negative regulation of cardiac muscle cell apoptotic process,GO:0030878~thyroid gland development,GO:0038194~thyroid-stimulating hormone signaling pathway,GO:0039003~pronephric field specification,GO:0042472~inner ear morphogenesis,GO:0042981~regulation of apoptotic process,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048793~pronephros development,GO:0048856~anatomical structure development,GO:0071371~cellular response to gonadotropin stimulus,GO:0071599~otic vesicle development,GO:0072108~positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis,GO:0072207~metanephric epithelium development,GO:0072221~metanephric distal convoluted tubule development,GO:0072278~metanephric comma-shaped body morphogenesis,GO:0072284~metanephric S-shaped body morphogenesis,GO:0072289~metanephric nephron tubule formation,GO:0072305~negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesis,GO:0072307~regulation of metanephric nephron tubule epithelial cell differentiation,GO:0090190~positive regulation of branching involved in ureteric bud morphogenesis,GO:1900212~negative regulation of mesenchymal cell apoptotic process involved in metanephros development,GO:1900215~negative regulation of apoptotic process involved in metanephric collecting duct development,GO:1900218~negative regulation of apoptotic process involved in metanephric nephron tubule development,GO:2000594~positive regulation of metanephric DCT cell differentiation,GO:2000611~positive regulation of thyroid hormone generation,GO:2000612~regulation of thyroid-stimulating hormone secretion,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0004996~thyroid-stimulating hormone receptor activity,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001523:Paired domain,IPR009057:Homeodomain-like,IPR022130:Paired-box protein 2 C-terminal,	hsa04918:Thyroid hormone synthesis,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05216:Thyroid cancer,	218700~Hypothyroidism, congenital, due to thyroid dysgenesis or hypoplasia,		SM00351:PAX,	KW-0221~Differentiation,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0984~Congenital hypothyroidism,	KW-0563~Paired box,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DNA_BIND:Paired,DOMAIN:Paired,DOMAIN:Pax2_C,REGION:Disordered,REGION:PAI subdomain,REGION:RED subdomain,
PXN	paxillin(PXN)	Homo sapiens		h_agrPathway:Agrin in Postsynaptic Differentiation,h_cell2cellPathway:Cell to Cell Adhesion Signaling,h_chemicalPathway:Apoptotic Signaling in Response to DNA Damage,h_cxcr4Pathway:CXCR4 Signaling Pathway,h_ecmPathway:Erk and PI-3 Kinase Are Necessary for Collagen Binding in Corneal Epithelia,h_integrinPathway:Integrin Signaling Pathway,h_mCalpainPathway:mCalpain and friends in Cell motility,h_metPathway:Signaling of Hepatocyte Growth Factor Receptor,h_uCalpainPathway:uCalpain and friends in Cell spread,h_vegfPathway:VEGF, Hypoxia, and Angiogenesis,		GO:0006355~regulation of transcription, DNA-templated,GO:0006936~muscle contraction,GO:0007155~cell adhesion,GO:0007160~cell-matrix adhesion,GO:0007165~signal transduction,GO:0007172~signal complex assembly,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0034446~substrate adhesion-dependent cell spreading,GO:0034614~cellular response to reactive oxygen species,GO:0043542~endothelial cell migration,GO:0048010~vascular endothelial growth factor receptor signaling pathway,GO:0051496~positive regulation of stress fiber assembly,GO:0060396~growth hormone receptor signaling pathway,	GO:0001725~stress fiber,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005875~microtubule associated complex,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0005925~focal adhesion,GO:0005938~cell cortex,GO:0030027~lamellipodium,	GO:0003712~transcription cofactor activity,GO:0005515~protein binding,GO:0008013~beta-catenin binding,GO:0017166~vinculin binding,GO:0019903~protein phosphatase binding,GO:0038191~neuropilin binding,GO:0046872~metal ion binding,	IPR001781:Zinc finger, LIM-type,IPR001904:Paxillin,	hsa04062:Chemokine signaling pathway,hsa04370:VEGF signaling pathway,hsa04510:Focal adhesion,hsa04670:Leukocyte transendothelial migration,hsa04810:Regulation of actin cytoskeleton,hsa05100:Bacterial invasion of epithelial cells,hsa05131:Shigellosis,hsa05135:Yersinia infection,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05203:Viral carcinogenesis,hsa05205:Proteoglycans in cancer,			SM00132:LIM,	KW-0130~Cell adhesion,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,KW-0965~Cell junction,		KW-0440~LIM domain,KW-0677~Repeat,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:LIM zinc-binding,DOMAIN:LIM zinc-binding 1,DOMAIN:LIM zinc-binding 2,DOMAIN:LIM zinc-binding 3,DOMAIN:LIM zinc-binding 4,MOTIF:LD motif 1,MOTIF:LD motif 2,MOTIF:LD motif 3,MOTIF:LD motif 4,MOTIF:LD motif 5,MUTAGEN:LL->RR: Loss of interaction with PDCD10.,REGION:Disordered,REGION:Required for binding to PARVA and ILK,
PIN1	peptidylprolyl cis/trans isomerase, NIMA-interacting 1(PIN1)	Homo sapiens		h_mPRPathway:How Progesterone Initiates the Oocyte Maturation,		GO:0000413~protein peptidyl-prolyl isomerization,GO:0001666~response to hypoxia,GO:0001932~regulation of protein phosphorylation,GO:0001934~positive regulation of protein phosphorylation,GO:0007049~cell cycle,GO:0007088~regulation of mitotic nuclear division,GO:0010468~regulation of gene expression,GO:0030182~neuron differentiation,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0031647~regulation of protein stability,GO:0032091~negative regulation of protein binding,GO:0032092~positive regulation of protein binding,GO:0032465~regulation of cytokinesis,GO:0032480~negative regulation of type I interferon production,GO:0035307~positive regulation of protein dephosphorylation,GO:0042177~negative regulation of protein catabolic process,GO:0043524~negative regulation of neuron apoptotic process,GO:0043525~positive regulation of neuron apoptotic process,GO:0043547~positive regulation of GTPase activity,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050808~synapse organization,GO:0050821~protein stabilization,GO:0051443~positive regulation of ubiquitin-protein transferase activity,GO:0060393~regulation of pathway-restricted SMAD protein phosphorylation,GO:0061051~positive regulation of cell growth involved in cardiac muscle cell development,GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:1900180~regulation of protein localization to nucleus,GO:1901796~regulation of signal transduction by p53 class mediator,GO:1902430~negative regulation of beta-amyloid formation,GO:2000146~negative regulation of cell motility,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0016607~nuclear speck,GO:0030496~midbody,GO:0036064~ciliary basal body,GO:0043005~neuron projection,GO:0098978~glutamatergic synapse,GO:0099524~postsynaptic cytosol,	GO:0003755~peptidyl-prolyl cis-trans isomerase activity,GO:0003774~motor activity,GO:0005515~protein binding,GO:0008013~beta-catenin binding,GO:0016853~isomerase activity,GO:0016859~cis-trans isomerase activity,GO:0031434~mitogen-activated protein kinase kinase binding,GO:0032794~GTPase activating protein binding,GO:0048156~tau protein binding,GO:0050815~phosphoserine binding,GO:0050816~phosphothreonine binding,GO:0051219~phosphoprotein binding,	IPR000297:Peptidyl-prolyl cis-trans isomerase, PpiC-type,IPR001202:WW domain,IPR023058:Peptidyl-prolyl cis-trans isomerase, PpiC-type, conserved site,	hsa04622:RIG-I-like receptor signaling pathway,			SM00456:WW,	KW-0131~Cell cycle,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0413~Isomerase,KW-0697~Rotamase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:PpiC,DOMAIN:WW,MUTAGEN:C->A: Loss of peptidyl-prolyl cis/trans isomerase activity; decrease in DNA repair of double-strand breaks by homologous recombination slightly less efficient than that observed with wild-type protein. No effect on RBBP8/CtIP.,MUTAGEN:K->A: Loss of peptidyl-prolyl cis/trans isomerase activity. No effect on the interaction with IRAK3/IRAK-M. Abolishes IL33-mediated increase of IRAK3/IRAK-M protein levels.,MUTAGEN:S->D,E: Loss of peptidyl-prolyl cis/trans isomerase activity, nuclear localization and cellular function.,MUTAGEN:W->A: Loss of binding to phosphorylated target proteins, including to phosphorylated RBBP8/CtIP; decrease in DNA repair of double-strand breaks by homologous recombination less efficient than that observed with wild-type protein. Abolishes interaction with IRAK3/IRAK-M. Abolishes IL33-mediated increase of IRAK3/IRAK-M protein levels.,MUTAGEN:Y->A: Reduced affinity for KIF20B.,REGION:Disordered,
PPIC	peptidylprolyl isomerase C(PPIC)	Homo sapiens				GO:0000413~protein peptidyl-prolyl isomerization,GO:0006457~protein folding,	GO:0005737~cytoplasm,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,	GO:0003755~peptidyl-prolyl cis-trans isomerase activity,GO:0005515~protein binding,GO:0016018~cyclosporin A binding,	IPR002130:Cyclophilin-like peptidyl-prolyl cis-trans isomerase domain,IPR020892:Cyclophilin-type peptidyl-prolyl cis-trans isomerase, conserved site,						KW-0963~Cytoplasm,				KW-0413~Isomerase,KW-0697~Rotamase,		DOMAIN:PPIase cyclophilin-type,
PPIE	peptidylprolyl isomerase E(PPIE)	Homo sapiens				GO:0000398~mRNA splicing, via spliceosome,GO:0000413~protein peptidyl-prolyl isomerization,GO:0006283~transcription-coupled nucleotide-excision repair,GO:0006355~regulation of transcription, DNA-templated,GO:0006457~protein folding,GO:0043312~neutrophil degranulation,GO:0045070~positive regulation of viral genome replication,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016607~nuclear speck,GO:0034774~secretory granule lumen,GO:0071007~U2-type catalytic step 2 spliceosome,GO:0071013~catalytic step 2 spliceosome,GO:1904813~ficolin-1-rich granule lumen,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0003755~peptidyl-prolyl cis-trans isomerase activity,GO:0005515~protein binding,GO:0008143~poly(A) binding,GO:0016018~cyclosporin A binding,	IPR000504:RNA recognition motif domain,IPR002130:Cyclophilin-like peptidyl-prolyl cis-trans isomerase domain,IPR012677:Nucleotide-binding, alpha-beta plait,IPR016304:Cyclophilin-type peptidyl-prolyl cis-trans isomerase E,IPR020892:Cyclophilin-type peptidyl-prolyl cis-trans isomerase, conserved site,	hsa03040:Spliceosome,		PIRSF001475:peptidyl-prolyl cis-trans isomerase E,	SM00360:RRM,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0747~Spliceosome,				KW-0413~Isomerase,KW-0694~RNA-binding,KW-0697~Rotamase,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:PPIase cyclophilin-type,DOMAIN:RRM,MUTAGEN:E->A: Slightly decreased affinity for KMT2A.,MUTAGEN:F->A: Expected to disrupt proline isomerase activity. Abolishes inhibition of KMT2A activity; when associated with A-191.,MUTAGEN:F->A: Impairs protein folding.,MUTAGEN:F->A: Strongly decreased affinity for KMT2A. Decreased affinity for RNA.,MUTAGEN:F->D: Abolishes interaction with KMT2A. Abolishes inhibition of KMT2A activity.,MUTAGEN:FM->EE: Expected to disrupt peptidylproline binding. Decreases interaction with KMT2A. Abolishes inhibition of KMT2A activity.,MUTAGEN:K->A: No effect on interaction with KMT2A.,MUTAGEN:L->A: Decreased affinity for KMT2A.,MUTAGEN:Missing: Abolishes interaction with KMT2A.,MUTAGEN:R->A: Expected to disrupt proline isomerase activity. Abolishes inhibition of KMT2A activity; when associated with A-196.,MUTAGEN:R->A: No effect on interaction with KMT2A.,MUTAGEN:Y->A: Decreased affinity for RNA.,REGION:Disordered,
PCM1	pericentriolar material 1(PCM1)	Homo sapiens				GO:0000086~G2/M transition of mitotic cell cycle,GO:0001764~neuron migration,GO:0007098~centrosome cycle,GO:0010389~regulation of G2/M transition of mitotic cell cycle,GO:0022027~interkinetic nuclear migration,GO:0031122~cytoplasmic microtubule organization,GO:0034453~microtubule anchoring,GO:0034454~microtubule anchoring at centrosome,GO:0035176~social behavior,GO:0035735~intraciliary transport involved in cilium assembly,GO:0050768~negative regulation of neurogenesis,GO:0060271~cilium assembly,GO:0071539~protein localization to centrosome,GO:0090316~positive regulation of intracellular protein transport,GO:0097150~neuronal stem cell population maintenance,GO:0097711~ciliary basal body docking,GO:1905515~non-motile cilium assembly,	GO:0000242~pericentriolar material,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005814~centriole,GO:0005829~cytosol,GO:0016020~membrane,GO:0031965~nuclear membrane,GO:0032991~macromolecular complex,GO:0034451~centriolar satellite,GO:0035869~ciliary transition zone,GO:0036064~ciliary basal body,GO:0045177~apical part of cell,	GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR024138:Pericentriolar material 1 protein,					KW-0970~Cilium biogenesis/degradation,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,KW-0966~Cell projection,	KW-0656~Proto-oncogene,	KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:PCM1_C,MUTAGEN:S->D: Phosphomimetic mutant.,REGION:Disordered,REGION:Interaction with BBS4,REGION:Interaction with HAP1,SITE:Breakpoint for translocation to form PCM1-JAK2 fusion protein,SITE:Breakpoint for translocation to form PCM1-RET fusion protein,
PEX11A	peroxisomal biogenesis factor 11 alpha(PEX11A)	Homo sapiens				GO:0007031~peroxisome organization,GO:0007165~signal transduction,GO:0016557~peroxisome membrane biogenesis,GO:0016559~peroxisome fission,GO:0019222~regulation of metabolic process,GO:0044375~regulation of peroxisome size,GO:0050873~brown fat cell differentiation,	GO:0005777~peroxisome,GO:0005778~peroxisomal membrane,GO:0005779~integral component of peroxisomal membrane,GO:0032991~macromolecular complex,	GO:0005515~protein binding,GO:0042803~protein homodimerization activity,	IPR008733:Peroxisomal biogenesis factor 11,	hsa04146:Peroxisome,				KW-0962~Peroxisome biogenesis,	KW-0472~Membrane,KW-0576~Peroxisome,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				MUTAGEN:KLK->SLS: No effect on peroxisomal location.,MUTAGEN:N->D: No effect on peroxisomal location.,REGION:Required for homodimerization, interaction with PEX11G, and peroxisomal localization,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
PXMP2	peroxisomal membrane protein 2(PXMP2)	Homo sapiens				GO:0045046~protein import into peroxisome membrane,	GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005778~peroxisomal membrane,GO:0005829~cytosol,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0032991~macromolecular complex,	GO:0005515~protein binding,	IPR007248:Mpv17/PMP22,	hsa04146:Peroxisome,					KW-0472~Membrane,KW-0576~Peroxisome,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Peroxisomal,TRANSMEM:Helical,
PECR	peroxisomal trans-2-enoyl-CoA reductase(PECR)	Homo sapiens				GO:0001561~fatty acid alpha-oxidation,GO:0006633~fatty acid biosynthetic process,GO:0008104~protein localization,GO:0033306~phytol metabolic process,	GO:0005739~mitochondrion,GO:0005777~peroxisome,GO:0005778~peroxisomal membrane,GO:0005829~cytosol,	GO:0005102~receptor binding,GO:0016491~oxidoreductase activity,GO:0019166~trans-2-enoyl-CoA reductase (NADPH) activity,	IPR002347:Glucose/ribitol dehydrogenase,	hsa04146:Peroxisome,				KW-0275~Fatty acid biosynthesis,KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,	KW-0576~Peroxisome,		KW-0175~Coiled coil,	KW-0521~NADP,	KW-0560~Oxidoreductase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,MOTIF:Microbody targeting signal,MUTAGEN:Missing: Abolishes localization to peroxisomes.,NP_BIND:NADP,
PPARD	peroxisome proliferator activated receptor delta(PPARD)	Homo sapiens		h_nuclearRsPathway:Nuclear Receptors in Lipid Metabolism and Toxicity,h_pparPathway:Basic mechanism of action of PPARa, PPARb(d) and PPARg and effects on gene expression,h_wntPathway:WNT Signaling Pathway,		GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006006~glucose metabolic process,GO:0006029~proteoglycan metabolic process,GO:0006091~generation of precursor metabolites and energy,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006367~transcription initiation from RNA polymerase II promoter,GO:0006629~lipid metabolic process,GO:0006631~fatty acid metabolic process,GO:0006635~fatty acid beta-oxidation,GO:0006776~vitamin A metabolic process,GO:0006915~apoptotic process,GO:0007507~heart development,GO:0007566~embryo implantation,GO:0008203~cholesterol metabolic process,GO:0008283~cell proliferation,GO:0008366~axon ensheathment,GO:0008654~phospholipid biosynthetic process,GO:0009062~fatty acid catabolic process,GO:0009749~response to glucose,GO:0009755~hormone-mediated signaling pathway,GO:0010628~positive regulation of gene expression,GO:0010887~negative regulation of cholesterol storage,GO:0014068~positive regulation of phosphatidylinositol 3-kinase signaling,GO:0014823~response to activity,GO:0014842~regulation of skeletal muscle satellite cell proliferation,GO:0014912~negative regulation of smooth muscle cell migration,GO:0015908~fatty acid transport,GO:0019216~regulation of lipid metabolic process,GO:0030154~cell differentiation,GO:0030308~negative regulation of cell growth,GO:0030522~intracellular receptor signaling pathway,GO:0031589~cell-substrate adhesion,GO:0032966~negative regulation of collagen biosynthetic process,GO:0033189~response to vitamin A,GO:0033993~response to lipid,GO:0035774~positive regulation of insulin secretion involved in cellular response to glucose stimulus,GO:0042060~wound healing,GO:0042311~vasodilation,GO:0043066~negative regulation of apoptotic process,GO:0043401~steroid hormone mediated signaling pathway,GO:0043415~positive regulation of skeletal muscle tissue regeneration,GO:0043616~keratinocyte proliferation,GO:0045598~regulation of fat cell differentiation,GO:0045600~positive regulation of fat cell differentiation,GO:0045662~negative regulation of myoblast differentiation,GO:0045684~positive regulation of epidermis development,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045923~positive regulation of fatty acid metabolic process,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046321~positive regulation of fatty acid oxidation,GO:0046697~decidualization,GO:0048662~negative regulation of smooth muscle cell proliferation,GO:0050680~negative regulation of epithelial cell proliferation,GO:0050728~negative regulation of inflammatory response,GO:0051546~keratinocyte migration,GO:0060612~adipose tissue development,GO:0071222~cellular response to lipopolysaccharide,GO:0071456~cellular response to hypoxia,GO:0097190~apoptotic signaling pathway,GO:1902894~negative regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1904659~glucose transmembrane transport,GO:2000288~positive regulation of myoblast proliferation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001103~RNA polymerase II repressing transcription factor binding,GO:0001223~transcription coactivator binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0003707~steroid hormone receptor activity,GO:0004879~RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding,GO:0005504~fatty acid binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0008144~drug binding,GO:0008270~zinc ion binding,GO:0008289~lipid binding,GO:0043565~sequence-specific DNA binding,GO:0051059~NF-kappaB binding,GO:0070539~linoleic acid binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000536:Nuclear hormone receptor, ligand-binding, core,IPR001628:Zinc finger, nuclear hormone receptor-type,IPR001723:Steroid hormone receptor,IPR003074:Peroxisome proliferator-activated receptor,IPR003075:Peroxisome proliferator-activated receptor, beta,IPR013088:Zinc finger, NHR/GATA-type,	hsa03320:PPAR signaling pathway,hsa04310:Wnt signaling pathway,hsa05200:Pathways in cancer,hsa05221:Acute myeloid leukemia,			SM00399:ZnF_C4,SM00430:HOLI,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0238~DNA-binding,KW-0675~Receptor,		COMPBIAS:Acidic residues,COMPBIAS:Polar residues,DNA_BIND:Nuclear receptor,DOMAIN:NR LBD,DOMAIN:Nuclear receptor,REGION:Disordered,ZN_FING:NR C4-type,
PPARG	peroxisome proliferator activated receptor gamma(PPARG)	Homo sapiens		h_nuclearRsPathway:Nuclear Receptors in Lipid Metabolism and Toxicity,h_PPARgPathway:Role of PPAR-gamma Coactivators in Obesity and Thermogenesis,h_pparPathway:Basic mechanism of action of PPARa, PPARb(d) and PPARg and effects on gene expression,h_vobesityPathway:Visceral Fat Deposits and the Metabolic Syndrome,		GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001890~placenta development,GO:0002674~negative regulation of acute inflammatory response,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006367~transcription initiation from RNA polymerase II promoter,GO:0006629~lipid metabolic process,GO:0006631~fatty acid metabolic process,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0007165~signal transduction,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007507~heart development,GO:0007584~response to nutrient,GO:0008217~regulation of blood pressure,GO:0009409~response to cold,GO:0009612~response to mechanical stimulus,GO:0009755~hormone-mediated signaling pathway,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0010742~macrophage derived foam cell differentiation,GO:0010745~negative regulation of macrophage derived foam cell differentiation,GO:0010862~positive regulation of pathway-restricted SMAD protein phosphorylation,GO:0010875~positive regulation of cholesterol efflux,GO:0010887~negative regulation of cholesterol storage,GO:0010888~negative regulation of lipid storage,GO:0010891~negative regulation of sequestering of triglyceride,GO:0015909~long-chain fatty acid transport,GO:0016525~negative regulation of angiogenesis,GO:0019216~regulation of lipid metabolic process,GO:0019395~fatty acid oxidation,GO:0030154~cell differentiation,GO:0030224~monocyte differentiation,GO:0030308~negative regulation of cell growth,GO:0030509~BMP signaling pathway,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0030514~negative regulation of BMP signaling pathway,GO:0030855~epithelial cell differentiation,GO:0031000~response to caffeine,GO:0031100~animal organ regeneration,GO:0032869~cellular response to insulin stimulus,GO:0032966~negative regulation of collagen biosynthetic process,GO:0033189~response to vitamin A,GO:0033993~response to lipid,GO:0035357~peroxisome proliferator activated receptor signaling pathway,GO:0035902~response to immobilization stress,GO:0042493~response to drug,GO:0042593~glucose homeostasis,GO:0042594~response to starvation,GO:0042752~regulation of circadian rhythm,GO:0042789~mRNA transcription from RNA polymerase II promoter,GO:0042953~lipoprotein transport,GO:0043388~positive regulation of DNA binding,GO:0043407~negative regulation of MAP kinase activity,GO:0043537~negative regulation of blood vessel endothelial cell migration,GO:0043627~response to estrogen,GO:0045087~innate immune response,GO:0045165~cell fate commitment,GO:0045600~positive regulation of fat cell differentiation,GO:0045668~negative regulation of osteoblast differentiation,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045923~positive regulation of fatty acid metabolic process,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046321~positive regulation of fatty acid oxidation,GO:0048384~retinoic acid receptor signaling pathway,GO:0048469~cell maturation,GO:0048511~rhythmic process,GO:0048662~negative regulation of smooth muscle cell proliferation,GO:0048714~positive regulation of oligodendrocyte differentiation,GO:0050728~negative regulation of inflammatory response,GO:0050872~white fat cell differentiation,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0051974~negative regulation of telomerase activity,GO:0055088~lipid homeostasis,GO:0060100~positive regulation of phagocytosis, engulfment,GO:0060336~negative regulation of interferon-gamma-mediated signaling pathway,GO:0060391~positive regulation of SMAD protein import into nucleus,GO:0060392~negative regulation of SMAD protein import into nucleus,GO:0060394~negative regulation of pathway-restricted SMAD protein phosphorylation,GO:0060694~regulation of cholesterol transporter activity,GO:0060965~negative regulation of gene silencing by miRNA,GO:0070165~positive regulation of adiponectin secretion,GO:0071300~cellular response to retinoic acid,GO:0071306~cellular response to vitamin E,GO:0071380~cellular response to prostaglandin E stimulus,GO:0071404~cellular response to low-density lipoprotein particle stimulus,GO:0071455~cellular response to hyperoxia,GO:0071456~cellular response to hypoxia,GO:0090258~negative regulation of mitochondrial fission,GO:1901558~response to metformin,GO:1902894~negative regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1903243~negative regulation of cardiac muscle hypertrophy in response to stress,GO:1903845~negative regulation of cellular response to transforming growth factor beta stimulus,GO:1904597~negative regulation of connective tissue replacement involved in inflammatory response wound healing,GO:1904706~negative regulation of vascular smooth muscle cell proliferation,GO:1904893~negative regulation of STAT cascade,GO:1905461~positive regulation of vascular associated smooth muscle cell apoptotic process,GO:1905563~negative regulation of vascular endothelial cell proliferation,GO:1905599~positive regulation of low-density lipoprotein receptor activity,GO:2000230~negative regulation of pancreatic stellate cell proliferation,GO:2000272~negative regulation of receptor activity,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0043231~intracellular membrane-bounded organelle,GO:0043235~receptor complex,GO:0048471~perinuclear region of cytoplasm,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001103~RNA polymerase II repressing transcription factor binding,GO:0001221~transcription cofactor binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003690~double-stranded DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0004879~RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding,GO:0004955~prostaglandin receptor activity,GO:0005515~protein binding,GO:0008022~protein C-terminus binding,GO:0008134~transcription factor binding,GO:0008270~zinc ion binding,GO:0019899~enzyme binding,GO:0019903~protein phosphatase binding,GO:0030331~estrogen receptor binding,GO:0033613~activating transcription factor binding,GO:0042277~peptide binding,GO:0042802~identical protein binding,GO:0043565~sequence-specific DNA binding,GO:0043621~protein self-association,GO:0046872~metal ion binding,GO:0046965~retinoid X receptor binding,GO:0050544~arachidonic acid binding,GO:0050692~DBD domain binding,GO:0050693~LBD domain binding,GO:0051393~alpha-actinin binding,GO:0070412~R-SMAD binding,GO:0070888~E-box binding,GO:0097677~STAT family protein binding,	IPR000536:Nuclear hormone receptor, ligand-binding, core,IPR001628:Zinc finger, nuclear hormone receptor-type,IPR001723:Steroid hormone receptor,IPR003074:Peroxisome proliferator-activated receptor,IPR003077:Peroxisome proliferator-activated receptor, gamma,IPR013088:Zinc finger, NHR/GATA-type,IPR022590:Peroxisome proliferator-activated receptor gamma, N-terminal,	hsa03320:PPAR signaling pathway,hsa04152:AMPK signaling pathway,hsa04211:Longevity regulating pathway,hsa04380:Osteoclast differentiation,hsa04714:Thermogenesis,hsa04932:Non-alcoholic fatty liver disease,hsa05016:Huntington disease,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05216:Thyroid cancer,hsa05417:Lipid and atherosclerosis,	125853~Diabetes, type 2,601665~Obesity, severe,604367~Insulin resistance, severe, digenic,604367~Lipodystrophy, familial partial, type 3,609338~Carotid intimal medial thickness 1,Obesity, resistance to~Obesity, resistance to,		SM00399:ZnF_C4,SM00430:HOLI,	KW-0090~Biological rhythms,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0219~Diabetes mellitus,KW-0225~Disease variant,KW-0550~Obesity,	KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0238~DNA-binding,KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	BINDING:Rosiglitazone; agonist,CARBOHYD:O-linked (GlcNAc) threonine,DNA_BIND:Nuclear receptor,DOMAIN:NR LBD,DOMAIN:Nuclear receptor,DOMAIN:PPARgamma_N,MOTIF:9aaTAD,REGION:Interaction with FAM120B,REGION:Rosiglitazon binding; agonist,ZN_FING:NR C4-type,
PMAIP1	phorbol-12-myristate-13-acetate-induced protein 1(PMAIP1)	Homo sapiens				GO:0001836~release of cytochrome c from mitochondria,GO:0001844~protein insertion into mitochondrial membrane involved in apoptotic signaling pathway,GO:0006915~apoptotic process,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0006974~cellular response to DNA damage stimulus,GO:0010498~proteasomal protein catabolic process,GO:0010907~positive regulation of glucose metabolic process,GO:0010917~negative regulation of mitochondrial membrane potential,GO:0042149~cellular response to glucose starvation,GO:0042981~regulation of apoptotic process,GO:0043029~T cell homeostasis,GO:0043065~positive regulation of apoptotic process,GO:0043280~positive regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0043331~response to dsRNA,GO:0043517~positive regulation of DNA damage response, signal transduction by p53 class mediator,GO:0046902~regulation of mitochondrial membrane permeability,GO:0051607~defense response to virus,GO:0071456~cellular response to hypoxia,GO:0072332~intrinsic apoptotic signaling pathway by p53 class mediator,GO:0072593~reactive oxygen species metabolic process,GO:0090200~positive regulation of release of cytochrome c from mitochondria,GO:0097193~intrinsic apoptotic signaling pathway,GO:1900740~positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway,GO:1902043~positive regulation of extrinsic apoptotic signaling pathway via death domain receptors,GO:1902237~positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway,GO:2001244~positive regulation of intrinsic apoptotic signaling pathway,	GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005829~cytosol,GO:0097136~Bcl-2 family protein complex,	GO:0005515~protein binding,	IPR024140:Phorbol-12-myristate-13-acetate-induced protein 1/Noxa,	hsa01524:Platinum drug resistance,hsa04115:p53 signaling pathway,hsa04210:Apoptosis,hsa04215:Apoptosis - multiple species,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05210:Colorectal cancer,				KW-0053~Apoptosis,	KW-0496~Mitochondrion,						MOTIF:BH3,MUTAGEN:F->E: Loss of interaction with MCL1 and of increased MCL1 degradation; when associated with E-29 and E-36.,MUTAGEN:F->I: Alters specificity of protein interaction and enhances pro-apoptotic activity; when associated with E-35.,MUTAGEN:K->E: Alters specificity of protein interaction and enhances pro-apoptotic activity; when associated with I-32.,MUTAGEN:L->A: Reduced interaction with BAX.,MUTAGEN:L->E: Loss of interaction with MCL1 and of increased MCL1 degradation; when associated with E-29 and E-32.,MUTAGEN:L->E: Loss of interaction with MCL1 and of increased MCL1 degradation; when associated with E-32 and E-32.,REGION:Disordered,REGION:Required for mitochondrial location,
PIK3C3	phosphatidylinositol 3-kinase catalytic subunit type 3(PIK3C3)	Homo sapiens				GO:0000045~autophagosome assembly,GO:0006468~protein phosphorylation,GO:0006497~protein lipidation,GO:0006661~phosphatidylinositol biosynthetic process,GO:0006897~endocytosis,GO:0006914~autophagy,GO:0007032~endosome organization,GO:0007049~cell cycle,GO:0010506~regulation of autophagy,GO:0016236~macroautophagy,GO:0016241~regulation of macroautophagy,GO:0016485~protein processing,GO:0030242~pexophagy,GO:0032465~regulation of cytokinesis,GO:0034162~toll-like receptor 9 signaling pathway,GO:0034497~protein localization to pre-autophagosomal structure,GO:0036092~phosphatidylinositol-3-phosphate biosynthetic process,GO:0042149~cellular response to glucose starvation,GO:0043201~response to leucine,GO:0045022~early endosome to late endosome transport,GO:0046854~phosphatidylinositol phosphorylation,GO:0048015~phosphatidylinositol-mediated signaling,GO:0050708~regulation of protein secretion,GO:0051301~cell division,GO:0097352~autophagosome maturation,	GO:0000407~pre-autophagosomal structure,GO:0005737~cytoplasm,GO:0005768~endosome,GO:0005770~late endosome,GO:0005777~peroxisome,GO:0005829~cytosol,GO:0005930~axoneme,GO:0016020~membrane,GO:0030496~midbody,GO:0030670~phagocytic vesicle membrane,GO:0034271~phosphatidylinositol 3-kinase complex, class III, type I,GO:0034272~phosphatidylinositol 3-kinase complex, class III, type II,GO:0035032~phosphatidylinositol 3-kinase complex, class III,GO:0044754~autolysosome,GO:0045335~phagocytic vesicle,	GO:0004672~protein kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016301~kinase activity,GO:0016303~1-phosphatidylinositol-3-kinase activity,GO:0052742~phosphatidylinositol kinase activity,	IPR000403:Phosphatidylinositol 3-/4-kinase, catalytic domain,IPR001263:Phosphoinositide 3-kinase, accessory (PIK) domain,IPR002420:Phosphatidylinositol 3-kinase C2 (PI3K C2) domain,IPR008290:Phosphatidylinositol 3-kinase, Vps34 type,IPR011009:Protein kinase-like domain,IPR015433:Phosphatidylinositol Kinase,IPR016024:Armadillo-type fold,IPR018936:Phosphatidylinositol 3/4-kinase, conserved site,	hsa00562:Inositol phosphate metabolism,hsa01100:Metabolic pathways,hsa04070:Phosphatidylinositol signaling system,hsa04136:Autophagy - other,hsa04140:Autophagy - animal,hsa04145:Phagosome,hsa04371:Apelin signaling pathway,hsa05010:Alzheimer disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05017:Spinocerebellar ataxia,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05152:Tuberculosis,hsa05167:Kaposi sarcoma-associated herpesvirus infection,		PIRSF000587:phosphatidylinositol 3-kinase, Vps34 type,	SM00142:PI3K_C2,SM00145:PI3Ka,SM00146:PI3Kc,	KW-0072~Autophagy,KW-0131~Cell cycle,KW-0132~Cell division,KW-0443~Lipid metabolism,	KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,			KW-0067~ATP-binding,KW-0464~Manganese,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:C2 PI3K-type,DOMAIN:PI3K/PI4K,DOMAIN:PIK helical,REGION:Disordered,
PIGB	phosphatidylinositol glycan anchor biosynthesis class B(PIGB)	Homo sapiens				GO:0006506~GPI anchor biosynthetic process,GO:0016254~preassembly of GPI anchor in ER membrane,GO:0097502~mannosylation,	GO:0005789~endoplasmic reticulum membrane,GO:0016021~integral component of membrane,	GO:0000026~alpha-1,2-mannosyltransferase activity,GO:0000030~mannosyltransferase activity,GO:0004376~glycolipid mannosyltransferase activity,	IPR005599:GPI mannosyltransferase,	hsa00563:Glycosylphosphatidylinositol (GPI)-anchor biosynthesis,hsa01100:Metabolic pathways,	618580~Developmental and epileptic encephalopathy 80,			KW-0337~GPI-anchor biosynthesis,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,	KW-0887~Epilepsy,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:Disordered,TRANSMEM:Helical,
PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha(PIK3CA)	Homo sapiens		h_achPathway:Role of nicotinic acetylcholine receptors in the regulation of apoptosis,h_aktPathway:AKT Signaling Pathway,h_arfPathway:Tumor Suppressor Arf Inhibits Ribosomal Biogenesis,h_badPathway:Regulation of BAD phosphorylation,h_bcellsurvivalPathway:B Cell Survival Pathway,h_cdc42racPathway:Role of PI3K subunit p85 in regulation of Actin Organization and Cell Migration,h_crebPathway:Transcription factor CREB and its extracellular signals,h_ctcfPathway:CTCF: First Multivalent Nuclear Factor,h_ctla4Pathway:The Co-Stimulatory Signal During T-cell Activation,h_cxcr4Pathway:CXCR4 Signaling Pathway,h_ecmPathway:Erk and PI-3 Kinase Are Necessary for Collagen Binding in Corneal Epithelia,h_edg1Pathway:Phospholipids as signalling intermediaries,h_egfPathway:EGF Signaling Pathway,h_eif4Pathway:Regulation of eIF4e and p70 S6 Kinase,h_erk5Pathway:Role of Erk5 in Neuronal Survival,h_fcer1Pathway:Fc Epsilon Receptor I Signaling in Mast Cells,h_gcrpathway:Corticosteroids and cardioprotection,h_ghPathway:Growth Hormone Signaling Pathway,h_gleevecPathway:Inhibition of Cellular Proliferation by Gleevec,H_gsk3Pathway:Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar Macrophages,h_hcmvPathway:Human Cytomegalovirus and Map Kinase Pathways,h_hdacPathway:Control of skeletal myogenesis by HDAC & calcium/calmodulin-dependent kinase (CaMK),h_her2Pathway:Role of ERBB2 in Signal Transduction and Oncology,h_igf1mtorPathway:Skeletal muscle hypertrophy is regulated via AKT/mTOR pathway,h_igf1Pathway:IGF-1 Signaling Pathway,h_igf1rPathway:Multiple antiapoptotic pathways from IGF-1R signaling lead to BAD phosphorylation,h_il2rbPathway:IL-2 Receptor Beta Chain in T cell Activation,h_il7Pathway:IL-7 Signal Transduction,h_insulinPathway:Insulin Signaling Pathway,h_longevityPathway:The IGF-1 Receptor and Longevity,h_metPathway:Signaling of Hepatocyte Growth Factor Receptor,h_mtorPathway:mTOR Signaling Pathway,h_nfatPathway:NFAT and Hypertrophy of the heart (Transcription in the broken heart),h_ngfPathway:Nerve growth factor pathway (NGF),h_nkcellsPathway:Ras-Independent pathway in NK cell-mediated cytotoxicity,h_par1pathway:Thrombin signaling and protease-activated receptors,h_pdgfPathway:PDGF Signaling Pathway,h_plcPathway:Phospholipase C Signaling Pathway,h_PparaPathway:Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha),h_ptenPathway:PTEN dependent cell cycle arrest and apoptosis,h_rac1Pathway:Rac 1 cell motility signaling pathway,h_raccycdPathway:Influence of Ras and Rho proteins on G1 to S Transition,h_rasPathway:Ras Signaling Pathway,h_tcrPathway:T Cell Receptor Signaling Pathway,h_tffPathway:Trefoil Factors Initiate  Mucosal Healing,h_tpoPathway:TPO Signaling Pathway,h_trkaPathway:Trka Receptor Signaling Pathway,h_vegfPathway:VEGF, Hypoxia, and Angiogenesis,		GO:0000165~MAPK cascade,GO:0001525~angiogenesis,GO:0001889~liver development,GO:0001944~vasculature development,GO:0006006~glucose metabolic process,GO:0006468~protein phosphorylation,GO:0006661~phosphatidylinositol biosynthetic process,GO:0006909~phagocytosis,GO:0007173~epidermal growth factor receptor signaling pathway,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007411~axon guidance,GO:0010468~regulation of gene expression,GO:0010592~positive regulation of lamellipodium assembly,GO:0010629~negative regulation of gene expression,GO:0014065~phosphatidylinositol 3-kinase signaling,GO:0014068~positive regulation of phosphatidylinositol 3-kinase signaling,GO:0014823~response to activity,GO:0014870~response to muscle inactivity,GO:0016242~negative regulation of macroautophagy,GO:0016310~phosphorylation,GO:0016477~cell migration,GO:0019221~cytokine-mediated signaling pathway,GO:0030036~actin cytoskeleton organization,GO:0030168~platelet activation,GO:0030835~negative regulation of actin filament depolymerization,GO:0031295~T cell costimulation,GO:0032008~positive regulation of TOR signaling,GO:0032147~activation of protein kinase activity,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0035994~response to muscle stretch,GO:0036092~phosphatidylinositol-3-phosphate biosynthetic process,GO:0038028~insulin receptor signaling pathway via phosphatidylinositol 3-kinase,GO:0038084~vascular endothelial growth factor signaling pathway,GO:0038095~Fc-epsilon receptor signaling pathway,GO:0038096~Fc-gamma receptor signaling pathway involved in phagocytosis,GO:0038128~ERBB2 signaling pathway,GO:0040014~regulation of multicellular organism growth,GO:0043201~response to leucine,GO:0043276~anoikis,GO:0043457~regulation of cellular respiration,GO:0043491~protein kinase B signaling,GO:0043524~negative regulation of neuron apoptotic process,GO:0043542~endothelial cell migration,GO:0044029~hypomethylation of CpG island,GO:0046854~phosphatidylinositol phosphorylation,GO:0048010~vascular endothelial growth factor receptor signaling pathway,GO:0048015~phosphatidylinositol-mediated signaling,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0050852~T cell receptor signaling pathway,GO:0050900~leukocyte migration,GO:0051897~positive regulation of protein kinase B signaling,GO:0055119~relaxation of cardiac muscle,GO:0060048~cardiac muscle contraction,GO:0060612~adipose tissue development,GO:0071333~cellular response to glucose stimulus,GO:0071464~cellular response to hydrostatic pressure,GO:0071548~response to dexamethasone,GO:0086003~cardiac muscle cell contraction,GO:0097009~energy homeostasis,GO:1903544~response to butyrate,GO:2000270~negative regulation of fibroblast apoptotic process,GO:2000653~regulation of genetic imprinting,GO:2000811~negative regulation of anoikis,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005942~phosphatidylinositol 3-kinase complex,GO:0005943~phosphatidylinositol 3-kinase complex, class IA,GO:0005944~phosphatidylinositol 3-kinase complex, class IB,GO:0014704~intercalated disc,GO:0016020~membrane,GO:0030027~lamellipodium,GO:0048471~perinuclear region of cytoplasm,	GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016301~kinase activity,GO:0016303~1-phosphatidylinositol-3-kinase activity,GO:0030295~protein kinase activator activity,GO:0035004~phosphatidylinositol 3-kinase activity,GO:0035005~1-phosphatidylinositol-4-phosphate 3-kinase activity,GO:0043560~insulin receptor substrate binding,GO:0046934~phosphatidylinositol-4,5-bisphosphate 3-kinase activity,GO:0052742~phosphatidylinositol kinase activity,GO:0052812~phosphatidylinositol-3,4-bisphosphate 5-kinase activity,	IPR000341:Phosphatidylinositol 3-kinase Ras-binding (PI3K RBD) domain,IPR000403:Phosphatidylinositol 3-/4-kinase, catalytic domain,IPR001263:Phosphoinositide 3-kinase, accessory (PIK) domain,IPR002420:Phosphatidylinositol 3-kinase C2 (PI3K C2) domain,IPR003113:Phosphatidylinositol 3-kinase adaptor-binding (PI3K ABD) domain,IPR011009:Protein kinase-like domain,IPR015433:Phosphatidylinositol Kinase,IPR016024:Armadillo-type fold,IPR018936:Phosphatidylinositol 3/4-kinase, conserved site,	hsa00562:Inositol phosphate metabolism,hsa01100:Metabolic pathways,hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa01522:Endocrine resistance,hsa01524:Platinum drug resistance,hsa04012:ErbB signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04024:cAMP signaling pathway,hsa04062:Chemokine signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04068:FoxO signaling pathway,hsa04070:Phosphatidylinositol signaling system,hsa04071:Sphingolipid signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04140:Autophagy - animal,hsa04150:mTOR signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04152:AMPK signaling pathway,hsa04210:Apoptosis,hsa04211:Longevity regulating pathway,hsa04213:Longevity regulating pathway - multiple species,hsa04218:Cellular senescence,hsa04360:Axon guidance,hsa04370:VEGF signaling pathway,hsa04380:Osteoclast differentiation,hsa04510:Focal adhesion,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04611:Platelet activation,hsa04613:Neutrophil extracellular trap formation,hsa04620:Toll-like receptor signaling pathway,hsa04625:C-type lectin receptor signaling pathway,hsa04630:JAK-STAT signaling pathway,hsa04650:Natural killer cell mediated cytotoxicity,hsa04660:T cell receptor signaling pathway,hsa04662:B cell receptor signaling pathway,hsa04664:Fc epsilon RI signaling pathway,hsa04666:Fc gamma R-mediated phagocytosis,hsa04668:TNF signaling pathway,hsa04670:Leukocyte transendothelial migration,hsa04722:Neurotrophin signaling pathway,hsa04725:Cholinergic synapse,hsa04750:Inflammatory mediator regulation of TRP channels,hsa04810:Regulation of actin cytoskeleton,hsa04910:Insulin signaling pathway,hsa04914:Progesterone-mediated oocyte maturation,hsa04915:Estrogen signaling pathway,hsa04917:Prolactin signaling pathway,hsa04919:Thyroid hormone signaling pathway,hsa04923:Regulation of lipolysis in adipocytes,hsa04926:Relaxin signaling pathway,hsa04929:GnRH secretion,hsa04930:Type II diabetes mellitus,hsa04931:Insulin resistance,hsa04932:Non-alcoholic fatty liver disease,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04935:Growth hormone synthesis, secretion and action,hsa04960:Aldosterone-regulated sodium reabsorption,hsa04973:Carbohydrate digestion and absorption,hsa05010:Alzheimer disease,hsa05017:Spinocerebellar ataxia,hsa05020:Prion disease,hsa05100:Bacterial invasion of epithelial cells,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05135:Yersinia infection,hsa05142:Chagas disease,hsa05146:Amoebiasis,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05210:Colorectal cancer,hsa05211:Renal cell carcinoma,hsa05212:Pancreatic cancer,hsa05213:Endometrial cancer,hsa05214:Glioma,hsa05215:Prostate cancer,hsa05218:Melanoma,hsa05220:Chronic myeloid leukemia,hsa05221:Acute myeloid leukemia,hsa05222:Small cell lung cancer,hsa05223:Non-small cell lung cancer,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,hsa05230:Central carbon metabolism in cancer,hsa05231:Choline metabolism in cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05415:Diabetic cardiomyopathy,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,	114480~Breast cancer, somatic,114500~Colorectal cancer, somatic,114550~Hepatocellular carcinoma, somatic,155500~Macrodactyly, somatic,162900~Nevus, epidermal, somatic,167000~Ovarian cancer, somatic,182000~Keratosis, seborrheic, somatic,211980~Nonsmall cell lung cancer, somatic,602501~Megalencephaly-capillary malformation-polymicrogyria syndrome, somatic,612918~CLOVE syndrome, somatic,613089~CLAPO syndrome, somatic,613659~Gastric cancer, somatic,615108~Cowden syndrome 5,		SM00142:PI3K_C2,SM00143:PI3K_p85B,SM00144:PI3K_rbd,SM00145:PI3Ka,SM00146:PI3Kc,	KW-0037~Angiogenesis,KW-0443~Lipid metabolism,KW-0581~Phagocytosis,		KW-0225~Disease variant,KW-0656~Proto-oncogene,	KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,		DOMAIN:C2 PI3K-type,DOMAIN:PI3K-ABD,DOMAIN:PI3K-RBD,DOMAIN:PI3K/PI4K,DOMAIN:PIK helical,SITE:Implicated in the recognition of ATP as well as PIP2. Also crucial for autophosphorylation of the p85alpha subunit,
PIK3C2B	phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta(PIK3C2B)	Homo sapiens				GO:0006661~phosphatidylinositol biosynthetic process,GO:0009267~cellular response to starvation,GO:0014065~phosphatidylinositol 3-kinase signaling,GO:0016310~phosphorylation,GO:0016477~cell migration,GO:0036092~phosphatidylinositol-3-phosphate biosynthetic process,GO:0043491~protein kinase B signaling,GO:0046854~phosphatidylinositol phosphorylation,GO:0048015~phosphatidylinositol-mediated signaling,GO:1905037~autophagosome organization,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005942~phosphatidylinositol 3-kinase complex,GO:0016020~membrane,GO:0030139~endocytic vesicle,GO:0043231~intracellular membrane-bounded organelle,	GO:0001727~lipid kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016303~1-phosphatidylinositol-3-kinase activity,GO:0035005~1-phosphatidylinositol-4-phosphate 3-kinase activity,GO:0035091~phosphatidylinositol binding,GO:0052742~phosphatidylinositol kinase activity,	IPR000008:C2 calcium-dependent membrane targeting,IPR000341:Phosphatidylinositol 3-kinase Ras-binding (PI3K RBD) domain,IPR000403:Phosphatidylinositol 3-/4-kinase, catalytic domain,IPR001263:Phosphoinositide 3-kinase, accessory (PIK) domain,IPR001683:Phox homologous domain,IPR002420:Phosphatidylinositol 3-kinase C2 (PI3K C2) domain,IPR011009:Protein kinase-like domain,IPR015433:Phosphatidylinositol Kinase,IPR016024:Armadillo-type fold,IPR018936:Phosphatidylinositol 3/4-kinase, conserved site,	hsa00562:Inositol phosphate metabolism,hsa01100:Metabolic pathways,hsa04070:Phosphatidylinositol signaling system,hsa05132:Salmonella infection,			SM00142:PI3K_C2,SM00144:PI3K_rbd,SM00145:PI3Ka,SM00146:PI3Kc,SM00239:C2,SM00312:PX,	KW-0443~Lipid metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0492~Microsome,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,		COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:C2,DOMAIN:C2 PI3K-type,DOMAIN:PI3K-RBD,DOMAIN:PI3K/PI4K,DOMAIN:PIK helical,DOMAIN:PX,REGION:Disordered,REGION:Interaction with GRB2,
PIP4K2B	phosphatidylinositol-5-phosphate 4-kinase type 2 beta(PIP4K2B)	Homo sapiens				GO:0006644~phospholipid metabolic process,GO:0006661~phosphatidylinositol biosynthetic process,GO:0007166~cell surface receptor signaling pathway,GO:0010506~regulation of autophagy,GO:0014066~regulation of phosphatidylinositol 3-kinase signaling,GO:0016310~phosphorylation,GO:0046627~negative regulation of insulin receptor signaling pathway,GO:0046854~phosphatidylinositol phosphorylation,GO:0090217~negative regulation of 1-phosphatidylinositol-4-phosphate 5-kinase activity,GO:1901796~regulation of signal transduction by p53 class mediator,GO:1902635~1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate biosynthetic process,GO:2000786~positive regulation of autophagosome assembly,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005776~autophagosome,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0005886~plasma membrane,	GO:0005515~protein binding,GO:0005524~ATP binding,GO:0005525~GTP binding,GO:0016307~phosphatidylinositol phosphate kinase activity,GO:0016308~1-phosphatidylinositol-4-phosphate 5-kinase activity,GO:0016309~1-phosphatidylinositol-5-phosphate 4-kinase activity,GO:0042803~protein homodimerization activity,	IPR002498:Phosphatidylinositol-4-phosphate 5-kinase, core,IPR023610:Phosphatidylinositol-4-phosphate 5-kinase,IPR027483:Phosphatidylinositol-4-phosphate 5-kinase, C-terminal,IPR027484:Phosphatidylinositol-4-phosphate 5-kinase, N-terminal domain,	hsa00562:Inositol phosphate metabolism,hsa01100:Metabolic pathways,hsa04070:Phosphatidylinositol signaling system,hsa04810:Regulation of actin cytoskeleton,			SM00330:PIPKc,	KW-0443~Lipid metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,			KW-0067~ATP-binding,KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	BINDING:ATP,BINDING:GTP,DOMAIN:PIPK,NP_BIND:ATP,NP_BIND:GTP,REGION:Required for interaction with PIP5K1A,
PCK2	phosphoenolpyruvate carboxykinase 2, mitochondrial(PCK2)	Homo sapiens	95.GLUCOSE_PRODUCTION_LIVER,			GO:0006090~pyruvate metabolic process,GO:0006094~gluconeogenesis,GO:0006107~oxaloacetate metabolic process,GO:0006116~NADH oxidation,GO:0019543~propionate catabolic process,GO:0032024~positive regulation of insulin secretion,GO:0032496~response to lipopolysaccharide,GO:0032869~cellular response to insulin stimulus,GO:0033993~response to lipid,GO:0042594~response to starvation,GO:0046327~glycerol biosynthetic process from pyruvate,GO:0070365~hepatocyte differentiation,GO:0071333~cellular response to glucose stimulus,GO:0071356~cellular response to tumor necrosis factor,GO:0071548~response to dexamethasone,GO:0071549~cellular response to dexamethasone stimulus,	GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005829~cytosol,	GO:0004611~phosphoenolpyruvate carboxykinase activity,GO:0004613~phosphoenolpyruvate carboxykinase (GTP) activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0016301~kinase activity,GO:0030145~manganese ion binding,GO:0046872~metal ion binding,	IPR008209:Phosphoenolpyruvate carboxykinase, GTP-utilising,IPR008210:Phosphoenolpyruvate carboxykinase, N-terminal,IPR013035:Phosphoenolpyruvate carboxykinase, C-terminal,IPR018091:Phosphoenolpyruvate carboxykinase, GTP-utilising, conserved site,	hsa00010:Glycolysis / Gluconeogenesis,hsa00020:Citrate cycle (TCA cycle),hsa00620:Pyruvate metabolism,hsa01100:Metabolic pathways,hsa03320:PPAR signaling pathway,hsa04068:FoxO signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04152:AMPK signaling pathway,hsa04910:Insulin signaling pathway,hsa04920:Adipocytokine signaling pathway,hsa04922:Glucagon signaling pathway,hsa04931:Insulin resistance,hsa04964:Proximal tubule bicarbonate reclamation,	261650~PEPCK deficiency, mitochondrial,	PIRSF001348:phosphoenolpyruvate carboxykinase (GTP),		KW-0312~Gluconeogenesis,	KW-0496~Mitochondrion,		KW-0809~Transit peptide,	KW-0342~GTP-binding,KW-0464~Manganese,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0670~Pyruvate,	KW-0210~Decarboxylase,KW-0418~Kinase,KW-0456~Lyase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	BINDING:GTP,BINDING:Substrate,DOMAIN:PEPCK_GTP,DOMAIN:PEPCK_N,METAL:Manganese,METAL:Manganese; via tele nitrogen,NP_BIND:GTP,REGION:Disordered,REGION:Substrate binding,TRANSIT:Mitochondrion,
PFKL	phosphofructokinase, liver type(PFKL)	Homo sapiens	95.GLUCOSE_PRODUCTION_LIVER,	h_glycolysisPathway:Glycolysis Pathway,h_ptdinsPathway:Phosphoinositides and their downstream targets.,		GO:0006002~fructose 6-phosphate metabolic process,GO:0006096~glycolytic process,GO:0009749~response to glucose,GO:0030388~fructose 1,6-bisphosphate metabolic process,GO:0043312~neutrophil degranulation,GO:0046676~negative regulation of insulin secretion,GO:0061621~canonical glycolysis,	GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005945~6-phosphofructokinase complex,GO:0016020~membrane,GO:0034774~secretory granule lumen,GO:0070062~extracellular exosome,GO:1904813~ficolin-1-rich granule lumen,	GO:0003872~6-phosphofructokinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016208~AMP binding,GO:0019900~kinase binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,GO:0048029~monosaccharide binding,GO:0070061~fructose binding,GO:0070095~fructose-6-phosphate binding,	IPR000023:Phosphofructokinase domain,IPR009161:6-phosphofructokinase, eukaryotic type,IPR015912:Phosphofructokinase, conserved site,IPR022953:Phosphofructokinase,	hsa00010:Glycolysis / Gluconeogenesis,hsa00030:Pentose phosphate pathway,hsa00051:Fructose and mannose metabolism,hsa00052:Galactose metabolism,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa01230:Biosynthesis of amino acids,hsa03018:RNA degradation,hsa04066:HIF-1 signaling pathway,hsa04152:AMPK signaling pathway,hsa04919:Thyroid hormone signaling pathway,hsa04922:Glucagon signaling pathway,hsa05230:Central carbon metabolism in cancer,	Hemolytic anemia due to phosphofructokinase deficiency~Hemolytic anemia due to phosphofructokinase deficiency,	PIRSF000533:ATP-dependent phosphofructokinase, eukaryotic type,		KW-0324~Glycolysis,	KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0021~Allosteric enzyme,KW-0418~Kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:ATP; via amide nitrogen,BINDING:Fructose 2,6-bisphosphate; allosteric activator,BINDING:Fructose 2,6-bisphosphate; allosteric activator; shared with dimeric partner,BINDING:Substrate,BINDING:Substrate; shared with dimeric partner,CARBOHYD:O-linked (GlcNAc) serine,DOMAIN:PFK,METAL:Magnesium; catalytic,MUTAGEN:S->A: Prevents GlcNAcylation and enhance enzyme activity.,MUTAGEN:T->A: Does not affect GlcNAcylation.,NP_BIND:ATP,REGION:C-terminal regulatory PFK domain 2,REGION:Disordered,REGION:Fructose 2,6-bisphosphate binding; allosteric activator,REGION:Interdomain linker,REGION:N-terminal catalytic PFK domain 1,REGION:Substrate binding,
PGM1	phosphoglucomutase 1(PGM1)	Homo sapiens				GO:0005975~carbohydrate metabolic process,GO:0005978~glycogen biosynthetic process,GO:0006006~glucose metabolic process,GO:0006094~gluconeogenesis,GO:0006096~glycolytic process,GO:0043312~neutrophil degranulation,	GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,GO:1904724~tertiary granule lumen,GO:1904813~ficolin-1-rich granule lumen,	GO:0000287~magnesium ion binding,GO:0004614~phosphoglucomutase activity,GO:0005515~protein binding,GO:0016868~intramolecular transferase activity, phosphotransferases,	IPR005841:Alpha-D-phosphohexomutase superfamily,IPR005843:Alpha-D-phosphohexomutase, C-terminal,IPR005844:Alpha-D-phosphohexomutase, alpha/beta/alpha domain I,IPR005845:Alpha-D-phosphohexomutase, alpha/beta/alpha domain II,IPR005846:Alpha-D-phosphohexomutase, alpha/beta/alpha domain III,IPR016055:Alpha-D-phosphohexomutase, alpha/beta/alpha I/II/III,IPR016066:Alpha-D-phosphohexomutase, conserved site,	hsa00010:Glycolysis / Gluconeogenesis,hsa00030:Pentose phosphate pathway,hsa00052:Galactose metabolism,hsa00230:Purine metabolism,hsa00500:Starch and sucrose metabolism,hsa00520:Amino sugar and nucleotide sugar metabolism,hsa01100:Metabolic pathways,hsa01250:Biosynthesis of nucleotide sugars,	614921~Congenital disorder of glycosylation, type It,			KW-0119~Carbohydrate metabolism,KW-0313~Glucose metabolism,	KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0322~Glycogen storage disease,KW-0900~Congenital disorder of glycosylation,		KW-0460~Magnesium,KW-0479~Metal-binding,	KW-0413~Isomerase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Phosphoserine intermediate,BINDING:Substrate,DOMAIN:PGM_PMM_I,DOMAIN:PGM_PMM_II,DOMAIN:PGM_PMM_III,DOMAIN:PGM_PMM_IV,METAL:Magnesium,METAL:Magnesium; via phosphate group,REGION:Substrate binding,
PHGDH	phosphoglycerate dehydrogenase(PHGDH)	Homo sapiens				GO:0006541~glutamine metabolic process,GO:0006544~glycine metabolic process,GO:0006564~L-serine biosynthetic process,GO:0006566~threonine metabolic process,GO:0007420~brain development,GO:0009448~gamma-aminobutyric acid metabolic process,GO:0010468~regulation of gene expression,GO:0019530~taurine metabolic process,GO:0021510~spinal cord development,GO:0021782~glial cell development,GO:0021915~neural tube development,GO:0022900~electron transport chain,GO:0031175~neuron projection development,GO:0070314~G1 to G0 transition,	GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0004617~phosphoglycerate dehydrogenase activity,GO:0009055~electron carrier activity,GO:0016491~oxidoreductase activity,GO:0016616~oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor,GO:0030060~L-malate dehydrogenase activity,GO:0051287~NAD binding,	IPR006139:D-isomer specific 2-hydroxyacid dehydrogenase, catalytic domain,IPR006140:D-isomer specific 2-hydroxyacid dehydrogenase, NAD-binding,IPR006236:D-3-phosphoglycerate dehydrogenase,	hsa00260:Glycine, serine and threonine metabolism,hsa00270:Cysteine and methionine metabolism,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa01230:Biosynthesis of amino acids,	256520~Neu-Laxova syndrome 1,601815~Phosphoglycerate dehydrogenase deficiency,			KW-0028~Amino-acid biosynthesis,KW-0718~Serine biosynthesis,		KW-0225~Disease variant,		KW-0520~NAD,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Proton donor,BINDING:NAD,BINDING:NAD; via carbonyl oxygen,COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:2-Hacid_dh,DOMAIN:2-Hacid_dh_C,NP_BIND:NAD,REGION:Disordered,
PGAM1	phosphoglycerate mutase 1(PGAM1)	Homo sapiens		h_glycolysisPathway:Glycolysis Pathway,		GO:0006094~gluconeogenesis,GO:0006096~glycolytic process,GO:0006110~regulation of glycolytic process,GO:0043312~neutrophil degranulation,GO:0043456~regulation of pentose-phosphate shunt,GO:0045730~respiratory burst,GO:0061621~canonical glycolysis,	GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0034774~secretory granule lumen,GO:0070062~extracellular exosome,GO:1904813~ficolin-1-rich granule lumen,	GO:0004082~bisphosphoglycerate mutase activity,GO:0004619~phosphoglycerate mutase activity,GO:0005515~protein binding,GO:0016787~hydrolase activity,GO:0019901~protein kinase binding,	IPR001345:Phosphoglycerate/bisphosphoglycerate mutase, active site,IPR005952:Phosphoglycerate mutase 1,IPR013078:Histidine phosphatase superfamily, clade-1,	hsa00010:Glycolysis / Gluconeogenesis,hsa00260:Glycine, serine and threonine metabolism,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa01230:Biosynthesis of amino acids,hsa04922:Glucagon signaling pathway,hsa05230:Central carbon metabolism in cancer,			SM00855:SM00855,	KW-0324~Glycolysis,					KW-0378~Hydrolase,KW-0413~Isomerase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton donor/acceptor,ACT_SITE:Tele-phosphohistidine intermediate,BINDING:Substrate,REGION:Substrate binding,SITE:Transition state stabilizer,
PIK3R3	phosphoinositide-3-kinase regulatory subunit 3(PIK3R3)	Homo sapiens			Cell division and chromosome partitioning,	GO:0001934~positive regulation of protein phosphorylation,GO:0002042~cell migration involved in sprouting angiogenesis,GO:0006661~phosphatidylinositol biosynthetic process,GO:0008286~insulin receptor signaling pathway,GO:0010628~positive regulation of gene expression,GO:0030335~positive regulation of cell migration,GO:0036092~phosphatidylinositol-3-phosphate biosynthetic process,GO:0043491~protein kinase B signaling,GO:0043551~regulation of phosphatidylinositol 3-kinase activity,GO:0046854~phosphatidylinositol phosphorylation,	GO:0005829~cytosol,GO:0005942~phosphatidylinositol 3-kinase complex,	GO:0001784~phosphotyrosine binding,GO:0005515~protein binding,GO:0016301~kinase activity,GO:0016303~1-phosphatidylinositol-3-kinase activity,GO:0046935~1-phosphatidylinositol-3-kinase regulator activity,	IPR000980:SH2 domain,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa01522:Endocrine resistance,hsa01524:Platinum drug resistance,hsa04012:ErbB signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04024:cAMP signaling pathway,hsa04062:Chemokine signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04068:FoxO signaling pathway,hsa04070:Phosphatidylinositol signaling system,hsa04071:Sphingolipid signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04140:Autophagy - animal,hsa04150:mTOR signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04152:AMPK signaling pathway,hsa04210:Apoptosis,hsa04211:Longevity regulating pathway,hsa04213:Longevity regulating pathway - multiple species,hsa04218:Cellular senescence,hsa04360:Axon guidance,hsa04370:VEGF signaling pathway,hsa04380:Osteoclast differentiation,hsa04510:Focal adhesion,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04611:Platelet activation,hsa04613:Neutrophil extracellular trap formation,hsa04620:Toll-like receptor signaling pathway,hsa04625:C-type lectin receptor signaling pathway,hsa04630:JAK-STAT signaling pathway,hsa04650:Natural killer cell mediated cytotoxicity,hsa04660:T cell receptor signaling pathway,hsa04662:B cell receptor signaling pathway,hsa04664:Fc epsilon RI signaling pathway,hsa04666:Fc gamma R-mediated phagocytosis,hsa04668:TNF signaling pathway,hsa04670:Leukocyte transendothelial migration,hsa04722:Neurotrophin signaling pathway,hsa04725:Cholinergic synapse,hsa04750:Inflammatory mediator regulation of TRP channels,hsa04810:Regulation of actin cytoskeleton,hsa04910:Insulin signaling pathway,hsa04914:Progesterone-mediated oocyte maturation,hsa04915:Estrogen signaling pathway,hsa04917:Prolactin signaling pathway,hsa04919:Thyroid hormone signaling pathway,hsa04923:Regulation of lipolysis in adipocytes,hsa04926:Relaxin signaling pathway,hsa04929:GnRH secretion,hsa04930:Type II diabetes mellitus,hsa04931:Insulin resistance,hsa04932:Non-alcoholic fatty liver disease,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04935:Growth hormone synthesis, secretion and action,hsa04960:Aldosterone-regulated sodium reabsorption,hsa04973:Carbohydrate digestion and absorption,hsa05010:Alzheimer disease,hsa05017:Spinocerebellar ataxia,hsa05020:Prion disease,hsa05100:Bacterial invasion of epithelial cells,hsa05131:Shigellosis,hsa05135:Yersinia infection,hsa05142:Chagas disease,hsa05146:Amoebiasis,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05210:Colorectal cancer,hsa05211:Renal cell carcinoma,hsa05212:Pancreatic cancer,hsa05213:Endometrial cancer,hsa05214:Glioma,hsa05215:Prostate cancer,hsa05218:Melanoma,hsa05220:Chronic myeloid leukemia,hsa05221:Acute myeloid leukemia,hsa05222:Small cell lung cancer,hsa05223:Non-small cell lung cancer,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,hsa05230:Central carbon metabolism in cancer,hsa05231:Choline metabolism in cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05415:Diabetic cardiomyopathy,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,			SM00252:SH2,				KW-0175~Coiled coil,KW-0677~Repeat,KW-0727~SH2 domain,		KW-0418~Kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	DOMAIN:SH2,DOMAIN:SH2 1,DOMAIN:SH2 2,REGION:Disordered,
PIK3R4	phosphoinositide-3-kinase regulatory subunit 4(PIK3R4)	Homo sapiens				GO:0006468~protein phosphorylation,GO:0006623~protein targeting to vacuole,GO:0006661~phosphatidylinositol biosynthetic process,GO:0010506~regulation of autophagy,GO:0016236~macroautophagy,GO:0016241~regulation of macroautophagy,GO:0030242~pexophagy,GO:0032465~regulation of cytokinesis,GO:0032801~receptor catabolic process,GO:0034162~toll-like receptor 9 signaling pathway,GO:0036092~phosphatidylinositol-3-phosphate biosynthetic process,GO:0042149~cellular response to glucose starvation,GO:0043552~positive regulation of phosphatidylinositol 3-kinase activity,GO:0045022~early endosome to late endosome transport,GO:0045324~late endosome to vacuole transport,GO:0097352~autophagosome maturation,	GO:0005768~endosome,GO:0005770~late endosome,GO:0005776~autophagosome,GO:0005829~cytosol,GO:0005930~axoneme,GO:0015630~microtubule cytoskeleton,GO:0016020~membrane,GO:0030670~phagocytic vesicle membrane,GO:0034271~phosphatidylinositol 3-kinase complex, class III, type I,GO:0034272~phosphatidylinositol 3-kinase complex, class III, type II,GO:0035032~phosphatidylinositol 3-kinase complex, class III,GO:0043231~intracellular membrane-bounded organelle,GO:0071561~nucleus-vacuole junction,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,	IPR000719:Protein kinase, catalytic domain,IPR001680:WD40 repeat,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR011989:Armadillo-like helical,IPR015943:WD40/YVTN repeat-like-containing domain,IPR016024:Armadillo-type fold,IPR017986:WD40-repeat-containing domain,IPR019775:WD40 repeat, conserved site,IPR021133:HEAT, type 2,	hsa04136:Autophagy - other,hsa04140:Autophagy - animal,hsa04371:Apelin signaling pathway,hsa05010:Alzheimer disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05017:Spinocerebellar ataxia,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05131:Shigellosis,			SM00220:S_TKc,SM00320:WD40,		KW-0472~Membrane,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0853~WD repeat,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0449~Lipoprotein,KW-0519~Myristate,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:ATP,DOMAIN:Protein kinase,LIPID:N-myristoyl glycine,NP_BIND:ATP,REGION:Disordered,REPEAT:HEAT,REPEAT:HEAT 1,REPEAT:HEAT 2,REPEAT:HEAT 3,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
PLA2G4A	phospholipase A2 group IVA(PLA2G4A)	Homo sapiens		h_eicosanoidPathway:Eicosanoid Metabolism,h_fcer1Pathway:Fc Epsilon Receptor I Signaling in Mast Cells,h_p38mapkPathway:p38 MAPK Signaling Pathway ,h_sppaPathway:Aspirin Blocks Signaling Pathway Involved in Platelet Activation,		GO:0001516~prostaglandin biosynthetic process,GO:0002827~positive regulation of T-helper 1 type immune response,GO:0006071~glycerol metabolic process,GO:0006640~monoacylglycerol biosynthetic process,GO:0006644~phospholipid metabolic process,GO:0006654~phosphatidic acid biosynthetic process,GO:0006663~platelet activating factor biosynthetic process,GO:0006690~icosanoid metabolic process,GO:0009395~phospholipid catabolic process,GO:0010572~positive regulation of platelet activation,GO:0019369~arachidonic acid metabolic process,GO:0019370~leukotriene biosynthetic process,GO:0032308~positive regulation of prostaglandin secretion,GO:0034478~phosphatidylglycerol catabolic process,GO:0034638~phosphatidylcholine catabolic process,GO:0035965~cardiolipin acyl-chain remodeling,GO:0036148~phosphatidylglycerol acyl-chain remodeling,GO:0036149~phosphatidylinositol acyl-chain remodeling,GO:0036150~phosphatidylserine acyl-chain remodeling,GO:0036151~phosphatidylcholine acyl-chain remodeling,GO:0036152~phosphatidylethanolamine acyl-chain remodeling,GO:0042127~regulation of cell proliferation,GO:0043032~positive regulation of macrophage activation,GO:0046475~glycerophospholipid catabolic process,GO:0050482~arachidonic acid secretion,GO:0071236~cellular response to antibiotic,	GO:0000139~Golgi membrane,GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005737~cytoplasm,GO:0005743~mitochondrial inner membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0043231~intracellular membrane-bounded organelle,	GO:0004622~lysophospholipase activity,GO:0004623~phospholipase A2 activity,GO:0005509~calcium ion binding,GO:0005544~calcium-dependent phospholipid binding,GO:0008374~O-acyltransferase activity,GO:0010314~phosphatidylinositol-5-phosphate binding,GO:0032266~phosphatidylinositol-3-phosphate binding,GO:0047498~calcium-dependent phospholipase A2 activity,GO:0047499~calcium-independent phospholipase A2 activity,GO:0070273~phosphatidylinositol-4-phosphate binding,GO:1902387~ceramide 1-phosphate binding,	IPR000008:C2 calcium-dependent membrane targeting,IPR002642:Lysophospholipase, catalytic domain,IPR016035:Acyl transferase/acyl hydrolase/lysophospholipase,	hsa00564:Glycerophospholipid metabolism,hsa00565:Ether lipid metabolism,hsa00590:Arachidonic acid metabolism,hsa00591:Linoleic acid metabolism,hsa00592:alpha-Linolenic acid metabolism,hsa01100:Metabolic pathways,hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04217:Necroptosis,hsa04270:Vascular smooth muscle contraction,hsa04370:VEGF signaling pathway,hsa04611:Platelet activation,hsa04664:Fc epsilon RI signaling pathway,hsa04666:Fc gamma R-mediated phagocytosis,hsa04724:Glutamatergic synapse,hsa04726:Serotonergic synapse,hsa04730:Long-term depression,hsa04750:Inflammatory mediator regulation of TRP channels,hsa04912:GnRH signaling pathway,hsa04913:Ovarian steroidogenesis,hsa04921:Oxytocin signaling pathway,hsa05231:Choline metabolism in cancer,	618372~Gastrointestinal ulceration, recurrent, with dysfunctional platelets,		SM00022:PLAc,SM00239:C2,	KW-0275~Fatty acid biosynthesis,KW-0276~Fatty acid metabolism,KW-0319~Glycerol metabolism,KW-0434~Leukotriene biosynthesis,KW-0442~Lipid degradation,KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,KW-0595~Phospholipid degradation,KW-0643~Prostaglandin biosynthesis,KW-0644~Prostaglandin metabolism,KW-1208~Phospholipid metabolism,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,		KW-0106~Calcium,KW-0446~Lipid-binding,KW-0479~Metal-binding,	KW-0378~Hydrolase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Nucleophile,ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:C2,DOMAIN:PLA2c,METAL:Calcium 1,METAL:Calcium 1; via carbonyl oxygen,METAL:Calcium 2,METAL:Calcium 2; via carbonyl oxygen,MUTAGEN:C->A: No effect on phospholipase activity.,MUTAGEN:C->A: No effect on phospholipase activity; when associated with A-139 and A-141.,MUTAGEN:C->A: No effect on phospholipase activity; when associated with A-139 and A-151.,MUTAGEN:C->A: No effect on phospholipase activity; when associated with A-141 and A-151.,MUTAGEN:C->A: No effect on phospholipase activity; when associated with A-324.,MUTAGEN:C->A: No effect on phospholipase activity; when associated with A-331.,MUTAGEN:C->A: No effect on phospholipase activity; when associated with A-620.,MUTAGEN:C->A: No effect on phospholipase activity; when associated with A-634.,MUTAGEN:D->A: Abolishes phospholipiase activity.,MUTAGEN:D->E: Reduces phospholipase activity 2000-fold.,MUTAGEN:D->N: Impairs phospholipase A2 and lysophospholipase activities in the absence of phosphoinositides. Has full activity in the presence of phosphoinositides.,MUTAGEN:D->N: Reduces phospholipase activity 300-fold.,MUTAGEN:K->A: Impairs phosphoinositide-stimulated phospholipase A2 activity.; when associated with A-541 and A-543.,MUTAGEN:K->A: Impairs phosphoinositide-stimulated phospholipase A2 activity.; when associated with A-541 and A-544.,MUTAGEN:K->A: Impairs phosphoinositide-stimulated phospholipase A2 activity; when associated with A-543 and A-544.,MUTAGEN:K->E: Impairs phosphoinositide-stimulated phospholipase A2 activity.,MUTAGEN:R->A,H: Abolishes phospholipase activity.,MUTAGEN:R->K: Reduces phospholipase activity 200-fold.,MUTAGEN:RKR->AAA: Impairs binding to ceramide-1-phosphate.,MUTAGEN:S->A,C,T: Abolishes both phospholipase and lysophospholipase activities.,MUTAGEN:S->A: 5-fold reduced phospholipase and lysophospholipase activities. 100-fold reduced phospholipase and lysophospholipase activities; when associated with A-577.,MUTAGEN:S->A: 7-fold reduced phospholipase and lysophospholipase activities. 100-fold reduced phospholipase and lysophospholipase activities; when associated with A-195.,MUTAGEN:S->A: Decreases agonist-stimulated release of arachidonic acid. Reduces phospholipase A2 activity; when associated with A-437; A-454 and A-727.,MUTAGEN:S->A: No effect on phospholipase or lysophospholipase activity.,MUTAGEN:S->A: Reduces phospholipase A2 activity; when associated with A-437; A-455 and A-505.,MUTAGEN:S->A: Reduces phospholipase A2 activity; when associated with A-437; A-505 and A-727.,MUTAGEN:S->A: Reduces phospholipase A2 activity; when associated with A-454; A-505 and A-727.,REGION:Disordered,REGION:Phospholipid binding,
PLA2G15	phospholipase A2 group XV(PLA2G15)	Homo sapiens				GO:0006629~lipid metabolic process,GO:0006644~phospholipid metabolic process,GO:0006650~glycerophospholipid metabolic process,GO:0006651~diacylglycerol biosynthetic process,GO:0006658~phosphatidylserine metabolic process,GO:0006672~ceramide metabolic process,GO:0009062~fatty acid catabolic process,GO:0034638~phosphatidylcholine catabolic process,GO:0046338~phosphatidylethanolamine catabolic process,GO:0046470~phosphatidylcholine metabolic process,GO:0046471~phosphatidylglycerol metabolic process,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005654~nucleoplasm,GO:0005764~lysosome,GO:0016020~membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,	GO:0004622~lysophospholipase activity,GO:0004806~triglyceride lipase activity,GO:0005543~phospholipid binding,GO:0008270~zinc ion binding,GO:0008374~O-acyltransferase activity,GO:0008970~phosphatidylcholine 1-acylhydrolase activity,GO:0016411~acylglycerol O-acyltransferase activity,GO:0047499~calcium-independent phospholipase A2 activity,GO:0052739~phosphatidylserine 1-acylhydrolase activity,GO:0052740~1-acyl-2-lysophosphatidylserine acylhydrolase activity,	IPR003386:Lecithin:cholesterol/phospholipid:diacylglycerol acyltransferase,	hsa00564:Glycerophospholipid metabolism,hsa04142:Lysosome,				KW-0276~Fatty acid metabolism,KW-0442~Lipid degradation,KW-0443~Lipid metabolism,	KW-0458~Lysosome,KW-0472~Membrane,KW-0964~Secreted,		KW-0732~Signal,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0012~Acyltransferase,KW-0378~Hydrolase,KW-0808~Transferase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	ACT_SITE:Acyl-ester intermediate,ACT_SITE:Charge relay system,BINDING:Substrate; via amide nitrogen,CARBOHYD:N-linked (GlcNAc...) asparagine,METAL:Zinc,MUTAGEN:D->A,C: Decreases membrane binding, phospholipase and transacylase activity at acidic pH.,MUTAGEN:D->F: Has no effect on membrane binding or transacylase activity at acidic pH. Increases membrane binding and transacylase activity at neutral pH by 2-fold and 8-fold, respectively.,MUTAGEN:K->A: No effect on phospholipase activity. Abolishes transacylase activity. Has no effect on association with membranes.,MUTAGEN:L->S: No effect on phospholipase activity. Strongly decreases transacylase activity and association with membranes.,MUTAGEN:N->A: Loss of glycosylation site. Leads to retention in the endoplasmic reticulum and nearly abolishes the production of the mature, active enzyme.,MUTAGEN:N->A: Loss of glycosylation site. Mildly reduces production of the mature, active enzyme.,MUTAGEN:N->A: Loss of glycosylation site. Slightly reduces production of the mature, active enzyme.,MUTAGEN:S->A: Abolishes phospholipase and transacylase activity. Abolishes association with membranes.,MUTAGEN:T->A: No effect on phospholipase activity. Strongly decreases transacylase activity and abolishes association with membranes.,MUTAGEN:V->S: No effect on phospholipase activity. Strongly decreases transacylase activity and association with membranes.,REGION:Disordered,
PLCB3	phospholipase C beta 3(PLCB3)	Homo sapiens				GO:0003073~regulation of systemic arterial blood pressure,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007223~Wnt signaling pathway, calcium modulating pathway,GO:0016042~lipid catabolic process,GO:0043647~inositol phosphate metabolic process,GO:0046488~phosphatidylinositol metabolic process,GO:0048015~phosphatidylinositol-mediated signaling,	GO:0005634~nucleus,GO:0005829~cytosol,GO:0016020~membrane,GO:0032991~macromolecular complex,GO:0099524~postsynaptic cytosol,	GO:0004435~phosphatidylinositol phospholipase C activity,GO:0004629~phospholipase C activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0045296~cadherin binding,	IPR000008:C2 calcium-dependent membrane targeting,IPR000909:Phospholipase C, phosphatidylinositol-specific , X domain,IPR001192:Phosphoinositide phospholipase C,IPR001711:Phospholipase C, phosphatidylinositol-specific, Y domain,IPR011992:EF-hand-like domain,IPR014815:PLC-beta, C-terminal,IPR015359:Phospholipase C, phosphoinositol-specific, EF-hand-like,IPR016280:Phosphatidylinositol-4, 5-bisphosphate phosphodiesterase beta,IPR017946:PLC-like phosphodiesterase, TIM beta/alpha-barrel domain,	hsa00562:Inositol phosphate metabolism,hsa01100:Metabolic pathways,hsa04015:Rap1 signaling pathway,hsa04020:Calcium signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04062:Chemokine signaling pathway,hsa04070:Phosphatidylinositol signaling system,hsa04071:Sphingolipid signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04270:Vascular smooth muscle contraction,hsa04310:Wnt signaling pathway,hsa04371:Apelin signaling pathway,hsa04540:Gap junction,hsa04611:Platelet activation,hsa04613:Neutrophil extracellular trap formation,hsa04621:NOD-like receptor signaling pathway,hsa04713:Circadian entrainment,hsa04720:Long-term potentiation,hsa04723:Retrograde endocannabinoid signaling,hsa04724:Glutamatergic synapse,hsa04725:Cholinergic synapse,hsa04726:Serotonergic synapse,hsa04728:Dopaminergic synapse,hsa04730:Long-term depression,hsa04742:Taste transduction,hsa04750:Inflammatory mediator regulation of TRP channels,hsa04911:Insulin secretion,hsa04912:GnRH signaling pathway,hsa04915:Estrogen signaling pathway,hsa04916:Melanogenesis,hsa04918:Thyroid hormone synthesis,hsa04919:Thyroid hormone signaling pathway,hsa04921:Oxytocin signaling pathway,hsa04922:Glucagon signaling pathway,hsa04924:Renin secretion,hsa04925:Aldosterone synthesis and secretion,hsa04926:Relaxin signaling pathway,hsa04927:Cortisol synthesis and secretion,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04929:GnRH secretion,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04934:Cushing syndrome,hsa04935:Growth hormone synthesis, secretion and action,hsa04961:Endocrine and other factor-regulated calcium reabsorption,hsa04970:Salivary secretion,hsa04971:Gastric acid secretion,hsa04972:Pancreatic secretion,hsa04973:Carbohydrate digestion and absorption,hsa05010:Alzheimer disease,hsa05016:Huntington disease,hsa05017:Spinocerebellar ataxia,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05131:Shigellosis,hsa05142:Chagas disease,hsa05143:African trypanosomiasis,hsa05146:Amoebiasis,hsa05163:Human cytomegalovirus infection,hsa05200:Pathways in cancer,hsa05415:Diabetic cardiomyopathy,hsa05417:Lipid and atherosclerosis,	618961~Spondylometaphyseal dysplasia with corneal dystrophy,	PIRSF000956:1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase beta,	SM00148:PLCXc,SM00149:PLCYc,SM00239:C2,	KW-0442~Lipid degradation,KW-0443~Lipid metabolism,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0242~Dwarfism,		KW-0106~Calcium,	KW-0378~Hydrolase,KW-0807~Transducer,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:C2,DOMAIN:PI-PLC X-box,DOMAIN:PI-PLC Y-box,REGION:Disordered,REGION:Interaction with SHANK2,
PLSCR1	phospholipid scramblase 1(PLSCR1)	Homo sapiens				GO:0006659~phosphatidylserine biosynthetic process,GO:0006915~apoptotic process,GO:0006953~acute-phase response,GO:0010288~response to lead ion,GO:0010628~positive regulation of gene expression,GO:0017121~phospholipid scrambling,GO:0030168~platelet activation,GO:0033003~regulation of mast cell activation,GO:0035456~response to interferon-beta,GO:0045071~negative regulation of viral genome replication,GO:0045089~positive regulation of innate immune response,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046718~viral entry into host cell,GO:0050765~negative regulation of phagocytosis,GO:0051607~defense response to virus,GO:0060368~regulation of Fc receptor mediated stimulatory signaling pathway,GO:0070782~phosphatidylserine exposure on apoptotic cell surface,GO:0090305~nucleic acid phosphodiester bond hydrolysis,GO:1905820~positive regulation of chromosome separation,GO:2000373~positive regulation of DNA topoisomerase (ATP-hydrolyzing) activity,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016020~membrane,GO:0045121~membrane raft,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0000287~magnesium ion binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0001618~virus receptor activity,GO:0003677~DNA binding,GO:0004518~nuclease activity,GO:0005154~epidermal growth factor receptor binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0017124~SH3 domain binding,GO:0017128~phospholipid scramblase activity,GO:0019899~enzyme binding,GO:0032791~lead ion binding,GO:0042609~CD4 receptor binding,GO:0045340~mercury ion binding,	IPR005552:Scramblase,					KW-0051~Antiviral defense,KW-0445~Lipid transport,KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0729~SH3-binding,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0460~Magnesium,	KW-0238~DNA-binding,KW-0378~Hydrolase,KW-0540~Nuclease,KW-0675~Receptor,KW-1183~Host cell receptor for virus entry,	KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,	COMPBIAS:Pro residues,LIPID:S-palmitoyl cysteine,MOTIF:Nuclear localization signal,MOTIF:PPXY motif 1,MOTIF:PPXY motif 2,MOTIF:SH3-binding 1,MOTIF:SH3-binding 2,MOTIF:SH3-binding 3,MUTAGEN:CCCPCC->AAAPAA: No palmitoylation; constitutively localizes in the nucleus.,MUTAGEN:D->A: Complete inactivation of the Ca(2+)-dependent phospholipid scrambling. No effect on its nuclease activity.,MUTAGEN:D->A: Reduces the Ca(2+)-dependent phospholipid scrambling.,MUTAGEN:F->A: Complete inactivation of the Ca(2+)-dependent phospholipid scrambling.,MUTAGEN:F->A: Reduces the Ca(2+)-dependent phospholipid scrambling.,MUTAGEN:H->A: 60% reduction in nuclease activity; when associated with A-12; A-111; A-211 and A-262.,MUTAGEN:H->A: 60% reduction in nuclease activity; when associated with A-12; A-53; A-111 and A-211.,MUTAGEN:H->A: 60% reduction in nuclease activity; when associated with A-12; A-53; A-111 and A-262.,MUTAGEN:H->A: 60% reduction in nuclease activity; when associated with A-12; A-53; A-211 and A-262.,MUTAGEN:H->A: 60% reduction in nuclease activity; when associated with A-53; A-111; A-211 and A-262.,MUTAGEN:I->A: Reduces the Ca(2+)-dependent phospholipid scrambling.,MUTAGEN:T->A: No induction by PKC/PRKCD.,MUTAGEN:Y->F: Decrease in phosphorylation.,REGION:Disordered,REGION:Interaction with hepatitis C virus E2 glycoprotein,REGION:Proline-rich domain (PRD),TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
PLSCR3	phospholipid scramblase 3(PLSCR3)	Homo sapiens				GO:0006915~apoptotic process,GO:0017121~phospholipid scrambling,GO:0032049~cardiolipin biosynthetic process,GO:0042593~glucose homeostasis,GO:0042632~cholesterol homeostasis,GO:0042981~regulation of apoptotic process,GO:0071222~cellular response to lipopolysaccharide,GO:0090199~regulation of release of cytochrome c from mitochondria,	GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,	GO:0000287~magnesium ion binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0017124~SH3 domain binding,GO:0017128~phospholipid scramblase activity,GO:0032791~lead ion binding,GO:0043621~protein self-association,GO:0045340~mercury ion binding,GO:0048306~calcium-dependent protein binding,	IPR005552:Scramblase,					KW-0053~Apoptosis,KW-0445~Lipid transport,KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0999~Mitochondrion inner membrane,		KW-0677~Repeat,KW-0729~SH3-binding,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,		KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,	COMPBIAS:Pro residues,LIPID:S-palmitoyl cysteine,MOTIF:PPxY motif,MOTIF:SH3-binding 1,MOTIF:SH3-binding 2,MOTIF:SH3-binding 3,MUTAGEN:F->A: Abolishes interaction with PDCD6; when associated with A-49.,MUTAGEN:F->A: Reduces interaction with PDCD6. Abolishes interaction with PDCD6; when associated with A-52.,MUTAGEN:F->V: Reduced phospholipid scramblase activity. Reduced calcium and magnesium-binding. Diminished apoptotic responsiveness. Defective mitochondrial structure and oxidative function. Reduced binding affinity for Pb(2+) and Hg(2+) ions. Increased cardiolipin biosynthesis from glycerol and decreased cardiolipin resynthesis from linoleic acid.,MUTAGEN:F->W: No effect on the interaction with PDCD6.,MUTAGEN:F->Y,L: Reduces interaction with PDCD6.,MUTAGEN:T->A: Fails to enhance apoptosis mediated by PRKCD activators.,MUTAGEN:T->D: Promotes apoptosis, more potent in lipid flippase activity.,REGION:Disordered,REGION:Proline-rich domain (PRD),TOPO_DOM:Mitochondrial intermembrane,TRANSMEM:Helical,
PMM2	phosphomannomutase 2(PMM2)	Homo sapiens			General function prediction only,	GO:0006013~mannose metabolic process,GO:0006486~protein glycosylation,GO:0006487~protein N-linked glycosylation,GO:0009298~GDP-mannose biosynthetic process,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0043025~neuronal cell body,	GO:0004615~phosphomannomutase activity,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR005002:Eukaryotic phosphomannomutase,IPR006379:HAD-superfamily hydrolase, subfamily IIB,IPR023214:HAD-like domain,	hsa00051:Fructose and mannose metabolism,hsa00520:Amino sugar and nucleotide sugar metabolism,hsa01100:Metabolic pathways,hsa01240:Biosynthesis of cofactors,hsa01250:Biosynthesis of nucleotide sugars,	212065~Congenital disorder of glycosylation, type Ia,				KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0900~Congenital disorder of glycosylation,		KW-0460~Magnesium,KW-0479~Metal-binding,	KW-0413~Isomerase,	KW-0007~Acetylation,	ACT_SITE:Nucleophile,ACT_SITE:Proton donor/acceptor,BINDING:Alpha-D-mannose 1-phosphate,METAL:Magnesium 1,METAL:Magnesium 1; via carbonyl oxygen,METAL:Magnesium 2; via carbonyl oxygen,REGION:Disordered,
PAICS	phosphoribosylaminoimidazole carboxylase and phosphoribosylaminoimidazolesuccinocarboxamide synthase(PAICS)	Homo sapiens				GO:0006177~GMP biosynthetic process,GO:0006189~'de novo' IMP biosynthetic process,GO:0009113~purine nucleobase biosynthetic process,GO:0009168~purine ribonucleoside monophosphate biosynthetic process,GO:0044208~'de novo' AMP biosynthetic process,GO:0097294~'de novo' XMP biosynthetic process,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0070062~extracellular exosome,	GO:0004638~phosphoribosylaminoimidazole carboxylase activity,GO:0004639~phosphoribosylaminoimidazolesuccinocarboxamide synthase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0042802~identical protein binding,GO:0043727~5-amino-4-imidazole carboxylate lyase activity,GO:0045296~cadherin binding,	IPR000031:N5-carboxyaminoimidazole ribonucleotide mutase PurE domain,IPR018236:SAICAR synthetase, conserved site,	hsa00230:Purine metabolism,hsa01100:Metabolic pathways,			SM01001:SM01001,	KW-0658~Purine biosynthesis,				KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0210~Decarboxylase,KW-0436~Ligase,KW-0456~Lyase,KW-0511~Multifunctional enzyme,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:For AIR carboxylase activity,ACT_SITE:For SAICAR synthetase activity,DOMAIN:AIRC,MUTAGEN:G->A: Loss of AIR carboxylase activity.,MUTAGEN:H->Y: Loss of AIR carboxylase activity.,MUTAGEN:S->A: Loss of AIR carboxylase activity.,MUTAGEN:S->A: No change of AIR carboxylase activity.,REGION:AIR carboxylase,REGION:Linker,REGION:SAICAR synthetase,SITE:Essential for AIR carboxylase activity,
PHKG2	phosphorylase kinase catalytic subunit gamma 2(PHKG2)	Homo sapiens				GO:0005977~glycogen metabolic process,GO:0005978~glycogen biosynthetic process,GO:0005980~glycogen catabolic process,GO:0006091~generation of precursor metabolites and energy,GO:0006468~protein phosphorylation,GO:0045819~positive regulation of glycogen catabolic process,	GO:0005829~cytosol,GO:0005964~phosphorylase kinase complex,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004689~phosphorylase kinase activity,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0005524~ATP binding,GO:0019899~enzyme binding,GO:0050321~tau-protein kinase activity,	IPR000719:Protein kinase, catalytic domain,IPR002291:Phosphorylase kinase, gamma catalytic subunit,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,	hsa04020:Calcium signaling pathway,hsa04910:Insulin signaling pathway,hsa04922:Glucagon signaling pathway,	613027~Glycogen storage disease IXc,		SM00220:S_TKc,	KW-0119~Carbohydrate metabolism,KW-0321~Glycogen metabolism,		KW-0225~Disease variant,KW-0322~Glycogen storage disease,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0112~Calmodulin-binding,KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:ATP,DOMAIN:Protein kinase,NP_BIND:ATP,REGION:Calmodulin-binding (domain-C),REGION:Calmodulin-binding (domain-N),
PHKA1	phosphorylase kinase regulatory subunit alpha 1(PHKA1)	Homo sapiens				GO:0005977~glycogen metabolic process,GO:0005980~glycogen catabolic process,GO:0006091~generation of precursor metabolites and energy,GO:0006468~protein phosphorylation,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005964~phosphorylase kinase complex,	GO:0004689~phosphorylase kinase activity,GO:0005516~calmodulin binding,	IPR008734:Phosphorylase kinase alpha/beta subunit,IPR008928:Six-hairpin glycosidase-like,IPR011613:Glycoside hydrolase family 15,IPR012341:Six-hairpin glycosidase,	hsa04020:Calcium signaling pathway,hsa04910:Insulin signaling pathway,hsa04922:Glucagon signaling pathway,	300559~Muscle glycogenosis,			KW-0119~Carbohydrate metabolism,KW-0321~Glycogen metabolism,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0322~Glycogen storage disease,			KW-0112~Calmodulin-binding,KW-0514~Muscle protein,	KW-0449~Lipoprotein,KW-0597~Phosphoprotein,KW-0636~Prenylation,	COMPBIAS:Polar residues,DOMAIN:Glyco_hydro_15,LIPID:S-farnesyl cysteine,REGION:Calmodulin-binding,REGION:Disordered,
PHKB	phosphorylase kinase regulatory subunit beta(PHKB)	Homo sapiens				GO:0005977~glycogen metabolic process,GO:0005980~glycogen catabolic process,GO:0006091~generation of precursor metabolites and energy,GO:0006468~protein phosphorylation,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005964~phosphorylase kinase complex,	GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0016301~kinase activity,	IPR008734:Phosphorylase kinase alpha/beta subunit,IPR008928:Six-hairpin glycosidase-like,IPR011613:Glycoside hydrolase family 15,	hsa04020:Calcium signaling pathway,hsa04910:Insulin signaling pathway,hsa04922:Glucagon signaling pathway,	261750~Phosphorylase kinase deficiency of liver and muscle, autosomal recessive,			KW-0119~Carbohydrate metabolism,KW-0321~Glycogen metabolism,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0322~Glycogen storage disease,	KW-0175~Coiled coil,		KW-0112~Calmodulin-binding,KW-0418~Kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0597~Phosphoprotein,KW-0636~Prenylation,	COMPBIAS:Polar residues,DOMAIN:Glyco_hydro_15,LIPID:S-farnesyl cysteine,REGION:Calmodulin-binding,REGION:Disordered,
PLS1	plastin 1(PLS1)	Homo sapiens			Cytoskeleton,	GO:0001951~intestinal D-glucose absorption,GO:0032532~regulation of microvillus length,GO:0040018~positive regulation of multicellular organism growth,GO:0051017~actin filament bundle assembly,GO:0051639~actin filament network formation,GO:0060088~auditory receptor cell stereocilium organization,GO:0060121~vestibular receptor cell stereocilium organization,GO:1902896~terminal web assembly,GO:1903078~positive regulation of protein localization to plasma membrane,	GO:0005737~cytoplasm,GO:0005884~actin filament,GO:0005903~brush border,GO:0032420~stereocilium,GO:0032432~actin filament bundle,GO:0070062~extracellular exosome,GO:1990357~terminal web,	GO:0005200~structural constituent of cytoskeleton,GO:0005509~calcium ion binding,GO:0051015~actin filament binding,	IPR001589:Actinin-type, actin-binding, conserved site,IPR001715:Calponin homology domain,IPR002048:EF-hand domain,IPR011992:EF-hand-like domain,IPR018247:EF-Hand 1, calcium-binding site,		618787~Deafness, autosomal dominant 76,		SM00033:CH,SM00054:EFh,		KW-0963~Cytoplasm,KW-0966~Cell projection,	KW-0209~Deafness,KW-0225~Disease variant,KW-1010~Non-syndromic deafness,	KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0009~Actin-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	CA_BIND:1,CA_BIND:2,DOMAIN:Calponin-homology (CH),DOMAIN:Calponin-homology (CH) 1,DOMAIN:Calponin-homology (CH) 2,DOMAIN:Calponin-homology (CH) 3,DOMAIN:Calponin-homology (CH) 4,DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,REGION:Actin-binding 1,REGION:Actin-binding 2,
PAFAH1B3	platelet activating factor acetylhydrolase 1b catalytic subunit 3(PAFAH1B3)	Homo sapiens				GO:0006629~lipid metabolic process,GO:0007283~spermatogenesis,GO:0007399~nervous system development,GO:0007420~brain development,GO:0016042~lipid catabolic process,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0008247~1-alkyl-2-acetylglycerophosphocholine esterase complex,GO:0016020~membrane,	GO:0003847~1-alkyl-2-acetylglycerophosphocholine esterase activity,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0044877~macromolecular complex binding,GO:0046982~protein heterodimerization activity,GO:0047179~platelet-activating factor acetyltransferase activity,		hsa00565:Ether lipid metabolism,hsa01100:Metabolic pathways,				KW-0442~Lipid degradation,KW-0443~Lipid metabolism,	KW-0963~Cytoplasm,				KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:SGNH_hydro,REGION:Disordered,
PAFAH1B1	platelet activating factor acetylhydrolase 1b regulatory subunit 1(PAFAH1B1)	Homo sapiens		h_Lis1Pathway:Lissencephaly gene (LIS1) in neuronal migration and development,		GO:0000086~G2/M transition of mitotic cell cycle,GO:0000132~establishment of mitotic spindle orientation,GO:0000226~microtubule cytoskeleton organization,GO:0001667~ameboidal-type cell migration,GO:0001675~acrosome assembly,GO:0001764~neuron migration,GO:0001961~positive regulation of cytokine-mediated signaling pathway,GO:0007017~microtubule-based process,GO:0007049~cell cycle,GO:0007052~mitotic spindle organization,GO:0007097~nuclear migration,GO:0007268~chemical synaptic transmission,GO:0007281~germ cell development,GO:0007399~nervous system development,GO:0007405~neuroblast proliferation,GO:0007611~learning or memory,GO:0008090~retrograde axonal transport,GO:0008344~adult locomotory behavior,GO:0009306~protein secretion,GO:0010389~regulation of G2/M transition of mitotic cell cycle,GO:0010977~negative regulation of neuron projection development,GO:0016042~lipid catabolic process,GO:0017145~stem cell division,GO:0019226~transmission of nerve impulse,GO:0021540~corpus callosum morphogenesis,GO:0021766~hippocampus development,GO:0021819~layer formation in cerebral cortex,GO:0021895~cerebral cortex neuron differentiation,GO:0021987~cerebral cortex development,GO:0030036~actin cytoskeleton organization,GO:0030154~cell differentiation,GO:0031023~microtubule organizing center organization,GO:0036035~osteoclast development,GO:0038026~reelin-mediated signaling pathway,GO:0040019~positive regulation of embryonic development,GO:0042249~establishment of planar polarity of embryonic epithelium,GO:0043087~regulation of GTPase activity,GO:0043622~cortical microtubule organization,GO:0045773~positive regulation of axon extension,GO:0045931~positive regulation of mitotic cell cycle,GO:0046329~negative regulation of JNK cascade,GO:0046469~platelet activating factor metabolic process,GO:0047496~vesicle transport along microtubule,GO:0048854~brain morphogenesis,GO:0050885~neuromuscular process controlling balance,GO:0051012~microtubule sliding,GO:0051081~nuclear envelope disassembly,GO:0051301~cell division,GO:0051660~establishment of centrosome localization,GO:0051661~maintenance of centrosome location,GO:0060117~auditory receptor cell development,GO:0061003~positive regulation of dendritic spine morphogenesis,GO:0070507~regulation of microtubule cytoskeleton organization,GO:0090102~cochlea development,GO:0090176~microtubule cytoskeleton organization involved in establishment of planar polarity,GO:0097711~ciliary basal body docking,GO:2000574~regulation of microtubule motor activity,	GO:0000235~astral microtubule,GO:0000776~kinetochore,GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005815~microtubule organizing center,GO:0005819~spindle,GO:0005829~cytosol,GO:0005871~kinesin complex,GO:0005874~microtubule,GO:0005875~microtubule associated complex,GO:0005881~cytoplasmic microtubule,GO:0005938~cell cortex,GO:0008247~1-alkyl-2-acetylglycerophosphocholine esterase complex,GO:0031252~cell leading edge,GO:0031514~motile cilium,GO:0031965~nuclear membrane,GO:0032420~stereocilium,GO:0043005~neuron projection,GO:0043025~neuronal cell body,GO:0045202~synapse,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:0090724~central region of growth cone,GO:1904115~axon cytoplasm,	GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0008201~heparin binding,GO:0034452~dynactin binding,GO:0042802~identical protein binding,GO:0043274~phospholipase binding,GO:0045505~dynein intermediate chain binding,GO:0046982~protein heterodimerization activity,GO:0051010~microtubule plus-end binding,GO:0051219~phosphoprotein binding,GO:0070840~dynein complex binding,	IPR001680:WD40 repeat,IPR006594:LisH dimerisation motif,IPR015943:WD40/YVTN repeat-like-containing domain,IPR017252:Dynein regulator LIS1,IPR017986:WD40-repeat-containing domain,IPR019775:WD40 repeat, conserved site,IPR020472:G-protein beta WD-40 repeat,	hsa00565:Ether lipid metabolism,hsa01100:Metabolic pathways,	607432~Lissencephaly 1,607432~Subcortical laminar heterotopia,	PIRSF037647:dynein regulator, Lis1 type,	SM00320:WD40,SM00667:LisH,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0221~Differentiation,KW-0442~Lipid degradation,KW-0443~Lipid metabolism,KW-0498~Mitosis,KW-0524~Neurogenesis,KW-0813~Transport,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0493~Microtubule,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0451~Lissencephaly,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0853~WD repeat,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:LisH,REGION:Disordered,REGION:Interaction with DCX,REGION:Interaction with NDE1,REGION:Interaction with NDEL1,REGION:Interaction with dynein and dynactin,REGION:Required for self-association and interaction with PAFAH1B2 and PAFAH1B3,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
PDGFA	platelet derived growth factor subunit A(PDGFA)	Homo sapiens	18.Cytokine_astocytes,88.Alternatively_Activated_APC,	h_edg1Pathway:Phospholipids as signalling intermediaries,h_inflamPathway:Cytokines and Inflammatory Response,h_pdgfPathway:PDGF Signaling Pathway,h_PparaPathway:Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha),		GO:0000165~MAPK cascade,GO:0001525~angiogenesis,GO:0001666~response to hypoxia,GO:0001775~cell activation,GO:0001942~hair follicle development,GO:0002053~positive regulation of mesenchymal cell proliferation,GO:0002576~platelet degranulation,GO:0007267~cell-cell signaling,GO:0008284~positive regulation of cell proliferation,GO:0008584~male gonad development,GO:0009410~response to xenobiotic stimulus,GO:0009611~response to wounding,GO:0009887~animal organ morphogenesis,GO:0010035~response to inorganic substance,GO:0010512~negative regulation of phosphatidylinositol biosynthetic process,GO:0010544~negative regulation of platelet activation,GO:0014068~positive regulation of phosphatidylinositol 3-kinase signaling,GO:0014910~regulation of smooth muscle cell migration,GO:0030031~cell projection assembly,GO:0030036~actin cytoskeleton organization,GO:0030198~extracellular matrix organization,GO:0030335~positive regulation of cell migration,GO:0031954~positive regulation of protein autophosphorylation,GO:0032355~response to estradiol,GO:0032526~response to retinoic acid,GO:0032956~regulation of actin cytoskeleton organization,GO:0035793~positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathway,GO:0042060~wound healing,GO:0043406~positive regulation of MAP kinase activity,GO:0043410~positive regulation of MAPK cascade,GO:0043588~skin development,GO:0048008~platelet-derived growth factor receptor signaling pathway,GO:0048146~positive regulation of fibroblast proliferation,GO:0048286~lung alveolus development,GO:0048839~inner ear development,GO:0050730~regulation of peptidyl-tyrosine phosphorylation,GO:0050919~negative chemotaxis,GO:0051781~positive regulation of cell division,GO:0051897~positive regulation of protein kinase B signaling,GO:0060683~regulation of branching involved in salivary gland morphogenesis by epithelial-mesenchymal signaling,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071560~cellular response to transforming growth factor beta stimulus,GO:1990401~embryonic lung development,	GO:0000139~Golgi membrane,GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0005796~Golgi lumen,GO:0005902~microvillus,GO:0009986~cell surface,GO:0016020~membrane,GO:0031093~platelet alpha granule lumen,GO:1990265~platelet-derived growth factor complex,	GO:0005161~platelet-derived growth factor receptor binding,GO:0005515~protein binding,GO:0005518~collagen binding,GO:0008083~growth factor activity,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0046982~protein heterodimerization activity,GO:0048407~platelet-derived growth factor binding,GO:0070851~growth factor receptor binding,	IPR000072:Platelet-derived growth factor (PDGF),IPR006782:Platelet-derived growth factor, N-terminal,IPR023581:Platelet-derived growth factor, conserved site,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04020:Calcium signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04540:Gap junction,hsa04630:JAK-STAT signaling pathway,hsa04810:Regulation of actin cytoskeleton,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05206:MicroRNAs in cancer,hsa05214:Glioma,hsa05215:Prostate cancer,hsa05218:Melanoma,hsa05231:Choline metabolism in cancer,hsa05418:Fluid shear stress and atherosclerosis,			SM00141:PDGF,		KW-0964~Secreted,		KW-0732~Signal,		KW-0217~Developmental protein,KW-0339~Growth factor,KW-0497~Mitogen,KW-9996~Developmental protein,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain,DOMAIN:PDGF_2,DOMAIN:PDGF_N,PROPEP:Removed in mature form,REGION:Disordered,REGION:Receptor binding site,
PLEKHM1	pleckstrin homology and RUN domain containing M1(PLEKHM1)	Homo sapiens				GO:0015031~protein transport,GO:0032418~lysosome localization,GO:0035556~intracellular signal transduction,GO:0045780~positive regulation of bone resorption,GO:1900029~positive regulation of ruffle assembly,GO:1902774~late endosome to lysosome transport,	GO:0005730~nucleolus,GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0010008~endosome membrane,GO:0031902~late endosome membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0044754~autolysosome,	GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR001849:Pleckstrin homology domain,IPR002219:Protein kinase C-like, phorbol ester/diacylglycerol binding,IPR004012:RUN,IPR011993:Pleckstrin homology-like domain,IPR025258:Domain of unknown function DUF4206,	hsa05132:Salmonella infection,	611497~Osteopetrosis, autosomal recessive 6,618107~Osteopetrosis, autosomal dominant 3,		SM00109:C1,SM00233:PH,SM00593:RUN,SM01175:SM01175,	KW-0072~Autophagy,KW-0653~Protein transport,KW-0813~Transport,	KW-0458~Lysosome,KW-0472~Membrane,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,	KW-0225~Disease variant,KW-0987~Osteopetrosis,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:PH 1,DOMAIN:PH 2,DOMAIN:Phorbol-ester/DAG-type,DOMAIN:RUN,MOTIF:LIR,MUTAGEN:C->G: Disrupts interaction with Rab7 and no localization to endososmal membranes; when associated with G-1021, L-1029 and G-1032.,MUTAGEN:C->G: Disrupts interaction with Rab7 and no localization to endososmal membranes; when associated with G-1024, L-1029 and G-1032.,MUTAGEN:C->G: Disrupts interaction with Rab7and no localization to endososmal membranes; when associated with G-1021, G-1024 and L-1029.,MUTAGEN:E->A: Disrupts interaction with RAB7A.,MUTAGEN:H->A: No effect on interaction with ARL8B. No effect on interaction with RAB7A.,MUTAGEN:H->A: Strongly reduces interaction with ARL8B. No effect on interaction with RAB7A. No effect on late endosome and lysosome clustering. Loss of interaction with ARL8B as well as late endosome and lysosome clustering; when associated with 119-A--A-123.,MUTAGEN:H->L: Disrupts interaction with Rab7 and no localization to endososmal membranes; when associated with G-1021, G-1024 and G-1032.,MUTAGEN:Missing: Disrupts interaction with RAB7A.,MUTAGEN:R->A: Disrupts interaction with RAB7A.,MUTAGEN:RAWLR->AAWLA: Reduces interaction with ARL8B. No effect on interaction with RAB7A. Loss of interaction with ARL8B as well as late endosome and lysosome clustering; when associated with A-60.,REGION:Disordered,REGION:Interaction with RAB7A,ZN_FING:Phorbol-ester/DAG-type,
PLEKHJ1	pleckstrin homology domain containing J1(PLEKHJ1)	Homo sapiens				GO:0001881~receptor recycling,GO:0007032~endosome organization,GO:0042147~retrograde transport, endosome to Golgi,	GO:0005769~early endosome,GO:0005802~trans-Golgi network,GO:0005829~cytosol,GO:0055037~recycling endosome,	GO:0005515~protein binding,	IPR001849:Pleckstrin homology domain,IPR011993:Pleckstrin homology-like domain,				SM00233:PH,								DOMAIN:PH,REGION:Disordered,
PLK1	polo like kinase 1(PLK1)	Homo sapiens	84.Ubiquitination_Pathways_Cell_Cycle,	h_g2Pathway:Cell Cycle: G2/M Checkpoint,		GO:0000070~mitotic sister chromatid segregation,GO:0000086~G2/M transition of mitotic cell cycle,GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000132~establishment of mitotic spindle orientation,GO:0000278~mitotic cell cycle,GO:0000281~mitotic cytokinesis,GO:0001578~microtubule bundle formation,GO:0006468~protein phosphorylation,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0007052~mitotic spindle organization,GO:0007062~sister chromatid cohesion,GO:0007076~mitotic chromosome condensation,GO:0007077~mitotic nuclear envelope disassembly,GO:0007094~mitotic spindle assembly checkpoint,GO:0007095~mitotic G2 DNA damage checkpoint,GO:0007098~centrosome cycle,GO:0007346~regulation of mitotic cell cycle,GO:0010389~regulation of G2/M transition of mitotic cell cycle,GO:0010800~positive regulation of peptidyl-threonine phosphorylation,GO:0016321~female meiosis chromosome segregation,GO:0016567~protein ubiquitination,GO:0018105~peptidyl-serine phosphorylation,GO:0030071~regulation of mitotic metaphase/anaphase transition,GO:0031145~anaphase-promoting complex-dependent catabolic process,GO:0031648~protein destabilization,GO:0032436~positive regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0032465~regulation of cytokinesis,GO:0043066~negative regulation of apoptotic process,GO:0043393~regulation of protein binding,GO:0045143~homologous chromosome segregation,GO:0045184~establishment of protein localization,GO:0045736~negative regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0045862~positive regulation of proteolysis,GO:0051081~nuclear envelope disassembly,GO:0051443~positive regulation of ubiquitin-protein transferase activity,GO:0051726~regulation of cell cycle,GO:0070194~synaptonemal complex disassembly,GO:0071168~protein localization to chromatin,GO:0072425~signal transduction involved in G2 DNA damage checkpoint,GO:0090435~protein localization to nuclear envelope,GO:0097711~ciliary basal body docking,GO:1900182~positive regulation of protein localization to nucleus,GO:1901673~regulation of mitotic spindle assembly,GO:1901990~regulation of mitotic cell cycle phase transition,GO:1902749~regulation of cell cycle G2/M phase transition,GO:1904668~positive regulation of ubiquitin protein ligase activity,GO:1904776~regulation of protein localization to cell cortex,GO:1905784~regulation of anaphase-promoting complex-dependent catabolic process,	GO:0000776~kinetochore,GO:0000785~chromatin,GO:0000795~synaptonemal complex,GO:0000922~spindle pole,GO:0000940~condensed chromosome outer kinetochore,GO:0000942~condensed nuclear chromosome outer kinetochore,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005814~centriole,GO:0005819~spindle,GO:0005829~cytosol,GO:0005876~spindle microtubule,GO:0015630~microtubule cytoskeleton,GO:0030496~midbody,GO:0034451~centriolar satellite,GO:0051233~spindle midzone,GO:0097431~mitotic spindle pole,	GO:0000287~magnesium ion binding,GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008017~microtubule binding,GO:0010997~anaphase-promoting complex binding,GO:0019901~protein kinase binding,GO:0042802~identical protein binding,	IPR000719:Protein kinase, catalytic domain,IPR000959:POLO box duplicated domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,	hsa04068:FoxO signaling pathway,hsa04110:Cell cycle,hsa04114:Oocyte meiosis,hsa04914:Progesterone-mediated oocyte maturation,			SM00220:S_TKc,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0137~Centromere,KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0995~Kinetochore,		KW-0677~Repeat,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Proton acceptor,BINDING:ATP,BINDING:ATP; via carbonyl oxygen,COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:POLO box,DOMAIN:POLO box 1,DOMAIN:POLO box 2,DOMAIN:Protein kinase,MOTIF:D-box that targets the protein for proteasomal degradation in anaphase,MUTAGEN:C->V: In analog-sensitive mutant; enlarged catalytic pocket to accommodate purine analogs; when associated with G-130.,MUTAGEN:D->A: Does not interfere with FRY-binding.,MUTAGEN:D->N: Abolishes kinase activity.,MUTAGEN:H->A: In pincer mutant; loss of centrosomal location and decreased interaction with phosphorylated CDC25C and BUB1; when associated with M-540.,MUTAGEN:K->M: In pincer mutant; loss of centrosomal location and decreased interaction with phosphorylated CDC25C and BUB1; when associated with A-538.,MUTAGEN:K->M: Loss of kinase activity. No effect on S-phase progression.,MUTAGEN:K->R: Loss of kinase activity. No effect on RIOK2-binding.,MUTAGEN:K->R: Severe mitotic defects leading to prometaphase delay. Increased localization at kinetochores leading to increased levels of phosphorylated BUBR1.,MUTAGEN:L->A: Interferes with ubiquitination and subsequent proteasomal degradation in anaphase; when associated with A-337.,MUTAGEN:L->A: No effect on centrosomal localization, nor on S-phase progression; when associated with A-414. Loss of centrosomal localization and of S-phase progression; when associated with A- 414 and A-415.,MUTAGEN:L->G: In analog-sensitive mutant; enlarged catalytic pocket to accommodate purine analogs; when associated with V-67.,MUTAGEN:R->A: Interferes with ubiquitination and subsequent proteasomal degradation in anaphase; when associated with A-340.,MUTAGEN:S->A: No change in activity. Increases activity and restores recovery after DNA damage checkpoint; when associated with D-210.,MUTAGEN:S->D: Increases activity. Results in a block in G1/S.,MUTAGEN:T->A: Abolishes activity. Abolishes checkpoint recovery.,MUTAGEN:T->D: Increases activity and restores recovery after DNA damage checkpoint.,MUTAGEN:T->V: Reduced catalytic activity, but no effect on affinity for ATP.,MUTAGEN:V->A: Loss of centrosomal localization and of S-phase progression; when associated with A- 414 and A-427.,MUTAGEN:W->F: Abolishes interaction with CDC25C and reduces centrosomal localization.,MUTAGEN:W->F: No effect on centrosomal localization, nor on S-phase progression; when asscociated with A-427. Loss of centrosomal localization and of S-phase progression; when associated with A- 415 and A-427.,NP_BIND:ATP,REGION:Activation loop,REGION:Disordered,REGION:Important for interaction with phosphorylated proteins,REGION:Linker,
PAN2	poly(A) specific ribonuclease subunit PAN2(PAN2)	Homo sapiens				GO:0000289~nuclear-transcribed mRNA poly(A) tail shortening,GO:0006397~mRNA processing,GO:0006508~proteolysis,GO:0010606~positive regulation of cytoplasmic mRNA processing body assembly,GO:0090503~RNA phosphodiester bond hydrolysis, exonucleolytic,	GO:0000932~P-body,GO:0005634~nucleus,GO:0005829~cytosol,GO:0031251~PAN complex,	GO:0000175~3'-5'-exoribonuclease activity,GO:0003676~nucleic acid binding,GO:0004535~poly(A)-specific ribonuclease activity,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR012337:Ribonuclease H-like domain,IPR013520:Exonuclease, RNase T/DNA polymerase III,IPR015943:WD40/YVTN repeat-like-containing domain,	hsa03018:RNA degradation,			SM00479:EXOIII,	KW-0507~mRNA processing,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0853~WD repeat,	KW-0479~Metal-binding,	KW-0269~Exonuclease,KW-0378~Hydrolase,KW-0540~Nuclease,	KW-0597~Phosphoprotein,	DOMAIN:Exonuclease,DOMAIN:USP,METAL:Divalent metal cation; catalytic,MUTAGEN:D->A: Loss of exonuclease activity.,REGION:Linker,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,
PARP1	poly(ADP-ribose) polymerase 1(PARP1)	Homo sapiens	39.Deg_of_Chromosomal_DNA,	h_aifPathway:Opposing roles of AIF in Apoptosis and Cell Survival,h_caspasePathway:Caspase Cascade in Apoptosis,h_chemicalPathway:Apoptotic Signaling in Response to DNA Damage,h_d4gdiPathway:D4-GDI Signaling Pathway,h_fasPathway:FAS signaling pathway ( CD95 ),h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_tnfr1Pathway:TNFR1 Signaling Pathway,		GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000715~nucleotide-excision repair, DNA damage recognition,GO:0000717~nucleotide-excision repair, DNA duplex unwinding,GO:0000723~telomere maintenance,GO:0000724~double-strand break repair via homologous recombination,GO:0006281~DNA repair,GO:0006287~base-excision repair, gap-filling,GO:0006293~nucleotide-excision repair, preincision complex stabilization,GO:0006294~nucleotide-excision repair, preincision complex assembly,GO:0006295~nucleotide-excision repair, DNA incision, 3'-to lesion,GO:0006296~nucleotide-excision repair, DNA incision, 5'-to lesion,GO:0006302~double-strand break repair,GO:0006366~transcription from RNA polymerase II promoter,GO:0006471~protein ADP-ribosylation,GO:0006915~apoptotic process,GO:0006974~cellular response to DNA damage stimulus,GO:0007005~mitochondrion organization,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0010332~response to gamma radiation,GO:0010613~positive regulation of cardiac muscle hypertrophy,GO:0010990~regulation of SMAD protein complex assembly,GO:0016540~protein autoprocessing,GO:0018312~peptidyl-serine ADP-ribosylation,GO:0018424~peptidyl-glutamic acid poly-ADP-ribosylation,GO:0023019~signal transduction involved in regulation of gene expression,GO:0030225~macrophage differentiation,GO:0030592~DNA ADP-ribosylation,GO:0032042~mitochondrial DNA metabolic process,GO:0032869~cellular response to insulin stimulus,GO:0032880~regulation of protein localization,GO:0033148~positive regulation of intracellular estrogen receptor signaling pathway,GO:0033683~nucleotide-excision repair, DNA incision,GO:0034599~cellular response to oxidative stress,GO:0034644~cellular response to UV,GO:0036211~protein modification process,GO:0042769~DNA damage response, detection of DNA damage,GO:0043504~mitochondrial DNA repair,GO:0044030~regulation of DNA methylation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050790~regulation of catalytic activity,GO:0051901~positive regulation of mitochondrial depolarization,GO:0060391~positive regulation of SMAD protein import into nucleus,GO:0070212~protein poly-ADP-ribosylation,GO:0070213~protein auto-ADP-ribosylation,GO:0070911~global genome nucleotide-excision repair,GO:0071294~cellular response to zinc ion,GO:1900182~positive regulation of protein localization to nucleus,GO:1901216~positive regulation of neuron death,GO:1903376~regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway,GO:1903518~positive regulation of single strand break repair,GO:1903827~regulation of cellular protein localization,GO:1904044~response to aldosterone,GO:1904357~negative regulation of telomere maintenance via telomere lengthening,GO:1904646~cellular response to beta-amyloid,GO:1904762~positive regulation of myofibroblast differentiation,GO:1905168~positive regulation of double-strand break repair via homologous recombination,GO:1990966~ATP generation from poly-ADP-D-ribose,GO:2000679~positive regulation of transcription regulatory region DNA binding,GO:2001170~negative regulation of ATP biosynthetic process,	GO:0000781~chromosome, telomeric region,GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005694~chromosome,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0016020~membrane,GO:0016604~nuclear body,GO:0032991~macromolecular complex,GO:0032993~protein-DNA complex,GO:0035861~site of double-strand break,GO:0090734~site of DNA damage,	GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0003950~NAD+ ADP-ribosyltransferase activity,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0008270~zinc ion binding,GO:0019899~enzyme binding,GO:0019901~protein kinase binding,GO:0030331~estrogen receptor binding,GO:0042802~identical protein binding,GO:0042826~histone deacetylase binding,GO:0047485~protein N-terminus binding,GO:0051287~NAD binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0070412~R-SMAD binding,GO:1990404~protein ADP-ribosylase activity,	IPR001357:BRCT domain,IPR001510:Zinc finger, PARP-type,IPR004102:Poly(ADP-ribose) polymerase, regulatory domain,IPR008288:NAD+ ADP-ribosyltransferase,IPR008893:WGR domain,IPR012317:Poly(ADP-ribose) polymerase, catalytic domain,IPR012982:PADR1,	hsa03410:Base excision repair,hsa04064:NF-kappa B signaling pathway,hsa04210:Apoptosis,hsa04217:Necroptosis,hsa05415:Diabetic cardiomyopathy,		PIRSF000489:poly(ADP-ribose) polymerase,	SM00292:BRCT,SM00773:WGR,SM01335:SM01335,SM01336:SM01336,	KW-0227~DNA damage,KW-0234~DNA repair,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0158~Chromosome,KW-0539~Nucleus,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0520~NAD,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0013~ADP-ribosylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:For poly [ADP-ribose] polymerase activity,BINDING:NAD,BINDING:NAD; via carbonyl oxygen,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:BRCT,DOMAIN:PARP alpha-helical,DOMAIN:PARP catalytic,DOMAIN:PARP-type,DOMAIN:WGR,MOTIF:Nuclear localization signal,MUTAGEN:C->R: <0.5% of wild-type activity.,MUTAGEN:D->G: Abolished interaction with TIMELESS.,MUTAGEN:D->N: 0.6% of wild-type activity.,MUTAGEN:E->A,D,Q,K: Poly-ADP-ribosyltransferase activity is inhibited while mono-ADP-ribosyltransferase activity is not affected; only monomers are added. Disrupts interaction with CHD1L.,MUTAGEN:E->Q: Does not affect ADP-ribosyltransferase activity.,MUTAGEN:F->S: 10% of wild-type activity.,MUTAGEN:H->A: Poly-ADP-ribosyltransferase activity is impaired while mono-ADP-ribosyltransferase activity is not affected; produces a mixture of short and mono ADP-ribose chains.,MUTAGEN:H->A: Strongly reduced serine ADP-ribosylation, caused by abolished interaction with HPF1.,MUTAGEN:K->I: Abolishes enzymatic activity.,MUTAGEN:L->F: 1.5% of wild-type activity.,MUTAGEN:L->P: 1.5% of wild-type activity.,MUTAGEN:LW->EE: Strongly reduced serine ADP-ribosylation, caused by abolished interaction with HPF1.,MUTAGEN:M->V: <0.5% of wild-type activity.,MUTAGEN:Missing: Abolished interaction with TIMELESS.,MUTAGEN:N->S: 4% of wild-type activity.,MUTAGEN:S->A: Abolishes automodification on serine following interaction with HPF1; when associated with A-499 and A-507.,MUTAGEN:S->A: Abolishes automodification on serine following interaction with HPF1; when associated with A-499 and A-519.,MUTAGEN:S->A: Abolishes automodification on serine following interaction with HPF1; when associated with A-507 and A-519.,MUTAGEN:VEVV->GEVQ: Strongly reduced interaction with TIMELESS.,MUTAGEN:Y->H: 14% of wild-type activity and increased branching 15-fold.,NP_BIND:NAD,REGION:Automodification domain,REGION:Disordered,ZN_FING:PARP-type 1,ZN_FING:PARP-type 2,
PARP2	poly(ADP-ribose) polymerase 2(PARP2)	Homo sapiens				GO:0006281~DNA repair,GO:0006284~base-excision repair,GO:0006302~double-strand break repair,GO:0006471~protein ADP-ribosylation,GO:0016570~histone modification,GO:0018312~peptidyl-serine ADP-ribosylation,GO:0030592~DNA ADP-ribosylation,GO:0061051~positive regulation of cell growth involved in cardiac muscle cell development,GO:0070212~protein poly-ADP-ribosylation,GO:0070213~protein auto-ADP-ribosylation,GO:0097191~extrinsic apoptotic signaling pathway,GO:1901215~negative regulation of neuron death,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0090734~site of DNA damage,	GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003950~NAD+ ADP-ribosyltransferase activity,GO:0005515~protein binding,GO:0031491~nucleosome binding,GO:1990404~protein ADP-ribosylase activity,	IPR004102:Poly(ADP-ribose) polymerase, regulatory domain,IPR008893:WGR domain,IPR012317:Poly(ADP-ribose) polymerase, catalytic domain,	hsa03410:Base excision repair,hsa04210:Apoptosis,			SM00773:WGR,	KW-0227~DNA damage,KW-0234~DNA repair,	KW-0158~Chromosome,KW-0539~Nucleus,			KW-0520~NAD,	KW-0238~DNA-binding,KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0013~ADP-ribosylation,KW-0597~Phosphoprotein,	ACT_SITE:For poly [ADP-ribose] polymerase activity,BINDING:NAD,BINDING:NAD; via carbonyl oxygen,COMPBIAS:Basic and acidic residues,DOMAIN:PARP alpha-helical,DOMAIN:PARP catalytic,DOMAIN:WGR,MOTIF:Nuclear localization signal,MUTAGEN:E->A: Abolished poly [ADP-ribose] polymerase activity without affecting localization to DNA damage sites.,MUTAGEN:H->A: Strongly reduced serine ADP-ribosylation, caused by abolished interaction with HPF1.,MUTAGEN:K->A: Decreased poly [ADP-ribose] polymerase activity.,MUTAGEN:K->A: Decreased poly [ADP-ribose] polymerase activity. Impaired formation of a complex with damaged DNA.,MUTAGEN:KK->AA: Reduced localization to the nucleus. Abolished localization to the nucleus; when associated with 21-A-A-22.,MUTAGEN:KR->AA: Reduced localization to the nucleus. Abolished localization to the nucleus; when associated with 37-A-A-38.,MUTAGEN:LW->EE: Strongly reduced serine ADP-ribosylation, caused by abolished interaction with HPF1.,MUTAGEN:N->A: Decreased poly [ADP-ribose] polymerase activity. Impaired formation of a complex with damaged DNA.,MUTAGEN:N->A: Does not affect poly [ADP-ribose] polymerase activity.,MUTAGEN:N->A: Reduced recruitment to DNA damage sites.,MUTAGEN:Q->A: Decreased poly [ADP-ribose] polymerase activity.,MUTAGEN:QF->RD: In PARP2-QFRD mutant; induces conformational change that bridges nucleosomes by binding to linker DNA ends and promotes interaction with HPF1.,MUTAGEN:R->A: Abolished formation of a complex with core nucleosome and HPF1, leading to abolished ability to catalyze serine ADP-ribosylation of histones.,MUTAGEN:V->A: Abolished formation of a complex with core nucleosome and HPF1, leading to abolished ability to catalyze serine ADP-ribosylation of histones.,MUTAGEN:W->A: Decreased poly [ADP-ribose] polymerase activity. Impaired formation of a complex with damaged DNA.,MUTAGEN:Y->F: Decreased poly [ADP-ribose] polymerase activity.,MUTAGEN:Y->F: Reduced recruitment to DNA damage sites. Decreased poly [ADP-ribose] polymerase activity.,NP_BIND:NAD,REGION:Disordered,
PUF60	poly(U) binding splicing factor 60(PUF60)	Homo sapiens				GO:0000380~alternative mRNA splicing, via spliceosome,GO:0000381~regulation of alternative mRNA splicing, via spliceosome,GO:0000398~mRNA splicing, via spliceosome,GO:0006376~mRNA splice site selection,GO:0006397~mRNA processing,GO:0006915~apoptotic process,GO:0008380~RNA splicing,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0030054~cell junction,	GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0045296~cadherin binding,	IPR000504:RNA recognition motif domain,IPR003954:RNA recognition motif domain, eukaryote,IPR006532:Poly-U binding splicing factor, half-pint,IPR012677:Nucleotide-binding, alpha-beta plait,	hsa03040:Spliceosome,	615583~Verheij syndrome,		SM00360:RRM,SM00361:RRM_1,	KW-0053~Apoptosis,KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,	KW-0677~Repeat,		KW-0238~DNA-binding,KW-0678~Repressor,KW-0687~Ribonucleoprotein,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,DOMAIN:RRM 3; atypical,REGION:Disordered,REGION:Inhibits homodimerization,REGION:Inhibits transcriptional repression, interaction with ERCC3 and apoptosis induction,
PNKP	polynucleotide kinase 3'-phosphatase(PNKP)	Homo sapiens				GO:0000718~nucleotide-excision repair, DNA damage removal,GO:0006261~DNA-dependent DNA replication,GO:0006281~DNA repair,GO:0006287~base-excision repair, gap-filling,GO:0006303~double-strand break repair via nonhomologous end joining,GO:0006979~response to oxidative stress,GO:0009314~response to radiation,GO:0010836~negative regulation of protein ADP-ribosylation,GO:0016311~dephosphorylation,GO:0032212~positive regulation of telomere maintenance via telomerase,GO:0042769~DNA damage response, detection of DNA damage,GO:0046939~nucleotide phosphorylation,GO:0051103~DNA ligation involved in DNA repair,GO:0051973~positive regulation of telomerase activity,GO:0090305~nucleic acid phosphodiester bond hydrolysis,GO:0098506~polynucleotide 3' dephosphorylation,GO:1904355~positive regulation of telomere capping,GO:2001034~positive regulation of double-strand break repair via nonhomologous end joining,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005739~mitochondrion,GO:0016020~membrane,GO:0035861~site of double-strand break,	GO:0003684~damaged DNA binding,GO:0003690~double-stranded DNA binding,GO:0004519~endonuclease activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016301~kinase activity,GO:0017076~purine nucleotide binding,GO:0046403~polynucleotide 3'-phosphatase activity,GO:0046404~ATP-dependent polydeoxyribonucleotide 5'-hydroxyl-kinase activity,	IPR006549:HAD-superfamily hydrolase, subfamily IIIA,IPR006550:Polynucleotide kinase 3-phosphatase, metazoan,IPR006551:Polynucleotide 3'-phosphatase,IPR008984:SMAD/FHA domain,IPR013954:Polynucleotide kinase 3 phosphatase,IPR023214:HAD-like domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,		605589~Charcot-Marie-Tooth disease, type 2B2,613402~Microcephaly, seizures, and developmental delay,616267~Ataxia-oculomotor apraxia 4,			KW-0227~DNA damage,KW-0234~DNA repair,	KW-0158~Chromosome,KW-0539~Nucleus,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0887~Epilepsy,KW-0905~Primary microcephaly,KW-0991~Mental retardation,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,KW-0418~Kinase,KW-0511~Multifunctional enzyme,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:FHA,DOMAIN:FHA_2,NP_BIND:ATP,REGION:Disordered,REGION:Kinase,REGION:Phosphatase,
KCTD5	potassium channel tetramerization domain containing 5(KCTD5)	Homo sapiens				GO:0016032~viral process,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0051260~protein homooligomerization,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0031463~Cul3-RING ubiquitin ligase complex,	GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0044877~macromolecular complex binding,GO:0097602~cullin family protein binding,	IPR000210:BTB/POZ-like,IPR003131:Potassium channel tetramerisation-type BTB domain,IPR011333:BTB/POZ fold,				SM00225:BTB,	KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,					KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:BTB,REGION:Disordered,
KCNK1	potassium two pore domain channel subfamily K member 1(KCNK1)	Homo sapiens				GO:0006813~potassium ion transport,GO:0030322~stabilization of membrane potential,GO:0035094~response to nicotine,GO:0035725~sodium ion transmembrane transport,GO:0060075~regulation of resting membrane potential,GO:0061337~cardiac conduction,GO:0071805~potassium ion transmembrane transport,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0008076~voltage-gated potassium channel complex,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0030425~dendrite,GO:0031526~brush border membrane,GO:0034705~potassium channel complex,GO:0043204~perikaryon,GO:0043231~intracellular membrane-bounded organelle,GO:0055037~recycling endosome,GO:0097060~synaptic membrane,GO:1902937~inward rectifier potassium channel complex,	GO:0005242~inward rectifier potassium channel activity,GO:0005267~potassium channel activity,GO:0005272~sodium channel activity,GO:0005515~protein binding,GO:0022841~potassium ion leak channel activity,GO:0042802~identical protein binding,	IPR001779:Two pore domain potassium channel, TWIK-1,IPR003092:Two pore domain potassium channel, TASK family,IPR003280:Two pore domain potassium channel,IPR005408:Two pore domain potassium channel, TWIK family,IPR013099:Ion transport 2,			PIRSF038061:potassium channel, subfamily K type,		KW-0406~Ion transport,KW-0633~Potassium transport,KW-0813~Transport,	KW-0472~Membrane,KW-0770~Synapse,KW-0965~Cell junction,KW-0966~Cell projection,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0630~Potassium,	KW-0407~Ion channel,KW-0631~Potassium channel,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),DISULFID:Interchain,DOMAIN:Ion_trans_2,INTRAMEM:Helical; Name=Pore helix 1,INTRAMEM:Helical; Name=Pore helix 2,MUTAGEN:C->A: Abolishes channel activity and formation of disulfide-linked homodimers.,MUTAGEN:H->K: Increases channel activity, and has only a minor effect on the inhibition by acidification of the extracellular medium.,MUTAGEN:H->N: Decreases channel activity and abolishes inhibition by acidification of the extracellular medium.,MUTAGEN:II->AA: Strongly increases location at the cell membrane.,MUTAGEN:K->A,C,D,Q,R: Converts the electrically silent channel that is present at the cell membrane to an active channel.,MUTAGEN:K->E: Converts the electrically silent channel that is present at the cell membrane to an active channel. No effect on retention in recycling endosomes.,MUTAGEN:L->A,V: Does not increase the low intrinsic channel activity.,MUTAGEN:L->D,N: Increases channel activity.,MUTAGEN:L->D: Increases channel activity.,MUTAGEN:L->F: No effect on selectivity for K(+) ions.,MUTAGEN:L->N,T: Increases channel activity.,MUTAGEN:L->S: Increases channel activity. Strongly increases channel activity; when associated with S-146.,MUTAGEN:L->S: Increases channel activity. Strongly increases channel activity; when associated with S-261.,MUTAGEN:LF->FY: Impairs selectivity for K(+) ions and increases permeability to Na(+) ions, both at pH 7.4 and at pH 6.,MUTAGEN:Missing: No effect on intracellular retention in recycling endosomes.,MUTAGEN:N->A: Abolishes N-glycosylation.,MUTAGEN:T->A: No effect on channel activity.,MUTAGEN:T->I: Abolishes change in ion selectivity in the presence of subphysiological K(+) levels.,MUTAGEN:T->L: Slighly decreases the increased permeability to Na(+) ions at pH 6.,MUTAGEN:Y->F: Strongly decreases activity of homodimeric channels and of heterodimeric channels formed with KCNK3 and with KCNK9. No effect on location at the cell membrane.,REGION:Important for intracellular retention in recycling endosomes,REGION:Selectivity filter 1,REGION:Selectivity filter 2,SITE:Important for increased permeability to Na(+) when K(+) levels are subphysiological,SITE:Part of a hydrophobic barrier that is stochastically dewetted and limits ion permeability,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
PRPF4	pre-mRNA processing factor 4(PRPF4)	Homo sapiens				GO:0000375~RNA splicing, via transesterification reactions,GO:0000398~mRNA splicing, via spliceosome,GO:0006396~RNA processing,GO:0008380~RNA splicing,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:0015030~Cajal body,GO:0016607~nuclear speck,GO:0046540~U4/U6 x U5 tri-snRNP complex,GO:0071001~U4/U6 snRNP,GO:0071005~U2-type precatalytic spliceosome,GO:0097525~spliceosomal snRNP complex,	GO:0005515~protein binding,GO:0017070~U6 snRNA binding,GO:0030621~U4 snRNA binding,	IPR001680:WD40 repeat,IPR014906:Pre-mRNA processing factor 4 (PRP4)-like,IPR015943:WD40/YVTN repeat-like-containing domain,IPR017986:WD40-repeat-containing domain,IPR019775:WD40 repeat, conserved site,IPR020472:G-protein beta WD-40 repeat,	hsa03040:Spliceosome,	615922~Retinitis pigmentosa 70,		SM00320:WD40,SM00500:SFM,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0747~Spliceosome,	KW-0225~Disease variant,KW-0682~Retinitis pigmentosa,	KW-0677~Repeat,KW-0853~WD repeat,			KW-0007~Acetylation,	COMPBIAS:Polar residues,DOMAIN:SFM,MUTAGEN:R->E: Decreases PRPF3 binding.,MUTAGEN:R->K: Decreases PRPF3 binding.,MUTAGEN:R->W: Decreases PRPF3 binding.,REGION:Disordered,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
PLOD3	procollagen-lysine,2-oxoglutarate 5-dioxygenase 3(PLOD3)	Homo sapiens				GO:0001701~in utero embryonic development,GO:0001886~endothelial cell morphogenesis,GO:0006493~protein O-linked glycosylation,GO:0008104~protein localization,GO:0017185~peptidyl-lysine hydroxylation,GO:0021915~neural tube development,GO:0030199~collagen fibril organization,GO:0032870~cellular response to hormone stimulus,GO:0032963~collagen metabolic process,GO:0042311~vasodilation,GO:0046947~hydroxylysine biosynthetic process,GO:0048730~epidermis morphogenesis,GO:0060425~lung morphogenesis,GO:0070831~basement membrane assembly,	GO:0005615~extracellular space,GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0005789~endoplasmic reticulum membrane,GO:0005791~rough endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005802~trans-Golgi network,GO:0070062~extracellular exosome,	GO:0005506~iron ion binding,GO:0005515~protein binding,GO:0008475~procollagen-lysine 5-dioxygenase activity,GO:0031418~L-ascorbic acid binding,GO:0033823~procollagen glucosyltransferase activity,GO:0050211~procollagen galactosyltransferase activity,	IPR001006:Procollagen-lysine 5-dioxygenase,IPR005123:Oxoglutarate/iron-dependent dioxygenase,IPR006620:Prolyl 4-hydroxylase, alpha subunit,	hsa00310:Lysine degradation,hsa00514:Other types of O-glycan biosynthesis,hsa01100:Metabolic pathways,	612394~Lysyl hydroxylase 3 deficiency,		SM00702:P4Hc,		KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0964~Secreted,	KW-0225~Disease variant,	KW-0732~Signal,	KW-0408~Iron,KW-0464~Manganese,KW-0479~Metal-binding,KW-0847~Vitamin C,	KW-0223~Dioxygenase,KW-0328~Glycosyltransferase,KW-0511~Multifunctional enzyme,KW-0560~Oxidoreductase,KW-0808~Transferase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	BINDING:2-oxoglutarate,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Fe2OG dioxygenase,METAL:Iron,METAL:Manganese,MUTAGEN:C->I: Strongly reduced glucosyltransferase activity. Strongly reduced galactosyltransferase activity.,MUTAGEN:D->A: Strongly decreased lysyl hydroxylase activity. No effect on glycosyltransferase activity.,MUTAGEN:DDD->ADA: Nearly abolishes glucosyltransferase activity. Nearly abolishes galactosyltransferase activity.,MUTAGEN:DDDDD->ADAAA: Loss of glucosyltransferase activity. Loss of galactosyltransferase activity.,MUTAGEN:L->D: No effect on dimerization, lysyl hydroxylase and glycosyltransferase activity.,MUTAGEN:L->I: Reduced glucosyltransferase activity.,MUTAGEN:L->R: Loss of lysyl hydroxylase activity and decreased glycosyltransferase activity.,MUTAGEN:R->N: Loss of dimerization. Loss of lysyl hydroxylase activity and no effect on glycosyltransferase activity.,MUTAGEN:T->N: Loss of dimerization. Loss of lysyl hydroxylase activity and decreased glycosyltransferase activity.,MUTAGEN:W->A: Decreased lysyl hydroxylase activity and loss of glycosyltransferase activity.,MUTAGEN:Y->A: Decreased lysyl hydroxylase and glycosyltransferase activity.,REGION:Accessory region,REGION:Disordered,REGION:Important for dimerization,REGION:Required for glycosyltransferase activity,REGION:UDP-sugar binding,
PGRMC1	progesterone receptor membrane component 1(PGRMC1)	Homo sapiens				GO:0006783~heme biosynthetic process,GO:0007411~axon guidance,GO:0007613~memory,GO:0008306~associative learning,GO:0043312~neutrophil degranulation,GO:0099563~modification of synaptic structure,GO:1903078~positive regulation of protein localization to plasma membrane,GO:1905809~negative regulation of synapse organization,	GO:0005741~mitochondrial outer membrane,GO:0005783~endoplasmic reticulum,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0012505~endomembrane system,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030868~smooth endoplasmic reticulum membrane,GO:0035579~specific granule membrane,GO:0043005~neuron projection,GO:0043025~neuronal cell body,GO:0044297~cell body,GO:0045202~synapse,	GO:0001540~beta-amyloid binding,GO:0005496~steroid binding,GO:0005515~protein binding,GO:0020037~heme binding,GO:0042803~protein homodimerization activity,GO:0046872~metal ion binding,	IPR001199:Cytochrome b5-like heme/steroid binding domain,				SM01117:SM01117,		KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0492~Microsome,KW-0496~Mitochondrion,KW-1000~Mitochondrion outer membrane,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0408~Iron,KW-0446~Lipid-binding,KW-0479~Metal-binding,KW-0754~Steroid-binding,	KW-0675~Receptor,	KW-0597~Phosphoprotein,	DOMAIN:Cytochrome b5 heme-binding,METAL:Iron (heme axial ligand),MUTAGEN:Y->F: Abolishes interaction with CYP1A1 and CYP3A4.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
PCNA	proliferating cell nuclear antigen(PCNA)	Homo sapiens		h_p53Pathway:p53 Signaling Pathway,		GO:0000083~regulation of transcription involved in G1/S transition of mitotic cell cycle,GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000723~telomere maintenance,GO:0006260~DNA replication,GO:0006272~leading strand elongation,GO:0006275~regulation of DNA replication,GO:0006283~transcription-coupled nucleotide-excision repair,GO:0006287~base-excision repair, gap-filling,GO:0006296~nucleotide-excision repair, DNA incision, 5'-to lesion,GO:0006297~nucleotide-excision repair, DNA gap filling,GO:0006298~mismatch repair,GO:0006977~DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest,GO:0007507~heart development,GO:0016032~viral process,GO:0016567~protein ubiquitination,GO:0019985~translesion synthesis,GO:0030855~epithelial cell differentiation,GO:0031297~replication fork processing,GO:0032077~positive regulation of deoxyribonuclease activity,GO:0032201~telomere maintenance via semi-conservative replication,GO:0032355~response to estradiol,GO:0033683~nucleotide-excision repair, DNA incision,GO:0034644~cellular response to UV,GO:0042276~error-prone translesion synthesis,GO:0042769~DNA damage response, detection of DNA damage,GO:0044849~estrous cycle,GO:0045739~positive regulation of DNA repair,GO:0045740~positive regulation of DNA replication,GO:0046686~response to cadmium ion,GO:0070301~cellular response to hydrogen peroxide,GO:0070987~error-free translesion synthesis,GO:0071466~cellular response to xenobiotic stimulus,GO:0071548~response to dexamethasone,GO:0097421~liver regeneration,GO:1900264~positive regulation of DNA-directed DNA polymerase activity,GO:1902065~response to L-glutamate,GO:1902990~mitotic telomere maintenance via semi-conservative replication,	GO:0000307~cyclin-dependent protein kinase holoenzyme complex,GO:0000781~chromosome, telomeric region,GO:0000785~chromatin,GO:0005634~nucleus,GO:0005652~nuclear lamina,GO:0005654~nucleoplasm,GO:0005657~replication fork,GO:0005813~centrosome,GO:0016604~nuclear body,GO:0030894~replisome,GO:0043596~nuclear replication fork,GO:0043626~PCNA complex,GO:0070062~extracellular exosome,GO:0070557~PCNA-p21 complex,	GO:0000701~purine-specific mismatch base pair DNA N-glycosylase activity,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003684~damaged DNA binding,GO:0005515~protein binding,GO:0008022~protein C-terminus binding,GO:0019899~enzyme binding,GO:0030331~estrogen receptor binding,GO:0030337~DNA polymerase processivity factor activity,GO:0030971~receptor tyrosine kinase binding,GO:0032139~dinucleotide insertion or deletion binding,GO:0032405~MutLalpha complex binding,GO:0035035~histone acetyltransferase binding,GO:0042802~identical protein binding,GO:0044877~macromolecular complex binding,GO:0070182~DNA polymerase binding,	IPR000730:Proliferating cell nuclear antigen, PCNA,IPR022648:Proliferating cell nuclear antigen, PCNA, N-terminal,IPR022649:Proliferating cell nuclear antigen, PCNA, C-terminal,IPR022659:Proliferating cell nuclear antigen, PCNA, conserved site,	hsa03030:DNA replication,hsa03410:Base excision repair,hsa03420:Nucleotide excision repair,hsa03430:Mismatch repair,hsa04110:Cell cycle,hsa04530:Tight junction,hsa05161:Hepatitis B,	615919~Ataxia-telangiectasia-like disorder 2,			KW-0227~DNA damage,KW-0234~DNA repair,KW-0235~DNA replication,KW-0945~Host-virus interaction,	KW-0539~Nucleus,	KW-0209~Deafness,KW-0225~Disease variant,KW-0242~Dwarfism,KW-0523~Neurodegeneration,			KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate,DOMAIN:PCNA_C,DOMAIN:PCNA_N,MUTAGEN:A->G: Complete loss of interaction with UHRF2.,MUTAGEN:I->A: Complete loss of interaction with UHRF2.,MUTAGEN:K->A: Inhibits recruitment to DNA damage sites, but nuclear localization is similar as the wild-type; in association with A-77.,MUTAGEN:K->A: Inhibits recruitment to DNA damage sites, but nuclear localization is similar as the wild-type; in association with A-80.,MUTAGEN:K->R: Abolishes ubiquitination. No effect on interaction with SHPRH.,MUTAGEN:K->R: Inhibits acetylation, recruitment to DNA damage sites, inducible ubiquitination and protein degradation, DNA replication and repair synthesis efficiencies, but homotrimer formation, nuclear recruitment to DNA damage sites, interactions with CREBBP, EP300 and POLD1 are similar as the wild-type; in association with R-13; R-14; R-20 and R-77.,MUTAGEN:K->R: Inhibits acetylation, recruitment to DNA damage sites, inducible ubiquitination and protein degradation, DNA replication and repair synthesis efficiencies, but homotrimer formation, nuclear recruitment to DNA damage sites, interactions with CREBBP, EP300 and POLD1 are similar as the wild-type; in association with R-13; R-14; R-20 and R-80.,MUTAGEN:K->R: Inhibits acetylation, recruitment to DNA damage sites, inducible ubiquitination and protein degradation, DNA replication and repair synthesis efficiencies, but homotrimer formation, nuclear recruitment to DNA damage sites, interactions with CREBBP, EP300 and POLD1 are similar as the wild-type; in association with R-13; R-14; R-77 and R-80.,MUTAGEN:K->R: Inhibits acetylation, recruitment to DNA damage sites, inducible ubiquitination and protein degradation, DNA replication and repair synthesis efficiencies, but homotrimer formation, nuclear recruitment to DNA damage sites, interactions with CREBBP, EP300 and POLD1 are similar as the wild-type; in association with R-13; R-20; R-77 and R-80.,MUTAGEN:K->R: Inhibits acetylation, recruitment to DNA damage sites, inducible ubiquitination and protein degradation, DNA replication and repair synthesis efficiencies, but homotrimer formation, nuclear recruitment to DNA damage sites, interactions with CREBBP, EP300 and POLD1 are similar as the wild-type; in association with R-14; R-20; R-77 and R-80.,MUTAGEN:LAPK->AAAA: Decrease in POLD3-binding.,MUTAGEN:M->A: Complete loss of interaction with UHRF2.,MUTAGEN:QLGI->AAAA: Strong decrease in POLD3-binding.,MUTAGEN:SHV->AAA: No effect on POLD3-binding.,MUTAGEN:VDK->AAA: No effect on POLD3-binding.,MUTAGEN:Y->A: Complete loss of interaction with UHRF2.,MUTAGEN:Y->F: Alters chromatin-associated PCNA stability and its function in DNA replication and repair.,REGION:Disordered,REGION:Interaction with NUDT15,
PSRC1	proline and serine rich coiled-coil 1(PSRC1)	Homo sapiens				GO:0001578~microtubule bundle formation,GO:0007080~mitotic metaphase plate congression,GO:0030308~negative regulation of cell growth,GO:0031116~positive regulation of microtubule polymerization,GO:0045737~positive regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0045893~positive regulation of transcription, DNA-templated,GO:0051301~cell division,GO:0060236~regulation of mitotic spindle organization,	GO:0000922~spindle pole,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005819~spindle,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005876~spindle microtubule,GO:0015630~microtubule cytoskeleton,GO:0030496~midbody,	GO:0005515~protein binding,GO:0008017~microtubule binding,	IPR026657:Proline/serine-rich coiled-coil protein 1/G2 and S phase-expressed protein 1,IPR026658:Proline/serine-rich coiled-coil protein 1,					KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0677~Repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:GTSE1_N,REGION:4 X 4 AA repeats of P-X-X-P,REGION:Disordered,REPEAT:1,REPEAT:2,REPEAT:3,REPEAT:4,
PRR7	proline rich 7, synaptic(PRR7)	Homo sapiens				GO:0002250~adaptive immune response,GO:0010942~positive regulation of cell death,GO:0031397~negative regulation of protein ubiquitination,GO:0033077~T cell differentiation in thymus,GO:0043065~positive regulation of apoptotic process,GO:0046632~alpha-beta T cell differentiation,GO:0099527~postsynapse to nucleus signaling pathway,GO:2001269~positive regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway,	GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0030425~dendrite,GO:0043005~neuron projection,GO:0048471~perinuclear region of cytoplasm,GO:0098839~postsynaptic density membrane,GO:0098978~glutamatergic synapse,GO:0099092~postsynaptic density, intracellular component,	GO:0005515~protein binding,GO:0036041~long-chain fatty acid binding,GO:0044389~ubiquitin-like protein ligase binding,GO:0044877~macromolecular complex binding,GO:1990782~protein tyrosine kinase binding,						KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0539~Nucleus,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,	COMPBIAS:Basic residues,MOTIF:PDZ-binding,MUTAGEN:Y->F: Reduced induction of apoptosis; when associated with F-139; F-153; F-166; F-177 and F-201.,MUTAGEN:Y->F: Reduced induction of apoptosis; when associated with F-139; F-153; F-166; F-177 and F-210.,MUTAGEN:Y->F: Reduced induction of apoptosis; when associated with F-139; F-153; F-166; F-201 and F-210.,MUTAGEN:Y->F: Reduced induction of apoptosis; when associated with F-139; F-153; F-177; F-201 and F-210.,MUTAGEN:Y->F: Reduced induction of apoptosis; when associated with F-139; F-166; F-177; F-201 and F-210.,MUTAGEN:Y->F: Reduced induction of apoptosis; when associated with F-153; F-166; F-177; F-201 and F-210.,REGION:Disordered,REGION:Required for apoptosis induction,REGION:Required for interaction with NMDA receptors,REGION:Required for internalization,REGION:Required for membrane localization,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type III membrane protein,
P4HA2	prolyl 4-hydroxylase subunit alpha 2(P4HA2)	Homo sapiens				GO:0018401~peptidyl-proline hydroxylation to 4-hydroxy-L-proline,GO:0022900~electron transport chain,GO:0030199~collagen fibril organization,	GO:0005654~nucleoplasm,GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0005829~cytosol,GO:0043231~intracellular membrane-bounded organelle,	GO:0004656~procollagen-proline 4-dioxygenase activity,GO:0005506~iron ion binding,GO:0009055~electron carrier activity,GO:0016702~oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen,GO:0031418~L-ascorbic acid binding,	IPR005123:Oxoglutarate/iron-dependent dioxygenase,IPR006620:Prolyl 4-hydroxylase, alpha subunit,IPR011990:Tetratricopeptide-like helical,IPR013026:Tetratricopeptide repeat-containing domain,IPR013547:Prolyl 4-hydroxylase alpha-subunit, N-terminal,IPR019734:Tetratricopeptide repeat,	hsa00330:Arginine and proline metabolism,hsa01100:Metabolic pathways,	617238~Myopia 25, autosomal dominant,		SM00702:P4Hc,		KW-0256~Endoplasmic reticulum,	KW-0225~Disease variant,	KW-0732~Signal,KW-0802~TPR repeat,	KW-0408~Iron,KW-0479~Metal-binding,KW-0847~Vitamin C,	KW-0223~Dioxygenase,KW-0560~Oxidoreductase,	KW-0325~Glycoprotein,	BINDING:2-oxoglutarate,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Fe2OG dioxygenase,DOMAIN:P4Ha_N,METAL:Iron,REPEAT:TPR,
P4HTM	prolyl 4-hydroxylase, transmembrane(P4HTM)	Homo sapiens				GO:0018401~peptidyl-proline hydroxylation to 4-hydroxy-L-proline,GO:0045646~regulation of erythrocyte differentiation,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016021~integral component of membrane,	GO:0004656~procollagen-proline 4-dioxygenase activity,GO:0005506~iron ion binding,GO:0005509~calcium ion binding,GO:0016706~oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors,GO:0031418~L-ascorbic acid binding,GO:0046872~metal ion binding,	IPR002048:EF-hand domain,IPR005123:Oxoglutarate/iron-dependent dioxygenase,IPR006620:Prolyl 4-hydroxylase, alpha subunit,IPR011992:EF-hand-like domain,IPR018247:EF-Hand 1, calcium-binding site,		618493~Hypotonia, hypoventilation, impaired intellectual development, dysautonomia, epilepsy, and eye abnormalities,		SM00702:P4Hc,		KW-0256~Endoplasmic reticulum,KW-0472~Membrane,	KW-0225~Disease variant,KW-0887~Epilepsy,KW-0991~Mental retardation,	KW-0677~Repeat,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0408~Iron,KW-0479~Metal-binding,KW-0847~Vitamin C,	KW-0223~Dioxygenase,KW-0560~Oxidoreductase,	KW-0325~Glycoprotein,	BINDING:2-oxoglutarate,CARBOHYD:N-linked (GlcNAc...) asparagine,CA_BIND:1,CA_BIND:2,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:Fe2OG dioxygenase,METAL:Iron,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
PRCP	prolylcarboxypeptidase(PRCP)	Homo sapiens				GO:0002155~regulation of thyroid hormone mediated signaling pathway,GO:0002353~plasma kallikrein-kinin cascade,GO:0003085~negative regulation of systemic arterial blood pressure,GO:0006508~proteolysis,GO:0007597~blood coagulation, intrinsic pathway,GO:0042593~glucose homeostasis,GO:0043312~neutrophil degranulation,GO:0043535~regulation of blood vessel endothelial cell migration,GO:0060055~angiogenesis involved in wound healing,GO:0097009~energy homeostasis,GO:2000377~regulation of reactive oxygen species metabolic process,	GO:0005886~plasma membrane,GO:0035577~azurophil granule membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0045178~basal part of cell,GO:0070062~extracellular exosome,GO:0101003~ficolin-1-rich granule membrane,	GO:0004180~carboxypeptidase activity,GO:0004185~serine-type carboxypeptidase activity,GO:0005515~protein binding,GO:0008236~serine-type peptidase activity,GO:0008239~dipeptidyl-peptidase activity,	IPR008758:Peptidase S28,	hsa04614:Renin-angiotensin system,hsa04974:Protein digestion and absorption,					KW-0458~Lysosome,		KW-0732~Signal,		KW-0121~Carboxypeptidase,KW-0378~Hydrolase,KW-0645~Protease,	KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	ACT_SITE:Charge relay system,CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:SKS domain,
PCCB	propionyl-CoA carboxylase subunit beta(PCCB)	Homo sapiens				GO:0006633~fatty acid biosynthetic process,GO:0006768~biotin metabolic process,GO:0019626~short-chain fatty acid catabolic process,	GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005829~cytosol,GO:0009317~acetyl-CoA carboxylase complex,GO:1902494~catalytic complex,	GO:0003989~acetyl-CoA carboxylase activity,GO:0004658~propionyl-CoA carboxylase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016874~ligase activity,	IPR000438:Acetyl-CoA carboxylase carboxyl transferase, beta subunit,IPR011762:Acetyl-coenzyme A carboxyltransferase, N-terminal,IPR011763:Acetyl-coenzyme A carboxyltransferase, C-terminal,	hsa00280:Valine, leucine and isoleucine degradation,hsa00630:Glyoxylate and dicarboxylate metabolism,hsa00640:Propanoate metabolism,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,	606054~Propionicacidemia,				KW-0496~Mitochondrion,	KW-0225~Disease variant,	KW-0732~Signal,KW-0809~Transit peptide,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0436~Ligase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:CoA carboxyltransferase C-terminal,DOMAIN:CoA carboxyltransferase N-terminal,REGION:Acyl-CoA binding,REGION:Carboxyltransferase,TRANSIT:Mitochondrion,
PTGS2	prostaglandin-endoperoxide synthase 2(PTGS2)	Homo sapiens		h_acetaminophenPathway:Mechanism of Acetaminophen Activity and Toxicity,h_eicosanoidPathway:Eicosanoid Metabolism,		GO:0001516~prostaglandin biosynthetic process,GO:0001525~angiogenesis,GO:0006954~inflammatory response,GO:0006979~response to oxidative stress,GO:0007566~embryo implantation,GO:0007568~aging,GO:0007612~learning,GO:0007613~memory,GO:0008217~regulation of blood pressure,GO:0008285~negative regulation of cell proliferation,GO:0009410~response to xenobiotic stimulus,GO:0009750~response to fructose,GO:0010042~response to manganese ion,GO:0010226~response to lithium ion,GO:0010575~positive regulation of vascular endothelial growth factor production,GO:0019221~cytokine-mediated signaling pathway,GO:0019233~sensory perception of pain,GO:0019371~cyclooxygenase pathway,GO:0019372~lipoxygenase pathway,GO:0030282~bone mineralization,GO:0030728~ovulation,GO:0031394~positive regulation of prostaglandin biosynthetic process,GO:0031622~positive regulation of fever generation,GO:0031915~positive regulation of synaptic plasticity,GO:0032227~negative regulation of synaptic transmission, dopaminergic,GO:0032355~response to estradiol,GO:0032496~response to lipopolysaccharide,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0033280~response to vitamin D,GO:0034356~NAD biosynthesis via nicotinamide riboside salvage pathway,GO:0034605~cellular response to heat,GO:0034612~response to tumor necrosis factor,GO:0034644~cellular response to UV,GO:0035633~maintenance of permeability of blood-brain barrier,GO:0042307~positive regulation of protein import into nucleus,GO:0042633~hair cycle,GO:0042759~long-chain fatty acid biosynthetic process,GO:0043065~positive regulation of apoptotic process,GO:0043154~negative regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0045429~positive regulation of nitric oxide biosynthetic process,GO:0045786~negative regulation of cell cycle,GO:0045907~positive regulation of vasoconstriction,GO:0045986~negative regulation of smooth muscle contraction,GO:0045987~positive regulation of smooth muscle contraction,GO:0046697~decidualization,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0050727~regulation of inflammatory response,GO:0050873~brown fat cell differentiation,GO:0051384~response to glucocorticoid,GO:0051926~negative regulation of calcium ion transport,GO:0051968~positive regulation of synaptic transmission, glutamatergic,GO:0070542~response to fatty acid,GO:0071260~cellular response to mechanical stimulus,GO:0071284~cellular response to lead ion,GO:0071318~cellular response to ATP,GO:0071456~cellular response to hypoxia,GO:0071471~cellular response to non-ionic osmotic stress,GO:0071498~cellular response to fluid shear stress,GO:0071636~positive regulation of transforming growth factor beta production,GO:0090050~positive regulation of cell migration involved in sprouting angiogenesis,GO:0090271~positive regulation of fibroblast growth factor production,GO:0090336~positive regulation of brown fat cell differentiation,GO:0090362~positive regulation of platelet-derived growth factor production,GO:0098869~cellular oxidant detoxification,GO:1902219~negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress,GO:1990776~response to angiotensin,	GO:0005637~nuclear inner membrane,GO:0005640~nuclear outer membrane,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0005789~endoplasmic reticulum membrane,GO:0005901~caveola,GO:0032991~macromolecular complex,GO:0043005~neuron projection,	GO:0004601~peroxidase activity,GO:0004666~prostaglandin-endoperoxide synthase activity,GO:0005515~protein binding,GO:0016702~oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen,GO:0019899~enzyme binding,GO:0020037~heme binding,GO:0042803~protein homodimerization activity,GO:0046872~metal ion binding,GO:0051213~dioxygenase activity,	IPR000742:Epidermal growth factor-like domain,IPR010255:Haem peroxidase,IPR019791:Haem peroxidase, animal, subgroup,	hsa00590:Arachidonic acid metabolism,hsa01100:Metabolic pathways,hsa04064:NF-kappa B signaling pathway,hsa04370:VEGF signaling pathway,hsa04625:C-type lectin receptor signaling pathway,hsa04657:IL-17 signaling pathway,hsa04668:TNF signaling pathway,hsa04723:Retrograde endocannabinoid signaling,hsa04726:Serotonergic synapse,hsa04913:Ovarian steroidogenesis,hsa04921:Oxytocin signaling pathway,hsa04923:Regulation of lipolysis in adipocytes,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05140:Leishmaniasis,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05200:Pathways in cancer,hsa05204:Chemical carcinogenesis - DNA adducts,hsa05206:MicroRNAs in cancer,hsa05222:Small cell lung cancer,				KW-0275~Fatty acid biosynthesis,KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,KW-0643~Prostaglandin biosynthesis,KW-0644~Prostaglandin metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0492~Microsome,KW-0539~Nucleus,		KW-0245~EGF-like domain,KW-0732~Signal,	KW-0349~Heme,KW-0408~Iron,KW-0479~Metal-binding,	KW-0223~Dioxygenase,KW-0560~Oxidoreductase,KW-0575~Peroxidase,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0702~S-nitrosylation,KW-1015~Disulfide bond,	ACT_SITE:For cyclooxygenase activity,ACT_SITE:Proton acceptor,BINDING:Substrate,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:EGF-like,METAL:Iron (heme axial ligand),MUTAGEN:C->S: Abolishes enzyme activity.,MUTAGEN:C->S: Does not affect activation by nitric oxid (NO).,MUTAGEN:C->S: Prevents activation by nitric oxid (NO).,MUTAGEN:G->V: Loss of cyclooxygenase activity. Loss of cyclooxygenase activity; when associated with T-516.,MUTAGEN:H->A: Reduces two-electron hydroperoxide reduction and cyclooxygenase activity. Catalyzes predominantly one-electron hydroperoxide reduction.,MUTAGEN:Q->N: Increases two-electron hydroperoxide reduction. Has no effect on cyclooxygenase activity.,MUTAGEN:Q->R: Impairs two-electron hydroperoxide reduction and cyclooxygenase activity.,MUTAGEN:Q->V: Impairs two-electron hydroperoxide reduction.,MUTAGEN:S->A: No effect on protein stability. Increased decrease of protein stability; when associated with A-371.,MUTAGEN:S->T: Decreased enzyme activity with arachidonic acid. Loss of cyclooxygenase activity; when associated with V-519.,MUTAGEN:Y->A: Decreased protein stability. Increased decrease of protein stability; when associated with A-516.,SITE:Aspirin-acetylated serine,
PSMB10	proteasome 20S subunit beta 10(PSMB10)	Homo sapiens				GO:0000165~MAPK cascade,GO:0000209~protein polyubiquitination,GO:0000902~cell morphogenesis,GO:0002223~stimulatory C-type lectin receptor signaling pathway,GO:0002376~immune system process,GO:0002479~antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent,GO:0006521~regulation of cellular amino acid metabolic process,GO:0006959~humoral immune response,GO:0010498~proteasomal protein catabolic process,GO:0010499~proteasomal ubiquitin-independent protein catabolic process,GO:0010972~negative regulation of G2/M transition of mitotic cell cycle,GO:0016032~viral process,GO:0016579~protein deubiquitination,GO:0031145~anaphase-promoting complex-dependent catabolic process,GO:0031146~SCF-dependent proteasomal ubiquitin-dependent protein catabolic process,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0036388~pre-replicative complex assembly,GO:0038061~NIK/NF-kappaB signaling,GO:0038095~Fc-epsilon receptor signaling pathway,GO:0042098~T cell proliferation,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0043488~regulation of mRNA stability,GO:0043687~post-translational protein modification,GO:0050852~T cell receptor signaling pathway,GO:0051603~proteolysis involved in cellular protein catabolic process,GO:0055085~transmembrane transport,GO:0060071~Wnt signaling pathway, planar cell polarity pathway,GO:0061418~regulation of transcription from RNA polymerase II promoter in response to hypoxia,GO:0070498~interleukin-1-mediated signaling pathway,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:1901990~regulation of mitotic cell cycle phase transition,GO:1902036~regulation of hematopoietic stem cell differentiation,	GO:0000502~proteasome complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005839~proteasome core complex,GO:0019774~proteasome core complex, beta-subunit complex,GO:1990111~spermatoproteasome complex,	GO:0004175~endopeptidase activity,GO:0004298~threonine-type endopeptidase activity,GO:0005515~protein binding,	IPR000243:Peptidase T1A, proteasome beta-subunit,IPR001353:Proteasome, subunit alpha/beta,IPR016050:Proteasome, beta-type subunit, conserved site,IPR023333:Proteasome B-type subunit,IPR024689:Proteasome beta subunit, C-terminal,	hsa03050:Proteasome,	619175~Proteasome-associated autoinflammatory syndrome 5,			KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0647~Proteasome,KW-0963~Cytoplasm,				KW-0378~Hydrolase,KW-0645~Protease,KW-0888~Threonine protease,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0865~Zymogen,	ACT_SITE:Nucleophile,DOMAIN:Pr_beta_C,PROPEP:Removed in mature form,SITE:Cleavage; by autolysis,
PSMB8	proteasome 20S subunit beta 8(PSMB8)	Homo sapiens		h_mhcPathway:Antigen Processing and Presentation,	Posttranslational modification, protein turnover, chaperones,	GO:0000165~MAPK cascade,GO:0000209~protein polyubiquitination,GO:0002223~stimulatory C-type lectin receptor signaling pathway,GO:0002479~antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent,GO:0006521~regulation of cellular amino acid metabolic process,GO:0010498~proteasomal protein catabolic process,GO:0010499~proteasomal ubiquitin-independent protein catabolic process,GO:0010972~negative regulation of G2/M transition of mitotic cell cycle,GO:0016032~viral process,GO:0016579~protein deubiquitination,GO:0019882~antigen processing and presentation,GO:0031145~anaphase-promoting complex-dependent catabolic process,GO:0031146~SCF-dependent proteasomal ubiquitin-dependent protein catabolic process,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0036388~pre-replicative complex assembly,GO:0038061~NIK/NF-kappaB signaling,GO:0038095~Fc-epsilon receptor signaling pathway,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0043488~regulation of mRNA stability,GO:0043687~post-translational protein modification,GO:0045444~fat cell differentiation,GO:0050852~T cell receptor signaling pathway,GO:0051603~proteolysis involved in cellular protein catabolic process,GO:0052548~regulation of endopeptidase activity,GO:0055085~transmembrane transport,GO:0060071~Wnt signaling pathway, planar cell polarity pathway,GO:0060337~type I interferon signaling pathway,GO:0061418~regulation of transcription from RNA polymerase II promoter in response to hypoxia,GO:0070498~interleukin-1-mediated signaling pathway,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:1901990~regulation of mitotic cell cycle phase transition,GO:1902036~regulation of hematopoietic stem cell differentiation,	GO:0000502~proteasome complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005839~proteasome core complex,GO:0019774~proteasome core complex, beta-subunit complex,GO:0070062~extracellular exosome,GO:1990111~spermatoproteasome complex,	GO:0004175~endopeptidase activity,GO:0004298~threonine-type endopeptidase activity,GO:0005515~protein binding,	IPR000243:Peptidase T1A, proteasome beta-subunit,IPR001353:Proteasome, subunit alpha/beta,IPR016050:Proteasome, beta-type subunit, conserved site,IPR023333:Proteasome B-type subunit,	hsa03050:Proteasome,	256040~Proteasome-associated autoinflammatory syndrome 1 and digenic forms,			KW-0221~Differentiation,KW-0391~Immunity,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0647~Proteasome,KW-0963~Cytoplasm,	KW-0225~Disease variant,			KW-0378~Hydrolase,KW-0645~Protease,KW-0888~Threonine protease,	KW-0597~Phosphoprotein,KW-0865~Zymogen,	ACT_SITE:Nucleophile,PROPEP:Removed in mature form,REGION:Disordered,SITE:Cleavage; by autolysis,
PSMD2	proteasome 26S subunit ubiquitin receptor, non-ATPase 2(PSMD2)	Homo sapiens			Posttranslational modification, protein turnover, chaperones,	GO:0000165~MAPK cascade,GO:0000209~protein polyubiquitination,GO:0002223~stimulatory C-type lectin receptor signaling pathway,GO:0002479~antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent,GO:0006521~regulation of cellular amino acid metabolic process,GO:0010972~negative regulation of G2/M transition of mitotic cell cycle,GO:0016579~protein deubiquitination,GO:0031145~anaphase-promoting complex-dependent catabolic process,GO:0031146~SCF-dependent proteasomal ubiquitin-dependent protein catabolic process,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0036388~pre-replicative complex assembly,GO:0038061~NIK/NF-kappaB signaling,GO:0038095~Fc-epsilon receptor signaling pathway,GO:0042176~regulation of protein catabolic process,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0043312~neutrophil degranulation,GO:0043488~regulation of mRNA stability,GO:0043687~post-translational protein modification,GO:0050790~regulation of catalytic activity,GO:0050852~T cell receptor signaling pathway,GO:0055085~transmembrane transport,GO:0060071~Wnt signaling pathway, planar cell polarity pathway,GO:0061418~regulation of transcription from RNA polymerase II promoter in response to hypoxia,GO:0070498~interleukin-1-mediated signaling pathway,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:1901990~regulation of mitotic cell cycle phase transition,GO:1902036~regulation of hematopoietic stem cell differentiation,	GO:0000502~proteasome complex,GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005838~proteasome regulatory particle,GO:0008540~proteasome regulatory particle, base subcomplex,GO:0016020~membrane,GO:0022624~proteasome accessory complex,GO:0034515~proteasome storage granule,GO:0034774~secretory granule lumen,GO:0070062~extracellular exosome,GO:1904813~ficolin-1-rich granule lumen,	GO:0005515~protein binding,GO:0030234~enzyme regulator activity,	IPR002015:Proteasome/cyclosome, regulatory subunit,IPR011989:Armadillo-like helical,IPR016024:Armadillo-type fold,IPR016643:26S proteasome regulatory complex, non-ATPase subcomplex, Rpn1 subunit,	hsa03050:Proteasome,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05017:Spinocerebellar ataxia,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05169:Epstein-Barr virus infection,		PIRSF015965:26S proteasome regulatory complex, non-ATPase subcomplex, Rpn1 subunit,			KW-0647~Proteasome,		KW-0677~Repeat,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:RPN1_RPN2_N,REGION:Disordered,REPEAT:PC 1,REPEAT:PC 2,REPEAT:PC 3,REPEAT:PC 4,REPEAT:PC 5,REPEAT:PC 6,REPEAT:PC 7,
PSMD4	proteasome 26S subunit ubiquitin receptor, non-ATPase 4(PSMD4)	Homo sapiens				GO:0000165~MAPK cascade,GO:0000209~protein polyubiquitination,GO:0002223~stimulatory C-type lectin receptor signaling pathway,GO:0002479~antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent,GO:0006521~regulation of cellular amino acid metabolic process,GO:0010972~negative regulation of G2/M transition of mitotic cell cycle,GO:0016579~protein deubiquitination,GO:0031145~anaphase-promoting complex-dependent catabolic process,GO:0031146~SCF-dependent proteasomal ubiquitin-dependent protein catabolic process,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0036388~pre-replicative complex assembly,GO:0038061~NIK/NF-kappaB signaling,GO:0038095~Fc-epsilon receptor signaling pathway,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0043248~proteasome assembly,GO:0043488~regulation of mRNA stability,GO:0043687~post-translational protein modification,GO:0050852~T cell receptor signaling pathway,GO:0055085~transmembrane transport,GO:0060071~Wnt signaling pathway, planar cell polarity pathway,GO:0061418~regulation of transcription from RNA polymerase II promoter in response to hypoxia,GO:0070498~interleukin-1-mediated signaling pathway,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:1901990~regulation of mitotic cell cycle phase transition,GO:1902036~regulation of hematopoietic stem cell differentiation,	GO:0000502~proteasome complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0008540~proteasome regulatory particle, base subcomplex,GO:0022624~proteasome accessory complex,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0031593~polyubiquitin binding,GO:0042802~identical protein binding,	IPR002035:von Willebrand factor, type A,IPR003903:Ubiquitin interacting motif,	hsa03050:Proteasome,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05017:Spinocerebellar ataxia,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05169:Epstein-Barr virus infection,			SM00327:VWA,SM00726:UIM,		KW-0647~Proteasome,		KW-0175~Coiled coil,KW-0677~Repeat,			KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:UIM 1,DOMAIN:UIM 2,DOMAIN:VWFA,REGION:Disordered,REGION:Essential for ubiquitin-binding,REGION:Interaction with UBQLN1,
PSMD10	proteasome 26S subunit, non-ATPase 10(PSMD10)	Homo sapiens				GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000165~MAPK cascade,GO:0000209~protein polyubiquitination,GO:0002223~stimulatory C-type lectin receptor signaling pathway,GO:0002479~antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent,GO:0006521~regulation of cellular amino acid metabolic process,GO:0006915~apoptotic process,GO:0007253~cytoplasmic sequestering of NF-kappaB,GO:0010972~negative regulation of G2/M transition of mitotic cell cycle,GO:0016579~protein deubiquitination,GO:0030307~positive regulation of cell growth,GO:0031145~anaphase-promoting complex-dependent catabolic process,GO:0031146~SCF-dependent proteasomal ubiquitin-dependent protein catabolic process,GO:0031398~positive regulation of protein ubiquitination,GO:0032088~negative regulation of NF-kappaB transcription factor activity,GO:0032436~positive regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0036388~pre-replicative complex assembly,GO:0038061~NIK/NF-kappaB signaling,GO:0038095~Fc-epsilon receptor signaling pathway,GO:0043066~negative regulation of apoptotic process,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0043409~negative regulation of MAPK cascade,GO:0043488~regulation of mRNA stability,GO:0043518~negative regulation of DNA damage response, signal transduction by p53 class mediator,GO:0043687~post-translational protein modification,GO:0045737~positive regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0050852~T cell receptor signaling pathway,GO:0055085~transmembrane transport,GO:0060071~Wnt signaling pathway, planar cell polarity pathway,GO:0061418~regulation of transcription from RNA polymerase II promoter in response to hypoxia,GO:0070498~interleukin-1-mediated signaling pathway,GO:0070682~proteasome regulatory particle assembly,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:0090201~negative regulation of release of cytochrome c from mitochondria,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:1901990~regulation of mitotic cell cycle phase transition,GO:1902036~regulation of hematopoietic stem cell differentiation,	GO:0000502~proteasome complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0045111~intermediate filament cytoskeleton,	GO:0005515~protein binding,GO:0008134~transcription factor binding,	IPR002110:Ankyrin repeat,IPR020683:Ankyrin repeat-containing domain,				SM00248:ANK,	KW-0053~Apoptosis,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0040~ANK repeat,KW-0677~Repeat,		KW-0143~Chaperone,		DOMAIN:Ankyrin_rpt-contain_dom,MUTAGEN:E->A: Abolishes interaction with RB1.,REGION:Interaction with RB1,REGION:Interaction with RELA,REGION:Required for nuclear localization,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,REPEAT:ANK 5,REPEAT:ANK 6,REPEAT:ANK 7,
PSMD9	proteasome 26S subunit, non-ATPase 9(PSMD9)	Homo sapiens				GO:0000165~MAPK cascade,GO:0000209~protein polyubiquitination,GO:0002223~stimulatory C-type lectin receptor signaling pathway,GO:0002479~antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0006521~regulation of cellular amino acid metabolic process,GO:0010972~negative regulation of G2/M transition of mitotic cell cycle,GO:0016579~protein deubiquitination,GO:0031145~anaphase-promoting complex-dependent catabolic process,GO:0031146~SCF-dependent proteasomal ubiquitin-dependent protein catabolic process,GO:0032024~positive regulation of insulin secretion,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0036388~pre-replicative complex assembly,GO:0038061~NIK/NF-kappaB signaling,GO:0038095~Fc-epsilon receptor signaling pathway,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0043488~regulation of mRNA stability,GO:0043687~post-translational protein modification,GO:0045893~positive regulation of transcription, DNA-templated,GO:0046676~negative regulation of insulin secretion,GO:0050852~T cell receptor signaling pathway,GO:0055085~transmembrane transport,GO:0060071~Wnt signaling pathway, planar cell polarity pathway,GO:0061418~regulation of transcription from RNA polymerase II promoter in response to hypoxia,GO:0070498~interleukin-1-mediated signaling pathway,GO:0070682~proteasome regulatory particle assembly,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:1901990~regulation of mitotic cell cycle phase transition,GO:1902036~regulation of hematopoietic stem cell differentiation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005838~proteasome regulatory particle,	GO:0003713~transcription coactivator activity,GO:0005515~protein binding,GO:0043425~bHLH transcription factor binding,	IPR001478:PDZ domain,	hsa03050:Proteasome,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05017:Spinocerebellar ataxia,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,			SM00228:PDZ,						KW-0143~Chaperone,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Nas2_N,DOMAIN:PDZ,REGION:Disordered,
PSME1	proteasome activator subunit 1(PSME1)	Homo sapiens				GO:0000165~MAPK cascade,GO:0000209~protein polyubiquitination,GO:0002223~stimulatory C-type lectin receptor signaling pathway,GO:0002479~antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent,GO:0006521~regulation of cellular amino acid metabolic process,GO:0010950~positive regulation of endopeptidase activity,GO:0010972~negative regulation of G2/M transition of mitotic cell cycle,GO:0016579~protein deubiquitination,GO:0019884~antigen processing and presentation of exogenous antigen,GO:0031145~anaphase-promoting complex-dependent catabolic process,GO:0031146~SCF-dependent proteasomal ubiquitin-dependent protein catabolic process,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0036388~pre-replicative complex assembly,GO:0038061~NIK/NF-kappaB signaling,GO:0038095~Fc-epsilon receptor signaling pathway,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0043488~regulation of mRNA stability,GO:0043687~post-translational protein modification,GO:0050852~T cell receptor signaling pathway,GO:0055085~transmembrane transport,GO:0060071~Wnt signaling pathway, planar cell polarity pathway,GO:0061136~regulation of proteasomal protein catabolic process,GO:0061418~regulation of transcription from RNA polymerase II promoter in response to hypoxia,GO:0070498~interleukin-1-mediated signaling pathway,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:1901990~regulation of mitotic cell cycle phase transition,GO:1902036~regulation of hematopoietic stem cell differentiation,GO:2000045~regulation of G1/S transition of mitotic cell cycle,	GO:0000502~proteasome complex,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0008537~proteasome activator complex,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0061133~endopeptidase activator activity,	IPR003185:Proteasome activator pa28, REG alpha subunit,IPR003186:Proteasome activator pa28, REG beta subunit,IPR009077:Proteasome activator pa28, REG alpha/beta subunit,	hsa03050:Proteasome,hsa04612:Antigen processing and presentation,					KW-0647~Proteasome,						COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:PA28_alpha,DOMAIN:PA28_beta,REGION:Disordered,
PSME2	proteasome activator subunit 2(PSME2)	Homo sapiens				GO:0000165~MAPK cascade,GO:0000209~protein polyubiquitination,GO:0002223~stimulatory C-type lectin receptor signaling pathway,GO:0002479~antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent,GO:0006521~regulation of cellular amino acid metabolic process,GO:0010950~positive regulation of endopeptidase activity,GO:0010972~negative regulation of G2/M transition of mitotic cell cycle,GO:0016579~protein deubiquitination,GO:0031145~anaphase-promoting complex-dependent catabolic process,GO:0031146~SCF-dependent proteasomal ubiquitin-dependent protein catabolic process,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0035722~interleukin-12-mediated signaling pathway,GO:0036388~pre-replicative complex assembly,GO:0038061~NIK/NF-kappaB signaling,GO:0038095~Fc-epsilon receptor signaling pathway,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0043488~regulation of mRNA stability,GO:0043687~post-translational protein modification,GO:0050852~T cell receptor signaling pathway,GO:0055085~transmembrane transport,GO:0060071~Wnt signaling pathway, planar cell polarity pathway,GO:0061136~regulation of proteasomal protein catabolic process,GO:0061418~regulation of transcription from RNA polymerase II promoter in response to hypoxia,GO:0070498~interleukin-1-mediated signaling pathway,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:1901990~regulation of mitotic cell cycle phase transition,GO:1902036~regulation of hematopoietic stem cell differentiation,GO:2000045~regulation of G1/S transition of mitotic cell cycle,	GO:0000502~proteasome complex,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0008537~proteasome activator complex,GO:0016020~membrane,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0061133~endopeptidase activator activity,	IPR003185:Proteasome activator pa28, REG alpha subunit,IPR003186:Proteasome activator pa28, REG beta subunit,IPR009077:Proteasome activator pa28, REG alpha/beta subunit,	hsa03050:Proteasome,hsa04612:Antigen processing and presentation,					KW-0647~Proteasome,					KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:PA28_alpha,DOMAIN:PA28_beta,REGION:Disordered,
PSMG1	proteasome assembly chaperone 1(PSMG1)	Homo sapiens				GO:0021930~cerebellar granule cell precursor proliferation,GO:0043248~proteasome assembly,GO:0051131~chaperone-mediated protein complex assembly,GO:0080129~proteasome core complex assembly,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0101031~chaperone complex,	GO:0005515~protein binding,GO:0060090~binding, bridging,GO:0070628~proteasome binding,	IPR016565:Proteasome assembly chaperone 1,			PIRSF010076:proteasome assembling chaperone-1,			KW-0256~Endoplasmic reticulum,KW-0963~Cytoplasm,				KW-0143~Chaperone,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	REGION:Disordered,
PSMF1	proteasome inhibitor subunit 1(PSMF1)	Homo sapiens				GO:0000165~MAPK cascade,GO:0000209~protein polyubiquitination,GO:0002223~stimulatory C-type lectin receptor signaling pathway,GO:0002479~antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0006521~regulation of cellular amino acid metabolic process,GO:0010951~negative regulation of endopeptidase activity,GO:0010972~negative regulation of G2/M transition of mitotic cell cycle,GO:0016579~protein deubiquitination,GO:0031145~anaphase-promoting complex-dependent catabolic process,GO:0031146~SCF-dependent proteasomal ubiquitin-dependent protein catabolic process,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0036388~pre-replicative complex assembly,GO:0038061~NIK/NF-kappaB signaling,GO:0038095~Fc-epsilon receptor signaling pathway,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0043488~regulation of mRNA stability,GO:0043687~post-translational protein modification,GO:0050852~T cell receptor signaling pathway,GO:0055085~transmembrane transport,GO:0060071~Wnt signaling pathway, planar cell polarity pathway,GO:0061418~regulation of transcription from RNA polymerase II promoter in response to hypoxia,GO:0070498~interleukin-1-mediated signaling pathway,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:1901799~negative regulation of proteasomal protein catabolic process,GO:1901990~regulation of mitotic cell cycle phase transition,GO:1902036~regulation of hematopoietic stem cell differentiation,	GO:0000502~proteasome complex,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005839~proteasome core complex,GO:0016020~membrane,GO:0048471~perinuclear region of cytoplasm,	GO:0004866~endopeptidase inhibitor activity,GO:0005515~protein binding,GO:0042803~protein homodimerization activity,GO:0046982~protein heterodimerization activity,GO:0070628~proteasome binding,	IPR013886:PI31 proteasome regulator,IPR021625:Proteasome Inhibitor PI31,	hsa03050:Proteasome,					KW-0256~Endoplasmic reticulum,KW-0647~Proteasome,KW-0963~Cytoplasm,					KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DOMAIN:PI31_Prot_C,DOMAIN:PI31_Prot_N,MUTAGEN:I->E: Abolishes interaction with FBXO7, but has no effect on homodimerization; when associated with E-83.,MUTAGEN:I->E: Abolishes interaction with FBXO7, but has no effect on homodimerization; when associated with E-90.,MUTAGEN:V->R: Abolishes homodimerization.,REGION:Disordered,REGION:Important for homodimerization and interaction with FBXO7,
PROS1	protein S(PROS1)	Homo sapiens		h_amiPathway:Acute Myocardial Infarction,h_extrinsicPathway:Extrinsic Prothrombin Activation Pathway,h_intrinsicPathway:Intrinsic Prothrombin Activation Pathway,		GO:0002576~platelet degranulation,GO:0006888~ER to Golgi vesicle-mediated transport,GO:0007596~blood coagulation,GO:0010951~negative regulation of endopeptidase activity,GO:0030195~negative regulation of blood coagulation,GO:0030449~regulation of complement activation,GO:0042730~fibrinolysis,GO:0050900~leukocyte migration,	GO:0000139~Golgi membrane,GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005789~endoplasmic reticulum membrane,GO:0005796~Golgi lumen,GO:0005886~plasma membrane,GO:0031093~platelet alpha granule lumen,GO:0070062~extracellular exosome,GO:0072562~blood microparticle,	GO:0004866~endopeptidase inhibitor activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,	IPR000152:EGF-type aspartate/asparagine hydroxylation site,IPR000294:Gamma-carboxyglutamic acid-rich (GLA) domain,IPR000742:Epidermal growth factor-like domain,IPR001791:Laminin G domain,IPR001881:EGF-like calcium-binding,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,IPR017857:Coagulation factor, subgroup, Gla domain,IPR018097:EGF-like calcium-binding, conserved site,	hsa04610:Complement and coagulation cascades,	612336~Thrombophilia due to protein S deficiency, autosomal dominant,614514~Thrombophilia due to protein S deficiency, autosomal recessive,		SM00069:GLA,SM00179:EGF_CA,SM00181:EGF,SM00282:LamG,	KW-0094~Blood coagulation,KW-0280~Fibrinolysis,KW-0356~Hemostasis,	KW-0964~Secreted,	KW-0225~Disease variant,KW-0792~Thrombophilia,	KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,		KW-0165~Cleavage on pair of basic residues,KW-0301~Gamma-carboxyglutamic acid,KW-0325~Glycoprotein,KW-0379~Hydroxylation,KW-0865~Zymogen,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 2; calcium-binding,DOMAIN:EGF-like 3; calcium-binding,DOMAIN:EGF-like 4; calcium-binding,DOMAIN:EGF_CA,DOMAIN:Gla,DOMAIN:LAM_G_DOMAIN,DOMAIN:Laminin G-like 1,DOMAIN:Laminin G-like 2,MUTAGEN:R->A,E: Markedly reduced secretion of the mutant.,MUTAGEN:R->K: No change in secretion of the mutant.,REGION:Thrombin-sensitive,SITE:Not glycosylated; in variant Heerlen,
PDIA5	protein disulfide isomerase family A member 5(PDIA5)	Homo sapiens				GO:0006457~protein folding,GO:0022900~electron transport chain,GO:0036498~IRE1-mediated unfolded protein response,	GO:0005788~endoplasmic reticulum lumen,GO:0005789~endoplasmic reticulum membrane,	GO:0003756~protein disulfide isomerase activity,GO:0005515~protein binding,GO:0015035~protein disulfide oxidoreductase activity,GO:0015037~peptide disulfide oxidoreductase activity,GO:0016491~oxidoreductase activity,	IPR013766:Thioredoxin domain,IPR017937:Thioredoxin, conserved site,						KW-0256~Endoplasmic reticulum,		KW-0676~Redox-active center,KW-0677~Repeat,KW-0732~Signal,		KW-0413~Isomerase,	KW-1015~Disulfide bond,	DISULFID:Redox-active,DOMAIN:Thioredoxin,DOMAIN:Thioredoxin 1,DOMAIN:Thioredoxin 2,DOMAIN:Thioredoxin 3,MOTIF:Prevents secretion from ER,
PRKAG2	protein kinase AMP-activated non-catalytic subunit gamma 2(PRKAG2)	Homo sapiens		h_chrebpPathway:ChREBP regulation by carbohydrates and cAMP,h_leptinPathway:Reversal of Insulin Resistance by Leptin,		GO:0005977~glycogen metabolic process,GO:0006110~regulation of glycolytic process,GO:0006468~protein phosphorylation,GO:0006469~negative regulation of protein kinase activity,GO:0006633~fatty acid biosynthetic process,GO:0006754~ATP biosynthetic process,GO:0006853~carnitine shuttle,GO:0007050~cell cycle arrest,GO:0010800~positive regulation of peptidyl-threonine phosphorylation,GO:0016126~sterol biosynthetic process,GO:0016236~macroautophagy,GO:0016241~regulation of macroautophagy,GO:0019217~regulation of fatty acid metabolic process,GO:0032147~activation of protein kinase activity,GO:0035556~intracellular signal transduction,GO:0042149~cellular response to glucose starvation,GO:0042304~regulation of fatty acid biosynthetic process,GO:0045860~positive regulation of protein kinase activity,GO:0046320~regulation of fatty acid oxidation,GO:0046324~regulation of glucose import,GO:0050790~regulation of catalytic activity,GO:0071900~regulation of protein serine/threonine kinase activity,GO:1901796~regulation of signal transduction by p53 class mediator,GO:2000480~negative regulation of cAMP-dependent protein kinase activity,	GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016021~integral component of membrane,GO:0031588~nucleotide-activated protein kinase complex,	GO:0004679~AMP-activated protein kinase activity,GO:0004862~cAMP-dependent protein kinase inhibitor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008603~cAMP-dependent protein kinase regulator activity,GO:0008607~phosphorylase kinase regulator activity,GO:0016208~AMP binding,GO:0016301~kinase activity,GO:0019887~protein kinase regulator activity,GO:0019901~protein kinase binding,GO:0030295~protein kinase activator activity,GO:0032559~adenyl ribonucleotide binding,GO:0043531~ADP binding,	IPR000644:Cystathionine beta-synthase, core,	hsa04068:FoxO signaling pathway,hsa04152:AMPK signaling pathway,hsa04211:Longevity regulating pathway,hsa04213:Longevity regulating pathway - multiple species,hsa04371:Apelin signaling pathway,hsa04530:Tight junction,hsa04710:Circadian rhythm,hsa04714:Thermogenesis,hsa04910:Insulin signaling pathway,hsa04920:Adipocytokine signaling pathway,hsa04921:Oxytocin signaling pathway,hsa04922:Glucagon signaling pathway,hsa04931:Insulin resistance,hsa04932:Non-alcoholic fatty liver disease,hsa04936:Alcoholic liver disease,hsa05410:Hypertrophic cardiomyopathy,	194200~Wolff-Parkinson-White syndrome,261740~Glycogen storage disease of heart, lethal congenital,600858~Cardiomyopathy, hypertrophic 6,		SM00116:CBS,	KW-0275~Fatty acid biosynthesis,KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,	KW-0472~Membrane,	KW-0122~Cardiomyopathy,KW-0225~Disease variant,KW-0322~Glycogen storage disease,	KW-0129~CBS domain,KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	BINDING:ADP 1; via amide nitrogen and carbonyl oxygen,BINDING:ADP 2,BINDING:AMP 1; via amide nitrogen and carbonyl oxygen,BINDING:AMP 2,BINDING:AMP 3,BINDING:AMP 3; via amide nitrogen and carbonyl oxygen,BINDING:ATP 1,BINDING:ATP 1; via amide nitrogen and carbonyl oxygen,BINDING:ATP 2,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:CBS,DOMAIN:CBS 1,DOMAIN:CBS 2,DOMAIN:CBS 3,DOMAIN:CBS 4,MOTIF:AMPK pseudosubstrate,MUTAGEN:V->S: Induces phosphorylation by AMPK.,NP_BIND:ADP 1,NP_BIND:ADP 2,NP_BIND:AMP 1,NP_BIND:AMP 2,NP_BIND:AMP 3,NP_BIND:ATP 1,NP_BIND:ATP 2,REGION:Disordered,TRANSMEM:Helical,
PACSIN3	protein kinase C and casein kinase substrate in neurons 3(PACSIN3)	Homo sapiens				GO:0006897~endocytosis,GO:0007010~cytoskeleton organization,GO:0030100~regulation of endocytosis,GO:0045806~negative regulation of endocytosis,GO:0051044~positive regulation of membrane protein ectodomain proteolysis,GO:0051926~negative regulation of calcium ion transport,GO:0097320~plasma membrane tubulation,	GO:0005737~cytoplasm,GO:0005768~endosome,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0005543~phospholipid binding,GO:0008092~cytoskeletal protein binding,GO:0008289~lipid binding,GO:0016301~kinase activity,GO:0019855~calcium channel inhibitor activity,GO:0042802~identical protein binding,	IPR001060:FCH domain,IPR001452:Src homology-3 domain,IPR027267:Arfaptin homology (AH) domain/BAR domain,				SM00055:FCH,SM00326:SH3,	KW-0254~Endocytosis,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0728~SH3 domain,	KW-0446~Lipid-binding,	KW-0418~Kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:F-BAR,DOMAIN:SH3,REGION:Disordered,
PRKCD	protein kinase C delta(PRKCD)	Homo sapiens		h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_keratinocytePathway:Keratinocyte Differentiation,		GO:0002223~stimulatory C-type lectin receptor signaling pathway,GO:0006468~protein phosphorylation,GO:0006915~apoptotic process,GO:0007049~cell cycle,GO:0007165~signal transduction,GO:0008631~intrinsic apoptotic signaling pathway in response to oxidative stress,GO:0010469~regulation of receptor activity,GO:0016064~immunoglobulin mediated immune response,GO:0016572~histone phosphorylation,GO:0018105~peptidyl-serine phosphorylation,GO:0018107~peptidyl-threonine phosphorylation,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0023021~termination of signal transduction,GO:0030168~platelet activation,GO:0030837~negative regulation of actin filament polymerization,GO:0032079~positive regulation of endodeoxyribonuclease activity,GO:0032091~negative regulation of protein binding,GO:0032147~activation of protein kinase activity,GO:0032930~positive regulation of superoxide anion generation,GO:0032956~regulation of actin cytoskeleton organization,GO:0034351~negative regulation of glial cell apoptotic process,GO:0034644~cellular response to UV,GO:0035307~positive regulation of protein dephosphorylation,GO:0035556~intracellular signal transduction,GO:0038096~Fc-gamma receptor signaling pathway involved in phagocytosis,GO:0042100~B cell proliferation,GO:0042119~neutrophil activation,GO:0042307~positive regulation of protein import into nucleus,GO:0042742~defense response to bacterium,GO:0043312~neutrophil degranulation,GO:0043407~negative regulation of MAP kinase activity,GO:0043488~regulation of mRNA stability,GO:0046627~negative regulation of insulin receptor signaling pathway,GO:0050728~negative regulation of inflammatory response,GO:0050732~negative regulation of peptidyl-tyrosine phosphorylation,GO:0050821~protein stabilization,GO:0051490~negative regulation of filopodium assembly,GO:0060326~cell chemotaxis,GO:0060333~interferon-gamma-mediated signaling pathway,GO:0070301~cellular response to hydrogen peroxide,GO:0071447~cellular response to hydroperoxide,GO:0090331~negative regulation of platelet aggregation,GO:0090398~cellular senescence,GO:1900163~positive regulation of phospholipid scramblase activity,GO:1904385~cellular response to angiotensin,GO:2000303~regulation of ceramide biosynthetic process,GO:2000304~positive regulation of ceramide biosynthetic process,GO:2000753~positive regulation of glucosylceramide catabolic process,GO:2000755~positive regulation of sphingomyelin catabolic process,GO:2001022~positive regulation of response to DNA damage stimulus,GO:2001235~positive regulation of apoptotic signaling pathway,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0016020~membrane,GO:0016363~nuclear matrix,GO:0035578~azurophil granule lumen,GO:0036019~endolysosome,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004697~protein kinase C activity,GO:0004698~calcium-dependent protein kinase C activity,GO:0004699~calcium-independent protein kinase C activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0004715~non-membrane spanning protein tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008047~enzyme activator activity,GO:0019899~enzyme binding,GO:0019900~kinase binding,GO:0019901~protein kinase binding,GO:0043560~insulin receptor substrate binding,GO:0046872~metal ion binding,	IPR000719:Protein kinase, catalytic domain,IPR000961:AGC-kinase, C-terminal,IPR002219:Protein kinase C-like, phorbol ester/diacylglycerol binding,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR014376:Protein kinase C, delta/epsilon/eta/theta types,IPR017441:Protein kinase, ATP binding site,IPR017892:Protein kinase, C-terminal,IPR020454:Diacylglycerol/phorbol-ester binding,IPR027436:Protein kinase C, delta,	hsa04062:Chemokine signaling pathway,hsa04140:Autophagy - animal,hsa04270:Vascular smooth muscle contraction,hsa04621:NOD-like receptor signaling pathway,hsa04625:C-type lectin receptor signaling pathway,hsa04666:Fc gamma R-mediated phagocytosis,hsa04722:Neurotrophin signaling pathway,hsa04750:Inflammatory mediator regulation of TRP channels,hsa04912:GnRH signaling pathway,hsa04915:Estrogen signaling pathway,hsa04930:Type II diabetes mellitus,hsa04931:Insulin resistance,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa05020:Prion disease,hsa05131:Shigellosis,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05415:Diabetic cardiomyopathy,	615559~Autoimmune lymphoproliferative syndrome, type III,	PIRSF000551:protein kinase C, delta/epsilon/eta/theta types,PIRSF501104:protein kinase C delta type [Parent=PIRSF000551],	SM00109:C1,SM00133:S_TK_X,SM00220:S_TKc,	KW-0053~Apoptosis,KW-0131~Cell cycle,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0043~Tumor suppressor,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0067~ATP-binding,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0862~Zinc,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:ATP,DOMAIN:AGC-kinase C-terminal,DOMAIN:C2,DOMAIN:Phorbol-ester/DAG-type,DOMAIN:Protein kinase,MUTAGEN:S->A: Loss of phosphorylation.,MUTAGEN:T->A: No effect on kinase activity.,NP_BIND:ATP,SITE:Cleavage; by caspase-3,SITE:Interaction with phosphotyrosine-containing peptide,ZN_FING:Phorbol-ester/DAG-type 1,ZN_FING:Phorbol-ester/DAG-type 2,
PRKCH	protein kinase C eta(PRKCH)	Homo sapiens		h_keratinocytePathway:Keratinocyte Differentiation,		GO:0006468~protein phosphorylation,GO:0007165~signal transduction,GO:0010744~positive regulation of macrophage derived foam cell differentiation,GO:0018105~peptidyl-serine phosphorylation,GO:0030154~cell differentiation,GO:0030168~platelet activation,GO:0034351~negative regulation of glial cell apoptotic process,GO:0035556~intracellular signal transduction,GO:0045618~positive regulation of keratinocyte differentiation,GO:0050861~positive regulation of B cell receptor signaling pathway,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0060252~positive regulation of glial cell proliferation,GO:1903078~positive regulation of protein localization to plasma membrane,GO:2000810~regulation of bicellular tight junction assembly,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0070062~extracellular exosome,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004697~protein kinase C activity,GO:0004698~calcium-dependent protein kinase C activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0019899~enzyme binding,GO:0046872~metal ion binding,	IPR000008:C2 calcium-dependent membrane targeting,IPR000719:Protein kinase, catalytic domain,IPR000961:AGC-kinase, C-terminal,IPR002219:Protein kinase C-like, phorbol ester/diacylglycerol binding,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR014376:Protein kinase C, delta/epsilon/eta/theta types,IPR015727:Protein kinase C mu-related,IPR017441:Protein kinase, ATP binding site,IPR017892:Protein kinase, C-terminal,IPR020454:Diacylglycerol/phorbol-ester binding,IPR027431:Protein kinase C, eta,	hsa04270:Vascular smooth muscle contraction,hsa04750:Inflammatory mediator regulation of TRP channels,	601367~Cerebral infarction, susceptibility to,	PIRSF000551:protein kinase C, delta/epsilon/eta/theta types,PIRSF501107:protein kinase C eta type [Parent=PIRSF000551],	SM00109:C1,SM00133:S_TK_X,SM00220:S_TKc,SM00239:C2,	KW-0221~Differentiation,	KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0067~ATP-binding,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0862~Zinc,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:ATP,DOMAIN:AGC-kinase C-terminal,DOMAIN:C2,DOMAIN:Phorbol-ester/DAG-type,DOMAIN:Protein kinase,NP_BIND:ATP,REGION:Disordered,ZN_FING:Phorbol-ester/DAG-type 1,ZN_FING:Phorbol-ester/DAG-type 2,
PRKCQ	protein kinase C theta(PRKCQ)	Homo sapiens		h_keratinocytePathway:Keratinocyte Differentiation,		GO:0000165~MAPK cascade,GO:0001558~regulation of cell growth,GO:0002376~immune system process,GO:0006355~regulation of transcription, DNA-templated,GO:0006509~membrane protein ectodomain proteolysis,GO:0006954~inflammatory response,GO:0007411~axon guidance,GO:0018105~peptidyl-serine phosphorylation,GO:0030168~platelet activation,GO:0032212~positive regulation of telomere maintenance via telomerase,GO:0032740~positive regulation of interleukin-17 production,GO:0032743~positive regulation of interleukin-2 production,GO:0032753~positive regulation of interleukin-4 production,GO:0035556~intracellular signal transduction,GO:0038095~Fc-epsilon receptor signaling pathway,GO:0042102~positive regulation of T cell proliferation,GO:0045652~regulation of megakaryocyte differentiation,GO:0046627~negative regulation of insulin receptor signaling pathway,GO:0050852~T cell receptor signaling pathway,GO:0050870~positive regulation of T cell activation,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051973~positive regulation of telomerase activity,GO:0060326~cell chemotaxis,GO:0070233~negative regulation of T cell apoptotic process,GO:0090330~regulation of platelet aggregation,GO:1904355~positive regulation of telomere capping,GO:2000318~positive regulation of T-helper 17 type immune response,GO:2000570~positive regulation of T-helper 2 cell activation,	GO:0001772~immunological synapse,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016235~aggresome,GO:0034451~centriolar satellite,	GO:0004674~protein serine/threonine kinase activity,GO:0004697~protein kinase C activity,GO:0004698~calcium-dependent protein kinase C activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0046872~metal ion binding,	IPR000719:Protein kinase, catalytic domain,IPR000961:AGC-kinase, C-terminal,IPR002219:Protein kinase C-like, phorbol ester/diacylglycerol binding,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR014376:Protein kinase C, delta/epsilon/eta/theta types,IPR017441:Protein kinase, ATP binding site,IPR017892:Protein kinase, C-terminal,IPR020454:Diacylglycerol/phorbol-ester binding,IPR027264:Protein kinase C, theta,	hsa04064:NF-kappa B signaling pathway,hsa04140:Autophagy - animal,hsa04270:Vascular smooth muscle contraction,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04660:T cell receptor signaling pathway,hsa04750:Inflammatory mediator regulation of TRP channels,hsa04920:Adipocytokine signaling pathway,hsa04931:Insulin resistance,hsa05131:Shigellosis,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,		PIRSF000551:protein kinase C, delta/epsilon/eta/theta types,PIRSF501105:protein kinase C theta type [Parent=PIRSF000551],	SM00109:C1,SM00133:S_TK_X,SM00220:S_TKc,	KW-0391~Immunity,KW-0395~Inflammatory response,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0862~Zinc,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:ATP,DOMAIN:AGC-kinase C-terminal,DOMAIN:C2,DOMAIN:Phorbol-ester/DAG-type,DOMAIN:Protein kinase,MUTAGEN:A->E: Constitutively active form.,MUTAGEN:K->A,E: Loss of kinase activity.,MUTAGEN:S->A: Reduction in kinase activity.,MUTAGEN:T->A: Loss of kinase activity.,MUTAGEN:T->A: Loss of transactivation of the IL2 promoter and translocation to the plasma membrane. No effect on kinase activity.,MUTAGEN:Y->F: Loss of function in T-cells proliferation. No effect on kinase activity.,NP_BIND:ATP,ZN_FING:Phorbol-ester/DAG-type 1,ZN_FING:Phorbol-ester/DAG-type 2,
PRKX	protein kinase X-linked(PRKX)	Homo sapiens				GO:0001525~angiogenesis,GO:0001935~endothelial cell proliferation,GO:0007155~cell adhesion,GO:0007165~signal transduction,GO:0018105~peptidyl-serine phosphorylation,GO:0030099~myeloid cell differentiation,GO:0030155~regulation of cell adhesion,GO:0030334~regulation of cell migration,GO:0031589~cell-substrate adhesion,GO:0043542~endothelial cell migration,GO:0046777~protein autophosphorylation,GO:0060562~epithelial tube morphogenesis,GO:0060993~kidney morphogenesis,GO:2000696~regulation of epithelial cell differentiation involved in kidney development,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005952~cAMP-dependent protein kinase complex,	GO:0004674~protein serine/threonine kinase activity,GO:0004691~cAMP-dependent protein kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,	IPR000719:Protein kinase, catalytic domain,IPR000961:AGC-kinase, C-terminal,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,				SM00133:S_TK_X,SM00220:S_TKc,	KW-0037~Angiogenesis,KW-0221~Differentiation,	KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0114~cAMP,KW-0547~Nucleotide-binding,	KW-0217~Developmental protein,KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:ATP,DOMAIN:AGC-kinase C-terminal,DOMAIN:Protein kinase,MUTAGEN:H->Q: Constitutive kinase activity; when associated with R-202.,MUTAGEN:K->R: Loss of function.,MUTAGEN:R->L: Increases the affinity for PRKAR2A and PRKAR2B.,MUTAGEN:W->R: Constitutive kinase activity; when associated with Q-93.,NP_BIND:ATP,REGION:Disordered,
PRKACA	protein kinase cAMP-activated catalytic subunit alpha(PRKACA)	Homo sapiens		h_gsPathway:Activation of cAMP-dependent protein kinase, PKA,		GO:0000086~G2/M transition of mitotic cell cycle,GO:0001707~mesoderm formation,GO:0001843~neural tube closure,GO:0002027~regulation of heart rate,GO:0002223~stimulatory C-type lectin receptor signaling pathway,GO:0002250~adaptive immune response,GO:0002862~negative regulation of inflammatory response to antigenic stimulus,GO:0003091~renal water homeostasis,GO:0006397~mRNA processing,GO:0006468~protein phosphorylation,GO:0007268~chemical synaptic transmission,GO:0007596~blood coagulation,GO:0010389~regulation of G2/M transition of mitotic cell cycle,GO:0010737~protein kinase A signaling,GO:0010881~regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion,GO:0016241~regulation of macroautophagy,GO:0018105~peptidyl-serine phosphorylation,GO:0018107~peptidyl-threonine phosphorylation,GO:0019221~cytokine-mediated signaling pathway,GO:0034199~activation of protein kinase A activity,GO:0034380~high-density lipoprotein particle assembly,GO:0034605~cellular response to heat,GO:0035584~calcium-mediated signaling using intracellular calcium source,GO:0043393~regulation of protein binding,GO:0045667~regulation of osteoblast differentiation,GO:0046777~protein autophosphorylation,GO:0046827~positive regulation of protein export from nucleus,GO:0048240~sperm capacitation,GO:0050804~modulation of synaptic transmission,GO:0051480~regulation of cytosolic calcium ion concentration,GO:0051726~regulation of cell cycle,GO:0055117~regulation of cardiac muscle contraction,GO:0060314~regulation of ryanodine-sensitive calcium-release channel activity,GO:0061136~regulation of proteasomal protein catabolic process,GO:0070417~cellular response to cold,GO:0070613~regulation of protein processing,GO:0071158~positive regulation of cell cycle arrest,GO:0071333~cellular response to glucose stimulus,GO:0071374~cellular response to parathyroid hormone stimulus,GO:0071377~cellular response to glucagon stimulus,GO:0071872~cellular response to epinephrine stimulus,GO:0086064~cell communication by electrical coupling involved in cardiac conduction,GO:0097711~ciliary basal body docking,GO:1901621~negative regulation of smoothened signaling pathway involved in dorsal/ventral neural tube patterning,GO:1903779~regulation of cardiac conduction,GO:1990044~protein localization to lipid particle,GO:2000810~regulation of bicellular tight junction assembly,	GO:0001669~acrosomal vesicle,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005930~axoneme,GO:0005952~cAMP-dependent protein kinase complex,GO:0016020~membrane,GO:0016607~nuclear speck,GO:0031588~nucleotide-activated protein kinase complex,GO:0031594~neuromuscular junction,GO:0034704~calcium channel complex,GO:0036126~sperm flagellum,GO:0043197~dendritic spine,GO:0044853~plasma membrane raft,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:0097225~sperm midpiece,GO:0097546~ciliary base,	GO:0000287~magnesium ion binding,GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004679~AMP-activated protein kinase activity,GO:0004691~cAMP-dependent protein kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0019901~protein kinase binding,GO:0019904~protein domain specific binding,GO:0030145~manganese ion binding,GO:0031625~ubiquitin protein ligase binding,GO:0034237~protein kinase A regulatory subunit binding,	IPR000719:Protein kinase, catalytic domain,IPR000961:AGC-kinase, C-terminal,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,	hsa01522:Endocrine resistance,hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04020:Calcium signaling pathway,hsa04024:cAMP signaling pathway,hsa04062:Chemokine signaling pathway,hsa04114:Oocyte meiosis,hsa04140:Autophagy - animal,hsa04211:Longevity regulating pathway,hsa04213:Longevity regulating pathway - multiple species,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04270:Vascular smooth muscle contraction,hsa04310:Wnt signaling pathway,hsa04340:Hedgehog signaling pathway,hsa04371:Apelin signaling pathway,hsa04530:Tight junction,hsa04540:Gap junction,hsa04611:Platelet activation,hsa04713:Circadian entrainment,hsa04714:Thermogenesis,hsa04720:Long-term potentiation,hsa04723:Retrograde endocannabinoid signaling,hsa04724:Glutamatergic synapse,hsa04725:Cholinergic synapse,hsa04726:Serotonergic synapse,hsa04727:GABAergic synapse,hsa04728:Dopaminergic synapse,hsa04740:Olfactory transduction,hsa04742:Taste transduction,hsa04750:Inflammatory mediator regulation of TRP channels,hsa04910:Insulin signaling pathway,hsa04911:Insulin secretion,hsa04912:GnRH signaling pathway,hsa04913:Ovarian steroidogenesis,hsa04914:Progesterone-mediated oocyte maturation,hsa04915:Estrogen signaling pathway,hsa04916:Melanogenesis,hsa04918:Thyroid hormone synthesis,hsa04919:Thyroid hormone signaling pathway,hsa04921:Oxytocin signaling pathway,hsa04922:Glucagon signaling pathway,hsa04923:Regulation of lipolysis in adipocytes,hsa04924:Renin secretion,hsa04925:Aldosterone synthesis and secretion,hsa04926:Relaxin signaling pathway,hsa04927:Cortisol synthesis and secretion,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04934:Cushing syndrome,hsa04935:Growth hormone synthesis, secretion and action,hsa04961:Endocrine and other factor-regulated calcium reabsorption,hsa04962:Vasopressin-regulated water reabsorption,hsa04970:Salivary secretion,hsa04971:Gastric acid secretion,hsa04976:Bile secretion,hsa05012:Parkinson disease,hsa05020:Prion disease,hsa05030:Cocaine addiction,hsa05031:Amphetamine addiction,hsa05032:Morphine addiction,hsa05034:Alcoholism,hsa05110:Vibrio cholerae infection,hsa05146:Amoebiasis,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05205:Proteoglycans in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05414:Dilated cardiomyopathy,	615830~Cushing syndrome, ACTH-independent adrenal, somatic,619142~Cardioacrofacial dysplasia 1,		SM00133:S_TK_X,SM00220:S_TKc,		KW-0282~Flagellum,KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0968~Cytoplasmic vesicle,KW-0969~Cilium,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-1062~Cushing syndrome,		KW-0067~ATP-binding,KW-0114~cAMP,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0449~Lipoprotein,KW-0519~Myristate,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:ATP,DOMAIN:AGC-kinase C-terminal,DOMAIN:Protein kinase,LIPID:N-myristoyl glycine,MUTAGEN:G->A: No phosphorylation.,MUTAGEN:K->R: Enhanced basal kinase activity; when associated with Q-96, L-121, A-124, K-182 and A-184.,MUTAGEN:L->Q: Enhanced basal kinase activity; when associated with R-48, L-121, A-124, K-182 and A-184.,MUTAGEN:M->L: Enhanced basal kinase activity; when associated with R-48, Q-96, A-124, K-182 and A-184.,MUTAGEN:Q->K: Enhanced basal kinase activity; when associated with R-48, Q-96, L-121, A-124 and A-184.,MUTAGEN:R->A: No phosphorylation.,MUTAGEN:T->A: Enhanced basal kinase activity; when associated with R-48, Q-96, L-121, A-124 and K-182.,MUTAGEN:T->A: No phosphorylation.,MUTAGEN:V->A: Enhanced basal kinase activity; when associated with R-48, Q-96, L-121, K-182 and A-184.,MUTAGEN:Y->A: Loss of allosteric regulation.,NP_BIND:ATP,REGION:Disordered,
PPP1R13B	protein phosphatase 1 regulatory subunit 13B(PPP1R13B)	Homo sapiens				GO:0006915~apoptotic process,GO:0042981~regulation of apoptotic process,GO:0045786~negative regulation of cell cycle,GO:0072332~intrinsic apoptotic signaling pathway by p53 class mediator,GO:1900740~positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway,GO:1901216~positive regulation of neuron death,GO:1901796~regulation of signal transduction by p53 class mediator,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0048471~perinuclear region of cytoplasm,	GO:0002039~p53 binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,	IPR001452:Src homology-3 domain,IPR002110:Ankyrin repeat,IPR020683:Ankyrin repeat-containing domain,				SM00248:ANK,SM00326:SH3,	KW-0053~Apoptosis,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0040~ANK repeat,KW-0175~Coiled coil,KW-0677~Repeat,KW-0728~SH3 domain,			KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Ankyrin_rpt-contain_dom,DOMAIN:SH3,REGION:Disordered,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,
PPP2R3C	protein phosphatase 2 regulatory subunit B''gamma(PPP2R3C)	Homo sapiens				GO:0000226~microtubule cytoskeleton organization,GO:0001782~B cell homeostasis,GO:0002759~regulation of antimicrobial humoral response,GO:0030865~cortical cytoskeleton organization,GO:0032147~activation of protein kinase activity,GO:0035303~regulation of dephosphorylation,GO:0043029~T cell homeostasis,GO:0045579~positive regulation of B cell differentiation,GO:0048536~spleen development,GO:0051900~regulation of mitochondrial depolarization,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005813~centrosome,GO:0005819~spindle,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR011992:EF-hand-like domain,IPR018247:EF-Hand 1, calcium-binding site,	hsa03015:mRNA surveillance pathway,hsa04071:Sphingolipid signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04152:AMPK signaling pathway,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04728:Dopaminergic synapse,hsa05165:Human papillomavirus infection,	618419~Gonadal dysgenesis, dysmorphic facies, retinal dystrophy, and myopathy,618420~Spermatogenic failure 36,				KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0182~Cone-rod dystrophy,KW-0209~Deafness,KW-0225~Disease variant,	KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,			CA_BIND:1,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:EF-hand_13,
PPP2R5A	protein phosphatase 2 regulatory subunit B'alpha(PPP2R5A)	Homo sapiens				GO:0006470~protein dephosphorylation,GO:0007165~signal transduction,GO:0031952~regulation of protein autophosphorylation,GO:0035307~positive regulation of protein dephosphorylation,GO:0090219~negative regulation of lipid kinase activity,GO:1903077~negative regulation of protein localization to plasma membrane,	GO:0000159~protein phosphatase type 2A complex,GO:0000775~chromosome, centromeric region,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0016020~membrane,GO:0030018~Z disc,GO:0031430~M band,	GO:0004721~phosphoprotein phosphatase activity,GO:0005515~protein binding,GO:0019888~protein phosphatase regulator activity,GO:0019900~kinase binding,GO:0072542~protein phosphatase activator activity,	IPR002554:Protein phosphatase 2A, regulatory B subunit, B56,IPR011989:Armadillo-like helical,IPR016024:Armadillo-type fold,	hsa03015:mRNA surveillance pathway,hsa04071:Sphingolipid signaling pathway,hsa04114:Oocyte meiosis,hsa04151:PI3K-Akt signaling pathway,hsa04152:AMPK signaling pathway,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04728:Dopaminergic synapse,hsa05165:Human papillomavirus infection,		PIRSF028043:serine/threonine-protein phosphatase 2A, subunit B56,			KW-0137~Centromere,KW-0158~Chromosome,KW-0539~Nucleus,KW-0963~Cytoplasm,					KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,REGION:Disordered,
PPP2R5E	protein phosphatase 2 regulatory subunit B'epsilon(PPP2R5E)	Homo sapiens				GO:0006470~protein dephosphorylation,GO:0007165~signal transduction,GO:0031952~regulation of protein autophosphorylation,GO:0050790~regulation of catalytic activity,	GO:0000159~protein phosphatase type 2A complex,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0019888~protein phosphatase regulator activity,GO:0072542~protein phosphatase activator activity,	IPR002554:Protein phosphatase 2A, regulatory B subunit, B56,IPR011989:Armadillo-like helical,IPR016024:Armadillo-type fold,	hsa03015:mRNA surveillance pathway,hsa04071:Sphingolipid signaling pathway,hsa04114:Oocyte meiosis,hsa04151:PI3K-Akt signaling pathway,hsa04152:AMPK signaling pathway,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04728:Dopaminergic synapse,hsa05165:Human papillomavirus infection,		PIRSF028043:serine/threonine-protein phosphatase 2A, subunit B56,			KW-0963~Cytoplasm,		KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	REGION:Disordered,
PTK2B	protein tyrosine kinase 2 beta(PTK2B)	Homo sapiens		h_achPathway:Role of nicotinic acetylcholine receptors in the regulation of apoptosis,h_at1rPathway:Angiotensin II mediated activation of JNK Pathway via Pyk2 dependent signaling,h_biopeptidesPathway:Bioactive Peptide Induced Signaling Pathway,h_ccr5Pathway:Pertussis toxin-insensitive CCR5 Signaling in Macrophage,h_cxcr4Pathway:CXCR4 Signaling Pathway,h_hbxPathway:Calcium Signaling by HBx of Hepatitis B virus,h_il7Pathway:IL-7 Signal Transduction,h_ionPathway:Ion Channel and Phorbal Esters Signaling Pathway,h_metPathway:Signaling of Hepatocyte Growth Factor Receptor,h_nkcellsPathway:Ras-Independent pathway in NK cell-mediated cytotoxicity,h_par1pathway:Thrombin signaling and protease-activated receptors,h_pyk2Pathway:Links between Pyk2 and Map Kinases,		GO:0000165~MAPK cascade,GO:0001525~angiogenesis,GO:0001556~oocyte maturation,GO:0001666~response to hypoxia,GO:0001954~positive regulation of cell-matrix adhesion,GO:0002040~sprouting angiogenesis,GO:0002250~adaptive immune response,GO:0002315~marginal zone B cell differentiation,GO:0002688~regulation of leukocyte chemotaxis,GO:0006468~protein phosphorylation,GO:0006915~apoptotic process,GO:0006968~cellular defense response,GO:0006970~response to osmotic stress,GO:0007165~signal transduction,GO:0007166~cell surface receptor signaling pathway,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007172~signal complex assembly,GO:0007173~epidermal growth factor receptor signaling pathway,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007229~integrin-mediated signaling pathway,GO:0008284~positive regulation of cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0008360~regulation of cell shape,GO:0009410~response to xenobiotic stimulus,GO:0009612~response to mechanical stimulus,GO:0009725~response to hormone,GO:0009749~response to glucose,GO:0010226~response to lithium ion,GO:0010595~positive regulation of endothelial cell migration,GO:0010656~negative regulation of muscle cell apoptotic process,GO:0010752~regulation of cGMP-mediated signaling,GO:0010758~regulation of macrophage chemotaxis,GO:0010976~positive regulation of neuron projection development,GO:0014009~glial cell proliferation,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0030154~cell differentiation,GO:0030155~regulation of cell adhesion,GO:0030307~positive regulation of cell growth,GO:0030335~positive regulation of cell migration,GO:0030500~regulation of bone mineralization,GO:0030502~negative regulation of bone mineralization,GO:0030838~positive regulation of actin filament polymerization,GO:0031175~neuron projection development,GO:0032960~regulation of inositol trisphosphate biosynthetic process,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0035235~ionotropic glutamate receptor signaling pathway,GO:0035902~response to immobilization stress,GO:0038083~peptidyl-tyrosine autophosphorylation,GO:0038110~interleukin-2-mediated signaling pathway,GO:0042127~regulation of cell proliferation,GO:0042220~response to cocaine,GO:0042493~response to drug,GO:0042542~response to hydrogen peroxide,GO:0042976~activation of Janus kinase activity,GO:0043066~negative regulation of apoptotic process,GO:0043149~stress fiber assembly,GO:0043267~negative regulation of potassium ion transport,GO:0043507~positive regulation of JUN kinase activity,GO:0043524~negative regulation of neuron apoptotic process,GO:0043534~blood vessel endothelial cell migration,GO:0043552~positive regulation of phosphatidylinositol 3-kinase activity,GO:0045087~innate immune response,GO:0045429~positive regulation of nitric oxide biosynthetic process,GO:0045453~bone resorption,GO:0045471~response to ethanol,GO:0045638~negative regulation of myeloid cell differentiation,GO:0045727~positive regulation of translation,GO:0045765~regulation of angiogenesis,GO:0045766~positive regulation of angiogenesis,GO:0045860~positive regulation of protein kinase activity,GO:0046330~positive regulation of JNK cascade,GO:0046777~protein autophosphorylation,GO:0048010~vascular endothelial growth factor receptor signaling pathway,GO:0048041~focal adhesion assembly,GO:0048167~regulation of synaptic plasticity,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0050848~regulation of calcium-mediated signaling,GO:0051000~positive regulation of nitric-oxide synthase activity,GO:0051279~regulation of release of sequestered calcium ion into cytosol,GO:0051591~response to cAMP,GO:0051592~response to calcium ion,GO:0051968~positive regulation of synaptic transmission, glutamatergic,GO:0060291~long-term synaptic potentiation,GO:0060292~long term synaptic depression,GO:0065003~macromolecular complex assembly,GO:0070098~chemokine-mediated signaling pathway,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071300~cellular response to retinoic acid,GO:0071498~cellular response to fluid shear stress,GO:0086100~endothelin receptor signaling pathway,GO:0090630~activation of GTPase activity,GO:2000058~regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process,GO:2000060~positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process,GO:2000114~regulation of establishment of cell polarity,GO:2000249~regulation of actin cytoskeleton reorganization,GO:2000310~regulation of NMDA receptor activity,GO:2000379~positive regulation of reactive oxygen species metabolic process,GO:2000463~positive regulation of excitatory postsynaptic potential,GO:2000538~positive regulation of B cell chemotaxis,GO:2000573~positive regulation of DNA biosynthetic process,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005925~focal adhesion,GO:0005938~cell cortex,GO:0014069~postsynaptic density,GO:0017146~NMDA selective glutamate receptor complex,GO:0030027~lamellipodium,GO:0030425~dendrite,GO:0030426~growth cone,GO:0031234~extrinsic component of cytoplasmic side of plasma membrane,GO:0043025~neuronal cell body,GO:0043197~dendritic spine,GO:0044297~cell body,GO:0045121~membrane raft,GO:0048471~perinuclear region of cytoplasm,GO:0097440~apical dendrite,GO:0098978~glutamatergic synapse,	GO:0004683~calmodulin-dependent protein kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0004715~non-membrane spanning protein tyrosine kinase activity,GO:0004972~NMDA glutamate receptor activity,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008022~protein C-terminus binding,GO:0031625~ubiquitin protein ligase binding,GO:0043423~3-phosphoinositide-dependent protein kinase binding,GO:0044877~macromolecular complex binding,	IPR000299:FERM domain,IPR000719:Protein kinase, catalytic domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR005189:Focal adhesion kinase, targeting (FAT) domain,IPR008266:Tyrosine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR011993:Pleckstrin homology-like domain,IPR014352:FERM/acyl-CoA-binding protein, 3-helical bundle,IPR017441:Protein kinase, ATP binding site,IPR019748:FERM central domain,IPR019749:Band 4.1 domain,IPR020635:Tyrosine-protein kinase, catalytic domain,	hsa04020:Calcium signaling pathway,hsa04062:Chemokine signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04650:Natural killer cell mediated cytotoxicity,hsa04670:Leukocyte transendothelial migration,hsa04912:GnRH signaling pathway,hsa05135:Yersinia infection,hsa05161:Hepatitis B,hsa05163:Human cytomegalovirus infection,hsa05170:Human immunodeficiency virus 1 infection,			SM00219:TyrKc,SM00295:B41,	KW-0037~Angiogenesis,KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-0966~Cell projection,KW-1003~Cell membrane,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:ATP,COMPBIAS:Pro residues,DOMAIN:FERM,DOMAIN:FERM_N_2,DOMAIN:Protein kinase,MUTAGEN:K->A: Abolishes kinase activity.,MUTAGEN:P->A: Loss of interaction with NPHP1.,MUTAGEN:Y->F: Abolishes autophosphorylation. Abolishes interaction with SRC.,MUTAGEN:Y->F: Loss of phosphorylation site. Strongly reduced interaction with GRB2.,NP_BIND:ATP,REGION:Disordered,REGION:Focal adhesion targeting (FAT),REGION:Interaction with TGFB1I1,
PTK2	protein tyrosine kinase 2(PTK2)	Homo sapiens	3.T_cell_receptor,68.Mitogen_signaling_in_growth_control,74.CD47-IAP_with_avB3,	h_achPathway:Role of nicotinic acetylcholine receptors in the regulation of apoptosis,h_agrPathway:Agrin in Postsynaptic Differentiation,h_at1rPathway:Angiotensin II mediated activation of JNK Pathway via Pyk2 dependent signaling,h_ccr3Pathway:CCR3 signaling in Eosinophils,h_cell2cellPathway:Cell to Cell Adhesion Signaling,h_chemicalPathway:Apoptotic Signaling in Response to DNA Damage,h_cxcr4Pathway:CXCR4 Signaling Pathway,h_ecmPathway:Erk and PI-3 Kinase Are Necessary for Collagen Binding in Corneal Epithelia,h_edg1Pathway:Phospholipids as signalling intermediaries,h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_integrinPathway:Integrin Signaling Pathway,h_mCalpainPathway:mCalpain and friends in Cell motility,h_metPathway:Signaling of Hepatocyte Growth Factor Receptor,h_ptenPathway:PTEN dependent cell cycle arrest and apoptosis,h_sppaPathway:Aspirin Blocks Signaling Pathway Involved in Platelet Activation,h_tffPathway:Trefoil Factors Initiate  Mucosal Healing,h_uCalpainPathway:uCalpain and friends in Cell spread,h_vegfPathway:VEGF, Hypoxia, and Angiogenesis,		GO:0000165~MAPK cascade,GO:0001525~angiogenesis,GO:0001890~placenta development,GO:0001932~regulation of protein phosphorylation,GO:0001934~positive regulation of protein phosphorylation,GO:0003007~heart morphogenesis,GO:0006468~protein phosphorylation,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007172~signal complex assembly,GO:0007173~epidermal growth factor receptor signaling pathway,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0007229~integrin-mediated signaling pathway,GO:0007411~axon guidance,GO:0008284~positive regulation of cell proliferation,GO:0008360~regulation of cell shape,GO:0010594~regulation of endothelial cell migration,GO:0010632~regulation of epithelial cell migration,GO:0010759~positive regulation of macrophage chemotaxis,GO:0010763~positive regulation of fibroblast migration,GO:0014068~positive regulation of phosphatidylinositol 3-kinase signaling,GO:0016477~cell migration,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0022408~negative regulation of cell-cell adhesion,GO:0030010~establishment of cell polarity,GO:0030154~cell differentiation,GO:0030155~regulation of cell adhesion,GO:0030335~positive regulation of cell migration,GO:0033628~regulation of cell adhesion mediated by integrin,GO:0035995~detection of muscle stretch,GO:0038007~netrin-activated signaling pathway,GO:0038096~Fc-gamma receptor signaling pathway involved in phagocytosis,GO:0042127~regulation of cell proliferation,GO:0043066~negative regulation of apoptotic process,GO:0043087~regulation of GTPase activity,GO:0043552~positive regulation of phosphatidylinositol 3-kinase activity,GO:0045087~innate immune response,GO:0045667~regulation of osteoblast differentiation,GO:0045860~positive regulation of protein kinase activity,GO:0046777~protein autophosphorylation,GO:0048010~vascular endothelial growth factor receptor signaling pathway,GO:0048013~ephrin receptor signaling pathway,GO:0048870~cell motility,GO:0051493~regulation of cytoskeleton organization,GO:0051893~regulation of focal adhesion assembly,GO:0051897~positive regulation of protein kinase B signaling,GO:0060396~growth hormone receptor signaling pathway,GO:0090303~positive regulation of wound healing,GO:1900024~regulation of substrate adhesion-dependent cell spreading,GO:2000060~positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process,GO:2000811~negative regulation of anoikis,	GO:0001725~stress fiber,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0005938~cell cortex,GO:0031234~extrinsic component of cytoplasmic side of plasma membrane,GO:0036064~ciliary basal body,GO:0042995~cell projection,GO:0043197~dendritic spine,GO:0043231~intracellular membrane-bounded organelle,	GO:0003779~actin binding,GO:0004672~protein kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0004715~non-membrane spanning protein tyrosine kinase activity,GO:0005102~receptor binding,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008432~JUN kinase binding,GO:0019901~protein kinase binding,GO:0019903~protein phosphatase binding,GO:0042169~SH2 domain binding,	IPR000299:FERM domain,IPR000719:Protein kinase, catalytic domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR005189:Focal adhesion kinase, targeting (FAT) domain,IPR008266:Tyrosine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR011993:Pleckstrin homology-like domain,IPR014352:FERM/acyl-CoA-binding protein, 3-helical bundle,IPR017441:Protein kinase, ATP binding site,IPR019748:FERM central domain,IPR019749:Band 4.1 domain,IPR020635:Tyrosine-protein kinase, catalytic domain,	hsa01522:Endocrine resistance,hsa04012:ErbB signaling pathway,hsa04062:Chemokine signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04360:Axon guidance,hsa04370:VEGF signaling pathway,hsa04510:Focal adhesion,hsa04670:Leukocyte transendothelial migration,hsa04810:Regulation of actin cytoskeleton,hsa04935:Growth hormone synthesis, secretion and action,hsa05100:Bacterial invasion of epithelial cells,hsa05131:Shigellosis,hsa05135:Yersinia infection,hsa05146:Amoebiasis,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05205:Proteoglycans in cancer,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05222:Small cell lung cancer,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,			SM00219:TyrKc,SM00295:B41,	KW-0037~Angiogenesis,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0217~Developmental protein,KW-0418~Kinase,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Proton acceptor,BINDING:ATP,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),DOMAIN:FERM,DOMAIN:FERM_N_2,DOMAIN:Focal_AT,DOMAIN:PK_Tyr_Ser-Thr,DOMAIN:Protein kinase,MUTAGEN:L->S: Loss of interaction with TGFB1I1.,MUTAGEN:V->G: Loss of interaction with TGFB1I1.,MUTAGEN:Y->F: Abolishes autophosphorylation. Abolishes interaction with SRC and activation of BMX.,NP_BIND:ATP,REGION:Disordered,REGION:Interaction with ARHGEF28,REGION:Interaction with TGFB1I1,
PTPN1	protein tyrosine phosphatase non-receptor type 1(PTPN1)	Homo sapiens				GO:0006470~protein dephosphorylation,GO:0007257~activation of JUN kinase activity,GO:0008286~insulin receptor signaling pathway,GO:0009966~regulation of signal transduction,GO:0009968~negative regulation of signal transduction,GO:0030100~regulation of endocytosis,GO:0030948~negative regulation of vascular endothelial growth factor receptor signaling pathway,GO:0030968~endoplasmic reticulum unfolded protein response,GO:0031532~actin cytoskeleton reorganization,GO:0033157~regulation of intracellular protein transport,GO:0034620~cellular response to unfolded protein,GO:0035335~peptidyl-tyrosine dephosphorylation,GO:0035791~platelet-derived growth factor receptor-beta signaling pathway,GO:0036498~IRE1-mediated unfolded protein response,GO:0043407~negative regulation of MAP kinase activity,GO:0043507~positive regulation of JUN kinase activity,GO:0046626~regulation of insulin receptor signaling pathway,GO:0046627~negative regulation of insulin receptor signaling pathway,GO:0060338~regulation of type I interferon-mediated signaling pathway,GO:0060397~JAK-STAT cascade involved in growth hormone signaling pathway,GO:0061098~positive regulation of protein tyrosine kinase activity,GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:1902202~regulation of hepatocyte growth factor receptor signaling pathway,GO:1902236~negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway,GO:1903896~positive regulation of IRE1-mediated unfolded protein response,GO:1903898~negative regulation of PERK-mediated unfolded protein response,GO:1990264~peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activity,GO:2000646~positive regulation of receptor catabolic process,	GO:0005737~cytoplasm,GO:0005759~mitochondrial matrix,GO:0005769~early endosome,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0030061~mitochondrial crista,GO:0032991~macromolecular complex,GO:0097443~sorting endosome,GO:0098554~cytoplasmic side of endoplasmic reticulum membrane,	GO:0003723~RNA binding,GO:0004725~protein tyrosine phosphatase activity,GO:0005158~insulin receptor binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0019899~enzyme binding,GO:0019901~protein kinase binding,GO:0030971~receptor tyrosine kinase binding,GO:0045296~cadherin binding,GO:0046875~ephrin receptor binding,GO:0051721~protein phosphatase 2A binding,	IPR000242:Protein-tyrosine phosphatase, receptor/non-receptor type,IPR000387:Protein-tyrosine/Dual specificity phosphatase,IPR003595:Protein-tyrosine phosphatase, catalytic,IPR012265:Protein-tyrosine phosphatase, non-receptor type-1/2,IPR016130:Protein-tyrosine phosphatase, active site,	hsa04520:Adherens junction,hsa04910:Insulin signaling pathway,hsa04931:Insulin resistance,hsa05208:Chemical carcinogenesis - reactive oxygen species,	125853~Insulin resistance, susceptibility to,	PIRSF000926:non-receptor tyrosine-protein phosphatase, 1/2 types,	SM00194:PTPc,SM00404:PTPc_motif,		KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,KW-0675~Receptor,KW-0904~Protein phosphatase,	KW-0007~Acetylation,KW-0558~Oxidation,KW-0597~Phosphoprotein,KW-0702~S-nitrosylation,	ACT_SITE:Phosphocysteine intermediate,BINDING:Substrate,CROSSLNK:N,N-(cysteine-1,S-diyl)serine (Cys-Ser); in inhibited form,DOMAIN:TYR_PHOSPHATASE_2,DOMAIN:Tyrosine-protein phosphatase,MUTAGEN:C->S: Catalytically inactive mutant; abolishes sulfhydration.,MUTAGEN:D->A: Substrate-trapping mutant.,MUTAGEN:S->A,D: No phosphorylation.,REGION:Disordered,REGION:Substrate binding,TRANSMEM:Helical,
PTPN12	protein tyrosine phosphatase non-receptor type 12(PTPN12)	Homo sapiens				GO:0006470~protein dephosphorylation,GO:0035335~peptidyl-tyrosine dephosphorylation,GO:0038128~ERBB2 signaling pathway,GO:0042058~regulation of epidermal growth factor receptor signaling pathway,GO:0042246~tissue regeneration,GO:0071345~cellular response to cytokine stimulus,GO:0071364~cellular response to epidermal growth factor stimulus,GO:1901185~negative regulation of ERBB signaling pathway,GO:2000587~negative regulation of platelet-derived growth factor receptor-beta signaling pathway,	GO:0002102~podosome,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005925~focal adhesion,GO:0042995~cell projection,	GO:0004721~phosphoprotein phosphatase activity,GO:0004725~protein tyrosine phosphatase activity,GO:0004726~non-membrane spanning protein tyrosine phosphatase activity,GO:0005515~protein binding,GO:0017124~SH3 domain binding,	IPR000242:Protein-tyrosine phosphatase, receptor/non-receptor type,IPR000387:Protein-tyrosine/Dual specificity phosphatase,IPR003595:Protein-tyrosine phosphatase, catalytic,IPR012266:Protein-tyrosine phosphatase, non-receptor type-12,IPR016130:Protein-tyrosine phosphatase, active site,		114500~Colon cancer, somatic,	PIRSF000932:non-receptor tyrosine-protein phosphatase, type 12,	SM00194:PTPc,SM00404:PTPc_motif,		KW-0963~Cytoplasm,KW-0965~Cell junction,KW-0966~Cell projection,	KW-0225~Disease variant,			KW-0378~Hydrolase,KW-0675~Receptor,KW-0904~Protein phosphatase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Phosphocysteine intermediate,BINDING:Substrate,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:TYR_PHOSPHATASE_2,DOMAIN:Tyrosine-protein phosphatase,MUTAGEN:D->A: Abolishes enzyme activity.,MUTAGEN:H->A: Decreases enzyme activity.,MUTAGEN:I->A: Nearly abolishes enzyme activity.,MUTAGEN:Q->A: Nearly abolishes enzyme activity.,MUTAGEN:R->A: Decreases enzyme activity.,MUTAGEN:S->E: Loss of phosphorylation site.,MUTAGEN:Y->A: Abolishes enzyme activity.,REGION:Disordered,REGION:Interaction with TGFB1I1,REGION:Substrate binding,
PTPN6	protein tyrosine phosphatase non-receptor type 6(PTPN6)	Homo sapiens		h_epoPathway:EPO Signaling Pathway,h_ghPathway:Growth Hormone Signaling Pathway,h_il2rbPathway:IL-2 Receptor Beta Chain in T cell Activation,h_il3Pathway:IL 3 signaling pathway,h_nkcellsPathway:Ras-Independent pathway in NK cell-mediated cytotoxicity,		GO:0002244~hematopoietic progenitor cell differentiation,GO:0002924~negative regulation of humoral immune response mediated by circulating immunoglobulin,GO:0006470~protein dephosphorylation,GO:0007186~G-protein coupled receptor signaling pathway,GO:0008284~positive regulation of cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0014068~positive regulation of phosphatidylinositol 3-kinase signaling,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0019221~cytokine-mediated signaling pathway,GO:0030154~cell differentiation,GO:0030168~platelet activation,GO:0030220~platelet formation,GO:0031295~T cell costimulation,GO:0032715~negative regulation of interleukin-6 production,GO:0032720~negative regulation of tumor necrosis factor production,GO:0033007~negative regulation of mast cell activation involved in immune response,GO:0033277~abortive mitotic cell cycle,GO:0033630~positive regulation of cell adhesion mediated by integrin,GO:0035335~peptidyl-tyrosine dephosphorylation,GO:0035556~intracellular signal transduction,GO:0035855~megakaryocyte development,GO:0042130~negative regulation of T cell proliferation,GO:0042267~natural killer cell mediated cytotoxicity,GO:0042981~regulation of apoptotic process,GO:0043312~neutrophil degranulation,GO:0043407~negative regulation of MAP kinase activity,GO:0045577~regulation of B cell differentiation,GO:0050732~negative regulation of peptidyl-tyrosine phosphorylation,GO:0050853~B cell receptor signaling pathway,GO:0050860~negative regulation of T cell receptor signaling pathway,GO:0050900~leukocyte migration,GO:0051279~regulation of release of sequestered calcium ion into cytosol,GO:0060338~regulation of type I interferon-mediated signaling pathway,GO:0070372~regulation of ERK1 and ERK2 cascade,GO:0070527~platelet aggregation,GO:0071345~cellular response to cytokine stimulus,GO:1905867~epididymis development,GO:2000045~regulation of G1/S transition of mitotic cell cycle,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005911~cell-cell junction,GO:0016020~membrane,GO:0032991~macromolecular complex,GO:0035580~specific granule lumen,GO:0042105~alpha-beta T cell receptor complex,GO:0070062~extracellular exosome,GO:1904724~tertiary granule lumen,	GO:0001784~phosphotyrosine binding,GO:0004725~protein tyrosine phosphatase activity,GO:0005001~transmembrane receptor protein tyrosine phosphatase activity,GO:0005515~protein binding,GO:0017124~SH3 domain binding,GO:0019901~protein kinase binding,GO:0042169~SH2 domain binding,GO:0050839~cell adhesion molecule binding,	IPR000242:Protein-tyrosine phosphatase, receptor/non-receptor type,IPR000387:Protein-tyrosine/Dual specificity phosphatase,IPR000980:SH2 domain,IPR003595:Protein-tyrosine phosphatase, catalytic,IPR012152:Protein-tyrosine phosphatase, non-receptor type-6, -11,IPR016130:Protein-tyrosine phosphatase, active site,	hsa04520:Adherens junction,hsa04630:JAK-STAT signaling pathway,hsa04650:Natural killer cell mediated cytotoxicity,hsa04660:T cell receptor signaling pathway,hsa04662:B cell receptor signaling pathway,hsa05130:Pathogenic Escherichia coli infection,hsa05140:Leishmaniasis,hsa05205:Proteoglycans in cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,		PIRSF000929:non-receptor tyrosine-protein phosphatase, 6/11 types,	SM00194:PTPc,SM00252:SH2,SM00404:PTPc_motif,		KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0727~SH2 domain,		KW-0378~Hydrolase,KW-0675~Receptor,KW-0904~Protein phosphatase,	KW-0597~Phosphoprotein,	ACT_SITE:Phosphocysteine intermediate,BINDING:Substrate,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:SH2,DOMAIN:SH2 1,DOMAIN:SH2 2,DOMAIN:TYR_PHOSPHATASE_2,DOMAIN:Tyrosine-protein phosphatase,REGION:Disordered,REGION:Substrate binding,
PTPRC	protein tyrosine phosphatase receptor type C(PTPRC)	Homo sapiens		h_blymphocytePathway:B Lymphocyte Cell Surface Molecules,h_cskPathway:Activation of Csk by cAMP-dependent Protein Kinase Inhibits Signaling through the T Cell Receptor,h_tcraPathway:Lck and Fyn tyrosine kinases in initiation of TCR Activation,h_tcytotoxicPathway:T Cytotoxic Cell Surface Molecules,h_thelperPathway:T Helper Cell Surface Molecules,		GO:0000187~activation of MAPK activity,GO:0001779~natural killer cell differentiation,GO:0001915~negative regulation of T cell mediated cytotoxicity,GO:0001916~positive regulation of T cell mediated cytotoxicity,GO:0001960~negative regulation of cytokine-mediated signaling pathway,GO:0002244~hematopoietic progenitor cell differentiation,GO:0002639~positive regulation of immunoglobulin production,GO:0002925~positive regulation of humoral immune response mediated by circulating immunoglobulin,GO:0006469~negative regulation of protein kinase activity,GO:0006470~protein dephosphorylation,GO:0006933~negative regulation of cell adhesion involved in substrate-bound cell migration,GO:0007159~leukocyte cell-cell adhesion,GO:0007166~cell surface receptor signaling pathway,GO:0010332~response to gamma radiation,GO:0010468~regulation of gene expression,GO:0016032~viral process,GO:0016311~dephosphorylation,GO:0030183~B cell differentiation,GO:0030217~T cell differentiation,GO:0030890~positive regulation of B cell proliferation,GO:0031668~cellular response to extracellular stimulus,GO:0031953~negative regulation of protein autophosphorylation,GO:0032677~regulation of interleukin-8 production,GO:0032703~negative regulation of interleukin-2 production,GO:0032743~positive regulation of interleukin-2 production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0034113~heterotypic cell-cell adhesion,GO:0035335~peptidyl-tyrosine dephosphorylation,GO:0035584~calcium-mediated signaling using intracellular calcium source,GO:0042098~T cell proliferation,GO:0042100~B cell proliferation,GO:0042102~positive regulation of T cell proliferation,GO:0042110~T cell activation,GO:0043312~neutrophil degranulation,GO:0043406~positive regulation of MAP kinase activity,GO:0043410~positive regulation of MAPK cascade,GO:0044770~cell cycle phase transition,GO:0044855~plasma membrane raft distribution,GO:0045059~positive thymic T cell selection,GO:0045060~negative thymic T cell selection,GO:0045588~positive regulation of gamma-delta T cell differentiation,GO:0045860~positive regulation of protein kinase activity,GO:0046425~regulation of JAK-STAT cascade,GO:0046641~positive regulation of alpha-beta T cell proliferation,GO:0048304~positive regulation of isotype switching to IgG isotypes,GO:0048539~bone marrow development,GO:0048864~stem cell development,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0050764~regulation of phagocytosis,GO:0050852~T cell receptor signaling pathway,GO:0050853~B cell receptor signaling pathway,GO:0050857~positive regulation of antigen receptor-mediated signaling pathway,GO:0051209~release of sequestered calcium ion into cytosol,GO:0051607~defense response to virus,GO:0051726~regulation of cell cycle,GO:0061097~regulation of protein tyrosine kinase activity,GO:0061099~negative regulation of protein tyrosine kinase activity,GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:1903615~positive regulation of protein tyrosine phosphatase activity,GO:1903979~negative regulation of microglial cell activation,GO:1904155~DN2 thymocyte differentiation,GO:1905451~positive regulation of Fc-gamma receptor signaling pathway involved in phagocytosis,GO:2000473~positive regulation of hematopoietic stem cell migration,GO:2000648~positive regulation of stem cell proliferation,GO:2001238~positive regulation of extrinsic apoptotic signaling pathway,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005925~focal adhesion,GO:0009897~external side of plasma membrane,GO:0009898~cytoplasmic side of plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030667~secretory granule membrane,GO:0032059~bleb,GO:0045121~membrane raft,GO:0070062~extracellular exosome,GO:0098857~membrane microdomain,	GO:0004725~protein tyrosine phosphatase activity,GO:0005001~transmembrane receptor protein tyrosine phosphatase activity,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0008201~heparin binding,GO:0019901~protein kinase binding,GO:0030506~ankyrin binding,GO:0030507~spectrin binding,GO:0043395~heparan sulfate proteoglycan binding,	IPR000242:Protein-tyrosine phosphatase, receptor/non-receptor type,IPR000387:Protein-tyrosine/Dual specificity phosphatase,IPR003595:Protein-tyrosine phosphatase, catalytic,IPR003961:Fibronectin, type III,IPR013783:Immunoglobulin-like fold,IPR016130:Protein-tyrosine phosphatase, active site,IPR016335:Leukocyte common antigen,IPR024739:Protein tyrosine phosphatase, receptor type, N-terminal,	hsa04514:Cell adhesion molecules,hsa04660:T cell receptor signaling pathway,hsa04666:Fc gamma R-mediated phagocytosis,hsa05132:Salmonella infection,hsa05340:Primary immunodeficiency,	608971~Severe combined immunodeficiency, T cell-negative, B-cell/natural killer-cell positive,609532~Hepatitis C virus, susceptibility to,	PIRSF002004:leukocyte common antigen,	SM00060:FN3,SM00194:PTPc,SM00404:PTPc_motif,	KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0705~SCID,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,KW-0675~Receptor,KW-0904~Protein phosphatase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	ACT_SITE:Phosphocysteine intermediate,BINDING:Substrate,CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine; atypical,COMPBIAS:Polar residues,DOMAIN:Fibronectin type-III,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,DOMAIN:PTP_N,DOMAIN:Tyrosine-protein phosphatase,DOMAIN:Tyrosine-protein phosphatase 1,DOMAIN:Tyrosine-protein phosphatase 2,MUTAGEN:C->S: Loss of activity. Abolishes interaction with SKAP1.,REGION:Disordered,REGION:Substrate binding,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
PTPRF	protein tyrosine phosphatase receptor type F(PTPRF)	Homo sapiens				GO:0006470~protein dephosphorylation,GO:0007155~cell adhesion,GO:0007185~transmembrane receptor protein tyrosine phosphatase signaling pathway,GO:0016477~cell migration,GO:0031102~neuron projection regeneration,GO:0035335~peptidyl-tyrosine dephosphorylation,GO:0048679~regulation of axon regeneration,GO:0099560~synaptic membrane adhesion,GO:1900121~negative regulation of receptor binding,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0043005~neuron projection,GO:0043025~neuronal cell body,GO:0070062~extracellular exosome,	GO:0004725~protein tyrosine phosphatase activity,GO:0005001~transmembrane receptor protein tyrosine phosphatase activity,GO:0008201~heparin binding,GO:0035373~chondroitin sulfate proteoglycan binding,GO:0044877~macromolecular complex binding,GO:0050839~cell adhesion molecule binding,	IPR000242:Protein-tyrosine phosphatase, receptor/non-receptor type,IPR000387:Protein-tyrosine/Dual specificity phosphatase,IPR003595:Protein-tyrosine phosphatase, catalytic,IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR003961:Fibronectin, type III,IPR007110:Immunoglobulin-like domain,IPR013098:Immunoglobulin I-set,IPR013783:Immunoglobulin-like fold,IPR016130:Protein-tyrosine phosphatase, active site,	hsa04514:Cell adhesion molecules,hsa04520:Adherens junction,hsa04910:Insulin signaling pathway,hsa04931:Insulin resistance,	616001~Breasts and/or nipples, aplasia or hypoplasia of, 2,		SM00060:FN3,SM00194:PTPc,SM00404:PTPc_motif,SM00408:IGc2,SM00409:IG,	KW-0130~Cell adhesion,	KW-0472~Membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0358~Heparin-binding,KW-0378~Hydrolase,KW-0675~Receptor,KW-0904~Protein phosphatase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Phosphocysteine intermediate,BINDING:Substrate,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Fibronectin type-III,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,DOMAIN:Fibronectin type-III 3,DOMAIN:Fibronectin type-III 4,DOMAIN:Fibronectin type-III 5,DOMAIN:Fibronectin type-III 6,DOMAIN:Fibronectin type-III 7,DOMAIN:Fibronectin type-III 8,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,DOMAIN:TYR_PHOSPHATASE_2,DOMAIN:Tyrosine-protein phosphatase,DOMAIN:Tyrosine-protein phosphatase 1,DOMAIN:Tyrosine-protein phosphatase 2,MUTAGEN:C->S: Loss of activity.,REGION:Disordered,REGION:Heparin-binding,REGION:Substrate binding,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
PTPRK	protein tyrosine phosphatase receptor type K(PTPRK)	Homo sapiens				GO:0006470~protein dephosphorylation,GO:0007155~cell adhesion,GO:0007165~signal transduction,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0008285~negative regulation of cell proliferation,GO:0010839~negative regulation of keratinocyte proliferation,GO:0016477~cell migration,GO:0030217~T cell differentiation,GO:0030336~negative regulation of cell migration,GO:0031175~neuron projection development,GO:0034394~protein localization to cell surface,GO:0034614~cellular response to reactive oxygen species,GO:0034644~cellular response to UV,GO:0035335~peptidyl-tyrosine dephosphorylation,GO:0045786~negative regulation of cell cycle,GO:0045892~negative regulation of transcription, DNA-templated,GO:0048041~focal adhesion assembly,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005911~cell-cell junction,GO:0005912~adherens junction,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030054~cell junction,GO:0031256~leading edge membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0004725~protein tyrosine phosphatase activity,GO:0005001~transmembrane receptor protein tyrosine phosphatase activity,GO:0005515~protein binding,GO:0008013~beta-catenin binding,GO:0019901~protein kinase binding,GO:0045295~gamma-catenin binding,	IPR000242:Protein-tyrosine phosphatase, receptor/non-receptor type,IPR000387:Protein-tyrosine/Dual specificity phosphatase,IPR000998:MAM domain,IPR003595:Protein-tyrosine phosphatase, catalytic,IPR003599:Immunoglobulin subtype,IPR003961:Fibronectin, type III,IPR007110:Immunoglobulin-like domain,IPR013098:Immunoglobulin I-set,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,IPR013783:Immunoglobulin-like fold,IPR016130:Protein-tyrosine phosphatase, active site,				SM00060:FN3,SM00137:MAM,SM00194:PTPc,SM00404:PTPc_motif,SM00409:IG,		KW-0472~Membrane,KW-0965~Cell junction,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,KW-0675~Receptor,KW-0904~Protein phosphatase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Phosphocysteine intermediate,BINDING:Substrate,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Fibronectin type-III,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,DOMAIN:Fibronectin type-III 3,DOMAIN:Fibronectin type-III 4,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type,DOMAIN:MAM,DOMAIN:TYR_PHOSPHATASE_2,DOMAIN:Tyrosine-protein phosphatase,DOMAIN:Tyrosine-protein phosphatase 1,DOMAIN:Tyrosine-protein phosphatase 2,REGION:Disordered,REGION:Substrate binding,SITE:Cleavage,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
PCMT1	protein-L-isoaspartate (D-aspartate) O-methyltransferase(PCMT1)	Homo sapiens				GO:0006479~protein methylation,GO:0030091~protein repair,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,GO:1903561~extracellular vesicle,	GO:0004719~protein-L-isoaspartate (D-aspartate) O-methyltransferase activity,GO:0005515~protein binding,GO:0045296~cadherin binding,	IPR000682:Protein-L-isoaspartate(D-aspartate) O-methyltransferase,						KW-0963~Cytoplasm,			KW-0949~S-adenosyl-L-methionine,	KW-0489~Methyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,	BINDING:S-adenosyl-L-homocysteine,BINDING:S-adenosyl-L-homocysteine; via amide nitrogen and carbonyl oxygen,REGION:S-adenosyl-L-homocysteine binding,
PLP2	proteolipid protein 2(PLP2)	Homo sapiens				GO:0006811~ion transport,GO:0006935~chemotaxis,GO:0019221~cytokine-mediated signaling pathway,GO:0034220~ion transmembrane transport,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,GO:0015075~ion transmembrane transporter activity,GO:0019956~chemokine binding,	IPR008253:Marvel,						KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:MARVEL,TRANSMEM:Helical,
PPOX	protoporphyrinogen oxidase(PPOX)	Homo sapiens				GO:0006779~porphyrin-containing compound biosynthetic process,GO:0006782~protoporphyrinogen IX biosynthetic process,GO:0006783~heme biosynthetic process,GO:0042493~response to drug,	GO:0005743~mitochondrial inner membrane,GO:0005758~mitochondrial intermembrane space,GO:0031304~intrinsic component of mitochondrial inner membrane,GO:0031305~integral component of mitochondrial inner membrane,GO:0031966~mitochondrial membrane,	GO:0004729~oxygen-dependent protoporphyrinogen oxidase activity,GO:0016491~oxidoreductase activity,GO:0050660~flavin adenine dinucleotide binding,	IPR002937:Amine oxidase,IPR004572:Protoporphyrinogen oxidase,	hsa00860:Porphyrin metabolism,hsa01100:Metabolic pathways,hsa01240:Biosynthesis of cofactors,	176200~Porphyria variegata,			KW-0350~Heme biosynthesis,KW-0627~Porphyrin biosynthesis,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,	KW-0225~Disease variant,		KW-0274~FAD,KW-0285~Flavoprotein,	KW-0560~Oxidoreductase,		BINDING:FAD; via amide nitrogen,BINDING:FAD; via amide nitrogen and carbonyl oxygen,COMPBIAS:Polar residues,DOMAIN:Amino_oxidase,MUTAGEN:F->A: Decreases enzyme activity by 50%.,MUTAGEN:G->A: Decreases enzyme activity by 64%.,MUTAGEN:L->A: Decreases enzyme activity by 86%.,MUTAGEN:L->N: Decreases enzyme activity by 95%.,MUTAGEN:L->P: Abolishes enzyme activity. Impairs protein folding and/or stability.,MUTAGEN:M->A: Decreases enzyme activity by 52%.,MUTAGEN:R->D: Decreases enzyme activity by 89%. Impairs protein folding and/or stability.,MUTAGEN:R->G: Decreases enzyme activity by 75%.,MUTAGEN:R->Q: Decreases enzyme activity by 90%. Strongly decreases affinity for protoporphyrinogen-IX.,MUTAGEN:S->I: Decreases enzyme activity by 87%. Impairs protein folding and/or stability.,MUTAGEN:V->A: Decreases enzyme activity by 45%.,MUTAGEN:V->L: No effect on enzyme activity.,NP_BIND:FAD,REGION:Disordered,
PCBD1	pterin-4 alpha-carbinolamine dehydratase 1(PCBD1)	Homo sapiens				GO:0006558~L-phenylalanine metabolic process,GO:0006729~tetrahydrobiopterin biosynthetic process,GO:0019293~tyrosine biosynthetic process, by oxidation of phenylalanine,GO:0043393~regulation of protein binding,GO:0045893~positive regulation of transcription, DNA-templated,	GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0003713~transcription coactivator activity,GO:0004505~phenylalanine 4-monooxygenase activity,GO:0005515~protein binding,GO:0008124~4-alpha-hydroxytetrahydrobiopterin dehydratase activity,GO:0042802~identical protein binding,	IPR001533:Transcriptional coactivator/pterin dehydratase,	hsa00790:Folate biosynthesis,hsa01100:Metabolic pathways,	264070~Hyperphenylalaninemia, BH4-deficient, D,			KW-0783~Tetrahydrobiopterin biosynthesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,			KW-0010~Activator,KW-0456~Lyase,	KW-0007~Acetylation,	REGION:Substrate binding,
PYCR1	pyrroline-5-carboxylate reductase 1(PYCR1)	Homo sapiens				GO:0006561~proline biosynthetic process,GO:0008652~cellular amino acid biosynthetic process,GO:0009064~glutamine family amino acid metabolic process,GO:0034599~cellular response to oxidative stress,GO:0051881~regulation of mitochondrial membrane potential,GO:0055129~L-proline biosynthetic process,GO:1903206~negative regulation of hydrogen peroxide-induced cell death,	GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,	GO:0004735~pyrroline-5-carboxylate reductase activity,GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR000304:Pyrroline-5-carboxylate reductase,IPR008927:6-phosphogluconate dehydrogenase, C-terminal-like,	hsa00330:Arginine and proline metabolism,hsa01100:Metabolic pathways,hsa01230:Biosynthesis of amino acids,	612940~Cutis laxa, autosomal recessive, type IIB,614438~Cutis laxa, autosomal recessive, type IIIB,	PIRSF000193:pyrroline-5-carboxylate reductase,		KW-0028~Amino-acid biosynthesis,KW-0346~Stress response,KW-0641~Proline biosynthesis,	KW-0496~Mitochondrion,	KW-0225~Disease variant,		KW-0521~NADP,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	BINDING:NADP,BINDING:NADP; via carbonyl oxygen,DOMAIN:F420_oxidored,DOMAIN:P5CR_dimer,MUTAGEN:E->A: Reduced enzyme activity.,NP_BIND:NADP,REGION:Disordered,
PDHX	pyruvate dehydrogenase complex component X(PDHX)	Homo sapiens				GO:0006086~acetyl-CoA biosynthetic process from pyruvate,GO:0006090~pyruvate metabolic process,GO:0061732~mitochondrial acetyl-CoA biosynthetic process from pyruvate,	GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005967~mitochondrial pyruvate dehydrogenase complex,GO:0045254~pyruvate dehydrogenase complex,	GO:0005515~protein binding,GO:0016746~transferase activity, transferring acyl groups,GO:0034604~pyruvate dehydrogenase (NAD+) activity,	IPR000089:Biotin/lipoyl attachment,IPR001078:2-oxoacid dehydrogenase acyltransferase, catalytic domain,IPR003016:2-oxo acid dehydrogenase, lipoyl-binding site,IPR004167:E3 binding,IPR011053:Single hybrid motif,IPR023213:Chloramphenicol acetyltransferase-like domain,	hsa01100:Metabolic pathways,	245349~Lacticacidemia due to PDX1 deficiency,				KW-0496~Mitochondrion,		KW-0450~Lipoyl,KW-0809~Transit peptide,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Pro residues,DOMAIN:2-oxoacid_dh,DOMAIN:Lipoyl-binding,DOMAIN:Peripheral subunit-binding (PSBD),MUTAGEN:A->M: Strongly decreased DLD binding.,MUTAGEN:E->A: Strongly decreased DLD binding.,MUTAGEN:I->A: Strongly decreased DLD binding.,MUTAGEN:I->R: Decreased interaction with DLD.,MUTAGEN:I->S: Decreased interaction with DLD.,MUTAGEN:K->A: Strongly decreased DLD binding.,MUTAGEN:N->A: Decreased DLD binding.,MUTAGEN:N->K: Moderately decreased interaction with DLD.,MUTAGEN:P->A: Strongly decreased DLD binding.,MUTAGEN:R->A: Strongly decreased DLD binding.,MUTAGEN:R->D: Decreased interaction with DLD.,MUTAGEN:S->A: Strongly decreased DLD binding.,REGION:Disordered,TRANSIT:Mitochondrion,
RALGDS	ral guanine nucleotide dissociation stimulator(RALGDS)	Homo sapiens		h_rasPathway:Ras Signaling Pathway,		GO:0000165~MAPK cascade,GO:0007165~signal transduction,GO:0007264~small GTPase mediated signal transduction,GO:0007265~Ras protein signal transduction,GO:0043547~positive regulation of GTPase activity,GO:0050790~regulation of catalytic activity,	GO:0005634~nucleus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005903~brush border,	GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,GO:0030695~GTPase regulator activity,	IPR000159:Ras-association,IPR000651:Ras-like guanine nucleotide exchange factor, N-terminal,IPR001895:Guanine-nucleotide dissociation stimulator CDC25,IPR008937:Ras guanine nucleotide exchange factor,IPR015758:Guanine nucleotide dissociation stimulator RalGDS,IPR019804:Ras guanine-nucleotide exchange factor, conserved site,IPR023578:Ras guanine nucleotide exchange factor, domain,	hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa05200:Pathways in cancer,hsa05210:Colorectal cancer,hsa05212:Pancreatic cancer,hsa05231:Choline metabolism in cancer,			SM00147:RasGEF,SM00229:RasGEFN,SM00314:RA,		KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0344~Guanine-nucleotide releasing factor,		COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:N-terminal Ras-GEF,DOMAIN:Ras-GEF,DOMAIN:Ras-associating,REGION:Disordered,
RHOA	ras homolog family member A(RHOA)	Homo sapiens	102.Cholesterol_Stress_Response,	h_akap13Pathway:Rho-Selective Guanine Exchange Factor AKAP13 Mediates Stress Fiber Formation,h_akapcentrosomePathway:Protein Kinase A at the Centrosome,h_cardiacEGFPathway:Role of EGF Receptor Transactivation by GPCRs in Cardiac Hypertrophy,h_ccr3Pathway:CCR3 signaling in Eosinophils,h_cdc42racPathway:Role of PI3K subunit p85 in regulation of Actin Organization and Cell Migration,h_ecmPathway:Erk and PI-3 Kinase Are Necessary for Collagen Binding in Corneal Epithelia,h_edg1Pathway:Phospholipids as signalling intermediaries,h_integrinPathway:Integrin Signaling Pathway,h_malPathway:Role of MAL in Rho-Mediated Activation of SRF,h_par1pathway:Thrombin signaling and protease-activated receptors,h_raccycdPathway:Influence of Ras and Rho proteins on G1 to S Transition,h_rasPathway:Ras Signaling Pathway,h_rhoPathway:Rho cell motility signaling pathway,h_tffPathway:Trefoil Factors Initiate  Mucosal Healing,h_uCalpainPathway:uCalpain and friends in Cell spread,		GO:0001666~response to hypoxia,GO:0001822~kidney development,GO:0001998~angiotensin-mediated vasoconstriction involved in regulation of systemic arterial blood pressure,GO:0002363~alpha-beta T cell lineage commitment,GO:0003100~regulation of systemic arterial blood pressure by endothelin,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007015~actin filament organization,GO:0007160~cell-matrix adhesion,GO:0007163~establishment or maintenance of cell polarity,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007264~small GTPase mediated signal transduction,GO:0007266~Rho protein signal transduction,GO:0007519~skeletal muscle tissue development,GO:0008360~regulation of cell shape,GO:0009410~response to xenobiotic stimulus,GO:0009612~response to mechanical stimulus,GO:0009749~response to glucose,GO:0010812~negative regulation of cell-substrate adhesion,GO:0010977~negative regulation of neuron projection development,GO:0016032~viral process,GO:0016477~cell migration,GO:0016579~protein deubiquitination,GO:0021762~substantia nigra development,GO:0021795~cerebral cortex cell migration,GO:0021861~forebrain radial glial cell differentiation,GO:0030036~actin cytoskeleton organization,GO:0030307~positive regulation of cell growth,GO:0030334~regulation of cell migration,GO:0030335~positive regulation of cell migration,GO:0030521~androgen receptor signaling pathway,GO:0030838~positive regulation of actin filament polymerization,GO:0030865~cortical cytoskeleton organization,GO:0031098~stress-activated protein kinase signaling cascade,GO:0031122~cytoplasmic microtubule organization,GO:0031532~actin cytoskeleton reorganization,GO:0032467~positive regulation of cytokinesis,GO:0032956~regulation of actin cytoskeleton organization,GO:0033144~negative regulation of intracellular steroid hormone receptor signaling pathway,GO:0033688~regulation of osteoblast proliferation,GO:0034329~cell junction assembly,GO:0034446~substrate adhesion-dependent cell spreading,GO:0035385~Roundabout signaling pathway,GO:0036089~cleavage furrow formation,GO:0038027~apolipoprotein A-I-mediated signaling pathway,GO:0042476~odontogenesis,GO:0042493~response to drug,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043124~negative regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043149~stress fiber assembly,GO:0043200~response to amino acid,GO:0043280~positive regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0043297~apical junction assembly,GO:0043312~neutrophil degranulation,GO:0043366~beta selection,GO:0043524~negative regulation of neuron apoptotic process,GO:0043525~positive regulation of neuron apoptotic process,GO:0043542~endothelial cell migration,GO:0043931~ossification involved in bone maturation,GO:0044319~wound healing, spreading of cells,GO:0045198~establishment of epithelial cell apical/basal polarity,GO:0045471~response to ethanol,GO:0045665~negative regulation of neuron differentiation,GO:0045666~positive regulation of neuron differentiation,GO:0045727~positive regulation of translation,GO:0045792~negative regulation of cell size,GO:0046039~GTP metabolic process,GO:0046638~positive regulation of alpha-beta T cell differentiation,GO:0048010~vascular endothelial growth factor receptor signaling pathway,GO:0048013~ephrin receptor signaling pathway,GO:0048015~phosphatidylinositol-mediated signaling,GO:0048812~neuron projection morphogenesis,GO:0050771~negative regulation of axonogenesis,GO:0050772~positive regulation of axonogenesis,GO:0050773~regulation of dendrite development,GO:0050919~negative chemotaxis,GO:0051056~regulation of small GTPase mediated signal transduction,GO:0051384~response to glucocorticoid,GO:0051496~positive regulation of stress fiber assembly,GO:0051893~regulation of focal adhesion assembly,GO:0051924~regulation of calcium ion transport,GO:0060071~Wnt signaling pathway, planar cell polarity pathway,GO:0060193~positive regulation of lipase activity,GO:0061383~trabecula morphogenesis,GO:0070507~regulation of microtubule cytoskeleton organization,GO:0071222~cellular response to lipopolysaccharide,GO:0071345~cellular response to cytokine stimulus,GO:0071803~positive regulation of podosome assembly,GO:0071902~positive regulation of protein serine/threonine kinase activity,GO:0090051~negative regulation of cell migration involved in sprouting angiogenesis,GO:0090307~mitotic spindle assembly,GO:0090324~negative regulation of oxidative phosphorylation,GO:0097498~endothelial tube lumen extension,GO:1901224~positive regulation of NIK/NF-kappaB signaling,GO:1902766~skeletal muscle satellite cell migration,GO:1903427~negative regulation of reactive oxygen species biosynthetic process,GO:1903673~mitotic cleavage furrow formation,GO:1904695~positive regulation of vascular smooth muscle contraction,GO:1904706~negative regulation of vascular smooth muscle cell proliferation,GO:1904753~negative regulation of vascular associated smooth muscle cell migration,GO:1904996~positive regulation of leukocyte adhesion to vascular endothelial cell,GO:1905244~regulation of modification of synaptic structure,GO:1905274~regulation of modification of postsynaptic actin cytoskeleton,GO:1990869~cellular response to chemokine,GO:2000145~regulation of cell motility,GO:2000177~regulation of neural precursor cell proliferation,GO:2000406~positive regulation of T cell migration,	GO:0005634~nucleus,GO:0005768~endosome,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0005938~cell cortex,GO:0030027~lamellipodium,GO:0030054~cell junction,GO:0030424~axon,GO:0030496~midbody,GO:0030667~secretory granule membrane,GO:0031234~extrinsic component of cytoplasmic side of plasma membrane,GO:0031410~cytoplasmic vesicle,GO:0031982~vesicle,GO:0032154~cleavage furrow,GO:0032587~ruffle membrane,GO:0042995~cell projection,GO:0043197~dendritic spine,GO:0043231~intracellular membrane-bounded organelle,GO:0043296~apical junction complex,GO:0070062~extracellular exosome,GO:0071944~cell periphery,GO:0098794~postsynapse,GO:0098978~glutamatergic synapse,GO:0101003~ficolin-1-rich granule membrane,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0017022~myosin binding,GO:0019003~GDP binding,GO:0019901~protein kinase binding,GO:0019904~protein domain specific binding,GO:0051022~Rho GDP-dissociation inhibitor binding,	IPR001806:Small GTPase superfamily,IPR003578:Small GTPase superfamily, Rho type,IPR005225:Small GTP-binding protein domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04062:Chemokine signaling pathway,hsa04071:Sphingolipid signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04144:Endocytosis,hsa04150:mTOR signaling pathway,hsa04270:Vascular smooth muscle contraction,hsa04310:Wnt signaling pathway,hsa04350:TGF-beta signaling pathway,hsa04360:Axon guidance,hsa04510:Focal adhesion,hsa04520:Adherens junction,hsa04530:Tight junction,hsa04611:Platelet activation,hsa04621:NOD-like receptor signaling pathway,hsa04625:C-type lectin receptor signaling pathway,hsa04660:T cell receptor signaling pathway,hsa04670:Leukocyte transendothelial migration,hsa04722:Neurotrophin signaling pathway,hsa04810:Regulation of actin cytoskeleton,hsa04921:Oxytocin signaling pathway,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04972:Pancreatic secretion,hsa05100:Bacterial invasion of epithelial cells,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05133:Pertussis,hsa05135:Yersinia infection,hsa05152:Tuberculosis,hsa05163:Human cytomegalovirus infection,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,hsa05210:Colorectal cancer,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,	618727~Ectodermal dysplasia with facial dysmorphism and acral, ocular, and brain anomalies, somatic mosaic,			KW-0131~Cell cycle,KW-0132~Cell division,KW-0945~Host-virus interaction,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0038~Ectodermal dysplasia,KW-0225~Disease variant,KW-0656~Proto-oncogene,		KW-0342~GTP-binding,KW-0460~Magnesium,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0013~ADP-ribosylation,KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0636~Prenylation,KW-0832~Ubl conjugation,	CARBOHYD:(Microbial infection) O-alpha-linked (GlcNAc) threonine; by C.novyi toxin TcdA; alternate,CARBOHYD:(Microbial infection) O-linked (Glc) threonine; by C.difficile toxins TcdA and TcdB; alternate,CARBOHYD:(Microbial infection) O-linked (GlcNAc) tyrosine; by Photorhabdus PAU_02230; alternate,LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,MUTAGEN:G->V: Increased Rho protein signal transduction. Constitutively active.,MUTAGEN:L->M: Converts geranyl-geranylation to farnesylation; does not prevent the cleavage by yopT.,MUTAGEN:Q->L: Causes constitutive activation.,MUTAGEN:T->A: Abolished monoglucosylation by C.difficile toxin TcdA. Abolished O-GlcNAcylation by C.novyi toxin TcdA.,MUTAGEN:T->N: Decreased Rho protein signal transduction. Decreased substrate adhesion-dependent cell spreading. Decreased stress fibers assembly. Decreased cytoplasmic microtubule organization.,MUTAGEN:Y->A: Abolishes interaction with DGKQ.,MUTAGEN:Y->F: Abolishes AMPylation by Haemophilus IbpA.,NP_BIND:GTP,PROPEP:Removed in mature form,SITE:Cleavage; by yopT,
REEP5	receptor accessory protein 5(REEP5)	Homo sapiens				GO:0007029~endoplasmic reticulum organization,GO:0032386~regulation of intracellular transport,GO:0090158~endoplasmic reticulum membrane organization,	GO:0005783~endoplasmic reticulum,GO:0016021~integral component of membrane,GO:0071782~endoplasmic reticulum tubular network,	GO:0005515~protein binding,	IPR004345:TB2/DP1/HVA22-related protein,						KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,		TRANSMEM:Helical,
RGS2	regulator of G protein signaling 2(RGS2)	Homo sapiens				GO:0001975~response to amphetamine,GO:0006417~regulation of translation,GO:0007049~cell cycle,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007283~spermatogenesis,GO:0007420~brain development,GO:0008277~regulation of G-protein coupled receptor protein signaling pathway,GO:0010519~negative regulation of phospholipase activity,GO:0010614~negative regulation of cardiac muscle hypertrophy,GO:0010976~positive regulation of neuron projection development,GO:0017148~negative regulation of translation,GO:0030728~ovulation,GO:0031279~regulation of cyclase activity,GO:0043407~negative regulation of MAP kinase activity,GO:0043547~positive regulation of GTPase activity,GO:0043951~negative regulation of cAMP-mediated signaling,GO:0045471~response to ethanol,GO:0045744~negative regulation of G-protein coupled receptor protein signaling pathway,GO:0050873~brown fat cell differentiation,GO:0055119~relaxation of cardiac muscle,GO:0060087~relaxation of vascular smooth muscle,GO:0060135~maternal process involved in female pregnancy,GO:0060452~positive regulation of cardiac muscle contraction,GO:0061052~negative regulation of cell growth involved in cardiac muscle cell development,GO:1900924~negative regulation of glycine import,	GO:0005634~nucleus,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0009898~cytoplasmic side of plasma membrane,GO:0043005~neuron projection,	GO:0001965~G-protein alpha-subunit binding,GO:0003924~GTPase activity,GO:0005096~GTPase activator activity,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0010855~adenylate cyclase inhibitor activity,GO:0048487~beta-tubulin binding,	IPR016137:Regulator of G protein signalling superfamily,IPR024066:Regulator of G-protein signaling, domain 1,	hsa04022:cGMP-PKG signaling pathway,hsa04740:Olfactory transduction,hsa04921:Oxytocin signaling pathway,			SM00315:RGS,	KW-0131~Cell cycle,KW-0810~Translation regulation,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,				KW-0343~GTPase activation,KW-0734~Signal transduction inhibitor,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:RGS,MUTAGEN:C->S: Changes specificity and confers GNAI1 binding; when associated with D-184. Strongly increases affinity for GNAI1 and GNAI3; when associated with D-184 and K-191.,MUTAGEN:E->A: Near loss of EIF2B5 binding and inhibition of in vitro translation; when associated with L-79; E-86; L-87; S-90; K-102; F-105; I-110 and L-114.,MUTAGEN:E->A: Near loss of EIF2B5 binding and inhibition of in vitro translation; when associated with L-79; L-87; S-90; K-102; F-105; I-110; E-111 and L-114.,MUTAGEN:E->K: Strongly increases affinity for GNAI1 and GNAI3; when associated with S-106 and D-184.,MUTAGEN:F->A: Near loss of EIF2B5 binding and inhibition of in vitro translation; when associated with L-79; E-86; L-87; S-90; K-102; I-110; E-111 and L-114.,MUTAGEN:F->D: Impairs association with plasma membrane.,MUTAGEN:I->A: Near loss of EIF2B5 binding and inhibition of in vitro translation; when associated with L-79; E-86; L-87; S-90; K-102; F-105; E-111 and L-114.,MUTAGEN:K->A: Near loss of EIF2B5 binding and inhibition of in vitro translation; when associated with L-79; E-86; L-87; S-90; F-105; I-110; E-111 and L-114.,MUTAGEN:L->A: Near loss of EIF2B5 binding and inhibition of in vitro translation; when associated with E-86; L-87; S-90; K-102; F-105; I-110; E-111 and L-114.,MUTAGEN:L->A: Near loss of EIF2B5 binding and inhibition of in vitro translation; when associated with L-79; E-86; L-87; S-90; K-102; F-105; I-110 and E-111.,MUTAGEN:L->A: Near loss of EIF2B5 binding and inhibition of in vitro translation; when associated with L-79; E-86; S-90; K-102; F-105; I-110; E-111 and L-114.,MUTAGEN:L->D: Impairs association with plasma membrane.,MUTAGEN:M->L: Loss of isoform 1 expression.,MUTAGEN:M->L: Loss of isoform 2 expression.,MUTAGEN:M->L: Loss of isoform 3 expression.,MUTAGEN:M->L: Loss of isoform 4 expression.,MUTAGEN:N->A: Decreases GTPase accelerating function but has no effect on translation inhibitory activity, suggesting that its role in translation is independent of its effects on G proteins.,MUTAGEN:N->D: Changes specificity and confers GNAI1 binding; when associated with D-184. Strongly increases affinity for GNAI1 and GNAI3; when associated with S-106 and K-191.,MUTAGEN:S->A: Near loss of EIF2B5 binding and inhibition of in vitro translation; when associated with L-79; E-86; L-87; K-102; F-105; I-110; E-111 and L-114.,MUTAGEN:W->D: Impairs association with plasma membrane.,REGION:Disordered,REGION:Necessary for membrane association,REGION:Necessary to inhibit protein synthesis,
RFX5	regulatory factor X5(RFX5)	Homo sapiens				GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR003150:DNA-binding RFX-type winged-helix domain,	hsa04612:Antigen processing and presentation,hsa05152:Tuberculosis,hsa05340:Primary immunodeficiency,	209920~Bare lymphocyte syndrome, type II, complementation group C,209920~Bare lymphocyte syndrome, type II, complementation group E,		SM01306:SM01306,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0705~SCID,			KW-0010~Activator,KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DNA_BIND:RFX-type winged-helix,DOMAIN:RFX-type winged-helix,DOMAIN:RFX5_N,MOTIF:PxLPxI/L motif; mediates interaction with RFXANK,REGION:Disordered,REGION:Leucine-rich region; critical for dimer formation and for interaction with RFXAP,REGION:N-terminal domain,
RFC2	replication factor C subunit 2(RFC2)	Homo sapiens				GO:0006260~DNA replication,GO:0006261~DNA-dependent DNA replication,GO:0006281~DNA repair,GO:0006283~transcription-coupled nucleotide-excision repair,GO:0006287~base-excision repair, gap-filling,GO:0006296~nucleotide-excision repair, DNA incision, 5'-to lesion,GO:0006297~nucleotide-excision repair, DNA gap filling,GO:0019985~translesion synthesis,GO:0032201~telomere maintenance via semi-conservative replication,GO:0032508~DNA duplex unwinding,GO:0033683~nucleotide-excision repair, DNA incision,GO:0042276~error-prone translesion synthesis,GO:0042769~DNA damage response, detection of DNA damage,GO:0070987~error-free translesion synthesis,GO:1900264~positive regulation of DNA-directed DNA polymerase activity,GO:1901796~regulation of signal transduction by p53 class mediator,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005663~DNA replication factor C complex,GO:0031390~Ctf18 RFC-like complex,	GO:0003677~DNA binding,GO:0003689~DNA clamp loader activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0017116~single-stranded DNA-dependent ATP-dependent DNA helicase activity,GO:0019899~enzyme binding,	IPR000523:Magnesium chelatase, ChlI subunit,IPR003593:AAA+ ATPase domain,IPR003959:ATPase, AAA-type, core,IPR008921:DNA polymerase III, clamp loader complex, gamma/delta/delta subunit, C-terminal,IPR013748:Replication factor C, C-terminal domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa03030:DNA replication,hsa03420:Nucleotide excision repair,hsa03430:Mismatch repair,			SM00382:AAA,	KW-0235~DNA replication,	KW-0539~Nucleus,	KW-0856~Williams-Beuren syndrome,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:AAA,DOMAIN:Mg_chelatase,DOMAIN:Rep_fac_C,NP_BIND:ATP,REGION:Disordered,
RFC5	replication factor C subunit 5(RFC5)	Homo sapiens				GO:0006260~DNA replication,GO:0006261~DNA-dependent DNA replication,GO:0006281~DNA repair,GO:0006283~transcription-coupled nucleotide-excision repair,GO:0006287~base-excision repair, gap-filling,GO:0006296~nucleotide-excision repair, DNA incision, 5'-to lesion,GO:0006297~nucleotide-excision repair, DNA gap filling,GO:0019985~translesion synthesis,GO:0032201~telomere maintenance via semi-conservative replication,GO:0032508~DNA duplex unwinding,GO:0033683~nucleotide-excision repair, DNA incision,GO:0042276~error-prone translesion synthesis,GO:0042769~DNA damage response, detection of DNA damage,GO:0070987~error-free translesion synthesis,GO:1900264~positive regulation of DNA-directed DNA polymerase activity,GO:1901796~regulation of signal transduction by p53 class mediator,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005663~DNA replication factor C complex,GO:0031390~Ctf18 RFC-like complex,	GO:0003677~DNA binding,GO:0003689~DNA clamp loader activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0017116~single-stranded DNA-dependent ATP-dependent DNA helicase activity,GO:0019899~enzyme binding,	IPR003593:AAA+ ATPase domain,IPR003959:ATPase, AAA-type, core,IPR008921:DNA polymerase III, clamp loader complex, gamma/delta/delta subunit, C-terminal,IPR013748:Replication factor C, C-terminal domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa03030:DNA replication,hsa03420:Nucleotide excision repair,hsa03430:Mismatch repair,			SM00382:AAA,	KW-0235~DNA replication,	KW-0539~Nucleus,		KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,		KW-0007~Acetylation,	DOMAIN:AAA,NP_BIND:ATP,REGION:Disordered,
RPA1	replication protein A1(RPA1)	Homo sapiens		h_p53hypoxiaPathway:Hypoxia and p53 in the Cardiovascular system,		GO:0000723~telomere maintenance,GO:0000724~double-strand break repair via homologous recombination,GO:0006260~DNA replication,GO:0006261~DNA-dependent DNA replication,GO:0006268~DNA unwinding involved in DNA replication,GO:0006270~DNA replication initiation,GO:0006281~DNA repair,GO:0006283~transcription-coupled nucleotide-excision repair,GO:0006284~base-excision repair,GO:0006287~base-excision repair, gap-filling,GO:0006289~nucleotide-excision repair,GO:0006293~nucleotide-excision repair, preincision complex stabilization,GO:0006294~nucleotide-excision repair, preincision complex assembly,GO:0006295~nucleotide-excision repair, DNA incision, 3'-to lesion,GO:0006296~nucleotide-excision repair, DNA incision, 5'-to lesion,GO:0006297~nucleotide-excision repair, DNA gap filling,GO:0006298~mismatch repair,GO:0006310~DNA recombination,GO:0006974~cellular response to DNA damage stimulus,GO:0007004~telomere maintenance via telomerase,GO:0019985~translesion synthesis,GO:0032201~telomere maintenance via semi-conservative replication,GO:0033683~nucleotide-excision repair, DNA incision,GO:0034502~protein localization to chromosome,GO:0036297~interstrand cross-link repair,GO:0042276~error-prone translesion synthesis,GO:0042769~DNA damage response, detection of DNA damage,GO:0051321~meiotic cell cycle,GO:0070987~error-free translesion synthesis,GO:1900034~regulation of cellular response to heat,GO:1901796~regulation of signal transduction by p53 class mediator,	GO:0000781~chromosome, telomeric region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005662~DNA replication factor A complex,GO:0016605~PML body,GO:0090734~site of DNA damage,	GO:0003677~DNA binding,GO:0003684~damaged DNA binding,GO:0003697~single-stranded DNA binding,GO:0005515~protein binding,GO:0043047~single-stranded telomeric DNA binding,GO:0046872~metal ion binding,GO:0098505~G-rich strand telomeric DNA binding,	IPR004365:Nucleic acid binding, OB-fold, tRNA/helicase-type,IPR004591:Replication factor-a protein 1 Rpa1,IPR007199:Replication factor-A protein 1, N-terminal,IPR012340:Nucleic acid-binding, OB-fold,IPR013955:Replication factor A, C-terminal,	hsa03030:DNA replication,hsa03420:Nucleotide excision repair,hsa03430:Mismatch repair,hsa03440:Homologous recombination,hsa03460:Fanconi anemia pathway,				KW-0227~DNA damage,KW-0233~DNA recombination,KW-0234~DNA repair,KW-0235~DNA replication,	KW-0539~Nucleus,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate,DNA_BIND:OB,DOMAIN:REPA_OB_2,DOMAIN:Rep-A_N,DOMAIN:Rep_fac-A_C,MUTAGEN:C->S: Loss of function in DNA replication and mismatch repair without effect on DNA-binding activity; when associated with S-500.,MUTAGEN:C->S: Loss of function in DNA replication and mismatch repair without effect on DNA-binding activity; when associated with S-503.,MUTAGEN:K->R: Significant reduction of sumoylation. Loss of sumoylation; when associated with R-577.,MUTAGEN:K->R: Slight sumoylation decrease. Loss of sumoylation; when associated with R-449.,MUTAGEN:R->E: Loss of HELB-binding; when associated with E-41.,MUTAGEN:R->E: Loss of HELB-binding; when associated with E-43.,REGION:Disordered,ZN_FING:C4-type,
RPA2	replication protein A2(RPA2)	Homo sapiens			DNA replication, recombination, and repair,	GO:0000723~telomere maintenance,GO:0000724~double-strand break repair via homologous recombination,GO:0006260~DNA replication,GO:0006270~DNA replication initiation,GO:0006283~transcription-coupled nucleotide-excision repair,GO:0006284~base-excision repair,GO:0006287~base-excision repair, gap-filling,GO:0006289~nucleotide-excision repair,GO:0006293~nucleotide-excision repair, preincision complex stabilization,GO:0006294~nucleotide-excision repair, preincision complex assembly,GO:0006295~nucleotide-excision repair, DNA incision, 3'-to lesion,GO:0006296~nucleotide-excision repair, DNA incision, 5'-to lesion,GO:0006297~nucleotide-excision repair, DNA gap filling,GO:0006298~mismatch repair,GO:0010569~regulation of double-strand break repair via homologous recombination,GO:0019985~translesion synthesis,GO:0031571~mitotic G1 DNA damage checkpoint,GO:0032201~telomere maintenance via semi-conservative replication,GO:0033683~nucleotide-excision repair, DNA incision,GO:0034502~protein localization to chromosome,GO:0036297~interstrand cross-link repair,GO:0042276~error-prone translesion synthesis,GO:0042769~DNA damage response, detection of DNA damage,GO:0070987~error-free translesion synthesis,GO:1900034~regulation of cellular response to heat,GO:1901796~regulation of signal transduction by p53 class mediator,GO:2000001~regulation of DNA damage checkpoint,	GO:0000781~chromosome, telomeric region,GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005662~DNA replication factor A complex,GO:0016604~nuclear body,GO:0016605~PML body,GO:0035861~site of double-strand break,	GO:0003684~damaged DNA binding,GO:0003697~single-stranded DNA binding,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0019903~protein phosphatase binding,GO:0031625~ubiquitin protein ligase binding,GO:0047485~protein N-terminus binding,GO:0098505~G-rich strand telomeric DNA binding,	IPR012340:Nucleic acid-binding, OB-fold,IPR014646:Replication protein A, subunit RPA32,IPR014892:Replication protein A, C-terminal,	hsa03030:DNA replication,hsa03420:Nucleotide excision repair,hsa03430:Mismatch repair,hsa03440:Homologous recombination,hsa03460:Fanconi anemia pathway,		PIRSF036949:replication protein A, RPA32 subunit,		KW-0227~DNA damage,KW-0233~DNA recombination,KW-0234~DNA repair,KW-0235~DNA replication,	KW-0539~Nucleus,				KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DNA_BIND:OB,DOMAIN:RPA_C,MUTAGEN:E->A: Abolishes interaction with RFWD3, leading to impair DNA interstrand cross-links (ICL) repair.,MUTAGEN:F->A: Abolishes interaction with RFWD3, leading to impair DNA interstrand cross-links (ICL) repair.,MUTAGEN:G->A: Does not affect interaction with RFWD3.,MUTAGEN:H->A: Abolishes interaction with RFWD3, leading to impair DNA interstrand cross-links (ICL) repair.,MUTAGEN:KK->RR: Impaired ubiquitination without affecting homologous recombination.,MUTAGEN:S->A: Increased RAD51 foci formation and homologous recombination efficiency at DNA double-strand breaks; when associated with A-4.,MUTAGEN:S->A: Increased RAD51 foci formation and homologous recombination efficiency at DNA double-strand breaks; when associated with A-8.,MUTAGEN:S->A: Reduces phosphorylation by CDK1.,MUTAGEN:S->D: Lower homologous recombination efficiency following DNA double strand break. Impaired DNA synthesis following DNA damage; when associated with D-33. No effect on cell-cycle progression, nor DNA synthesis in undamaged cells; when associated with D-23; D-29 and D-33. Impaired DNA double strand breaks repair; when associated with D-23; D-29 and D-33. Extended DNA damage-induced G2-M checkpoint; when associated with D-23; D-29 and D-33. Preferentially interacts with RAD51; when associated with D-23; D-29 and D-33.,MUTAGEN:S->D: Lower homologous recombination efficiency following DNA double strand break. Impaired DNA synthesis following DNA damage; when associated with D-8. No effect on cell-cycle progression, nor DNA synthesis in undamaged cells; when associated with D-8; D-23 and D-29. Impaired DNA double strand breaks repair; when associated with D-8; D-23 and D-29. Extended DNA damage-induced G2-M checkpoint; when associated with D-8; D-23 and D-29. Preferentially interacts with RAD51; when associated with D-8; D-23 and D-29.,MUTAGEN:S->D: No effect on DNA synthesis following DNA damage; when associated with D-23. No effect on cell-cycle progression, nor DNA synthesis in undamaged cells; when associated with D-8; D-23 and D-33. Impaired DNA double strand breaks repair; when associated with D-8; D-23 and D-33. Extended DNA damage-induced G2-M checkpoint; when associated with D-8; D-23 and D-33. Preferentially interacts with RAD51; when associated with D-8; D-23 and D-33.,MUTAGEN:S->D: No effect on DNA synthesis following DNA damage; when associated with D-29. No effect on cell-cycle progression, nor DNA synthesis in undamaged cells; when associated with D-8; D-29 and D-33. Impaired DNA double strand breaks repair; when associated with D-8; D-29 and D-33. Extended DNA damage-induced G2-M checkpoint; when associated with D-8; D-29 and D-33. Preferentially interacts with RAD51; when associated with D-8; D-29 and D-33.,REGION:Disordered,REGION:Interaction with RAD52, TIPIN, UNG and XPA,
RPA3	replication protein A3(RPA3)	Homo sapiens				GO:0000723~telomere maintenance,GO:0000724~double-strand break repair via homologous recombination,GO:0006260~DNA replication,GO:0006270~DNA replication initiation,GO:0006281~DNA repair,GO:0006283~transcription-coupled nucleotide-excision repair,GO:0006284~base-excision repair,GO:0006287~base-excision repair, gap-filling,GO:0006289~nucleotide-excision repair,GO:0006293~nucleotide-excision repair, preincision complex stabilization,GO:0006294~nucleotide-excision repair, preincision complex assembly,GO:0006295~nucleotide-excision repair, DNA incision, 3'-to lesion,GO:0006296~nucleotide-excision repair, DNA incision, 5'-to lesion,GO:0006297~nucleotide-excision repair, DNA gap filling,GO:0006298~mismatch repair,GO:0006310~DNA recombination,GO:0007346~regulation of mitotic cell cycle,GO:0019985~translesion synthesis,GO:0032201~telomere maintenance via semi-conservative replication,GO:0033683~nucleotide-excision repair, DNA incision,GO:0036297~interstrand cross-link repair,GO:0042127~regulation of cell proliferation,GO:0042276~error-prone translesion synthesis,GO:0042769~DNA damage response, detection of DNA damage,GO:0070987~error-free translesion synthesis,GO:1900034~regulation of cellular response to heat,GO:1901796~regulation of signal transduction by p53 class mediator,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005662~DNA replication factor A complex,GO:0035861~site of double-strand break,	GO:0003677~DNA binding,GO:0003684~damaged DNA binding,GO:0003697~single-stranded DNA binding,GO:0005515~protein binding,	IPR012340:Nucleic acid-binding, OB-fold,IPR013970:Replication factor A protein 3,	hsa03030:DNA replication,hsa03420:Nucleotide excision repair,hsa03430:Mismatch repair,hsa03440:Homologous recombination,hsa03460:Fanconi anemia pathway,				KW-0227~DNA damage,KW-0233~DNA recombination,KW-0234~DNA repair,KW-0235~DNA replication,	KW-0539~Nucleus,					KW-0007~Acetylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),
RTN2	reticulon 2(RTN2)	Homo sapiens				GO:0010467~gene expression,GO:0046324~regulation of glucose import,GO:0065002~intracellular protein transmembrane transport,GO:1902430~negative regulation of beta-amyloid formation,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005882~intermediate filament,GO:0009986~cell surface,GO:0014802~terminal cisterna,GO:0016021~integral component of membrane,GO:0030018~Z disc,GO:0030176~integral component of endoplasmic reticulum membrane,GO:0030315~T-tubule,GO:0033017~sarcoplasmic reticulum membrane,	GO:0005515~protein binding,	IPR003388:Reticulon,		604805~Spastic paraplegia 12, autosomal dominant,				KW-0206~Cytoskeleton,KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0703~Sarcoplasmic reticulum,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0890~Hereditary spastic paraplegia,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Reticulon,REGION:Disordered,TRANSMEM:Helical,
RAI14	retinoic acid induced 14(RAI14)	Homo sapiens			General function prediction only,	GO:0007283~spermatogenesis,GO:0030154~cell differentiation,GO:0097190~apoptotic signaling pathway,GO:1901222~regulation of NIK/NF-kappaB signaling,	GO:0001650~fibrillar center,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005938~cell cortex,GO:0030054~cell junction,	GO:0003779~actin binding,GO:0005515~protein binding,	IPR002110:Ankyrin repeat,IPR020683:Ankyrin repeat-containing domain,				SM00248:ANK,	KW-0221~Differentiation,KW-0744~Spermatogenesis,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0965~Cell junction,		KW-0040~ANK repeat,KW-0175~Coiled coil,KW-0677~Repeat,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Ankyrin_rpt-contain_dom,MOTIF:Nuclear localization signal,REGION:Disordered,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,REPEAT:ANK 5,REPEAT:ANK 6,REPEAT:ANK 7,
RBKS	ribokinase(RBKS)	Homo sapiens				GO:0006098~pentose-phosphate shunt,GO:0019303~D-ribose catabolic process,GO:0046835~carbohydrate phosphorylation,	GO:0005634~nucleus,GO:0005829~cytosol,	GO:0004747~ribokinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,	IPR002139:Ribokinase,IPR002173:Carbohydrate/puine kinase, PfkB, conserved site,IPR011611:Carbohydrate kinase PfkB,IPR011877:Ribokinase, bacterial,	hsa00030:Pentose phosphate pathway,hsa01100:Metabolic pathways,				KW-0119~Carbohydrate metabolism,	KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0630~Potassium,	KW-0418~Kinase,KW-0808~Transferase,		ACT_SITE:Proton acceptor,BINDING:ATP,BINDING:Substrate,DOMAIN:PfkB,METAL:Potassium,METAL:Potassium; via carbonyl oxygen,NP_BIND:ATP,REGION:Disordered,REGION:Substrate binding,
RPP38	ribonuclease P/MRP subunit p38(RPP38)	Homo sapiens				GO:0001682~tRNA 5'-leader removal,GO:0006364~rRNA processing,GO:0090502~RNA phosphodiester bond hydrolysis, endonucleolytic,	GO:0000172~ribonuclease MRP complex,GO:0001650~fibrillar center,GO:0005654~nucleoplasm,GO:0005655~nucleolar ribonuclease P complex,GO:0005730~nucleolus,GO:0030681~multimeric ribonuclease P complex,	GO:0004526~ribonuclease P activity,GO:0005515~protein binding,GO:0033204~ribonuclease P RNA binding,	IPR004038:Ribosomal protein L7Ae/L30e/S12e/Gadd45,	hsa03008:Ribosome biogenesis in eukaryotes,				KW-0698~rRNA processing,KW-0819~tRNA processing,	KW-0539~Nucleus,				KW-0378~Hydrolase,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Ribosomal_L7Ae,
RNH1	ribonuclease/angiogenin inhibitor 1(RNH1)	Homo sapiens				GO:0006402~mRNA catabolic process,GO:0043086~negative regulation of catalytic activity,GO:0045765~regulation of angiogenesis,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0032311~angiogenin-PRI complex,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0008428~ribonuclease inhibitor activity,	IPR001611:Leucine-rich repeat,IPR006553:Leucine-rich repeat, cysteine-containing subtype,				SM00367:LRR_CC,		KW-0963~Cytoplasm,		KW-0433~Leucine-rich repeat,KW-0677~Repeat,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	MUTAGEN:Missing: A significant decrease in binding affinity with RNASE1, slight decrease for the ANG ligand, no real change in binding affinity for RNASE2.,MUTAGEN:R->A: 25-fold reduction in binding affinity for RNASE2.,MUTAGEN:W->A: 40-fold reduction in binding affinity for RNASE2.,MUTAGEN:W->A: Binding affinity decreased 5000-fold over the wild type for RNASE2; when associated with A-264 and A-319.,MUTAGEN:W->A: Substantially decreased binding affinity for RNASE2. Binding affinity decreased 5000-fold over the wild type for RNASE2; when associated with A-262 and A-264.,MUTAGEN:W->A: Substantially decreased binding affinity for RNASE2. Binding affinity decreased 5000-fold over the wild type for RNASE2; when associated with A-262 and A-319.,MUTAGEN:YD->AA: Substantially decreases binding affinity for RNASE1, ANG and RNASE2.,REGION:2 X 5 AA tandem repeats of S-L-D-I-Q,REPEAT:LRR 1,REPEAT:LRR 10,REPEAT:LRR 11,REPEAT:LRR 12,REPEAT:LRR 13,REPEAT:LRR 14,REPEAT:LRR 15,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,REPEAT:LRR 8,REPEAT:LRR 9,
RAE1	ribonucleic acid export 1(RAE1)	Homo sapiens				GO:0000972~transcription-dependent tethering of RNA polymerase II gene DNA at nuclear periphery,GO:0006110~regulation of glycolytic process,GO:0006405~RNA export from nucleus,GO:0006406~mRNA export from nucleus,GO:0006409~tRNA export from nucleus,GO:0007049~cell cycle,GO:0016032~viral process,GO:0016925~protein sumoylation,GO:0019058~viral life cycle,GO:0019083~viral transcription,GO:0051301~cell division,GO:0060236~regulation of mitotic spindle organization,GO:0060964~regulation of gene silencing by miRNA,GO:0071407~cellular response to organic cyclic compound,GO:0075733~intracellular transport of virus,GO:1900034~regulation of cellular response to heat,	GO:0000922~spindle pole,GO:0001650~fibrillar center,GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005643~nuclear pore,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0043657~host cell,GO:0097431~mitotic spindle pole,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0043130~ubiquitin binding,	IPR001680:WD40 repeat,IPR015943:WD40/YVTN repeat-like-containing domain,IPR017986:WD40-repeat-containing domain,IPR019775:WD40 repeat, conserved site,IPR020472:G-protein beta WD-40 repeat,	hsa03013:Nucleocytoplasmic transport,hsa05014:Amyotrophic lateral sclerosis,hsa05164:Influenza A,			SM00320:WD40,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,KW-0813~Transport,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0732~Signal,KW-0853~WD repeat,			KW-0597~Phosphoprotein,	REGION:Disordered,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
RPN1	ribophorin I(RPN1)	Homo sapiens				GO:0006464~cellular protein modification process,GO:0006486~protein glycosylation,GO:0006487~protein N-linked glycosylation,GO:0018279~protein N-linked glycosylation via asparagine,GO:0019082~viral protein processing,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005791~rough endoplasmic reticulum,GO:0005829~cytosol,GO:0008250~oligosaccharyltransferase complex,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0042470~melanosome,	GO:0003723~RNA binding,GO:0004579~dolichyl-diphosphooligosaccharide-protein glycotransferase activity,GO:0005515~protein binding,GO:0016740~transferase activity,	IPR007676:Ribophorin I,	hsa00510:N-Glycan biosynthesis,hsa00513:Various types of N-glycan biosynthesis,hsa01100:Metabolic pathways,hsa04141:Protein processing in endoplasmic reticulum,					KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0175~Coiled coil,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0808~Transferase,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
RPIA	ribose 5-phosphate isomerase A(RPIA)	Homo sapiens				GO:0006014~D-ribose metabolic process,GO:0006098~pentose-phosphate shunt,GO:0009052~pentose-phosphate shunt, non-oxidative branch,GO:0019693~ribose phosphate metabolic process,	GO:0005829~cytosol,GO:0016021~integral component of membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0004751~ribose-5-phosphate isomerase activity,GO:0005515~protein binding,GO:0030246~carbohydrate binding,GO:0042802~identical protein binding,GO:0048029~monosaccharide binding,	IPR004788:Ribose 5-phosphate isomerase, type A,IPR007324:Sugar-binding domain, putative,IPR020672:Ribose-5-phosphate isomerase, type A, subgroup,	hsa00030:Pentose phosphate pathway,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa01230:Biosynthesis of amino acids,	608611~Ribose 5-phosphate isomerase deficiency,				KW-0472~Membrane,	KW-0225~Disease variant,KW-0622~Neuropathy,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0413~Isomerase,	KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:Sugar-bind,REGION:Disordered,TRANSMEM:Helical,
RRP12	ribosomal RNA processing 12 homolog(RRP12)	Homo sapiens				GO:0006364~rRNA processing,	GO:0005634~nucleus,GO:0005730~nucleolus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0031965~nuclear membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0003723~RNA binding,	IPR012978:Uncharacterised domain NUC173,IPR016024:Armadillo-type fold,						KW-0472~Membrane,KW-0539~Nucleus,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),DOMAIN:NUC173,REGION:Disordered,TRANSMEM:Helical,
RRP1B	ribosomal RNA processing 1B(RRP1B)	Homo sapiens				GO:0006364~rRNA processing,GO:0006397~mRNA processing,GO:0006915~apoptotic process,GO:0008380~RNA splicing,GO:0010923~negative regulation of phosphatase activity,GO:0016032~viral process,GO:0034260~negative regulation of GTPase activity,GO:0043065~positive regulation of apoptotic process,GO:0043484~regulation of RNA splicing,GO:0043923~positive regulation by host of viral transcription,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0098586~cellular response to virus,	GO:0000791~euchromatin,GO:0000792~heterochromatin,GO:0001652~granular component,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005730~nucleolus,GO:0005829~cytosol,GO:0030687~preribosome, large subunit precursor,GO:0030688~preribosome, small subunit precursor,	GO:0003713~transcription coactivator activity,GO:0003723~RNA binding,GO:0005515~protein binding,	IPR010301:Nucleolar, Nop52,					KW-0053~Apoptosis,KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0158~Chromosome,KW-0539~Nucleus,				KW-0010~Activator,	KW-0007~Acetylation,KW-0164~Citrullination,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,MUTAGEN:F->A: Abolishes interaction with protein phosphatase PP1 subunits PPP1CB and PPP1CC; when associated with A-684.,MUTAGEN:V->A: Abolishes interaction with protein phosphatase PP1 subunits PPP1CB and PPP1CC; when associated with A-686.,REGION:Disordered,
RPL39L	ribosomal protein L39 like(RPL39L)	Homo sapiens				GO:0006412~translation,GO:0007283~spermatogenesis,	GO:0022625~cytosolic large ribosomal subunit,	GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR000077:Ribosomal protein L39e,IPR020083:Ribosomal protein L39e, conserved site,IPR023626:Ribosomal protein L39e domain,										KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,
RPS5	ribosomal protein S5(RPS5)	Homo sapiens				GO:0000028~ribosomal small subunit assembly,GO:0000184~nuclear-transcribed mRNA catabolic process, nonsense-mediated decay,GO:0002181~cytoplasmic translation,GO:0006412~translation,GO:0006413~translational initiation,GO:0006450~regulation of translational fidelity,GO:0006614~SRP-dependent cotranslational protein targeting to membrane,GO:0019083~viral transcription,	GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005925~focal adhesion,GO:0015935~small ribosomal subunit,GO:0016020~membrane,GO:0022626~cytosolic ribosome,GO:0022627~cytosolic small ribosomal subunit,GO:0070062~extracellular exosome,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0019843~rRNA binding,	IPR000235:Ribosomal protein S5/S7,IPR005716:Ribosomal protein S5/S7, eukaryotic/archaeal,IPR020606:Ribosomal protein S7, conserved site,IPR023798:Ribosomal protein S7 domain,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,		PIRSF002122:ribosomal protein, S7p/S7a/S5e/organellar S7 types,							KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:Ribosomal_S7,
RPS6KA1	ribosomal protein S6 kinase A1(RPS6KA1)	Homo sapiens	87.Activation_ERK-MAPK_Synaptic_Act,	h_badPathway:Regulation of BAD phosphorylation,h_crebPathway:Transcription factor CREB and its extracellular signals,h_erk5Pathway:Role of Erk5 in Neuronal Survival,h_erkPathway:Erk1/Erk2 Mapk Signaling pathway,h_g2Pathway:Cell Cycle: G2/M Checkpoint,h_ghPathway:Growth Hormone Signaling Pathway,h_igf1rPathway:Multiple antiapoptotic pathways from IGF-1R signaling lead to BAD phosphorylation,h_mapkPathway:MAPKinase Signaling Pathway,h_melanocytePathway:Melanocyte Development and Pigmentation Pathway,h_mPRPathway:How Progesterone Initiates the Oocyte Maturation,		GO:0006915~apoptotic process,GO:0007049~cell cycle,GO:0007165~signal transduction,GO:0007268~chemical synaptic transmission,GO:0018105~peptidyl-serine phosphorylation,GO:0030307~positive regulation of cell growth,GO:0035556~intracellular signal transduction,GO:0043066~negative regulation of apoptotic process,GO:0043154~negative regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0043555~regulation of translation in response to stress,GO:0043620~regulation of DNA-templated transcription in response to stress,GO:0045597~positive regulation of cell differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0072574~hepatocyte proliferation,GO:2000491~positive regulation of hepatic stellate cell activation,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0045202~synapse,	GO:0000287~magnesium ion binding,GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004711~ribosomal protein S6 kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0043027~cysteine-type endopeptidase inhibitor activity involved in apoptotic process,	IPR000719:Protein kinase, catalytic domain,IPR000961:AGC-kinase, C-terminal,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR016239:Ribosomal protein S6 kinase II,IPR017441:Protein kinase, ATP binding site,IPR017892:Protein kinase, C-terminal,	hsa04010:MAPK signaling pathway,hsa04114:Oocyte meiosis,hsa04150:mTOR signaling pathway,hsa04714:Thermogenesis,hsa04720:Long-term potentiation,hsa04722:Neurotrophin signaling pathway,hsa04914:Progesterone-mediated oocyte maturation,hsa04931:Insulin resistance,hsa05135:Yersinia infection,hsa05207:Chemical carcinogenesis - receptor activation,		PIRSF000606:ribosomal protein S6 kinase II,	SM00133:S_TK_X,SM00220:S_TKc,	KW-0131~Cell cycle,KW-0346~Stress response,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,	KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:ATP,COMPBIAS:Polar residues,DOMAIN:AGC-kinase C-terminal,DOMAIN:Protein kinase,DOMAIN:Protein kinase 1,DOMAIN:Protein kinase 2,NP_BIND:ATP,REGION:Disordered,
RPS6	ribosomal protein S6(RPS6)	Homo sapiens		h_igf1mtorPathway:Skeletal muscle hypertrophy is regulated via AKT/mTOR pathway,h_mtorPathway:mTOR Signaling Pathway,		GO:0000082~G1/S transition of mitotic cell cycle,GO:0000184~nuclear-transcribed mRNA catabolic process, nonsense-mediated decay,GO:0001890~placenta development,GO:0002181~cytoplasmic translation,GO:0002309~T cell proliferation involved in immune response,GO:0006364~rRNA processing,GO:0006412~translation,GO:0006413~translational initiation,GO:0006614~SRP-dependent cotranslational protein targeting to membrane,GO:0006924~activation-induced cell death of T cells,GO:0007369~gastrulation,GO:0008284~positive regulation of cell proliferation,GO:0019083~viral transcription,GO:0022605~oogenesis stage,GO:0031929~TOR signaling,GO:0033077~T cell differentiation in thymus,GO:0042274~ribosomal small subunit biogenesis,GO:0042593~glucose homeostasis,GO:0043065~positive regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0048821~erythrocyte development,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005844~polysome,GO:0015935~small ribosomal subunit,GO:0016020~membrane,GO:0022626~cytosolic ribosome,GO:0022627~cytosolic small ribosomal subunit,GO:0030425~dendrite,GO:0036464~cytoplasmic ribonucleoprotein granule,GO:0044297~cell body,GO:0048471~perinuclear region of cytoplasm,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0019901~protein kinase binding,	IPR001377:Ribosomal protein S6e,IPR014401:Ribosomal protein S6, eukaryotic,IPR018282:Ribosomal protein S6e, conserved site,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa03010:Ribosome,hsa04066:HIF-1 signaling pathway,hsa04150:mTOR signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04371:Apelin signaling pathway,hsa04714:Thermogenesis,hsa04910:Insulin signaling pathway,hsa05171:Coronavirus disease - COVID-19,hsa05205:Proteoglycans in cancer,		PIRSF002129:ribosomal protein S6e,	SM01405:SM01405,						KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,KW-0379~Hydroxylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),MUTAGEN:R->X: Abolishes hydroxylation by KDM8.,MUTAGEN:SS->AA: Abolishes phosphorylation by PASK.,REGION:Disordered,
RRS1	ribosome biogenesis regulator 1 homolog(RRS1)	Homo sapiens				GO:0000027~ribosomal large subunit assembly,GO:0000055~ribosomal large subunit export from nucleus,GO:0000447~endonucleolytic cleavage in ITS1 to separate SSU-rRNA from 5.8S rRNA and LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA),GO:0002244~hematopoietic progenitor cell differentiation,GO:0007080~mitotic metaphase plate congression,GO:0042273~ribosomal large subunit biogenesis,GO:1901796~regulation of signal transduction by p53 class mediator,GO:1902570~protein localization to nucleolus,	GO:0000794~condensed nuclear chromosome,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005783~endoplasmic reticulum,GO:0030687~preribosome, large subunit precursor,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008097~5S rRNA binding,	IPR007023:Ribosomal biogenesis regulatory protein,					KW-0690~Ribosome biogenesis,	KW-0539~Nucleus,					KW-0007~Acetylation,KW-0164~Citrullination,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,
RNF167	ring finger protein 167(RNF167)	Homo sapiens				GO:0000209~protein polyubiquitination,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0045786~negative regulation of cell cycle,	GO:0005737~cytoplasm,GO:0012505~endomembrane system,GO:0016021~integral component of membrane,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0046872~metal ion binding,GO:0061630~ubiquitin protein ligase activity,	IPR001841:Zinc finger, RING-type,IPR003137:Protease-associated domain, PA,IPR011016:Zinc finger, RING-CH-type,IPR013083:Zinc finger, RING/FYVE/PHD-type,				SM00184:RING,SM00744:RINGv,	KW-0833~Ubl conjugation pathway,	KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-0863~Zinc-finger,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,	KW-0325~Glycoprotein,KW-0832~Ubl conjugation,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Pro residues,DOMAIN:PA,DOMAIN:RING-type,MUTAGEN:I->A: Drastically increased stability; reduction in auto-ubiquitination activity; loss of cell delay/arrest in G1.,MUTAGEN:W->A: Drastically increased stability; reduction in auto-ubiquitination activity; loss of cell delay/arrest in G1.,REGION:Disordered,TRANSMEM:Helical,ZN_FING:RING-type; atypical,
SCCPDH	saccharopine dehydrogenase (putative)(SCCPDH)	Homo sapiens				GO:0002576~platelet degranulation,GO:0009247~glycolipid biosynthetic process,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0005811~lipid particle,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030496~midbody,GO:0031093~platelet alpha granule lumen,	GO:0016491~oxidoreductase activity,	IPR005097:Saccharopine dehydrogenase / Homospermidine synthase,						KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Sacchrp_dh_C,DOMAIN:Sacchrp_dh_NADP,TRANSMEM:Helical,
SGCB	sarcoglycan beta(SGCB)	Homo sapiens				GO:0007517~muscle organ development,GO:0048747~muscle fiber development,GO:0055013~cardiac muscle cell development,GO:0097084~vascular smooth muscle cell development,	GO:0005737~cytoplasm,GO:0005856~cytoskeleton,GO:0005887~integral component of plasma membrane,GO:0016010~dystrophin-associated glycoprotein complex,GO:0016012~sarcoglycan complex,GO:0016021~integral component of membrane,GO:0042383~sarcolemma,	GO:0005515~protein binding,	IPR006875:Sarcoglycan complex subunit protein,	hsa05410:Hypertrophic cardiomyopathy,hsa05412:Arrhythmogenic right ventricular cardiomyopathy,hsa05414:Dilated cardiomyopathy,hsa05416:Viral myocarditis,	604286~Muscular dystrophy, limb-girdle, autosomal recessive 4,				KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0947~Limb-girdle muscular dystrophy,	KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
SCARB1	scavenger receptor class B member 1(SCARB1)	Homo sapiens				GO:0001935~endothelial cell proliferation,GO:0006702~androgen biosynthetic process,GO:0006707~cholesterol catabolic process,GO:0006898~receptor-mediated endocytosis,GO:0010595~positive regulation of endothelial cell migration,GO:0010867~positive regulation of triglyceride biosynthetic process,GO:0010886~positive regulation of cholesterol storage,GO:0010899~regulation of phosphatidylcholine catabolic process,GO:0015914~phospholipid transport,GO:0015920~lipopolysaccharide transport,GO:0031663~lipopolysaccharide-mediated signaling pathway,GO:0032497~detection of lipopolysaccharide,GO:0033344~cholesterol efflux,GO:0034375~high-density lipoprotein particle remodeling,GO:0034381~plasma lipoprotein particle clearance,GO:0034383~low-density lipoprotein particle clearance,GO:0034384~high-density lipoprotein particle clearance,GO:0035461~vitamin transmembrane transport,GO:0042060~wound healing,GO:0042632~cholesterol homeostasis,GO:0043534~blood vessel endothelial cell migration,GO:0043654~recognition of apoptotic cell,GO:0043691~reverse cholesterol transport,GO:0044406~adhesion of symbiont to host,GO:0046718~viral entry into host cell,GO:0050764~regulation of phagocytosis,GO:0050892~intestinal absorption,GO:0051000~positive regulation of nitric-oxide synthase activity,GO:0070328~triglyceride homeostasis,GO:0070508~cholesterol import,	GO:0005737~cytoplasm,GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005901~caveola,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0030666~endocytic vesicle membrane,GO:0031528~microvillus membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,	GO:0001530~lipopolysaccharide binding,GO:0001540~beta-amyloid binding,GO:0001618~virus receptor activity,GO:0001786~phosphatidylserine binding,GO:0001875~lipopolysaccharide receptor activity,GO:0005044~scavenger receptor activity,GO:0005215~transporter activity,GO:0005515~protein binding,GO:0005545~1-phosphatidylinositol binding,GO:0008035~high-density lipoprotein particle binding,GO:0008289~lipid binding,GO:0030169~low-density lipoprotein particle binding,GO:0034185~apolipoprotein binding,GO:0034186~apolipoprotein A-I binding,GO:0042802~identical protein binding,GO:0070506~high-density lipoprotein particle receptor activity,	IPR002159:CD36 antigen,IPR005428:Adhesion molecule CD36,	hsa04145:Phagosome,hsa04913:Ovarian steroidogenesis,hsa04925:Aldosterone synthesis and secretion,hsa04927:Cortisol synthesis and secretion,hsa04934:Cushing syndrome,hsa04975:Fat digestion and absorption,hsa04976:Bile secretion,hsa04977:Vitamin digestion and absorption,hsa04979:Cholesterol metabolism,hsa05160:Hepatitis C,	610762~High density lipoprotein cholesterol level QTL6,			KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,KW-1183~Host cell receptor for virus entry,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Pro residues,LIPID:S-palmitoyl cysteine,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SCRN1	secernin 1(SCRN1)	Homo sapiens				GO:0006508~proteolysis,GO:0006887~exocytosis,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0031965~nuclear membrane,	GO:0005515~protein binding,GO:0016805~dipeptidase activity,GO:0070004~cysteine-type exopeptidase activity,	IPR005322:Peptidase C69, dipeptidase A,					KW-0268~Exocytosis,	KW-0963~Cytoplasm,		KW-0175~Coiled coil,			KW-0007~Acetylation,
SPP1	secreted phosphoprotein 1(SPP1)	Homo sapiens		h_npp1Pathway:Regulators of Bone Mineralization,		GO:0001503~ossification,GO:0001649~osteoblast differentiation,GO:0006710~androgen catabolic process,GO:0006954~inflammatory response,GO:0007155~cell adhesion,GO:0007165~signal transduction,GO:0007566~embryo implantation,GO:0030198~extracellular matrix organization,GO:0031214~biomineral tissue development,GO:0033280~response to vitamin D,GO:0043687~post-translational protein modification,GO:0044267~cellular protein metabolic process,GO:0045780~positive regulation of bone resorption,GO:0045893~positive regulation of transcription, DNA-templated,GO:0046697~decidualization,GO:0048545~response to steroid hormone,GO:0048685~negative regulation of collateral sprouting of intact axon in response to injury,GO:0071394~cellular response to testosterone stimulus,GO:2000866~positive regulation of estradiol secretion,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0005794~Golgi apparatus,GO:0031982~vesicle,GO:0042995~cell projection,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0005125~cytokine activity,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0050840~extracellular matrix binding,	IPR002038:Osteopontin,IPR019841:Osteopontin, conserved site,	hsa04151:PI3K-Akt signaling pathway,hsa04371:Apelin signaling pathway,hsa04510:Focal adhesion,hsa04512:ECM-receptor interaction,hsa04620:Toll-like receptor signaling pathway,hsa04929:GnRH secretion,hsa05165:Human papillomavirus infection,			SM00017:OSTEO,	KW-0091~Biomineralization,KW-0130~Cell adhesion,	KW-0964~Secreted,		KW-0732~Signal,	KW-0730~Sialic acid,	KW-0202~Cytokine,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:O-linked (GalNAc...) threonine,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,MOTIF:Cell attachment site,REGION:Disordered,
SPR	sepiapterin reductase(SPR)	Homo sapiens				GO:0006729~tetrahydrobiopterin biosynthetic process,GO:0006809~nitric oxide biosynthetic process,GO:0046146~tetrahydrobiopterin metabolic process,GO:0050999~regulation of nitric-oxide synthase activity,	GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0004033~aldo-keto reductase (NADP) activity,GO:0004757~sepiapterin reductase activity,GO:0050661~NADP binding,	IPR002347:Glucose/ribitol dehydrogenase,IPR006393:Sepiapterin reductase,	hsa00790:Folate biosynthesis,hsa01100:Metabolic pathways,hsa01240:Biosynthesis of cofactors,	612716~Dystonia, dopa-responsive, due to sepiapterin reductase deficiency,				KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-1023~Dystonia,		KW-0521~NADP,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	BINDING:NADP,BINDING:Substrate,BINDING:Substrate; via amide nitrogen,MUTAGEN:S->A: Abolishes phosphorylation by CaMK2. No effect on kinetic parameters.,NP_BIND:NADP,REGION:Substrate binding,
SQSTM1	sequestosome 1(SQSTM1)	Homo sapiens				GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000422~mitophagy,GO:0000423~macromitophagy,GO:0000425~macropexophagy,GO:0001659~temperature homeostasis,GO:0001934~positive regulation of protein phosphorylation,GO:0002376~immune system process,GO:0002931~response to ischemia,GO:0006468~protein phosphorylation,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0006606~protein import into nucleus,GO:0006914~autophagy,GO:0006915~apoptotic process,GO:0007032~endosome organization,GO:0008104~protein localization,GO:0010821~regulation of mitochondrion organization,GO:0016197~endosomal transport,GO:0016236~macroautophagy,GO:0030154~cell differentiation,GO:0031397~negative regulation of protein ubiquitination,GO:0035556~intracellular signal transduction,GO:0035973~aggrephagy,GO:0043065~positive regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043122~regulation of I-kappaB kinase/NF-kappaB signaling,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046578~regulation of Ras protein signal transduction,GO:0061635~regulation of protein complex stability,GO:0070342~brown fat cell proliferation,GO:0070498~interleukin-1-mediated signaling pathway,GO:0097009~energy homeostasis,GO:0098780~response to mitochondrial depolarisation,GO:1900273~positive regulation of long-term synaptic potentiation,GO:1903078~positive regulation of protein localization to plasma membrane,GO:1905719~protein localization to perinuclear region of cytoplasm,	GO:0000407~pre-autophagosomal structure,GO:0000932~P-body,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005764~lysosome,GO:0005770~late endosome,GO:0005776~autophagosome,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0016234~inclusion body,GO:0016235~aggresome,GO:0016605~PML body,GO:0030017~sarcomere,GO:0043231~intracellular membrane-bounded organelle,GO:0044753~amphisome,GO:0044754~autolysosome,GO:0070062~extracellular exosome,GO:0097225~sperm midpiece,GO:0097413~Lewy body,	GO:0004674~protein serine/threonine kinase activity,GO:0005080~protein kinase C binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0019899~enzyme binding,GO:0019901~protein kinase binding,GO:0030971~receptor tyrosine kinase binding,GO:0031625~ubiquitin protein ligase binding,GO:0035255~ionotropic glutamate receptor binding,GO:0042169~SH2 domain binding,GO:0042802~identical protein binding,GO:0043130~ubiquitin binding,GO:0044877~macromolecular complex binding,GO:0070530~K63-linked polyubiquitin binding,	IPR000270:Phox/Bem1p,IPR000433:Zinc finger, ZZ-type,IPR009060:UBA-like,IPR015940:Ubiquitin-associated/translation elongation factor EF1B, N-terminal, eukaryote,	hsa04137:Mitophagy - animal,hsa04140:Autophagy - animal,hsa04217:Necroptosis,hsa04218:Cellular senescence,hsa04380:Osteoclast differentiation,hsa05014:Amyotrophic lateral sclerosis,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05131:Shigellosis,hsa05418:Fluid shear stress and atherosclerosis,	167250~Paget disease of bone 3,616437~Frontotemporal dementia and/or amyotrophic lateral sclerosis 3,617145~Neurodegeneration with ataxia, dystonia, and gaze palsy, childhood-onset,617158~Myopathy, distal, with rimmed vacuoles,		SM00165:UBA,SM00291:ZnF_ZZ,SM00666:PB1,	KW-0053~Apoptosis,KW-0072~Autophagy,KW-0221~Differentiation,KW-0391~Immunity,	KW-0256~Endoplasmic reticulum,KW-0458~Lysosome,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,	KW-0036~Amyotrophic lateral sclerosis,KW-0225~Disease variant,KW-0523~Neurodegeneration,	KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:PB1,DOMAIN:UBA,DOMAIN:ZZ-type,METAL:Zinc 1,METAL:Zinc 2,MOTIF:LIR,MOTIF:TRAF6-binding,MUTAGEN:D->A: No effect on interaction with PRKCI.,MUTAGEN:D->A: No effect on interactions with PRKCZ and PRKCI.,MUTAGEN:D->A: No effect on interactions with PRKCZ, PRKCI and NBR1. Loss of localization in cytoplasmic inclusion bodies. Loss of dimerization; when associated with A-7.,MUTAGEN:D->A: Strongly decreased interaction with KEAP1.,MUTAGEN:DDD->ADA: 75% decrease in MAP1LC3B-binding.,MUTAGEN:E->A: No effect on interaction with PRKCI.,MUTAGEN:E->A: Strongly decreased interaction with KEAP1.,MUTAGEN:E->K: Decreased activation of NF-kappa-B.,MUTAGEN:EE->AA: No effect on MAP1LC3B-binding.,MUTAGEN:F->V: Loss of polyubiquitin-binding.,MUTAGEN:G->A: Strongly decreased interaction with KEAP1.,MUTAGEN:G->K: Decreased activation of NF-kappa-B.,MUTAGEN:I->V: Partial loss of polyubiquitin-binding. Loss of localization to cytoplasmic inclusion bodies.,MUTAGEN:K->A: Loss of interactions with PRKCZ, PRCKI and NBR1. Loss of dimerization; when associated with A-69.,MUTAGEN:K->A: No effect on interaction with PRKCI.,MUTAGEN:K->R: Decreased ubiquitination by the BCR(KEAP1) complex, leading to decreased sequestering activity.,MUTAGEN:L->V: Loss of polyubiquitin-binding.,MUTAGEN:L->V: No effect on polyubiquitin-binding.,MUTAGEN:RR->AA: Loss of interaction with PRKCI. Alters dimerization.,MUTAGEN:S->A: Abolished ability to promote relocalization of 'Lys-63'-linked ubiquitinated STING1 to autophagosomes.,MUTAGEN:S->A: No effect on MAP1LC3B-binding.,MUTAGEN:T->A: Strongly decreased interaction with KEAP1.,MUTAGEN:W->A: Strong decrease in MAP1LC3B-binding, disrupts interaction with GABARAP.,MUTAGEN:Y->A: No effect on interaction with PRKCZ.,MUTAGEN:Y->F: No effect on interaction with LCK.,REGION:Disordered,REGION:Interaction with GABRR3,REGION:Interaction with KEAP1,REGION:Interaction with LCK,REGION:Interaction with NTRK1,REGION:Interaction with PAWR,REGION:Interaction with PRKCZ and dimerization,REGION:LIM protein-binding (LB),REGION:MAP1LC3B-binding,SITE:Breakpoint for translocation to form the NUP214-SQSTM1 fusion protein,ZN_FING:ZZ-type,
SPTLC2	serine palmitoyltransferase long chain base subunit 2(SPTLC2)	Homo sapiens				GO:0006686~sphingomyelin biosynthetic process,GO:0009058~biosynthetic process,GO:0030148~sphingolipid biosynthetic process,GO:0046511~sphinganine biosynthetic process,GO:0046512~sphingosine biosynthetic process,GO:0046513~ceramide biosynthetic process,GO:0060612~adipose tissue development,GO:1904504~positive regulation of lipophagy,	GO:0005789~endoplasmic reticulum membrane,GO:0016021~integral component of membrane,GO:0017059~serine C-palmitoyltransferase complex,	GO:0004758~serine C-palmitoyltransferase activity,GO:0016740~transferase activity,GO:0030170~pyridoxal phosphate binding,	IPR001917:Aminotransferase, class-II, pyridoxal-phosphate binding site,IPR004839:Aminotransferase, class I/classII,IPR015421:Pyridoxal phosphate-dependent transferase, major region, subdomain 1,IPR015422:Pyridoxal phosphate-dependent transferase, major region, subdomain 2,IPR015424:Pyridoxal phosphate-dependent transferase,	hsa00600:Sphingolipid metabolism,hsa01100:Metabolic pathways,hsa04071:Sphingolipid signaling pathway,	613640~Neuropathy, hereditary sensory and autonomic, type IC,			KW-0443~Lipid metabolism,KW-0746~Sphingolipid metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0622~Neuropathy,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0663~Pyridoxal phosphate,	KW-0012~Acyltransferase,KW-0808~Transferase,		DOMAIN:Aminotran_1_2,TRANSMEM:Helical,
PRSS23	serine protease 23(PRSS23)	Homo sapiens				GO:0006508~proteolysis,GO:0043687~post-translational protein modification,GO:0044267~cellular protein metabolic process,	GO:0005634~nucleus,GO:0005788~endoplasmic reticulum lumen,GO:0070062~extracellular exosome,	GO:0004252~serine-type endopeptidase activity,GO:0005515~protein binding,	IPR001254:Peptidase S1,IPR009003:Trypsin-like cysteine/serine peptidase domain,IPR018114:Peptidase S1, trypsin family, active site,						KW-0964~Secreted,		KW-0732~Signal,		KW-0378~Hydrolase,KW-0645~Protease,KW-0720~Serine protease,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Charge relay system,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,REGION:Disordered,
STK10	serine/threonine kinase 10(STK10)	Homo sapiens			DNA replication, recombination, and repair,	GO:0006468~protein phosphorylation,GO:0007049~cell cycle,GO:0043312~neutrophil degranulation,GO:0046777~protein autophosphorylation,GO:0071593~lymphocyte aggregation,GO:2000401~regulation of lymphocyte migration,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0035579~specific granule membrane,GO:0070062~extracellular exosome,	GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,	IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,IPR022165:Polo kinase kinase,	hsa04914:Progesterone-mediated oocyte maturation,			SM00220:S_TKc,	KW-0131~Cell cycle,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:ATP,BINDING:Su11274; inhibitor; via amide nitrogen,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Protein kinase,MUTAGEN:K->I: Loss of kinase activity.,NP_BIND:ATP,REGION:Activation segment,REGION:Disordered,REGION:Su11274 binding; inhibitor,
STK25	serine/threonine kinase 25(STK25)	Homo sapiens				GO:0006468~protein phosphorylation,GO:0006979~response to oxidative stress,GO:0007163~establishment or maintenance of cell polarity,GO:0007165~signal transduction,GO:0032874~positive regulation of stress-activated MAPK cascade,GO:0036481~intrinsic apoptotic signaling pathway in response to hydrogen peroxide,GO:0042542~response to hydrogen peroxide,GO:0046777~protein autophosphorylation,GO:0050772~positive regulation of axonogenesis,GO:0051645~Golgi localization,GO:0051683~establishment of Golgi localization,GO:0090168~Golgi reassembly,	GO:0000139~Golgi membrane,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0070062~extracellular exosome,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0042803~protein homodimerization activity,GO:0046872~metal ion binding,	IPR000719:Protein kinase, catalytic domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,				SM00220:S_TKc,		KW-0333~Golgi apparatus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:ATP,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Protein kinase,MUTAGEN:D->A: Loss of kinase activity.,MUTAGEN:K->R: Loss of kinase activity and autophosphorylation.,NP_BIND:ATP,REGION:Disordered,
SERPINE1	serpin family E member 1(SERPINE1)	Homo sapiens		h_fibrinolysisPathway:Fibrinolysis Pathway,h_plateletAppPathway:Platelet Amyloid Precursor Protein Pathway,		GO:0001525~angiogenesis,GO:0002576~platelet degranulation,GO:0007623~circadian rhythm,GO:0010469~regulation of receptor activity,GO:0010757~negative regulation of plasminogen activation,GO:0010951~negative regulation of endopeptidase activity,GO:0014912~negative regulation of smooth muscle cell migration,GO:0030194~positive regulation of blood coagulation,GO:0030195~negative regulation of blood coagulation,GO:0030198~extracellular matrix organization,GO:0030336~negative regulation of cell migration,GO:0032757~positive regulation of interleukin-8 production,GO:0033629~negative regulation of cell adhesion mediated by integrin,GO:0035491~positive regulation of leukotriene production involved in inflammatory response,GO:0042730~fibrinolysis,GO:0045766~positive regulation of angiogenesis,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048260~positive regulation of receptor-mediated endocytosis,GO:0050729~positive regulation of inflammatory response,GO:0050829~defense response to Gram-negative bacterium,GO:0051918~negative regulation of fibrinolysis,GO:0061044~negative regulation of vascular wound healing,GO:0061045~negative regulation of wound healing,GO:0071222~cellular response to lipopolysaccharide,GO:0090026~positive regulation of monocyte chemotaxis,GO:0090399~replicative senescence,GO:0097187~dentinogenesis,GO:1901331~positive regulation of odontoblast differentiation,GO:1902042~negative regulation of extrinsic apoptotic signaling pathway via death domain receptors,GO:2000098~negative regulation of smooth muscle cell-matrix adhesion,GO:2000352~negative regulation of endothelial cell apoptotic process,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0031093~platelet alpha granule lumen,GO:0070062~extracellular exosome,GO:0097180~serine protease inhibitor complex,GO:1904090~peptidase inhibitor complex,	GO:0002020~protease binding,GO:0004867~serine-type endopeptidase inhibitor activity,GO:0005102~receptor binding,GO:0005515~protein binding,	IPR000215:Serpin family,IPR023795:Protease inhibitor I4, serpin, conserved site,IPR023796:Serpin domain,	hsa04066:HIF-1 signaling pathway,hsa04115:p53 signaling pathway,hsa04218:Cellular senescence,hsa04371:Apelin signaling pathway,hsa04390:Hippo signaling pathway,hsa04610:Complement and coagulation cascades,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa05142:Chagas disease,	613329~Plasminogen activator inhibitor-1 deficiency,Transcription of plasminogen activator inhibitor, modulator of~Transcription of plasminogen activator inhibitor, modulator of,		SM00093:SERPIN,		KW-0964~Secreted,		KW-0732~Signal,		KW-0646~Protease inhibitor,KW-0722~Serine protease inhibitor,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:SERPIN,MUTAGEN:G->C: Increased half-life of the active form when associated with C-197.,MUTAGEN:Q->C: Increased half-life of the active form when associated with C-355.,SITE:Reactive bond,
SESN1	sestrin 1(SESN1)	Homo sapiens				GO:0016239~positive regulation of macroautophagy,GO:0034198~cellular response to amino acid starvation,GO:0042149~cellular response to glucose starvation,GO:0071233~cellular response to leucine,GO:0072593~reactive oxygen species metabolic process,GO:0098869~cellular oxidant detoxification,GO:1901031~regulation of response to reactive oxygen species,GO:1904262~negative regulation of TORC1 signaling,GO:1990253~cellular response to leucine starvation,	GO:0001650~fibrillar center,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0016684~oxidoreductase activity, acting on peroxide as acceptor,GO:0051920~peroxiredoxin activity,GO:0070728~leucine binding,	IPR006730:PA26 p53-induced protein (sestrin),	hsa04115:p53 signaling pathway,hsa04211:Longevity regulating pathway,					KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0560~Oxidoreductase,	KW-0597~Phosphoprotein,	ACT_SITE:Cysteine sulfenic acid (-SOH) intermediate,BINDING:Leucine,BINDING:Leucine; via carbonyl oxygen,MUTAGEN:C->S: Loss of the ability to decrease intracellular reactive oxygen species.,REGION:C-terminal domain; mediates TORC1 regulation,REGION:Leucine-binding,REGION:N-terminal domain; may mediate the alkylhydroperoxide reductase activity,
STAT1	signal transducer and activator of transcription 1(STAT1)	Homo sapiens	11.IL-6_gp130-Jak-STAT,12.IL-6_type_cytok-signal-transduct,17.Activators-CAM,2.Cytokine_Receptors,48.mice_minus_JAKs_and_STATs,75.Stats_activators_of_Apoptosis,	h_biopeptidesPathway:Bioactive Peptide Induced Signaling Pathway,h_chemicalPathway:Apoptotic Signaling in Response to DNA Damage,h_egfPathway:EGF Signaling Pathway,h_gleevecPathway:Inhibition of Cellular Proliferation by Gleevec,h_ifnaPathway:IFN alpha signaling pathway,h_ifngPathway:IFN gamma signaling pathway ,h_il10Pathway:IL-10 Anti-inflammatory Signaling Pathway,h_il22bpPathway:IL22 Soluble Receptor Signaling Pathway ,h_mapkPathway:MAPKinase Signaling Pathway,h_p38mapkPathway:p38 MAPK Signaling Pathway ,h_pdgfPathway:PDGF Signaling Pathway,h_tpoPathway:TPO Signaling Pathway,		GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001937~negative regulation of endothelial cell proliferation,GO:0002053~positive regulation of mesenchymal cell proliferation,GO:0002230~positive regulation of defense response to virus by host,GO:0003340~negative regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis,GO:0006355~regulation of transcription, DNA-templated,GO:0006952~defense response,GO:0007165~signal transduction,GO:0007221~positive regulation of transcription of Notch receptor target,GO:0007259~JAK-STAT cascade,GO:0007584~response to nutrient,GO:0008015~blood circulation,GO:0009410~response to xenobiotic stimulus,GO:0009612~response to mechanical stimulus,GO:0010742~macrophage derived foam cell differentiation,GO:0016032~viral process,GO:0016525~negative regulation of angiogenesis,GO:0019221~cytokine-mediated signaling pathway,GO:0032727~positive regulation of interferon-alpha production,GO:0032869~cellular response to insulin stimulus,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0034097~response to cytokine,GO:0035456~response to interferon-beta,GO:0035458~cellular response to interferon-beta,GO:0038113~interleukin-9-mediated signaling pathway,GO:0038114~interleukin-21-mediated signaling pathway,GO:0042127~regulation of cell proliferation,GO:0042493~response to drug,GO:0042542~response to hydrogen peroxide,GO:0042981~regulation of apoptotic process,GO:0043124~negative regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043434~response to peptide hormone,GO:0045648~positive regulation of erythrocyte differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046725~negative regulation by virus of viral protein levels in host cell,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0051591~response to cAMP,GO:0051607~defense response to virus,GO:0051770~positive regulation of nitric-oxide synthase biosynthetic process,GO:0060333~interferon-gamma-mediated signaling pathway,GO:0060334~regulation of interferon-gamma-mediated signaling pathway,GO:0060337~type I interferon signaling pathway,GO:0061326~renal tubule development,GO:0070102~interleukin-6-mediated signaling pathway,GO:0070106~interleukin-27-mediated signaling pathway,GO:0070757~interleukin-35-mediated signaling pathway,GO:0071345~cellular response to cytokine stimulus,GO:0071346~cellular response to interferon-gamma,GO:0071407~cellular response to organic cyclic compound,GO:0072136~metanephric mesenchymal cell proliferation involved in metanephros development,GO:0072162~metanephric mesenchymal cell differentiation,GO:0072308~negative regulation of metanephric nephron tubule epithelial cell differentiation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0030424~axon,GO:0030425~dendrite,GO:0032991~macromolecular complex,GO:0048471~perinuclear region of cytoplasm,GO:0070721~ISGF3 complex,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000979~RNA polymerase II core promoter sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001222~transcription corepressor binding,GO:0001223~transcription coactivator binding,GO:0003677~DNA binding,GO:0003690~double-stranded DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005164~tumor necrosis factor receptor binding,GO:0005515~protein binding,GO:0016922~ligand-dependent nuclear receptor binding,GO:0019899~enzyme binding,GO:0031730~CCR5 chemokine receptor binding,GO:0035035~histone acetyltransferase binding,GO:0035257~nuclear hormone receptor binding,GO:0042393~histone binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0043565~sequence-specific DNA binding,GO:0044389~ubiquitin-like protein ligase binding,GO:0045296~cadherin binding,GO:0051721~protein phosphatase 2A binding,GO:0070491~repressing transcription factor binding,GO:1990841~promoter-specific chromatin binding,	IPR000980:SH2 domain,IPR001217:STAT transcription factor, core,IPR008967:p53-like transcription factor, DNA-binding,IPR012345:STAT transcription factor, DNA-binding, subdomain,IPR013799:STAT transcription factor, protein interaction,IPR013800:STAT transcription factor, all-alpha,IPR013801:STAT transcription factor, DNA-binding,IPR015988:STAT transcription factor, coiled coil,IPR022752:Signal transducer and activation of transcription 1, TAZ2 binding domain, C-terminal,	hsa04062:Chemokine signaling pathway,hsa04217:Necroptosis,hsa04380:Osteoclast differentiation,hsa04620:Toll-like receptor signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04625:C-type lectin receptor signaling pathway,hsa04630:JAK-STAT signaling pathway,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04917:Prolactin signaling pathway,hsa04919:Thyroid hormone signaling pathway,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04935:Growth hormone synthesis, secretion and action,hsa05140:Leishmaniasis,hsa05145:Toxoplasmosis,hsa05152:Tuberculosis,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,hsa05212:Pancreatic cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05321:Inflammatory bowel disease,	613796~Immunodeficiency 31B, mycobacterial and viral infections, autosomal recessive,614162~Immunodeficiency 31C, chronic mucocutaneous candidiasis, autosomal dominant,614892~Immunodeficiency 31A, mycobacteriosis, autosomal dominant,		SM00964:SM00964,	KW-0051~Antiviral defense,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0175~Coiled coil,KW-0727~SH2 domain,		KW-0010~Activator,KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0013~ADP-ribosylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:SH2,DOMAIN:STAT_int,MUTAGEN:AEN->CEC: Enhances STAT1 nuclear translocation and interferon (IFN)-stimulated gene (ISG) expression in response to IFN-beta stimulation. Reduces viral load in infected cultured cells.,MUTAGEN:E->Q: Loss of ADP-ribosylation and increased Tyr-701 phosphorylation; when associated with Q-657.,MUTAGEN:E->Q: Loss of ADP-ribosylation and increased Tyr-701 phosphorylation; when associated with Q-705.,MUTAGEN:K->A: No effect on IFN-alpha-induced STAT1 phosphorylation and nuclear translocation.,MUTAGEN:K->A: Strongly reduced IFN-alpha-induced STAT1 phosphorylation and nuclear translocation. Does not affect ability to homodimerize.,MUTAGEN:K->R: Abolishes sumoylation by SUMO1. Increased IFN-gamma-mediated transactivation.,MUTAGEN:K->R: Sumoylated.,MUTAGEN:KK->AA: No effect on IFN-alpha-induced STAT1 phosphorylation and nuclear translocation.,MUTAGEN:S->A: Decreased transcriptional activation. No effect on basal sumoylation. No enhancement of sumoylation on MAPK stimulation. No PRKCD-induced apoptosis. Upon IFNB induction, phosphorylated at Y-701 but not at S-708.,MUTAGEN:S->A: Phosphorylated at Y-701 upon IFNB induction.,MUTAGEN:S->D: No change in enhancement of MAPK-induced sumoylation. Basal interaction with PIAS1. Interaction with PIAS1 increased on MAPK stimulation.,MUTAGEN:S->D: Not phosphorylated at Y-701 upon IFNB induction.,MUTAGEN:S->E: No change in enhancement of MAPK-induced sumoylation.,MUTAGEN:Y->E: Not phosphorylated at S-708 upon IFNB induction.,MUTAGEN:Y->F: No effect on basal sumoylation. Enhances sumoylation in the presence of MAPK stimulation. Phosphorylated at S-708 upon IFNB induction.,
STAT3	signal transducer and activator of transcription 3(STAT3)	Homo sapiens	11.IL-6_gp130-Jak-STAT,12.IL-6_type_cytok-signal-transduct,48.mice_minus_JAKs_and_STATs,	h_biopeptidesPathway:Bioactive Peptide Induced Signaling Pathway,h_egfPathway:EGF Signaling Pathway,h_erkPathway:Erk1/Erk2 Mapk Signaling pathway,h_her2Pathway:Role of ERBB2 in Signal Transduction and Oncology,h_il10Pathway:IL-10 Anti-inflammatory Signaling Pathway,h_il22bpPathway:IL22 Soluble Receptor Signaling Pathway ,h_il6Pathway:IL 6 signaling pathway,h_metPathway:Signaling of Hepatocyte Growth Factor Receptor,h_pdgfPathway:PDGF Signaling Pathway,h_stat3Pathway:Stat3 Signaling Pathway,h_tpoPathway:TPO Signaling Pathway,		GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001659~temperature homeostasis,GO:0001754~eye photoreceptor cell differentiation,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006606~protein import into nucleus,GO:0006952~defense response,GO:0006954~inflammatory response,GO:0007165~signal transduction,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0007259~JAK-STAT cascade,GO:0007399~nervous system development,GO:0008283~cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0010507~negative regulation of autophagy,GO:0010628~positive regulation of gene expression,GO:0016032~viral process,GO:0016310~phosphorylation,GO:0019221~cytokine-mediated signaling pathway,GO:0019827~stem cell population maintenance,GO:0019953~sexual reproduction,GO:0030335~positive regulation of cell migration,GO:0030522~intracellular receptor signaling pathway,GO:0032355~response to estradiol,GO:0032731~positive regulation of interleukin-1 beta production,GO:0032733~positive regulation of interleukin-10 production,GO:0032755~positive regulation of interleukin-6 production,GO:0032757~positive regulation of interleukin-8 production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0032870~cellular response to hormone stimulus,GO:0033210~leptin-mediated signaling pathway,GO:0035019~somatic stem cell population maintenance,GO:0035723~interleukin-15-mediated signaling pathway,GO:0038111~interleukin-7-mediated signaling pathway,GO:0038113~interleukin-9-mediated signaling pathway,GO:0038114~interleukin-21-mediated signaling pathway,GO:0038155~interleukin-23-mediated signaling pathway,GO:0040014~regulation of multicellular organism growth,GO:0042127~regulation of cell proliferation,GO:0042531~positive regulation of tyrosine phosphorylation of STAT protein,GO:0042593~glucose homeostasis,GO:0042755~eating behavior,GO:0042789~mRNA transcription from RNA polymerase II promoter,GO:0043434~response to peptide hormone,GO:0044320~cellular response to leptin stimulus,GO:0044321~response to leptin,GO:0045648~positive regulation of erythrocyte differentiation,GO:0045747~positive regulation of Notch signaling pathway,GO:0045766~positive regulation of angiogenesis,GO:0045820~negative regulation of glycolytic process,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048708~astrocyte differentiation,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051726~regulation of cell cycle,GO:0060019~radial glial cell differentiation,GO:0060259~regulation of feeding behavior,GO:0060396~growth hormone receptor signaling pathway,GO:0060397~JAK-STAT cascade involved in growth hormone signaling pathway,GO:0070102~interleukin-6-mediated signaling pathway,GO:0070106~interleukin-27-mediated signaling pathway,GO:0070757~interleukin-35-mediated signaling pathway,GO:0071345~cellular response to cytokine stimulus,GO:0072538~T-helper 17 type immune response,GO:0072540~T-helper 17 cell lineage commitment,GO:0097009~energy homeostasis,GO:1900017~positive regulation of cytokine production involved in inflammatory response,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1904685~positive regulation of metalloendopeptidase activity,GO:1905564~positive regulation of vascular endothelial cell proliferation,GO:1905618~positive regulation of miRNA mediated inhibition of translation,GO:2000635~negative regulation of primary miRNA processing,GO:2000637~positive regulation of gene silencing by miRNA,GO:2000737~negative regulation of stem cell differentiation,GO:2001223~negative regulation of neuron migration,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001103~RNA polymerase II repressing transcription factor binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0004879~RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0019901~protein kinase binding,GO:0019903~protein phosphatase binding,GO:0031490~chromatin DNA binding,GO:0035591~signaling adaptor activity,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0046983~protein dimerization activity,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0070878~primary miRNA binding,	IPR000980:SH2 domain,IPR001217:STAT transcription factor, core,IPR008967:p53-like transcription factor, DNA-binding,IPR012345:STAT transcription factor, DNA-binding, subdomain,IPR013799:STAT transcription factor, protein interaction,IPR013800:STAT transcription factor, all-alpha,IPR013801:STAT transcription factor, DNA-binding,IPR015988:STAT transcription factor, coiled coil,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa04062:Chemokine signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04068:FoxO signaling pathway,hsa04217:Necroptosis,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04630:JAK-STAT signaling pathway,hsa04659:Th17 cell differentiation,hsa04917:Prolactin signaling pathway,hsa04920:Adipocytokine signaling pathway,hsa04931:Insulin resistance,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04935:Growth hormone synthesis, secretion and action,hsa05145:Toxoplasmosis,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05163:Human cytomegalovirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05169:Epstein-Barr virus infection,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05212:Pancreatic cancer,hsa05221:Acute myeloid leukemia,hsa05223:Non-small cell lung cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05321:Inflammatory bowel disease,hsa05417:Lipid and atherosclerosis,	147060~Hyper-IgE recurrent infection syndrome,615952~Autoimmune disease, multisystem, infantile-onset, 1,		SM00964:SM00964,	KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0219~Diabetes mellitus,KW-0225~Disease variant,KW-0242~Dwarfism,	KW-0175~Coiled coil,KW-0727~SH2 domain,		KW-0010~Activator,KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:SH2,DOMAIN:STAT_int,MOTIF:Essential for nuclear import,MUTAGEN:EE->AA: Inhibits leptin-mediated transactivation of CCND1 promoter. No effect on interaction with INPP5F.,MUTAGEN:Y->F: Inhibits leptin-mediated transactivation of CCND1 promoter.,REGION:Disordered,
STAT5B	signal transducer and activator of transcription 5B(STAT5B)	Homo sapiens	48.mice_minus_JAKs_and_STATs,	h_epoPathway:EPO Signaling Pathway,h_ghPathway:Growth Hormone Signaling Pathway,h_gleevecPathway:Inhibition of Cellular Proliferation by Gleevec,h_il22bpPathway:IL22 Soluble Receptor Signaling Pathway ,h_il2Pathway:IL 2 signaling pathway,h_il2rbPathway:IL-2 Receptor Beta Chain in T cell Activation,h_il3Pathway:IL 3 signaling pathway,h_il7Pathway:IL-7 Signal Transduction,h_PparaPathway:Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha),h_tpoPathway:TPO Signaling Pathway,		GO:0001553~luteinization,GO:0001779~natural killer cell differentiation,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006952~defense response,GO:0007259~JAK-STAT cascade,GO:0007565~female pregnancy,GO:0007595~lactation,GO:0019218~regulation of steroid metabolic process,GO:0019221~cytokine-mediated signaling pathway,GO:0019530~taurine metabolic process,GO:0019915~lipid storage,GO:0030856~regulation of epithelial cell differentiation,GO:0032355~response to estradiol,GO:0032743~positive regulation of interleukin-2 production,GO:0032819~positive regulation of natural killer cell proliferation,GO:0032825~positive regulation of natural killer cell differentiation,GO:0032870~cellular response to hormone stimulus,GO:0033077~T cell differentiation in thymus,GO:0035723~interleukin-15-mediated signaling pathway,GO:0038110~interleukin-2-mediated signaling pathway,GO:0038111~interleukin-7-mediated signaling pathway,GO:0038113~interleukin-9-mediated signaling pathway,GO:0040014~regulation of multicellular organism growth,GO:0040018~positive regulation of multicellular organism growth,GO:0042104~positive regulation of activated T cell proliferation,GO:0042127~regulation of cell proliferation,GO:0042448~progesterone metabolic process,GO:0043029~T cell homeostasis,GO:0043066~negative regulation of apoptotic process,GO:0043434~response to peptide hormone,GO:0045579~positive regulation of B cell differentiation,GO:0045588~positive regulation of gamma-delta T cell differentiation,GO:0045647~negative regulation of erythrocyte differentiation,GO:0045648~positive regulation of erythrocyte differentiation,GO:0045931~positive regulation of mitotic cell cycle,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0045954~positive regulation of natural killer cell mediated cytotoxicity,GO:0046543~development of secondary female sexual characteristics,GO:0046544~development of secondary male sexual characteristics,GO:0048541~Peyer's patch development,GO:0050729~positive regulation of inflammatory response,GO:0060397~JAK-STAT cascade involved in growth hormone signaling pathway,GO:0070669~response to interleukin-2,GO:0070670~response to interleukin-4,GO:0070672~response to interleukin-15,GO:0071363~cellular response to growth factor stimulus,GO:0071364~cellular response to epidermal growth factor stimulus,GO:0097531~mast cell migration,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003682~chromatin binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0035259~glucocorticoid receptor binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0046983~protein dimerization activity,	IPR000980:SH2 domain,IPR001217:STAT transcription factor, core,IPR008967:p53-like transcription factor, DNA-binding,IPR012345:STAT transcription factor, DNA-binding, subdomain,IPR013799:STAT transcription factor, protein interaction,IPR013800:STAT transcription factor, all-alpha,IPR013801:STAT transcription factor, DNA-binding,IPR015988:STAT transcription factor, coiled coil,	hsa04012:ErbB signaling pathway,hsa04062:Chemokine signaling pathway,hsa04217:Necroptosis,hsa04630:JAK-STAT signaling pathway,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04917:Prolactin signaling pathway,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04935:Growth hormone synthesis, secretion and action,hsa05161:Hepatitis B,hsa05162:Measles,hsa05166:Human T-cell leukemia virus 1 infection,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05207:Chemical carcinogenesis - receptor activation,hsa05220:Chronic myeloid leukemia,hsa05221:Acute myeloid leukemia,hsa05223:Non-small cell lung cancer,	102578~Leukemia, acute promyelocytic, somatic,245590~Growth hormone insensitivity with immune dysregulation 1, autosomal recessive,618985~Growth hormone insensitivity with immune dysregulation 2, autosomal dominant,		SM00252:SH2,SM00964:SM00964,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0242~Dwarfism,	KW-0727~SH2 domain,		KW-0010~Activator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	DOMAIN:SH2,DOMAIN:STAT_int,MUTAGEN:T->A: Abolishes interaction with INSR.,MUTAGEN:Y->F: Abolishes phosphorylation by HCK.,REGION:Required for interaction with NMI,
STAP2	signal transducing adaptor family member 2(STAP2)	Homo sapiens				GO:0042531~positive regulation of tyrosine phosphorylation of STAT protein,	GO:0005829~cytosol,GO:0005886~plasma membrane,	GO:0005515~protein binding,GO:0035591~signaling adaptor activity,	IPR000980:SH2 domain,IPR011993:Pleckstrin homology-like domain,						KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0727~SH2 domain,			KW-0597~Phosphoprotein,	COMPBIAS:Pro residues,DOMAIN:PH,DOMAIN:SH2,MUTAGEN:Y->F: Decrease in tyrosine phosphorylation.,MUTAGEN:Y->F: Loss of tyrosine phosphorylation.,MUTAGEN:Y->F: Small decrease in tyrosine phosphorylation.,REGION:Disordered,
SSBP2	single stranded DNA binding protein 2(SSBP2)	Homo sapiens				GO:0006355~regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,GO:0005737~cytoplasm,	GO:0003697~single-stranded DNA binding,	IPR006594:LisH dimerisation motif,IPR008116:Sequence-specific single-strand DNA-binding protein,				SM00667:LisH,		KW-0539~Nucleus,				KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:LisH,REGION:Disordered,
SIRT3	sirtuin 3(SIRT3)	Homo sapiens				GO:0006471~protein ADP-ribosylation,GO:0006476~protein deacetylation,GO:0007005~mitochondrion organization,GO:0007568~aging,GO:0009060~aerobic respiration,GO:0016575~histone deacetylation,GO:0032024~positive regulation of insulin secretion,GO:0034983~peptidyl-lysine deacetylation,GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:1901671~positive regulation of superoxide dismutase activity,GO:1902553~positive regulation of catalase activity,GO:2000304~positive regulation of ceramide biosynthetic process,GO:2000378~negative regulation of reactive oxygen species metabolic process,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0032991~macromolecular complex,	GO:0003950~NAD+ ADP-ribosyltransferase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0016740~transferase activity,GO:0017136~NAD-dependent histone deacetylase activity,GO:0019899~enzyme binding,GO:0034979~NAD-dependent protein deacetylase activity,GO:0043565~sequence-specific DNA binding,GO:0070403~NAD+ binding,	IPR003000:Sirtuin family,IPR017328:NAD-dependent deacetylase sirtuin-2, sirtuin family, class I,IPR026590:Sirtuin family, catalytic core domain,IPR026591:Sirtuin family, catalytic core small domain,	hsa00760:Nicotinate and nicotinamide metabolism,hsa01100:Metabolic pathways,hsa05230:Central carbon metabolism in cancer,		PIRSF037938:NAD-dependent deacetylase sirtuin-2, eukaryotic type,			KW-0496~Mitochondrion,		KW-0732~Signal,KW-0809~Transit peptide,	KW-0479~Metal-binding,KW-0520~NAD,KW-0862~Zinc,	KW-0808~Transferase,		ACT_SITE:Proton acceptor,BINDING:NAD; via amide nitrogen,DOMAIN:Deacetylase sirtuin-type,METAL:Zinc,MUTAGEN:H->Y: Loss of function.,MUTAGEN:N->A: Loss of function.,MUTAGEN:R->G,Q: Reduces targeting to mitochondrion; when associated with G-17 or Q-17.,MUTAGEN:R->G,Q: Reduces targeting to mitochondrion; when associated with G-21 or Q-21.,MUTAGEN:R->G,Q: Suppresses targeting to mitochondrion; when associated with G-13 or Q-13.,MUTAGEN:R->G,Q: Suppresses targeting to mitochondrion; when associated with G-7 or Q-7.,MUTAGEN:RR->GG: Abolishes processing by MPP (in vitro).,NP_BIND:NAD,REGION:Disordered,TRANSIT:Mitochondrion,
SLC1A4	solute carrier family 1 member 4(SLC1A4)	Homo sapiens				GO:0006865~amino acid transport,GO:0006868~glutamine transport,GO:0015698~inorganic anion transport,GO:0015808~L-alanine transport,GO:0015811~L-cystine transport,GO:0015813~L-glutamate transport,GO:0015824~proline transport,GO:0015825~L-serine transport,GO:0015826~threonine transport,GO:0034589~hydroxyproline transport,GO:0035249~synaptic transmission, glutamatergic,GO:0035524~proline transmembrane transport,GO:0050890~cognition,GO:1903812~L-serine import into cell,GO:1904273~L-alanine import across plasma membrane,	GO:0005813~centrosome,GO:0005882~intermediate filament,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030425~dendrite,GO:0042470~melanosome,GO:0043025~neuronal cell body,GO:0045202~synapse,GO:0070062~extracellular exosome,	GO:0005254~chloride channel activity,GO:0015171~amino acid transmembrane transporter activity,GO:0015175~neutral amino acid transmembrane transporter activity,GO:0015180~L-alanine transmembrane transporter activity,GO:0015183~L-aspartate transmembrane transporter activity,GO:0015184~L-cystine transmembrane transporter activity,GO:0015186~L-glutamine transmembrane transporter activity,GO:0015193~L-proline transmembrane transporter activity,GO:0015194~L-serine transmembrane transporter activity,GO:0015195~L-threonine transmembrane transporter activity,GO:0015293~symporter activity,GO:0034590~L-hydroxyproline transmembrane transporter activity,	IPR001991:Sodium:dicarboxylate symporter,IPR018107:Sodium:dicarboxylate symporter, conserved site,		616657~Spastic tetraplegia, thin corpus callosum, and progressive microcephaly,			KW-0769~Symport,KW-0813~Transport,	KW-0472~Membrane,	KW-0225~Disease variant,KW-0887~Epilepsy,KW-0991~Mental retardation,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SLC11A2	solute carrier family 11 member 2(SLC11A2)	Homo sapiens				GO:0001666~response to hypoxia,GO:0003032~detection of oxygen,GO:0006783~heme biosynthetic process,GO:0006824~cobalt ion transport,GO:0006825~copper ion transport,GO:0006826~iron ion transport,GO:0006828~manganese ion transport,GO:0006879~cellular iron ion homeostasis,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0007611~learning or memory,GO:0010039~response to iron ion,GO:0015675~nickel cation transport,GO:0015676~vanadium ion transport,GO:0015692~lead ion transport,GO:0033212~iron assimilation,GO:0034599~cellular response to oxidative stress,GO:0034755~iron ion transmembrane transport,GO:0035434~copper ion transmembrane transport,GO:0035444~nickel cation transmembrane transport,GO:0048813~dendrite morphogenesis,GO:0048821~erythrocyte development,GO:0055072~iron ion homeostasis,GO:0060586~multicellular organismal iron ion homeostasis,GO:0070574~cadmium ion transmembrane transport,GO:0070588~calcium ion transmembrane transport,GO:0071421~manganese ion transmembrane transport,GO:0071577~zinc II ion transmembrane transport,GO:0098656~anion transmembrane transport,GO:1902600~hydrogen ion transmembrane transport,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0005769~early endosome,GO:0005770~late endosome,GO:0005773~vacuole,GO:0005802~trans-Golgi network,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0031410~cytoplasmic vesicle,GO:0031526~brush border membrane,GO:0031902~late endosome membrane,GO:0045177~apical part of cell,GO:0045178~basal part of cell,GO:0048471~perinuclear region of cytoplasm,GO:0055037~recycling endosome,GO:0070826~paraferritin complex,GO:1903561~extracellular vesicle,	GO:0005375~copper ion transmembrane transporter activity,GO:0005381~iron ion transmembrane transporter activity,GO:0005384~manganese ion transmembrane transporter activity,GO:0005385~zinc ion transmembrane transporter activity,GO:0005515~protein binding,GO:0015086~cadmium ion transmembrane transporter activity,GO:0015087~cobalt ion transmembrane transporter activity,GO:0015093~ferrous iron transmembrane transporter activity,GO:0015094~lead ion transmembrane transporter activity,GO:0015099~nickel cation transmembrane transporter activity,GO:0015100~vanadium ion transmembrane transporter activity,GO:0015295~solute:proton symporter activity,GO:0022890~inorganic cation transmembrane transporter activity,GO:0046870~cadmium ion binding,GO:0046873~metal ion transmembrane transporter activity,GO:0046915~transition metal ion transmembrane transporter activity,GO:1905394~retromer complex binding,	IPR001046:Natural resistance-associated macrophage like,	hsa04142:Lysosome,hsa04216:Ferroptosis,hsa04978:Mineral absorption,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,	206100~Anemia, hypochromic microcytic, with iron overload 1,			KW-0406~Ion transport,KW-0410~Iron transport,KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0967~Endosome,KW-1000~Mitochondrion outer membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0408~Iron,		KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,MUTAGEN:D->A: Abolishes ion transport across the cell membrane.,MUTAGEN:L->A: Abolishes localization at early endosomes and leads to localization at late endosomes and lysosomes.,MUTAGEN:M->A: Abolishes ion transport across the cell membrane.,MUTAGEN:N->A: Decreases affinity for divalent metal cations. Impairs ion transport across the cell membrane.,MUTAGEN:Y->A: Abolishes localization at early endosomes and leads to localization at late endosomes and lysosomes.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SLC2A6	solute carrier family 2 member 6(SLC2A6)	Homo sapiens				GO:0006110~regulation of glycolytic process,GO:0008645~hexose transport,GO:0015755~fructose transport,GO:0070837~dehydroascorbic acid transport,GO:1904659~glucose transmembrane transport,	GO:0005765~lysosomal membrane,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0005353~fructose transmembrane transporter activity,GO:0005355~glucose transmembrane transporter activity,GO:0005515~protein binding,GO:0022857~transmembrane transporter activity,GO:0033300~dehydroascorbic acid transporter activity,GO:0055056~D-glucose transmembrane transporter activity,	IPR003663:Sugar/inositol transporter,IPR005828:General substrate transporter,IPR005829:Sugar transporter, conserved site,IPR020846:Major facilitator superfamily domain,					KW-0762~Sugar transport,KW-0813~Transport,	KW-0458~Lysosome,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	BINDING:Monosaccharide,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:MFS,MOTIF:Dileucine internalization motif,REGION:Disordered,REGION:Monosaccharide binding,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=10,TRANSMEM:Helical; Name=11,TRANSMEM:Helical; Name=12,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,TRANSMEM:Helical; Name=8,TRANSMEM:Helical; Name=9,
SLC25A13	solute carrier family 25 member 13(SLC25A13)	Homo sapiens			Signal transduction mechanisms / Cytoskeleton / Cell division and chromosome partitioning / General function prediction only,	GO:0006094~gluconeogenesis,GO:0006754~ATP biosynthetic process,GO:0006810~transport,GO:0006839~mitochondrial transport,GO:0009066~aspartate family amino acid metabolic process,GO:0015810~aspartate transport,GO:0015813~L-glutamate transport,GO:0043490~malate-aspartate shuttle,GO:0045333~cellular respiration,GO:0051592~response to calcium ion,GO:0070778~L-aspartate transport,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005887~integral component of plasma membrane,	GO:0005313~L-glutamate transmembrane transporter activity,GO:0005509~calcium ion binding,GO:0015171~amino acid transmembrane transporter activity,GO:0015172~acidic amino acid transmembrane transporter activity,GO:0015183~L-aspartate transmembrane transporter activity,GO:0022857~transmembrane transporter activity,GO:0042802~identical protein binding,	IPR002048:EF-hand domain,IPR002067:Mitochondrial carrier protein,IPR011992:EF-hand-like domain,IPR018108:Mitochondrial substrate/solute carrier,IPR023395:Mitochondrial carrier domain,		603471~Citrullinemia, adult-onset type II,605814~Citrullinemia, type II, neonatal-onset,			KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,	KW-0225~Disease variant,KW-0988~Intrahepatic cholestasis,	KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	CA_BIND:1,CA_BIND:2,CA_BIND:3,DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:EF-hand 3,DOMAIN:EF-hand 4,METAL:Calcium,METAL:Calcium; via carbonyl oxygen,REGION:C-terminal domain,REGION:Carrier domain,REGION:Linker loop domain,REGION:N-terminal domain,REPEAT:Solcar 1,REPEAT:Solcar 2,REPEAT:Solcar 3,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,
SLC25A14	solute carrier family 25 member 14(SLC25A14)	Homo sapiens				GO:0006839~mitochondrial transport,GO:0008272~sulfate transport,GO:0009060~aerobic respiration,GO:0015709~thiosulfate transport,GO:0015729~oxaloacetate transport,GO:0035435~phosphate ion transmembrane transport,GO:0071422~succinate transmembrane transport,GO:0071423~malate transmembrane transport,GO:1902356~oxaloacetate(2-) transmembrane transport,GO:1902358~sulfate transmembrane transport,GO:1902600~hydrogen ion transmembrane transport,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,	GO:0015116~sulfate transmembrane transporter activity,GO:0015117~thiosulfate transmembrane transporter activity,GO:0015131~oxaloacetate transmembrane transporter activity,GO:0015140~malate transmembrane transporter activity,GO:0015141~succinate transmembrane transporter activity,GO:0015297~antiporter activity,	IPR002030:Mitochondrial brown fat uncoupling protein,IPR018108:Mitochondrial substrate/solute carrier,IPR023395:Mitochondrial carrier domain,					KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				REPEAT:Solcar,REPEAT:Solcar 1,REPEAT:Solcar 2,REPEAT:Solcar 3,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,
SLC25A4	solute carrier family 25 member 4(SLC25A4)	Homo sapiens		h_etcPathway:Electron Transport Reaction in Mitochondria,		GO:0000002~mitochondrial genome maintenance,GO:0006091~generation of precursor metabolites and energy,GO:0008637~apoptotic mitochondrial changes,GO:0015853~adenine transport,GO:0015866~ADP transport,GO:0016032~viral process,GO:0046902~regulation of mitochondrial membrane permeability,GO:0060546~negative regulation of necroptotic process,GO:1901526~positive regulation of macromitophagy,GO:1902600~hydrogen ion transmembrane transport,GO:1990544~mitochondrial ATP transmembrane transport,GO:1990845~adaptive thermogenesis,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005757~mitochondrial permeability transition pore complex,GO:0005887~integral component of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0032592~integral component of mitochondrial membrane,	GO:0005471~ATP:ADP antiporter activity,GO:0005515~protein binding,GO:0015078~hydrogen ion transmembrane transporter activity,GO:0015207~adenine transmembrane transporter activity,GO:0017077~oxidative phosphorylation uncoupler activity,	IPR002067:Mitochondrial carrier protein,IPR002113:Adenine nucleotide translocator 1,IPR018108:Mitochondrial substrate/solute carrier,IPR023395:Mitochondrial carrier domain,	hsa04020:Calcium signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04217:Necroptosis,hsa04218:Cellular senescence,hsa04613:Neutrophil extracellular trap formation,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05016:Huntington disease,hsa05017:Spinocerebellar ataxia,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05164:Influenza A,hsa05166:Human T-cell leukemia virus 1 infection,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05415:Diabetic cardiomyopathy,	609283~Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 2,615418~Mitochondrial DNA depletion syndrome 12B (cardiomyopathic type) AR,617184~Mitochondrial DNA depletion syndrome 12A (cardiomyopathic type) AD,			KW-0050~Antiport,KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,	KW-0122~Cardiomyopathy,KW-0225~Disease variant,KW-0935~Progressive external ophthalmoplegia,KW-1274~Primary mitochondrial disease,	KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0702~S-nitrosylation,	BINDING:ADP,MOTIF:Nucleotide carrier signature motif,REGION:Important for transport activity,REPEAT:Solcar,REPEAT:Solcar 1,REPEAT:Solcar 2,REPEAT:Solcar 3,TOPO_DOM:Mitochondrial intermembrane,TOPO_DOM:Mitochondrial matrix,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,
SLC25A46	solute carrier family 25 member 46(SLC25A46)	Homo sapiens				GO:0000266~mitochondrial fission,GO:0000422~mitophagy,GO:0006839~mitochondrial transport,GO:0007416~synapse assembly,GO:0016358~dendrite development,GO:0021554~optic nerve development,GO:0021702~cerebellar Purkinje cell differentiation,GO:0022011~myelination in peripheral nervous system,GO:0031987~locomotion involved in locomotory behavior,GO:0048936~peripheral nervous system neuron axonogenesis,GO:0061564~axon development,GO:0090149~mitochondrial membrane fission,	GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,	IPR018108:Mitochondrial substrate/solute carrier,IPR023395:Mitochondrial carrier domain,		616505~Neuropathy, hereditary motor and sensory, type VIB,619303~Pontocerebellar hypoplasia, type 1E,			KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-1000~Mitochondrion outer membrane,	KW-0144~Charcot-Marie-Tooth disease,KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0622~Neuropathy,	KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,REGION:Disordered,REPEAT:Solcar,REPEAT:Solcar 1,REPEAT:Solcar 2,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,
SLC27A3	solute carrier family 27 member 3(SLC27A3)	Homo sapiens				GO:0001676~long-chain fatty acid metabolic process,GO:0015908~fatty acid transport,GO:0015909~long-chain fatty acid transport,	GO:0005739~mitochondrion,GO:0005783~endoplasmic reticulum,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0031966~mitochondrial membrane,	GO:0000166~nucleotide binding,GO:0004467~long-chain fatty acid-CoA ligase activity,GO:0005324~long-chain fatty acid transporter activity,GO:0005524~ATP binding,GO:0031957~very long-chain fatty acid-CoA ligase activity,GO:0047676~arachidonate-CoA ligase activity,	IPR000873:AMP-dependent synthetase/ligase,IPR020845:AMP-binding, conserved site,IPR025110:Domain of unknown function DUF4009,	hsa04931:Insulin resistance,				KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,	KW-0472~Membrane,KW-0496~Mitochondrion,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0436~Ligase,		BINDING:ATP,COMPBIAS:Basic and acidic residues,DOMAIN:AMP-binding,DOMAIN:AMP-binding_C,NP_BIND:ATP,REGION:Disordered,TRANSMEM:Helical,
SLC35A1	solute carrier family 35 member A1(SLC35A1)	Homo sapiens				GO:0005975~carbohydrate metabolic process,GO:0006464~cellular protein modification process,GO:0008643~carbohydrate transport,GO:0015782~CMP-N-acetylneuraminate transport,GO:0072334~UDP-galactose transmembrane transport,	GO:0000139~Golgi membrane,GO:0005794~Golgi apparatus,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0030173~integral component of Golgi membrane,	GO:0005456~CMP-N-acetylneuraminate transmembrane transporter activity,GO:0005459~UDP-galactose transmembrane transporter activity,GO:0005515~protein binding,GO:0015165~pyrimidine nucleotide-sugar transmembrane transporter activity,GO:0015297~antiporter activity,	IPR007271:Nucleotide-sugar transporter,		603585~Congenital disorder of glycosylation, type IIf,	PIRSF005799:nucleotide-sugar transporter,		KW-0762~Sugar transport,KW-0813~Transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,	KW-0900~Congenital disorder of glycosylation,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,				BINDING:CMP-sialic acid,REGION:CMP-sialic acid binding,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
SLC35A3	solute carrier family 35 member A3(SLC35A3)	Homo sapiens				GO:0006047~UDP-N-acetylglucosamine metabolic process,GO:0008643~carbohydrate transport,GO:0072334~UDP-galactose transmembrane transport,GO:1990569~UDP-N-acetylglucosamine transmembrane transport,	GO:0000139~Golgi membrane,GO:0005794~Golgi apparatus,GO:0016021~integral component of membrane,GO:0030173~integral component of Golgi membrane,	GO:0005459~UDP-galactose transmembrane transporter activity,GO:0005462~UDP-N-acetylglucosamine transmembrane transporter activity,GO:0005515~protein binding,GO:0015165~pyrimidine nucleotide-sugar transmembrane transporter activity,	IPR007271:Nucleotide-sugar transporter,		615553~Arthrogryposis, mental retardation, and seizures,	PIRSF005799:nucleotide-sugar transporter,		KW-0762~Sugar transport,KW-0813~Transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,	KW-0887~Epilepsy,KW-0991~Mental retardation,KW-1268~Autism spectrum disorder,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,				TRANSMEM:Helical,
SLC35B1	solute carrier family 35 member B1(SLC35B1)	Homo sapiens				GO:0008643~carbohydrate transport,GO:0015786~UDP-glucose transport,GO:0055085~transmembrane transport,GO:0072334~UDP-galactose transmembrane transport,	GO:0016021~integral component of membrane,GO:0030173~integral component of Golgi membrane,GO:0030176~integral component of endoplasmic reticulum membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0005459~UDP-galactose transmembrane transporter activity,GO:0005460~UDP-glucose transmembrane transporter activity,GO:0005515~protein binding,GO:0022857~transmembrane transporter activity,	IPR013657:UAA transporter,					KW-0762~Sugar transport,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	MOTIF:Di-lysine motif,TRANSMEM:Helical,
SLC35F2	solute carrier family 35 member F2(SLC35F2)	Homo sapiens				GO:0055085~transmembrane transport,	GO:0016021~integral component of membrane,	GO:0022857~transmembrane transporter activity,	IPR009262:Protein of unknown function DUF914, eukaryotic,					KW-0813~Transport,	KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	TRANSMEM:Helical,
SLC37A4	solute carrier family 37 member 4(SLC37A4)	Homo sapiens				GO:0001780~neutrophil homeostasis,GO:0002318~myeloid progenitor cell differentiation,GO:0005977~glycogen metabolic process,GO:0006006~glucose metabolic process,GO:0006089~lactate metabolic process,GO:0006094~gluconeogenesis,GO:0006641~triglyceride metabolic process,GO:0006874~cellular calcium ion homeostasis,GO:0007584~response to nutrient,GO:0008202~steroid metabolic process,GO:0008643~carbohydrate transport,GO:0009749~response to glucose,GO:0014070~response to organic cyclic compound,GO:0015760~glucose-6-phosphate transport,GO:0030593~neutrophil chemotaxis,GO:0032682~negative regulation of chemokine production,GO:0035166~post-embryonic hemopoiesis,GO:0035435~phosphate ion transmembrane transport,GO:0042593~glucose homeostasis,GO:0042632~cholesterol homeostasis,GO:0043085~positive regulation of catalytic activity,GO:0045730~respiratory burst,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030176~integral component of endoplasmic reticulum membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0005515~protein binding,GO:0015152~glucose-6-phosphate transmembrane transporter activity,GO:0022857~transmembrane transporter activity,GO:0061513~glucose 6-phosphate:inorganic phosphate antiporter activity,	IPR000849:Sugar phosphate transporter,IPR011701:Major facilitator superfamily,IPR020846:Major facilitator superfamily domain,IPR021159:Glycerate/sugar phosphate transporter, conserved site,	hsa04973:Carbohydrate digestion and absorption,	232220~Glycogen storage disease Ib,232240~Glycogen storage disease Ic,619525~Congenital disorder of glycosylation, type IIw,	PIRSF002808:hexose phosphate transporter,		KW-0050~Antiport,KW-0762~Sugar transport,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,	KW-0225~Disease variant,KW-0322~Glycogen storage disease,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,				DOMAIN:MFS,TRANSMEM:Helical,
SLC5A6	solute carrier family 5 member 6(SLC5A6)	Homo sapiens			General function prediction only,	GO:0006768~biotin metabolic process,GO:0006814~sodium ion transport,GO:0015878~biotin transport,GO:0015887~pantothenate transmembrane transport,GO:0015939~pantothenate metabolic process,GO:0055085~transmembrane transport,GO:1904200~iodide transmembrane transport,GO:1905135~biotin import across plasma membrane,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009925~basal plasma membrane,GO:0012506~vesicle membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0031526~brush border membrane,	GO:0005515~protein binding,GO:0008523~sodium-dependent multivitamin transmembrane transporter activity,GO:0015225~biotin transporter activity,GO:0015233~pantothenate transmembrane transporter activity,GO:0015293~symporter activity,GO:0022857~transmembrane transporter activity,GO:0090482~vitamin transmembrane transporter activity,	IPR001734:Sodium/solute symporter,IPR018212:Sodium/solute symporter, conserved site,	hsa04977:Vitamin digestion and absorption,	618973~Neurodegeneration, infantile-onset, biotin-responsive,			KW-0406~Ion transport,KW-0739~Sodium transport,KW-0769~Symport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0523~Neurodegeneration,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0092~Biotin,KW-0915~Sodium,		KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,MUTAGEN:C->A,S: Decrease in biotin transport.,MUTAGEN:C->A: No effect on biotin transport.,MUTAGEN:C->A: Reduced membrane localization.,MUTAGEN:C->A: Reduced membrane localization. Decrease in biotin transport.,MUTAGEN:C->S,M: Decrease in biotin transport.,MUTAGEN:N->A: No effect on biotin transport.,MUTAGEN:N->A: Reduced protein levels. Decrease in biotin transport.,MUTAGEN:N->A: Slight decrease in protein levels. Decrease in biotin transport.,MUTAGEN:S->A: No effect on biotin transport.,MUTAGEN:S->A: No effect on protein levels or membrane localization.,MUTAGEN:T->A: No effect on biotin transport.,MUTAGEN:T->A: Reduced membrane localization. Decrease in biotin transport.,MUTAGEN:T->A: Resistant to phorbol 12-myristate 13-acetate (PMA)-induced inhibition of biotin transport. No effect on protein levels or membrane localization.,REGION:Disordered,TRANSMEM:Helical,
SORBS3	sorbin and SH3 domain containing 3(SORBS3)	Homo sapiens				GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006936~muscle contraction,GO:0007015~actin filament organization,GO:0007155~cell adhesion,GO:0031589~cell-substrate adhesion,GO:0043410~positive regulation of MAPK cascade,GO:0051495~positive regulation of cytoskeleton organization,GO:0051496~positive regulation of stress fiber assembly,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005925~focal adhesion,GO:0030055~cell-substrate junction,	GO:0005200~structural constituent of cytoskeleton,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0017166~vinculin binding,	IPR001452:Src homology-3 domain,IPR003127:Sorbin-like,				SM00326:SH3,SM00459:Sorb,	KW-0130~Cell adhesion,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0965~Cell junction,		KW-0677~Repeat,KW-0728~SH3 domain,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:SH3,DOMAIN:SH3 1,DOMAIN:SH3 2,DOMAIN:SH3 3,DOMAIN:SoHo,MUTAGEN:W->F: Loss of SOS-binding ability.,MUTAGEN:Y->V: Loss of SOS-binding ability.,REGION:Binds to SOS,REGION:Binds to vinculin,REGION:Disordered,
SNX11	sorting nexin 11(SNX11)	Homo sapiens				GO:0006886~intracellular protein transport,GO:0016050~vesicle organization,	GO:0005768~endosome,GO:0016020~membrane,	GO:0005515~protein binding,GO:0035091~phosphatidylinositol binding,GO:1901981~phosphatidylinositol phosphate binding,	IPR001683:Phox homologous domain,				SM00312:PX,	KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,KW-0967~Endosome,			KW-0446~Lipid-binding,			BINDING:Phosphatidylinositol 3-phosphate,DOMAIN:PX,MUTAGEN:IEACV->AAAAA: Impairs function in membrane trafficking.,MUTAGEN:R->A: Abolishes lipid-binding.,REGION:Disordered,REGION:Important for membrane trafficking,
SNX13	sorting nexin 13(SNX13)	Homo sapiens				GO:0006886~intracellular protein transport,GO:0009968~negative regulation of signal transduction,GO:0015031~protein transport,GO:0043547~positive regulation of GTPase activity,	GO:0005769~early endosome,GO:0016021~integral component of membrane,GO:0031901~early endosome membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0032266~phosphatidylinositol-3-phosphate binding,GO:0035091~phosphatidylinositol binding,	IPR001683:Phox homologous domain,IPR003114:Phox-associated domain,IPR013937:Sorting nexin, C-terminal,IPR016137:Regulator of G protein signalling superfamily,				SM00312:PX,SM00313:PXA,SM00315:RGS,	KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,KW-0967~Endosome,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0446~Lipid-binding,	KW-0734~Signal transduction inhibitor,		BINDING:Phosphatidylinositol 3-phosphate,BINDING:Phosphatidylinositol 3-phosphate; via amide nitrogen and carbonyl oxygen,DOMAIN:PX,DOMAIN:PXA,DOMAIN:RGS,TRANSMEM:Helical,
SNX6	sorting nexin 6(SNX6)	Homo sapiens				GO:0006886~intracellular protein transport,GO:0007175~negative regulation of epidermal growth factor-activated receptor activity,GO:0016241~regulation of macroautophagy,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0042147~retrograde transport, endosome to Golgi,GO:0043524~negative regulation of neuron apoptotic process,GO:0045892~negative regulation of transcription, DNA-templated,GO:0071364~cellular response to epidermal growth factor stimulus,GO:1904646~cellular response to beta-amyloid,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005764~lysosome,GO:0005768~endosome,GO:0005829~cytosol,GO:0030904~retromer complex,GO:0030905~retromer, tubulation complex,GO:0031901~early endosome membrane,GO:0097422~tubular endosome,	GO:0005515~protein binding,GO:0034452~dynactin binding,GO:0034713~type I transforming growth factor beta receptor binding,GO:0035091~phosphatidylinositol binding,GO:0042803~protein homodimerization activity,	IPR001683:Phox homologous domain,IPR014637:Sorting nexin, Snx5/Snx6 types,IPR015404:Vps5 C-terminal,IPR027267:Arfaptin homology (AH) domain/BAR domain,	hsa04144:Endocytosis,		PIRSF036924:sorting nexin, Snx5/Snx6 types,		KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,		KW-0175~Coiled coil,	KW-0446~Lipid-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:BAR,DOMAIN:PX,DOMAIN:Vps5,MUTAGEN:Q->A: No effect on subcellular location.,MUTAGEN:R->A: No effect on subcellular location.,MUTAGEN:R->A: Reduces interaction with SNX1. Abolishes location at endosome membranes.,REGION:Disordered,REGION:Interaction with PIM1,REGION:Membrane-binding amphipathic helix,REGION:Phosphatidylinositol bisphosphate binding,
SNX7	sorting nexin 7(SNX7)	Homo sapiens			Intracellular trafficking and secretion / General function prediction only,	GO:0015031~protein transport,GO:2000786~positive regulation of autophagosome assembly,	GO:0005769~early endosome,GO:0030659~cytoplasmic vesicle membrane,GO:0031901~early endosome membrane,	GO:0005515~protein binding,GO:0035091~phosphatidylinositol binding,	IPR001683:Phox homologous domain,IPR027267:Arfaptin homology (AH) domain/BAR domain,				SM00312:PX,	KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,KW-0967~Endosome,			KW-0446~Lipid-binding,			BINDING:Phosphatidylinositol 3-phosphate,DOMAIN:BAR,DOMAIN:PX,REGION:Disordered,
SPTAN1	spectrin alpha, non-erythrocytic 1(SPTAN1)	Homo sapiens		h_deathPathway:Induction of apoptosis through DR3 and DR4/5 Death Receptors ,h_fasPathway:FAS signaling pathway ( CD95 ),h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_PDZsPathway:Synaptic Proteins at the Synaptic Junction,h_tnfr1Pathway:TNFR1 Signaling Pathway,h_uCalpainPathway:uCalpain and friends in Cell spread,		GO:0000165~MAPK cascade,GO:0006888~ER to Golgi vesicle-mediated transport,GO:0007411~axon guidance,GO:0030036~actin cytoskeleton organization,GO:0043312~neutrophil degranulation,GO:0051693~actin filament capping,	GO:0005576~extracellular region,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0005938~cell cortex,GO:0008091~spectrin,GO:0015630~microtubule cytoskeleton,GO:0016020~membrane,GO:0030054~cell junction,GO:0030864~cortical actin cytoskeleton,GO:0035580~specific granule lumen,GO:0042995~cell projection,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,GO:1903561~extracellular vesicle,GO:1904724~tertiary granule lumen,	GO:0003779~actin binding,GO:0005200~structural constituent of cytoskeleton,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0045296~cadherin binding,GO:0051015~actin filament binding,	IPR001452:Src homology-3 domain,IPR002017:Spectrin repeat,IPR002048:EF-hand domain,IPR011992:EF-hand-like domain,IPR014837:EF-hand, Ca insensitive,IPR018159:Spectrin/alpha-actinin,IPR018247:EF-Hand 1, calcium-binding site,	hsa04210:Apoptosis,	613477~Developmental and epileptic encephalopathy 5,		SM00054:EFh,SM00150:SPEC,SM00326:SH3,		KW-0206~Cytoskeleton,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0887~Epilepsy,KW-0991~Mental retardation,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0728~SH3 domain,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0009~Actin-binding,KW-0112~Calmodulin-binding,KW-0117~Actin capping,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	CA_BIND:1,CA_BIND:2,COMPBIAS:Basic and acidic residues,DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:EF-hand 3,DOMAIN:SH3,REGION:Disordered,REPEAT:Spectrin 1,REPEAT:Spectrin 10,REPEAT:Spectrin 11,REPEAT:Spectrin 12,REPEAT:Spectrin 13,REPEAT:Spectrin 14,REPEAT:Spectrin 15,REPEAT:Spectrin 16,REPEAT:Spectrin 17,REPEAT:Spectrin 18,REPEAT:Spectrin 19,REPEAT:Spectrin 2,REPEAT:Spectrin 20,REPEAT:Spectrin 3,REPEAT:Spectrin 4,REPEAT:Spectrin 5,REPEAT:Spectrin 6,REPEAT:Spectrin 7,REPEAT:Spectrin 8,REPEAT:Spectrin 9,SITE:Cleavage; by mu-calpain,
SYNE2	spectrin repeat containing nuclear envelope protein 2(SYNE2)	Homo sapiens				GO:0007097~nuclear migration,GO:0021817~nucleokinesis involved in cell motility in cerebral cortex radial glia guided migration,GO:0030335~positive regulation of cell migration,GO:0031022~nuclear migration along microfilament,GO:0051642~centrosome localization,GO:1902017~regulation of cilium assembly,	GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005640~nuclear outer membrane,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005925~focal adhesion,GO:0016021~integral component of membrane,GO:0016529~sarcoplasmic reticulum,GO:0030018~Z disc,GO:0031258~lamellipodium membrane,GO:0031527~filopodium membrane,GO:0031965~nuclear membrane,GO:0031981~nuclear lumen,GO:0033017~sarcoplasmic reticulum membrane,GO:0034993~LINC complex,GO:0045111~intermediate filament cytoskeleton,GO:0070062~extracellular exosome,	GO:0003779~actin binding,GO:0005515~protein binding,GO:0051015~actin filament binding,	IPR001589:Actinin-type, actin-binding, conserved site,IPR001715:Calponin homology domain,IPR002017:Spectrin repeat,IPR012315:Klarsicht/ANC-1/syne-1 homology,IPR018159:Spectrin/alpha-actinin,		612999~Emery-Dreifuss muscular dystrophy 5, autosomal dominant,		SM00033:CH,SM00150:SPEC,SM01249:SM01249,		KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0703~Sarcoplasmic reticulum,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-1067~Emery-Dreifuss muscular dystrophy,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0009~Actin-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DISULFID:Interchain (with C-563 in SUN2),DOMAIN:Calponin-homology (CH),DOMAIN:Calponin-homology (CH) 1,DOMAIN:Calponin-homology (CH) 2,DOMAIN:KASH,MUTAGEN:L->A: Disrupts interaction with SUN2.,MUTAGEN:P->A: Disrupts interaction with SUN2.,MUTAGEN:Y->A: Disrupts interaction with SUN2.,REGION:Actin-binding,REGION:Disordered,REGION:Sufficient for interaction with SUN2,REPEAT:Spectrin 1,REPEAT:Spectrin 10,REPEAT:Spectrin 11,REPEAT:Spectrin 12,REPEAT:Spectrin 13,REPEAT:Spectrin 14,REPEAT:Spectrin 15,REPEAT:Spectrin 16,REPEAT:Spectrin 17,REPEAT:Spectrin 18,REPEAT:Spectrin 19,REPEAT:Spectrin 2,REPEAT:Spectrin 20,REPEAT:Spectrin 21,REPEAT:Spectrin 22,REPEAT:Spectrin 23,REPEAT:Spectrin 24,REPEAT:Spectrin 25,REPEAT:Spectrin 26,REPEAT:Spectrin 27,REPEAT:Spectrin 28,REPEAT:Spectrin 29,REPEAT:Spectrin 3,REPEAT:Spectrin 30,REPEAT:Spectrin 31,REPEAT:Spectrin 32,REPEAT:Spectrin 33,REPEAT:Spectrin 34,REPEAT:Spectrin 35,REPEAT:Spectrin 36,REPEAT:Spectrin 37,REPEAT:Spectrin 38,REPEAT:Spectrin 39,REPEAT:Spectrin 4,REPEAT:Spectrin 40,REPEAT:Spectrin 41,REPEAT:Spectrin 42,REPEAT:Spectrin 43,REPEAT:Spectrin 44,REPEAT:Spectrin 45,REPEAT:Spectrin 46,REPEAT:Spectrin 47,REPEAT:Spectrin 48,REPEAT:Spectrin 49,REPEAT:Spectrin 5,REPEAT:Spectrin 50,REPEAT:Spectrin 51,REPEAT:Spectrin 52,REPEAT:Spectrin 53,REPEAT:Spectrin 54,REPEAT:Spectrin 55,REPEAT:Spectrin 56,REPEAT:Spectrin 6,REPEAT:Spectrin 7,REPEAT:Spectrin 8,REPEAT:Spectrin 9,TOPO_DOM:Cytoplasmic,TOPO_DOM:Perinuclear space,TRANSMEM:Helical; Anchor for type IV membrane protein,
SPEN	spen family transcriptional repressor(SPEN)	Homo sapiens		h_carm-erPathway:CARM1 and Regulation of the Estrogen Receptor,		GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000398~mRNA splicing, via spliceosome,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007219~Notch signaling pathway,GO:0016032~viral process,GO:0045892~negative regulation of transcription, DNA-templated,GO:0050769~positive regulation of neurogenesis,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0017053~transcriptional repressor complex,GO:0070062~extracellular exosome,	GO:0001085~RNA polymerase II transcription factor binding,GO:0003676~nucleic acid binding,GO:0003677~DNA binding,GO:0003714~transcription corepressor activity,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,	IPR000504:RNA recognition motif domain,IPR010912:Spen paralogue/orthologue C-terminal, metazoa,IPR012677:Nucleotide-binding, alpha-beta plait,IPR012921:Spen paralogue and orthologue SPOC, C-terminal,IPR016194:SPOC like C-terminal domain,		619312~Radio-Tartaglia syndrome,		SM00360:RRM,	KW-0804~Transcription,KW-0805~Transcription regulation,KW-0914~Notch signaling pathway,KW-0945~Host-virus interaction,	KW-0539~Nucleus,		KW-0175~Coiled coil,KW-0677~Repeat,		KW-0010~Activator,KW-0238~DNA-binding,KW-0678~Repressor,KW-0694~RNA-binding,	KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:RID,DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,DOMAIN:RRM 3,DOMAIN:RRM 4,DOMAIN:SPOC,REGION:Disordered,REGION:Interaction with MSX2,REGION:Interaction with RBPSUH,
SPAG4	sperm associated antigen 4(SPAG4)	Homo sapiens				GO:0006998~nuclear envelope organization,GO:0007283~spermatogenesis,GO:0030154~cell differentiation,	GO:0005635~nuclear envelope,GO:0005637~nuclear inner membrane,GO:0005639~integral component of nuclear inner membrane,GO:0005737~cytoplasm,GO:0005856~cytoskeleton,GO:0016021~integral component of membrane,GO:0031514~motile cilium,GO:0034993~LINC complex,	GO:0005198~structural molecule activity,GO:0005515~protein binding,GO:0043495~protein anchor,	IPR008979:Galactose-binding domain-like,IPR012919:Sad1/UNC-like, C-terminal,					KW-0221~Differentiation,KW-0744~Spermatogenesis,	KW-0206~Cytoskeleton,KW-0282~Flagellum,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0969~Cilium,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				COMPBIAS:Polar residues,DOMAIN:SUN,REGION:Disordered,TRANSMEM:Helical,
SPAG7	sperm associated antigen 7(SPAG7)	Homo sapiens					GO:0005634~nucleus,	GO:0003676~nucleic acid binding,GO:0005515~protein binding,	IPR001374:Single-stranded nucleic acid binding R3H,IPR017330:Sperm associated antigen, SPAG7,			PIRSF037943:sperm-associated antigen, SPAG7 type,	SM00393:R3H,		KW-0539~Nucleus,		KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:R3H,MOTIF:Nuclear localization signal,REGION:Disordered,
SYK	spleen associated tyrosine kinase(SYK)	Homo sapiens	74.CD47-IAP_with_avB3,	h_bcrPathway:BCR Signaling Pathway,h_fcer1Pathway:Fc Epsilon Receptor I Signaling in Mast Cells,h_il2Pathway:IL 2 signaling pathway,h_il2rbPathway:IL-2 Receptor Beta Chain in T cell Activation,h_nkcellsPathway:Ras-Independent pathway in NK cell-mediated cytotoxicity,h_sppaPathway:Aspirin Blocks Signaling Pathway Involved in Platelet Activation,		GO:0001525~angiogenesis,GO:0001775~cell activation,GO:0001945~lymph vessel development,GO:0002092~positive regulation of receptor internalization,GO:0002223~stimulatory C-type lectin receptor signaling pathway,GO:0002250~adaptive immune response,GO:0002281~macrophage activation involved in immune response,GO:0002283~neutrophil activation involved in immune response,GO:0002366~leukocyte activation involved in immune response,GO:0002554~serotonin secretion by platelet,GO:0002862~negative regulation of inflammatory response to antigenic stimulus,GO:0006468~protein phosphorylation,GO:0006606~protein import into nucleus,GO:0007159~leukocyte cell-cell adhesion,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007229~integrin-mediated signaling pathway,GO:0007257~activation of JUN kinase activity,GO:0009887~animal organ morphogenesis,GO:0010543~regulation of platelet activation,GO:0010803~regulation of tumor necrosis factor-mediated signaling pathway,GO:0016032~viral process,GO:0018105~peptidyl-serine phosphorylation,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0019221~cytokine-mediated signaling pathway,GO:0019370~leukotriene biosynthetic process,GO:0030154~cell differentiation,GO:0030168~platelet activation,GO:0030593~neutrophil chemotaxis,GO:0031334~positive regulation of protein complex assembly,GO:0031623~receptor internalization,GO:0032481~positive regulation of type I interferon production,GO:0032725~positive regulation of granulocyte macrophage colony-stimulating factor production,GO:0032733~positive regulation of interleukin-10 production,GO:0032735~positive regulation of interleukin-12 production,GO:0032752~positive regulation of interleukin-3 production,GO:0032753~positive regulation of interleukin-4 production,GO:0032755~positive regulation of interleukin-6 production,GO:0032757~positive regulation of interleukin-8 production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0032928~regulation of superoxide anion generation,GO:0032930~positive regulation of superoxide anion generation,GO:0033630~positive regulation of cell adhesion mediated by integrin,GO:0035556~intracellular signal transduction,GO:0038063~collagen-activated tyrosine kinase receptor signaling pathway,GO:0038095~Fc-epsilon receptor signaling pathway,GO:0038096~Fc-gamma receptor signaling pathway involved in phagocytosis,GO:0038110~interleukin-2-mediated signaling pathway,GO:0038156~interleukin-3-mediated signaling pathway,GO:0042742~defense response to bacterium,GO:0043280~positive regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0043306~positive regulation of mast cell degranulation,GO:0043313~regulation of neutrophil degranulation,GO:0043366~beta selection,GO:0043507~positive regulation of JUN kinase activity,GO:0045087~innate immune response,GO:0045579~positive regulation of B cell differentiation,GO:0045588~positive regulation of gamma-delta T cell differentiation,GO:0045780~positive regulation of bone resorption,GO:0046638~positive regulation of alpha-beta T cell differentiation,GO:0046641~positive regulation of alpha-beta T cell proliferation,GO:0046777~protein autophosphorylation,GO:0048514~blood vessel morphogenesis,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0050764~regulation of phagocytosis,GO:0050850~positive regulation of calcium-mediated signaling,GO:0050853~B cell receptor signaling pathway,GO:0051090~regulation of sequence-specific DNA binding transcription factor activity,GO:0051712~positive regulation of killing of cells of other organism,GO:0070372~regulation of ERK1 and ERK2 cascade,GO:0071226~cellular response to molecule of fungal origin,GO:0071396~cellular response to lipid,GO:0071404~cellular response to low-density lipoprotein particle stimulus,GO:0071639~positive regulation of monocyte chemotactic protein-1 production,GO:0090237~regulation of arachidonic acid secretion,GO:0090330~regulation of platelet aggregation,GO:1990858~cellular response to lectin,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0019815~B cell receptor complex,GO:0031234~extrinsic component of cytoplasmic side of plasma membrane,GO:0032009~early phagosome,GO:0032991~macromolecular complex,GO:0042101~T cell receptor complex,	GO:0001784~phosphotyrosine binding,GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0004715~non-membrane spanning protein tyrosine kinase activity,GO:0005102~receptor binding,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016170~interleukin-15 receptor binding,GO:0019901~protein kinase binding,GO:0019902~phosphatase binding,GO:0035325~Toll-like receptor binding,GO:0042169~SH2 domain binding,GO:0043274~phospholipase binding,GO:0097110~scaffold protein binding,	IPR000719:Protein kinase, catalytic domain,IPR000980:SH2 domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR008266:Tyrosine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR012234:Tyrosine-protein kinase, non-receptor SYK/ZAP-70,IPR017441:Protein kinase, ATP binding site,IPR020635:Tyrosine-protein kinase, catalytic domain,IPR023420:Tyrosine-protein kinase SYK/ZAP-70, inter-SH2 domain,	hsa04064:NF-kappa B signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04380:Osteoclast differentiation,hsa04611:Platelet activation,hsa04613:Neutrophil extracellular trap formation,hsa04625:C-type lectin receptor signaling pathway,hsa04650:Natural killer cell mediated cytotoxicity,hsa04662:B cell receptor signaling pathway,hsa04664:Fc epsilon RI signaling pathway,hsa04666:Fc gamma R-mediated phagocytosis,hsa05152:Tuberculosis,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05171:Coronavirus disease - COVID-19,hsa05203:Viral carcinogenesis,	619381~Immunodeficiency 82 with systemic inflammation,	PIRSF000604:tyrosine-protein kinase, SYK/ZAP-70 type,	SM00219:TyrKc,SM00252:SH2,	KW-0037~Angiogenesis,KW-0391~Immunity,KW-0399~Innate immunity,KW-0945~Host-virus interaction,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0727~SH2 domain,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Proton acceptor,BINDING:ATP,COMPBIAS:Polar residues,DOMAIN:Protein kinase,DOMAIN:SH2,DOMAIN:SH2 1,DOMAIN:SH2 2,MUTAGEN:S->A: Abolishes YWHAG binding.,MUTAGEN:Y->F: Loss of interaction with BLNK.,NP_BIND:ATP,REGION:Disordered,REGION:Interdomain A,REGION:Interdomain B,
SPRED2	sprouty related EVH1 domain containing 2(SPRED2)	Homo sapiens				GO:0000188~inactivation of MAPK activity,GO:0007275~multicellular organism development,GO:0008543~fibroblast growth factor receptor signaling pathway,GO:0009966~regulation of signal transduction,GO:0010719~negative regulation of epithelial to mesenchymal transition,GO:0010801~negative regulation of peptidyl-threonine phosphorylation,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0043086~negative regulation of catalytic activity,GO:0043409~negative regulation of MAPK cascade,GO:0043517~positive regulation of DNA damage response, signal transduction by p53 class mediator,GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:0090311~regulation of protein deacetylation,GO:1902747~negative regulation of lens fiber cell differentiation,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0030658~transport vesicle membrane,	GO:0005173~stem cell factor receptor binding,GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0030291~protein serine/threonine kinase inhibitor activity,	IPR000697:EVH1,IPR007875:Sprouty,IPR011993:Pleckstrin homology-like domain,IPR023337:c-Kit-binding domain,				SM00461:WH1,		KW-0472~Membrane,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,					KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:KBD,DOMAIN:SPR,DOMAIN:WH1,MUTAGEN:Y->F: No affect on phosphorylation or ubiquitination.,MUTAGEN:Y->F: No affect on phosphorylation or ubiquitination; when associated with F-264.,MUTAGEN:Y->F: No affect on phosphorylation or ubiquitination; when associated with F-266.,MUTAGEN:Y->F: Reduces ubiquitination and CBL-induced phosphorylation; when associated with F-228.,MUTAGEN:Y->F: Reduces ubiquitination and CBL-induced phosphorylation; when associated with F-231.,REGION:Disordered,
STMN1	stathmin 1(STMN1)	Homo sapiens		h_stathminPathway:Stathmin and breast cancer resistance to antimicrotubule agents,		GO:0000281~mitotic cytokinesis,GO:0007019~microtubule depolymerization,GO:0007052~mitotic spindle organization,GO:0007165~signal transduction,GO:0007409~axonogenesis,GO:0007420~brain development,GO:0009615~response to virus,GO:0031110~regulation of microtubule polymerization or depolymerization,GO:0031115~negative regulation of microtubule polymerization,GO:0031175~neuron projection development,GO:0035024~negative regulation of Rho protein signal transduction,GO:0035556~intracellular signal transduction,GO:0048012~hepatocyte growth factor receptor signaling pathway,GO:0051272~positive regulation of cellular component movement,GO:0051497~negative regulation of stress fiber assembly,GO:0061436~establishment of skin barrier,GO:0070495~negative regulation of thrombin-activated receptor signaling pathway,GO:1905098~negative regulation of guanyl-nucleotide exchange factor activity,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005874~microtubule,GO:0016020~membrane,GO:0043005~neuron projection,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0015631~tubulin binding,	IPR000956:Stathmin family,	hsa04010:MAPK signaling pathway,hsa05206:MicroRNAs in cancer,		PIRSF002285:Op18/stathmin,		KW-0221~Differentiation,KW-0524~Neurogenesis,	KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0963~Cytoplasm,		KW-0175~Coiled coil,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	DOMAIN:SLD,REGION:Disordered,
SCP2	sterol carrier protein 2(SCP2)	Homo sapiens				GO:0006635~fatty acid beta-oxidation,GO:0006694~steroid biosynthetic process,GO:0006699~bile acid biosynthetic process,GO:0006701~progesterone biosynthetic process,GO:0006869~lipid transport,GO:0007031~peroxisome organization,GO:0008104~protein localization,GO:0008206~bile acid metabolic process,GO:0015914~phospholipid transport,GO:0032367~intracellular cholesterol transport,GO:0032385~positive regulation of intracellular cholesterol transport,GO:0032959~inositol trisphosphate biosynthetic process,GO:0033540~fatty acid beta-oxidation using acyl-CoA oxidase,GO:0036109~alpha-linolenic acid metabolic process,GO:0045940~positive regulation of steroid metabolic process,GO:0071071~regulation of phospholipid biosynthetic process,GO:0072659~protein localization to plasma membrane,GO:1901373~lipid hydroperoxide transport,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005777~peroxisome,GO:0005782~peroxisomal matrix,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0016020~membrane,GO:0032991~macromolecular complex,GO:0043231~intracellular membrane-bounded organelle,	GO:0000062~fatty-acyl-CoA binding,GO:0003988~acetyl-CoA C-acyltransferase activity,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0008289~lipid binding,GO:0008526~phosphatidylinositol transporter activity,GO:0015485~cholesterol binding,GO:0016747~transferase activity, transferring acyl groups other than amino-acyl groups,GO:0032934~sterol binding,GO:0033814~propanoyl-CoA C-acyltransferase activity,GO:0036042~long-chain fatty acyl-CoA binding,GO:0050632~propionyl-CoA C2-trimethyltridecanoyltransferase activity,GO:0050633~acetyl-CoA C-myristoyltransferase activity,GO:0070538~oleic acid binding,	IPR002155:Thiolase,IPR003033:SCP2 sterol-binding domain,IPR016039:Thiolase-like,IPR020613:Thiolase, conserved site,IPR020615:Thiolase, acyl-enzyme intermediate active site,IPR020616:Thiolase, N-terminal,IPR020617:Thiolase, C-terminal,	hsa00120:Primary bile acid biosynthesis,hsa01040:Biosynthesis of unsaturated fatty acids,hsa01100:Metabolic pathways,hsa01212:Fatty acid metabolism,hsa03320:PPAR signaling pathway,hsa04146:Peroxisome,	613724~Leukoencephalopathy with dystonia and motor neuropathy,	PIRSF000429:acetyl-CoA acetyltransferase,		KW-0443~Lipid metabolism,KW-0445~Lipid transport,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0496~Mitochondrion,KW-0576~Peroxisome,KW-0963~Cytoplasm,		KW-0809~Transit peptide,	KW-0446~Lipid-binding,	KW-0012~Acyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:SCP2,DOMAIN:Thiolase_C,DOMAIN:Thiolase_N,MOTIF:Microbody targeting signal,MUTAGEN:G->D: Strongly reduces sterol carrier and phosphatidylcholine transfer activity; when associated with D-528.,MUTAGEN:N->D: Strongly reduces sterol carrier and phosphatidylcholine transfer activity; when associated with D-530.,MUTAGEN:N->I: Strongly reduces sterol carrier and phosphatidylcholine transfer activity.,REGION:Disordered,SITE:Cleavage,
SFN	stratifin(SFN)	Homo sapiens		h_EfpPathway:Estrogen-responsive protein Efp controls cell cycle and breast tumors growth,		GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0001836~release of cytochrome c from mitochondria,GO:0003334~keratinocyte development,GO:0006469~negative regulation of protein kinase activity,GO:0006977~DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest,GO:0007165~signal transduction,GO:0008630~intrinsic apoptotic signaling pathway in response to DNA damage,GO:0010482~regulation of epidermal cell division,GO:0010839~negative regulation of keratinocyte proliferation,GO:0030307~positive regulation of cell growth,GO:0031424~keratinization,GO:0034613~cellular protein localization,GO:0043154~negative regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0045606~positive regulation of epidermal cell differentiation,GO:0046827~positive regulation of protein export from nucleus,GO:0061436~establishment of skin barrier,GO:1900740~positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway,	GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0008426~protein kinase C inhibitor activity,GO:0019901~protein kinase binding,GO:0042802~identical protein binding,GO:0045296~cadherin binding,GO:0051219~phosphoprotein binding,	IPR000308:14-3-3 protein,IPR023409:14-3-3 protein, conserved site,IPR023410:14-3-3 domain,	hsa04110:Cell cycle,hsa04115:p53 signaling pathway,hsa04960:Aldosterone-regulated sodium reabsorption,		PIRSF000868:14-3-3 protein,	SM00101:14_3_3,		KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0964~Secreted,					KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	SITE:Interaction with phosphoserine on interacting protein,
SMC1A	structural maintenance of chromosomes 1A(SMC1A)	Homo sapiens				GO:0000070~mitotic sister chromatid segregation,GO:0006281~DNA repair,GO:0007062~sister chromatid cohesion,GO:0007064~mitotic sister chromatid cohesion,GO:0009314~response to radiation,GO:0019827~stem cell population maintenance,GO:0051301~cell division,GO:0051321~meiotic cell cycle,GO:0072423~response to DNA damage checkpoint signaling,GO:0090307~mitotic spindle assembly,	GO:0000775~chromosome, centromeric region,GO:0000776~kinetochore,GO:0000777~condensed chromosome kinetochore,GO:0000794~condensed nuclear chromosome,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005829~cytosol,GO:0008278~cohesin complex,GO:0016363~nuclear matrix,GO:0030893~meiotic cohesin complex,GO:0034991~nuclear meiotic cohesin complex,GO:0097431~mitotic spindle pole,	GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0036033~mediator complex binding,GO:0046982~protein heterodimerization activity,	IPR003395:RecF/RecN/SMC,IPR010935:SMCs flexible hinge,IPR024704:Structural maintenance of chromosomes protein,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04110:Cell cycle,hsa04114:Oocyte meiosis,	300590~Cornelia de Lange syndrome 2,301044~Developmental and epileptic encephalopathy 85, with or without midline brain defects,	PIRSF005719:structural maintenance of chromosomes protein,	SM00968:SM00968,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0227~DNA damage,KW-0234~DNA repair,KW-0469~Meiosis,KW-0498~Mitosis,	KW-0137~Centromere,KW-0158~Chromosome,KW-0539~Nucleus,KW-0995~Kinetochore,	KW-0225~Disease variant,KW-0887~Epilepsy,KW-0991~Mental retardation,	KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:SMC hinge,DOMAIN:SMC_N,MUTAGEN:S->A: Reduces phosphorylation and the S-phase checkpoint activation. Abolishes S-phase activation; when associated with A-966.,MUTAGEN:S->A: Reduces phosphorylation and the S-phase checkpoint activation. Increases sensitivity to DNA methylation. Abolishes S-phase activation; when associated with A-957.,NP_BIND:ATP,REGION:Disordered,
SMC3	structural maintenance of chromosomes 3(SMC3)	Homo sapiens				GO:0000278~mitotic cell cycle,GO:0006275~regulation of DNA replication,GO:0006281~DNA repair,GO:0007062~sister chromatid cohesion,GO:0007064~mitotic sister chromatid cohesion,GO:0019827~stem cell population maintenance,GO:0051276~chromosome organization,GO:0051301~cell division,GO:0051321~meiotic cell cycle,GO:0090307~mitotic spindle assembly,	GO:0000775~chromosome, centromeric region,GO:0000785~chromatin,GO:0000800~lateral element,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005829~cytosol,GO:0008278~cohesin complex,GO:0016363~nuclear matrix,GO:0030893~meiotic cohesin complex,GO:0034990~nuclear mitotic cohesin complex,GO:0034991~nuclear meiotic cohesin complex,GO:0097431~mitotic spindle pole,	GO:0003682~chromatin binding,GO:0003690~double-stranded DNA binding,GO:0003777~microtubule motor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0036033~mediator complex binding,GO:0046982~protein heterodimerization activity,GO:0048487~beta-tubulin binding,GO:0061775~cohesin ATPase activity,GO:0070840~dynein complex binding,	IPR003395:RecF/RecN/SMC,IPR010935:SMCs flexible hinge,IPR024704:Structural maintenance of chromosomes protein,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04110:Cell cycle,hsa04114:Oocyte meiosis,	610759~Cornelia de Lange syndrome 3,	PIRSF005719:structural maintenance of chromosomes protein,	SM00968:SM00968,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0227~DNA damage,KW-0234~DNA repair,KW-0469~Meiosis,KW-0498~Mitosis,	KW-0137~Centromere,KW-0158~Chromosome,KW-0539~Nucleus,	KW-0225~Disease variant,KW-0991~Mental retardation,	KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:SMC hinge,MUTAGEN:K->A: 20% loss of sister chromatid cohesion, no effect on cohesin complex assembly; when associated with A-105.,MUTAGEN:K->A: 20% loss of sister chromatid cohesion, no effect on cohesin complex assembly; when associated with A-106.,MUTAGEN:K->Q: No effect on sister chromatid cohesion, nor on cohesin complex assembly; when associated with Q-105.,MUTAGEN:K->Q: No effect on sister chromatid cohesion, nor on cohesin complex assembly; when associated with Q-106.,MUTAGEN:K->R: Stabilizes interaction with PDS5A and WAPL; when associated with R-105.,MUTAGEN:K->R: Stabilizes interaction with PDS5A and WAPL; when associated with R-106.,NP_BIND:ATP,REGION:Disordered,
SMC4	structural maintenance of chromosomes 4(SMC4)	Homo sapiens				GO:0000070~mitotic sister chromatid segregation,GO:0007049~cell cycle,GO:0007076~mitotic chromosome condensation,GO:0010032~meiotic chromosome condensation,GO:0045132~meiotic chromosome segregation,GO:0051276~chromosome organization,GO:0051301~cell division,GO:0051383~kinetochore organization,GO:1905821~positive regulation of chromosome condensation,	GO:0000775~chromosome, centromeric region,GO:0000796~condensin complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005829~cytosol,GO:0016607~nuclear speck,	GO:0003682~chromatin binding,GO:0003697~single-stranded DNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,	IPR003395:RecF/RecN/SMC,IPR010935:SMCs flexible hinge,IPR024704:Structural maintenance of chromosomes protein,IPR027417:P-loop containing nucleoside triphosphate hydrolase,			PIRSF005719:structural maintenance of chromosomes protein,	SM00968:SM00968,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0226~DNA condensation,KW-0498~Mitosis,	KW-0158~Chromosome,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DOMAIN:SMC hinge,DOMAIN:SMC_N,NP_BIND:ATP,REGION:Disordered,
SDHB	succinate dehydrogenase complex iron sulfur subunit B(SDHB)	Homo sapiens		h_etcPathway:Electron Transport Reaction in Mitochondria,		GO:0006099~tricarboxylic acid cycle,GO:0006105~succinate metabolic process,GO:0009060~aerobic respiration,GO:0022904~respiratory electron transport chain,	GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005749~mitochondrial respiratory chain complex II, succinate dehydrogenase complex (ubiquinone),GO:0005886~plasma membrane,GO:0031966~mitochondrial membrane,	GO:0005515~protein binding,GO:0008177~succinate dehydrogenase (ubiquinone) activity,GO:0009055~electron carrier activity,GO:0046872~metal ion binding,GO:0048039~ubiquinone binding,GO:0051537~2 iron, 2 sulfur cluster binding,GO:0051538~3 iron, 4 sulfur cluster binding,GO:0051539~4 iron, 4 sulfur cluster binding,	IPR001041:2Fe-2S ferredoxin-type domain,IPR004489:Succinate dehydrogenase/fumarate reductase iron-sulphur protein,IPR006058:2Fe-2S ferredoxin, iron-sulphur binding site,IPR009051:Alpha-helical ferredoxin,IPR012675:Beta-grasp domain,IPR017896:4Fe-4S ferredoxin-type, iron-sulpur binding domain,IPR017900:4Fe-4S ferredoxin, iron-sulphur binding, conserved site,IPR025192:Succinate dehydogenase/fumarate reductase N-terminal,	hsa00020:Citrate cycle (TCA cycle),hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa04714:Thermogenesis,hsa04932:Non-alcoholic fatty liver disease,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05415:Diabetic cardiomyopathy,	115310~Paragangliomas 4,171300~Pheochromocytoma,606764~Gastrointestinal stromal tumor,606864~Paraganglioma and gastric stromal sarcoma,619224~Mitochondrial complex II deficiency, nuclear type 4,			KW-0249~Electron transport,KW-0813~Transport,KW-0816~Tricarboxylic acid cycle,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,	KW-0225~Disease variant,	KW-0809~Transit peptide,	KW-0001~2Fe-2S,KW-0003~3Fe-4S,KW-0004~4Fe-4S,KW-0408~Iron,KW-0411~Iron-sulfur,KW-0479~Metal-binding,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,	BINDING:Ubiquinone; shared with DHSD,DOMAIN:2Fe-2S ferredoxin-type,DOMAIN:4Fe-4S ferredoxin-type,METAL:Iron-sulfur 1 (2Fe-2S),METAL:Iron-sulfur 2 (4Fe-4S),METAL:Iron-sulfur 3 (3Fe-4S),REGION:Disordered,REGION:Interaction with SDHAF1,TRANSIT:Mitochondrion,
ST7	suppression of tumorigenicity 7(ST7)	Homo sapiens				GO:0030198~extracellular matrix organization,GO:0045595~regulation of cell differentiation,	GO:0016020~membrane,GO:0016021~integral component of membrane,		IPR007311:ST7,IPR011990:Tetratricopeptide-like helical,						KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:Disordered,TRANSMEM:Helical,
SOCS2	suppressor of cytokine signaling 2(SOCS2)	Homo sapiens				GO:0001558~regulation of cell growth,GO:0007259~JAK-STAT cascade,GO:0007595~lactation,GO:0009966~regulation of signal transduction,GO:0016567~protein ubiquitination,GO:0019221~cytokine-mediated signaling pathway,GO:0032355~response to estradiol,GO:0032870~cellular response to hormone stimulus,GO:0035556~intracellular signal transduction,GO:0038111~interleukin-7-mediated signaling pathway,GO:0040015~negative regulation of multicellular organism growth,GO:0043066~negative regulation of apoptotic process,GO:0043551~regulation of phosphatidylinositol 3-kinase activity,GO:0043687~post-translational protein modification,GO:0045666~positive regulation of neuron differentiation,GO:0046426~negative regulation of JAK-STAT cascade,GO:0046854~phosphatidylinositol phosphorylation,GO:0060396~growth hormone receptor signaling pathway,GO:0060749~mammary gland alveolus development,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005942~phosphatidylinositol 3-kinase complex,	GO:0005131~growth hormone receptor binding,GO:0005159~insulin-like growth factor receptor binding,GO:0005515~protein binding,GO:0008269~JAK pathway signal transduction adaptor activity,GO:0046935~1-phosphatidylinositol-3-kinase regulator activity,	IPR000980:SH2 domain,IPR001496:SOCS protein, C-terminal,	hsa04630:JAK-STAT signaling pathway,hsa04910:Insulin signaling pathway,hsa04917:Prolactin signaling pathway,hsa04930:Type II diabetes mellitus,hsa04935:Growth hormone synthesis, secretion and action,			SM00252:SH2,SM00253:SOCS,SM00969:SM00969,	KW-0341~Growth regulation,KW-0833~Ubl conjugation pathway,			KW-0727~SH2 domain,		KW-0734~Signal transduction inhibitor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:SH2,DOMAIN:SOCS box,MUTAGEN:K->R: Increased protein half-life.,MUTAGEN:K->R: No effect on protein half-life.,REGION:Disordered,REGION:Interaction with AREL1,
SMNDC1	survival motor neuron domain containing 1(SMNDC1)	Homo sapiens				GO:0000375~RNA splicing, via transesterification reactions,GO:0000398~mRNA splicing, via spliceosome,GO:0006397~mRNA processing,GO:0006915~apoptotic process,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:0005737~cytoplasm,GO:0015030~Cajal body,GO:0016607~nuclear speck,	GO:0003723~RNA binding,GO:0005515~protein binding,	IPR002999:Tudor domain,IPR010304:Survival motor neuron,	hsa03040:Spliceosome,			SM00333:TUDOR,	KW-0053~Apoptosis,KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0747~Spliceosome,		KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Tudor,MOTIF:Nuclear localization signal,MUTAGEN:FAGYGNAEVT->YAGYGNAEVQ: Increases binding to substrate containing dimethylated arginine.,
SYNGR3	synaptogyrin 3(SYNGR3)	Homo sapiens				GO:0001504~neurotransmitter uptake,GO:0021762~substantia nigra development,GO:0032411~positive regulation of transporter activity,GO:0045055~regulated exocytosis,	GO:0008021~synaptic vesicle,GO:0016021~integral component of membrane,GO:0030672~synaptic vesicle membrane,GO:0031594~neuromuscular junction,	GO:0005515~protein binding,GO:0042169~SH2 domain binding,GO:0047485~protein N-terminus binding,	IPR008253:Marvel,IPR016579:Synaptogyrin,			PIRSF011282:synaptogyrin,			KW-0472~Membrane,KW-0770~Synapse,KW-0965~Cell junction,KW-0968~Cytoplasmic vesicle,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:MARVEL,REGION:Disordered,TRANSMEM:Helical,
SYPL1	synaptophysin like 1(SYPL1)	Homo sapiens				GO:0007268~chemical synaptic transmission,	GO:0005887~integral component of plasma membrane,GO:0008021~synaptic vesicle,GO:0016021~integral component of membrane,GO:0030141~secretory granule,GO:0030285~integral component of synaptic vesicle membrane,GO:0030672~synaptic vesicle membrane,GO:0042470~melanosome,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0017075~syntaxin-1 binding,	IPR001285:Synaptophysin/synaptoporin,IPR008253:Marvel,						KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:MARVEL,TOPO_DOM:Cytoplasmic,TOPO_DOM:Vesicular,TRANSMEM:Helical,
SNAP25	synaptosome associated protein 25(SNAP25)	Homo sapiens		h_botulinPathway:Blockade of Neurotransmitter Relase by Botulinum Toxin,		GO:0001504~neurotransmitter uptake,GO:0006836~neurotransmitter transport,GO:0006887~exocytosis,GO:0006906~vesicle fusion,GO:0007268~chemical synaptic transmission,GO:0007269~neurotransmitter secretion,GO:0007626~locomotory behavior,GO:0008306~associative learning,GO:0010975~regulation of neuron projection development,GO:0016079~synaptic vesicle exocytosis,GO:0016081~synaptic vesicle docking,GO:0016082~synaptic vesicle priming,GO:0031629~synaptic vesicle fusion to presynaptic active zone membrane,GO:0043312~neutrophil degranulation,GO:0050796~regulation of insulin secretion,GO:0060291~long-term synaptic potentiation,GO:0071805~potassium ion transmembrane transport,GO:0098967~exocytic insertion of neurotransmitter receptor to postsynaptic membrane,GO:0099590~neurotransmitter receptor internalization,	GO:0001917~photoreceptor inner segment,GO:0005737~cytoplasm,GO:0005802~trans-Golgi network,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0008021~synaptic vesicle,GO:0016020~membrane,GO:0030426~growth cone,GO:0031201~SNARE complex,GO:0031234~extrinsic component of cytoplasmic side of plasma membrane,GO:0031982~vesicle,GO:0035579~specific granule membrane,GO:0036477~somatodendritic compartment,GO:0042734~presynaptic membrane,GO:0043005~neuron projection,GO:0045202~synapse,GO:0048471~perinuclear region of cytoplasm,GO:0070032~synaptobrevin 2-SNAP-25-syntaxin-1a-complexin I complex,GO:0070821~tertiary granule membrane,GO:0098794~postsynapse,GO:0098978~glutamatergic synapse,	GO:0005249~voltage-gated potassium channel activity,GO:0005484~SNAP receptor activity,GO:0005515~protein binding,GO:0017075~syntaxin-1 binding,GO:0019905~syntaxin binding,GO:0048306~calcium-dependent protein binding,	IPR000727:Target SNARE coiled-coil domain,IPR000928:SNAP-25,	hsa04721:Synaptic vesicle cycle,hsa04911:Insulin secretion,	616330~Myasthenic syndrome, congenital, 18,		SM00397:t_SNARE,		KW-0472~Membrane,KW-0770~Synapse,KW-0771~Synaptosome,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0991~Mental retardation,KW-1004~Congenital myasthenic syndrome,	KW-0175~Coiled coil,KW-0677~Repeat,			KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,	DOMAIN:T-SNARE coiled-coil homology,DOMAIN:t-SNARE coiled-coil homology 1,DOMAIN:t-SNARE coiled-coil homology 2,LIPID:S-palmitoyl cysteine,MUTAGEN:A->R: Not cleaved by BoNT/C.,MUTAGEN:D->A: Decreased cleavage by BoNT/C, no change in cleavage by BoNT/A.,MUTAGEN:I->E: Small decrease in affinity for C.botulinum BoNT/A, increased efficiency of BoNT/C cleavage.,MUTAGEN:M->E: Small decrease in affinity for C.botulinum BoNT/A.,MUTAGEN:M->Y: Slight decrease in affinity for BoNT/A, increases kcat for BoNT/A.,MUTAGEN:P->A: Decreased binding affinity for ZDHHC17.,MUTAGEN:Q->A: Decreased binding affinity for ZDHHC17.,MUTAGEN:Q->A: Decreased cleavage by C.botulinum BoNT/C, no change in cleavage by C.botulinum BoNT/A (botA).,MUTAGEN:R->A: No effect on ZDHHC17 binding.,MUTAGEN:S->A: No effect on ZDHHC17 binding.,MUTAGEN:V->A: Mildly decreased binding affinity for ZDHHC17.,REGION:Disordered,REGION:Interaction with CENPF,REGION:Interaction with ZDHHC17,SITE:(Microbial infection) Cleavage; by C.botulinum neurotoxin type A (BoNT/A, botA),SITE:(Microbial infection) Cleavage; by C.botulinum neurotoxin type C (BoNT/C),SITE:(Microbial infection) Cleavage; by C.botulinum neurotoxin type E (BoNT/E),
STX1A	syntaxin 1A(STX1A)	Homo sapiens		h_botulinPathway:Blockade of Neurotransmitter Relase by Botulinum Toxin,		GO:0001956~positive regulation of neurotransmitter secretion,GO:0006836~neurotransmitter transport,GO:0006886~intracellular protein transport,GO:0006887~exocytosis,GO:0006906~vesicle fusion,GO:0007269~neurotransmitter secretion,GO:0009629~response to gravity,GO:0010701~positive regulation of norepinephrine secretion,GO:0010807~regulation of synaptic vesicle priming,GO:0016079~synaptic vesicle exocytosis,GO:0016081~synaptic vesicle docking,GO:0016192~vesicle-mediated transport,GO:0016925~protein sumoylation,GO:0017156~calcium ion regulated exocytosis,GO:0017157~regulation of exocytosis,GO:0019221~cytokine-mediated signaling pathway,GO:0030073~insulin secretion,GO:0031629~synaptic vesicle fusion to presynaptic active zone membrane,GO:0032940~secretion by cell,GO:0033605~positive regulation of catecholamine secretion,GO:0035493~SNARE complex assembly,GO:0045048~protein insertion into ER membrane,GO:0045956~positive regulation of calcium ion-dependent exocytosis,GO:0048278~vesicle docking,GO:0048488~synaptic vesicle endocytosis,GO:0050796~regulation of insulin secretion,GO:0072657~protein localization to membrane,GO:2000463~positive regulation of excitatory postsynaptic potential,	GO:0001669~acrosomal vesicle,GO:0005576~extracellular region,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0008021~synaptic vesicle,GO:0008076~voltage-gated potassium channel complex,GO:0012505~endomembrane system,GO:0014069~postsynaptic density,GO:0016021~integral component of membrane,GO:0030141~secretory granule,GO:0030285~integral component of synaptic vesicle membrane,GO:0030424~axon,GO:0031201~SNARE complex,GO:0031965~nuclear membrane,GO:0042641~actomyosin,GO:0043005~neuron projection,GO:0048787~presynaptic active zone membrane,GO:0070032~synaptobrevin 2-SNAP-25-syntaxin-1a-complexin I complex,GO:0070033~synaptobrevin 2-SNAP-25-syntaxin-1a-complexin II complex,GO:0070044~synaptobrevin 2-SNAP-25-syntaxin-1a complex,GO:0098978~glutamatergic synapse,GO:0099056~integral component of presynaptic membrane,	GO:0000149~SNARE binding,GO:0005484~SNAP receptor activity,GO:0005515~protein binding,GO:0019855~calcium channel inhibitor activity,GO:0019869~chloride channel inhibitor activity,GO:0019900~kinase binding,GO:0019904~protein domain specific binding,GO:0032028~myosin head/neck binding,GO:0042802~identical protein binding,GO:0043008~ATP-dependent protein binding,GO:0044325~ion channel binding,GO:0044877~macromolecular complex binding,GO:0047485~protein N-terminus binding,GO:0048306~calcium-dependent protein binding,	IPR000727:Target SNARE coiled-coil domain,IPR006011:Syntaxin, N-terminal,IPR006012:Syntaxin/epimorphin, conserved site,IPR010989:t-SNARE,	hsa04130:SNARE interactions in vesicular transport,hsa04721:Synaptic vesicle cycle,hsa04911:Insulin secretion,hsa05016:Huntington disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05031:Amphetamine addiction,			SM00397:t_SNARE,SM00503:SynN,	KW-0268~Exocytosis,KW-0532~Neurotransmitter transport,KW-0813~Transport,	KW-0472~Membrane,KW-0770~Synapse,KW-0771~Synaptosome,KW-0964~Secreted,KW-0965~Cell junction,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,	KW-0856~Williams-Beuren syndrome,	KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),DOMAIN:T-SNARE coiled-coil homology,DOMAIN:t-SNARE coiled-coil homology,MUTAGEN:K->R: Complete loss of sumoylation; when associated with R-252 and R-253.,MUTAGEN:K->R: Complete loss of sumoylation; when associated with R-252 and R-256.,MUTAGEN:K->R: Complete loss of sumoylation; when associated with R-253 and R-256.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Anchor for type IV membrane protein,
STX4	syntaxin 4(STX4)	Homo sapiens			Intracellular trafficking and secretion,	GO:0002639~positive regulation of immunoglobulin production,GO:0006886~intracellular protein transport,GO:0006887~exocytosis,GO:0006892~post-Golgi vesicle-mediated transport,GO:0006906~vesicle fusion,GO:0008284~positive regulation of cell proliferation,GO:0016192~vesicle-mediated transport,GO:0017157~regulation of exocytosis,GO:0019221~cytokine-mediated signaling pathway,GO:0030335~positive regulation of cell migration,GO:0031629~synaptic vesicle fusion to presynaptic active zone membrane,GO:0034394~protein localization to cell surface,GO:0034599~cellular response to oxidative stress,GO:0035493~SNARE complex assembly,GO:0035774~positive regulation of insulin secretion involved in cellular response to glucose stimulus,GO:0043085~positive regulation of catalytic activity,GO:0043311~positive regulation of eosinophil degranulation,GO:0045785~positive regulation of cell adhesion,GO:0048278~vesicle docking,GO:0048284~organelle fusion,GO:0050921~positive regulation of chemotaxis,GO:0060291~long-term synaptic potentiation,GO:0071346~cellular response to interferon-gamma,GO:1902041~regulation of extrinsic apoptotic signaling pathway via death domain receptors,GO:1903078~positive regulation of protein localization to plasma membrane,GO:1903575~cornified envelope assembly,GO:1990668~vesicle fusion with endoplasmic reticulum-Golgi intermediate compartment (ERGIC) membrane,GO:2000010~positive regulation of protein localization to cell surface,	GO:0000322~storage vacuole,GO:0005615~extracellular space,GO:0005768~endosome,GO:0005773~vacuole,GO:0005802~trans-Golgi network,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0008021~synaptic vesicle,GO:0009986~cell surface,GO:0012505~endomembrane system,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0030027~lamellipodium,GO:0030670~phagocytic vesicle membrane,GO:0031201~SNARE complex,GO:0032589~neuron projection membrane,GO:0035749~myelin sheath adaxonal region,GO:0036477~somatodendritic compartment,GO:0042581~specific granule,GO:0043197~dendritic spine,GO:0043219~lateral loop,GO:0045202~synapse,GO:0048471~perinuclear region of cytoplasm,GO:0048787~presynaptic active zone membrane,GO:0070062~extracellular exosome,GO:0098794~postsynapse,GO:0098978~glutamatergic synapse,	GO:0000149~SNARE binding,GO:0005484~SNAP receptor activity,GO:0005515~protein binding,GO:0016230~sphingomyelin phosphodiesterase activator activity,	IPR000727:Target SNARE coiled-coil domain,IPR006011:Syntaxin, N-terminal,IPR006012:Syntaxin/epimorphin, conserved site,IPR010989:t-SNARE,	hsa04130:SNARE interactions in vesicular transport,hsa04962:Vasopressin-regulated water reabsorption,			SM00397:t_SNARE,SM00503:SynN,	KW-0532~Neurotransmitter transport,KW-0813~Transport,	KW-0472~Membrane,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:SynN,DOMAIN:T-SNARE coiled-coil homology,DOMAIN:t-SNARE coiled-coil homology,REGION:Disordered,REGION:Interaction with CENPF,SITE:Required for neurite tip localization,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Anchor for type IV membrane protein,
STXBP1	syntaxin binding protein 1(STXBP1)	Homo sapiens			Intracellular trafficking and secretion,	GO:0002576~platelet degranulation,GO:0003006~developmental process involved in reproduction,GO:0006836~neurotransmitter transport,GO:0006886~intracellular protein transport,GO:0006904~vesicle docking involved in exocytosis,GO:0007269~neurotransmitter secretion,GO:0007274~neuromuscular synaptic transmission,GO:0007412~axon target recognition,GO:0010807~regulation of synaptic vesicle priming,GO:0015031~protein transport,GO:0016082~synaptic vesicle priming,GO:0016188~synaptic vesicle maturation,GO:0016192~vesicle-mediated transport,GO:0031333~negative regulation of protein complex assembly,GO:0031630~regulation of synaptic vesicle fusion to presynaptic membrane,GO:0032229~negative regulation of synaptic transmission, GABAergic,GO:0032355~response to estradiol,GO:0035493~SNARE complex assembly,GO:0035542~regulation of SNARE complex assembly,GO:0043306~positive regulation of mast cell degranulation,GO:0043524~negative regulation of neuron apoptotic process,GO:0045956~positive regulation of calcium ion-dependent exocytosis,GO:0050821~protein stabilization,GO:0060292~long term synaptic depression,GO:0070527~platelet aggregation,GO:0071346~cellular response to interferon-gamma,GO:0072659~protein localization to plasma membrane,GO:0099525~presynaptic dense core vesicle exocytosis,GO:1903296~positive regulation of glutamate secretion, neurotransmission,GO:2000367~regulation of acrosomal vesicle exocytosis,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0030141~secretory granule,GO:0030424~axon,GO:0031091~platelet alpha granule,GO:0032991~macromolecular complex,GO:0045335~phagocytic vesicle,GO:0048471~perinuclear region of cytoplasm,GO:0048787~presynaptic active zone membrane,GO:0070062~extracellular exosome,GO:0098794~postsynapse,GO:0098978~glutamatergic synapse,	GO:0000149~SNARE binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0017075~syntaxin-1 binding,GO:0019901~protein kinase binding,GO:0019904~protein domain specific binding,GO:0019905~syntaxin binding,GO:0042802~identical protein binding,GO:0043274~phospholipase binding,GO:0047485~protein N-terminus binding,	IPR001619:Sec1-like protein,IPR027482:Sec1-like, domain 2,	hsa04721:Synaptic vesicle cycle,	612164~Developmental and epileptic encephalopathy 4,	PIRSF005715:vesicle trafficking protein, VPS45/Sec1 type,		KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0887~Epilepsy,KW-0991~Mental retardation,				KW-0597~Phosphoprotein,
STXBP2	syntaxin binding protein 2(STXBP2)	Homo sapiens			Intracellular trafficking and secretion,	GO:0001909~leukocyte mediated cytotoxicity,GO:0002576~platelet degranulation,GO:0006886~intracellular protein transport,GO:0006904~vesicle docking involved in exocytosis,GO:0007269~neurotransmitter secretion,GO:0015031~protein transport,GO:0016192~vesicle-mediated transport,GO:0043304~regulation of mast cell degranulation,GO:0043312~neutrophil degranulation,	GO:0005576~extracellular region,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0030141~secretory granule,GO:0042581~specific granule,GO:0042582~azurophil granule,GO:0044194~cytolytic granule,GO:0070062~extracellular exosome,GO:0070820~tertiary granule,GO:0098793~presynapse,	GO:0005515~protein binding,GO:0017075~syntaxin-1 binding,GO:0019905~syntaxin binding,GO:0030348~syntaxin-3 binding,	IPR001619:Sec1-like protein,IPR027482:Sec1-like, domain 2,		613101~Hemophagocytic lymphohistiocytosis, familial, 5, with or without microvillus inclusion disease,	PIRSF005715:vesicle trafficking protein, VPS45/Sec1 type,		KW-0268~Exocytosis,KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,	KW-0225~Disease variant,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,				REGION:Disordered,TRANSMEM:Helical,
SNCA	synuclein alpha(SNCA)	Homo sapiens		h_parkinPathway:Role of Parkin in the Ubiquitin-Proteasomal Pathway,h_parkinsonsPathway:Alpha-synuclein and Parkin-mediated proteolysis in Parkinson's disease,		GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001774~microglial cell activation,GO:0001921~positive regulation of receptor recycling,GO:0001933~negative regulation of protein phosphorylation,GO:0001956~positive regulation of neurotransmitter secretion,GO:0001963~synaptic transmission, dopaminergic,GO:0006469~negative regulation of protein kinase activity,GO:0006631~fatty acid metabolic process,GO:0006638~neutral lipid metabolic process,GO:0006644~phospholipid metabolic process,GO:0006915~apoptotic process,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0007006~mitochondrial membrane organization,GO:0007268~chemical synaptic transmission,GO:0007568~aging,GO:0008344~adult locomotory behavior,GO:0009410~response to xenobiotic stimulus,GO:0010040~response to iron(II) ion,GO:0010517~regulation of phospholipase activity,GO:0010642~negative regulation of platelet-derived growth factor receptor signaling pathway,GO:0014048~regulation of glutamate secretion,GO:0014059~regulation of dopamine secretion,GO:0016079~synaptic vesicle exocytosis,GO:0016082~synaptic vesicle priming,GO:0022898~regulation of transmembrane transporter activity,GO:0031115~negative regulation of microtubule polymerization,GO:0031623~receptor internalization,GO:0031648~protein destabilization,GO:0032026~response to magnesium ion,GO:0032410~negative regulation of transporter activity,GO:0032496~response to lipopolysaccharide,GO:0032769~negative regulation of monooxygenase activity,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0034341~response to interferon-gamma,GO:0034599~cellular response to oxidative stress,GO:0035067~negative regulation of histone acetylation,GO:0035493~SNARE complex assembly,GO:0035543~positive regulation of SNARE complex assembly,GO:0040012~regulation of locomotion,GO:0042416~dopamine biosynthetic process,GO:0042493~response to drug,GO:0042775~mitochondrial ATP synthesis coupled electron transport,GO:0043030~regulation of macrophage activation,GO:0043065~positive regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043154~negative regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0043524~negative regulation of neuron apoptotic process,GO:0044344~cellular response to fibroblast growth factor stimulus,GO:0045807~positive regulation of endocytosis,GO:0045920~negative regulation of exocytosis,GO:0045921~positive regulation of exocytosis,GO:0045963~negative regulation of dopamine metabolic process,GO:0048148~behavioral response to cocaine,GO:0048169~regulation of long-term neuronal synaptic plasticity,GO:0048488~synaptic vesicle endocytosis,GO:0048489~synaptic vesicle transport,GO:0050729~positive regulation of inflammatory response,GO:0050808~synapse organization,GO:0050812~regulation of acyl-CoA biosynthetic process,GO:0051259~protein oligomerization,GO:0051262~protein tetramerization,GO:0051281~positive regulation of release of sequestered calcium ion into cytosol,GO:0051583~dopamine uptake involved in synaptic transmission,GO:0051585~negative regulation of dopamine uptake involved in synaptic transmission,GO:0051612~negative regulation of serotonin uptake,GO:0051621~regulation of norepinephrine uptake,GO:0051622~negative regulation of norepinephrine uptake,GO:0060079~excitatory postsynaptic potential,GO:0060291~long-term synaptic potentiation,GO:0060732~positive regulation of inositol phosphate biosynthetic process,GO:0070495~negative regulation of thrombin-activated receptor signaling pathway,GO:0070555~response to interleukin-1,GO:0071280~cellular response to copper ion,GO:0071872~cellular response to epinephrine stimulus,GO:0071902~positive regulation of protein serine/threonine kinase activity,GO:0097435~supramolecular fiber organization,GO:1901214~regulation of neuron death,GO:1901215~negative regulation of neuron death,GO:1901216~positive regulation of neuron death,GO:1902957~negative regulation of mitochondrial electron transport, NADH to ubiquinone,GO:1903284~positive regulation of glutathione peroxidase activity,GO:1903285~positive regulation of hydrogen peroxide catabolic process,GO:1903421~regulation of synaptic vesicle recycling,GO:1903426~regulation of reactive oxygen species biosynthetic process,GO:1904307~response to desipramine,GO:1904715~negative regulation of chaperone-mediated autophagy,GO:1905606~regulation of presynapse assembly,GO:1990000~amyloid fibril formation,GO:2000377~regulation of reactive oxygen species metabolic process,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005640~nuclear outer membrane,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005743~mitochondrial inner membrane,GO:0005758~mitochondrial intermembrane space,GO:0005759~mitochondrial matrix,GO:0005764~lysosome,GO:0005791~rough endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0005938~cell cortex,GO:0015629~actin cytoskeleton,GO:0016020~membrane,GO:0016234~inclusion body,GO:0030424~axon,GO:0030426~growth cone,GO:0030672~synaptic vesicle membrane,GO:0031092~platelet alpha granule membrane,GO:0032991~macromolecular complex,GO:0043025~neuronal cell body,GO:0043195~terminal bouton,GO:0043679~axon terminus,GO:0045202~synapse,GO:0048471~perinuclear region of cytoplasm,GO:0098794~postsynapse,GO:0099512~supramolecular fiber,	GO:0000149~SNARE binding,GO:0000287~magnesium ion binding,GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0003779~actin binding,GO:0004860~protein kinase inhibitor activity,GO:0005507~copper ion binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005543~phospholipid binding,GO:0008017~microtubule binding,GO:0008198~ferrous iron binding,GO:0008270~zinc ion binding,GO:0016491~oxidoreductase activity,GO:0019894~kinesin binding,GO:0019904~protein domain specific binding,GO:0030544~Hsp70 protein binding,GO:0042393~histone binding,GO:0042802~identical protein binding,GO:0043014~alpha-tubulin binding,GO:0043027~cysteine-type endopeptidase inhibitor activity involved in apoptotic process,GO:0043274~phospholipase binding,GO:0047485~protein N-terminus binding,GO:0048156~tau protein binding,GO:0048487~beta-tubulin binding,GO:0050544~arachidonic acid binding,GO:0051219~phosphoprotein binding,GO:0070840~dynein complex binding,GO:1903136~cuprous ion binding,	IPR001058:Synuclein,IPR002460:Alpha-synuclein,	hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05022:Pathways of neurodegeneration - multiple diseases,	127750~Dementia, Lewy body,168601~Parkinson disease 1,605543~Parkinson disease 4,				KW-0034~Amyloid,KW-0472~Membrane,KW-0539~Nucleus,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0964~Secreted,KW-0965~Cell junction,	KW-0026~Alzheimer disease,KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0907~Parkinson disease,KW-0908~Parkinsonism,	KW-0677~Repeat,	KW-0186~Copper,KW-0479~Metal-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Acidic residues,COMPBIAS:Polar residues,METAL:Copper,MUTAGEN:D->A: Impairs copper-binding.,MUTAGEN:E->K: Increases oligomerization.,MUTAGEN:E->K: No effect on oligomerization.,MUTAGEN:H->A: Impairs copper-binding.,MUTAGEN:Missing: Does not affect polymerization into amyloid fibrils.,MUTAGEN:Missing: Impairs polymerization into amyloid fibrils.,MUTAGEN:Missing: Reduces polymerization into amyloid fibrils.,MUTAGEN:Y->F: Abolishes osmotic stress-induced phosphorylation.,MUTAGEN:Y->F: No effect on osmotic stress-induced phosphorylation.,REGION:4 X 11 AA tandem repeats of [EGS]-K-T-K-[EQ]-[GQ]-V-X(4),REGION:Disordered,REGION:Interaction with SERF1A,REPEAT:1,REPEAT:2,REPEAT:3; approximate,REPEAT:4,
TSEN2	tRNA splicing endonuclease subunit 2(TSEN2)	Homo sapiens				GO:0000379~tRNA-type intron splice site recognition and cleavage,GO:0006388~tRNA splicing, via endonucleolytic cleavage and ligation,GO:0006397~mRNA processing,GO:0090502~RNA phosphodiester bond hydrolysis, endonucleolytic,	GO:0000214~tRNA-intron endonuclease complex,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005813~centrosome,GO:0005829~cytosol,	GO:0000213~tRNA-intron endonuclease activity,GO:0003676~nucleic acid binding,GO:0005515~protein binding,GO:0016829~lyase activity,	IPR006676:tRNA-splicing endonuclease,IPR006677:tRNA intron endonuclease, catalytic domain-like,IPR006678:tRNA intron endonuclease, N-terminal,IPR011856:tRNA endonuclease-like domain,IPR016589:tRNA-splicing endonuclease, SEN2 subunit,		612389~Pontocerebellar hypoplasia type 2B,	PIRSF011789:tRNA-splicing endonuclease, SEN2 subunit,		KW-0507~mRNA processing,KW-0819~tRNA processing,	KW-0539~Nucleus,	KW-0523~Neurodegeneration,KW-1021~Pontocerebellar hypoplasia,			KW-0255~Endonuclease,KW-0378~Hydrolase,KW-0456~Lyase,KW-0540~Nuclease,	KW-0597~Phosphoprotein,	DOMAIN:tRNA_int_endo,DOMAIN:tRNA_int_endo_N,REGION:Disordered,
TXLNA	taxilin alpha(TXLNA)	Homo sapiens		h_cytokinePathway:Cytokine Network,		GO:0006887~exocytosis,GO:0019221~cytokine-mediated signaling pathway,GO:0042113~B cell activation,	GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,	GO:0005515~protein binding,GO:0019905~syntaxin binding,	IPR026183:Taxilin family,					KW-0268~Exocytosis,			KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
TCTN1	tectonic family member 1(TCTN1)	Homo sapiens				GO:0001701~in utero embryonic development,GO:0001841~neural tube formation,GO:0008589~regulation of smoothened signaling pathway,GO:0021523~somatic motor neuron differentiation,GO:0021537~telencephalon development,GO:0021904~dorsal/ventral neural tube patterning,GO:0021956~central nervous system interneuron axonogenesis,GO:0030030~cell projection organization,GO:0060271~cilium assembly,GO:0097711~ciliary basal body docking,GO:1904491~protein localization to ciliary transition zone,	GO:0005615~extracellular space,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0016020~membrane,GO:0036038~MKS complex,		IPR011677:Domain of unknown function DUF1619,		614173~Joubert syndrome 13,			KW-0970~Cilium biogenesis/degradation,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,KW-0964~Secreted,KW-0966~Cell projection,	KW-0979~Joubert syndrome,KW-1186~Ciliopathy,	KW-0732~Signal,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:DUF1619,REGION:Disordered,
TERT	telomerase reverse transcriptase(TERT)	Homo sapiens		h_achPathway:Role of nicotinic acetylcholine receptors in the regulation of apoptosis,h_telPathway:Telomeres, Telomerase, Cellular Aging, and  Immortality,		GO:0000723~telomere maintenance,GO:0001172~transcription, RNA-templated,GO:0006278~RNA-dependent DNA biosynthetic process,GO:0007004~telomere maintenance via telomerase,GO:0007005~mitochondrion organization,GO:0010629~negative regulation of gene expression,GO:0022616~DNA strand elongation,GO:0030177~positive regulation of Wnt signaling pathway,GO:0030422~production of siRNA involved in RNA interference,GO:0031647~regulation of protein stability,GO:0032092~positive regulation of protein binding,GO:0042635~positive regulation of hair cycle,GO:0043524~negative regulation of neuron apoptotic process,GO:0045766~positive regulation of angiogenesis,GO:0046326~positive regulation of glucose import,GO:0046686~response to cadmium ion,GO:0051000~positive regulation of nitric-oxide synthase activity,GO:0070200~establishment of protein localization to telomere,GO:0071456~cellular response to hypoxia,GO:0071897~DNA biosynthetic process,GO:0090399~replicative senescence,GO:1900087~positive regulation of G1/S transition of mitotic cell cycle,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1903620~positive regulation of transdifferentiation,GO:1903704~negative regulation of production of siRNA involved in RNA interference,GO:1903799~negative regulation of production of miRNAs involved in gene silencing by miRNA,GO:1904707~positive regulation of vascular smooth muscle cell proliferation,GO:1904751~positive regulation of protein localization to nucleolus,GO:1904754~positive regulation of vascular associated smooth muscle cell migration,GO:1904837~beta-catenin-TCF complex assembly,GO:2000352~negative regulation of endothelial cell apoptotic process,GO:2000648~positive regulation of stem cell proliferation,GO:2000773~negative regulation of cellular senescence,GO:2001240~negative regulation of extrinsic apoptotic signaling pathway in absence of ligand,	GO:0000333~telomerase catalytic core complex,GO:0000781~chromosome, telomeric region,GO:0000783~nuclear telomere cap complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005697~telomerase holoenzyme complex,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016605~PML body,GO:0016607~nuclear speck,GO:0031379~RNA-directed RNA polymerase complex,GO:0042645~mitochondrial nucleoid,GO:1990572~TERT-RMRP complex,	GO:0000049~tRNA binding,GO:0001223~transcription coactivator binding,GO:0003677~DNA binding,GO:0003720~telomerase activity,GO:0003721~telomerase RNA reverse transcriptase activity,GO:0003723~RNA binding,GO:0003964~RNA-directed DNA polymerase activity,GO:0003968~RNA-directed 5'-3' RNA polymerase activity,GO:0005515~protein binding,GO:0008022~protein C-terminus binding,GO:0042162~telomeric DNA binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0046872~metal ion binding,GO:0047485~protein N-terminus binding,GO:0051087~chaperone binding,GO:0070034~telomerase RNA binding,GO:0098680~template-free RNA nucleotidyltransferase,	IPR000477:Reverse transcriptase,IPR003545:Telomere reverse transcriptase,IPR021891:Telomerase ribonucleoprotein complex - RNA-binding domain,	hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05200:Pathways in cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,	601626~Leukemia, acute myeloid,613989~Dyskeratosis congenita, autosomal dominant 2,613989~Dyskeratosis congenita, autosomal recessive 4,614742~Pulmonary fibrosis and/or bone marrow failure, telomere-related, 1,615134~Melanoma, cutaneous malignant, 9,		SM00975:SM00975,		KW-0158~Chromosome,KW-0539~Nucleus,KW-0779~Telomere,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-1011~Dyskeratosis congenita,	KW-0732~Signal,	KW-0460~Magnesium,KW-0479~Metal-binding,	KW-0238~DNA-binding,KW-0548~Nucleotidyltransferase,KW-0687~Ribonucleoprotein,KW-0695~RNA-directed DNA polymerase,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	DOMAIN:Reverse transcriptase,DOMAIN:Telomerase_RBD,METAL:Magnesium; catalytic,MOTIF:Bipartite nuclear localization signal,MOTIF:TFLY; involved in RNA binding,MUTAGEN:D->A: Loss of telomerase activity.,MUTAGEN:D->A: Loss of telomerase activity. In the absence of TR, no loss of binding to telomeric primers.,MUTAGEN:DD->AA: Loss of telomerase activity.,MUTAGEN:L->Y: Moderate reduction in telomerase activity, no change in repeat extension rate nor on nucleotide incorporation fidelity. Little further reduction in activity but 13.5-fold increase in nucleotide incorporation fidelity; when associated with M-867.,MUTAGEN:Q->A: About 80% loss of enzymatic activity. Greatly reduced incorporation of second nucleotide. Altered strength of binding to ssDNA. Little effect on repeat addition processivity, nor on TR interaction nor on protein levels.,MUTAGEN:Q->N: About 85% loss of enzymatic activity. Greatly reduced incorporation of second nucleotide. Altered strength of binding to ssDNA. No effect on protein levels nor on TR interaction.,MUTAGEN:Q->T: About 90% loss of enzymatic activity. Greatly reduced incorporation of second nucleotide. Altered strength of binding to ssDNA. No effect on protein levels nor on TR interaction.,MUTAGEN:R->A: Abolishes telomerase catalytic activity.,MUTAGEN:S->A: Abolishes phosphorylation by DYRK2.,MUTAGEN:V->A: About 75% reduction in telomerase activity, about 80% reduction in repeat reduction rate and 3.9-fold increase in nucleotide incorporation fidelity.,MUTAGEN:V->M: About 75% reduction in telomerase activity, about 50% reduction in repeat extension rate and 5.2-fold increase in nucleotide incorporation fidelity. Little further reduction in activity and 13.5-fold increase in nucleotide incorporation fidelity; when associated with Y-866.,MUTAGEN:V->T: Severe reduction in telomerase activity, about 50% reduction in repeat extension rate and 2.2-fold increase in nucleotide incorporation fidelity. No further reduction in activity but 2.8-fold increase in nucleotide incorporation fidelity; when associated with Y-866.,MUTAGEN:W->A: Defective in high-affinity TERC interactions.,MUTAGEN:WCGLL->AAAAA: Completely abolishes telomerase-mediated primer extension and reduced binding to short telomeric primers. Complete loss of catalytic activity but no further loss of binding to telomeric primers; when associated with 137-A--A-141.,MUTAGEN:WGLLL->AAAAA: Reduced catalytic activity and repeat addition processivity. Complete loss of catalytic activity but no loss of binding to telomeric primers; when associated with 930-A--A-934.,MUTAGEN:Y->F: Abolishes oxidative stress-induced phosphorylation and RAN binding. Impaired nuclear export and enhanced antiapoptotic activity against ROS-dependent apoptosis induction. Impaired interaction with PTPN11. No dephosphorylation by PTPN11.,REGION:CP motif,REGION:CTE,REGION:Disordered,REGION:GQ motif,REGION:Linker,REGION:Primer grip sequence,REGION:QFP motif,REGION:RNA-interacting domain 1,REGION:RNA-interacting domain 2,REGION:Required for oligomerization,REGION:Required for regulating specificity for telomeric DNA and for processivity for primer elongation,SITE:Required for nucleotide incorporation and primer extension rate,SITE:Required for optimal binding of telomeric ssDNA and incorporation of nucleotides at the second position of the template,
TES	testin LIM domain protein(TES)	Homo sapiens				GO:0008285~negative regulation of cell proliferation,GO:0042127~regulation of cell proliferation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0030054~cell junction,GO:0032991~macromolecular complex,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0045296~cadherin binding,GO:0046872~metal ion binding,	IPR001781:Zinc finger, LIM-type,IPR010442:PET domain,				SM00132:LIM,		KW-0963~Cytoplasm,KW-0965~Cell junction,		KW-0440~LIM domain,KW-0677~Repeat,	KW-0479~Metal-binding,KW-0862~Zinc,			COMPBIAS:Basic and acidic residues,DOMAIN:LIM zinc-binding,DOMAIN:LIM zinc-binding 1,DOMAIN:LIM zinc-binding 2,DOMAIN:LIM zinc-binding 3,DOMAIN:PET,MUTAGEN:C->A: Abolishes interaction with ACTL7A.,MUTAGEN:C->A: Abolishes localization at focal adhesions.,REGION:Disordered,
TESK1	testis associated actin remodelling kinase 1(TESK1)	Homo sapiens				GO:0001934~positive regulation of protein phosphorylation,GO:0007283~spermatogenesis,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0030036~actin cytoskeleton organization,GO:0031953~negative regulation of protein autophosphorylation,GO:0032880~regulation of protein localization,GO:0032956~regulation of actin cytoskeleton organization,GO:0042326~negative regulation of phosphorylation,GO:0051496~positive regulation of stress fiber assembly,GO:0051650~establishment of vesicle localization,GO:0071901~negative regulation of protein serine/threonine kinase activity,GO:0090521~glomerular visceral epithelial cell migration,GO:1900026~positive regulation of substrate adhesion-dependent cell spreading,GO:1900182~positive regulation of protein localization to nucleus,GO:1902018~negative regulation of cilium assembly,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0030027~lamellipodium,GO:0031410~cytoplasmic vesicle,GO:0048471~perinuclear region of cytoplasm,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008022~protein C-terminus binding,GO:0019901~protein kinase binding,GO:0046872~metal ion binding,	IPR000719:Protein kinase, catalytic domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR008266:Tyrosine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR015782:Testis-specific kinase 1,IPR017441:Protein kinase, ATP binding site,						KW-0206~Cytoskeleton,KW-0963~Cytoplasm,KW-0966~Cell projection,			KW-0067~ATP-binding,KW-0460~Magnesium,KW-0464~Manganese,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0488~Methylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:ATP,COMPBIAS:Pro residues,DOMAIN:Protein kinase,MUTAGEN:D->A: Abolishes inhibition of SPRY4-mediated repression of cell spreading. No effect on interaction with SPRY4 or colocalization with SPRY4 at vesicular spots in the cytoplasm.,NP_BIND:ATP,REGION:Disordered,REGION:Required for interaction with PARVA,REGION:Required for interaction with SPRED1 and SPRY2. Required for TESK1-mediated dephosphorylation of SPRY2 and SPRY2 inhibition of ERK phosphorylation,REGION:Required for interaction with YWHAB,
TEX10	testis expressed 10(TEX10)	Homo sapiens				GO:0006364~rRNA processing,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005739~mitochondrion,GO:0071339~MLL1 complex,	GO:0005515~protein binding,	IPR011989:Armadillo-like helical,IPR016024:Armadillo-type fold,IPR021133:HEAT, type 2,IPR024679:Pre-rRNA-processing protein IPI1/Testis-expressed sequence 10 protein,						KW-0539~Nucleus,KW-0963~Cytoplasm,					KW-0597~Phosphoprotein,	DOMAIN:Ipi1_N,REPEAT:HEAT,
TSPAN3	tetraspanin 3(TSPAN3)	Homo sapiens					GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0070062~extracellular exosome,		IPR000301:Tetraspanin,IPR008952:Tetraspanin, EC2 domain,IPR018499:Tetraspanin/Peripherin,IPR018503:Tetraspanin, conserved site,			PIRSF002419:tetraspanin,			KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TSPAN4	tetraspanin 4(TSPAN4)	Homo sapiens	73.Integrins_and_other_cell-surface_receptors,			GO:0065003~macromolecular complex assembly,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005925~focal adhesion,GO:0016021~integral component of membrane,GO:0031982~vesicle,	GO:0003823~antigen binding,GO:0005178~integrin binding,GO:0005515~protein binding,	IPR000301:Tetraspanin,IPR008952:Tetraspanin, EC2 domain,IPR018499:Tetraspanin/Peripherin,IPR018503:Tetraspanin, conserved site,			PIRSF002419:tetraspanin,			KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TSPAN6	tetraspanin 6(TSPAN6)	Homo sapiens				GO:0039532~negative regulation of viral-induced cytoplasmic pattern recognition receptor signaling pathway,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:1901223~negative regulation of NIK/NF-kappaB signaling,	GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0070062~extracellular exosome,	GO:0005515~protein binding,	IPR000301:Tetraspanin,IPR008952:Tetraspanin, EC2 domain,IPR018499:Tetraspanin/Peripherin,IPR018503:Tetraspanin, conserved site,			PIRSF002419:tetraspanin,			KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TXNDC9	thioredoxin domain containing 9(TXNDC9)	Homo sapiens				GO:0000226~microtubule cytoskeleton organization,GO:0006457~protein folding,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0030496~midbody,	GO:0005515~protein binding,GO:0045296~cadherin binding,	IPR013766:Thioredoxin domain,						KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	DOMAIN:Thioredoxin,
TXNL4B	thioredoxin like 4B(TXNL4B)	Homo sapiens				GO:0000398~mRNA splicing, via spliceosome,GO:0007049~cell cycle,	GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:0005682~U5 snRNP,GO:0005829~cytosol,GO:0046540~U4/U6 x U5 tri-snRNP complex,	GO:0005515~protein binding,	IPR004123:mRNA splicing factor, thioredoxin-like U5 snRNP,			PIRSF017199:thioredoxin-like protein, 4A/4B type,	SM01410:SM01410,	KW-0131~Cell cycle,KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,						REGION:Disordered,
TXNRD1	thioredoxin reductase 1(TXNRD1)	Homo sapiens				GO:0001707~mesoderm formation,GO:0001887~selenium compound metabolic process,GO:0007165~signal transduction,GO:0008283~cell proliferation,GO:0015949~nucleobase-containing small molecule interconversion,GO:0019222~regulation of metabolic process,GO:0034599~cellular response to oxidative stress,GO:0045454~cell redox homeostasis,GO:0098869~cellular oxidant detoxification,	GO:0001650~fibrillar center,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0004791~thioredoxin-disulfide reductase activity,GO:0005515~protein binding,GO:0015035~protein disulfide oxidoreductase activity,GO:0016491~oxidoreductase activity,GO:0016668~oxidoreductase activity, acting on a sulfur group of donors, NAD(P) as acceptor,GO:0050660~flavin adenine dinucleotide binding,GO:0097573~glutathione oxidoreductase activity,	IPR002109:Glutaredoxin,IPR003953:FAD binding domain,IPR004099:Pyridine nucleotide-disulphide oxidoreductase, dimerisation,IPR006338:Thioredoxin/glutathione reductase selenoprotein,IPR012999:Pyridine nucleotide-disulphide oxidoreductase, class I, active site,IPR016156:FAD/NAD-linked reductase, dimerisation,IPR023753:Pyridine nucleotide-disulphide oxidoreductase, FAD/NAD(P)-binding domain,	hsa00450:Selenocompound metabolism,hsa05200:Pathways in cancer,hsa05225:Hepatocellular carcinoma,		PIRSF000350:mercury(II) reductase, MerA type,		KW-0249~Electron transport,KW-0813~Transport,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0676~Redox-active center,	KW-0274~FAD,KW-0285~Flavoprotein,KW-0520~NAD,KW-0521~NADP,KW-0547~Nucleotide-binding,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,BINDING:FAD,BINDING:FAD; via amide nitrogen and carbonyl oxygen,BINDING:NAD; via amide nitrogen,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Cysteinyl-selenocysteine (Cys-Sec),DISULFID:Redox-active,DOMAIN:FAD_binding_2,DOMAIN:Glutaredoxin,DOMAIN:Pyr_redox_2,DOMAIN:Pyr_redox_dim,NON_STD:Selenocysteine,NP_BIND:FAD,NP_BIND:NAD,REGION:Disordered,
TBXA2R	thromboxane A2 receptor(TBXA2R)	Homo sapiens		h_eicosanoidPathway:Eicosanoid Metabolism,		GO:0006954~inflammatory response,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007584~response to nutrient,GO:0009410~response to xenobiotic stimulus,GO:0019932~second-messenger-mediated signaling,GO:0030194~positive regulation of blood coagulation,GO:0033574~response to testosterone,GO:0038193~thromboxane A2 signaling pathway,GO:0042493~response to drug,GO:0045471~response to ethanol,GO:0045766~positive regulation of angiogenesis,GO:0045777~positive regulation of blood pressure,GO:0045907~positive regulation of vasoconstriction,GO:0045987~positive regulation of smooth muscle contraction,GO:0050790~regulation of catalytic activity,GO:0071222~cellular response to lipopolysaccharide,GO:0090051~negative regulation of cell migration involved in sprouting angiogenesis,	GO:0001669~acrosomal vesicle,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0016607~nuclear speck,	GO:0004960~thromboxane receptor activity,GO:0004961~thromboxane A2 receptor activity,GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR001105:Thromboxane receptor,IPR008365:Prostanoid receptor,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04020:Calcium signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04611:Platelet activation,	614009~Bleeding disorder, platelet-type, 13, susceptibility to,				KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Pro residues,DOMAIN:G_PROTEIN_RECEP_F1_2,MUTAGEN:L->R: Suppresses antagonist binding.,MUTAGEN:R->Q: Reduces antagonist binding.,MUTAGEN:W->L: Reduces antagonist binding.,MUTAGEN:W->R: Reduces antagonist binding.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
TJP1	tight junction protein 1(TJP1)	Homo sapiens				GO:0007043~cell-cell junction assembly,GO:0008284~positive regulation of cell proliferation,GO:0030335~positive regulation of cell migration,GO:0031032~actomyosin structure organization,GO:0032496~response to lipopolysaccharide,GO:0034334~adherens junction maintenance,GO:0035329~hippo signaling,GO:0035633~maintenance of permeability of blood-brain barrier,GO:0042493~response to drug,GO:0043066~negative regulation of apoptotic process,GO:0043116~negative regulation of vascular permeability,GO:0045216~cell-cell junction organization,GO:0045471~response to ethanol,GO:0051493~regulation of cytoskeleton organization,GO:0051497~negative regulation of stress fiber assembly,GO:0071000~response to magnetism,GO:0071333~cellular response to glucose stimulus,GO:0071896~protein localization to adherens junction,GO:0090557~establishment of endothelial intestinal barrier,GO:0098609~cell-cell adhesion,GO:1901888~regulation of cell junction assembly,GO:1902396~protein localization to bicellular tight junction,GO:1903672~positive regulation of sprouting angiogenesis,GO:1905605~positive regulation of maintenance of permeability of blood-brain barrier,GO:2000049~positive regulation of cell-cell adhesion mediated by cadherin,GO:2000250~negative regulation of actin cytoskeleton reorganization,GO:2000810~regulation of bicellular tight junction assembly,	GO:0002102~podosome,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005912~adherens junction,GO:0005921~gap junction,GO:0005923~bicellular tight junction,GO:0016323~basolateral plasma membrane,GO:0030054~cell junction,GO:0032991~macromolecular complex,GO:0042995~cell projection,GO:0043296~apical junction complex,GO:0045177~apical part of cell,GO:0070160~occluding junction,	GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0008022~protein C-terminus binding,GO:0045296~cadherin binding,GO:0050839~cell adhesion molecule binding,	IPR000906:ZU5,IPR001452:Src homology-3 domain,IPR001478:PDZ domain,IPR005417:Zona occludens protein,IPR005418:Zona occludens protein ZO-1,IPR008144:Guanylate kinase,IPR008145:Guanylate kinase/L-type calcium channel,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04520:Adherens junction,hsa04530:Tight junction,hsa04540:Gap junction,hsa05110:Vibrio cholerae infection,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05130:Pathogenic Escherichia coli infection,			SM00072:GuKc,SM00218:ZU5,SM00228:PDZ,		KW-0303~Gap junction,KW-0472~Membrane,KW-0796~Tight junction,KW-0965~Cell junction,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0728~SH3 domain,		KW-0112~Calmodulin-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Guanylate kinase-like,DOMAIN:PDZ,DOMAIN:PDZ 1,DOMAIN:PDZ 2,DOMAIN:PDZ 3,DOMAIN:SH3,DOMAIN:ZU5,MUTAGEN:K->A: Abolishes interaction with GJA1.,MUTAGEN:MC->AA: Abolishes interaction with CDC42BPB.,MUTAGEN:Missing: Abolishes interaction with CDC42BPB and MYZAP.,MUTAGEN:R->A: Strongly reduced interaction with GJA1.,REGION:Actin-binding region (ABR),REGION:Disordered,REGION:Occludin (OCLN)-binding region,
TIMELESS	timeless circadian regulator(TIMELESS)	Homo sapiens				GO:0000076~DNA replication checkpoint,GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0002009~morphogenesis of an epithelium,GO:0006260~DNA replication,GO:0006281~DNA repair,GO:0006974~cellular response to DNA damage stimulus,GO:0007623~circadian rhythm,GO:0009582~detection of abiotic stimulus,GO:0030324~lung development,GO:0042752~regulation of circadian rhythm,GO:0043111~replication fork arrest,GO:0044770~cell cycle phase transition,GO:0045892~negative regulation of transcription, DNA-templated,GO:0048478~replication fork protection,GO:0048754~branching morphogenesis of an epithelial tube,GO:0051301~cell division,GO:0072711~cellular response to hydroxyurea,GO:0072719~cellular response to cisplatin,GO:1904976~cellular response to bleomycin,GO:1905168~positive regulation of double-strand break repair via homologous recombination,GO:2000781~positive regulation of double-strand break repair,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0031298~replication fork protection complex,GO:0035861~site of double-strand break,	GO:0003677~DNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR006906:Timeless protein,IPR007725:Timeless C-terminal,					KW-0090~Biological rhythms,KW-0131~Cell cycle,KW-0132~Cell division,KW-0227~DNA damage,KW-0234~DNA repair,KW-0498~Mitosis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0158~Chromosome,KW-0539~Nucleus,				KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,MUTAGEN:R->G: Abolishes interaction with PARP1.,REGION:Disordered,REGION:Interaction with PARP1,REGION:Required for homodimerization and for interaction with CRY1 and CHEK1,REGION:Required for nuclear localization,
TLR4	toll like receptor 4(TLR4)	Homo sapiens		h_dcPathway:Dendritic cells in regulating TH1 and TH2 Development,H_gsk3Pathway:Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar Macrophages,h_nfkbPathway:NF-kB Signaling Pathway,h_tollPathway:Toll-Like Receptor Pathway,	Function unknown,	GO:0000187~activation of MAPK activity,GO:0002218~activation of innate immune response,GO:0002224~toll-like receptor signaling pathway,GO:0002246~wound healing involved in inflammatory response,GO:0002322~B cell proliferation involved in immune response,GO:0002537~nitric oxide production involved in inflammatory response,GO:0002730~regulation of dendritic cell cytokine production,GO:0002755~MyD88-dependent toll-like receptor signaling pathway,GO:0002756~MyD88-independent toll-like receptor signaling pathway,GO:0006909~phagocytosis,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0007249~I-kappaB kinase/NF-kappaB signaling,GO:0007252~I-kappaB phosphorylation,GO:0010572~positive regulation of platelet activation,GO:0010628~positive regulation of gene expression,GO:0010838~positive regulation of keratinocyte proliferation,GO:0014002~astrocyte development,GO:0014911~positive regulation of smooth muscle cell migration,GO:0016046~detection of fungus,GO:0030890~positive regulation of B cell proliferation,GO:0031663~lipopolysaccharide-mediated signaling pathway,GO:0032496~response to lipopolysaccharide,GO:0032497~detection of lipopolysaccharide,GO:0032689~negative regulation of interferon-gamma production,GO:0032700~negative regulation of interleukin-17 production,GO:0032707~negative regulation of interleukin-23 production,GO:0032715~negative regulation of interleukin-6 production,GO:0032720~negative regulation of tumor necrosis factor production,GO:0032722~positive regulation of chemokine production,GO:0032727~positive regulation of interferon-alpha production,GO:0032728~positive regulation of interferon-beta production,GO:0032729~positive regulation of interferon-gamma production,GO:0032731~positive regulation of interleukin-1 beta production,GO:0032732~positive regulation of interleukin-1 production,GO:0032733~positive regulation of interleukin-10 production,GO:0032735~positive regulation of interleukin-12 production,GO:0032755~positive regulation of interleukin-6 production,GO:0032757~positive regulation of interleukin-8 production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0034128~negative regulation of MyD88-independent toll-like receptor signaling pathway,GO:0034142~toll-like receptor 4 signaling pathway,GO:0035666~TRIF-dependent toll-like receptor signaling pathway,GO:0036120~cellular response to platelet-derived growth factor stimulus,GO:0042088~T-helper 1 type immune response,GO:0042116~macrophage activation,GO:0042742~defense response to bacterium,GO:0043032~positive regulation of macrophage activation,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043406~positive regulation of MAP kinase activity,GO:0045087~innate immune response,GO:0045348~positive regulation of MHC class II biosynthetic process,GO:0045429~positive regulation of nitric oxide biosynthetic process,GO:0045671~negative regulation of osteoclast differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046330~positive regulation of JNK cascade,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0050729~positive regulation of inflammatory response,GO:0050829~defense response to Gram-negative bacterium,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051770~positive regulation of nitric-oxide synthase biosynthetic process,GO:0060729~intestinal epithelial structure maintenance,GO:0060907~positive regulation of macrophage cytokine production,GO:0070266~necroptotic process,GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0070430~positive regulation of nucleotide-binding oligomerization domain containing 1 signaling pathway,GO:0070434~positive regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway,GO:0071222~cellular response to lipopolysaccharide,GO:0071223~cellular response to lipoteichoic acid,GO:0071260~cellular response to mechanical stimulus,GO:0071346~cellular response to interferon-gamma,GO:0097190~apoptotic signaling pathway,GO:1900017~positive regulation of cytokine production involved in inflammatory response,GO:1900227~positive regulation of NLRP3 inflammasome complex assembly,GO:1901224~positive regulation of NIK/NF-kappaB signaling,GO:1903223~positive regulation of oxidative stress-induced neuron death,GO:1903428~positive regulation of reactive oxygen species biosynthetic process,GO:1903974~positive regulation of cellular response to macrophage colony-stimulating factor stimulus,GO:1904466~positive regulation of matrix metallopeptidase secretion,GO:1904646~cellular response to beta-amyloid,GO:2000343~positive regulation of chemokine (C-X-C motif) ligand 2 production,	GO:0001726~ruffle,GO:0001891~phagocytic cup,GO:0005737~cytoplasm,GO:0005769~early endosome,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0010008~endosome membrane,GO:0016021~integral component of membrane,GO:0031226~intrinsic component of plasma membrane,GO:0043235~receptor complex,GO:0046696~lipopolysaccharide receptor complex,GO:0048471~perinuclear region of cytoplasm,	GO:0001530~lipopolysaccharide binding,GO:0001540~beta-amyloid binding,GO:0001875~lipopolysaccharide receptor activity,GO:0004888~transmembrane signaling receptor activity,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0038023~signaling receptor activity,GO:0042802~identical protein binding,GO:0046982~protein heterodimerization activity,GO:0050135~NAD(P)+ nucleosidase activity,GO:0061809~NAD+ nucleotidase, cyclic ADP-ribose generating,	IPR000157:Toll/interleukin-1 receptor homology (TIR) domain,IPR000483:Cysteine-rich flanking region, C-terminal,IPR001611:Leucine-rich repeat,IPR003591:Leucine-rich repeat, typical subtype,IPR017241:Toll-like receptor,	hsa04064:NF-kappa B signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04145:Phagosome,hsa04151:PI3K-Akt signaling pathway,hsa04217:Necroptosis,hsa04613:Neutrophil extracellular trap formation,hsa04620:Toll-like receptor signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04936:Alcoholic liver disease,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05133:Pertussis,hsa05134:Legionellosis,hsa05135:Yersinia infection,hsa05140:Leishmaniasis,hsa05142:Chagas disease,hsa05144:Malaria,hsa05145:Toxoplasmosis,hsa05146:Amoebiasis,hsa05152:Tuberculosis,hsa05161:Hepatitis B,hsa05162:Measles,hsa05164:Influenza A,hsa05170:Human immunodeficiency virus 1 infection,hsa05171:Coronavirus disease - COVID-19,hsa05205:Proteoglycans in cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05321:Inflammatory bowel disease,hsa05323:Rheumatoid arthritis,hsa05417:Lipid and atherosclerosis,		PIRSF037595:toll-like receptor, 1/2/4/6/10 types [Parent=PIRSF800008],	SM00082:LRRCT,SM00255:TIR,SM00369:LRR_TYP,	KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,	KW-0472~Membrane,KW-0966~Cell projection,KW-0967~Endosome,KW-1003~Cell membrane,	KW-0913~Age-related macular degeneration,	KW-0433~Leucine-rich repeat,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0520~NAD,	KW-0378~Hydrolase,KW-0675~Receptor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:LRRCT,DOMAIN:TIR,MUTAGEN:D->K: Abolishes LPS-response.,MUTAGEN:E->R: Abolishes LPS-response.,MUTAGEN:H->A: Partially diminishes NF-kappa-B activation induced by Ni(2+). Strongly reduces NF-kappa-B activation induced by Ni(2+); when associated with A-431. Suppresses NF-kappa-B activation induced by Ni(2+); when associated with A-456.,MUTAGEN:H->A: Partially diminishes NF-kappa-B activation induced by Ni(2+). Strongly reduces NF-kappa-B activation induced by Ni(2+); when associated with A-431. Suppresses NF-kappa-B activation induced by Ni(2+); when associated with A-458.,MUTAGEN:H->A: Partially diminishes NF-kappa-B activation induced by Ni(2+). Strongly reduces NF-kappa-B activation induced by Ni(2+); when associated with A-456 or A-458.,MUTAGEN:N->A: Abolishes LPS-response and prevents the cell surface expression.,MUTAGEN:P->H,R,E: Abolishes MYD88-binding and LPS-response.,MUTAGEN:R->E: Abolishes LPS-response.,REPEAT:LRR 1,REPEAT:LRR 10,REPEAT:LRR 11,REPEAT:LRR 12,REPEAT:LRR 13,REPEAT:LRR 14,REPEAT:LRR 15,REPEAT:LRR 16,REPEAT:LRR 17,REPEAT:LRR 18,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,REPEAT:LRR 8,REPEAT:LRR 9,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TICAM1	toll like receptor adaptor molecule 1(TICAM1)	Homo sapiens				GO:0002281~macrophage activation involved in immune response,GO:0002735~positive regulation of myeloid dendritic cell cytokine production,GO:0002756~MyD88-independent toll-like receptor signaling pathway,GO:0006954~inflammatory response,GO:0007249~I-kappaB kinase/NF-kappaB signaling,GO:0010508~positive regulation of autophagy,GO:0010628~positive regulation of gene expression,GO:0016032~viral process,GO:0030890~positive regulation of B cell proliferation,GO:0031398~positive regulation of protein ubiquitination,GO:0031663~lipopolysaccharide-mediated signaling pathway,GO:0032092~positive regulation of protein binding,GO:0032722~positive regulation of chemokine production,GO:0032728~positive regulation of interferon-beta production,GO:0032755~positive regulation of interleukin-6 production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0032816~positive regulation of natural killer cell activation,GO:0034128~negative regulation of MyD88-independent toll-like receptor signaling pathway,GO:0034138~toll-like receptor 3 signaling pathway,GO:0035666~TRIF-dependent toll-like receptor signaling pathway,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043254~regulation of protein complex assembly,GO:0043330~response to exogenous dsRNA,GO:0045087~innate immune response,GO:0045429~positive regulation of nitric oxide biosynthetic process,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051607~defense response to virus,GO:0070266~necroptotic process,GO:0071222~cellular response to lipopolysaccharide,GO:0097190~apoptotic signaling pathway,GO:1900017~positive regulation of cytokine production involved in inflammatory response,	GO:0005739~mitochondrion,GO:0005776~autophagosome,GO:0005829~cytosol,GO:0010008~endosome membrane,GO:0097342~ripoptosome,	GO:0003953~NAD+ nucleosidase activity,GO:0005515~protein binding,GO:0019901~protein kinase binding,	IPR017278:Toll-interleukin I receptor domain-containing adaptor protein, Ticam,IPR025735:RHIM domain,	hsa04064:NF-kappa B signaling pathway,hsa04217:Necroptosis,hsa04620:Toll-like receptor signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04936:Alcoholic liver disease,hsa05133:Pertussis,hsa05135:Yersinia infection,hsa05142:Chagas disease,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05417:Lipid and atherosclerosis,	614850~Encephalopathy, acute, infection-induced (herpes-specific), susceptibility to, 6,	PIRSF037744:toll-interleukin I receptor domain-containing adaptor protein, Ticam type,		KW-0051~Antiviral defense,KW-0053~Apoptosis,KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,KW-0945~Host-virus interaction,	KW-0496~Mitochondrion,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,	KW-0225~Disease variant,				KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:TIR,MOTIF:TRAF6-binding,MOTIF:pLxIS motif,MUTAGEN:C->R: Complete loss of cleavage by HCV NS3/4A protease.,MUTAGEN:D->E: Resistant to caspase cleavage, no effect on TRIM38-mediated degradation; when associated with E-281.,MUTAGEN:D->E: Resistant to caspase cleavage, no effect on TRIM38-mediated degradation; when associated with E-289.,MUTAGEN:E->A: Loss of TCAM1-induced NF-kappa-B activation. Reduces interaction with TRAF6 and activation of NF-kappa-B signaling pathway; when associated with A-88 and A-303.,MUTAGEN:E->A: Loss of TCAM1-induced NF-kappa-B and IRF3 activation.,MUTAGEN:E->A: Reduces binding to TRAF6 and activation of NFKB signaling pathway; when associated with A-252 and A-303.,MUTAGEN:E->A: Reduces binding to TRAF6 and activation of NFKB signaling pathway; when associated with A-88 and A-252.,MUTAGEN:P->H: Abolishes interaction with TLR3.,MUTAGEN:Q->A: Complete loss of cleavage by CV3B; when associated with A-653; A-659 and A-671.,MUTAGEN:Q->A: Complete loss of cleavage by CV3B; when associated with A-653; A-659 and A-702.,MUTAGEN:Q->A: Complete loss of cleavage by CV3B; when associated with A-653; A-671 and A-702.,MUTAGEN:Q->A: Complete loss of cleavage by CV3B; when associated with A-659; A-671 and A-702.,MUTAGEN:Q->A: Complete loss of cleavage by Seneca Valley virus protease 3C.,MUTAGEN:Q->A: No effect on cleavage by Seneca Valley virus protease 3C.,MUTAGEN:Q->R: No cleavage by HAV 3CD.,MUTAGEN:S->A: Abolished interaction with IRF3.,MUTAGEN:S->A: Decreased interaction with IRF3.,MUTAGEN:SQSPT->AQAPA: Abolished ability to activate IRF3.,REGION:Disordered,REGION:Sufficient to induce apoptosis,REGION:TRIF-NTD,SITE:(Microbial infection) Cleavage by CV3B,SITE:(Microbial infection) Cleavage; by viral EV68 protease C,SITE:(Microbial infection) Cleavage; by viral HAV 3CD,SITE:(Microbial infection) Cleavage; by viral HCV NS3/4A,SITE:(Microbial infection) Cleavage; by viral Seneca Valley virus protease 3C,
TOR1A	torsin family 1 member A(TOR1A)	Homo sapiens				GO:0000338~protein deneddylation,GO:0006979~response to oxidative stress,GO:0006996~organelle organization,GO:0006998~nuclear envelope organization,GO:0007155~cell adhesion,GO:0031175~neuron projection development,GO:0034504~protein localization to nucleus,GO:0044319~wound healing, spreading of cells,GO:0045104~intermediate filament cytoskeleton organization,GO:0048489~synaptic vesicle transport,GO:0048499~synaptic vesicle membrane organization,GO:0051085~chaperone mediated protein folding requiring cofactor,GO:0051584~regulation of dopamine uptake involved in synaptic transmission,GO:0061077~chaperone-mediated protein folding,GO:0071712~ER-associated misfolded protein catabolic process,GO:0071763~nuclear membrane organization,GO:0072321~chaperone-mediated protein transport,GO:1900244~positive regulation of synaptic vesicle endocytosis,GO:2000008~regulation of protein localization to cell surface,	GO:0005635~nuclear envelope,GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0008021~synaptic vesicle,GO:0016020~membrane,GO:0030141~secretory granule,GO:0030426~growth cone,GO:0030659~cytoplasmic vesicle membrane,GO:0031965~nuclear membrane,GO:0042406~extrinsic component of endoplasmic reticulum membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0045202~synapse,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008092~cytoskeletal protein binding,GO:0016787~hydrolase activity,GO:0016887~ATPase activity,GO:0019894~kinesin binding,GO:0042802~identical protein binding,GO:0051082~unfolded protein binding,GO:0051787~misfolded protein binding,	IPR010448:Torsin,IPR017378:Torsin, subgroup,IPR027417:P-loop containing nucleoside triphosphate hydrolase,		128100~Dystonia-1, torsion,618947~Arthrogryposis multiplex congenita 5,Dystonia-1, modifier of~Dystonia-1, modifier of,	PIRSF038079:torsin,			KW-0206~Cytoskeleton,KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-0966~Cell projection,KW-0968~Cytoplasmic vesicle,	KW-0225~Disease variant,KW-1023~Dystonia,	KW-0732~Signal,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0143~Chaperone,KW-0378~Hydrolase,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) (high mannose) asparagine,MUTAGEN:A->F: Inhibits sequence signal cleavage.,MUTAGEN:E->Q: Loss of ATP hydrolysis. Loss of interaction with KLHL14. Localizes in the nuclear envelope. No effect on interaction with TOR1AIP1.,MUTAGEN:K->A: Loss of ATP-binding. No effect on interaction with KLHL14. Increases interaction with TOR1AIP1 and TOR1AIP2. Abolishes interaction with SLC6A3.,MUTAGEN:N->Q: Reduces N-glycosylation.,MUTAGEN:V->F: Inhibits sequence signal cleavage.,MUTAGEN:V->N: N-glycosylated.,NP_BIND:ATP,REGION:Interaction with KLC1,REGION:Interaction with SNAPIN,REGION:Interaction with SYNE3,
TLK2	tousled like kinase 2(TLK2)	Homo sapiens			Cell division and chromosome partitioning,	GO:0001672~regulation of chromatin assembly or disassembly,GO:0006325~chromatin organization,GO:0006468~protein phosphorylation,GO:0006974~cellular response to DNA damage stimulus,GO:0007049~cell cycle,GO:0007059~chromosome segregation,GO:0010507~negative regulation of autophagy,GO:0018105~peptidyl-serine phosphorylation,GO:0032435~negative regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0035556~intracellular signal transduction,GO:0071480~cellular response to gamma radiation,	GO:0005634~nucleus,GO:0005882~intermediate filament,GO:0048471~perinuclear region of cytoplasm,	GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0042802~identical protein binding,	IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,IPR027086:Serine/threonine-protein kinase TOUSLED-like,		618050~Mental retardation, autosomal dominant 57,		SM00220:S_TKc,	KW-0131~Cell cycle,KW-0227~DNA damage,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0991~Mental retardation,	KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0156~Chromatin regulator,KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:ATP,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Protein kinase,MUTAGEN:D->A: Loss of kinase activity.,NP_BIND:ATP,REGION:Disordered,
TRAK2	trafficking kinesin protein 2(TRAK2)	Homo sapiens				GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006493~protein O-linked glycosylation,GO:0006605~protein targeting,GO:0008333~endosome to lysosome transport,GO:0022008~neurogenesis,GO:0047496~vesicle transport along microtubule,GO:0048311~mitochondrion distribution,GO:0048813~dendrite morphogenesis,GO:0050771~negative regulation of axonogenesis,GO:0098957~anterograde axonal transport of mitochondrion,GO:0098972~anterograde dendritic transport of mitochondrion,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005769~early endosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0030425~dendrite,GO:0031410~cytoplasmic vesicle,GO:0032839~dendrite cytoplasm,GO:0043025~neuronal cell body,GO:0044295~axonal growth cone,GO:1904115~axon cytoplasm,	GO:0005102~receptor binding,GO:0005515~protein binding,GO:0017022~myosin binding,GO:0019894~kinesin binding,GO:0019899~enzyme binding,GO:0030911~TPR domain binding,GO:0050811~GABA receptor binding,	IPR006933:HAP1, N-terminal,IPR022154:Trafficking kinesin-binding protein domain,	hsa04727:GABAergic synapse,				KW-0813~Transport,	KW-0496~Mitochondrion,KW-0963~Cytoplasm,KW-0967~Endosome,		KW-0175~Coiled coil,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:HAP1 N-terminal,DOMAIN:Milton,REGION:Disordered,REGION:Interaction with HGS,
TRAPPC3	trafficking protein particle complex subunit 3(TRAPPC3)	Homo sapiens				GO:0006888~ER to Golgi vesicle-mediated transport,GO:0006891~intra-Golgi vesicle-mediated transport,GO:0048193~Golgi vesicle transport,GO:0048208~COPII vesicle coating,	GO:0000139~Golgi membrane,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0030008~TRAPP complex,GO:0033106~cis-Golgi network membrane,	GO:0005515~protein binding,	IPR007194:Transport protein particle (TRAPP) component,IPR016721:TRAPP I complex, Bet3,IPR024096:NO signalling/Golgi transport  ligand-binding domain,			PIRSF018293:TRAPP I complex, Bet3 subunit,		KW-0813~Transport,KW-0931~ER-Golgi transport,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,					KW-0449~Lipoprotein,KW-0564~Palmitate,	LIPID:S-palmitoyl cysteine,MUTAGEN:C->S: Loss of palmitoylation.,MUTAGEN:DYE->KVR: Impairs interaction with TRAPPC1.,
TRAPPC6A	trafficking protein particle complex subunit 6A(TRAPPC6A)	Homo sapiens				GO:0006888~ER to Golgi vesicle-mediated transport,GO:0043087~regulation of GTPase activity,GO:0048193~Golgi vesicle transport,GO:0048208~COPII vesicle coating,GO:1903232~melanosome assembly,	GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005801~cis-Golgi network,GO:0005802~trans-Golgi network,GO:0005829~cytosol,GO:0030008~TRAPP complex,	GO:0005515~protein binding,	IPR007194:Transport protein particle (TRAPP) component,IPR024096:NO signalling/Golgi transport  ligand-binding domain,					KW-0813~Transport,KW-0931~ER-Golgi transport,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,					KW-0597~Phosphoprotein,
TCEAL4	transcription elongation factor A like 4(TCEAL4)	Homo sapiens					GO:0005634~nucleus,	GO:0003746~translation elongation factor activity,GO:0005515~protein binding,GO:0050699~WW domain binding,	IPR021156:Transcription elongation factor A-like/Brain expressed X-linked-like,					KW-0648~Protein biosynthesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0251~Elongation factor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,REGION:Disordered,
TCEA2	transcription elongation factor A2(TCEA2)	Homo sapiens				GO:0006351~transcription, DNA-templated,GO:0006354~DNA-templated transcription, elongation,GO:0006355~regulation of transcription, DNA-templated,GO:0032784~regulation of DNA-templated transcription, elongation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005813~centrosome,GO:0008023~transcription elongation factor complex,	GO:0003676~nucleic acid binding,GO:0003677~DNA binding,GO:0003746~translation elongation factor activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,	IPR001222:Zinc finger, TFIIS-type,IPR003617:Transcription elongation factor, TFIIS/CRSP70, N-terminal, sub-type,IPR003618:Transcription elongation factor S-II, central domain,IPR006289:Transcription elongation factor, TFIIS,IPR017923:Transcription factor IIS, N-terminal,			PIRSF006704:transcription elongation factor, IIS type,	SM00440:ZnF_C2C2,SM00509:TFS2N,SM00510:TFS2M,	KW-0648~Protein biosynthesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0251~Elongation factor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:TFIIS N-terminal,DOMAIN:TFIIS central,DOMAIN:TFIIS-type,METAL:Zinc,REGION:Disordered,ZN_FING:TFIIS-type,
TCERG1	transcription elongation regulator 1(TCERG1)	Homo sapiens				GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006397~mRNA processing,GO:0008380~RNA splicing,GO:0032968~positive regulation of transcription elongation from RNA polymerase II promoter,GO:0034244~negative regulation of transcription elongation from RNA polymerase II promoter,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016607~nuclear speck,	GO:0001103~RNA polymerase II repressing transcription factor binding,GO:0003712~transcription cofactor activity,GO:0003713~transcription coactivator activity,GO:0003714~transcription corepressor activity,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0044390~ubiquitin-like protein conjugating enzyme binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0070063~RNA polymerase binding,	IPR001202:WW domain,IPR002713:FF domain,	hsa03040:Spliceosome,			SM00441:FF,SM00456:WW,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0175~Coiled coil,KW-0677~Repeat,		KW-0010~Activator,KW-0678~Repressor,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:FF,DOMAIN:FF 1,DOMAIN:FF 2,DOMAIN:FF 3,DOMAIN:FF 4,DOMAIN:FF 5,DOMAIN:FF 6,DOMAIN:WW,DOMAIN:WW 1,DOMAIN:WW 2,DOMAIN:WW 3,MOTIF:Nuclear localization signal,MUTAGEN:FFY->AAA: No effect.,MUTAGEN:YYY->AAA: Loss of interaction with SF1. Reduces repression of transcription by 35%. Reduces repression of transcription by 63%; when associated with 148-AAA-150.,MUTAGEN:YYY->AAA: Reduces repression of transcription by 35%. Reduces repression of transcription by 63%; when associated with 446-AAA-448.,REGION:Disordered,
TFAP2A	transcription factor AP-2 alpha(TFAP2A)	Homo sapiens				GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001822~kidney development,GO:0003404~optic vesicle morphogenesis,GO:0003409~optic cup structural organization,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007605~sensory perception of sound,GO:0008285~negative regulation of cell proliferation,GO:0010628~positive regulation of gene expression,GO:0010842~retina layer formation,GO:0010944~negative regulation of transcription by competitive promoter binding,GO:0021559~trigeminal nerve development,GO:0021623~oculomotor nerve formation,GO:0030501~positive regulation of bone mineralization,GO:0035115~embryonic forelimb morphogenesis,GO:0042127~regulation of cell proliferation,GO:0042472~inner ear morphogenesis,GO:0043066~negative regulation of apoptotic process,GO:0043525~positive regulation of neuron apoptotic process,GO:0045595~regulation of cell differentiation,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048701~embryonic cranial skeleton morphogenesis,GO:0048856~anatomical structure development,GO:0060021~palate development,GO:0060349~bone morphogenesis,GO:0061029~eyelid development in camera-type eye,GO:0070172~positive regulation of tooth mineralization,GO:0071281~cellular response to iron ion,GO:2000378~negative regulation of reactive oxygen species metabolic process,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR004979:Transcription factor AP-2,IPR008121:Transcription factor AP-2 alpha, N-terminal,IPR013854:Transcription factor AP-2, C-terminal,		113620~Branchiooculofacial syndrome,			KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,			KW-0010~Activator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:TF_AP-2,MOTIF:PPxY motif,MUTAGEN:S->A: No phosphorylation.,REGION:Disordered,REGION:H-S-H (helix-span-helix), dimerization,
TFDP1	transcription factor Dp-1(TFDP1)	Homo sapiens		h_cellcyclePathway:Cyclins and Cell Cycle Regulation,h_fbw7Pathway:Cyclin E Destruction Pathway,h_g1Pathway:Cell Cycle: G1/S Check Point ,h_p27Pathway:Regulation of p27 Phosphorylation during Cell Cycle Progression,h_raccycdPathway:Influence of Ras and Rho proteins on G1 to S Transition,h_skp2e2fPathway:E2F1 Destruction Pathway,		GO:0000083~regulation of transcription involved in G1/S transition of mitotic cell cycle,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0006977~DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest,GO:0008544~epidermis development,GO:0043276~anoikis,GO:0043433~negative regulation of sequence-specific DNA binding transcription factor activity,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0051726~regulation of cell cycle,GO:0070317~negative regulation of G0 to G1 transition,GO:0070345~negative regulation of fat cell proliferation,GO:1900087~positive regulation of G1/S transition of mitotic cell cycle,GO:1900740~positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway,GO:2000278~regulation of DNA biosynthetic process,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0035189~Rb-E2F complex,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0000987~core promoter proximal region sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0019904~protein domain specific binding,	IPR003316:Transcription factor E2F/dimerisation partner (TDP),IPR014889:Transcription factor DP, C-terminal,IPR015648:Transcription factor DP,	hsa04110:Cell cycle,hsa04350:TGF-beta signaling pathway,		PIRSF009404:transcription factor DP,	SM01138:SM01138,SM01372:SM01372,	KW-0131~Cell cycle,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,		KW-0010~Activator,KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:DP,DOMAIN:E2F_TDP,MOTIF:DEF box,REGION:DCB1,REGION:DCB2,REGION:Dimerization,REGION:Disordered,REGION:Enhances binding of RB protein to E2F,REGION:Interaction with CEBPA,
TCFL5	transcription factor like 5(TCFL5)	Homo sapiens				GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006355~regulation of transcription, DNA-templated,GO:0006366~transcription from RNA polymerase II promoter,GO:0007275~multicellular organism development,GO:0007283~spermatogenesis,GO:0030154~cell differentiation,GO:0042127~regulation of cell proliferation,GO:0045595~regulation of cell differentiation,	GO:0000785~chromatin,GO:0001673~male germ cell nucleus,GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0046983~protein dimerization activity,GO:1990837~sequence-specific double-stranded DNA binding,	IPR011598:Myc-type, basic helix-loop-helix (bHLH) domain,				SM00353:HLH,	KW-0221~Differentiation,KW-0744~Spermatogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:BHLH,DOMAIN:bHLH,REGION:Disordered,REGION:R1 epitope (recognized by Chagas's antibodies),REGION:R3 epitope (recognized by Chagas's antibodies),
TGFB3	transforming growth factor beta 3(TGFB3)	Homo sapiens		h_alkPathway:ALK in cardiac myocytes,h_ctcfPathway:CTCF: First Multivalent Nuclear Factor,h_erythPathway:Erythrocyte Differentiation Pathway,h_g1Pathway:Cell Cycle: G1/S Check Point ,h_il1rPathway:Signal transduction through IL1R,h_inflamPathway:Cytokines and Inflammatory Response,h_mapkPathway:MAPKinase Signaling Pathway,h_nktPathway:Selective expression of chemokine receptors during T-cell polarization,h_p38mapkPathway:p38 MAPK Signaling Pathway ,h_slrp2Pathway:Function of SLRP in Bone: An Integrated View,h_tgfbPathway:TGF beta signaling pathway,h_tob1Pathway:Role of Tob in T-cell activation,		GO:0000187~activation of MAPK activity,GO:0001666~response to hypoxia,GO:0001701~in utero embryonic development,GO:0002576~platelet degranulation,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0007435~salivary gland morphogenesis,GO:0007565~female pregnancy,GO:0007568~aging,GO:0008284~positive regulation of cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0010862~positive regulation of pathway-restricted SMAD protein phosphorylation,GO:0010936~negative regulation of macrophage cytokine production,GO:0030501~positive regulation of bone mineralization,GO:0030509~BMP signaling pathway,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0030879~mammary gland development,GO:0032570~response to progesterone,GO:0032967~positive regulation of collagen biosynthetic process,GO:0034616~response to laminar fluid shear stress,GO:0042060~wound healing,GO:0042127~regulation of cell proliferation,GO:0042476~odontogenesis,GO:0042704~uterine wall breakdown,GO:0043065~positive regulation of apoptotic process,GO:0043410~positive regulation of MAPK cascade,GO:0043524~negative regulation of neuron apoptotic process,GO:0043627~response to estrogen,GO:0043932~ossification involved in bone remodeling,GO:0045216~cell-cell junction organization,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048286~lung alveolus development,GO:0048565~digestive tract development,GO:0048702~embryonic neurocranium morphogenesis,GO:0048839~inner ear development,GO:0050714~positive regulation of protein secretion,GO:0051491~positive regulation of filopodium assembly,GO:0051496~positive regulation of stress fiber assembly,GO:0051781~positive regulation of cell division,GO:0060325~face morphogenesis,GO:0060364~frontal suture morphogenesis,GO:0060391~positive regulation of SMAD protein import into nucleus,GO:0060395~SMAD protein signal transduction,GO:0070483~detection of hypoxia,GO:1904706~negative regulation of vascular smooth muscle cell proliferation,GO:1905075~positive regulation of occluding junction disassembly,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0030141~secretory granule,GO:0030315~T-tubule,GO:0031093~platelet alpha granule lumen,GO:0043025~neuronal cell body,GO:0043231~intracellular membrane-bounded organelle,	GO:0005114~type II transforming growth factor beta receptor binding,GO:0005125~cytokine activity,GO:0005160~transforming growth factor beta receptor binding,GO:0005515~protein binding,GO:0008083~growth factor activity,GO:0034713~type I transforming growth factor beta receptor binding,GO:0034714~type III transforming growth factor beta receptor binding,GO:0042802~identical protein binding,GO:0044877~macromolecular complex binding,GO:0050431~transforming growth factor beta binding,	IPR001111:Transforming growth factor-beta, N-terminal,IPR001839:Transforming growth factor-beta, C-terminal,IPR015615:Transforming growth factor-beta-related,IPR015618:Transforming growth factor beta 3,IPR016319:Transforming growth factor-beta,IPR017948:Transforming growth factor beta, conserved site,	hsa04010:MAPK signaling pathway,hsa04060:Cytokine-cytokine receptor interaction,hsa04068:FoxO signaling pathway,hsa04110:Cell cycle,hsa04218:Cellular senescence,hsa04350:TGF-beta signaling pathway,hsa04390:Hippo signaling pathway,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa05140:Leishmaniasis,hsa05142:Chagas disease,hsa05144:Malaria,hsa05145:Toxoplasmosis,hsa05146:Amoebiasis,hsa05152:Tuberculosis,hsa05161:Hepatitis B,hsa05166:Human T-cell leukemia virus 1 infection,hsa05200:Pathways in cancer,hsa05210:Colorectal cancer,hsa05211:Renal cell carcinoma,hsa05212:Pancreatic cancer,hsa05220:Chronic myeloid leukemia,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,hsa05321:Inflammatory bowel disease,hsa05323:Rheumatoid arthritis,hsa05410:Hypertrophic cardiomyopathy,hsa05414:Dilated cardiomyopathy,hsa05415:Diabetic cardiomyopathy,	107970~Arrhythmogenic right ventricular dysplasia 1,615582~Loeys-Dietz syndrome 5,	PIRSF001787:transforming growth factor-beta [Parent=PIRSF800009],	SM00204:TGFB,		KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0122~Cardiomyopathy,KW-0225~Disease variant,	KW-0732~Signal,		KW-0339~Growth factor,KW-0497~Mitogen,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0488~Methylation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DISULFID:Interchain,DOMAIN:TGF_BETA_2,DOMAIN:TGFb_propeptide,MOTIF:Cell attachment site,MUTAGEN:Q->R: Abolishes methylation by N6AMT1.,REGION:Disordered,
TGFBR2	transforming growth factor beta receptor 2(TGFBR2)	Homo sapiens		h_alkPathway:ALK in cardiac myocytes,h_ctcfPathway:CTCF: First Multivalent Nuclear Factor,h_nthiPathway:NFkB activation by Nontypeable Hemophilus influenzae,h_tgfbPathway:TGF beta signaling pathway,h_tob1Pathway:Role of Tob in T-cell activation,		GO:0001568~blood vessel development,GO:0001569~branching involved in blood vessel morphogenesis,GO:0001570~vasculogenesis,GO:0001666~response to hypoxia,GO:0001701~in utero embryonic development,GO:0001947~heart looping,GO:0002053~positive regulation of mesenchymal cell proliferation,GO:0002088~lens development in camera-type eye,GO:0002651~positive regulation of tolerance induction to self antigen,GO:0002663~positive regulation of B cell tolerance induction,GO:0002666~positive regulation of T cell tolerance induction,GO:0003148~outflow tract septum morphogenesis,GO:0003149~membranous septum morphogenesis,GO:0003151~outflow tract morphogenesis,GO:0003181~atrioventricular valve morphogenesis,GO:0003186~tricuspid valve morphogenesis,GO:0003214~cardiac left ventricle morphogenesis,GO:0003274~endocardial cushion fusion,GO:0003430~growth plate cartilage chondrocyte growth,GO:0006468~protein phosphorylation,GO:0006898~receptor-mediated endocytosis,GO:0006915~apoptotic process,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0007182~common-partner SMAD protein phosphorylation,GO:0007219~Notch signaling pathway,GO:0007224~smoothened signaling pathway,GO:0007369~gastrulation,GO:0007420~brain development,GO:0007507~heart development,GO:0007566~embryo implantation,GO:0007568~aging,GO:0007584~response to nutrient,GO:0008284~positive regulation of cell proliferation,GO:0009410~response to xenobiotic stimulus,GO:0009612~response to mechanical stimulus,GO:0009749~response to glucose,GO:0010468~regulation of gene expression,GO:0010634~positive regulation of epithelial cell migration,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0010862~positive regulation of pathway-restricted SMAD protein phosphorylation,GO:0018105~peptidyl-serine phosphorylation,GO:0018107~peptidyl-threonine phosphorylation,GO:0030154~cell differentiation,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0031100~animal organ regeneration,GO:0032147~activation of protein kinase activity,GO:0032924~activin receptor signaling pathway,GO:0035162~embryonic hemopoiesis,GO:0040008~regulation of growth,GO:0042060~wound healing,GO:0042127~regulation of cell proliferation,GO:0042493~response to drug,GO:0043011~myeloid dendritic cell differentiation,GO:0043415~positive regulation of skeletal muscle tissue regeneration,GO:0043627~response to estrogen,GO:0045766~positive regulation of angiogenesis,GO:0048545~response to steroid hormone,GO:0048565~digestive tract development,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0048701~embryonic cranial skeleton morphogenesis,GO:0051138~positive regulation of NK T cell differentiation,GO:0060044~negative regulation of cardiac muscle cell proliferation,GO:0060389~pathway-restricted SMAD protein phosphorylation,GO:0060412~ventricular septum morphogenesis,GO:0060434~bronchus morphogenesis,GO:0060440~trachea formation,GO:0060443~mammary gland morphogenesis,GO:0060463~lung lobe morphogenesis,GO:0070723~response to cholesterol,GO:0071363~cellular response to growth factor stimulus,GO:1905007~positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formation,GO:1905317~inferior endocardial cushion morphogenesis,GO:1990086~lens fiber cell apoptotic process,GO:1990428~miRNA transport,GO:2000379~positive regulation of reactive oxygen species metabolic process,GO:2000563~positive regulation of CD4-positive, alpha-beta T cell proliferation,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005901~caveola,GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,GO:0043235~receptor complex,GO:0045121~membrane raft,GO:0070021~transforming growth factor beta1-type II receptor-type I receptor complex,	GO:0004674~protein serine/threonine kinase activity,GO:0004675~transmembrane receptor protein serine/threonine kinase activity,GO:0005024~transforming growth factor beta-activated receptor activity,GO:0005026~transforming growth factor beta receptor activity, type II,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0005539~glycosaminoglycan binding,GO:0017002~activin-activated receptor activity,GO:0031435~mitogen-activated protein kinase kinase kinase binding,GO:0034713~type I transforming growth factor beta receptor binding,GO:0034714~type III transforming growth factor beta receptor binding,GO:0046332~SMAD binding,GO:0046872~metal ion binding,GO:0048185~activin binding,GO:0050431~transforming growth factor beta binding,	IPR000333:Activin type II/Transforming growth factor-beta II receptor,IPR000719:Protein kinase, catalytic domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR015013:Transforming growth factor beta receptor 2 ectodomain,IPR017194:Transforming growth factor-beta receptor, type II,IPR017441:Protein kinase, ATP binding site,	hsa04010:MAPK signaling pathway,hsa04060:Cytokine-cytokine receptor interaction,hsa04068:FoxO signaling pathway,hsa04144:Endocytosis,hsa04218:Cellular senescence,hsa04350:TGF-beta signaling pathway,hsa04380:Osteoclast differentiation,hsa04390:Hippo signaling pathway,hsa04520:Adherens junction,hsa04659:Th17 cell differentiation,hsa04926:Relaxin signaling pathway,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa05142:Chagas disease,hsa05161:Hepatitis B,hsa05166:Human T-cell leukemia virus 1 infection,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05210:Colorectal cancer,hsa05212:Pancreatic cancer,hsa05220:Chronic myeloid leukemia,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,hsa05415:Diabetic cardiomyopathy,	133239~Esophageal cancer, somatic,610168~Loeys-Dietz syndrome 2,614331~Colorectal cancer, hereditary nonpolyposis, type 6,	PIRSF037393:transforming growth factor-beta receptor, type II,	SM00220:S_TKc,	KW-0053~Apoptosis,KW-0221~Differentiation,KW-0341~Growth regulation,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0362~Hereditary nonpolyposis colorectal cancer,KW-0989~Craniosynostosis,KW-0993~Aortic aneurysm,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0460~Magnesium,KW-0464~Manganese,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0675~Receptor,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,BINDING:ATP,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Protein kinase,DOMAIN:ecTbetaR2,MUTAGEN:K->R: Abolishes kinase activity, TGF-beta signaling and interaction with DAXX.,NP_BIND:ATP,REGION:Sufficient for interaction with CLU,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TIMM17B	translocase of inner mitochondrial membrane 17B(TIMM17B)	Homo sapiens				GO:0006626~protein targeting to mitochondrion,GO:0030150~protein import into mitochondrial matrix,	GO:0005743~mitochondrial inner membrane,GO:0005744~mitochondrial inner membrane presequence translocase complex,GO:0016021~integral component of membrane,GO:0031305~integral component of mitochondrial inner membrane,	GO:0005515~protein binding,GO:0008320~protein transmembrane transporter activity,	IPR005678:Mitochondrial inner membrane translocase complex, subunit Tim17,					KW-0653~Protein transport,KW-0811~Translocation,KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-1015~Disulfide bond,	COMPBIAS:Basic and acidic residues,REGION:Disordered,TRANSMEM:Helical,
TIMM22	translocase of inner mitochondrial membrane 22(TIMM22)	Homo sapiens				GO:0006626~protein targeting to mitochondrion,GO:0045039~protein import into mitochondrial inner membrane,GO:0071806~protein transmembrane transport,	GO:0005743~mitochondrial inner membrane,GO:0016021~integral component of membrane,GO:0042721~mitochondrial inner membrane protein insertion complex,	GO:0005515~protein binding,GO:0008320~protein transmembrane transporter activity,GO:0030943~mitochondrion targeting sequence binding,			618851~Combined oxidative phosphorylation deficiency 43,			KW-0653~Protein transport,KW-0811~Translocation,KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,	KW-0225~Disease variant,KW-1274~Primary mitochondrial disease,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-1015~Disulfide bond,	TRANSMEM:Helical,
TIMM9	translocase of inner mitochondrial membrane 9(TIMM9)	Homo sapiens				GO:0006626~protein targeting to mitochondrion,GO:0007605~sensory perception of sound,GO:0045039~protein import into mitochondrial inner membrane,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005758~mitochondrial intermembrane space,GO:0042719~mitochondrial intermembrane space protein transporter complex,GO:0042721~mitochondrial inner membrane protein insertion complex,	GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0032977~membrane insertase activity,GO:0042803~protein homodimerization activity,GO:0051087~chaperone binding,	IPR004217:Tim10/DDP family zinc finger,					KW-0653~Protein transport,KW-0811~Translocation,KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,			KW-0479~Metal-binding,KW-0862~Zinc,	KW-0143~Chaperone,	KW-0007~Acetylation,KW-1015~Disulfide bond,	DOMAIN:zf-Tim10_DDP,MOTIF:Twin CX3C motif,
TOMM34	translocase of outer mitochondrial membrane 34(TOMM34)	Homo sapiens				GO:0006626~protein targeting to mitochondrion,	GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005829~cytosol,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0005515~protein binding,GO:0031072~heat shock protein binding,	IPR001440:Tetratricopeptide TPR-1,IPR011990:Tetratricopeptide-like helical,IPR013026:Tetratricopeptide repeat-containing domain,IPR019734:Tetratricopeptide repeat,				SM00028:TPR,		KW-0472~Membrane,KW-0496~Mitochondrion,KW-0963~Cytoplasm,KW-1000~Mitochondrion outer membrane,		KW-0677~Repeat,KW-0802~TPR repeat,		KW-0143~Chaperone,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,REPEAT:TPR 1,REPEAT:TPR 2,REPEAT:TPR 3,REPEAT:TPR 4,REPEAT:TPR 5,REPEAT:TPR 6,
TRAM2	translocation associated membrane protein 2(TRAM2)	Homo sapiens				GO:0006616~SRP-dependent cotranslational protein targeting to membrane, translocation,GO:0032964~collagen biosynthetic process,GO:0045048~protein insertion into ER membrane,	GO:0016021~integral component of membrane,GO:0030176~integral component of endoplasmic reticulum membrane,	GO:0005515~protein binding,	IPR006634:TRAM/LAG1/CLN8 homology domain,IPR013599:TRAM1-like protein,IPR016447:Translocation associated membrane protein,			PIRSF005449:translocation associated membrane protein,	SM00724:TLC,	KW-0653~Protein transport,KW-0811~Translocation,KW-0813~Transport,	KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:TLC,DOMAIN:TRAM1,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TM9SF2	transmembrane 9 superfamily member 2(TM9SF2)	Homo sapiens				GO:0006672~ceramide metabolic process,GO:0006688~glycosphingolipid biosynthetic process,GO:0010908~regulation of heparan sulfate proteoglycan biosynthetic process,GO:0072657~protein localization to membrane,	GO:0005768~endosome,GO:0005794~Golgi apparatus,GO:0005856~cytoskeleton,GO:0005887~integral component of plasma membrane,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0070062~extracellular exosome,		IPR004240:Nonaspanin (TM9SF),						KW-0206~Cytoskeleton,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0967~Endosome,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
TM9SF3	transmembrane 9 superfamily member 3(TM9SF3)	Homo sapiens				GO:0072657~protein localization to membrane,	GO:0016020~membrane,GO:0016021~integral component of membrane,		IPR004240:Nonaspanin (TM9SF),						KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,TRANSMEM:Helical,
TMCO1	transmembrane and coiled-coil domains 1(TMCO1)	Homo sapiens				GO:0006874~cellular calcium ion homeostasis,GO:0006983~ER overload response,GO:0032469~endoplasmic reticulum calcium ion homeostasis,GO:0070588~calcium ion transmembrane transport,	GO:0000139~Golgi membrane,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0016021~integral component of membrane,GO:0030176~integral component of endoplasmic reticulum membrane,	GO:0005262~calcium channel activity,GO:0005515~protein binding,GO:0043022~ribosome binding,	IPR002809:Protein of unknown function DUF106, transmembrane,IPR008559:Uncharacterised conserved protein UCP023322, transmembrane eukaryotic,		213980~Craniofacial dysmorphism, skeletal anomalies, and mental retardation syndrome,	PIRSF023322:transmembrane protein,	SM01415:SM01415,	KW-0109~Calcium transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,	KW-0225~Disease variant,KW-0955~Glaucoma,KW-0991~Mental retardation,	KW-0175~Coiled coil,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,	KW-0107~Calcium channel,KW-0407~Ion channel,	KW-0597~Phosphoprotein,	INTRAMEM:Pore-forming,MUTAGEN:D->A: Abolishes the calcium channel activity.,MUTAGEN:D->E: Retains some of the calcium channel activity.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
TMED10	transmembrane p24 trafficking protein 10(TMED10)	Homo sapiens				GO:0001822~kidney development,GO:0006886~intracellular protein transport,GO:0006888~ER to Golgi vesicle-mediated transport,GO:0006890~retrograde vesicle-mediated transport, Golgi to ER,GO:0007030~Golgi organization,GO:0032732~positive regulation of interleukin-1 production,GO:0035459~cargo loading into vesicle,GO:0035964~COPI-coated vesicle budding,GO:0043279~response to alkaloid,GO:0045055~regulated exocytosis,GO:0048199~vesicle targeting, to, from or within Golgi,GO:0048205~COPI coating of Golgi vesicle,GO:0048208~COPII vesicle coating,GO:0050714~positive regulation of protein secretion,GO:0071806~protein transmembrane transport,GO:1902003~regulation of beta-amyloid formation,GO:1902960~negative regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic process,	GO:0000139~Golgi membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005793~endoplasmic reticulum-Golgi intermediate compartment,GO:0005794~Golgi apparatus,GO:0005801~cis-Golgi network,GO:0005886~plasma membrane,GO:0012507~ER to Golgi transport vesicle membrane,GO:0016021~integral component of membrane,GO:0030133~transport vesicle,GO:0030134~ER to Golgi transport vesicle,GO:0030137~COPI-coated vesicle,GO:0030140~trans-Golgi network transport vesicle,GO:0030667~secretory granule membrane,GO:0033116~endoplasmic reticulum-Golgi intermediate compartment membrane,GO:0042470~melanosome,GO:0042589~zymogen granule membrane,GO:0070765~gamma-secretase complex,	GO:0005515~protein binding,GO:0008320~protein transmembrane transporter activity,GO:0019905~syntaxin binding,GO:0044877~macromolecular complex binding,	IPR009038:GOLD,IPR015720:TMP21-related,	hsa05130:Pathogenic Escherichia coli infection,			SM01190:SM01190,	KW-0653~Protein transport,KW-0813~Transport,KW-0931~ER-Golgi transport,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0488~Methylation,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:GOLD,MOTIF:COPI vesicle coat-binding,MOTIF:COPII vesicle coat-binding,MUTAGEN:FF->AA: Disrupts interaction with COPG1 and association with coatomer; when associated with 215-A-A-216.,MUTAGEN:FF->AA: No decrease in binding to COPG1. Disrupts interaction with SEC23A.,MUTAGEN:KK->AA: Disrupts interaction with COPG1 and association with coatomer; when associated with 211-A-A-212.,MUTAGEN:KK->AA: Significant reduction in binding to COPG1.,REGION:Interaction with ARF1 and IL1B,REGION:Interaction with COPG1,REGION:Required for TMED10 and TMED2 cis-Golgi network localization,REGION:Required for interaction with STX17,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
TMEM109	transmembrane protein 109(TMEM109)	Homo sapiens				GO:0034220~ion transmembrane transport,GO:0034765~regulation of ion transmembrane transport,GO:0042771~intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator,GO:0060548~negative regulation of cell death,GO:0071480~cellular response to gamma radiation,	GO:0005640~nuclear outer membrane,GO:0016021~integral component of membrane,GO:0033017~sarcoplasmic reticulum membrane,GO:0070062~extracellular exosome,	GO:0005244~voltage-gated ion channel activity,GO:0005515~protein binding,						KW-0406~Ion transport,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,KW-0703~Sarcoplasmic reticulum,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0407~Ion channel,KW-0851~Voltage-gated channel,		TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
TMEM50A	transmembrane protein 50A(TMEM50A)	Homo sapiens				GO:0032511~late endosome to vacuole transport via multivesicular body sorting pathway,	GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0016021~integral component of membrane,GO:0043025~neuronal cell body,GO:0097386~glial cell projection,	GO:0005515~protein binding,	IPR007919:Uncharacterised protein family UPF0220,						KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	TRANSMEM:Helical,
TMEM97	transmembrane protein 97(TMEM97)	Homo sapiens				GO:0001558~regulation of cell growth,GO:0042632~cholesterol homeostasis,	GO:0005764~lysosome,GO:0005783~endoplasmic reticulum,GO:0005791~rough endoplasmic reticulum,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0030867~rough endoplasmic reticulum membrane,GO:0031965~nuclear membrane,	GO:0005515~protein binding,	IPR016964:Transmembrane protein 6/97,			PIRSF031032:transmembrane protein 97,			KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				DOMAIN:EXPERA,MUTAGEN:D->N: Abolishes DTG binding.,MUTAGEN:D->N: Decreases DTG binding.,MUTAGEN:E->Q: Decreases DTG binding.,MUTAGEN:E->Q: No effect on DTG binding.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,
TRIB1	tribbles pseudokinase 1(TRIB1)	Homo sapiens				GO:0006468~protein phosphorylation,GO:0006469~negative regulation of protein kinase activity,GO:0007254~JNK cascade,GO:0014912~negative regulation of smooth muscle cell migration,GO:0031665~negative regulation of lipopolysaccharide-mediated signaling pathway,GO:0032436~positive regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0032496~response to lipopolysaccharide,GO:0043405~regulation of MAP kinase activity,GO:0043433~negative regulation of sequence-specific DNA binding transcription factor activity,GO:0045645~positive regulation of eosinophil differentiation,GO:0045651~positive regulation of macrophage differentiation,GO:0045659~negative regulation of neutrophil differentiation,GO:0048662~negative regulation of smooth muscle cell proliferation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0004672~protein kinase activity,GO:0004860~protein kinase inhibitor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008134~transcription factor binding,GO:0031434~mitogen-activated protein kinase kinase binding,GO:0031625~ubiquitin protein ligase binding,GO:0055106~ubiquitin-protein transferase regulator activity,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,	IPR000719:Protein kinase, catalytic domain,IPR011009:Protein kinase-like domain,IPR024104:Pseudokinase tribbles family/serine-threonine-protein kinase 40,IPR024105:Pseudokinase tribbles, TRB1,				SM00220:S_TKc,						KW-0649~Protein kinase inhibitor,		COMPBIAS:Pro residues,DOMAIN:Protein kinase,MOTIF:COP1-binding,MUTAGEN:D->A: Decreased interaction with COP1.,MUTAGEN:E->A: Decreased interaction with COP1.,MUTAGEN:I->A: Decreased interaction with COP1.,MUTAGEN:P->A: Strongly decreased interaction with COP1.,MUTAGEN:Q->A: Decreased interaction with COP1.,MUTAGEN:V->I,A: Loss of interaction with COP1.,MUTAGEN:Y->A: No effect on interaction with COP1.,REGION:Disordered,
TRIB3	tribbles pseudokinase 3(TRIB3)	Homo sapiens				GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006468~protein phosphorylation,GO:0006469~negative regulation of protein kinase activity,GO:0010506~regulation of autophagy,GO:0010827~regulation of glucose transport,GO:0019222~regulation of metabolic process,GO:0032092~positive regulation of protein binding,GO:0032436~positive regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0032869~cellular response to insulin stimulus,GO:0034976~response to endoplasmic reticulum stress,GO:0043405~regulation of MAP kinase activity,GO:0045599~negative regulation of fat cell differentiation,GO:0045717~negative regulation of fatty acid biosynthetic process,GO:0045892~negative regulation of transcription, DNA-templated,GO:0051443~positive regulation of ubiquitin-protein transferase activity,GO:0051897~positive regulation of protein kinase B signaling,GO:0051898~negative regulation of protein kinase B signaling,GO:0070059~intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,	GO:0003714~transcription corepressor activity,GO:0004672~protein kinase activity,GO:0004860~protein kinase inhibitor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0019901~protein kinase binding,GO:0031434~mitogen-activated protein kinase kinase binding,GO:0031625~ubiquitin protein ligase binding,GO:0055106~ubiquitin-protein transferase regulator activity,	IPR000719:Protein kinase, catalytic domain,IPR011009:Protein kinase-like domain,IPR024104:Pseudokinase tribbles family/serine-threonine-protein kinase 40,IPR024106:Pseudokinase tribbles, TRB3,	hsa04931:Insulin resistance,			SM00220:S_TKc,	KW-0053~Apoptosis,KW-0346~Stress response,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0649~Protein kinase inhibitor,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:Protein kinase,REGION:Disordered,REGION:Interaction with DDIT3/CHOP,
TRIM13	tripartite motif containing 13(TRIM13)	Homo sapiens				GO:0009653~anatomical structure morphogenesis,GO:0010332~response to gamma radiation,GO:0010942~positive regulation of cell death,GO:0016239~positive regulation of macroautophagy,GO:0016567~protein ubiquitination,GO:0030433~ubiquitin-dependent ERAD pathway,GO:0032897~negative regulation of viral transcription,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0044790~negative regulation by host of viral release from host cell,GO:0045087~innate immune response,GO:0045893~positive regulation of transcription, DNA-templated,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051260~protein homooligomerization,GO:0051865~protein autoubiquitination,GO:1902187~negative regulation of viral release from host cell,GO:1904380~endoplasmic reticulum mannose trimming,	GO:0005737~cytoplasm,GO:0005789~endoplasmic reticulum membrane,GO:0016021~integral component of membrane,GO:0044322~endoplasmic reticulum quality control compartment,GO:0097038~perinuclear endoplasmic reticulum,	GO:0003713~transcription coactivator activity,GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0061630~ubiquitin protein ligase activity,	IPR000210:BTB/POZ-like,IPR000315:Zinc finger, B-box,IPR001841:Zinc finger, RING-type,IPR003131:Potassium channel tetramerisation-type BTB domain,IPR011333:BTB/POZ fold,IPR013083:Zinc finger, RING/FYVE/PHD-type,IPR017907:Zinc finger, RING-type, conserved site,IPR027370:RING-type zinc-finger, LisH dimerisation motif,				SM00184:RING,SM00225:BTB,SM00336:BBOX,	KW-0391~Immunity,KW-0399~Innate immunity,KW-0833~Ubl conjugation pathway,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-0863~Zinc-finger,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,	KW-0832~Ubl conjugation,	DOMAIN:B box-type,DOMAIN:BTB,DOMAIN:RING-type,METAL:Zinc,MUTAGEN:C->A: Absence of polyubiquitination. Stability of protein increased. No enhanced apoptosis on ionizing radiation induction. No ubiquitination of AKT1 or MDM2. Decreased p53/TP53 stability. No effect on induction of autophagy during ER stress.,TRANSMEM:Helical,ZN_FING:B box-type,ZN_FING:RING-type,
TRIM2	tripartite motif containing 2(TRIM2)	Homo sapiens			Carbohydrate transport and metabolism,Signal transduction mechanisms,	GO:0000209~protein polyubiquitination,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0043523~regulation of neuron apoptotic process,	GO:0005737~cytoplasm,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0046872~metal ion binding,GO:0061630~ubiquitin protein ligase activity,	IPR000315:Zinc finger, B-box,IPR001258:NHL repeat,IPR001298:Filamin/ABP280 repeat,IPR001841:Zinc finger, RING-type,IPR003649:B-box, C-terminal,IPR011042:Six-bladed beta-propeller, TolB-like,IPR013017:NHL repeat, subgroup,IPR013083:Zinc finger, RING/FYVE/PHD-type,IPR013783:Immunoglobulin-like fold,IPR014756:Immunoglobulin E-set,IPR017868:Filamin/ABP280 repeat-like,IPR017907:Zinc finger, RING-type, conserved site,IPR027370:RING-type zinc-finger, LisH dimerisation motif,		615490~Charcot-Marie-Tooth disease, type 2R,		SM00184:RING,SM00336:BBOX,SM00502:BBC,SM00557:IG_FLMN,	KW-0833~Ubl conjugation pathway,	KW-0963~Cytoplasm,	KW-0144~Charcot-Marie-Tooth disease,KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0622~Neuropathy,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,DOMAIN:B box-type,DOMAIN:RING-type,DOMAIN:zf-RING_UBOX,METAL:Zinc,REGION:Disordered,REPEAT:Filamin,REPEAT:NHL,REPEAT:NHL 1,REPEAT:NHL 2,REPEAT:NHL 3,REPEAT:NHL 4,REPEAT:NHL 5,REPEAT:NHL 6,ZN_FING:B box-type,ZN_FING:RING-type,
TPM1	tropomyosin 1(TPM1)	Homo sapiens				GO:0003065~positive regulation of heart rate by epinephrine,GO:0006936~muscle contraction,GO:0006937~regulation of muscle contraction,GO:0007010~cytoskeleton organization,GO:0007015~actin filament organization,GO:0008016~regulation of heart contraction,GO:0008360~regulation of cell shape,GO:0030049~muscle filament sliding,GO:0030336~negative regulation of cell migration,GO:0031529~ruffle organization,GO:0032781~positive regulation of ATPase activity,GO:0034614~cellular response to reactive oxygen species,GO:0042060~wound healing,GO:0045214~sarcomere organization,GO:0045785~positive regulation of cell adhesion,GO:0051496~positive regulation of stress fiber assembly,GO:0055010~ventricular cardiac muscle tissue morphogenesis,GO:0060048~cardiac muscle contraction,GO:1904706~negative regulation of vascular smooth muscle cell proliferation,GO:1904753~negative regulation of vascular associated smooth muscle cell migration,	GO:0001725~stress fiber,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005862~muscle thin filament tropomyosin,GO:0005884~actin filament,GO:0015629~actin cytoskeleton,GO:0016021~integral component of membrane,GO:0030017~sarcomere,GO:0032059~bleb,GO:0032587~ruffle membrane,	GO:0003779~actin binding,GO:0005200~structural constituent of cytoskeleton,GO:0005515~protein binding,GO:0008092~cytoskeletal protein binding,GO:0008307~structural constituent of muscle,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0046982~protein heterodimerization activity,GO:0051015~actin filament binding,	IPR000533:Tropomyosin,	hsa04260:Cardiac muscle contraction,hsa04261:Adrenergic signaling in cardiomyocytes,hsa05206:MicroRNAs in cancer,hsa05410:Hypertrophic cardiomyopathy,hsa05414:Dilated cardiomyopathy,	115196~Cardiomyopathy, hypertrophic, 3,611878~Cardiomyopathy, dilated, 1Y,611878~Left ventricular noncompaction 9,				KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,	KW-0122~Cardiomyopathy,KW-0225~Disease variant,	KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0009~Actin-binding,KW-0514~Muscle protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	MUTAGEN:K->N: Impairs interaction with LMOD2 and TMOD1.,MUTAGEN:S->A: Loss of phosphorylation and decreased formation of actin stress fibers.,MUTAGEN:S->E: Increased formation of actin stress fibers.,REGION:Disordered,TRANSMEM:Helical,
TSKU	tsukushi, small leucine rich proteoglycan(TSKU)	Homo sapiens				GO:0003431~growth plate cartilage chondrocyte development,GO:0008203~cholesterol metabolic process,GO:0010468~regulation of gene expression,GO:0010977~negative regulation of neuron projection development,GO:0021540~corpus callosum morphogenesis,GO:0021670~lateral ventricle development,GO:0021766~hippocampus development,GO:0021960~anterior commissure morphogenesis,GO:0030178~negative regulation of Wnt signaling pathway,GO:0032911~negative regulation of transforming growth factor beta1 production,GO:0033344~cholesterol efflux,GO:0042060~wound healing,GO:0042632~cholesterol homeostasis,GO:0042635~positive regulation of hair cycle,GO:0043010~camera-type eye development,GO:0060122~inner ear receptor stereocilium organization,GO:0061073~ciliary body morphogenesis,GO:0097009~energy homeostasis,GO:0098868~bone growth,GO:1904761~negative regulation of myofibroblast differentiation,	GO:0005615~extracellular space,	GO:0050431~transforming growth factor beta binding,	IPR001611:Leucine-rich repeat,IPR003591:Leucine-rich repeat, typical subtype,				SM00369:LRR_TYP,	KW-0524~Neurogenesis,	KW-0964~Secreted,		KW-0433~Leucine-rich repeat,KW-0677~Repeat,KW-0732~Signal,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:LRRNT,REPEAT:LRR 1,REPEAT:LRR 10,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,REPEAT:LRR 8,REPEAT:LRR 9,
TUBB6	tubulin beta 6 class V(TUBB6)	Homo sapiens				GO:0000226~microtubule cytoskeleton organization,GO:0000278~mitotic cell cycle,GO:0007017~microtubule-based process,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005874~microtubule,GO:0070062~extracellular exosome,	GO:0003924~GTPase activity,GO:0005200~structural constituent of cytoskeleton,GO:0005515~protein binding,GO:0005525~GTP binding,	IPR000217:Tubulin,IPR002453:Beta tubulin,IPR003008:Tubulin/FtsZ, GTPase domain,IPR008280:Tubulin/FtsZ, C-terminal,IPR013838:Beta tubulin, autoregulation binding site,IPR017975:Tubulin, conserved site,IPR018316:Tubulin/FtsZ, 2-layer sandwich domain,IPR023123:Tubulin, C-terminal,	hsa04145:Phagosome,hsa04540:Gap junction,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05130:Pathogenic Escherichia coli infection,hsa05132:Salmonella infection,	617732~Facial palsy, congenitla, with ptosis and velopharyngeal dysfunction,		SM00864:SM00864,SM00865:SM00865,		KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0175~Coiled coil,	KW-0342~GTP-binding,KW-0547~Nucleotide-binding,		KW-0597~Phosphoprotein,KW-1017~Isopeptide bond,	DOMAIN:Tubulin,DOMAIN:Tubulin_C,NP_BIND:GTP,
TP53BP1	tumor protein p53 binding protein 1(TP53BP1)	Homo sapiens				GO:0000077~DNA damage checkpoint,GO:0006302~double-strand break repair,GO:0006303~double-strand break repair via nonhomologous end joining,GO:0006974~cellular response to DNA damage stimulus,GO:0045830~positive regulation of isotype switching,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0051260~protein homooligomerization,GO:0071481~cellular response to X-ray,GO:2000042~negative regulation of double-strand break repair via homologous recombination,	GO:0000776~kinetochore,GO:0000777~condensed chromosome kinetochore,GO:0000781~chromosome, telomeric region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005657~replication fork,GO:0005737~cytoplasm,GO:0016604~nuclear body,GO:0035861~site of double-strand break,GO:1990391~DNA repair complex,	GO:0001102~RNA polymerase II activating transcription factor binding,GO:0002039~p53 binding,GO:0003684~damaged DNA binding,GO:0003712~transcription cofactor activity,GO:0005515~protein binding,GO:0035064~methylated histone binding,GO:0042162~telomeric DNA binding,GO:0042393~histone binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0061649~ubiquitinated histone binding,	IPR001357:BRCT domain,IPR002999:Tudor domain,IPR014722:Ribosomal protein L2 domain 2,IPR015125:Tumour suppressor p53-binding protein-1 Tudor domain,	hsa04621:NOD-like receptor signaling pathway,			SM00292:BRCT,	KW-0227~DNA damage,KW-0234~DNA repair,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0137~Centromere,KW-0158~Chromosome,KW-0539~Nucleus,KW-0995~Kinetochore,		KW-0677~Repeat,		KW-0010~Activator,KW-0238~DNA-binding,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:53-BP1_Tudor,DOMAIN:BRCT,DOMAIN:BRCT 1,DOMAIN:BRCT 2,MOTIF:GAR,MOTIF:UDR,MUTAGEN:D->A: Does not affect recruitment to double strand breaks.,MUTAGEN:D->A: Loss of interaction with histone H4 that has been dimethylated at 'Lys-20' (H4K20me2). Abolishes recruitment to double strand breaks. Loss of interaction with histone H4 that has been dimethylated at 'Lys-20' (H4K20me2). Abolishes recruitment to double strand breaks; when associated with A-1495.,MUTAGEN:D->R: Abolishes recruitment to double strand breaks and induces defects in class-switch recombination (CSR).,MUTAGEN:E->A: Does not affect recruitment to double strand breaks.,MUTAGEN:I->A: Strongly reduced recruitment to double strand breaks. Defects in class-switch recombination (CSR).,MUTAGEN:K->A: Does not affect recruitment to double strand breaks.,MUTAGEN:L->A: Reduced recruitment to double strand breaks.,MUTAGEN:L->A: Strongly reduced recruitment to double strand breaks. Defects in class-switch recombination (CSR). Does not affect interaction with histone H4 dimethylated at 'Lys-20' (H4K20me2). Impaired interaction with histone H2A monoubiquitinated at 'Lys-15' (H2AK15ub).,MUTAGEN:N->A: Reduced recruitment to double strand breaks.,MUTAGEN:R->A: No detectable effect on methylation by PRMT1 (in vitro). Loss of methylation; when associated with A-1396; A-1398; A-1400 and A-1401.,MUTAGEN:R->A: No detectable effect on methylation by PRMT1 (in vitro). Loss of methylation; when associated with A-1396; A-1398; A-1400 and A-1403.,MUTAGEN:R->A: No detectable effect on methylation by PRMT1 (in vitro). Loss of methylation; when associated with A-1396; A-1398; A-1401 and A-1403.,MUTAGEN:R->A: No detectable effect on methylation by PRMT1 (in vitro). Loss of methylation; when associated with A-1396; A-1400; A-1401 and A-1403.,MUTAGEN:R->A: No detectable effect on methylation by PRMT1 (in vitro). Loss of methylation; when associated with A-1398; A-1400; A-1401 and A-1403.,MUTAGEN:R->A: Reduced recruitment to double strand breaks.,MUTAGEN:R->K: No detectable effect on methylation by PRMT1 (in vitro).,MUTAGEN:R->K: Reduced methylation by PRMT1 (in vitro). Strongly reduced methylation; when associated with K-1398. Strongly reduced methylation; when associated with K-1400.,MUTAGEN:R->K: Reduced methylation by PRMT1 (in vitro). Strongly reduced methylation; when associated with K-1398. Strongly reduced methylation; when associated with K-1401.,MUTAGEN:R->K: Reduced methylation by PRMT1 (in vitro). Strongly reduced methylation; when associated with K-1400. Strongly reduced methylation; when associated with K-1401.,MUTAGEN:RGRR->AGAA: No effect on in class-switch recombination (CSR).,MUTAGEN:S->A: Constitutive recruitment to mitotic DNA lesions, leading to mitotic defects; when associated with A-1609.,MUTAGEN:S->A: In 28A: Defects in recruitment to double strand breaks (DSBs), abolished interaction with RIF1 and abolished ability to repair DSBs; when associated with A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437; A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698; A-784; A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171 and A-1219. In 8A: Does not affect interaction with RIF1 and ability to promote immunoglobulin class-switch recombination (CSR), but abolishes interaction with PAXIP1 and ability to promote NHEJ of dysfunctional telomeres; when associated with A-13; A-25; A-29; A-105; A-166; A-176 and A-178.,MUTAGEN:S->A: In 28A: Defects in recruitment to double strand breaks (DSBs), abolished interaction with RIF1 and abolished ability to repair DSBs; when associated with A-6; A-13; A-25; A-105; A-166; A-176; A-178; A-302; A-437; A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698; A-784; A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171 and A-1219. In 8A: Does not affect interaction with RIF1 and ability to promote immunoglobulin class-switch recombination (CSR), but abolishes interaction with PAXIP1 and ability to promote NHEJ of dysfunctional telomeres; when associated with A-6; A-13; A-25; A-105; A-166; A-176 and A-178.,MUTAGEN:S->A: In 28A: Defects in recruitment to double strand breaks (DSBs), abolished interaction with RIF1 and abolished ability to repair DSBs; when associated with A-6; A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437; A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698; A-784; A-831; A-855; A-1068; A-1086; A-1104; A-1148; A-1171 and A-1219.,MUTAGEN:S->A: In 28A: Defects in recruitment to double strand breaks (DSBs), abolished interaction with RIF1 and abolished ability to repair DSBs; when associated with A-6; A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437; A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698; A-784; A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148 and A-1171.,MUTAGEN:S->A: In 28A: Defects in recruitment to double strand breaks (DSBs), abolished interaction with RIF1 and abolished ability to repair DSBs; when associated with A-6; A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437; A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698; A-784; A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1171 and A-1219.,MUTAGEN:S->A: In 28A: Defects in recruitment to double strand breaks (DSBs), abolished interaction with RIF1 and abolished ability to repair DSBs; when associated with A-6; A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437; A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698; A-784; A-831; A-855; A-892; A-1068; A-1086; A-1148; A-1171 and A-1219.,MUTAGEN:S->A: In 28A: Defects in recruitment to double strand breaks (DSBs), abolished interaction with RIF1 and abolished ability to repair DSBs; when associated with A-6; A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437; A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698; A-784; A-831; A-855; A-892; A-1068; A-1104; A-1148; A-1171 and A-1219.,MUTAGEN:S->A: In 28A: Defects in recruitment to double strand breaks (DSBs), abolished interaction with RIF1 and abolished ability to repair DSBs; when associated with A-6; A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437; A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698; A-784; A-831; A-855; A-892; A-1086; A-1104; A-1148; A-1171 and A-1219.,MUTAGEN:S->A: In 28A: Defects in recruitment to double strand breaks (DSBs), abolished interaction with RIF1 and abolished ability to repair DSBs; when associated with A-6; A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437; A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698; A-784; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171 and A-1219.,MUTAGEN:S->A: In 28A: Defects in recruitment to double strand breaks (DSBs), abolished interaction with RIF1 and abolished ability to repair DSBs; when associated with A-6; A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437; A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698; A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171 and A-1219.,MUTAGEN:S->A: In 28A: Defects in recruitment to double strand breaks (DSBs), abolished interaction with RIF1 and abolished ability to repair DSBs; when associated with A-6; A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437; A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-784; A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171 and A-1219.,MUTAGEN:S->A: In 28A: Defects in recruitment to double strand breaks (DSBs), abolished interaction with RIF1 and abolished ability to repair DSBs; when associated with A-6; A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437; A-452; A-523; A-543; A-580; A-625; A-696; A-698; A-784; A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171 and A-1219.,MUTAGEN:S->A: In 28A: Defects in recruitment to double strand breaks (DSBs), abolished interaction with RIF1 and abolished ability to repair DSBs; when associated with A-6; A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437; A-452; A-523; A-543; A-580; A-674; A-696; A-698; A-784; A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171 and A-1219.,MUTAGEN:S->A: In 28A: Defects in recruitment to double strand breaks (DSBs), abolished interaction with RIF1 and abolished ability to repair DSBs; when associated with A-6; A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437; A-452; A-523; A-543; A-625; A-674; A-696; A-698; A-784; A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171 and A-1219.,MUTAGEN:S->A: In 28A: Defects in recruitment to double strand breaks (DSBs), abolished interaction with RIF1 and abolished ability to repair DSBs; when associated with A-6; A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437; A-452; A-543; A-580; A-625; A-674; A-696; A-698; A-784; A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171 and A-1219.,MUTAGEN:S->A: In 28A: Defects in recruitment to double strand breaks (DSBs), abolished interaction with RIF1 and abolished ability to repair DSBs; when associated with A-6; A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437; A-523; A-543; A-580; A-625; A-674; A-696; A-698; A-784; A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171 and A-1219.,MUTAGEN:S->A: In 28A: Defects in recruitment to double strand breaks (DSBs), abolished interaction with RIF1 and abolished ability to repair DSBs; when associated with A-6; A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698; A-784; A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171 and A-1219.,MUTAGEN:S->A: In 28A: Defects in recruitment to double strand breaks (DSBs), abolished interaction with RIF1 and abolished ability to repair DSBs; when associated with A-6; A-13; A-25; A-29; A-105; A-166; A-176; A-302; A-437; A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698; A-784; A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171 and A-1219. In 8A: Does not affect interaction with RIF1 and ability to promote immunoglobulin class-switch recombination (CSR), but abolishes interaction with PAXIP1 and ability to promote NHEJ of dysfunctional telomeres; when associated with A-6; A-13; A-25; A-29; A-105; A-166 and A-176.,MUTAGEN:S->A: In 28A: Defects in recruitment to double strand breaks (DSBs), abolished interaction with RIF1 and abolished ability to repair DSBs; when associated with A-6; A-13; A-25; A-29; A-105; A-166; A-178; A-302; A-437; A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698; A-784; A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171 and A-1219. In 8A: Does not affect interaction with RIF1 and ability to promote immunoglobulin class-switch recombination (CSR), but abolishes interaction with PAXIP1 and ability to promote NHEJ of dysfunctional telomeres; when associated with A-6; A-13; A-25; A-29; A-105; A-166 and A-178.,MUTAGEN:S->A: In 28A: Defects in recruitment to double strand breaks (DSBs), abolished interaction with RIF1 and abolished ability to repair DSBs; when associated with A-6; A-13; A-25; A-29; A-105; A-176; A-178; A-302; A-437; A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698; A-784; A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171 and A-1219. In 8A: Does not affect interaction with RIF1 and ability to promote immunoglobulin class-switch recombination (CSR), but abolishes interaction with PAXIP1 and ability to promote NHEJ of dysfunctional telomeres; when associated with A-6; A-13; A-25; A-29; A-105; A-176 and A-178.,MUTAGEN:S->A: In 28A: Defects in recruitment to double strand breaks (DSBs), abolished interaction with RIF1 and abolished ability to repair DSBs; when associated with A-6; A-13; A-25; A-29; A-166; A-176; A-178; A-302; A-437; A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698; A-784; A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171 and A-1219. In 8A: Does not affect interaction with RIF1 and ability to promote immunoglobulin class-switch recombination (CSR), but abolishes interaction with PAXIP1 and ability to promote NHEJ of dysfunctional telomeres; when associated with A-6; A-13; A-25; A-29; A-166; A-176 and A-178.,MUTAGEN:S->A: In 28A: Defects in recruitment to double strand breaks (DSBs), abolished interaction with RIF1 and abolished ability to repair DSBs; when associated with A-6; A-13; A-29; A-105; A-166; A-176; A-178; A-302; A-437; A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698; A-784; A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171 and A-1219. In 8A: Does not affect interaction with RIF1 and ability to promote immunoglobulin class-switch recombination (CSR), but abolishes interaction with PAXIP1 and ability to promote NHEJ of dysfunctional telomeres; when associated with A-6; A-13; A-29; A-105; A-166; A-176 and A-178.,MUTAGEN:S->A: In 28A: Defects in recruitment to double strand breaks (DSBs), abolished interaction with RIF1 and abolished ability to repair DSBs; when associated with A-6; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437; A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698; A-784; A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171 and A-1219. In 8A: Does not affect interaction with RIF1 and ability to promote immunoglobulin class-switch recombination (CSR), but abolishes interaction with PAXIP1 and ability to promote NHEJ of dysfunctional telomeres; when associated with A-6; A-25; A-29; A-105; A-166; A-176 and A-178.,MUTAGEN:S->D: Phosphomimetic mutant that abolishes recruitment to double strand breaks; when associated with E-1609.,MUTAGEN:SQS->AQA: Loss of phosphorylation site.,MUTAGEN:T->A: Constitutive recruitment to mitotic DNA lesions, leading to mitotic defects; when associated with A-1618.,MUTAGEN:T->A: In 28A: Defects in recruitment to double strand breaks (DSBs), abolished interaction with RIF1 and abolished ability to repair DSBs; when associated with A-6; A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437; A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698; A-784; A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148 and A-1219.,MUTAGEN:T->A: In 28A: Defects in recruitment to double strand breaks (DSBs), abolished interaction with RIF1 and abolished ability to repair DSBs; when associated with A-6; A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437; A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698; A-784; A-831; A-892; A-1068; A-1086; A-1104; A-1148; A-1171 and A-1219.,MUTAGEN:T->A: In 28A: Defects in recruitment to double strand breaks (DSBs), abolished interaction with RIF1 and abolished ability to repair DSBs; when associated with A-6; A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437; A-452; A-523; A-543; A-580; A-625; A-674; A-698; A-784; A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171 and A-1219.,MUTAGEN:T->A: In 28A: Defects in recruitment to double strand breaks (DSBs), abolished interaction with RIF1 and abolished ability to repair DSBs; when associated with A-6; A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437; A-452; A-523; A-580; A-625; A-674; A-696; A-698; A-784; A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171 and A-1219.,MUTAGEN:T->A: In 28A: Defects in recruitment to double strand breaks (DSBs), abolished interaction with RIF1 and abolished ability to repair DSBs; when associated with A-6; A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-437; A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698; A-784; A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171 and A-1219.,MUTAGEN:T->E: Phosphomimetic mutant that abolishes recruitment to double strand breaks; when associated with D-1618.,MUTAGEN:W->A,H: Loss of interaction with histone H4 that has been dimethylated at 'Lys-20' (H4K20me2). Abolishes recruitment to double strand breaks. Loss of interaction with histone H4 that has been dimethylated at 'Lys-20' (H4K20me2). Abolishes recruitment to double strand breaks; when associated with A-1521.,MUTAGEN:W->F: No effect on recruitment to double strand breaks.,MUTAGEN:W->V: Reduces recruitment to double strand breaks.,MUTAGEN:Y->A: Increases affinity for histone H4 that has been dimethylated at 'Lys-20'. No effect on recruitment to double strand breaks.,MUTAGEN:Y->A: Reduces affinity for histone H4 that has been dimethylated at 'Lys-20'.,MUTAGEN:Y->L,Q: Abolishes recruitment to double strand breaks.,MUTAGEN:Y->S: Decreases affinity for histone H4 that has been dimethylated at 'Lys-20'.,REGION:Disordered,REGION:Interaction with dimethylated histone H4,REGION:Tudor-like,
TP53BP2	tumor protein p53 binding protein 2(TP53BP2)	Homo sapiens				GO:0007049~cell cycle,GO:0007165~signal transduction,GO:0042981~regulation of apoptotic process,GO:0045786~negative regulation of cell cycle,GO:0072332~intrinsic apoptotic signaling pathway by p53 class mediator,GO:1900119~positive regulation of execution phase of apoptosis,GO:1900740~positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway,GO:1901216~positive regulation of neuron death,GO:1901796~regulation of signal transduction by p53 class mediator,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0030054~cell junction,GO:0048471~perinuclear region of cytoplasm,	GO:0002039~p53 binding,GO:0005515~protein binding,GO:0017124~SH3 domain binding,GO:0042802~identical protein binding,GO:0051059~NF-kappaB binding,	IPR001452:Src homology-3 domain,IPR002110:Ankyrin repeat,IPR020683:Ankyrin repeat-containing domain,	hsa04390:Hippo signaling pathway,			SM00248:ANK,SM00326:SH3,	KW-0053~Apoptosis,KW-0131~Cell cycle,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0040~ANK repeat,KW-0175~Coiled coil,KW-0677~Repeat,KW-0728~SH3 domain,KW-0729~SH3-binding,			KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:SH3,MOTIF:SH3-binding,MUTAGEN:W->K: Loss of interaction with APC2.,REGION:Disordered,REGION:Interaction with APPBP1,REGION:Mediates interaction with APC2,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,
TP53	tumor protein p53(TP53)	Homo sapiens	1.RBphosphoE2F,152.altered_synaptic_signalling-neurodegenerative_disorders,157.14-3-3_Cell_Cycle,38.Cell_cycle_arrest_and_apoptosis_ceramide,94.E2F_transcriptional_activity_cell_cycle,99.NF-kB_activation,	h_arfPathway:Tumor Suppressor Arf Inhibits Ribosomal Biogenesis,h_atmPathway:ATM Signaling Pathway,h_atrbrcaPathway:Role of BRCA1,  BRCA2 and ATR in Cancer Susceptibility,h_btg2Pathway:BTG family proteins and cell cycle regulation,h_chemicalPathway:Apoptotic Signaling in Response to DNA Damage,h_ctcfPathway:CTCF: First Multivalent Nuclear Factor,h_EfpPathway:Estrogen-responsive protein Efp controls cell cycle and breast tumors growth,h_g1Pathway:Cell Cycle: G1/S Check Point ,h_g2Pathway:Cell Cycle: G2/M Checkpoint,h_p53hypoxiaPathway:Hypoxia and p53 in the Cardiovascular system,h_p53Pathway:p53 Signaling Pathway,h_plk3Pathway:Regulation of cell cycle progression by Plk3,h_pmlPathway:Regulation of transcriptional activity by PML,h_rbPathway:RB Tumor Suppressor/Checkpoint Signaling in response to DNA damage,h_rnaPathway:Double Stranded RNA Induced Gene Expression,h_telPathway:Telomeres, Telomerase, Cellular Aging, and  Immortality,h_tertPathway:Overview of telomerase protein component gene hTert Transcriptional Regulation ,h_tidPathway:Chaperones modulate interferon Signaling Pathway,		GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000733~DNA strand renaturation,GO:0001701~in utero embryonic development,GO:0001756~somitogenesis,GO:0001836~release of cytochrome c from mitochondria,GO:0002244~hematopoietic progenitor cell differentiation,GO:0002309~T cell proliferation involved in immune response,GO:0002326~B cell lineage commitment,GO:0002360~T cell lineage commitment,GO:0002931~response to ischemia,GO:0006289~nucleotide-excision repair,GO:0006302~double-strand break repair,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006606~protein import into nucleus,GO:0006914~autophagy,GO:0006915~apoptotic process,GO:0006974~cellular response to DNA damage stimulus,GO:0006977~DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest,GO:0006978~DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator,GO:0006979~response to oxidative stress,GO:0006983~ER overload response,GO:0007049~cell cycle,GO:0007050~cell cycle arrest,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0007265~Ras protein signal transduction,GO:0007369~gastrulation,GO:0007406~negative regulation of neuroblast proliferation,GO:0007569~cell aging,GO:0008104~protein localization,GO:0008156~negative regulation of DNA replication,GO:0008285~negative regulation of cell proliferation,GO:0008340~determination of adult lifespan,GO:0009299~mRNA transcription,GO:0009303~rRNA transcription,GO:0009651~response to salt stress,GO:0010165~response to X-ray,GO:0010332~response to gamma radiation,GO:0010628~positive regulation of gene expression,GO:0010666~positive regulation of cardiac muscle cell apoptotic process,GO:0016032~viral process,GO:0016579~protein deubiquitination,GO:0019221~cytokine-mediated signaling pathway,GO:0021549~cerebellum development,GO:0030308~negative regulation of cell growth,GO:0030330~DNA damage response, signal transduction by p53 class mediator,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0031065~positive regulation of histone deacetylation,GO:0031497~chromatin assembly,GO:0031571~mitotic G1 DNA damage checkpoint,GO:0033077~T cell differentiation in thymus,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0034103~regulation of tissue remodeling,GO:0034613~cellular protein localization,GO:0034644~cellular response to UV,GO:0035264~multicellular organism growth,GO:0035690~cellular response to drug,GO:0035794~positive regulation of mitochondrial membrane permeability,GO:0036003~positive regulation of transcription from RNA polymerase II promoter in response to stress,GO:0042149~cellular response to glucose starvation,GO:0042493~response to drug,GO:0042771~intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator,GO:0042981~regulation of apoptotic process,GO:0043065~positive regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043153~entrainment of circadian clock by photoperiod,GO:0043504~mitochondrial DNA repair,GO:0043516~regulation of DNA damage response, signal transduction by p53 class mediator,GO:0043525~positive regulation of neuron apoptotic process,GO:0045861~negative regulation of proteolysis,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045899~positive regulation of RNA polymerase II transcriptional preinitiation complex assembly,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046677~response to antibiotic,GO:0046827~positive regulation of protein export from nucleus,GO:0048147~negative regulation of fibroblast proliferation,GO:0048511~rhythmic process,GO:0048512~circadian behavior,GO:0048539~bone marrow development,GO:0048568~embryonic organ development,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0050821~protein stabilization,GO:0051097~negative regulation of helicase activity,GO:0051262~protein tetramerization,GO:0051276~chromosome organization,GO:0051402~neuron apoptotic process,GO:0051726~regulation of cell cycle,GO:0051974~negative regulation of telomerase activity,GO:0060218~hematopoietic stem cell differentiation,GO:0060260~regulation of transcription initiation from RNA polymerase II promoter,GO:0060333~interferon-gamma-mediated signaling pathway,GO:0060411~cardiac septum morphogenesis,GO:0061419~positive regulation of transcription from RNA polymerase II promoter in response to hypoxia,GO:0065003~macromolecular complex assembly,GO:0070059~intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress,GO:0070245~positive regulation of thymocyte apoptotic process,GO:0070266~necroptotic process,GO:0071158~positive regulation of cell cycle arrest,GO:0071456~cellular response to hypoxia,GO:0071466~cellular response to xenobiotic stimulus,GO:0071479~cellular response to ionizing radiation,GO:0071480~cellular response to gamma radiation,GO:0071494~cellular response to UV-C,GO:0071850~mitotic cell cycle arrest,GO:0072331~signal transduction by p53 class mediator,GO:0072332~intrinsic apoptotic signaling pathway by p53 class mediator,GO:0072717~cellular response to actinomycin D,GO:0090200~positive regulation of release of cytochrome c from mitochondria,GO:0090343~positive regulation of cell aging,GO:0090399~replicative senescence,GO:0090403~oxidative stress-induced premature senescence,GO:0097193~intrinsic apoptotic signaling pathway,GO:0097252~oligodendrocyte apoptotic process,GO:1900119~positive regulation of execution phase of apoptosis,GO:1900740~positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway,GO:1901525~negative regulation of macromitophagy,GO:1901796~regulation of signal transduction by p53 class mediator,GO:1902108~regulation of mitochondrial membrane permeability involved in apoptotic process,GO:1902253~regulation of intrinsic apoptotic signaling pathway by p53 class mediator,GO:1902749~regulation of cell cycle G2/M phase transition,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1903451~negative regulation of G1 to G0 transition,GO:1903799~negative regulation of production of miRNAs involved in gene silencing by miRNA,GO:1903800~positive regulation of production of miRNAs involved in gene silencing by miRNA,GO:1904024~negative regulation of glucose catabolic process to lactate via pyruvate,GO:1905856~negative regulation of pentose-phosphate shunt,GO:1990144~intrinsic apoptotic signaling pathway in response to hypoxia,GO:1990248~regulation of transcription from RNA polymerase II promoter in response to DNA damage,GO:1990440~positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress,GO:2000269~regulation of fibroblast apoptotic process,GO:2000378~negative regulation of reactive oxygen species metabolic process,GO:2000379~positive regulation of reactive oxygen species metabolic process,GO:2000772~regulation of cellular senescence,GO:2001244~positive regulation of intrinsic apoptotic signaling pathway,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005657~replication fork,GO:0005667~transcription factor complex,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005783~endoplasmic reticulum,GO:0005813~centrosome,GO:0005815~microtubule organizing center,GO:0005829~cytosol,GO:0016021~integral component of membrane,GO:0016363~nuclear matrix,GO:0016604~nuclear body,GO:0016605~PML body,GO:0017053~transcriptional repressor complex,GO:0032991~macromolecular complex,GO:0035861~site of double-strand break,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0000987~core promoter proximal region sequence-specific DNA binding,GO:0001046~core promoter sequence-specific DNA binding,GO:0001085~RNA polymerase II transcription factor binding,GO:0001094~TFIID-class transcription factor binding,GO:0001216~bacterial-type RNA polymerase transcriptional activator activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0002020~protease binding,GO:0002039~p53 binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0003730~mRNA 3'-UTR binding,GO:0005507~copper ion binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0008270~zinc ion binding,GO:0019899~enzyme binding,GO:0019901~protein kinase binding,GO:0019903~protein phosphatase binding,GO:0030971~receptor tyrosine kinase binding,GO:0031625~ubiquitin protein ligase binding,GO:0035033~histone deacetylase regulator activity,GO:0035035~histone acetyltransferase binding,GO:0036310~annealing helicase activity,GO:0042802~identical protein binding,GO:0042826~histone deacetylase binding,GO:0043621~protein self-association,GO:0046872~metal ion binding,GO:0046982~protein heterodimerization activity,GO:0047485~protein N-terminus binding,GO:0051087~chaperone binding,GO:0051721~protein phosphatase 2A binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0097371~MDM2/MDM4 family protein binding,GO:0097718~disordered domain specific binding,GO:1990841~promoter-specific chromatin binding,	IPR002117:p53 tumour suppressor family,IPR008967:p53-like transcription factor, DNA-binding,IPR010991:p53, tetramerisation domain,IPR011615:p53, DNA-binding domain,IPR012346:p53/RUNT-type transcription factor, DNA-binding domain,IPR013872:p53 transactivation domain,IPR015155:PLAA family ubiquitin binding, PFU,	hsa01522:Endocrine resistance,hsa01524:Platinum drug resistance,hsa04010:MAPK signaling pathway,hsa04071:Sphingolipid signaling pathway,hsa04110:Cell cycle,hsa04115:p53 signaling pathway,hsa04137:Mitophagy - animal,hsa04151:PI3K-Akt signaling pathway,hsa04210:Apoptosis,hsa04211:Longevity regulating pathway,hsa04216:Ferroptosis,hsa04218:Cellular senescence,hsa04310:Wnt signaling pathway,hsa04722:Neurotrophin signaling pathway,hsa04919:Thyroid hormone signaling pathway,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05131:Shigellosis,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05203:Viral carcinogenesis,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,hsa05210:Colorectal cancer,hsa05212:Pancreatic cancer,hsa05213:Endometrial cancer,hsa05214:Glioma,hsa05215:Prostate cancer,hsa05216:Thyroid cancer,hsa05217:Basal cell carcinoma,hsa05218:Melanoma,hsa05219:Bladder cancer,hsa05220:Chronic myeloid leukemia,hsa05222:Small cell lung cancer,hsa05223:Non-small cell lung cancer,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,hsa05230:Central carbon metabolism in cancer,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,	114480~Breast cancer, somatic,114500~Colorectal cancer,114550~Hepatocellular carcinoma, somatic,137800~Glioma susceptibility 1,151623~Li-Fraumeni syndrome,202300~Adrenocortical carcinoma, pediatric,259500~Osteosarcoma,260500~Choroid plexus papilloma,607107~Nasopharyngeal carcinoma, somatic,614740~Basal cell carcinoma 7,618165~Bone marrow failure syndrome 5,Pancreatic cancer, somatic 260350~Pancreatic cancer, somatic 260350,			KW-0053~Apoptosis,KW-0090~Biological rhythms,KW-0131~Cell cycle,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,KW-1210~Necrosis,	KW-0206~Cytoskeleton,KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0043~Tumor suppressor,KW-0225~Disease variant,KW-0435~Li-Fraumeni syndrome,KW-9993~Li-Fraumeni syndrome,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0238~DNA-binding,KW-0678~Repressor,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:P53,DOMAIN:P53_TAD,DOMAIN:P53_tetramer,DOMAIN:PFU,DOMAIN:TAD2,METAL:Zinc,MOTIF:Bipartite nuclear localization signal,MOTIF:Nuclear export signal,MOTIF:TADI,MOTIF:TADII,MOTIF:[KR]-[STA]-K motif,MUTAGEN:E->A: Abolishes SUMO1 conjugation.,MUTAGEN:F->A: Reduced SUMO1 conjugation.,MUTAGEN:G->E: Abolishes binding to USP7.,MUTAGEN:K->A: Abolishes SUMO1 conjugation, in vitro and in vivo.,MUTAGEN:K->A: Abolishes acetylation by CREBBP.,MUTAGEN:K->A: Loss of nuclear localization; when associated with A-319 and A-320.,MUTAGEN:K->A: Loss of nuclear localization; when associated with A-319 and A-321.,MUTAGEN:K->A: Loss of nuclear localization; when associated with A-320 and A-321.,MUTAGEN:K->R: Abolishes dimethylation by EHMT1 and EHMT2.,MUTAGEN:K->R: Abolishes monomethylation by KMT5A.,MUTAGEN:K->R: Abolishes ubiquitination by MUL1.,MUTAGEN:K->R: Induces a decrease in methylation by SMYD2.,MUTAGEN:K->R: Induces a decrease in protein stabilization.,MUTAGEN:KK->RR: Abolishes polyubiquitination by MKRN1.,MUTAGEN:L->A: Abolishes S-315 phosphorylation by CDK2/cyclin A.,MUTAGEN:LW->QS: Loss of interaction with MDM2, leading to constitutively increased TP53 protein levels.,MUTAGEN:Missing: Alters interaction with WWOX.,MUTAGEN:P->D: Abolishes binding to USP7.,MUTAGEN:R->S: Does not induce SNAI1 degradation.,MUTAGEN:RGRER->KGKEK: Reduced methylation by PRMT5. Reduced nuclear localization. Decreased binding to promoters of target genes. Reduced transcriptional activity. Decrease in cell cycle arrest.,MUTAGEN:S->A: Abolishes binding to USP7.,MUTAGEN:S->A: Abolishes phosphorylation by DYRK2 and HIPK2 and acetylation of K-382 by CREBBP.,MUTAGEN:S->A: Abolishes phosphorylation site. Abolishes increase in protein levels after DNA damage.,MUTAGEN:S->A: Abolishes phosphorylation.,MUTAGEN:S->A: Abolishes strongly phosphorylation.,MUTAGEN:S->A: Loss of interaction with PPP2R5C, PPP2CA AND PPP2R1A.,MUTAGEN:S->D: Abolishes phosphorylation by MAPKAPK5.,MUTAGEN:S->D: Constitutively increased TP53 protein levels.,MUTAGEN:S->E: Inhibits slightly its transcriptional activity.,MUTAGEN:S->E: Inhibits strongly its transcriptional activity.,MUTAGEN:T->A: Blocks phosphorylation by TAF1.,MUTAGEN:T->A: No effect SUMO1 conjugation.,MUTAGEN:T->A: No effect on interaction with MDM2 and increase in protein levels after DNA damage.,MUTAGEN:T->E: Inhibits strongly its transcriptional activity.,REGION:Basic (repression of DNA-binding),REGION:Disordered,REGION:Interaction with AXIN1,REGION:Interaction with CARM1,REGION:Interaction with CCAR2,REGION:Interaction with DNA,REGION:Interaction with E4F1,REGION:Interaction with HIPK1,REGION:Interaction with HIPK2,REGION:Interaction with HRMT1L2,REGION:Interaction with USP7,REGION:Interaction with WWOX,REGION:Interaction with the 53BP2 SH3 domain,REGION:Oligomerization,REGION:Required for interaction with FBXO42,REGION:Required for interaction with ZNF385A,REGION:Transcription activation (acidic),SITE:Interaction with DNA,TRANSMEM:Helical,
TWF2	twinfilin actin binding protein 2(TWF2)	Homo sapiens				GO:0010591~regulation of lamellipodium assembly,GO:0010592~positive regulation of lamellipodium assembly,GO:0010976~positive regulation of neuron projection development,GO:0030030~cell projection organization,GO:0030042~actin filament depolymerization,GO:0030837~negative regulation of actin filament polymerization,GO:0032532~regulation of microvillus length,GO:0032956~regulation of actin cytoskeleton organization,GO:0042989~sequestering of actin monomers,GO:0045773~positive regulation of axon extension,GO:0051016~barbed-end actin filament capping,GO:0071300~cellular response to retinoic acid,GO:0071363~cellular response to growth factor stimulus,	GO:0005737~cytoplasm,GO:0005856~cytoskeleton,GO:0005884~actin filament,GO:0030016~myofibril,GO:0030027~lamellipodium,GO:0030175~filopodium,GO:0030426~growth cone,GO:0032420~stereocilium,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0003779~actin binding,GO:0003785~actin monomer binding,GO:0005080~protein kinase C binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0005546~phosphatidylinositol-4,5-bisphosphate binding,GO:0045296~cadherin binding,GO:0051015~actin filament binding,	IPR002108:Actin-binding, cofilin/tropomyosin type,				SM00102:ADF,	KW-0970~Cilium biogenesis/degradation,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,KW-0966~Cell projection,		KW-0175~Coiled coil,KW-0677~Repeat,		KW-0009~Actin-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:ADF-H,DOMAIN:ADF-H 1,DOMAIN:ADF-H 2,REGION:Disordered,
UBQLN2	ubiquilin 2(UBQLN2)	Homo sapiens				GO:0000045~autophagosome assembly,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0016241~regulation of macroautophagy,GO:0030433~ubiquitin-dependent ERAD pathway,GO:1900186~negative regulation of clathrin-dependent endocytosis,GO:1903071~positive regulation of ER-associated ubiquitin-dependent protein catabolic process,GO:1904021~negative regulation of G-protein coupled receptor internalization,GO:2000785~regulation of autophagosome assembly,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005776~autophagosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0031410~cytoplasmic vesicle,	GO:0005515~protein binding,GO:0031593~polyubiquitin binding,GO:0042802~identical protein binding,	IPR000626:Ubiquitin,IPR006636:Heat shock chaperonin-binding,IPR009060:UBA-like,IPR015940:Ubiquitin-associated/translation elongation factor EF1B, N-terminal, eukaryote,IPR016024:Armadillo-type fold,	hsa04141:Protein processing in endoplasmic reticulum,hsa05014:Amyotrophic lateral sclerosis,	300857~Amyotrophic lateral sclerosis 15, with or without frontotemporal dementia,		SM00165:UBA,SM00213:UBQ,SM00727:STI1,	KW-0072~Autophagy,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,	KW-0036~Amyotrophic lateral sclerosis,KW-0225~Disease variant,KW-0523~Neurodegeneration,	KW-0677~Repeat,			KW-0007~Acetylation,	COMPBIAS:Polar residues,DOMAIN:STI1 1,DOMAIN:STI1 2,DOMAIN:STI1 3,DOMAIN:STI1 4,DOMAIN:UBA,DOMAIN:Ubiquitin-like,REGION:12 X 3 AA tandem repeats of P-X-X,REGION:Disordered,REPEAT:1,REPEAT:10,REPEAT:11,REPEAT:12,REPEAT:2,REPEAT:3,REPEAT:4,REPEAT:5,REPEAT:6,REPEAT:7,REPEAT:8,REPEAT:9,
UBE2A	ubiquitin conjugating enzyme E2 A(UBE2A)	Homo sapiens				GO:0000209~protein polyubiquitination,GO:0001835~blastocyst hatching,GO:0006281~DNA repair,GO:0006301~postreplication repair,GO:0006325~chromatin organization,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0008284~positive regulation of cell proliferation,GO:0009411~response to UV,GO:0016567~protein ubiquitination,GO:0016574~histone ubiquitination,GO:0033522~histone H2A ubiquitination,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0051865~protein autoubiquitination,GO:0060135~maternal process involved in female pregnancy,GO:0070936~protein K48-linked ubiquitination,GO:0070979~protein K11-linked ubiquitination,	GO:0000785~chromatin,GO:0001741~XY body,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0033503~HULC complex,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016740~transferase activity,GO:0031625~ubiquitin protein ligase binding,GO:0043130~ubiquitin binding,GO:0061631~ubiquitin conjugating enzyme activity,	IPR000608:Ubiquitin-conjugating enzyme, E2,IPR016135:Ubiquitin-conjugating enzyme/RWD-like,IPR023313:Ubiquitin-conjugating enzyme, active site,	hsa04120:Ubiquitin mediated proteolysis,	300860~Intellectual developmental disorder, X-linked syndromic, Nascimento type,			KW-0227~DNA damage,KW-0234~DNA repair,KW-0833~Ubl conjugation pathway,		KW-0225~Disease variant,KW-0991~Mental retardation,	KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0156~Chromatin regulator,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Glycyl thioester intermediate,DOMAIN:UBC core,
UBE2C	ubiquitin conjugating enzyme E2 C(UBE2C)	Homo sapiens				GO:0000209~protein polyubiquitination,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0007096~regulation of exit from mitosis,GO:0010458~exit from mitosis,GO:0010994~free ubiquitin chain polymerization,GO:0016567~protein ubiquitination,GO:0030071~regulation of mitotic metaphase/anaphase transition,GO:0031145~anaphase-promoting complex-dependent catabolic process,GO:0031536~positive regulation of exit from mitosis,GO:0051301~cell division,GO:0070936~protein K48-linked ubiquitination,GO:0070979~protein K11-linked ubiquitination,GO:1901990~regulation of mitotic cell cycle phase transition,GO:1904668~positive regulation of ubiquitin protein ligase activity,	GO:0000151~ubiquitin ligase complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005680~anaphase-promoting complex,GO:0005829~cytosol,GO:0005886~plasma membrane,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016740~transferase activity,GO:0044389~ubiquitin-like protein ligase binding,GO:0061630~ubiquitin protein ligase activity,GO:0061631~ubiquitin conjugating enzyme activity,	IPR000608:Ubiquitin-conjugating enzyme, E2,IPR016135:Ubiquitin-conjugating enzyme/RWD-like,IPR023313:Ubiquitin-conjugating enzyme, active site,	hsa04120:Ubiquitin mediated proteolysis,				KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,KW-0833~Ubl conjugation pathway,				KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Glycyl thioester intermediate,DOMAIN:UBC core,MUTAGEN:C->S: Loss of function; inhibition of cyclin-B degradation.,REGION:Disordered,
UBE2J1	ubiquitin conjugating enzyme E2 J1(UBE2J1)	Homo sapiens				GO:0000209~protein polyubiquitination,GO:0007286~spermatid development,GO:0018279~protein N-linked glycosylation via asparagine,GO:0030433~ubiquitin-dependent ERAD pathway,GO:0032680~regulation of tumor necrosis factor production,GO:1904153~negative regulation of retrograde protein transport, ER to cytosol,	GO:0005634~nucleus,GO:0005789~endoplasmic reticulum membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,GO:0005524~ATP binding,GO:0031625~ubiquitin protein ligase binding,GO:0061631~ubiquitin conjugating enzyme activity,	IPR000608:Ubiquitin-conjugating enzyme, E2,IPR016135:Ubiquitin-conjugating enzyme/RWD-like,	hsa04120:Ubiquitin mediated proteolysis,hsa04141:Protein processing in endoplasmic reticulum,hsa05012:Parkinson disease,hsa05022:Pathways of neurodegeneration - multiple diseases,				KW-0833~Ubl conjugation pathway,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Glycyl thioester intermediate,COMPBIAS:Polar residues,DOMAIN:UBC core,MUTAGEN:C->S: Loss of catalytic activity. Slows down degradation of misfolded proteins from the ER.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical; Anchor for type IV membrane protein,
UBE2L6	ubiquitin conjugating enzyme E2 L6(UBE2L6)	Homo sapiens		h_parkinPathway:Role of Parkin in the Ubiquitin-Proteasomal Pathway,		GO:0000209~protein polyubiquitination,GO:0006464~cellular protein modification process,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0019985~translesion synthesis,GO:0032020~ISG15-protein conjugation,GO:0032480~negative regulation of type I interferon production,GO:1990000~amyloid fibril formation,	GO:0000151~ubiquitin ligase complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016740~transferase activity,GO:0031625~ubiquitin protein ligase binding,GO:0042296~ISG15 transferase activity,GO:0043130~ubiquitin binding,GO:0061631~ubiquitin conjugating enzyme activity,	IPR000608:Ubiquitin-conjugating enzyme, E2,IPR016135:Ubiquitin-conjugating enzyme/RWD-like,IPR023313:Ubiquitin-conjugating enzyme, active site,	hsa04120:Ubiquitin mediated proteolysis,hsa05012:Parkinson disease,hsa05022:Pathways of neurodegeneration - multiple diseases,				KW-0833~Ubl conjugation pathway,				KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0808~Transferase,	KW-0832~Ubl conjugation,	ACT_SITE:Glycyl thioester intermediate,DOMAIN:UBC core,
UFM1	ubiquitin fold modifier 1(UFM1)	Homo sapiens				GO:0007420~brain development,GO:0033146~regulation of intracellular estrogen receptor signaling pathway,GO:0034976~response to endoplasmic reticulum stress,GO:0042308~negative regulation of protein import into nucleus,GO:0043066~negative regulation of apoptotic process,GO:0061709~reticulophagy,GO:0071569~protein ufmylation,GO:1990592~protein K69-linked ufmylation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,	GO:0005515~protein binding,	IPR005375:Ubiquitin-fold modifier 1,		617899~Leukodystrophy, hypomyelinating, 14,	PIRSF038027:ubiquitin-fold modifier 1,		KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-1026~Leukodystrophy,				KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Gly-Lys) (interchain with K-? in acceptor proteins),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in UFM1),MUTAGEN:A->F,Q: Abolished ability to be activated by UBA5.,MUTAGEN:E->A: Abolished ability to be activated by UBA5.,MUTAGEN:G->A: Confers resistance to cleavage.,MUTAGEN:L->A: Abolished ability to be activated by UBA5.,MUTAGEN:R->A: Slightly reduced interaction with UFM1.,PROPEP:Removed in mature form,
UBR7	ubiquitin protein ligase E3 component n-recognin 7(UBR7)	Homo sapiens				GO:0016567~protein ubiquitination,	GO:0005737~cytoplasm,	GO:0008270~zinc ion binding,GO:0061630~ubiquitin protein ligase activity,	IPR003126:Zinc finger, N-recognin,IPR011011:Zinc finger, FYVE/PHD-type,IPR013083:Zinc finger, RING/FYVE/PHD-type,		619189~Li-Campeau syndrome,		SM00396:ZnF_UBR1,	KW-0833~Ubl conjugation pathway,			KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:UBR-type,REGION:Disordered,ZN_FING:PHD-type; atypical,ZN_FING:UBR-type,
UBE3B	ubiquitin protein ligase E3B(UBE3B)	Homo sapiens				GO:0000209~protein polyubiquitination,GO:0006511~ubiquitin-dependent protein catabolic process,		GO:0016874~ligase activity,GO:0061630~ubiquitin protein ligase activity,	IPR000048:IQ motif, EF-hand binding site,IPR000569:HECT,	hsa04120:Ubiquitin mediated proteolysis,	244450~Kaufman oculocerebrofacial syndrome,		SM00015:IQ,SM00119:HECTc,	KW-0833~Ubl conjugation pathway,		KW-0225~Disease variant,KW-0991~Mental retardation,			KW-0436~Ligase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Glycyl thioester intermediate,DOMAIN:HECT,DOMAIN:IQ,REGION:Disordered,
UBE3C	ubiquitin protein ligase E3C(UBE3C)	Homo sapiens				GO:0000209~protein polyubiquitination,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0035519~protein K29-linked ubiquitination,GO:0070936~protein K48-linked ubiquitination,	GO:0000502~proteasome complex,GO:0005634~nucleus,	GO:0005515~protein binding,GO:0061630~ubiquitin protein ligase activity,	IPR000048:IQ motif, EF-hand binding site,IPR000569:HECT,	hsa04120:Ubiquitin mediated proteolysis,			SM00015:IQ,SM00119:HECTc,	KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0647~Proteasome,				KW-0808~Transferase,		ACT_SITE:Glycyl thioester intermediate,COMPBIAS:Basic and acidic residues,DOMAIN:HECT,DOMAIN:IQ,MUTAGEN:C->A: No stimulation of in vitro CAND2 ubiquitination.,REGION:Cis-determinant of acceptor ubiquitin-binding,REGION:Disordered,
USP1	ubiquitin specific peptidase 1(USP1)	Homo sapiens				GO:0001501~skeletal system development,GO:0006281~DNA repair,GO:0006282~regulation of DNA repair,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0009411~response to UV,GO:0016579~protein deubiquitination,GO:0035520~monoubiquitinated protein deubiquitination,GO:0036297~interstrand cross-link repair,GO:0042769~DNA damage response, detection of DNA damage,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,	GO:0004197~cysteine-type endopeptidase activity,GO:0004843~thiol-dependent ubiquitin-specific protease activity,GO:0005515~protein binding,GO:0008233~peptidase activity,	IPR001394:Peptidase C19, ubiquitin carboxyl-terminal hydrolase 2,IPR018200:Peptidase C19, ubiquitin carboxyl-terminal hydrolase 2, conserved site,	hsa03460:Fanconi anemia pathway,				KW-0227~DNA damage,KW-0234~DNA repair,KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,				KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0068~Autocatalytic cleavage,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Nucleophile,ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:USP,MUTAGEN:C->S: Loss of catalytic activity including autolysis.,MUTAGEN:E->K: Strongly reduces interaction with WDR48 and activation by WDR48.,MUTAGEN:GG->AA: Loss of autolysis-mediated degradation upon UV irradiation. No effect on catalytic activity.,REGION:Disordered,SITE:Cleavage; by autolysis,
USP14	ubiquitin specific peptidase 14(USP14)	Homo sapiens				GO:0007268~chemical synaptic transmission,GO:0010951~negative regulation of endopeptidase activity,GO:0016579~protein deubiquitination,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0045087~innate immune response,GO:0050920~regulation of chemotaxis,GO:0061136~regulation of proteasomal protein catabolic process,GO:1903070~negative regulation of ER-associated ubiquitin-dependent protein catabolic process,	GO:0000502~proteasome complex,GO:0005634~nucleus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0031410~cytoplasmic vesicle,GO:0045202~synapse,GO:0070062~extracellular exosome,	GO:0004197~cysteine-type endopeptidase activity,GO:0004843~thiol-dependent ubiquitin-specific protease activity,GO:0004866~endopeptidase inhibitor activity,GO:0005515~protein binding,GO:0070628~proteasome binding,	IPR000626:Ubiquitin,IPR001394:Peptidase C19, ubiquitin carboxyl-terminal hydrolase 2,IPR018200:Peptidase C19, ubiquitin carboxyl-terminal hydrolase 2, conserved site,IPR019954:Ubiquitin conserved site,				SM00213:UBQ,	KW-0391~Immunity,KW-0399~Innate immunity,KW-0833~Ubl conjugation pathway,	KW-0472~Membrane,KW-0647~Proteasome,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0175~Coiled coil,		KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Nucleophile,ACT_SITE:Proton acceptor,DOMAIN:USP,DOMAIN:Ubiquitin-like,
USP22	ubiquitin specific peptidase 22(USP22)	Homo sapiens				GO:0006325~chromatin organization,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0007049~cell cycle,GO:0009792~embryo development ending in birth or egg hatching,GO:0016574~histone ubiquitination,GO:0016578~histone deubiquitination,GO:0016579~protein deubiquitination,GO:0035521~monoubiquitinated histone deubiquitination,GO:0035522~monoubiquitinated histone H2A deubiquitination,GO:0043966~histone H3 acetylation,GO:0043967~histone H4 acetylation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045931~positive regulation of mitotic cell cycle,	GO:0000124~SAGA complex,GO:0005654~nucleoplasm,	GO:0003713~transcription coactivator activity,GO:0004843~thiol-dependent ubiquitin-specific protease activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0010485~H4 histone acetyltransferase activity,GO:0019899~enzyme binding,GO:0030374~ligand-dependent nuclear receptor transcription coactivator activity,	IPR001394:Peptidase C19, ubiquitin carboxyl-terminal hydrolase 2,IPR001607:Zinc finger, UBP-type,IPR013083:Zinc finger, RING/FYVE/PHD-type,IPR018200:Peptidase C19, ubiquitin carboxyl-terminal hydrolase 2, conserved site,					KW-0131~Cell cycle,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0156~Chromatin regulator,KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0007~Acetylation,	ACT_SITE:Nucleophile,ACT_SITE:Proton acceptor,COMPBIAS:Polar residues,DOMAIN:USP,METAL:Zinc 1,METAL:Zinc 2,METAL:Zinc 3,MUTAGEN:H->A: Impairs its function as a positive modulator of androgen receptor transactivation; when associated with A-471.,MUTAGEN:H->A: Impairs its function as a positive modulator of androgen receptor transactivation; when associated with A-479.,REGION:Disordered,ZN_FING:UBP-type,
USP7	ubiquitin specific peptidase 7(USP7)	Homo sapiens			Posttranslational modification, protein turnover, chaperones,	GO:0006111~regulation of gluconeogenesis,GO:0006283~transcription-coupled nucleotide-excision repair,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0007275~multicellular organism development,GO:0010216~maintenance of DNA methylation,GO:0016032~viral process,GO:0016567~protein ubiquitination,GO:0016579~protein deubiquitination,GO:0031647~regulation of protein stability,GO:0032088~negative regulation of NF-kappaB transcription factor activity,GO:0032435~negative regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0035520~monoubiquitinated protein deubiquitination,GO:0035616~histone H2B conserved C-terminal lysine deubiquitination,GO:0042752~regulation of circadian rhythm,GO:0048511~rhythmic process,GO:0050821~protein stabilization,GO:0051090~regulation of sequence-specific DNA binding transcription factor activity,GO:0070536~protein K63-linked deubiquitination,GO:0071108~protein K48-linked deubiquitination,GO:1901537~positive regulation of DNA demethylation,GO:1901796~regulation of signal transduction by p53 class mediator,GO:1904353~regulation of telomere capping,GO:1905279~regulation of retrograde transport, endosome to Golgi,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005829~cytosol,GO:0016604~nuclear body,GO:0016605~PML body,GO:0032991~macromolecular complex,	GO:0002039~p53 binding,GO:0004197~cysteine-type endopeptidase activity,GO:0004843~thiol-dependent ubiquitin-specific protease activity,GO:0005515~protein binding,GO:0008022~protein C-terminus binding,GO:0008134~transcription factor binding,GO:0031625~ubiquitin protein ligase binding,GO:0101005~ubiquitinyl hydrolase activity,GO:1990380~Lys48-specific deubiquitinase activity,	IPR001394:Peptidase C19, ubiquitin carboxyl-terminal hydrolase 2,IPR002083:MATH,IPR008974:TRAF-like,IPR018200:Peptidase C19, ubiquitin carboxyl-terminal hydrolase 2, conserved site,IPR024729:Peptidase C19  domain,	hsa04068:FoxO signaling pathway,hsa05169:Epstein-Barr virus infection,hsa05203:Viral carcinogenesis,	616863~Hao-Fountain syndrome,		SM00061:MATH,	KW-0090~Biological rhythms,KW-0227~DNA damage,KW-0234~DNA repair,KW-0833~Ubl conjugation pathway,KW-0945~Host-virus interaction,	KW-0158~Chromosome,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,		KW-0217~Developmental protein,KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Nucleophile,ACT_SITE:Proton acceptor,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate,DOMAIN:MATH,DOMAIN:USP,MUTAGEN:C->A: Complete loss of activity. Localized in the nucleus and does not inhibit FOXO4-dependent transcriptional activity. Loss of ability to deubiquitinate CRY2.,MUTAGEN:C->S: Catalytically inactive mutant. No effect on p53/TP53 and PTEN binding but is defective in deubiquitinating p53/TP53 and PTEN. Partial loss of KMT2E/mml5 deubiquitination. Decreases deubiquitinase activity toward 'Lys-48'-polyubiquitinated ALKBH3. Reduced deubiquitination of REST.,MUTAGEN:D->A: Decreased binding to p53/TP53 and MDM2.,MUTAGEN:H->A: Complete loss of activity.,MUTAGEN:W->A: Loss of binding to p53/TP53 and MDM2.,REGION:Disordered,REGION:Interaction with ICP0/VMW110,REGION:Interaction with TSPYL5,REGION:Interaction with p53/TP53, MDM2 and EBNA1,REGION:Necessary for nuclear localization,
VPS72	vacuolar protein sorting 72 homolog(VPS72)	Homo sapiens				GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006355~regulation of transcription, DNA-templated,GO:0035019~somatic stem cell population maintenance,GO:0043486~histone exchange,GO:0043967~histone H4 acetylation,GO:0043968~histone H2A acetylation,GO:0051726~regulation of cell cycle,GO:1905168~positive regulation of double-strand break repair via homologous recombination,	GO:0000786~nucleosome,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016607~nuclear speck,GO:0032991~macromolecular complex,GO:0035267~NuA4 histone acetyltransferase complex,	GO:0003677~DNA binding,GO:0005515~protein binding,GO:0042393~histone binding,	IPR008895:YL1 nuclear,IPR013272:YL1 nuclear, C-terminal,				SM00993:SM00993,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0156~Chromatin regulator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),MUTAGEN:DDEY->ADAA: Almost abolishes interaction with H2AZ1 and H2BC11. Abolishes interaction with H2AZ1 and H2BC11 and exchange of H2A for H2AZ1 in nucleosomes; when associated with A-29--37-A.,MUTAGEN:FYQTTYGGF->AAQTTAGGA: Highly decreases interaction with H2AZ1 and H2BC11. Abolishes interaction with H2AZ1 and H2BC11 and exchange of H2A for H2AZ1 in nucleosomes; when associated with A-43--46-A.,REGION:Disordered,
VAV3	vav guanine nucleotide exchange factor 3(VAV3)	Homo sapiens				GO:0001525~angiogenesis,GO:0006906~vesicle fusion,GO:0006974~cellular response to DNA damage stimulus,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007229~integrin-mediated signaling pathway,GO:0007264~small GTPase mediated signal transduction,GO:0008361~regulation of cell size,GO:0009410~response to xenobiotic stimulus,GO:0030032~lamellipodium assembly,GO:0030168~platelet activation,GO:0030593~neutrophil chemotaxis,GO:0030890~positive regulation of B cell proliferation,GO:0035556~intracellular signal transduction,GO:0038095~Fc-epsilon receptor signaling pathway,GO:0038096~Fc-gamma receptor signaling pathway involved in phagocytosis,GO:0042493~response to drug,GO:0043065~positive regulation of apoptotic process,GO:0043087~regulation of GTPase activity,GO:0043552~positive regulation of phosphatidylinositol 3-kinase activity,GO:0045785~positive regulation of cell adhesion,GO:0048010~vascular endothelial growth factor receptor signaling pathway,GO:0048013~ephrin receptor signaling pathway,GO:0050853~B cell receptor signaling pathway,GO:0051056~regulation of small GTPase mediated signal transduction,	GO:0001772~immunological synapse,GO:0005829~cytosol,	GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005096~GTPase activator activity,GO:0005154~epidermal growth factor receptor binding,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR000219:Dbl homology (DH) domain,IPR000980:SH2 domain,IPR001331:Guanine-nucleotide dissociation stimulator, CDC24, conserved site,IPR001452:Src homology-3 domain,IPR001715:Calponin homology domain,IPR001849:Pleckstrin homology domain,IPR002219:Protein kinase C-like, phorbol ester/diacylglycerol binding,IPR003096:Smooth muscle protein/calponin,IPR011993:Pleckstrin homology-like domain,IPR022613:Calmodulin-regulated spectrin-associated protein, CH domain,	hsa04015:Rap1 signaling pathway,hsa04024:cAMP signaling pathway,hsa04062:Chemokine signaling pathway,hsa04510:Focal adhesion,hsa04650:Natural killer cell mediated cytotoxicity,hsa04660:T cell receptor signaling pathway,hsa04662:B cell receptor signaling pathway,hsa04664:Fc epsilon RI signaling pathway,hsa04666:Fc gamma R-mediated phagocytosis,hsa04670:Leukocyte transendothelial migration,hsa04810:Regulation of actin cytoskeleton,hsa05135:Yersinia infection,hsa05205:Proteoglycans in cancer,hsa05417:Lipid and atherosclerosis,			SM00033:CH,SM00109:C1,SM00233:PH,SM00252:SH2,SM00325:RhoGEF,SM00326:SH3,	KW-0037~Angiogenesis,			KW-0677~Repeat,KW-0727~SH2 domain,KW-0728~SH3 domain,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0344~Guanine-nucleotide releasing factor,	KW-0597~Phosphoprotein,	DOMAIN:Calponin-homology (CH),DOMAIN:DH,DOMAIN:PH,DOMAIN:Phorbol-ester/DAG-type,DOMAIN:SH2,DOMAIN:SH3,DOMAIN:SH3 1,DOMAIN:SH3 2,REGION:Sufficient for interaction with ROS1,ZN_FING:Phorbol-ester/DAG-type,
VAT1	vesicle amine transport 1(VAT1)	Homo sapiens			Energy production and conversion / General function prediction only,	GO:0010637~negative regulation of mitochondrial fusion,GO:0043312~neutrophil degranulation,	GO:0005576~extracellular region,GO:0005741~mitochondrial outer membrane,GO:0016021~integral component of membrane,GO:0035578~azurophil granule lumen,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0016491~oxidoreductase activity,	IPR002364:Quinone oxidoreductase/zeta-crystallin, conserved site,IPR011032:GroES-like,IPR013149:Alcohol dehydrogenase, C-terminal,IPR013154:Alcohol dehydrogenase GroES-like,IPR020843:Polyketide synthase, enoylreductase,				SM00829:SM00829,		KW-0472~Membrane,KW-0496~Mitochondrion,KW-0963~Cytoplasm,KW-1000~Mitochondrion outer membrane,				KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:ADH_N,DOMAIN:PKS_ER,REGION:Disordered,
VGLL4	vestigial like family member 4(VGLL4)	Homo sapiens				GO:0006355~regulation of transcription, DNA-templated,GO:0030178~negative regulation of Wnt signaling pathway,GO:0030308~negative regulation of cell growth,GO:0035331~negative regulation of hippo signaling,GO:0045892~negative regulation of transcription, DNA-templated,GO:0060044~negative regulation of cardiac muscle cell proliferation,GO:1903364~positive regulation of cellular protein catabolic process,	GO:0005634~nucleus,	GO:0001223~transcription coactivator binding,GO:0005515~protein binding,	IPR006627:TDU repeat,				SM00711:TDU,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,					KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
WFS1	wolframin ER transmembrane glycoprotein(WFS1)	Homo sapiens				GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001822~kidney development,GO:0003091~renal water homeostasis,GO:0006983~ER overload response,GO:0007601~visual perception,GO:0007605~sensory perception of sound,GO:0022417~protein maturation by protein folding,GO:0030433~ubiquitin-dependent ERAD pathway,GO:0030968~endoplasmic reticulum unfolded protein response,GO:0031016~pancreas development,GO:0031398~positive regulation of protein ubiquitination,GO:0032469~endoplasmic reticulum calcium ion homeostasis,GO:0034976~response to endoplasmic reticulum stress,GO:0036498~IRE1-mediated unfolded protein response,GO:0042048~olfactory behavior,GO:0042593~glucose homeostasis,GO:0043066~negative regulation of apoptotic process,GO:0043069~negative regulation of programmed cell death,GO:0043433~negative regulation of sequence-specific DNA binding transcription factor activity,GO:0043524~negative regulation of neuron apoptotic process,GO:0043687~post-translational protein modification,GO:0044267~cellular protein metabolic process,GO:0045927~positive regulation of growth,GO:0050821~protein stabilization,GO:0050877~neurological system process,GO:0051247~positive regulation of protein metabolic process,GO:0051928~positive regulation of calcium ion transport,GO:0055074~calcium ion homeostasis,GO:1902236~negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway,GO:1903573~negative regulation of response to endoplasmic reticulum stress,GO:1903892~negative regulation of ATF6-mediated unfolded protein response,GO:2000675~negative regulation of type B pancreatic cell apoptotic process,	GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0005789~endoplasmic reticulum membrane,GO:0016021~integral component of membrane,GO:0030141~secretory granule,GO:0030176~integral component of endoplasmic reticulum membrane,GO:0030285~integral component of synaptic vesicle membrane,GO:0030425~dendrite,	GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0031625~ubiquitin protein ligase binding,GO:0033613~activating transcription factor binding,GO:0048306~calcium-dependent protein binding,GO:0051117~ATPase binding,GO:0070628~proteasome binding,	IPR011990:Tetratricopeptide-like helical,IPR026208:Wolframin,IPR026209:Wolframin family,	hsa04141:Protein processing in endoplasmic reticulum,	116400~Cataract 41,125853~Diabetes mellitus, noninsulin-dependent, association with,222300~Wolfram syndrome 1,600965~Deafness, autosomal dominant 6/14/38,614296~Wolfram-like syndrome, autosomal dominant,				KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,	KW-0209~Deafness,KW-0218~Diabetes insipidus,KW-0219~Diabetes mellitus,KW-0225~Disease variant,KW-0898~Cataract,KW-1010~Non-syndromic deafness,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,REGION:Disordered,REGION:Interaction with ATP6V1A,TOPO_DOM:Lumenal,TRANSMEM:Helical,
ZDHHC6	zinc finger DHHC-type palmitoyltransferase 6(ZDHHC6)	Homo sapiens			General function prediction only,	GO:0006612~protein targeting to membrane,GO:0010636~positive regulation of mitochondrial fusion,GO:0018230~peptidyl-L-cysteine S-palmitoylation,GO:0018345~protein palmitoylation,GO:0043543~protein acylation,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0016021~integral component of membrane,	GO:0005515~protein binding,GO:0016409~palmitoyltransferase activity,GO:0016747~transferase activity, transferring acyl groups other than amino-acyl groups,GO:0019706~protein-cysteine S-palmitoyltransferase activity,	IPR001452:Src homology-3 domain,IPR001594:Zinc finger, DHHC-type, palmitoyltransferase,						KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0728~SH3 domain,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0012~Acyltransferase,KW-0808~Transferase,	KW-0449~Lipoprotein,KW-0564~Palmitate,	ACT_SITE:S-palmitoyl cysteine intermediate,DOMAIN:DHHC,DOMAIN:SH3,LIPID:S-palmitoyl cysteine,MOTIF:Di-lysine motif,MUTAGEN:C->A: Abolishes palmitoylation, leading to impaired homooligomeization and decreased catalytic activity; when associated with 328-A-A-329.,MUTAGEN:CC->AA: Abolishes palmitoylation, leading to impaired homooligomeization and decreased catalytic activity; when associated with A-343.,MUTAGEN:E->A: Does not affect localization to the endoplasmic reticulum.,MUTAGEN:K->A: Impaired localization to the endoplasmic reticulum.,MUTAGEN:N->A: Does not affect localization to the endoplasmic reticulum.,MUTAGEN:R->A: Does not affect localization to the endoplasmic reticulum.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
ZMIZ1	zinc finger MIZ-type containing 1(ZMIZ1)	Homo sapiens				GO:0001570~vasculogenesis,GO:0001701~in utero embryonic development,GO:0003007~heart morphogenesis,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0007296~vitellogenesis,GO:0007569~cell aging,GO:0021852~pyramidal neuron migration,GO:0030521~androgen receptor signaling pathway,GO:0033233~regulation of protein sumoylation,GO:0045582~positive regulation of T cell differentiation,GO:0045747~positive regulation of Notch signaling pathway,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048096~chromatin-mediated maintenance of transcription,GO:0048146~positive regulation of fibroblast proliferation,GO:0048589~developmental growth,GO:0048844~artery morphogenesis,GO:0060395~SMAD protein signal transduction,GO:1903508~positive regulation of nucleic acid-templated transcription,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0003713~transcription coactivator activity,GO:0008270~zinc ion binding,GO:0030374~ligand-dependent nuclear receptor transcription coactivator activity,GO:0046332~SMAD binding,	IPR004181:Zinc finger, MIZ-type,IPR013083:Zinc finger, RING/FYVE/PHD-type,		618659~Neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies,			KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0991~Mental retardation,	KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,	KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:SP-RING-type,DOMAIN:Zmiz1_N,METAL:Zinc,REGION:Disordered,REGION:Sufficient for transactivation activity; sufficient for interaction with NOTCH1,REGION:Transactivation domain,ZN_FING:SP-RING-type,
ZMYM2	zinc finger MYM-type containing 2(ZMYM2)	Homo sapiens					GO:0005829~cytosol,GO:0016605~PML body,	GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0031624~ubiquitin conjugating enzyme binding,	IPR010507:Zinc finger, MYM-type,IPR011017:TRASH domain,IPR021893:Protein of unknown function DUF3504,		619522~Neurodevelopmental-craniofacial syndrome with variable renal and cardiac abnormalities,		SM00746:TRASH,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:MYM-type,DOMAIN:TRASH,REGION:Disordered,SITE:Breakpoint for translocation to form ZMYM2-FGFR1,ZN_FING:MYM-type 1,ZN_FING:MYM-type 2,ZN_FING:MYM-type 3,ZN_FING:MYM-type 4,ZN_FING:MYM-type 5,ZN_FING:MYM-type 6,ZN_FING:MYM-type 7,ZN_FING:MYM-type 8,ZN_FING:MYM-type 9,
ZNF131	zinc finger protein 131(ZNF131)	Homo sapiens				GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006357~regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0045111~intermediate filament cytoskeleton,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0046872~metal ion binding,	IPR000210:BTB/POZ-like,IPR011333:BTB/POZ fold,IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,				SM00225:BTB,SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0678~Repressor,	KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:BTB,DOMAIN:C2H2-type,MOTIF:Nuclear localization signal 1,MOTIF:Nuclear localization signal 2,MUTAGEN:K->R: No effect on sumoylation. Complete loss of CBX4 sumoylation; when associated with R-477 and R-601.,MUTAGEN:K->R: No effect on sumoylation; when associated with R-242 and R-281.,MUTAGEN:K->R: No effect on sumoylation; when associated with R-281 and R-289.,MUTAGEN:K->R: Significant loss of sumoylation. Complete loss of CBX4 sumoylation; when associated with R-477 and R-610.,MUTAGEN:K->R: Small loss of sumoylation. Complete loss of CBX4 sumoylation; when associated with R-601 and R-610.,REGION:Disordered,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4; degenerate,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6,
ZNF274	zinc finger protein 274(ZNF274)	Homo sapiens			General function prediction only,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:1900112~regulation of histone H3-K9 trimethylation,	GO:0005634~nucleus,GO:0005730~nucleolus,GO:0005737~cytoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,GO:0046872~metal ion binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001909:Krueppel-associated box,IPR003309:Transcription regulator SCAN,IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,	hsa04722:Neurotrophin signaling pathway,			SM00349:KRAB,SM00355:ZnF_C2H2,SM00431:SCAN,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0678~Repressor,		COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,DOMAIN:C2H2-type,DOMAIN:KRAB,DOMAIN:KRAB 1,DOMAIN:KRAB 2,DOMAIN:SCAN box,REGION:Disordered,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,
ZNF318	zinc finger protein 318(ZNF318)	Homo sapiens				GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0051321~meiotic cell cycle,	GO:0005654~nucleoplasm,GO:0005829~cytosol,	GO:0003676~nucleic acid binding,GO:0008270~zinc ion binding,GO:0042803~protein homodimerization activity,	IPR003604:Zinc finger, U1-type,				SM00451:ZnF_U1,	KW-0469~Meiosis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0678~Repressor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,REGION:Interaction with AR,ZN_FING:Matrin-type 1,ZN_FING:Matrin-type 2,
ZNF395	zinc finger protein 395(ZNF395)	Homo sapiens				GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016607~nuclear speck,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000987~core promoter proximal region sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0046872~metal ion binding,	IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:DUF4772,MOTIF:Nuclear export signal,MUTAGEN:L->A: No change in subcellular location; when associated with A-109.,MUTAGEN:L->A: No change in subcellular location; when associated with A-113.,MUTAGEN:M->A: No shuttle from the nucleus to the cytoplasm; when associated with A-169.,MUTAGEN:M->A: No shuttle from the nucleus to the cytoplasm; when associated with A-172.,REGION:Disordered,ZN_FING:C2H2-type,
ZNF451	zinc finger protein 451(ZNF451)	Homo sapiens				GO:0010468~regulation of gene expression,GO:0016925~protein sumoylation,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0060633~negative regulation of transcription initiation from RNA polymerase II promoter,GO:2000616~negative regulation of histone H3-K9 acetylation,	GO:0005634~nucleus,GO:0016021~integral component of membrane,GO:0016605~PML body,	GO:0003714~transcription corepressor activity,GO:0005515~protein binding,GO:0046872~metal ion binding,GO:0061665~SUMO ligase activity,	IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,				SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,KW-0833~Ubl conjugation pathway,	KW-0472~Membrane,KW-0539~Nucleus,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0812~Transmembrane,KW-0863~Zinc-finger,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:C2H2-type,DOMAIN:PIN_11,MOTIF:PLRP,MUTAGEN:G->E: Mildly reduces E3 SUMO-protein ligase activity.,MUTAGEN:G->GGSGG: Nearly abolishes E3 SUMO-protein ligase activity (in vitro).,MUTAGEN:IDLV->ADAA: Nearly abolishes E3 SUMO-protein ligase activity (in vitro).,MUTAGEN:IQFV->AQAA: Nearly abolishes E3 SUMO-protein ligase activity (in vitro).,MUTAGEN:K->R: No effect on negative regulation of SMAD4-mediated transcription activation.,MUTAGEN:L->LGSGG: Nearly abolishes E3 SUMO-protein ligase activity (in vitro).,MUTAGEN:LV->AA: Impairs interaction with SUMO1. No effect on negative regulation of SMAD4-mediated transcription activation.,MUTAGEN:PLRP->ALRA: Reduces E3 SUMO-protein ligase activity by 97% (in vitro).,MUTAGEN:PLRP->GLRG: Nearly abolishes E3 SUMO-protein ligase activity (in vitro).,MUTAGEN:R->A: Reduces E3 SUMO-protein ligase activity by 96% (in vitro).,MUTAGEN:R->E: Mildly reduces E3 SUMO-protein ligase activity.,REGION:Disordered,REGION:Important for interaction with SMAD4,REGION:Important for interaction with SUMO1 and SUMO2,REGION:Important for ubiquitin binding,REGION:Interaction with SUMO2 1,REGION:Interaction with SUMO2 2,REGION:Sufficient for E3 SUMO-protein ligase activity,TRANSMEM:Helical,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 10,ZN_FING:C2H2-type 11,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6,ZN_FING:C2H2-type 7; atypical,ZN_FING:C2H2-type 8,ZN_FING:C2H2-type 9,
ZNF586	zinc finger protein 586(ZNF586)	Homo sapiens			General function prediction only,	GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0046872~metal ion binding,	IPR001909:Krueppel-associated box,IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,				SM00349:KRAB,SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,		DOMAIN:KRAB,REGION:Disordered,ZN_FING:C2H2-type 10,ZN_FING:C2H2-type 11,ZN_FING:C2H2-type 1; degenerate,ZN_FING:C2H2-type 2; degenerate,ZN_FING:C2H2-type 3; degenerate,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6,ZN_FING:C2H2-type 7,ZN_FING:C2H2-type 8,ZN_FING:C2H2-type 9,
ZNF589	zinc finger protein 589(ZNF589)	Homo sapiens			General function prediction only,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0046872~metal ion binding,	IPR001909:Krueppel-associated box,IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,	hsa05168:Herpes simplex virus 1 infection,			SM00349:KRAB,SM00355:ZnF_C2H2,		KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0678~Repressor,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:C2H2-type,DOMAIN:KRAB,REGION:Disordered,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,
ZW10	zw10 kinetochore protein(ZW10)	Homo sapiens				GO:0000070~mitotic sister chromatid segregation,GO:0000132~establishment of mitotic spindle orientation,GO:0000278~mitotic cell cycle,GO:0006888~ER to Golgi vesicle-mediated transport,GO:0006890~retrograde vesicle-mediated transport, Golgi to ER,GO:0007030~Golgi organization,GO:0007052~mitotic spindle organization,GO:0007080~mitotic metaphase plate congression,GO:0007094~mitotic spindle assembly checkpoint,GO:0007096~regulation of exit from mitosis,GO:0015031~protein transport,GO:0034501~protein localization to kinetochore,GO:0051301~cell division,GO:0051321~meiotic cell cycle,GO:0065003~macromolecular complex assembly,GO:0072413~signal transduction involved in mitotic cell cycle checkpoint,	GO:0000776~kinetochore,GO:0000777~condensed chromosome kinetochore,GO:0000922~spindle pole,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005811~lipid particle,GO:0005828~kinetochore microtubule,GO:0005829~cytosol,GO:0016020~membrane,GO:0070939~Dsl1/NZR complex,GO:1990423~RZZ complex,	GO:0005515~protein binding,GO:0019237~centromeric DNA binding,	IPR009361:RZZ complex, subunit Zw10,					KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,KW-0653~Protein transport,KW-0813~Transport,KW-0931~ER-Golgi transport,	KW-0137~Centromere,KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0551~Lipid droplet,KW-0963~Cytoplasm,KW-0995~Kinetochore,		KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	REGION:Interaction with RINT1,REGION:Interaction with ZWINT,
